PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DELGADO, A; SALTO, R; MARQUES, S; RAMOS, JL				DELGADO, A; SALTO, R; MARQUES, S; RAMOS, JL			SINGLE AMINO-ACIDS CHANGES IN THE SIGNAL RECEPTOR DOMAIN OF XYLR RESULTED IN MUTANTS THAT STIMULATE TRANSCRIPTION IN THE ABSENCE OF EFFECTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS TOL PLASMID; INTEGRATION HOST FACTOR; UPPER-PATHWAY OPERON; UPSTREAM REGULATORY SEQUENCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ACTIVATOR PROTEIN; XYLENE METABOLISM; GENE XYLS; PUTIDA	The XylR protein positively controls expression from the Pseudomonas putida TOL plasmid sigma(54)-dependent ''upper'' pathway operon promoter (Pu) and the xylS gene promoter (Ps), in response to the presence of aromatic effecters. Two mutant XylR regulators able to stimulate transcription from Pu and Ps in the absence of effecters were isolated. These mutants exhibited single point mutations, namely Asp(135) --> Asn and Pro(85) --> Ser. Both mutations are located in the amino termini domain of XylR, which is thought to be responsible for interactions with effecters. The effector profile of XylRP85S was similar to that of wild-type XylR protein; however, XylRD135N exhibited an altered pattern of effector recognition: with m-nitrotoluene it stimulated transcription from the Pu promoter above the high basal level, whereas this nitroarene inhibited the wild-type regulator, Previous work (Delgado, A., and Ramos, J. L. (1994) J. Biol, Chem, 269, 8059-8062) showed that residue 172 was involved in effector interactions, as mutant XylRE172K also recognized m-nitrotoluene. However, double mutant XylR135N/E172K did not stimulate transcription in the absence of effector, but retained the ability to stimulate transcription with m-nitrotoluene. Transcription mediated by XylRD135N and XylRP85S from Pu::lacZ was analyzed in detail. Like the wild-type regulator, XylRD135N and XylRP85S required sigma(54) for full transcription activation, but in contrast with the wild-type regulator, XylRD135N, but not XylRP85S, stimulated transcription from Pu in the absence of the integration host factor protein, XylRD135N, also in contrast with XylR and XylRP85S, mediated transcription from a mutant Pu promoter that lacked one of the up stream regulator binding sites (Delta UAS1), but not when both upstream regulator binding sites were deleted, The level of autoregulation of XylRD135N was at least a fold higher than that found with the wild-type XylR regulator and the mutant XylRP85S.	CSIC,DEPT BIOCHEM MOLEC & CELLULAR BIOL PLANTS,ESTAC EXPTL ZAIDIN,E-18008 GRANADA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ)			Marqués, Silvia/B-8079-2012; Salto, Rafael/A-6486-2011; Delgado, Asunción/HGU-5527-2022	Marqués, Silvia/0000-0002-6289-3348; Salto, Rafael/0000-0002-7044-3611; Ramos, Juan L./0000-0002-8731-7435				ABRIL MA, 1993, MOL GEN GENET, V239, P281, DOI 10.1007/BF00281629; ABRIL MA, 1991, J BIOL CHEM, V266, P15832; ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BIEK DP, 1989, J BACTERIOL, V171, P2056, DOI 10.1128/jb.171.4.2056-2065.1989; BUCK M, 1986, NATURE, V320, P374, DOI 10.1038/320374a0; CLAVERIEMARTIN F, 1992, J MOL BIOL, V227, P996, DOI 10.1016/0022-2836(92)90516-M; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DELGADO A, 1994, J BIOL CHEM, V269, P8059; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; DIXON R, 1986, MOL GEN GENET, V203, P129, DOI 10.1007/BF00330393; DIXON R, 1991, MOL MICROBIOL, V5, P1657, DOI 10.1111/j.1365-2958.1991.tb01913.x; DRUMMOND M, 1986, EMBO J, V5, P441, DOI 10.1002/j.1460-2075.1986.tb04230.x; GOMADA M, 1992, MOL GEN GENET, V233, P419, DOI 10.1007/BF00265439; HOLTEL A, 1992, NUCLEIC ACIDS RES, V20, P1755, DOI 10.1093/nar/20.7.1755; HOLTEL A, 1990, MOL MICROBIOL, V4, P1551, DOI 10.1111/j.1365-2958.1990.tb02066.x; INOUYE S, 1989, GENE, V85, P145; INOUYE S, 1990, J MOL BIOL, V216, P251, DOI 10.1016/S0022-2836(05)80317-1; INOUYE S, 1987, P NATL ACAD SCI USA, V84, P5182, DOI 10.1073/pnas.84.15.5182; INOUYE S, 1988, GENE, V66, P301; INOUYE S, 1984, P NATL ACAD SCI-BIOL, V81, P1688, DOI 10.1073/pnas.81.6.1688; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KLOSE KE, 1993, J MOL BIOL, V232, P67, DOI 10.1006/jmbi.1993.1370; KNOWLES JR, 1987, SCIENCE, V236, P1252; KOHLER T, 1989, J BACTERIOL, V171, P4326; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LEE JH, 1994, J BIOL CHEM, V269, P20401; MACNEIL D, 1981, J BACTERIOL, V146, P260, DOI 10.1128/JB.146.1.260-268.1981; MARQUES S, 1993, MOL MICROBIOL, V9, P923, DOI 10.1111/j.1365-2958.1993.tb01222.x; MARQUES S, 1993, BIOCHIM BIOPHYS ACTA, V1216, P227, DOI 10.1016/0167-4781(93)90149-8; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; PEREZMARTIN J, 1994, J BIOL CHEM, V269, P22657; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; RAMOS JL, 1986, P NATL ACAD SCI USA, V83, P8467, DOI 10.1073/pnas.83.22.8467; RAMOS JL, 1987, MOL MICROBIOL, V1, P297; SANDERS DA, 1992, J BACTERIOL, V174, P5117, DOI 10.1128/JB.174.15.5117-5122.1992; SHINGLER V, 1994, J BACTERIOL, V176, P1555, DOI 10.1128/jb.176.6.1555-1560.1994; SHINGLER V, 1993, J BACTERIOL, V175, P1596, DOI 10.1128/JB.175.6.1596-1604.1993; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; WEGLENSKI P, 1989, J BACTERIOL, V171, P4479, DOI 10.1128/JB.171.8.4479-4485.1989; WORSEY MJ, 1975, J BACTERIOL, V124, P7, DOI 10.1128/JB.124.1.7-13.1975	41	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5144	5150		10.1074/jbc.270.10.5144	http://dx.doi.org/10.1074/jbc.270.10.5144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890623	hybrid			2022-12-25	WOS:A1995QL58000031
J	BALDWIN, AN; SHOOTER, EM				BALDWIN, AN; SHOOTER, EM			ZONE MAPPING OF THE BINDING DOMAIN OF THE RAT LOW-AFFINITY NERVE GROWTH-FACTOR RECEPTOR BY THE INTRODUCTION OF NOVEL N-GLYCOSYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY 217C; NGF RECEPTOR; TRK PROTOONCOGENE; CRYSTAL-STRUCTURE; TYROSINE KINASE; LIGAND-BINDING; PC12 CELLS; PROTEINS; HEMAGGLUTININ; CARBOHYDRATE	The binding of NGF (nerve growth factor) to the rat low affinity nerve growth factor receptor (p75(NGFR)) has been studied by site-directed mutagenesis of the receptor. Introduction of non-native N-glycosylation sites within the binding domain indicates that the second of the characteristic cysteine-rich repeats may be particularly important to NGF binding. Two mutants of the second repeat, S42N and S66N, are glycosylated and bind NGF at a drastically reduced level, while still maintaining a conformation recognized by the monoclonal antibody against p75, MC192. Alanine substitution at these sites does not affect NGF binding. Two other mutations that result in local structural changes in the second repeat also greatly decrease binding. One of these altered residues, Ser(50), appears to play an essential structural role, since it cannot be replaced by Asn, Ala, or Thr without loss of both NGF binding and MC192 recognition on a Western. Glycosylation of selected sites in the other repeats has little effect on NGF binding or antibody recognition. The introduction of non-native N-glycosylation sites may provide a generally useful scanning technique for the study of protein-protein interactions.			BALDWIN, AN (corresponding author), STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER; NINDS NIH HHS [NS04270] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN AN, 1992, J BIOL CHEM, V267, P8352; BALDWIN AN, 1994, J BIOL CHEM, V269, P11456; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BATTLEMAN DS, 1993, J NEUROSCI, V13, P941; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BIRREN SJ, 1992, SCIENCE, V257, P395, DOI 10.1126/science.1321502; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHRAMBACH A, 1976, METHODS PROTEIN SEPA, V2, P27; CUMMINGHAM BC, 1989, SCIENCE, V243, P1330; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; FERRARI G, 1991, EXP NEUROL, V112, P183, DOI 10.1016/0014-4886(91)90068-N; FILIPOVIC I, 1989, J BIOL CHEM, V264, P8815; GALLAGHER P, 1988, J CELL BIOL, V107, P2059, DOI 10.1083/jcb.107.6.2059; GROB PM, 1983, J BIOL CHEM, V258, P4136; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HSU KC, 1993, J BIOL CHEM, V268, P16430; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KERN G, 1992, PROTEIN SCI, V1, P120; KIM HH, 1994, J BIOL CHEM, V269, P12345; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUMAR S, 1990, J NEUROSCI RES, V27, P408, DOI 10.1002/jnr.490270320; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEDBETTER JA, 1981, J EXP MED, V153, P1503, DOI 10.1084/jem.153.6.1503; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; SKEHEL JJ, 1984, P NATL ACAD SCI-BIOL, V81, P1779, DOI 10.1073/pnas.81.6.1779; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALE RD, 1985, METHOD ENZYMOL, V109, P21; VERDI JM, 1994, P NATL ACAD SCI USA, V91, P3949, DOI 10.1073/pnas.91.9.3949; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VIDAL S, 1989, J VIROL, V63, P892, DOI 10.1128/JVI.63.2.892-900.1989; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WESTKAMP G, 1991, NEURON, V6, P649; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; YAN H, 1991, J BIOL CHEM, V266, P12099	53	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4594	4602		10.1074/jbc.270.9.4594	http://dx.doi.org/10.1074/jbc.270.9.4594			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876230	hybrid			2022-12-25	WOS:A1995QK08400063
J	LEE, J; JAYARAM, M				LEE, J; JAYARAM, M			ROLE OF PARTNER HOMOLOGY IN DNA RECOMBINATION - COMPLEMENTARY BASE-PAIRING ORIENTS THE 5'-HYDROXYL FOR STRAND JOINING DURING FLP SITE-SPECIFIC RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-LAMBDA; INTEGRASE FAMILY; HALF-SITE; PROTEIN; SUBSTRATE; CLEAVAGE; MECHANISM; RESOLUTION; CATALYSIS; MUTATIONS	Absolute homology between partner substrates within the strand exchange region is an essential requirement for recombination mediated by the yeast site-specific recombinase Flp. Using combinations of specially designed half- and full-site Flp substrates, we demonstrate that the strand joining step of recombination is exquisitely sensitive to spacer homology. At each exchange point, 2-3 spacer nucleotides adjacent to the nick within the cleaved strand of one substrate must base pair with the corresponding segment of the un-nicked strand from the second substrate for efficient strand joining in the recombinant mode. In accordance with the ''cis-activation/trans-nucleophilic attack'' model for each of the two transesterification steps of Flp recombination (strand cleavage and strand joining), we propose that the limited strand pairing orients the DNA-nucleophile (5'-hydroxyl) for attack on its target diester (3'-phosphotyrosyl-Flp). During one round of recombination, 4-6 terminal base pairs of the spacer (2-3 base pairs at each spacer end) must unpair, following strand cleavage, within a DNA substrate and pair with the partner substrate prior to strand union. In this model, the extent of branch migration of the covalently closed Holliday intermediate is limited to the central core of the spacer. The templated positioning of reactive nucleic acid groups (which is central to the model) may be utilized by other recombination systems and by RNA splicing reactions.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; AMIN A, 1991, MOL CELL BIOL, V11, P4497, DOI 10.1128/MCB.11.9.4497; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BAUER CE, 1985, J MOL BIOL, V181, P187, DOI 10.1016/0022-2836(85)90084-1; BAUER CE, 1984, COLD SPRING HARB SYM, V49, P699, DOI 10.1101/SQB.1984.049.01.079; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V2, P1859; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; BROACH JR, 1991, MOL BIOL YEAST SACCH, P297; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; COWART M, 1991, J MOL BIOL, V220, P621, DOI 10.1016/0022-2836(91)90105-F; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DIXON JE, 1993, J MOL BIOL, V234, P522, DOI 10.1006/jmbi.1993.1608; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; JELTSCH A, 1993, P NATL ACAD SCI USA, V90, P8499, DOI 10.1073/pnas.90.18.8499; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; KOWALCZYKOWSKI SC, 1994, EXPERIENTIA, V50, P204, DOI 10.1007/BF01924003; LEE J, 1993, J BIOL CHEM, V268, P17564; LEHMAN IR, 1976, SCIENCE, V186, P790; Maniatis T., 1982, MOL CLONING; MCCULLOCH R, 1994, EMBO J, V13, P1844, DOI 10.1002/j.1460-2075.1994.tb06453.x; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NASH HA, 1987, P NATL ACAD SCI USA, V84, P4049, DOI 10.1073/pnas.84.12.4049; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1989, CELL, V59, P197, DOI 10.1016/0092-8674(89)90881-7; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PAN GH, 1992, J BIOL CHEM, V267, P12397; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; QIAN XH, 1992, J BIOL CHEM, V267, P7794; RADDING CM, 1991, J BIOL CHEM, V266, P5355; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SENECOFF JF, 1986, J BIOL CHEM, V261, P7380; SERRE MC, 1992, J MOL BIOL, V225, P621, DOI 10.1016/0022-2836(92)90390-6; WEISBERG RA, 1983, J MOL BIOL, V170, P319, DOI 10.1016/S0022-2836(83)80151-X; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	37	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4042	4052		10.1074/jbc.270.8.4042	http://dx.doi.org/10.1074/jbc.270.8.4042			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876153	hybrid			2022-12-25	WOS:A1995QH68800086
J	RIDDERSTRALE, M; DEGERMAN, E; TORNQVIST, H				RIDDERSTRALE, M; DEGERMAN, E; TORNQVIST, H			GROWTH-HORMONE STIMULATES THE TYROSINE PHOSPHORYLATION OF THE INSULIN-RECEPTOR SUBSTRATE-1 AND ITS ASSOCIATION WITH PHOSPHATIDYLINOSITOL 3-KINASE IN PRIMARY ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							3T3-F442A PREADIPOCYTES; KINASE-ACTIVITY; PROTEIN-KINASE; RAT ADIPOCYTES; INTACT-CELLS; IRS-1; IDENTIFICATION; PURIFICATION; ACTIVATION; BINDING	Insulin receptor substrate-1 (IRS-1) is tyrosine-phosphorylated in response to insulin resulting in association with and activation of phosphatidylinositol 3-kinase (PI 3-kinase), thereby initiating some of the effects of insulin, We have recently shown that the insulin-like effects of growth hormone (GH) in adipocytes can be inhibited by the selective PI 3-kinase inhibitor wortmannin (Ridderstrale, M., and Tornqvist, H. (1994) Biochem. Biophys. Res. Commun. 203, 306-310), suggesting a similar role for PI 3-kinase in GH action. Here we show that IRS-1 is tyrosine-phosphorylated in a time- and dose-dependent manner in response to GH in primary rat adipocytes, This phosphorylation coincided with the extent of interaction between IRS-1 and the 85-kDa subunit of PI 3-kinase as evidenced by coimmunoprecipitation. Stimulation with 23 nM GH increased the PI 3-kinase activity associated with IRS-1 4-fold, Our data suggest that GH-induced tyrosine phosphorylation of IRS-1 and the subsequent docking of PI 3-kinase are important postreceptor events in GH action. The mechanism for the phosphorylation of IRS-1 induced by GH is unknown, but involvement of JAK2, the only known GH receptor-associated tyrosine kinase, seems possible.	LUND UNIV, DEPT PEDIAT, S-22100 LUND, SWEDEN	Lund University	RIDDERSTRALE, M (corresponding author), LUND UNIV, DEPT MED & PHYSIOL CHEM, MOLEC SIGNALING SECT, POB 94, S-22100 LUND, SWEDEN.		Ridderstråle, Martin/F-7678-2012					ANDERSON NG, 1992, BIOCHEM J, V284, P649, DOI 10.1042/bj2840649; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AVRUCH J, 1990, HDB EXPT PHARM, V92, P313; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ESCOBEDO JA, 1991, CELL, V65, P413; Gliemann J, 1967, Diabetologia, V3, P382, DOI 10.1007/BF02342631; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOODMAN HM, 1981, ENDOCRINOLOGY, V109, P120, DOI 10.1210/endo-109-1-120; GRICHTING G, 1983, ENDOCRINOLOGY, V113, P1111, DOI 10.1210/endo-113-3-1111; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1993, J BIOL CHEM, V268, P4391; LAM K, 1994, J BIOL CHEM, V269, P20648; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKADA T, 1994, J BIOL CHEM, V269, P3568; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; RIDDERSTRALE M, 1994, BIOCHEM BIOPH RES CO, V203, P306, DOI 10.1006/bbrc.1994.2182; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROUPAS P, 1994, TRENDS ENDOCRIN MET, V5, P154, DOI 10.1016/1043-2760(94)90012-4; SCHLOOTWEG MC, 1991, J MOL ENDOCRINOL, V6, P179; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TASHIROHASHIMOTO Y, 1989, J BIOL CHEM, V264, P6879; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	49	119	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3471	3474		10.1074/jbc.270.8.3471	http://dx.doi.org/10.1074/jbc.270.8.3471			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876077	hybrid			2022-12-25	WOS:A1995QH68800003
J	SAITOH, H; TAKAGAKI, K; MAJIMA, M; NAKAMURA, T; MATSUKI, A; KASAI, M; NARITA, H; ENDO, M				SAITOH, H; TAKAGAKI, K; MAJIMA, M; NAKAMURA, T; MATSUKI, A; KASAI, M; NARITA, H; ENDO, M			ENZYMATIC RECONSTRUCTION OF GLYCOSAMINOGLYCAN OLIGOSACCHARIDE CHAINS USING THE TRANSGLYCOSYLATION REACTION OF BOVINE TESTICULAR HYALURONIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCURONIDASE; LINKAGE REGION; SULFATE; SUBSTRATE; ASSAY	The reconstruction of glycosaminoglycan chains using the transglycosylation reaction of testicular hyaluronidase was investigated, First, the optimal conditions for the transglycosylation reaction catalyzed by the enzyme were determined by incubation with the enzyme, using hyaluronic acid (M(r) = 800,000) as a donor and pyridylaminated hyaluronic acid hexasaccharide having glucuronic acid at the nonreducing terminal as an acceptor, The carbohydrate chains as reaction products were determined by high performance liquid chromatography and mass spectrometry, The optimal pH for hydrolysis by the enzyme was found to be about 5.0, whereas that for the transglycosylation reaction was about 7.0. Sodium chloride in the reaction medium inhibited the transglycosylation reaction, Under the optimal conditions, the carbohydrate chains were sequentially transferred along with disaccharide units to the nonreducing terminal of the acceptor and elongated up to docosasaccharide from the acceptor, pyridylaminated hexasaccharide. Using a combination of hyaluronic acid, chondroitin, and chondroitin 4- and B-sulfate as an acceptor and a donor, it was possible to reconstruct hybrid chains, which were natural or unnatural types of glycosaminoglycan chains. Therefore, it is highly likely that application of the transglycosylation reaction using testicular hyaluronidase would facilitate artificial reconstruction of glycosaminoglycans having some physiological functions,	HIROSAKI UNIV, SCH MED, DEPT BIOCHEM, HIROSAKI, AOMORI 036, JAPAN; KUSHIRO JR COLL, KUSHIRO 085, JAPAN	Hirosaki University								ABE J, 1988, CARBOHYD RES, V176, P87, DOI 10.1016/0008-6215(88)84060-6; BARDALES RM, 1989, J BIOL CHEM, V264, P19893; BARRETT AJ, 1972, LYSOSOMES LABORATORY, P110; BORDERS CL, 1968, J BIOL CHEM, V243, P3756; DANISHEF.I, 1966, J BIOL CHEM, V241, P143; GORHAM SD, 1975, CONNECT TISSUE RES, V3, P17, DOI 10.3109/03008207509152337; GOTO F, 1993, PURE APPL CHEM, V65, P793, DOI 10.1351/pac199365040793; HIGHSMITH S, 1975, J BIOL CHEM, V250, P7473; HIMENO M, 1974, J BIOCHEM, V76, P1243, DOI 10.1093/oxfordjournals.jbchem.a130677; HOFFMAN P, 1956, J BIOL CHEM, V219, P653; KANTOR TG, 1957, J AM CHEM SOC, V79, P152, DOI 10.1021/ja01558a040; KNUDSEN PJ, 1980, J CHROMATOGR, V187, P373, DOI 10.1016/S0021-9673(00)80469-0; KON A, 1991, J BIOCHEM-TOKYO, V110, P132, DOI 10.1093/oxfordjournals.jbchem.a123531; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LINKER A, 1956, J BIOL CHEM, V219, P13; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MAJIMA M, 1985, TOHOKU J EXP MED, V146, P83, DOI 10.1620/tjem.146.83; Meyer K, 1971, ENZYMES, P307; NAKAMURA T, 1990, J BIOL CHEM, V265, P5390; NAKAMURA T, 1990, ANAL BIOCHEM, V191, P21, DOI 10.1016/0003-2697(90)90380-R; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; OTOTANI N, 1972, ANAL BIOCHEM, V45, P462; REISSIG JL, 1955, J BIOL CHEM, V217, P959; Roden L, 1989, CIBA F SYMP, P76; SAITO H, 1968, J BIOL CHEM, V243, P1536; TAKAGAKI K, 1994, BIOCHEMISTRY-US, V33, P6503, DOI 10.1021/bi00187a017; TAKAGAKI K, 1992, GLYCOCONJUGATE J, V9, P174, DOI 10.1007/BF00731162; TAKAGAKI K, 1992, J BIOL CHEM, V267, P18558; TAKAGAKI K, 1990, J BIOL CHEM, V265, P854; TAKAGAKI K, 1988, J BIOL CHEM, V263, P7000; USUI T, 1988, BIOCHIM BIOPHYS ACTA, V953, P179, DOI 10.1016/0167-4838(88)90022-2; WEISSMANN B, 1955, J BIOL CHEM, V216, P783	32	90	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3741	3747		10.1074/jbc.270.8.3741	http://dx.doi.org/10.1074/jbc.270.8.3741			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876114	hybrid			2022-12-25	WOS:A1995QH68800044
J	GUVAKOVA, MA; YAKUBOV, LA; VLODAVSKY, I; TONKINSON, JL; STEIN, CA				GUVAKOVA, MA; YAKUBOV, LA; VLODAVSKY, I; TONKINSON, JL; STEIN, CA			PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES BIND TO BASIC FIBROBLAST GROWTH-FACTOR, INHIBIT ITS BINDING TO CELL-SURFACE RECEPTORS, AND REMOVE IT FROM LOW-AFFINITY BINDING-SITES OIL EXTRACELLULAR-MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; ENDOTHELIAL-CELLS; SURAMIN; HEPARIN; OLIGONUCLEOTIDES; TRANSFORMATION; STIMULATION; MECHANISM; MEMBRANE; REVERSAL	We studied the interactions of phosphorothioate oligodeoxynucleotides and heparin-binding growth factors. By means of a gel mobility shift assay, we demonstrated that phosphodiester and phosphorothioate homopolymers bound to basic fibroblast growth factor (bFGF). Binding of a probe phosphodiester oligodeoxynucleotide could also be shown for other proteins of the FGF family, including acidic fibroblast growth factor (aFGF), Kaposi's growth factor (FGF-4) as well as for the bFGF-related vascular endothelial growth factor, VEGF. No binding to epidermal growth factor (EGF) was observed. In addition, using a radioreceptor assay, we have shown that phosphorothioate homopolymers of cytidine and thymidine blocked binding of not only I-125-bFGF, but also of I-125-PDGF to NIH 3T3 cells, whereas phosphodiester oligodeoxynucleotides were ineffective. The extent of blockade of binding was dependent on the chain length of the phosphorothioate oligodeoxynucleotide. Furthermore, we have examined the effects of 18-mer phosphorothioate oligodeoxynucleotides of different sequences on I-125-bFGF binding to low and high affinity sites on both NIR 3T3 fibroblasts and DU-145 prostate cancer cells. Despite the fact that we have observed inhibition of bFGF binding by the 18-mer phosphorothioate oligodeoxynucleotides for both the high and low affinity classes of bFGF receptor, the inhibition was sequence-selective only for the high affinity receptors. We have also demonstrated that phosphorothioate homopolymers of cytidine and thymidine release bFGF bound to low affinity receptors in extracellular matrix (ECM). Finally, the most potent phosphorothioate oligodeoxynucleotides used in these experiments (e.g. SdC28) were inhibitors of bFGF-induced DNA synthesis in NIH 3T3 cells.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; RUSSIAN ACAD SCI,INST CYTOL & GENET,NOVOSIBIRSK 630090,RUSSIA; RUSSIAN ACAD SCI,INST BIOORGAN CHEM,NOVOSIBIRSK 630090,RUSSIA; HADASSAH UNIV HOSP,DEPT ONCOL,IL-91120 JERUSALEM,ISRAEL	Columbia University; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; Hebrew University of Jerusalem								AMALRIC F, 1994, BIOCHEM PHARMACOL, V47, P111, DOI 10.1016/0006-2952(94)90443-X; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; CARDONCARDO C, 1990, LAB INVEST, V63, P832; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; EISENBERGER MA, 1993, J NATL CANCER I, V85, P611, DOI 10.1093/jnci/85.8.611; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GOSPODAROWICZ D, 1977, EXP EYE RES, V25, P75, DOI 10.1016/0014-4835(77)90248-2; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227; KAJIO T, 1992, FEBS LETT, V306, P243, DOI 10.1016/0014-5793(92)81009-B; KNORRE DG, 1985, ADV ENZYME REGUL, V24, P277, DOI 10.1016/0065-2571(85)90082-2; MACIAG T, 1994, RECENT PROG HORM RES, V49, P105; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; PRESTRELSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P314, DOI 10.1016/0003-9861(92)90401-H; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; Sambrook J, 1989, MOL CLONING LABORATO; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; Stein C A, 1993, Antisense Res Dev, V3, P19; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1993, CANCER RES, V53, P2239; STEIN CA, 1989, J CLIN ONCOL, V7, P499, DOI 10.1200/JCO.1989.7.4.499; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; Vlasov V V, 1993, Biokhimiia, V58, P1247; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; WELLSTEIN A, 1991, JNCI-J NATL CANCER I, V83, P716, DOI 10.1093/jnci/83.10.716; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; YAKUBOV L, 1993, J BIOL CHEM, V268, P18818; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZUGMAIER G, 1991, J NATL CANCER I, V84, P1716	38	289	302	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2620	2627		10.1074/jbc.270.6.2620	http://dx.doi.org/10.1074/jbc.270.6.2620			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852327	hybrid			2022-12-25	WOS:A1995QF53500035
J	LAMBETH, JD; KWAK, JY; BOWMAN, EP; PERRY, D; UHLINGER, DJ; LOPEZ, I				LAMBETH, JD; KWAK, JY; BOWMAN, EP; PERRY, D; UHLINGER, DJ; LOPEZ, I			ADP-RIBOSYLATION FACTOR FUNCTIONS SYNERGISTICALLY WITH A 50-KDA CYTOSOLIC FACTOR IN CELL-FREE ACTIVATION OF HUMAN NEUTROPHIL PHOSPHOLIPASE-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHATIDIC-ACID; BINDING PROTEIN; GTP; MEMBRANE; CALCIUM; PHOSPHOHYDROLASE; STIMULATION; INVOLVEMENT; HYDROLYSIS; BRAIN	Proteins in both the cytosol and plasma membrane are needed to reconstitute cell-free phospholipase D activity from phagocytes (Olson, S., Bowman, E. P., and Lambeth, J. D. (1991) J. Biol. Chem. 266, 17236-17242); membrane factors include a small GTP-binding protein in the Rho family (Bowman, E., Uhlinger, D. J., and Lambeth, J. D. (1993) J. Biol. Chem. 268, 21509-21512), ADP-ribosylation factor (ARF) was recently implicated as the cytosolic factor, as it activates phospholipase D in HL-60 membranes, Herein, we show that ion exchange chromatography separates ARF from the major phospholipase D-stimulating cytosolic factor, Both bovine brain ARF and recombinant human ARF-1 stimulated a small amount of phospholipase D activity in the absence of cytosol (about 10% of the response seen with cytosol), With a high concentration of ARF-depleted cytosol, ARF did not further activate, However, at low cytosol, ARF caused marked activation. Thus, ARF synergizes with the cytosolic factor in phospholipase D activation.			LAMBETH, JD (corresponding author), EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA.				NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NCI NIH HHS [CA46508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTHES JC, 1989, BIOCHEM BIOPH RES CO, V163, P657, DOI 10.1016/0006-291X(89)92187-6; ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALSINDE J, 1989, EUR J BIOCHEM, V186, P717, DOI 10.1111/j.1432-1033.1989.tb15265.x; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DEMATTELS MA, 1994, NATURE, V364, P818; HORWITZ J, 1992, J NEUROCHEM, V59, P1474, DOI 10.1111/j.1471-4159.1992.tb08463.x; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KATER LA, 1976, J CLIN INVEST, V57, P1173, DOI 10.1172/JCI108385; KROLL MH, 1989, J CELL PHYSIOL, V139, P558, DOI 10.1002/jcp.1041390315; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MOOLENAAR WH, 1991, ADV CANCER RES, V57, P87; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NELSON DH, 1986, BIOCHEM BIOPH RES CO, V138, P463, DOI 10.1016/0006-291X(86)90303-7; NODA M, 1989, BIOCHEMISTRY-US, V28, P7936, DOI 10.1021/bi00445a057; OHSAKO S, 1981, J BIOL CHEM, V256, P945; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PERRY DK, 1992, J IMMUNOL, V149, P2749; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; SAITO M, 1975, ARCH BIOCHEM BIOPHYS, V169, P318, DOI 10.1016/0003-9861(75)90346-X; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768	31	63	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2431	2434		10.1074/jbc.270.6.2431	http://dx.doi.org/10.1074/jbc.270.6.2431			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852301	hybrid			2022-12-25	WOS:A1995QF53500006
J	GAVALAS, A; ZALKIN, H				GAVALAS, A; ZALKIN, H			ANALYSIS OF THE CHICKEN GPAT AIRC BIDIRECTIONAL PROMOTER FOR DE-NOVO PURINE NUCLEOTIDE SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE GENE; DIVERGENT TRANSCRIPTS; BINDING PROTEINS; EXPRESSION; INITIATOR; SEQUENCE; IDENTIFICATION; EFFICIENT; COLLAGEN; UPSTREAM	GPAT and AIRC encode two enzymes that catalyze steps 1 and 6 plus 7, respectively, of the de novo purine biosynthetic pathway. The chicken genes are closely linked and divergently transcribed from an similar to 230-base pair intergenic region, The promoter was scanned by deletion mutagenesis in a bireporter vector that allowed assay of transcriptional activity in both directions in transfected HepG2 and chicken LMH cells, Three classes of deletions were obtained: those affecting bidirectional transcription, those predominantly affecting GPAT transcription, and those predominantly affecting AIRC transcription, Defects in bidirectional transcription resulted from removal of an initiator-like element overlapping the AIRC transcription start site, as well as deletions removing a series of GC and CCAAT boxes from the AIRC proximal half of the promoter and a CCAAT-containing segment from the GPAT side. Several regions in the GPAT proximal half of the promoter, including an octamer-like motif downstream from the transcription start site, were required predominantly for GPAT expression. Evidence for interaction of HeLa nuclear proteins with some of these sites was obtained by gel retardation, DNase I, and methylation interference assays. Overall, the results showed that the intergenic region is an integrated bidirectional promoter and that a novel initiator-like element plays a central role in coordinating expression of the divergently transcribed AIRC and GPAT genes.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus			Gavalas, Anthony/F-5817-2015	Gavalas, Anthony/0000-0003-4897-0359	NIDDK NIH HHS [DK20524] Funding Source: Medline; NIGMS NIH HHS [GM46466] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BARTON JW, 1991, GENOMICS, V9, P314, DOI 10.1016/0888-7543(91)90259-H; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAYTON KA, 1994, J BIOL CHEM, V269, P5313; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHANG Y, 1991, ONCOGENE, V6, P1979; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COLOMBO P, 1992, P NATL ACAD SCI USA, V89, P6358, DOI 10.1073/pnas.89.14.6358; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUJII H, 1992, FEBS LETT, V314, P33, DOI 10.1016/0014-5793(92)81455-U; GAVALAS A, 1993, MOL CELL BIOL, V13, P4784, DOI 10.1128/MCB.13.8.4784; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HENTSCHEL CC, 1981, CELL, V25, P301, DOI 10.1016/0092-8674(81)90048-9; HERR W, 1992, TRANSCRIPTIONAL REGU, V1, P1103; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; NGUYEN QT, 1991, NUCLEIC ACIDS RES, V19, P5339, DOI 10.1093/nar/19.19.5339; RIZZO MG, 1990, EXP CELL RES, V188, P286, DOI 10.1016/0014-4827(90)90172-7; SAFFER JD, 1984, NUCLEIC ACIDS RES, V12, P4769, DOI 10.1093/nar/12.11.4769; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILLING LJ, 1989, MOL CELL BIOL, V9, P4568, DOI 10.1128/MCB.9.10.4568; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHIMADA T, 1989, J BIOL CHEM, V264, P20171; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOININEN R, 1988, J BIOL CHEM, V263, P17217; TSUI HW, 1993, GENE, V131, P201, DOI 10.1016/0378-1119(93)90294-D; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WINGENDER E, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P11	35	35	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2403	2410		10.1074/jbc.270.5.2403	http://dx.doi.org/10.1074/jbc.270.5.2403			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836476	hybrid			2022-12-25	WOS:A1995QE49300064
J	MOLINARI, M; ANAGLI, J; CARAFOLI, E				MOLINARI, M; ANAGLI, J; CARAFOLI, E			PEST SEQUENCES DO NOT INFLUENCE SUBSTRATE SUSCEPTIBILITY TO CALPAIN PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTES; DOMAIN; ENZYME; PUMP; PROTEINS; SITE	Mutations lowering the PEST score of domains surrounding the calmodulin (CaM)-binding region of the plasma membrane Ca2+-ATPase failed to influence the susceptibility of the enzyme to mu-calpain (mu-CANP). Synthetic peptides corresponding to the high PEST score C-terminal sequences A18 and B28 had no effect on the rate of pump proteolysis by mu-CANP, i,e, the peptides did not compete for a putative high PEST score recognition site for mu-CANP in the pump molecule. An accessible CaM-binding region appears to be critical for substrate (i.e, the Ca2+ pump) proteolysis and probably also for its recognition by mu-CANP; phosphorylation of the CaM-binding domain of the pump or its occupation by CaM significantly decreased the rate of proteolysis.	ETH ZURICH, INST BIOCHEM 3, CH-8092 ZURICH, SWITZERLAND	ETH Zurich			Molinari, Maurizio/N-2587-2019; Carafoli, Ernesto/K-5192-2016	Molinari, Maurizio/0000-0002-7636-5829; Carafoli, Ernesto/0000-0002-7826-0094				CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CONG JY, 1989, J BIOL CHEM, V264, P10096; CONG JY, 1993, J BIOL CHEM, V268, P25740; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; MELLONI E, 1982, BIOCHEM BIOPH RES CO, V106, P731, DOI 10.1016/0006-291X(82)91772-7; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; PONTREMOLI S, 1988, BIOCHEM BIOPH RES CO, V157, P867, DOI 10.1016/S0006-291X(88)80955-0; PONTREMOLI S, 1985, BIOCHEM INT, V11, P35; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693	21	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2032	2035		10.1074/jbc.270.5.2032	http://dx.doi.org/10.1074/jbc.270.5.2032			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836429	hybrid			2022-12-25	WOS:A1995QE49300010
J	ALVES, F; VOGEL, W; MOSSIE, K; MILLAUER, B; HOFLER, H; ULLRICH, A				ALVES, F; VOGEL, W; MOSSIE, K; MILLAUER, B; HOFLER, H; ULLRICH, A			DISTINCT STRUCTURAL CHARACTERISTICS OF DISCOIDIN-I SUBFAMILY RECEPTOR TYROSINE KINASES AND COMPLEMENTARY EXPRESSION IN HUMAN CANCER	ONCOGENE			English	Note						RECEPTOR TYROSINE KINASE; SIGNAL TRANSDUCTION; DISCOIDIN I MOTIF; SH3 BINDING SITE; TUMOR INVASION	GROWTH-FACTOR RECEPTOR; BINDING; DOMAIN; IDENTIFICATION; MOLECULE; FAMILY; SIGNAL; CELLS; ACID	Mammary carcinoma kinase 10 (MCK-10) and colon carcinoma kinase 2 (CCK-2) constitute a subclass of receptor tyrosine kinases characterized by a discoidin I motif in the extracellular domain and a large cytoplasmic juxtamembrane (JM) region. While the ectodomain structure suggests a common role in cell aggregation, the JM domains of MCK-10 and CCK-2 are structurally most divergent and display features that suggest an involvement in signal generation and definition. MCK-10 occurs in at least three isoforms, which contain alternatively spliced consensus sequences for internalization and SH3 domain interaction. The presence of the 37 amino acid insert affects receptor autophosphorylation and changes ectodomain glycosylation. Proteolytic cleavage within the extracellular domain of MCK-10 generates a membrane-anchored kinase domain and releases a soluble ectodomain fragment including the discoidin I homology domain. CCK-2 and MCK-10 expression was found in connective and epithelial tissues, respectively, which in cancers of epithelial origin results in mutually exclusive expression in stroma and tumor cells, indicating a possible involvement of this class of RTKs in tumor invasion.	MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY; SUGEN INC, DEPT MOLEC BIOL, REDWOOD CITY, CA 94063 USA; TECH UNIV MUNICH, KLINIKUM RECHTS ISAR, INST ALLGEMEINE & PATHOL ANAT, D-81675 MUNICH, GERMANY	Max Planck Society; Technical University of Munich								ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAUDE P, 1973, J CELL BIOL, V58, P390, DOI 10.1083/jcb.58.2.390; DIMARCO E, 1993, J BIOL CHEM, V268, P24290; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENDLY BM, 1990, CANCER RES, V50, P1550; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KARN T, 1993, ONCOGENE, V8, P3433; LAI C, 1994, ONCOGENE, V9, P877; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEREZ JL, 1994, ONCOGENE, V9, P211; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZERLIN M, 1993, ONCOGENE, V8, P2731; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	211	219	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					609	618						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845687				2022-12-25	WOS:A1995QF64800023
J	FIXMAN, ED; NAUJOKAS, MA; RODRIGUES, GA; MORAN, MF; PARK, M				FIXMAN, ED; NAUJOKAS, MA; RODRIGUES, GA; MORAN, MF; PARK, M			EFFICIENT CELL-TRANSFORMATION BY THE TPR-MET ONCOPROTEIN IS DEPENDENT UPON TYROSINE-489 IN THE CARBOXY-TERMINUS	ONCOGENE			English	Article						MET; ONCOPROTEIN; CELL TRANSFORMATION; SUBSTRATES; TYROSINE PHOSPHORYLATION	HEPATOCYTE GROWTH-FACTOR; PAPILLARY THYROID CARCINOMAS; GUANINE-NUCLEOTIDE EXCHANGE; SCATTER FACTOR-RECEPTOR; PHOSPHOLIPASE-C-GAMMA; GRB2 ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; KINASE-ACTIVITY; SH3 DOMAINS	The receptor for hepatocyte growth factor/scatter factor (HGF/SF) was originally identified as an oncogene, Tpr-Met, which consists of the cytoplasmic tyrosine kinase domain of the HGF/SF receptor (Met) fused downstream of sequences encoded by the tpr gene. As a consequence of this rearrangement the Tpr-Met fusion oncoprotein is localized to the cytoplasm and is a constitutively activated kinase. To identify signalling pathways important for Tpr-Met-mediated cell transformation we have generated tyrosine to phenylalanine mutants of Tpr-Met that are compromised in their ability to transform Fischer rat 3T3 (Fr3T3) cells in culture, We show that a single tyrosine residue in the carboxy terminus of Tpr-Met (residue 489) is essential for efficient transformation of Fr3T3 cells by this oncoprotein, Mutation of tyrosine 489 to phenylalanine does not affect the exogenous kinase activity of the Tpr-Met oncoprotein toward casein, but it impairs the ability of the mutant protein to bind to and activate phosphatidylinositol 3 kinase in vivo and completely abolishes the in vivo association with the Grb2 adaptor protein as well as the association and/or phosphorylation of an unknown protein of 110 kDa, These data are consistent with a single tyrosine residue in the Tpr-Met oncoprotein being essential for the activation of several signalling pathways which lead to the transformation of Fr3T3 fibroblasts.	MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT MED, MOLEC ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT ONCOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT BIOCHEM, MONTREAL, PQ H3A 1A1, CANADA; UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; University of Toronto			Moran, Michael/GYD-3631-2022					ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BEAR SE, 1989, P NATL ACAD SCI USA, V63, P2959; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; CROWE AJ, 1994, ONCOGENE, V9, P537; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FALETTO DL, 1993, SIGNAL TRANSDUCTION, P108; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GIORDANO S, 1989, ONCOGENE, V4, P1383; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GRECO A, 1992, ONCOGENE, V7, P237; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HALABAN R, 1992, ONCOGENE, V7, P2195; HARLOW E, 1988, ANTIBODIES LABORATOR; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; KAZKAUSKAS A, 1992, MOL CELL BIOL, V12, P2534; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANZI C, 1992, ONCOGENE, V7, P2189; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LONGATI P, 1994, ONCOGENE, V9, P49; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359	79	81	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					237	249						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838524				2022-12-25	WOS:A1995QC62400003
J	CHANMUGAM, P; FENG, LL; LIOU, SE; JANG, BOC; BOUDREAU, M; YU, G; LEE, JH; KWON, HJ; BEPPU, T; YOSHIDA, M; XIA, YY; WILSON, CB; HWANG, D				CHANMUGAM, P; FENG, LL; LIOU, SE; JANG, BOC; BOUDREAU, M; YU, G; LEE, JH; KWON, HJ; BEPPU, T; YOSHIDA, M; XIA, YY; WILSON, CB; HWANG, D			RADICICOL, A PROTEIN-TYROSINE KINASE INHIBITOR, SUPPRESSES THE EXPRESSION OF MITOGEN-INDUCIBLE CYCLOOXYGENASE IN MACROPHAGES STIMULATED WITH LIPOPOLYSACCHARIDE AND IN EXPERIMENTAL GLOMERULONEPHRITIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; MESSENGER-RNA; SIGNAL TRANSDUCTION; COMPLEMENTARY-DNA; G/H SYNTHASE; HERBIMYCIN-A; SRC-FAMILY; GENE; PHOSPHORYLATION; CELLS	Two isoforms of cyclooxygenase (COX) have been identified in eukaryotic cells: a constitutively expressed COX-1 and mitogen-inducible COX-2, which is selectively expressed in response to various inflammatory stimuli. Thus, COX-2 instead of COX-1 is implicated to produce prostanoids mediating inflammatory responses. Major efforts have been focused on identifying nonsteroidal anti inflammatory drugs (NSAIDS) which can selectively inhibit the enzyme activity of COX-2. Such NSAlDS would be more desirable anti-inflammatory agents in comparison to NSAIDS which inhibit both COX-1 and COX-2. Other than glucocorticoids, pharmacological agents which can selectively suppress the expression of COX-2 without affecting that of COX-1 have not been identified. We report here that radicicol, a fungal antibiotic, is a potent protein tyrosine kinase inhibitor, and that it inhibits the expression of COX-2 without affecting COX-1 expression in lipopolysaccharide (LPS)-stimulated macrophages with the IC50 value of 27 nM. Radicicol inhibited tyrosine phosphorylation of p53/56(lyn), a Src family tyrosine kinase and one of the major tyrosine-phosphorylated proteins in LPS-stimulated macrophages. Radicicol also inhibited COX-2 expression in vivo in glomeruli of rats with experimental glomerulonephritis induced by the anti-glomerular basement membrane antibodies, in which COX-2 expression is known to be enhanced. The enzyme activity of COX-1 or COX-2 was not affected by radicicol in macrophages. Radicicol also suppressed the COX-2 expression induced by IL-1(beta) in rat smooth muscle cells. Other protein tyrosine kinase inhibitors suppressed the LPS-induced COX-2 expression in macrophages but at much higher concentrations than needed for radicicol. Radicicol did not inhibit the COX-2 expression induced by phorbol 12-myristate 13-acetate in macrophages. These results suggest that the activation of tyrosine-specific protein kinases is the proximal obligatory step in the LPS-induced signal transduction pathway leading to the induction of COX-2 expression in macrophages. The magnitude of the inhibition of COX-2 protein synthesis by radicicol was much greater than that of the steady state levels of COX-2 mRNA. These results suggest that radicicol inhibits COX-2 expression mainly at post-transcriptional steps.	LOUISIANA STATE UNIV, PENNINGTON BIOMED RES CTR, BATON ROUGE, LA 70808 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV TOKYO, DEPT BIOTECHNOL, TOKYO 113, JAPAN	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Scripps Research Institute; University of Tokyo			권, 호정/AAS-3642-2021; Boudreau, Mary/E-4721-2015; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674	NIDDK NIH HHS [R01 DK-41868, R01 DK-20043] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041868, R01DK020043] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BLANTZ RC, 1976, J CLIN INVEST, V58, P899, DOI 10.1172/JCI108543; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; CHANDLER DB, 1987, J IMMUNOL, V139, P893; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELMOTTE P, 1953, NATURE, V171, P344, DOI 10.1038/171344a0; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; Feng L., 1993, Journal of the American Society of Nephrology, V4, P452; FENG L, 1995, IN PRESS J CLIN INVE; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; GLASER KB, 1990, J BIOL CHEM, V265, P8658; HAN JH, 1993, J BIOL CHEM, V268, P25009; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JONES DA, 1993, J BIOL CHEM, V268, P9049; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; KWON HJ, 1992, CANCER RES, V52, P6926; LEE SH, 1992, J BIOL CHEM, V267, P25934; McCAPRA FRANK, 1964, TETRAHEDRON LETT, V15/16, P869; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIRRINGTON RN, 1964, TETRAHEDRON LETT, V7, P365; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; NOZAWA K, 1979, J NAT PROD, V42, P374, DOI 10.1021/np50004a004; OBANION MK, 1991, J BIOL CHEM, V266, P23261; POWELL WS, 1982, METHOD ENZYMOL, V86, P467; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WHITTLE BJR, 1980, NATURE, V284, P271, DOI 10.1038/284271a0; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	40	123	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5418	5426		10.1074/jbc.270.10.5418	http://dx.doi.org/10.1074/jbc.270.10.5418			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890656	hybrid			2022-12-25	WOS:A1995QL58000072
J	KURACHI, S; HITOMI, Y; FURUKAWA, M; KURACHI, K				KURACHI, S; HITOMI, Y; FURUKAWA, M; KURACHI, K			ROLE OF INTRON-I IN EXPRESSION OF THE HUMAN FACTOR-IX GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOPHILIA-B LEYDEN; TRANSGENIC MICE; NUCLEOTIDE-SEQUENCE; BINDING-SITE; PLASMID DNA; PROMOTER; CELLS; DISRUPTION; EFFICIENCY; ELEMENT	The first intron (intron I) of the human factor IX gene, which has been previously suggested of having an expression-augmenting activity, was systematically studied for its potential enhancer activity. When tested with the chloramphenicol acetyltransferase expression vector with a minimal factor IX promoter, subregions of intron I showed only marginal enhancing activities (1.7-1.9-fold enhancement at the highest). Smaller subregions encompassing nucleotides 5660-6350 of the intron sequence even showed some weak negative regulatory activities (similar to 50% suppression at the highest), while a cytomegalovirus enhancer sequence, which was used as the positive control, had a 7-fold enhancement. A set of three factor IX minigene expression vectors with the same factor IX promoter were then constructed: p-416FIXc which contained the factor IX cDNA, p-416FIXm1 which contained the factor IX cDNA with a largely truncated intron I, and p-416FIXm2 which contained the factor IX cDNA with the intron I sequence further truncated. The p-416FIXm1 and p-416FIXm2 constructs showed 7-9-fold higher expression activities than p-416FIXc. The elevated factor IX antigen levels agreed well with the grossly elevated factor IX clotting activity and mRNA levels. These results indicate that the expression enhancing activity of intron I is not due to specific enhancer elements present in the intron subsequences, but is due to functional splicing sequences present in the precursor mRNAs produced from the minigene constructs containing intron I. By being efficiently assembled into spliceosome complexes, transcripts with splicing sequences may be better protected in the nucleus from random degradations than those without such sequences.	UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038644] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00042] Funding Source: Medline; NHLBI NIH HHS [HL38644] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austen D, 1975, LAB MANUAL BLOOD COA, P59; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BRIET E, 1982, NEW ENGL J MED, V306, P788, DOI 10.1056/NEJM198204013061306; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P4395, DOI 10.1128/MCB.8.10.4395; BUSBY S, 1985, NATURE, V316, P271, DOI 10.1038/316271a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; HIROSAWA S, 1990, P NATL ACAD SCI USA, V87, P4421, DOI 10.1073/pnas.87.12.4421; JALLAT S, 1990, EMBO J, V9, P3295, DOI 10.1002/j.1460-2075.1990.tb07529.x; KORB M, 1993, NUCLEIC ACIDS RES, V21, P5901, DOI 10.1093/nar/21.25.5901; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; KURACHI K, 1993, BLOOD COAGUL FIBRIN, V4, P953, DOI 10.1097/00001721-199304060-00013; KURACHI S, 1994, BIOCHEMISTRY-US, V33, P1580, DOI 10.1021/bi00172a039; LAMOND AI, 1993, BIOESSAYS, V15, P595, DOI 10.1002/bies.950150905; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PICKETTS DJ, 1993, NAT GENET, V3, P175, DOI 10.1038/ng0293-175; REIJNEN MJ, 1993, BLOOD, V82, P151, DOI 10.1182/blood.V82.1.151.bloodjournal821151; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; STERNER DA, 1993, MOL CELL BIOL, V13, P2677, DOI 10.1128/MCB.13.5.2677; YAO SN, 1991, P NATL ACAD SCI USA, V88, P8101, DOI 10.1073/pnas.88.18.8101; YAO SN, 1992, BIOTECHNIQUES, V12, P525; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	29	82	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5276	5281		10.1074/jbc.270.10.5276	http://dx.doi.org/10.1074/jbc.270.10.5276			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890639	hybrid			2022-12-25	WOS:A1995QL58000051
J	DREWETT, JG; FENDLY, BM; GARBERS, DL; LOWE, DG				DREWETT, JG; FENDLY, BM; GARBERS, DL; LOWE, DG			NATRIURETIC PEPTIDE RECEPTOR-B (GUANYLYL CYCLASE-B) MEDIATES C-TYPE NATRIURETIC PEPTIDE RELAXATION OF PRECONTRACTED RAT AORTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; MICROBIAL ORIGIN; SMOOTH-MUSCLE; 2ND MESSENGER; ATRIAL; ACTIVATION; ANTAGONIST; EXPRESSION; INHIBITION; HS-142-1	The most potent known agonist for the natriuretic peptide receptor-B (NPR-B)/guanylyl cyclase-B is C-type natriuretic peptide (CNP). A homologous ligand-receptor system consists of atrial natriuretic peptide (ANP) and NPR-A/guanylyl cyclase-A A third member of this family is NPR-C, a non-guanylyl cyclase receptor. Monoclonal antibodies were raised against NPR-B by immunizing mice with a purified receptor-IgG fusion protein consisting of the extracellular domain of NPR-B and the Pc portion of human IgG-gamma(1). One monoclonal antibody, 3G12, did not recognize NPR-A or NPR-C and bound to human and rat NPR-B. CNP binding to NPR-B and stimulation of cGMP synthesis were inhibited by 3G12. With cells isolated from either the media or adventitia layers of rat thoracic aorta, 3G12 did not interfere with ANP-stimulated cGMP synthesis, but it inhibited CNP-stimulated cGMP levels in cells from both layers. CNP (IC50 = 10 nM) and ANP (IC50 = 1 nM) caused relaxation of phenylephrine-contracted rat aortic rings. 3G12 caused a marked increase in the IC50 for CNP, from 10 nM to 140 nM, but failed to affect ANP-mediated relaxation. Therefore, our results for the first time demonstrate that CNP relaxes vascular smooth muscle by virtue of its binding to NPR-B.	GENENTECH INC, DEPT CARDIOVASC RES, S SAN FRANCISCO, CA 94080 USA; MED COLL WISCONSIN, DEPT PHARMACOL & TOXICOL, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, CARDIOVASC RES CTR, MILWAUKEE, WI 53226 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Roche Holding; Genentech; Medical College of Wisconsin; Medical College of Wisconsin; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BOND JS, 1989, PROTEOLYTIC ENZYMES, P241; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; DEAN AD, 1994, AM J PHYSIOL, V266, pF491, DOI 10.1152/ajprenal.1994.266.3.F491; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DELPORTE C, 1992, EUR J PHARMACOL, V224, P183, DOI 10.1016/0014-2999(92)90803-C; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DREWETT JG, 1989, J PHARMACOL EXP THER, V248, P135; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURUYA M, 1993, BIOCHEM BIOPH RES CO, V193, P248, DOI 10.1006/bbrc.1993.1616; GUTKOWSKA J, 1989, ENDOCR REV, V10, P519, DOI 10.1210/edrv-10-4-519; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P1447; HUANG CL, 1986, P NATL ACAD SCI USA, V83, P8015, DOI 10.1073/pnas.83.20.8015; IMURA R, 1992, MOL PHARMACOL, V42, P982; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; LIGHT DB, 1989, SCIENCE, V243, P383, DOI 10.1126/science.2463673; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWE DG, 1990, NUCLEIC ACIDS RES, V18, P3412, DOI 10.1093/nar/18.11.3412; LOWE DG, 1992, J BIOL CHEM, V267, P21691; LUCAS C, 1990, J IMMUNOL, V145, P1415; MAACK T, 1986, BIOCHEM PHARMACOL, V35, P2057, DOI 10.1016/0006-2952(86)90570-8; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MAYER B, 1993, BIOCHEM PHARMACOL, V45, P367, DOI 10.1016/0006-2952(93)90072-5; MORISHITA Y, 1991, BIOCHEM BIOPH RES CO, V176, P949, DOI 10.1016/0006-291X(91)90374-G; NAKAMURA M, 1994, CIRCULATION, V90, P1210, DOI 10.1161/01.CIR.90.3.1210; OHYAMA Y, 1992, BIOCHEM BIOPH RES CO, V189, P336, DOI 10.1016/0006-291X(92)91563-6; RICHARD V, 1990, AM J PHYSIOL, V259, pH1433, DOI 10.1152/ajpheart.1990.259.5.H1433; SALVESEN G, 1989, PROTEOLYTIC ENZYMES, P98; SANO T, 1992, J PHARMACOL EXP THER, V260, P825; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; STANTON BA, 1991, CAN J PHYSIOL PHARM, V69, P1546, DOI 10.1139/y91-230; STEVENS TL, 1994, HYPERTENSION, V23, P613, DOI 10.1161/01.HYP.23.5.613; STINGO AJ, 1992, AM J PHYSIOL, V262, pH308, DOI 10.1152/ajpheart.1992.262.1.H308; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; SUGA SI, 1992, CIRC RES, V71, P34, DOI 10.1161/01.RES.71.1.34; TAWARAGI Y, 1990, BIOCHEM BIOPH RES CO, V172, P627, DOI 10.1016/0006-291X(90)90720-8; VONGELDERN TW, 1990, MOL PHARMACOL, V38, P771; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; WEI CM, 1993, AM J PHYSIOL, V264, pH71	49	77	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4668	4674		10.1074/jbc.270.9.4668	http://dx.doi.org/10.1074/jbc.270.9.4668			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876238	hybrid			2022-12-25	WOS:A1995QK08400072
J	FERRO, KL; COLLINS, CA				FERRO, KL; COLLINS, CA			MICROTUBULE-INDEPENDENT PHOSPHOLIPID STIMULATION OF CYTOPLASMIC DYNEIN ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN ATPASE; VESICLE TRANSPORT; ACTIVATED ATPASE; ADP RELEASE; MYOSIN-I; BINDING; PROTEIN; PHOSPHORYLATION; ACTIN; HEAVY	In this study we report that phospholipid vesicles activate ATP hydrolysis by cytoplasmic dynein but not kinesin, consistent with reported differences in the organelle/vesicle binding of these motor proteins, Dynein activation by phospholipids was comparable with that seen in the presence of microtubules but was not sensitive to moderate salt concentrations and was independent of the net charge of the phospholipid, suggesting that the means of interaction between dynein and the lipid vesicle was not strictly ionic in nature, Based on this result, previous data that show that the interaction between dynein and vesicles is not ATP sensitive, and the concentration dependence observed for lipid activation of cytoplasmic dynein, it is likely that the binding interaction between dynein and liposomes is a stable one, In contrast to a previous report, microtubules increased the hydrolysis rate of all naturally occurring nucleotides tested, whereas only ATPase activity was stimulated by phospholipids. As ATP is the physiologically relevant substrate and is the only nucleotide to promote motility, the activation of only the ATPase by phospholipids may represent a means of discriminating between coupled and uncoupled nucleotide hydrolysis in vitro.			FERRO, KL (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MOLEC & CELL BIOL, CHICAGO, IL 60611 USA.							ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; ALLAN VJ, 1991, J CELL BIOL, V113, P347, DOI 10.1083/jcb.113.2.347; COHN SA, 1987, NATURE, V328, P160, DOI 10.1038/328160a0; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GRISSOM PM, 1992, CELL MOTIL CYTOSKEL, V21, P281, DOI 10.1002/cm.970210404; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; HOLZBAUR ELF, 1989, BIOCHEMISTRY-US, V28, P7010, DOI 10.1021/bi00443a034; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; LACEY ML, 1992, J BIOL CHEM, V267, P4793; LACEY ML, 1994, CELL MOTIL CYTOSKEL, V28, P205, DOI 10.1002/cm.970280304; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIN SXH, 1993, J CELL SCI, V105, P579; LIN SXH, 1992, J CELL SCI, V101, P125; LIN SXH, 1991, J CELL BIOL, V115, P168; LYE RJ, 1987, CELL, V51, P309, DOI 10.1016/0092-8674(87)90157-7; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; NEELY MD, 1990, J BIOL CHEM, V265, P8691; NEELY MD, 1988, J CELL BIOL, V107, P1767, DOI 10.1083/jcb.107.5.1767; PALLINI V, 1983, J SUBMICR CYTOL PATH, V15, P229; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SADHU A, 1992, J BIOL CHEM, V267, P11352; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SCHNAPP BJ, 1992, J CELL BIOL, V119, P389, DOI 10.1083/jcb.119.2.389; SCHROEDER CC, 1990, J CELL BIOL, V111, P2553, DOI 10.1083/jcb.111.6.2553; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; SHIMIZU T, 1992, EUR J BIOCHEM, V206, P911, DOI 10.1111/j.1432-1033.1992.tb17000.x; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VALE RD, 1992, J CELL BIOL, V119, P1589, DOI 10.1083/jcb.119.6.1589; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; YU H, 1992, J BIOL CHEM, V267, P20457; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	47	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4492	4496		10.1074/jbc.270.9.4492	http://dx.doi.org/10.1074/jbc.270.9.4492			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876216	hybrid			2022-12-25	WOS:A1995QK08400049
J	YU, G; SHEN, FS; STURCH, S; AQUINO, A; GLAZER, RI; FELSTED, RL				YU, G; SHEN, FS; STURCH, S; AQUINO, A; GLAZER, RI; FELSTED, RL			REGULATION OF HIV-1 GAG PROTEIN SUBCELLULAR TARGETING BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MATRIX PROTEIN; STRUCTURAL PROTEINS; MEMBRANE ASSOCIATION; FINE-STRUCTURE; D RETROVIRUSES; LIFE-CYCLE; TYPE-1; CELLS; PRECURSOR	The human immunodeficiency virus type 1 internal structural protein precursor, p55, and its corresponding matrix proteolytic fragment, p17, are phosphorylated at Ser(111) by protein kinase C. COS-7 cells transfected with plasmids encoding either the wild-type or Ser(111) --> Ala mutated human immunodeficiency virus type 1 gag gene matrix domain proteins were treated with phorbol 12-myristate 13-acetate (PMA), and the phosphorylation of the expressed p17 proteins was examined by radioimmunoprecipitation, SDS-polyacrylamide gel electrophoresis, and autoradiography, PMA treatment of transfected cells resulted in a 4-5-fold increase in wild-type p17 (but not mutated p17) phosphorylation; however, mutated p17 exhibited a low basal level of phosphorylation that was not affected by PMA, suggesting that additional sites were phosphorylated, PMA treatment of cells expressing wild-type p17 produced a dramatic shift in the localization of p17 from the cytosol to the membrane fraction within 8-15 min, followed by a slow quantitative dissociation of p17 back into the cytosol by 90 min, The cytosol-to-membrane translocation was dependent on N-myristoylated p17 since cells expressing p17 with a Gly(2) --> Ala mutation did not localize to the membrane, PMA also failed to induce the translocation of fully N-myristoylated Ser(111) --> Ala p17, suggesting that p17 phosphorylation at Ser(111) was responsible for membrane association, This conclusion was confirmed by the finding of phosphorylated wild-type p17 in the membrane fraction only after PMA treatment, These results suggest that a ''myristoyl-protein switch'' regulates the reversible membrane targeting of p17 by protein kinase C-mediated phosphorylation. This signal may provide a mechanism for the cellular regulation of virus development through modulation of gag protein-related developmental steps such as capsid targeting, assembly, encapsidation, budding, and maturation.	NCI,DIV CANC TREATMENT,BIOL CHEM LAB,DEV THERAPEUT PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BIEMANS R, 1992, AIDS, V6, P541, DOI 10.1097/00002030-199206000-00003; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; BURNETTE B, 1993, J BIOL CHEM, V268, P8698; CANN AJ, 1989, AIDS, V3, pS19, DOI 10.1097/00002030-198901001-00004; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DELCHAMBRE M, 1989, EMBO J, V8, P2653, DOI 10.1002/j.1460-2075.1989.tb08405.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORFMAN T, 1994, J VIROL, V68, P1689, DOI 10.1128/JVI.68.3.1689-1696.1994; FELSTED RL, 1989, DEV CANCER CHEMOTHER, V2, P95; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; GELDERBLOM HR, 1988, MICRON MICROSC ACTA, V19, P41, DOI 10.1016/0739-6260(88)90039-1; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GOWDA SD, 1989, J VIROL, V63, P1451, DOI 10.1128/JVI.63.3.1451-1454.1989; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES TA, 1990, J VIROL, V64, P2265, DOI 10.1128/JVI.64.5.2265-2279.1990; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARX PA, 1988, LAB INVEST, V58, P112; MYERS G, 1990, HUMAN RETROVIRUSES A; PAPSIDERO LD, 1989, J VIROL, V63, P267, DOI 10.1128/JVI.63.1.267-272.1989; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; RHEE SS, 1991, EMBO J, V10, P535, DOI 10.1002/j.1460-2075.1991.tb07980.x; RHEE SS, 1990, J VIROL, V64, P4383, DOI 10.1128/JVI.64.9.4383-4389.1990; RHEE SS, 1990, CELL, V63, P77, DOI 10.1016/0092-8674(90)90289-Q; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; YU XF, 1992, J VIROL, V66, P4966, DOI 10.1128/JVI.66.8.4966-4971.1992; YU XF, 1992, J VIROL, V66, P5667, DOI 10.1128/JVI.66.9.5667-5670.1992; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	39	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4792	4796		10.1074/jbc.270.9.4792	http://dx.doi.org/10.1074/jbc.270.9.4792			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876252	hybrid			2022-12-25	WOS:A1995QK08400088
J	FLORDELLIS, CS; BERGUERAND, M; GOUACHE, P; BARBU, V; GAVRAS, H; HANDY, DE; BEREZIAT, G; MASLIAH, J				FLORDELLIS, CS; BERGUERAND, M; GOUACHE, P; BARBU, V; GAVRAS, H; HANDY, DE; BEREZIAT, G; MASLIAH, J			ALPHA(2) ADRENERGIC-RECEPTOR SUBTYPES EXPRESSED IN CHINESE-HAMSTER OVARY CELLS ACTIVATE DIFFERENTIALLY MITOGEN-ACTIVATED PROTEIN-KINASE BY A P21(RAS) INDEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; ALPHA-2-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; MAP KINASE; ALPHA-2B-ADRENERGIC RECEPTOR; ALPHA(2)-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; RAT-TISSUES; FIBROBLASTS; STIMULATION	Epinephrine stimulation of rat alpha(2D), alpha(2B), and alpha(2C) adrenergic receptor subtypes, expressed stably in Chinese hamster ovary (CHO) cells, caused a rapid, transient activation of mitogen-activated protein kinase (MAPK), with subtype-specific different efficiencies. The order of activation was CHO-2B similar to CHO-2D >> CHO-2C. Pertussis toxin blocked the stimulation of MAPK enzymatic activity and the parallel MAPK phosphorylation, demonstrating that these responses are mediated by pertussis toxin-sensitive G(i) proteins. Contrary to what has been reported for the alpha(2A) subtype expressed in rat-1 fibroblasts, epinephrine did not cause any detectable activation of p21(ras) in the CHO transfectants. Furthermore, combined application of epinephrine and phorbol myristate acetate had a potent cooperative but not additive effect in clones CHO-2D and CHO-2B but not in CHO-2C, suggesting that protein kinase C is probably differently involved in the signaling by the three alpha(2) receptor subtypes. These results show that in CHO cells, the different alpha(2) adrenergic receptor subtypes utilize differential pathways to activate MAPK in a p21(ras)-independent way.	CHU ST ANTOINE,BIOCHEM LAB,F-75571 PARIS 12,FRANCE; BOSTON UNIV,SCH MED,HYPERTENS & ATHEROSCLEROSIS SECT,BOSTON,MA 02118	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Boston University	FLORDELLIS, CS (corresponding author), CHU ST ANTOINE,CNRS,URA 1283,27 RUE CHALIGNY,F-75571 PARIS 12,FRANCE.			Handy, Diane/0000-0002-4310-8527				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BARBU V, 1993, EXP CLIN ENDOCRINOL, V101, P84; BARONDELAGE S, 1994, J BIOL CHEM, V269, P18686; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRESNAHAN MR, 1990, BIOCHIM BIOPHYS ACTA, V1052, P439, DOI 10.1016/0167-4889(90)90153-5; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BYLUND DB, 1992, FASEB J, V6, P832, DOI 10.1096/fasebj.6.3.1346768; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1992, J BIOL CHEM, V267, P15795; FLORDELLIS CS, 1990, HYPERTENSION, V15, P881, DOI 10.1161/01.HYP.15.6.881; FLORDELLIS CS, 1991, P NATL ACAD SCI USA, V88, P1019, DOI 10.1073/pnas.88.3.1019; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HANDY DE, 1993, HYPERTENSION, V21, P861, DOI 10.1161/01.HYP.21.6.861; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JONES SB, 1990, MOL PHARMACOL, V39, P239; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEVISTRE R, 1993, EUR J BIOCHEM, V23, P295; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LORENZ W, 1990, MOL PHARMACOL, V38, P599; REMAURY A, 1993, BIOCHEM J, V292, P283, DOI 10.1042/bj2920283; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SETH A, 1992, J BIOL CHEM, V267, P24796; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; TOURNIER C, 1995, IN PRESS EUR J BIOCH; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WINITZ S, 1993, J BIOL CHEM, V268, P19196; ZENG DW, 1991, MOL BRAIN RES, V10, P219, DOI 10.1016/0169-328X(91)90064-5; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	36	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3491	3494		10.1074/jbc.270.8.3491	http://dx.doi.org/10.1074/jbc.270.8.3491			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876081	hybrid			2022-12-25	WOS:A1995QH68800008
J	KLAMPFER, L; CHENKIANG, S; VILCEK, J				KLAMPFER, L; CHENKIANG, S; VILCEK, J			ACTIVATION OF THE TSG-6 GENE BY NF-IL6 REQUIRES 2 ADJACENT NF-IL6 BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; C/EBP FAMILY; EXPRESSION NF-IL6; HUMAN FIBROBLASTS; INTERLEUKIN-6; PROTEIN; MEMBER	Tumor necrosis factor (TNF)-stimulated gene 6 (TSG-6) encodes a protein expressed during inflammation. We have previously shown that transcription factors of the NF-IL6 and AP-1 families cooperatively modulate activation of the TSG-6 gene by TNF or interleukin I (IL-1) through a promoter region that contains an NF-IL6 site (-106 to -114) and an AP-I element (-126 to -119). In this study we report the identification of an additional NF-IL6 site (NF-IL6*) located at positions -92 to -83. Footprinting and electrophoretic mobility shift assay suggested that NF-IL6 binds with higher affinity to the newly identified NF-IL6* site than to the earlier identified promoter-distal NF-IL6 site and that the two sites cooperate in binding NF-IL6. TNF and IL-I stimulate specific binding of nuclear proteins to the NF-IL6* site more efficiently than to the promoter-distal NF-IL6 site. Moreover, a mutation in the NF-IL6* site abolished transactivation of the TSG-6 promoter by NF-IL6 despite the presence of the intact promoter-distal NF-IL6 site. A mutation in the promoter distal NF-IL6 site also greatly decreased activation of the TSG-6 promoter by NF-IL6. We conclude that the two NF-IL6 sites are functionally interdependent in the activation of the TSG-6 gene.	NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	New York University; New York University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R35CA049731] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA49731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, INTERLEUKINS MOL BIO, P299; CHENKIANG S, 1993, CURR OPIN IMMUNOL, V5, P124, DOI 10.1016/0952-7915(93)90091-6; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FENG P, 1993, J BIOL CHEM, V268, P9387; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HSU W, 1993, MOL CELL BIOL, V13, P2515, DOI 10.1128/MCB.13.4.2515; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEE TH, 1993, J BIOL CHEM, V268, P6154; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Maxam A M, 1980, Methods Enzymol, V65, P499; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPERGEL JM, 1992, J VIROL, V66, P1021, DOI 10.1128/JVI.66.2.1021-1030.1992; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TESMER VM, 1993, P NATL ACAD SCI USA, V90, P7298, DOI 10.1073/pnas.90.15.7298; TONIATTI C, 1990, EMBO J, V9, P4467, DOI 10.1002/j.1460-2075.1990.tb07897.x; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; WISNIEWSKI HG, 1994, BIOCHEMISTRY-US, V33, P7423, DOI 10.1021/bi00189a049; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225	32	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3677	3682		10.1074/jbc.270.8.3677	http://dx.doi.org/10.1074/jbc.270.8.3677			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876106				2022-12-25	WOS:A1995QH68800035
J	WILSON, BS; KAPP, N; LEE, RJ; PFEIFFER, JR; MARTINEZ, AM; PLATT, Y; LETOURNEUR, F; OLIVER, JM				WILSON, BS; KAPP, N; LEE, RJ; PFEIFFER, JR; MARTINEZ, AM; PLATT, Y; LETOURNEUR, F; OLIVER, JM			DISTINCT FUNCTIONS OF THE FC-EPSILON-R1 GAMMA-SUBUNITS AND BETA-SUBUNITS IN THE CONTROL OF FC-EPSILON-R1-MEDIATED TYROSINE KINASE ACTIVATION AND SIGNALING RESPONSES IN RBL-2H3 MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; FC-EPSILON-RI; HIGH-AFFINITY RECEPTOR; T-CELL; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; CYTOPLASMIC DOMAINS; IMMUNOGLOBULIN-E; IGE RECEPTOR; PHOSPHORYLATION	In RBL-2H3 rat tumor mast cells, cross-linking the high affinity IgE receptor, Fc epsilon R1, activates the protein-tyrosine kinases Lyn and Syk and initiates a series of responses including protein tyrosine phosphorylation, inositol 1,4,5-trisphosphate synthesis, Ca2+ mobilization, secretion, membrane ruffling, and actin plaque assembly, The development of chimeric receptors containing cytoplasmic domains of individual subunits of the heterotrimeric (alpha beta gamma(2)) Fc epsilon R1 has simplified analyses of early signaling events in RBL-2H3 cells, Here, RBL-2H3 cells were transfected with cDNAs encoding the extracellular and transmembrane domains of the interleukin-2 receptor alpha subunit (the Tac antigen) joined to the C-terminal cytoplasmic domains of the Fc epsilon R1 gamma and beta subunits (TT gamma and TT beta), Both sequences contain tyrosine activation motifs implicated in antigen receptor signal transduction, TT gamma and TT beta are expressed independently of the native Fc epsilon R1, as demonstrated by the ability of Tac cross-linking agents to trigger the clustering and internalization through coated pits of both chimeric receptors without co clustering the Fc epsilon R1. A full range of signaling activities is induced by TT gamma crosslinking; the TT gamma-induced responses are slower and, except for Lyn activation, smaller than the Fc epsilon R1-induced responses, In striking contrast, TT beta cross-linking elicits no tyrosine phosphorylation or signaling responses, it impairs basal activities measured in secretion and anti-PY (anti-phosphotyrosine antibody) immune complex kinase assays, and it antagonizes Fc epsilon R1-induced Lyn and Syk activation, protein-tyrosine phosphorylation, and signaling responses, We hypothesize that the isolated beta subunit binds a specific kinase or coupling protein(s) required for signaling activity, sequestering it from the signal-transducing gamma subunit, Binding the same kinase or coupling protein to the beta subunit of the intact Fc epsilon R1 may serve instead to present it to the adjacent gamma subunit, resulting in enhanced kinase activation and signaling responses.	UNIV NEW MEXICO, SCH MED, DEPT PATHOL, CELL PATHOL LAB, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, SCH MED, CTR CANC RES & TREATMENT, ALBUQUERQUE, NM 87131 USA; BASEL INST IMMUNOL, CH-4058 BASEL, SWITZERLAND	University of New Mexico; University of New Mexico				Letourneur, Francois/0000-0003-2232-6127	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049814] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49814] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER G, 1991, J BIOL CHEM, V266, P22613; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BECKER EL, 1972, J EXP MED, V135, P376, DOI 10.1084/jem.135.2.376; BIEBER T, 1994, IMMUNOL TODAY, V15, P52, DOI 10.1016/0167-5699(94)90132-5; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BURG DL, 1993, J BIOL CHEM, V268, P2304; CAMBIER JC, 1992, FASEB J, V6, P3207, DOI 10.1096/fasebj.6.13.1397843; CHALLISS RAJ, 1988, BIOCHEM BIOPH RES CO, V157, P684, DOI 10.1016/S0006-291X(88)80304-8; DEANIN GG, 1991, BIOCHEM BIOPH RES CO, V179, P551, DOI 10.1016/0006-291X(91)91406-3; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GEAHLEN RL, 1989, BIOCHEM BIOPH RES CO, V165, P241, DOI 10.1016/0006-291X(89)91060-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KAMPS MP, 1991, METHOD ENZYMOL, V201, P101; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEE RJ, 1992, CYTOMETRY, V13, P127, DOI 10.1002/cyto.990130204; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIU FT, 1980, J IMMUNOL, V124, P2728; MAO SY, 1993, J IMMUNOL, V151, P2760; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MILLARD PJ, 1988, P NATL ACAD SCI USA, V85, P1854, DOI 10.1073/pnas.85.6.1854; OLIVER JM, 1988, PROG ALLERGY, V42, P185; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PFEIFFER JR, 1994, J IMMUNOL, V152, P270; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; QIAN DP, 1993, P NATL ACAD SCI USA, V90, P11875, DOI 10.1073/pnas.90.24.11875; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RAVETCH JV, 1994, NAT GENET, V7, P117, DOI 10.1038/ng0694-117; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAKAMOTO N, 1994, BBA-MOL CELL RES, V1221, P291, DOI 10.1016/0167-4889(94)90253-4; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SEAGRAVE J, 1991, J CELL PHYSIOL, V148, P139, DOI 10.1002/jcp.1041480117; STUMP RF, 1987, J IMMUNOL, V139, P881; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	49	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4013	4022		10.1074/jbc.270.8.4013	http://dx.doi.org/10.1074/jbc.270.8.4013			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876149	hybrid			2022-12-25	WOS:A1995QH68800082
J	PRIOLA, SA; CAUGHEY, B; WEHRLY, K; CHESEBRO, B				PRIOLA, SA; CAUGHEY, B; WEHRLY, K; CHESEBRO, B			A 60-KDA PRION PROTEIN (PRP) WITH PROPERTIES OF BOTH THE NORMAL AND SCRAPIE-ASSOCIATED FORMS OF PRP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; PHYSICAL-PROPERTIES; AGENT; PURIFICATION; RESISTANT; PHOSPHOLIPASE; BIOSYNTHESIS; INFECTIVITY; CONVERSION; FIBRILS	Scrapie is a transmissible spongiform encephalopathy of sheep and other mammals in which disease appears to be caused by the accumulation of an abnormal form of a host protein, prion protein (PrP), in the brain and other tissues. The process by which the normal protease-sensitive form of PrP is converted into the abnormal protease-resistant form is unknown. Several hypotheses predict that oligomeric forms of either the normal or abnormal PrP may act as intermediates in the conversion process. We have now identified a 60-kDa PrP derived from hamster PrP expressed in murine neuroblastoma cells, Peptide mapping studies provided evidence that the 60-kDa PrP was composed solely of PrP and, based on its molecular mass, appeared to be a PrP dimer. The 60-kDa PrP was not dissociated under sev eral harsh denaturing conditions, which indicated that it was covalently linked. It was similar to the disease-associated form of PrP in that it formed large aggre gates. However, it resembled the normal form of PrP in that it was sensitive to proteinase K and had a short metabolic half-life. The 60-kDa PrP, therefore, had characteristics of both the normal and disease-associated forms of PrP. Formation and aggregation of the 60-kDa hamster PrP occurs in uninfected mouse neuroblastoma cells, which suggests that hamster PrP has a predispo sition to aggregate even in the absence of scrapie infec tivity. Similar 60-kDa PrP bands were identified in scrapie-infected hamster brain but not in uninfected brain. Therefore, a 60-kDa molecule might participate in the scrapie-associated conversion of protease-sensitive PrP to protease-resistant PrP.			PRIOLA, SA (corresponding author), NIAID, ROCKY MT LABS, PERSISTENT VIRAL DIS LAB, HAMILTON, MT 59840 USA.							AIKEN JM, 1990, MICROBIOL REV, V54, P242, DOI 10.1128/MMBR.54.3.242-246.1990; ALPER T, 1985, NATURE, V317, P750, DOI 10.1038/317750a0; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; BENDHEIM PE, 1988, J INFECT DIS, V158, P1198, DOI 10.1093/infdis/158.6.1198; BENDHEIM PE, 1986, P NATL ACAD SCI USA, V63, P1212; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1984, BIOCHEMISTRY-US, V23, P5898, DOI 10.1021/bi00320a002; BOLTON DC, 1988, NOVEL INFECTIOUS AGE, P164; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; CAUGHEY B, 1988, P NATL ACAD SCI USA, V85, P4657, DOI 10.1073/pnas.85.13.4657; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY B, 1993, J VIROL, V67, P6270, DOI 10.1128/JVI.67.10.6270-6272.1993; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; Dickinson AG., 1979, SLOW TRANSMISSIBLE D, P13; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; EKLUND CM, 1963, P SOC EXP BIOL MED, V112, P974, DOI 10.3181/00379727-112-28225; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KASCSAK RJ, 1987, J VIROL, V61, P8688; Kimberlin R.H., 1990, SE VIROL, V1, P153; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OESCH B, 1994, BIOCHEMISTRY-US, V33, P5926, DOI 10.1021/bi00185a033; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PATTISON IH, 1967, VET REC, V80, P2, DOI 10.1136/vr.80.1.2; PRIOLA SA, 1994, J VIROL, V68, P4873, DOI 10.1128/JVI.68.8.4873-4878.1994; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; RACE RE, 1988, J VIROL, V62, P2845, DOI 10.1128/JVI.62.8.2845-2849.1988; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; Rohwer R G, 1991, Curr Top Microbiol Immunol, V172, P195; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SKLAVIADIS TK, 1989, J VIROL, V63, P1212, DOI 10.1128/JVI.63.3.1212-1222.1989; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Tarentino A L, 1978, Methods Enzymol, V50, P574; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x	50	79	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3299	3305		10.1074/jbc.270.7.3299	http://dx.doi.org/10.1074/jbc.270.7.3299			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852415	hybrid			2022-12-25	WOS:A1995QG47100062
J	VERGERES, G; RAMSDEN, J; WASKELL, L				VERGERES, G; RAMSDEN, J; WASKELL, L			THE CARBOXYL-TERMINUS OF THE MEMBRANE-BINDING DOMAIN OF CYTOCHROME B(5) SPANS THE BILAYER OF THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOACTIVATABLE PHOSPHOLIPIDS; MICROSOMAL-MEMBRANES; EMBEDDED SEGMENT; CROSS-LINKING; PROTEINS; INSERTION; VESICLES; B5; PARTICIPATION; TRANSLOCATION	Preliminary studies (Vergeres, G., and Waskell, L. (1992) J. Biol. Chem. 267, 12583-12591) have suggested that the carboxyl terminal membrane-binding domain of cytochrome b(5) traverses the membrane and that the carboxyl terminus is in the lumen of the endoplasmic reticulum. In order to confirm and extend these studies, additional experiments were conducted. The gene coding for rat cytochrome b(5) was transcribed and the resulting mRNA was translated in vitro in a rabbit reticulocyte lysate in the presence of microsomes. The binding and topology of cytochrome b(5) were investigated by treating microsomes containing the newly incorporated cytochrome b(5) with carboxypeptidase Y and trypsin. Our studies indicate that cytochrome b(5) is inserted both co- and post-translationally into microsomes in a topology in which the membrane binding domain spans the bilayer with its COOH terminus in the lumen. Cytochrome b(5) is also incorporated into microsomes pretreated with trypsin in a topology indistinguishable from the one resulting from the insertion of the protein into untreated microsomes, reconfirming that cytochrome b(5) does not use the signal recognition particle-dependent translocation machinery. Our results do not allow a distinction to be made between a spontaneous insertion mode or some other trypsin-resistant receptor-mediated mechanism. A role for Pro(115) in the middle of the membrane-binding domain of cytochrome b(5) was also examined by mutating it to an alanine and subsequently characterizing the ability of the mutant protein to be incorporated into membranes. The mutant protein inserted more slowly in vitro into microsomes as well as into pure lipid bilayers by a factor of 2 to 3.	UNIV CALIF SAN FRANCISCO, VET ADM MED CTR, DEPT ANESTHESIA, SAN FRANCISCO, CA 94121 USA; VET ADM MED CTR, DEPT ANESTHESIOL, SAN FRANCISCO, CA 94121 USA; UNIV BASEL, BIOCTR, DEPT BIOPHYS CHEM, CH-4056 BASEL, SWITZERLAND	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Basel					NIGMS NIH HHS [GM 35333] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; ARINC E, 1987, J BIOL CHEM, V262, P15563; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BENDZKO P, 1982, EUR J BIOCHEM, V123, P121, DOI 10.1111/j.1432-1033.1982.tb06507.x; BORGESE N, 1993, FEBS LETT, V325, P70, DOI 10.1016/0014-5793(93)81416-W; CALABRO MA, 1976, J BIOL CHEM, V251, P2113; CANOVADAVIS E, 1985, BIOCHEM PHARMACOL, V34, P1907, DOI 10.1016/0006-2952(85)90307-7; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; DARRIGO A, 1993, J BIOL CHEM, V268, P2802; ENOCH HG, 1979, J BIOL CHEM, V254, P6483; GREENHUT SF, 1993, BIOCHIM BIOPHYS ACTA, V1149, P1, DOI 10.1016/0005-2736(93)90018-U; GRINSTEAD GF, 1982, J BIOL CHEM, V257, P3937; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; High Stephen, 1993, Trends in Cell Biology, V3, P335, DOI 10.1016/0962-8924(93)90103-8; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TC, 1977, BIOCHIM BIOPHYS ACTA, V489, P25, DOI 10.1016/0005-2760(77)90228-4; LETO TL, 1979, J BIOL CHEM, V254, P5015; LITHGOW T, 1993, FEBS LETT, V329, P1, DOI 10.1016/0014-5793(93)80179-X; MATHEWS FS, 1972, J MOL BIOL, V64, P449, DOI 10.1016/0022-2836(72)90510-4; MEYER DI, 1980, J CELL BIOL, V87, P503, DOI 10.1083/jcb.87.2.503; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; MORIMOTO T, 1983, METHOD ENZYMOL, V96, P121; OKADA Y, 1982, EUR J BIOCHEM, V122, P393, DOI 10.1111/j.1432-1033.1982.tb05894.x; OSHINO N, 1982, HEPATIC CYTOCHROME P, P407; OZOLS J, 1989, BIOCHIM BIOPHYS ACTA, V997, P121, DOI 10.1016/0167-4838(89)90143-X; RACHUBINSKI RA, 1980, J CELL BIOL, V84, P705, DOI 10.1083/jcb.84.3.705; RAMSDEN JJ, 1992, J PHYS CHEM-US, V96, P3388, DOI 10.1021/j100187a038; RAMSDEN JJ, 1993, J STAT PHYS, V73, P853, DOI 10.1007/BF01052813; RAMSDEN JJ, 1993, BIOCHEMISTRY-US, V32, P523, DOI 10.1021/bi00053a017; RAMSDEN JJ, 1993, J PHYS CHEM-US, V97, P4479, DOI 10.1021/j100119a036; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROSEMAN MA, 1977, J BIOL CHEM, V252, P4842; SCHACHTER H, 1980, BIOCH GLYCOPROTEINS, P85; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; TAKAGAKI Y, 1983, J BIOL CHEM, V258, P9128; TAKAGAKI Y, 1983, J BIOL CHEM, V258, P9136; TIEN PK, 1971, APPL OPTICS, V10, P2395, DOI 10.1364/AO.10.002395; TRETYACHENKOLADOKHINA VG, 1993, BIOCHIM BIOPHYS ACTA, V1153, P163, DOI 10.1016/0005-2736(93)90401-K; VERGERES G, 1992, J BIOL CHEM, V267, P12583; VERGERES G, 1993, J CELL SCI, V106, P249; von Smoluchowski M, 1916, PHYS Z, V17, P557; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WASKELL LA, 1991, METHOD ENZYMOL, V206, P523; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001	50	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3414	3422		10.1074/jbc.270.7.3414	http://dx.doi.org/10.1074/jbc.270.7.3414			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852428	hybrid			2022-12-25	WOS:A1995QG47100078
J	ARENDT, CW; OSTERGAARD, HL				ARENDT, CW; OSTERGAARD, HL			CD45 PROTEIN-TYROSINE-PHOSPHATASE IS SPECIFICALLY ASSOCIATED WITH A 116-KDA TYROSINE-PHOSPHORYLATED GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; HUMAN LYMPHOCYTES-T; LEUKOCYTE-COMMON ANTIGEN; PHOSPHOTYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION; CYTOPLASMIC DOMAIN; ZETA-CHAIN; KINASE; ACTIVATION; TRANSMEMBRANE	CD45 is a protein-tyrosine phosphatase expressed on all cells of hematopoietic origin. In an attempt to further characterize CD45 function, we set out to identify molecule(s) that specifically associate with CD45. A 116-kDa protein was detected in immunoprecipitates from CD45(+) cells but not CD45(-) cells. The association between CD45 and this 116-kDa protein can be reconstituted by mixing lysates from CD45(-) cell lines with purified CD45. p116 appears to associate with CD45 through the external, transmembrane, or membrane-proximal region of CD45 since p116 is associated with a mutant form of CD45 possessing a truncated cytoplasmic domain. The association of p116 with CD45 is not isoform-specific as p116 associates equally well with various CD45 isoforms. We have determined that p116 is a tyrosine-phosphorylated glycoprotein and that it is associated with CD45 in all hematopoietic cells examined, Because of its broad distribution, it is possible that identification of pile will provide additional insight into the function of CD45 in lymphoid as well as non-lymphoid hematopoietic cells.	UNIV ALBERTA,DEPT IMMUNOL,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HYMAN R, 1982, IMMUNOGENETICS, V15, P413, DOI 10.1007/BF00364264; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JOHNSON P, 1989, J EXP MED, V169, P1179, DOI 10.1084/jem.169.3.1179; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KANE KP, 1989, MOL IMMUNOL, V26, P759, DOI 10.1016/0161-5890(89)90036-9; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PEYRON JF, 1991, INT IMMUNOL, V3, P1357, DOI 10.1093/intimm/3.12.1357; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TAKEDA A, 1994, J BIOL CHEM, V269, P2357; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377	34	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2313	2319						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836464				2022-12-25	WOS:A1995QE49300052
J	PARADA, CA; YOON, JB; ROEDER, RG				PARADA, CA; YOON, JB; ROEDER, RG			A NOVEL LBP-1-MEDIATED RESTRICTION OF HIV-1 TRANSCRIPTION AT THE LEVEL OF ELONGATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; LONG TERMINAL REPEAT; VIRUS TYPE-1 PROMOTER; NF-KAPPA-B; TAT PROTEIN; ACTIVATES TRANSCRIPTION; COOPERATIVE INTERACTION; XENOPUS-OOCYTES; GENE-EXPRESSION; MESSENGER-RNA	The cellular factor, LBP-1, can repress HIV-1 transcription by preventing the binding of TFIID to the promoter. Here we have analyzed the effect of recombinant LBP-1 on HIV-1 transcription in vitro by using a ''pulse-chase'' assay. LBP-1 had no effect on initiation from a preformed preinitiation complex and elongation to position +13 (''pulse''). However, addition of LBP-1 after RNA polymerase was stalled at +13 strongly inhibited further elongation (''chase'') by reducing RNA polymerase processivity, Severe mutations of the high affinity LBP-1 binding sites between -4 and +21 did not relieve the LBP-1-dependent block. However, LBP-1 could bind independently to upstream low affinity sites (-80 to -4), suggesting that these sites mediate the effect of LBP-1 on elongation. These results demonstrate a novel function of LBP-1, restricting HIV-1 transcription at the level of elongation. In addition, Tat was found to suppress the antiprocessivity effect of LBP-1 on HIV-1 transcription in nuclear extracts. These findings strongly suggest that LBP-1 may provide a natural mechanism for restricting the elongation of HIV-1 transcripts and that this may be a target for the action of Tat in enhancing transcription.			PARADA, CA (corresponding author), ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA.			Yoon, Jong-Bok/0000-0002-3563-0702	NIAID NIH HHS [AI27397] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENGAL E, 1991, J VIROL, V65, P4910, DOI 10.1128/JVI.65.9.4910-4918.1991; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BIELINSKA A, 1989, J VIROL, V63, P4097, DOI 10.1128/JVI.63.9.4097-4100.1989; Bohan Cindy A., 1992, Gene Expression, V2, P391; BRADDOCK M, 1993, FASEB J, V7, P214, DOI 10.1096/fasebj.7.1.8422967; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FASHANACHI F, 1994, NATURE, V367, P295; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GRAEBLE MA, 1993, P NATL ACAD SCI USA, V90, P6184, DOI 10.1073/pnas.90.13.6184; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HAN P, 1991, NUCLEIC ACIDS RES, V19, P7225, DOI 10.1093/nar/19.25.7225; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JEANG KT, 1993, J BIOL CHEM, V268, P24940; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KAMINE J, 1992, J VIROL, V66, P3932, DOI 10.1128/JVI.66.6.3932-3936.1992; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KESSLER M, 1992, J VIROL, V66, P4488, DOI 10.1128/JVI.66.7.4488-4496.1992; KESSLER M, 1991, P NATL ACAD SCI USA, V88, P10018, DOI 10.1073/pnas.88.22.10018; KREUZER KN, 1984, J BIOL CHEM, V259, P5339; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LU XB, 1993, J VIROL, V67, P1752, DOI 10.1128/JVI.67.4.1752-1760.1993; MADORE SJ, 1993, J VIROL, V67, P3703, DOI 10.1128/JVI.67.7.3703-3711.1993; MALIM MH, 1989, J VIROL, V63, P3213, DOI 10.1128/JVI.63.8.3213-3219.1989; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEULIA T, 1993, MOL CELL BIOL, V13, P5647, DOI 10.1128/MCB.13.9.5647; OLSEN HS, 1992, J VIROL, V66, P5594, DOI 10.1128/JVI.66.9.5594-5597.1992; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; REINES D, 1992, J BIOL CHEM, V267, P3795; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; SPENCER CA, 1990, ONCOGENE, V5, P777; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TOOHEY MG, 1989, GENE DEV, V3, P265, DOI 10.1101/gad.3.3.265; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T; YOON JB, 1994, MOL CELL BIOL, V14, P176; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	63	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2274	2283		10.1074/jbc.270.5.2274	http://dx.doi.org/10.1074/jbc.270.5.2274			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836461	hybrid			2022-12-25	WOS:A1995QE49300047
J	WANG, ZY; QIU, QQ; HUANG, J; GURRIERI, M; DEUEL, TF				WANG, ZY; QIU, QQ; HUANG, J; GURRIERI, M; DEUEL, TF			PRODUCTS OF ALTERNATIVELY SPLICED TRANSCRIPTS OF THE WILMS-TUMOR SUPPRESSOR GENE, WT1, HAVE ALTERED DNA-BINDING SPECIFICITY AND REGULATE TRANSCRIPTION IN DIFFERENT WAYS	ONCOGENE			English	Article						WT1; TRANSCRIPTIONAL FACTOR; ZINC FINGER PROTEIN; ALTERNATIVE SPLICING	ZINC FINGER GENE; EXPRESSION; KRUPPEL; PROTEIN; CELLS; REPRESSION; DOMAINS; GROWTH; LOCUS; E1A	The Wilms' tumor susceptibility gene, wt1, encodes a transcription factor of the zinc finger protein family. Mutations in the WT1 gene product have been detected in both sporadic and familial Wilms' tumors, suggesting that alterations in WT1 may disrupt its normal function as a transcriptional regulator. The transcripts of wt1 are alternatively spliced; however, roles of the alternatively spliced forms have not been defined. The major transcript of wt1 encodes a WT1 protein [WT1(+KTS)+17AA] that contains three amino acids (+KTS) between the third and fourth zinc fingers and a serine-rich, 17 amino acid (+17AA) domain N-terminal to the zinc finger region. We now show that the WT1(+KTS) forms functionally bind to a unique G + C-rich sequence within the PDGF A-chain promoter. We also show that WT1 (+KTS)+17AA functions as a strong transciptional repressor and that +17AA alone fused to the zinc-finger domain of WT1 or to the heterologous DNA binding domain of GAL4 functions independently as a repressor. Deletion of four serine residues within +17AA abolishes the repressor activity of +17AA. These results indicate that wt1 products with +17AA contain an additional dominant repressor domain and that the presence or absence of +KTS determines alternative DNA binding specificity.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Huang, Jeffrey K./AAH-2418-2021; Huang, Jeffrey/J-5248-2017	Huang, Jeffrey K./0000-0003-0996-9451; Huang, Jeffrey/0000-0003-0996-9451	NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL31102, HL14147] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R01HL031102, R37HL031102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; BASCH I, 1993, EMBO J, V12, P4229; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BORDEREAUX D, 1990, ONCOGENE, V5, P925; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; GESSLER M, 1990, NATURE, V343, P744; GORMAN GM, 1982, MOL CELL BIOL, V8, P1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HSA TT, 1992, SCIENCE, V257, P1946; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIN XH, 1992, J BIOL CHEM, V267, P25614; MADDEN SL, 1992, SCIENCE, V253, P1550; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; RAUSCHER FJ, 1990, SCIENCE, V250, P1257; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WANG ZY, 1993, P NATL ACAD SCI USA, V268, P8896; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	35	82	86	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					415	422						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845666				2022-12-25	WOS:A1995QF64800001
J	CHLICHLIA, K; MOLDENHAUER, G; DANIEL, PT; BUSSLINGER, M; GAZZOLO, L; SCHIRRMACHER, V; KHAZAIE, K				CHLICHLIA, K; MOLDENHAUER, G; DANIEL, PT; BUSSLINGER, M; GAZZOLO, L; SCHIRRMACHER, V; KHAZAIE, K			IMMEDIATE EFFECTS OF REVERSIBLE HTLV-1 TAX FUNCTION - T-CELL ACTIVATION AND APOPTOSIS	ONCOGENE			English	Article						HTLV-1 TAX; CD3; CD28; ESTROGEN RECEPTOR; T-CELL ACTIVATION; APOPTOSIS	VIRUS TYPE-I; LEUKEMIA-VIRUS; IL-2 RECEPTOR; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; GENE-EXPRESSION; BINDING DOMAINS; B-CELLS; INTERLEUKIN-2; INDUCTION	The tax protein of Human T-cell leukemia virus type 1 (HTLV-1) is important for the transforming properties of this virus in vitro and is considered to be responsible for the early stages of leukemogenesis in infected hosts. To address the early consequences of HTLV-1 tax function, we have constructed fusion proteins containing tax sequence either aminoterminal (taxER) or carboxyterminal (ERtax) of the hormone binding domain of the human estrogen receptor (ER). Addition of estrogen or the antagonist hydroxytamoxifen to Jurkat T-cells expressing these constructs led to the trans-activation or responsive promoters and upregulation of cell surface markers CD28, CD69 and CD5 but not CD25 (IL2R-alpha subunit) or B7 (ligand for CD28). Additional stimulation of the T-cell receptor CD3 complex, led to the upregulation of CD25. B7 was upregulated by concomittent activation of ERtax and CD3 or CD28 pathways, These events were in part reversible upon withdrawal of hormone and inactivation of ERtax. Severe inhibition of proliferation, and apoptosis was observed with cells which had been subjected to short term (3 days) activation of the tax fusion proteins and the CD3 complex, Induction of ERtax activity for longer than 3 days promoted cell death independently of CD3 stimulation. Co-stimulation through the CD28 cell surface molecule did not suppress induction of apoptosis.	GERMAN CANC RES CTR,DEPT TUMOR IMMUNOL,D-69120 HEIDELBERG,GERMANY; MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; ALEXIS CARREL MED SCH,MOLEC & CELLULAR IMMUNOVIROL LAB,CNRS,UMR 30,LYON,FRANCE	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Centre National de la Recherche Scientifique (CNRS)			Chlichlia, Katerina/Q-3948-2019; Busslinger, Meinrad J./J-1249-2016	Busslinger, Meinrad J./0000-0002-9111-9351; Chlichlia, Katerina/0000-0003-4952-0675				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BIEBERICH CJ, 1993, VIROLOGY, V196, P309, DOI 10.1006/viro.1993.1481; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DOI T, 1989, EMBO J, V8, P1953, DOI 10.1002/j.1460-2075.1989.tb03600.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FRANCHINI G, 1984, P NATL ACAD SCI-BIOL, V81, P6207, DOI 10.1073/pnas.81.19.6207; FUJII M, 1991, ONCOGENE, V6, P1023; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P287, DOI 10.1089/aid.1993.9.287; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HAFAR OK, 1993, P NATL ACAD SCI USA, V90, P11094; HATTORI T, 1981, BLOOD, V58, P645; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HOSHINO H, 1983, P NATL ACAD SCI-BIOL, V80, P7337, DOI 10.1073/pnas.80.23.7337; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KELLY K, 1992, ONCOGENE, V7, P1463; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LINSLEY PS, 1993, J IMMUNOL, V150, P3161; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1991, J VIROL, V65, P3349, DOI 10.1128/JVI.65.6.3349-3353.1991; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PUNT JA, 1994, J EXP MED, V179, P709, DOI 10.1084/jem.179.2.709; RUBEN S M, 1990, New Biologist, V2, P894; SANSOM DM, 1993, EUR J IMMUNOL, V23, P295, DOI 10.1002/eji.1830230148; SCHWARTING R, 1989, CLUSTER REPORT CD69, P428; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; TSUDA H, 1984, BRIT J CANCER, V50, P843, DOI 10.1038/bjc.1984.266; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; VALLE A, 1990, IMMUNOLOGY, V69, P531; VANLIER RAW, 1988, EUR J IMMUNOL, V18, P167; VANLIER RAW, 1989, LEUKOCYTE TYPING, V4, P353; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEISS RA, 1990, CANCER CELL-MON REV, V2, P281; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YODOI J, 1986, IMMUNOL REV, V92, P135, DOI 10.1111/j.1600-065X.1986.tb01498.x; YOSHIDA M, 1986, AIDS RES, V2, pS17	61	86	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					269	277						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838527				2022-12-25	WOS:A1995QC62400006
J	MONSON, EK; DITTA, GS; HELINSKI, DR				MONSON, EK; DITTA, GS; HELINSKI, DR			THE OXYGEN SENSOR PROTEIN, FIXL, OF RHIZOBIUM-MELILOTI - ROLE OF HISTIDINE-RESIDUES IN HEME-BINDING, PHOSPHORYLATION, AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; REGULATOR-II NR(II); ESCHERICHIA-COLI; PHOSPHATASE-ACTIVITIES; PHENOTYPIC SELECTION; KINASE-ACTIVITY; GENE-PRODUCT; NIFA; AUTOPHOSPHORYLATION; TRANSCRIPTION	The two component system sensor/response regulator pair, FixL/FixJ, controls the expression of Rhizobium meliloti nitrogen fixation (nif and fix) genes in response to changes in oxygen concentration. A truncated version of FixL, FixL(*), is an oxygen-binding hemoprotein kinase that phosphorylates and dephosphorylates the nif and fix gene transcriptional activator, FixJ. Phosphorylation of FixJ is required for optimal transcriptional activation, and anaerobic conditions in vitro result in a substantial increase in the level of FixJ-phosphate. In this study, site-directed mutagenesis was carried out at histidine residues in FixL(*). Mutant FixL(*) derivatives were purified and analyzed in vitro for their heme/oxygen binding properties and phosphorylation/dephosphorylation activities. Mutation of histidine 285, the putative autophosphorylation site, to glutamine results in the loss of FixL(*) phosphorylation activities. However, this mutant protein retains a substantial level of FixJ-phosphate dephosphorylation activity. Mutation of histidine 194 to asparagine results in the loss of heme binding and in the failure of FixL(*) to regulate its phosphorylation/dephosphorylation activities in response to changes in oxygen concentration. The FixL(*)H194N mutant protein also exhibits an increased FixJ phosphorylation activity under aerobic conditions. This study provides further evidence for the importance of the heme binding domain of FixL(*) in regulating FixJ phosphorylation and dephosphorylation activities in response to oxygen.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044400] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM44400-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRON PG, 1993, P NATL ACAD SCI USA, V90, P3506, DOI 10.1073/pnas.90.8.3506; AGRON PG, 1994, RES MICROBIOL, V145, P454, DOI 10.1016/0923-2508(94)90094-9; AGRON PG, 1993, THESIS U CALIFORNIA; AGUILAR OM, 1987, J BACTERIOL, V169, P5393, DOI 10.1128/jb.169.12.5393-5400.1987; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P125; ATKINSON MR, 1993, J BACTERIOL, V175, P7016, DOI 10.1128/jb.175.21.7016-7023.1993; BAKER TA, 1984, P NATL ACAD SCI-BIOL, V81, P6779, DOI 10.1073/pnas.81.21.6779; BATUT J, 1989, EMBO J, V8, P1279, DOI 10.1002/j.1460-2075.1989.tb03502.x; BEUZARD Y, 1972, FEBS LETT, V27, P76, DOI 10.1016/0014-5793(72)80413-7; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; CANGELOSI GA, 1990, P NATL ACAD SCI USA, V87, P6708, DOI 10.1073/pnas.87.17.6708; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; DEPHILIP P, 1992, MOL GEN GENET, V235, P49, DOI 10.1007/BF00286180; DEPHILIP P, 1990, J BACTERIOL, V172, P4255, DOI 10.1128/jb.172.8.4255-4262.1990; DITTA G, 1987, J BACTERIOL, V169, P3217, DOI 10.1128/jb.169.7.3217-3223.1987; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILLESGONZALEZ MA, 1993, J BIOL CHEM, V268, P16293; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOIS AF, 1993, J BIOL CHEM, V268, P4370; LOIS AF, 1993, J BACTERIOL, V175, P1103, DOI 10.1128/JB.175.4.1103-1109.1993; MELCHERS LS, 1989, EMBO J, V8, P1919, DOI 10.1002/j.1460-2075.1989.tb03595.x; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; Ninfa A J, 1991, Genet Eng (N Y), V13, P39; NINFA AJ, 1986, P NATL ACAD SCI USA, V85, P5492; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; NOONAN B, 1992, MOL GEN GENET, V234, P423, DOI 10.1007/BF00538701; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; REYRAT JM, 1993, J BACTERIOL, V175, P6867, DOI 10.1128/jb.175.21.6867-6872.1993; Sambrook J, 1989, MOL CLONING LABORATO; SHIMODA N, 1990, P NATL ACAD SCI USA, V87, P6684, DOI 10.1073/pnas.87.17.6684; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STUDIER FW, 1985, J MOL BIOL, V189, P113; SZETO WW, 1984, CELL, V36, P1035, DOI 10.1016/0092-8674(84)90053-9; VIERA J, 1987, METHOD ENZYMOL, V153, P3; VIRTS EL, 1988, P NATL ACAD SCI USA, V85, P3062, DOI 10.1073/pnas.85.9.3062; WEINSTEIN M, 1992, MOL MICROBIOL, V6, P2041, DOI 10.1111/j.1365-2958.1992.tb01377.x; WEINSTEIN M, 1993, GENE, V134, P145, DOI 10.1016/0378-1119(93)90088-K; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	48	82	82	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5243	5250		10.1074/jbc.270.10.5243	http://dx.doi.org/10.1074/jbc.270.10.5243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890634	hybrid			2022-12-25	WOS:A1995QL58000046
J	GRADY, EF; SLICE, LW; BRANT, WO; WALSH, JH; PAYAN, DG; BUNNETT, NW				GRADY, EF; SLICE, LW; BRANT, WO; WALSH, JH; PAYAN, DG; BUNNETT, NW			DIRECT OBSERVATION OF ENDOCYTOSIS OF GASTRIN-RELEASING PEPTIDE AND ITS RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; GUINEA-PIG PANCREAS; MEDIATED ENDOCYTOSIS; DISPERSED ACINI; DOWN-REGULATION; BOMBESIN; INTERNALIZATION; DESENSITIZATION; DEGRADATION; TRANSFERRIN	Endocytosis of the gastrin releasing peptide receptor (GRP-R) may regulate cellular responses to GRP. We observed endocytosis in transfected epithelial cells by confocal microscopy using cyanine 3 GRP (cyanine 3.18-labeled gastrin releasing peptide) and GRP-R antibodies, At 4 degrees C, cy3-GRP and GRP-R were confined to the plasma membrane, After 5 min at 37 degrees C, ligand and receptor were internalized into early endosomes with fluorescein isothiocyanate-transferrin, After 10 min, cy3-GRP and GRP-R were in perinuclear vesicles, and at 60 min cy3-GRP was in large, central vesicles, while GRP-R was at the cell surface. We quantified surface GRP-R using an antibody to an extracellular epitope and an I-125-labeled secondary antibody. After exposure to GRP, there was a loss and subsequent recovery of surface GRP-R. Recovery was unaffected by cycloheximide, and thus independent of new protein synthesis, but was attenuated by acidotropic agents, and therefore required endosomal acidification, Internalization of I-125-GRP, assessed using an acid wash, was maximal after 10-20 min, and was clathrin-mediated since it was inhibited by by perosmolar sucrose and phenylarsine oxide, Thus, GRP and its receptor are rapidly internalized into early endosomes and then dissociate in an acidified compartment, GRP is probably degraded whereas the GRP-R recycles.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF LOS ANGELES,W LOS ANGELES VET ADM CTR,CTR GASTROENTER BIOL,CURE VA,LOS ANGELES,CA 90073	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles				Bunnett, Nigel W./0000-0003-3367-0644	NIDDK NIH HHS [DK 39957, DK 43207] Funding Source: Medline; NINDS NIH HHS [NS 21710] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039957, R01DK039957, R56DK043207, R01DK043207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021710] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTON PA, 1991, PEPTIDES, V12, P375, DOI 10.1016/0196-9781(91)90029-O; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERTACCINI G, 1974, BRIT J PHARMACOL, V52, P219, DOI 10.1111/j.1476-5381.1974.tb09703.x; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; BROCCARDO M, 1976, BRIT J PHARMACOL, V55, P221; BROWN KD, 1988, BIOCHEM J, V252, P227, DOI 10.1042/bj2520227; BUNNETT N, 1994, GUT PEPTIDES BIOCH P, P423; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; FROST SC, 1985, J BIOL CHEM, V260, P2646; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LEE PC, 1980, AM J PHYSIOL, V238, pG213, DOI 10.1152/ajpgi.1980.238.3.G213; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; OKAMOTO A, 1994, BIOCHEM J, V299, P683, DOI 10.1042/bj2990683; PANDOL SJ, 1982, J BIOL CHEM, V257, P2024; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SLICE LW, 1994, J BIOL CHEM, V269, P21755; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186; VIGNA SR, 1994, J NEUROSCI, V14, P834; WAKSHULL EM, 1985, P NATL ACAD SCI USA, V82, P8513, DOI 10.1073/pnas.82.24.8513; WANG LH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P232, DOI 10.1016/0167-4889(93)90028-N; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; YU SS, 1993, J BIOL CHEM, V268, P337; ZACHARY I, 1987, EMBO J, V6, P2233, DOI 10.1002/j.1460-2075.1987.tb02495.x; ZHU WY, 1991, AM J PHYSIOL, V261, pG57, DOI 10.1152/ajpgi.1991.261.1.G57	38	82	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4603	4611		10.1074/jbc.270.9.4603	http://dx.doi.org/10.1074/jbc.270.9.4603			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876231	hybrid			2022-12-25	WOS:A1995QK08400064
J	HONDA, Z; TAKANO, T; HIROSE, N; SUZUKI, T; MUTO, A; KUME, S; MIKOSHIBA, K; ITOH, K; SHIMIZU, T				HONDA, Z; TAKANO, T; HIROSE, N; SUZUKI, T; MUTO, A; KUME, S; MIKOSHIBA, K; ITOH, K; SHIMIZU, T			G(Q) PATHWAY DESENSITIZES CHEMOTACTIC RECEPTOR-INDUCED CALCIUM SIGNALING VIA INOSITOL TRISPHOSPHATE RECEPTOR DOWN-REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR RECEPTOR; PHOSPHOLIPASE-C; THROMBOXANE-A2 RECEPTOR; G-PROTEINS; EXPRESSION; CLONING; CELLS; LEUKOCYTES; MECHANISMS	Desensitization of a chemotactic receptor is an adaptive process that terminates inflammation, Although homologous desensitization can be well explained by the action of specific receptor kinases, the mechanisms of heterologous desensitization remain elusive. As an approach to evaluate the roles of G(q) pathway in desensitization of calcium signaling, we expressed a constitutively active G(q) alpha mutant (G(q) alpha Q-L) together with platelet-activating factor (PAF) receptor in Xenopus laevis oocytes, G(q) alpha Q-L expression completely attenuated the calcium-sensitive chloride current and the Ca-45 release elicited by PAF. The G(q)-mediated desensitization could not be ascribed to G protein/receptor uncoupling via receptor phosphorylation, because (i) PAF-induced inositol 1,4,5-trisphosphate (IP3) synthesis was only partially suppressed and (ii) a mutated PAF receptor devoid of all Ser and Thr in the third cytoplasmic loop and in the C-terminal tail was also completely desensitized by G(q) alpha Q-L. In G(q) alpha Q-L expressing oocytes, microinjection of IP3 failed to elicit the calcium response, and the IP3, receptor, detected by a specific antibody, disappeared. Thus, the G(q)-mediated desensitization can be most likely explained by IP3 receptor down-regulation. These novel mechanisms may explain in part heterologous desensitization in chemotactic factor-stimulated inflammatory cells.	UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo; University of Tokyo	HONDA, Z (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED & PHYS THERAPY,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.		Mikoshiba, Katsuhiko/N-7943-2015; Kume, Shoen/M-4356-2016	Kume, Shoen/0000-0002-4292-205X				AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BJORNSON AB, 1993, J INFECT DIS, V168, P120, DOI 10.1093/infdis/168.1.120; DEVIVO M, 1994, J BIOL CHEM, V269, P19671; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; EXTON JH, 1993, ADV SEC MESS PHOSPH, V28, P65; FROELICH CJ, 1989, CLIN IMMUNOL IMMUNOP, V50, P132, DOI 10.1016/0090-1229(89)90228-6; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; KOH YY, 1993, AM J RESP CELL MOL, V8, P493, DOI 10.1165/ajrcmb/8.5.493; KOZASA T, 1993, P NATL ACAD SCI USA, V91, P504; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; MAGNUSSON A, 1993, FEBS LETT, V323, P229, DOI 10.1016/0014-5793(93)81345-Z; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; QIAN NX, 1994, J BIOL CHEM, V269, P17417; SHENKER A, 1991, J BIOL CHEM, V266, P9309; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; TAKANO T, 1994, J BIOL CHEM, V269, P22453; WOJCIKIEWICZ RJH, 1992, J NEUROCHEM, V59, P383, DOI 10.1111/j.1471-4159.1992.tb08916.x; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; WU DQ, 1992, J BIOL CHEM, V267, P1811; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	31	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4840	4844		10.1074/jbc.270.9.4840	http://dx.doi.org/10.1074/jbc.270.9.4840			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876256	hybrid			2022-12-25	WOS:A1995QK08400093
J	IVANENKO, A; MCKEMY, DD; KENYON, JL; AIREY, JA; SUTKO, JL				IVANENKO, A; MCKEMY, DD; KENYON, JL; AIREY, JA; SUTKO, JL			EMBRYONIC CHICKEN SKELETAL-MUSCLE CELLS FAIL TO DEVELOP NORMAL EXCITATION-CONTRACTION COUPLING IN THE ABSENCE OF THE ALPHA-RYANODINE RECEPTOR - IMPLICATIONS FOR A 2-RYANODINE RECEPTOR SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FOOT PROTEIN ISOFORMS; CALCIUM-RELEASE; EXPRESS; IDENTIFICATION; LOCALIZATION; CHANNELS; CULTURES; FIBERS	Two ryanodine receptor (RyR), sarcoplasmic reticulum Ca2+ release channels, alpha and beta, co-exist in chicken skeletal muscles. To investigate a two-RyR Ca2+ release system, we compared electrically evoked Ca2+ transients in Crooked Neck Dwarf (cn/cn) cultured muscle cells, which do not make alpha RyR, and normal (+/?) cells. At day 3 in culture, Ca2+ release in +/? cells required extracellular Ca2+ (Ca-o(2+)), and Ca2+ transients had slow kinetics. At day 5, Ca2+ release was Ca-o(2+)-independent in 40% of the cells, and transients were more rapid. By day 7, all +/? cells had Ca-o(2+)-independent Ca2+ release. Contractions were observed in +/? cells on all days. Ca2+ transients were observed in cn/cn cells on days 3, 5, and 7, but in each case they were Ca-o(2+)-dependent and exhibited slow kinetics. Localized vesiculations, not contractions, occurred in cn/cn cells. By day 10, Ca2+ transients were no longer observed in cn/cn cells even in Ca-o(2+). Sarcoplasmic reticulum Ca2+ was not depleted, as caffeine induced Ca2+ transients. Thus, in the absence of alpha RyR there is a failure to develop Ca-o(2+)-independent Ca2+ release and contractions and to sustain Ca-o(2+)-dependent release. Moreover, contributions by the alpha RyR cannot be duplicated by the beta RyR alone.	UNIV NEVADA,SCH MED,DEPT PHARMACOL 318,RENO,NV 89557; UNIV NEVADA,SCH MED,DEPT PHYSIOL,RENO,NV 89557	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno				Kenyon, James/0000-0001-8699-4680	PHS HHS [27470] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIREY JA, 1993, DEV DYNAM, V197, P169, DOI 10.1002/aja.1001970303; AIREY JA, 1993, BIOCHEMISTRY-US, V32, P5739, DOI 10.1021/bi00073a003; AIREY JA, 1993, DEV DYNAM, V197, P189, DOI 10.1002/aja.1001970304; AIREY JA, 1990, J BIOL CHEM, V265, P14187; BANDMAN E, 1982, J CELL BIOL, V93, P698, DOI 10.1083/jcb.93.3.698; BULL R, 1993, FEBS LETT, V331, P223, DOI 10.1016/0014-5793(93)80341-Q; CERNY LC, 1986, J CELL BIOL, V103, P2153, DOI 10.1083/jcb.103.6.2153; COGNARD C, 1992, PFLUG ARCH EUR J PHY, V422, P207, DOI 10.1007/BF00370424; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GIANNINI G, 1995, IN PRESS J CELL BIOL; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; JACQUEMOND V, 1991, BIOPHYS J, V60, P867, DOI 10.1016/S0006-3495(91)82120-8; KIDOKORO Y, 1988, P NATL ACAD SCI USA, V85, P1978, DOI 10.1073/pnas.85.6.1978; KIENY M, 1988, Biological Structures and Morphogenesis, V1, P15; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; MARAYAMA T, 1992, J BIOCH, V112, P514; OBRIEN J, 1993, BIOPHYS J, V65, P2418, DOI 10.1016/S0006-3495(93)81303-1; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; PAPE PC, 1993, J GEN PHYSIOL, V102, P295, DOI 10.1085/jgp.102.2.295; PERCIVAL AL, 1994, BIOPHYS J, V67, P1834, DOI 10.1016/S0006-3495(94)80665-4; POWELL JA, 1990, FASEB J, V4, P2798, DOI 10.1096/fasebj.4.10.2197156; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; RIOS E, 1988, NEWS PHYSIOL SCI, V3, P223, DOI 10.1152/physiologyonline.1988.3.6.223; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0	29	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4220	4223		10.1074/jbc.270.9.4220	http://dx.doi.org/10.1074/jbc.270.9.4220			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876181	hybrid			2022-12-25	WOS:A1995QK08400011
J	MARZULLO, L; CANNIO, R; GIARDINA, P; SANTINI, MT; SANNIA, G				MARZULLO, L; CANNIO, R; GIARDINA, P; SANTINI, MT; SANNIA, G			VERATRYL ALCOHOL OXIDASE FROM PLEUROTUS-OSTREATUS PARTICIPATES IN LIGNIN BIODEGRADATION AND PREVENTS POLYMERIZATION OF LACCASE-OXIDIZED SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHANEROCHAETE-CHRYSOSPORIUM; DEGRADING BASIDIOMYCETE; HYDROGEN-PEROXIDE; PURIFICATION; DEGRADATION; GENES	Oxidative enzymes (laccases and peroxidases) isolated from the culture media of different fungi are involved in the basic mechanism of ligninolysis via radical intermediates, However, experiments aimed at reproducing natural biodegradation in vitro have been unsuccessful so far since the single biocatalysts alone are not able to solubilize lignins because of the simultaneous recondensation of these intermediates, FAD oxidases can prevent this side reaction in lignin depolymerization by reducing quinonoids and radical compounds, This study investigates the possible role of a laccase and a FAD-dependent aryl alcohol oxidase (veratryl alcohol oxidase, VAO) excreted by the basidiomycete Pleurotus ostreatus, In fact, we found that VAO is able to reduce synthetic quinones, laccase-generated quinonoids, and phenoxy radicals with concomitant oxidation of veratryl alcohol to veratryl aldehyde, This cooperative action of laccase and VAO also prevented the polymerization of phenolic compounds and reduced the molecular weight of soluble lignosulfonates to a significant extent.	UNIV NAPLES FEDERICO II,DIPARTIMENTO CHIM ORGAN & BIOL,I-80134 NAPLES,ITALY; IST SUPER SANITA,ULTRASTRUTTURE LAB,I-00161 ROME,ITALY	University of Naples Federico II; Istituto Superiore di Sanita (ISS)			Marzullo, Liberato/C-4408-2008; Giardina, Paola/F-4130-2011	Marzullo, Liberato/0000-0001-6133-4483; Giardina, Paola/0000-0002-5446-8130; SANNIA, Giovanni/0000-0002-7986-6223				BOURBONNAIS R, 1988, BIOCHEM J, V255, P445, DOI 10.1042/bj2550445; CALDWELL ES, 1969, BIOCHIM BIOPHYS ACTA, V184, P420, DOI 10.1016/0304-4165(69)90046-4; DEJONG E, 1992, EUR J BIOCHEM, V208, P651; GALLIANO H, 1991, ENZYME MICROB TECH, V13, P478, DOI 10.1016/0141-0229(91)90005-U; GREEN TR, 1977, NATURE, V268, P78, DOI 10.1038/268078a0; GUILLEN F, 1990, APPL MICROBIOL BIOT, V32, P465, DOI 10.1007/BF00903784; GUILLEN F, 1994, APPL ENVIRON MICROB, V60, P2811; GUTIERREZ A, 1994, APPL ENVIRON MICROB, V60, P1783; HAEMMERLI SD, 1986, FEMS MICROBIOL LETT, V35, P33, DOI 10.1111/j.1574-6968.1986.tb01494.x; HAMMEL KE, 1993, J BIOL CHEM, V268, P12274; HARVEY PJ, 1986, FEBS LETT, V195, P242, DOI 10.1016/0014-5793(86)80168-5; HUOPONEN K, 1990, GENE, V89, P145, DOI 10.1016/0378-1119(90)90218-G; IWAHARA S, 1980, J FERMENT TECHNOL, V58, P183; KIMURA Y, 1990, APPL MICROBIOL BIOT, V32, P436, DOI 10.1007/BF00903779; KODURI RS, 1994, BIOCHEMISTRY-US, V33, P4425; LEONOWICZ A, 1985, PHYTOCHEMISTRY, V24, P393, DOI 10.1016/S0031-9422(00)80734-7; LUNDQUIST K, 1978, PHYTOCHEMISTRY, V17, P1676, DOI 10.1016/S0031-9422(00)94674-0; MUHEIM A, 1990, ENZYME MICROB TECH, V12, P204, DOI 10.1016/0141-0229(90)90039-S; ODIER E, 1988, BIOCHIMIE, V70, P847, DOI 10.1016/0300-9084(88)90117-4; PALMIERI G, 1993, APPL MICROBIOL BIOT, V39, P632, DOI 10.1007/BF00205066; SAMEJIMA M, 1992, EUR J BIOCHEM, V202, P103; SANNIA G, 1991, BIOCHIM BIOPHYS ACTA, V1073, P114, DOI 10.1016/0304-4165(91)90190-R; SHAH MM, 1993, BIOCHEM BIOPH RES CO, V191, P887, DOI 10.1006/bbrc.1993.1300; SHIMADA M, 1981, ARCH MICROBIOL, V129, P321, DOI 10.1007/BF00414706; SHIN KS, 1993, EUR J BIOCHEM, V215, P747, DOI 10.1111/j.1432-1033.1993.tb18088.x; SKLARZ G, 1986, PHYTOCHEMISTRY, V25, P2537; TONON F, 1988, APPL ENVIRON MICROB, V54, P466, DOI 10.1128/AEM.54.2.466-472.1988; WARIISHI H, 1994, BIOCHEMISTRY-US, V33, P5545, DOI 10.1021/bi00184a025	28	106	110	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3823	3827		10.1074/jbc.270.8.3823	http://dx.doi.org/10.1074/jbc.270.8.3823			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876125	hybrid			2022-12-25	WOS:A1995QH68800055
J	POKALSKY, C; WICK, P; HARMS, E; LYTLE, FE; VANETTEN, RL				POKALSKY, C; WICK, P; HARMS, E; LYTLE, FE; VANETTEN, RL			FLUORESCENCE RESOLUTION OF THE INTRINSIC TRYPTOPHAN RESIDUES OF BOVINE PROTEIN TYROSYL PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-PHOSPHATASE; 2 TRYPTOPHAN; MUTANTS; HEART; REPRESSOR	Fluorescence steady-state and lifetime measurements have been performed that permit the differentiation of the 2 intrinsic tryptophan residues in bovine low molecular weight phosphotyrosyl protein phosphatase (BPTP), Spectral information was obtained by use of two single-tryptophan mutant proteins, W39F and W49F, and the double mutant protein W39,49F, Fluorescence measurements show that Trp(39) is characterized by a large blue shift, a low quantum yield, and a shorter mean lifetime compared to Trp(49). Solute fluorescence quenching studies of W39F reveal that Trp(49) is, highly exposed to the aqueous environment, In contrast, Trp(39) is situated within a hydrophobic core and is only partially accessible to quenching agents such as acrylamide, iodide ion, and cesium ion, The fluorescence contributions of Trp(39),and Trp(49) are additive, and their sum is equivalent to that observed for wild type BPTP, Calculated intramolecular distances between Trp(39) or Trp(49) and, 5-[[C(acetylamino)-ethyl]amino]naphthalene-1-sulfonate group covalently bound at Cys(12) or Cys(17) of the respective protein mutants, place Trp(49) within 10 Angstrom and Trp(39) at least 20 Angstrom from the active site, The fluorescence decay of the single tryptophan mutants and, surprisingly, wild type BPTP were each adequately fitted as biexponential, The latter is a consequence of the imprecision involved in determining actual minima in a three- and four-exponential fitting, Comparison of quenching results of wild type BPTP with those of the single tryptophan mutant proteins indicates that minor fluorescence components, easily resolved using a biexponential fitting for the mutant proteins, are unresolvable for wild type BPTP, These minor components skewed the weighted magnitudes and induced perturbations in lifetimes for the tryptophan fluorescence of wild type BPTP, which directly influenced the calculated values of K-sv and k(q).	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA; PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027003] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 27003] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK MJ, 1983, ANAL BIOCHEM, V135, P233, DOI 10.1016/0003-2697(83)90756-X; BOIVIN P, 1986, BIOCHEM BIOPH RES CO, V134, P557, DOI 10.1016/S0006-291X(86)80456-9; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHERNOFF J, 1985, ARCH BIOCHEM BIOPHYS, V240, P135, DOI 10.1016/0003-9861(85)90016-5; DAVIS JP, 1994, J BIOL CHEM, V269, P8734; Demas J. N., 1983, EXCITED STATE LIFETI; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DRYDEN DTF, 1989, BIOCHIM BIOPHYS ACTA, V997, P313, DOI 10.1016/0167-4838(89)90202-1; EFTINK MR, 1987, BIOCHEMISTRY-US, V26, P8338, DOI 10.1021/bi00399a047; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1993, BIOCHEMISTRY-US, V32, P9189, DOI 10.1021/bi00086a026; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HARRIS JM, 1980, REV SCI INSTRUM, V51, P988, DOI 10.1063/1.1136324; HART KW, 1993, ADV SPECTROSC, V20, P195; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KASHA M, 1952, J CHEM PHYS, V20, P71, DOI 10.1063/1.1700199; KIRBY EP, 1970, J BIOL CHEM, V245, P6300; KRONMAN MJ, 1970, FINE STRUCTURE PROTE, P00271; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; LEATHERBARROW RJ, 1987, ENZYME MECHANISMS, P83; LOGAN TM, 1994, BIOCHEMISTRY-US, V33, P11087, DOI 10.1021/bi00203a005; MAS MT, 1994, BIOCHEMISTRY-US, V33, P2217; O'Connor D. V., 1984, TIME CORRELATED SING; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; ROYER CA, 1990, BIOPHYS J, V58, P363, DOI 10.1016/S0006-3495(90)82383-3; SAINI MS, 1981, J BIOL CHEM, V256, P453; STOLE E, 1994, J BIOL CHEM, V269, P7919; STRYJEWSKI W, 1986, EUR J BIOCHEM, V158, P547, DOI 10.1111/j.1432-1033.1986.tb09789.x; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WAHEED A, 1988, BIOCHEMISTRY-US, V27, P4265, DOI 10.1021/bi00412a010; WALDMAN ADB, 1987, BIOCHIM BIOPHYS ACTA, V913, P66, DOI 10.1016/0167-4838(87)90233-0; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; YOUNG L, 1994, PROTEIN SCI, V3, P717; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; ZHANG ZY, 1990, THESIS PURDUE U	41	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3809	3815		10.1074/jbc.270.8.3809	http://dx.doi.org/10.1074/jbc.270.8.3809			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876123	hybrid			2022-12-25	WOS:A1995QH68800053
J	SONOBE, MH; YOSHIDA, T; MURAKAMI, M; KAMEDA, T; IBA, H				SONOBE, MH; YOSHIDA, T; MURAKAMI, M; KAMEDA, T; IBA, H			FRA-2 PROMOTER CAN RESPOND TO SERUM-STIMULATION THROUGH AP-1 COMPLEXES	ONCOGENE			English	Article						TRANSCRIPTION; AUTOREGULATION; FRA-2; AP-1; SERUM-STIMULATION	C-FOS; ANTISENSE RNA; JUN PROTEINS; GENE FAMILY; CELLS; DNA; EXPRESSION; ONCOGENE; GROWTH; TRANSCRIPTION	fra-2 (fos-related antigen-2) expression is detected at a basal level even in growth-arrested chicken embryo fibroblasts (CEF), but upon serum-stimulation high levels of its transcripts are transiently observed. This induction is delayed and prolonged compared to that of c-fos. Transient expression experiments in CEF using a series of constructs of chicken fra-2 promoter region linked to the CAT reporter gene indicated previously that serum response element (SRE) is not required for full serum inducibility. In this report, we show that constructs in which the CRE-Like sequence and both AP-1 binding sites are disrupted lack serum inducibility, suggesting that either of these enhancers is important in serum induction of fra-2. In growth-arrested CEF, small amounts of Fra-2/c-Jun complex bind to the AP-1 consensus sequences in fra-2 promoter, while a significant part of the enhanced AP-1 binding activity after 60-120 min of serum stimulation is attributable to c-Fos/c-Jun heterodimer. At later times Fra-2/c-Jun again becomes the main complex. Transient expression assays in F9 cells indicated that c-Fos/c-Jun heterodimers have strong stimulatory effects on fra-2 promoter activity, while Fra-2/c-Jun complex has lower transcriptional activity than that of c-Jun homodimer. These results suggest that c-Fos (induced at earlier times) and c-Jun proteins are at least partly responsible for serum-induced expression of fra-2.	UNIV TOKYO,INST MED SCI,DEPT TUMOR VIRUS RES,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Sonobe, Martha/I-2877-2015					CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FOLETTA VC, 1994, ONCOGENE, V9, P3305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKUNO H, 1993, ONCOGENE, V8, P695; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; VANBEVEREN C, 1983, CELL, V27, P1241; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WEBSTER KA, 1990, MOL CELL BIOL, V10, P2402, DOI 10.1128/MCB.10.5.2402; YANISCHPERRON C, 1985, GENE, V4, P103; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	38	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					689	696						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862446				2022-12-25	WOS:A1995QH61200008
J	SUN, Y; HILDESHEIM, A; LANIER, AEP; CAO, Y; YAO, KT; RAABTRAUB, N; YANG, CS				SUN, Y; HILDESHEIM, A; LANIER, AEP; CAO, Y; YAO, KT; RAABTRAUB, N; YANG, CS			NO POINT MUTATION BUT DECREASED EXPRESSION OF THE P16/MTS1 TUMOR-SUPPRESSOR GENE IN NASOPHARYNGEAL CARCINOMAS	ONCOGENE			English	Note						NASOPHARYNGEAL CARCINOMA; TUMOR SUPPRESSOR GENE; GENE MUTATION AND EXPRESSION	P53; PROGRESSION; LINKAGE; REGION; PCR; DNA	Nasopharyngeal carcinoma (NPC) is a malignancy which occurs at high incidence in southern China and southeast Asia. The molecular mechanism of this disease, however, is not well understood. Recently, a homozygous deletion and/or loss of heterozygosity on chromosome 9p21-22 was found in several primary NPCs (Huang et al., Cancer Res, 54: 4003-4006, 1994), suggesting that a potential tumor suppressor gene(s) residing in this region may play a role in nasopharyngeal carcinogenesis. Since p16/MTS1, a potential tumor suppressor gene, whose mutations/deletions are frequently found in variety of tumor cells, was mapped to chromosome 9p21, we investigated the possible involvement of this gene in the development of NPC by mutational and Northern blot analysis. SSCP-direct sequencing revealed no point mutations of the p16/MTS-1 gene in any of 42 primary NPC biopsies from three geographical regions nor in two NPC cell lines. We did, however, observe a codon 140(ala-->thr) polymorphism in the gene, which has been previously reported as a point mutation. Furthermore, Northern analysis revealed a decreased expression of the p16/MTS1 gene in two out of two NPC cell lines as compared with immortalized/nontransformed cell lines. These results suggest that down regulation rather than a point mutation of the p16/MTS1 gene may play a role in the genesis of NPC.	NCI, FREDERICK CANC RES & DEV CTR, CELL BIOL SECT, VIRAL CARCINOGENESIS LAB, FREDERICK, MD USA; NCI, ENVIRONM EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; US PHS, INDIAN HLTH SERV, ALASKA AREA NAT HLTH SERV, ANCHORAGE, AK USA; HUNAN MED UNIV, INST HUMAN CANC, CHANGSHA, PEOPLES R CHINA; UNIV N CAROLINA, DEPT MICROBIOL, CHAPEL HILL, NC USA; NATL TAIWAN UNIV, COLL MED, INST MICROBIOL, TAIPEI 10764, TAIWAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Public Health Service; Central South University; University of North Carolina; University of North Carolina Chapel Hill; National Taiwan University								BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; HILDESHEIM A, 1993, EPIDEMIOL REV, V15, P466, DOI 10.1093/oxfordjournals.epirev.a036130; HUANG DP, 1994, CANCER RES, V54, P4003; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LU SJ, 1990, NATURE, V346, P470, DOI 10.1038/346470a0; MORI T, 1994, CANCER RES, V54, P3396; NAWROZ H, 1994, CANCER RES, V54, P1152; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SUN Y, 1993, ONCOGENE, V8, P791; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1993, BIOTECHNIQUES, V15, P372; SUN Y, 1992, CANCER RES, V52, P1907; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; SUN Y, 1992, BIOTECHNIQUES, V12, P639; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; VANDERRIET P, 1994, CANCER RES, V54, P1156; YA C, 1991, MOL CARCINOGEN, V4, P297, DOI 10.1002/mc.2940040408	23	71	85	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					785	788						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862458				2022-12-25	WOS:A1995QH61200021
J	TONJES, RR; LOHLER, J; OSULLIVAN, JF; KAY, GF; SCHMIDT, GH; DALEMANS, W; PAVIRANI, A; PAUL, D				TONJES, RR; LOHLER, J; OSULLIVAN, JF; KAY, GF; SCHMIDT, GH; DALEMANS, W; PAVIRANI, A; PAUL, D			AUTOCRINE MITOGEN IGEGF COOPERATES WITH C-MYC OR WITH THE HCS LOCUS DURING HEPATOCARCINOGENESIS IN TRANSGENIC MICE	ONCOGENE			English	Note						LIVER CANCER; TRANSGENIC MICE; EGF; C-MYC; ONCOGENE COOPERATION	GROWTH-FACTOR-ALPHA; HEPATOCELLULAR-CARCINOMA; CHEMICAL CARCINOGENESIS; LIVER NEOPLASIA; TGF-ALPHA; GENE; TUMORS; OVEREXPRESSION; ONCOGENESIS; PANCREAS	Hepatocarcinogenesis is deterministic in transgenic mice expressing in the liver gene construct Alb-DS4 that encodes\autocrine growth factor IgEGF (D Stern et al, (1987), Science 235: 321-324), causing their death within 7.1 months. Hepatic expression of construct AAT-myc encoding murine c-myc causes liver cancer in 44% of the mice at 14.8 months. Cooperation of these genes was evident in CD2F1 transgenics bearing Alb-DS4 plus AAT-myc, in which accelerated hepatocellular carcinoma (HCC) formation caused death of all mice within 4.4 months. Alb-DS4 also cooperates with the Hcs locus, which in C3H/HeJ mice mediates high susceptibility to spontaneous hepatocarcinogenesis, causing accelerated formation of HCC to which mice succumbed at 5.1 months. Thus, genes that predispose to HCC formation cooperate in transgenic mice and their interaction is a key to understand mechanisms that cause liver cancer.	FRAUNHOFER INST TOXICOL & MOLEK BIOL,DEPT CELL BIOL,D-30625 HANNOVER,GERMANY; UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY; TRANSGENE SA,F-67082 STRASBOURG,FRANCE	Fraunhofer Gesellschaft; Heinrich Pette Institute; University of Hamburg; Transgene SA			Kay, Graham F/A-4130-2011					AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5224; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; DRINKWATER NR, 1986, CARCINOGENESIS, V7, P1701, DOI 10.1093/carcin/7.10.1701; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HOFFMANN B, 1989, J CELL PHYSIOL, V139, P654, DOI 10.1002/jcp.1041390328; HOFFMANN B, 1990, J CELL PHYSIOL, V142, P149, DOI 10.1002/jcp.1041420118; HOGAN B, 1986, MANIPULATING MOUSE E; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HWANG DL, 1990, REGUL PEPTIDES, V29, P103, DOI 10.1016/0167-0115(90)90073-6; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; LEE GH, 1992, CANCER RES, V52, P5162; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MURAKAMI H, 1993, CANCER RES, V53, P1719; ORIAN JM, 1990, JNCI-J NATL CANCER I, V82, P393, DOI 10.1093/jnci/82.5.393; OSULLIVAN JF, 1991, NATURE, V352, P200, DOI 10.1038/352200a0; PERRAUD F, 1991, EXP CELL RES, V195, P59, DOI 10.1016/0014-4827(91)90500-T; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; Sambrook J, 1989, MOL CLONING LABORATO; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SCHULTEHERMANN R, 1985, ARCH TOXICOL, V57, P147, DOI 10.1007/BF00290879; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; TAKAGI H, 1992, CANCER RES, V52, P5171; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0	34	56	59	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					765	768						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862454				2022-12-25	WOS:A1995QH61200017
J	GETTEMANS, J; DEVILLE, Y; WAELKENS, E; VANDEKERCKHOVE, J				GETTEMANS, J; DEVILLE, Y; WAELKENS, E; VANDEKERCKHOVE, J			THE ACTIN-BINDING PROPERTIES OF THE PHYSARUM ACTIN-FRAGMIN COMPLEX - REGULATION OF CALCIUM, PHOSPHOLIPIDS, AND PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MODULATING PROTEIN; PLASMA GELSOLIN; POLYCEPHALUM; FILAMENTS; DOMAIN; PROFILIN; SEQUENCE; IDENTIFICATION	The actin-binding properties of the actin-fragmin complex hom Physarum polycephalum microplasmodia were investigated with respect to regulation by Ca2+, phospholipids, and phosphorylation of the actin subunit by the endogenous actin-fragmin kinase. Fragmin possesses two high affinity actin-binding sites and probably also a third, low affinity site. Its nucleating and F-actin severing activities are inhibited by phosphatidylinositol 4,5-bisphosphate (PIP2). Actin-fragmin specifically binds PIP2 which competes with actin for the Ca2+-sensitive site. However, PIP2, cannot dissociate the actin-fragmin complex nor the actin(2)-fragmin trimer. Efficient F-actin nucleating activity by actin-fragmin is only observed with unphosphorylated actin-fragmin, in the absence of PIP2 and at high Ca2+ (> mu M) concentrations. In the presence of PIP2, actin-fragmin only caps actin filaments when unphosphorylated. The results suggest that in the cell, hydrolysis of PIP2, concomitant with the increase of cytosolic Ca2+, could promote subcortical actin polymerization.	KATHOLIEKE UNIV LEUVEN,DIV BIOCHEM,B-3000 LOUVAIN,BELGIUM	KU Leuven	GETTEMANS, J (corresponding author), STATE UNIV GHENT,DEPT BIOCHEM,PHYSIOL CHEM LAB,LEDEGANCKSTR 35,B-9000 GHENT,BELGIUM.							AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER SL, 1983, J BIOL CHEM, V258, P5013; BRYAN J, 1986, J CELL BIOL, V102, P1439, DOI 10.1083/jcb.102.4.1439; BRYAN J, 1986, J CELL BIOL, V106, P1553; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; COUE M, 1985, J BIOL CHEM, V260, P5033; DITSCH A, 1994, EUR J BIOCHEM, V224, P223, DOI 10.1111/j.1432-1033.1994.tb20015.x; EICHINGER L, 1992, BIOCHEMISTRY-US, V31, P4779, DOI 10.1021/bi00135a006; FURUHASHI K, 1990, J CELL BIOL, V111, P1081, DOI 10.1083/jcb.111.3.1081; GETTEMANS J, 1993, EUR J BIOCHEM, V214, P111, DOI 10.1111/j.1432-1033.1993.tb17902.x; GETTEMANS J, 1992, EMBO J, V11, P3185, DOI 10.1002/j.1460-2075.1992.tb05395.x; GOLDSCHMIDTCLER.PJ, 1991, SCIENCE, V251, P1231; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HASEGAWA T, 1980, BIOCHEMISTRY-US, V19, P2677, DOI 10.1021/bi00553a021; HINSSEN H, 1981, EUR J CELL BIOL, V23, P234; HINSSEN H, 1981, EUR J CELL BIOL, V23, P225; HOFMANN A, 1992, CELL MOTIL CYTOSKEL, V23, P133, DOI 10.1002/cm.970230206; HOLMES KC, 1990, NATURE, V347, P37; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAM LE, 1993, J BIOL CHEM, V268, P14202; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MARKUS MA, 1994, PROTEIN SCI, V3, P70; MARUTA H, 1983, J BIOL CHEM, V258, P151; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; MCLAUGHLIN PJ, 1993, NATURE, V364, P677; OHNUMA M, 1993, J BIOCHEM-TOKYO, V114, P718, DOI 10.1093/oxfordjournals.jbchem.a124243; OHNUMA M, 1988, ZOOL SCI, V5, P691; ONODA K, 1993, J BIOL CHEM, V268, P4106; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SELVE N, 1987, EUR J BIOCHEM, V168, P111, DOI 10.1111/j.1432-1033.1987.tb13394.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; SUN HQ, 1994, J BIOL CHEM, V269, P9473; VANDEKERCKHOVE J, 1992, Current Opinion in Cell Biology, V4, P36, DOI 10.1016/0955-0674(92)90056-I; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1979, NATURE, V281, P581; YU FX, 1992, J BIOL CHEM, V267, P14616	46	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2644	2651		10.1074/jbc.270.6.2644	http://dx.doi.org/10.1074/jbc.270.6.2644			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852332	hybrid			2022-12-25	WOS:A1995QF53500040
J	SATO, A; NISHINO, T; NODA, K; AMAYA, Y; NISHINO, T				SATO, A; NISHINO, T; NODA, K; AMAYA, Y; NISHINO, T			THE STRUCTURE OF CHICKEN LIVER XANTHINE DEHYDROGENASE - CDNA CLONING AND THE DOMAIN-STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DINUCLEOTIDE-BINDING-SITE; DROSOPHILA-MELANOGASTER; O-2-DEPENDENT TYPES; CALLIPHORA-VICINA; ROSY LOCUS; OXIDASE; PROTEIN; SEQUENCE; GENE; PURIFICATION	The amino acid sequence of chicken Liver xanthine dehydrogenase (EC 1.1.1.204) was determined by cDNA cloning and partial amino acid sequencing of the purified enzyme. The enzyme consisted of 1358 amino acids with calculated molecular mass of 149,633 Da. In order to compare the structure of the chicken and rat enzymes, limited proteolysis was performed with the purified chicken Liver xanthine dehydrogenase. When the enzyme was digested with subtilisin, it was not converted fi om the NAD-dependent dehydrogenase type to the O-2-dependent oxidase type, in contrast with the mammalian enzyme. However, the enzyme was cleaved mainly into three fragments in a manner similar to that for the rat enzyme at pH 8.2 (20, 37, and 84 kDa) and retaining a full complement of redox centers. The cleavage sites were identified by determination of aminoterminal sequences of the produced fragments. It was concluded that the 20-kDa fragment was amino-terminal, the 84-kDa fragment carboxyl-terminal, and the 37-kDa fragment an intermediate portion in the enzyme protein. On the other hand, when the enzyme was digested with the same protease at pH 10.5, the sample contained only the 20- and 84-kDa portions and lacked the 37-kDa portion. The resultant sample possessed xanthine dichlorophenol indophenol reductase activity, indicating that the molybdenum center remained intact. The absorption spectrum showed the sample was very similar to deflavo-enzyme. From these results and sequence analyses, the domain structure of the enzyme is discussed.	NIPPON MED COLL, DEPT BIOCHEM & MOLEC BIOL, BUNKYO KU, TOKYO 113, JAPAN; YOKOHAMA CITY UNIV, SCH MED, DEPT BIOCHEM, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN	Nippon Medical School; Yokohama City University								AMAYA Y, 1990, J BIOL CHEM, V265, P14170; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW CW, 1994, NUCLEIC ACIDS RES, V22, P1846, DOI 10.1093/nar/22.10.1846; COUGHLAN MP, 1979, J BIOL CHEM, V254, P694; COUGHLAN MP, 1986, IRCS MED SCI-BIOCHEM, V14, P736; Della Corte E, 1968, Biochem J, V108, P349; Eger BT, 1994, FLAVINS AND FLAVOPROTEINS 1993, P727; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; Hille R., 1985, Metal Ions in Biology, V7, P443; HOUDE M, 1989, GENE, V85, P391, DOI 10.1016/0378-1119(89)90432-0; HUNT J, 1992, J BIOL CHEM, V267, P21479; ICHIDA K, 1993, GENE, V133, P279; KEITH TP, 1987, GENETICS, V116, P67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CS, 1987, GENETICS, V116, P55; Maniatis T., 1982, MOL CLONING; MASSEY V, 1989, J BIOL CHEM, V264, P10567; NAGLER LG, 1976, BIOCHIM BIOPHYS ACTA, V427, P78, DOI 10.1016/0005-2795(76)90287-7; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; NISHINO T, 1974, BIOCHIM BIOPHYS ACTA, V341, P93, DOI 10.1016/0005-2744(74)90069-2; NISHINO T, 1989, J BIOL CHEM, V264, P5468; NISHINO T, 1989, J BIOL CHEM, V264, P2518; NISHINO T, 1982, J BIOL CHEM, V257, P7348; NISHINO T, 1987, BIOCHEMISTRY-US, V26, P3068, DOI 10.1021/bi00385a018; Nishino T, 1994, FLAVINS AND FLAVOPROTEINS 1993, P699; RAJAGOPALAN KV, 1967, J BIOL CHEM, V242, P4097; ROCHERCHAMBONNET C, 1987, GENE, V59, P201, DOI 10.1016/0378-1119(87)90328-3; SAITO T, 1989, J BIOL CHEM, V264, P10015; SAITO T, 1989, J BIOL CHEM, V264, P15930; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; STIRPE F, 1969, J BIOL CHEM, V244, P3855; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690	37	71	72	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2818	2826		10.1074/jbc.270.6.2818	http://dx.doi.org/10.1074/jbc.270.6.2818			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852355	hybrid			2022-12-25	WOS:A1995QF53500065
J	SWAMY, N; BRISSON, M; RAY, R				SWAMY, N; BRISSON, M; RAY, R			TRP-145 IS ESSENTIAL FOR THE BINDING OF 25-HYDROXYVITAMIN-D-3 TO HUMAN SERUM VITAMIN-D BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-SPECIFIC COMPONENT; ALPHA-FETOPROTEIN; GC-GLOBULIN; ALBUMIN; LYMPHOCYTES; MEMBER; FAMILY; ACTIN	Chemical modification of specific amino acid residues in a protein has been a valuable tool in identifying amino acid residues that are responsible for ligand binding of a protein. In the present investigation, we targeted Trp and His residues in human serum vitamin D-binding protein (hDBP) by modifying them with specific chemical modifiers. We also evaluated the results of these modifications in the binding of 25-hydroxy[26(27)-H-3]vitamin D-3 ([H-3]25-OH-D-3) to hDBP. We observed a dose dependent loss of binding activity by N-bromosuccinimide (specific for Trp). Similar results were observed with diethylpyrocarbonate (specific for His). Furthermore, loss of [H-3]25-OH-D-3-binding was protected by preincubation of hDBP samples with an excess of 25-hydroxyvitamin D-3. These results strongly emphasized the importance of Trp (single residue at position 145) and 1 His residue (out of a total of 6) in the vitamin D sterol-binding by vitamin D-binding protein.	BOSTON UNIV,SCH MED,DEPT BIOORGAN & PROT CHEM,VITAMIN D LAB,BOSTON,MA 02118	Boston University				Ray, Rahul/0000-0002-2078-2201	NIDDK NIH HHS [DK 44337, DK 47418] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044337, R01DK047418] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COOKE NE, 1985, J CLIN INVEST, V76, P2420, DOI 10.1172/JCI112256; COOKE NE, 1989, ENDOCR REV, V10, P294, DOI 10.1210/edrv-10-3-294; HADDAD JG, 1982, ARCH BIOCHEM BIOPHYS, V213, P538, DOI 10.1016/0003-9861(82)90581-1; MILES EW, 1972, METHOD ENZYMOL, V25, P431; OVADI J, 1969, ACTA BIOCHIMICA B A, V4, P365; PETRINI M, 1985, J BIOL CHEM, V260, P1804; PETRINI M, 1983, NATURE, V306, P73, DOI 10.1038/306073a0; RAY R, 1991, BIOCHEMISTRY-US, V30, P4809, DOI 10.1021/bi00233a024; RAY R, 1991, BIOCHEMISTRY-US, V30, P7638, DOI 10.1021/bi00244a036; RAY R, 1986, BIOCHEMISTRY-US, V25, P4729, DOI 10.1021/bi00365a001; SCHOENTGEN F, 1986, BIOCHIM BIOPHYS ACTA, V871, P189, DOI 10.1016/0167-4838(86)90173-1; SPANDE TF, 1966, BIOCHEMISTRY-US, V5, P1926, DOI 10.1021/bi00870a020; VANBAELEN H, 1980, J BIOL CHEM, V255, P2270; YAMAMOTO N, 1991, P NATL ACAD SCI USA, V88, P8539, DOI 10.1073/pnas.88.19.8539; YANG F, 1985, P NATL ACAD SCI USA, V82, P7994, DOI 10.1073/pnas.82.23.7994; [No title captured]	16	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2636	2639		10.1074/jbc.270.6.2636	http://dx.doi.org/10.1074/jbc.270.6.2636			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852330	hybrid			2022-12-25	WOS:A1995QF53500038
J	TAYLOR, JM; DAVIES, JD; PETERSON, CA				TAYLOR, JM; DAVIES, JD; PETERSON, CA			REGULATION OF THE MYOBLAST-SPECIFIC EXPRESSION OF THE HUMAN BETA-ENOLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENOLASE; SATELLITE CELLS; GROWTH-FACTOR; VIMENTIN PROMOTER; EARLY MYOGENESIS; BINDING-FACTOR; DNA-BINDING; ENHANCER; TRANSCRIPTION; SEQUENCE	The muscle-specific beta-enolase gene is expressed in proliferating adult myoblasts as well as in differentiated myotubes. Through deletion-transfection analysis, we identified a 79-base pair enhancer from the beta-enolase gene that leads to high level expression of a reporter gene in myoblasts, but not in fibroblasts. Following myoblast differentiation into myotubes, the activity of the enhancer declined, indicating that beta-enolase gene expression in myotubes is mediated by other regulators, possibly the myogenic helix-loop-helix family of transcription factors. Electrophoretic mobility shift assays indicated that proteins present in myoblast nuclear extracts specifically bind to the 3' half of the 79-base pair enhancer. This region contains an ets DNA-binding motif which is required not only for high level activity in myoblasts, but also for repressing activity in fibroblasts. Furthermore, the beta-enolase myoblast-specific enhancer shows limited similarity to the myoblast-specific enhancer associated with the human desmin gene, suggesting that gene expression in adult myoblasts may be coordinately regulated.	UNIV ARKANSAS MED SCI HOSP,DEPT MED,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; JOHN L MCCLELLAN MEM VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Geriatric Research Education & Clinical Center					NIA NIH HHS [AG10523] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG010523] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARBIERI G, 1990, DIFFERENTIATION, V45, P179, DOI 10.1111/j.1432-0436.1990.tb00471.x; BORRAS T, 1988, DEV BIOL, V127, P209, DOI 10.1016/0012-1606(88)90202-3; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; COSSU G, 1987, CURR TOP DEV BIOL, V23, P185; COSSU G, 1985, EXP CELL RES, V160, P403, DOI 10.1016/0014-4827(85)90187-9; COSSU G, 1987, DEV BIOL, V123, P43, DOI 10.1016/0012-1606(87)90425-8; DARVILLE MI, 1992, NUCLEIC ACIDS RES, V20, P3575, DOI 10.1093/nar/20.14.3575; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FARRELL FX, 1990, MOL CELL BIOL, V10, P2349, DOI 10.1128/MCB.10.5.2349; FELDMAN JL, 1991, DEV BIOL, V143, P320, DOI 10.1016/0012-1606(91)90083-F; FELDMAN JL, 1992, DEV BIOL, V153, P217, DOI 10.1016/0012-1606(92)90107-R; GIALLONGO A, 1993, EUR J BIOCHEM, V214, P367, DOI 10.1111/j.1432-1033.1993.tb17932.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HARTLEY RS, 1992, DEV BIOL, V153, P206, DOI 10.1016/0012-1606(92)90106-Q; HARTLEY RS, 1991, DEV BIOL, V148, P249, DOI 10.1016/0012-1606(91)90334-Y; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; KELLER A, 1992, MECH DEVELOP, V38, P41, DOI 10.1016/0925-4773(92)90037-K; LAMANDE N, 1989, P NATL ACAD SCI USA, V86, P4445, DOI 10.1073/pnas.86.12.4445; LI ZL, 1993, J BIOL CHEM, V268, P10403; LI ZL, 1991, J BIOL CHEM, V266, P6562; LILLIE JW, 1989, CURR TOP MICROBIOL, V144, P191; LUCAS M, 1992, DIFFERENTIATION, V51, P1, DOI 10.1111/j.1432-0436.1992.tb00674.x; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ORKIN SH, 1992, BLOOD, V80, P575; PESHAVARIA M, 1991, BIOCHEM J, V275, P427, DOI 10.1042/bj2750427; PETERSON CA, 1992, DEV BIOL, V151, P626, DOI 10.1016/0012-1606(92)90201-Q; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; SAX CM, 1989, GENE, V78, P235, DOI 10.1016/0378-1119(89)90226-6; SHACKELFORD JE, 1981, J BIOL CHEM, V256, P6423; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TWEEDIE S, 1991, SOMAT CELL MOLEC GEN, V17, P215, DOI 10.1007/BF01232818; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VANDEKLUNDERT FAJM, 1992, GENE, V122, P337, DOI 10.1016/0378-1119(92)90223-C; WASYLYK B, 1993, EUR J BIOCHEM, V221, P7; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; YABLONKAREUVENI Z, 1993, DEV BIOL, V156, P307, DOI 10.1006/dbio.1993.1079; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	53	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2535	2540		10.1074/jbc.270.6.2535	http://dx.doi.org/10.1074/jbc.270.6.2535			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852315	hybrid			2022-12-25	WOS:A1995QF53500023
J	DIRKX, R; THOMAS, A; LI, LS; LERNMARK, A; SHERWIN, RS; DECAMILLI, P; SOLIMENA, M				DIRKX, R; THOMAS, A; LI, LS; LERNMARK, A; SHERWIN, RS; DECAMILLI, P; SOLIMENA, M			TARGETING OF THE 67-KDA ISOFORM OF GLUTAMIC-ACID DECARBOXYLASE TO INTRACELLULAR ORGANELLES IS MEDIATED BY ITS INTERACTION WITH THE NH2-TERMINAL REGION OF THE 65-KDA ISOFORM OF GLUTAMIC-ACID DECARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; STIFF-MAN SYNDROME; TERMINAL-SPECIFIC PHOSPHOPROTEIN; SYNAPTIC-LIKE MICROVESICLES; I PROTEIN-I; COFACTOR INTERACTIONS; AUTOANTIBODIES; FORMS; GAD-65; BRAIN	The two isoforms of glutamic acid decarboxylase (GAD), GAD67 and GAD65, synthesize the neurotransmitter gamma-aminobutyric acid in neurons and pancreatic beta-cells. Previous studies suggest that GAD67 is a soluble cytosolic protein, whereas GAD65 is membrane-associated. Here, we study the intracellular distribution of GAD67 in neurons, pancreatic beta-cells, and fibroblasts transfected either with GAD65 and GAD67 together or with GAD67 alone. Neuronal GAD67 is partially recovered with GAD65 in membrane-containing pellet fractions and Triton X-114 detergent phases. The two proteins co-immunoprecipitate from extracts of brain and GAD65-GAD67 co-transfected fibroblasts, but not when extracts of GAD65 and GAD67 transfected fibroblasts were mixed and used as a starting material for immunoprecipitation, GAD67 is concentrated in the Golgi complex region in GAD65-GAD67 co-transfected fibroblasts, but not in fibroblasts transfected with GAD67 alone. A pool of neuronal GAD67 co-localizes with GAD65 in the Golgi complex region and in many synapses. The two proteins also co-localize in the perinuclear region of some pancreatic beta-cells. GAD67 interacts with the NH2-terminal region of GAD65, even in the absence of palmitoylation of this region of GAD65. Taken together, our results indicate that GAD65-GAD67 association occurs in vivo and is required for the targeting of GAD67 to membranes.	YALE UNIV, SCH MED, DEPT INTERNAL MED, ENDOCRINOL SECT, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06520 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; KAROLINSKA INST, KAROLINSKA HOSP, DEPT ENDOCRINOL, S-17176 STOCKHOLM, SWEDEN	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; University of Washington; University of Washington Seattle; Karolinska Institutet; Karolinska University Hospital			Solimena, Michele/GVS-5990-2022; Lernmark, Åke/F-8140-2015; Solimena, Michele/E-1275-2011	Lernmark, Åke/0000-0003-1735-0499; 	NIDDK NIH HHS [DK-45735, DK-43078, R01 DK026190] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026190, P30DK045735, P01DK043078] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BAEKKESKOV S, 1988, DIABETOLOGIA, V31, pA466; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUTLER MH, 1993, J EXP MED, V178, P2097, DOI 10.1084/jem.178.6.2097; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHANG YC, 1988, J NEUROSCI, V8, P2123; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRISTGAU S, 1991, J BIOL CHEM, V266, P21257; CHRISTGAU S, 1992, J CELL BIOL, V118, P309, DOI 10.1083/jcb.118.2.309; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; ERLANDER MG, 1991, NEUROCHEM RES, V16, P215, DOI 10.1007/BF00966084; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; ESCLAPEZ M, 1994, J NEUROSCI, V14, P1834, DOI 10.1523/JNEUROSCI.14-03-01834.1994; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KARLSEN AE, 1992, DIABETES, V41, P1355, DOI 10.2337/diabetes.41.10.1355; KAUFMAN DL, 1991, J NEUROCHEM, V56, P720, DOI 10.1111/j.1471-4159.1991.tb08211.x; KOBAYASHI Y, 1987, J NEUROSCI, V7, P2768; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGAY F, 1987, J NEUROCHEM, V48, P1022, DOI 10.1111/j.1471-4159.1987.tb05620.x; LI LS, 1994, J IMMUNOL, V152, P930; MARTIN DL, 1991, J NEUROSCI, V11, P2725; MARTIN DL, 1991, NEUROCHEM RES, V16, P243, DOI 10.1007/BF00966087; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; MCLAUGHLIN BJ, 1975, BRAIN RES, V85, P355, DOI 10.1016/0006-8993(75)90813-6; MUNDIGL O, 1994, CURR OPIN CELL BIOL, V6, P561, DOI 10.1016/0955-0674(94)90077-9; OERTEL WH, 1981, NEUROSCIENCE, V6, P2689, DOI 10.1016/0306-4522(81)90113-5; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; SHI YG, 1994, J CELL BIOL, V124, P927, DOI 10.1083/jcb.124.6.927; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; SOLIMENA M, 1993, P NATL ACAD SCI USA, V90, P3073, DOI 10.1073/pnas.90.7.3073; SOLIMENA M, 1994, J CELL BIOL, V126, P331, DOI 10.1083/jcb.126.2.331; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; SOLIMENA M, 1994, IN PRESS J ENDOCRINO; SORENSON RL, 1991, DIABETES, V40, P1365, DOI 10.2337/diabetes.40.11.1365; THOMASREETZ A, 1993, P NATL ACAD SCI USA, V90, P5317, DOI 10.1073/pnas.90.11.5317; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VELLOSO LA, 1993, J CLIN INVEST, V91, P2084, DOI 10.1172/JCI116431; WYBORSKI RJ, 1990, MOL BRAIN RES, V8, P193, DOI 10.1016/0169-328X(90)90016-7; XU T, 1992, DEVELOPMENT, V115, P913	41	74	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2241	2246		10.1074/jbc.270.5.2241	http://dx.doi.org/10.1074/jbc.270.5.2241			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836456				2022-12-25	WOS:A1995QE49300041
J	KODANDAPANI, R; VEERAPANDIAN, B; KUNICKI, TJ; ELY, KR				KODANDAPANI, R; VEERAPANDIAN, B; KUNICKI, TJ; ELY, KR			CRYSTAL-STRUCTURE OF THE OPG2 FAB - AN ANTIRECEPTOR ANTIBODY THAT MIMICS AN RGD CELL-ADHESION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PLATELET-AGGREGATION INHIBITOR; NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL STRUCTURE; CRYSTALLOGRAPHIC REFINEMENT; MONOCLONAL-ANTIBODY; SECONDARY STRUCTURE; MACROMOLECULAR STRUCTURES; ALPHA-5-BETA-1 INTEGRIN; SURFACE GLYCOPROTEIN	Cell surface receptors called integrins mediate di verse cell adhesion phenomena through recognition of the sequence arginine glycine aspartic acid (RGD) present in proteins such as fibronectin and fibrinogen. Platelet aggregation in hemostasis is mediated by the binding of fibrinogen to the gpIIb/IIIa integrin. The OPG2 antibody binds the gpIIb/IIIa receptor and acts as a ligand mimic due to the presence of an arginine-tyrosine-aspartic acid (RYD) sequence in the CDR3 loop of the heavy chain. The RYD loop and side chains are ordered in the 2.0-Angstrom resolution crystal structure of the Fab fragment from this antireceptor antibody, Moreover, the RYD loop assumes two clearly defined conformations that may correspond to the orientations of the loop in the free state or bound to integrin, This molecule will serve as a tool for understanding protein-integrin recognition in platelet aggregation and other RGD-mediated cell adhesion interactions.	LA JOLLA CANC RES FDN, CTR CANC RES, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute					NHLBI NIH HHS [HL46979] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046979] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAT TN, 1984, J APPL CRYSTALLOGR, V17, P244, DOI 10.1107/S0021889884011456; BOGUSKY MJ, 1992, INT J PEPT PROT RES, V39, P63; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BUSK M, 1992, J BIOL CHEM, V267, P5790; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CELIKEL R, 1993, ACTA CRYSTALLOGR D, V49, P421, DOI 10.1107/S0907444993002501; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; COOKE RM, 1991, EUR J BIOCHEM, V202, P323, DOI 10.1111/j.1432-1033.1991.tb16379.x; DALVIT C, 1991, EUR J BIOCHEM, V202, P315, DOI 10.1111/j.1432-1033.1991.tb16378.x; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; FAN ZC, 1992, J MOL BIOL, V228, P188, DOI 10.1016/0022-2836(92)90500-J; FAUCHERE JL, 1993, INT J PEPT PROT RES, V42, P440; FUREY W, 1990, 40TH ACA ANN M NEW O, P33; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1991, CHEM IMMUNOL, V50, P75; GURRATH M, 1992, EUR J BIOCHEM, V210, P911, DOI 10.1111/j.1432-1033.1992.tb17495.x; HE XM, 1992, P NATL ACAD SCI USA, V89, P7154, DOI 10.1073/pnas.89.15.7154; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; LU XJ, 1993, BIOCHEM J, V296, P21, DOI 10.1042/bj2960021; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MCDOWELL RS, 1992, BIOCHEMISTRY-US, V31, P4766, DOI 10.1021/bi00135a004; NIIYA K, 1987, BLOOD, V70, P475; NISHIMURA SL, 1993, MOL BIOL CELL S, V4, P285; NOWLIN DM, 1993, J BIOL CHEM, V268, P20352; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; Pflugrath J. W., 1984, Methods and Applications in Crystallographic Computing. International Summer School on Crystallographic Computing, P404; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; ROSSMANN MG, 1972, MOL REPLACEMENT METH, V13; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; SENN H, 1993, J MOL BIOL, V232, P907, DOI 10.1006/jmbi.1993.1439; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SOTERIADOU KP, 1992, J BIOL CHEM, V267, P13980; TAUB R, 1989, J BIOL CHEM, V264, P259; TAUB R, 1992, BIOCHEMISTRY-US, V31, P7431, DOI 10.1021/bi00148a001; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TOMIYAMA Y, 1992, BLOOD, V79, P2303; TSCHOPP JF, 1993, CORONARY ARTERY DIS, V4, P1; VIX O, 1993, PROTEINS, V15, P339, DOI 10.1002/prot.340150402; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461	62	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2268	2273		10.1074/jbc.270.5.2268	http://dx.doi.org/10.1074/jbc.270.5.2268			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836460	hybrid			2022-12-25	WOS:A1995QE49300046
J	HUANG, RP; ADAMSON, ED				HUANG, RP; ADAMSON, ED			A BIOLOGICAL ROLE FOR EGR-1 IN CELL-SURVIVAL FOLLOWING ULTRA-VIOLET IRRADIATION	ONCOGENE			English	Article						ANTISENSE EGR-1; NIH3T3; IMMUNOBLOTTING; OXIDATIVE STRESS; DNA DAMAGE	IONIZING-RADIATION; CANCER MORTALITY; P53 GENE; C-FOS; PROTEIN; UV; ACTIVATION; INDUCTION; ELEMENTS; PROMOTER	The response to ultra-violet (u.v.) irradiation varies among cells, but commonly involves the rapid increase in expression of one or more transcription factors. The specific roles of this increased expression are largely unknown. We show here that in mouse NIH3T3 cells, Egr-1 expression is increased two-fold 10 min after u.v. irradiation, rises to a maximum (eightfold induction) after about 2 h and then declines. The expression of p53 protein is also strongly induced but is maximal between 2 to 4 h before declining. In contrast, the expression of c-Fos, and c-Jun proteins are only slightly affected by u.v. The Egr-1 response is independent of the growth state of the cells but depends on tyrosine kinase and protein kinase C activities. c-Ha-Ras is also involved in the induction of Egr-1 in u.v. irradiated cells. Evidence presented suggests that the mechanism for the response involves oxidative stress rather than DNA damage. We show that Egr-1 functions in the protection of cells against u.v. damage since NIH3T3 cells that constitutively; express antisense Egr-1 and consequently cannot produce an Egr-1 response to u.v., grow at a rate 26% less than similarly irradiated parental cells and 36% less than nonirradiated parental cells. This is the second protective role described for Egr-1.			HUANG, RP (corresponding author), LA JOLLA CANC RES FDN,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NCI NIH HHS [P30-CA30199] Funding Source: Medline; NICHD NIH HHS [HD 21957] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021957] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BLAUSTEIN AR, 1994, P NATL ACAD SCI USA, V91, P1791, DOI 10.1073/pnas.91.5.1791; BRYANT PE, 1992, MUTAT RES, V268, P27, DOI 10.1016/0027-5107(92)90079-H; BUSCHER M, 1988, ONCOGENE, V3, P301; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DING RC, 1992, J BIOL CHEM, V267, P12804; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORNACE AJ, 1992, ANN REV GENET, V26, P506; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V86, P901; GARLAND FC, 1990, PREV MED, V19, P614, DOI 10.1016/0091-7435(90)90058-R; GHOSH R, 1993, MOL CELL BIOL, V13, P6992, DOI 10.1128/MCB.13.11.6992; GINSBERG D, 1990, ONCOGENE, V5, P1285; GORHAM ED, 1989, CAN J PUBLIC HEALTH, V80, P96; GORHAM ED, 1990, INT J EPIDEMIOL, V19, P820, DOI 10.1093/ije/19.4.820; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; HALLAHAN DE, 1992, RADIAT RES, V129, P345, DOI 10.2307/3578035; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HUANG RP, 1994, ONCOGENE, V9, P1367; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; HUANG RP, 1994, J CELL BIOCHEM, V57, P1; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MERCOLA D, 1992, ONCOGENE, V7, P1793; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; OCHI T, 1987, P NATL ACAD SCI USA, V84, P990, DOI 10.1073/pnas.84.4.990; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RACHAL MJ, 1989, NUCLEIC ACIDS RES, V17, P5135, DOI 10.1093/nar/17.13.5135; RONAI ZA, 1988, ONCOGENE, V2, P201; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SATOH MS, 1992, NATURE, V365, P356; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; WILSON RE, 1993, ONCOGENE, V8, P3229; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XANTHOUDAKIS S, 1992, EMBO J, V11, P3233; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	47	63	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					467	475						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845671				2022-12-25	WOS:A1995QF64800007
J	LI, YJ; LAURENTPUIG, P; SALMON, RJ; THOMAS, G; HAMELIN, R				LI, YJ; LAURENTPUIG, P; SALMON, RJ; THOMAS, G; HAMELIN, R			POLYMORPHISMS AND PROBABLE LACK OF MUTATION IN THE WAF1-CIP1 GENE IN COLORECTAL-CANCER	ONCOGENE			English	Note						WAF1-CTP1 GENE; POLYMORPHISM; COLORECTAL	GRADIENT GEL-ELECTROPHORESIS; WILD-TYPE P53; ALLELOTYPE; PROTEIN; APOPTOSIS; INHIBITOR; KINASES; P21	WAF1/CIP1, a gene up-regulated by p53 encodes an inhibitor of cyclin-dependent kinases. Induction of WAF1/CIP1 in cells,vith intact p53 is believed to be instrumental in cell cycle arrest and apoptosis caused by DNA damage. In a model system, WAF1/CIP1 has been shown to have tumor suppressive activity. It is not known however whether WAF1/CIP1 is mutated in human primary tumors. Cells from colorectal cancer have been shown to acquire a series of genetic alterations, including frequent p53 mutations. Thus colorectal tumors, particularly those without identified p53 mutations, are good candidate to search for putative WAF1/CIP1 mutations. DNA extracted from 45 tumors, (including 28 tumors for which p53 mutations had previously been searched for and not found) were PCR amplified for exon 2 of WAF1/CIP1. A search for point mutations was performed in each amplified product using a denaturing gradient gel electrophoresis (DGGE) technique which enables the efficient screening of codons 9 to 139 (i.e. 80% of the WAF1/CIP1 coding sequence). TWO different DNA variants were identified and shown to be present in constitutional DNAs of the corresponding patients. The first variant, a C to A transversion at codon 31, changes a serine for an arginine and was detected in eight tumors (18% of the cases). The second variant, detected in a single case (2%) is a silent A to T transversion at the third base of codon 91. DNA extracted from 70 unrelated members from the Centre d'Etude du Polymorphisme Humain (CEPH) was screened for these polymorphisms. The ser/arg polymorphism of codon 31 was detected in seven cases (10%) thus suggesting that it is not associated with a marked colorectal cancer predisposition. The polymorphism on codon 91 was not detected. Two additional variants (arginine to histidine at position 67 and threonine to methionine at position 80) were observed once each in the CEPH family members. Somatic mutation of the WAF1/CIP1 gene was not observed, indicating that, unless there are hot spots for mutations outside the screened region, this gene is not a frequent site of point mutation in colorectal cancer.	INST CURIE,GENET TUMEURS LAB,F-75231 PARIS 05,FRANCE; INST CURIE,MED SECT,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			laurent-puig, pierre/B-2226-2013; Laurent-Puig, Pierre/K-3641-2019	laurent-puig, pierre/0000-0001-8475-5459; Laurent-Puig, Pierre/0000-0001-8475-5459				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HAMELIN R, 1993, ONCOGENE, V8, P2213; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORITA R, 1991, CANCER RES, V51, P820; MOYRET C, 1994, ONCOGENE, V9, P1739; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SATO T, 1991, CANCER RES, V51, P5118; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	26	92	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					599	601						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845685				2022-12-25	WOS:A1995QF64800021
J	FRANCO, M; CHARDIN, P; CHABRE, M; PARIS, S				FRANCO, M; CHARDIN, P; CHABRE, M; PARIS, S			MYRISTOYLATION OF ADP-RIBOSYLATION FACTOR-1 FACILITATES NUCLEOTIDE EXCHANGE AT PHYSIOLOGICAL MG2+ LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-DEPENDENT BINDING; COP-COATED VESICLES; GOLGI MEMBRANES; BREFELDIN-A; FACTOR ARF; GUANINE-NUCLEOTIDE; ESCHERICHIA-COLI; PHOSPHOLIPASE-D; CHOLERA-TOXIN; PROTEIN	Recombinant N-myristoylated bovine ADP-ribosylation factor 1 (myr-rARF1) has been expressed in bacteria and purified to near homogeneity with a high (85%) myristoylation efficiency. Myr-rARF1 and nonmyristoylated rARF1 have been compared with respect to their kinetics of guanine nucleotide exchange and their interactions with phospholipids. Myristoylation is shown to allow the release of bound GDP at physiological (mM) concentrations of Mg2+. GDP dissociation is slow in the absence of phospholipids but is accelerated a-fold in the presence of phospholipid vesicles. On the contrary, myristoylation decreases 10-fold the rate of dissociation of GTP or guanosine 5'-O-(thiotriphosphate) (GTP gamma S) in the presence of phospholipids. As a result, myr-ARF1 can be spontaneously activated by GTP or GTP gamma S (t1/2 similar to 30 min at 37 degrees C) at 1 mM Mg2+, in the sole presence of phospholipid membranes without the need for a nucleotide exchange factor. In contrast to the nonacylated protein, the GDP-bound form of myr-ARF1 interacts with phospholipids, as demonstrated by its cosedimentation with phospholipid vesicles and its comigration with phospholipid/cholate micelles on gel filtration. The interaction is, however, weaker than for the GTP-bound form, suggesting that only the myristate in myr-ARF1(GDP) interacts with phospholipids, whereas both the myristate and the amino-terminal hydrophobic residues in myr-ARF1(GTP) bind to phospholipids.	CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Franco, Michel/ABH-4993-2020; FRANCO, michel/AAA-9735-2021	Franco, Michel/0000-0003-1853-8661; 				BALCH WE, 1992, J BIOL CHEM, V267, P13053; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FRANCO M, 1993, J BIOL CHEM, V268, P24531; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	26	147	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1337	1341		10.1074/jbc.270.3.1337	http://dx.doi.org/10.1074/jbc.270.3.1337			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836400	hybrid			2022-12-25	WOS:A1995QB15600055
J	KIM, K; NAMGOONG, SY; JAYARAM, M; HARSHEY, RM				KIM, K; NAMGOONG, SY; JAYARAM, M; HARSHEY, RM			STEP-ARREST MUTANTS OF PHAGE MU-TRANSPOSASE - IMPLICATIONS IN DNA-PROTEIN ASSEMBLY, MU-END CLEAVAGE, AND STRAND TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; FLP RECOMBINASE; INVITRO TRANSPOSITION; REACTION-MECHANISM; 3'-5' EXONUCLEASE; ESCHERICHIA-COLI; ION CATALYSIS; POLYMERASE-I; ACTIVE-SITE; AMINO-ACID	We describe the isolation and characterization of Mu A variants arrested at specific steps of transposition. Mutations at 13 residues within the Mu A protein were analyzed for precise excision of Mu DNA in vivo. A subset of the defective variants (altered at Asp(269), Asp(294), Gly(348), and Glu(392)) were tested in specific steps of transposition in vitro. It is possible that at least some residues of the Asp(269)-Asp(294)-Glu(392) triad may have functional similarities to those of the conserved Asp-Asp-Glu motif found in several transposases and retroviral integrases. Mu A(D269V) is defective in high-order DNA-protein assembly, Mu end cleavage, and strand transfer. The assembly defect, but not the catalytic defect, can be overcome by precleavage of Mu ends, Mu A(E392A) can assemble the synaptic complex, but cannot cleave Mu ends, A mutation of Gly(348) to aspartic acid within Mu A permits the uncoupling of cleavage and strand transfer activities. This mutant is completely defective in synaptic assembly and Mu end cleavage in presence of Mg2+. The assembly defect is alleviated by replacing Mg2+ with Ca2+. Some Mu end cleavage is observed with this mutant in the presence of Mn2+. When presented with precleaved Mu ends, Mu A(G348D) exhibits efficient strand transfer activity.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6645; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BETERMIER M, 1989, MOL MICROBIOL, V3, P1159, DOI 10.1111/j.1365-2958.1989.tb00266.x; BREMER E, 1988, GENE, V71, P177, DOI 10.1016/0378-1119(88)90089-3; BUKHARI AI, 1975, J MOL BIOL, V96, P87, DOI 10.1016/0022-2836(75)90183-7; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; HARSHEY RM, 1985, P NATL ACAD SCI USA, V82, P7676, DOI 10.1073/pnas.82.22.7676; HARSHEY RM, 1986, J GENET, V65, P159, DOI 10.1007/BF02931149; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KRAMER W, 1993, NUCLEIC ACIDS RES, V12, P9441; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; LEE J, 1993, J BIOL CHEM, V268, P17564; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; Maniatis T., 1982, MOL CLONING; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; NAMGOONG S, 1994, J MOL BIOL, V238, P514, DOI 10.1006/jmbi.1994.1311; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PRIESS H, 1987, PHAGE MU, P277; QIAN XH, 1990, J BIOL CHEM, V265, P21779; RADSTROM P, 1994, J BACTERIOL, V176, P3257, DOI 10.1128/jb.176.11.3257-3268.1994; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; Suck D, 1992, CURR OPIN STRUC BIOL, V2, P84; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; VANGENT DC, 1993, NUCLEIC ACIDS RES, V21, P3373, DOI 10.1093/nar/21.15.3373	41	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1472	1479		10.1074/jbc.270.3.1472	http://dx.doi.org/10.1074/jbc.270.3.1472			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836417	hybrid			2022-12-25	WOS:A1995QB15600074
J	HIGASHITSUJI, H; ARII, S; FURUTANI, M; IMAMURA, M; KANEKO, Y; TAKENAWA, J; NAKAYAMA, H; FUJITA, J				HIGASHITSUJI, H; ARII, S; FURUTANI, M; IMAMURA, M; KANEKO, Y; TAKENAWA, J; NAKAYAMA, H; FUJITA, J			ENHANCED EXPRESSION OF MULTIPLE PROTEIN-TYROSINE PHOSPHATASES IN THE REGENERATING MOUSE-LIVER - ISOLATION OF PTP-RL10, A NOVEL CYTOPLASMIC-TYPE PHOSPHATASE WITH SEQUENCE HOMOLOGY TO CYTOSKELETAL PROTEIN-4.1	ONCOGENE			English	Note						PARTIAL HEPATECTOMY; LIVER REGENERATION; PROTEIN TYROSINE PHOSPHATASE; PTP-RL10, EZRIN; BAND 4.1	IMMEDIATE-EARLY GENE; MOLECULAR-CLONING; CDNA SEQUENCE; RECEPTOR; FAMILY; IDENTIFICATION; GROWTH; MEMBER; EZRIN; BAND-4.1	To elucidate the role that protein tyrosine phosphatases (PTPs) may play in liver regeneration, PTPs expressed in the mouse liver after partial hepatectomy (PH) were investigated by a PCR-based cloning method, Sequencing of 115 cDNA clones identified 10 different sequences including MPTP (T cell PTP), PTP-1B, PTP-P19, mR-PTP mu, R-PTP alpha, PTP NE-3 (PTP-P1), R-PTP-kappa and the murine homologue of human LAR, The remaining two sequences, PTP-RL9 and PTP-RL10, encoded novel PTPs. PTP-RL10 cDNA contained an open reading frame of 1176 amino acids with no apparent membrane-spanning region. The amino-terminal region had sequence homology to those of human erythrocyte protein 4.1 and ezrin, cytoskeletal proteins. In the regenerating liver, the levels of five PTP gene mRNAs (MPTP, PTP-P19, R-PTP alpha, LAR homologue, and PTP-RL9) increased within 6h, decreased to the normal level by 24h, and increased again at 48 to 72 h after PH, The levels of PTP-1B and R-PTP-kappa mRNAs peaked within 6 h, decreased gradually, and returned to the normal level by 168 h after PH, In contrast, the levels of two PTP mRNAs (mR-PTP mu and PTP-RL10) peaked at 48 to 72 h, and returned to the normal level by 168 h after PH, No expression of PTP NE-3 was detected in the liver by Northern blotting, The differential expression of multiple PTPs during the prereplicative and post-replicative stages of liver regeneration suggests that PTPs are involved in the regulation of growth and differentiation of liver cells.	KYOTO UNIV,FAC MED,DEPT SURG 1,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT CLIN MOLEC BIOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University; Kyoto University								BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOEHM T, 1993, ONCOGENE, V8, P1385; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUCHER NLR, 1963, INT REV CYTOL, V15, P245, DOI 10.1016/S0074-7696(08)61119-5; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; CORREAS I, 1986, J BIOL CHEM, V261, P3362; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; FAUSTO N, 1989, LAB INVEST, V60, P4; FAUSTO N, 1990, HEPATOLOGY TXB LIVER, P49; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GRISHAM JW, 1962, CANCER RES, V22, P842; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HERTOG JD, 1992, BIOCHEM BIOPH RES CO, V184, P1241; Higgins GM, 1931, ARCH PATHOL, V12, P186; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KANEKO Y, 1993, BIOCHEM BIOPH RES CO, V197, P625, DOI 10.1006/bbrc.1993.2525; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYASAKA H, 1992, BIOCHEM BIOPH RES CO, V185, P818, DOI 10.1016/0006-291X(92)91700-Z; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; PAN MG, 1993, J BIOL CHEM, V268, P19284; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHEPENS J, 1992, MOL BIOL REP, V16, P241, DOI 10.1007/BF00419663; STRAIN AJ, 1994, EXP CELL RES, V210, P253, DOI 10.1006/excr.1994.1037; STREULI M, 1988, J EXP MED, V168, P1553; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WILGENBUS KK, 1993, GENOMICS, V16, P199, DOI 10.1006/geno.1993.1159; YANG Q, 1993, J BIOL CHEM, V268, P6622; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1991, BLOOD, V78, P2222; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	52	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					407	414						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838537				2022-12-25	WOS:A1995QC62400021
J	SPARKS, DL; ANANTHARAMAIAH, GM; SEGREST, JP; PHILLIPS, MC				SPARKS, DL; ANANTHARAMAIAH, GM; SEGREST, JP; PHILLIPS, MC			EFFECT OF THE CHOLESTEROL CONTENT OF RECONSTITUTED LPA-I ON LECITHIN-CHOLESTEROL ACYLTRANSFERASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; LIPID TRANSFER PROTEIN; PLASMA-LIPOPROTEINS; ESTERIFICATION; PARTICLES; CHARGE; ESTER; RECOMBINANTS; METABOLISM	The production of cholesteryl ester (CE) by lecithin: cholesterol acyl transferase (LCAT) is elevated significantly in hyperlipidemic subjects at high risk for coronary artery disease. To elucidate the molecular events involved, the relationship between LCAT activation and apolipoprotein (apo) A-I charge and structure in high density lipoproteins (HDL) has been studied in both native HDL and homogeneous recombinant HDL (Lp2A-I) particles containing apoA-I, palmitoyloleoyl phosphatidylcholine and cholesterol. Increasing the cholesterol content of discoidal Lp2A-I from 4 to 26 molecules/particle raises the maximum rate of cholesterol esterification by LCAT (V-max) from 3.1 to 9.2 nmol CE/h/unit of LCAT and increases the apparent K-m from 0.5 to 3.5 mu M cholesterol. Similarly, increasing the cholesterol content in triolein core-containing Lp2A-I (4-18 molecules/particle) and in native HDL(3) (12-21 molecules/particle) also significantly increases the V-max for LCAT (2.8-7.7 and 0.5-3.6 nmol CE/h, respectively) and raises the K-m values (7.6-36.9 and 7.3-8.5 mu M cholesterol, respectively). In contrast, changes in the cholesterol content of native and recombinant HDL have no significant effect on the apparent K-m values when expressed in terms of the concentration of either apoA-I or palmitoyloleoyl phosphatidylcholine. This appears to indicate that interfacial cholesterol content has no effect on the binding affinity of LCAT to different LpA-I particles but directly affects catalysis by modulating the interaction of cholesterol molecules with the active site of LCAT. Increasing the cholesterol content of the different HDL particles progressively increases the particle net negative charge, and these changes in apoA-I charge are strongly correlated with both the V-max and apparent K-m values for LCAT, This suggests that the conformation and charge of apoA-I play a central role in LCAT activation and that these parameters are influenced by the amount of cholesterol in the surface of HDL particles.	UNIV ALABAMA,MED CTR,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,MED CTR,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,MED CTR,ATHEROSCLEROSIS RES UNIT,BIRMINGHAM,AL 35294; MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Drexel University	SPARKS, DL (corresponding author), UNIV OTTAWA,INST HEART,LIPOPROT & ATHEROSCLEROSIS GRP,1053 CARLING AVE,OTTAWA,ON K1Y 4E9,CANADA.			Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL22633, HL34343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343, P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albers J J, 1986, Methods Enzymol, V129, P763; AZEMA C, 1990, BIOCHIM BIOPHYS ACTA, V1046, P73, DOI 10.1016/0005-2760(90)90096-G; BARTER PJ, 1985, ATHEROSCLEROSIS, V58, P97, DOI 10.1016/0021-9150(85)90058-9; BARTER PJ, 1984, BIOCHIM BIOPHYS ACTA, V793, P260, DOI 10.1016/0005-2760(84)90328-X; BOLIN DJ, 1993, J BIOL CHEM, V269, P7429; BREWER HB, 1986, METHOD ENZYMOL, V128, P228; DOBIASOVA M, 1992, J LIPID RES, V33, P1411; DOBIASOVA M, 1983, ADV LIPID RES, V20, P107; DOBIASOVA M, 1991, ARTERIOSCLER THROMB, V11, P64, DOI 10.1161/01.ATV.11.1.64; EISENBERG S, 1984, J LIPID RES, V25, P1017; FURUKAWA Y, 1979, J BIOL CHEM, V254, P7213; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIRZ R, 1970, BIOCHIM BIOPHYS ACTA, V207, P364, DOI 10.1016/0005-2795(70)90029-2; JAUHIAINEN M, 1990, HYPERCHOLESTEROLEMIA, P71; JONAS A, 1986, BIOCHIM BIOPHYS ACTA, V876, P474, DOI 10.1016/0005-2760(86)90034-2; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1985, BIOCHEMISTRY-US, V24, P3508, DOI 10.1021/bi00335a018; JONAS A, 1983, BIOCHIM BIOPHYS ACTA, V794, P361; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; LUNDKATZ S, 1993, BIOCHEMISTRY-US, V269, P4729; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MASSEY JB, 1985, BIOCHEMISTRY-US, V24, P7110, DOI 10.1021/bi00346a014; MATZ CE, 1982, J BIOL CHEM, V257, P4585; MORTON RE, 1988, J BIOL CHEM, V263, P12235; NAKAGAWA M, 1973, BIOCHIM BIOPHYS ACTA, V296, P577; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NISHIDA HI, 1993, J BIOL CHEM, V268, P16352; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; RITTER MC, 1977, J BIOL CHEM, V252, P1208; RUTTENBERG HL, 1973, BIOCHIM BIOPHYS ACTA, V326, P419; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1989, J LIPID RES, V30, P1491; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; SPARKS DL, 1989, BIOCHEM CELL BIOL, V67, P358, DOI 10.1139/o89-056; SPARKS DL, 1992, J LIPID RES, V33, P128; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; TALL AR, 1978, BIOCHIM BIOPHYS ACTA, V513, P185, DOI 10.1016/0005-2736(78)90172-4	40	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5151	5157		10.1074/jbc.270.10.5151	http://dx.doi.org/10.1074/jbc.270.10.5151			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890624	hybrid			2022-12-25	WOS:A1995QL58000032
J	CHANG, E; GOLDBERG, H				CHANG, E; GOLDBERG, H			REQUIREMENTS FOR TRANSFORMING GROWTH-FACTOR-BETA REGULATION OF THE PRO-ALPHA-2(I) COLLAGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; GENE-EXPRESSION; MESSENGER-RNA; II RECEPTOR; TRANSCRIPTIONAL ACTIVATION; METALLOPROTEINASE GENE; RESPONSIVE ELEMENT; LUNG FIBROBLASTS; TISSUE INHIBITOR; TRANSGENIC MICE	Experiments were designed to clarify the role of several proteins, junB, retinoblastoma protein (RB), and the transforming growth factor-beta (TGF-beta) receptors that are potential intermediates in TGF-beta activation of the alpha 2(I) collagen promoter, Treatment of NIH-3T3 cells with TGF-alpha increased the activity of a transiently transfected murine alpha 2(I) collagen promoter (nucleotides -350 to +54) fused to a luciferase reporter gene 9-fold. Cotransfection of a junB stimulated the basal activity of the alpha 2(I) collagen promoter 93-fold, respectively. Expression of antisense junB RNA attenuated the effect of TGF-beta. Simian virus 40 large T antigen, an inhibitor RE function, did not prevent TGF-beta effects on the alpha 2(I) collagen promoter, A chimeric receptor containing the extracellular domain of the colony-stimulating factor-1 receptor and the intracellular domain of the type I TGF-beta receptor enhanced alpha 2(I) collagen promoter activity 4.8-fold, whereas a similar chimera containing the type II receptor intracellular domain had much weaker effects, Similar results were obtained with a plasminogen activator inhibitor-1 promoter, previously shown to be activated by TGF-beta through AP-1 elements. We conclude that TGF-beta activates the alpha 2(I) collagen and plasminogen activator inhibitor-1 promoters in NIH-3T3 cells through junB and the type I TGF-beta receptor kinase domain.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT PEDIAT,DIV NEPHROL,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARMENDARIZBORUN.J, 1992, J BIOL CHEM, V267, P14313; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BOYLE WJ, 1994, CELL, V64, P573; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CURRAN T, 1987, ONCOGENE, V2, P79; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; EGHBALI M, 1991, CIRC RES, V69, P483, DOI 10.1161/01.RES.69.2.483; FINE A, 1989, J BIOL CHEM, V264, P16988; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FREEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; GOLDSTEIN RH, 1990, J BIOL CHEM, V265, P13623; HEINO J, 1990, J BIOL CHEM, V265, P10181; HSU JC, 1993, CANCER RES, V53, P3789; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; JONES CL, 1991, KIDNEY INT, V40, P1020, DOI 10.1038/ki.1991.310; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Koskinen PJ, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000292; KURATA S, 1991, J BIOL CHEM, V266, P9997; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LI L, 1990, J BIOL CHEM, V265, P1556; LIBOI E, 1988, BIOCHEM BIOPH RES CO, V151, P298, DOI 10.1016/0006-291X(88)90593-1; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; PERONIN M, 1992, INT J CANCER, V51, P980; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; VIARD I, 1993, FEBS LETT, V328, P94, DOI 10.1016/0014-5793(93)80972-W; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WESTERGRENTHORS.G, 1993, J CLIN INVEST, V92, P632; WOOD WM, 1989, J BIOL CHEM, V264, P14840; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	58	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4473	4477		10.1074/jbc.270.9.4473	http://dx.doi.org/10.1074/jbc.270.9.4473			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876214	hybrid			2022-12-25	WOS:A1995QK08400046
J	CHU, RY; VARANASI, U; CHU, S; LIN, YL; USUDA, N; RAO, MS; REDDY, JK				CHU, RY; VARANASI, U; CHU, S; LIN, YL; USUDA, N; RAO, MS; REDDY, JK			OVEREXPRESSION AND CHARACTERIZATION OF THE HUMAN PEROXISOMAL ACYL-COA OXIDASE IN INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION ENZYMES; HUMAN-LIVER; NUCLEOTIDE-SEQUENCE; ZELLWEGER SYNDROME; COENZYME-A; RAT-LIVER; ACID; EXPRESSION; HETEROGENEITY; DISORDER	Human liver peroxisomes contain two acyl-CoA oxidases, namely, pahmitoyl-CoA oxidase and a branched chain acyl-CoA oxidase, The palmitoyl-CoA oxidase (ACOX) oxidizes the CoA esters of straight chain fatty acids and prostaglandins and donates electrons directly to molecular oxygen, thereby producing H2O2. The inducibility of this H2O2-generating ACOX in rat and mouse liver by peroxisome proliferators and the postulated role of the resulting oxidative stress in hepatocarcinogenesis generated interest in characterizing the structure and function of human ACOX. We have constructed a full-length cDNA encoding a 660-amino acid residue human ACOX and produced a catalytically active human ACOX protein at high levels in Spodoptera frugiperda (Sf9) insect cells using the baculovirus vector, Immunoblot analysis demonstrated that the full-length 72-kDa polypeptide (component A) was partially processed into its constituent 51-kDa (component B) and 21-kDa (component C) products, respectively, Recombinant protein (similar to 20 mg/l x 10(9) cells) was purified to homogeneity by a single-step procedure on a nickel-nitrilo-triacetic acid affinity column, Using the purified enzyme, K-m and V-max values for palmitoyl-CoA were found to be 10 mu M and 1.4 units/mg of protein, respectively, The maximal activities for saturated fatty acids were observed with C-12-18 substrates. The overexpressed human ACOX protein was identified in the cytoplasm of the insect cells by immunocytochemical staining, individual expression of either the truncated ACOX 51-kDa (component B) or the 21-kDa (component C) revealed lack of enzyme activity, but co-infection of the insect cells with recombinant viruses expressing components B and C resulted in the formation of an enzymatically active heterodimeric B + C complex which could subsequently be inactivated by dissociating with detergent.	NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM23750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVARES K, 1992, P NATL ACAD SCI USA, V89, P4908, DOI 10.1073/pnas.89.11.4908; AOYAMA T, 1994, J BIOL CHEM, V269, P19088; AOYAMA T, 1994, BIOCHEM BIOPH RES CO, V198, P1113, DOI 10.1006/bbrc.1994.1158; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONFMAN M, 1979, BIOCHEM BIOPH RES CO, V88, P1030, DOI 10.1016/0006-291X(79)91512-2; CASTEELS M, 1990, J LIPID RES, V31, P1865; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU R, 1994, BIOCHEM BIOPH RES CO, V200, P178, DOI 10.1006/bbrc.1994.1431; Hashimoto T, 1992, Prog Clin Biol Res, V375, P19; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; OSUMI T, 1980, J BIOCHEM, V87, P1735, DOI 10.1093/oxfordjournals.jbchem.a132918; OSUMI T, 1993, BIOCHIMIE, V75, P243, DOI 10.1016/0300-9084(93)90083-5; POLLTHE BT, 1988, AM J HUM GENET, V42, P422; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; REDDY JK, 1992, MECHANISM CARCINOGEN, P225; Sambrook J, 1989, MOL CLONING LABORATO; SANTOS MJ, 1992, J CELL PHYSIOL, V151, P103, DOI 10.1002/jcp.1041510115; SANTOS MJ, 1985, P NATL ACAD SCI USA, V82, P6556, DOI 10.1073/pnas.82.19.6556; SUZUKI Y, 1988, CLIN CHIM ACTA, V172, P65, DOI 10.1016/0009-8981(88)90121-0; SUZUKI Y, 1994, AM J HUM GENET, V54, P36; TANAKA K, 1992, PROG CLIN BIOL RES, V375, P95; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHOVE GF, 1993, J BIOL CHEM, V268, P10335; VARANASI U, 1994, P NATL ACAD SCI USA, V91, P3107, DOI 10.1073/pnas.91.8.3107; WEBB AC, 1991, BIOTECHNIQUES, V11, P512	29	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4908	4915		10.1074/jbc.270.9.4908	http://dx.doi.org/10.1074/jbc.270.9.4908			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876265	hybrid			2022-12-25	WOS:A1995QK08400103
J	KOTKOW, KJ; DEITCHER, SR; FURIE, B; FURIE, BC				KOTKOW, KJ; DEITCHER, SR; FURIE, B; FURIE, BC			THE 2ND KRINGLE DOMAIN OF PROTHROMBIN PROMOTES FACTOR VA-MEDIATED PROTHROMBIN ACTIVATION BY PROTHROMBINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; FACTOR-XA; COMPLEX; MEMBRANE; BINDING; PHOSPHOLIPIDS; KINETICS; ABSENCE; PROTEIN; FIBRIN	The incorporation of factor Xa into the prothrombinase complex, factor Xa-factor Va-phospholipid-Ca(II), results in an approximately 10(5)-fold higher rate of substrate activation than that of the enzyme alone, To examine the role of the prothrombin kringle domains in the interaction with prothrombinase we have employed site-directed mutagenesis to produce prothrombin species that lack either the first kringle domain, PT/Delta K1, or the second kringle domain, PT/Delta K2. Previously, we have shown that these proteins are fully carboxylated and that they bind to phospholipid vesicles. In this investigation we demonstrate that cleavage at Arg(271). Thr(272) and Arg(320)-Ile(321) peptide bonds occurs upon activation with prothrombinase to yield normal thrombin from both PT/Delta K1 and PT/Delta K2. In the absence of factor Va, the K-m(app) for the activation of PT/Delta K1, PT/Delta K2, or plasma-derived prothrombin by factor Xa-phospholipid-Ca(II) are equivalent, The K-m(app) for the activation of PT/Delta K2, by prothrombinase is approximately 4-5 fold higher than that obtained for plasma derived prothrombin or PT/Delta K1. These data demonstrate that the prothrombin kringle domains do not contribute significantly to the binding affinity of the substrate-enzyme interaction, In the absence of factor Va, equivalent k(cat) values were obtained for all of the prothrombin species when they were activated by factor Xa-Ca(II)-phospholipid, In contrast, a 7-fold lower k(cat) value was obtained for the activation of PT/Delta K2 by prothrombinase as compared with that obtained for plasma prothrombin or PT/Delta K1. Collectively, these data suggest that determinants within the second prothrombin kringle domain interact with factor Va to elicit a significant acceleration in the catalytic rate of substrate turnover, Indeed, in contrast to plasma derived prothrombin, no direct binding of PT/Delta K2 to factor Va to form the PT/Delta K2-factor Va complex could be demonstrated by 90 degrees Light scattering.	TUFTS UNIV NEW ENGLAND MED CTR, CTR HEMOSTASIS & THROMBOSIS RES, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University					NHLBI NIH HHS [HL18834, HL42433] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018834, R37HL018834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1975, J BIOL CHEM, V250, P2150; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; ESMON CT, 1974, J BIOL CHEM, V249, P7791; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JACOBS M, 1994, J BIOL CHEM, V269, P25494; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN GR, 1988, J BIOL CHEM, V263, P1023; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; ROSING J, 1980, J BIOL CHEM, V255, P274; SZOKA F, 1980, BIOCHIM BIOPHYS ACTA, V601, P559, DOI 10.1016/0005-2736(80)90558-1; URANO S, 1989, P NATL ACAD SCI USA, V86, P2568, DOI 10.1073/pnas.86.8.2568; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; WALKER RK, 1992, CIRCULATION S1, V86, P1858	25	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4551	4557		10.1074/jbc.270.9.4551	http://dx.doi.org/10.1074/jbc.270.9.4551			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876224	hybrid			2022-12-25	WOS:A1995QK08400057
J	SOMMERS, CH; MILLER, EJ; DUJON, B; PRAKASH, S; PRAKASH, L				SOMMERS, CH; MILLER, EJ; DUJON, B; PRAKASH, S; PRAKASH, L			CONDITIONAL LETHALITY OF NULL MUTATIONS IN RTH1 THAT ENCODES THE YEAST COUNTERPART OF A MAMMALIAN 5'-EXONUCLEASE TO 3'-EXONUCLEASE REQUIRED FOR LAGGING-STRAND DNA-SYNTHESIS IN RECONSTITUTED SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EXCISION-REPAIR GENE; SACCHAROMYCES-CEREVISIAE; RECOMBINATION; MUTANTS; RAD2; ESCHERICHIA-COLI-K12; REPLICATION; DISRUPTION; PROTEINS; SEQUENCE	A 5'- to 3'-exonuclease of about 45 kDa has been purified from various mammalian sources and shown to be required for the completion of lagging strand synthesis in reconstituted DNA replication systems. RTH1 encodes the yeast Saccharomyces cerevisiae counterpart of the mammalian enzyme. To determine the in vivo biological role of RTH1-encoded 5'- to 3'-exonuclease, we have examined the effects of an rth1 Delta mutation on various cellular processes. rth1 Delta mutants grow poorly at 30 degrees C, and a cessation in growth occurs upon transfer of the mutant to 37 degrees C. At the restrictive temperature, the rth1 Delta mutant exhibits a terminal cell cycle morphology similar to that of mutants defective in DNA replication, and levels of spontaneous mitotic recombination are elevated in the rth1 Delta mutant even at the permissive temperature, The rth1 Delta mutation does not affect UV or gamma-ray sensitivity but enhances sensitivity to the alkylating agent methyl methanesulfonate, The role of RTH1 in DNA replication and in repair of alkylation damage is discussed.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOPHYS,ROCHESTER,NY 14642; INST PASTEUR,CNRS,URA 1149,UNITE GENET MOLEC LEVURES,F-75724 PARIS 15,FRANCE	University of Rochester; University of Rochester; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Dujon, Bernard/AAL-8410-2021; Dujon, Bernard A/F-4971-2010; Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Dujon, Bernard/0000-0003-4661-3534; Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NATIONAL CANCER INSTITUTE [R01CA041261, R37CA041261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER; NCI NIH HHS [CA41261] Funding Source: Medline; NIGMS NIH HHS [GM19261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HABRAKEN Y, 1994, NUCLEIC ACIDS RES, V22, P3312, DOI 10.1093/nar/22.16.3312; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARTWELL LH, 1985, GENETICS, V110, P381; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; KONRAD EB, 1973, J MOL BIOL, V77, P519, DOI 10.1016/0022-2836(73)90220-9; KONRAD EB, 1974, P NATL ACAD SCI USA, V71, P2048, DOI 10.1073/pnas.71.5.2048; KONRAD EB, 1977, J BACTERIOL, V130, P167, DOI 10.1128/JB.130.1.167-172.1977; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MONTELONE BA, 1981, J BACTERIOL, V147, P517, DOI 10.1128/JB.147.2.517-525.1981; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; PRAKASH L, 1977, GENETICS, V86, P33; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803	24	165	170	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4193	4196		10.1074/jbc.270.9.4193	http://dx.doi.org/10.1074/jbc.270.9.4193			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876174	hybrid			2022-12-25	WOS:A1995QK08400004
J	BOULARAND, S; DARMON, MC; MALLET, J				BOULARAND, S; DARMON, MC; MALLET, J			THE HUMAN TRYPTOPHAN-HYDROXYLASE GENE - AN UNUSUAL SPLICING COMPLEXITY IN THE 5'-UNTRANSLATED REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; STRUCTURAL CHARACTERIZATION; PHENYLALANINE-HYDROXYLASE; TYROSINE HYDROXYLASES; FUNCTIONAL DOMAINS; CARCINOID-TUMORS; CDNA LIBRARIES; PINEAL-GLAND; EXPRESSION; SEQUENCE	We report the isolation and the organization of the gene encoding human tryptophan hydroxylase (TPH) and an analysis of the corresponding mRNAs. The gene spans a region of 29 kilobases, which contains at least 11 exons and a variably spliced 5'-untranslated region (5'-UTR). The sequence of the coding region and the majority of the positions of the intron-exon boundaries of human TPH gene are very similar to those encoding human tyrosine hydroxylase and phenylalanine hydroxylase, the other members of the aromatic amino acid hydroxylase family. Phylogenetic analysis evidences the early divergence and the independent evolution of the three hydroxylase types. TPR cDNA cloning and anchored polymerase chain reaction revealed a diversity of the TPH mRNA, which is restricted to the 5'-UTR. Four TPH mRNA species were detected by Northern blot with pineal gland and carcinoid tumor RNAs. These messengers are transcribed from a single transcriptional initiation site, and their diversity results from differential splicing of three intron-like regions and of three exons located in the 5'-UTR Analysis by S1 nuclease protection revealed that the intron-like regions in the 5'-UTR are mostly unspliced and that TPH mRNA species where the three intron-like regions are eliminated are present at low level in pineal gland and not detectable in carcinoid tumors.			BOULARAND, S (corresponding author), CNRS,GENET MOLEC NEUROTRANSMISS & PROC NEURODEGENERATI,F-91198 GIF SUR YVETTE,FRANCE.		Darmon, Michele/F-8708-2011	Darmon, Michele/0000-0001-9730-6273				BIGUET NF, 1986, EMBO J, V5, P287, DOI 10.1002/j.1460-2075.1986.tb04211.x; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOULARAND S, 1990, NUCLEIC ACIDS RES, V18, P4257, DOI 10.1093/nar/18.14.4257; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARDINALI DP, 1981, ENDOCR REV, V2, P327, DOI 10.1210/edrv-2-3-327; CIVELLI O, 1982, J BIOL CHEM, V257, P6783; DARMON MC, 1986, FEBS LETT, V206, P43, DOI 10.1016/0014-5793(86)81337-0; DARMON MC, 1988, J NEUROCHEM, V51, P312, DOI 10.1111/j.1471-4159.1988.tb04871.x; DELORT J, 1989, NUCLEIC ACIDS RES, V17, P6439, DOI 10.1093/nar/17.16.6439; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMAS S, 1989, J NEUROSCI RES, V24, P537, DOI 10.1002/jnr.490240412; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FELDMAN JM, 1986, AM J MED, V81, P41, DOI 10.1016/0002-9343(86)90583-8; FELDMAN JM, 1987, SEMIN ONCOL, V14, P237; GREEN CB, 1994, J NEUROCHEM, V62, P2420; GRENETT HE, 1987, P NATL ACAD SCI USA, V84, P5530, DOI 10.1073/pnas.84.16.5530; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HART R P, 1991, Molecular and Cellular Neuroscience, V2, P71, DOI 10.1016/1044-7431(91)90041-L; IZZO P, 1988, EUR J BIOCHEM, V174, P569, DOI 10.1111/j.1432-1033.1988.tb14136.x; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; JEFFREYS AJ, 1988, NUCLEIC ACIDS RES, V16, P10953, DOI 10.1093/nar/16.23.10953; Kaufman S., 1974, MOL MECH OXYGEN ACTI, P285; KOSAK M, 1986, P NATL ACAD SCI USA, V83, P2850; KOSAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385; KOSAK M, 1989, J CELL BIOL, V108, P229; KOSAK M, 1991, J CELL BIOL, V115, P887; KUHN DM, 1980, J BIOL CHEM, V255, P4137; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; LEDLEY FD, 1985, BIOCHEMISTRY-US, V24, P3389, DOI 10.1021/bi00335a001; LEDLEY FD, 1985, SOMAT CELL MOLEC GEN, V13, P575; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MISAWA H, 1992, J BIOL CHEM, V267, P20392; NECKAMEYER WS, 1992, J BIOL CHEM, V267, P4199; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; OH SK, 1992, GENE DEV, V9, P1643; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SAVAKIS C, 1986, DEV BIOL, V114, P194, DOI 10.1016/0012-1606(86)90395-7; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHEIN HM, 1971, LIFE SCI, V10, P935, DOI 10.1016/0024-3205(71)90358-4; STOLL J, 1990, GENOMICS, V7, P88, DOI 10.1016/0888-7543(90)90522-V; STOLL J, 1991, J NEUROSCI RES, V28, P457, DOI 10.1002/jnr.490280402; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; VIGNY A, 1982, BIOCHEM BIOPH RES CO, V106, P1, DOI 10.1016/0006-291X(82)92049-6; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865; WURTMAN RJ, 1963, SCIENCE, V141, P277, DOI 10.1126/science.141.3577.277; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YANG XJ, 1994, P NATL ACAD SCI USA, V91, P6659, DOI 10.1073/pnas.91.14.6659	53	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3748	3756		10.1074/jbc.270.8.3748	http://dx.doi.org/10.1074/jbc.270.8.3748			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876115	hybrid			2022-12-25	WOS:A1995QH68800045
J	JOW, L; MUKHERJEE, R				JOW, L; MUKHERJEE, R			THE HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) SUBTYPE NUC1 REPRESSES THE ACTIVATION OF HPPAR-ALPHA AND THYROID-HORMONE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; RETINOIC ACID; FATTY-ACIDS; RESPONSIVE ELEMENT; TRANS-ACTIVATION; IDENTIFICATION; SUPERFAMILY; PROTEINS; DOMAINS; MEMBER	We have cloned two human peroxisome proliferator-activated receptor (PPAR) subtypes, hPPAR alpha and hNUC1. hPPAR alpha is activated by clofibric acid and other PPAR activators. hNUC1 is not activated by these compounds acting instead as a repressor of hPPAR alpha: and human thyroid hormone receptor transcriptional activation. Repression is specific since hNUC1 does not significantly repress activation by the progesterone or retinoic acid receptors. We demonstrate co-operative binding of hNUC1 and hRXR alpha to a PPAR-responsive element and show that in the presence of hRXR alpha, the affinity of hNUC1 for the peroxisome proliferator is comparable to that of hPPAR alpha. Furthermore, repression of hPPAR alpha can be overcome by transfecting excess hPPAR alpha. We propose that hNUC1 represses the activity of hPPAR alpha by titrating out a factor required for activation. Our data further suggests convergence of thyroid hormone- and peroxisome-mediated fatty acid metabolism pathways. Overcoming hNUC1 repression could be a means of increasing the activity of these receptors.	LIGAND PHARMACEUT INC,DEPT MOLEC BIOL,SAN DIEGO,CA 92121	Ligand Pharmaceuticals								ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P1; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERGER TS, 1992, J STEROID BIOCHEM, V41, P733, DOI 10.1016/0960-0760(92)90414-E; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HERTZ R, 1993, BIOCHIMIE, V75, P257, DOI 10.1016/0300-9084(93)90085-7; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; NESTEL PJ, 1990, ANNU REV NUTR, V10, P149, DOI 10.1146/annurev.nu.10.070190.001053; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PHILLIPSON BE, 1985, NEW ENGL J MED, V312, P1210, DOI 10.1056/NEJM198505093121902; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMSONO K, 1991, CELL, V65, P1255; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244	28	79	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3836	3840		10.1074/jbc.270.8.3836	http://dx.doi.org/10.1074/jbc.270.8.3836			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876127	hybrid			2022-12-25	WOS:A1995QH68800057
J	SHIRE, D; CARILLON, C; KAGHAD, M; CALANDRA, B; RINALDICARMONA, M; LEFUR, G; CAPUT, D; FERRARA, P				SHIRE, D; CARILLON, C; KAGHAD, M; CALANDRA, B; RINALDICARMONA, M; LEFUR, G; CAPUT, D; FERRARA, P			AN AMINO-TERMINAL VARIANT OF THE CENTRAL CANNABINOID RECEPTOR RESULTING FROM ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BETA-2-ADRENERGIC RECEPTORS; MOLECULAR-CLONING; BINDING-SITES; RAT-BRAIN; EXPRESSION; CELLS; IDENTIFICATION; LOCALIZATION; SPECIFICITY	The cDNA sequences encoding the central cannabinoid receptor, CB1, are known for two species, rat and human. However, little information concerning the flanking, noncoding regions is presently available. We have isolated two overlapping clones from a human lung cDNA Library with CB1 cDNA inserts. One of these, cann7, contains a short stretch of the CB1 coding region and 4 kilobase pairs Orb) of the 3'-untranslated region (UTR), including two polyadenylation signals. The other, cann6, is identical to cann7 upstream from the first polyadenylation signal, and in addition, it contains the whole coding region and extends for 1.8 kb into the 5'-UTR. Comparison of cann6 with the published sequence (Gerard, C. M., Mollereau, C., Vassart, G., and Parmentier, M. (1991) Biochem. J. 279, 129-134) shows the coding regions to be identical, but reveals important differences in the flanking regions. Notably, the cann6 sequence appears to be that of an immature transcript, containing 1.8 kb of an intronic sequence in the 5'-UTR. In addition, polymerase chain reaction amplification of the CB1 coding region in the IM-9 cell line cDNA resulted in two fragments, one containing the whole CB1 coding region and the second lacking a 167-base pair intron within the sequence encoding the amino-terminal tail of the receptor. This alternatively spliced form would translate to an NH2-terminal modified isoform (CB1A) of the receptor, shorter than CB1 by 61 amino acids. In addition, the first 28 amino acids of the putative truncated receptor are completely different from those of CB1, containing more hydrophobic residues. Rat CB1 mRNA is similarly alternatively spliced. A study of the distribution of the human CB1 and CB1A mRNAs by reverse transcription-polymerase chain reaction analysis showed the presence of both CB1 and CB1A throughout the brain and in all the peripheral tissues examined, with CB1A being present in amounts of up to 20% of CB1.	SANOFI RECH,F-34184 MONTPELLIER,FRANCE	Sanofi-Aventis; Sanofi France	SHIRE, D (corresponding author), SANOFI RECH,LABEGE INNOPOLE VOIE 1,BP 137,F-31676 LABEGE 04,FRANCE.							BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432-1033.1993.tb17910.x; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTTREZ F, 1994, NUCLEIC ACIDS RES, V22, P2712, DOI 10.1093/nar/22.13.2712; DEFONSECA FR, 1993, NEUROREPORT, V4, P135, DOI 10.1097/00001756-199302000-00005; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HOWLETT AC, 1984, MOL PHARMACOL, V26, P532; HOWLETT AC, 1991, PHARMACOL BIOCHEM BE, V40, P565, DOI 10.1016/0091-3057(91)90364-8; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JANSEN EM, 1992, BRAIN RES, V575, P93, DOI 10.1016/0006-8993(92)90428-C; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MAILLEUX P, 1992, NEUROSCI LETT, V143, P200, DOI 10.1016/0304-3940(92)90265-9; MAILLEUX P, 1992, NEUROSCI LETT, V147, P179, DOI 10.1016/0304-3940(92)90589-Y; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MCLAUGHLIN CR, 1993, DEV BRAIN RES, V76, P75, DOI 10.1016/0165-3806(93)90124-S; MINTY A, 1993, EUR CYTOKINE NETW, V4, P99; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; PETTIT DAD, 1994, BIOCHEM PHARMACOL, V48, P1231, DOI 10.1016/0006-2952(94)90161-9; RANDS E, 1990, J BIOL CHEM, V265, P10759; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341	34	265	283	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3726	3731		10.1074/jbc.270.8.3726	http://dx.doi.org/10.1074/jbc.270.8.3726			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876112	hybrid			2022-12-25	WOS:A1995QH68800042
J	WITHIAMLEITCH, M; RUBIN, RP; KOSHLUKOVA, SE; ALETTA, JM				WITHIAMLEITCH, M; RUBIN, RP; KOSHLUKOVA, SE; ALETTA, JM			IDENTIFICATION AND CHARACTERIZATION OF CARBOXYL ESTER HYDROLASE AS A PHOSPHOLIPID HYDROLYZING ENZYME OF ZYMOGEN GRANULE MEMBRANES FROM RAT EXOCRINE PANCREAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-POLYACRYLAMIDE GELS; SODIUM DODECYL-SULFATE; GUINEA-PIG PANCREAS; SUBSTRATE-SPECIFICITY; ADRENAL-MEDULLA; PROTEINS; LIPASE; PURIFICATION; BINDING; LYSOPHOSPHOLIPASE	Salt-washed (0.6 M NaCl) zymogen granule membranes (ZGM) of rat pancreatic acinar cells were utilized to identify and characterize membrane protein(s) responsible for phospholipase and lysophospholipase activities. Five major bands were identified in salt-washed ZGM by Coomassie Brilliant Blue. A 70-kDa protein with enzymatic activity was retained in significant quantities after several washes with 0.6 nr NaCl but could be displaced hom ZGM by 2 nz NaCl or by 100 mg/ml heparin. By contrast, GP2, an integral membrane protein, was not displaced under these conditions. These findings suggest that the enzyme is a peripheral membrane protein of ZGM. Renaturation of ZGM proteins following electrophoresis revealed that the 70-kDa protein possessed phospholipase activity. Identification of the 70-kDa protein as a membrane-associated carboxyl ester hydrolase was based upon: (a) the use of a specific polyclonal antiserum, (b) N-terminal sequence, (c) two-dimensional gel analysis, (d) enzymatic characterization, and (e) co-localization to an area of a non-reducing gel containing significant phospholipase activity. Other ZGM proteins, namely GP2 and GP3, could not be demonstrated to possess phospholipase activity under the experimental conditions employed. Our finding that carboxyl ester hydrolase from ZGM exhibits PLA(1) and lysophospholipase activities represents the first identification and characterization of a protein responsible for phospholipase activity in secretory granule membranes.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT PHARMACOL & TOXICOL, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIADDK NIH HHS [AM-28029] Funding Source: Medline; NIDCR NIH HHS [DE-05764] Funding Source: Medline; NIGMS NIH HHS [GM-07145] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM028029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005764] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; BOSNER MS, 1989, J BIOL CHEM, V264, P20261; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; CREUTZ CE, 1981, J CELL BIOL, V91, P247, DOI 10.1083/jcb.91.1.247; DEH ME, 1985, ANAL BIOCHEM, V150, P166, DOI 10.1016/0003-2697(85)90456-7; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; ERLANSON C, 1975, SCAND J GASTROENTERO, V10, P401; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GHOSH S, 1991, LIPIDS, V26, P793, DOI 10.1007/BF02536160; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HILDEBRANDT E, 1991, BIOCHEMISTRY-US, V30, P464, DOI 10.1021/bi00216a023; HUSEBYE ES, 1987, BIOCHIM BIOPHYS ACTA, V920, P120, DOI 10.1016/0005-2760(87)90251-7; HYUN J, 1969, J BIOL CHEM, V244, P1937; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KRONQUIST KE, 1977, ARCH BIOCHEM BIOPHYS, V182, P188, DOI 10.1016/0003-9861(77)90298-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEL D, 1984, BIOCHIM BIOPHYS ACTA, V769, P611, DOI 10.1016/0005-2736(84)90060-9; LEBEL D, 1988, BIOCHEM BIOPH RES CO, V154, P818, DOI 10.1016/0006-291X(88)90213-6; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P136, DOI 10.1016/0005-2744(80)90049-2; MACDONAL.RJ, 1972, BIOCHEM BIOPH RES CO, V49, P377, DOI 10.1016/0006-291X(72)90421-4; MIZUNO M, 1991, BIOCHIM BIOPHYS ACTA, V1084, P21, DOI 10.1016/0005-2760(91)90050-R; MIZUNO NK, 1990, LIPIDS, V25, P760, DOI 10.1007/BF02544048; MOSKOWITZ N, 1982, SCIENCE, V216, P305, DOI 10.1126/science.6278597; MURTHY SK, 1962, BIOCHEM J, V83, P460, DOI 10.1042/bj0830460; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAQUET MR, 1982, EUR J CELL BIOL, V28, P20; PIND S, 1987, BIOCHIM BIOPHYS ACTA, V901, P78, DOI 10.1016/0005-2736(87)90258-6; POOLE AR, 1970, NATURE, V227, P810, DOI 10.1038/227810a0; REGGIO HA, 1978, J CELL BIOL, V77, P288, DOI 10.1083/jcb.77.2.288; RONZIO RA, 1978, BIOCHIM BIOPHYS ACTA, V508, P65, DOI 10.1016/0005-2736(78)90189-X; RUBIN RP, 1990, BIOCHIM BIOPHYS ACTA, V1045, P245, DOI 10.1016/0005-2760(90)90127-J; RUBIN RP, 1991, BIOCHEM BIOPH RES CO, V177, P22, DOI 10.1016/0006-291X(91)91942-6; RUDD EA, 1984, LIPASES; SCHEELE GA, 1981, METHOD CELL BIOL, V23, P345, DOI 10.1016/S0091-679X(08)61508-3; SCHEELE GA, 1978, J CELL BIOL, V78, P110, DOI 10.1083/jcb.78.1.110; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; VANDENBOSCH H, 1973, BIOCHIM BIOPHYS ACTA, V296, P94, DOI 10.1016/0005-2760(73)90048-9; WAITE M, 1985, J LIPID RES, V26, P1379; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G; Whittaker VP, 1972, METHODS NEUROCHEMIST, P1; WISHART MJ, 1993, J BIOL CHEM, V268, P10303; WITHIAMLEITCH M, 1993, BIOCHEM BIOPH RES CO, V194, P1167, DOI 10.1006/bbrc.1993.1945	44	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3780	3787		10.1074/jbc.270.8.3780	http://dx.doi.org/10.1074/jbc.270.8.3780			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876119				2022-12-25	WOS:A1995QH68800049
J	ZAKO, M; SHINOMURA, T; UJITA, M; ITO, K; KIMATA, K				ZAKO, M; SHINOMURA, T; UJITA, M; ITO, K; KIMATA, K			EXPRESSION OF PG-M(V3), AN ALTERNATIVELY SPLICED FORM OF PG-M WITHOUT A CHONDROITIN SULFATE ATTACHMENT REGION IN MOUSE AND HUMAN TISSUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX MOLECULES; CORE PROTEIN; CDNA CLONES; PROTEOGLYCAN; BRAIN; CARTILAGE; VERSICAN; ADHESION; SYSTEM; ACID	We showed previously that the alternative splicing of chondroitin sulfate attachment domains (CS alpha and CS beta) yielded multiforms of the PG-M core protein in mouse. A transcript encoding a new short form of the core protein PG-M(V3) was found in various mouse tissues using polymerase chain reaction. DNA sequences of the polymerase chain reaction products suggested that PG-M(V3) had no chondroitin sulfate attachment domain, PG-(V3) was also detected in various human tissues. The presence of a transcript for PG-M(V3) was further supported by Northern blot analysis. Southern blot analysis confirmed that multiforms of the PG-M core protein, including PG-M(V3), were derived hom a single genomic locus by an alternative splicing mechanism. Because PG-M(V3) has no chondroitin sulfate attachment region, which is the most distinctive portion of a proteoglycan molecule, this form may have a unique function.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN	Aichi Medical University								BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; BIGNAMI A, 1993, ANAT EMBRYOL, V188, P419; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DELPECH B, 1993, EUR J CANCER, V7, P1012; DOEGE K, 1987, J BIOL CHEM, V262, P17757; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HENNIG AK, 1993, DEV BRAIN RES, V73, P261, DOI 10.1016/0165-3806(93)90146-2; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; IIJIMA N, 1991, J NEUROCHEM, V56, P706, DOI 10.1111/j.1471-4159.1991.tb08207.x; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; IWATA M, 1993, J NEUROSCI, V13, P195; IWATA M, 1993, J BIOL CHEM, V268, P15061; JAWORSKI DM, 1994, J CELL BIOL, V125, P495, DOI 10.1083/jcb.125.2.495; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; KUSUKAWA N, 1990, BIOTECHNIQUES, V9, P66; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; MARRET S, 1994, J NEUROCHEM, V62, P1285; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERIDES G, 1992, J BIOL CHEM, V267, P23883; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; RAUCH U, 1992, J BIOL CHEM, V267, P19536; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; UJITA M, J BIOL CHEM, V269, P27603; VENSTROM KA, 1993, FASEB J, V7, P996, DOI 10.1096/fasebj.7.11.8370483; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YAMAGATA M, 1993, J CELL SCI, V106, P55; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	38	109	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3914	3918		10.1074/jbc.270.8.3914	http://dx.doi.org/10.1074/jbc.270.8.3914			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876137	hybrid			2022-12-25	WOS:A1995QH68800068
J	TAKEGAWA, K; TABUCHI, M; YAMAGUCHI, S; KONDO, A; KATO, I; IWAHARA, S				TAKEGAWA, K; TABUCHI, M; YAMAGUCHI, S; KONDO, A; KATO, I; IWAHARA, S			SYNTHESIS OF NEOGLYCOPROTEINS USING OLIGOSACCHARIDE-TRANSFER ACTIVITY WITH ENDO-BETA-N-ACETYLGLUCOSAMINIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ARTHROBACTER-PROTOPHORMIAE; FLAVOBACTERIUM-MENINGOSEPTICUM; TRANSGLYCOSYLATION ACTIVITY; CHORIONIC-GONADOTROPIN; GLYCOSYLATION SITES; CARBOHYDRATE MOIETY; ENZYMATIC-SYNTHESIS; CHICKEN OVALBUMIN; MOLECULAR-CLONING	We describe a novel method for the enzymatic synthesis of neoglycoproteins. Endo-beta-N-acetylglucosaminidase from Arthrobacter protophormiae (Endo-A) had high levels of transglycosylation activity. The enzyme activity of Endo-A was markedly increased by adding 4-L-aspartyl-glycosylamine (GlcNAc-Asn) to the reaction mixture, Digesting (Man)(6)(GlcNAc)(2) with the enzyme in the presence of GlcNAc-Asn gave a mixture of hydrolytic ((Man)(6)GlcNAc) and transglycosylic ((Man)(6)(GlcNAc)(2)Asn) products. By means of transglycosylation, (Man)(6)GlcNAc was transferred en bloc to the partially deglycosylated ovalbumin glycopeptide (EEKYN(GlcNAc) LTSVL) concomitant with the hydrolysis of (Man)(6)(GlcNAc)(2)Asn. The structure of the transglycosylation product was designated as (Man)(6)(GlcNAc)(2)-peptide by amino acid composition and sequence analysis as well as ion mass spectrometry. The enzyme also transferred oligosaccharide to partially deglycosylated ribonuclease B (GlcNAc-protein) during the hydrolysis of (Man)(6)(GlcNAc)(2)Asn. Native ribonuclease B had (Man)(5-9) (GIcNAc)(2) as its heterogeneous N-linked sugar chains. High performance liquid chromatography showed that all of the N-linked sugar chains of the synthetic neoribonuclease of the pyridylamino derivatives were modified to (Man)(6)(GlcNAc)(2).	TAKARA SHUZO CO LTD,BIOTECHNOL RES LABS,OTSU,SHIGA 52021,JAPAN	Takara Holdings Inc.	TAKEGAWA, K (corresponding author), KAGAWA UNIV,FAC AGR,DEPT BIORESOURCE SCI,MIKI,KAGAWA 76107,JAPAN.		Tabuchi, Mitsuaki/E-9544-2010; Tabuchi, Mitsuaki/AAY-7378-2021	Tabuchi, Mitsuaki/0000-0002-2042-691X; Tabuchi, Mitsuaki/0000-0002-2042-691X				BARDALES RM, 1989, J BIOL CHEM, V264, P19893; BRUINS AP, 1987, ANAL CHEM, V59, P2642, DOI 10.1021/ac00149a003; COTE GL, 1990, GLYCOCONJUGATE J, V7, P145, DOI 10.1007/BF01050377; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; GOTO M, 1988, BIO-TECHNOL, V6, P67, DOI 10.1038/nbt0188-67; Gray W.R., 1967, METHODS ENZYMOL, V11, P139, DOI [10.1016/S0076-6879(67)11014-8, DOI 10.1016/S0076-6879(67)11014-8]; HASE S, 1986, J BIOCHEM-TOKYO, V100, P1; HSIEH P, 1983, J BIOL CHEM, V258, P2548; HUANG CC, 1970, CARBOHYD RES, V13, P127, DOI 10.1016/S0008-6215(00)84902-2; ISHIHARA H, 1981, BIOCHIM BIOPHYS ACTA, V669, P261; ITO S, 1975, ARCH BIOCHEM BIOPHYS, V171, P78, DOI 10.1016/0003-9861(75)90009-0; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MCREYNOLDS L, 1978, NATURE, V273, P723, DOI 10.1038/273723a0; MENCKE AJ, 1982, J BIOL CHEM, V257, P4799; NILSSON KGI, 1988, TRENDS BIOTECHNOL, V6, P256, DOI 10.1016/0167-7799(88)90058-3; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; SHARES BT, 1986, P NATL ACAD SCI USA, V83, P1993; TAI T, 1977, J BIOL CHEM, V252, P6687; TAKEGAWA K, 1991, BIOCHEM INT, V25, P585; TAKEGAWA K, 1991, BIOCHEM INT, V24, P849; TAKEGAWA K, 1989, APPL ENVIRON MICROB, V55, P3107, DOI 10.1128/AEM.55.12.3107-3112.1989; TAKEGAWA K, 1991, BIOCHEM INT, V25, P829; TAKEGAWA K, 1991, J FERMENT BIOENG, V71, P278, DOI 10.1016/0922-338X(91)90282-L; TAKEGAWA K, 1991, EUR J BIOCHEM, V202, P175, DOI 10.1111/j.1432-1033.1991.tb16359.x; TARENTINO AL, 1992, J BIOL CHEM, V267, P3868; TARENTINO AL, 1993, J BIOL CHEM, V268, P9702; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TRIMBLE RB, 1986, J BIOL CHEM, V261, P2000; TSUDA E, 1988, BIOCHEMISTRY-US, V27, P5646, DOI 10.1021/bi00415a038; YAMAMOTO K, 1986, AGR BIOL CHEM TOKYO, V50, P421, DOI 10.1080/00021369.1986.10867399; YAMAMOTO K, 1986, J FERMENT BIOENG, V64, P397, DOI 10.1016/0385-6380(86)90026-9; YAN SCB, 1987, METHOD ENZYMOL, V138, P413	39	107	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3094	3099		10.1074/jbc.270.7.3094	http://dx.doi.org/10.1074/jbc.270.7.3094			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852391	hybrid			2022-12-25	WOS:A1995QG47100033
J	MURRELL, AM; GREEN, AR				MURRELL, AM; GREEN, AR			REGULATION OF LINEAGE RESTRICTED HEMATOPOIETIC TRANSCRIPTION FACTORS IN CELL HYBRIDS	ONCOGENE			English	Article						SCL/TAL1; GATA-1; GATA-2; GATA-3; CELL HYBRIDS	GATA-BINDING PROTEINS; SCL GENE-PRODUCT; LOOP-HELIX GENE; ERYTHROID-DIFFERENTIATION; HEMATOPOIETIC-CELLS; DNA METHYLATION; MESSENGER-RNA; OCTAMER MOTIF; GLOBIN GENES; EXPRESSION	SCL, GATA-1, GATA-2 and GATA-3 encode lineage restricted haemopoietic transcription factors. We have previously shown that SCL, GATA-1 and GATA-2 are expressed in multipotent progenitors prior to lineage commitment, but are down-regulated during granulocyte/monocyte differentiation. The phenomenon of gene extinction in cell hybrids may reveal negative regulatory mechanisms operating during normal differentiation. We have therefore analysed the regulation of SCL, GATA-1, GATA-2 and GATA-3 in cell hybrids formed by the fusion of cell lines representing different haemopoietic lineages. Expression of GATA-3 was extinguished in both human and murine erythroid x T cell hybrids, an observation which suggests that erythroid cells contain factors capable of repressing GATA-3 expression. By contrast expression of SCL, GATA-1 and GATA-2 was not extinguished in erythroid x T or in erythroid x B cell hybrids. These data suggest that T cells and B cells do not contain trams-acting factors capable of down-regulating expression of SCL, GATA-1 or GATA-2 and therefore raise the possibility that a 'hit and run' mechanism may repress these genes during normal haemopoiesis, HpaII sites within the SCL promoter were unmethylated in erythroid cells but methylated in T cells. Erythroid x T and erythroid x B cell hybrids both methylated and unmethylated SCL thus implicating a heritable cis-acting mechanism in the regulation of the SCL gene in lymphoid cell lines. These results provide the first analysis of SCL and GATA gene regulation in stable cell hybrids.	UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND	University of Cambridge				Green, Anthony/0000-0002-9795-0218	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKROYD J, 1987, ONCOGENE, V1, P347; ALBERTS B, 1990, NATURE, V344, P193, DOI 10.1038/344193a0; ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BARON MH, 1994, MOL CELL BIOL, V14, P3108, DOI 10.1128/MCB.14.5.3108; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BAUMANN H, 1985, MOL GEN GENET, V201, P505, DOI 10.1007/BF00331347; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOSHART M, 1993, TRENDS GENET, V9, P240, DOI 10.1016/0168-9525(93)90088-Y; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1993, SCIENCE, V262, P56; CROSS MA, 1994, ONCOGENE, V9, P3013; CROTTA S, 1990, NUCLEIC ACIDS RES, V18, P6863, DOI 10.1093/nar/18.23.6863; DEISSEROTH A, 1975, P NATL ACAD SCI USA, V72, P1102, DOI 10.1073/pnas.72.3.1102; DEISSEROTH A, 1979, P NATL ACAD SCI USA, V76, P21; ELWOOD NJ, 1994, LEUKEMIA, V8, P106; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOURDEAU H, 1990, ANNU REV CELL BIOL, V6, P69, DOI 10.1146/annurev.cb.06.110190.000441; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, INT J CELL CLONING, V10, P269, DOI 10.1002/stem.5530100504; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GREEN AR, 1993, EXP HEMATOL, V21, P525; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; HECHT F, 1984, SCIENCE, V226, P1445, DOI 10.1126/science.6438800; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HWANG LY, 1993, ONCOGENE, V8, P3043; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KIM KJ, 1979, J IMMUNOL, V122, P549; LESHKOWITZ D, 1991, MOL CELL BIOL, V11, P1547, DOI 10.1128/MCB.11.3.1547; MATSUI Y, 1989, GENE, V77, P325, DOI 10.1016/0378-1119(89)90080-2; MCCORMICK A, 1988, CELL, V55, P379, DOI 10.1016/0092-8674(88)90061-X; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MOUTHON MA, 1993, BLOOD, V81, P647; NITSCH D, 1993, GENE DEV, V7, P308, DOI 10.1101/gad.7.2.308; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PAPAYANNOPOULOU T, 1985, P NATL ACAD SCI USA, V82, P780, DOI 10.1073/pnas.82.3.780; PETERSEN JA, 1972, P NATL ACAD SCI USA, V69, P571, DOI 10.1073/pnas.69.3.571; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PYATI J, 1980, P NATL ACAD SCI-BIOL, V77, P3435, DOI 10.1073/pnas.77.6.3435; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SHEN LY, 1993, MOL CELL BIOL, V13, P3530, DOI 10.1128/MCB.13.6.3530; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TSAI FY, 1993, BLOOD, V82, pA86; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VISVADER J, 1991, ONCOGENE, V6, P195; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WORTON RG, 1979, METHOD ENZYMOL, P322; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZANG CC, 1992, P NATL ACAD SCI USA, V89, P7511; ZON LI, 1991, J BIOL CHEM, V266, P22948; ZON LI, 1992, NUCLEIC ACIDS RES, V20, P1812, DOI 10.1093/nar/20.7.1812; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668; ZON LI, 1993, BLOOD, V81, P3234	76	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					631	639						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862440				2022-12-25	WOS:A1995QH61200002
J	MU, D; PARK, CH; MATSUNAGA, T; HSU, DS; REARDON, JT; SANCAR, A				MU, D; PARK, CH; MATSUNAGA, T; HSU, DS; REARDON, JT; SANCAR, A			RECONSTITUTION OF HUMAN DNA-REPAIR EXCISION NUCLEASE IN A HIGHLY DEFINED SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNA POLYMERASE-II; TRANSCRIPTION; HELICASE; EXTRACT; PROTEIN; ERCC1	Xeroderma pigmentosum is a hereditary disease caused by defective DNA repair. Somatic cell genetics and biochemical studies with cell-free extracts indicate that at least 16 polypeptides are required to carry out the repair reaction proper, i.e. the removal of the lesion from the DNA by the dual incisions of the damaged strand. To find out if these proteins are necessary and sufficient for excision repair, they were obtained at a high level of purity in five fractions. The mixture of these five fractions reconstituted the excision nuclease (excinuclease) activity. Using the reconstituted excinuclease, we found that the excised fragment remains associated with the post-incision DNA-protein complex, suggesting that accessory proteins are needed to release the excised oligomer.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BIGGERSTAFF M, 1992, EMBO J, V12, P3685; BUSCH D, 1994, MUTAGENESIS, V9, P301, DOI 10.1093/mutage/9.4.301; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; FLORES O, 1992, J BIOL CHEM, V267, P2786; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HOEIJMAKERS JHJ, 1994, NATURE, V371, P654, DOI 10.1038/371654a0; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; MA LB, 1994, NUCLEIC ACIDS RES, V22, P4095, DOI 10.1093/nar/22.20.4095; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARK CH, 1993, NUCLEIC ACIDS RES, V21, P5110, DOI 10.1093/nar/21.22.5110; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; STEFANINI M, 1991, CANCER RES, V51, P3965; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; THOMPSON LH, 1989, ENVIRON MOL MUTAGEN, V14, P264, DOI 10.1002/em.2850140409; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	31	406	415	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2415	2418		10.1074/jbc.270.6.2415	http://dx.doi.org/10.1074/jbc.270.6.2415			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852297	Green Published, hybrid			2022-12-25	WOS:A1995QF53500002
J	RANI, CSS; ABE, A; CHANG, Y; ROSENZWEIG, N; SALTIEL, AR; RADIN, NS; SHAYMAN, JA				RANI, CSS; ABE, A; CHANG, Y; ROSENZWEIG, N; SALTIEL, AR; RADIN, NS; SHAYMAN, JA			CELL-CYCLE ARREST INDUCED BY ALL INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE - CORRELATION WITH CYCLIN-DEPENDENT KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GANGLIOSIDE-MEDIATED MODULATION; PROTEIN-KINASE; GROWTH; PHOSPHORYLATION; RECEPTOR; DNA; CERAMIDE; INSULIN; CDC2; SPHINGOLIPIDS	In an attempt to define the basis for sphingolipid regulation of cell proliferation, we studied the effects of glucosylceramide (GlcCer) synthase inhibition by three-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) on NIH 3T3 cells overexpressing insulin-like growth factor-1 (IGF-1) receptors, PDMP treatment resulted in a time-dependent decrease in GlcCer levels and an increase in cellular ceramide levels, PDMP abolished serum and IGF-1-stimulated cell proliferation, as measured by a reduction in [H-3]thymidine incorporation, protein, and DNA levels, However it did not affect IGF-1-mediated early signaling events, including receptor tyrosine kinase, MAP kinase, and phosphatidylinositol 3-kinase activities, Two-color flow cytometry with propidium iodide and 5-bromo-2'-deoxyuridine monophosphate labeling revealed an arrest of the cell cycle at G(1)/S and G(2)/M transitions in an asynchronous population of cells, These changes were time dependent, with maximal effects seen by 12-24 h. Removal of PDMP from the cell medium resulted in reversal of the cell cycle changes, with cells re-entering the S phase. The cell cycle arrest at the G(1)/S and G(2)/M transitions was confirmed in cells synchronized by pretreatment with nocodazole, aphidicolin, or hydroxyurea, and released from blockade in the presence of PDMP, A decrease in the activities of two cyclin-dependent kinases, p34(edc2) kinase and cdk2 kinase, was observed with PDMP treatment, When cell ceramide levels were increased by N-acetylsphingosine, comparable changes in the cell cycle distribution were seen, However, sphingomyelinase treatment was without effect, Therefore, it appears that ceramide mediates in part the inhibitory effect of GlcCer synthase inhibition on IGF-1-induced cell proliferation in 3T3 cells, The rapid production of decreased cyclin-dependent kinase activities by PDMP suggests that one of the crucial sites of action of the inhibitor lies in this area.	UNIV MICHIGAN,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	University of Michigan System; University of Michigan; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NIDDK NIH HHS [DK41487, DK39255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255, R01DK041487] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1992, EUR J BIOCHEM, V210, P765, DOI 10.1111/j.1432-1033.1992.tb17479.x; ABE A, 1994, IN PRESS J LIPID RES; BORCHARDT RA, 1994, BBA-LIPID LIPID MET, V1212, P327, DOI 10.1016/0005-2760(94)90207-0; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CARSON KG, 1994, TETRAHEDRON LETT, V35, P2659, DOI 10.1016/S0040-4039(00)76999-1; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1989, CLIN CHIM ACTA, V185, P333, DOI 10.1016/0009-8981(89)90224-6; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, ADV LIPID RES, V25, P43; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HOY CA, 1989, CYTOMETRY, V10, P718, DOI 10.1002/cyto.990100608; INOKUCHI J, 1990, CANCER RES, V50, P6731; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO H, 1993, J BIOL CHEM, V268, P2655; LEE KJ, 1985, CARBOHYD RES, V144, P148, DOI 10.1016/0008-6215(85)85015-1; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSHAK DR, 1991, J CELL BIOCHEM, V45, P391, DOI 10.1002/jcb.240450413; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; PANG L, 1994, J BIOL CHEM, V269, P10604; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; RADIN NS, 1993, ADV LIPID RES, V26, P183; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; SHAYMAN JA, 1994, IN PRESS LIPOBIOLOGY; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SUNDARAM KS, 1984, J NEUROCHEM, V42, P577, DOI 10.1111/j.1471-4159.1984.tb02716.x; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOUCHSTONE JC, 1983, CLIN CHEM, V29, P1951; WANG E, 1991, J BIOL CHEM, V266, P14486; YANAGA F, 1994, BIOCHEM J, V298, P733, DOI 10.1042/bj2980733; ZADOR IZ, 1993, J CLIN INVEST, V91, P797, DOI 10.1172/JCI116299; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	48	153	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2859	2867		10.1074/jbc.270.6.2859	http://dx.doi.org/10.1074/jbc.270.6.2859			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852361	hybrid			2022-12-25	WOS:A1995QF53500071
J	SWOBODA, I; JILEK, A; FERREIRA, F; ENGEL, E; HOFFMANNSOMMERGRUBER, K; SCHEINER, O; KRAFT, D; BREITENEDER, H; PITTENAUER, E; SCHMID, E; VICENTE, O; HEBERLEBORS, E; AHORN, H; BREITENBACH, M				SWOBODA, I; JILEK, A; FERREIRA, F; ENGEL, E; HOFFMANNSOMMERGRUBER, K; SCHEINER, O; KRAFT, D; BREITENEDER, H; PITTENAUER, E; SCHMID, E; VICENTE, O; HEBERLEBORS, E; AHORN, H; BREITENBACH, M			ISOFORMS OF BET-V-1, THE MAJOR BIRCH POLLEN ALLERGEN, ANALYZED BY LIQUID-CHROMATOGRAPHY, MASS-SPECTROMETRY, AND CDNA CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PR PROTEINS; GENE; PURIFICATION; LOCALIZATION; TRANSCRIPTS; EXPRESSION; ANTIBODIES; VERRUCOSA; HORNBEAM; ALDER	Bet v 1, the major allergen of birch pollen, displays a considerable degree of heterogeneity. Several charge variants have been detected by two-dimensional IgE immunoblots and isoelectric focusing techniques. This heterogeneity has been attributed to glycosylation (or other post-translational modifications) or to isogenes coding for Bet vl isoforms and/or allelic variants. However, until now, only limited structural data for Bet v 1 have been published, Recently, we described the expression, purification, and immunological properties of recombinant Bet v 1 (rBet v 1) produced in Escherichia coli as a non-fusion protein (Ferreira, F. D., Hoffmann-Sommergruber, K., Breiteneder, H., Pettenburger, K., Ebner, C., Sammergruber, W., Steiner, R., Bohle, B., Sperr, W. R., Valent, P., Kungl, A. J., Breitenbach, Ri., Kraft, D,, and Scheiner, O. (1993) J. Biol. Chem. 268, 19574-19580). Here, we present a more detailed structural characterization of Bet v 1 by both cDNA cloning and mass spectrometry. Thirteen different cDNA clones coding for Bet v 1 isoforms were obtained by polymerase chain reaction amplification of birch pollen cDNA with a sequence specific 5'-terminal primer and a nonspecific S'-terminal primer or by immunological screening of a birch pollen cDNA Library. These isoforms are referred to as Bet v Ib to Bet v In, whereas the previously isolated Bet v 1 cDNA (Breiteneder, H., Pettenburger, K., Bite, A., Valenta, R., Kraft, D., Rumpold, H., Scheiner, O., and Breitenbach, M. (1989) EMBO J. 8, 1935-1938) is now referred to as Bet v la. High performance liquid chromatography and plasma desorption mass spectrometry of proteolytic fragments of purified natural Bet v 1 (nBet v 1) and rBet v la were used to (i) confirm the primary structure of all Bet v 1 isoforms and (ii) to investigate any possible postsynthetic modifications on rBet v la or on the natural mixture of isoallergens obtained from birch pollen. Except for the cleavage of initiating methionine, no postsynthetic modifications were found in either nBet v 1 or rBet v 1a.	SALZBURG UNIV,INST GENET & ALLGEMEINE BIOL,A-5020 SALZBURG,AUSTRIA; UNIV VIENNA,INST ALLGEMEINE & EXPTL PATHOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST MIKROBIOL & GENET,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,INST ANALYT CHEM,A-1090 VIENNA,AUSTRIA; ERNST BOHRINGER INST ARZNEIMITTELFORSCH,A-1120 VIENNA,AUSTRIA	Salzburg University; University of Vienna; University of Vienna; University of Vienna			Ferreira, Fatima/E-4889-2011; Vicente, Oscar/A-3858-2009; Ferreira, Fatima/AAB-4321-2019; ENGEL, Erwan/HHC-1529-2022	Ferreira, Fatima/0000-0003-0989-2335; Vicente, Oscar/0000-0001-5076-3784; Ferreira, Fatima/0000-0003-0989-2335; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X; Swoboda, Ines/0000-0002-9164-1721				BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG AG, 1991, BIOL MASS SPECTROM, V20, P565, DOI 10.1002/bms.1200200910; CROWELL DN, 1992, PLANT MOL BIOL, V18, P459, DOI 10.1007/BF00040662; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FRISTENSKY B, 1988, PLANT MOL BIOL, V11, P713, DOI 10.1007/BF00017470; GROTE M, 1991, J HISTOCHEM CYTOCHEM, V39, P1395, DOI 10.1177/39.10.1940310; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; IPSEN H, 1989, EPITOPES ATOPIC ALLE, P3; JACOBS S, 1959, NATURE, V183, P262, DOI 10.1038/183262a0; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; MATTON DP, 1989, MOL PLANT MICROBE IN, V2, P325, DOI 10.1094/MPMI-2-325; NIELSEN PF, 1988, BIOMED ENVIRON MASS, V17, P355, DOI 10.1002/bms.1200170503; NILSEN BM, 1991, J BIOL CHEM, V266, P2660; PEDERSEN J, 1993, BIOCHIM BIOPHYS ACTA, V1202, P13, DOI 10.1016/0167-4838(93)90057-X; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMSSICH IE, 1988, MOL GEN GENET, V213, P93, DOI 10.1007/BF00333403; TSARBOPOULOS A, 1988, ANAL BIOCHEM, V171, P113, DOI 10.1016/0003-2697(88)90131-5; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V87, P677, DOI 10.1016/0091-6749(91)90388-5; VESTLING MM, 1990, ANAL CHEM, V62, P2391, DOI 10.1021/ac00220a025; WALTER MH, 1990, MOL GEN GENET, V222, P353, DOI 10.1007/BF00633840; WARNER SAJ, 1992, PLANT MOL BIOL, V19, P555, DOI 10.1007/BF00026782	31	173	191	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2607	2613		10.1074/jbc.270.6.2607	http://dx.doi.org/10.1074/jbc.270.6.2607			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852325	hybrid			2022-12-25	WOS:A1995QF53500033
J	VOELKERDING, KV; STEFFEN, DW; ZAIDI, SHE; MALTER, JS				VOELKERDING, KV; STEFFEN, DW; ZAIDI, SHE; MALTER, JS			POSTTRANSCRIPTIONAL REGULATION OF THE P53 TUMOR-SUPPRESSOR GENE DURING GROWTH-INDUCTION OF HUMAN PERIPHERAL-BLOOD MONONUCLEAR-CELLS	ONCOGENE			English	Article						P53; POSTTRANSCRIPTIONAL REGULATION	MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; C-FOS; PHORBOL ESTER; PROTEIN; EXPRESSION; MYC; ACTIVATION; STABILITY; DIFFERENTIATION	Regulation of p53 gene expression at the posttranscriptional level was investigated during growth induction of human peripheral blood mononuclear cells (PBMCs). Freshly isolated PBMCs, which are in the G(0) phase of the cell cycle, were shown to express low levels of p53 mRNA that was rapidly degraded with a half life of Ih. The rapid decay of p53 mRNA in quiescent PBMCs was dependent on global protein synthesis as treatment with cycloheximide resulted in stabilization of the p53 message. PBMCs were stimulated to enter the cell cycle by treatment with a combination of the mitogenic lectin phytohemagglutinin (PHA) and phorbol ester (TPA). Progressive stabilization of the p53 message occurred in PBMCs during growth induction. By 24 h of incubation in the presence of PHA and TPA, the half life of p53 mRNA was 6 h and p53 mRNA steady state levels were increased 4.5 to 5.0-fold. p53 protein was not detected in quiescent PBMCs, but was readily detected in PBMCs stimulated for 24 h with PHA and TPA. Stabilization of p53 mRNA was observed in PBMCs treated with either PHA or TPA, but to a lesser degree than when PKA and TPA were used as co-stimulants. These results indicate that differential degradation of p53 messenger RNA occurs in quiescent vs mitogen stimulated PBMCs and suggest that post-transcriptional regulation importantly contributes to increased p53 mRNA steady state levels as PBMCs enter the cell cycle.	UNIV WISCONSIN,CTR COMPREHENS CANC,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison	VOELKERDING, KV (corresponding author), UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53792, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045213] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK45213] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMAN A, 1992, IMMUNOLOGY, V76, P465; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONNIEU A, 1988, ONCOGENE RES, V3, P155; CALABRETTA B, 1986, CANCER RES, V46, P5738; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KINZLER KW, 1992, CELL, V70, P523; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3172; MERCER WE, 1985, EXP CELL RES, V100, P31; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; OSIPOVICH OA, 1992, ONCOGENE, V7, P549; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777	32	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					515	521						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845676				2022-12-25	WOS:A1995QF64800012
J	KITAGAWA, M; HIGASHI, H; SUZUKITAKAHASHI, I; SEGAWA, K; HANKS, SK; TAYA, Y; NISHIMURA, S; OKUYAMA, A				KITAGAWA, M; HIGASHI, H; SUZUKITAKAHASHI, I; SEGAWA, K; HANKS, SK; TAYA, Y; NISHIMURA, S; OKUYAMA, A			PHOSPHORYLATION OF E2F-1 BY CYCLIN A-CDK2	ONCOGENE			English	Article						E2F; CYCLIN DEPENDENT KINASE; CELL CYCLE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; BINDING PROTEIN; CDC2 KINASE; DEPENDENT REGULATION; SUSCEPTIBILITY GENE; RB PROTEIN; S-PHASE; CDK2	Transcription factor E2F-1 has a putative consensus sequence for phosphorylation by cyclin dependent kinase (Ser-Pro-X-Lys/Arg). Therefore, we studied the phosphorylation of E2F-1 in vivo and in vitro and its biological functions. E2F-1 was prepared by immunoprecipitation with anti-E2F-1 antibody from IMR32 lysates and was effectively phosphorylated by human cyclin A-cdk2 which was expressed in insect cells using baculovirus system. GST-EZF-1 was phosphorylated by cyclin A-cdk2 more efficiently than by cyclin E-cdk2. Cyclin D1-cdk4 phosphorylated PRE but scarcely phosphorylated GST-E2F-1 or H1 histone. The 60 kd protein precipitated with anti-E2F-1 antibody was phosphorylated in vivo. Phospho-peptide mapping indicated that its cleavage profile was identical with that of E2F-1 phosphorylated by cyclin A-cdk2 in vitro. This 60 kd protein, which is likely to be E2F-1, was not phosphorylated during the GO and early G1 phase, Phosphorylation of E2F-1 began from the S phase while phosphorylation of pRB started nearly at G1/S. The in vivo phosphorylation of E2F-1 was inhibited by butyrolactone I, a cyclin-dependent kinase inhibitor (Kitagawa et al., 1993, Oncogene, 8, 2425-2432). The binding of E2F-1 to E2 promoter was found to be reduced by phosphorylation of E2F-1 by cyclin A-cdk2, suggesting that phosphorylation of E2F-1 may induce shut off of gene expression at the transcriptional level. These results suggest that E2F-1 is phosphorylated by cyclin A-cdkZ in the S phase in vivo as well as in vitro and that its phosphorylation by cyclin A-cdkZ may modulate its activity.	KEIO UNIV,SCH MED,DEPT MICROBIOL,SHINJYUKU KU,TOKYO 160,JAPAN; VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	Keio University; Vanderbilt University; National Cancer Center - Japan	KITAGAWA, M (corresponding author), MERCK RES LABS,BANYU TSUKUBA RES INST COLLABORAT,OKUBO 3,TSUKUBA,IBARAKI 30033,JAPAN.		Higashi, Hideaki/F-6872-2012					AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V66, P1217; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; GIRARD F, 1993, CELL, V67, P1169; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUBER HE, 1993, P NATL ACAD SCI USA, V99, P3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KITAGAWA M, 1994, ONCOGENE, V9, P2549; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KITAGAWA M, 1993, ONCOGENE, V8, P2425; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORI N, 1990, ONCOGENE, V5, P1713; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARTRIDGE JF, 1991, EMBO J, V10, P3819, DOI 10.1002/j.1460-2075.1991.tb04951.x; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171	53	116	119	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					229	236						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838523				2022-12-25	WOS:A1995QC62400002
J	SOZZANI, P; CAMBON, C; VITA, N; SEGUELAS, MH; CAPUT, D; FERRARA, P; PIPY, B				SOZZANI, P; CAMBON, C; VITA, N; SEGUELAS, MH; CAPUT, D; FERRARA, P; PIPY, B			INTERLEUKIN-13 INHIBITS PROTEIN-KINASE C-TRIGGERED RESPIRATORY BURST IN HUMAN MONOCYTES - ROLE OF CALCIUM AND CYCLIC-AMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN B-CELLS; NADPH OXIDASE; POLYMORPHONUCLEAR LEUKOCYTES; ADENYLATE-CYCLASE; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; ACTIVATION; CAMP; PHOSPHORYLATION; REDISTRIBUTION	Interleukin 13 (IL-13), a novel cytokine produced by activated lymphocytes modulates some monocyte functions, but no data is available concerning the signal transduction pathway. We show here, the inhibitory effect of IL-13 on 12-O-tetradecanoylphorbol-13-acetate (TPA)-triggered reactive oxygen intermediate production in human monocytes and the signals involved in this response. Our results show that IL-13 produces rapid and transient phosphoinositide hydrolysis and intracellular Ca2+ mobilization. Furthermore, IL-13 induces intracellular cAMP accumulation through inositol 1,4,5-trisphosphate-dependent Ca2+ mobilization. Metabolic inhibitors were used to relate the first steps in signaling pathways to the inhibitory effect of IL-13 on TPA-triggered reactive oxygen intermediate production. Indeed, inhibitors of phospholipase C (neomycin), intracellular Ca2+ mobilization (8-[N,N-diethylamino]-octyl 3,4,5-trimethoxybenzoate hydrochloride), adenylate cyclase (Delta(9)-tetrahydrocannabinol), and protein kinase A (N [2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide) impair the IL-13 inhibitory response. Altogether these observations indicate that modulatory effect of IL-13 on the TPA-induced oxidative burst is the result of the intracellular cAMP accumulation through an inositol 1,4,5-trisphosphate-induced Ca2+ mobilization-dependent pathway.	UNIV TOULOUSE 3,CHU RANGUEIL,IFR L BUGNARD,INSERM,CJF 9107,F-31054 TOULOUSE,FRANCE; SANOFI RECH,F-31676 LABEGE INNOPOLE,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Sanofi-Aventis				Pipy, Bernard/0000-0001-8060-7029				ABRAMSON SL, 1990, J IMMUNOL, V144, P625; BAUMGOLD J, 1992, LIFE SCI, V50, P1755, DOI 10.1016/0024-3205(92)90058-W; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; DENIS M, 1994, AIDS RES HUM RETROV, V10, P795, DOI 10.1089/aid.1994.10.795; DEWAAL MR, 1993, J IMMUNOL, V151, P1; DOYLE AG, 1994, EUR J IMMUNOL, V24, P1441, DOI 10.1002/eji.1830240630; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; FINNEY M, 1990, EUR J IMMUNOL, V20, P151, DOI 10.1002/eji.1830200122; FORGUE MF, 1991, CARCINOGENESIS, V12, P449, DOI 10.1093/carcin/12.3.449; GENNARO R, 1986, BIOCHEM BIOPH RES CO, V134, P305, DOI 10.1016/0006-291X(86)90563-2; HEBERT JM, 1993, FEBS LETT, V328, P268; ISHITOYA J, 1987, J IMMUNOL, V138, P1201; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Keppel G., 1973, DESIGN ANAL RES HDB; KOHLER I, 1994, FEBS LETT, V345, P187, DOI 10.1016/0014-5793(94)00438-2; KOLB JP, 1993, J IMMUNOL, V150, P4798; LEHN M, 1989, J IMMUNOL, V143, P3020; MACNEIL S, 1985, CELL CALCIUM, V6, P213; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MITSUYAMA T, 1993, BIOCHIM BIOPHYS ACTA, V1117, P167; MONTANER LJ, 1993, J EXP MED, V178, P743, DOI 10.1084/jem.178.2.743; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MYERS MA, 1985, J IMMUNOL, V135, P3411; OLIVIER M, 1992, J IMMUNOL, V148, P1188; PENA C, 1980, MOL IMMUNOL, V17, P1487, DOI 10.1016/0161-5890(80)90174-1; PHILLIPS WA, 1992, BIOCHEM BIOPH RES CO, V182, P727, DOI 10.1016/0006-291X(92)91792-O; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; SALIMATH BP, 1992, CELL SIGNAL, V4, P651, DOI 10.1016/0898-6568(92)90046-B; SAVITHA G, 1993, CELL SIGNAL, V5, P107, DOI 10.1016/0898-6568(93)90063-R; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SIMCHOWITZ L, 1980, J IMMUNOL, V124, P1482; SINGH VK, 1993, IMMUNOL LETT, V35, P239, DOI 10.1016/0165-2478(93)90189-9; TAKENAWA T, 1986, J BIOL CHEM, V261, P1092; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; VERGHESE MW, 1985, J BIOL CHEM, V260, P6769; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; WOLFSON M, 1985, J IMMUNOL, V135, P2057; WU Z, 1991, J BIOL CHEM, V268, P23766; ZIEGLERHEITBROC.HW, 1992, BLOOD, V79, P503; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	44	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5084	5088		10.1074/jbc.270.10.5084	http://dx.doi.org/10.1074/jbc.270.10.5084			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890616	hybrid			2022-12-25	WOS:A1995QL58000023
J	SPILLMANN, D; THOMASOATES, JE; VANKUIK, JA; VLIEGENTHART, JFG; MISEVIC, G; BURGER, MM; FINNE, J				SPILLMANN, D; THOMASOATES, JE; VANKUIK, JA; VLIEGENTHART, JFG; MISEVIC, G; BURGER, MM; FINNE, J			CHARACTERIZATION OF A NOVEL SULFATED CARBOHYDRATE UNIT IMPLICATED IN THE CARBOHYDRATE-CARBOHYDRATE-MEDIATED CELL-AGGREGATION OF THE MARINE SPONGE MICROCIONA-PROLIFERA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE; LIQUID-CHROMATOGRAPHY; PORCINE THYROGLOBULIN; H-1-NMR SPECTROSCOPY; OVINE LUTROPIN; BINDING; OLIGOSACCHARIDES; RECOGNITION; GLYCAN; GLYCOPROTEINS	Species-specific cell reaggregation in the marine sponge Microciona prolifera is mediated by an adhesion proteoglycan. Two interactions are involved in the process: a Ca2+-dependent homophilic binding between proteoglycan molecules and a Ca2+-independent binding between the molecule and cells. Both interactions are mediated by the glycan moieties of the proteoglycan. The interaction of the proteoglycan with itself has been characterized as a carbohydrate-carbohydrate interaction of multiple low affinity sites. The monoclonal antibodies Block 1 and Block 2 raised against the purified aggregation proteoglycan and selected for inhibition of aggregation bind to these glycans. In a previous report the structure, Pyr<(6)(4)>Gal beta 1-4GlcNAc beta 1-3Fuc STRUCTURE 1 was assigned to the oligosaccharide reacting with Block 1 antibody (Spillmann, D., Hard, K., Thomas-Gates, J., Vliegenthart, J. F. G., Misevic, G., Burger, M. M., and Finne, J. (1993) J. Biol, Chem. 268, 13378-13387), By the technique of attaching the water-soluble acid-degraded fragments to a lipid carrier for immunochemical detection and by chemical, enzymatic and spectroscopic methods the structure, GlcNAc beta 1-3Fuc\3SO(3) STRUCTURE 2 was assigned to the oligosaccharide reacting with the aggregation- blocking monoclonal antibody Block 2. The structure, Gal alpha 1-2Gal beta 1-4GlcNAc beta 1-3Fuc\3SO(3) was assigned to a major nonreactive oligosaccharide, which outlined the molecular requirements of antibody binding of the two aggregation-associated epitopes. These data demonstrate that two different functional sites with distinct structural characteristics and antibody reactivities are involved in the reaggregation of sponge cells, a model of carbohydrate carbohydrate-mediated cell interactions.	UNIV TURKU, DEPT MED BIOCHEM, SF-20520 TURKU, FINLAND; FRIEDRICH MIESCHER INST, CH-4058 BASEL, SWITZERLAND; UNIV UTRECHT, DEPT MASS SPECTROMETRY, 3508 TB UTRECHT, NETHERLANDS; UNIV UTRECHT, BIJVOET CTR BIOMOLEC RES, DEPT BIOORGAN CHEM, 3508 TB UTRECHT, NETHERLANDS	University of Turku; Friedrich Miescher Institute for Biomedical Research; Utrecht University; Utrecht University			Misevic, Gradimir/D-8294-2016; Finne, Jukka/B-6881-2008	Misevic, Gradimir/0000-0001-5047-2936; Finne, Jukka/0000-0002-8076-3344				ADAMS G. A., 1965, METHOD CARBOHYD CHEM, V5, P269; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; CHAPLIN MF, 1982, ANAL BIOCHEM, V123, P336, DOI 10.1016/0003-2697(82)90455-9; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; DELL A, 1991, CARBOHYD RES, V209, P33, DOI 10.1016/0008-6215(91)80143-B; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FEIZI T, 1994, METHOD ENZYMOL, V230, P484; Galtsoff PS, 1925, J EXP ZOOL, V42, P223, DOI 10.1002/jez.1400420110; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HAKOMORI S, 1993, BIOCHEM SOC T, V21, P583, DOI 10.1042/bst0210583; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JANSSON PE, 1987, CARBOHYD RES, V162, P111, DOI 10.1016/0008-6215(87)80205-7; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; KAMERLING JP, 1988, FEBS LETT, V241, P246, DOI 10.1016/0014-5793(88)81070-6; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; KOJIMA N, 1992, TRENDS GLYCOSCI GLYC, V4, P491; LAMPIO A, 1991, ANAL BIOCHEM, V197, P132, DOI 10.1016/0003-2697(91)90368-4; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MAGNANI JL, 1985, ANAL BIOCHEM, V150, P12; MARION D, 1983, BIOCHEM BIOPH RES CO, V117, P479; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; MUIR L, 1969, J BIOL CHEM, V244, P2343; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; PARKKINEN J, 1987, METHOD ENZYMOL, V138, P289, DOI 10.1016/0076-6879(87)38024-3; PFEIFFER G, 1992, GLYCOBIOLOGY, V2, P411, DOI 10.1093/glycob/2.5.411; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; SPILLMANN D, 1994, GLYCOCONJUGATE J, V11, P169, DOI 10.1007/BF00731214; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; TURNER RS, 1973, NATURE, V244, P509, DOI 10.1038/244509a0; VANSTEIJN AMP, 1989, RECL TRAV CHIM PAY B, V108, P374; VARKI A, 1994, P NATL ACAD SCI USA, V94, P7390; WEISSHAAR G, 1990, EUR J BIOCHEM, V192, P741, DOI 10.1111/j.1432-1033.1990.tb19285.x; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204	42	68	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5089	5097		10.1074/jbc.270.10.5089	http://dx.doi.org/10.1074/jbc.270.10.5089			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890617	Green Submitted, hybrid			2022-12-25	WOS:A1995QL58000024
J	BUSBY, RW; CHANG, MDT; BUSBY, RC; WIMP, J; TOWNSEND, CA				BUSBY, RW; CHANG, MDT; BUSBY, RC; WIMP, J; TOWNSEND, CA			EXPRESSION AND PURIFICATION OF 2 ISOZYMES OF CLAVAMINATE SYNTHASE AND INITIAL CHARACTERIZATION OF THE IRON-BINDING SITE - GENERAL ERROR ANALYSIS IN POLYMERASE CHAIN-REACTION AMPLIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOPENICILLIN-N-SYNTHASE; CLAVULANIC ACID BIOSYNTHESIS; DEACETOXYCEPHALOSPORIN-C SYNTHETASE; X-RAY-ABSORPTION; ACTIVE-SITE; STREPTOMYCES-CLAVULIGERUS; CEPHALOSPORIUM-ACREMONIUM; SPECTROPHOTOMETRIC ASSAY; ORTHO-PHTHALDIALDEHYDE; REPLICATION ERRORS	Clavaminate synthase is an Fe2+-, O-2-, and alpha-ketoglutarate-dependent oxygenase that catalyzes three transformations in the biosynthesis of the important beta-lactamase inhibitor clavulanic acid, The genes from Streptomyces clavuligerus encoding two isoenzymes of clavaminate synthase have been over-expressed in Escherichia coli to give soluble proteins whose reactions, kinetic properties, and molecular masses are in excellent agreement with the wild-type isozymes, Preliminary investigation of the active site of clavaminate synthase was undertaken using diethyl pyrocarbonate and N-ethylmaleimide. Each was inhibitory to catalytic activity. Protection from inactivation in the presence of these reagents by Fe2+, O-2, and alpha-ketoglutaric acid was thwarted by the rapid self-inactivation of the enzyme in the absence of substrate, However, protection was achieved when Co2+, a potent competitive inhibitor of clavaminate synthase 2 with respect to Fe2+, was substituted. This is consistent with the presence of histidine and cysteine, respectively at or near the active site and possibly involved in iron binding. In the course of constructing the expression vector, a simply applied general error analysis of the polymerase chain reaction was formulated to calculate the proportion of correctly replicated DNA and guide the design of experiments using this method.	JOHNS HOPKINS UNIV, DEPT CHEM, BALTIMORE, MD 21218 USA; NATL TSING HUA UNIV, DEPT LIFE SCI, HSINCHU 30043, TAIWAN; DREXEL UNIV, DEPT MATH & COMP SCI, PHILADELPHIA, PA 19104 USA	Johns Hopkins University; National Tsing Hua University; Drexel University			Houston, Todd A/A-9932-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014937, R56AI014937, R01AI014937] Funding Source: NIH RePORTER; NIAID NIH HHS [AI14937] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALDWIN JE, 1990, J CHEM SOC CHEM COMM, P617, DOI 10.1039/c39900000617; BALDWIN JE, 1987, BIOCHEM J, V245, P831, DOI 10.1042/bj2450831; BALDWIN JE, 1992, J ANTIBIOT, V45, P1378, DOI 10.7164/antibiotics.45.1378; BALDWIN JE, 1993, J CHEM SOC CHEM COMM, P500, DOI 10.1039/c39930000500; BASAK A, 1990, J AM CHEM SOC, V112, P1654, DOI 10.1021/ja00160a069; BERGSEID M, 1991, STRATEGIES, V4, P11; BIRD AE, 1982, ANALYST, V107, P1241, DOI 10.1039/an9820701241; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W W, 1979, Methods Enzymol, V63, P103; DOTZLAF JE, 1987, J BACTERIOL, V169, P1611, DOI 10.1128/jb.169.4.1611-1618.1987; ELSON SW, 1987, J CHEM SOC CHEM COMM, P1736, DOI 10.1039/c39870001736; ELSON SW, 1993, J CHEM SOC CHEM COMM, P1212, DOI 10.1039/c39930001212; ELSON SW, 1987, J CHEM SOC CHEM COMM, P1738; HANAUSKEABEL HM, 1982, J THEOR BIOL, V94, P421, DOI 10.1016/0022-5193(82)90320-4; HASHIMOTO T, 1993, FEBS LETT, V329, P35, DOI 10.1016/0014-5793(93)80187-Y; HAYAISHI O, 1976, ENZYMES, V12, P119; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Kivirikko KI, 1980, ENZYMOLOGY POSTTRANS, P53; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; KOHSAKA M, 1976, BIOCHEM BIOPH RES CO, V70, P465, DOI 10.1016/0006-291X(76)91069-X; KRAWCZAK M, 1989, NUCLEIC ACIDS RES, V17, P2197, DOI 10.1093/nar/17.6.2197; KRIAUCIUNAS A, 1991, J BIOL CHEM, V266, P11779; KROL WJ, 1991, J ORG CHEM, V56, P728, DOI 10.1021/jo00002a045; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLOR EJ, 1994, TETRAHEDRON, V50, P8737, DOI 10.1016/S0040-4020(01)85347-3; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; Maniatis T., 1982, MOL CLONING; MARSH EN, 1992, BIOCHEMISTRY-US, V31, P12648, DOI 10.1021/bi00165a015; Miles E W, 1977, Methods Enzymol, V47, P431; MING LJ, 1991, BIOCHEMISTRY-US, V30, P11653, DOI 10.1021/bi00114a007; MYLLYLA R, 1992, BIOCHEM J, V286, P923, DOI 10.1042/bj2860923; NICHOLSON NH, 1994, J CHEM SOC CHEM COMM, P1281, DOI 10.1039/c39940001281; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; POPENOE EA, 1969, ARCH BIOCHEM BIOPHYS, V133, P286, DOI 10.1016/0003-9861(69)90456-1; RANDALL CR, 1993, BIOCHEMISTRY-US, V32, P6664, DOI 10.1021/bi00077a020; REISS J, 1990, NUCLEIC ACIDS RES, V18, P973, DOI 10.1093/nar/18.4.973; SALOWE SP, 1990, BIOCHEMISTRY-US, V29, P6499, DOI 10.1021/bi00479a023; SALOWE SP, 1991, BIOCHEMISTRY-US, V30, P2281, DOI 10.1021/bi00222a034; SAMSON SM, 1987, P NATL ACAD SCI USA, V84, P5705, DOI 10.1073/pnas.84.16.5705; SCHEIDEGGER A, 1984, J ANTIBIOT, V37, P522, DOI 10.7164/antibiotics.37.522; SCOTT RA, 1992, BIOCHEMISTRY-US, V31, P4596, DOI 10.1021/bi00134a009; SIEGEL B, 1979, BIOORG CHEM, V8, P219, DOI 10.1016/0045-2068(79)90007-5; STREET IP, 1990, BIOCHEMISTRY-US, V29, P7531, DOI 10.1021/bi00484a023; SVEDAS VJK, 1980, ANAL BIOCHEM, V101, P188, DOI 10.1016/0003-2697(80)90059-7; TOWNSEND CA, 1988, J CHEM SOC CHEM COMM, P1234, DOI 10.1039/c39880001234; TOWNSEND CA, 1993, BIOCHEM SOC T, V21, P208, DOI 10.1042/bst0210208	48	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4262	4269		10.1074/jbc.270.9.4262	http://dx.doi.org/10.1074/jbc.270.9.4262			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876185	hybrid			2022-12-25	WOS:A1995QK08400016
J	FRENCH, AR; TADAKI, DK; NIYOGI, SK; LAUFFENBURGER, DA				FRENCH, AR; TADAKI, DK; NIYOGI, SK; LAUFFENBURGER, DA			INTRACELLULAR TRAFFICKING OF EPIDERMAL GROWTH-FACTOR FAMILY LIGANDS IS DIRECTLY INFLUENCED BY THE PH SENSITIVITY OF THE RECEPTOR-LIGAND INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE FC-RECEPTORS; FACTOR-ALPHA; HUMAN-FIBROBLASTS; INSULIN-RECEPTOR; CELL-LINE; INTERNALIZATION; DEGRADATION; ENDOCYTOSIS; BINDING; COMPARTMENTATION	Using members of the epidermal growth factor (EGF) family as well as site-directed recombinant human EGF mutants, we investigated how ligand binding properties influence endosomal sorting. Mouse EGF (mEGF), human EGF (hEGF), and transforming growth factor alpha (TGF alpha) bind to the human EGF receptor (EGFR) with similar affinities at pH 7.4. However, the binding properties of these ligands have substantially different pH sensitivities resulting in varying degrees of dissociation from the receptors at lower pH levels characteristic of endosomes. we employed a steady-state sorting assay to determine the fraction of Ligand sorted to recycling versus degradation as a function of the number of intracellular ligand molecules in mouse B82 fibroblasts. mEGF, hEGF, and TGF alpha display significantly different steady-state endosomal sorting patterns which correspond to the extent of their dissociation at endosomal pH. Moreover, several recombinant hEGF mutants with differing affinities exhibit altered endosomal sorting compared to hEGF, demonstrating a similar direct relationship between ligand binding properties and endosomal sorting outcomes. Intracellular trafficking of the EGF ligands was also monitored by measuring the observed degradation rate constants. These likewise show marked differences that correlate with the differing pH sensitivities of the ligands' binding properties.	UNIV ILLINOIS, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA; UNIV TENNESSEE, GRAD SCH BIOMED SCI, OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA; OAK RIDGE NATL LAB, PROT ENGN & MOLEC MUTAGENESIS PROGRAM, OAK RIDGE, TN 37831 USA	University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory	FRENCH, AR (corresponding author), UNIV ILLINOIS, DEPT CHEM ENGN, URBANA, IL 61801 USA.							BRENNER DA, 1989, DNA-J MOLEC CELL BIO, V8, P279, DOI 10.1089/dna.1.1989.8.279; BURGERT HG, 1983, EXP CELL RES, V144, P127, DOI 10.1016/0014-4827(83)90447-0; CAMPION SR, 1992, J CELL BIOCHEM, V50, P35; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GIBSON AE, 1989, AM J PHYSIOL, V257, pC182, DOI 10.1152/ajpcell.1989.257.2.C182; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KORC M, 1989, J BIOL CHEM, V264, P14990; KORC M, 1987, CANCER RES, V47, P4909; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; LAUFFENBURGER DA, 1994, IN PRESS HDB BIOMEDI; LINDERMAN JJ, 1988, J THEOR BIOL, V132, P203, DOI 10.1016/S0022-5193(88)80157-7; LOW DA, 1981, P NATL ACAD SCI-BIOL, V78, P2340, DOI 10.1073/pnas.78.4.2340; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIYAKE Y, 1989, J BIOL CHEM, V264, P16584; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; RAUB TJ, 1986, EXP CELL RES, V165, P73, DOI 10.1016/0014-4827(86)90534-3; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SORKIN AD, 1988, EXP CELL RES, V175, P192, DOI 10.1016/0014-4827(88)90266-2; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; TADAKI DK, 1993, J BIOL CHEM, V268, P10114; UKKONEN P, 1986, J EXP MED, V163, P952, DOI 10.1084/jem.163.4.952; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1	41	186	192	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4334	4340		10.1074/jbc.270.9.4334	http://dx.doi.org/10.1074/jbc.270.9.4334			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876195	hybrid			2022-12-25	WOS:A1995QK08400026
J	GOMES, XV; WOLD, MS				GOMES, XV; WOLD, MS			STRUCTURAL-ANALYSIS OF HUMAN REPLICATION PROTEIN-A - MAPPING FUNCTIONAL DOMAINS OF THE 70-KDA SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SIMIAN VIRUS-40 DNA; POLYMERASE-ALPHA-PRIMASE; BINDING-PROTEIN; SV40 ORIGIN; T-ANTIGEN; FACTOR-A; SACCHAROMYCES-CEREVISIAE; INVITRO REPLICATION; PURIFIED PROTEINS	Replication protein A (RPA) is a heterotrimeric single-stranded DNA-binding protein that is essential for DNA metabolism. Human RPA is composed of subunits of 70, 32, and 14 kDa with intrinsic DNA-binding activity localized to the 616-amino acid, 70-kDa subunit (RPA70). We have made a series of C-terminal deletions to map the functional domains of RPA70. Deletion of the C terminus resulted in polypeptides that were significantly more soluble than RPA70 but were unable to form stable complexes with the other two subunits of RPA. These data suggest that the C-terminal region of RPA70 may be important for complex formation. The DNA-binding do main was localized to a region of RPA70 between residues 1 and 441. A mutant containing residues 1-441 bound oligonucleotides with an intrinsic affinity close to wild-type RPA complex. This mutant also appeared to bind with reduced cooperativity. We conclude that the C terminus of RPA70 and the 32- and 14-kDa subunits are not involved directly with interactions with DNA but may have a role in cooperativity of RPA binding. RPA70 deletion mutants were not able to support DNA replication even in the presence of a complex of the 32- and 14-kDa subunits, suggesting that the heterotrimeric complex is essential for DNA replication. The putative zinc finger in the C terminus of RPA70 is not required for single-stranded DNA-binding activity.	UNIV IOWA, SCH MED, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	University of Iowa			Wold, Marc/F-5806-2010	Wold, Marc/0000-0002-4580-1624	NIGMS NIH HHS [GM44721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; ATRAZHEV A, 1992, EUR J BIOCHEM, V210, P855, DOI 10.1111/j.1432-1033.1992.tb17489.x; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BROWN GW, 1994, MOL BIOCHEM PARASIT, V63, P135, DOI 10.1016/0166-6851(94)90016-7; BROWN GW, 1992, P NATL ACAD SCI USA, V89, P10227, DOI 10.1073/pnas.89.21.10227; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANG F, 1993, J CELL SCI, V106, P983; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KAMAKAKA RT, 1994, MOL CELL BIOL, V14, P5114, DOI 10.1128/MCB.14.8.5114; KENNY MK, 1990, J BIOL CHEM, V265, P769; KIM C, 1995, IN PRESS BIOCHEMISTR; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KORN D, 1979, COLD SPRING HARB SYM, V43, P613, DOI 10.1101/SQB.1979.043.01.068; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1991, J BIOL CHEM, V266, P22707; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MELENDY T, 1993, J BIOL CHEM, V268, P3389; Melendy T., 1992, V6, P129; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; NAKAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4292, DOI 10.1093/nar/19.15.4292; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SEO YS, 1991, J BIOL CHEM, V266, P13161; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMMES P, 1992, J BIOL CHEM, V267, P6063; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; UMBRICHT CB, 1993, J BIOL CHEM, V268, P6131; VILLEMAIN JL, 1993, BIOCHEMISTRY-US, V32, P11235, DOI 10.1021/bi00092a038; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	62	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4534	4543		10.1074/jbc.270.9.4534	http://dx.doi.org/10.1074/jbc.270.9.4534			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876222	hybrid			2022-12-25	WOS:A1995QK08400055
J	NAUSEEF, WM; MCCORMICK, SJ; CLARK, RA				NAUSEEF, WM; MCCORMICK, SJ; CLARK, RA			CALRETICULIN FUNCTIONS AS A MOLECULAR CHAPERONE IN THE BIOSYNTHESIS OF MYELOPEROXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA HL-60 CELLS; ENDOPLASMIC-RETICULUM MEMBRANE; INTRACELLULAR-TRANSPORT; PROTEIN; CALNEXIN; INDUCTION; HEME; FIBROBLASTS; DEFICIENCY; MATURATION	Myeloperoxidase (MPO), a lysosomal heme protein found exclusively in neutrophils and monocytes, is necessary for-efficient oxygen-dependent microbicidal activity. Acquisition of heme by the heme-free MPO precursor apopro-MPO appears to be a prerequisite for its subsequent proteolytic processing and advancement along the biosynthetic pathway to mature MPO. We present data indicating that calreticulin (CRT), a high capacity calcium-binding protein residing in the lumen of the endoplasmic reticulum of a wide variety of cells, interacts specifically with fully glycosylated apopro-MPO. Biosynthetically radiolabelled CRT (60 kDa) and apopro-MPO (90 kDa) were coprecipitated from PLB 985 cells by monospecific antiserum against CRT when the immunoprecipitations were performed either under nondenaturing conditions or following reversible crosslinking, Nonglycosylated MPO precursors synthesized in the presence of tunicamycin did not interact with CRT, The CRT-apopro-MPO interaction was restricted to an early phase of MPO biosynthesis, and CRT did not interact with the later appearing, heme containing species of MPO, i.e, pro-MPO or the heavy subunit of mature MPO. These data show that CRT participates in the post-translational processing of MPO, perhaps by maintaining apopro-MPO in a conformation competent to accommodate insertion of the heme group, In this general way, CRT shares certain functional properties with the structurally homologous transmembrane calcium-binding endoplasmic reticulum protein calnexin, Both interact with glycosylated biosynthetic precursors of proteins selectively expressed in specialized cells.	VET ADM MED CTR,DEPT MED,IOWA CITY,IA 52242	US Department of Veterans Affairs; Veterans Health Administration (VHA)	NAUSEEF, WM (corresponding author), UNIV IOWA,COLL MED,DEPT MED,200 HAWKINS DR,IOWA CITY,IA 52242, USA.		Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619; Nauseef, William/0000-0003-4032-757X	BLRD VA [I01 BX000513] Funding Source: Medline; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER	BLRD VA; Veterans Affairs(US Department of Veterans Affairs)		AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; AKIN DT, 1987, ARCH BIOCHEM BIOPHYS, V255, P428, DOI 10.1016/0003-9861(87)90411-5; AKIN DT, 1987, ARCH BIOCHEM BIOPHYS, V257, P451, DOI 10.1016/0003-9861(87)90590-X; AKIN DT, 1986, J BIOL CHEM, V261, P8370; ARNLJOTS K, 1987, J BIOL CHEM, V262, P10430; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CASTANEDA VL, 1992, EXP HEMATOL, V20, P916; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DENNING GM, 1993, MOL BIOL CELL, V4, P135; DINAUER MC, 1992, ANNU REV MED, V43, P117, DOI 10.1146/annurev.med.43.1.117; DUPUIS M, 1993, J EXP MED, V177, P1, DOI 10.1084/jem.177.1.1; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Ezekowitz R A, 1992, Curr Top Microbiol Immunol, V181, P283; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUAN SH, 1991, BIOCHEMISTRY-US, V30, P9892, DOI 10.1021/bi00105a012; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUR SJ, 1989, J BIOL CHEM, V264, P8542; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Johnson K. R., 1991, PEROXIDASES CHEM BIO, P63; Kelley William L., 1992, Current Opinion in Cell Biology, V4, P984, DOI 10.1016/0955-0674(92)90130-5; Klebanoff S. J, 1991, PEROXIDASES CHEM BIO, V1, P1; KLEBANOFF SJ, 1970, SCIENCE, V169, P1095, DOI 10.1126/science.169.3950.1095; KOEFFLER HP, 1985, BLOOD, V65, P484; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LENTER M, 1994, J BIOL CHEM, V269, P12263; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; NAUSEEF W M, 1990, Hematologic Pathology, V4, P165; NAUSEEF WM, 1986, BLOOD, V67, P865; NAUSEEF WM, 1983, J CLIN INVEST, V71, P1297, DOI 10.1172/JCI110880; NAUSEEF WM, 1990, BLOOD, V76, P2622; NAUSEEF WM, 1987, BLOOD, V70, P1143; NAUSEEF WM, 1992, BLOOD, V80, P2622; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OFARRELL PH, 1977, J BIOL CHEM, V250, P4007; OLDEN K, 1979, P NATL ACAD SCI USA, V76, P791, DOI 10.1073/pnas.76.2.791; OLSSON I, 1984, BIOCHEM J, V223, P911, DOI 10.1042/bj2230911; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PINNIX IB, 1994, ARCH BIOCHEM BIOPHYS, V312, P447, DOI 10.1006/abbi.1994.1331; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; SARGAN DR, 1986, BIOCHEMISTRY-US, V25, P6252, DOI 10.1021/bi00368a062; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; STROMBERG K, 1986, EUR J CELL BIOL, V39, P424; TAYLOR KL, 1990, BIOCHEMISTRY-US, V29, P1533, DOI 10.1021/bi00458a026; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599; YAMADA M, 1982, J BIOL CHEM, V257, P5980; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	62	226	228	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4741	4747		10.1074/jbc.270.9.4741	http://dx.doi.org/10.1074/jbc.270.9.4741			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876246	hybrid			2022-12-25	WOS:A1995QK08400082
J	SMITH, KP; LIU, B; SCOTT, C; SHARP, ZD				SMITH, KP; LIU, B; SCOTT, C; SHARP, ZD			PIT-1 EXHIBITS A UNIQUE PROMOTER SPACING REQUIREMENT FOR ACTIVATION AND SYNERGISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT GROWTH-HORMONE; CELL-SPECIFIC EXPRESSION; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; PROLACTIN GENE; ELEMENTS; BINDING; INVITRO; DNA; DISTANCE	The developmentally regulated Pit-1 transcription factor is involved in the activation of prolactin, growth hormone, and TSH beta expression. Using templates with spacing mutations to program an in. vitro transcription system, the activity of a single Pit-1 proximal binding site within the rat prolactin promoter was shown to have a unique bimodal distance requirement, Transcription activity rapidly decreased with each 5-base pair (bp) addition to the spacing between the binding site and the TATA box, When positioned 20 bp upstream from its normal -36 position in the prolactin promoter, the activity of the Pit-1 binding site is reduced to basal levels, Placement of the site at a position 30 bp upstream resulted in a return of Pit-1-mediated activation. Using transient transfection assays in GH(3) cells, the prime bimodal sites are also a requirement for optimum expression of chimeric prolactin-luciferase reporter con constructs, interestingly optimal synergism of transcription in vivo by the prolactin distal enhancer, containing four Pit-1 binding sites and an estrogen responsive dement, is also sensitive to the placement of the proximal Pit-1 binding site. These data have important implications for Pit-1 activator function in pituitary cells and for general models of transcription synergism.	UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio					NIDDK NIH HHS [DK38546] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038546, R29DK038546] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BARRON EA, 1989, MOL CELL BIOL, V9, P817, DOI 10.1128/MCB.9.2.817; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CAO Z, 1988, MOL CELL BIOL, V8, P5432, DOI 10.1128/MCB.8.12.5432; CAO ZD, 1987, MOL CELL BIOL, V7, P3402, DOI 10.1128/MCB.7.10.3402; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CATANZARO DF, 1987, MOL ENDOCRINOL, V1, P90, DOI 10.1210/mend-1-1-90; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; HARVEY C, 1991, MOL ENDOCRINOL, V5, P836, DOI 10.1210/mend-5-6-836; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; LIN SC, 1994, DEVELOPMENT, V120, P515; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NELSON C, 1986, NATURE, V322, P557, DOI 10.1038/322557a0; PAPE LK, 1990, GENE DEV, V4, P52, DOI 10.1101/gad.4.1.52; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PEERS B, 1990, MOL CELL BIOL, V10, P4690, DOI 10.1128/MCB.10.9.4690; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; Sambrook J, 1989, MOL CLONING LABORATO; SMITH KP, 1991, BIOCHEM BIOPH RES CO, V177, P790, DOI 10.1016/0006-291X(91)91858-A; TAKAHASHI K, 1991, NATURE, V319, P121; TANSEY WP, 1993, J BIOL CHEM, V268, P14906; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; WOLF JB, 1990, NUCLEIC ACIDS RES, V18, P4905; WU L, 1988, GENE DEV, V2, P403, DOI 10.1101/gad.2.4.403; YE ZS, 1987, J BIOL CHEM, V262, P6313; ZHOU YH, 1994, EMBO J, V13, P4549, DOI 10.1002/j.1460-2075.1994.tb06776.x	43	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4484	4491		10.1074/jbc.270.9.4484	http://dx.doi.org/10.1074/jbc.270.9.4484			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876215	hybrid			2022-12-25	WOS:A1995QK08400048
J	BROSTROM, MA; PROSTKO, CR; GMITTER, D; BROSTROM, CO				BROSTROM, MA; PROSTKO, CR; GMITTER, D; BROSTROM, CO			INDEPENDENT SIGNALING OF GRP78 GENE-TRANSCRIPTION AND PHOSPHORYLATION OF EUKARYOTIC INITIATION-FACTOR 2-ALPHA BY THE STRESSED ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR SEQUESTERED CALCIUM; GH3 PITUITARY-CELLS; HEAT-SHOCK PROTEINS; TRANSMEMBRANE PROTEIN; CHRONIC DEPRIVATION; MAMMALIAN-CELLS; BREFELDIN-A; EXPRESSION; KINASE; ER	Perturbation of endoplasmic reticular (ER) function signals increased expression of the gene encoding the ER resident chaperone Grp78/BiP and rapid suppression of translational initiation accompanied by phosphorylation of the alpha-subunit of eukaryotic initiation factor 2 (eIF-2). eIF2 alpha phosphorylation and grp78 mRNA induction were measured in GH, pituitary cells subjected to varied degrees of ER stress to ascertain whether activation of an eIF-2 alpha kinase is involved in both events. grp78 mRNA was induced at low concentrations of ionomycin and dithiothreitol that did not provoke eIF-2 alpha phosphorylation or inhibition of amino acid incorporation. Mobilization of the bulk of cell-associated Ca2+ and the induction of grp78 mRNA occurred at comparable low concentrations of ionomycin, whereas phosphorylation of eIF-2 alpha and inhibition of protein synthesis required higher ionophore concentrations. Pretreatment for 1 h with cycloheximide suppressed grp78 mRNA induction and eIF-2 alpha phosphorylation in response to either stressor. Prolonged (17 h) cycloheximide blockade increased eIF-2 alpha phosphorylation without inducing grp78 mRNA Upon release from the blockade, grp78 mRNA was induced and eIF-2 alpha was dephosphorylated. Translational tolerance to ionomycin or dithiothreitol, accompanied by dephosphorylation of eIF-2 alpha, was observed whenever grp78 mRNA was induced. Induction of grp78 mRNA preceded significant eIF-2 alpha phosphorylation during treatment with brefeldin A It is concluded that signaling of grp78 gene transcription can occur independently of eIF-2 alpha phosphorylation or translational repression and that greater degrees of ER stress are required for eIF-2 alpha phosphorylation than for grp78 mRNA induction.			BROSTROM, MA (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PHARMACOL, PISCATAWAY, NJ 08854 USA.				NIDDK NIH HHS [DK 35393] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035393] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROSTROM CO, 1983, J BIOL CHEM, V258, P4390; BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; BROSTROM MA, 1993, NUTRITION GENE EXPRE, P117; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; CHIN KV, 1987, J BIOL CHEM, V262, P16509; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KIM YK, 1987, J CELL PHYSIOL, V133, P553, DOI 10.1002/jcp.1041330317; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; KUZNETSOV G, 1993, J BIOL CHEM, V268, P2001; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LIU ES, 1992, J BIOL CHEM, V267, P7128; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; MATTS RL, 1992, J BIOL CHEM, V267, P18168; MELLOR H, 1994, FEBS LETT, V350, P143, DOI 10.1016/0014-5793(94)00756-X; MORI K, 1993, CELL, V74, P743; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PORUCHYNSKY MS, 1991, J CELL BIOL, V114, P651, DOI 10.1083/jcb.114.4.651; PRICE BD, 1992, J CELL PHYSIOL, V152, P545, DOI 10.1002/jcp.1041520314; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; PROSTKO CR, 1991, J BIOL CHEM, V266, P19790; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; RESENDEZ E, 1986, J CELL BIOL, V103, P2145, DOI 10.1083/jcb.103.6.2145; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SAMUEL CE, 1992, PHARMACOL THERAPEUT, V54, P307, DOI 10.1016/0163-7258(92)90005-K; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071	41	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4127	4132		10.1074/jbc.270.8.4127	http://dx.doi.org/10.1074/jbc.270.8.4127			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876163				2022-12-25	WOS:A1995QH68800097
J	CAMPBELL, GS; MEYER, DJ; RAZ, R; LEVY, DE; SCHWARTZ, J; CARTERSU, C				CAMPBELL, GS; MEYER, DJ; RAZ, R; LEVY, DE; SCHWARTZ, J; CARTERSU, C			ACTIVATION OF ACUTE-PHASE RESPONSE FACTOR (APRF)/STAT3 TRANSCRIPTION FACTOR BY GROWTH-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; TYROSINE PHOSPHORYLATION; C-FOS; INTERFERON-ALPHA; BINDING; PROTEIN; PROMOTER; ELEMENT; KINASE; GAMMA	The mechanisms by which the binding of growth hormone (GH) to its cell surface receptor elicits changes in gene transcription are largely unknown. The transcription factor Stat1/p91 has been shown to be activated by GH Here we show that acute phase response factor or Stat3 (or an antigenically related protein), is also activated by GH, Stats has been implicated in the interleukin-6-dependent induction of acute phase response genes, GH promotes in 3T3-F442A fibroblasts the tyrosyl phosphorylation of a protein immunoprecipitated by antibodies to Stats. This protein co-migrates with a tyrosyl phosphorylated protein from cells treated with leukemia inhibitory factor, a cytokine known 60 activate Stat3. Tyrosyl phosphorylated Stats is also observed in response to interferon-gamma. Stat3 is present in GH-inducible DNA-binding complexes that bind the sis-inducible element in the c-fos promoter and the acute phase response element in the alpha(2),-macroglobulin promoter. The ability of GH to activate both Stat1 and Stat3 (i.e. increase their tyrosyl phosphorylation and ability to bind to DNA) suggests that gene regulation by GH involves multiple Stat proteins. Shared transcription factors among hormones and cytokines that activate JAK kinases provide an explanation for shared responses, while the ability of the different Ligands to differentially recruit various Stat family members suggests mechanisms by which specificity in gene regulation could be achieved.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016	University of Michigan System; University of Michigan; New York University; New York University			Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022	Levy, David/0000-0002-7320-7788; 	NIAID NIH HHS [R01-AI28900] Funding Source: Medline; NIDDK NIH HHS [R01-DK34171, R01 DK042932, R01 DK034171] Funding Source: Medline; NIGMS NIH HHS [GM07315] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R01DK042932] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FELDMAN GM, 1994, J BIOL CHEM, V269, P10747; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; RAZ R, 1994, J BIOL CHEM, V269, P24391; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; VOGEL J, 1986, MOL CELL BIOL, V6, P3550, DOI 10.1128/MCB.6.10.3550; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG A, 1994, P NATL SCI US, V91, P4806; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	36	172	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3974	3979		10.1074/jbc.270.8.3974	http://dx.doi.org/10.1074/jbc.270.8.3974			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876144	hybrid			2022-12-25	WOS:A1995QH68800077
J	DONATH, MJSH; LENTING, PJ; VANMOURIK, JA; MERTENS, K				DONATH, MJSH; LENTING, PJ; VANMOURIK, JA; MERTENS, K			THE ROLE OF CLEAVAGE OF THE LIGHT-CHAIN AT POSITIONS ARG(1689) OR ARG(1721) IN SUBUNIT INTERACTION AND ACTIVATION OF HUMAN BLOOD-COAGULATION FACTOR-VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; VON-WILLEBRAND FACTOR; SEVERE HEMOPHILIA-A; VONWILLEBRAND-FACTOR; FACTOR-XA; MONOCLONAL-ANTIBODIES; BIOLOGICAL-ACTIVITY; FACTOR-IXA; PROTEIN-C; FACTOR-VA	The role of Factor VIII Light chain cleavage in Factor VIII activation and subunit interaction was investigated. Purified Factor VIII was dissociated into its separate subunits, and the isolated light chain was cleaved by thrombin at position Arg(1689) or by Factor Xa at position Arg(1721). These Factor VIII light chain derivatives then were used for reconstitution with purified Factor VIII heavy chain to obtain heterodimers that were exclusively cleaved within the Light chain, Intact and cleaved light chain could effectively be reassociated with heavy chain, with concomitant regain of Factor VIII cofactor function. The association rate constant of Factor Xa-cleaved light chain was found to be 3-fold lower than that of thrombin-cleaved or intact light chain, suggesting a role of the region Ser(1690)-Arg(1721) in subunit assembly. Dissociation rate constants, however, were independent of Factor VIII light chain cleavage. Low ionic strength was observed to promote association but to destabilize the Factor VIII heterodimer. At high ionic strength, Factor VIII dissociation was extremely slow (k(off) approximate to 10(-5) s(-1)) for all Factor VIII light chain derivatives, indicating that Factor VIII light chain cleavage is not related to Factor VIII dissociation. Furthermore, Factor VIII light chain cleavage does not affect enzyme-cofactor assembly, since the various light chain derivatives proved equally efficient in binding to Factor IXa (K-d approximate to 15 nM). Studies in a purified Factor X-activating system demonstrated that thrombin and Factor Xa activate Factor VIII to the same extent. However, Factor Xa differed from thrombin in that it cleaved at Arg(1721) rather than at Arg(1689). Reassociated heterodimers of Factor VIII heavy chain and intact light chain did not promote Factor X activation. In contrast, heterodimers that contained cleaved light chain exhibited substantial Factor VIIIa activity. These data demonstrate that a single cleavage at either Arg(1689) or Arg(1721) converts the inactive Factor VIII heterodimer into an active cofactor of Factor IXa.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT BLOOD COAGULAT,1066 CX AMSTERDAM,NETHERLANDS				Lenting, Peter/AAH-5663-2019; Lenting, Peter/F-8269-2013	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429				ALY AM, 1992, J CLIN INVEST, V89, P1382, DOI 10.1172/JCI115726; ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; ARAI M, 1990, BLOOD, V75, P384; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1987, J BIOL CHEM, V262, P3285; ESMON CT, 1979, J BIOL CHEM, V254, P964; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1993, THROMB HAEMOSTASIS, V70, P63; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FESS DN, 1982, BLOOD, V59, P594; GILBERT GE, 1990, J BIOL CHEM, V265, P815; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; JOHNSON DJD, 1994, THROMB HAEMOSTASIS, V71, P428; KAUFMAN RJ, 1992, ANNU REV MED, V43, P325, DOI 10.1146/annurev.med.43.1.325; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1991, J BIOL CHEM, V266, P740; LEYTE A, 1989, BIOCHEM J, V263, P187, DOI 10.1042/bj2630187; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MAHLER HR, 1967, BIOL CHEM, P220; MANN KG, 1990, BLOOD, V76, P1; MCDONALD M, 1991, THROMB HAEMOSTASIS, V65, P943; MERTENS K, 1984, BIOCHEM J, V223, P607, DOI 10.1042/bj2230607; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MERTENS K, 1993, BRIT J HAEMATOL, V85, P133, DOI 10.1111/j.1365-2141.1993.tb08656.x; MERTENS K, 1984, BIOCHEM J, V223, P559; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NEUENSCHWANDER P, 1990, ANAL BIOCHEM, V184, P347, DOI 10.1016/0003-2697(90)90692-3; NORDFANG O, 1988, J BIOL CHEM, V263, P1115; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OBRIEN DP, 1989, BLOOD, V73, P2117; OBRIEN DP, 1990, BLOOD, V75, P1664; PITTMAN DD, 1989, THROMB HAEMOSTASIS, V61, P161; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; STEL HV, 1984, BLOOD, V63, P1408; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1992, J BIOL CHEM, V267, P19896	49	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3648	3655		10.1074/jbc.270.8.3648	http://dx.doi.org/10.1074/jbc.270.8.3648			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876103	hybrid			2022-12-25	WOS:A1995QH68800031
J	DONG, BH; SILVERMAN, RH				DONG, BH; SILVERMAN, RH			2-5A-DEPENDENT RNASE MOLECULES DIMERIZE DURING ACTIVATION BY 2-5A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE EXPRESSION; PROTEIN-SYNTHESIS; CROSS-LINKING; INTERFERON; ENDORIBONUCLEASE; ENZYME	2-5A-dependent RNase is an interferon-inducible enzyme that requires 5'-phosphorylated, 2',5'-linked oligoadenylates (2-5A) for its endoribonuclease activity against single-stranded RNAs. We demonstrate here that recombinant, human 2-5A-dependent RNase forms stable homodimers during its stimulation by 2-5A. The protein dimers were observed to form only upon binding to 2-5A, as shown using gel filtration chromatography and chemical cross-linking and after centrifugation in glycerol gradients. A monoclonal antibody to 2-5A-dependent RNase was prepared and used to probe the subunit structure of the enzyme in the presence or absence of 2-5A Using oligoadenylates of different length, structure, and 5'-phosphorylation states we determined that conversion of 2-5A-dependent RNase from its monomeric, inactive form to its homodimeric, active form required the presence of functional 2-5A These results demonstrate that the catalytically active form of 2-5A-dependent RNase is a homodimer.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NCI NIH HHS [5R01 CA44059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAYARD B, 1994, EUR J BIOCHEM, V223, P403, DOI 10.1111/j.1432-1033.1994.tb19007.x; BISBAL C, 1989, EUR J BIOCHEM, V179, P595, DOI 10.1111/j.1432-1033.1989.tb14588.x; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DONG BH, 1994, J BIOL CHEM, V269, P14153; FLOYDSMITH G, 1986, METHOD ENZYMOL, V119, P489; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; NILSEN TW, 1981, J BIOL CHEM, V256, P751; REVEL M, 1979, REGULATION MACROMOLE, P341; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SALEHZADA T, 1993, J BIOL CHEM, V268, P7733; SILVERMAN RH, 1985, ANAL BIOCHEM, V144, P450, DOI 10.1016/0003-2697(85)90141-1; SLATTERY E, 1979, P NATL ACAD SCI USA, V76, P4778, DOI 10.1073/pnas.76.10.4778; WRESCHNER DH, 1982, EUR J BIOCHEM, V124, P261; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	17	218	224	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4133	4137		10.1074/jbc.270.8.4133	http://dx.doi.org/10.1074/jbc.270.8.4133			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876164	hybrid			2022-12-25	WOS:A1995QH68800098
J	FLYNN, DC; KOAY, TC; HUMPHRIES, CG; GUAPPONE, AC				FLYNN, DC; KOAY, TC; HUMPHRIES, CG; GUAPPONE, AC			AFAP-120 - A VARIANT FORM OF THE SRC SH2/SH3-BINDING PARTNER AFAP-110 IS DETECTED IN BRAIN AND CONTAINS A NOVEL INTERNAL SEQUENCE WHICH BINDS TO A 67-KDA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING RAT-BRAIN; EXPRESS HIGH-LEVELS; GENE-PRODUCT; C-SRC; TYROSINE PHOSPHORYLATION; STABLE ASSOCIATION; MAMMALIAN-CELLS; SH3 DOMAINS; GROWTH CONE; PP60C-SRC	SH2 and SH3 domains have been characterized as functional domains that mediate protein-protein interactions in signal transduction. Recently, the cDNA sequence of a novel Src- and Fyn-binding protein called AFAP-110, for Actin-Filament Associated Protein-110 kDa, was reported. This protein was distinctive in that it is both an SH2 and SH3 binding partner for the nonreceptor tyrosine kinases Src and Fyn. Here, we report the characterization of an alternatively processed form of AFAP-110 that encodes an additional 258 base pair (bp) Of Open reading frame. Transient expression of this full-length clone reveals a molecular mass of 120 kDa. Western blot analysis indicate that a larger 120-kDa variant of AFAP-110 can be detected in brain and is not detectable in any other tissues examined. Northern blot analysis indicate that the novel 258-bp insert can be detected in brain RNA but not chick embryo fibroblast RNA. We propose the name AFAP-120, for Actin Filament-Associated Protein-120 kDa. Expression of the 258-bp novel insert (NINS) as a glutathione S-transferase encoded fusion protein permits adsorption of a 67kDa protein from tissue lysates. Deletion analysis of the NINS indicates that the interaction with p67 can be attributed to a proline-rich motif that resembles an SH3-binding motif. We hypothesize that AFAP-1S0 facilitates interactions in brain between SH2/SH3 signaling proteins and actin filaments and that a proline-rich motif in the NINS may exist to facilitate additional interactions between cellular proteins in brain and actin filaments.	W VIRGINIA UNIV,DEPT MICROBIOL & IMMUNOL,MORGANTOWN,WV 26506	West Virginia University	FLYNN, DC (corresponding author), W VIRGINIA UNIV,MARY BABB RANDOLPH CANC CTR,MORGANTOWN,WV 26506, USA.				NCRR NIH HHS [2S07RR05433-31] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005433] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FLYNN DC, 1992, ONCOGENE, V7, P579; HARLOW E, 1988, ANTIBODIES LABORATOR; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KEMP BE, 1990, TRENDS BIOCHEM SCI, V17, P342; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBEAU JM, 1987, MOL CELL BIOL, V7, P4115, DOI 10.1128/MCB.7.11.4115; LEVY BT, 1984, DEV BIOL, V104, P9, DOI 10.1016/0012-1606(84)90031-9; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LYNCH SA, 1986, J NEUROSCI RES, V16, P127; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALLER MD, 1993, PROG NUCLEIC ACID RE, V44, P205, DOI 10.1016/S0079-6603(08)60221-4; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SHORES CG, 1987, J BIOL CHEM, V262, P9477; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOBUE K, 1988, BIOCHEM BIOPH RES CO, V157, P1383, DOI 10.1016/S0006-291X(88)81028-3; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; WEISTLER OD, 1988, MOL CELL BIOL, V8, P502	50	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3894	3899		10.1074/jbc.270.8.3894	http://dx.doi.org/10.1074/jbc.270.8.3894			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876134	hybrid			2022-12-25	WOS:A1995QH68800065
J	GLATIGNY, A; SCAZZOCCHIO, C				GLATIGNY, A; SCAZZOCCHIO, C			CLONING AND MOLECULAR CHARACTERIZATION OF HXA, THE GENE CODING FOR THE XANTHINE DEHYDROGENASE (PURINE HYDROXYLASE-I) OF ASPERGILLUS-NIDULANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NITROGEN METABOLITE REPRESSION; ENCODING NITRATE REDUCTASE; DINUCLEOTIDE-BINDING-SITE; AMINO-ACID-SEQUENCE; IRON-SULFUR CENTERS; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; REGULATORY GENE; ROSY LOCUS; NEUROSPORA-CRASSA	We have cloned and sequenced the hxA gene coding for the xanthine dehydrogenase (purine hydroxylase I) of Aspergillus nidulans. The gene codes for a polypeptide of 1363 amino acids. The sequencing of a nonsense mutation, hxA5, proves formally that the clones isolated correspond to the hxA gene. The gene sequence is interrupted by three introns. Similarity searches reveal two iron-sulfur centers and a NAD/FAD-binding domain and have enabled a consensus sequence to be determined for the molybdenum cofactor-binding domain. The A. nidulans sequence is a useful outclass for the other known sequences, which are all from metazoans. In particular, it gives added significance to the missense mutations sequenced in Drosophila melanogaster and leads to the conclusion that while one of the recently sequenced human genes codes for a xanthine dehydrogenase, the other one must code for a different molybdenum-containing hydroxylase, possibly an aldehyde oxidase. The transcription of the hxA gene is induced by the uric acid analogue 2-thiouric acid and repressed by ammonium. Induction necessitates the product of the uaY regulatory gene.	UNIV PARIS 11, CTR ORSAY, INST MICROBIOL & GENET, CNRS, UA 1354, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ALDERSON T, 1967, MUTAT RES, V8, P255; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMAYA Y, 1990, J BIOL CHEM, V265, P14170; ARAMAYO R, 1990, NUCLEIC ACIDS RES, V18, P3415, DOI 10.1093/nar/18.11.3415; ARST HN, 1973, MOL GEN GENET, V126, P111, DOI 10.1007/BF00330988; Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BALLANCE DJ, 1986, YEAST, V2, P229, DOI 10.1002/yea.320020404; BANKS GR, 1993, GENE, V131, P69, DOI 10.1016/0378-1119(93)90670-X; BEARD ME, 1987, P NATL ACAD SCI USA, V84, P7433, DOI 10.1073/pnas.84.21.7433; BERSE B, 1983, GENE, V25, P109, DOI 10.1016/0378-1119(83)90173-7; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BURGER G, 1991, MOL CELL BIOL, V11, P5746, DOI 10.1128/MCB.11.11.5746; BURGER G, 1991, MOL CELL BIOL, V11, P795, DOI 10.1128/MCB.11.2.795; BUXTON FP, 1989, GENE, V84, P329, DOI 10.1016/0378-1119(89)90507-6; CHENG C, 1989, PLANT MOL BIOL, V13, P731; CHENG CL, 1988, EMBO J, V7, P3309, DOI 10.1002/j.1460-2075.1988.tb03201.x; CHOVNICK A, 1990, PROG CLIN BIOL RES, V344, P1; CHOVNICK A, 1977, CELL, V11, P1, DOI 10.1016/0092-8674(77)90312-9; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; COTTMAN RE, 1979, J PHYS CHEM-US, V83, P2392; COUGHLAN MP, 1979, P ROY IRISH ACAD B, V79, P169; COUGHLAN MP, 1980, EUR J BIOCHEM, V105, P81, DOI 10.1111/j.1432-1033.1980.tb04476.x; COUGHLAN MP, 1984, ARCH BIOCHEM BIOPHYS, V229, P596, DOI 10.1016/0003-9861(84)90192-9; COUGHLAN MP, 1980, MOLYBDENUM MOLYBDENU, P121; COURTRIGHT JB, 1976, ADV GENET, V18, P249, DOI 10.1016/S0065-2660(08)60440-X; COVE DJ, 1979, BIOL REV, V54, P291, DOI 10.1111/j.1469-185X.1979.tb01014.x; DARLINGTON AJ, 1967, J BACTERIOL, V93, P937, DOI 10.1128/JB.93.3.937-940.1967; DARLINGTON AJ, 1965, NATURE, V206, P599, DOI 10.1038/206599a0; DIOLEZ A, 1993, GENE, V131, P61, DOI 10.1016/0378-1119(93)90669-T; DOYLE WA, 1994, BIOCHEM J, V300, P915, DOI 10.1042/bj3000915; EDMONDSON D, 1973, J BIOL CHEM, V248, P6135; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FREUDENBERG W, 1988, FEMS MICROBIOL LETT, V52, P13; FU YH, 1990, P NATL ACAD SCI USA, V87, P5331, DOI 10.1073/pnas.87.14.5331; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GORFINKIEL L, 1993, J BIOL CHEM, V268, P23376; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GRAY M, 1991, GENETICS, V127, P139; GRUBER H, 1992, GENE, V120, P75, DOI 10.1016/0378-1119(92)90011-D; Gurr S. J., 1987, SPECIAL PUBLICATIONS, P93; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANSELMAN F, 1984, THESIS U ESSEX; HAWKINS AR, 1987, CURR GENET, V11, P491, DOI 10.1007/BF00384611; HIRSCHBERG R, 1972, J BACTERIOL, V112, P392, DOI 10.1128/JB.112.1.392-397.1972; HOUDE M, 1989, GENE, V85, P391, DOI 10.1016/0378-1119(89)90432-0; HUGHES RK, 1992, BIOCHEMISTRY-US, V31, P3073, DOI 10.1021/bi00127a007; HUGHES RK, 1992, BIOCHEM J, V285, P507, DOI 10.1042/bj2850507; ICHIDA K, 1993, GENE, V133, P279; IMHOFF D, 1979, FEMS MICROBIOL LETT, V5, P155; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; KEITH TP, 1987, GENETICS, V116, P67; Kinghorn J. R., 1989, Molecular and genetic aspects of nitrate assimilation., P385; KRENITSKY TA, 1972, ARCH BIOCHEM BIOPHYS, V150, P585, DOI 10.1016/0003-9861(72)90078-1; KRENITSKY TA, 1974, COMP BIOCHEM PHYSIOL, V49, P687, DOI 10.1016/0305-0491(74)90256-9; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LEE CS, 1987, GENETICS, V116, P55; LEWIS NJ, 1978, EUR J BIOCHEM, V91, P311, DOI 10.1111/j.1432-1033.1978.tb20967.x; LEWIS NJ, 1977, EUR J BIOCHEM, V76, P441, DOI 10.1111/j.1432-1033.1977.tb11613.x; LLOYD AT, 1991, MOL GEN GENET, V230, P288, DOI 10.1007/BF00290679; LOCKINGTON RA, 1985, GENE, V33, P137, DOI 10.1016/0378-1119(85)90088-5; LOWE DJ, 1978, BIOCHEM J, V169, P471, DOI 10.1042/bj1690471; LOWE DJ, 1972, BIOCHEM J, V130, P239, DOI 10.1042/bj1300239; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MEHRA RK, 1989, J GEN MICROBIOL, V135, P273; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; NELSON MA, 1989, MOL CELL BIOL, V9, P1271, DOI 10.1128/MCB.9.3.1271; NISHINO T, 1989, J BIOL CHEM, V264, P5468; NISHINO T, 1987, BIOCHEMISTRY-US, V26, P3068, DOI 10.1021/bi00385a018; OESTREICHER N, 1993, J BIOL CHEM, V268, P23382; OKAMOTO PM, 1991, MOL GEN GENET, V227, P213, DOI 10.1007/BF00259673; PATEMAN JA, 1964, NATURE, V201, P58, DOI 10.1038/201058a0; PROSSER IM, 1990, PLANT MOL BIOL, V15, P187, DOI 10.1007/BF00017743; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; RILEY MA, 1989, MOL BIOL EVOL, V6, P33; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCAZZOCC.C, 1968, BIOCHIM BIOPHYS ACTA, V166, P557, DOI 10.1016/0005-2787(68)90243-8; SCAZZOCCHIO C, 1973, EUR J BIOCHEM, V36, P428, DOI 10.1111/j.1432-1033.1973.tb02928.x; SCAZZOCCHIO C, 1982, GENETICS, V100, P185; SCAZZOCCHIO C, 1973, MOL GEN GENET, V125, P147, DOI 10.1007/BF00268868; SCAZZOCCHIO C, 1978, EUR J BIOCHEM, V91, P99, DOI 10.1111/j.1432-1033.1978.tb20942.x; SCAZZOCCHIO C, 1994, ASPERGILLUS 50 YEARS, P221; SCAZZOCCHIO C, 1966, THESIS U CAMBRIDGE; SCAZZOCCHIO C, 1980, MOLYBDENUM MOLYBDENU, P489; SCHNORR KM, 1991, MOL GEN GENET, V227, P411, DOI 10.1007/BF00273931; SEALYLEWIS HM, 1979, MOL GEN GENET, V174, P105, DOI 10.1007/BF00433311; SEALYLEWIS HM, 1978, MOL GEN GENET, V164, P303, DOI 10.1007/BF00333161; Sherman F., 1978, METHODS YEAST GENETI; SUAREZ T, 1991, MOL GEN GENET, V230, P369, DOI 10.1007/BF00280293; TAMAKI T, 1989, J BIOCHEM-TOKYO, V106, P541, DOI 10.1093/oxfordjournals.jbchem.a122889; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; THOENES U, 1994, EUR J BIOCHEM, V220, P901, DOI 10.1111/j.1432-1033.1994.tb18693.x; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; TOMSETT AB, 1979, GENET RES, V34, P19, DOI 10.1017/S001667230001925X; UPSHALL A, 1986, MOL GEN GENET, V204, P349, DOI 10.1007/BF00425521; VAUCHERET H, 1989, PLANT MOL BIOL, V12, P597, DOI 10.1007/BF00036974; WAHL RC, 1982, J BIOL CHEM, V257, P3958; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; XU P, 1994, BIOCHEM BIOPH RES CO, V199, P998, DOI 10.1006/bbrc.1994.1328; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	103	81	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3534	3550		10.1074/jbc.270.8.3534	http://dx.doi.org/10.1074/jbc.270.8.3534			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876088	hybrid			2022-12-25	WOS:A1995QH68800015
J	SHACKELFORD, RE; MISRA, UK; FLORINECASTEEL, K; THAI, SF; PIZZO, SV; ADAMS, DO				SHACKELFORD, RE; MISRA, UK; FLORINECASTEEL, K; THAI, SF; PIZZO, SV; ADAMS, DO			OXIDIZED LOW-DENSITY-LIPOPROTEIN SUPPRESSES ACTIVATION OF NF-KAPPA-B IN MACROPHAGES VIA A PERTUSSIS-TOXIN-SENSITIVE SIGNALING MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MURINE PERITONEAL-MACROPHAGES; EXPRESSION; TRANSCRIPTION; ATHEROSCLEROSIS; GENE; LIPOPOLYSACCHARIDE; INDUCTION; CELLS; RNA; GRO	The interaction of oxidized low density lipoprotein (ox-LDL) and macrophages is generally believed to be a significant inductive step in atherogenesis. Endocytosis of ox-LDL by scavenger receptors (SR) on macrophages is one result of this interaction, as is suppressed expression of several lipopolysaccharide (LPS)-stimulated, inflammatory genes such as tumor necrosis factor-alpha (TNF-alpha). Events subsequent to SR ligation, including intracellular signaling events if any, have not been established, We report here that ox-LDL initiates rapid hydrolysis of phosphatidylinositol 4,5-bisphosphate 2 (PIP2) and intracellular fluxes of Ca2+ in macrophages, both of which are sensitive to pertussis toxin, ox-LDL also suppresses the LPS-induced binding of macrophage extracts to an NF kappa B sequence oligonucleotide and the LPS-initiated accumulation of RNA specific for TNF-alpha. These latter two effects are pertussis toxin-sensitive. Ligation of SR by ox-LDL thus initiates a pertussis toxin-sensitive signaling pathway in macrophages, which involves hydrolysis of PIP2 and which can suppress expression of the TNF-alpha gene by modulating activation of NF kappa B.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University					NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002922] Funding Source: NIH RePORTER; NCI NIH HHS [CA 29589] Funding Source: Medline; NHLBI NIH HHS [HL 24066] Funding Source: Medline; NIEHS NIH HHS [ES 02922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANDALIBI A, 1993, BIOCHEM SOC T, V21, P651, DOI 10.1042/bst0210651; ANISOWICZ A, 1991, J IMMUNOL, V147, P520; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; COGSWELL JP, 1994, J IMMUNOL, V153, P712; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUET C, 1991, J IMMUNOL, V147, P1694; FONG KL, 1973, J BIOL CHEM, V248, P7792; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; Hatch F T, 1968, Adv Lipid Res, V6, P1; INTRONA M, 1987, J IMMUNOL, V138, P3891; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KAUFMAN PA, 1992, J CLIN INVEST, V90, P121, DOI 10.1172/JCI115824; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MISRA UK, 1994, J BIOL CHEM, V269, P18303; MOREL DW, 1986, LAB INVEST, V55, P419; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J, 1989, MOL CLONING LABORATO; STEINBERG D, 1983, ARTERIOSCLEROSIS, V3, P283, DOI 10.1161/01.ATV.3.4.283; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; THAI SF, 1995, IN PRESS J LEUKOCYTE, V57; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; XIE QW, 1994, J BIOL CHEM, V269, P4705	33	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3475	3478		10.1074/jbc.270.8.3475	http://dx.doi.org/10.1074/jbc.270.8.3475			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876078				2022-12-25	WOS:A1995QH68800004
J	ZHANG, Q; TECTOR, M; SALTER, RD				ZHANG, Q; TECTOR, M; SALTER, RD			CALNEXIN RECOGNIZES CARBOHYDRATE AND PROTEIN DETERMINANTS OF CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; ANTIGENS; HLA-A2; GLYCOPROTEINS; MATURATION; CELL	Proper folding of nascent polypeptides is essential for their function and is monitored by intracellular ''quality control'' elements. The molecular chaperone calnexin participates in this process by retaining in the endoplasmic reticulum a variety of unfolded proteins, including class I major histocompatibility complex molecules, We transfected human B cell Lines with genes encoding either wild-type HLA-A2 heavy chains or mutant heavy chains lacking sites for glycosylation or deficient in binding to beta(2)-microglobulin (beta(2)m) In CIR cells, calnexin did not associate detectably with wild-type heavy chains but bound strongly to mutant heavy chains unable to bind beta(2)m Removal of the glycosylation addition site by further mutagenesis prevented binding of mutant heavy chains to calnexin, In Daudi cells, deficient in synthesis of beta(2)m, wild-type HLA-A2 heavy chains, but not a nonglycosylated mutant, bound calnexin. Castanospermine, which blocks trimming of glucose residues from asparagine-linked glycans, inhibited association of calnexin with heavy chains encoded by a second class I gene, HLA-B*0702. Although initiation of calnexin binding appears to depend on the presence of oligosaccharide on the substrate, removal of the glycan from calnexin-associated heavy chains by digestion with endoglycosidase H did not disrupt the interaction, These results suggest that calnexin first recognizes carbohydrate on substrate proteins and then binds more stably to peptide determinants, which disappear upon folding.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Salter, Russell/0000-0003-4553-2986				DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, CURR BIOL, V3, P884; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMB CA, 1992, J IMMUNOL, V148, P3478; ORTMANN E, 1994, NATURE, V368, P864; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; OWEN MJ, 1981, J BIOL CHEM, V256, P8987; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; PARHAM P, 1979, J IMMUNOL, V123, P342; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; SALTER RD, 1992, HUM IMMUNOL, V35, P40, DOI 10.1016/0198-8859(92)90093-3; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; TECTOR M, 1994, J BIOL CHEM, V269, P25816; WAYS JP, 1986, J IMMUNOL, V137, P217; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	21	93	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3944	3948		10.1074/jbc.270.8.3944	http://dx.doi.org/10.1074/jbc.270.8.3944			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876141	hybrid			2022-12-25	WOS:A1995QH68800073
J	TSEN, G; HALFTER, W; KROGER, S; COLE, GJ				TSEN, G; HALFTER, W; KROGER, S; COLE, GJ			AGRIN IS A HEPARAN-SULFATE PROTEOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; N-CAM; ACETYLCHOLINE-RECEPTOR; ORGANIZING PROTEIN; NEURITE OUTGROWTH; SKELETAL-MUSCLES; BINDING DOMAIN; GLYCOSAMINOGLYCANS; IDENTIFICATION; DEPENDS	In the present study we have identified the extracellular matrix protein agrin as a major heparan sulfate proteoglycan (HSPG) in embryonic chick brain. Using monoclonal antibodies and a polyclonal antiserum to the core protein of a previously identified HSPG from embryonic chick brain, our expression screened a random-primed E9 chick brain cDNA library. Twelve cDNAs were isolated that were shown to be identical to the chick extracellular matrix protein agrin. Western blot analysis and immunocytochemistry confirmed that agrin is a HSPG that is identical with the HSPG from embryonic chick brain. A polyclonal antiserum to recombinant agrin protein recognized agrin as a diffuse band of over 400 kDa in extracts from brain and vitreous humor. The agrin immunoreactivity on the blot was shifted to a defined band of approximately 250 kDa after treatment of the samples with heparitinase or nitrous acid, and this banding pattern was indistinguishable from immunoreactivity obtained with antibodies to the brain HSPG. We also show that agrin binds tightly to anion exchange beads, indicating that the molecule is highly negatively charged which is a hallmark of all proteoglycans. Furthermore, the agrin antiserum recognizes the affinity purified HSPG from chick brain and vitreous humor. Immunocytochemistry demonstrated that agrin is expressed in developing brain, and is especially abundant in developing axonal tracts, in a distribution identical to the staining of the brain HSPG with monoclonal antibodies. We also show that the anti-HSPG antibodies stain the synaptic site of the neuromuscular junction, in agreement with agrin expression. Thus, our studies demonstrate that chick agrin is a HSPG that is prominent in the embryonic chick brain. Since previous studies hom our laboratories have shown that this proteoglycan interacts with neural cell adhesion molecule, our studies raise the interesting possibility that neural cell adhesion molecule and agrin are interactive partners that may regulate a variety of cell adhesion processes during neural development, including synaptogenesis.	OHIO STATE UNIV,CTR NEUROBIOTECHNOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT ANAT CELL BIOL & NEUROBIOL,COLUMBUS,OH 43210; UNIV PITTSBURGH,DEPT NEUROBIOL,PITTSBURGH,PA 15261; MAX PLANCK INST BRAIN RES,DEPT NEUROANAT,D-60528 FRANKFURT,GERMANY	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Max Planck Society				Kroger, Stephan/0000-0002-4626-1690	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029934] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29934] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BURG M, 1990, ARCH BIOCHEM BIOPHYS, V276, P396, DOI 10.1016/0003-9861(90)90738-K; BURG MA, 1994, J NEUROBIOL, V25, P1, DOI 10.1002/neu.480250102; BURG MA, 1995, IN PRESS J NEUROSCI; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CASTELLOT JJ, 1986, J CELL BIOL, V102, P1979, DOI 10.1083/jcb.102.5.1979; COHEN MW, 1994, J NEUROSCI, V14, P3293; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; COLE GJ, 1985, J CELL BIOL, V100, P1192, DOI 10.1083/jcb.100.4.1192; COLE GJ, 1991, NEURON, V7, P1007, DOI 10.1016/0896-6273(91)90345-Z; COLE GJ, 1986, J CELL BIOL, V99, P1605; COVAULT J, 1986, J CELL BIOL, V102, P716, DOI 10.1083/jcb.102.3.716; COVAULT J, 1985, P NATL ACAD SCI USA, V82, P4544, DOI 10.1073/pnas.82.13.4544; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GODFREY EW, 1991, EXP CELL RES, V195, P99, DOI 10.1016/0014-4827(91)90504-N; GORDON H, 1993, J NEUROSCI, V13, P586; HAGEN SG, 1993, J BIOL CHEM, V268, P7261; HALFTER W, 1993, J NEUROSCI, V13, P2863; HANTAZAMBROISE D, 1987, J NEUROSCI, V7, P2293; HASCALL VC, 1994, METHOD ENZYMOL, V230, P390; HOCH W, 1994, J CELL BIOL, V126, P1, DOI 10.1083/jcb.126.1.1; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KALLAPUR SG, 1992, J NEUROSCI RES, V33, P538, DOI 10.1002/jnr.490330406; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; MA E, 1994, J NEUROSCI, V14, P2943; MA JY, 1993, J BIOL CHEM, V268, P25108; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OCONNOR LT, 1994, J NEUROSCI, V14, P1141, DOI 10.1523/JNEUROSCI.14-03-01141.1994; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; RIOPELLE RJ, 1990, BRAIN RES, V525, P92, DOI 10.1016/0006-8993(90)91324-A; ROGERS SL, 1985, J NEUROSCI, V5, P369; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUBERT D, 1985, J CELL BIOL, V101, P1071, DOI 10.1083/jcb.101.3.1071; THOMAS WS, 1993, DEV BIOL, V158, P523, DOI 10.1006/dbio.1993.1210; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; WALLACE BG, 1990, J NEUROSCI, V10, P3576	51	231	235	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3392	3399		10.1074/jbc.270.7.3392	http://dx.doi.org/10.1074/jbc.270.7.3392			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852425	hybrid			2022-12-25	WOS:A1995QG47100075
J	WONG, KK; HARDIN, JD; BOAST, S; COOPER, CL; MERRELL, KT; DOYLE, TG; GOFF, SP; CALAME, KL				WONG, KK; HARDIN, JD; BOAST, S; COOPER, CL; MERRELL, KT; DOYLE, TG; GOFF, SP; CALAME, KL			A ROLE FOR C-ABL IN C-MYC REGULATION	ONCOGENE			English	Article						C-ABL; C-MYC; TRANSCRIPTION TYROSINE KINASE; ABL(ML) MOUSE	NF-KAPPA-B; TYROSINE KINASE; CELL-CYCLE; V-ABL; MESSENGER-RNA; GENE; BINDING; TRANSFORMATION; PROTEIN; PROMOTER	c-Abl, a nonreceptor tyrosine kinase, appears to play a role in cell cycle progression, cell proliferation and differentiation. Mice homozygous for a mutation in c-abl (abl(ml)), show pleiotropic abnormalities, including neonatal death, developmental defects, susceptibility to infection and dehydration (Schwartzberg et al., 1991). However, the exact substrates of c-Abl and the signal transduction pathways it might initiate are not known. We have examined how c-Abl affects c-myc expression by studying abl(ml) mice. Quantitative riboprobe analyses demonstrated that in the heart, liver, thymus, brain, testes, intestines and lung, there were no differences in the-steady-state level of c-myc RNA between the abl(ml) mice and Littermate controls. However, in adrenal glands, kidneys and splenic B cells, c-myc RNA levels were decreased approximately 50% compared to littermate controls. Induction of c-myc mRNA following activation of splenic B cells with LPS is also defective in abl(ml) splenocytes. Finally, me show that c-Abl can directly transactivate c-myc transcription. These results suggest that c-Abl is involved in the normal transcription regulation of c-myc in selected tissues and that decreased c-myc RNA could be one cause of abnormalities in the abl(ml) mice.	COLUMBIA UNIV, COLL PHYS & SURG, INTEGRATED PROGRAM CELLULAR MOLEC & BIOPHYS STUDI, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT MICROBIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute			Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547				BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DUYAO MP, 1990, CURR TOP MICROBIOL, V166, P211; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARDIN JD, 1994, UNPUB; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MONROE JG, 1983, J IMMUNOL, V130, P626; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Robertson E, 1987, TERATOCARCINOMAS EMB; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN R, 1993, ONCOGENES TUMOR SUPP, P167; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	47	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					705	711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862448				2022-12-25	WOS:A1995QH61200010
J	ARUNACHALAM, B; CRESSWELL, P				ARUNACHALAM, B; CRESSWELL, P			MOLECULAR REQUIREMENTS FOR THE INTERACTION OF CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES AND INVARIANT CHAIN WITH CALNEXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; INTRACELLULAR-TRANSPORT; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; ALPHA-CHAIN; BETA-CHAIN; PROTEIN; BINDING; GLYCOPROTEINS; CHAPERONE	Molecular chaperones are believed to retain misfolded and incompletely assembled oligomeric proteins in the endoplasmic reticulum (ER). Here, we have further analyzed the association of one such chaperone, calnexin, with human major histocompatibility complex class II alpha and beta subunits and the invariant chain. Calnexin associates with transport-competent invariant chain trimers (p33 or p41), as well as ER-retained trimers (p35/33 or p43/41), suggesting that ER retention of the latter is not because of calnexin association. Neither the replacement of the transmembrane segment of the DR beta subunit with a glycosyl phosphatidylinositol anchor nor deglycosylation of any of these proteins with tunicamycin or endoglycosidase H treatment abolished calnexin association. Using a cell-permeabilization system, we were unable to observe association of newly synthesized glycopeptides with calnexin, arguing that calnexin may not act Like a simple lectin for association with glycoproteins. The results indicate that neither transmembrane regions nor N-linked glycans are exclusively responsible for calnexin association. Based on our data and the observations of others, we suggest that these features may have varying significance for different glycoproteins in determining their interaction with calnexin.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University				Arunachalam, Arun/0000-0001-6486-5722	NIAID NIH HHS [AI23081] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023081, R01AI023081] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ALTMAN JD, 1993, P NATL ACAD SCI USA, V90, P10330, DOI 10.1073/pnas.90.21.10330; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ARUNACHALAM B, 1994, INT IMMUNOL, V6, P439, DOI 10.1093/intimm/6.3.439; AUBRY JP, 1994, J IMMUNOL, V152, P5806; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DRICKAMER K, 1981, J BIOL CHEM, V256, P5827; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FUERST TR, 1986, P NATL ACAD SCI USA, V8, P8122; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Kelley William L., 1992, Current Opinion in Cell Biology, V4, P984, DOI 10.1016/0955-0674(92)90130-5; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMB CA, 1992, J IMMUNOL, V148, P3478; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE JS, 1982, NATURE, V299, P750, DOI 10.1038/299750a0; LOEB JA, 1987, J BIOL CHEM, V262, P3022; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; OSULLIVAN DM, 1987, J EXP MED, V166, P444, DOI 10.1084/jem.166.2.444; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RADKA SF, 1984, HUM IMMUNOL, V10, P177, DOI 10.1016/0198-8859(84)90038-7; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; SCREIBER KL, 1994, INT IMMUNOL, V6, P101; STRUBIN M, 1984, EMBO J, V3, P869, DOI 10.1002/j.1460-2075.1984.tb01898.x; STRUBIN M, 1986, EMBO J, V5, P3483, DOI 10.1002/j.1460-2075.1986.tb04673.x; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; WADA I, 1991, J BIOL CHEM, V266, P19599	52	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2784	2790		10.1074/jbc.270.6.2784	http://dx.doi.org/10.1074/jbc.270.6.2784			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852350	hybrid			2022-12-25	WOS:A1995QF53500060
J	LIN, HY; MOUSTAKAS, A; KNAUS, P; WELLS, RG; HENIS, YI; LODISH, HF				LIN, HY; MOUSTAKAS, A; KNAUS, P; WELLS, RG; HENIS, YI; LODISH, HF			THE SOLUBLE EXOPLASMIC DOMAIN OF THE TYPE-II TRANSFORMING GROWTH-FACTOR (TGF)-BETA RECEPTOR - A HETEROGENEOUSLY GLYCOSYLATED PROTEIN WITH HIGH-AFFINITY AND SELECTIVITY FOR TGF-BETA LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCAN BETAGLYCAN; MEMBRANE PROTEOGLYCAN; EXPRESSION CLONING; CRYSTAL-STRUCTURE; CELL-LINES; KINASE; COMPLEX; ACTIVIN; GROWTH-FACTOR-BETA-2; PURIFICATION	The transforming growth factor (TGF)-beta type II receptor is a transmembrane serine/threonine kinase which is essential for all TGF-beta induced signals. In several cell types TGF-beta 2 is as potent as TGF-beta 1 or TGF-beta 3 in inducing cellular responses, yet TGF-beta 2 does not bind to the majority of expressed type II receptors. Here we characterized the properties of the soluble extracellular domain of the human TGF-beta type II receptor synthesized in COS-7 cells, Like the membrane-attached type II receptor, the soluble receptor contains complex N-linked oligosaccharides as well as additional sialic acid residues that cause it to migrate heterogenously upon SDS-polyacrylamide gel electrophoresis. I-125-TGF-beta 1 binds to and is chemically cross-linked to this protein. Unlabeled TGF-beta 1 inhibits the binding of I-125-TGF-beta 1 with an apparent dissociation constant (K-d) of similar to 200 pM, similar to the apparent K-d (similar to 50 pM) of the cell-surface type II receptor. TGF-beta 3 inhibits the binding of I-125-TGF-beta 1 to the soluble type II receptor with a similar dissociation constant, similar to 500 pM. In contrast, I-125-TGF-beta 2 cannot bind and be chemically cross-linked to the soluble type II receptor, nor does as much as a 125-fold excess of unlabeled TGF-beta 2 inhibit the binding of I-125-TGF-beta 1 to the soluble receptor. This is the first demonstration of the binding affinities of the type II receptor in the absence of the other cell-surface molecules known to bind TGF-beta. Expressed alone in COS-7 cells the type II receptor also cannot bind TGF-beta 2; co-expression of type III receptor enables the type II receptor to bind TGF-beta 2. Thus, the type III receptor or some other component is required for transmission of TGF-beta 2-induced signals by the type II receptor.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; TEL AVIV UNIV,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL; BRIGHAM & WOMENS HOSP,DIV GASTROENTEROL,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Tel Aviv University; Harvard University; Brigham & Women's Hospital	LIN, HY (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.			Henis, Yoav/0000-0002-1408-3877	NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NCI NIH HHS [CA-63260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1991, J BIOL CHEM, V266, P23282; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BHUSHAN A, 1994, MOL CELL BIOL, V14, P4280, DOI 10.1128/MCB.14.6.4280; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEIFETZ S, 1988, J BIOL CHEM, V263, P10783; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1994, CELL MOL BIOL, V40, P337; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1992, CELL, V70, P1069; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANN REV CELL BIOL, V6, P8597; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	42	118	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2747	2754		10.1074/jbc.270.6.2747	http://dx.doi.org/10.1074/jbc.270.6.2747			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852346	hybrid			2022-12-25	WOS:A1995QF53500055
J	CATASTI, P; FONTENOT, JD; BRADBURY, E; GUPTA, G				CATASTI, P; FONTENOT, JD; BRADBURY, E; GUPTA, G			LOCAL AND GLOBAL STRUCTURAL-PROPERTIES OF THE HIV-MN V3 LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRINCIPAL NEUTRALIZING DETERMINANT; ENVELOPE GLYCOPROTEIN; CELL TROPISM; TYPE-1; ANTIBODIES; SEQUENCE; DOMAIN; GP120; IDENTIFICATION	Studies of the feasibility of a subunit vaccine to protect against human immunodeficiency virus (HIV) infection have principally focused on the third variable (V3) loop, The principal neutralizing determinant (PND) of HIV-1 is located inside the V3 loop of the surface envelope glycoprotein, gp120. However, progress toward a PND-based vaccine has been impeded by the amino acid sequence variability in the V3 loops of different HN isolates, Theoretical studies revealed that the variability in sequence and structure of the V3 loop is confined to the N- and C-terminal sides of the conserved GPG crest, This leaves three regions of the V3 loop conserved both in sequence and secondary structure, We present the results of NMR studies that test the validity of our theoretical predictions. Structural studies are reported for the HIV-V3 loop (HIV-MN) in the linear and cyclic (S-S-bridged) forms. For the V3 loop sequence of the HIV-MN isolate, the three conserved secondary structural elements are as underlined below: CTRPNYNKRKRIHIGPGRAFYTTKNIIGTIROAHC(turns, turn helix) Finally, the conformational requirement of the PND in the V3 loop-antibody interaction is tested by monitoring the monoclonal antibody binding to the HIV-MN V3 loop in the linear and cyclic forms by enzyme-linked immunosorbent assay, The binding data reveal that the cyclic V3 loop is a better ligand for the monoclonal antibodies than the linear form although the latter has the same sequence. This means that the monoclonal antibodies recognize the PNDs as conformational epitopes.	LOS ALAMOS NATL LAB,THEORET BIOL & BIOPHYS GRP,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,DIV LS,LOS ALAMOS,NM 87545; UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; University of California System; University of California Davis					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032891] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04795] Funding Source: Medline; NIAID NIH HHS [R01 AI32891-01A2] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHANDRASEKHAR K, 1991, BIOCHEMISTRY-US, V30, P9187, DOI 10.1021/bi00102a009; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; DELEAGE G, 1989, PREDICTION PROTEIN S, P587; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; FREED EO, 1991, J VIROL, V65, P333; GEYER H, 1988, J BIOL CHEM, V263, P11760; GORNY MK, 1991, P NATL ACAD SCI USA, V88, P3238, DOI 10.1073/pnas.88.8.3238; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GUPTA G, 1993, J BIOMOL STRUCT DYN, V11, P345, DOI 10.1080/07391102.1993.10508731; GUPTA G, 1988, BIOCHEMISTRY-US, V27, P3423; GUPTA G, 1990, 5 C CENT GARD PAR, P99; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; ROTERMAN IK, 1989, J BIOMOL STRUCT DYN, V7, P1; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; VERONESE FD, 1993, J BIOL CHEM, V268, P25894; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; WYATT R, 1992, J VIROL, V66, P6997, DOI 10.1128/JVI.66.12.6997-7004.1992; ZVI A, 1992, BIOCHEMISTRY-US, V31, P6972, DOI 10.1021/bi00145a015	26	86	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2224	2232		10.1074/jbc.270.5.2224	http://dx.doi.org/10.1074/jbc.270.5.2224			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836454	hybrid			2022-12-25	WOS:A1995QE49300039
J	QUITTERER, U; SCHRODER, C; MULLERESTERL, W; REHM, H				QUITTERER, U; SCHRODER, C; MULLERESTERL, W; REHM, H			EFFECTS OF BRADYKININ AND ENDOTHELIN-1 ON THE CALCIUM HOMEOSTASIS OF MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; CULTURED HUMAN-FIBROBLASTS; VASOCONSTRICTOR PEPTIDE; INTRACELLULAR CA2+; LYS-BRADYKININ; DNA-SYNTHESIS; RECEPTOR; CLONING; RELEASE; POTENT	Ca2+ mobilization from intracellular stores is a major event in the signaling cascade triggered by peptide hormone receptors. The transient rise in intracellular free Ca2+ concentration ([Ca2+](i)) is well characterized, but little is known about alterations of total cell Ca. Therefore we established a technique to determine changes in total cell Ca during hormone stimulation of Ca-45-loaded cells. Bradykinin and endothelin-l reduced total cell Ca by up to 56% in HF-15 cells, COS-7 cells, and CHO K1 cells transfected with the rat B2 receptor cDNA. In Rat-1 cells and PC-12 cells, stimulation with endothelin-l or bradykinin did not result in a net decrease in total cell Ca at physiological extracellular Ca2+ concentration. Decrease in total cell Ca was preceded by an increase in [Ca2+](i) and blunting of the transient rise in [Ca2+](i) by a Ca2+ chelator prevented the hormone-induced decrease in total cell Ca. Previous reduction of total cell Ca by one hormone suppressed the transient rise in [Ca2+](i) induced by another. The data present evidence that the hormones bradykinin and endothelin-l are capable of switching off the Ca2+-mobilizing signal transduction pathway in a cell by depleting intracellular Ca stores. This process is accompanied by a significant reduction of total cell Ca.			QUITTERER, U (corresponding author), INST PHYSIOL CHEM & PATHOBIOCHEM, DUESBERGWEG 6, D-55099 MAINZ, GERMANY.							ABDALLA S, 1993, J BIOL CHEM, V268, P17277; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; ARMSTRONG D, 1954, NATURE, V174, P791, DOI 10.1038/174791a0; BAUMGARTEN LB, 1992, J BIOL CHEM, V267, P10524; CUTHBERT AW, 1982, BRIT J PHARMACOL, V75, P587, DOI 10.1111/j.1476-5381.1982.tb09178.x; EGUCHI S, 1992, FEBS LETT, V302, P243, DOI 10.1016/0014-5793(92)80451-L; FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511; FASOLATO C, 1988, J BIOL CHEM, V263, P17350; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GAUDREAU P, 1981, CAN J PHYSIOL PHARM, V59, P371, DOI 10.1139/y81-059; GREENBAUM LM, 1963, BIOCHEM PHARMACOL, V12, P325, DOI 10.1016/0006-2952(63)90057-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; HIRATA Y, 1988, BIOCHEM BIOPH RES CO, V154, P868, DOI 10.1016/0006-291X(88)90220-3; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; ITOH Y, 1988, FEBS LETT, V231, P440, DOI 10.1016/0014-5793(88)80867-6; KAUFMANN J, 1993, J BIOL CHEM, V268, P9079; LAGNADO L, 1994, NATURE, V367, P273, DOI 10.1038/367273a0; MARSDEN PA, 1989, BIOCHEM BIOPH RES CO, V158, P86, DOI 10.1016/S0006-291X(89)80180-9; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MIASIRO N, 1988, BIOCHEM BIOPH RES CO, V156, P312, DOI 10.1016/S0006-291X(88)80841-6; MILLER RC, 1993, TRENDS PHARMACOL SCI, V14, P54, DOI 10.1016/0165-6147(93)90031-E; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; MULDOON LL, 1991, AM J PHYSIOL, V260, pC1273, DOI 10.1152/ajpcell.1991.260.6.C1273; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OWEN NE, 1983, J CELL PHYSIOL, V117, P23, DOI 10.1002/jcp.1041170105; OWEN NE, 1983, CELL, V32, P979, DOI 10.1016/0092-8674(83)90082-X; REISER G, 1992, EXP CELL RES, V202, P440, DOI 10.1016/0014-4827(92)90097-R; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAWUTZ DG, 1992, EUR J PHARM-MOLEC PH, V227, P309, DOI 10.1016/0922-4106(92)90009-K; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; Weil A, 1914, H-S Z PHYSIOL CHEM, V89, P349, DOI 10.1515/bchm2.1914.89.5.349; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	41	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					1992	1999		10.1074/jbc.270.5.1992	http://dx.doi.org/10.1074/jbc.270.5.1992			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836425	hybrid			2022-12-25	WOS:A1995QE49300005
J	SHI, W; OSAWA, S; DICKERSON, CD; WEISS, ER				SHI, W; OSAWA, S; DICKERSON, CD; WEISS, ER			RHODOPSIN MUTANTS DISCRIMINATE SITES IMPORTANT FOR THE ACTIVATION OF RHODOPSIN KINASE AND G(T)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR KINASES; AMINO-ACID; TRANSDUCIN; PHOSPHORYLATION; BOVINE; PROTEINS; BINDING; ROD; ANTIBODIES; MEMBRANES	The cytoplasmic loops of rhodopsin, the rod cell photoreceptor, play important regulatory roles in the activation of both rhodopsin kinase and the rod cell G protein, G(t). A number of studies have identified domains in rhodopsin that are important for the activation of G(t). However, less is known concerning the cytoplasmic regions that regulate phosphorylation of the photoreceptor by rhodopsin kinase, To identify regions that participate in these processes, a series of alanine mutations were generated in the three cytoplasmic loops of rhodopsin and transiently expressed in HEK-293 cells, Membranes prepared from these cells were reconstituted with the opsin chromophore, Il-cis-retinal, and characterized for their ability to undergo light dependent phosphorylation by rhodopsin kinase and to catalyze GTP gamma S (guanosine 5'-O-(3-thiotriphosphate)) binding to G(t). We have identified mutants that fall into three distinct categories: 1) those that show altered phosphorylation but normal C-t activation, such as T62A/V63A/Q64A and R147A/F148A/G149A in Loops I and II, respectively; 2) mutants that have reduced ability to activate G(t) but are phosphorylated normally, including T242A/T243A and V250A/T251A/R252A in Loop III; and 3) mutants that affect both phosphorylation and G(t) activation, including A233G/A234G/A235G and A233N/A234N/A235N in Loop III, The use of these two assays in parallel have allowed us to distinguish the presence of distinct functional domains within the cytoplasmic loops which are specific for interaction with rhodopsin kinase or G(t).	UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Weiss, Ellen/AAK-9868-2020		NIGMS NIH HHS [GM47438, GM43582] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043582, R29GM043582, R55GM047438, R29GM047438] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NG, 1992, EUR J BIOCHEM, V208, P659, DOI 10.1111/j.1432-1033.1992.tb17232.x; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KLAPPER MH, 1977, BIOCHEM BIOPH RES CO, V78, P1018, DOI 10.1016/0006-291X(77)90523-X; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIN KC, 1993, J BIOL CHEM, V268, P9400; MORO O, 1993, J BIOL CHEM, V268, P22273; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OSAWA S, 1994, MOL PHARMACOL, V46, P1036; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P21249; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PHILLIPS WJ, 1994, BIOCHEM J, V299, P351, DOI 10.1042/bj2990351; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; PISTORIUS AMA, 1994, BIOCHEM BIOPH RES CO, V198, P1040, DOI 10.1006/bbrc.1994.1148; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; ROBINSON PR, 1994, P NATL ACAD SCI USA, V91, P5411, DOI 10.1073/pnas.91.12.5411; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P5460, DOI 10.1021/bi00367a017; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; WONG SKF, 1994, J BIOL CHEM, V269, P18968	44	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2112	2119		10.1074/jbc.270.5.2112	http://dx.doi.org/10.1074/jbc.270.5.2112			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836439	hybrid			2022-12-25	WOS:A1995QE49300022
J	MA, QF; HERSCHMAN, HR				MA, QF; HERSCHMAN, HR			THE YEAST HOMOLOG YTIS11, OF THE MAMMALIAN TIS11 GENE FAMILY IS A NONESSENTIAL, GLUCOSE REPRESSIBLE GENE	ONCOGENE			English	Article						TIS11; IMMEDIATE-EARLY GENE; YEAST; PRIMARY RESPONSE GENE	PRIMARY RESPONSE GENE; TETRADECANOYL PHORBOL ACETATE; SWISS 3T3 CELLS; SCHIZOSACCHAROMYCES-POMBE; GROWTH-FACTORS; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; MIG1 REPRESSOR; PROTEINS; CDNA	The murine TIS11 primary response gene is rapidly and transiently induced in response to many extracellular signals, A CX(8)CX(5)CX(3)H sequence is present twice in the TIS11 protein, in two additional murine proteins, TIS11B and TIS11D, that share regions of strong sequence conservation with THS11, and in a Drosophila homologue (DTIS11). Although immunolocalization of TIS11 protein to the nucleus and zinc binding have lead to the speculation that the TIS11 family proteins are transcription factors, no function for these proteins has yet been clearly determined. We have now identified a TIS11 homologue, YTIS11, from Saccharomyces cerevisiae. The Ytis11p protein conserves both the two putative zinc finger CX(8)CX(5)CX(3)H sequences and the spacing between them, as web as additional amino acids in this region. The amino terminal 169 amino acid portion of Ytis11p protein, which contains a large number of acidic amino acids, can serve as transactivator when fused to the Ga14 DNA-binding domain. Expression of the YTIS11 gene is not induced in response to DNA damaging agents, heat shock, sporulation conditions, or mating factor. However, YTIS11 expression is subjected to rapid glucose repression. Disruption of the YTIS11 gene in the M12B strain of Saccharomyces cerevisiae does not effect viability, growth in rich or synthetic medium, mating, or spore formation. However, YTIS11 gene disruption causes an alteration in metabolism that is reflected by a pH color change when cells are grown on YP plates supplemented with 2% glucose. Overexpression of murine TIS11 or TIS11B proteins dramatically attenuates the growth of both ytis11 and wild-type yeast.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,US DOE,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; United States Department of Energy (DOE); University of California System; University of California Los Angeles					PHS HHS [M24797] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARNARD RC, 1993, NUCLEIC ACIDS RES, V21, P3580, DOI 10.1093/nar/21.15.3580; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BOUTRY M, 1977, BIOCHIM BIOPHYS ACTA, V464, P602, DOI 10.1016/0005-2736(77)90034-7; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CONWAY EJ, 1950, BIOCHEM J, V47, P360, DOI 10.1042/bj0470360; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; FOURY F, 1975, J BIOL CHEM, V250, P2354; FOURY F, 1977, J BIOL CHEM, V252, P4577; GOMPERTS M, 1990, ONCOGENE, V5, P1081; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KANEDA N, 1992, GENE, V118, P289, DOI 10.1016/0378-1119(92)90202-Z; LAI WS, 1990, J BIOL CHEM, V265, P16556; LIM RW, 1987, ONCOGENE, V1, P263; MA QF, 1991, ONCOGENE, V6, P1277; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NIE XF, 1994, IN PRESS GENE; ROSE MD, 1990, COLD SPRING HARBOR L; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SIGLER K, 1980, FOLIA MICROBIOL, V25, P311, DOI 10.1007/BF02876611; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V79, P3454; ULASZEWSKI S, 1987, J BIOL CHEM, V262, P223; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WESTERBEEKMARRE.CA, 1988, EUR J BIOCHEM, V174, P611	33	37	39	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					487	494						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845673				2022-12-25	WOS:A1995QF64800009
J	TAYLOR, JP; POMERANTZ, RJ; OAKES, JW; KHALILI, K; AMINI, S				TAYLOR, JP; POMERANTZ, RJ; OAKES, JW; KHALILI, K; AMINI, S			A CNS-ENRICHED FACTOR THAT BINDS TO NF-KAPPA-B AND IS REQUIRED FOR INTERACTION WITH HIV-1 TAT	ONCOGENE			English	Note						TAT; HIV-1; NF-KAPPA-B; TRANSCRIPTION FACTOR; TAR	HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATOR GENE; INDEPENDENT ACTIVATION; TRANSCRIPTION FACTOR; KAPOSIS-SARCOMA; NASCENT RNA; PROTEIN; TYPE-1; CELLS	The Human Immunodeficiency Virus type 1 (HIV-1) Tat protein is a potent activator of transcription directed by the long terminal repeat (LTR), an essential step in the life-cycle of HIV-1. While interaction of Tat with an RNA element encoded by downstream LTR sequences (termed TAR) is commonly considered essential to activation, numerous recent reports have implicated upstream transcription elements within the LTR as participants in mediating this activation. We have recently demonstrated that Tat activation occurs independent of the TAR element in certain cells derived from the central nervous system (CNS), and that this activation is mediated by the kappa B domain of the LTR. Further, CNS-derived cells were found to contain kappa B-binding activity capable of both interacting with Tat and activating LTR transcription in vitro, The present study demonstrates that the kappa B-binding transcription factor derived from CNS cells consists of a component indistinguishable from prototypical Nuclear Factor-kappa B (NEF-kappa B) (in size, mobility on native gel, kinetics of activation and cognate binding sequence) as well as a supershifting component that is dissociable under certain conditions. The supershifting activity is found to stabilize binding of the presumed NF-kappa B to DNA. Further, only the form of NF-kappa B which is associated with this supershifting activity is capable of binding Tat. We hypothesize a model in which Tat utilizes this interaction to activate HIV-1 through the NF-kappa B domain of the LTR in circumstances where TAR is absent. This model has implications with respect to the ability of Tat to alter cellular gene expression and perhaps contribute to the array of problems seen in HIV-1 infection such as altered immune status, CNS toxicity, and the formation of tumors.	THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,MOLEC NEUROVIROL SECT,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV INFECT DIS,DORRANCE H HAMILTON LABS,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University			Taylor, J. Paul/N-2482-2018	Taylor, J. Paul/0000-0002-5794-0349	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028272, R01AI031836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030916] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI28272, AI31836] Funding Source: Medline; NINDS NIH HHS [P01 NS30916] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGASRA O, 1992, J VIROL, V66, P7522, DOI 10.1128/JVI.66.12.7522-7528.1992; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; CUPP C, 1993, ONCOGENE, V8, P2231; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; Frankel AD, 1992, CURR OPIN GENET DEV, V2, P293, DOI 10.1016/S0959-437X(05)80287-4; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HUANG LM, 1993, J VIROL, V67, P6937, DOI 10.1128/JVI.67.12.6937-6944.1993; JEANG KT, 1992, J BIOL CHEM, V267, P17891; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KIM CM, 1992, ONCOGENE, V7, P1525; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NABELL LM, 1994, CELL GROWTH DIFFER, V5, P87; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; TAYLOR JP, 1993, VIROLOGY, V195, P780, DOI 10.1006/viro.1993.1430; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0	39	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					395	400						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838536				2022-12-25	WOS:A1995QC62400019
J	LU, HS; HARA, S; WONG, LWI; JONES, MD; KATTA, V; TRAIL, G; ZOU, AH; BRANKOW, D; COLE, S; HU, S; WEN, DZ				LU, HS; HARA, S; WONG, LWI; JONES, MD; KATTA, V; TRAIL, G; ZOU, AH; BRANKOW, D; COLE, S; HU, S; WEN, DZ			POSTTRANSLATIONAL PROCESSING OF MEMBRANE-ASSOCIATED NEU DIFFERENTIATION FACTOR PROISOFORMS EXPRESSED IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; C-ERBB-2 PROTEIN; RECEPTOR; LIGAND; HEREGULIN; ONCOGENE; TISSUES; PROTOONCOGENE; ACTIVATOR; BINDING	Expression vectors constructed from human and rat pro-neu differentiation factor (NDF) cDNAs were transfected in Chinese hamster ovary cells for expression of recombinant NDF molecules. Soluble NDF forms were released into culture medium after post-translational processing of the membrane-bound pro-NDF forms. Different human and rat NDF isoforms, after being purified from the culture medium, were subjected to structural and biochemical characterizations. The isolated human and rat NDF isoforms have been proteolytically processed at a specific site at the N terminus, which is different from that observed for the processing of rat or human MIF molecule prepared from natural origins. The processing of each recombinant NDF isoform at its C terminus was heterogeneous but consistently occurred at nearby peptide bonds. Specific N- and C-terminal processing by Chinese hamster ovary cells has resulted in the production of two types (alpha and beta) of recombinant NDFs containing 222-225 amino acid residues. Both human and rat NDF molecules are heavily glycosylated at two of the three potential Asn-linked glycosylation sites and contain O-linked sugars at 11 of the Thr/Ser sites. Glycosylation occurs at a short, Ser/Thr-rich spacer region that connects the N-terminal immunoglobulin homology unit to the epidermal growth factor domain. Cellular phosphorylation assay indicated that these secreted forms contain similar biological activity in receptor tyrosine autophosphorylation of mammary tumor cells.			LU, HS (corresponding author), AMGEN INC,AMGEN CTR,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.			Jones, Michael/0000-0001-7541-7634				COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; HENRICKSON W, 1992, COLD SPRING HARB SYM, V57, P549; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JONES MD, 1994, ANAL BIOCHEM, V216, P125; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; LOFTS FJ, 1992, BREAST CANCER CELLUL; LU HS, 1986, J CHROMATOGR, V368, P215, DOI 10.1016/S0021-9673(00)91065-3; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; LU HS, 1991, J BIOL CHEM, V266, P8102; LU HS, 1995, IN PRESS J CHROMATOG; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MAGUIRE HC, 1989, J INVEST DERMATOL, V92, P786, DOI 10.1111/1523-1747.ep12696796; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; MORI S, 1989, LAB INVEST, V61, P93; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NATALI PG, 1990, INT J CANCER, V45, P457, DOI 10.1002/ijc.2910450314; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRESS MF, 1990, ONCOGENE, V5, P953; QUIRKE P, 1989, BRIT J CANCER, V60, P64, DOI 10.1038/bjc.1989.221; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHACHTER AL, 1984, NATURE, V312, P513; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027	41	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4775	4783		10.1074/jbc.270.9.4775	http://dx.doi.org/10.1074/jbc.270.9.4775			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876250	hybrid			2022-12-25	WOS:A1995QK08400086
J	WOLF, BA; WERTKIN, AM; JOLLY, YC; YASUDA, RP; WOLFE, BB; KONRAD, RJ; MANNING, D; RAVI, S; WILLIAMSON, JR; LEE, VMY				WOLF, BA; WERTKIN, AM; JOLLY, YC; YASUDA, RP; WOLFE, BB; KONRAD, RJ; MANNING, D; RAVI, S; WILLIAMSON, JR; LEE, VMY			MUSCARINIC REGULATION OF ALZHEIMERS-DISEASE AMYLOID PRECURSOR PROTEIN SECRETION AND AMYLOID BETA-PROTEIN PRODUCTION IN HUMAN NEURONAL NT2N CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED PANCREATIC-ISLETS; PHOSPHOLIPASE-C; RAT-BRAIN; DIACYLGLYCEROL ACCUMULATION; INOSITOL TRISPHOSPHATE; CHOLINERGIC RECEPTORS; INSULIN-SECRETION; ARACHIDONIC-ACID; NTERA-2 CELLS; GLUCOSE	The Alzheimer amyloid precursor protein (APP) undergoes complex processing resulting in the production of a 4-kDa amyloid peptide (A beta) which has been implicated in the pathogenesis of Alzheimer's disease, Recent studies have shown that cells can secrete carboxyl ter minus truncated APP derivatives (APP-S) in response to physiological stimulus. We have used human central nervous system neurons (NT2N) derived from a teratocarcinoma cell line (NT2) to study the signal transduction pathways involved in APP-S secretion and AP production. Muscarinic receptors (m2 and m3) as well as the heterotrimeric GTP binding protein G(q) and the beta 1 isoform of phospholipase C were present in NT2N neurons, Stimulation of the muscarinic receptor with carbachol resulted in phospholipase C activation as shown by a transient increase in the second messengers 1,2-diacyl-sn-glycerol and inositol 1,4,5-trisphosphate. Carbachol also caused an increase in intracellular Ca2+ levels measured in single NT2N neurons, Under these conditions, carbachol caused a time-dependent a-fold increase in APP-S secretion into the medium, In contrast, prolonged treatment with carbachol caused a decrease in A beta production into the medium. These results suggest that APP-S secretion and A beta production in NT2N neurons are regulated by the muscarinic/phospholipase C signal transduction pathway, Furthermore, activation of this pathway results in dissociation of APP-S secretion and A beta production.	UNIV PENN, SCH MED, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA; GEORGETOWN UNIV, SCH MED, DEPT PHARMACOL, WASHINGTON, DC 20007 USA	University of Pennsylvania; University of Pennsylvania; Georgetown University	WOLF, BA (corresponding author), UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, 217 JOHN MORGAN, PHILADELPHIA, PA 19104 USA.				NATIONAL INSTITUTE ON AGING [P01AG009973, P01AG011542, P30AG010124] Funding Source: NIH RePORTER; NIA NIH HHS [AG-09973, AG-10124, AG-11542] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARAI H, 1991, ANN NEUROL, V30, P686, DOI 10.1002/ana.410300509; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOTHMER J, 1994, BBA-MOL BASIS DIS, V1225, P111, DOI 10.1016/0925-4439(94)90068-X; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COCKCROFT S, 1992, BIOCHEM J, V288, P1; DYRKS T, 1994, FEBS LETT, V349, P210, DOI 10.1016/0014-5793(94)00671-7; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GAGNON AW, 1991, BLOOD, V78, P1247; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GREENAMYRE JT, 1993, CEREBROVAS BRAIN MET, V5, P61; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HANSEN CA, 1991, J BIOL CHEM, V266, P18573; Harden T. Kendall, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P11; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; HULME EC, 1993, CELL SIGNAL, V5, P687, DOI 10.1016/0898-6568(93)90030-P; HUNG AY, 1993, J BIOL CHEM, V268, P22959; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; JOACHIM CL, 1992, ALZ DIS ASSOC DIS, V6, P7, DOI 10.1097/00002093-199205000-00003; KONRAD RJ, 1992, BIOCHEM J, V287, P283, DOI 10.1042/bj2870283; KONRAD RJ, 1993, MOL CELL ENDOCRINOL, V92, P135, DOI 10.1016/0303-7207(93)90084-W; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LI M, 1991, MOL PHARMACOL, V40, P28; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MARX J, 1993, SCIENCE, V259, P457, DOI 10.1126/science.8424167; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Price DL, 1991, BRAIN PATHOL, V1, P287, DOI 10.1111/j.1750-3639.1991.tb00672.x; RHEE SG, 1991, METHOD ENZYMOL, V197, P502; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLACK BE, 1993, J BIOL CHEM, V268, P21097; SLOTKIN TA, 1994, J CLIN INVEST, V94, P696, DOI 10.1172/JCI117387; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; TURK J, 1986, BIOCHEM J, V237, P259, DOI 10.1042/bj2370259; WAHLESTEDT C, 1994, TRENDS PHARMACOL SCI, V15, P42, DOI 10.1016/0165-6147(94)90107-4; WALL SJ, 1991, MOL PHARMACOL, V40, P783; WALL SJ, 1991, MOL PHARMACOL, V39, P643; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WOLF BA, 1991, J CLIN INVEST, V87, P31, DOI 10.1172/JCI114988; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026; WOLF BA, 1986, J BIOL CHEM, V261, P3501; WOLF BA, 1989, FEBS LETT, V248, P35, DOI 10.1016/0014-5793(89)80426-0; WOLF BA, 1988, J BIOL CHEM, V263, P3565; WOLF BA, 1990, J CLIN INVEST, V85, P482, DOI 10.1172/JCI114463; WURTMAN RJ, 1994, J CLIN INVEST, V94, P470, DOI 10.1172/JCI117356; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849; YASUDA RP, 1993, MOL PHARMACOL, V43, P149	68	190	197	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4916	4922		10.1074/jbc.270.9.4916	http://dx.doi.org/10.1074/jbc.270.9.4916			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876266	hybrid			2022-12-25	WOS:A1995QK08400104
J	HATAKEYAMA, T; NAGATOMO, H; YAMASAKI, N				HATAKEYAMA, T; NAGATOMO, H; YAMASAKI, N			INTERACTION OF THE HEMOLYTIC LECTIN CEL-III FROM THE MARINE INVERTEBRATE CUCUMARIA-ECHINATA WITH THE ERYTHROCYTE-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HOLOTHURIA-POLII ECHINODERMATA; PORE-FORMING PROTEIN; CELOMIC FLUID; ANIMAL LECTINS; SEA-URCHIN; PURIFICATION; AFFINITY; RECOGNITION; STIMULATION	GEL-III is one of four Ca2+-dependent galactose/N-acetylgalactosamine (GalNAc)-binding lectins from the marine invertebrate Cucumaria echinata which exhibits hemolytic activity, especially toward rabbit and human erythrocytes. The hemolytic activity of GEL-III was also Ca2+-dependent and was found to be inhibited by galactose or GalNAc-containing carbohydrates, suggesting that the hemolysis was caused by GEL-III binding to specific carbohydrates on the erythrocyte membrane by Ca2+-dependent lectin activity, followed by partial destruction of the membrane. The activity of GEL-III was highest at 10 degrees C and decreased markedly with increasing temperature, unlike usual enzymatic reactions. The hemolytic activity of GEL-III increased with increasing pH from neutral to 10, but almost no hemolysis was observed below pH 6.5. Immunoblotting analysis of proteins from the erythrocyte membrane after treatment with GEL-III indicated that GEL-III aggregates were irreversibly bound to the membrane. When erythrocytes were incubated with GEL-III in the presence of dextran with molecular masses greater than 4 kDa, lysis was impeded considerably, while a concomitant release of ATP was detected from these osmotically protected cells. It was found that GEL-III released carboxyfluorescein from artificial globoside-containing lipid vesicles, and it is suggested that GEL-III is a novel pore-forming protein with the characteristics of a Ca2+-dependent lectin, which may act as a toxic protein to foreign microorganisms.			HATAKEYAMA, T (corresponding author), KYUSHU UNIV, FAC AGR, BIOCHEM LAB, HIGASHI KU, HAKOZAKI 6-10-1, FUKUOKA 812, JAPAN.			Hatakeyama, Tomomitsu/0000-0002-9505-1980				BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BERTHEUSSEN K, 1983, DEV COMP IMMUNOL, V7, P21, DOI 10.1016/0145-305X(83)90051-4; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; CANICATTI C, 1987, EXPERIENTIA, V43, P611, DOI 10.1007/BF02126350; CANICATTI C, 1988, DEV COMP IMMUNOL, V12, P55, DOI 10.1016/0145-305X(88)90024-9; DeLuca M., 1978, METHOD ENZYMOL, V57, P3, DOI DOI 10.1016/0076-6879(78)57003-1; DOERY HM, 1965, J GEN MICROBIOL, V40, P283, DOI 10.1099/00221287-40-2-283; DRICKAMER K, 1993, BIOCHEM SOC T, V21, P456, DOI 10.1042/bst0210456; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GIGA Y, 1987, J BIOL CHEM, V262, P6197; HATAKEYAMA T, 1994, J BIOCHEM, V116, P209, DOI 10.1093/oxfordjournals.jbchem.a124495; HIMESHIMA T, 1994, J BIOCHEM-TOKYO, V115, P689, DOI 10.1093/oxfordjournals.jbchem.a124397; HIRAYAMA T, 1983, FEBS LETT, V157, P46, DOI 10.1016/0014-5793(83)81113-2; KAISER ET, 1987, ANNU REV BIOPHYS BIO, V16, P561; KOMANO H, 1980, J BIOL CHEM, V255, P2919; KONSKA G, 1994, J BIOCHEM-TOKYO, V116, P519, DOI 10.1093/oxfordjournals.jbchem.a124555; LAZAROVICI P, 1986, J BIOL CHEM, V261, P6704; MacFarlane MG, 1941, BIOCHEM J, V35, P884, DOI 10.1042/bj0350884; MANGEL A, 1992, EUR J BIOCHEM, V210, P499, DOI 10.1111/j.1432-1033.1992.tb17448.x; MURAMOTO K, 1990, BIOCHIM BIOPHYS ACTA, V1039, P42, DOI 10.1016/0167-4838(90)90224-4; NAKAJIMA H, 1982, GANN, V73, P627; PARK NG, 1992, BIOCHEMISTRY-US, V31, P12241, DOI 10.1021/bi00163a038; PARRINELLO N, 1979, DEV COMP IMMUNOL, V3, P45, DOI 10.1016/S0145-305X(79)80005-1; PARRINELLO N, 1981, DEV COMP IMMUNOL, V5, P33, DOI 10.1016/S0145-305X(81)80005-5; RYOYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V320, P157, DOI 10.1016/0304-4165(73)90175-X; SCHERRER R, 1971, J BACTERIOL, V107, P718, DOI 10.1128/JB.107.3.718-735.1971; SHINODA S, 1993, MICROBIOL IMMUNOL, V37, P405, DOI 10.1111/j.1348-0421.1993.tb03229.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUZUKI T, 1990, J BIOL CHEM, V265, P1274; TAKAGI T, 1994, J BIOCHEM-TOKYO, V116, P598, DOI 10.1093/oxfordjournals.jbchem.a124566; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TEICHBERG VI, 1988, J BIOL CHEM, V263, P14086; WALKER B, 1992, J BIOL CHEM, V267, P21782; YAMAZAKI M, 1983, JPN J CANCER RES, V74, P576; YOUNG JDE, 1986, P NATL ACAD SCI USA, V83, P5668, DOI 10.1073/pnas.83.15.5668	36	97	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3560	3564		10.1074/jbc.270.8.3560	http://dx.doi.org/10.1074/jbc.270.8.3560			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876091	hybrid			2022-12-25	WOS:A1995QH68800018
J	KELLER, SH; KREIENKAMP, HJ; KAWANISHI, C; TAYLOR, P				KELLER, SH; KREIENKAMP, HJ; KAWANISHI, C; TAYLOR, P			MOLECULAR DETERMINANTS CONFERRING ALPHA-TOXIN RESISTANCE IN RECOMBINANT DNA-DERIVED ACETYLCHOLINE-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BINDING-SITE; MUSCLE-CELLS; AMINO-ACIDS; SUBUNIT; LIGAND; RESIDUES; IDENTIFICATION; BUNGAROTOXIN; EXPRESSION	Sequences of the alpha-subunits of the nicotinic acetylcholine receptor from the snake and mongoose contain several differences in the region between amino acids 183 and 200. Receptors from both of these species reveal resistance to the snake alpha-toxins presumably arising as a protective evolutionary mechanism. Sequence differences include the added glycosylation signals at residue 187 in the mongoose and at residues 189 and 111 in snake. Although previous observations with peptides and fusion proteins either synthesized chemically or in a bacterial expression system indicate that certain amino acid residues may contribute to the resistance, our findings with the intact receptor in an eukaryotic expression system indicate the major role for glycosylation. In this study, we show that addition of glycosylation signals gives rise to virtually complete glycosylation at the added sites, although heterogeneity of oligosaccharide processing is evident. By analysis of combinations of mutants, we document that glycosylation exerts the predominant influence on alpha-toxin binding. Substitutions at other residues are largely without influence as single mutations but appear to decrease affinity further in multiple mutants, particularly where the receptor is glycosylated at the 187 and 189 positions. Glycosylation exerts a major influence on the dissociation as well as the association rates of the alpha-toxin-receptor complex, suggesting that the decrease for cu-toxin affinity is not simply a consequence of restricted diffusional access, rather glycosylation affects the conformation and stability of the bound complex.	YOKOHAMA CITY UNIV, DEPT PSYCHIAT, YOKOHAMA, KANAGAWA 232, JAPAN	Yokohama City University	KELLER, SH (corresponding author), UNIV CALIF SAN DIEGO, DEPT PHARMACOL, 0636, LA JOLLA, CA 92093 USA.			Kreienkamp, Hans-Jurgen/0000-0002-8871-9970	NIGMS NIH HHS [GM24437] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; AYLWIN ML, 1994, FEBS LETT, V349, P99, DOI 10.1016/0014-5793(94)00649-0; BARCHAN D, 1992, P NATL ACAD SCI USA, V89, P7717, DOI 10.1073/pnas.89.16.7717; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BULLER AL, 1990, J MEMBRANE BIOL, V115, P179, DOI 10.1007/BF01869456; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; CHATURVEDI V, 1993, BIOCHEMISTRY-US, V32, P9570, DOI 10.1021/bi00088a008; CHATURVEDI V, 1992, BIOCHEMISTRY-US, V31, P1370, DOI 10.1021/bi00120a012; COHEN JB, 1991, J BIOL CHEM, V266, P23354; CONTITRONCONI BM, 1991, BIOCHEMISTRY-US, V30, P2575, DOI 10.1021/bi00224a003; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GRIESMANN GE, 1990, J NEUROCHEM, V54, P1541, DOI 10.1111/j.1471-4159.1990.tb01202.x; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MERLIE JP, 1982, J BIOL CHEM, V257, P2694; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NEUMANN D, 1986, P NATL ACAD SCI USA, V83, P9250, DOI 10.1073/pnas.83.23.9250; NEUMANN D, 1989, P NATL ACAD SCI USA, V86, P7255, DOI 10.1073/pnas.86.18.7255; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; OHANA B, 1991, BIOCHEM BIOPH RES CO, V179, P648, DOI 10.1016/0006-291X(91)91421-8; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; PETAJAREPO UE, 1993, BIOCHEM J, V292, P839, DOI 10.1042/bj2920839; PRIVES JM, 1980, P NATL ACAD SCI-BIOL, V77, P5263, DOI 10.1073/pnas.77.9.5263; RUSSO D, 1991, MOL ENDOCRINOL, V5, P29, DOI 10.1210/mend-5-1-29; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1991, J BIOL CHEM, V266, P13679; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1	35	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4165	4171		10.1074/jbc.270.8.4165	http://dx.doi.org/10.1074/jbc.270.8.4165			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876169	hybrid			2022-12-25	WOS:A1995QH68800103
J	LI, JF; EASTMAN, A				LI, JF; EASTMAN, A			APOPTOSIS IN AN INTERLEUKIN-2-DEPENDENT CYTOTOXIC T-LYMPHOCYTE CELL-LINE IS ASSOCIATED WITH INTRACELLULAR ACIDIFICATION - ROLE OF THE NA+/H+-ANTIPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ENDONUCLEASE ACTIVATION; DNA FRAGMENTATION; GROWTH-FACTOR; INTERNUCLEOSOMAL FRAGMENTATION; OKADAIC ACID; DEATH; THYMOCYTES; CALCIUM; STIMULATION	Apoptosis is a form of cell death associated with DNA fragmentation and chromatin condensation. We recently established that intracellular acidification occurred during apoptosis following cytotoxic insult. The current studies were designed to determine whether intracellular acidification was more generally associated with apoptosis, specifically in a model of growth factor withdrawal. Upon withdrawal of interleukin-2, CTLL-2 cells accumulated in the G(1) phase of the cell cycle and started to fragment their DNA around 12 h concurrent with both decreased pH and increased Ca2+. Chelation of Ca2+ did not inhibit DNA digestion, whereas incubation with a calcium ionophore pre vented both acidification and DNA digestion Hence,. acidification rather than increased Ca2+ was associated with apoptosis. The acidified cells represented a discrete population up to 0.7 pH units below normal. The extent of acidification depended upon the extracellular pH; above pH 6.3, intracellular pH was significantly below extracellular pH, whereas below pH 6.3, the cells still regulated their pH. inhibition of the Na+/H+-antiport prevented the apoptotic cells from regulating their intracellular pH under these acidic conditions. These results demonstrate that apoptotic cells retain a functional antiport but that its set-point has changed, Many survival factors are known to phosphorylate and activate the antiport, hence apoptosis is likely to be associated with dephosphorylation. Although acidification always occurred during apoptosis, maintaining intracellular pH above 7.2 did not prevent apoptosis, suggesting that an acid pH is not essential for apoptosis, We hypothesize that other critical regulators of apoptosis must be subject to dephosphorylation.	DARTMOUTH COLL,SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755; DARTMOUTH COLL,SCH MED,NORRIS COTTON CANC CTR,HANOVER,NH 03755	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center					NATIONAL CANCER INSTITUTE [R01CA050224, R55CA050224, P30CA023108] Funding Source: NIH RePORTER; NCI NIH HHS [CA50224, CA23108] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER PE, 1979, J EXP MED, V149, P273, DOI 10.1084/jem.149.1.273; BARRY MA, 1993, CANCER RES, V53, P2349; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BROWN DG, 1993, J BIOL CHEM, V268, P3037; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EASTMAN A, 1993, TOXICOL APPL PHARM, V121, P160, DOI 10.1006/taap.1993.1141; EASTMAN A, 1992, CANCER INVEST, V10, P229, DOI 10.3109/07357909209032765; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ISEKI R, 1991, J IMMUNOL, V147, P4286; June C H, 1990, Methods Cell Biol, V33, P37; KAPUS A, 1994, J BIOL CHEM, V269, P23544; MADHUS IH, 1988, BIOCHEM J, V250, P1; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MORANA S, 1994, INT J ONCOL, V5, P153; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; ORMEROD MG, 1993, CYTOMETRY, V14, P595, DOI 10.1002/cyto.990140603; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; RODRIGUEZTARDUC.G, 1990, EMBO J, V9, P2997; RODRIGUEZTARDUC.G, 1989, BIOCHEM BIOPH RES CO, V164, P1069; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SONG QZ, 1992, J CELL PHYSIOL, V153, P550, DOI 10.1002/jcp.1041530316; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; SORENSON CM, 1988, CANCER RES, V48, P4484; SWANN K, 1985, NATURE, V314, P274, DOI 10.1038/314274a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZHIVOTOVSKY B, 1993, EXP CELL RES, V207, P163, DOI 10.1006/excr.1993.1176	36	207	215	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3203	3211		10.1074/jbc.270.7.3203	http://dx.doi.org/10.1074/jbc.270.7.3203			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852405	hybrid			2022-12-25	WOS:A1995QG47100049
J	DENBAKKER, MA; RIEGMAN, PHJ; HEKMAN, RACP; BOERSMA, W; JANSSEN, PJA; VANDERKWAST, TH; ZWARTHOFF, EC				DENBAKKER, MA; RIEGMAN, PHJ; HEKMAN, RACP; BOERSMA, W; JANSSEN, PJA; VANDERKWAST, TH; ZWARTHOFF, EC			THE PRODUCT OF THE NF2 TUMOR-SUPPRESSOR GENE LOCALIZES NEAR THE PLASMA-MEMBRANE AND IS HIGHLY EXPRESSED IN MUSCLE-CELLS	ONCOGENE			English	Article						NF2; TUMOR SUPPRESSOR GENE; CYTOSKELETON; MUSCLE CELLS	BILATERAL ACOUSTIC NEUROFIBROMATOSIS; TYPE-2 NEUROFIBROMATOSIS; UNITED-KINGDOM; RADIXIN; EZRIN; TALIN; CYTOSKELETON; CONFIRMATION; FAMILY; MOESIN	Neurofibromatosis type 2 (NF2) is a disease resulting in the formation of schwannomas of the eighth cranial nerve, and other central nervous system tumours. A tumour suppressor gene has been found to be responsible for this disorder. The 595 amino acid NF2 protein shows a great deal of homology to a superfamily of membrane organizing proteins. To generate antibodies against the NF2 protein four synthetic peptides (SP) were injected in rabbits. COS cells transfected with an NF2 cDNA construct in an expression vector were used for immunocytochemical staining experiments; lysates of transfected COS cells were used for Western blotting experiments, as were lysates of E. coli cultures transformed with an NF2 cDNA construct subcloned in a prokaryotic expression vector. In western blots all sera detected a band indicating the appropriate molecular weight in lysates of transfected COS cells and E. coli. Immunocytochemical staining experiments indicate that the NF2 protein localizes in or near the cell membrane. Immunohistochemical staining of human tissue sections demonstrated the presence of the NF2 protein in muscle-, and Schwann cells. These results support the hypothesis that the NF2 protein functions as a membrane organizing element.	TNO, MBL, DEPT IMMUNOL, 2280 HV RIJSWIJK, NETHERLANDS	Netherlands Organization Applied Science Research	DENBAKKER, MA (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PATHOL, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Riegman, Peter/GLS-0041-2022	Van der Kwast, Theodorus/0000-0001-8640-5786				ALGRAIN M, 1993, CURR BIOL, V3, P451, DOI 10.1016/0960-9822(93)90354-Q; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; CLAUDIO JO, 1994, HUM MOL GENET, V3, P185; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; GUTMANN DH, 1993, ARCH NEUROL-CHICAGO, V50, P1185, DOI 10.1001/archneur.1993.00540110065007; HARA T, 1994, CANCER RES, V54, P330; HAWKES R, 1986, METHOD ENZYMOL, V121, P484; IRVING RM, 1994, HUM MOL GENET, V3, P347, DOI 10.1093/hmg/3.2.347; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; KUPFER MIK, 1989, ARCH OPHTHALMOL-CHIC, V107, P541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDAU K, 1993, BRIT J OPHTHALMOL, V77, P646, DOI 10.1136/bjo.77.10.646; LOWLY DR, 1993, CIBA F S, V176, P67; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; MULVIHILL JJ, 1990, ANN INTERN MED, V113, P39, DOI 10.7326/0003-4819-113-1-39; PAKKANEN R, 1988, J CELL BIOCHEM, V38, P65, DOI 10.1002/jcb.240380107; PYKETT MJ, 1994, HUM MOL GENET, V3, P559, DOI 10.1093/hmg/3.4.559; RAGGE NK, 1993, BRIT J OPHTHALMOL, V77, P662, DOI 10.1136/bjo.77.10.662; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RICCARDI V M, 1989, Neurofibromatosis, V2, P284; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBIO MP, 1994, CANCER RES, V54, P45; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SATO N, 1992, J CELL SCI, V103, P131; STERNBERGER LA, 1979, J HISTOCHEM CYTOCHEM, V27, P1424, DOI 10.1177/27.11.92498; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; VISKOCHIL D, 1993, ANNU REV NEUROSCI, V16, P183, DOI 10.1146/annurev.ne.16.030193.001151; WEBB MAP, 1986, NEW ENGL J MED, V315, P1553; ZEGERS ND, 1991, BIOCHIM BIOPHYS ACTA, V1073, P23, DOI 10.1016/0304-4165(91)90178-J	40	48	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					757	763						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862453				2022-12-25	WOS:A1995QH61200016
J	MASSON, PJ; COUP, D; MILLET, J; BROWN, NL				MASSON, PJ; COUP, D; MILLET, J; BROWN, NL			THE EFFECT OF THE BETA-D-XYLOSIDE NAROPARCIL ON CIRCULATING PLASMA GLYCOSAMINOGLYCANS - AN EXPLANATION OF ITS KNOWN ANTITHROMBOTIC ACTIVITY IN THE RABBIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN COFACTOR-II; CHONDROITIN SULFATE CHAINS; EMBRYONIC-CHICKEN CARTILAGE; DERMATAN SULFATE; THROMBIN INHIBITION; ENDOTHELIAL-CELLS; MATRIX FORMATION; CULTURED-CELLS; BIOSYNTHESIS; PROTEOGLYCAN	beta-D-Xylosides are known to initiate or prime free glycosaminoglycan (GAG) chain synthesis in cell and tissue culture. As such, the effect of the venous antithrombotic beta-D-xyloside, naroparcil, was investigated on the plasma GAG profile in the rabbit after oral administration, Using dose-response experiments, we showed that antithrombin activity via antithrombin III and heparin cofactor II was increased in parallel with GAG plasma levels compared to control, A more detailed qualitative examination of plasma GAGs by cellulose acetate electrophoresis and ion-exchange chromatography, following oral administration of naroparcil at 400 mg/kg, revealed the presence of higher density charged molecules compared to control, The extracted GAGs were found to activate inhibition of thrombin by heparin cofactor II and contained approximately 25% of a dermatan sulfate-like compound (undetectable in control), which could be responsible for the antithrombotic effect, Using radiolabeled naroparcil, we found radiolabeled GAG fractions and the fact that naroparcil was a substrate for galactosyltransferase I, the second enzyme responsible for GAG chain polymerization, suggested that the compound could initiate in vivo the biosynthesis of antithrombotic free GAG chains, This is, to our knowledge, the first description of the in vivo effect of a beta-D-xyloside on GAG biosynthesis; furthermore, this is correlated with an antithrombotic action.			MASSON, PJ (corresponding author), LABS FOURNIER SCA, CTR RECH & DEV, 50 RUE DIJON, BP 90, F-21121 DAIX, FRANCE.							AMAR J, 1990, BRIT J HAEMATOL, V76, P94, DOI 10.1111/j.1365-2141.1990.tb07842.x; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY B, 1989, BIOCHEM J, V262, P225, DOI 10.1042/bj2620225; COSTER L, 1991, BIOCHEM J, V276, P533, DOI 10.1042/bj2760533; DUPOUY D, 1988, THROMB HAEMOSTASIS, V60, P236; FERNANDEZ FA, 1987, THROMB HAEMOSTASIS, V57, P286; FISCHER AM, 1982, THROMB HAEMOSTASIS, V47, P104; FRANSSON LA, 1992, GLYCOCONJUGATE J, V9, P45, DOI 10.1007/BF00731177; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GALLIGANI L, 1975, J BIOL CHEM, V250, P5400; GENSINI GF, 1990, HAEMOSTASIS, V20, P129; GORDON PB, 1986, CARBOHYD RES, V151, P121, DOI 10.1016/S0008-6215(00)90334-3; HEMKER HC, 1991, SEMIN THROMB HEMOST, V17, P29; IMANARI T, 1992, J CHROMATOGR-BIOMED, V574, P142, DOI 10.1016/0378-4347(92)80109-4; JANDROTPERRUS M, 1988, EUR J BIOCHEM, V174, P359, DOI 10.1111/j.1432-1033.1988.tb14106.x; KANWAR YS, 1984, J CELL BIOL, V99, P715, DOI 10.1083/jcb.99.2.715; KOLSET SO, 1990, BIOCHEM J, V265, P637, DOI 10.1042/bj2650637; LINHARDT RJ, 1989, ANAL BIOCHEM, V181, P288, DOI 10.1016/0003-2697(89)90245-5; LINHARDT RJ, 1986, APPL BIOCHEM BIOTECH, V12, P135; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MILLET J, 1994, THROMB HAEMOSTASIS, V72, P874; MILLET J, 1992, THROMB HAEMOSTASIS, V67, P176; MILLET J, 1992, THROMB RES, V65, pS158; MURATA K, 1980, METHODS CARBOHYDRATE, V8, P81; MURRAY E, 1983, BIOCHIM BIOPHYS ACTA, V763, P299, DOI 10.1016/0167-4889(83)90138-6; NAGASAKA T, 1989, EXP HEMATOL, V17, P923; OFOSU FA, 1988, THROMB HAEMOSTASIS, V60, P188; OFOSU FA, 1984, BLOOD, V64, P727; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; ROBINSON J, 1984, J BIOL CHEM, V259, P3818; ROBINSON JA, 1981, BIOCHEM J, V194, P839, DOI 10.1042/bj1940839; SCHWARTZ NB, 1979, J BIOL CHEM, V254, P2271; SCHWARTZ NB, 1974, P NATL ACAD SCI USA, V71, P4047, DOI 10.1073/pnas.71.10.4047; SCOTT TA, 1953, ANAL CHEM, V25, P1656, DOI 10.1021/ac60083a023; SCULLY MF, 1988, BIOCHEM J, V254, P547, DOI 10.1042/bj2540547; SENO N, 1970, ANAL BIOCHEM, V37, P197, DOI 10.1016/0003-2697(70)90280-0; SHIMADA K, 1991, JPN CIRC J, V55, P1016, DOI 10.1253/jcj.55.1016; SHIMADA K, 1987, ARTERIOSCLEROSIS, V7, P627, DOI 10.1161/01.ATV.7.6.627; SIE P, 1993, BLOOD, V81, P1771; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; STEVENS RL, 1983, J BIOL CHEM, V258, P5977; STEVENS RL, 1982, J BIOL CHEM, V257, P253; TAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514; TERHO TT, 1971, ANAL BIOCHEM, V41, P471, DOI 10.1016/0003-2697(71)90167-9; TOLLEFSEN DM, 1986, J BIOL CHEM, V261, P8854; VANRYNMCKENNA J, 1989, ANN NY ACAD SCI, V556, P304	49	75	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2662	2668		10.1074/jbc.270.6.2662	http://dx.doi.org/10.1074/jbc.270.6.2662			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852334	hybrid			2022-12-25	WOS:A1995QF53500042
J	MURAKAMI, M; KARNIK, SS; HUSAIN, A				MURAKAMI, M; KARNIK, SS; HUSAIN, A			HUMAN PROCHYMASE ACTIVATION - A NOVEL ROLE FOR HEPARIN IN ZYMOGEN PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-I; MAST-CELL PROTEASE; MOLECULAR-CLONING; SERINE PROTEASE; SUBSTANCE-P; HUMAN HEART; CHYMASE; IDENTIFICATION; GENE; PURIFICATION	Human prochymase is packaged with heparin in mast cell granules and appears to be activated by dipeptidylpeptidase I. We show that a high affinity interaction between heparin and prochymase allows the 2-residue propeptide to be cleaved by dipeptidylpeptidase I. A conserved Glu in the propeptide is necessary for this heparin effect. Following propeptide cleavage, capture of the newly generated NH2 terminus by an ''activation groove'' on the enzyme activates the enzyme and concurrently prevents a progressive degradation of the NH2 terminus by dipeptidylpeptidase I. Surrogate peptide studies show that the activation groove is unoccupied in prochymase and is specific for the chymase NH2 terminus. These observations indicate that heparin is an important cofactor in the prochymase activation process and explain how dipeptidylpeptidase I, a nonspecific processing enzyme, can effect a specific cleavage of the zymogen propeptide.	CLEVELAND CLIN FDN, RES INST, DEPT MOLEC CARDIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation			Karnik, Sadashiva/Y-2477-2019; Husain, Ahsan/J-6861-2012	Karnik, Sadashiva/0000-0003-0746-2753; Husain, Ahsan/0000-0003-3426-3469	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004871] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044201, P50HL033713] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04871] Funding Source: Medline; NHLBI NIH HHS [HL44201, HL33713, R01 HL057470] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BRAIN SD, 1988, NATURE, V335, P73, DOI 10.1038/335073a0; CAUGHEY GH, 1990, BIOCHEMISTRY-US, V29, P5166, DOI 10.1021/bi00473a024; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEYOUNG MB, 1987, ARCH BIOCHEM BIOPHYS, V254, P222, DOI 10.1016/0003-9861(87)90098-1; DIKOV MM, 1994, J BIOL CHEM, V269, P25897; EVIN G, 1984, P NATL ACAD SCI-BIOL, V81, P48, DOI 10.1073/pnas.81.1.48; FLETCHER TS, 1987, BIOCHEMISTRY-US, V26, P7256, DOI 10.1021/bi00397a010; GOLDSTEIN SM, 1987, J IMMUNOL, V139, P2724; JENNE DE, 1989, BIOCHEMISTRY-US, V28, P7953, DOI 10.1021/bi00445a060; KINOSHITA A, 1991, J BIOL CHEM, V266, P19192; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAGUNOFF D, 1976, ARCH BIOCHEM BIOPHYS, V173, P554, DOI 10.1016/0003-9861(76)90292-7; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCGUIRE MJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P280, DOI 10.1016/0003-9861(92)90519-3; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; SALI A, 1993, J BIOL CHEM, V268, P9023; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; STROUD RM, 1977, ANNU REV BIOPHYS BIO, V6, P177, DOI 10.1146/annurev.bb.06.060177.001141; Summers MD, 1987, TEXAS AGR EXPT STATI; TANI T, 1988, J BIOL CHEM, V263, P1231; URATA H, 1991, J BIOL CHEM, V266, P17173; URATA H, 1990, J BIOL CHEM, V265, P22348; URATA H, 1993, J BIOL CHEM, V268, P24318; URATA H, 1993, J CLIN INVEST, V91, P1269, DOI 10.1172/JCI116325; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; WINTROUB BU, 1984, J INVEST DERMATOL, V83, P336, DOI 10.1111/1523-1747.ep12264144	35	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2218	2223		10.1074/jbc.270.5.2218	http://dx.doi.org/10.1074/jbc.270.5.2218			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836453	hybrid			2022-12-25	WOS:A1995QE49300038
J	YEH, JI; GULVE, EA; RAMEH, L; BIRNBAUM, MJ				YEH, JI; GULVE, EA; RAMEH, L; BIRNBAUM, MJ			THE EFFECTS OF WORTMANNIN ON RAT SKELETAL-MUSCLE - DISSOCIATION OF SIGNALING PATHWAYS FOR INSULIN-ACTIVATED AND CONTRACTION-ACTIVATED HEXOSE-TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; GLUCOSE-TRANSPORT; EPITROCHLEARIS MUSCLE; RECEPTOR SUBSTRATE-1; STIMULATION; LIVER; PHOSPHORYLATION; TRANSDUCTION; RESISTANT; HYPOXIA	Both the anabolic hormone insulin and contractile activity stimulate the uptake of glucose into mammalian skeletal muscle, In this study, we examined the role of phosphatidylinositol 3-kinase (PI 3-kinase), a putative mediator of insulin actions, in the stimulation of hexose uptake in response to hormone and contraction, Phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-triphosphate accumulate in skeletal muscle exposed to insulin but not hypoxia, which mimics stimulation of the contractile-dependent pathway of hexose transport activation, The fungal metabolite wortmannin, an inhibitor of PI 3-kinase, completely blocks the appearance of 3'-phospholipids in response to insulin, Moreover, wortmannin entirely prevented the increase in hexose uptake in muscle exposed to insulin but was without effect on muscle stimulated by repetitive contraction or hypoxia, These results support the view that PI 3-kinase is involved in the signaling pathways mediating insulin-responsive glucose transport in skeletal muscle but is not required for stimulation by hypoxia or contraction, Furthermore, these data indicate that there exist at least two signaling pathways leading to activation of glucose transport in skeletal muscle with differential sensitivities to wortmannin.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; GD SEARLE & CO,ST LOUIS,MO 63167; BETH ISRAEL HOSP,DEPT MED,DIV SIGNAL TRANSDUCT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center				Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039519] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39519] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD RJ, 1992, FASEB J, V6, P3238, DOI 10.1096/fasebj.6.14.1426762; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CARTEE GD, 1992, AM J PHYSIOL, V263, pR70, DOI 10.1152/ajpregu.1992.263.1.R70; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN KS, 1993, AM J PHYSIOL, V265, pE736, DOI 10.1152/ajpendo.1993.265.5.E736; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Goldberg A L, 1975, Methods Enzymol, V39, P82; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; HENRIKSEN EJ, 1989, AM J PHYSIOL, V256, pE662, DOI 10.1152/ajpendo.1989.256.5.E662; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KIPNIS DM, 1959, ANN NY ACAD SCI, V82, P354, DOI 10.1111/j.1749-6632.1959.tb44916.x; NESHER R, 1980, AM J PHYSIOL, V239, pE454, DOI 10.1152/ajpendo.1980.239.6.E454; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; OKADA T, 1994, J BIOL CHEM, V269, P3568; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YOUNG DA, 1986, J BIOL CHEM, V261, P6049	30	312	312	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2107	2111		10.1074/jbc.270.5.2107	http://dx.doi.org/10.1074/jbc.270.5.2107			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836438	hybrid			2022-12-25	WOS:A1995QE49300021
J	SAPI, E; FLICK, MB; GILMOREHEBERT, M; RODOV, S; KACINSKI, BM				SAPI, E; FLICK, MB; GILMOREHEBERT, M; RODOV, S; KACINSKI, BM			TRANSCRIPTIONAL REGULATION OF THE C-FMS (CSF-1R) PROTOONCOGENE IN HUMAN BREAST-CARCINOMA CELLS BY GLUCOCORTICOIDS	ONCOGENE			English	Article						C-FMS; PROTOONCOGENE; GLUCOCORTICOIDS; BREAST NEOPLASMS; TRANSCRIPTIONAL REGULATION RU486	COLONY-STIMULATING FACTOR; GENE-EXPRESSION; RECEPTOR GENE; MESSENGER-RNA; GROWTH-FACTOR; V-FMS; ADENOCARCINOMAS; MONOCYTES; INVITRO; PRODUCT	Expression of the macrophage colony stimulating factor CSF-1 and its receptor, the c-fms proto-oncogene, has been observed in macrophages, trophoblast and in a variety of neoplasms of epithelial origin including those of the breast. We have reported earlier (Oncogene, 1991, 6: 941-952) that c-fms transcript and protein expression were dramatically increased in several breast carcinoma cell lines by glucocorticoids which are essential humoral regulators of normal mammary epithelial cell differentiation. In this communication, we demonstrate that levels of c-fms transcript and protein increased significantly within the first few hours of glucocorticoid treatment, and that these increases were completely abolished by pretreatment of cells with mifepristone (RU486). We also demonstrate that such early increases in c-fms transcript levels could not be attributed to prolongation of transcript half-life. Both promoters of the c-fms gene were found to exhibit some basal activity in breast carcinoma cell lines and both were stimulated 2-3-fold by glucocorticoids. However the first promoter was shown to be responsible for more than 95% of the observed c-fms transcription. Sequence upstream of both promoters was found to contain potential 'glucocorticoid response elements' (GREs), and in each case, elimination of the GRE closest to the promoter abolished glucocorticoid stimulation. Our observations suggest that one mechanism by which glucocorticoids regulate the proliferation and differentiation of neoplastic mammary epithelial cells is through their regulation of transcription of the gene for the receptor of a ubiquitous cytokine, CSF-1.	YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University					NATIONAL CANCER INSTITUTE [R01CA047292] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-47292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKKER GH, 1987, CANCER TREAT REP, V71, P1021; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BRUCKNER A, 1992, CANCER RES, V52, P3043; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CHAMBERS SK, 1993, EXP HEMATOL, V21, P1328; CHAMBERS SK, 1994, STEROIDS, V59, P514, DOI 10.1016/0039-128X(94)90069-8; COPE CL, 1972, ADRENAL STEROIDS DIS; COUSSENS L, 1986, NATURE, V320, P180; DAITER E, 1992, J CLIN ENDOCR METAB, V74, P850, DOI 10.1210/jc.74.4.850; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FILDERMAN AE, 1992, CANCER RES, V52, P3661; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAGNE D, 1985, J STEROID BIOCHEM, V23, P247, DOI 10.1016/0022-4731(85)90401-7; GAILLARD RC, 1985, J CLIN ENDOCR METAB, V61, P1009, DOI 10.1210/jcem-61-6-1009; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GUSELLA GL, 1990, J IMMUNOL, V111, P3571; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HEISTERKAMP N, 1983, VIROLOGY, V126, P248, DOI 10.1016/0042-6822(83)90476-2; HORIGUCHI J, 1988, BIOCHEM BIOPH RES CO, V157, P395, DOI 10.1016/S0006-291X(88)80060-3; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; KACINSKI BM, 1991, ONCOGENE, V6, P941; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KLIJN JGM, 1989, CANCER RES, V49, P2851; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MANDELONDE T, 1987, HORMONAL MANIPULATIO; Maniatis T., 1982, MOL CLONING; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROBERTS WM, 1992, BLOOD, V79, P586; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SHERR CJ, 1985, CELL, V41, P666; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WEBER B, 1989, MOL CELL BIOL, V9, P768; WILLIAMS TM, 1989, ANAL BIOCHEM, V176, P28, DOI 10.1016/0003-2697(89)90267-4; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	49	53	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					529	542						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845678				2022-12-25	WOS:A1995QF64800014
J	PLET, A; EICK, D; BLANCHARD, JM				PLET, A; EICK, D; BLANCHARD, JM			ELONGATION AND PREMATURE TERMINATION OF TRANSCRIPTS INITIATED FROM C-FOS AND C-MYC PROMOTERS SHOW DISSIMILAR PATTERNS	ONCOGENE			English	Article						IN VIVO FOOTPRINT; C-FOS AND C-MYC; PROTOONCOGENES; INTRAGENIC BLOCK; ELONGATION	RNA POLYMERASE-II; SEQUENCE REQUIREMENTS; DROSOPHILA-MELANOGASTER; TRANS-ACTIVATION; GENE-EXPRESSION; DOWN-REGULATION; MESSENGER-RNA; INVIVO; BLOCK; CELLS	RNA polymerase II seems to be prone to stop at intrinsic pause sites, thus introducing a further potential level of regulation. It was recently shown that RNA polymerase Lf was held at the P2 promoter of c-myc gene. We confirmed the presence of engaged polymerases in the murine fibroblastic Ltk(-) and pre-B lymphoid 70Z3 cell lines. High resolution run-on analysis and in vivo permanganate-dependent footprinting showed that this holds true for the c-fos gene in unstimulated cells where a strong block to transcription elongation was evidenced. In contrast to what was observed in the c-myc gene, an even more intense signal was observed in run-on experiments downstream to the promoter, on a c-fos oligonucleotide including position +385 where an in vitro transcription arrest site was previously mapped. Genomic footprinting of DNA from intact cells and isolated nuclei confirmed the involvement of several thymidines belonging to a T-rich stretch in a melted region which was not detected upon polymerase release. In order to observe a short abortive c-fos transcript accumulating in vivo we resorted to microinjection of c-fos templates in Xenopus oocytes where transcripts were stable.	UNIV MONTPELLIER 2,MONTPELLIER 1,FRANCE; FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY	Universite de Montpellier	PLET, A (corresponding author), INST GENET MOLEC MONTPELLIER,CNRS,UMR 9942,BP 5051,1919 ROUTE MENDE,MONTPELLIER 1,FRANCE.							ASSELIN C, 1989, ONCOGENE, V4, P549; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLANCHARD JM, 1988, BIOCHIMIE, V70, P877, DOI 10.1016/0300-9084(88)90228-3; BONNIEU A, 1989, ONCOGENE, V4, P881; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1994, TRENDS GENET, V10, P292, DOI 10.1016/0168-9525(90)90013-V; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KOHLHUBER F, 1993, ONCOGENE, V8, P1099; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MIDDLETON KM, 1990, MOL CELL BIOL, V10, P727, DOI 10.1128/MCB.10.2.727; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MIRKOVITCH J, 1992, MOL BIOL CELL, V3, P1085, DOI 10.1091/mbc.3.10.1085; MORGAN GT, 1984, NUCLEIC ACIDS RES, V12, P6043, DOI 10.1093/nar/12.15.6043; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; PLET A, 1992, ONCOGENE, V7, P1847; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SALDITTGEORGIEF.M, 1980, CELL, V19, P69; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SZENTIRMAY MN, 1993, EMBO J, V12, P4677, DOI 10.1002/j.1460-2075.1993.tb06156.x; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843	44	72	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					319	328						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838531				2022-12-25	WOS:A1995QC62400011
J	AMES, JB; PORUMB, T; TANAKA, T; IKURA, M; STRYER, L				AMES, JB; PORUMB, T; TANAKA, T; IKURA, M; STRYER, L			AMINO-TERMINAL MYRISTOYLATION INDUCES COOPERATIVE CALCIUM-BINDING TO RECOVERIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; INDUCED CONFORMATIONAL CHANGE; ROD GUANYLATE-CYCLASE; MULTIDIMENSIONAL NMR; GLOBULAR DOMAINS; SKELETAL-MUSCLE; PEPTIDE COMPLEX; CA2+ BINDING; TROPONIN-C; CALMODULIN	Recoverin, a new member of the EF-hand protein superfamily, serves as a Ca2+ sensor in vision, A myristoyl or related N-acyl group covalently attached to the amino terminus of recoverin enables it to bind to disc membranes when the Ca2+ level is elevated. Ca2+-bound recoverin prolongs the lifetime of photoexcited rhodopsin, most likely by blocking its phosphorylation, We report here Ca2+ binding studies of myristoylated and unmyristoylated recombinant recoverin using flow dialysis, fluorescence, and NMR spectroscopy, Unmyristoylated recoverin exhibits heterogeneous and uncooperative binding of two Ca2+ with dissociation constants of 0.11 and 6.9 mu M. In contrast, two Ca2+ bind cooperatively to myristoylated recoverin with a Hill coefficient of 1.75 and an apparent dissociation constant of 17 mu M. Thus, the attached myristoyl group lowers the calcium affinity of the protein and induces cooperativity in Ca2+ binding, One-dimensional H-1 and two-dimensional N-15-H-1 shift correlation NMR spectra of myristoylated recoverin measured as a function of Ca2+ concentration show that a concerted conformational change occurs when two Ca2+ are bound. The Ca2+ binding and NMR data can be fit to a concerted allosteric model in which the two Ca2+ binding sites have different affinities in both the T and R states, The T and R conformational states are defined in terms of the Ca2+-myristoyl switch; in the T state, the myristoyl group is sequestered inside the protein, whereas in the R state, the myristoyl group is extruded, Ca2+ binds to the It state at least 10,000-fold more tightly than to T, In this model, the dissociation constants of the two sites in the It state of the myristoyl ated protein are 0.11 and 6.9 mu M, as in unmyristoylated recoverin, The ratio of the unliganded form of T to that of R is estimated to be 400 for myristoylated and <0.05 for unmyristoylated recoverin, Thus, the attached myristoyl group has two related roles: it shifts the T/R ratio of the unliganded protein more than 8000-fold, and serves as a membrane anchor for the fully Liganded protein.	STANFORD UNIV, SCH MED, DEPT NEUROBIOL, STANFORD, CA 94305 USA; ONTARIO CANC INST, DIV MOLEC & STRUCT BIOL, TORONTO, ON M4X 1K9, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M4X 1K9, CANADA	Stanford University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto				Ikura, Mitsuhiko/0000-0002-9524-1303	NATIONAL EYE INSTITUTE [F32EY006418, R01EY002005, R37EY002005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024032, R37GM024032] Funding Source: NIH RePORTER; NEI NIH HHS [EY02005, EY06418-02] Funding Source: Medline; NIGMS NIH HHS [GM24032] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKKE M, 1991, J MOL BIOL, V220, P173, DOI 10.1016/0022-2836(91)90389-N; AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; ANGLISTER J, 1993, J BIOMOL NMR, V3, P121; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Dahlquist F W, 1978, Methods Enzymol, V48, P270; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; IIDA S, 1988, J BIOCHEM-TOKYO, V103, P482, DOI 10.1093/oxfordjournals.jbchem.a122296; IKURA M, 1983, BIOCHEMISTRY-US, V22, P2573, DOI 10.1021/bi00279a039; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KATAOKA M, 1993, J BIOCHEM-TOKYO, V114, P535, DOI 10.1093/oxfordjournals.jbchem.a124212; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KLEVIT RE, 1984, EUR J BIOCHEM, V139, P109, DOI 10.1111/j.1432-1033.1984.tb07983.x; Koch K W, 1994, Rev Physiol Biochem Pharmacol, V125, P149, DOI 10.1007/BFb0030910; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; LINSE S, 1991, J BIOL CHEM, V266, P8050; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MINOWA O, 1984, J BIOCHEM-TOKYO, V96, P1175, DOI 10.1093/oxfordjournals.jbchem.a134935; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OGAWA Y, 1986, J BIOCHEM-TOKYO, V99, P81, DOI 10.1093/oxfordjournals.jbchem.a135482; PORUMB T, 1994, ANAL BIOCHEM, V220, P227, DOI 10.1006/abio.1994.1332; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; THULIN E, 1984, BIOCHEMISTRY-US, V23, P1862, DOI 10.1021/bi00303a043; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; TSUDA S, 1988, BIOCHEMISTRY-US, V27, P4120, DOI 10.1021/bi00411a032; WYLIE DC, 1988, CALMODULIN, P1; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569; [No title captured]; [No title captured]	42	144	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4526	4533		10.1074/jbc.270.9.4526	http://dx.doi.org/10.1074/jbc.270.9.4526			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876221	hybrid			2022-12-25	WOS:A1995QK08400054
J	GRIERSON, JP; MELDOLESI, J				GRIERSON, JP; MELDOLESI, J			SHEAR STRESS-INDUCED [CA2+](I) TRANSIENTS AND OSCILLATIONS IN MOUSE FIBROBLASTS ARE MEDIATED BY ENDOGENOUSLY RELEASED ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; LYSOPHOSPHATIDIC ACID; PHOSPHOINOSITIDASE-C; PHOSPHOLIPASE-C; RELAXING FACTOR; FREE CALCIUM; PC12 CELLS; RECEPTOR; FLOW; ACTIVATION	The effects of ATP, U-73122, apyrase, and saline shear stress on [Ca2+](i) homeostasis were studied in fura-2 loaded, mouse fibroblast cells (L929), both in suspension and plated on glass, Release of internal Ca2+ was induced by ATP, via a receptor identified pharmacologically as a P-2U type, In single cells, low concentrations of ATP evoked [Ca2+](i) oscillations, These events were blocked by the putative phospholipase C inhibitor, U-73122 (but not by the inactive analog U-73343) and by the ATP/ADPase, apyrase, In addition, both these agents reduced the [Ca2+](i) of unstimulated cells, especially after stirring, and blocked spontaneously occurring [Ca2+](i) oscillations, which suggested an already activated state of the ATP receptor, independent from exogenous stimulations, Moreover, it was found that stirring of the cells was correlated with a steady accumulation of inositol phosphates, also blockable by apyrase, and that [Ca2+](i) mobilization could be induced by puffs of saline in single cells, The transition to a Ca2+-free environment also provoked [Ca2+](i) oscillations, most likely via the increase in ATP(4-) concentration, This evidence suggests that endogenous ATP is released from L fibroblasts in response to fluid shear stress, and this results in an autocrine, tonic up-regulation of the phosphoinositide signaling system and an ensuing alteration in Ca2+ homeostasis, Up until now, such a response to shear stress was believed to be unique to endothelial cells.	B CECCARELLI CTR,I-20132 MILAN,ITALY; S RAFFAELE SCI INST,DIBIT,I-20132 MILAN,ITALY		GRIERSON, JP (corresponding author), UNIV MILAN,CNR,DEPT PHARMACOL,VIA OLGETTINA 58,I-20132 MILAN,ITALY.							ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; ANDO J, 1991, BIOCHEM BIOPH RES CO, V179, P1192, DOI 10.1016/0006-291X(91)91698-C; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BHAGYALAKSHMI A, 1992, J VASC RES, V29, P443, DOI 10.1159/000158963; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BOEYNAEMS JM, 1990, TRENDS PHARMACOL SCI, V11, P34, DOI 10.1016/0165-6147(90)90039-B; DAVIDSON JS, 1990, ENDOCRINOLOGY, V126, P80, DOI 10.1210/endo-126-1-80; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; FINE J, 1989, BIOCHEM J, V263, P371, DOI 10.1042/bj2630371; FISCHER GA, 1994, J BIOL CHEM, V269, P19216; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GROHOVAZ F, 1991, J CELL BIOL, V113, P1341, DOI 10.1083/jcb.113.6.1341; HAHN K, 1992, NATURE, V359, P736, DOI 10.1038/359736a0; HEBDA PA, 1993, DERMATOL CLIN, V11, P685, DOI 10.1016/S0733-8635(18)30221-3; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JALINK K, 1990, J BIOL CHEM, V265, P12232; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; KORENAGA R, 1994, BIOCHEM BIOPH RES CO, V198, P213, DOI 10.1006/bbrc.1994.1030; LIN TA, 1993, J NEUROCHEM, V60, P1115, DOI 10.1111/j.1471-4159.1993.tb03262.x; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571; MILNER P, 1990, BIOCHEM BIOPH RES CO, V170, P649, DOI 10.1016/0006-291X(90)92141-L; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MURRIN RJA, 1992, MOL PHARMACOL, V41, P561; NIEWIAROWSKI S, 1973, J LAB CLIN MED, V82, P605; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; OIKI S, 1988, J MEMBRANE BIOL, V105, P23, DOI 10.1007/BF01871103; OKADA Y, 1982, J PHYSIOL-LONDON, V327, P449, DOI 10.1113/jphysiol.1982.sp014242; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; WATSON S, 1993, TRENDS PHARM SCI S, V14, P38; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3	34	97	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4451	4456		10.1074/jbc.270.9.4451	http://dx.doi.org/10.1074/jbc.270.9.4451			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876211	hybrid			2022-12-25	WOS:A1995QK08400043
J	HII, CST; FERRANTE, A; EDWARDS, YS; HUANG, ZH; HARTFIELD, PJ; RATHJEN, DA; POULOS, A; MURRAY, AW				HII, CST; FERRANTE, A; EDWARDS, YS; HUANG, ZH; HARTFIELD, PJ; RATHJEN, DA; POULOS, A; MURRAY, AW			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE BY ARACHIDONIC-ACID IN RAT-LIVER EPITHELIAL WB CELLS BY A PROTEIN-KINASE C-DEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYUNSATURATED FATTY-ACIDS; MAP KINASE; HUMAN-NEUTROPHILS; RECEPTOR; ISLETS; CA-2+; RAF-1	Arachidonic acid (20:4(n-6)), which is released by cells responding to a wide range of stimuli, may play an important role in intracellular signaling. We now report that incubation of WB cells with 20:4(n-6) resulted in the appearance of several tyrosine-phosphorylated cytosolic proteins. Two of the phosphotyrosine-containing proteins, migrating in SDS-polyacrylamide gels of approximately 43 and 45 kDa, corresponded in mobility to phosphorylated species of the 42- and 44-kDa mitogen-activated protein kinase (MAPK) isoforms. Immunoblots of soluble fractions from unstimulated WR cells with anti-MAPK antibodies revealed the presence of the 42- and 44 kDa isoforms of MAPK. Upon incubation with 20:4(n-6), the mobility of both isoforms was retarded, consistent with their activation by phosphorylation. Chromatography of soluble fractions from these cells on Mono Q columns revealed early and late eluting peaks of myelin basic protein kinase activity, which contained the 42- and 44-kDa MAPK isoforms, respectively. Activation of MAPK was transient, peaking at 5 min, and was detectable at 5 mu M 20:4(n-6). Further studies into the mechanisms by which MAPK was activated by 20:4(n-6) strongly suggested the involvement of protein kinase C (PRC). Not only did incubation of WB cells with 20:4(n-6) result in the translocation of PKC alpha, delta, and epsilon to a particulate fraction, it was found that the fatty acid failed to activate MAPK in cells pretreated for 26 h with phorbol la myristate 13-acetate, which depleted WE cells of PKC alpha, delta, and epsilon. In addition, fatty acids of the n-3 series were effective activators of MAPK. The present study, to our knowledge, is the first to report that polyunsaturated fatty acids can cause the activation of MAPK.	WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,ADELAIDE,SA 5006,AUSTRALIA; FLINDERS UNIV S AUSTRALIA,SCH BIOL SCI,BEDFORD PK,SA 5042,AUSTRALIA	Womens & Childrens Hospital Australia; Flinders University South Australia	HII, CST (corresponding author), WOMENS & CHILDRENS HOSP,DEPT IMMUNOL,ADELAIDE,SA 5006,AUSTRALIA.		Hartfield, Perry/B-1139-2012					ABRAMSON SB, 1991, J IMMUNOL, V147, P231; ANEL A, 1994, J BIOL CHEM, V269, P9506; AYLSWORTH CF, 1986, CANCER RES, V46, P4527; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; BAND AM, 1992, J MOL ENDOCRINOL, V8, P95, DOI 10.1677/jme.0.0080095; BATES EJ, 1992, J LEUKOCYTE BIOL, V53, P420; Bazan NG, 1992, ESSENTIAL FATTY ACID, P107; BELCH JJF, 1992, ESSENTIAL FATTY ACID, P356; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHOW SC, 1990, J BIOL CHEM, V265, P902; CLARKE SD, 1993, PROG LIPID RES, V32, P139, DOI 10.1016/0163-7827(93)90013-M; FERRANTE A, 1994, J CLIN INVEST, V93, P1063, DOI 10.1172/JCI117056; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; HARDY SJ, 1994, J NEUROCHEM, V62, P1546; HII CST, 1994, BIOCHEM J, V303, P475, DOI 10.1042/bj3030475; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KHAN WA, 1994, J BIOL CHEM, V269, P9729; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NAKAMURA K, 1989, EUR J PHARMACOL, V160, P61, DOI 10.1016/0014-2999(89)90654-7; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; WARNER LC, 1993, ONCOGENE, V8, P3249; WOLF BA, 1986, J BIOL CHEM, V261, P3501; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	33	105	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4201	4204		10.1074/jbc.270.9.4201	http://dx.doi.org/10.1074/jbc.270.9.4201			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876176	hybrid			2022-12-25	WOS:A1995QK08400006
J	SELBY, CP; SANCAR, A				SELBY, CP; SANCAR, A			STRUCTURE AND FUNCTION OF TRANSCRIPTION-REPAIR COUPLING FACTOR .1. STRUCTURAL DOMAINS AND BINDING-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-SPECIFIC REPAIR; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TERNARY COMPLEXES; GENE; PURIFICATION; INVITRO; UVRA	The 130-kDa mfd gene product is required for coupling transcription to repair in Escherichia coli. Mfd displaces E. coli RNA polymerase (Pol) stalled at a lesion, binds to the damage recognition protein UvrA, and increases the template strand repair rate during transcription. Here, the interactions of Mfd (transcription-repair coupling factor, TRCF) with DNA, RNA Pol, and UvrA were investigated, TRCF bound nonspecifically to double stranded DNA; binding to DNA produced alternating DNase I-protected and -hypersensitive regions, suggesting possible wrapping of the DNA around the enzyme. Weaker binding to single stranded DNA and no binding to single stranded RNA were observed. DNA binding required ATP, and hydrolysis of ATP promoted dissociation. Removal of a stalled RNA Pol also requires ATP hydrolysis. Apparently, TRCF recognizes a stalled elongation complex by directly interacting with RNA Pol, since binding to a synthetic transcription bubble was no stronger than binding to double stranded DNA, and binding to free RNA Pol holoenzyme and to initiation and elongation complexes in the absence of adenosine 5'-O-(thiotriphosphate) were observed. Structure-function analysis showed that residues 379-571 are involved in binding to a stalled RNAP. The helicase mo tifs region, residues 571-931, binds to ATP and duplex polynucleotide (DNA:DNA or DNA:RNA). Dissociation of the ternary complex upon hydrolysis of ATP also requires the carboxyl terminus of TRCF, Finally, residues 1-378 bind to UvrA and deliver the damage recognition component of the excision nuclease to the lesion.			SELBY, CP (corresponding author), UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NIGMS NIH HHS [GM32833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; REARDON JT, 1993, J BIOL CHEM, V268, P21301; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V281, P1; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; WASHBURN BK, 1991, J BACTERIOL, V173, P2569, DOI 10.1128/jb.173.8.2569-2575.1991; WITKIN EM, 1994, BIOESSAYS, V16, P437, DOI 10.1002/bies.950160613; WITKIN EM, 1966, SCIENCE, V152, P1345, DOI 10.1126/science.152.3727.1345	17	125	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4882	4889		10.1074/jbc.270.9.4882	http://dx.doi.org/10.1074/jbc.270.9.4882			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876261	hybrid			2022-12-25	WOS:A1995QK08400099
J	SIEMEISTER, G; ALHASANI, H; KLEIN, HW; KELLNER, S; STREICHER, R; KRONE, W; MULLERWIELAND, D				SIEMEISTER, G; ALHASANI, H; KLEIN, HW; KELLNER, S; STREICHER, R; KRONE, W; MULLERWIELAND, D			RECOMBINANT HUMAN INSULIN-RECEPTOR SUBSTRATE-1 PROTEIN - TYROSINE PHOSPHORYLATION AND IN-VITRO BINDING OF INSULIN-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNAL TRANSMISSION; SH3 DOMAIN; IRS-1; CELLS; EXPRESSION; POLYMERASE; SUBUNIT; GENE	Insulin receptor substrate-1 (IRS-1) is a major endogenous substrate of the insulin receptor, To study the interaction of the insulin receptor with IRS-1 in vitro, we expressed in Escherichia coli the amino acids 516-777 of human IRS-1 (hIRS-p30) covering five potential tyrosine phosphorylation sites within YXXM motifs, Kinetic data for tyrosine phosphorylation of hIRS-p30 by partially purified insulin receptor and insulin-like growth factor I receptor and by baculovirus-expressed insulin receptor kinase domain were determined, Native insulin receptor demonstrated the highest affinity to hIRS-p30 (K-m = 6.8 +/- 0.6 mu M), followed by the insulin-like growth factor I receptor (K-m = 9.9 +/- 1.0 mu M). We used the soluble recombinant insulin receptor kinase domain, which phosphorylated hIRS-p30 with high affinity (K-m = 11.9 +/- 0.8 mu M), and affinity columns prepared by coupling hIRS-p30 to NHS-activated Sepharose for binding assays, The insulin receptor kinase domain phosphorylated the hIRS-p30 on the column, was bound by the immobilized hIRS-p30, and was eluted with high salt buffer, Autophosphorylated and EDTA-inactivated insulin receptor kinase domain was bound only by immobilized hIRS-p30 protein that had been prephosphorylated, Our results indicate that the recombinant hIRS-p30 protein is a high affinity substrate for insulin receptor and insulin-like growth factor I receptor in vitro, Moreover, we show that only tyrosine-phosphorylated hIRS-p30 is able to bind to the insulin receptor.	UNIV COLOGNE, INNERE MED KLIN & POLIKLIN 2, D-50924 COLOGNE, GERMANY; UNIV DUSSELDORF, DIABET FORSCHUNGSINST, D-40225 DUSSELDORF, GERMANY	University of Cologne; Heinrich Heine University Dusseldorf								ALHASANI H, 1994, FEBS LETT, V349, P17, DOI 10.1016/0014-5793(94)00632-6; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HEIDENREICH K, 1994, BIOL CHEM H-S, V375, P99, DOI 10.1515/bchm3.1994.375.2.99; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KAHN CR, 1993, HORM RES, V39, P93, DOI 10.1159/000182793; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1985, METHOD ENZYMOL, V109, P609; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	36	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4870	4874		10.1074/jbc.270.9.4870	http://dx.doi.org/10.1074/jbc.270.9.4870			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876259	hybrid			2022-12-25	WOS:A1995QK08400097
J	TOMONAGA, T; LEVENS, D				TOMONAGA, T; LEVENS, D			HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN-K IS A DNA-BINDING TRANSACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING; ESCHERICHIA-COLI; PROTEIN; GENE; PURIFICATION; EXPRESSION; ACID; FMR1	We have previously reported that heterogeneous nuclear ribonucleoprotein K (hnRNP K) binds to the pyrimidine-rich strand of the CT element found in the human c-myc gene and activates CT reporter-driven gene expression in vivo. We now characterize the DNA and protein requirements for the interaction of hnRNP K with the CT element, First, hnRNP K is shown to preferentially bind single-stranded DNA over RNA or native double-stranded DNA Using specific oligoribonucleotide or deoxyribonucleotide probes with specific or nonspecific RNA or DNA competitors, electrophoretic mobility shift assay revealed hnRNP K: to be a DNA-binding protein. Specific binding was not simply a reflection of binding to pyrimidine-rich sequences as the number and arrangement of individual CT elements governed interactions with hnRNP K; at least two CT repeats separated by at least three nucleotides are required for binding, indicating the existence of particular stereochemical constraints regulating CT-hnRNP K complex formation. Deletion analysis showed that hnRNP K possesses several nonoverlapping, DNA binding domains, each capable of specific: binding with the CT element and preferring DNA over RNA. Each sequence recognition domain is composed of at least one K homology motif, while a larger portion of hnRNP It may be required for stable RNA binding, Additional experiments indicate that the N-terminal 35 residues of hnRNP K are necessary for transactivating the CT element. These results indicate that hnRNP K is a RNA-binding protein and transcriptional activator.	NCI,PATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Levens, David/C-9216-2009	Levens, David/0000-0002-7616-922X				ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; PAVLOV AR, 1994, J BIOL CHEM, V269, P12968; PELHAM HRB, 1988, P NATL ACAD SCI USA, V77, P4170; RUSSEL M, 1976, J BIOL CHEM, V251, P7263; SHIMAMOTO N, 1987, NUCLEIC ACIDS RES, V15, P5241, DOI 10.1093/nar/15.13.5241; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VONHIPPEL PH, 1982, J MOL BIOL, V162, P795, DOI 10.1016/0022-2836(82)90548-4; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	29	167	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4875	4881		10.1074/jbc.270.9.4875	http://dx.doi.org/10.1074/jbc.270.9.4875			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876260	hybrid			2022-12-25	WOS:A1995QK08400098
J	ANDJELKOVIC, M; JONES, PF; GROSSNIKLAUS, U; CRON, P; SCHIER, AF; DICK, M; BILBE, G; HEMMINGS, BA				ANDJELKOVIC, M; JONES, PF; GROSSNIKLAUS, U; CRON, P; SCHIER, AF; DICK, M; BILBE, G; HEMMINGS, BA			DEVELOPMENTAL REGULATION OF EXPRESSION AND ACTIVITY OF MULTIPLE FORMS OF THE DROSOPHILA RAC PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SIGNALING PROTEINS; CATALYTIC SUBUNIT; BINDING-PROTEIN; GENE; SEQUENCE; RECEPTOR; ENCODES; FAMILY; LOCUS	We have characterized the Drosophila homologue of the proto-oncogenic RAG protein kinase (DRAG-PH). The DRAG-PH gene gives rise to two transcripts with the same coding potential, generated by the use of two different polyadenylation signals. Each transcript encodes two polypeptides because of the presence of a weaker initiator ACG codon, upstream hom the major AUG, such that the larger protein contains an N-terminal extension. Like the human isoforms, DRAC-PKs possess a novel signaling region, the pleckstrin homology domain. DRAG-PH proteins have a similar expression pattern, being regulated both maternally and zygotically, and are expressed throughout Drosophila development. Antisera specific for recombinant DRAG-PR and for its C terminus detected two polypeptides of 66 and 85 kDa in Drosophila extracts. The antirecombinant antisera also recognized a polypeptide of 120 kDa from Drosophila, which apparently shared an epitope related to DRAG-PH sequences. The role of p120 appears to be restricted compared with that of DRAG-PH, since it was not detected in larvae or adult flies. There was no spatial restriction of DRAG-PH expression during embryogenesis, suggesting that localized activation might be a regulatory mechanism for its function. DRAG-PH possesses an intrinsic kinase activity that is similar to 8-fold higher in adult flies than in 0-3-h embryos undergoing rapid mitotic cycles.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND; CIBA GEIGY LTD, BIOTECHNOL, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; University of Basel; Novartis			Grossniklaus, Ueli/A-2736-2012; Grossniklaus, Ueli/E-9995-2016	Grossniklaus, Ueli/0000-0002-0522-8974; Schier, Alexander Franz/0000-0001-7645-5325				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BIGS WH, 1992, P NATL ACAD SCI USA, V89, P6295; BOECK R, 1992, J VIROL, V66, P1765, DOI 10.1128/JVI.66.3.1765-1768.1992; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYD L, 1993, P NATL ACAD SCI USA, V90, P9164, DOI 10.1073/pnas.90.19.9164; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESIMONE SM, 1993, MOL CELL BIOL, V13, P3641, DOI 10.1128/MCB.13.6.3641; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FRANKE TF, 1994, ONCOGENE, V9, P141; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; GUPTA KC, 1994, BIOCHEM BIOPH RES CO, V201, P567, DOI 10.1006/bbrc.1994.1739; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; INGLEY E, 1994, IN PRESS J CELL BIOC, V56, P436; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; OHSAKO S, 1993, J BIOL CHEM, V268, P2052; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; ROSENTHAL A, 1987, EMBO J, V6, P433, DOI 10.1002/j.1460-2075.1987.tb04773.x; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SIEGFRIED E, 1990, TRENDS GENET, V6, P357, DOI 10.1016/0168-9525(90)90277-D; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; SUGAYA R, 1994, J BIOCHEM, V115, P150, DOI 10.1093/oxfordjournals.jbchem.a124292; SUGIHARA H, 1990, J BIOL CHEM, V265, P21714; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WINICK J, 1993, DEVELOPMENT, V119, P1055; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160	72	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4066	4075		10.1074/jbc.270.8.4066	http://dx.doi.org/10.1074/jbc.270.8.4066			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876156	hybrid			2022-12-25	WOS:A1995QH68800089
J	CHEN, ZQ; LEFEBVRE, D; BAI, XH; REAUME, A; ROSSANT, J; LYE, SJ				CHEN, ZQ; LEFEBVRE, D; BAI, XH; REAUME, A; ROSSANT, J; LYE, SJ			IDENTIFICATION OF 2 REGULATORY ELEMENTS WITHIN THE PROMOTER REGION OF THE MOUSE CONNEXIN-43 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP JUNCTION PROTEIN; MAMMALIAN-CELLS; MESSENGER-RNA; EXPRESSION; RAT; COMMUNICATION; TRANSCRIPTION; PROGESTERONE; PREGNANCY; ESTROGEN	To define the minimal sequences required for expression of the connexin 43 gene (cx43) in myometrial cells, we generated 5' deletion constructs of a fragment extending 1686 base pairs upstream and 162 base pairs downstream of the transcription start site and determined their ability to drive expression of the chloramphenicol acetyltransferase reporter gene in transfected myometrial cell lines, Our investigation revealed two cis-acting regulatory elements within this fragment, Deletion of a region extending from -102 to -92 led to an increase of the promoter activity by greater than 10-fold, indicating a presence of a repressor element, Deletion of a region extending from -72 to -62 caused a decrease of the promoter activity of a similar extent, implying the existence of a positive element, Electrophoretic mobility shift assays demonstrated that synthetic oligonucleotides derived from these two small regions can each bind with a nuclear protein(s) prepared from myometrial cells, and an introduction of three and two base substitutions into each of these oligomers was sufficient to abolish their protein binding capability, These same mutations, when incorporated in the chloramphenicol acetyltransferase constructs, diminished regulatory functions of the negative and positive elements, and the protein(s) that bind to these functional elements was found in several tissues known to express cx43 gene,	UNIV TORONTO, DEPT OBSTET & GYNAECOL, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, DEPT MED & MOLEC GENET, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University of Toronto	CHEN, ZQ (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAM DEV & FETAL HLTH, 600 UNIV AVE, TORONTO, ON M5G 1X5, CANADA.		Lye, Stephen J/E-7269-2013	Lye, Stephen J/0000-0002-3305-4406				BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; CHOW L, 1994, AM J OBSTET GYNECOL, V170, P788, DOI 10.1016/S0002-9378(94)70284-5; DELEON JR, 1994, J MOL CELL CARDIOL, V26, P379, DOI 10.1006/jmcc.1994.1047; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; GARFIELD RE, 1988, ONSET LABOR CELLULAR, P55; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM F, 1978, VIROLOGY, V52, P456; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIRKMAN H, 1970, CANCER RES, V30, P794; LANG LM, 1991, AM J PHYSIOL, V260, pE787, DOI 10.1152/ajpendo.1991.260.5.E787; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LI ZY, 1993, AM J PHYSIOL, V265, pG911, DOI 10.1152/ajpgi.1993.265.5.G911; LOK S, 1989, NUCLEIC ACIDS RES, V17, P3563, DOI 10.1093/nar/17.9.3563; LYE SJ, 1993, ENDOCRINOLOGY, V132, P2380, DOI 10.1210/en.132.6.2380; MCNUTT CM, 1994, J ENDOCRINOL, V141, P195, DOI 10.1677/joe.0.1410195; MEAKIN SO, 1989, EXP EYE RES, V48, P131, DOI 10.1016/0014-4835(89)90026-2; MEHTA PP, 1992, MOL BIOL CELL, V3, P839, DOI 10.1091/mbc.3.8.839; PEREZREYES N, 1992, P NATL ACAD SCI USA, V89, P1224, DOI 10.1073/pnas.89.4.1224; PETROCELLI T, 1993, ENDOCRINOLOGY, V133, P284, DOI 10.1210/en.133.1.284; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; RISEK B, 1991, DEVELOPMENT, V113, P165; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SULLIVAN R, 1993, GENE, V130, P191, DOI 10.1016/0378-1119(93)90419-4; VALDIMARSSON G, 1991, MOL REPROD DEV, V30, P18, DOI 10.1002/mrd.1080300103; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175; WIESEN JF, 1993, ENDOCRINOLOGY, V133, P741, DOI 10.1210/en.133.2.741; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WINTERHAGER E, 1991, EUR J CELL BIOL, V55, P133; YU W, 1994, P ROY SOC B-BIOL SCI, V255, P125, DOI 10.1098/rspb.1994.0018	30	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3863	3868		10.1074/jbc.270.8.3863	http://dx.doi.org/10.1074/jbc.270.8.3863			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876131	hybrid			2022-12-25	WOS:A1995QH68800061
J	PAN, M; STEVENS, BR				PAN, M; STEVENS, BR			DIFFERENTIATION-DEPENDENT AND PROTEIN KINASE-C-DEPENDENT REGULATION OF ALANINE TRANSPORT VIA SYSTEM-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; BORDER MEMBRANE-VESICLES; CELL-LINE CACO-2; INTESTINE; COLON; POTENT	The regulation of sodium-dependent L-alanine transport is described for the first time in intestinal cells, Substrate analogue inhibition patterns and Dixon analyses indicated that uptake occurred via transport system B, an epithelial cell variant of systems B-0,B-+ and ASC. System B served > 95% of the Na+-dependent alanine uptake in both undifferentiated (2 days postpassaging) and differentiated (> 9 days postpassaging) states of the human Caco-2 cultured intestinal cell line. (Methylamino)isobutyric acid-inhibitable system A transport accounted for < 5% of total alanine uptake. System B activity was greater in undifferentiated cells compared with the differentiated state, and activity at any differentiation state was stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA), The maximal stimulation, determined by TPA dose-response/exposure time data, was attributable to a change in cell transport capacity (V-max), with K-m unaffected. The V-max of system B was greater in 9-day-old cells (2.79 +/- 0.21 nmol min(-1) mg of protein(-1); K-m = 164 +/- 26 mu M alanine), decreasing to V-max = 0.51 +/- 0.03 nmol min(-1) mg of protein(-1) (K-m = 159 +/- 14 mu M) in 9-day-old cells. Regardless of differentiation status, the sodium-activation Hill coefficient was 1.06 +/- 0.10, and the alanine passive diffusion permeability coefficient was 0.53 +/- 0.08 mu l min(-1) mg of protein(-1). Phorbol ester up-regulated the V-max of system B in 2-day-old cells to V-max = 6.32 +/- 0.37 nmol min(-1) mg of protein(-1) (K-m = 169 +/- 18 mu M), and in 9-day-old cells to V-max = 1.42 +/- 0.05 nmole min(-1) mg of protein(-1) (K-m = 180 +/- 10 mu M). Phorbol ester stimulation of transport occurred after at least 6 h of continual exposure, and was blocked by the protein kinase C inhibitors chelerythrine or photoactivated calphostin C. Protein synthesis inhibitors cycloheximide and actinomycin D each blocked the phorbol ester upregulation of system B activity. It is concluded that Caco-2 cells regulate carrier-mediated sodium-dependent transport of L-alanine by changing the membrane capacity to transport alanine via system B and that this regulation involves de novo protein synthesis under the control of protein kinase C.	UNIV FLORIDA,COLL MED,DEPT PHYSIOL,GAINESVILLE,FL 32610	State University System of Florida; University of Florida								BERTRAN J, 1994, CELL PHYSIOL BIOCHEM, V4, P217, DOI 10.1159/000154728; BLAIS A, 1987, J MEMBRANE BIOL, V99, P113, DOI 10.1007/BF01871231; BRANDSCH M, 1994, BIOCHEM J, V299, P253, DOI 10.1042/bj2990253; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BUDDINGTON RK, 1990, AM J PHYSIOL, V259, pG544, DOI 10.1152/ajpgi.1990.259.4.G544; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; DIAMOND J, 1991, NEWS PHYSIOL SCI, V6, P92, DOI 10.1152/physiologyonline.1991.6.2.92; GERENCSER GA, 1994, J EXP BIOL, V196, P59; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; KARASOV WH, 1989, ADAPTATION DEV GASTA, P157; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KOEPSELL H, 1994, CELL PHYSIOL BIOCHEM, V4, P206, DOI 10.1159/000154727; KONG CT, 1993, J BIOL CHEM, V268, P1509; MACKENZIE B, 1994, J BIOL CHEM, V269, P22488; MAENZ DD, 1992, J BIOL CHEM, V267, P22079; MAILLIARD M, 1995, IN PRESS GASTROENTER; MALO C, 1991, GASTROENTEROLOGY, V100, P1644, DOI 10.1016/0016-5085(91)90664-7; PINTO M, 1983, BIOL CELL, V47, P323; SALLOUM RM, 1991, AM J PHYSIOL, V261, pG22, DOI 10.1152/ajpgi.1991.261.1.G22; SALLOUM RM, 1990, J SURG RES, V48, P635, DOI 10.1016/0022-4804(90)90244-V; SEGAL IH, 1976, BIOCH CALCULATIONS, P441; SOUBA WW, 1992, BIOCHEM BIOPH RES CO, V188, P746, DOI 10.1016/0006-291X(92)91119-B; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; STEVENS BR, 1992, AM J PHYSIOL, V263, pR458, DOI 10.1152/ajpregu.1992.263.3.R458; STEVENS BR, 1992, MAMMALIAN AMINO ACID; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; VANWINKLE LJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P173, DOI 10.1016/0304-4157(88)90024-X	28	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3582	3587		10.1074/jbc.270.8.3582	http://dx.doi.org/10.1074/jbc.270.8.3582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876094	hybrid			2022-12-25	WOS:A1995QH68800021
J	POKRYWKA, NJ; GOLDFARB, DS				POKRYWKA, NJ; GOLDFARB, DS			NUCLEAR EXPORT PATHWAYS OF TRANSFER-RNA AND 40-S RIBOSOMES INCLUDE BOTH COMMON AND SPECIFIC INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BINDING-PROTEIN; XENOPUS-OOCYTES; PORE COMPLEX; TRANSPORT; SIGNALS; TRANSLOCATION; IMPORT; CELL	Different classes of RNAs are exported from Xenopus laevis oocyte nuclei by facilitated pathways. We have performed kinetic competition analyses to investigate the relationship between the export pathways of microinjected tRNA and ribosomal subunits. Saturating concentrations of ribosomal subunits do not compete tRNA export. Thus, the saturable factor in the ribosomal subunit export pathway is not limiting for tRNA export. The co-microinjection of ribosomal subunits did, however, stimulate the rate of tRNA export. Co-injected mRNA also stimulated tRNA export. tRNA export itself displays positive cooperative export kinetics that are abrogated by saturating concentrations of rRNA. These results are consistent with the existence of common high affinity RNA-binding sites that can be titrated with tRNA, rRNA or ribosomal subunits, and mRNA. Furthermore, high concentrations of tRNA are also shown to have moderate inhibitory effects on 40 S subunit export, indicating a lower affinity common intermediate also shared by mRNA.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	University of Rochester								ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; CALZONE FJ, 1982, NUCLEIC ACIDS RES, V10, P2145, DOI 10.1093/nar/10.6.2145; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DELPOZZO G, 1994, J MOL BIOL, V240, P193, DOI 10.1006/jmbi.1994.1435; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HASELBECK RC, 1993, BIOCHEMISTRY-US, V32, P8575, DOI 10.1021/bi00084a026; HE XP, 1994, J CELL SCI, V107, P903; HUANG S, 1994, J CELL BIOL, V126, P877, DOI 10.1083/jcb.126.4.877; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KHANNAGUPTA A, 1989, P NATL ACAD SCI USA, V86, P1791, DOI 10.1073/pnas.86.6.1791; Krug RM, 1993, CURR OPIN CELL BIOL, V5, P944, DOI 10.1016/0955-0674(93)90074-Z; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; Maquat LE, 1991, CURR OPIN CELL BIOL, V3, P1004, DOI 10.1016/0955-0674(91)90121-E; MELCHIOR F, 1993, J CELL BIOL, V269, P9289; MICHAUD N, 1993, EXP CELL RES, V208, P128, DOI 10.1006/excr.1993.1230; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHEER U, 1988, NUCLEOCYTOPLASMIC TR, P5; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; TOBIAN JA, 1985, CELL, V43, P415, DOI 10.1016/0092-8674(85)90171-0; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	38	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3619	3624		10.1074/jbc.270.8.3619	http://dx.doi.org/10.1074/jbc.270.8.3619			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876098	hybrid			2022-12-25	WOS:A1995QH68800026
J	YEO, EJ; EXTON, JH				YEO, EJ; EXTON, JH			STIMULATION OF PHOSPHOLIPASE-D BY EPIDERMAL GROWTH-FACTOR REQUIRES PROTEIN-KINASE-C ACTIVATION IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE-DERIVED DIACYLGLYCEROL; PHORBOL 12-MYRISTATE 13-ACETATE; INOSITOL-LIPID HYDROLYSIS; GTP-BINDING PROTEIN; HUMAN-NEUTROPHILS; PERTUSSIS TOXIN; FACTOR RECEPTOR; ALPHA-THROMBIN; FATTY-ACIDS; D PATHWAY	The proposal that epidermal growth factor (EGF) activates phospholipase D (PLD) by a mechanism(s) not involving phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) hydrolysis was examined in Swiss 3T3 fibroblasts. EGF, basic fibroblast growth factor (bFGF), bombesin, and platelet-derived growth factor (PDGF) activated PLD as measured by transphosphatidylation of butanol to phosphatidylbutanol. The increase in inositol phosphates induced by bFGF, EGF, or bombesin was significantly enhanced by Re-31-8220, an inhibitor of protein kinase C (PKC), suggesting that PtdIns(4,5)P-2-hydrolyzing phospholipase is coupled to the receptors for these agonists but that the response is downregulated by PI(C. Activation of PLD by EGF was inhibited dose dependently by the PKC inhibitors bisindolylnaleimide and Re-31-8220, which also inhibited the effects of bFGF, bombesin, and PDGF. Downregulation of PRC by prolonged treatment with 4 beta-phorbol 12-myristate 13-acetate also abolished EGF- and PDGF-stimulated phosphatidylbutanol formation. EGF and bombesin induced biphasic translocations of PKC delta and epsilon to the membrane that were detectable at 15 s. In the presence of Re-31-8220, translocation of PKC alpha became evident, and membrane association of the delta- and E-isozymes was enhanced and/or sustained in response to the two agonists. The inhibitor also enhanced EGF-stimulated [H-3]diacylglycerol formation in cells preincubated with [H-3]arachidonic acid, which labeled predominantly phosphatidylinositol, but inhibited [H-3]diacylglycerol production in cells preincubated with [H-3]myristic acid, which labeled mainly phosphatidylcholine. These data support the conclusion that EGF can stimulate diacylglycerol formation from PtdIns(4,5)P-2 and that PKC performs the dual role of down-regulating this response as well as mediating phosphatidylcholine hydrolysis. In summary, all of the results of the study indicate that PLD activation by EGF is downstream of PtdIns(4,5)P-2-hydrolyzing phospholipase and is dependent upon subsequent PKC activation.	VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOLEC BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040919] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-40919] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGWU DE, 1991, J IMMUNOL, V146, P3895; AHMED A, 1994, AM J PHYSIOL, V266, pC206, DOI 10.1152/ajpcell.1994.266.1.C206; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BALBOA MA, 1992, J EXP MED, V176, P9, DOI 10.1084/jem.176.1.9; BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BESTERMAN JM, 1986, J BIOL CHEM, V261, P723; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRISCOE CP, 1994, BIOCHEM J, V298, P61, DOI 10.1042/bj2980061; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P265, DOI 10.1016/0167-4889(91)90166-U; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; ELDAR H, 1993, J BIOL CHEM, V268, P12560; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; HA KS, 1993, J BIOL CHEM, V268, P10534; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG CF, 1990, J BIOL CHEM, V265, P14858; JOHNSON RM, 1987, J BIOL CHEM, V262, P17285; KANAHO Y, 1992, J BIOL CHEM, V267, P23554; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LALLEMAIN G, 1986, FEBS LETT, V197, P344, DOI 10.1016/0014-5793(86)80354-4; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LEE LS, 1979, P NATL ACAD SCI USA, V76, P5168, DOI 10.1073/pnas.76.10.5168; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LYNCH CJ, 1985, J BIOL CHEM, V260, P2844; MCKINNON M, 1994, BBA-MOL CELL RES, V1222, P109, DOI 10.1016/0167-4889(94)90031-0; MOEHREN G, 1994, J BIOL CHEM, V269, P838; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PAI JK, 1991, CELL REGUL, V2, P897, DOI 10.1091/mbc.2.11.897; PFEILSCHIFTER J, 1993, FEBS LETT, V331, P267, DOI 10.1016/0014-5793(93)80350-4; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; PRICE BD, 1989, BIOCHEM J, V264, P509, DOI 10.1042/bj2640509; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SIMPSON CMF, 1987, NEUROCHEMISTRY PRACT, P193; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; SONG JG, 1994, CELL GROWTH DIFFER, V5, P79; SWENDSEN CL, 1987, BIOCHIM BIOPHYS ACTA, V919, P79, DOI 10.1016/0005-2760(87)90220-7; TAKAYAMA H, 1987, BIOCHIM BIOPHYS ACTA, V922, P314; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WAHL M, 1988, J BIOL CHEM, V263, P7581; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YEO EJ, 1994, J BIOL CHEM, V269, P27823	64	143	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3980	3988		10.1074/jbc.270.8.3980	http://dx.doi.org/10.1074/jbc.270.8.3980			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876145	hybrid			2022-12-25	WOS:A1995QH68800078
J	YOUNG, EC; BERLINER, E; MAHTANI, HK; PEREZRAMIREZ, B; GELLES, J				YOUNG, EC; BERLINER, E; MAHTANI, HK; PEREZRAMIREZ, B; GELLES, J			SUBUNIT INTERACTIONS IN DIMERIC KINESIN HEAVY-CHAIN DERIVATIVES THAT LACK THE KINESIN ROD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; DROSOPHILA KINESIN; ELECTRON-MICROSCOPY; EXPRESSION; IDENTIFICATION; MICROTUBULES; MOTILITY; SEQUENCE; MOVEMENT; PROTEIN	The N-terminal residues of the two heavy chains of the motor enzyme kinesin form two globular ''heads''; the heads are attached to a ''rod'' domain which is a two-stranded cu-helical colied-coli, Interaction between the heads is thought to be important to kinesin function, The rod may not be necessary for head-head interactions because a heavy chain N-terminal fragment containing only residues from the head and adjacent region forms dimers (Huang, T,-G,, Suhan, J,, and Hackney, D, D, (1994) J, Biol. Chem. 269, 16502-16507), However, the nature and stability of the subunit-subunit interactions in such derivatives are unclear, To examine the physical properties of heavy chain interaction in and near the head domains, we characterized the self-association behavior of two dimeric kinesin derivatives predicted (Lupas, k, van Dyke, Ri., and Stock, J, (1991) Science 252, 1162-1164) to lack the rod, Derivative K448-BIO contains the 448 N-terminal residues of Drosophila kinesin heavy chain fused at the C terminus to a a-residue Linker and a C-terminal fragment from Escherichia coli biotin carboxyl carrier protein; derivative K448-L is the same except that it lacks the biotin carboxyl carrier protein fragment, Both derivatives expressed in insect cells display microtubule-stimulated ATPase activity; K448-BIO also displays microtubule motility, Equilibrium sedimentation and gel filtration indicate that purified K448-BIO and H448-L at 0.02-0.4 mg/ml form homogeneous solutions of homodimers with no detectable formation of monomers or higher order oligomers, Derivative self-association is non covalent but extremely stable with an association constant greater than or equal to 2 x 10(8) M(-1). Stable subunit-subunit association induced by structures in and near the kinesin heads may be necessary for full mechanochemical function.	BRANDEIS UNIV, GRAD DEPT BIOCHEM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, BIOPHYS PROGRAM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA	Brandeis University; Brandeis University; Brandeis University				Young, Edgar C./0000-0002-8453-088X				AMOS LA, 1987, J CELL SCI, V87, P105; BERLINER E, 1994, J BIOL CHEM, V269, P8610; BERLINER E, 1995, IN PRESS NATURE; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGLANDER SW, 1965, ANAL BIOCHEM, V12, P579, DOI 10.1016/0003-2697(65)90225-3; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GELLES J, 1995, IN PRESS BIOPHYS J; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HENRIKSON KP, 1979, ANAL BIOCHEM, V94, P366, DOI 10.1016/0003-2697(79)90374-9; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SHEARWIN KE, 1994, BIOCHEMISTRY-US, V33, P885, DOI 10.1021/bi00170a006; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VANHOLDE KE, 1985, PHYSICAL BIOCH, P124; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	47	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3926	3931		10.1074/jbc.270.8.3926	http://dx.doi.org/10.1074/jbc.270.8.3926			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876139	hybrid			2022-12-25	WOS:A1995QH68800070
J	DEB, A; BHATTACHARYYA, D; DAS, J				DEB, A; BHATTACHARYYA, D; DAS, J			A 25-KDA BETA-LACTAM-INDUCED OUTER-MEMBRANE PROTEIN OF VIBRIO-CHOLERAE - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; POLYACRYLAMIDE GELS; CELLS; ANTIBIOTICS; RESOLUTION; MUTANTS; PORIN	A 25-kDa outer membrane protein, induced following treatment of Vibrio cholerae cells with beta-lactam antibiotics and constituting about 8-10% of the total outer membrane proteins of beta-lactam-resistant mutants, has been purified to homogeneity. It is a basic (pI 8.5) protein rich in beta-sheet structure and is a homodimer, the monomers being held together by hydrophobic interactions. The effective hydrophobicity of the protein is low, and a large part of the protein is exposed on the surface of the outer membrane. The protein does not have beta-lactamase or autolytic activity and is not a penicillin-binding protein. The Stoke's radius of the 25-kDa protein (26 A) is comparable to the pore size of the V. cholerae OmpF-like porin. Proteoliposome swelling assay showed that the 25-kDa protein might block the pores of OmpF through which beta-lactam antibiotics normally enter the cells. Twenty-two amino acid residues from the N-terminal end of the 25-kDa protein have been sequenced, and a 32-mer oligonucleotide probe was synthesized using the amino acid residues 2-12. This probe was used to identify the gene encoding the 25-kDa protein. The beta-lactam-resistant cells are insensitive to changes in the osmolarity of the growth medium in contrast to the wild type cells which exhibit osmoregulation of OmpF and OmpC synthesis. All beta-lactam-resistant mutants examined are resistant to novobiocin.	INDIAN INST CHEM BIOL, DEPT BIOPHYS, Kolkata 700032, W BENGAL, INDIA; INDIAN INST CHEM BIOL, DIV PROT ENGN, Kolkata 700032, W BENGAL, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)								CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CHAKRABARTI D, 1984, J GEN MICROBIOL, V130, P2023; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; HALES BA, 1985, J ANTIMICROB CHEMOTH, V16, P671, DOI 10.1093/jac/16.5.671; KATO A, 1980, BIOCHIM BIOPHYS ACTA, V624, P13, DOI 10.1016/0005-2795(80)90220-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHIA A, 1984, J GEN MICROBIOL, V130, P2027; LOHIA A, 1985, J BACTERIOL, V163, P1158, DOI 10.1128/JB.163.3.1158-1166.1985; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAUL S, 1992, J GEN MICROBIOL, V138, P755, DOI 10.1099/00221287-138-4-755; PRESTIDGE LS, 1957, J BACTERIOL, V74, P48, DOI 10.1128/JB.74.1.48-59.1957; ROY NK, 1982, J GEN MICROBIOL, V128, P349; SAMMONS DW, 1981, ELECTROPHORESIS, V2, P135, DOI 10.1002/elps.1150020303; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIFFERLI DM, 1988, ANTIMICROB AGENTS CH, V32, P1609, DOI 10.1128/AAC.32.11.1609; SCHOENLE EJ, 1984, J BIOL CHEM, V259, P2112; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; SENGUPTA TK, 1990, BIOCHEM BIOPH RES CO, V171, P1175, DOI 10.1016/0006-291X(90)90808-Z; SENGUPTA TK, 1992, ANTIMICROB AGENTS CH, V36, P788, DOI 10.1128/AAC.36.4.788; SIEHNEL R, 1990, MOL MICROBIOL, V4, P831, DOI 10.1111/j.1365-2958.1990.tb00653.x; SUGARMAN B, 1979, J INFECT DIS, V140, P622, DOI 10.1093/infdis/140.4.622; SUKUPOLVI S, 1989, BIOCHIM BIOPHYS ACTA, V988, P377, DOI 10.1016/0304-4157(89)90011-7; TAI PC, 1985, ANAL BIOCHEM, V144, P199, DOI 10.1016/0003-2697(85)90105-8; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2	30	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2914	2920		10.1074/jbc.270.7.2914	http://dx.doi.org/10.1074/jbc.270.7.2914			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852369	hybrid			2022-12-25	WOS:A1995QG47100008
J	ANTELMAN, D; MACHEMER, T; HUYGHE, BG; SHEPARD, HM; MANEVAL, D; JOHNSON, DE				ANTELMAN, D; MACHEMER, T; HUYGHE, BG; SHEPARD, HM; MANEVAL, D; JOHNSON, DE			INHIBITION OF TUMOR-CELL PROLIFERATION IN-VITRO AND IN-VIVO BY EXOGENOUS P110(RB), THE RETINOBLASTOMA TUMOR-SUPPRESSOR PROTEIN	ONCOGENE			English	Article						RETINOBLASTOMA; TUMOR SUPPRESSOR; PROTEIN THERAPY	BLADDER-CARCINOMA CELLS; RB GENE SUPPRESSES; SUSCEPTIBILITY GENE; GROWTH SUPPRESSION; ALTERED EXPRESSION; CANCER-CELLS; LUNG-CANCER; TAT PROTEIN; G1 PHASE; PRODUCT	Reconstitution of retinoblastoma gene (RE) deficient tumor cells with RE generally leads to growth suppression in vitro and/or reduced tumorigenicity in nude mice. An alternate approach to gene replacement is the delivery of the RE gene product (p110(RB)) into cells lacking its expression. In this report we demonstrate that exogenously added p110(RB) is taken up by and localized to the nucleus of cultured cells and has growth suppression properties similar to endogenous RE. RE-negative (RB(neg)) tumor cells are preferentially growth inhibited while most RE-positive (RB(pos)) tumor cells and normal cells are much less sensitive. We have extended these studies to relevant nude mouse xenograft models for human lung cancer. Local or systemic administration of p110(RB) inhibits armor growth in treated animals. These results represent the first use of a tumor suppressor protein as a potential cancer therapeutic.			ANTELMAN, D (corresponding author), CANJI INC,3030 SCI PK RD,SUITE 310,SAN DIEGO,CA 92121, USA.							AURUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334; BAILYES EM, 1982, BIOCHEM J, V203, P245, DOI 10.1042/bj2030245; BANERJEE A, 1992, CANCER RES, V52, P6297; BODYCOTE J, 1986, P NATL ACAD SCI USA, V83, P4749, DOI 10.1073/pnas.83.13.4749; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOOKSTEIN R, 1990, MOL CELL BIOL, V9, P1628; CASEY G, 1991, ONCOGENE, V6, P1791; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; FUNG YKT, 1993, ONCOGENE, V8, P2659; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KORNBLAU SM, 1994, CANCER RES, V54, P242; KORNBLAU SM, 1992, CANCER RES, V52, P4587; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; NEVINS JR, 1992, SCIENCE, V258, P424; OLDHAM KG, 1971, ANAL BIOCHEM, V44, P143, DOI 10.1016/0003-2697(71)90355-1; OOKAWA K, 1993, ONCOGENE, V8, P2175; PEREZ F, 1992, J CELL SCI, V102, P717; PITKANEN K, 1993, EXP CELL RES, V207, P99, DOI 10.1006/excr.1993.1167; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; REISSMANN PT, 1993, ONCOGENE, V8, P1913; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHIMIZU E, 1994, ONCOGENE, V9, P2441; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WANG NP, 1993, ONCOGENE, V8, P279; WEN SF, 1994, J IMMUNOL METHODS, V169, P231, DOI 10.1016/0022-1759(94)90267-4; XU HJ, 1993, INT J CANCER, V53, P781, DOI 10.1002/ijc.2910530513; YONEMURA Y, 1993, INT J ONCOL, V3, P71; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	51	18	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					697	704						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862447				2022-12-25	WOS:A1995QH61200009
J	NIINO, YS; CHAKRABORTY, S; BROWN, BJ; MASSEY, V				NIINO, YS; CHAKRABORTY, S; BROWN, BJ; MASSEY, V			A NEW OLD YELLOW ENZYME OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; SEQUENCE; EXPRESSION; CLONING; OXIDASE; CONSTANTS; PROTEINS; RNA	In 1993, the first gene of Old Yellow Enzyme (OYE) of Saccharomyces cerevisiae was cloned (Stott, K,, Saito, K,, Thiele, D. J,, and Massey, V, (1993) J, Biol, Chem, 268, 6097-6106) and named OYE2 to distinguish it from the first OYE gene cloned from Saccharomyces carlsbergenesis (Saito, K,, Thiele, D, J,, Davio, M,, Lockridge, O., and Massey, V, (1991) J, Biol, Chem, 266, 20720-20724), The analysis of an OYE2 deletion mutant suggested that S, cerevisiae had at least two OYE genes. In the present study, we cloned a new OYE species named OYE3 and analyzed the OYE3 protein expressed in Escherichia coli, OYE3 consists of 400 amino acid residues and its molecular mass calculated by electrospray mass spectrometry is 44,788 daltons, in good agreement with the value of 44,920 daltons predicted from the amino acid sequence derived from the DNA sequence, In the downstream region of the OYE3 gene, the cytochrome oxidase (COX10) gene exists with a 426-base pair intermediate sequence, Some of the physicochemical and kinetic properties of OYE2 and OYE3 have been determined. Although the two enzymes are clearly closely related, they show differences in ligand binding properties and in their catalytic activities with oxygen and cyclohexen-2-one as accepters.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00042] Funding Source: Medline; NIGMS NIH HHS [GM 11106] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ AS, 1975, J BIOL CHEM, V251, P5321; BEINERT WD, 1985, EUR J BIOCHEM, V152, P573, DOI 10.1111/j.1432-1033.1985.tb09234.x; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BOYED G, 1992, FEBS LETT, V308, P271; Bright H.B., 1975, ENZYMES, V12B, P421; Brown BJ, 1994, FLAVINS AND FLAVOPROTEINS 1993, P391; CIGAN AM, 1987, GENE, V59, P1; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; DONAHUE TF, 1990, METHOD ENZYMOL, V185, P366; FELDMAN D, 1984, P NATL ACAD SCI-BIOL, V81, P4722, DOI 10.1073/pnas.81.15.4722; FISH KM, 1990, J BIOL CHEM, V265, P19665; Fox KM, 1994, FLAVINS AND FLAVOPROTEINS 1993, P381; FRANKLUND CV, 1993, J BACTERIOL, V175, P3002, DOI 10.1128/JB.175.10.3002-3012.1993; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HENIKOFF S, 1983, CELL, V33, P607, DOI 10.1016/0092-8674(83)90441-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU XL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P187, DOI 10.1016/0167-4781(93)90113-R; MADANI ND, 1994, P NATL ACAD SCI USA, V91, P922, DOI 10.1073/pnas.91.3.922; MALLONEE DH, 1990, J BACTERIOL, V172, P7011, DOI 10.1128/jb.172.12.7011-7019.1990; MASSEY V, 1986, J BIOL CHEM, V261, P1215; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; Massey V, 1994, FLAVINS AND FLAVOPROTEINS 1993, P371; MIURA R, 1986, J BIOCHEM-TOKYO, V99, P901, DOI 10.1093/oxfordjournals.jbchem.a135551; NAKAMURA T, 1965, J BIOCHEM, V57, P554, DOI 10.1093/oxfordjournals.jbchem.a128114; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; SAIKI RK, 1993, SCIENCE, V239, P487; SAITO K, 1991, J BIOL CHEM, V266, P20720; Sambrook J, 1989, MOL CLONING LABORATO; SCHOPFER LM, 1991, STUDY ENZYMES, V2, P247; SHERMAN F, 1986, LABORATORY COURSE MA; STOTT K, 1993, J BIOL CHEM, V268, P6097; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA S, 1989, CELL, V57, P675, DOI 10.1016/0092-8674(89)90136-0; Theorell H, 1935, BIOCHEM Z, V275, P344; Warburg O, 1933, BIOCHEM Z, V266, P377; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	39	103	113	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					1983	1991		10.1074/jbc.270.5.1983	http://dx.doi.org/10.1074/jbc.270.5.1983			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836424	hybrid			2022-12-25	WOS:A1995QE49300004
J	DYCK, JRB; SILVA, NLCL; FLIEGEL, L				DYCK, JRB; SILVA, NLCL; FLIEGEL, L			ACTIVATION OF THE NA+/H+ EXCHANGER GENE BY THE TRANSCRIPTION FACTOR AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACETYL-COA CARBOXYLASE; NA/H ANTIPORTER; PROMOTER SEQUENCES; INSULIN INDUCTION; BINDING-PROTEINS; CAMP ACTION; EXPRESSION; CELLS; ACID	We have isolated and characterized regions important for expression of the mouse Na+/H+ exchanger gene. A 1.1-kilobase fragment upstream of the 5'-untranslated region contains specific DNA moths characteristic of promoter and enhancer elements including a TATA box two CAAT boxes, an SP-1 site, a cyclic AMP response element-binding site, and an AP-2-like site. This 1.1-kilobase fragment directs transcription of a luciferase reporter gene in mouse fibroblasts (NIH 3T3) and human Hep G2 cells, Deletion or mutation of an AP-2-like site 100 base pairs from the start site of transcription resulted in loss of most of the reporter plasmid activity. In addition, cotransfection of an AP-2 expression plasmid and the mouse promoter/luciferase plasmid increased the amount of Na+/H+ exchanger-directed transcription in AP-2-deficient Hep G2 cells, Moreover, mobility shift analysis indicated that a putative AP-2-binding site is capable of binding purified AP-2 protein and a specific protein from nuclear extracts of NIH 3T3 cells. The results show that the transcription factor AP-2 may play an important role in regulation of transcription of the mouse Na+/H+ exchanger gene.	UNIV ALBERTA,FAC MED,DEPT PEDIAT,CARDIOVASC DIS RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,FAC MED,DEPT BIOCHEM,CARDIOVASC DIS RES GRP,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta				Dyck, Jason/0000-0002-7045-2884				ARGENTIN S, 1991, J BIOL CHEM, V266, P23315; BORON WF, 1993, J GEN PHYSIOL, V81, P29; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DYCK JRB, 1992, FEBS LETT, V310, P255, DOI 10.1016/0014-5793(92)81343-K; FENSTERMAKER RA, 1989, MOL ENDOCRINOL, V3, P1070, DOI 10.1210/mend-3-7-1070; FLIEGEL L, 1993, MOL CELL BIOCHEM, V125, P137, DOI 10.1007/BF00936442; FLIEGEL L, 1991, FEBS LETT, V279, P25, DOI 10.1016/0014-5793(91)80241-T; FLIEGEL L, 1993, BIOCHEM J, V296, P273, DOI 10.1042/bj2960273; GRINSTEIN S, 1983, J GEN PHYSIOL, V82, P619, DOI 10.1085/jgp.82.5.619; HORIE S, 1992, P NATL ACAD SCI USA, V89, P5236, DOI 10.1073/pnas.89.12.5236; HORIE S, 1992, J CLIN INVEST, V89, P365, DOI 10.1172/JCI115594; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KOLYADA AY, 1994, BBA-GENE STRUCT EXPR, V1217, P54; MILLER RT, 1991, J BIOL CHEM, V266, P10813; MILLER RT, 1987, J BIOL CHEM, V262, P9115; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MOE OW, 1991, J CLIN INVEST, V88, P1703, DOI 10.1172/JCI115487; PARK K, 1993, J BIOL CHEM, V268, P17811; PARK KR, 1991, J BIOL CHEM, V266, P12249; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; RAO GN, 1992, J CELL PHYSIOL, V151, P361, DOI 10.1002/jcp.1041510217; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	25	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1375	1381		10.1074/jbc.270.3.1375	http://dx.doi.org/10.1074/jbc.270.3.1375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836405	hybrid			2022-12-25	WOS:A1995QB15600060
J	PAPINI, E; ROSSETTO, O; CUTLER, DF				PAPINI, E; ROSSETTO, O; CUTLER, DF			VESICLE-ASSOCIATED MEMBRANE-PROTEIN (VAMP) SYNAPTOBREVIN-2 IS ASSOCIATED WITH DENSE CORE SECRETORY GRANULES IN PC12 NEUROENDOCRINE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL-MEDULLARY CELLS; SYNAPTIC VESICLE; TETANUS-TOXIN; CATECHOLAMINE RELEASE; SYNAPTOBREVIN; BIOGENESIS; NEUROTOXICITY; RECEPTORS; CLEAVAGE; SURFACE	The presence and intracellular distribution of vesicle-associated membrane protein-1 (VAMP-1) and VAMP-2 were investigated in the PC12 neuroendocrine cell line using isotype-specific polyclonal antibodies. VAMP-2 was detected in the total membrane fraction, while VAMP-1 was undetectable. Subcellular fractionation demonstrates that a substantial amount of the VAMP-2 (24-36%) is associated with dense core, catecholamine-containing granules (DCGs). This was confirmed by immunofluorescence microscopy. The L chain of tetanus neurotoxin, known to inhibit granule mediated secretion in permeabilized PC12 cells, as well as botulinum neurotoxins F and G, effectively cleaved DCG-associated VAMP-2. These data demonstrate that VAMP-2 is present on the secretory granules of PC12 cells.	UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOL,LONDON WC1E 6BT,ENGLAND; UNIV PADUA,DIPARTIMENTO SCI BIOMED,I-35100 PADUA,ITALY	University of London; University College London; University of London; University College London; University of Padua			rossetto, ornella/AAC-3866-2022; Papini, Emanuele/AAE-6961-2022	rossetto, ornella/0000-0002-6113-3857; Papini, Emanuele/0000-0001-6033-4473; Cutler, Daniel/0000-0002-4288-7530	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bartlett S F, 1974, Methods Enzymol, V31, P379; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BITTNER MA, 1988, J NEUROCHEM, V51, P451, DOI 10.1111/j.1471-4159.1988.tb01059.x; BRAUN JEA, 1994, J BIOL CHEM, V269, P5328; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHIN AC, 1993, GENE, V131, P175, DOI 10.1016/0378-1119(93)90291-A; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; CRAMER LP, 1992, PROTEIN TARGETING PR; CUTLER DF, 1990, J CELL BIOL, V110, P721, DOI 10.1083/jcb.110.3.721; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FACCHIANO F, 1992, J BIOL CHEM, V267, P13267; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; HOHNEZELL B, 1993, FEBS LETT, V336, P175, DOI 10.1016/0014-5793(93)81635-D; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KNIGHT DE, 1982, J MEMBRANE BIOL, V68, P107, DOI 10.1007/BF01872259; KNIGHT DE, 1986, FEBS LETT, V207, P222, DOI 10.1016/0014-5793(86)81492-2; KNIGHT DE, 1985, NATURE, V317, P719, DOI 10.1038/317719a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; RALSTON E, 1994, J BIOL CHEM, V269, P15403; RINDLER M J, 1992, Current Opinion in Cell Biology, V4, P616, DOI 10.1016/0955-0674(92)90080-V; ROSSETTO O, 1992, BIOCHEM J, V285, P9, DOI 10.1042/bj2850009; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHIAVO G, 1994, J BIOL CHEM, V269, P20213; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VAITUKAITIS JL, 1981, METHOD ENZYMOL, V73, P4652	37	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1332	1336		10.1074/jbc.270.3.1332	http://dx.doi.org/10.1074/jbc.270.3.1332			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836399	hybrid			2022-12-25	WOS:A1995QB15600054
J	KHANDJIAN, EW				KHANDJIAN, EW			HEAT-TREATMENT INDUCES DEPHOSPHORYLATION OF PRB AND DISSOCIATION OF T-ANTIGEN PRB COMPLEX DURING TRANSFORMING INFECTION WITH SV40	ONCOGENE			English	Article						HEAT SHOCK; RETINOBLASTOMA; S-PHASE; T-ANTIGEN PRB COMPLEX; HSP71; PROLIFERATION	RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; LARGE-TUMOR-ANTIGEN; MOUSE KIDNEY-CELLS; SIMIAN VIRUS-40; SHOCK PROTEINS; SUSCEPTIBILITY GENE; NUCLEAR COLOCALIZATION; IMMUNOLOGICAL EVIDENCE; TRANSCRIPTION FACTOR	The effects of heat treatment on key cell cycle regulatory molecules is currently unknown. Using primary mouse kidney cell cultures induced to re-enter S-phase by transforming infection with SV40, the effects of thermal treatment on the phosphorylation state of the Retinoblastoma gene product (pRb) and on its ability to bind T-antigen were examined. Time course analysis showed no detectable inhibition of cellular protein and T-antigen synthesis up to 180 min treatment at 42.5 degrees C, while a gradual disappearance of the phosphorylated forms of pRb was observed after 90 min. Dephosphorylation of pRb was shown to correlate with inhibition of SV40-induced DNA synthesis. Also, large T-antigen/pRb protein complex was affected since a gradual dissociation of the hypophosphorylated pRb from large T-antigen was observed concomitant to the inhibition of DNA synthesis. The effects of heat treatment were found to be reversible after shifting the cultures to 37 degrees C. Cells were shown to resume DNA synthesis concomitant to the reappearance of the phosphorylated forms of pRb and rebinding of the hypophosphorylated form to large T-antigen within 6-8 h after recovery at 37 degrees C. In addition, no evidence for a bona fide hsp71/large T-antigen protein complex was seen under the experimental conditions used. The data strongly suggest that inhibition of DNA synthesis by heat treatment might involve either an increase in phosphatase activity or the inhibition of a pRb kinase activity.	UNIV LAVAL,FAC MED,DEPT BIOCHIM,QUEBEC CITY,PQ,CANADA	Laval University	KHANDJIAN, EW (corresponding author), HOP ST FRANCOIS ASSISE,UNITE RECH GENET HUMAINE & MOLEC,QUEBEC CITY,PQ G1L 3L5,CANADA.							ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; ANGELIDIS CE, 1988, EUR J BIOCHEM, V172, P27, DOI 10.1111/j.1432-1033.1988.tb13851.x; ANGHILERI LJ, 1986, HYPERTHERMIA CANCER, V1; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CURRIE RW, 1991, BIOCHEM CELL BIOL, V69, P375, DOI 10.1139/o91-057; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; DUBOIS MF, 1989, J BIOL CHEM, V264, P12165; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EHRHART JC, 1988, ONCOGENE, V3, P595; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FORTIN CA, 1994, MOL CELL BIOL, V72, P239; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLOVER CVC, 1982, P NATL ACAD SCI-BIOL, V79, P1781, DOI 10.1073/pnas.79.6.1781; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HENRIKSSON M, 1992, EXP CELL RES, V203, P383, DOI 10.1016/0014-4827(92)90012-W; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; ISSELS RD, 1988, RECENT RESULTS CANCE, V107; KHANDJIAN EW, 1983, MOL CELL BIOL, V3, P1; KHANDJIAN EW, 1992, ONCOGENE, V7, P909; KHANDJIAN EW, 1988, ONCOGENE, V3, P195; KOSKINEN PJ, 1991, J VIROL, V65, P842, DOI 10.1128/JVI.65.2.842-851.1991; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LASZLO A, 1992, CELL PROLIFERAT, V25, P59, DOI 10.1111/j.1365-2184.1992.tb01482.x; LATHANGUE NB, 1987, BIOSCIENCE REP, V7, P475, DOI 10.1007/BF01116504; LEE WH, 1991, COLD SH Q B, V56, P211; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LUDLOW JW, 1993, ONCOGENE, V8, P331; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MACEJAK DG, 1991, VIROLOGY, V180, P120, DOI 10.1016/0042-6822(91)90015-4; MAY E, 1991, VIROLOGY, V180, P285, DOI 10.1016/0042-6822(91)90033-8; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; NIHEI T, 1993, CANCER LETT, V73, P181, DOI 10.1016/0304-3835(93)90262-8; NOVER L., 1991, HEAT SHOCK RESPONSE; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; ROBERTS AB, 1991, CANCER CELL-MON REV, V3, P19; ROSE TM, 1992, BIOCHEM CELL BIOL, V70, P149, DOI 10.1139/o92-022; ROTI JLR, 1992, CELL PROLIFERAT, V25, P89, DOI 10.1111/j.1365-2184.1992.tb01483.x; SALZMAN NP, 1986, PAPOVAVIRUSES, V1; SAWAI ET, 1989, J VIROL, V63, P3961, DOI 10.1128/JVI.63.9.3961-3973.1989; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STREFFER C, 1987, RECENT RESULTS CANCE, V104; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; STURZBECHER HW, 1988, ONCOGENE, V1, P201; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; WALTER G, 1987, J VIROL, V61, P405, DOI 10.1128/JVI.61.2.405-410.1987; WHITE E, 1988, J VIROL, V62, P4153, DOI 10.1128/JVI.62.11.4153-4166.1988; WHITSON RH, 1992, J CELL BIOCHEM, V48, P305, DOI 10.1002/jcb.240480311; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; YEHIELY F, 1992, CELL GROWTH DIFFER, V3, P803; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479	71	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					359	367						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838534				2022-12-25	WOS:A1995QC62400015
J	JORDAN, R; MCMACKEN, R				JORDAN, R; MCMACKEN, R			MODULATION OF THE ATPASE ACTIVITY OF THE MOLECULAR CHAPERONE DNAK BY PEPTIDES AND THE DNAJ AND GRPE HEAT-SHOCK PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIALIZED NUCLEOPROTEIN STRUCTURES; LAMBDA-P-PROTEIN; BACTERIOPHAGE-LAMBDA; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; REPLICATION; INITIATION; ORIGIN; GROEL; BINDING	Previous studies have demonstrated that the Escherichia coli DnaK, DnaJ, and GrpE heat shock proteins participate in the initiation of bacteriophage A DNA replication by mediating the required disassembly of a preinitiation nucleoprotein structure that is formed at the phage replication origin, To gain some understanding in a simpler system of how the DnaJ and GrpE cochaperonins influence the activity of DnaK, we have examined the effect of the cochaperonins on the weak intrinsic ATPase activity of the molecular chaperone DnaK in the presence and absence of peptide effecters, We have found that random sequence peptide chains of 8 or 9 amino acid residues in length yield optimal (10-fold) activation of the DnaK ATPase, whereas peptides with 5 or fewer residues fail to stimulate the ATPase of this bacterial hsp70 homologue, Furthermore, we have discovered that those peptides that interact best with DnaK, as judged by their K-A as activators of ATP hydrolysis by DnaK, also act as strong inhibitors of lambda DNA replication in vitro, The inhibitory effect of peptides on lambda DNA replication was overcome by increasing the concentration of DnaK in the replication system, Diminished inhibition was also found when the replication system was supplemented with GrpE cochaperonin, a protein known to increase the effectiveness of DnaK action in lambda DNA replication, These and other results suggest that the peptide-binding site of DnaK is required for its function in lambda DNA replication, Apparently, peptides sequester free DnaK protein and block X DNA replication by reducing the amount of DnaK: that is free to mediate disassembly of nucleoprotein preinitiation structures, In related studies, we have found that DnaJ, like short peptides, activates the intrinsic ATPase activity of DnaK, DnaJ, however, is substantially more potent in this regard, since it activates DnaK at concentrations 1000-fold below those required for a peptide of random sequence, By itself, the GrpE cochaperonin has no effect on the peptide-independent ATPase activity of DnaK, but GrpE does vigorously stimulate the peptide-dependent ATPase of the DnaK chaperone, Under steady-state conditions, the V-max of ATP hydrolysis by DnaK was elevated approximately 40-fold by the presence of GrpE and saturating level of peptides.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036526] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36526] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CYR DM, 1992, J BIOL CHEM, V267, P20927; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DODSON M, 1989, J BIOL CHEM, V264, P10719; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GROSS CA, 1990, STRESS PROTEINS BIOL, P167; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEBOWITZ JH, 1985, P NATL ACAD SCI USA, V82, P3988, DOI 10.1073/pnas.82.12.3988; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; WALL D, 1994, J BIOL CHEM, V269, P5446; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	31	118	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4563	4569		10.1074/jbc.270.9.4563	http://dx.doi.org/10.1074/jbc.270.9.4563			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876226	hybrid			2022-12-25	WOS:A1995QK08400059
J	KEDISHVILI, NY; BOSRON, WF; STONE, CL; HURLEY, TD; PEGGS, CF; THOMASSON, HR; POPOV, KM; CARR, LG; EDENBERG, HJ; LI, TK				KEDISHVILI, NY; BOSRON, WF; STONE, CL; HURLEY, TD; PEGGS, CF; THOMASSON, HR; POPOV, KM; CARR, LG; EDENBERG, HJ; LI, TK			EXPRESSION AND KINETIC CHARACTERIZATION OF RECOMBINANT HUMAN STOMACH ALCOHOL-DEHYDROGENASE - ACTIVE-SITE AMINO-ACID-SEQUENCE EXPLAINS SUBSTRATE-SPECIFICITY COMPARED WITH LIVER ISOZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-PROPERTIES; PURIFICATION; ISOENZYMES; PROTEINS; METABOLISM; BINDING; CLONING; ETHANOL; CDNA	A full-length 1966-base pair clone of the human class IV alcohol dehydrogenase (sigma-ADH) was isolated from a human stomach cDNA library. The 373-amino acid sigma-ADH encoded by this cDNA was expressed in Escherichia coli, The specific activity of the recombinant enzyme for ethanol oxidation at pH 7.5 and 25 degrees C, calculated from active-site titration of NADH binding, was 92 +/- 9 units/mg, Kinetic analysis of the catalytic efficiency (k(cat)/K-M) of recombinant sigma-ADH for oxidation of primary alcohols indicated broad substrate specificity, Recombinant human sigma-ADH exhibited high catalytic efficiency for oxidation of all-trans-retinol to all-trans-retinal. This pathway is important in the synthesis of the transcriptional regulator all-trans-retinoic acid, Secondary alcohols and 3 beta-hydroxysteroids were inactive with sigma-ADH or were oxidized with very low efficiency, The K-M of a-ADH for ethanol was 25 mM, and the K-M for primary straight chain alcohols decreased substantially as chain length increased. There are important amino acid differences in the alcohol-binding site between the human class IV (sigma) and human class I (beta) alcohol dehydrogenases that appear to explain the high catalytic efficiency for all-trans-retinol, the high k(cat) for ethanol, and the low catalytic efficiency for secondary alcohols of sigma-ADH relative to beta(1)-ADH, For example, modeling the binding of all-trans-retinol in the human beta(1)-ADH structure suggested that coordination of retinol to the active-site zinc is hindered by a loop from residues 114 to 120 that is at the entrance to the alcohol-binding site, The deletion of Gly-117 in human sigma-ADH and a substitution of Leu for the bulky Tyr-110 appear to facilitate retinol access to the active-site zinc.	INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	KEDISHVILI, NY (corresponding author), INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 635 BARNHILL DR, MS 405, INDIANAPOLIS, IN 46202 USA.			HURLEY, THOMAS/0000-0002-5942-1163; Edenberg, Howard/0000-0003-0344-9690; Kedishvili, Natalia/0000-0001-6917-4891	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA007117, K21AA000148, R37AA002342] Funding Source: NIH RePORTER; NIAAA NIH HHS [R37-AA07117, R37-AA02342, K21-AA00148] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BOSRON WF, 1979, BIOCHEMISTRY-US, V18, P1101, DOI 10.1021/bi00573a026; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; BOSRON WF, 1993, SEMIN LIVER DIS, V13, P126, DOI 10.1055/s-2007-1007344; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; Cleland W W, 1979, Methods Enzymol, V63, P103; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; EKLUND H, 1990, EUR J BIOCHEM, V193, P303, DOI 10.1111/j.1432-1033.1990.tb19337.x; FARRES J, 1994, EUR J BIOCHEM, V224, P549, DOI 10.1111/j.1432-1033.1994.00549.x; FENG DF, 1990, METHOD ENZYMOL, V183, P375; GENTRY RT, 1994, J LAB CLIN MED, V123, P21; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOOG JO, 1992, EUR J BIOCHEM, V205, P519, DOI 10.1111/j.1432-1033.1992.tb16808.x; HOOG JO, 1987, BIOSCIENCE REP, V7, P969, DOI 10.1007/BF01122131; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; HURLEY TD, 1994, J MOL BIOL, V239, P415, DOI 10.1006/jmbi.1994.1382; HURLEY TD, 1995, ENZYMOLOGY MOL BIOL, V5; IKUTA T, 1985, P NATL ACAD SCI USA, V82, P2703, DOI 10.1073/pnas.82.9.2703; KEDISHVILI NY, 1995, ENZYMOLOGY MOL BIOL, V5; MORENO A, 1991, J BIOL CHEM, V266, P1128; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PARES X, 1990, METHOD ENZYMOL, V189, P436; PARES X, 1994, P NATL ACAD SCI USA, V91, P1893, DOI 10.1073/pnas.91.5.1893; PARES X, 1985, ALCOHOL, V2, P43, DOI 10.1016/0741-8329(85)90013-8; PARK DH, 1992, J BIOL CHEM, V267, P5527; PARK DH, 1991, J BIOL CHEM, V266, P13296; SATRE MA, 1994, J BIOL CHEM, V269, P15606; STONE CL, 1989, J BIOL CHEM, V264, P11112; STONE CL, 1993, J BIOL CHEM, V268, P892; STONE CL, 1993, ALCOHOL CLIN EXP RES, V17, P911, DOI 10.1111/j.1530-0277.1993.tb00863.x; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; YIN SJ, 1993, ALCOHOL CLIN EXP RES, V17, P376, DOI 10.1111/j.1530-0277.1993.tb00779.x; YIN SJ, 1990, BIOCHEM INT, V22, P829; YOKOYAMA H, 1994, BIOCHEM BIOPH RES CO, V203, P219, DOI 10.1006/bbrc.1994.2170; YONETANI T, 1962, ARCH BIOCHEM BIOPHYS, V99, P433, DOI 10.1016/0003-9861(62)90291-6	39	79	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3625	3630		10.1074/jbc.270.8.3625	http://dx.doi.org/10.1074/jbc.270.8.3625			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876099	hybrid			2022-12-25	WOS:A1995QH68800027
J	MURAD, AO; DECOCK, J; BROWN, D; SMERDON, MJ				MURAD, AO; DECOCK, J; BROWN, D; SMERDON, MJ			VARIATIONS IN TRANSCRIPTION-REPAIR COUPLING IN MOUSE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; STRAND-SPECIFIC REPAIR; TUMOR VIRUS PROMOTER; NUCLEOSOME CORE DNA; GLUCOCORTICOID RECEPTOR; YEAST MINICHROMOSOME; ACTIVE GENE; GROUP-C; SEQUENCE; CHROMATIN	Formation and repair of W-induced cyclobutane pyrimidine dimers (CPDs) was examined in three different genes in mouse L cells: 1) a stably integrated insert (called LTL), consisting of a herpes simplex virus thymidine kinase gene (th) fused to a hormone inducible promotor (LTR); 2) the constitutively expressed protooncogene c-abl; and 3) the inactive immunoglobulin J chain gene, Transcription of the tk gene is induced >50-fold by dexamethasone. There is a nonuniform distribution of CPDs in LTL DNA irradiated in vitro, being 4-fold higher in the LTR than in the th gene, indicating the LTR may be damaged preferentially in irradiated cells, Repair of CPDs occurs efficiently in both strands of LTL and is unaffected by hormone induction of th gene transcription. Transcription of tit mRNA is very sensitive to UV damage and follows single hit kinetics with UV dose. Furthermore, tit mRNA expression rapidly recovers during repair incubation, Transcription-coupled repair occurs in these cells, however, since only the transcribed strand of c-abl is efficiently repaired of CPDs; the nontranscribed strand as well as both strands of the J chain gene are inefficiently repaired. Thus, repair in the LTL construct may reflect a lack of transcription-coupled repair in either the LTR promotor or the LTL insertion region of chromatin.	WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	Washington State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004106] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04106] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BEATO M, 1991, NUCLEAR HORMONE RECE, P197; BECKER MM, 1989, J BIOL CHEM, V264, P4163; BEDOYAN J, 1992, J BIOL CHEM, V267, P5996; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1988, DNA REPAIR LABORATOR, P347; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; CANN GM, 1982, P NATL ACAD SCI-BIOL, V79, P6656, DOI 10.1073/pnas.79.21.6656; DECOCK JGR, 1991, NUCLEIC ACIDS RES, V19, P3289, DOI 10.1093/nar/19.12.3289; DECOCK JGR, 1992, MUTAT RES, V293, P11, DOI 10.1016/0921-8777(92)90003-L; DECOCK JGR, 1992, MUTAT RES, V274, P85, DOI 10.1016/0921-8777(92)90055-8; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FRANKLIN WA, 1986, MUTAT RES, V165, P1, DOI 10.1016/0167-8817(86)90002-7; FREIFELDER D, 1982, PHYSICAL CHEM STUDEN, P700; FRIEDBERG EC, 1994, MUTAT RES, V307, P5, DOI 10.1016/0027-5107(94)90272-0; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; GALE JM, 1988, J MOL BIOL, V204, P949, DOI 10.1016/0022-2836(88)90054-X; GORDON LK, 1982, RADIAT RES, V89, P99, DOI 10.2307/3575688; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; Maniatis T., 1982, MOL CLONING; MAULDIN SK, 1994, MUTAT RES, V314, P187, DOI 10.1016/0921-8777(94)90082-5; MITCHELL DL, 1992, NUCLEIC ACIDS RES, V20, P225, DOI 10.1093/nar/20.2.225; MITCHELL DL, 1990, RADIAT RES, V123, P299, DOI 10.2307/3577736; MURAD AO, 1991, THESIS WASHINGTON ST; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PINA B, 1990, J MOL BIOL, V216, P975, DOI 10.1016/S0022-2836(99)80015-1; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PROTICSABLJIC M, 1985, P NATL ACAD SCI USA, V82, P6622, DOI 10.1073/pnas.82.19.6622; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RUVEN HJT, 1994, MUTAT RES-DNA REPAIR, V315, P189, DOI 10.1016/0921-8777(94)90018-3; SAUERBIER W, 1976, ADV RADIAT BIOL, V6, P49; SELBY CP, 1990, J BIOL CHEM, V265, P21330; Smerdon MJ, 1991, CURR OPIN CELL BIOL, V3, P422, DOI 10.1016/0955-0674(91)90069-B; SMERDON MJ, 1979, BIOCHEMISTRY-US, V18, P3732, DOI 10.1021/bi00584a014; SMERDON MJ, 1993, ALFRED BENZON SYMP S, V35, P258; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SMITH CA, 1987, J CELL SCI, P225; SMITH CA, 1981, DNA REPAIR LABORAT B, V1, P289; TANG MS, 1991, BIOCHEMISTRY-US, V30, P7021, DOI 10.1021/bi00242a030; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	49	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3949	3957		10.1074/jbc.270.8.3949	http://dx.doi.org/10.1074/jbc.270.8.3949			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876142	hybrid			2022-12-25	WOS:A1995QH68800074
J	STEINMAN, HM				STEINMAN, HM			THE BCL-2 ONCOPROTEIN FUNCTIONS AS A PROOXIDANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; OXIDATIVE STRESS; SUPEROXIDE DISMUTASES; KAPPA-B; OXYGEN; MANGANESE; CATALASES; CELLS	The mechanism by which the bcl-2 oncogene exerts its anti-apoptotic and antioxidant action is unknown. We found that expression of bcl-2 in superoxide dismutase-deficient (SOD-) Escherichia coli resulted in increased transcription of the KatG catalase-peroxidase, a 13-fold increase in KatG activity and a 100-fold increase in resistance to hydrogen peroxide. In addition, mutation rate was increased 3-fold, and katG and oxyR, a transcriptional regulator of katG induction, were required for aerobic survival. These data indicate that Bcl-2 acts as a pro-oxidant in E. coli, i.e. Bcl-2 generates reactive oxygen intermediates. In support of a pro-oxidant mechanism in eukaryotic cells, we found a 73% increase in superoxide dismutase activity in a murine B-cell line overexpressing Bcl-2. Increases in reduced glutathione and in oxyradical damage to DNA, previously observed in other overexpressing cell lines, are additional evidence for a pro-oxidant mechanism. Thus, Bcl-2 does not appear to be an antioxidant. Instead, Bcl-2 appears to influence levels of reactive oxygen intermediates that induce endogenous cellular antioxidants. This activity of Bcl-2 may control, entry into apoptosis.			STEINMAN, HM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.				NIGMS NIH HHS [GM 40468] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; CLARE DA, 1984, ANAL BIOCHEM, V140, P532, DOI 10.1016/0003-2697(84)90204-5; DEMPLE B, 1983, NATURE, V304, P466, DOI 10.1038/304466a0; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; GONZALEZFLECHA B, 1994, J BACTERIOL, V176, P2293; GREEN MJ, 1984, METHOD ENZYMOL, V105, P3; HEIMBERGER A, 1988, BIOCHEM BIOPH RES CO, V154, P392, DOI 10.1016/0006-291X(88)90698-5; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOPKIN KA, 1992, J BIOL CHEM, V267, P24253; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; LOEWEN PC, 1985, ARCH BIOCHEM BIOPHYS, V243, P144, DOI 10.1016/0003-9861(85)90782-9; LOEWEN PC, 1992, MOL BIOL FREE RADICA, P97; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MOODY CS, 1982, P NATL ACAD SCI-BIOL, V79, P2855, DOI 10.1073/pnas.79.9.2855; RAY S, 1994, P NATL ACAD SCI USA, V91, P5548, DOI 10.1073/pnas.91.12.5548; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHWEIZER H, 1983, MOL GEN GENET, V192, P293, DOI 10.1007/BF00327683; SILHAVY TJ, 1984, EXPT GENE FUSIONS, P99; STEINMAN HM, 1992, MOL GEN GENET, V232, P427, DOI 10.1007/BF00266247; STEINMAN HM, 1985, J BACTERIOL, V162, P1255, DOI 10.1128/JB.162.3.1255-1260.1985; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929	29	136	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3487	3490						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876080				2022-12-25	WOS:A1995QH68800007
J	ATAR, D; BACKX, PH; APPEL, MM; GAO, WD; MARBAN, E				ATAR, D; BACKX, PH; APPEL, MM; GAO, WD; MARBAN, E			EXCITATION-TRANSCRIPTION COUPLING MEDIATED BY ZINC INFLUX THROUGH VOLTAGE-DEPENDENT CALCIUM CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PITUITARY-CELLS; SPATIAL MEMORY; HEAVY-METALS; MEMBRANE; DEXAMETHASONE; STIMULATION; BINDING; NEURONS; CA-2+	Electrical activity initiates a program of selective gene expression in excitable cells, Although such transcriptional activation is commonly attributed to depolarization-induced changes in intracellular Ca2+, zinc represents a viable alternative given its prominent role as a cofactor in DNA-binding proteins coupled with evidence that Zn2+ can enter excitable cells in a voltage-dependent manner. Here it is shown that Zn2+ entry into heart cells depends upon electrical stimulation and occurs via dihydropyridine-sensitive Ca2+ channels. The addition of extracellular Zn2+ to spontaneously depolarizing GH3 pituitary tumor cells induced the expression of a reporter gene driven by the metallothionein promoter, an effect that was prevented by exposure to dihydropyridine Ca2+ channel blockers. Thus, Zn2+ influx through L-type Ca2+ channels can mediate voltage-dependent gene expression.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205	Johns Hopkins University			Marban, Eduardo/GWC-8514-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044065] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 44065] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARSLAN P, 1985, J BIOL CHEM, V260, P2719; BACKX PH, 1993, CIRC RES, V72, P890, DOI 10.1161/01.RES.72.4.890; BACKX PH, 1993, AM J PHYSIOL, V264, pH1098, DOI 10.1152/ajpheart.1993.264.4.H1098; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERS DM, 1991, EXCITATION CONTRACTI, P17; BUSSELBERG D, 1992, BRAIN RES, V593, P77, DOI 10.1016/0006-8993(92)91266-H; COLEMAN TA, 1991, MOL CELL ENDOCRINOL, V75, P91, DOI 10.1016/0303-7207(91)90223-F; DAVIS JRE, 1991, MOL ENDOCRINOL, V5, P8, DOI 10.1210/mend-5-1-8; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; FABIATO A, 1979, J PHYSIOL-PARIS, V72, P463; FREDERICKSON RE, 1990, BEHAV BRAIN RES, V38, P25, DOI 10.1016/0166-4328(90)90021-6; FUCHS F, 1971, BIOCHIM BIOPHYS ACTA, V245, P221, DOI 10.1016/0005-2728(71)90025-9; FUKUDA J, 1977, SCIENCE, V196, P309, DOI 10.1126/science.847472; GAO WD, 1994, CIRC RES, V74, P408, DOI 10.1161/01.RES.74.3.408; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUIDOLIN D, 1992, ANN NY ACAD SCI, V673, P187, DOI 10.1111/j.1749-6632.1992.tb27452.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1992, IONIC CHANNELS EXCIT, P83; KALMAN D, 1988, J GEN PHYSIOL, V92, P531, DOI 10.1085/jgp.92.4.531; KARIN M, 1980, NATURE, V286, P295, DOI 10.1038/286295a0; KARIN M, 1979, SCIENCE, V204, P176, DOI 10.1126/science.432639; KAWA K, 1979, J MEMBRANE BIOL, V49, P325, DOI 10.1007/BF01868990; MOE GW, 1989, J AM COLL CARDIOL, V13, P173, DOI 10.1016/0735-1097(89)90567-6; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; SCHERUBL H, 1991, P ROY SOC B-BIOL SCI, V245, P127, DOI 10.1098/rspb.1991.0098; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; SHANG M, 1990, NEURON, V4, P477; Smith RM, 1974, CRITICAL STABILITY C, V1-6; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; WILLIAMS DA, 1987, SCIENCE, V235, P1644, DOI 10.1126/science.3103219; WINEGAR BD, 1990, J PHYSIOL-LONDON, V425, P563, DOI 10.1113/jphysiol.1990.sp018118	35	201	208	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2473	2477		10.1074/jbc.270.6.2473	http://dx.doi.org/10.1074/jbc.270.6.2473			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852308	hybrid			2022-12-25	WOS:A1995QF53500014
J	KNOPS, J; SUOMENSAARI, S; LEE, M; MCCONLOGUE, L; SEUBERT, P; SINHA, S				KNOPS, J; SUOMENSAARI, S; LEE, M; MCCONLOGUE, L; SEUBERT, P; SINHA, S			PROTEIN-TYPE SPECIFIC-INHIBITION OF A-BETA RELEASE BY BAFILOMYCIN A1, A SELECTIVE INHIBITOR OF VACUOLAR ATPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; H+-ATPASE; CULTURED-CELLS; PEPTIDE; MUTATION; IDENTIFICATION; ACIDIFICATION; INTERMEDIATE; DEGRADATION	Treatment of human 293 cells transfected with amyloid precursor protein (APP)(K595N,M596L) (the ''Swedish'' mutation) with a specific inhibitor of the vacuolar H+-ATPases, bafilomycin A1 (baf A), leads to a patent inhibition of the release of the A beta peptide. This is accompanied by a selective inhibition of beta-secretase activity. Surprisingly, baf A did not inhibit the production of A beta from either wild-type APP (WT APP) or from APP(V717I) (the ''Hardy'' mutation), expressed in the same cell type. In contrast, the robust production of A beta from a human neuroglioma-derived cell line (HS683) transfected with WT APP, or from primary human mixed brain cultures (HMBC) expressing genomic WT APP, were also effectively inhibited by baf A. The inhibition of A beta production from the HMBC was also accompanied by the inhibition of beta-s-APP release. No inhibition of alpha-s-APP release was seen in any of the cell types tested. These results indicate that intracellular acidic processes are rate-limiting for beta-secretase cleavage and A beta production from SW APP, but not WT APP, in the peripheral 293 cell line. Furthermore, such acidic processes also play a rate-limiting role in A beta release from human central nervous system-derived cells, including HMBC. Differential trafficking of the SW APP into an acidic compartment conducive to beta-secretase cleavage and A beta release could be one explanation for the increased production of A beta observed on expression of this mutation.	ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080									BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FLOOR E, 1990, J NEUROCHEM, V55, P1663, DOI 10.1111/j.1471-4159.1990.tb04954.x; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; KNOPS J, 1992, J BIOL CHEM, V267, P16022; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LUKACS GL, 1990, J BIOL CHEM, V265, P21099; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NELSON N, 1991, TRENDS PHARMACOL SCI, V12, P71, DOI 10.1016/0165-6147(91)90501-I; ODA K, 1991, BIOCHEM BIOPH RES CO, V178, P369, DOI 10.1016/0006-291X(91)91823-U; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SELKOE DJ, 1995, IN PRESS ANN REV CEL, V10; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	26	103	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2419	2422		10.1074/jbc.270.6.2419	http://dx.doi.org/10.1074/jbc.270.6.2419			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852298	hybrid			2022-12-25	WOS:A1995QF53500003
J	ZVARITCH, E; VELLANI, F; GUERINI, D; CARAFOLI, E				ZVARITCH, E; VELLANI, F; GUERINI, D; CARAFOLI, E			A SIGNAL FOR ENDOPLASMIC-RETICULUM RETENTION LOCATED AT THE CARBOXYL-TERMINUS OF THE PLASMA-MEMBRANE CA2+-ATPASE ISOFORM 4CI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; ION MOTIVE ATPASES; CA2+ PUMP; GOLGI RETENTION; CALCIUM-PUMP; TRANSMEMBRANE DOMAIN; MOLECULAR CHARACTERIZATION; CYTOPLASMIC DOMAINS; PROTEIN-DEGRADATION; HUMAN-ERYTHROCYTES	The plasma membrane Ca2+-ATPase isoform 4b (PMCA4CI) with truncations in the cytoplasmically exposed COOH-terminal tail was expressed in COS and HeLa cells and in Sf9 cells using the baculovirus system. The truncated protein terminating with the acidic sequence Glu(1067)-Arg(1087) was retained within the endoplasmic reticulum (ER), whereas mutants lacking this sequence or having it at a distance from the COOH terminus were delivered to the plasma membrane. Although the truncated protein retained in the endoplasmic reticulum was still able to form a Ca2+-dependent phosphoenzyme, it underwent partial degradation, Substitution of glutamic and aspartic residue(s) in the acidic region promoted rescue of the protein to the plasma membrane. The results suggest that the sequence Glu(1067)-Arg(1087) encodes a mashed signal for ER retention and for the degradation of the protein. However, its presence at the COOH terminus was not sufficient to induce ER-retention and degradation; when the sequence was attached to the full-length PMCA protein, normal plasma delivery was observed. Evidently, ER retention and degradation required the presence of the sequence in its specific location within the PMCA structure. The degradation of the protein retained in the endoplasmic reticulum occurred through the proteolytic attack at cytoplasmically exposed residues (amino acid sequence 720-750) by a cytoplasmic PEST sequence-related protease different from calpain.	ETH ZURICH, INST BIOCHEM, CH-8092 ZURICH, SWITZERLAND; RUSSIAN ACAD SCI, SHEMYAKIN INST BIOORGAN CHEM, MOSCOW 117871, RUSSIA	ETH Zurich; Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CIEHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAROFF H, 1983, J CELL BIOL, V97, P652, DOI 10.1083/jcb.97.3.652; HEIM R, 1992, J BIOL CHEM, V267, P24476; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; MURRE C, 1984, NATURE, V307, P432, DOI 10.1038/307432a0; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PUDDINGTON L, 1986, J CELL BIOL, V102, P2147, DOI 10.1083/jcb.102.6.2147; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1986, J BIOL CHEM, V261, P9552; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; ZIMMERMANN J, 1990, NUCLEIC ACIDS RES, V18, P1067, DOI 10.1093/nar/18.4.1067; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012; ZVARITCH E, 1992, 8TH INT S CALC BIND	53	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2679	2688		10.1074/jbc.270.6.2679	http://dx.doi.org/10.1074/jbc.270.6.2679			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852337	hybrid			2022-12-25	WOS:A1995QF53500045
J	ALTMANN, SW; KASTELEIN, RA				ALTMANN, SW; KASTELEIN, RA			RATIONAL DESIGN OF A MOUSE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR ANTAGONIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTOR; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; HUMAN INTERLEUKIN-4; AFFINITY BINDING; ESCHERICHIA-COLI; GROWTH-HORMONE; LIGAND-BINDING; CLONING; PROTEIN	Mouse granulocyte-macrophage colony-stimulating factor (mGM-CSF) proteins with substitutions at residues in the first alpha-helix were examined for biological activity and receptor binding properties. Substitution at the buried residue His(15) affected both bioactivity and receptor binding. Of the four surface-exposed positions examined (Arg(11), Lys(14), Lys(20), and Glu(21)) only substitutions at Glu(21) impaired bioactivity. Proteins with charge reversal substitutions at this position were partial agonists and weak antagonists of native mGM-CSF action. All substitutions at Glu(21) abrogated high affinity binding. Lys(14) and Lys(20) substitution proteins showed various receptor binding defects. Qualitative and quantitative measurement of these binding defects identified Lys(14) as a residue that interacts specifically with the beta subunit of the mGM-CSF receptor, whereas Lys(20) appeared to exist at the GM-R alpha-subunit/GM-R beta-subunit interface as substitutions at this position produce both high and low affinity binding losses. These determinations permitted the design of a more potent mGM-CSF antagonist.	DNAX RES INST MOLEC & CELLULAR BIOL INC, DEPT MOLEC BIOL, PALO ALTO, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.								ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ABRAMS JS, 1992, IMMUNOL REV, V127, P5, DOI 10.1111/j.1600-065X.1992.tb01406.x; ALTMANN SW, 1991, J BIOL CHEM, V266, P5333; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROWN CB, 1990, J IMMUNOL, V144, P2184; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GREENBERG R, 1988, CURR MICROBIOL, V17, P321, DOI 10.1007/BF01570872; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERCUS TR, 1994, BLOOD, V83, P3500; HOWARDFLANDERS P, 1964, GENETICS, V49, P237; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1991, BLOOD, V77, P1033; KASTELEIN RA, 1993, ONCOGENE, V8, P231; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE C, 1991, J MOL BIOL, V217, P373, DOI 10.1016/0022-2836(91)90550-P; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; LUNDELL D, 1990, J IND MICROBIOL, V5, P215, DOI 10.1007/BF01569679; MCKAY DB, 1992, SCIENCE, V257, P412, DOI 10.1126/science.257.5068.412; MEROPOL NJ, 1992, J BIOL CHEM, V267, P14266; MESSING J, 1983, METHOD ENZYMOL, V101, P20; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1986, BLOOD, V67, P257; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MIYAJIMA A, 1986, EMBO J, V5, P1193, DOI 10.1002/j.1460-2075.1986.tb04346.x; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEELIG GF, 1994, J BIOL CHEM, V269, P5548; SHANAFELT AB, 1991, J BIOL CHEM, V266, P13804; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHANAFELT AB, 1989, P NATL ACAD SCI USA, V86, P4872, DOI 10.1073/pnas.86.13.4872; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U	41	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2233	2240		10.1074/jbc.270.5.2233	http://dx.doi.org/10.1074/jbc.270.5.2233			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836455	hybrid			2022-12-25	WOS:A1995QE49300040
J	OBRIEN, MC; MCKAY, DB				OBRIEN, MC; MCKAY, DB			HOW POTASSIUM AFFECTS THE ACTIVITY OF THE MOLECULAR CHAPERONE HSC70 .1. POTASSIUM IS REQUIRED FOR OPTIMAL ATPASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; UNCOATING ATPASE; PEPTIDE BINDING; HYDROLYSIS; FRAGMENT; HSP70; GROEL; SITE; K+	Several functions of the 70-kilodalton heat shock cognate protein (Hsc70), such as peptide binding/release and clathrin uncoating, have been shown to require potassium ions. We have examined the effect of monovalent ions on the ATPase activity of Hsc70. The steady-state ATPase activities of Hsc70 and its amino-terminal 44-kDa ATPase fragment are minimal in the absence of K+ and reach a maximum at similar to 0.1 M [K+]. Activation of the ATPase turnover correlates with the ionic radii of monovalent ions; those that are at least 0.3 Angstrom smaller (Na+ and Li+) or larger (Cs+) than K+ show negligible activation, whereas ions with radii differing only similar to 0.1 Angstrom from that of K+ (NH4+ and Rb+) activate to approximately half the turnover rate observed with K+. Single turnover experiments with Hsc70 demonstrate that ATP hydrolysis is 5-fold slower with Na+ than with K+. The equilibrium binding of ADP or ATP to Hsc70 is unperturbed when K+ is replaced with Na+. These results are consistent with a role for monovalent ions as specific cofactors in the enzymatic hydrolysis of ATP.	STANFORD UNIV,SCH MED,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928, F32GM015141] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39928, GM-15141] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; DELUCAFLAHERTY C, 1990, CELL, V62, P375; EVANS HJ, 1966, ANN REV PLANT PHYSIO, V17, P47, DOI 10.1146/annurev.pp.17.060166.000403; FERSHT A, 1985, ENZYME STRUCTURE MEC, P131; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WANG TF, 1993, J BIOL CHEM, V268, P26049; WEAST RC, 1982, CRC HDB CHEM PHYSICS, pF156; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251	28	99	100	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2247	2250		10.1074/jbc.270.5.2247	http://dx.doi.org/10.1074/jbc.270.5.2247			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836457	hybrid			2022-12-25	WOS:A1995QE49300042
J	WILBANKS, SM; MCKAY, DB				WILBANKS, SM; MCKAY, DB			HOW POTASSIUM AFFECTS THE ACTIVITY OF THE MOLECULAR CHAPERONE HSC70 .2. POTASSIUM BINDS SPECIFICALLY IN THE ATPASE ACTIVE-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; HYDROLYSIS; COMPLEX; RESOLUTION; FRAGMENT; HSP70	Crystallographic anomalous scattering from potassium at 1.7 Angstrom resolution reveals two monovalent ions that interact with MgADP and P-i in the nucleotide binding cleft of wild-type recombinant bovine Hsc70 ATPase fragment. K+ at site 1 interacts with oxygens of the beta-phosphate of ADP, whereas K+ at site 2 interacts with an oxygen of P-i. Both K+ ions also interact with specific H2O molecules in the first hydration shell of the octahedrally coordinated Mg2+ ion and with specific protein ligands. In crystals that have Na+ present, K+ is replaced by a Na+ ion at site 1 and by a Na(+)similar to H2O pair at site 2. The K+ ions are positioned where they could stabilize binding of a beta,gamma-bidentate MgATP complex with Hsc70, as well as a transition state during ATP hydrolysis, suggesting that monovalent ions act as specific metal cofactors in the ATPase reaction of Hsc70.	STANFORD UNIV, SCH MED, DEPT CELL BIOL, BECKMAN LABS STRUCT BIOL, STANFORD, CA 94305 USA	Stanford University				Wilbanks, Sigurd/0000-0001-7565-8913	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39928] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMIAK DA, 1980, ACTA CRYSTALLOGR B, V36, P2585, DOI 10.1107/S056774088000948X; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DELUCAFLAHERTY C, 1988, J MOL BIOL, V200, P749, DOI 10.1016/0022-2836(88)90487-1; EVANS HJ, 1966, ANN REV PLANT PHYSIO, V17, P47, DOI 10.1146/annurev.pp.17.060166.000403; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FLETTERICK RJ, 1975, P NATL ACAD SCI USA, V72, P38, DOI 10.1073/pnas.72.1.38; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; Ibers J. A., 1974, INT TABLES XRAY CRYS, VIV, P149; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KENNARD O, 1971, PROC R SOC LON SER-A, V325, P401, DOI 10.1098/rspa.1971.0177; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LOWENSTEIN JM, 1960, BIOCHEM J, V75, P269, DOI 10.1042/bj0750269; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; MERRITT EA, 1980, ACTA CRYSTALLOGR B, V36, P2576, DOI 10.1107/S0567740880009478; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; ROSE IA, 1960, J BIOL CHEM, V235, P1170; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; STEIGEMANN W, 1974, THESIS TU MUNCHEN; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; SWAMINATHAN P, 1980, ACTA CRYSTALLOGR B, V36, P2576; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893	33	130	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2251	2257		10.1074/jbc.270.5.2251	http://dx.doi.org/10.1074/jbc.270.5.2251			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836458	hybrid			2022-12-25	WOS:A1995QE49300043
J	CHEN, PC; LIN, HH; WEISSMAN, BE				CHEN, PC; LIN, HH; WEISSMAN, BE			A FUNCTIONAL-ANALYSIS OF TUMOR-SUPPRESSOR ACTIVITY FOR PERIPHERAL NEUROEPITHELIOMAS BY MONOCHROMOSOME TRANSFER	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENES; MICROCELL HYBRIDIZATION; PNET	NORMAL HUMAN CHROMOSOME-11; DINUCLEOTIDE REPEAT POLYMORPHISMS; HUMAN NEUROBLASTOMA-CELLS; POLYMERASE CHAIN-REACTION; HUMAN CANCER; TUMORIGENICITY; LINE; GROWTH; AMPLIFICATION; EXPRESSION	The microcell hybridization technique provides a powerful method for the identification and characterization of tumor suppressor genes. By introducing chromosomes from a normal human cell into a tumor cell, several studies have presented functional evidence for the presence of tumor suppressor activity. In order to map the location(s) of functional tumor suppressor gene(s) for peripheral neuroepithelioma (PNET) cells, we have used the microcell hybridization technique to transfer three individual human chromosomes into three different PNET cell lines, A673, SK-N-MC and TC32. We could not isolate microcell hybrids from one of the cell lines as the transferred chromosome tended to fragment upon transfer. Introduction of chromosome 13 into the remaining two cell lines caused a marked inhibition of in vitro and in vivo growth. Chromosome 11 appeared to harbor a functional tumor suppressor gene while transfer of chromosome 17 caused a suppression of growth in culture, presumably due to the presence of the p53 tumor suppressor gene. Thus, each cell line showed a different response to the introduction off normal genetic information suggesting diverse genetic abnormalities among these tumors of similar histological or origin.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CYTOGENET LAB,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA044470] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AURIAS A, 1983, NEW ENGL J MED, V309, P496; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANERJEE A, 1992, CANCER RES, V52, P6297; BENEDICT WF, 1984, CANCER RES, V44, P3471; BIEDLER JL, 1973, CANCER RES, V33, P2643; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAHILL TC, 1990, PRENATAL DIAG, V10, P795, DOI 10.1002/pd.1970101206; CHEN PC, 1994, MOL CELL BIOL, V14, P534, DOI 10.1128/MCB.14.1.534; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EGE T, 1974, EXP CELL RES, V87, P378, DOI 10.1016/0014-4827(74)90494-7; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GIARD DJ, 1974, J NATL CANCER I, V51, P1417; GORMAN PA, 1991, CANCER GENET CYTOGEN, V51, P13, DOI 10.1016/0165-4608(91)90003-D; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRIFFIN CA, 1988, CANCER RES, V48, P175; HALL JM, 1992, AM J HUM GENET, V50, P1235; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KUGOH HM, 1990, ONCOGENE, V5, P1637; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1992, ONCOGENE, V7, P2013; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PASQUALE SR, 1988, CANCER RES, V48, P2715; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SCHOTT DR, 1994, CANCER RES, V54, P1393; SHIMIZU M, 1990, ONCOGENE, V5, P185; STANBRIDGE EJ, 1981, ISRAEL J MED SCI, V17, P563; STANBRIDGE EJ, 1992, CANCER SURV, V12, P5; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4636, DOI 10.1093/nar/18.15.4636-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4036, DOI 10.1093/nar/18.13.4036; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEISSMAN BE, 1983, JNCI-J NATL CANCER I, V70, P667; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WEISSMAN BE, 1990, CANCER SURV, V9, P475; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V21, P185; YAMADA H, 1990, ONCOGENE, V5, P1141; YANDELL DW, 1989, AM J HUM GENET, V45, P547	47	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					577	586						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845683				2022-12-25	WOS:A1995QF64800019
J	MANSUR, CP; MARCUS, B; DALAL, S; ANDROPHY, EJ				MANSUR, CP; MARCUS, B; DALAL, S; ANDROPHY, EJ			THE DOMAIN OF P53 REQUIRED FOR BINDING HPV-16 E6 IS SEPARABLE FROM THE DEGRADATION DOMAIN	ONCOGENE			English	Article						PAPILLOMAVIRUS E6 PROTEIN; P53; TRANSCRIPTIONAL ACTIVATION	HUMAN PAPILLOMAVIRUS TYPE-16; SV40 LARGE T; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; MUTANT P53; DNA-BINDING; PROTEIN; ONCOPROTEIN; TRANSACTIVATION; SEQUENCES	The E6 proteins of specific cancer-associated human papillomaviruses (HPVs) complex with and mediate degradation of the cellular anti-oncogene p53 in vitro. A critical property of p53 is its ability to stimulate transcription from promoters containing its recognition sequence. HPV E6, mutant p53 proteins, and several DNA tumor virus oncogenes inhibit the transcriptional activity of wild-type p53. In this report, the structural requirements for the interaction between HPV 16 E6 and p53 were examined both in vivo and in vitro. p53-stimulated transcription was efficiently inhibited by wild-type HPV 16 E6 and E6 mutants competent for p53 binding and degradation. A series of p53 deletions and hybrid proteins with heterologous DNA binding, dimerization and transactivation domains were analysed for transcriptional interaction with HPV 16 E6 to determine the domains of p53 required for transcriptional inhibition. These chimeric proteins were also analysed for E6 binding and E6-mediated degradation in vitro. In both assays, complex formation with E6 was mediated through the amino-terminal 345 amino acids of p53 without a specific requirement for its C-terminus. Hybrid proteins containing residues 161-345 of p53 also bound E6, but this segment of p53 was not susceptible to E6 induced proteolysis. A second region of p53, within its N-terminal 160 aa, is required for E6 induced degradation of complexed p53. Taken together, these results suggest that the complex formation between E6 and p53 is not mediated through the C-terminus of p53 and that binding and degradation are separable.	TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts University	MANSUR, CP (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DEPT DERMATOL, BOSTON, MA 02111 USA.			Mansur, Claire/0000-0002-2470-3443; Androphy, Elliot/0000-0002-8104-0703	NATIONAL CANCER INSTITUTE [R01CA044174] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA44174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROOK T, 1994, ONCOGENE, V9, P1225; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DIMAIO D, 1991, ADV CANCER RES, V56, P133; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRAKASH SS, 1992, GENE DEV, V6, P105, DOI 10.1101/gad.6.1.105; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SEGAWA K, 1993, ONCOGENE, V8, P543; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; VOUSDEN KH, 1989, ONCOGENE, V4, P153; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	57	35	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					457	465						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845670				2022-12-25	WOS:A1995QF64800006
J	LEIBOVITCH, MP; SOLHONNE, B; GUILLIER, M; VERELLE, P; LEIBOVITCH, SA				LEIBOVITCH, MP; SOLHONNE, B; GUILLIER, M; VERELLE, P; LEIBOVITCH, SA			DIRECT RELATIONSHIP BETWEEN THE EXPRESSION OF TUMOR-SUPPRESSOR H19 MESSENGER-RNA AND C-MOS PROTOONCOGENE DURING MYOGENESIS	ONCOGENE			English	Article						H19; C-MOS; MYOGENESIS; GENE; EXPRESSION	SOMATIC-CELL EXPRESSION; MYOSIN LIGHT CHAIN-1; MURINE SARCOMA-VIRUS; SKELETAL-MUSCLE; MESSENGER-RNA; ALPHA-ACTIN; MOUSE; GENE; CDNA; DIFFERENTIATION	We have cloned and sequenced an almost complete c-DNA and the entire genomic sequence of rat the H19 gene, which is developmentally regulated in skeletal muscle, The data base comparison revealed a 92% homology with mouse gene H19. However the rat H19 ORFs do not display significant homology with the H19 ORFs from other species, In contrast to the mouse, the rat H19 mRNA is not easily detectable in fetal rat skeletal fibers. Its level increases after birth (up to 12 to 18 days) and remains stable thereafter. The pattern of H19 mRNA expression in rat muscle in vivo is very similar to the c-mos gene expression in this tissue, suggesting an interrelationship between H19 and c-mos products during muscle differentiation. Indeed, our results indicate that overexpression of c-mos protein in the muscle cell line C2C12 induces a concomitant increase of H19 mRNA expression. Furthermore, repression of c-mos protein expression by anti-sense RNAs extinguishes H19 mRNA expression and inhibits the differentiation process. These data suggest a relationship between c-mos and H19 expression and, in addition, the involvement of both gene products in the process of myogenesis.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 126,F-94805 VILLEJUIF,FRANCE; CTR PERRIN,RADIOTHERAPIE SERV,F-53011 CLERMONT FERRAND,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	LEIBOVITCH, MP (corresponding author), INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,UA 1158,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.							BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1992, ONCOGENE, V7, P1757; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; GARFINKEL LI, 1982, J BIOL CHEM, V257, P1078; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P447; GOAD WB, 1982, NUCLEIC ACIDS RES, V10, P247, DOI 10.1093/nar/10.1.247; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GUILLIER M, 1991, NUCLEIC ACIDS RES, V19, P1339, DOI 10.1093/nar/19.6.1339; HAN DKM, 1992, CIRC RES, V71, P711, DOI 10.1161/01.RES.71.3.711; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HERZOG NK, 1989, ONCOGENE, V4, P1307; KURATA N, 1989, EMBO J, V8, P457, DOI 10.1002/j.1460-2075.1989.tb03398.x; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIBOVITCH SA, 1989, ONCOGENE RES, V4, P157; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; LEIBOVITCH SA, 1993, ONCOGENE, V8, P2361; LENORMAND JL, 1993, NUCLEIC ACIDS RES, V21, P695, DOI 10.1093/nar/21.3.695; LI CCH, 1993, ONCOGENE, V8, P1685; LI H, 1994, J CELL BIOL, V124, P827, DOI 10.1083/jcb.124.5.827; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; OKAZAKI K, 1992, EMBO J, V11, P2443; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; POIRIER F, 1991, DEVELOPMENT, V113, P1105; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; ROBERT B, 1984, CELL, V39, P129, DOI 10.1016/0092-8674(84)90198-3; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SHIBUYA EK, 1988, DEV BIOL, V129, P253, DOI 10.1016/0012-1606(88)90179-0; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TSUI LV, 1993, INT J ONCOL, V2, P493; VOGEL M, 1987, DEV BIOL, V119, P481, DOI 10.1016/0012-1606(87)90051-0; WILES MV, 1988, DEVELOPMENT, V104, P403; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	46	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					251	260						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838525				2022-12-25	WOS:A1995QC62400004
J	LOMAS, DA; ELLIOTT, PR; CHANG, WSW; WARDELL, MR; CARRELL, RW				LOMAS, DA; ELLIOTT, PR; CHANG, WSW; WARDELL, MR; CARRELL, RW			PREPARATION AND CHARACTERIZATION OF LATENT ALPHA(1)-ANTITRYPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-PROTEINASE INHIBITOR; PLASMINOGEN-ACTIVATOR INHIBITOR; CRYSTAL-STRUCTURE; ENDOTHELIAL-CELLS; ANTITHROMBIN-III; REACTIVE CENTER; ALPHA-1-ANTITRYPSIN; SERPINS; RESOLUTION; MODEL	Members of the serine proteinase inhibitor or serpin superfamily have a common molecular architecture based on a dominant five-membered A beta-pleated sheet and a mobile reactive center loop. The reactive center loop has been shown to adopt a range of conformations from the three turn alpha-helix of ovalbumin to the cleaved or latent inhibitor in which the reactive center loop is fully inserted into the A sheet of the molecule. While the cleaved state can be achieved in all inhibitory serpins only plasminogen activator inhibitor-1 and, more recently, antithrombin have been shown to adopt the latent conformation. We show here that the archetypal serpin, alpha(1)-antitrypsin, can also be induced to adopt the latent conformation by heating at high temperatures in 0.7 M citrate for 12 h. The resulting species elutes at a lower sodium chloride concentration on an anion exchange column and has a more cathodal electrophoretic mobility on non-denaturing polyacrylamide gel electrophoresis and isoelectric focusing than native M antitrypsin. Latent antitrypsin is inactive as an inhibitor of bovine alpha-chymotrypsin, is stable to unfolding with 8 M urea, and is more resistant to heat-induced loop-sheet polymerization than native but less resistant than cleaved antitrypsin. The reactive center loop of latent antitrypsin is inaccessible to proteolytic cleavage, and its occupancy of the A sheet prevents the molecule accepting an exogenous reactive center loop peptide. The activity of latent antitrypsin may be increased from <1% to approximately 35% by refolding from 6 M guanidinium chloride.			LOMAS, DA (corresponding author), UNIV CAMBRIDGE, CTR MRC, DEPT HAEMATOL, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.		Chang, Wun-Shaing Wayne/C-1202-2010		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AULAK KS, 1993, J BIOL CHEM, V268, P18088; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CARRELL RW, 1993, NATURE, V364, P737, DOI 10.1038/364737a0; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; ELDERING E, 1994, J CELL BIOCH S18D, V154, pS319; FABER JP, 1993, J HEPATOL, V18, P313, DOI 10.1016/S0168-8278(05)80275-2; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; KATAGIRI K, 1988, EUR J BIOCHEM, V176, P81, DOI 10.1111/j.1432-1033.1988.tb14253.x; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEVIN EG, 1987, BLOOD, V70, P1090; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LOMAS DA, 1993, AM J PHYSIOL, V265, pL211, DOI 10.1152/ajplung.1993.265.3.L211; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MIKUS P, 1993, EUR J BIOCHEM, V218, P1071, DOI 10.1111/j.1432-1033.1993.tb18467.x; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TRAVIS J, 1981, METHOD ENZYMOL, V80, P754; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251	45	142	151	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5282	5288		10.1074/jbc.270.10.5282	http://dx.doi.org/10.1074/jbc.270.10.5282			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890640	hybrid			2022-12-25	WOS:A1995QL58000052
J	KRISTIE, TM; POMERANTZ, JL; TWOMEY, TC; PARENT, SA; SHARP, PA				KRISTIE, TM; POMERANTZ, JL; TWOMEY, TC; PARENT, SA; SHARP, PA			THE CELLULAR C1 FACTOR OF THE HERPES-SIMPLEX VIRUS ENHANCER COMPLEX IS A FAMILY OF POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS DNA-REPLICATION; NUCLEAR FACTOR-III; HISTONE H2B GENE; OCTAMER-BINDING PROTEINS; OCT-1 HOMEO DOMAIN; RNA POLYMERASE-III; TRANSCRIPTION FACTOR; HELA-CELLS; U2 SNRNA; TRANSACTIVATOR VP16	The alpha/immediate early genes of herpes simplex virus are regulated by the specific assembly of a multiprotein enhancer complex containing the Oct-1 POU domain protein, the viral alpha-transinduction factor alpha TIF, (VP16, ICP25), and the C1 cellular factor, The C1 factor from mammalian cells is a heterogeneous but related set of polypeptides that interact directly with the alpha-transinduction factor to form a heteromeric protein complex, The isolation of cDNAs encoding the polypeptides of the C1 factor suggests that these proteins are proteolytic products of a novel precursor. The sequence of the amino termini of these polypeptide products indicate that the proteins are generated by site-specific cleavages within a reiterated 20-amino acid sequence. Although the C1 factor appears to be ubiquitously expressed, it is localized to subnuclear structures in specific cell types.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,MIT,DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,RAHWAY,NJ 07065	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Merck & Company	KRISTIE, TM (corresponding author), NIAID,VIRAL DIS LAB,BLDG 4,RM 133,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Pomerantz, Joel L./0000-0002-5030-1018	NCI NIH HHS [P30-CA14051, P01-CA42063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; BARK C, 1987, NATURE, V328, P356, DOI 10.1038/328356a0; BEVERLY S, 1987, CURRENT PROTOCOLS MO; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FERREIRA JA, 1994, J CELL BIOL, V126, P11, DOI 10.1083/jcb.126.1.11; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILMAN M, 1987, CURRENT PROTOCOLS MO; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; Harlow E, 1988, IMMUNIZATION ANTIBOD, P53; HARLOW E, 1988, CELL STAINING ANTIBO, P359; HASSAN AB, 1994, J CELL SCI, V107, P425; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KRISTIE TM, 1988, J VIROL, V62, P1145, DOI 10.1128/JVI.62.4.1145-1157.1988; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MOIR RD, 1994, J CELL BIOL, V125, P1201, DOI 10.1083/jcb.125.6.1201; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; MULLERIMMERGLUC.MM, 1990, EMBO J, V9, P1625; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; ONEILL EA, 1988, J BIOL CHEM, V263, P931; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; PRUIJN GJM, 1987, EMBO J, V6, P3771, DOI 10.1002/j.1460-2075.1987.tb02712.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO R, 1994, J BIOL CHEM, V269, P17267; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SIVE HL, 1986, MOL CELL BIOL, V6, P3329, DOI 10.1128/MCB.6.10.3329; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WERSTUCK G, 1989, J VIROL, V63, P5509, DOI 10.1128/JVI.63.12.5509-5513.1989; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; YANG J, 1991, EMBO J, V10, P2291, DOI 10.1002/j.1460-2075.1991.tb07765.x; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235	64	93	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4387	4394		10.1074/jbc.270.9.4387	http://dx.doi.org/10.1074/jbc.270.9.4387			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876203	hybrid			2022-12-25	WOS:A1995QK08400034
J	VAITHILINGAM, IS; MCDONALD, W; MALOTT, DW; DELMAESTRO, RF				VAITHILINGAM, IS; MCDONALD, W; MALOTT, DW; DELMAESTRO, RF			AN EXTRACELLULAR PROTEASOME-LIKE STRUCTURE FROM C6 ASTROCYTOMA-CELLS WITH SERINE COLLAGENASE-IV ACTIVITY AND METALLO-DEPENDENT ACTIVITY ON ALPHA-CASEIN AND BETA-INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTINUOUS SPECTROPHOTOMETRIC ASSAY; PROTEOLYTIC ACTIVITY; TISSUE INHIBITOR; TUMOR-CELLS; METALLOPROTEINASES; LOCALIZATION; METASTASIS; GROWTH	An extracellular proteasome-like (EP) structure has been isolated from serum-free media conditioned by C6 astrocytoma cells, EP has a native molecular mass of 1000 kDa and is composed of three subunits, two isoelectric variants at 70 kDa and one at 65 kDa, The extracellular proteasome degraded collagen TV, alpha-casein, beta-insulin, and certain synthetic peptide substrates. A 68-kDa type IV collagenase, identified as the activated form of gelatinase A, was also isolated from this medium, The type IV collagenase activity of the proteasome was sensitive to serine protease inhibitors, while the 68-kDa collagenase IV represented the matrix metalloprotease gelatinase A. The general protease activity of the proteasome was sensitive to metalloprotease inhibitors, Western blot analysis indicates a sequence relationship between the 68-kDa type IV collagenase and either one or both of the 70-kDa isoelectric variants of the proteasome; however, the two enzymes appear to be distinct functionally, Comparison with known proteasomes indicates that EP represents a novel proteasome. The complexity of degradative enzymes in the extracellular microenvironment implies that complete inhibition of tumor growth requires at least a combination of serine and metalloprotease inhibitors.	UNIV WESTERN ONTARIO,VICTORIA HOSP,DEPT CLIN NEUROL SCI,DIV NEUROSURG,BRAIN RES LABS,LONDON,ON N6A 4G5,CANADA; VICTORIA HOSP,DEPT PATHOL,LONDON,ON N6A 4G5,CANADA	University of Victoria; Western University (University of Western Ontario); University of Victoria; Western University (University of Western Ontario)								ALVAREZ OA, 1990, J NATL CANCER I, V82, P589, DOI 10.1093/jnci/82.7.589; AMSTERDAM A, 1989, P NATL ACAD SCI USA, V90, P99; BEYETTE JR, 1992, MUSCLE NERVE, V15, P1023, DOI 10.1002/mus.880150907; BOSMAN FT, 1989, HISTOCHEM J, V21, P629, DOI 10.1007/BF01002481; DAHLMANN B, 1992, EUR J BIOCHEM, V208, P789, DOI 10.1111/j.1432-1033.1992.tb17249.x; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DECLERCK YA, 1992, CANCER RES, V52, P701; FEDER J, 1970, BIOCHEMISTRY-US, V9, P2784, DOI 10.1021/bi00816a005; HEWITT RE, 1991, INT J CANCER, V49, P666, DOI 10.1002/ijc.2910490507; HOLMQUIST B, 1979, ANAL BIOCHEM, V95, P540, DOI 10.1016/0003-2697(79)90769-3; KRAMER SP, 1968, J SURG RES, V8, P253, DOI 10.1016/0022-4804(68)90095-4; LYUBLINSKAYA LA, 1974, ANAL BIOCHEM, V62, P371, DOI 10.1016/0003-2697(74)90169-9; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OZAKI M, 1992, J BIOL CHEM, V267, P21678; PALMER A, 1994, EUR J CELL BIOL, V64, P163; RAJABI M, 1987, OBSTET GYNECOL, V69, P179; RIVETT AJ, 1993, BIOCHEM J, V291, P1; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TANAKA K, 1992, NEW BIOL, V4, P173; TSUDA TT, 1993, FEBS LETT, V319, P35, DOI 10.1016/0014-5793(93)80032-P; VAITHILINGAM I, 1989, BIOCHEM INT, V19, P1297; VAITHILINGAM IS, 1992, J NEUROSURG, V77, P595, DOI 10.3171/jns.1992.77.4.0595; VAITHILINGAM IS, 1991, J NEURO-ONCOL, V10, P203, DOI 10.1007/BF00177532; VAITHILINGAM IS, 1992, CAN J NEUROL SCI, V19, P17, DOI 10.1017/S0317167100042487; VANWART HE, 1981, ANAL BIOCHEM, V113, P356, DOI 10.1016/0003-2697(81)90089-0; WADA M, 1993, J LAB CLIN MED, V121, P215; WEITMAN D, 1992, J BIOL CHEM, V267, P6977; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210	31	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4588	4593		10.1074/jbc.270.9.4588	http://dx.doi.org/10.1074/jbc.270.9.4588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876229	hybrid			2022-12-25	WOS:A1995QK08400062
J	BENO, DWA; BRADY, LM; BISSONNETTE, M; DAVIS, BH				BENO, DWA; BRADY, LM; BISSONNETTE, M; DAVIS, BH			PROTEIN-KINASE-C AND MITOGEN-ACTIVATED PROTEIN-KINASE ARE REQUIRED FOR 1,25-DIHYDROXYVITAMIN D-3-STIMULATED EGR INDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PHOSPHOINOSITIDE TURNOVER; RAT HEPATIC LIPOCYTES; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; CELL ACTIVATION; RETINOIC ACID; MUSCLE-CELLS; MAP KINASES; RAF-1; PHOSPHORYLATION	Recent studies have demonstrated that 1,25-dihydroxyvitamin D-3 (D3) can activate Raf kinase and induce Egr expression in cultured rat hepatic Ito cells (Lissoos, T, W,, Beno, D, W, A, and Davis, B, EI. (1993) J. Biol, Chem, 268, 25132-25138), Since Raf is an upstream activator of mitogen-activated protein kinase (MAPK), the current study evaluated the ability of D3 to activate MAPK, D3-activated MAPK and induced its cytoplasmic to perinuclear translocation in Ito cells, MAPK activation was found to be protein kinase C-dependent, which was analogous to previous studies of D3 and Raf activation. To further explore the D3 cascade, a series of transient transfections were performed using dominant negative raf and MAPK mutant plasmids which effectively block Ras-induced Raf and MAPK activity, respectively, D3 induced a marked increase in the expression of a chloramphenicol acetyltransferase reporter gene linked to the Egr promoter (egr-CAT). When the dominant negative Raf plasmid was co-transfected, there was no significant reduction in egr-CAT. In contrast, when the dominant negative MAPK plasmid was co-transfected, egr-CAT induction was completely abolished, These results suggest that 1) D3 stimulates MAPK via a protein kinase C-dependent pathway, 2) D3-induced Egr expression can occur via a pathway independent of Ras-induced Raf, and 3) D3 absolutely requires MAPK activity for Egr expression.	UNIV CHICAGO,DEPT MED,GASTROENTEROL SECT,CHICAGO,IL 60637	University of Chicago					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040223, K08DK002022, P30DK042086] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40223, DK 02022, DK 42086] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BENO DWA, 1994, BBA-MOL CELL RES, V1222, P292, DOI 10.1016/0167-4889(94)90181-3; BISSONNETTE M, 1994, AM J PHYSIOL, V267, pG465, DOI 10.1152/ajpgi.1994.267.3.G465; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CLEMENS TL, 1988, ENDOCRINOLOGY, V122, P1224, DOI 10.1210/endo-122-4-1224; DAVIS BH, 1993, BIOCHEM J, V294, P785, DOI 10.1042/bj2940785; DAVIS BH, 1991, BIOCHEM J, V278, P43, DOI 10.1042/bj2780043; DAVIS BH, 1987, J BIOL CHEM, V262, P10280; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DRITTANTI L, 1989, BIOCHIM BIOPHYS ACTA, V1014, P112, DOI 10.1016/0167-4889(89)90022-0; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; FRIEDMAN SL, 1992, HEPATOLOGY, V16, pA143; HALLINE AG, 1994, ENDOCRINOLOGY, V134, P1710, DOI 10.1210/en.134.4.1710; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JURUTKA PW, 1993, J BIOL CHEM, V268, P6791; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KHALIL RA, 1993, AM J PHYSIOL, V265, pC406, DOI 10.1152/ajpcell.1993.265.2.C406; KOBAYASHI Y, 1992, HEPATOLOGY, V16, pA143; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LISSOOS TW, 1993, J BIOL CHEM, V268, P25132; LISSOOS TW, 1993, HEPATOLOGY, V18, pA161; MITSUHASHI T, 1991, J CLIN INVEST, V87, P1889, DOI 10.1172/JCI115213; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PINZANI M, 1990, ENDOCRINOLOGY, V127, P2343, DOI 10.1210/endo-127-5-2343; RAPP UR, 1991, ONCOGENE, V6, P495; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROUET P, 1992, BIOTECHNIQUES, V13, P700; RUPPRECHT HD, 1993, AM J PHYSIOL, V265, pF351, DOI 10.1152/ajprenal.1993.265.3.F351; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SEGER R, 1992, J BIOL CHEM, V267, P14373; SETH A, 1992, J BIOL CHEM, V267, P24796; SOZERI O, 1992, ONCOGENE, V7, P2259; TIEN XY, 1993, AM J PHYSIOL, V265, pG143, DOI 10.1152/ajpgi.1993.265.1.G143; WALI RK, 1990, J CLIN INVEST, V85, P1296, DOI 10.1172/JCI114567; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	48	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3642	3647		10.1074/jbc.270.8.3642	http://dx.doi.org/10.1074/jbc.270.8.3642			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876102	hybrid			2022-12-25	WOS:A1995QH68800030
J	ODA, T; CHEN, CH; WU, HC				ODA, T; CHEN, CH; WU, HC			CERAMIDE REVERSES BREFELDIN-A (BFA) RESISTANCE IN BFA-RESISTANT CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PERIPHERAL MEMBRANE-PROTEIN; GOLGI-APPARATUS; INTRACELLULAR TRANSLOCATION; ADP-RIBOSYLTRANSFERASE; NUCLEOTIDES MODULATE; CULTURED FIBROBLASTS; SECRETORY PROTEINS; PSEUDOMONAS TOXIN; RAT HEPATOCYTES	We have found that C-6 ceramide, a cell-permeable ceramide analog, partially restored the brefeldin A (BFA) sensitivity in a BFA-resistant mutant of Vero cells (BER-40) and in the naturally BFA-resistant Madin-Darby canine kidney (MDCK) cells. Incubation of BER-40 and MDCK cells with low concentrations of C-6 ceramide resulted in (i) a pronounced increase in BFA cytotoxicity as measured by the inhibition of [H-3]thymidine incorporation and the inhibition of colony formation by BFA, (ii) a significant protection by BFA against ricin cytotoxicity, and (iii) an inhibition of bulk protein secretion by BFA in BER-40 and MDCK: cells. Related sphingolipids including sphingosine, sphingomyelin, and lactosylceramide and other unrelated Lipid second messengers such as arachidonic acid and 1,2-diacylglycerol did not elicit the protection of BER-40 and MDCK cells against ricin cytotoxicity by BFA. C-6 ceramide was the most effective among the ceramides with different acyl chain lengths. Interestingly, dihydro-C-6 ceramide, which lacks the trans double bond in the sphingoid base, had no effect. On the other hand, C-6 ceramide did not enhance BFA sensitivity in BFA-sensitive Vero cells. The LD(50) of C-6 ceramide were similar in Vero and BER-40 cells. Fluorescence microscopic studies revealed that C-6 ceramide induced the redistribution of P-COP from the Golgi membranes to a more dispersed localization in both BFA-sensitive and BFA-resistant cell Lines, mimicking the effect of BFA. Suboptimal concentration of C-6 ceramide also restored the effect of BFA on the beta-COP distribution in BER-40 and MDCK cells. These results indicate that C-6 ceramide restores the BFA sensitivity in BFA-resistant BER-40 and MDCK cells.	UNIFORMED SERV UNIV HLTH SCI, DEPT IMMUNOL & MICROBIOL, BETHESDA, MD 20814 USA	Uniformed Services University of the Health Sciences - USA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028810] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28810] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; CHEN C, 1992, EXP CELL RES, V203, P321, DOI 10.1016/0014-4827(92)90005-S; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HAKOMORI SI, 1983, HDB LIPID RES, V3, P327; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; ITO M, 1986, J BIOL CHEM, V261, P14278; KIM MY, 1991, J BIOL CHEM, V266, P484; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LINARDIC CM, 1992, J BIOL CHEM, V267, P14909; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LOW SH, 1991, J BIOL CHEM, V266, P17729; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ODA T, 1993, J BIOL CHEM, V268, P12596; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; ROSENWALD AG, 1993, J BIOL CHEM, V268, P4577; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; SUGAI M, 1992, J BIOL CHEM, V267, P21297; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; YOSHIDA T, 1990, EXP CELL RES, V190, P11, DOI 10.1016/0014-4827(90)90137-Y; ZEUZEM S, 1991, FEBS LETT, V288, P143, DOI 10.1016/0014-5793(91)81021-Y; ZIZI M, 1991, J BIOL CHEM, V266, P18443	45	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4088	4092		10.1074/jbc.270.8.4088	http://dx.doi.org/10.1074/jbc.270.8.4088			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876158	hybrid			2022-12-25	WOS:A1995QH68800091
J	WRAY, JW; ABELES, RH				WRAY, JW; ABELES, RH			THE METHIONINE SALVAGE PATHWAY IN KLEBSIELLA-PNEUMONIAE AND RAT-LIVER - IDENTIFICATION AND CHARACTERIZATION OF 2 NOVEL DIOXYGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-METHYLTHIORIBOSE KINASE; MICROBIAL-METABOLISM; CARBON-MONOXIDE; ENZYME; QUINOLINE	The 5-methylthio-D-ribose moiety of 5'-(methylthio)adenosine is converted to methionine in a wide variety of organisms, 1,2-Dihydroxy-3-keto-5-methylthiopentene anion (an aci-reductone) is an advanced intermediate in the methionine salvage pathway present in the Gram-negative bacterium Klebsiella pneumoniae and rat liver, This metabolite is oxidized spontaneously in air to formate and 2-keto-4-methylthiobutyric acid (the alpha-keto acid precursor of methionine), Previously, we had purified an enzyme (E2) from Klebsiella which catalyzes the oxidative degradation of the aci-reductone to formate, CO, and methylthiopropionic acid. To further characterize the reactions of the aci-reductone we used its desthio analog, 1-2-dihydroxy-3-ketohexene anion (III), which was described previously, This molecule undergoes the analogous enzymatic and non-enzymatic reactions of the natural substrate, namely the formation of formate, CO, and butyrate from III, Experiments with O-18(2) show that E2 is a dioxygenase which incorporates one molecule of O-18 into formate and butyric acid, No cofactor has been identified, We were unable to find an enzyme which catalyzes the conversion of 1,2-dihydroxy-3-keto-5-methylthiopentane to a keto acid precursor of methionine, The keto acid is probably produced non enzymically in Klebsiella. We have, however, identified and purified an enzyme (E3) from rat liver, which catalyzes the formation of formate and 2-oxopentanoic acid from III, This enzyme has a monomeric molecular mass of 28,000 daltons, and no chromophoric cofactor has been identified, Experiments with O-18(2) show that E3 is a dioxygenase which incorporates an O-18 molecule into formate and the alpha-keto acid, In rat liver CO formation was not detected,	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	University of Oregon					NIGMS NIH HHS [GM07596] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELL LM, 1991, BIOCHEMISTRY-US, V30, P7883, DOI 10.1021/bi00246a002; BARTON, 1965, J CHEM SOC 3, P3563; BAUER L, 1994, FEMS MICROBIOL LETT, V117, P299; BOTT G, 1990, BIOL CHEM H-S, V371, P999, DOI 10.1515/bchm3.1990.371.2.999; DEBEYER A, 1993, BIOL CHEM H-S, V374, P101, DOI 10.1515/bchm3.1993.374.1-6.101; DUERRE JA, 1962, J BIOL CHEM, V237, P3737; FERRO AJ, 1978, J BIOL CHEM, V253, P6021; FERRO AJ, 1976, BIOCHIM BIOPHYS ACTA, V438, P487, DOI 10.1016/0005-2744(76)90264-3; FURFINE ES, 1988, J BIOL CHEM, V263, P9598; GERSMANN HR, 1971, J CHEM SOC C, V12, P2230; GIANOTTI AJ, 1990, J BIOL CHEM, V265, P831; HUTCHINSON CR, 1977, J LABELLED COMPD RAD, V13, P571, DOI 10.1002/jlcr.2580130415; Maxwell J C, 1978, Methods Enzymol, V54, P302; MYERS RW, 1993, J BIOL CHEM, V268, P24785; OKA T, 1971, BIOCHEM BIOPH RES CO, V43, P1, DOI 10.1016/S0006-291X(71)80076-1; RUSSELL GA, 1968, ADV CHEM SER, V75, P174; SIMPSON FJ, 1960, BIOCHEM BIOPH RES CO, V2, P15, DOI 10.1016/0006-291X(60)90255-2; STARK BP, 1967, EXTRUSION REACTIONS, P16; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TRACKMAN PC, 1981, BIOCHEM BIOPH RES CO, V103, P1238, DOI 10.1016/0006-291X(81)90255-2; Tsuji J., 1969, SYNTHESIS-STUTTGART, P157, DOI DOI 10.1055/S-1969-34197; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Waterman M R, 1978, Methods Enzymol, V52, P456; WESTLAKE DWS, 1959, CAN J MICROBIOL, V5, P621, DOI 10.1139/m59-076; WRAY JW, 1993, J BIOL CHEM, V268, P21466	25	100	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3147	3153		10.1074/jbc.270.7.3147	http://dx.doi.org/10.1074/jbc.270.7.3147			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852397	hybrid			2022-12-25	WOS:A1995QG47100040
J	SHAULIAN, E; HAVIV, I; SHAUL, Y; OREN, M				SHAULIAN, E; HAVIV, I; SHAUL, Y; OREN, M			TRANSCRIPTIONAL REPRESSION BY THE C-TERMINAL DOMAIN OF P53	ONCOGENE			English	Article						P53; TRANSCRIPTION; TRANSACTIVATION	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR GENES; TATA-BINDING PROTEIN; DNA-BINDING; RESPONSIVE ELEMENT; ACTIVATION DOMAIN; SEQUENCE; TRANSFORMATION; INHIBITION	We have previously shown that monomeric p53 can transactivate target genes in vivo and that C-terminal fragments of p53 are oncogenic. To further elaborate these findings a series of C-terminal truncations of p53 was generated. The transactivation capacity and the ability of the truncated p53 to suppress oncogene-mediated transformation were studied. We found that p53 truncated at amino acid 303 (p53wtdl303) can still function in both assays, though less efficiently than full length wild type (wt) p53. Transforming C-terminal fragments inhibited transactivation induced by full length wt p53. Surprisingly, they also inhibited transactivation by wtdl303, with which they do not share e any overlapping sequences. Furthermore, the C-terminal fragments repressed the transactivation domains of several viral and cellular transcriptional activators. These data raise the possibility that the C-terminal domain of p53 may compete with the p53 transactivation domain for a common basal transcription factor.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science			Haviv, Izhak/E-3782-2015	Haviv, Izhak/0000-0002-0837-5005	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, IN PRESS GENE DEV; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BERNS A, 1994, CURR BIOL, V4, P137, DOI 10.1016/S0960-9822(94)00031-X; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1944, SCIENCE, V265, P386; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HUPP TR, 1994, IN PRESS COLD SPRING, V59; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reed Michael, 1993, Gene Expression, V3, P95; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	80	73	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					671	680						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862444				2022-12-25	WOS:A1995QH61200006
J	GOLDWASSER, E; ALIBALI, P; GARDNER, A				GOLDWASSER, E; ALIBALI, P; GARDNER, A			DIFFERENTIAL INHIBITION BY IODONIUM COMPOUNDS OF INDUCED ERYTHROPOIETIN EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CAROTID-BODY; NADPH OXIDASE; PO2 SENSOR; PROTEIN; CELLS; GENE; NEUTROPHILS	Diphenylene iodonium chloride suppresses the cobaltous chloride-induced expression of erythropoietin by Hep3B cells to about 50% at a concentration of 30 nM. At that concentration, it has no effect on the response to low oxygen. The related compound iodonium diphenyl chloride acts similarly but is a much less effective inhibitor. If, as reported, diphenylene iodonium chloride is a specific inhibitor of cytochrome b, it follows that the response to CoCl2 is dependent on that enzyme but the response to hypoxia is not.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago					NHLBI NIH HHS [HL30121, HL21676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030121, R37HL021676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKER H, 1989, FEBS LETT, V256, P75, DOI 10.1016/0014-5793(89)81721-1; BERU N, 1986, MOL CELL BIOL, V6, P2571, DOI 10.1128/MCB.6.7.2571; CROSS AR, 1987, BIOCHEM PHARMACOL, V36, P489, DOI 10.1016/0006-2952(87)90356-X; DELPIANO MA, 1989, BRAIN RES, V482, P235, DOI 10.1016/0006-8993(89)91186-4; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; FISHMAN MC, 1985, P NATL ACAD SCI USA, V82, P1448, DOI 10.1073/pnas.82.5.1448; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOLDBERG MA, 1982, P NATL ACAD SCI USA, V84, P7972; GOLDWASSER E, 1957, SCIENCE, V125, P1085, DOI 10.1126/science.125.3257.1085; GORLACH A, 1993, BIOCHEM J, V290, P771; JIANG C, 1994, P NATL ACAD SCI USA, V91, P7198, DOI 10.1073/pnas.91.15.7198; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; SHERWOOD JB, 1979, BLOOD, V54, P885; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0	16	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2628	2629		10.1074/jbc.270.6.2628	http://dx.doi.org/10.1074/jbc.270.6.2628			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852328	hybrid			2022-12-25	WOS:A1995QF53500036
J	KULAS, DT; ZHANG, WR; GOLDSTEIN, BJ; FURLANETTO, RW; MOONEY, RA				KULAS, DT; ZHANG, WR; GOLDSTEIN, BJ; FURLANETTO, RW; MOONEY, RA			INSULIN-RECEPTOR SIGNALING IS AUGMENTED BY ANTISENSE INHIBITION OF THE PROTEIN-TYROSINE-PHOSPHATASE LAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LEUKOCYTE COMMON ANTIGEN; TRANSMEMBRANE PHOSPHOTYROSINE PHOSPHATASE; GROWTH FACTOR-I; PHOSPHATIDYLINOSITOL 3'-KINASE; INTACT-CELLS; DEPHOSPHORYLATION; ACTIVATION; EXPRESSION; KINASE; STIMULATION	Considerable evidence has shown that most physiologic responses to insulin require activation of the intrinsic tyrosine kinase of the insulin receptor, Biochemical studies have also supported the hypothesis that receptor kinase activity can be modulated by cellular protein tyrosine phosphatases (PTPases), which have not yet been identified, To test the hypothesis that the transmembrane PTPase LAR can modulate insulin receptor signaling in vivo, antisense RNA expression was used to specifically suppress LAR protein levels by 63% in the rat hepatoma cell line, McA-RH7777. Hormone-dependent autophosphorylation of the insulin receptor was increased by approximately 150% in the antisense-expressing cells at all insulin concentrations tested. This increase in autophosphorylation was paralleled by a 35% increase in insulin receptor tyrosine kinase activity. Reduced LAR levels did not alter non-hormone-dependent tyrosine phosphorylation nor basal insulin receptor tyrosine phosphorylation and kinase activity. Most significantly, reduced LAR levels resulted in a 350% increase in insulin-dependent phosphatidylinositol 3-kinase activity. These studies provide unique in vivo evidence that LAR is involved In the modulation of insulin receptor signaling in intact cells.	UNIV ROCHESTER,SCH MED & DENT,DEPT LAB MED & PATHOL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV ENDOCRINOL & METAB DIS,PHILADELPHIA,PA 19107	University of Rochester; University of Rochester; Jefferson University					NCI NIH HHS [R01-CA38981] Funding Source: Medline; NIDDK NIH HHS [R01-DK43396, R01-DK38138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038138, R01DK043396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; GOLDSTEIN BJ, 1993, RECEPTOR, V3, P1; GOLDSTEIN BJ, 1991, ADV PROTEIN PHOSPHAT, V6, P1; HASHIMOTO N, 1992, BIOCHEM BIOPH RES CO, V188, P1305, DOI 10.1016/0006-291X(92)91373-X; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LONGO FM, 1993, J BIOL CHEM, V268, P26503; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; MOONEY RA, 1992, J BIOL CHEM, V267, P14054; OKADA T, 1994, J BIOL CHEM, V269, P3568; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAY BA, 1993, J BIOL CHEM, V268, P26409; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597	21	141	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2435	2438		10.1074/jbc.270.6.2435	http://dx.doi.org/10.1074/jbc.270.6.2435			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852302	hybrid			2022-12-25	WOS:A1995QF53500007
J	STROHMEIER, GR; REPPERT, SM; LENCER, WI; MADARA, JL				STROHMEIER, GR; REPPERT, SM; LENCER, WI; MADARA, JL			THE A(2B) ADENOSINE RECEPTOR MEDIATES CAMP RESPONSES TO ADENOSINE RECEPTOR AGONISTS IN HUMAN INTESTINAL EPITHELIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-DERIVED SECRETAGOGUE; CHLORIDE SECRETION; CELL-LINE; MOLECULAR-CLONING; CL SECRETION; T84 CELLS; ELECTROLYTE SECRETION; MESSENGER SYSTEMS; APICAL MEMBRANE; EXPRESSION	Adenosine is thought to be a major effector in immunological stimulation of Cl- secretion in intestinal epithelia. Previous studies indicate that both apical and basolateral domains of intestinal epithelial cells possess functionally defined adenosine receptors. However, it is unclear whether the same receptor subclass is expressed, what the receptor subclass(es) is, or how the receptors signal the Cl- secretory response. We now characterize the intestinal epithelial adenosine receptor subtype using the model epithelium, T84. Both apical and basolateral adenosine receptor agonist response profiles revealed a hierarchy (ED(50)) of 5'-(N-ethylcarboxamido)adenosine > adenosine > CGS-21680. Similarly, inhibition studies revealed identical ID50 hierarchies for apical and basolateral antagonism by xanthine amine congener > 1,3-diethyl-8-phenylxanthine > aminophylline. Analyses of both agonist and antagonist pharmacological hierarchies in Chinese hamster ovary cells stably expressing the A(2b) receptor revealed these same hierarchies, Northern blots performed on RNA extracted from polarized T84 monolayers demonstrated no detectable message for A(1) or A(2a) adenosine receptor, but strong hybridization was detected for the A(2b) adenosine receptor. Subsequent Northern blots of RNA prepared from human alimentary tract revealed that A(2b) adenosine receptor message was heavily expressed throughout the colon, in the appendix, and more modestly expressed in the small intestine (ileum), Analyses of cAMP generation in T84 cells in response to adenosine indicated that the basolateral A(2b) receptor elicits Cl- secretion through this signaling pathway, Stimulation of Cl- secretion through the apical A(2b) receptor exhibited relatively small but significant increases in cAMP compared with basolateral stimulation, The protein kinase A inhibitor H-89, used at concentrations that did not affect short circuit current responses to the Ca2+-mediated agonist carbachol, effectively inhibited short circuit current elicited by either apical or basolateral adenosine, These data suggest that the major intestinal epithelial adenosine receptor is the A(2b) subclass, which is positively coupled to adenylate cyclase, Such observations have potentially important implications for the treatment of diarrheal diseases.	MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS HOSP,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	STROHMEIER, GR (corresponding author), BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV GASTROINTESTINAL PATHOL,20 SHATTUCK ST,THORN 1419,BOSTON,MA 02115, USA.			Lencer, Wayne/0000-0001-7346-2730	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047662, R01DK035932, R01DK042125, R37DK035932] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35932, DK-42125, DK-47662] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRETT KE, 1993, AM J PHYSIOL, V264, pC446, DOI 10.1152/ajpcell.1993.264.2.C446; BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; BARRETT KE, 1989, AM J PHYSIOL, V256, pC197; BARRETT KE, 1990, AM J PHYSIOL, V258, pC902, DOI 10.1152/ajpcell.1990.258.5.C902; Binder HJ, 1987, PHYSL GASTROINTESTIN, P1389; BRUNER G, 1993, NEUROSCI LETT, V162, P105, DOI 10.1016/0304-3940(93)90571-2; BRUNS RF, 1986, MOL PHARMACOL, V29, P331; Chang Eugene B., 1994, P2027; COLGAN SP, 1992, J LEUKOCYTE BIOL, V52, P183, DOI 10.1002/jlb.52.2.183; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CRONSTEIN BN, 1992, J IMMUNOL, V148, P2201; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; DHO S, 1992, AM J PHYSIOL, V262, pC67, DOI 10.1152/ajpcell.1992.262.1.C67; DOBBINS JW, 1984, J CLIN INVEST, V74, P929, DOI 10.1172/JCI111511; FENOGLIOPREISER CM, 1989, GASTROINTESTINAL PAT, P427; GRASL M, 1984, J PHYSIOL-LONDON, V346, P93, DOI 10.1113/jphysiol.1984.sp015009; HALM DR, 1988, AM J PHYSIOL, V254, pC505, DOI 10.1152/ajpcell.1988.254.4.C505; HALM DR, 1990, TXB SECRETORY DIARRH, P47; KEMP PJ, 1993, AM J PHYSIOL, V265, pL323, DOI 10.1152/ajplung.1993.265.4.L323; KUMAR NB, 1982, AM J SURG PATHOL, V6, P523, DOI 10.1097/00000478-198209000-00004; LINDEN J, 1993, MOL PHARMACOL, V44, P524; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; MADARA JL, 1992, J CLIN INVEST, V89, P1938, DOI 10.1172/JCI115800; MADARA JL, 1993, J CLIN INVEST, V91, P2320, DOI 10.1172/JCI116462; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MANDEL KG, 1986, J BIOL CHEM, V261, P704; MARQUARDT DL, 1984, P NATL ACAD SCI-BIOL, V81, P6192, DOI 10.1073/pnas.81.19.6192; MOHUCZYDOMINIAK D, 1992, AM J PHYSIOL, V263, pC1289, DOI 10.1152/ajpcell.1992.263.6.C1289; NASH S, 1991, J CLIN INVEST, V87, P1474, DOI 10.1172/JCI115156; NASH S, 1987, J CLIN INVEST, V80, P1104, DOI 10.1172/JCI113167; PARKOS CA, 1992, J CELL BIOL, V117, P757, DOI 10.1083/jcb.117.4.757; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; PIERCE KD, 1992, BIOCHEM BIOPH RES CO, V187, P86, DOI 10.1016/S0006-291X(05)81462-7; PRATT AD, 1986, AM J PHYSIOL, V251, pC167, DOI 10.1152/ajpcell.1986.251.2.C167; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; RIVKEES SA, 1992, MOL ENDOCRINOL, V6, P1598, DOI 10.1210/me.6.10.1598; SHAPIRO M, 1991, J CLIN INVEST, V87, P1903, DOI 10.1172/JCI115215; SMBROOK J, 1989, MOL CLONING LABORTOR; STEHLE JH, 1992, MOL ENDOCRINOL, V6, P384, DOI 10.1210/me.6.3.384; WANG YZ, 1990, AM J PHYSIOL, V258, pG432, DOI 10.1152/ajpgi.1990.258.3.G432; WEINSTEIN L, 1978, SEMINARS INFECTIOUS, V1, P89; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054; WILLIAMS M, 1987, ANNU REV PHARMACOL, V27, P315	44	198	202	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2387	2394		10.1074/jbc.270.5.2387	http://dx.doi.org/10.1074/jbc.270.5.2387			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836474	hybrid, Green Submitted			2022-12-25	WOS:A1995QE49300062
J	VASIOUKHIN, V; SERFAS, MS; SIYANOVA, EY; POLONSKAIA, M; COSTIGAN, VJ; LIU, B; THOMASON, A; TYNER, AL				VASIOUKHIN, V; SERFAS, MS; SIYANOVA, EY; POLONSKAIA, M; COSTIGAN, VJ; LIU, B; THOMASON, A; TYNER, AL			A NOVEL INTRACELLULAR EPITHELIAL-CELL TYROSINE KINASE IS EXPRESSED IN THE SKIN AND GASTROINTESTINAL-TRACT	ONCOGENE			English	Article						INTESTINE; SKIN; TYROSINE KINASE; EPITHELIA	SH3 DOMAINS; TERMINAL DIFFERENTIATION; SIGNAL TRANSDUCTION; GENE-EXPRESSION; PROTEIN-KINASE; STEM-CELLS; MOUSE; FAMILY; RAS; DROSOPHILA	A portion of the catalytic domain of a novel tyrosine kinase was cloned from mouse intestinal crypt cells, in a screen designed to identify kinases that may play a role in the regeneration of the intestinal epithelium (E Siyanova, MS Serfas, IA Mazo and AL Tyner, Oncogene 9, 2053-2057). We have cloned a cDNA encoding this kinase, termed sik for src-related intestinal kinase. The sik cDNA encodes a 451 amino acid protein that shares 80% identity with the recently cloned human tyrosine kinase, brk. Sequences found in src family kinases, such as SH2 and SH3 domains and a putative regulatory tyrosine at the carboxy terminus are found in the sik kinase. In contrast, sik lacks a myristylation site. The protein encoded by the sik cDNA has tyrosine kinase activity when expressed in E. coli, We have determined that sik is expressed only in epithelial tissues, including the skin and lining of the alimentary canal, and using in situ hybridization we show that expression of sik mRNA is restricted to the cell layers immediately above the proliferative cell zone in these epithelia, The sik mRNA is first detected at day 15.5 of gestation in the mouse embryo, where it is expressed in the newly forming granular layer of the skin. The restricted expression of sik to differentiating cells of rapidly renewing epithelia suggests that sik may play a specialized role in these tissues.	UNIV ILLINOIS, COLL MED, DEPT GENET, CHICAGO, IL 60612 USA; AMGEN INC, AMGEN CTR, DEPT MOLEC BIOL, THOUSAND OAKS, CA 91320 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Amgen				Tyner, Angela/0000-0001-7448-8625; Vasioukhin, Valeri/0000-0002-6730-0281	NIDDK NIH HHS [R01 DK044525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044525] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FISHER C, 1987, CURR TOP DEV BIOL, V22, P209; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERMOS JA, 1971, J CELL BIOL, V50, P255, DOI 10.1083/jcb.50.1.255; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; LEE ST, 1993, ONCOGENE, V8, P3403; LINDBERG RA, 1988, ONCOGENE, V3, P629; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MESSIER B, 1960, AM J ANAT, V106, P247, DOI 10.1002/aja.1001060305; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OTTILIE S, 1992, ONCOGENE, V7, P1625; PAWSON T, 1994, CURR OPIN GENET DEV, V4, P1, DOI 10.1016/0959-437X(94)90084-1; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RUGH R, 1991, MOUSE ITS REPRODUCTI; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TYNER AL, 1990, J CELL BIOL, V110, P915, DOI 10.1083/jcb.110.4.915; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	76	79	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					349	357						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838533				2022-12-25	WOS:A1995QC62400014
J	CHO, MJ; CUMMINGS, RD				CHO, MJ; CUMMINGS, RD			GALECTIN-1, A BETA-GALACTOSIDE-BINDING LECTIN IN CHINESE-HAMSTER OVARY CELLS .2. LOCALIZATION AND BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLLACTOSAMINE CHAINS; S-TYPE LECTIN; CALF HEART; EXTRACELLULAR-MATRIX; MUSCLE LECTIN; LUNG; AGGLUTININ; DEFICIENT; MECHANISM; ADHESION	In the accompanying study (Cho, M., and Cummings, R. D. (1995) J. Biol. Chem. 270, 5198-5206), we reported that Chinese hamster ovary (CHO) cells synthesize galectin-1. We have now used several approaches to define the subcellular location and biosynthesis of galectin-1 in these cells. Galectin-1 was present on the cell surface, as assessed by immunofluorescent staining with monospecific antibody to the protein. Quantitation of the surface localized galectin-1 was achieved by metabolically radiolabeling cells with [S-35]Met/Cys and measuring the amount of lectin (i) sensitive to trypsin, (ii) accessible to biotinylating reagents, and (iii) accessible to the haptenic disaccharide lactose. By all three procedures, approximate to 1/2 of the radiolabeled galectin-1 associated with cells was shown to be on the cell surface with the remainder intracellular. The kinetics of externalization of galectin-1 was monitored by pulse-chase radiolabeling, and it was shown that cells secrete the protein with a t(1/2) approximate to 20 h. The cell surface form of galectin-1 in CHO cells was active and bound to surface glycoconjugates, but lectin accumulating in the culture media was inactive. Lectin synthesized by mutant Lec8 CHO cells, which are unable to galactosylate glycoproteins, was not found on the surface and quantitatively accumulated in the media in an inactive form. Taken together, our results demonstrate that galectin-1 is quantitatively externalized by CHO cells and can associate with surface glycoconjugates where the lectin activity is stabilized.			CHO, MJ (corresponding author), UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CTR MOLEC MED, OKLAHOMA CITY, OK 73190 USA.				NATIONAL CANCER INSTITUTE [R01CA037626] Funding Source: NIH RePORTER; NCI NIH HHS [CA37626] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN HJ, 1990, J CELL BIOCHEM, V43, P43, DOI 10.1002/jcb.240430105; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BRILES EB, 1977, J BIOL CHEM, V252, P1107; BRILES EB, 1979, J CELL BIOL, V81, P528, DOI 10.1083/jcb.81.3.528; CHO MJ, 1995, J BIOL CHEM, V270, P5198, DOI 10.1074/jbc.270.10.5198; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEWAARD A, 1976, J BIOL CHEM, V251, P7581; DO KY, 1990, BIOCHEM BIOPH RES CO, V173, P1123, DOI 10.1016/S0006-291X(05)80902-7; GITT MA, 1986, P NATL ACAD SCI USA, V83, P7603, DOI 10.1073/pnas.83.20.7603; HARRISON FL, 1992, J CELL SCI, V101, P635; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P775, DOI 10.1093/jb/101.3.775; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; NOWAK TP, 1976, BIOCHEM BIOPH RES CO, V68, P650, DOI 10.1016/0006-291X(76)91195-5; ORR GA, 1981, J BIOL CHEM, V256, P761; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; SMITH DF, 1990, J BIOL CHEM, V265, P6225; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; TEICHBERG VI, 1975, P NATL ACAD SCI USA, V72, P1383, DOI 10.1073/pnas.72.4.1383; TRACEY BM, 1992, J BIOL CHEM, V267, P10342; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	25	120	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5207	5212		10.1074/jbc.270.10.5207	http://dx.doi.org/10.1074/jbc.270.10.5207			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890631	hybrid			2022-12-25	WOS:A1995QL58000040
J	FARRENS, DL; KHORANA, HG				FARRENS, DL; KHORANA, HG			STRUCTURE AND FUNCTION IN RHODOPSIN .11. MEASUREMENT OF THE RATE OF METARHODOPSIN-II DECAY BY FLUORESCENCE SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE RHODOPSIN; CONFORMATIONAL-CHANGES; PATHWAYS	An increase in fluorescence is observed upon light activation of bovine rhodopsin. The rate of increase is monoexponential (t(1/2) = 15.5 min) at 20 degrees C in 0.1% lauryl maltoside, pH 6.0, and parallels the rate of decay of metarhodopsin II. We show that the increase in fluorescence is due to the release of free retinal, which no longer quenches the tryptophan fluorescence. An extrinsic fluorescence reporter group, pyrene maleimide, attached to bovine rhodopsin also shows an increase in pyrene fluorescence on illumination. The rate of increase in pyrene fluorescence matches the rate of increase in tryptophan fluorescence. This result has been used to develop a micromethod, requiring on the order of 1 mu g of rhodopsin, for measurement of metarhodopsin II decay. An Arrhenius plot derived from the fluorescence assay shows the energy of activation barrier for retinal release from rhodopsin to be 20.2 kcal/mol in 0.1% dodecyl maltoside at pH 6.0.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL EYE INSTITUTE [F32EY006465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER; NEI NIH HHS [1-F32-EY06465] Funding Source: Medline; NIGMS NIH HHS [GM28289] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT N, 1982, EUR J BIOCHEM, V127, P97, DOI 10.1111/j.1432-1033.1982.tb06842.x; BLAZYNSKI C, 1984, VISION RES, V24, P459, DOI 10.1016/0042-6989(84)90043-9; BLAZYNSKI C, 1981, VISION RES, V21, P833, DOI 10.1016/0042-6989(81)90183-8; BOROCHOVNEORI H, 1983, BIOCHEMISTRY-US, V22, P197, DOI 10.1021/bi00270a029; BOWNDS D, 1965, NATURE, V205, P254, DOI 10.1038/205254a0; CHIBA T, 1978, BIOCHEM BIOPH RES CO, V85, P551, DOI 10.1016/0006-291X(78)91198-1; DEGRIP WJ, 1982, METHOD ENZYMOL, V81, P197; EBREY TG, 1968, VISION RES, V8, P965, DOI 10.1016/0042-6989(68)90071-0; EBREY TG, 1971, P NATL ACAD SCI USA, V68, P713, DOI 10.1073/pnas.68.4.713; EBREY TG, 1972, PHOTOCHEM PHOTOBIOL, V15, P585, DOI 10.1111/j.1751-1097.1972.tb06269.x; FARRENS DL, 1992, PHOTOCHEM PHOTOBIOL, V54, P313; HUBBARD R, 1965, COLD SPRING HARB SYM, V30, P301, DOI 10.1101/SQB.1965.030.01.032; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KROFP A, 1967, VISION RES, V7, P811, DOI 10.1016/0042-6989(67)90001-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RESEK JF, 1994, P NATL ACAD SCI USA, V91, P7643, DOI 10.1073/pnas.91.16.7643; SAKAMOTO T, 1995, P NATL ACAD SCI USA, V92, P249, DOI 10.1073/pnas.92.1.249; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	22	170	170	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5073	5076		10.1074/jbc.270.10.5073	http://dx.doi.org/10.1074/jbc.270.10.5073			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890614	hybrid			2022-12-25	WOS:A1995QL58000021
J	YANG, B; JUNG, D; RAFAEL, JA; CHAMBERLAIN, JS; CAMPBELL, KP				YANG, B; JUNG, D; RAFAEL, JA; CHAMBERLAIN, JS; CAMPBELL, KP			IDENTIFICATION OF ALPHA-SYNTROPHIN BINDING TO SYNTROPHIN TRIPLET, DYSTROPHIN, AND UTROPHIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; GLYCOPROTEIN COMPLEX; POINT MUTATIONS; PROTEIN; TORPEDO; DEFICIENCY; ASSOCIATION; SARCOLEMMA; TISSUE	Syntrophin represents three cytoplasmic components of the dystrophin-glycoprotein complex that links the cytoskeleton to the extracellular matrix in skeletal muscle. alpha-Syntrophin has now been translated in vitro and shown to associate directly with all three components of the syntrophin triplet and with dystrophin. The in vitro translated 71-kDa non-muscle dystrophin isoform, containing the cysteine-rich/C-terminal domain, can also interact with the syntrophin triplet. The syntrophin binding motif in dystrophin was localized to exons 73 and 74 including amino acids 3447-3481 by comparing the interactions of alpha-syntrophin and seven overlapping human dystrophin fusion proteins. More than one syntrophin interaction site in this binding motif was suggested. alpha-Syntrophin also interacts directly with a C-terminal utrophin fusion protein. alpha-Syntrophin is localized to the muscle sarcolemma as well as to the neuromuscular junction in control mouse muscle. However, similar to utrophin, alpha-syntrophin is only present at the neuromuscular junction in mdx mouse muscle in which dystrophin is absent. Our data suggest that alpha-syntrophin binds all syntrophin isoforms, and syntrophin directly interacts with dystrophin through more than one binding site in dystrophin exons 73 and 74 including amino acids 3447-3481.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR HUMAN GENOME,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Rafael-Fortney, Jill/E-3909-2011	Campbell, Kevin/0000-0003-2066-5889; Chamberlain, Jeffrey/0000-0001-5299-0059				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; ANDERSON MS, 1992, TRENDS BIOCHEM SCI, V17, P289, DOI 10.1016/0968-0004(92)90437-E; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CARTAUD A, 1993, J BIOL CHEM, V268, P13019; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; COX GA, 1994, NAT GENET, V8, P333, DOI 10.1038/ng1294-333; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GREENBERG DS, 1994, NAT GENET, V8, P340, DOI 10.1038/ng1294-340; Harian J. E., 1994, NATURE, V371, P168, DOI 10.1038/371168a0; IBRAGHINOVBESKR, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOENIG M, 1989, AM J HUM GENET, V45, P498; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LENK U, 1993, HUM MOL GENET, V2, P1877, DOI 10.1093/hmg/2.11.1877; MATSUMURA K, 1993, J CLIN INVEST, V92, P866, DOI 10.1172/JCI116661; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; ROBERTS RG, 1992, P NATL ACAD SCI USA, V89, P2331, DOI 10.1073/pnas.89.6.2331; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; YANG B, 1994, J BIOL CHEM, V269, P6040; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	37	115	119	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					4975	4978		10.1074/jbc.270.10.4975	http://dx.doi.org/10.1074/jbc.270.10.4975			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890602	hybrid			2022-12-25	WOS:A1995QL58000006
J	ALI, MS; SHENOY, BC; ESWARAN, D; ANDERSSON, LA; ROCHE, TE; PATEL, MS				ALI, MS; SHENOY, BC; ESWARAN, D; ANDERSSON, LA; ROCHE, TE; PATEL, MS			IDENTIFICATION OF THE TRYPTOPHAN RESIDUE IN THE THIAMIN PYROPHOSPHATE BINDING-SITE OF MAMMALIAN PYRUVATE-DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-KETOACID DEHYDROGENASE; MAGNETIC CIRCULAR-DICHROISM; BETA-SUBUNIT; 3-DIMENSIONAL STRUCTURE; ACID DEHYDROGENASE; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; CDNA CLONES; COMPLEX; COMPONENT	The pyruvate dehydrogenase (E1) component of the mammalian pyruvate dehydrogenase complex catalyzes the oxidative decarboxylation of pyruvate with the formation of an acetyl residue and reducing equivalents, which are transferred sequentially to the dihydrolipoyl acetyltransferase and dihydrolipoamide dehydrogenase components, To examine the role of tryptophanyl residue(s) in the active site of E1, the enzyme was modified with the tryptophan-specific reagent N-bromosuccinimide. Modification of 2 tryptophan residues/mol of bovine E1 (out of 12 in a tetramer alpha(2) beta(2)) resulted in complete inactivation of the enzyme. The inactivation was prevented by preincubation with thiamin pyrophosphate (TPP), indicating that the modified tryptophan residue(s) is a part of the active site of this enzyme. Fluorescence studies showed that thiamin pyrophosphate interacts with tryptophan residue(s) of E1, The magnetic circular dichroism (MCD) spectral intensity at similar to 292 nm was decreased by similar to 15% for E1 + TPP relative to the intensity for E1 alone, Because this MCD band is uniquely sensitive to and quantitative for tryptophan, the simplest interpretation is that 1 out of 6 tryptophan residues present in E1 (alpha beta dimer) interacts with TPP. The natural circular dichroism (CD) spectrum of E1 is dramatically altered upon binding TPP, with concomitant induction of optical activity at similar to 263 nm for the nonchiral TPP macrocyle, From CD Studies, it is also inferred that loss of activity following N-bromosuccinimide treatment occurred without significant changes in the overall secondary structure of the protein, A single peptide was isolated by differential peptide mapping in the presence and absence of thiamin pyrophosphate following modification with N-bromosuccinimide. This peptide generated from human E1 was found to correspond to amino acid residues 116-143 in the deduced sequence of human E1 beta, suggesting that the tryptophan residue 135 in the beta subunit of human E1 functions in the active site of E1. The amino acid sequences surrounding this tryptophan residue are conserved in E1 beta from several species, suggesting that this region may constitute a structurally and/or functionally essential part of the enzyme.	SUNY BUFFALO, DEPT BIOCHEM, BUFFALO, NY 14214 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, MANHATTAN, KS 66506 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Case Western Reserve University; Kansas State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018320, R01DK020478, R55DK018320] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20478, DK18320] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBINSSON B, 1989, J PHYS CHEM-US, V93, P6646, DOI 10.1021/j100355a016; BARTH G, 1972, J AM CHEM SOC, V94, P1293, DOI 10.1021/ja00759a041; DAHL HHM, 1987, J BIOL CHEM, V262, P7398; DIEFENBACH RJ, 1991, BIOCHEM J, V276, P439, DOI 10.1042/bj2760439; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HAWKINS CF, 1990, EUR J BIOCHEM, V191, P337, DOI 10.1111/j.1432-1033.1990.tb19128.x; HO L, 1989, P NATL ACAD SCI USA, V86, P5330, DOI 10.1073/pnas.86.14.5330; HO L, 1990, GENE, V86, P297, DOI 10.1016/0378-1119(90)90294-2; HOLMES CFB, 1986, EUR J BIOCHEM, V155, P173, DOI 10.1111/j.1432-1033.1986.tb09473.x; HOLMQUIS.B, 1973, BIOCHEMISTRY-US, V12, P4409, DOI 10.1021/bi00746a018; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; KHAILOVA LS, 1989, ANN NY ACAD SCI, V573, P36, DOI 10.1111/j.1749-6632.1989.tb14985.x; KHAILOVA LS, 1982, BIOCHEM INT, V5, P525; KOCHETOV GA, 1970, BIOCHEM BIOPH RES CO, V41, P1134, DOI 10.1016/0006-291X(70)90203-2; KOROCHKINA LG, 1984, BIOCHEM INT, V9, P491; KOROTCHKINA LG, 1995, IN PRESS PROTEIN EXP; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; MATUDA S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P1, DOI 10.1016/0167-4781(91)90076-X; OBRIEN TA, 1980, J BIOL CHEM, V255, P3302; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; ROCHE TE, 1972, BIOCHEM BIOPH RES CO, V48, P840, DOI 10.1016/0006-291X(72)90684-5; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; Spande T.F., 1967, DETERMINATION TRYPTO, P498; STEPP LR, 1985, BIOCHEMISTRY-US, V24, P7187, DOI 10.1021/bi00346a026; STRICKLAND EH, 1970, BIOCHEMISTRY-US, V9, P4914, DOI 10.1021/bi00827a013; SUNDSTROM M, 1992, FEBS LETT, V313, P229, DOI 10.1016/0014-5793(92)81197-T; URATA Y, 1991, J NUTR SCI VITAMINOL, V37, P257; WEXLER ID, 1991, FEBS LETT, V282, P209, DOI 10.1016/0014-5793(91)80479-M; WHEELOCK MJ, 1991, MOL BIOCHEM PARASIT, V45, P9, DOI 10.1016/0166-6851(91)90022-X; ZHAO Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P207, DOI 10.1016/0167-4781(92)90014-Q	32	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4570	4574		10.1074/jbc.270.9.4570	http://dx.doi.org/10.1074/jbc.270.9.4570			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876227	hybrid			2022-12-25	WOS:A1995QK08400060
J	CHEN, LX; ZHANG, ZP; SCAFONAS, A; CAVALLI, RC; GABRIEL, JL; SOPRANO, KJ; SOPRANO, DR				CHEN, LX; ZHANG, ZP; SCAFONAS, A; CAVALLI, RC; GABRIEL, JL; SOPRANO, KJ; SOPRANO, DR			ARGININE-132 OF CELLULAR RETINOIC ACID-BINDING PROTEIN (TYPE-II) IS IMPORTANT FOR BINDING OF RETINOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; P2 MYELIN PROTEIN; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; CRABP-I; DIFFERENTIAL PATTERN; MOLECULAR-CLONING; RAT; EXPRESSION; RECEPTORS	Cellular retinoic acid binding protein type II (CRABP-II) is one of two small molecular weight, cytosolic proteins which specifically bind retinoic acid (RA). Crystallographic and site-directed mutagenesis studies of several related proteins have indicated that either one or two conserved amino acid residues, homologous to positions Arg(111) and Arg(132) of CRABP-II are important for the binding of the hydrophobic ligand. In this report we have prepared site-directed mutations of these two positions of CRABP-II, Arg(111) and Arg(132), as well as Lys(82) to determine the role of these residues in the binding of Rk Recombinant wild type and mutant CRABP-II proteins were expressed and purified, and the affinity for retinoids was determined by fluorometric titration and binding of H-3-labeled compounds. K82A displayed an identical K-d for all-trans-RA as wild type CRABP-II and the K-d for all-trans-RA of R111A was only slightly higher, On the other hand, the two Arg(132) mutants, R132A and R132Q, of CRABP-II demonstrated undetectable binding of all-trans-RA. Taken together these data demonstrate that Arg(132) is a critical amino acid residue for the binding of RA by CRABP-II.	TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044841, R01DK044517, T32DK007162] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 T32DK07162, DK44841, DK44517] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASTROM A, 1991, J BIOL CHEM, V266, P17662; BAILEY JS, 1988, J BIOL CHEM, V263, P9326; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; CHENG L, 1991, J BIOL CHEM, V266, P24404; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DOLLE P, 1990, DEVELOPMENT, V110, P1133; EADS J, 1993, J BIOL CHEM, V268, P26375; ELLER MS, 1992, EXP CELL RES, V198, P328, DOI 10.1016/0014-4827(92)90387-N; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Gudas Lorraine J., 1994, P443; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MULLERFAHRNOW A, 1991, EUR J BIOCHEM, V199, P271, DOI 10.1111/j.1432-1033.1991.tb16120.x; Ong David E., 1994, P283; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SACCHETTINI JC, 1988, J BIOL CHEM, V263, P5815; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIEGENTHALER G, 1986, J INVEST DERMATOL, V86, P42, DOI 10.1111/1523-1747.ep12283788; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUMP DG, 1991, J BIOL CHEM, V266, P4622; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; XU ZH, 1992, BIOCHEMISTRY-US, V31, P3484, DOI 10.1021/bi00128a024; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG JH, 1992, PROTEINS, V13, P87, DOI 10.1002/prot.340130202	41	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4518	4525		10.1074/jbc.270.9.4518	http://dx.doi.org/10.1074/jbc.270.9.4518			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876220	hybrid			2022-12-25	WOS:A1995QK08400053
J	NISSEN, MS; REEVES, R				NISSEN, MS; REEVES, R			CHANGES IN SUPERHELICITY ARE INTRODUCED INTO CLOSED CIRCULAR DNA BY BINDING OF HIGH-MOBILITY GROUP PROTEIN I/Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE INTERLEUKIN-2 CDNA; MINOR-GROOVE BINDERS; HMG-I; CHROMOSOMAL-PROTEINS; SATELLITE DNA; SUPERCOILED DNA; GENE-REGULATION; BETA GENE; SEQUENCE; CELLS	Mammalian high mobility group HMG-YY chromatin proteins bind to the minor groove of AT-rich DNA sequences with high affinity both in vivo and in vitro. Topoisomerase I-mediated relaxation assays, analyzed by one and two dimensional agarose gel electrophoresis, indicate that binding of recombinant human HMG-I/Y to closed circular DNA introduces positive supercoils at low protein to nucleotide molar ratios and negative supercoils at higher ratios, This is interpreted to mean that HMG-I/Y binding initially causes bending of the DNA helix followed by unwinding of the helix. In contrast, binding of another minor groove binding Ligand, netropsin, introduces positive supercoils only, An in vitro produced mutant HMG-I/Y protein lacking the negatively charged carboxyl-terminal domain binds Mammalian high mobility group HMG-YY chromatin proteins bind to the minor groove of AT-rich DNA sequences with high affinity both in vivo and in vitro. Topoisomerase I-mediated relaxation assays, analyzed by one and two dimensional agarose gel electrophoresis, indicate that binding of recombinant human HMG-I/Y to closed circular DNA introduces positive supercoils at low protein to nucleotide molar ratios and negative supercoils at higher ratios, This is interpreted to mean that HMG-I/Y binding initially causes bending of the DNA helix followed by unwinding of the helix. In contrast, binding of another minor groove binding Ligand, netropsin, introduces positive supercoils only, An in vitro produced mutant HMG-I/Y protein lacking the negatively charged carboxyl-terminal domain binds A . T-rich DNA approximately 1.4-fold better than the native protein, yet it is estimated to be 8-10-fold more effective at introducing negative supercoils. This finding suggests that the highly acidic C-terminal region of the HMG-I/Y protein may function as a regulatory domain influencing the amount of topological change induced in DNA substrates by binding of the protein. Footprinting of HMG-I/Y on negatively supercoiled A . T-rich DNA using diethylpyrocarbonate suggests that the protein is able to recognize, bind to, and alter the conformation of non-B-form DNA.	WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164; WASHINGTON STATE UNIV,DEPT GENET & CELL BIOL,PULLMAN,WA 99164	Washington State University; Washington State University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026356] Funding Source: NIH RePORTER; NIAID NIH HHS [5-R01-AI26356] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATES AD, 1993, DNA TOPOLOGY, P114; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHURCHILL MEA, 1990, BIOCHEMISTRY-US, V29, P6043, DOI 10.1021/bi00477a023; CHUVPILO S, 1994, NUCLEIC ACIDS RES, V21, P5694; COLL M, 1989, BIOCHEMISTRY-US, V28, P310, DOI 10.1021/bi00427a042; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; EVANS JNS, 1992, B MAG RESON, V14, P171; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; JACOBSEN K, 1990, PLANT CELL, V2, P85, DOI 10.1105/tpc.2.1.85; JOHN S, 1994, IN PRESS MOL CELL BI; JOHNSON KR, 1990, EXP CELL RES, V187, P69, DOI 10.1016/0014-4827(90)90118-T; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KAPLAN DJ, 1988, NUCLEIC ACIDS RES, V16, P10375, DOI 10.1093/nar/16.21.10375; KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8; KOPKA ML, 1992, NUCLEIC ACID TARGETE, P303; LEHN DA, 1988, BIOCHEM INT, V16, P963; LEVINGER L, 1982, P NATL ACAD SCI-BIOL, V79, P7152, DOI 10.1073/pnas.79.23.7152; LUND T, 1987, BIOCHEM BIOPH RES CO, V146, P725, DOI 10.1016/0006-291X(87)90589-4; LUND T, 1985, FEBS LETT, V180, P275, DOI 10.1016/0014-5793(85)81085-1; LUND T, 1983, FEBS LETT, V152, P163, DOI 10.1016/0014-5793(83)80370-6; MANFIOLETTI G, 1992, NUCLEIC ACIDS RES, V19, P6793; MCLEAN MJ, 1994, DNA PROTEIN INTERACT, P89; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PFAFFLE P, 1990, J BIOL CHEM, V265, P16821; PULLEYBLANK DE, 1975, J MOL BIOL, V91, P1, DOI 10.1016/0022-2836(75)90368-X; RADIC MZ, 1992, CHROMOSOMA, V101, P602, DOI 10.1007/BF00360537; RAM T, 1992, GENETICS MOL BIOL BR, P65; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1993, J BIOL CHEM, V268, P21137; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; Sambrook J, 1989, MOL CLONING LABORATO; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SNOUNOU G, 1983, J MOL BIOL, V167, P211, DOI 10.1016/S0022-2836(83)80043-6; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SOTELONIETO J, 1994, PLANT CELL, V6, P287; STORL K, 1993, FEBS LETT, V334, P49, DOI 10.1016/0014-5793(93)81678-S; STORL K, 1993, FEBS LETT, V317, P157, DOI 10.1016/0014-5793(93)81513-Y; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON EM, 1994, MOL CELL BIOL, V14, P4694, DOI 10.1128/MCB.14.7.4694; TJADEN G, 1994, PLANT CELL, V6, P107, DOI 10.1105/tpc.6.1.107; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WANG JC, 1974, J MOL BIOL, V89, P783, DOI 10.1016/0022-2836(74)90053-9; WEGNER M, 1990, BIOCHEM BIOPH RES CO, V166, P1110, DOI 10.1016/0006-291X(90)90981-R; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; ZHOA K, 1993, EMBO J, V12, P3237; ZIMMER C, 1989, NUCLEIC ACIDS RES, V10, P1721	61	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4355	4360		10.1074/jbc.270.9.4355	http://dx.doi.org/10.1074/jbc.270.9.4355			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876198	hybrid			2022-12-25	WOS:A1995QK08400029
J	GARY, JD; CLARKE, S				GARY, JD; CLARKE, S			PURIFICATION AND CHARACTERIZATION OF AN ISOASPARTYL DIPEPTIDASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; ASPARTYL RESIDUES; DIHYDROOROTASE; SEQUENCE; SURVIVAL; PEPTIDE; SITE; GENE; K-12; ACCUMULATION	We have identified a gene (iadA) in Escherichia coli encoding a 41-kDa polypeptide that catalyzes the hydrolytic cleavage of L-isoaspartyl, or L-beta-aspartyl, dipeptides. We demonstrate at least a 3000-fold purification of the enzyme to homogeneity from crude cytosol. From the amino-terminal amino acid sequence obtained hom this preparation, we designed an oligonucleotide that allowed us to map the gene to the 98-min region of the chromosome and to clone and obtain the DNA sequence of the gene. Examination of the deduced amino acid sequence revealed no similarities to other peptidases or proteases, while a marked similarity was found with several dihydroorotases and imidases, reflecting the similarity in the structures of the substrates for these enzymes. Using an E. coli strain containing a plasmid overexpressing this gene, me were able to purify sufficient amounts of the dipeptidase to characterize its substrate specificity. We also examined the phenotype of two E. coli strains where this isoaspartyl dipeptidase gene was deleted. We inserted a chloramphenicol cassette into the disrupted coding region of iadA in both a parent strain (MC1000) and a derivative strain (CL1010) lacking pcm, the gene encoding the L-isoaspartyl methyltransferase involved in the repair of isomerized proteins. We found that the iadA deletion does not result in reduced stationary phase or heat shock survival. Analysis of isoaspartyl dipeptidase activity in the deletion strain revealed a second activity of lower native molecular weight that accounts for approximately 31% of the total activity in the parent strain MC1000. The presence of this second activity may account for the absence of an observable phenotype in the iadA mutant cells.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-07185, GM26020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; BROWN DC, 1991, J BIOL CHEM, V266, P1597; BRUNAUER LS, 1986, J BIOL CHEM, V261, P2538; BUCHANAN DL, 1966, BIOCHEMISTRY-US, V5, P3240, DOI 10.1021/bi00874a026; BUCKHOLZ RG, 1991, YEAST, V7, P913, DOI 10.1002/yea.320070903; BURTON EG, 1989, J NUTR, V119, P713, DOI 10.1093/jn/119.5.713; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHRISTOPHERSON RI, 1979, J BIOL CHEM, V254, P2506; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; CLARKE S, 1992, STABILITY PROTEIN PH, P1; CONLIN CA, 1994, J BACTERIOL, V176, P1552, DOI 10.1128/jb.176.5.1552-1553.1994; DODD IB, 1987, J MOL BIOL, V194, P557, DOI 10.1016/0022-2836(87)90681-4; DORER FE, 1968, ARCH BIOCHEM BIOPHYS, V127, P490, DOI 10.1016/0003-9861(68)90253-1; FU JC, 1991, J BIOL CHEM, V266, P14562; GHIM SY, 1994, MICROBIOL-UK, V140, P479, DOI 10.1099/00221287-140-3-479; HALEY EE, 1966, BIOCHEMISTRY-US, V5, P3229, DOI 10.1021/bi00874a024; HALEY EE, 1968, J BIOL CHEM, V243, P5748; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; JENKINS DE, 1988, J BACTERIOL, V170, P3910, DOI 10.1128/jb.170.9.3910-3914.1988; JIN SF, 1994, J BACTERIOL, V176, P4669, DOI 10.1128/JB.176.15.4669-4679.1994; JOHNSON BA, 1990, BIOCHEMISTRY-US, V29, P4373, DOI 10.1021/bi00470a017; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOINTE G, 1994, APPL ENVIRON MICROB, V60, P888, DOI 10.1128/AEM.60.3.888-895.1994; LI C, 1992, P NATL ACAD SCI USA, V89, P9885, DOI 10.1073/pnas.89.20.9885; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; MANDELSTAM J, 1958, BIOCHEM J, V69, P110, DOI 10.1042/bj0690110; MANDELSTAM J, 1960, BACTERIOL REV, V24, P289, DOI 10.1128/MMBR.24.3.289-308.1960; Miller J.H., 1972, EXPT MOL GENETICS; MOORE S, 1968, J BIOL CHEM, V243, P6281; MURRAY ED, 1984, J BIOL CHEM, V259, P722; PAYNE JW, 1972, J GEN MICROBIOL, V71, P267, DOI 10.1099/00221287-71-2-267; PLANCOT MT, 1969, B SOC CHIM BIOL, V51, P1111; QUINN CL, 1991, J BIOL CHEM, V266, P9113; REEVE CA, 1984, J BACTERIOL, V160, P1041, DOI 10.1128/JB.160.3.1041-1046.1984; REEVE CA, 1984, J BACTERIOL, V157, P758, DOI 10.1128/JB.157.3.758-763.1984; REYNOLDS TR, 1992, BIOTECHNIQUES, V12, P518; RUDD KE, 1992, SHORT COURSE BACTERI; Sambrook J, 1989, MOL CLONING LABORATO; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; SETLOW P, 1975, J BACTERIOL, V122, P642, DOI 10.1128/JB.122.2.642-649.1975; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; Silhavy T.J., 1984, EXPT GENE FUSIONS; SIMMONDS S, 1976, BIOCHEMISTRY-US, V15, P261, DOI 10.1021/bi00647a004; SLATER S, 1993, J BACTERIOL, V175, P4260, DOI 10.1128/JB.175.13.4260-4262.1993; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; SUNG YC, 1992, J BACTERIOL, V174, P3645, DOI 10.1128/JB.174.11.3645-3650.1992; SUZUKI H, 1993, J BACTERIOL, V175, P6038, DOI 10.1128/JB.175.18.6038-6040.1993; TABOR S, 1989, J BIOL CHEM, V264, P6447; WASHABAUGH MW, 1984, J BIOL CHEM, V259, P3293; WASHABAUGH MW, 1986, J BIOL CHEM, V261, P5920; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; YANG YS, 1993, J BIOL CHEM, V268, P10870; YEN C, 1980, J MOL BIOL, V143, P35, DOI 10.1016/0022-2836(80)90123-0	59	39	43	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4076	4087		10.1074/jbc.270.8.4076	http://dx.doi.org/10.1074/jbc.270.8.4076			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876157	hybrid			2022-12-25	WOS:A1995QH68800090
J	SOYAL, SM; SEELOS, C; LINLEE, YC; SANDERS, S; GOTTO, AM; HACHEY, DL; PATSCH, W				SOYAL, SM; SEELOS, C; LINLEE, YC; SANDERS, S; GOTTO, AM; HACHEY, DL; PATSCH, W			THYROID-HORMONE INFLUENCES THE MATURATION OF APOLIPOPROTEIN-A-I MESSENGER-RNA IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; C-III; SUCROSE DIET; TRANSCRIPTION; SEQUENCES; TRIIODOTHYRONINE; AMPLIFICATION; CHOLESTEROL; METABOLISM; PRECURSOR	Chronic administration of thyroid hormone (T-3) increases apolipoprotein (ape) A-I gene expression in rat liver, That transcriptional activity of the apoA-I gene is reduced to 50% of control, whereas abundance levels of nuclear and total cellular apoA-I mRNA are increased 3-fold, implies more effective apoA-I mRNA maturation. To study hormonal effects on apoA-I RNA processing, we quantified mRNA precursors in control and T-3-treated rats (50 mu g/100 g body weight for 7 days). Northern blotting, amplification of reverse-transcribed RNA, and ribonuclease protection assays showed that the splicing pathway is branched, in that either intron 1 or intron 2 is removed first from the primary transcript, whereas intron 3 is removed last. In T-3-treated rats, abundance levels of the primary transcript, the intron 1-containing precursor devoid of intron 2, the intron 2 containing precursor devoid of intron 1, the intron S-containing precursor lacking both introns 1 and 2, and nuclear mRNA were 65, 183, 78, 195, and 268% of controls, Compared with control rats, the half-life of the intron 1-containing precursor, measured after injection of actinomycin D, was increased 2-fold in T-3-treated rats. In contrast, half-lives of the primary transcript and the intron 2-containing precursor were similar in control and T-3-treated rats. Ribonuclease protection assays revealed an RNA species extending from the transcription start site close to the 3' end of intron 1. The abundance of this RNA fragment, probably representing a degradation product, was 2.5-fold higher in control than in T-3-treated animals (p < 0.001). Sequences of apoA-I mRNA precursors were identical in control and T-3-treated rats which excluded hormonal effects on splice-site selection or post-transcriptional editing of apoA-I transcripts. Compartmental modeling of apoA-I mRNA processing suggested that chronic thyroid hormone administration enhances apoA-I mRNA maturation more than 7-fold by protecting the intron 1-containing precursor devoid of intron 2 from degradation and by facilitating the splicing of intron 1 from this precursor.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine					NHLBI NIH HHS [HL27341, R01 HL34457] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL027341, R01HL034457, P60HL027341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANIELLO F, 1991, P NATL ACAD SCI USA, V88, P4035, DOI 10.1073/pnas.88.9.4035; APOSTOLOPOULOS JJ, 1988, BIOCHEM BIOPH RES CO, V154, P997, DOI 10.1016/0006-291X(88)90238-0; APOSTOLOPOULOS JJ, 1987, J LIPID RES, V28, P642; BADIMON JJ, 1990, J CLIN INVEST, V353, P265; BIERMAN EL, 1991, ADV EXP MED BIOL, V285, P81; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOSTON RC, 1981, COMPUT PROG BIOMED, V13, P111, DOI 10.1016/0010-468X(81)90089-1; CAFFARELLI E, 1987, EMBO J, V6, P3493, DOI 10.1002/j.1460-2075.1987.tb02674.x; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FOSTER DM, 1983, COMPARTMENTAL DISTRI, P73; Gelfand D.H., 1990, PC PRO, P129; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; KILEDJIAN M, 1991, J BIOL CHEM, V266, P4207; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LINLEE YC, 1993, J LIPID RES, V34, P249; LINLEE YC, 1993, CIRCULATION, V88, P421; MACIEJKO JJ, 1983, NEW ENGL J MED, V309, P385, DOI 10.1056/NEJM198308183090701; MCNALLY MT, 1991, VIROLOGY, V185, P99, DOI 10.1016/0042-6822(91)90758-4; MILLER GJ, 1975, LANCET, V1, P16; NORTHEMANN W, 1985, J BIOL CHEM, V260, P6200; NOWICKA G, 1990, J LIPID RES, V31, P1947; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OPPENHEIMER JH, 1975, ENDOCR RES COMMUN, V2, P309, DOI 10.1080/07435807509089004; PATSCH W, 1993, CIRCULATION, V88, P73; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; RADOSAVLJEVIC M, 1992, ATHEROSCLEROSIS, V95, P147, DOI 10.1016/0021-9150(92)90018-C; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SHEMER R, 1990, J BIOL CHEM, V265, P1010; SORCITHOMAS M, 1988, J BIOL CHEM, V263, P5183; STROBL W, 1989, J BIOL CHEM, V264, P1190; STROBL W, 1990, J CLIN INVEST, V85, P659, DOI 10.1172/JCI114489; STROBL W, 1993, J CLIN INVEST, V92, P1766, DOI 10.1172/JCI116765; TAM SP, 1985, J BIOL CHEM, V260, P1670; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WILCOX HG, 1982, J LIPID RES, V23, P1159; WU AL, 1979, J BIOL CHEM, V254, P7316	47	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3996	4004		10.1074/jbc.270.8.3996	http://dx.doi.org/10.1074/jbc.270.8.3996			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876147	hybrid			2022-12-25	WOS:A1995QH68800080
J	MCCORMACK, AL; MONONEN, I; KAARTINEN, V; YATES, JR				MCCORMACK, AL; MONONEN, I; KAARTINEN, V; YATES, JR			LOCALIZATION OF THE DISULFIDE BOND INVOLVED IN POSTTRANSLATIONAL PROCESSING OF GLYCOSYLASPARAGINASE AND DISRUPTED BY A MUTATION IN THE FINNISH-TYPE ASPARTYLGLYCOSAMINURIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTYLGLUCOSAMINURIA; GLYCOASPARAGINASE; SUBUNITS	The heavy chain of human glycosylasparaginase (N-4-(beta-N-acetylglucosaminyl)-L-asparaginase (EC 3.5.1.26)) has five cysteinyl residues (Cys-61, Cys-64, Cys-69, Cys-163, and Cys-179). A Cys-163 to serine substitution due to a point mutation in the glycosylasparaginase gene causes the most common disorder of glycoprotein degradation, the Finnish-type aspartylglycosaminuria. To localize the potential disulfide bonds, the isolated heavy chain of human leukocyte glycosylasparaginase was treated with the enzyme alpha-chymotrypsin, and the resulting peptides were separated by high performance liquid chromatography prior to and after reduction and S-carboxymethylation. The peptide containing the Cys-163 residue and the peptide to which it is connected with a disulfide were structurally characterized by mass spectrometry. The disulfide bond crucial for catalytic activity, subunit processing, and biological transport of glycosylasparaginase was located close to the carboxyl terminus of the heavy chain at positions 163 and 179.	UNIV WASHINGTON,DEPT MOLEC BIOTECHNOL,SEATTLE,WA 98195; KUOPIO UNIV HOSP,DEPT CLIN CHEM,SF-70211 KUOPIO,FINLAND; UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90054	University of Washington; University of Washington Seattle; Kuopio University Hospital; University of Eastern Finland; Children's Hospital Los Angeles; University of Southern California			Kaartinen, Vesa/AAU-5396-2021	Kaartinen, Vesa/0000-0002-9432-510X				FISHER KJ, 1990, FEBS LETT, V269, P440, DOI 10.1016/0014-5793(90)81211-6; FISHER KJ, 1993, FEBS LETT, V323, P271, DOI 10.1016/0014-5793(93)81355-4; FISHER KJ, 1991, J BIOL CHEM, V266, P12105; GRIFFIN PR, 1991, INT J MASS SPECTROM, V111, P131, DOI 10.1016/0168-1176(91)85052-N; HUNT DF, 1986, P NATL ACAD SCI USA, V84, P620; KAARTINEN V, 1992, J BIOL CHEM, V267, P6855; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; MONONEN I, 1991, P NATL ACAD SCI USA, V88, P2941, DOI 10.1073/pnas.88.7.2941; MONONEN I, 1993, FASEB J, V7, P1247, DOI 10.1096/fasebj.7.13.8405810; SYVANEN AC, 1992, GENOMICS, V12, P590, DOI 10.1016/0888-7543(92)90452-X	10	9	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3212	3215		10.1074/jbc.270.7.3212	http://dx.doi.org/10.1074/jbc.270.7.3212			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852406	hybrid			2022-12-25	WOS:A1995QG47100050
J	THOMAS, EL; BOZEMAN, PM; JEFFERSON, MM; KING, CC				THOMAS, EL; BOZEMAN, PM; JEFFERSON, MM; KING, CC			OXIDATION OF BROMIDE BY THE HUMAN-LEUKOCYTE ENZYMES MYELOPEROXIDASE AND EOSINOPHIL PEROXIDASE - FORMATION OF BROMAMINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLET OXYGEN PRODUCTION; ANTI-MICROBIAL SYSTEM; HYDROGEN-PEROXIDE; ISOLATED NEUTROPHILS; ESCHERICHIA-COLI; AMINO-ACIDS; CHLORIDE; THIOCYANATE; OXIDANTS; BROMOPEROXIDASE	Myeloperoxidase and eosinophil peroxidase catalyzed the oxidation of bromide ion by hydrogen peroxide (H2O2) and produced a brominating agent that reacted with amine compounds to form bromamines, which are long-lived oxidants containing covalent nitrogen-bromine bonds. Results were consistent with oxidation of bromide to an equilibrium mixture of hypobromous acid (HOBr) and hypobromite ion (OBr-). Up to 1 mol of bromamine was produced per mole of H2O2, indicating that bromamine formation prevented the reduction of HOBr/OBr- by H2O2 and the loss of oxidizing and brominating activity. Bromamines differed from HOBr/OBr- in that bromamines reacted slowly with H2O2, were not reduced by dimethyl sulfoxide, and had absorption spectra similar to those of chloramines, but shifted 36 nm toward higher wavelengths. Mono- and di-bromo derivatives (RNHBr and RNHBr(2)) of the beta-amino acid taurine were relatively stable with half-lives of 70 and 16 h at pH 7, 37 degrees C. The mono-bromamine was obtained with a 200-fold excess of amine over the amount of HOBr/OBr- and the di-bromamine at a 2:1 ratio of HOBr/OBr- to the amine. In the presence of physiologic levels of both bromide (0.1 mM) and chloride (0.1 M), myeloperoxidase and eosinophil peroxidase produced mixtures of bromamines and chloramines containing 6 +/- 4% and 88 +/- 4% bromamine. In contrast, only the mono-chloramine derivative (RNHCl) was formed when a mixture of hypochlorous acid (HOCl) and hypochlorite ion (OCl-) was added to solutions containing bromide and excess amine. The rapid formation of the chloramine prevented the oxidation of bromide by HOCl/OCl-, and the chloramine did not react with bromide within 1 h at 37 degrees C. The results indicate that when enzyme catalyzed bromide or chloride oxidation took place in the presence of an amine compound at 10 mM or higher, bromamines were not produced in secondary reactions such as the oxidation of bromide by HOCl/OCl- and the exchange of bromide with chlorine atoms of chloramines. Therefore, the amount of bromamine produced by myeloperoxidase or eosinophil peroxidase was equal to the amount of bromide oxidized by the enzyme. Bromide was preferred over chloride as the substrate for both enzymes.	UNIV TENNESSEE, DENT RES CTR, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; ST JUDE CHILDRENS RES HOSP, DIV CRIT CARE & PULM MED, MEMPHIS, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital				Jefferson, M. Margaret/0000-0001-8650-3159	NHLBI NIH HHS [HL02373] Funding Source: Medline; NIAID NIH HHS [AI16795] Funding Source: Medline; NIDCR NIH HHS [DE04235] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE004235] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGNER K, 1963, ACTA CHEM SCAND, V17, pS332; ANDREWS PC, 1981, J BIOL CHEM, V256, P4211; AUNE TM, 1977, EUR J BIOCHEM, V80, P209, DOI 10.1111/j.1432-1033.1977.tb11873.x; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P177, DOI 10.1016/0167-4838(84)90125-0; BOZEMAN PM, 1992, BIOCHEM PHARMACOL, V44, P553, DOI 10.1016/0006-2952(92)90449-S; BOZEMAN PM, 1990, J IMMUNOL METHODS, V126, P125, DOI 10.1016/0022-1759(90)90020-V; BUCHBERGER W, 1988, J CHROMATOGR-BIOMED, V432, P57, DOI 10.1016/S0378-4347(00)80633-7; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; CRAMER R, 1981, BLOOD, V58, P1112; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HARRISON JE, 1976, CANCER ENZYMOLOGY, V2, P305; HOLZBECHER J, 1980, CLIN BIOCHEM, V13, P277, DOI 10.1016/S0009-9120(80)80009-9; HOOGLAND H, 1987, BIOCHIM BIOPHYS ACTA, V916, P76, DOI 10.1016/0167-4838(87)90212-3; HURST JK, 1984, J BIOL CHEM, V259, P4812; HURST JK, 1991, PEROXIDASES CHEM BIO, V1, P37; JONG EC, 1980, J IMMUNOL, V124, P1378; KANOFSKY JR, 1989, ARCH BIOCHEM BIOPHYS, V274, P229, DOI 10.1016/0003-9861(89)90434-7; KANOFSKY JR, 1984, J CLIN INVEST, V74, P1489, DOI 10.1172/JCI111562; KANOFSKY JR, 1983, J BIOL CHEM, V258, P5991; KANOFSKY JR, 1988, J BIOL CHEM, V263, P9692; KANOFSKY JR, 1984, J BIOL CHEM, V259, P5596; KETTLE AJ, 1991, BIOCHEM PHARMACOL, V41, P1485, DOI 10.1016/0006-2952(91)90565-M; KNIGHT LC, 1978, BIOCHIM BIOPHYS ACTA, V534, P185, DOI 10.1016/0005-2795(78)90001-6; LEARN DB, 1990, J LEUKOCYTE BIOL, V48, P174, DOI 10.1002/jlb.48.2.174; MANTHEY JA, 1984, METHOD ENZYMOL, V107, P439; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; MCELVANY KD, 1980, J NUCL MED, V21, P953; OKA S, 1981, ANAL CHEM, V53, P588, DOI 10.1021/ac00227a007; RAMSEY PG, 1982, J IMMUNOL, V128, P415; RITTER CL, 1989, CHEM RES TOXICOL, V2, P325, DOI 10.1021/tx00011a010; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; SLUNGAARD A, 1990, J EXP MED, V171, P2025, DOI 10.1084/jem.171.6.2025; TEST ST, 1986, ADV FREE RADICAL BIO, V2, P91, DOI 10.1016/S8755-9668(86)80025-4; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1979, INFECT IMMUN, V25, P110, DOI 10.1128/IAI.25.1.110-116.1979; THOMAS EL, 1987, MUTAT RES, V188, P35, DOI 10.1016/0165-1218(87)90112-1; THOMAS EL, 1979, INFECT IMMUN, V23, P522, DOI 10.1128/IAI.23.2.522-531.1979; THOMAS EL, 1983, J CLIN INVEST, V72, P441, DOI 10.1172/JCI110992; THOMAS EL, 1986, J BIOL CHEM, V261, P9694; THOMAS EL, 1985, J BIOL CHEM, V260, P3321; THOMAS EL, 1991, PEROXIDASES CHEM BIO, V1, P83; WAJON JE, 1982, INORG CHEM, V21, P4258, DOI 10.1021/ic00142a030; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WOOD JL, 1975, CHEM BIOCH THIOCYANI, P156	46	173	181	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2906	2913		10.1074/jbc.270.7.2906	http://dx.doi.org/10.1074/jbc.270.7.2906			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852368	hybrid			2022-12-25	WOS:A1995QG47100007
J	LEFRANCOISMARTINEZ, AM; MARTINEZ, A; ANTOINE, B; RAYMONDJEAN, M; KAHN, A				LEFRANCOISMARTINEZ, AM; MARTINEZ, A; ANTOINE, B; RAYMONDJEAN, M; KAHN, A			UPSTREAM STIMULATORY FACTOR PROTEINS ARE MAJOR COMPONENTS OF THE GLUCOSE RESPONSE COMPLEX OF THE L-TYPE PYRUVATE-KINASE GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR BINDS; S14 GENE; ELEMENT; DNA; HEPATOCYTES; EXPRESSION; TISSUE; USF	L-type pyruvate kinase (L-PK) gene transcription is induced by glucose through its glucose response element (GIRE) composed of two degenerated E boxes able to bind in vitro ubiquitous upstream stimulator factor (USF) proteins. Here we demonstrate in vivo, by transient transfections in hepatoma cells, that (i) native USF proteins synthesized from expression vectors can act as transactivators of the L-PK promoter via the GIRE, stimulating transcription without glucose and, therefore, decreasing the glucose responsiveness of the promoter; (ii) expression of the truncated USF proteins, able to bind the GIRE but devoid of the NH2-terminal activation domain, represses the activation of the L-PK promoter by glucose; and (iii) a similar repression of the glucose effect is observed upon expression of mutant USF proteins devoid of the basic DNA binding domain, able to dimerize with endogenous USF but not to bind the GIRE. We conclude that USF proteins are components of the transcriptional glucose response complex assembled on the L-PK gene promoter.	UNIV PARIS 05, INST COCHIN GENET MOLEC, INSERM, U129, F-75014 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite								BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COGNET M, 1991, J BIOL CHEM, V266, P7368; DOIRON B, 1994, J BIOL CHEM, V269, P10213; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HENRION A, 1994, IN PRESS GENOMICS; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEVRAT F, 1993, EXP CELL RES, V209, P307, DOI 10.1006/excr.1993.1315; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8	21	112	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2640	2643		10.1074/jbc.270.6.2640	http://dx.doi.org/10.1074/jbc.270.6.2640			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852331	hybrid			2022-12-25	WOS:A1995QF53500039
J	MANUEL, RC; LATHAM, KA; DODSON, ML; LLOYD, RS				MANUEL, RC; LATHAM, KA; DODSON, ML; LLOYD, RS			INVOLVEMENT OF GLUTAMIC-ACID-23 IN THE CATALYTIC MECHANISM OF T4 ENDONUCLEASE-V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BETA-ELIMINATION REACTION; DIMER-DNA GLYCOSYLASE; ABASIC SITES; T4-ENDONUCLEASE-V; BACTERIOPHAGE-T4; GENE; TERMINUS; REPAIR; SYN	Bacteriophage T4 endonuclease V has both pyrimidine dimer-specific DNA glycosylase and abasic (AP) lyase activities, which are sequential yet biochemically separable functions, Previous studies using chemical modification and site-directed mutagenesis techniques have shown that the catalytic activities are mediated through the alpha-amino group of the enzyme forming a covalent (imino) intermediate, However, in addition to the amino-terminal active site residue, examination of the x-ray crystal structure of endonuclease V reveals the presence of Glu-23 near the active site, and this residue has been strongly implicated in the reaction chemistry, In order to understand the role of Glu-23 in the reaction mechanism, four different mutations (E23Q, E23C, E23H, E23D) were constructed, and the mutant proteins were evaluated for DNA glycosylase and AP lyase activities using defined substrates and specific in vitro and in vivo assays, Replacement of Glu-23 with Gln, Cys, or His completely abolished DNA glycosylase and AP lyase activities, while replacement with Asp retained negligible amounts of glycosylase activity, but retained near wild type levels of AP lyase activity, Gel shift assays revealed that all four mutant proteins can recognize and bind to thymine dimers, The results indicate that Glu-23 is the candidate for stabilizing the charge of the imino intermediate that is likely to require an acidic group in the active site of the enzyme.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston				Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004091] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04091] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; DOI T, 1992, P NATL ACAD SCI USA, V89, P9420, DOI 10.1073/pnas.89.20.9420; DOWD DR, 1989, BIOCHEMISTRY-US, V28, P8699, DOI 10.1021/bi00448a005; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HORI N, 1992, NUCLEIC ACIDS RES, V20, P4761, DOI 10.1093/nar/20.18.4761; HOWARDFL.P, 1969, J BACTERIOL, V97, P1134, DOI 10.1128/JB.97.3.1134-1141.1969; LATHAM AK, 1994, BIOCHEMISTRY-US, V33, P9024; LATHAM AK, 1994, ANN NY ACAD SCI, V726, P181; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; SEAWELL PC, 1980, BIOCHEMISTRY-US, V19, P1685, DOI 10.1021/bi00549a026; SEAWELL PC, 1980, J VIROL, V35, P790, DOI 10.1128/JVI.35.3.790-796.1980; SMITH CA, 1993, J BIOL CHEM, V268, P11143; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171	22	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2652	2661		10.1074/jbc.270.6.2652	http://dx.doi.org/10.1074/jbc.270.6.2652			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852333	hybrid			2022-12-25	WOS:A1995QF53500041
J	TOTH, I; ROGERS, JT; MCPHEE, JA; ELLIOTT, SM; ABRAMSON, SL; BRIDGES, KR				TOTH, I; ROGERS, JT; MCPHEE, JA; ELLIOTT, SM; ABRAMSON, SL; BRIDGES, KR			ASCORBIC-ACID ENHANCES IRON-INDUCED FERRITIN TRANSLATION IN HUMAN LEUKEMIA AND HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT BINDING-PROTEIN; RESPONSIVE ELEMENT; MESSENGER-RNA; TRANSFERRIN RECEPTOR; REGULATORY ELEMENT; GENE; BIOSYNTHESIS; EXPRESSION; METABOLISM; INDUCTION	Ascorbate is an important cofactor in many cellular metabolic reactions and is intimately linked to iron homeostasis. Continuously cultured cells are ascorbate deficient due to the lability of the vitamin in solution and to the fact that daily supplementation of media with ascorbate is unusual. We found that ascorbate repletion alone did not alter ferritin synthesis. However, ascorbate-replete human hepatoma cells, Hep3B and HepG2, as well as K562 human leukemia cells achieved a substantially higher cellular ferritin content in response to a challenge with iron than did their ascorbate-deficient counterparts grown under standard culture conditions. Most of the elevation in ferritin content was due to an increase in de novo ferritin synthesis of greater than 50-fold, as shown by in vivo labeling with [S-35]methionine and immunoprecipitation. RNA-blot analysis showed only minor changes in steady state levels of ferritin mRNA, suggesting that ascorbate enhances iron-induced ferritin synthesis primarily by post-transcriptional events. Transient gene expression experiments using chloramphenicol acetyltransferase reporter gene constructs showed that the ascorbate effect on ferritin translation is not mediated through the stem-loop near the translational start site that transduces ferritin synthesis in response to cytokines. The data suggest that ascorbate possibly modifies the action of the iron-responsive element on ferritin translation, although more precise structure-function studies are needed to clarify this issue. These data demonstrate a novel role of ascorbate as a signaling molecule in posttranscriptional gene regulation. The mechanism by which ascorbate modulates cellular iron metabolism is complex and requires additional detailed investigation.			TOTH, I (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA.			Rogers, Jack/0000-0003-1262-8578	NHLBI NIH HHS [HL 45794] Funding Source: Medline; NIAID NIH HHS [AI 32717] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032717] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; BRIDGES KR, 1986, J BIOL CHEM, V261, P14273; BRIDGES KR, 1987, J BIOL CHEM, V262, P14773; BRIDGES KR, 1984, J BIOL CHEM, V259, P2970; BURNS JJ, 1957, NATURE, V180, P552, DOI 10.1038/180553a0; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; Constanzo F, 1986, NUCLEIC ACIDS RES, V14, P721; COULSON RMR, 1993, P NATL ACAD SCI USA, V90, P7613, DOI 10.1073/pnas.90.16.7613; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DENTE L, 1985, NUCLEIC ACIDS RES, V13, P3941, DOI 10.1093/nar/13.11.3941; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; HICKSTEIN DD, 1993, BLOOD, V82, P2537; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; HOFFMAN KE, 1991, AM J CLIN NUTR, V54, pS1188, DOI 10.1093/ajcn/54.6.1188s; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LESCOAT G, 1991, LIVER, V11, P24; LOBREAUX S, 1993, EMBO J, V12, P651, DOI 10.1002/j.1460-2075.1993.tb05698.x; MATTIA E, 1986, J BIOL CHEM, V261, P4587; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; Moser U., 1991, HDB VITAMINS, P195; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MUNRO HN, 1990, J CELL BIOCHEM, V44, P107, DOI 10.1002/jcb.240440205; NISHIKIMI M, 1991, AM J CLIN NUTR, V54, pS1203, DOI 10.1093/ajcn/54.6.1203s; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROGERS JT, 1994, NUCLEIC ACIDS RES, V22, P2678, DOI 10.1093/nar/22.13.2678; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STADTMAN ER, 1991, AM J CLIN NUTR, V54, pS1125, DOI 10.1093/ajcn/54.6.1125s; Szent-Gyorgyi A, 1928, BIOCHEM J, V22, P1387, DOI 10.1042/bj0221387; TESTA U, 1991, J BIOL CHEM, V266, P13925; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x	46	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2846	2852		10.1074/jbc.270.6.2846	http://dx.doi.org/10.1074/jbc.270.6.2846			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852359	hybrid			2022-12-25	WOS:A1995QF53500069
J	BIESINGER, B; TSYGANKOV, AY; FICKENSCHER, H; EMMRICH, F; FLECKENSTEIN, B; BOLEN, JB; BROKER, BM				BIESINGER, B; TSYGANKOV, AY; FICKENSCHER, H; EMMRICH, F; FLECKENSTEIN, B; BOLEN, JB; BROKER, BM			THE PRODUCT OF THE HERPESVIRUS-SAIMIRI OPEN READING FRAME-1 (TIP) INTERACTS WITH T-CELL-SPECIFIC KINASE P56(LCK) IN TRANSFORMED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; HUMAN LYMPHOCYTES-T; VIRUS TYPE-I; SIGNAL-TRANSDUCTION; SRC-FAMILY; RECEPTOR; GROWTH; CLONES; LINES; IMMORTALIZATION	Subgroup C strains of Herpesvirus saimiri, a leukemogenic virus of non human primates, transform human T cells to permanent growth in culture, These cells retain their antigen specificity, and they are becoming widely used as a model for activated human T cells, Though a variety of human cell types can be infected by H. saimiri, transformation appears to be specific for CD4+ and CD8+ T cells, Our investigation of early signaling events in H. saimiri-transformed T cells revealed a novel 40-kDa phosphoprotein complexed with the T cell-specific tyrosine protein kinase p56(lck). This protein, termed Tip (tyrosine kinase interacting protein), is identified as a viral protein encoded by the open reading frame 1 (ORF1), In the transformed cells Tip is expressed together with the gene product of ORF2, the viral onco protein StpC, which acts on epithelial cells, The H. saimiri genome has 75 ORFs, but only ORF1 and ORF2 are transcribed in transformed human cells, Tip is phosphorylated on tyrosine in cell-free systems containing Lck, indicating that the viral protein is a substrate for this T cell-specific kinase, Alteration of T cell signaling pathways by Tip may be the second event complementing the action of StpC in a new mechanism of T cell transformation.	UNIV ERLANGEN NURNBERG, INST KLIN & MOLEK VIROL, D-91054 ERLANGEN, GERMANY; BRISTOL MYERS SQUIBB CO, DEPT MOLEC BIOL, SIGNAL TRANSDUCT LAB, PRINCETON, NJ 08543 USA; UNIV ERLANGEN NURNBERG, MAX PLANCK GESELL, INST KLIN IMMUNOL, ARBEITSGRP RHEUMATOL, D-91054 ERLANGEN, GERMANY	University of Erlangen Nuremberg; Bristol-Myers Squibb; Max Planck Society; University of Erlangen Nuremberg			Fickenscher, Helmut/A-3004-2010; Tsygankov, Alexander Y/K-6205-2017; Bröker, Barbara M/O-4850-2015; Fickenscher, Helmut/J-9655-2019	Bröker, Barbara M/0000-0002-5020-8542; Fickenscher, Helmut/0000-0003-0043-1153				ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ADAM D, 1993, J BIOL CHEM, V268, P19882; ADLER HT, 1992, ONCOGENE, V7, P1191; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BEVERLEY P, 1986, HDB EXPT IMMUNOLOGY, V2; BIESINGER B, 1990, VIROLOGY, V176, P505, DOI 10.1016/0042-6822(90)90020-R; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BROKER BM, 1994, EUR J IMMUNOL, V24, P843, DOI 10.1002/eji.1830240411; BROKER BM, 1993, J IMMUNOL, V151, P1184; BURKHARDT AL, 1992, J VIROL, V66, P5161, DOI 10.1128/JVI.66.8.5161-5167.1992; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; DECARLI M, 1993, J IMMUNOL, V151, P5022; DESEAU V, 1987, J CELL BIOCHEM, V35, P113, DOI 10.1002/jcb.240350205; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; ELLINGER S, 1989, J CLIN MICROBIOL, V27, P971, DOI 10.1128/JCM.27.5.971-976.1989; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; INATSUKI A, 1989, J IMMUNOL, V143, P1327; JUNG JU, 1991, J VIROL, V65, P6953, DOI 10.1128/JVI.65.12.6953-6960.1991; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KASCHKADIERICH C, 1982, J VIROL, V44, P295, DOI 10.1128/JVI.44.1.295-310.1982; KLAGES S, 1993, ONCOGENE, V8, P713; LONGNECKER R, 1993, J VIROL, V67, P5068, DOI 10.1128/JVI.67.8.5068-5074.1993; MEDVECZKY MM, 1993, VIROLOGY, V196, P402, DOI 10.1006/viro.1993.1495; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; MITTRUCKER HW, 1993, INT IMMUNOL, V5, P985, DOI 10.1093/intimm/5.8.985; MITTRUCKER HW, 1992, J EXP MED, V176, P909, DOI 10.1084/jem.176.3.909; MURPHY C, 1994, ONCOGENE, V9, P221; MURTHY SCS, 1989, J VIROL, V63, P3307, DOI 10.1128/JVI.63.8.3307-3314.1989; NICK S, 1993, VIROLOGY, V194, P875, DOI 10.1006/viro.1993.1334; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; SEE YP, 1990, PROTEIN STRUCTURE PR, P1; SIMMER B, 1991, J GEN VIROL, V72, P1953, DOI 10.1099/0022-1317-72-8-1953; SPANA C, 1993, PROTEIN EXPRES PURIF, V4, P390, DOI 10.1006/prep.1993.1051; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; YSSEL H, 1989, J IMMUNOL, V142, P2279	43	119	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4729	4734		10.1074/jbc.270.9.4729	http://dx.doi.org/10.1074/jbc.270.9.4729			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876245	hybrid			2022-12-25	WOS:A1995QK08400080
J	CREIGHTON, S; GOODMAN, MF				CREIGHTON, S; GOODMAN, MF			GEL KINETIC-ANALYSIS OF DNA-POLYMERASE FIDELITY IN THE PRESENCE OF PROOFREADING USING BACTERIOPHAGE-T4 DNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASES; 5' EXONUCLEASE ACTIVITY; SPONTANEOUS MUTATION; BIOCHEMICAL BASIS; REVERSE-TRANSCRIPTASE; REPLICATION FIDELITY; WILD-TYPE; TRANSIENT MISALIGNMENT; INSERTION FIDELITY; KLENOW FRAGMENT	A gel fidelity assay, previously used in the analysis of DNA polymerases having no associated 3' to 5' exonuclease activity, has been generalized for use with polymerases that contain exonucleolytic proofreading. The main purpose of this study was the development of a general analysis, using a standard Markov model, to convert experimentally observed DNA primer gel bands arising from insertion and proofreading of right and wrong deoxyribonucleotides, into nucleotide incorporation velocities and, most importantly, fidelities. The model has been applied primarily to an analysis of polymerase kinetics and fidelity in the presence of a next correct rescue dNTP, but the model can be conveniently modified to investigate other experimental designs, In the presence of rescue dNTP, direct competition occurs between excision or extension of a mismatch. At concentrations of rescue dNTP sufficient to suppress the gel band intensity at the mismatch target site, nucleotide incorporation and misincorporation rates can be ob obtained from the ratios of gel band intensities 3' (downstream) and 5' (upstream) to the target site, measured as a function dNTP concentration for ''wrong'' and ''right'' dNTP substrates. The polymerase misincorporation efficiency, in the presence of proofreading, is given by the ratio of wrong to right incorporation efficiencies, V-max/K-m, obtained from the gel band ratios. The bacteriophage T4 polymerase with a highly active 3'-exonuclease activity was used to illustrate the assay, Nucleotide misincorporation efficiencies measured at several template sites were dCMP . A similar or equal to 10(-6), dGMP . A similar or equal to 10(-5), dTMP . T similar or equal to 2 x 10(-4), and dAMP . A < 10(-7). Proofreading of the dGMP . A mispair was suppressed by about 3-fold in the presence of high concentrations of next correct ''rescue'' dNTP causing a concomitant reduction in the fidelity of dGMP . A to about 3 x 10(-5).	UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089	University of Southern California					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042554, R37GM021422, R01GM021422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011398] Funding Source: NIH RePORTER; NIA NIH HHS [AG11398] Funding Source: Medline; NIGMS NIH HHS [GM42554, GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMAN RA, 1993, Q REV BIOPHYS, V26, P225, DOI 10.1017/S0033583500002869; BERNARDI F, 1979, J MOL BIOL, V129, P93, DOI 10.1016/0022-2836(79)90062-7; BESSMAN MJ, 1974, J MOL BIOL, V88, P409, DOI 10.1016/0022-2836(74)90491-4; BESSMAN MJ, 1977, J MOL BIOL, V116, P115, DOI 10.1016/0022-2836(77)90122-X; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; BLOOM LB, 1993, BIOCHEMISTRY-US, V32, P11247, DOI 10.1021/bi00092a039; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CAI H, 1993, J BIOL CHEM, V268, P23567; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P347; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; GALAS DJ, 1978, J MOL BIOL, V88, P653; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GOODMAN R, 1988, INTRO STOCHASTIC MOD, P127; HALL ZW, 1968, J MOL BIOL, V36, P321, DOI 10.1016/0022-2836(68)90158-7; HERSHFIELD MS, 1972, J BIOL CHEM, V247, P3393; HILLEBRAND GG, 1985, J BIOL CHEM, V260, P3116; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1984, J BIOL CHEM, V259, P1539; LASKEN RS, 1985, P NATL ACAD SCI USA, V82, P1301, DOI 10.1073/pnas.82.5.1301; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; NOSSAL NG, 1973, DNA SYNTHESIS IN VIT; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533; PLESS RC, 1983, BIOCHEMISTRY-US, V22, P4905, DOI 10.1021/bi00290a006; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; REDDY MK, 1992, J BIOL CHEM, V267, P14157; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; RONEN A, 1976, MUTAT RES, V34, P21, DOI 10.1016/0027-5107(76)90258-X; SINHA NK, 1987, P NATL ACAD SCI USA, V84, P915, DOI 10.1073/pnas.84.4.915; TRAUTNER TA, 1962, P NATL ACAD SCI USA, V48, P449, DOI 10.1073/pnas.48.3.449; VANKAMPEN NG, 1992, STOCHASTIC PROCESSES, P73; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YU H, 1992, J BIOL CHEM, V267, P10888	45	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4759	4774		10.1074/jbc.270.9.4759	http://dx.doi.org/10.1074/jbc.270.9.4759			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876249	hybrid			2022-12-25	WOS:A1995QK08400085
J	GUALBERTO, A; LOWRY, J; SANTORO, IM; WALSH, K				GUALBERTO, A; LOWRY, J; SANTORO, IM; WALSH, K			PARAMETERS THAT INFLUENCE THE EXTENT OF SITE OCCUPANCY BY A CANDIDATE TELOMERE END-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; LAC REPRESSOR; TRANSCRIPTION FACTOR; RNA-POLYMERASE; SYNTHETIC DNA; 3' TERMINUS; SEQUENCE; SUBUNIT; GENES; IDENTIFICATION	The MF3 protein specifically recognizes telomeric and non-telomeric DNA probes that can form G.G base-paired structures (Gualberto, A., Patrick, R. M., and Walsh, K. (1992) Genes & Dev, 6, 815-824). Here we further characterize the nucleic acid recognition properties of MF3 and present a mathematical analysis that evaluates the potential extent of telomere site occupancy by this factor. The substitution of dI at dG positions in telomeric DNA probes revealed that a single dG at any position within the internal repeat was sufficient for high affinity binding to MF3, The RNA analogs of high affinity DNA sites were not bound specifically by MF3, but the substitution of dU for dT in a DNA probe had little or no effect on binding These data demonstrate that ribose ring structure is a critical feature of nucleoprotein complex formation, and this ribose specificity may enable MF3 to occupy sites of unusual DNA structure while minimizing interactions with cellular RNAs. Collectively, the nucleic acid binding properties of MF3 suggest that it may occupy a significant fraction of sites at telomere ends or other G-rich regions of altered DNA structure in vivo.	TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DIV CARDIOVASC RES,BOSTON,MA 02135; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	St. Elizabeth's Medical Center; Tufts University; Case Western Reserve University; University of North Carolina; University of North Carolina Chapel Hill				Gualberto, Antonio/0000-0002-6590-839X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50692] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FANG GW, 1991, NUCLEIC ACIDS RES, V19, P5515, DOI 10.1093/nar/19.20.5515; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; GOLDE A, 1962, VIROLOGY, V16, P9, DOI 10.1016/0042-6822(62)90197-6; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HICKE BJ, 1990, P NATL ACAD SCI USA, V87, P1481, DOI 10.1073/pnas.87.4.1481; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KAOHUANG Y, 1977, P NATL ACAD SCI USA, V74, P4228, DOI 10.1073/pnas.74.10.4228; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LIU ZP, 1993, P NATL ACAD SCI USA, V90, P3157, DOI 10.1073/pnas.90.8.3157; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P1387, DOI 10.1093/nar/20.6.1387; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; RAGHURAMAN MK, 1989, NUCLEIC ACIDS RES, V17, P4235, DOI 10.1093/nar/17.11.4235; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; Saenger W., 1984, PRINCIPLES NUCL ACID, P51; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; VESELKOV AG, 1993, NATURE, V364, P496, DOI 10.1038/364496a0; WALSH K, 1992, J BIOL CHEM, V267, P13714; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	30	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4509	4517		10.1074/jbc.270.9.4509	http://dx.doi.org/10.1074/jbc.270.9.4509			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876219	hybrid, Green Published			2022-12-25	WOS:A1995QK08400052
J	ZHU, JH; REYNET, C; CALDWELL, JS; KAHN, CR				ZHU, JH; REYNET, C; CALDWELL, JS; KAHN, CR			CHARACTERIZATION OF RAD, A NEW MEMBER OF RAS/GTPASE SUPERFAMILY, AND ITS REGULATION BY A UNIQUE GTPASE-ACTIVATING PROTEIN (GAP)-LIKE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; MUTATIONAL ANALYSIS; CATALYTIC DOMAIN; BINDING PROTEIN; XENOPUS-OOCYTES; PHOSPHORYLATION; P21; LOCALIZATION; PROTEOLYSIS; ADIPOCYTES	We have recently identified a new member of the Ras/GTPase superfamily termed Rad which has unique sequence features and is overexpressed in the skeletal muscle of humans with type II diabetes (Reynet, C., and Kahn, C. R. (1993) Science, 262, 1441-1444), When expressed in bacteria as a glutathione S-transferase fusion protein, Rad bound [alpha(32)P]GTP quickly and saturably, Binding was specific for guanine nucleotides and displayed unique magnesium dependence such that both GTP and GDP binding were optimal at relatively high Mg2+ concentrations (1-10 mM), Rad had low intrinsic GTPase activity which was greatly enhanced by a GTPase-activating protein (GAP) activity present in various tissues and cell lines. Several known GAPs had no stimulatory effect toward Rad, Conversion of Ser to Asn at position 66 in Rad (equivalent to position 12 in Ras) resulted in a total loss of GTP binding. Mutation of pro(61) (equivalent to Gly(12) in Ras) or Gln(109) (equivalent to Gln(61) in Ras) had no effect on Rad GTPase activity, whereas creation of a double mutation at these positions resulted in exceptionally high intrinsic GTPase activity, lit vitro, Rad was phosphorylated by the catalytic subunit of cAMP-dependent protein kinase (PK). Phosphopeptide mapping indicated two PKA phosphorylation sites near the C-OOH terminus. Rad also coprecipitated a serine/threonine kinase activity from extracts of various tissues and cell lines which catalyzed phosphorylation on Rad but was not inhibited by PKA inhibitor. Thus, Rad is a GTP-binding protein and a GTPase which has some structure/function similarities to Ras, but displays unique features. Rad may also be phosphorylated on serine/threonine residues by PHA and other kinases, as well as regulated by its own GAP which is present in many tissues and cell types.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK045935] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36836, DK 45935] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; CORMONT M, 1993, J BIOL CHEM, V268, P19491; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1986, J BIOL CHEM, V261, P963; HATA Y, 1991, J BIOL CHEM, V266, P6571; KAELIN WG, 1993, CELL, V64, P521; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MURRAY RK, 1990, HARPERS BIOCH, P441; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUNYER T, 1984, J BIOL CHEM, V259, P5447; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; ZIMMERMANN P, 1990, AM J PHYSIOL, V263, pG396	37	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4805	4812		10.1074/jbc.270.9.4805	http://dx.doi.org/10.1074/jbc.270.9.4805			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876254	hybrid			2022-12-25	WOS:A1995QK08400090
J	CHAI, XY; BOERMAN, MHEM; ZHAI, Y; NAPOLI, JL				CHAI, XY; BOERMAN, MHEM; ZHAI, Y; NAPOLI, JL			CLONING OF A CDNA FOR LIVER MICROSOMAL RETINOL DEHYDROGENASE - A TISSUE-SPECIFIC, SHORT-CHAIN ALCOHOL-DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING PROPERTIES; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; CORTICOSTEROID 11-BETA-DEHYDROGENASE; ESCHERICHIA-COLI; RAT-TISSUES; VITAMIN-A; CRABP-I; ACID; PROTEINS; EXPRESSION	Retinoic acid, a hormone biosynthesized hom retinol, controls numerous biological systems by regulating eukaryotic gene expression hom conception through death. This work reports the cloning and expression of a Liver cDNA encoding a microsomal retinol dehydrogenase (RoDH), which catalyzes the primary and rate-limiting step in retinoic acid synthesis. The predicted amino acid sequence and biochemical data obtained from the recombinant enzyme verify it as a short-chain alcohol dehydrogenase. Like microsomal RoDH, the recombinant enzyme recognized as substrate retinol bound to cellular retinol-binding protein, had higher activity with NADP rather than NAD, was stimulated by ethanol or phosphatidylcholine, was not inhibited by 4-methylpyrazole, was inhibited by phenylarsine oxide and carbenoxolone and localized to microsomes. RoDH recognized the physiological form of retinol, holocellular retinol-binding protein, with a K-m of 0.9 mu M, a value lower than the similar to 5 mu M concentration of holocellular retinol binding protein in liver. Northern and Western blot analyses revealed RoDH expression only in rat Liver, despite enzymatic activity in liver, brain, kidney, lung, and testes. These data suggest that tissue specific isozyme(s) of short chain alcohol dehydrogenases catalyze the first step in retinoic acid biogenesis and further strengthen the evidence that the ''cassette'' of retinol bound to cellular retinol-binding protein serves as a physiological substrate.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIDDK NIH HHS [DK36870] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036870] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI N, 1981, J BIOL CHEM, V256, P9471; AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; BERLETH ES, 1992, J BIOL CHEM, V267, P16403; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCHILL P, 1992, BIOCHEMISTRY-US, V31, P3793, DOI 10.1021/bi00130a009; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; CHYTIL F, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P61; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DELONG A, 1993, CELL, V74, P757, DOI 10.1016/0092-8674(93)90522-R; EDWARDS CRW, 1993, J STEROID BIOCHEM, V45, P1, DOI 10.1016/0960-0760(93)90114-C; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FESUS L, 1991, EUR J CELL BIOL, V56, P170; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GUSTAFSON AL, 1993, DEVELOPMENT, V117, P451; HOFFMAN RD, 1992, J BIOL CHEM, V267, P14005; JAUHIAINEN M, 1988, J BIOL CHEM, V263, P6525; KROOK M, 1990, BIOCHEMISTRY-US, V29, P738, DOI 10.1021/bi00455a021; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LI E, 1991, J BIOL CHEM, V266, P3622; LOHNES D, 1992, J CELL SCI S, V16, P69; Lotan R, 1988, Prog Clin Biol Res, V259, P261; MARKS AR, 1992, J BIOL CHEM, V267, P15459; MONDER C, 1989, ENDOCRINOLOGY, V125, P1046, DOI 10.1210/endo-125-2-1046; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; NAPOLI JL, 1992, BIOCHIM BIOPHYS ACTA, V1120, P183, DOI 10.1016/0167-4838(92)90267-H; NAPOLI JL, 1990, METHOD ENZYMOL, V189, P470; NAPOLI JL, 1994, BASIC SCI CLIN ASPEC, P135; ONG DE, 1982, J BIOL CHEM, V257, P13385; ONG DE, 1994, NUTR REV, V52, pS24; PELTOKETO H, 1988, FEBS LETT, V239, P73, DOI 10.1016/0014-5793(88)80548-9; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; PETKOVICH M, 1992, ANNU REV NUTR, V12, P443, DOI 10.1146/annurev.nu.12.070192.002303; POSCH KC, 1992, J BIOL CHEM, V267, P19676; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; POSCH KC, 1989, ARCH BIOCHEM BIOPHYS, V274, P171, DOI 10.1016/0003-9861(89)90428-1; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; WERMUTH B, 1992, PROSTAGLANDINS, V44, P5, DOI 10.1016/0090-6980(92)90102-Y; WU L, 1993, J BIOL CHEM, V268, P12964	46	128	137	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3900	3904		10.1074/jbc.270.8.3900	http://dx.doi.org/10.1074/jbc.270.8.3900			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876135	hybrid			2022-12-25	WOS:A1995QH68800066
J	CHAUDHARY, S; TORA, L; DAVIDSON, I				CHAUDHARY, S; TORA, L; DAVIDSON, I			CHARACTERIZATION OF A HELA-CELL FACTOR WHICH NEGATIVELY REGULATES TRANSCRIPTIONAL ACTIVATION IN-VITRO BY TRANSCRIPTIONAL ENHANCER FACTOR-I (TEF-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; DNA TOPOISOMERASE-I; TATA-LESS PROMOTER; TFIID COMPLEX; MEDIATED INHIBITION; PROTEIN-BINDING; SIMIAN VIRUS-40; SV40 ENHANCER; DISTINCT; SEQUENCE	A novel negatively acting factor has been identified and partially purified from HeLa and BJA-B cell extracts by chromatographic fractionation. Addition of this factor to HeLa cell extracts or to a reconstituted HeLa cell transcription system repressed transcriptional activation by a chimeric activator, GAL-TEF-1, containing the activation function of transcriptional enhancer factor-1 (TEF-1), In contrast, this factor did not repress transactivation by the chimeric GAL-VP16 activator, Repression of transactivation by GAL-TEF-1 could be alleviated by the addition of immunopurified HeLa cell TFIID, but not by increased quantities of GAL-TEF-1, These observations suggest that this negatively acting factor represses transactivation by interfering with the function of, or competing for, the TATA-binding protein-associated coactivators which mediate the activity TEF-1.	UNIV LOUIS PASTEUR STRASBOURG 1,COLL FRANCE,INST GENET & BIOL MOLEC & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250; Davidson, Irwin/0000-0001-5533-1171				BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROU C, 1993, NUCLEIC ACIDS RES, V21, P4011, DOI 10.1093/nar/21.17.4011; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CAHILL MA, 1994, FEBS LETT, V334, P105; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DAVIDSON I, 1986, NATURE, V323, P544, DOI 10.1038/323544a0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; Drapkin R, 1993, CURR OPIN CELL BIOL, V5, P469, DOI 10.1016/0955-0674(93)90013-G; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GILL G, 1994, P NATL SCI US, V72, P192; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; INOSTROZA JA, 1991, CELL, V70, P477; ISHIJI T, 1992, EMBO J, V6, P2271; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; LESCURE A, 1994, EMBO J, V13, P116; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WEINZEIRL RO, 1993, NATURE, V862, P511; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674; WHITE JH, 1992, EMBO J, V6, P2229; WILDEMAN AG, 1986, MOL CELL BIOL, V6, P2098, DOI 10.1128/MCB.6.6.2098; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	52	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3631	3637		10.1074/jbc.270.8.3631	http://dx.doi.org/10.1074/jbc.270.8.3631			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876100	hybrid			2022-12-25	WOS:A1995QH68800028
J	DELAPENA, P; DELCAMINO, D; PARDO, LA; DOMINGUEZ, P; BARROS, F				DELAPENA, P; DELCAMINO, D; PARDO, LA; DOMINGUEZ, P; BARROS, F			G(S) COUPLES THYROTROPIN-RELEASING-HORMONE RECEPTORS EXPRESSED IN XENOPUS OOCYTES TO PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; ANTERIOR-PITUITARY-CELLS; PERTUSSIS TOXIN; ALPHA-SUBUNIT; MOLECULAR-CLONING; SEQUENCE DETERMINATION; ADENYLYL CYCLASE; LAEVIS OOCYTES; BETA-SUBUNITS; CDNA	Coupling of thyrotropin-releasing hormone (TRH) receptors to individual G-proteins has been studied in Xenopus oocytes injected with receptor cRNA and antisense oligonucleotides to mRNA encoding different G-protein alpha- and beta-subunits. Injection of antisenses which target mRNA sequences shared by several G-protein alpha or beta gamma polypeptides effectively blocked Ca2+-dependent Cl- currents induced by TRH through activation of phospholipase C. Three different alpha(s)-specific antisense oligonucleotides complementary to sequences located in different positions along the coding region of the alpha(s) protein mRNA were highly effective in inhibiting TRH-induced responses. Anti-alpha(o), -alpha(q), -alpha(i), or -alpha(z) oligonucleotides were not able to modify the TRH-evoked response. In contrast, anti-alpha(o), but not anti-alpha(s), oligonucleotides blocked the response to serotonin in oocytes injected with serotonin 5-HT1(c) receptor cRNA. Cholera toxin catalyzed the [P-32]ADP-ribosylation of 40-42- and 50-52-kDa proteins in GH(3) cell plasma membranes, [P-32]ADP-ribosylation of oocyte membranes with the toxin labeled several proteins. These include a single 50-55-kDa substrate, which is clearly diminished in membranes from anti-alpha(s)-injected oocytes. Amplification of oocyte RNA in a polymerase chain reaction system and sequencing of the amplified products demonstrated that anti-alpha(s) oligonucleotides selectively recognize the message for the Xenopus alpha(s) polypeptide. It is concluded that G(s), but not G(o), G(q), G(i), or G(z), couples TRH receptors expressed in oocytes to activation of phospholipase C and subsequent inositol 1,4,5-trisphosphate-dependent stimulation of Ca2+-dependent Cl- currents.			DELAPENA, P (corresponding author), UNIV OVIEDO,FAC MED,DEPT BIOL FUNC,AREA BIOQUIM & BIOL MOLEC,E-33006 OVIEDO,SPAIN.		Barros, Francisco/O-6647-2019; De-la-Pena-Cortines, Pilar/B-1453-2012; Pardo, Luis/C-5066-2013; Dominguez, Pedro/A-8266-2012; Barros, Francisco/H-3297-2015	Barros, Francisco/0000-0001-9040-1948; De-la-Pena-Cortines, Pilar/0000-0002-3915-730X; Pardo, Luis/0000-0003-1375-4349; Dominguez, Pedro/0000-0003-4788-1071; Barros, Francisco/0000-0001-9040-1948				ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BARROS F, 1994, PFLUG ARCH EUR J PHY, V426, P221, DOI 10.1007/BF00374775; BARROS F, 1993, FEBS LETT, V336, P433, DOI 10.1016/0014-5793(93)80851-K; BARROS F, 1991, FEBS LETT, V279, P33, DOI 10.1016/0014-5793(91)80243-V; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLITZER RD, 1993, J BIOL CHEM, V268, P7532; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CODINA J, 1988, J BIOL CHEM, V263, P6746; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; CRUCIANI RA, 1993, P NATL ACAD SCI USA, V90, P3019, DOI 10.1073/pnas.90.7.3019; DELAPENA P, 1992, BIOCHEM J, V284, P891, DOI 10.1042/bj2840891; DELAPENA P, 1992, J BIOL CHEM, V267, P25703; DELGADO LM, 1992, FEBS LETT, V311, P411; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GOLLASCH M, 1993, P NATL ACAD SCI USA, V90, P6265, DOI 10.1073/pnas.90.13.6265; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; HUNG DT, 1992, J BIOL CHEM, V267, P20831; ITOH H, 1988, J BIOL CHEM, V263, P6656; JOUNEAUX C, 1994, J BIOL CHEM, V269, P1845; KANEKO S, 1992, FEBS LETT, V299, P179, DOI 10.1016/0014-5793(92)80242-9; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; MA HW, 1993, J BIOL CHEM, V268, P19915; MATSUOKA M, 1990, J BIOL CHEM, V265, P13215; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P239, DOI 10.1016/0165-6147(93)90019-G; MOLLARD P, 1990, BIOCHEM J, V268, P345, DOI 10.1042/bj2680345; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; MORIARTY TM, 1990, G PROTEINS, P479; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; OLATE J, 1990, FEBS LETT, V268, P27, DOI 10.1016/0014-5793(90)80964-K; OLATE J, 1984, FEBS LETT, V175, P25; OZAWA S, 1986, PHYSIOL REV, V66, P887, DOI 10.1152/physrev.1986.66.4.887; SADLER SE, 1984, MOL PHARMACOL, V26, P526; SHAPIRO RA, 1993, J BIOL CHEM, V268, P21734; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; TAYLOR CW, 1990, BIOCHEM J, V272, P1; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WU DQ, 1992, J BIOL CHEM, V267, P25798; ZHAO DY, 1992, ENDOCRINOLOGY, V130, P3529, DOI 10.1210/en.130.6.3529	45	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3554	3559		10.1074/jbc.270.8.3554	http://dx.doi.org/10.1074/jbc.270.8.3554			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876090	hybrid			2022-12-25	WOS:A1995QH68800017
J	FOUNTOULAKIS, M; MESA, C; SCHMID, G; GENTZ, R; MANNEBERG, M; ZULAUF, M; DEMBIC, Z; GAROTTA, G				FOUNTOULAKIS, M; MESA, C; SCHMID, G; GENTZ, R; MANNEBERG, M; ZULAUF, M; DEMBIC, Z; GAROTTA, G			INTERFERON-GAMMA RECEPTOR EXTRACELLULAR DOMAIN EXPRESSED AS IGG FUSION PROTEIN IN CHINESE-HAMSTER OVARY CELLS - PURIFICATION, BIOCHEMICAL-CHARACTERIZATION, AND STOICHIOMETRY OF BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; IFN-GAMMA; ACCESSORY FACTOR; BIOLOGICAL-ACTIVITY; SOLUBLE HUMAN; SIGNAL; ANTIBODIES; INTERACTS; INHIBITOR; COMPLEX	Agents that antagonize the functions of interferon gamma (IFN gamma) are potential pharmaceuticals against several immunological and inflammatory disorders. IFN gamma receptor-immunoglobulin G fusion proteins (IFN gamma R-IgG) function as antagonists of endogenous IFN gamma and have longer half-lives in vivo in comparison with soluble IFN gamma receptors (sIFN gamma R), consisting of the extracellular region of the native sequence. A fusion protein comprising the extracellular domain of the human LFN gamma receptor and the hinge, CH2 and CH3 domains of the human IgG3 constant region, was expressed in Chinese hamster ovary cells. The IFN gamma R-IgG3 fusion protein was secreted into the culture medium as a 175-kDa glycoprotein and was purified over Protein G-Sepharose, DEAE-Sepharose, and size exclusion chromatography. IFN gamma R-IgG3 bound IFN gamma in solid phase assays and ligand blots, competed for the binding of radiolabeled IFN gamma to the cell surface receptor of Raji cells, and inhibited the IFN gamma-mediated antiviral activity with an efficiency at least one order of magnitude higher than that of the soluble receptor produced in the same expression system. Two IFN gamma R-IgG3 fusion proteins bound two IFN gamma dimers forming a complex of approximately 380 kDa. In immunodiffusion assays, the IFN gamma R-IgG3 fusion protein did not precipitate IFN gamma. Dissociation of bound IFN gamma from IFN gamma R-IgG3 was 2-fold slower than from the sIFN gamma R produced in insect cells.	F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES,DEPT BIOTECHNOL,CH-4002 BASEL,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES,DEPT PHYS,CH-4002 BASEL,SWITZERLAND	Roche Holding; Roche Holding	FOUNTOULAKIS, M (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PRPG,PHARMACEUT RES,DEPT GENE TECHNOL,BLDG 15-16,CH-4002 BASEL,SWITZERLAND.		Dembic, Zlatko/A-1833-2008	Dembic, Zlatko/0000-0002-9970-6497				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ANTONI G, 1989, ANAL BIOCHEM, V179, P158, DOI 10.1016/0003-2697(89)90217-0; AXELROD A, 1994, J BIOL CHEM, V269, P15533; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOBELI H, 1988, J BIOTECHNOL, V7, P199, DOI 10.1016/0168-1656(88)90052-1; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; Evans T. J., 1994, European Cytokine Network, V5, P203; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FOUNTOULAKIS M, 1989, J IMMUNOL, V143, P3266; FOUNTOULAKIS M, 1993, ANAL BIOCHEM, V208, P270, DOI 10.1006/abio.1993.1045; FOUNTOULAKIS M, 1991, EUR J BIOCHEM, V198, P441, DOI 10.1111/j.1432-1033.1991.tb16034.x; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; FOUNTOULAKIS M, 1992, BIO-TECHNOL, V10, P1143, DOI 10.1038/nbt1092-1143; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; FOUNTOULAKIS M, 1992, J BIOL CHEM, V267, P7095; FOUNTOULAKIS M, 1992, J BIOCHEM BIOPH METH, V24, P265, DOI 10.1016/0165-022X(94)90078-7; FOUNTOULAKIS M, 1995, IN PRESS J CHEM TECH; GAROTTA G, 1989, PHARMACOL RES, V21, P5, DOI 10.1016/S1043-6618(89)80013-1; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; GENTZ R, 1992, EUR J BIOCHEM, V210, P545, DOI 10.1111/j.1432-1033.1992.tb17453.x; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; KALINA U, 1993, J VIROL, V67, P1702, DOI 10.1128/JVI.67.3.1702-1706.1993; KURSCHNER C, 1992, J IMMUNOL, V149, P4096; KURSCHNER C, 1992, J BIOL CHEM, V267, P9354; LANDOLFO S, 1991, J IMMUNOL RES, V3, P81; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NICOLETTI F, 1990, LANCET, V336, P319, DOI 10.1016/0140-6736(90)91860-D; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; OZMEN L, 1993, J IMMUNOL, V150, P2698; OZMEN L, 1993, INT REV EXP PATHOL, V34, P137; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; SCHMID G, 1994, ANIMAL CELL TECHNOLO, P625; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STUBER D, 1993, BIOCHEMISTRY-US, V32, P2423; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; VALENTE G, 1992, EUR J IMMUNOL, V22, P2403, DOI 10.1002/eji.1830220933; VANLOON APGM, 1991, J LEUKOCYTE BIOL, V49, P462, DOI 10.1002/jlb.49.5.462	50	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3958	3964		10.1074/jbc.270.8.3958	http://dx.doi.org/10.1074/jbc.270.8.3958			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876143	hybrid			2022-12-25	WOS:A1995QH68800075
J	HARELBRONSTEIN, M; DIBROV, P; OLAMI, Y; PINNER, E; SCHULDINER, S; PADAN, E				HARELBRONSTEIN, M; DIBROV, P; OLAMI, Y; PINNER, E; SCHULDINER, S; PADAN, E			MH1, A 2ND-SITE REVERTANT OF ALL ESCHERICHIA-COLI MUTANT LACKING NA+/H+ ANTIPORTERS (DELTA-NHAA-DELTA-NHAB), REGAINS NA+ RESISTANCE AND A CAPACITY TO EXCRETE NA+ IN A DELTA-MU(H)+-INDEPENDENT FASHION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTIVE RESPIRATORY-CHAIN; ION-TRANSPORT; SODIUM; GENE; PROTON; CLONING; ENERGETICS; EXPRESSION; CELLS; ANT	The Escherichia coli mutant Delta nhaA Delta nhaB (EP432), which lacks the two specific Na+/H+ antiporter genes, is incapable of efficiently excreting Na+. Accordingly at low K+ (6 mM) medium, its intracellular Na+ concentration is only slightly lower (1,5-2x) than the extracellular concentration (50 mM), explaining the high sensitivity to Na+ (less than or equal to 30 mM) of the mutant, This Na+ sensitivity is shown to be a powerful selection for spontaneous second-site suppressor mutations that allow growth on high Na+ (less than or equal to 0.6 M) with a rate similar to that of the wild type. One such mutation, MH1, maps at 25.7 min on the E, coli chromosome. It confers Na+ but not Li+ resistance upon Delta nhaA Delta nhaB cells and exposes a Nac-excreting capacity, maintaining a Na+ gradient of about 8-10 (at 50 mM extracellular Na+), which is similar to that of the wild type, Although lower, Na+ excretion capacity is also observed in the Delta nhaA Delta nhaB mutant when grown in medium containing higher K+ (70 mM). This capacity is accompanied with a shift in the sensitivity of the mutant to higher Na+ concentrations (greater than or equal to 300 mar). Whereas Na+ excretion by a wild type carrying Delta unc is uncoupler sensitive, that of MH1 Delta unc is dependent on respiration in an uncoupler-insensitive fashion. It is concluded that under some conditions (high HC in the medium or in MH1-Like mutants), a primary pump driven by respiration is responsible for Na+ extrusion when the Na+/H+ antiporters are not active.			HARELBRONSTEIN, M (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DIV MICROBIAL & MOLEC ECOL,IL-91904 JERUSALEM,ISRAEL.		Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				AVETISYAN AV, 1989, FEBS LETT, V254, P17, DOI 10.1016/0014-5793(89)81000-2; AVETISYAN AV, 1992, FEBS LETT, V306, P199, DOI 10.1016/0014-5793(92)80999-W; AVETISYAN AV, 1993, FEBS LETT, V3, P267; BOOS W, 1987, J BIOL CHEM, V262, P13212; BORBOLLA MG, 1984, ARCH BIOCHEM BIOPHYS, V229, P98, DOI 10.1016/0003-9861(84)90134-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS LK, 1991, METHOD ENZYMOL, V204, P43; BROSIUS J, 1992, METHOD ENZYMOL, V216, P469; CASTLE AM, 1986, J BIOL CHEM, V261, P7797; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DIBROV PA, 1991, BIOCHIM BIOPHYS ACTA, V1056, P209, DOI 10.1016/S0005-2728(05)80052-0; DIMROTH P, 1992, ALKALI CATION TRANSP, P77; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; IVEY DM, 1993, J BIOL CHEM, V268, P11296; JOSHI AK, 1989, J BIOL CHEM, V264, P2126; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KARPEL R, 1991, J BIOL CHEM, V266, P21753; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miller J. H., 1992, SHORT COURSE BACTERI, P263; OHYAMA T, 1994, J BACTERIOL, V176, P4311, DOI 10.1128/jb.176.14.4311-4315.1994; PADAN E, 1989, J BIOL CHEM, V264, P20297; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; PADAN E, 1992, ALKALI CATION TRANSP, P3; PAN JW, 1990, J BIOL CHEM, V265, P9247; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1993, J BIOL CHEM, V268, P1729; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; ROSEN BP, 1986, ANNU REV MICROBIOL, V40, P263, DOI 10.1146/annurev.mi.40.100186.001403; SKULACHEV VP, 1984, TRENDS BIOCHEM SCI, V9, P483, DOI 10.1016/0968-0004(84)90317-7; SKULACHEV VP, 1988, MEMBRANE BIOENERGETI, P293; TAKASE K, 1993, J BIOL CHEM, V268, P11610; TOKUDA H, 1985, MICROBIOL SCI, V2, P65; Walderhaug M.O., 1987, ION TRANSPORT PROKAR, P85; WEST IC, 1974, BIOCHEM J, V144, P87, DOI 10.1042/bj1440087	35	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3816	3822		10.1074/jbc.270.8.3816	http://dx.doi.org/10.1074/jbc.270.8.3816			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876124	hybrid			2022-12-25	WOS:A1995QH68800054
J	RORDORFNIKOLIC, T; VANHORN, DJ; CHEN, DX; WHITE, MF; BACKER, JM				RORDORFNIKOLIC, T; VANHORN, DJ; CHEN, DX; WHITE, MF; BACKER, JM			REGULATION OF PHOSPHATIDYLINOSITOL 3'-KINASE BY TYROSYL PHOSPHOPROTEINS - FULL ACTIVATION REQUIRES OCCUPANCY OF BOTH SH2 DOMAINS IN THE 85-KDA REGULATORY SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR KINASE INSERT; PDGF RECEPTOR; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; GROWTH-FACTOR; INTACT-CELLS; PHOSPHOINOSITIDE 3-KINASE; PI 3-KINASE; PHOSPHORYLATION; BINDING	Phosphatidylinositol 3'-kinase (PI 3'-kinase) is activated in insulin-stimulated cells by the binding of the SH2 domains in its 85-kDa regulatory subunit to insulin receptor substrate-1 (IRS-1). We have previously shown that both tyrosyl-phosphorylated IRS-l and mono-phosphopeptides containing a single YXXM motif activate PI 3'-kinase in vitro. However, activation by the monophosphopeptides was significantly less potent than activation by the multiply phosphorylated IRS-1. We now show that the increased potency of PI 3'-kinase activation by IRS-1 relative to phosphopeptide is not due to tertiary structural features IRS-l, as PI 3'-kinase is activated normally by denatured, reduced, and carboxymethylated IRS-1. Furthermore, activation of PI 3'-kinase by bis-phosphorylated peptides containing two YXXM motifs is 100-fold more potent than the corresponding mono-phosphopeptides and similar to activation by IRS-1. These data suggest that tyrosyl-phosphorylated IRS-1 or bis-phosphorylated peptides bind simultaneously to both SH2 domains of p85. However, these data cannot differentiate between an activation mechanism that requires two-site occupancy for maximal activity as opposed to one in which bivalent binding enhances the occupancy of a single activating site. To distinguish between these possibilities, we produced recombinant PI 3'-kinase containing either wild-type p85 or p85 mutated in its N-terminal, C-terminal, or both SH2 domains. We find that mutation of either SH2 domains significantly reduced phosphopeptide binding and decreased PI 3'-kinase activation by 50%, whereas mutation of both SH2 domains completely blocked binding and activation. These data provide the first direct evidence that full activation of PI 3'-kinase by tyrosylphosphorylated proteins requires occupancy of both SH2 domains in p85.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,DEPT MED,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK-44541] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044541] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PARKER PJ, 1993, CELL GROWTH DIFFER, V3, P747; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	35	209	209	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3662	3666		10.1074/jbc.270.8.3662	http://dx.doi.org/10.1074/jbc.270.8.3662			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876105	hybrid			2022-12-25	WOS:A1995QH68800033
J	BORCHELT, DR; GUARNIERI, M; WONG, PC; LEE, MK; SLUNT, HS; XU, ZS; SISODIA, SS; PRICE, DL; CLEVELAND, DW				BORCHELT, DR; GUARNIERI, M; WONG, PC; LEE, MK; SLUNT, HS; XU, ZS; SISODIA, SS; PRICE, DL; CLEVELAND, DW			SUPEROXIDE-DISMUTASE-1 SUBUNITS WITH MUTATIONS LINKED TO FAMILIAL AMYOTROPHIC-LATERAL-SCLEROSIS DO NOT AFFECT WILD-TYPE SUBUNIT FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS	Mutations in superoxide dismutase 1 (SOD1) have been linked to familial amyotrophic lateral sclerosis, a dominantly inherited motor neuron disorder of midlife. Because SOD1 is a homodimeric enzyme, dimerization of mutant and wild-type SOD1 subunits could dominantly alter the activity, stability, or localization of wild-type SOD1 subunits. To explore these possibilities, we used transient and stable gene transfection to express high levels of either of two mutant human SOD1 subunits in the presence of limited levels of wild-type mouse and/or human SOD1 subunits. Although both mutant subunits displayed diminished half-lives and free radical scavenging activities, their presence caused no change in the half-life or activity of wild-type SOD1 subunits. Our data indicate that mutant subunits do not dominantly affect the function of wild-type SOD1 subunits. These findings, together with observations that many mutant SOD1 subunits retain significant stability and activity, suggest that motor neuron damage in familial amyotrophic lateral sclerosis is caused by the acquisition of injurious properties by mutant SOD1 subunits.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Cleveland, Don/AAN-9783-2021; Lee, Michael K/D-9491-2013	Lee, Michael K/0000-0001-5865-9682; Cleveland, Don/0000-0002-1934-3682	NIA NIH HHS [AG 05146] Funding Source: Medline; NINDS NIH HHS [NS 20471, NS 27036] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS020471, P50NS020471, R37NS027036, R01NS027036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; ELSHAFEY A, 1994, HUM MOL GENET, V3, P363, DOI 10.1093/hmg/3.2.363; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; FRIDOVICH I, 1974, ADV ENZYMOL RAMB, V41, P35; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALINOWSKI DP, 1979, BIOCHEMISTRY-US, V18, P237, DOI 10.1021/bi00568a037; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; NAKANO R, 1994, BIOCHEM BIOPH RES CO, V200, P695, DOI 10.1006/bbrc.1994.1506; OGASAWARA M, 1993, NAT GENET, V5, P323, DOI 10.1038/ng1293-323; RAINERO I, 1994, NEUROLOGY, V44, P347, DOI 10.1212/WNL.44.2.347; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN JD, 1994, P NATL ACAD SCI USA, V91, P4155, DOI 10.1073/pnas.91.10.4155; SHERMAN L, 1983, P NATL ACAD SCI-BIOL, V80, P5465, DOI 10.1073/pnas.80.18.5465; SIDDIQUE T, 1989, NEUROLOGY, V39, P919, DOI 10.1212/WNL.39.7.919; WEISSMANN C, 1994, SCIENCE, V264, P528, DOI 10.1126/science.7909168; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	26	137	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3234	3238		10.1074/jbc.270.7.3234	http://dx.doi.org/10.1074/jbc.270.7.3234			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852409	hybrid			2022-12-25	WOS:A1995QG47100053
J	POTTER, JD; SHENG, ZL; PAN, BS; ZHAO, JJ				POTTER, JD; SHENG, ZL; PAN, BS; ZHAO, JJ			A DIRECT REGULATORY ROLE FOR TROPONIN-T AND A DUAL ROLE FOR TROPONIN-C IN THE CA2+ REGULATION OF MUSCLE-CONTRACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; BIOLOGICAL-ACTIVITY; INHIBITORY REGION; CROSS-LINKING; TROPOMYOSIN; BINDING; FRAGMENTS; SUBUNITS; ACTIN; CA-2+	Troponin (Tn), containing three subunits: Ca2+ binding (TnC), inhibitory (TnI), and tropomyosin binding (TnT), plays a crucial role in the Ca2+ regulation of vertebrate striated muscle contraction. These three subunits function by interacting with each other and with the other thin filament proteins. Previous studies suggested that the primary role of TnT is to anchor the TnI.TnC complex to the thin filament, primarily through its interactions with TnI and tropomyosin. We propose here a new role for TnT. Our results indicate that, when TnT is combined with the TnI.TnC complex, there is an activation of actomyosin ATPase that is Ca2+-dependent. To determine whether the latter results from a direct effect of TnC on TnT or indirectly from an effect of TnC on TnI which is transmitted to TnT, we prepared a deletion mutant (deletion of residues 1-57) of TnI, TnI(d57) (Sheng et al. (1992) J. Biol. Chem. 267, 25407-25413), which interacts with TnC but not TnT. Both wild type (TnI.TnC.TnT) and mutant (TnI(d57).Tnc.TnT) Tn complexes demonstrated equivalent activity in the Ca2+ regulation of actomyosin-S1 ATPase activity. Similarly, both TnT and TnI(d57) could equally reconstitute TnI-depleted skinned muscle fibers. Therefore, since TnI(d57) does not interact with TnT, these results suggest that TnT reconstitutes native Ca2+ sensitivity via direct interaction with TnC. Thus Ca2+ binding to TnC would have a dual role: 1) release of the ATPase inhibition by TnI and 2) activation of the ATPase through interaction with TnT.			POTTER, JD (corresponding author), UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,MIAMI,FL 33101, USA.				NIAMS NIH HHS [AR37701, AR40727] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040727, R01AR037701] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8; CHONG PCS, 1982, J BIOL CHEM, V257, P1667; FARAH CS, 1994, J BIOL CHEM, V269, P5230; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; Greaser M. L., 1972, COLD SPRING HARB SYM, V37, P235; GREASER ML, 1973, J BIOL CHEM, V248, P2125; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HITCHCOCK SE, 1975, EUR J BIOCHEM, V52, P255, DOI 10.1111/j.1432-1033.1975.tb03993.x; HITCHCOCKDEGREG.SE, 1982, J BIOL CHEM, V257, P7372; HORWITZ J, 1979, J BIOL CHEM, V254, P350; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; PAN BS, 1992, J BIOL CHEM, V267, P23052; PARDER JD, 1982, METHOD ENZYMOL, V85, P234; PEARLSTONE JR, 1978, CAN J BIOCHEM CELL B, V56, P521, DOI 10.1139/o78-080; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PERRY SV, 1972, COLD SPRING HARB SYM, V37, P251; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; POTTER JD, 1993, BIOPHYS J, V64, pA137; REISER PJ, 1992, J PHYSIOL-LONDON, V449, P573, DOI 10.1113/jphysiol.1992.sp019102; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; SHENG Z, 1991, J BIOL CHEM, V266, P5711; SHENG Z, 1993, BIOPHYS J, V64, pA136; SHENG Z, 1992, J BIOL CHEM, V268, P25407; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SHENG ZL, 1993, J BIOL CHEM, V268, P3016; STRAUSS JD, 1992, FEBS LETT, V310, P229, DOI 10.1016/0014-5793(92)81338-M; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; WEEKS RA, 1978, BIOCHEM J, V173, P449, DOI 10.1042/bj1730449; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	38	144	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2557	2562		10.1074/jbc.270.6.2557	http://dx.doi.org/10.1074/jbc.270.6.2557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852318	hybrid			2022-12-25	WOS:A1995QF53500026
J	SCHONFELD, HJ; SCHMIDT, D; SCHRODER, H; BUKAU, B				SCHONFELD, HJ; SCHMIDT, D; SCHRODER, H; BUKAU, B			THE DNAK CHAPERONE SYSTEM OF ESCHERICHIA-COLI - QUATERNARY STRUCTURES AND INTERACTIONS OF THE DNAK AND GRPE COMPONENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATPASE ACTIVITY; PROTEIN; PURIFICATION	The DnaK (Hsp70), DnaJ, and GrpE heat shock proteins of Escherichia coli constitute a cellular chaperone system for protein folding, Substrate interactions are controlled by the ATPase activity of DnaK which itself is regulated by the nucleotide exchange factor GrpE, To understand the structure-function relationship of this chaperone system, the quaternary structures of DnaK, GrpE, and DnaK-GrpE complexes were analyzed by gel filtration chromatography, dynamic light scattering, analytical ultracentrifugation, and native gel electrophoresis. GrpE formed dimers in solution, DnaK formed monomers, dimers, and higher mole mass oligomers, the equilibrium between these forms being dependent on the DnaK concentration, The behavior of DnaK and GrpE in gel filtration and dynamic light scattering suggested elongated shapes of both molecules, In the absence of added nucleotides, DnaK and GrpE formed stable complexes containing one molecule of DnaK and two molecules of GrpE. A 44-kDa N-terminal ATPase fragment of DnaK also formed complexes with GrpE with the same 1:2 stoichiometry. DnaK-GrpE complex formation was unaffected by elimination of DnaK-bound nucleotides or addition of saturating concentrations of a DnaK peptide substrate. These findings allow the correlation of DnaK-GrpE interactions with a role for GrpE in the functional cycle of the DnaK chaperone system.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	SCHONFELD, HJ (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND.			Bukau, Bernd/0000-0003-0521-7199				ANG D, 1988, THESIS U UTAH SALT L; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CASPERS P, 1994, CELL MOL BIOL, V40, P635; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; JOHNSON C, 1989, J BACTERIOL, V171, P1590, DOI 10.1128/jb.171.3.1590-1596.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1993, FEBS LETT, V336, P124, DOI 10.1016/0014-5793(93)81624-9; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; SCHOENFELD HJ, 1991, J BIOL CHEM, V266, P3863; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SCHUCK P, 1994, PROG COLL POL SCI S, V94, P1; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; [No title captured]	25	147	149	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2183	2189		10.1074/jbc.270.5.2183	http://dx.doi.org/10.1074/jbc.270.5.2183			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836448	hybrid			2022-12-25	WOS:A1995QE49300033
J	LESSNICK, SL; BRAUN, BS; DENNY, CT; MAY, WA				LESSNICK, SL; BRAUN, BS; DENNY, CT; MAY, WA			MULTIPLE DOMAINS MEDIATE TRANSFORMATION BY THE EWINGS-SARCOMA EWS/FLI-1 FUSION GENE	ONCOGENE			English	Article						EWINGS SARCOMA; EWS/FLI-1; ETS PROTEINS; CHIMERIC TRANSCRIPTION FACTOR	CHIMERIC TRANSCRIPTION FACTOR; DNA-BINDING DOMAIN; TRANSACTIVATION DOMAIN; PRE-B; ACTIVATION; TRANSLOCATION; PROTEINS; FAMILY; FLI-1; LIPOSARCOMA	The (11;22) chromosomal translocation found in Ewing's sarcoma and related tumors fuses the amino terminus of the EWS protein to the DNA-binding domain of the FLI-1 transcription factor. In contrast to normal FLI-1, the EWS/FLI-1 fusion transforms NIH3T3 cells and this activity requires both EWS and FLI-1 sequences. Reporter gene assays showed that the portion of EWS fused to FLI-1 encodes a strong transcriptional activation domain. To determine whether this function is necessary for transformation by EWS/FLI-1, deletion analysis of EWS was performed. We found that the EWS domain could be functionally subdivided into two regions: (i) an amino terminal domain (domain A) which transforms efficiently when fused to FLI-1 but has little transactivation activity in a model system and (ii) a distal region (domain B) which transactivates efficiently but transforms less efficiently when fused to FLI-1. Replacement of the EWS domain with known heterologous transcriptional activation domains yielded chimeric FLI-1 fusions that in some instances could transform NM3T3 cells. Finally we demonstrate that EWS/FLI-1 and related FLI-1 chimeras are able to cooperate,vith another transcription factor to activate a model reporter gene. These results further demonstrate that EWS/FLI-1 is an aberrant transcription factor and suggest that the EWS domain mediates important protein-protein interactions with other factors resulting in the transcriptional modulation of target genes.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,GWYNNE HAZEN CHERRY MEM LABS,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL CANCER INSTITUTE [P01CA012800, R01CA050443] Funding Source: NIH RePORTER; NCI NIH HHS [CA12800, CA50443] Funding Source: Medline; NIGMS NIH HHS [GM08042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; FLEMINGTON EK, 1992, J VIROL, V66, P922, DOI 10.1128/JVI.66.2.922-929.1992; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS J, 1992, BLOOD, V80, P2953; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NYE JA, 1992, GENE DEV, V67, P975; OHNO T, 1993, CANCER RES, V53, P5859; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAO VN, 1993, ONCOGENE, V8, P2167; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; WU YL, 1990, NUCLEIC ACIDS RES, V18, P1919, DOI 10.1093/nar/18.7.1919; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	36	152	161	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					423	431						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845667				2022-12-25	WOS:A1995QF64800002
J	LU, HS; CHANG, D; PHILO, JS; ZHANG, K; NARHI, LO; LIU, NL; ZHANG, M; SUN, JL; WEN, J; YANAGIHARA, D; KARUNAGARAN, D; YARDEN, Y; RATZKIN, B				LU, HS; CHANG, D; PHILO, JS; ZHANG, K; NARHI, LO; LIU, NL; ZHANG, M; SUN, JL; WEN, J; YANAGIHARA, D; KARUNAGARAN, D; YARDEN, Y; RATZKIN, B			STUDIES ON THE STRUCTURE AND FUNCTION OF GLYCOSYLATED AND NONGLYCOSYLATED NEU DIFFERENTIATION FACTORS - SIMILARITIES AND DIFFERENCES OF THE ALPHA-ISOFORM AND BETA-ISOFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY-STRUCTURE; INFRARED-SPECTRA; PROTEIN; HEREGULIN; LIGAND; FORMS; BANDS	Comparative analyses of both glycosylated and non glycosylated neu differentiation factor (NDF) isoforms revealed significant similarities and differences of their overall structures and functions. Biophysical analyses confirmed that all NDF isoforms are monomeric, but have an extended ellipsoidal shape in solution. All full-length NDFs are similar in secondary and tertiary structures and they contain no alpha-helix but are abundant in beta-strand structures. A small NDF fragment containing only the epidermal growth factor domain is also rich in beta-strand structures, but exhibits tertiary structure different from the long NDF forms. Monoclonal antibodies that selectively recognize epidermal growth factor domains of human NDF-alpha or NDF-beta can specifically bind the respective NDF-alpha and -beta isoforms independent of NDF origins. Western blot analysis and quantitative binding assays further identify that an NDF preparation produced naturally from Rat1-EJ cells contains both alpha and beta isoforms in a 3 to 2 ratio. In receptor binding competition experiments, human and rat NDF-beta isoforms have higher affinity than NDF-alpha isoforms. NDF-beta isoforms can dramatically enhance the stimulation of DNA synthesis for transfected NIH3T3 cells that overexpress HER-3 and HER-4 receptors, while NDF-alpha isoforms can only stimulate proliferation of HER-4-transfected cells with lower activity. Taken together, NDF-alpha and -beta isoforms share similar gross protein conformations but are biologically distinct.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	LU, HS (corresponding author), AMGEN INC,AMGEN CTR,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.		Philo, John S/A-8804-2009; Karunagaran, Devarajan/A-8148-2010; YARDEN, YOSEF/K-1467-2012	Philo, John S/0000-0003-3418-0356; Karunagaran, Devarajan/0000-0001-9331-8947; 				ARAKAWA T, 1992, ANAL BIOCHEM, V203, P53, DOI 10.1016/0003-2697(92)90042-6; ARAKAWA T, 1994, ARCH BIOCHEM BIOPHYS, V308, P267, DOI 10.1006/abbi.1994.1037; ARNOLD GE, 1992, BIOCHEMISTRY-US, V31, P7948, DOI 10.1021/bi00149a028; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; HENDRICKSON WA, 1992, COLD SPRING HARB SYM, V57, P549, DOI 10.1101/SQB.1992.057.01.060; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNTER T, 1992, COLD SPRING HARB SYM, V57, P25, DOI 10.1101/SQB.1992.057.01.005; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LU HS, 1995, IN PRESS J CHROMATOG; LU HS, 1994, J BIOL CHEM, V270, P4775; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; NAGATA K, 1994, EMBO J, V13, P3517, DOI 10.1002/j.1460-2075.1994.tb06658.x; NARHI LO, 1992, BIOCHEMISTRY-US, V31, P182; NOWINSKI RC, 1979, VIROLOGY, V93, P111, DOI 10.1016/0042-6822(79)90280-0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PHILO JS, 1993, BIOCHEMISTRY-US, V32, P10812, DOI 10.1021/bi00091a036; PHILO JS, 1995, IN PRESS MODERN ANAL; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRESTRELSKI SJ, 1992, J BIOL CHEM, V267, P319; PRESTRELSKI SJ, 1991, INT J PEPT PROT RES, V37, P508; PRESTRELSKI SJ, 1991, BIOCHEMISTRY-US, V30, P133, DOI 10.1021/bi00215a020; SHIRE SJ, 1992, DS837 BECKM INSTR TE; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUSI H, 1983, BIOCHEM BIOPH RES CO, V115, P391, DOI 10.1016/0006-291X(83)91016-1; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	32	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4784	4791		10.1074/jbc.270.9.4784	http://dx.doi.org/10.1074/jbc.270.9.4784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876251	hybrid			2022-12-25	WOS:A1995QK08400087
J	MUKHERJEE, B; BURMA, S; HASNAIN, SE				MUKHERJEE, B; BURMA, S; HASNAIN, SE			THE 30-KDA PROTEIN-BINDING TO THE INITIATOR OF THE BACULOVIRUS POLYHEDRIN PROMOTER ALSO BINDS SPECIFICALLY TO THE CODING STRAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE GENE-EXPRESSION; RNA POLYMERASE-II; DNA-BINDING; TRANSCRIPTION; IDENTIFICATION; ELEMENT; SITE; SEQUENCES; VIRUS	We previously reported the purification and characterization of the polyhedrin promoter-binding protein (PPBP), an unusual DNA-binding protein that interacts with transcriptionally important motifs of the baculovirus polyhedrin gene promoter (S, Burma, B, Mukherjee, A. Jain, S. Habib, and S.E, Hasnain, J, Biol. Chem, (1994) 269, 2750-2757, PPBP also exhibits a sequence-specific single-stranded DNA-binding activity. Gel retardations and competition analyses with double- and single-stranded oligonucleotides indicated that PPBP binds the coding strand and not the noncoding strand of the promoter, This was further confirmed by UV crosslinking and Southwestern blotting experiments, Gel retardations with mutated oligonucleotides indicated that both dsDNA and ssDNA binding involve common AATA-AATAAGTATT motifs, However, ssDNA binding is dependent upon ionic interactions unlike dsDNA binding, which is mainly through nonionic interactions, The affinity of PPBP for the coding strand appears to be higher than that for duplex promoter DNA, Interestingly, the PPBP-coding strand complex has a longer half-life (similar to 60 min) than the PPBP-duplex promoter complex (similar to 15 min), PPBP represents a unique example of an ''initiator'' promoter-binding protein with dual dsDNA and ssDNA binding activities, and this reconciles very well with the unusual binding characteristics displayed by it, The formation of the PPBP-coding strand complex in vivo may be a crucial step for the exceptionally high and repeated rounds of transcriptional activity of the baculovirus polyhedrin gene promoter.	NATL INST IMMUNOL,EUKARYOT GENE EXPRESS LAB,NEW DELHI 110067,INDIA	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)			HASNAIN, SEYED/C-1492-2009	Hasnain, Seyed/0000-0002-2967-0791				BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURMA S, 1994, J BIOL CHEM, V269, P2750; CHODOSH L, 1988, CURRENT PROTOCOLS MO, V2; CHOO Y, 1993, NUCLEIC ACIDS RES, V21, P3341, DOI 10.1093/nar/21.15.3341; CRICK F, 1971, NATURE, V234, P25, DOI 10.1038/234025a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GRAYHACK EJ, 1992, MOL CELL BIOL, V12, P3573, DOI 10.1128/MCB.12.8.3573; JARVIS DL, 1992, RECOMBINANT DNA VACC, P265; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KUMAR A, 1986, J BIOL CHEM, V261, P1266; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LI YH, 1993, J VIROL, V67, P5260, DOI 10.1128/JVI.67.9.5260-5268.1993; Luckow V. A, 1991, Recombinant DNA technology and applications., P97; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MOLLEGAARD NE, 1994, P NATL ACAD SCI USA, V91, P3892, DOI 10.1073/pnas.91.9.3892; MORRIS TD, 1994, GENE, V140, P147, DOI 10.1016/0378-1119(94)90538-X; MORRIS TD, 1994, VIROLOGY, V200, P360; NORDSTROM LA, 1993, J BIOL CHEM, V268, P13193; OOI BG, 1989, J MOL BIOL, V210, P721, DOI 10.1016/0022-2836(89)90105-8; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PASSARELLI AL, 1993, J VIROL, V67, P2149, DOI 10.1128/JVI.67.4.2149-2158.1993; PASSARELLI AL, 1993, J VIROL, V67, P3481, DOI 10.1128/JVI.67.6.3481-3488.1993; PASSARELLI AL, 1993, VIROLOGY, V197, P704, DOI 10.1006/viro.1993.1646; POSSEE RD, 1987, NUCLEIC ACIDS RES, V15, P10233, DOI 10.1093/nar/15.24.10233; POSSEE RD, 1991, VIROLOGY, V185, P229, DOI 10.1016/0042-6822(91)90770-C; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RANKIN C, 1988, GENE, V70, P39, DOI 10.1016/0378-1119(88)90102-3; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STARK HC, 1992, P NATL ACAD SCI USA, V89, P2180, DOI 10.1073/pnas.89.6.2180; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; ZENTGRAF U, 1992, NUCLEIC ACIDS RES, V20, P3685, DOI 10.1093/nar/20.14.3685	35	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4405	4411		10.1074/jbc.270.9.4405	http://dx.doi.org/10.1074/jbc.270.9.4405			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876205	hybrid			2022-12-25	WOS:A1995QK08400037
J	LATHAM, KA; TAYLOR, JS; LLOYD, RS				LATHAM, KA; TAYLOR, JS; LLOYD, RS			T4 ENDONUCLEASE-V PROTECTS THE DNA STRAND OPPOSITE A THYMINE DIMER FROM CLEAVAGE BY THE FOOTPRINTING REAGENTS DNASE-I AND 1,10-PHENANTHROLINE-COPPER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COLI RNA-POLYMERASE; BETA-ELIMINATION REACTION; ALDEHYDIC ABASIC SITES; X-RAY STRUCTURE; ESCHERICHIA-COLI; NUCLEASE ACTIVITY; PYRIMIDINE DIMER; CIS-SYN; DUPLEX D(GCGTTGCG).D(CGCAACGC)	The glycosylase/abasic lyase T4 endonuclease V initiates the repair of ultraviolet light-induced pyrimidine dimers. This enzyme forms an imino intermediate between its N-terminal alpha-NH2 group and C-1' of the 5'-residue within the dimer. Sodium borohydride was used to covalently trap endonuclease V to a 49-base pair oligodeoxynucleotide containing a site-specific cyclobutane thymine dimer. The bound and free oligonucleotides were then subjected to nuclease protection assays using DNase I and a complex of I,10-phenanthroline-copper. There was a large region of protection from both nucleases produced by endonuclease V evident on the strand opposite and asymmetrically opposed to the dimer. Little protection was seen on the dimer-containing strand, The existence of a footprint with the 1,10-phenanthroline-copper cleavage agent indicated that endonuclease V was interacting with the DNA predominantly via the minor groove, Methylation by dimethyl sulfate yielded no areas of protection when endonuclease V was covalently attached to the DNA, indicating that the protein may closely approach the DNA without direct contact with the bases near the thymine dimer, The Escherichia coli proteins Fpg and photolyase display a very different pattern of nuclease protection on their respective substrates, implying that endonuclease V recognizes pyrimidine dimers by a novel mechanism.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555; VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,CTR MOLEC TOXICOL,NASHVILLE,TN 37232; WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63130	University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University; Vanderbilt University; Washington University (WUSTL)			Taylor, John-Stephen/AAA-3218-2020	Taylor, John-Stephen/0000-0002-8615-7257; Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL CANCER INSTITUTE [R37CA040463, R01CA040463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004091] Funding Source: NIH RePORTER; NCI NIH HHS [CA40463] Funding Source: Medline; NIEHS NIH HHS [ES04091] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUGUSTINE ML, 1991, BIOCHEMISTRY-US, V30, P8052, DOI 10.1021/bi00246a025; BAER M, 1989, MOL CELL BIOL, V9, P4777, DOI 10.1128/MCB.9.11.4777; BAILLY V, 1989, BIOCHEM J, V259, P751, DOI 10.1042/bj2590751; Brenowitz M., 1989, CURRENT PROTOCOLS MO; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DOI T, 1992, P NATL ACAD SCI USA, V89, P9420, DOI 10.1073/pnas.89.20.9420; DOWD DR, 1989, BIOCHEMISTRY-US, V28, P8699, DOI 10.1021/bi00448a005; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; FREDERICK CA, 1984, NATURE, V309, P327, DOI 10.1038/309327a0; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GANESAN AK, 1986, BIOCHEMISTRY-US, V25, P5751, DOI 10.1021/bi00367a060; GORDON LK, 1980, J BIOL CHEM, V255, P2047; GRUSKIN EA, 1988, J BIOL CHEM, V263, P12728; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HORI N, 1992, NUCLEIC ACIDS RES, V20, P4761, DOI 10.1093/nar/20.18.4761; IWAI S, 1994, BIOCHEMISTRY-US, V33, P5581, DOI 10.1021/bi00184a029; JOHNSRUD L, 1978, P NATL ACAD SCI USA, V75, P5314, DOI 10.1073/pnas.75.11.5314; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; KEMMINK J, 1987, EUR J BIOCHEM, V162, P37, DOI 10.1111/j.1432-1033.1987.tb10538.x; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; KUWABARA M, 1986, BIOCHEMISTRY-US, V25, P7401, DOI 10.1021/bi00371a023; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAHM A, 1991, J MOL BIOL, V221, P645; LEE BJ, 1994, BIOCHEMISTRY-US, V33, P57, DOI 10.1021/bi00167a008; LLOYD RS, 1980, NUCLEIC ACIDS RES, V8, P5113, DOI 10.1093/nar/8.21.5113; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MARSHALL LE, 1981, BIOCHEMISTRY-US, V20, P244, DOI 10.1021/bi00505a003; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MCMILLAN S, 1981, J VIROL, V40, P211, DOI 10.1128/JVI.40.1.211-223.1981; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; PRINCE MA, 1991, J BIOL CHEM, V266, P10686; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; SEAWELL PC, 1980, BIOCHEMISTRY-US, V19, P1685, DOI 10.1021/bi00549a026; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; SIGMAN DS, 1986, ACCOUNTS CHEM RES, V19, P180, DOI 10.1021/ar00126a004; SMITH CA, 1993, J BIOL CHEM, V268, P11143; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TCHOU J, 1993, J BIOL CHEM, V268, P26738; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V	47	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3765	3771		10.1074/jbc.270.8.3765	http://dx.doi.org/10.1074/jbc.270.8.3765			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876117	hybrid			2022-12-25	WOS:A1995QH68800047
J	MACDONALD, GH; ITOHLINDSTROM, Y; TING, JPY				MACDONALD, GH; ITOHLINDSTROM, Y; TING, JPY			THE TRANSCRIPTIONAL REGULATORY PROTEIN, YB-1, PROMOTES SINGLE-STRANDED REGIONS IN THE DRA PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; BINDING-PROTEIN; ESCHERICHIA-COLI; MESSENGER-RNA; Y-BOX; EXPRESSION; GENE; FAMILY; CELLS; SITE	YB-1 is a member of a newly defined family of DNA- and RNA-binding proteins, the Y box factors. These proteins have been shown to affect gene expression at both the transcriptional and translational levels. Recently, we showed that YB-1 represses interferon-gamma-induced transcription of class II human major histocompatibility (MHC) genes (1). Studies in this report characterize the DNA binding properties of purified, recombinant YB-1 on the MRC class II DRA promoter. The generation of YE-l-specific antibodies further permitted an analysis of the DNA binding properties of endogenous YB-1. YB-1 specifically binds single-stranded templates of the DRA promoter with greater affinity than double-stranded templates. The single-stranded DNA binding sites of YB-1 were mapped to the X box, whereas the double-stranded binding sites were mapped to the Y box of the DRA promoter, by methylation interference analysis. Most significantly, YB-1 can induce or stabilize single-stranded regions in the X and Y elements of the DRA promoter, as revealed by mung bean nuclease analysis. In concert with the findings that YB-1 represses DRA transcription, this study of YB-1 binding properties suggests a model of repression in which YB-1 binding results in single-stranded regions within the promoter, thus preventing loading and/or function of other DRA-specific transactivating factors.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	MACDONALD, GH (corresponding author), UNIV N CAROLINA,DEPT IMMUNOL MICROBIOL,CHAPEL HILL,NC 27599, USA.				NCI NIH HHS [R01 CA-48185, CA-37172] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTIOK S, 1994, MOL CELL BIOL, V14, P6004, DOI 10.1128/MCB.14.9.6004; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; CHEN LL, 1993, CELL GROWTH DIFFER, V4, P975; COGSWELL JP, 1990, P NATL ACAD SCI USA, V87, P7703, DOI 10.1073/pnas.87.19.7703; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; FABER M, 1990, J BIOL CHEM, V265, P22243; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; GRAUMANN P, 1994, FEBS LETT, V338, P157, DOI 10.1016/0014-5793(94)80355-2; GREUEL BT, 1990, VIROLOGY, V177, P33, DOI 10.1016/0042-6822(90)90457-3; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; KANDALA JC, 1994, VIROLOGY, V198, P514, DOI 10.1006/viro.1994.1062; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; Kato M, 1991, Nucleic Acids Symp Ser, P35; KERR D, 1994, J VIROL, V68, P7637, DOI 10.1128/JVI.68.11.7637-7643.1994; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN XH, 1992, J BIOL CHEM, V267, P25614; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; Maxam A M, 1980, Methods Enzymol, V65, P499; MURRAY MT, 1993, P NATL ACAD SCI USA, V89, P11; OZER J, 1993, GENE, V133, P187, DOI 10.1016/0378-1119(93)90637-I; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; SANTRA M, 1994, J BIOL CHEM, V269, P579; SHEIDEREIT L, 1984, P NATL ACAD SCI USA, V66, P3029; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1993, BIOESSAYS, V16, P245; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873	36	125	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3527	3533		10.1074/jbc.270.8.3527	http://dx.doi.org/10.1074/jbc.270.8.3527			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876087	Green Published, hybrid			2022-12-25	WOS:A1995QH68800014
J	MCINTOSH, JM; GHOMASHCHI, F; GELB, MH; DOOLEY, DJ; STOEHR, SJ; GIORDANI, AB; NAISBITT, SR; OLIVERA, BM				MCINTOSH, JM; GHOMASHCHI, F; GELB, MH; DOOLEY, DJ; STOEHR, SJ; GIORDANI, AB; NAISBITT, SR; OLIVERA, BM			CONODIPINE-M, A NOVEL PHOSPHOLIPASE-A(2) ISOLATED FROM THE VENOM OF THE MARINE SNAIL CONUS-MAGUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; CALCIUM-CHANNEL ANTAGONISTS; PRODUCT-CONTAINING VESICLES; INTERFACIAL CATALYSIS; COMPETITIVE INHIBITORS; OMEGA-CONOTOXIN; GAMMA-CARBOXYGLUTAMATE; POLYPEPTIDE TOXIN; BETA-BUNGAROTOXIN; BILAYER INTERFACE	We describe the purification and first biochemical characterization of an enzymatic activity in venom from the marine snail Conus magus. This enzyme, named conodipine-M, is a novel phospholipase A(2) with a molecular mass of 13.6 kDa and is comprised of two polypeptide chains linked by one or more disulfide bonds. The amino acid sequence of conodipine-M shows little if any homology to other previously sequenced phospholipase A(2) enzymes (PLA(2)s). Conodipine-M thus represents a new group of PLA(2)s. This is remarkable, since conodipine-M displays a number of properties that are similar to those of previously characterized 14-kDa PLA(2)s. The enzyme shows little, if any, phospholipase A(1), diacylglycerol lipase, triacylglycerol lipase, or lysophospholipase activities. Conodipine-M hydrolyzes the sn-2 ester of various preparations of phospholipid only in the presence of calcium and with specific activities that are comparable to those of well known 14-kDa snake venom and pancreatic PLA(2)s. The Conus enzyme binds tightly to vesicles of the negatively charged phospholipid 1,2-dimyristoyl-sn-glycero-3-phosphomethanol and catalyzes the hydrolysis of this substrate in a processive fashion. Conodipine-M does not significantly discriminate against phospholipids with unsaturated versus saturated fatty acids at the sn-2 position or with different polar head groups. Linoleoyl amide and a phospholipid analog containing an alkylphosphono group at the sn-2 position are potent inhibitors of conodipine-M. We suggest that the functional resemblance of conodipine-M to other PLA(2)s might be explained by the utilization of similar catalytic residues.	UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA; UNIV WASHINGTON, DEPT CHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT NEUROSCI, ANN ARBOR, MI 48106 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT CHEM, ANN ARBOR, MI 48106 USA	Utah System of Higher Education; University of Utah; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Pfizer; Pfizer	MCINTOSH, JM (corresponding author), UNIV UTAH, DEPT PSYCHIAT, 201 S BIOL, SALT LAKE CITY, UT 84112 USA.			gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL36235] Funding Source: Medline; NIGMS NIH HHS [P01 GM 48677] Funding Source: Medline; NIMH NIH HHS [K20 MH00929] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036235, R23HL036235, R37HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH000929] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABE T, 1977, EUR J BIOCHEM, V80, P1, DOI 10.1111/j.1432-1033.1977.tb11849.x; [Anonymous], 1987, PHOSPHOLIPASES; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BENISHIN CG, 1990, MOL PHARMACOL, V38, P164; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; BOTES DP, 1974, J BIOL CHEM, V249, P3827; CHANG C C, 1985, Proceedings of the National Science Council Republic of China Part B Life Sciences, V9, P126; CLARK C, 1981, TOXICON, V19, P691, DOI 10.1016/0041-0101(81)90106-9; CRUZ LJ, 1985, J TOXICOL-TOXIN REV, V4, P107, DOI 10.3109/15569548509014416; CRUZ LJ, 1978, ARCH BIOCHEM BIOPHYS, V190, P539, DOI 10.1016/0003-9861(78)90308-9; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; CRUZ LJ, 1987, J BIOL CHEM, V262, P15821; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1983, ENZYMES, P307; DOOLEY DJ, 1987, J NEUROCHEM, V49, P900, DOI 10.1111/j.1471-4159.1987.tb00978.x; EVENBERG A, 1977, J BIOL CHEM, V252, P1189; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; FRAENKELCONRAT H, 1983, J TOXICOL-TOXIN REV, V1, P205; GELB MH, 1992, BIOORG MED CHEM LETT, V2, P1335, DOI 10.1016/S0960-894X(00)80508-9; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; GONOI T, 1987, MOL PHARMACOL, V32, P691; GRAY WR, 1981, J BIOL CHEM, V256, P4734; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HALPERT J, 1975, J BIOL CHEM, V250, P6990; HAMMERLAND LG, 1992, EUR J PHARM-MOLEC PH, V226, P239, DOI 10.1016/0922-4106(92)90067-6; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; HOWARD BD, 1980, ANNU REV PHARMACOL, V20, P307, DOI 10.1146/annurev.pa.20.040180.001515; JAIN MK, 1992, J MED CHEM, V35, P3584, DOI 10.1021/jm00097a018; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7306, DOI 10.1021/bi00243a036; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7340, DOI 10.1021/bi00243a039; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JAIN MK, 1989, BIOCHEMISTRY-US, V28, P4135, DOI 10.1021/bi00436a002; JAIN MK, 1995, IN PRESS METHODS ENZ; KERR LM, 1984, NATURE, V308, P282, DOI 10.1038/308282a0; KOBAYASHI J, 1985, TOXICON, V23, P783, DOI 10.1016/0041-0101(85)90009-1; KOBAYASHI J, 1982, BIOCHEM BIOPH RES CO, V105, P1389, DOI 10.1016/0006-291X(82)90941-X; KONDO K, 1978, J BIOCHEM-TOKYO, V83, P101, DOI 10.1093/oxfordjournals.jbchem.a131881; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MCINTOSH JM, 1993, TOXICON, V31, P1561, DOI 10.1016/0041-0101(93)90340-O; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; MOCZYDLOWSKI E, 1986, P NATL ACAD SCI USA, V83, P5321, DOI 10.1073/pnas.83.14.5321; MYERS RA, 1991, BIOCHEMISTRY-US, V30, P9370, DOI 10.1021/bi00102a034; NIELSEN DB, 1994, TOXICON, V32, P845, DOI 10.1016/0041-0101(94)90009-4; Nieuwenhuizen W, 1974, Methods Enzymol, V32, P147; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; ROSENBERG P, 1990, PHOSPHOLIPASES, P67; SAXENA VK, 1992, NEUROCHEM INT, V20, P69, DOI 10.1016/0197-0186(92)90127-D; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHON KJ, 1994, BIOCHEMISTRY-US, V33, P11420, DOI 10.1021/bi00204a003; Stoehr S. J., 1992, Society for Neuroscience Abstracts, V18, P971; STRONG PN, 1976, P NATL ACAD SCI USA, V73, P178, DOI 10.1073/pnas.73.1.178; SUPAVILAI P, 1984, J NEURAL TRANSM, V60, P149, DOI 10.1007/BF01249091; VANDENBERGH CJ, 1989, J CELL BIOCHEM, V39, P379, DOI 10.1002/jcb.240390404; VOLWERK JJ, 1974, BIOCHEMISTRY-US, V13, P1446, DOI 10.1021/bi00704a020; YUAN W, 1990, BIOCHEMISTRY-US, V29, P6082, DOI 10.1021/bi00477a028; YUAN W, 1990, THESIS U WASHINGTON; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	67	87	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3518	3526		10.1074/jbc.270.8.3518	http://dx.doi.org/10.1074/jbc.270.8.3518			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876086	hybrid			2022-12-25	WOS:A1995QH68800013
J	RAMPAL, AL; JHUN, BH; KIM, S; LIU, HZ; MANKA, M; LACHAAL, M; SPANGLER, RA; JUNG, CY				RAMPAL, AL; JHUN, BH; KIM, S; LIU, HZ; MANKA, M; LACHAAL, M; SPANGLER, RA; JUNG, CY			OKADAIC ACID STIMULATES GLUCOSE-TRANSPORT IN RAT ADIPOCYTES BY INCREASING THE EXTERNALIZATION RATE-CONSTANT OF GLUT4 RECYCLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CELL; PROTEIN-PHOSPHORYLATION; APPARENT TRANSLOCATION; PLASMA-MEMBRANE; INSULIN; METABOLISM; INHIBITOR; MECHANISM; KINETICS; VANADATE	GLUT4, the major insulin-responsive glucose transporter isoform in rat adipocytes, rapidly recycles between the cell surface and an intracellular pool with two first order rate constants, one for internalization (k(in)) and the other for externalization (k(ex)). Insulin decreases k(in) by 2.8-fold and increases h(ex) by 3.3-fold, thus increasing the steady-state cell surface GLUT4 level by approximately 8-fold (Jhun, B, H,, Rampal, k L., Liu, H., Lachaal, M., and Jung, C, (1992) J. Biol. Chem. 267, 17710-17715), To gain an insight into the biochemical mechanisms that modulate these rate constants, we studied the effects upon them of okadaic acid (OKA), a phosphatase inhibitor that exerts a insulin-like effect on glucose transport in adipocytes, OKA stimulated 3-O-methylglucose transport maximally 3.1-fold and increased the cell surface GLUT4 level 3.4-fold. When adipocytes were pulse-labeled with an impermeant, covalently reactive glucose analog, [H-3]1,3-bis-(3-deoxy-D-glucopyranose-3-yloxy)-2 -propyl 4-benzoylbenzoate, and the time course of labeled CfLUT4 recycling was followed, the k(in) was found to increase 2.8-fold upon maximal stimulation by OKA, whereas the k(in), remained unchanged within experimental error, These findings demonstrate that ORA mimics the insulin effect on only GLUT4 externalization and suggest that insulin stimulates GLUT4 externalization by increasing the phosphorylation state of a serine/threonine phosphoprotein, probably by inhibiting protein phosphatase 1 or 2A.	VET ADM MED CTR,BIOPHYS LAB,BUFFALO,NY 14215; SUNY BUFFALO,DEPT BIOPHYS SCI,BUFFALO,NY 14215	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Kim, Sung Soo/S-2540-2017	Kim, Sung Soo/0000-0002-6817-7668	NIDDK NIH HHS [DK13376] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013376] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDINI G, 1992, J BIOL CHEM, V266, P4037; BEGUM N, 1993, J BIOL CHEM, V268, P3352; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIRMBAUM MJ, 1992, INT REV CYTOL A, V137, P239; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CORVERA S, 1991, J BIOL CHEM, V266, P9271; CUSHMAN SW, 1984, FED PROC, V43, P2251; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DUBYAK GR, 1980, J BIOL CHEM, V255, P5306; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JHUN BH, 1991, J BIOL CHEM, V266, P22260; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; MARTZ A, 1986, J BIOL CHEM, V261, P3606; MAY JM, 1979, J BIOL CHEM, V254, P9017; ROBINSON LJ, 1992, AM J PHYSIOL, V263, P383; SHISHEVA A, 1991, ENDOCRINOLOGY, V129, P2279; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANTI JF, 1991, J BIOL CHEM, V266, P2099; TOYODA N, 1986, J BIOL CHEM, V261, P2117; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	30	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3938	3943		10.1074/jbc.270.8.3938	http://dx.doi.org/10.1074/jbc.270.8.3938			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876140	hybrid			2022-12-25	WOS:A1995QH68800072
J	RAO, SS; KOHTZ, DS				RAO, SS; KOHTZ, DS			POSITIVE AND NEGATIVE REGULATION OF D-TYPE CYCLIN EXPRESSION IN SKELETAL MYOBLASTS BY BASIC FIBROBLAST GROWTH-FACTOR AND TRANSFORMING GROWTH-FACTOR-BETA - A ROLE FOR CYCLIN D1 IN CONTROL OF MYOBLAST DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR GENES; MYOGENIC DIFFERENTIATION; CELL-CYCLE; G1 PHASE; DNA-BINDING; FAMILY; MYOD; PROLIFERATION; MEMBER; G(1)	Differentiation of skeletal myoblasts in culture is negatively regulated by certain growth factors, including basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGF beta). We investigated the effects of bFGF and TGF beta on D-type cyclin expression in skeletal myoblasts. When myoblasts were induced to differentiate in low mitogen medium, expression of cyclin D1 rapidly fell below detectable levels. In contrast, expression of cyclin D3 increased to levels exceeding those present in myoblasts. Expression of cyclin D1 was induced iii myoblasts by bFGF and TGF beta (albeit with different kinetics for each factor), while induction of cyclin D3 expression was inhibited by these growth factors. Although these results are consistent with other reports showing induction of cyclin D1 by growth factors, induction of cyclin D3 expression during terminal differentiation of myoblasts and inhibition of this induction by growth factors is surprising. These results suggest that cyclin D3, previously thought to be only a positive regulator of cell cycle progression, may also function in the cellular context of terminal differentiated muscle. Stable expression of cyclin D1 from an ectopic viral promoter inhibits C2C12 myoblast differentiation, but only in those clones where the level of cyclin D1 expression does not significantly exceed that present in control myoblasts stimulated by bFGF. Together, these result suggest that cyclin D1 expression functions in the inhibition of myoblast differentiation by certain growth factors.			RAO, SS (corresponding author), CUNY MT SINAI SCH MED, DEPT PATHOL 1194, NEW YORK, NY 10029 USA.							BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COLE F, 1993, J BIOL CHEM, V268, P1580; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LATHROP B, 1985, J CELL BIOL, V103, P1799; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Sambrook J, 1989, MOL CLONING LABORATO; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	46	130	132	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4093	4100		10.1074/jbc.270.8.4093	http://dx.doi.org/10.1074/jbc.270.8.4093			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876159	hybrid			2022-12-25	WOS:A1995QH68800092
J	HSU, SC; DEFRANCO, DB				HSU, SC; DEFRANCO, DB			SELECTIVITY OF CELL-CYCLE REGULATION OF GLUCOCORTICOID RECEPTOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; C-JUN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTORS; HORMONE RECEPTORS; BINDING ACTIVITY; GENE-EXPRESSION; DOWN-REGULATION; DNA-BINDING; PHOSPHORYLATION	The restricted expression of some genes to distinct stages of the cell cycle is often brought about through alterations in the activity and/or abundance of specific transcription factors. Many cells have been shown to be unresponsive to glucocorticoid hormone action during the G(2) phase of the mammalian cell cycle, suggesting that some activities of the glucocorticoid receptor (GR), a ligand-activated transcription factor, are subjected to cell cycle control. We show here that GR insensitivity in G(2) is selective, affecting receptor-mediated transactivation from a simple glucocorticoid response element, but not repression from a composite glucocorticoid response element. Since glucocorticoid-dependent down-regulation of GR protein levels is also unaffected in G(2), distinct activities of the receptor that participate in this homologous down-regulation must be operating as effectively in G(2)-synchronized cells as in asynchronous cells. Finally, the phosphorylation state of the GR is altered in G(2)-synchronized cells reflecting, in part, both site-specific phosphorylation and dephosphorylation events. These results suggest that, while GR may be a target for cell cycle regulated kinases and phosphatases, the resulting changes in receptor phosphorylation have an impact only on selected GR functions.	UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA43037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043037] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALAM T, 1993, J BIOL CHEM, V268, P15681; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENOR S, 1993, MOL CELL BIOL, V13, P331, DOI 10.1128/MCB.13.1.331; BERKOFLINT Y, 1994, EMBO J, V13, P646, DOI 10.1002/j.1460-2075.1994.tb06303.x; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BURNSTEIN KL, 1991, STEROIDS, V56, P52, DOI 10.1016/0039-128X(91)90124-E; DANIELSEN M, 1984, MOL CELL BIOL, V4, P449, DOI 10.1128/MCB.4.3.449; DEFRANCO D, 1986, MOL CELL BIOL, V6, P993, DOI 10.1128/MCB.6.4.993; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DONG Y, 1988, MOL ENDOCRINOL, V2, P1256, DOI 10.1210/mend-2-12-1256; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FANGER BO, 1986, ARCH BIOCHEM BIOPHYS, V249, P116, DOI 10.1016/0003-9861(86)90566-7; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; HAFFAR OK, 1987, MOL CELL BIOL, V7, P1508, DOI 10.1128/MCB.7.4.1508; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KILMARTIN JV, 1993, J CELL BIOL, V123, P10952; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; MARTIN DW, 1970, P NATL ACAD SCI USA, V65, P1064, DOI 10.1073/pnas.65.4.1064; MCKINNEY JD, 1991, TRENDS BIOCHEM SCI, V16, P430, DOI 10.1016/0968-0004(91)90170-Z; MENDEL DB, 1986, NATURE, V324, P478, DOI 10.1038/324478a0; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MOYER ML, 1993, J BIOL CHEM, V268, P22933; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; ORTI E, 1989, J BIOL CHEM, V264, P9728; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; REIK A, 1994, MOL ENDOCRINOL, V8, P490, DOI 10.1210/me.8.4.490; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOMERS JP, 1992, MOL ENDOCRINOL, V7, P26; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577; Zolnierowicz S, 1994, Trends Cell Biol, V4, P61, DOI 10.1016/0962-8924(94)90012-4	59	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3359	3364		10.1074/jbc.270.7.3359	http://dx.doi.org/10.1074/jbc.270.7.3359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852422	hybrid			2022-12-25	WOS:A1995QG47100070
J	RAHMATULLAH, M; GINNAN, R; ROBISHAW, JD				RAHMATULLAH, M; GINNAN, R; ROBISHAW, JD			SPECIFICITY OF G-PROTEIN ALPHA-GAMMA SUBUNIT INTERACTIONS - N-TERMINAL 15 AMINO-ACIDS OF GAMMA-SUBUNIT SPECIFIES INTERACTION WITH ALPHA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA; BOVINE BRAIN; RECEPTORS; CELLS	The existence of multiple alpha, beta, and gamma subunits raises questions regarding the assembly of particular G proteins. Based on the results of a previous study (Rahmatullah, M., and Robishaw, J. D. (1994) J. Biol. Chem. 269, 3574-3580), we hypothesized that the assembly of G proteins may be determined by the interactions of the more structurally diverse alpha and gamma subunits. This hypothesis was confirmed in the present study by showing striking differences in the abilities of the gamma(1) and gamma(2) subunits to interact with the the alpha(o) subunit. Chimeras of the gamma(1) and gamma(2) subunits were used to delineate which region is responsible. Support for the importance of the N-terminal region of the gamma subunit comes from our observations that 1) the gamma(2) subunit and the gamma(211) chimera bound strongly to the alpha(o)-agarose matrix, but the gamma(1) subunit and the gamma(112) chimera bound weakly, if at all; 2) an N-terminal peptide made to the gamma(2) subunit blocked the binding of the gamma(211) chimera to the alpha(o) agarose matrix; 3) both the gamma(211) chimera and the N-terminal peptide were able to partially protect the alpha(o) subunit against tryptic cleavage; and 4) the gamma(211) chimera, but not the gamma(112) chimera, supported ADP-ribosylation of the alpha(o) subunit.	GEISINGER MED CLIN, WEIS CTR RES, DANVILLE, PA 17822 USA	Geisinger Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039867, R01GM039867] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39867] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAHMATULLAH M, 1994, J BIOL CHEM, V269, P3574; ROBISHAW JD, 1994, METHOD ENZYMOL, V237, P498; ROBISHAW JD, 1993, ANAL BIOCHEM, V208, P283, DOI 10.1006/abio.1993.1047; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SOHMA H, 1992, BIOCHEM BIOPH RES CO, V184, P175, DOI 10.1016/0006-291X(92)91175-P; SPRRING DJ, 1994, J BIOL CHEM, V269, P22882; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; UEDA N, 1994, J BIOL CHEM, V269, P4388	23	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2946	2951		10.1074/jbc.270.7.2946	http://dx.doi.org/10.1074/jbc.270.7.2946			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852373				2022-12-25	WOS:A1995QG47100012
J	SUZUKI, H; KANAZAWA, T				SUZUKI, H; KANAZAWA, T			THE TRYPTOPHAN FLUORESCENCE CHANGE UPON CONFORMATIONAL TRANSITION OF THE PHOSPHOENZYME INTERMEDIATE IN SARCOPLASMIC-RETICULUM CA2+-ATPASE IS REVEALED IN THE ABSENCE OF K+ AND THE PRESENCE OF LASALOCID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; INTRINSIC FLUORESCENCE; CATALYTIC CYCLE; CA-2+-ATPASE; CALCIUM; ATPASE; HYDROLYSIS; CA-2+; STATE; SITE	ATP-induced changes in the tryptophan fluorescence of the Ca2+-ATPase were determined with sarcoplasmic reticulum vesicles at pH 7.0 and 0 degrees C by steady-state measurements in the presence of Ca2+ and the absence of K+ with and without added lasalocid (a carboxylic ionophore, 50 mu m), which was previously shown to cause a predominant accumulation of the ADP-insensitive form of the phosphoenzyme intermediate (EP) (Kawashima, T., Hare, H., and Kanazawa, T. (1990) J. Biol, Chem. 265, 10993-10999), When ATP was added in the absence of lasalocid, the fluorescence decreased by 1.7%. The addition of lasalocid quenched 71% of the fluorescence but did not reduce the ATP-induced fluorescence drop. The fluorescence drop and the EP formation were also determined in the presence of lasalocid by stopped-flow spectrometry and continuous-flow rapid quenching. The observed fluorescence drop was biphasic, The first phase coincided with the formation of EP, which was largely ADP-sensitive in this early stage of the reaction, The second phase was much slower than the first phase and coincided with the accumulation of ADP-insensitive EP. When the transition of EP from the ADP-sensitive form to the ADP-insensitive form was blocked by N-ethylmaleimide treatment, the second phase disappeared, and the fluorescence drop entirely coincided with the formation of ADP sensitive EP. These findings demonstrate that the first phase of the fluorescence drop is attributed to the formation of ADP-sensitive EP, the second phase being attributed to the transition of EP from the ADP sensitive form to the ADP-insensitive form, The present results reveal the conditions that definitely discriminate these two phases.			SUZUKI, H (corresponding author), ASAHIKAWA MED COLL,DEPT BIOCHEM,ASAHIKAWA 078,HOKKAIDO,JAPAN.							ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; BRANDL CJ, 1986, CELL, V55, P597; CHAMPEIL P, 1986, FEBS LETT, V206, P93, DOI 10.1016/0014-5793(86)81347-3; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEFORESTA B, 1990, EUR J BIOCHEM, V194, P383; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; DUPONT Y, 1985, STRUCTURE FUNCTION S, P225; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; HARA H, 1986, J BIOL CHEM, V261, P6584; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V68, P593, DOI 10.1093/oxfordjournals.jbchem.a129392; KAWAKITA M, 1980, J BIOCHEM, V87, P609, DOI 10.1093/oxfordjournals.jbchem.a132785; KAWASHIMA T, 1990, J BIOL CHEM, V265, P10993; KUBO K, 1990, BIOCHIM BIOPHYS ACTA, V1040, P251, DOI 10.1016/0167-4838(90)90084-S; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINOSE M, 1967, PFLUGERS ARCH, V294, P82; NAKAMURA S, 1994, J BIOL CHEM, V269, P16015; OBARA M, 1988, J BIOL CHEM, V263, P3690; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; SUZUKI H, 1994, BIOCHEMISTRY-US, V33, P8240, DOI 10.1021/bi00193a010; TAKAKUWA Y, 1979, BIOCHEM BIOPH RES CO, V88, P1209, DOI 10.1016/0006-291X(79)91108-2; TAKISAWA H, 1981, NATURE, V290, P271, DOI 10.1038/290271a0; VERJOVSKIALMEID.S, 1981, J BIOL CHEM, V256, P2662; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706	30	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3089	3093		10.1074/jbc.270.7.3089	http://dx.doi.org/10.1074/jbc.270.7.3089			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852390	hybrid			2022-12-25	WOS:A1995QG47100032
J	WIESE, RJ; MASTICK, CC; LAZAR, DF; SALTIEL, AR				WIESE, RJ; MASTICK, CC; LAZAR, DF; SALTIEL, AR			ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE AND PHOSPHATIDYLINOSITOL 3'-KINASE IS NOT SUFFICIENT FOR THE HORMONAL-STIMULATION OF GLUCOSE-UPTAKE, LIPOGENESIS, OR GLYCOGEN-SYNTHESIS IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE-PHOSPHORYLATION; ENDOGENOUS SUBSTRATE; PHOSPHATASE INHIBITOR; SIGNALING PATHWAYS; RAT ADIPOCYTES; OKADAIC ACID; INTACT RAT; IRS-1; CELLS	The precise mechanism by which insulin regulates glucose metabolism is not fully understood. However, it is known that insulin activates two enzymes, phosphatidylinositol 3'-kinase (PI 3'-K) and mitogen-activated protein kinase (MAPK), which may be involved in stimulating the metabolic effects of insulin. The role of these enzymes in glucose metabolism was examined by comparing the effects of insulin, platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) in 3T3-L1 adipocytes. Treatment of the cells with PDGF or EGF for 5 min increased the MAPK activity 3-5-fold, while insulin treatment produced a 2.5-fold increase. The MAPK activity remained elevated for 1 h after either PDGF or insulin treatment. PDGF and insulin, but not EGF, caused a transient increase in the amount PI 3'-K activity coprecipitated with tyrosine phosphorylated proteins. Although PDGF and insulin caused a similar increase in the activities of these two enzymes, only insulin caused substantial increases in glucose utilization. Insulin increased the transport of glucose and the synthesis of lipid 4- and 17-fold, respectively, while PDGF did not affect these processes significantly. Glycogen synthesis was increased 15-fold in response to insulin and only 3-fold in response to PDGF. Thus, the activation of MAPK and PI 3'-K are not sufficient for the complete stimulation of glucose transport, lipid synthesis, or glycogen synthesis by hormones in 3T3-L1 adipocytes, suggesting a requirement for other signaling mechanisms that may be uniquely responsive to insulin.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT SIGNAL TRANDSUCT,ANN ARBOR,MI 48105	Pfizer			Mastick, Cynthia/G-9841-2017; Saltiel, Alan/L-3632-2019	Mastick, Cynthia/0000-0003-4769-5412; Saltiel, Alan/0000-0002-9726-9828				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CORVERA S, 1991, J BIOL CHEM, V266, P9271; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; FOLLI F, 1992, J BIOL CHEM, V267, P22171; HARING HU, 1987, P NATL ACAD SCI USA, V84, P113, DOI 10.1073/pnas.84.1.113; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOFFMANN RD, 1988, P NATL ACAD SCI USA, V85, P8835; IZUMI T, 1987, J BIOL CHEM, V262, P1282; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACHICAO F, 1987, BIOCHEM J, V243, P797, DOI 10.1042/bj2430797; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OKADA T, 1994, J BIOL CHEM, V269, P3568; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; PANG L, 1993, BIOCHEM BIOPH RES CO, V196, P301, DOI 10.1006/bbrc.1993.2249; PANG L, 1994, J BIOL CHEM, V269, P10604; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SALTIEL AR, 1990, DIABETES CARE, V13, P244, DOI 10.2337/diacare.13.3.244; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SEDOUL JC, 1985, BIOCHEM J, V227, P887; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TOBE K, 1993, J BIOL CHEM, V268, P11167; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	58	148	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3442	3446		10.1074/jbc.270.7.3442	http://dx.doi.org/10.1074/jbc.270.7.3442			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852430	hybrid			2022-12-25	WOS:A1995QG47100082
J	XIAO, JH; DURAND, B; CHAMBON, P; VOORHEES, JJ				XIAO, JH; DURAND, B; CHAMBON, P; VOORHEES, JJ			ENDOGENOUS RETINOIC-ACID RECEPTOR (RAR) RETINOID-X RECEPTOR (RXR) HETERODIMERS ARE THE MAJOR FUNCTIONAL FORMS REGULATING RETINOID-RESPONSIVE ELEMENTS IN ADULT HUMAN KERATINOCYTES - BINDING OF LIGANDS TO RAR ONLY IS SUFFICIENT FOR RAR-RXR HETERODIMERS TO CONFER LIGAND-DEPENDENT ACTIVATION OF HRAR-BETA-2/RARE (DR5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; HUMAN SKIN; TERMINAL DIFFERENTIATION; TOPICAL TRETINOIN; NUCLEAR RECEPTORS; PHOTODAMAGED SKIN; DIRECT REPEAT; BETA-GENE; VITAMIN-D; MOUSE	We have examined how retinoic acid receptors (RARs) and retinoid X receptors (RXRs) at physiological concentrations regulate distinct retinoid-responsive elements, hRAR beta 2/beta RARE (DR5) and rCRBPII/RXRE (DR1), in keratinocytes from human skin, a major retinoid target. In vitro, endogenous RAR gamma and RXRs bound to these elements as heterodimers (RAR-RXR) but not homodimers (RAR.RAR or RXR.RXR). In cultured keratinocytes, all-trans retinoic acid, 9-cis retinoic acid, and CD367 activated beta RARE but not RXRE via endogenous RAR.RXR (ED(50) = 2.3, 3.8, and 0.3 nM respectively) whereas SR11237 showed no significant effect. All-trans retinoic acid, 9-cis retinoic acid, and SR11237 activated RXRE via overexpressed RXR.RXR (ED(50) = 110, 120, and 11 nM, respectively), indicating interconversion between retinoic acid isomers, whereas co-overexpression of RAR alpha or RAR gamma suppressed this activation. Unlike 9cRA, CD367 neither induced formation of nor activated RXR.RXR. Overexpression of RAR or RXR mutated in transactivation domain AF-2 suppressed endogenous receptor activity over beta RARE. Our data suggest that 1) in keratinocytes, RAR.RXR-mediated pathway dominates over that mediated by RXR.RXR; 2) RAR-selective CD367 and RXR-selective SR11237 can be used to identify these two distinct pathways, respectively; 3) beta RARE is mainly regulated by RAR.RXR, in which RAR alone confers ligand inducibility whereas AF-2 of unliganded RXR is required for transactivation by liganded RAR AF-2; 4) lack of RXRE activity in keratinocytes is due to low endogenous levels of RXR.RXR and inhibition by RAR.RXR; and 5) interaction among RXRs is much lower than that between RAR and RXR.	INST GENET & BIOL MOLEC & CELLULAIRE,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	XIAO, JH (corresponding author), UNIV MICHIGAN,DEPT DERMATOL,KRESGE I,RM 6558,1301 E CATHERINE ST,ANN ARBOR,MI 48109, USA.		DURAND, Beatrice C/J-6387-2015; Voorhees, John/AAM-9966-2020	DURAND, Beatrice C/0000-0002-0047-288X; Voorhees, John/0000-0003-1856-785X				ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ANESKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862, DOI 10.1128/MCB.12.11.4862; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BOYCE ST, 1986, IN VITRO MODELS CANC, V3, P245; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BULENGORANSBY SM, 1993, NEW ENGL J MED, V328, P1438, DOI 10.1056/NEJM199305203282002; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; ELDER JT, 1992, J INVEST DERMATOL, V98, P673, DOI 10.1111/1523-1747.ep12499896; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; ELDER JT, 1992, J INVEST DERMATOL, V98, pS36, DOI 10.1111/1523-1747.ep12462180; FISCHER GJ, 1994, J BIOL CHEM, V269, P20629; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GENDIMENICO GJ, 1994, J INVEST DERMATOL, V102, P676, DOI 10.1111/1523-1747.ep12374092; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEIDM, 1902, CELL, V68, P377; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; MENDELSOHN C, 1994, MECH DEVELOP, V45, P227, DOI 10.1016/0925-4773(94)90010-8; NAGPAL S, 1993, EMBO J, V2, P2349; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; OLSEN EA, 1992, J AM ACAD DERMATOL, V26, P215, DOI 10.1016/0190-9622(92)70030-J; PECK GL, 1994, RETINOIDS BIOL CHEM, P209; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; RAFAL ES, 1992, NEW ENGL J MED, V326, P368, DOI 10.1056/NEJM199202063260603; REDFERN CPF, 1992, J CELL SCI, V102, P113; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SAMBROOK J, 1989, MOL CLONING LAORATOR; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; UNDERHILL TM, 1994, MOL ENDOCRINOL, V8, P274, DOI 10.1210/me.8.3.274; VOLLBERG TM, 1992, MOL ENDOCRINOL, V6, P667, DOI 10.1210/mend.6.5.1318502; VOORHEES JJ, 1972, ARCH DERMATOL, V105, P695, DOI 10.1001/archderm.105.5.695; WEINSTEIN GD, 1991, ARCH DERMATOL, V127, P659, DOI 10.1001/archderm.127.5.659; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1993, RECEPTOR, V3, P183; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	73	84	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3001	3011		10.1074/jbc.270.7.3001	http://dx.doi.org/10.1074/jbc.270.7.3001			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852380	Green Submitted			2022-12-25	WOS:A1995QG47100020
J	FERRACINI, R; DIRENZO, MF; SCOTLANDI, K; BALDINI, N; OLIVERO, M; LOLLINI, P; CREMONA, O; CAMPANACCI, M; COMOGLIO, PM				FERRACINI, R; DIRENZO, MF; SCOTLANDI, K; BALDINI, N; OLIVERO, M; LOLLINI, P; CREMONA, O; CAMPANACCI, M; COMOGLIO, PM			THE MET/HGF RECEPTOR IS OVER-EXPRESSED IN HUMAN OSTEOSARCOMAS AND IS ACTIVATED BY EITHER A PARACRINE OR AN AUTOCRINE CIRCUIT	ONCOGENE			English	Article						OSTEOSARCOMA; GROWTH FACTORS; TYROSINE KINASE RECEPTOR	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; HUMAN MET PROTOONCOGENE; FACTOR SCATTER FACTOR; SINGLE CHAIN FORM; C-MET; EPITHELIAL-CELLS; PHOSPHATASE-ACTIVITY; MOLECULAR-CLONING; HEPATOPOIETIN-A	The c-MET oncogene encodes the receptor for the Hepatocyte Growth Factor/Scatter Factor (HGF), a cytokine that stimulates the invasive growth of normal and neoplastic cells. The Met/HGF receptor is expressed by epithelial cells and its ligand by cells of mesenchymal origin. Receptor-ligand interaction occurs via a paracrine circuit. We studied the expression of the Met/HGF receptor and of its ligand in mesenchymal human tumours by examining 39 clinical samples of bone tumours. The Met/HGF receptor was not detectable in the majority of bone tumours, as expected from their mesenchymal origin. Notably, the receptor was overexpressed in 60% of the osteosarcomas examined. In 12 osteosarcoma cell lines the Met/HGF receptor was overexpressed, phosphorylated by HGF stimulation and fully functional, HGF was detected in two out of seven clinical specimens of osteosarcoma. The ligand and the receptor are co-expressed in two clonal osteosarcoma cell lines. In these lines the Met/HGF receptor was constitutively phosphorylated; phosphorylation was suppressed by suramin treatment, a known blocker of autocrine loops. These data suggest that activation of the Met/HGF receptor by a paracrine or an autocrine mechanism might play a role in the particularly aggressive behaviour of osteosarcomas.	UNIV SASSARI, SCH MED, IST ISTOL & EMBRIOL, I-07100 SASSARI, ITALY; UNIV TURIN, SCH MED, IRCC, TURIN, ITALY; UNIV TURIN, SCH MED, DEPT MED SCI, TURIN, ITALY; IST ORTOPED RIZZOLI, BOLOGNA, ITALY; UNIV BOLOGNA, SCH MED, INST CANC, BOLOGNA, ITALY	University of Sassari; University of Turin; University of Turin; IRCCS Istituto Ortopedico Rizzoli; University of Bologna	FERRACINI, R (corresponding author), SALUZZO GEN HOSP, SALUZZO, ITALY.		olivero, martina/J-4811-2018; Cremona, Ottavio/AAB-8793-2019; Baldini, Nicola/J-4806-2016; Ferracini, Riccardo/AAL-4622-2020; DI RENZO, Maria Flavia/B-6091-2012; Lollini, Pier Luigi/A-7644-2008; Scotlandi, Katia/J-9009-2016	olivero, martina/0000-0002-6815-3498; Cremona, Ottavio/0000-0001-9462-1040; Baldini, Nicola/0000-0003-2228-3833; DI RENZO, Maria Flavia/0000-0002-5093-3373; Lollini, Pier Luigi/0000-0003-1702-4108; Scotlandi, Katia/0000-0001-6114-9499; Comoglio, Paolo/0000-0002-7056-5328				ARAKI N, 1991, CLIN ORTHOP RELAT R, V270, P271; ASHIHARA T, 1986, ACTA HISTOCHEM CYTOC, V19, P51, DOI 10.1267/ahc.19.51; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROWDER TM, 1989, CANCER CELL-MON REV, V1, P9; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Campanacci M., 1990, BONE SOFT TISSUE TUM, V2nd, P455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGLIANO A, 1991, BONE, V12, P365, DOI 10.1016/8756-3282(91)90024-D; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; ENNEKING WF, 1991, CLIN MUSCULOSKELETAL, P411; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FERRACINI R, 1993, IT J MINERAL ELECTRO, V3, P199; GALIMI F, 1994, UNPUB J CELL BIOL; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOHJI K, 1994, JPN J CANCER RES, V85, P152, DOI 10.1111/j.1349-7006.1994.tb02076.x; GOORIN AM, 1981, SURG CLIN N AM, V61, P1379; GRANO M, 1994, J BONE MINER RES, V9, P1013; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KANDA H, 1993, ONCOGENE, V8, P3047; KUNIYASU H, 1993, INT J CANCER, V55, P72, DOI 10.1002/ijc.2910550114; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU C, 1992, ONCOGENE, V7, P181; MARS WM, 1993, AM J PATHOL, V143, P949; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; MILLER CW, 1990, CANCER RES, V50, P7950; MIURA Y, 1993, CLIN ORTHOP RELAT R, V300, P225; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIZUNO K, 1992, BIOCHEM BIOPH RES CO, V189, P1631, DOI 10.1016/0006-291X(92)90264-L; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA S, 1994, CYTOKINE, V6, P285, DOI 10.1016/1043-4666(94)90025-6; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; SCOTLANDI K, 1992, ANN ONCOL, V3, pS29, DOI 10.1093/annonc/3.suppl_2.S29; SCOTLANDI K, 1993, INT J ONCOL, V3, P963; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TEBBI CK, 1988, PEDIATR ANN, V17, P285, DOI 10.3928/0090-4481-19880401-08; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WU JX, 1990, ONCOGENE, V5, P989; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZHEN Z, 1994, ONCOGENE, V9, P1691	77	255	265	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					739	749						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862451				2022-12-25	WOS:A1995QH61200014
J	KRAMER, D; METT, H; EVANS, A; REGENASS, U; DIEGELMAN, P; PORTER, CW				KRAMER, D; METT, H; EVANS, A; REGENASS, U; DIEGELMAN, P; PORTER, CW			STABLE AMPLIFICATION OF THE S-ADENOSYLMETHIONINE DECARBOXYLASE GENE IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE; ACTIVATED IRREVERSIBLE INHIBITOR; ADENOSYL-L-METHIONINE; L1210 LEUKEMIA-CELLS; ORNITHINE DECARBOXYLASE; METHYLGLYOXAL BIS(GUANYLHYDRAZONE); POLYAMINE ANALOGS; MAMMALIAN-CELLS; MELANOMA-CELLS; POTENT	A Chinese hamster ovary cell subline (CHO/664) >1000-fold resistant to the S-adenosylmethionine decarboxylase (AdoMetDC) inhibitor, CGP-48664 (4-(aminoiminomethyl)-2,3-dihydro-1H-inden-l-one-diamino-methylenehydrazone), has been developed and characterized, The cells were also cross-resistant to the highly specific nucleoside analog inhibitor of AdoMetDC, MDL-73811. These unique cells stably overexpress AdoMetDC due to a 10-16-fold amplification of the AdoMetDC gene, which resulted in a similar increase in AdoMetDC transcript levels. In the presence of 100 mu M CGP-48664, the CHO/664 cells displayed AdoMetDC activities similar to the parental line. Following removal of the inhibitor, AdoMetDC activity increased steadily over 20 days to 10-12 times that found in parental CHO cells, Decarboxylated (de) AdoMet pools accumulated rapidly from <5 pmol/10(6) cells to similar to 1000-1500 pmol/10(6) cells at 3 days due to diffusion away of intracellular inhibitor and to the depletion of putrescine and spermidine as aminopropyl accepters in dcAdoMet-mediated synthase reactions, Polyamine pools shifted as putrescine, and spermidine pools were processed forward to spermine, During the period from 3 days to 20 days, dcAdoMet pools fell steadily and eventually stabilized at 100-200 pmol/10(6) cells, Providing excess putrescine at this time as an aminopropyl acceptor rapidly lowered dcAdoMet pools and led to a near normalization of polyamine pools, indicating that both dcAdoMet and putrescine are essential in maintaining steady-state polyamine pool profiles, As with cell line variants that overproduce ornithine decarboxylase, polyamine transport was found to be increased in CHO/664 cells due to an apparent inability of the system to down-regulate polyamine transport in response to polyamine excess, Given the unique metabolic disturbances seen in these cells, we anticipate that in addition to providing a useful system for evaluating the specificity of newly developed AdoMetDC inhibitors, they will undoubtedly prove valuable for investigating the various regulatory interrelationships involved in polyamine homeostasis and possibly other aspects of purine metabolism.	ROSWELL PK CANC INST,GRACE CANC DRUG CTR,BUFFALO,NY 14263; CIBA GEIGY LTD,RES DEPT,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND	Roswell Park Cancer Institute; Novartis					NATIONAL CANCER INSTITUTE [R01CA022153] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16406, CA-22153] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN LR, 1988, FOCUS, V10, P35; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BERGERON RJ, 1989, CANCER RES, V49, P2959; BERGERON RJ, 1988, J MED CHEM, V31, P1183, DOI 10.1021/jm00401a019; CASARA P, 1989, J AM CHEM SOC, V111, P9111, DOI 10.1021/ja00207a024; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; HYVONEN T, 1994, BBA-MOL CELL RES, V1221, P279, DOI 10.1016/0167-4889(94)90251-8; IGARASHI K, 1984, CANCER RES, V44, P5326; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KAMEJI T, 1993, BIOCHEM J, V289, P581, DOI 10.1042/bj2890581; KANAMOTO R, 1993, J BIOL CHEM, V268, P9393; KHAN NA, 1992, J CELL PHYSIOL, V152, P310, DOI 10.1002/jcp.1041520212; KHOMUTOV RM, 1983, BIOORG KHIM+, V9, P130; KRAMER DL, 1993, J CELL PHYSIOL, V155, P399, DOI 10.1002/jcp.1041550222; KRAMER DL, 1989, BIOCHEM J, V259, P325, DOI 10.1042/bj2590325; LIBBY PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P238, DOI 10.1016/0003-9861(91)90291-P; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; MAMONT PS, 1982, EUR J BIOCHEM, V123, P499; MANDEL JL, 1978, J CELL PHYSIOL, V97, P335, DOI 10.1002/jcp.1040970308; MANIATIS T, 1989, MOL CLONING LABORATO, P458; MARIC SC, 1992, J BIOL CHEM, V267, P18915; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; MCCONLOGUE L, 1983, J BIOL CHEM, V258, P2083; MIHICH E, 1975, HDB EXPT PHARMACOLOG, V38, P766; MITCHELL JLA, 1992, BIOCHEM BIOPH RES CO, V186, P81, DOI 10.1016/S0006-291X(05)80778-8; MOSHIER JA, 1993, CANCER RES, V53, P2618; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PAJUNEN A, 1988, J BIOL CHEM, V263, P17040; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, BIOCHEM J, V202, P519, DOI 10.1042/bj2020519; PEGG AE, 1988, BIOCHEMISTRY-US, V27, P1408, DOI 10.1021/bi00405a003; PERSSON L, 1988, CANCER RES, V48, P4807; Porter C. W., 1992, V62, P301; PORTER CW, 1985, CANCER RES, V45, P2050; PORTER CW, 1990, BIOCHEM J, V268, P207, DOI 10.1042/bj2680207; PULKKA A, 1993, GENOMICS, V16, P342, DOI 10.1006/geno.1993.1195; REGENASS U, 1994, CANCER RES, V54, P3210; REGENASS U, 1992, CANCER RES, V52, P4712; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; SHANTZ LM, 1994, CANCER RES, V54, P2313; SHANTZ LM, 1992, BIOCHEM J, V288, P511, DOI 10.1042/bj2880511; SHAPPELL NW, 1993, FEBS LETT, V321, P179, DOI 10.1016/0014-5793(93)80103-2; SIREAR S, 1987, CANCER RES, V47, P1339; SNAPKA RM, 1983, P NATL ACAD SCI-BIOL, V80, P7533, DOI 10.1073/pnas.80.24.7533; STANEK J, 1993, J MED CHEM, V36, P2168, DOI 10.1021/jm00067a014; STANEK J, 1993, J MED CHEM, V36, P46, DOI 10.1021/jm00053a007; STJERNBORG L, 1991, BIOCHIM BIOPHYS ACTA, V1090, P188, DOI 10.1016/0167-4781(91)90100-Z; SUZUKI T, 1993, EUR J BIOCHEM, V215, P247, DOI 10.1111/j.1432-1033.1993.tb18029.x; WILLIAMSASHMAN HG, 1986, BIOCHEM PHARMACOL, V35, P1217, DOI 10.1016/0006-2952(86)90263-7; WISEMAN A, 1983, CANCER RES, V43, P5937; WU YQ, 1992, J MED CHEM, V35, P3196, DOI 10.1021/jm00095a015; YARLETT N, 1988, MOL BIOCHEM PARASIT, V27, P1, DOI 10.1016/0166-6851(88)90019-9	52	54	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2124	2132		10.1074/jbc.270.5.2124	http://dx.doi.org/10.1074/jbc.270.5.2124			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836441	hybrid			2022-12-25	WOS:A1995QE49300024
J	ORDENTLICH, A; BARAK, D; KRONMAN, C; ARIEL, N; SEGALL, Y; VELAN, B; SHAFFERMAN, A				ORDENTLICH, A; BARAK, D; KRONMAN, C; ARIEL, N; SEGALL, Y; VELAN, B; SHAFFERMAN, A			CONTRIBUTION OF AROMATIC MOIETIES OF TYROSINE-133 AND OF THE ANIONIC SUBSITE TRYPTOPHAN-86 TO CATALYTIC EFFICIENCY AND ALLOSTERIC MODULATION OF ACETYLCHOLINESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; ACTIVE-CENTER; MOLECULAR RECOGNITION; TORPEDO-CALIFORNICA; BINDING; RESIDUES; RECEPTOR; SITE; TRIMETHYL; PROTEIN	Substitution of Trp-86, in the active center of human acetylcholinesterase (HuAChE), by aliphatic but not by aromatic residues resulted in a several thousandfold decrease in reactivity toward charged substrate and inhibitors but only a severalfold decrease for noncharged substrate and inhibitors. The W86A and W86E HuAChE enzymes exhibit at least a 100-fold increase in the Michaelis-Menten constant or 100-10,000-fold increase in inhibition constants toward various charged inhibitors, as compared to W86F HuAChE or the wild type enzyme. On the other hand, replacement of Glu-202, the only acidic residue proximal to the catalytic site, by glutamine resulted in a nonselective decrease in reactivity toward charged and noncharged substrates or inhibitors. Thus, the quaternary nitrogen groups of substrates and other active center ligands, are stabilized by cation-aromatic interaction with Trp-86 rather than by ionic interactions, while noncharged ligands appear to bind to distinct site(s) in HuAChE. Analysis of the Y133F and Y133A HuAChE mutated enzymes suggests that the highly conserved Tyr-133 plays a dual role in the active center: (a) its hydroxyl appears to maintain the functional orientation of Glu-202 by hydrogen bonding and (b) its aromatic moiety maintains the functional orientation of the anionic subsite Trp-86. In the absence of aromatic interactions between Tyr-133 and Trp-86, the tryptophan acquires a conformation that obstructs the active site leading, in the Y133A enzyme, to several hundredfold decrease in rates of catalysis, phosphorylation, or in affinity to reversible active site inhibitors. It is proposed that allosteric modulation of acetylcholinesterase activity, induced by binding to the peripheral anionic sites, proceeds through such conformational change of Trp-86 from a functional anionic subsite state to one that restricts access of substrates to the active center.	ISRAEL INST BIOL RES, DEPT BIOCHEM, IL-70450 NESS ZIONA, ISRAEL; ISRAEL INST BIOL RES, DEPT ORGAN CHEM, IL-70450 NESS ZIONA, ISRAEL									AXELSEN PH, 1994, PROTEIN SCI, V3, P188; BARAK D, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P195; BARAK D, 1994, J BIOL CHEM, V269, P6296; BARNETT P, 1977, J BIOL CHEM, V252, P7200; BERMAN HA, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P149; BERMAN HA, 1986, BIOCHIM BIOPHYS ACTA, V872, P125, DOI 10.1016/0167-4838(86)90155-X; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; COHEN SG, 1987, BIOORG CHEM, V15, P237, DOI 10.1016/0045-2068(87)90022-8; COHEN SG, 1984, J MED CHEM, V27, P1643, DOI 10.1021/jm00378a020; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FOURNIER D, 1993, CHEM-BIOL INTERACT, V87, P233, DOI 10.1016/0009-2797(93)90047-3; FRAENKEL Y, 1990, BIOCHEMISTRY-US, V29, P2617, DOI 10.1021/bi00462a027; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GAO J, 1993, BIOPHYS J, V65, P43, DOI 10.1016/S0006-3495(93)81031-2; GAREL L, 1993, J AM CHEM SOC, V115, P11652, DOI 10.1021/ja00077a096; GENTRY MK, 1991, CHOLINESTERASES STRU, P394; GNATT A, 1994, J NEUROCHEM, V62, P749; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HASAN FB, 1980, J BIOL CHEM, V255, P3898; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; KEARNEY PC, 1993, J AM CHEM SOC, V115, P9907, DOI 10.1021/ja00075a006; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCCURDY A, 1992, J AM CHEM SOC, V114, P10314, DOI 10.1021/ja00052a031; NAIR HK, 1994, BIOCHEMISTRY-US, V33, P8566, DOI 10.1021/bi00194a023; OBRIEN RD, 1971, DRUG DESIGN, V2, P161; ORDENTLICH A, 1993, FEBS LETT, V334, P215, DOI 10.1016/0014-5793(93)81714-B; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; REMERS WA, 1971, CHEM HETEROCYCLIC CO, V25, P57; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SAXENA A, 1993, BIOCHEM BIOPH RES CO, V197, P343, DOI 10.1006/bbrc.1993.2481; SCHNEIDER HJ, 1991, ANGEW CHEM INT EDIT, V30, P1417, DOI 10.1002/anie.199114171; SHAFFERMAN A, 1994, EMBO J, V13, P3448, DOI 10.1002/j.1460-2075.1994.tb06650.x; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x; WESS J, 1993, LIFE SCI, V53, P1447, DOI 10.1016/0024-3205(93)90618-D; WILSON IB, 1952, J BIOL CHEM, V197, P215	54	102	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2082	2091		10.1074/jbc.270.5.2082	http://dx.doi.org/10.1074/jbc.270.5.2082			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836436	hybrid			2022-12-25	WOS:A1995QE49300018
J	DREBIN, JA; HARTZELL, SW; GRIFFIN, C; CAMPBELL, MJ; NIEDERHUBER, JE				DREBIN, JA; HARTZELL, SW; GRIFFIN, C; CAMPBELL, MJ; NIEDERHUBER, JE			MOLECULAR-CLONING AND CHROMOSOMAL LOCALIZATION OF THE HUMAN HOMOLOG OF A B-LYMPHOCYTE SPECIFIC PROTEIN-TYROSINE KINASE (BLK)	ONCOGENE			English	Article						BLK; PROTEIN TYROSINE KINASE; B LYMPHOCYTE	CELL ANTIGEN RECEPTOR; TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR; TRANSFORMING PROTEIN; CONSERVED FEATURES; BINDING SITE; SH3 DOMAINS; SRC FAMILY; PHOSPHORYLATION; CARCINOMA	A cDNA encoding the human homologue of the murine protein tyrosine kinase, blk, has been cloned from a human B-lymphocyte cDNA library by cross-species hybridization using the murine blk cDNA as a probe. The sequence of the 2608 bp human blk cDNA clone contains an open reading frame encoding a predicted 505 amino acid protein with SH3, SH2 and catalytic domains that contain consensus sequences of the src protein tyrosine kinase family. Comparison of human and murine blk sequences indicated that they share 86% amino acid identity, the most conserved region being the catalytic domain (93% identity). Like the murine blk gene, human blk is expressed only in B lymphocytes. The human blk gene was mapped to chromosome 8 at p22-23.	STANFORD UNIV, SCH MED, DEPT SURG, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT SURG, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21205 USA	Stanford University; Stanford University; Johns Hopkins University; Johns Hopkins University					NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000373] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00373] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CANNIZZARO LA, 1984, CYTOGENET CELL GENET, V38, P308, DOI 10.1159/000132079; CARLOCK LR, 1986, SOMAT CELL MOLEC GEN, V12, P163, DOI 10.1007/BF01560663; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; EMI M, 1993, J BIOL CHEM, V268, P2120; FAGAN K, 1988, HUM GENET, V79, P365; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FONG D, 1992, HUM GENET, V89, P10, DOI 10.1007/BF00207033; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GRIFFIN CA, 1987, P NATL ACAD SCI USA, V84, P512, DOI 10.1073/pnas.84.2.512; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HICKMAN D, 1994, BICH J, P441; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIN JJ, 1992, J IMMUNOL, V149, P1548; LINDBLOM A, 1993, CANCER RES, V53, P4356; MACOSKA JA, 1994, CANCER RES, V54, P3824; Marshall CJ, 1985, RNA TUMOR VIRUSES MO, P487; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RESH MD, 1990, ONCOGENE, V5, P1437; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SHECHTER I, 1994, GENOMICS, V20, P116, DOI 10.1006/geno.1994.1135; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SPARKES R S, 1987, Genomics, V1, P138, DOI 10.1016/0888-7543(87)90005-X; SPARKES RS, 1989, GENOMICS, V5, P240, DOI 10.1016/0888-7543(89)90052-9; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WASYLYSHYN ML, 1991, SURGERY, V110, P265; WONG WW, 1985, P NATL ACAD SCI USA, V82, P7711, DOI 10.1073/pnas.82.22.7711; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	59	16	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					477	486						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845672				2022-12-25	WOS:A1995QF64800008
J	EITZEN, GA; AITCHISON, JD; SZILARD, RK; VEENHUIS, M; NUTTLEY, WM; RACHUBINSKI, RA				EITZEN, GA; AITCHISON, JD; SZILARD, RK; VEENHUIS, M; NUTTLEY, WM; RACHUBINSKI, RA			THE YARROWIA-LIPOLYTICA GENE PAY2 ENCODES A 42-KDA PEROXISOMAL INTEGRAL MEMBRANE-PROTEIN ESSENTIAL FOR MATRIX PROTEIN IMPORT AND PEROXISOME ENLARGEMENT BUT NOT FOR PEROXISOME PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; YEAST PICHIA-PASTORIS; SACCHAROMYCES-CEREVISIAE; ZELLWEGER SYNDROME; TARGETING SIGNAL; HANSENULA-POLYMORPHA; CANDIDA-TROPICALIS; 3-KETOACYL-COA THIOLASE; DEFICIENT MUTANTS; CARBOXY TERMINUS	PAY genes are required for peroxisome assembly in the yeast Yarrowia lipolytica. Here we show that a mutant strain, pay2, is disrupted for the import of proteins targeted by either peroxisomal targeting signal-1 or -2. Electron microscopy of pay2 cells revealed the presence of small peroxisomal ''ghosts,'' similar to the vesicular structures found in fibroblasts of patients with the human peroxisome assembly disorder, Zellweger syndrome. Functional complementation of pay2 with a plasmid library of Y. lipolytica genomic DNA identified a gene, PAY2, that restores growth of pay2 on oleic acid, import of catalase and multifunctional enzyme into peroxisomes, and formation of wild type peroxisomes. The PAY2 gene encodes Pay2p, a hydrophobic polypeptide of 404 amino acids. An antibody raised against Pay2p recognizes a polypeptide of similar to 42-kDa whose synthesis is induced by growth of Y. lipolytica on oleic acid, Pay2p is a peroxisomal integral membrane protein, as it localizes to carbonate stripped peroxisomal membranes. Pay2p shows no identity to any known protein. Our results suggest that Pay2p is essential for the activity of the peroxisomal import machinery but does not affect the initial steps of peroxisomal membrane proliferation.	UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON,AB T6G 2H7,CANADA; UNIV GRONINGEN,ELECTRON MICROSCOPY LAB,9750 AA HAREN,NETHERLANDS	University of Alberta; University of Groningen			Eitzen, Gary/D-3682-2009					AITCHISON JD, 1991, J BIOL CHEM, V266, P23197; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CIGAN AM, 1987, GENE, V59, P1; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; CRANE DI, 1994, J BIOL CHEM, V269, P21835; CREGG JM, 1990, YEAST, V6, P87, DOI 10.1002/yea.320060202; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P2432; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; FUJIKI Y, 1986, J BIOL CHEM, V261, P5787; GAILLARDIN CM, 1973, ARCH MIKROBIOL, V92, P69, DOI 10.1007/BF00409513; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; GODECKE A, 1989, CURR GENET, V16, P13, DOI 10.1007/BF00411078; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1992, YEAST, V8, P613, DOI 10.1002/yea.320080805; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; KAMIRYO T, 1982, J BACTERIOL, V152, P269; KRISANS SK, 1985, J LIPID RES, V26, P1324; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LITHGOW T, 1993, FEBS LETT, V329, P1, DOI 10.1016/0014-5793(93)80179-X; LIU H, 1992, J BACTERIOL, V174, P4943, DOI 10.1128/JB.174.15.4943-4951.1992; MCCAMMON MT, 1994, J CELL BIOL, V124, P915, DOI 10.1083/jcb.124.6.915; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; NEEDLEMAN RB, 1975, ANAL BIOCHEM, V64, P545, DOI 10.1016/0003-2697(75)90466-2; NUTTLEY WM, 1994, J BIOL CHEM, V269, P556; NUTTLEY WM, 1993, YEAST, V9, P507, DOI 10.1002/yea.320090506; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; THOMPSON SL, 1987, J BIOL CHEM, V262, P17420; VANDERKLEI IJ, 1991, YEAST, V7, P195, DOI 10.1002/yea.320070302; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VEENHUIS M, 1990, J CELL SCI, V96, P583; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531; WATERHAM HR, 1992, YEAST, V8, P961, DOI 10.1002/yea.320081106; WENDLAND M, 1993, J CLIN INVEST, V92, P2462, DOI 10.1172/JCI116854; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; YAJIMA S, 1992, HUM GENET, V88, P491, DOI 10.1007/BF00219334; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220; ZHANG JW, 1993, J CELL BIOL, V123, P1133, DOI 10.1083/jcb.123.5.1133	63	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1429	1436		10.1074/jbc.270.3.1429	http://dx.doi.org/10.1074/jbc.270.3.1429			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836411	Green Submitted, hybrid			2022-12-25	WOS:A1995QB15600068
J	BAECKSTROM, D; KARLSSON, N; HANSSON, GC				BAECKSTROM, D; KARLSSON, N; HANSSON, GC			PURIFICATION AND CHARACTERIZATION OF SIALYL-LE(A)-CARRYING MUCINS OF HUMAN BILE - EVIDENCE FOR THE PRESENCE OF MUC1 AND MUC3 APOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; INTESTINAL MUCIN; DIFUCOGANGLIOSIDE VI3NEUACV3III3FUC2NLC6; CA50-CARRYING ANTIGEN; PANCREATIC-CANCER; GALLBLADDER MUCIN; SEQUENCE-ANALYSIS; CORE PROTEIN	Purification of sialyl-Le(a)-carrying mucins from primary human bile by trichloroacetic acid precipitation, delipidation, and gel filtration in guanidinium chloride gave three separable fractions, one of which was further purified by affinity chromatography. These fractions, named SBG1 (for soluble bile glycoprotein), SBG2, and SBG3 had molecular masses of >1100, 800-950, and 100-250 kDa, respectively, as estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Their mucin characteristics were indicated by a high carbohydrate content, ranging from 74 to 95%. The carbohydrate compositions indicated the presence of very long fucosylated polylactosamine chains. Amino acid analyses showed high abundance of serine and threonine in all three fractions (19-36%), confirming their mucin-like nature. Immunochemical analyses of deglycosylated samples detected the MUC1 mucin apoprotein in SBG2 and the MUC3 protein in SBG1. To our knowledge, this is the first report of a MUC3 mucin being purified. This mucin showed no significant reduction in size upon trypsin treatment or disulfide bond reduction and alkylation. Gel filtration of three samples of secondary bile showed that the size distribution of sialyl-Le(a)-carrying glycoproteins was similar to that found in primary bile, and immunochemical analysis showed that the MUC1 protein was present in all three samples. In one sample an additional fraction was isolated, which was insoluble in 6 M guanidinium chloride, but was solubilized upon reduction and alkylation. mRNAs hom gallbladder epithelia were analyzed in Northern blot hybridizations showing that the MUC1 and MUC3 but not the MUC2 mucin apoprotein genes were expressed.			BAECKSTROM, D (corresponding author), GOTHENBURG UNIV,DEPT MED BIOCHEM,MED AREGATAN 9,S-41390 GOTHENBURG,SWEDEN.		Karlsson, Niclas/G-5235-2013; Hansson, Gunnar C/A-1236-2009; Hansson, Gunnar C./AAF-7324-2019	Karlsson, Niclas/0000-0002-3045-2628; Hansson, Gunnar C/0000-0002-1900-1869; Hansson, Gunnar C./0000-0002-1900-1869				ALBERT MB, 1988, DIGEST DIS SCI, V33, P1223, DOI 10.1007/BF01536670; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; BAECKSTROM D, 1993, CANCER RES, V53, P755; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BROCKHAUS M, 1985, VOX SANG, V48, P34, DOI 10.1111/j.1423-0410.1985.tb00142.x; BURCHELL J, 1987, CANCER RES, V47, P5476; CARLSTEDT I, 1985, ESSAYS BIOCHEM, V20, P40; CARLSTEDT I, 1993, J BIOL CHEM, V268, P18771; FUKUSHI Y, 1985, CANCER RES, V45, P3711; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1987, J BIOL CHEM, V262, P1092; GUM JR, 1992, J BIOL CHEM, V267, P21375; HAGLUND C, 1987, INT J CANCER, V39, P477, DOI 10.1002/ijc.2910390412; HANSSON GC, 1994, BIOCHEM BIOPH RES CO, V198, P181, DOI 10.1006/bbrc.1994.1026; HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; HO SB, 1993, CANCER RES, V53, P641; JOHANSSON C, 1991, TUMOR BIOL, V12, P159, DOI 10.1159/000217701; JOHANSSON C, 1991, INT J CANCER, V48, P757, DOI 10.1002/ijc.2910480521; KJELDSEN T, 1988, CANCER RES, V48, P2214; LAN MS, 1987, J BIOL CHEM, V262, P12863; LINDHOLM L, 1983, INT ARCH ALLER A IMM, V71, P178, DOI 10.1159/000233384; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MARTENSSON S, 1988, SCAND J CLIN LAB INV, V48, P633, DOI 10.3109/00365518809085783; MASUZAWA Y, 1992, J BIOCHEM-TOKYO, V112, P609, DOI 10.1093/oxfordjournals.jbchem.a123948; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; OHSHIO G, 1990, AM J GASTROENTEROL, V85, P1370; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SMITH BF, 1984, J BIOL CHEM, V259, P2170; SMITH BF, 1990, HEPATOLOGY, V12, pS183; SOJAR HT, 1987, METHOD ENZYMOL, V138, P341; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; THORNTON DJ, 1989, ANAL BIOCHEM, V182, P160, DOI 10.1016/0003-2697(89)90735-5; YAMASAKI T, DIGEST DIS SCI, V909, P93; YANG HJ, 1971, J BIOL CHEM, V246, P1192	42	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14430	14437						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	7848403				2022-12-25	WOS:A1994NM06500022
J	HU, YM; KOHLHAW, GB				HU, YM; KOHLHAW, GB			ADDITIVE ACTIVATION OF YEAST LEU4 TRANSCRIPTION BY MULTIPLE CIS-ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ISOPROPYLMALATE SYNTHASE; AMINO-ACID BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; RESPONSIVE ELEMENTS; GENERAL CONTROL; NUCLEOTIDE-SEQUENCE; HIS4 TRANSCRIPTION; REGULATORY GENE; GCN4 PROTEIN; PROMOTER	The LEU4 gene of Saccharomyces cerevisiae and the enzyme encoded by LEU4, alpha-isopropylmalate synthase, occupy a special position in amino acid metabolism. alpha-Isopropylmalate synthase catalyzes the first committed step in leucine biosynthesis. However, the reaction product alpha-isopropylmalate is not only an intermediate in the leucine biosynthetic pathway, but also functions as co activator of at least six genes, both within and outside of the leucine pathway. The metabolic importance of alpha-isopropylmalate appears to be reflected in the surprisingly multifaceted regulation of LEU4 expression. This report describes an analysis of functional cis elements in the LEU4 promoter. Five such elements were identified. Three distal elements, designated UAS(LEU), GCE-A, and GCE-B, are responsible for regulation by the regulatory proteins Leu3p and Gcn4p, respectively. The incremental activation of LEU4 by these elements is additive and independent. In addition, two proximal elements were localized. One of these con forms to the TATA consensus sequence and exhibits high affinity for TATA binding protein. The other element shows strong sequence identity with the Bas2p binding site and appears to be involved in basal and phosphate-mediated regulation of LEU4.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [GM15102] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BAI YL, 1991, NUCLEIC ACIDS RES, V19, P5991, DOI 10.1093/nar/19.21.5991; BAICHWAL VR, 1983, CURR GENET, V7, P369, DOI 10.1007/BF00445877; BELTZER JP, 1988, J BIOL CHEM, V263, P368; BELTZER JP, 1986, J BIOL CHEM, V261, P5160; BRANDL CJ, 1989, P NATL ACAD SCI USA, V86, P2652, DOI 10.1073/pnas.86.8.2652; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; CHANG LFL, 1984, GENETICS, V108, P91; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; DAVIS LG, 1986, BASIC METHODS MOL BI, P250; DONAHUE TF, 1983, CELL, V32, P89, DOI 10.1016/0092-8674(83)90499-3; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; FALCO SC, 1985, NUCLEIC ACIDS RES, V13, P4011, DOI 10.1093/nar/13.11.4011; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAMPSEY DM, 1981, J BIOL CHEM, V256, P3791; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HU YM, 1995, MOL CELL BIOL, V15, P52, DOI 10.1128/MCB.15.1.52; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LITSKE JG, 1986, NUCLEIC ACIDS RES, V14, P9631, DOI 10.1093/nar/14.24.9631; LOPES JM, 1993, J BACTERIOL, V175, P4235, DOI 10.1128/JB.175.13.4235-4238.1993; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; LUCHE RM, 1990, MOL CELL BIOL, V10, P3884, DOI 10.1128/MCB.10.8.3884; MOSCH HU, 1990, EMBO J, V9, P2951, DOI 10.1002/j.1460-2075.1990.tb07487.x; MOSCH HU, 1991, J BIOL CHEM, V266, P20453; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; PELLMAN D, 1990, NATURE, V348, P82, DOI 10.1038/348082a0; PETERS MH, 1990, ARCH BIOCHEM BIOPHYS, V276, P294, DOI 10.1016/0003-9861(90)90041-V; REMBOUTSIKA E, 1994, MOL CELL BIOL, V14, P5547, DOI 10.1128/MCB.14.8.5547; REMBOUTSIKA E, 1994, THESIS PURDUE U W LA; RUBIN GM, 1974, EUR J BIOCHEM, V41, P197, DOI 10.1111/j.1432-1033.1974.tb03260.x; SCHMIDHEINI T, 1990, MOL GEN GENET, V224, P57, DOI 10.1007/BF00259451; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; STRUHL K, 1987, MOL CELL BIOL, V7, P104, DOI 10.1128/MCB.7.1.104; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; ZHOU K, 1990, J BIOL CHEM, V265, P17409	45	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5270	5275		10.1074/jbc.270.10.5270	http://dx.doi.org/10.1074/jbc.270.10.5270			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890638	hybrid			2022-12-25	WOS:A1995QL58000050
J	RIIKONEN, A; TIKKANEN, R; JALANKO, A; PELTONEN, L				RIIKONEN, A; TIKKANEN, R; JALANKO, A; PELTONEN, L			IMMEDIATE INTERACTION BETWEEN THE NASCENT SUBUNITS AND 2 CONSERVED AMINO-ACIDS TRP(34) AND THR(206) ARE NEEDED FOR THE CATALYTIC ACTIVITY OF ASPARTYLGLUCOSAMINIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATION; LIVER; COMPLEX; DISEASE; CDNA	Aspartylglucosaminidase (AGA, EC 3.5.1.26) is a dimeric lysosomal hydrolase involved in the degradation of glycoproteins, The synthesized precursor polypeptide of AGA is rapidly activated in the endoplasmic reticulum by proteolysis into two subunits, Expression of the alpha- and beta-subunits of AGA in separate cDNA constructs showed that independently folded subunits totally lack enzyme activity, and even when co-expressed in vitro they fail to produce an active heterodimer of the enzyme, Both of the subunits are required for the enzyme activity, and the immediate interaction of the subunits in the endoplasmic reticulum is necessary for the correct folding of the dimeric enzyme molecule. The specific amino acid residues essential for the active site of the AGA enzyme were further analyzed by site directed mutagenesis and in vitro expression of mutagenized constructs, Replacement of Thr(206), the most aminoterminal residue of the beta-subunit, with Ser resulted in a complete loss of enzyme activity without influencing intracellular processing or transport of the mutant polypeptide to the lysosomes, Analogously, replacement of the most amino-terminal tryptophan, Trp(34) with Phe or Ser in the alpha-subunit, resulted in a totally inactive enzyme without influencing the intracellular processing or stability of the polypeptide, These results suggest that the catalytic center of this amidase is formed by the interaction of the amino-terminal parts of two subunits and requires both Trp(34) in the alpha-subunit and Thr(206) in the beta-subunit.	NATL PUBL HLTH INST,DEPT HUMAN MOLEC GENET,SF-00300 HELSINKI,FINLAND	Finland National Institute for Health & Welfare				Tikkanen, Ritva/0000-0002-8393-1825				AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; Autio S, 1972, J Ment Defic Res, V1, P1; BROWN CA, 1993, AM J HUM GENET, V53, P497; DUGAL B, 1977, BIOCHEM J, V165, P497, DOI 10.1042/bj1650497; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FISHER KJ, 1993, FEBS LETT, V323, P271, DOI 10.1016/0014-5793(93)81355-4; HALILA R, 1991, BIOCHEM J, V276, P251, DOI 10.1042/bj2760251; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; IKONEN E, 1991, GENOMICS, V11, P206, DOI 10.1016/0888-7543(91)90120-4; IKONEN E, 1991, P NATL ACAD SCI USA, V88, P11222, DOI 10.1073/pnas.88.24.11222; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; KOHNO M, 1972, BIOCHIM BIOPHYS ACTA, V258, P600, DOI 10.1016/0005-2744(72)90252-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKINO M, 1966, BIOCHEM BIOPH RES CO, V24, P961, DOI 10.1016/0006-291X(66)90344-5; MAKINO M, 1968, J BIOCHEM, V63, P186, DOI 10.1093/oxfordjournals.jbchem.a128760; MAURY P, 1980, J LAB CLIN MED, V96, P838; POLLITT RJ, 1968, LANCET, V2, P253; RIIKONEN A, 1994, DNA CELL BIOL, V13, P257, DOI 10.1089/dna.1994.13.257; SAVOLAINEN H, 1976, BIOCHEM J, V153, P749, DOI 10.1042/bj1530749; Spande T.F., 1967, DETERMINATION TRYPTO, P498; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P2829, DOI 10.1093/nar/18.9.2829; TIKKANEN R, 1995, IN PRESS DNA CELL BI; TOLLERSRUD OK, 1992, BIOCHEM J, V282, P891, DOI 10.1042/bj2820891; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P	25	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4903	4907		10.1074/jbc.270.9.4903	http://dx.doi.org/10.1074/jbc.270.9.4903			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876264	hybrid			2022-12-25	WOS:A1995QK08400102
J	ZGOMBICKNIGHT, M; FOGLIO, MH; DUESTER, G				ZGOMBICKNIGHT, M; FOGLIO, MH; DUESTER, G			GENOMIC STRUCTURE AND EXPRESSION OF THE ADH7 GENE ENCODING HUMAN CLASS-IV ALCOHOL-DEHYDROGENASE, THE FORM MOST EFFICIENT FOR RETINOL METABOLISM IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT FORMALDEHYDE DEHYDROGENASE; BINDING-PROTEIN; TRANSCRIPTION INITIATION; NUCLEOTIDE-SEQUENCE; MOLECULAR ANALYSIS; MOUSE EPIDERMIS; MESSENGER-RNAS; HUMAN STOMACH; BETA-SUBUNIT; ACID	Human alcohol dehydrogenase (ADH) consists of a family of five evolutionarily related classes of enzymes that collectively function in the metabolism of a wide variety of alcohols including ethanol and retinol, Class TV ADH has been found to be the most active as a retinol dehydrogenase, thus it may participate in retinoic acid synthesis, The gene encoding class IV ADH (ADH7) has now been cloned and subjected to molecular examination, Southern blot analysis indicated that class TV ADH is encoded by a single unique gene and has no related pseudogenes. The class TV ADH gene is divided into nine exons, consistent with the highly conserved intron/exon structure of other mammalian ADH genes, The predicted amino acid sequence of the exon coding regions indicates that a protein of 373 amino acids, excluding the amino-terminal methionine, would be translated, sharing greater sequence identity with class I ADH (69%) than with classes II, III, or V (59-61%), Expression of class Pr ADH mRNA was detected in human stomach but not liver, This correlates with previous protein studies, which have indicated that class IV ADH is the major stomach ADH but unlike other ADHs is absent from liver, Primer extension studies using human stomach RNA were performed to identify the transcription initiation site lying 100 base pairs upstream of the ATG translation start codon. Nucleotide sequence analysis of the promoter region indicated the absence of a TATA box sequence often located about 25 base pairs upstream of the start site as well as the absence of GC boxes, which are quite often seen in promoters lacking a TATA box. The class TV ADH promoter thus differs from the other ADH promoters, which contain either a TATA box (classes I and II) or CC-boxes (class III), suggesting a fundamentally different form of transcriptional regulation.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Duester, Gregg/0000-0003-4335-3650	NIAAA NIH HHS [AA07261] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007261] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AUSUBEL FM, 1989, CURRENT PROTOTOCOLS, V2; BILANCHONE V, 1986, NUCLEIC ACIDS RES, V14, P3911, DOI 10.1093/nar/14.9.3911; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CECI JD, 1987, GENE, V59, P171, DOI 10.1016/0378-1119(87)90325-8; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; CONNOR MJ, 1988, CANCER RES, V48, P7038; CRABB DW, 1989, GENOMICS, V5, P906, DOI 10.1016/0888-7543(89)90133-X; DANIELSSON O, 1994, P NATL ACAD SCI USA, V91, P4980, DOI 10.1073/pnas.91.11.4980; DANIELSSON O, 1992, P NATL ACAD SCI USA, V89, P9247, DOI 10.1073/pnas.89.19.9247; DE LUCA LM, 1991, FASEB J, V5, P2924; DESIMONE V, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119, DOI 10.1016/0167-4781(92)90001-G; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; DUESTER G, 1986, J BIOL CHEM, V261, P2027; FARRES J, 1994, EUR J BIOCHEM, V224, P549, DOI 10.1111/j.1432-1033.1994.00549.x; GIRI PR, 1989, BIOCHEM BIOPH RES CO, V164, P453, DOI 10.1016/0006-291X(89)91741-5; HEDEN LO, 1986, FEBS LETT, V194, P327, DOI 10.1016/0014-5793(86)80111-9; HOOG JO, 1987, BIOCHEMISTRY-US, V26, P1926, DOI 10.1021/bi00381a021; HOOG JO, 1986, EUR J BIOCHEM, V159, P215, DOI 10.1111/j.1432-1033.1986.tb09855.x; HUR MW, 1992, GENE, V121, P305, DOI 10.1016/0378-1119(92)90135-C; IKUTA T, 1986, BIOCHEM BIOPH RES CO, V140, P1020, DOI 10.1016/0006-291X(86)90737-0; JORNVALL H, 1987, P NATL ACAD SCI USA, V84, P2580, DOI 10.1073/pnas.84.9.2580; JORNVALL H, 1993, ADV EXP MED BIOL, V328, P533; KIM CI, 1992, ARCH BIOCHEM BIOPHYS, V294, P388, DOI 10.1016/0003-9861(92)90700-7; KOIVUSALO M, 1989, FEBS LETT, V257, P105, DOI 10.1016/0014-5793(89)81797-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MATSUO Y, 1989, FEBS LETT, V243, P57, DOI 10.1016/0014-5793(89)81217-7; MATSUO Y, 1990, AM J HUM GENET, V46, P85; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORENO A, 1991, J BIOL CHEM, V266, P1128; PARES X, 1994, P NATL ACAD SCI USA, V91, P1893, DOI 10.1073/pnas.91.5.1893; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; Sambrook J, 1989, MOL CLONING LABORATO; SATRE MA, 1994, J BIOL CHEM, V269, P15606; STEWART MJ, 1990, GENE, V90, P271, DOI 10.1016/0378-1119(90)90190-3; STONE CL, 1993, ALCOHOL CLIN EXP RES, V17, P911, DOI 10.1111/j.1530-0277.1993.tb00863.x; VANBAHRLINDSTRO.H, 1986, BIOCHEMISTRY-US, V25, P2465; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; VONBAHRLINDSTROM H, 1991, GENE, V103, P269, DOI 10.1016/0378-1119(91)90285-J; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; YASUNAMI M, 1991, P NATL ACAD SCI USA, V88, P7610, DOI 10.1073/pnas.88.17.7610; YIN SJ, 1993, ALCOHOL CLIN EXP RES, V17, P376, DOI 10.1111/j.1530-0277.1993.tb00779.x; YIN SJ, 1990, BIOCHEM INT, V22, P829; YIN SJ, 1988, BIOCHEM GENET, V26, P343; YOKOYAMA H, 1994, BIOCHEM BIOPH RES CO, V203, P219, DOI 10.1006/bbrc.1994.2170; ZHANG K, 1987, GENE, V57, P27, DOI 10.1016/0378-1119(87)90173-9	48	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4305	4311		10.1074/jbc.270.9.4305	http://dx.doi.org/10.1074/jbc.270.9.4305			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876191	hybrid			2022-12-25	WOS:A1995QK08400022
J	BUSCH, AE; WALDEGGER, S; HERZER, T; RABER, G; GULBINS, E; TAKUMI, T; MORIYOSHI, H; NAKANISHI, S; LANG, F				BUSCH, AE; WALDEGGER, S; HERZER, T; RABER, G; GULBINS, E; TAKUMI, T; MORIYOSHI, H; NAKANISHI, S; LANG, F			MOLECULAR-BASIS OF I-SK PROTEIN-REGULATION BY OXIDATION OR CHELATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; XENOPUS-OOCYTES; INDUCED ARRHYTHMIAS; MEMBRANE-PROTEIN; MINK CHANNELS; KINASE-C; ISK; K+; MUTATIONS; CLONING	Slowly activating I-sK channels were expressed in Xenopus oocytes and exposed to oxidative agents. Oxidative treatment reduced the resulting current I-sK, while no inhibition was observed for I-sK protein mutants carrying a Ser mutation instead of a highly conserved Cys residue in the intracellular domain. In contrast, Hg2+, which may not only oxidize thiol groups but also form chelates with dibasic amino acids, caused a use-dependent, positive regulation of I-sK. This effect was reversed in an I-sK protein mutant with a deletion in the extracellular domain. These data suggest opposite effects of peroxides and Hg2+ on I-sK, a peroxide-mediated I-sK inhibition by intracellular oxidation and a Hg2+-mediated I-sK increase, caused by extracellular Hg2+ chelation of the I-sK protein.	OSAKA UNIV,FAC MED,DEPT PHARMACOL,SUITA,OSAKA 565,JAPAN; KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN	Osaka University; Kyoto University	BUSCH, AE (corresponding author), UNIV TUBINGEN,INST PHYSIOL 1,D-72076 TUBINGEN,GERMANY.		Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342				ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; BUSCH AE, 1992, J PHYSIOL-LONDON, V450, P491, DOI 10.1113/jphysiol.1992.sp019138; BUSCH AE, 1992, SCIENCE, V255, P1705, DOI 10.1126/science.1553557; BUSCH AE, 1994, BIOCHEM BIOPH RES CO, V202, P265, DOI 10.1006/bbrc.1994.1922; BUSCH AE, 1994, MOL PHARMACOL, V46, P750; BUSCH AE, 1993, CELL PHYSIOL BIOCHEM, V3, P270, DOI 10.1159/000154692; BUSCH AE, 1993, FEBS LETT, V334, P221, DOI 10.1016/0014-5793(93)81715-C; BUSCH AE, 1993, BIOCHEM BIOPH RES CO, V197, P473, DOI 10.1006/bbrc.1993.2503; CERBAI E, 1991, CIRCULATION, V84, P1773, DOI 10.1161/01.CIR.84.4.1773; FREEMAN LC, 1993, CIRC RES, V73, P968, DOI 10.1161/01.RES.73.5.968; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; HICE RE, 1994, PFLUG ARCH EUR J PHY, V426, P139, DOI 10.1007/BF00374681; HONORE E, 1992, EMBO J, V10, P2805; MURAI T, 1989, BIOCHEM BIOPH RES CO, V161, P176, DOI 10.1016/0006-291X(89)91577-5; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; VARNUM MD, 1993, P NATL ACAD SCI USA, V90, P11528, DOI 10.1073/pnas.90.24.11528; VARNUM MD, 1993, BIOPHYS J, V64, pA198; WOODWARD B, 1985, J MOL CELL CARDIOL, V17, P485, DOI 10.1016/S0022-2828(85)80053-5	20	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3638	3641		10.1074/jbc.270.8.3638	http://dx.doi.org/10.1074/jbc.270.8.3638			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876101	hybrid			2022-12-25	WOS:A1995QH68800029
J	CHEN, H; LEIPPRANDT, JR; TRAVISS, CE; SOPHER, BL; JONES, MZ; CAVANAGH, KT; FRIDERICI, KH				CHEN, H; LEIPPRANDT, JR; TRAVISS, CE; SOPHER, BL; JONES, MZ; CAVANAGH, KT; FRIDERICI, KH			MOLECULAR-CLONING AND CHARACTERIZATION OF BOVINE BETA-MANNOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE DISEASE; MESSENGER-RNA; THYROID STRUCTURE; FEMALE-PATIENT; DEFICIENCY; PURIFICATION; HEXOSAMINIDASE; ACCUMULATION; FIBROBLASTS; EXPRESSION	Deficiency of lysosomal beta-mannosidase activity results in a severe neurodegenerative disease in goats and cattle and a relatively milder phenotype in humans. A cDNA coding for the entire beta-mannosidase protein is described, Mixed oligonucleotides derived from bovine beta-mannosidase peptide sequences were used to screen a bovine thyroid cDNA library, Clones covering about 80% of the C-terminal region were recovered, The missing 5'-region was obtained using the technique of 5'-rapid amplification of cDNA ends. The composite cDNA contains 3852 nucleotides, encoding 879 amino acids. The N-terminal methionine is followed by 16 amino acids displaying the characteristics of a typical signal peptide sequence. The deduced amino acid sequence is colinear with all peptide sequences determined by protein microsequencing, Northern blot analysis demonstrates a single 4.2-kilobase transcript in various tissues from both normal and affected goats and calves, The mRNA level is decreased in tissues of affected beta-mannosidosis animals, The gene encoding beta-mannosidase is localized to human chromosome 4 as shown by Southern analysis of rodent/human somatic cell hybrids, This is the first report of cloning of lysosomal beta-mannosidase.	MICHIGAN STATE UNIV,DEPT PATHOL,E LANSING,MI 48824	Michigan State University					NINDS NIH HHS [NS16886] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016886] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBITT B, 1991, J AM VET MED ASSOC, V198, P109; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOLE PJ, 1981, BOLE VET J, V57, P504; BOYER PJ, 1990, LAB INVEST, V63, P100; BRYAN L, 1990, BIOCHEM BIOPH RES CO, V173, P491, DOI 10.1016/S0006-291X(05)80060-9; CAVANAGH K, 1982, AM J VET RES, V48, P1058; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; COOPER A, 1986, NEW ENGL J MED, V315, P1231; COOPER A, 1991, J INHERIT METAB DIS, V14, P18, DOI 10.1007/BF01804383; COOPER A, 1988, J INHERIT METAB DIS, V11, P17, DOI 10.1007/BF01800054; DORLAND L, 1988, J INHERIT METAB DIS, V11, P255, DOI 10.1007/BF01804251; FISHER R A, 1987, American Journal of Human Genetics, V41, pA165; FREI JI, 1988, BIOCHEM J, V249, P871, DOI 10.1042/bj2490871; HARTLEY WJ, 1973, ACTA NEUROPATHOL, V25, P325, DOI 10.1007/BF00691760; IWASAKI Y, 1989, J BIOCHEM-TOKYO, V106, P331, DOI 10.1093/oxfordjournals.jbchem.a122853; JOLLY RD, 1990, NEW ZEAL VET J, V38, P102, DOI 10.1080/00480169.1990.35628; JONES MZ, 1981, J BIOL CHEM, V256, P5185; JONES MZ, 1981, J BIOL CHEM, V256, P5181; JONES MZ, 1983, J NEUROPATH EXP NEUR, V42, P268, DOI 10.1097/00005072-198305000-00005; JONES MZ, 1992, J INHERIT METAB DIS, V15, P57, DOI 10.1007/BF01800344; JONES MZ, 1984, J INHERIT METAB DIS, V7, P80, DOI 10.1007/BF01805811; KLEIJER WJ, 1990, J INHERIT METAB DIS, V13, P867, DOI 10.1007/BF01800211; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYOSAKA S, 1985, CHEM PHARM BULL, V33, P256; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LEVADE T, 1994, ANN NEUROL, V35, P116, DOI 10.1002/ana.410350119; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; LOVELL KL, 1991, J INHERIT METAB DIS, V14, P228, DOI 10.1007/BF01800594; LOVELL KL, 1983, ACTA NEUROPATHOL, V62, P121, DOI 10.1007/BF00684928; LUNDIN LG, 1987, BIOCHEM GENET, V25, P603, DOI 10.1007/BF00554361; MAHURAN DJ, 1988, J BIOL CHEM, V263, P4612; MAHURAN DJ, 1991, BIOCHIM BIOPHYS ACTA, V1096, P87, DOI 10.1016/0925-4439(91)90044-A; ODOWD BF, 1985, P NATL ACAD SCI USA, V82, P1184, DOI 10.1073/pnas.82.4.1184; POENARU L, 1992, CLIN GENET, V41, P331; Sambrook J, 1989, MOL CLONING LABORATO; SOPHER BL, 1993, BIOCHEM J, V289, P343, DOI 10.1042/bj2890343; SOPHER BL, 1992, J BIOL CHEM, V267, P6178; STEIN C, 1989, J BIOL CHEM, V264, P1252; STOLTZFUS LJ, 1992, J BIOL CHEM, V267, P6570; VANPELT J, 1990, CLIN CHIM ACTA, V187, P55, DOI 10.1016/0009-8981(90)90261-P; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WENGER DA, 1986, NEW ENGL J MED, V315, P1201, DOI 10.1056/NEJM198611063151906; WIJBURG H, 1992, EUR J PEDIATR, V151, P311, DOI 10.1007/BF02072238; ZHANG ZX, 1994, HUM MOL GENET, V3, P139, DOI 10.1093/hmg/3.1.139	46	32	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3841	3848		10.1074/jbc.270.8.3841	http://dx.doi.org/10.1074/jbc.270.8.3841			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876128	hybrid			2022-12-25	WOS:A1995QH68800058
J	COPELAND, WC; TAN, XH				COPELAND, WC; TAN, XH			ACTIVE-SITE MAPPING OF THE CATALYTIC MOUSE PRIMASE SUBUNIT BY ALANINE SCANNING MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; INITIATION; YEAST; RNA; REPLICATION; CELLS; PURIFICATION	In the eukaryotic cell, DNA synthesis is initiated by DNA primase associated with DNA polymerase alpha. The eukaryotic primase is composed of two subunits, p49 and p58, where the p49 subunit contains the catalytic active site, Mutagenesis of the cDNA for the p49 subunit was initiated to demonstrate a functional correlation of conserved residues among the eukaryotic primases and DNA polymerases, Fourteen invariant charged residues in the smaller catalytic mouse primase subunit, p49, were changed to alanine, These mutant proteins were expressed, purified, and enzymatically characterized for primer synthesis, Analyses of the mutant proteins indicate that residues 104-111 are most critical for primer synthesis and form part of the active site, Alanine substitution in residues Glu(105), Asp(109) and Asp(111) produced protein with no detectable activity in direct primase assays, indicating that these residues may form part of a conserved carboxylic triad also observed in the active sites of DNA polymerases and reverse transcriptases, Ah other mutant proteins showed a dramatic decrease in catalysis, while mutation of two residues, Arg(162) and Arg(163), caused an increase in K-m(NTP). Analysis of these mutant proteins in specific assays designed to separately investigate dinucleotide formation (initiation) and elongation of primer indicates that these two activities utilize the same active site within the p49 subunit, Finally, mutations in three active site codons produced protein with reduced affinity with the p58 subunit, suggesting that p58 may interact directly with active site residues.			COPELAND, WC (corresponding author), NIEHS,MOLEC GENET LAB,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953				BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; CONWAY RC, 1982, P NATL ACAD SCI USA, V79, P2523; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; COPELAND WC, 1993, J BIOL CHEM, V268, P26179; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; FRANCESCONI S, 1991, P NATL ACAD SCI USA, V88, P3877, DOI 10.1073/pnas.88.9.3877; GRONOSTAJSKI RM, 1984, J BIOL CHEM, V259, P9479; KAGUNI LS, 1983, J BIOL CHEM, V258, P9037; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KORNBERG A, 1992, DNA REPLICATION, P275; KUCHTA RD, 1990, J BIOL CHEM, V265, P16158; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LONGHESE MP, 1993, GENETICS, V133, P183; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; PANDEY VN, 1994, J BIOL CHEM, V269, P13259; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; PLEVANI P, 1987, NUCLEIC ACIDS RES, V15, P7975; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; ROTH YF, 1987, EUR J BIOCHEM, V165, P473, DOI 10.1111/j.1432-1033.1987.tb11463.x; SANTOCANALE C, 1993, J BIOL CHEM, V268, P1343; SANTOCANALE C, 1992, GENE, V113, P199, DOI 10.1016/0378-1119(92)90396-7; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; SEVERINOV K, 1994, J BIOL CHEM, V269, P20826; SHEAFF RJ, 1994, BIOCHEMISTRY-US, V33, P2247, DOI 10.1021/bi00174a035; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; SHEAFF RJ, 1994, J BIOL CHEM, V269, P19225; SHIODA M, 1982, P NATL ACAD SCI-BIOL, V79, P7209, DOI 10.1073/pnas.79.23.7209; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TSENG BY, 1979, J MOL BIOL, V129, P531, DOI 10.1016/0022-2836(79)90467-4; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; ZHANG SS, 1990, J MOL BIOL, V216, P475, DOI 10.1016/0022-2836(90)90370-2	39	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3905	3913		10.1074/jbc.270.8.3905	http://dx.doi.org/10.1074/jbc.270.8.3905			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876136	hybrid			2022-12-25	WOS:A1995QH68800067
J	THOMAS, PQ; JOHNSON, BV; RATHJEN, J; RATHJEN, PD				THOMAS, PQ; JOHNSON, BV; RATHJEN, J; RATHJEN, PD			SEQUENCE, GENOMIC ORGANIZATION, AND EXPRESSION OF THE NOVEL HOMEOBOX GENE HESX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION INHIBITING ACTIVITY; EMBRYONIC STEM-CELLS; MYELOID-LEUKEMIA; MOUSE EMBRYOS; HOMEODOMAIN; INVITRO; ANTENNAPEDIA; DROSOPHILA; BRAIN; FORMS	Extensive analyses of homeobox gene expression and function during murine embryogenesis have demonstrated that homeobox gene products are key components in the establishment of pattern formation and regional identity during development. In this paper we report the molecular characterization and expression of a novel murine homeobox sequence, Hesx1, isolated from pluripotent embryonic stem cells, Hesx1 is expressed as two transcripts of 1.0 and 1.2 kilobases which encode an identical 185 amino acid open reading frame, The transcripts differ in the 3'-untranslated region due to the differential utilization of a weak splice donor site located immediately downstream of the translation termination codon. The Hesx1 homeodomain shared 80% identity with the Xenopus homeoprotein XANF-1 and was less than 50% related to other homeodomain sequences, Hesx1 and XANF-1 therefore constitute the founder members of a new homeodomain class, Hesx1 expression was down-regulated during embryonic stem cell differentiation and was detected in tissue-specific RNA samples derived from the embryonic liver, and at lower levels in viscera, amnion, and yolk sac, Expression in adult mice was not detected, These sites of expression are consistent with a role for Hesx1 in the regulation of developmental decisions in the early mouse embryo and during fetal hematopoiesis.	UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5005,AUSTRALIA	University of Adelaide			Thomas, Paul Q/K-4497-2012	Johnson, Brett/0000-0003-3883-3158				BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; Burglin T., 1994, GUIDEBOOK HOMEOBOX G; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DEJONG R, 1993, DEV BIOL, V157, P133, DOI 10.1006/dbio.1993.1118; DIETRICH W, 1992, GENETICS, V131, P423; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EDWARDS DR, 1985, MOL CELL BIOL, V5, P3280, DOI 10.1128/MCB.5.11.3280; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; Kaufman M.H., 1992, ATLAS MOUSE DEV; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LINTS TJ, 1993, DEVELOPMENT, V119, P419; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURTHA MT, 1991, P NATL ACAD SCI USA, V88, P10711, DOI 10.1073/pnas.88.23.10711; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROBERTSON M, 1993, DEV GENET, V14, P165, DOI 10.1002/dvg.1020140303; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Smith A G, 1992, Semin Cell Biol, V3, P385, DOI 10.1016/1043-4682(92)90010-S; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; THOMAS PQ, 1992, NUCLEIC ACIDS RES, V20, P5840, DOI 10.1093/nar/20.21.5840; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; ZARAISKY AG, 1992, DEV BIOL, V152, P373, DOI 10.1016/0012-1606(92)90144-6	44	95	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3869	3875		10.1074/jbc.270.8.3869	http://dx.doi.org/10.1074/jbc.270.8.3869			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876132	hybrid			2022-12-25	WOS:A1995QH68800062
J	HERRMANN, C; MARTIN, GA; WITTINGHOFER, A				HERRMANN, C; MARTIN, GA; WITTINGHOFER, A			QUANTITATIVE-ANALYSIS OF THE COMPLEX BETWEEN P21(RAS) AND THE RAS-BINDING DOMAIN OF THE HUMAN RAF-1 PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; HA-RAS; ACTIVATING PROTEIN; GRB2; P21; IDENTIFICATION; ASSOCIATION; P21(H-RAS); INTERACTS; MECHANISM	The Ras-binding domain (RBD) of human Raf-1 was purified from Escherichia coli, and its interaction with Ras was investigated. Its dissociation constant with p21(ras)guanyl-5'-yl imidodiphosphate was found to be 18 nM, with a slight preference for H-ras over K- and N-ras. Oncogenic forms bind with slightly lower affinity. The affinity of RED for effector region mutants or the GDP-bound form of p21(ras) is in the micromolar range, which means that 100-fold lower affinity is not sufficient for signal transduction. The rate of the GTPase of p21(ras) is not modified by RED. Since P-i release is found not to be rate limiting, the Ras-Raf signal of the cell may be terminated by the intrinsic GTPase of p2l(ras).	MAX PLANCK INST MOLEK PHYSIOL,D-44139 DORTMUND,GERMANY; ONYX PHARMACEUT,RICHMOND,CA 94806	Max Planck Society								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CALES C, 1988, NATURE, V32, P548; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1993, J BIOL CHEM, V268, P923; JOHN J, 1988, J BIOL CHEM, V263, P11792; JOHN J, 1992, THESIS U HEIDELBERG; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SCHWEINS T, 1994, STRUCT BIOL, V1, P476; SHHIROUZU M, 1994, ONCOGENE, V9, P2153; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; YAMASAKI K, 1994, BIOCHEMISTRY-US, V33, P65, DOI 10.1021/bi00167a009; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	37	294	299	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2901	2905		10.1074/jbc.270.7.2901	http://dx.doi.org/10.1074/jbc.270.7.2901			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852367				2022-12-25	WOS:A1995QG47100006
J	SCHAEFFER, P; LAPLACE, MC; SAVI, P; PFLIEGER, AM; GULLY, D; HERBERT, JM				SCHAEFFER, P; LAPLACE, MC; SAVI, P; PFLIEGER, AM; GULLY, D; HERBERT, JM			HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS EXPRESS HIGH-AFFINITY NEUROTENSIN RECEPTORS COUPLED TO INTRACELLULAR CALCIUM-RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHATES; SMOOTH-MUSCLE; NITRIC-OXIDE; CYCLIC-GMP; BINDING; RATS; PEPTIDES; N1E-115; SITES; BRAIN	The binding of I-125-neurotensin (NT) to human umbilical vein endothelial cell monolayers was studied. At 20 degrees C, I-125-NT bound to a single class of binding sites with a dissociation constant of 0.23 +/- 0.08 nM and a binding site density of 5500 +/- 1300 sites/cell (n = 3). I-125-NT also bound to human aortic endothelial cells with a dissociation constant of 0.6 +/- 0.26 nM and a binding site density of 32000 +/- 1700 sites/cell. Association and dissociation kinetics were of a pseudo-first order ana gave association and dissociation rate constant values of 1.6 x 10(6) M(-1) s(-1) and 3.5 x 10(-4) s(-1), respectively. I-125-NT binding was inhibited by NT analogues with a rank order of potency similar to that characterizing brain high affinity NT binding sites (K-0.5, nM): NT8-13 (0.11) > NT (0.35) > acetyl-NT8-13 (1.5) > [Phe(11)]NT (12) > [D-Tyr(11)]NT (> 1000). I-125-NT binding was also inhibited by the non-peptide NT antagonist SR 48692 (K-i = 16 nM) but was not affected by levocabastine, an inhibitor of low affinity brain NT binding sites. NT had no effect on cGMP levels in endothelial cells but NT and its analogues increased Ca-45(2+) efflux from endothelial cells at nanomolar concentrations with a rank order of potency which was identical to that observed in binding experiments. This effect was inhibited by SR 48692 (IC50 = 8 nM). NT was able to increase phosphoinositide turnover in these cells, and this effect was blocked by SR 48692. The correlation between dissociation constants of NT analogues in binding experiments and IC50 values in Ca-45(2+) efflux experiments was very high (r = 0.997) with a slope near unity, indicating that I-125-NT binding sites ard functional NT receptors coupled to phosphoinositide hydrolysis and Ca2+ release in human umbilical vein endothelial cells.	SANOFI RECH,HAEMOBIOL RES DEPT,F-31036 TOULOUSE,FRANCE	Sanofi-Aventis; Sanofi France			Schaeffer, Paul/D-7069-2014; Schaeffer, Paul/AAZ-9961-2020	Schaeffer, Paul/0000-0002-2835-1801; Schaeffer, Paul/0000-0002-2835-1801				AHMAD S, 1987, BIOCHIM BIOPHYS ACTA, V896, P224, DOI 10.1016/0005-2736(87)90183-0; AMADH S, 1991, PEPTIDES, V12, P623; AMAR S, 1985, BIOCHEM BIOPH RES CO, V129, P117, DOI 10.1016/0006-291X(85)91411-1; BACHELARD H, 1992, BRIT J PHARMACOL, V105, P191, DOI 10.1111/j.1476-5381.1992.tb14234.x; BARSHAVIT Z, 1982, NEUROPEPTIDES, V2, P325, DOI 10.1016/0143-4179(82)90070-1; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; BOZOU JC, 1989, BIOCHEM J, V264, P871, DOI 10.1042/bj2640871; BUHNER S, 1989, CAN J PHYSIOL PHARM, V67, P1534, DOI 10.1139/y89-247; CARRAWAY R, 1973, J BIOL CHEM, V248, P6854; CARRAWAY RE, 1991, PEPTIDES, V12, P1105, DOI 10.1016/0196-9781(91)90066-X; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIPAOLA ED, 1990, EUR J PHARMACOL, V175, P279, DOI 10.1016/0014-2999(90)90565-N; DORLEANSJUSTE P, 1985, EUR J PHARMACOL, V114, P9, DOI 10.1016/0014-2999(85)90515-1; FORSTERMANN U, 1990, MOL PHARMACOL, V38, P7; GILBERT JA, 1984, EUR J PHARMACOL, V99, P245, DOI 10.1016/0014-2999(84)90248-6; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; HE P, 1990, AM J PHYSIOL, V258, pH1366; HELMSTAEDTER V, 1977, CELL TISSUE RES, V184, P445; KEOURAC R, 1981, LIFE SCI, V28, P2477; KITABGI P, 1985, Reviews in Clinical and Basic Pharmacology, V5, P397; KITABGI P, 1984, PEPTIDES, V5, P917, DOI 10.1016/0196-9781(84)90117-7; KOMORI S, 1992, BRIT J PHARMACOL, V107, P790, DOI 10.1111/j.1476-5381.1992.tb14525.x; LAZARUS LH, 1977, J BIOL CHEM, V252, P7180; LAZARUS LH, 1977, J BIOL CHEM, V252, P7174; MAZELLA J, 1988, J BIOL CHEM, V263, P144; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OBARA H, 1989, PEPTIDES, V10, P241, DOI 10.1016/0196-9781(89)90100-9; QUIRION R, 1980, LIFE SCI, V27, P1889, DOI 10.1016/0024-3205(80)90435-X; RIOUX F, LIFE SCI, V27, P259; SCHOTTE A, 1986, N-S ARCH PHARMACOL, V333, P400, DOI 10.1007/BF00500016; SUMNERS C, 1982, HYPERTENSION, V4, P888, DOI 10.1161/01.HYP.4.6.888; SUNDLER F, 1977, HISTOCHEMISTRY, V53, P24; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; WATSON MA, 1992, J NEUROCHEM, V59, P1967, DOI 10.1111/j.1471-4159.1992.tb11035.x; [No title captured]	37	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3409	3413		10.1074/jbc.270.7.3409	http://dx.doi.org/10.1074/jbc.270.7.3409			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852427	hybrid			2022-12-25	WOS:A1995QG47100077
J	BLAKESLEY, VA; KATO, H; ROBERTS, CT; LEROITH, D				BLAKESLEY, VA; KATO, H; ROBERTS, CT; LEROITH, D			MUTATION OF A CONSERVED AMINO-ACID RESIDUE (TRYPTOPHAN-1173) IN THE TYROSINE KINASE DOMAIN OF THE IGF-I RECEPTOR ABOLISHES AUTOPHOSPHORYLATION BUT DOES NOT ELIMINATE BIOLOGIC FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INSULIN-RECEPTOR; SIGNAL TRANSDUCTION; GROWTH; REPLACEMENT; FAMILY; HORMONE; MUTANT; SITES	The amino acid sequence of the tyrosine kinase domain of the insulin-like growth factor-I (IGF-I) receptor is 84% identical to the sequence of the analogous region of the insulin receptor, A naturally occurring mutation of the tryptophan residue at position 1200 of the insulin receptor to serine results in impaired beta subunit autophosphorylation of wheat germ agglutinin-purified receptors, severely impaired thymidine incorporation and moderately reduced glycogen synthesis; however, glucose uptake was unaffected. To study the importance of this residue in IGF-I receptor function, we mutated the analogous tryptophan residue at position 1173 of the IGF-I receptor to serine and overexpressed the mutant receptor in NIH-3T3 cells, In cell Lines overexpressing this mutant IGF-I receptor, beta subunit autophosphorylation was severely reduced. Additionally, the overexpressed mutant receptors exhibited a dominant-negative effect on IGF-I-stimulated autophosphorylation of endogenous mouse IGF-I receptors, Phosphorylation of insulin receptor substrate (IRS)-1 in intact cells by the mutant IGF-I receptors was similar to the level of IRS-1 phosphorylation seen in the parental NIH-3T3 cells, but there was no obvious dominant-negative effect on IRS-1 phosphorylation. Wheat germ agglutinin-purified mutant receptors were as active in phosphorylating poly(Glu,Tyr) 4:1 as wild-type IGF-I receptors, suggesting that, in intact cells, additional factors are necessary in order for the IGF-I receptor to phosphorylate IRS-1, Thymidine incorporation was severely reduced in one clone overexpressing the mutant IGF-I receptor and abolished in a second clone, Glucose uptake in both clones was reduced to about half of that seen in a cell line overexpressing mild-type IGF-I receptors. Thus, we propose that the tryptophan residue at position 1173 of the IGF-I receptor is important in the regulation of autophosphorylation in vivo. This study again confirms that high levels of autophosphorylation are not required for mediation of all of the biologic activities of the IGF-I receptor.	NIDDK,DIABET BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				ADAMO M, 1991, BIOFACTORS, V3, P151; [Anonymous], 1991, INSULIN LIKE GROWTH; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FILIPEK A, 1993, MOL CELL BIOCHEM, V120, P103, DOI 10.1007/BF00926082; FORMISANO P, 1993, J BIOL CHEM, V268, P5241; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IWANISHI M, 1993, DIABETOLOGIA, V36, P414, DOI 10.1007/BF00402277; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOLLER DE, 1990, MOL ENDOCRINOL, V4, P1183, DOI 10.1210/mend-4-8-1183; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEMER J, 1987, J BIOL CHEM, V262, P7693; SHIER P, 1989, J BIOL CHEM, V264, P14605; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZHANG B, 1991, J BIOL CHEM, V266, P990	30	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2764	2769		10.1074/jbc.270.6.2764	http://dx.doi.org/10.1074/jbc.270.6.2764			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852347	hybrid			2022-12-25	WOS:A1995QF53500057
J	CORBETT, JD; MICKOLS, WE; MAESTRE, MF				CORBETT, JD; MICKOLS, WE; MAESTRE, MF			EFFECT OF HEMOGLOBIN CONCENTRATION ON NUCLEATION AND POLYMER FORMATION IN SICKLE RED-BLOOD-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S POLYMERIZATION; DELAY TIME; DEOXYGENATION; ERYTHROCYTES; SCATTERING; MECHANISM; KINETICS; GELATION; LIGHT; SHEAR	We have used differential polarization imaging microscopy to measure the amount and orientation of aligned sickle hemoglobin polymer in quickly deoxygenated sickle red blood cells. Images of the angular orientation of the aligned polymer at each point in the cell allowed for determination of the inclination of individual domains, providing detailed information regarding the polymerization and elongation of sickle hemoglobin polymers ex vivo. We found that the number of aligned polymer domains increased with increasing mean cell hemoglobin concentration. Sickle and holly leaf-shaped cells contained single or few domains of aligned polymer, while more compact cells such as irreversibly sickled cells contained many domains. A new class of cells was discovered by examination of images of the angular orientation of aligned polymer, which contained a single central nucleation site, with growth of polymer occurring outward in all directions in a spherulite-like domain.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, CHEM BIODYNAM LAB, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV BIOL & MED, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM010840, R01GM010840] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01613] Funding Source: Medline; NIAID NIH HHS [AI 08427] Funding Source: Medline; NIGMS NIH HHS [GM 10840] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAKURA T, 1984, J LAB CLIN MED, V104, P987; BASAK S, 1988, BIOPHYS J, V54, P829, DOI 10.1016/S0006-3495(88)83020-0; BEACH DA, 1987, BIOPHYS J, V52, P947, DOI 10.1016/S0006-3495(87)83287-3; BERTLES JF, 1969, BLOOD-J HEMATOL, V33, P884, DOI 10.1182/blood.V33.6.884.884; BRIEHL RW, 1982, BLOOD CELLS, V8, P201; BRIEHL RW, 1989, ANN NY ACAD SCI, V565, P295, DOI 10.1111/j.1749-6632.1989.tb24177.x; CHRISTOPH GW, 1983, BIOPHYS J, V41, pA415; DOU Q, 1993, BIOPHYS J, V65, P2068, DOI 10.1016/S0006-3495(93)81237-2; DYKES G, 1978, NATURE, V272, P506, DOI 10.1038/272506a0; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FERRONE FA, 1985, J MOL BIOL, V183, P611, DOI 10.1016/0022-2836(85)90175-5; FERRONE FA, 1980, BIOPHYS J, V32, P361, DOI 10.1016/S0006-3495(80)84962-9; FERRONE FA, 1985, J MOL BIOL, V183, P591, DOI 10.1016/0022-2836(85)90174-3; GILL SJ, 1980, J MOL BIOL, V140, P299, DOI 10.1016/0022-2836(80)90107-2; HARRIS JW, 1950, P SOC EXP BIOL MED, V75, P197, DOI 10.3181/00379727-75-18144; HOFRICHTER J, 1973, P NATL ACAD SCI USA, V70, P3604, DOI 10.1073/pnas.70.12.3604; HOFRICHTER J, 1978, BIOPHYS J, V21, P20; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; KAUL DK, 1991, BLOOD, V77, P1353; KAUL DK, 1989, P NATL ACAD SCI USA, V86, P3356, DOI 10.1073/pnas.86.9.3356; KIM M, 1991, BIOPHYS J, V59, P1171, DOI 10.1016/S0006-3495(91)82333-5; KIM M, 1987, BIOPHYS J, V52, P929, DOI 10.1016/S0006-3495(87)83286-1; KIM M, 1987, BIOPHYS J, V52, P911, DOI 10.1016/S0006-3495(87)83285-X; MADGOFFFAIRCHIL.B, 1986, BIOPHYS J, V49, P67; MADONIA F, 1983, NATURE, V302, P412, DOI 10.1038/302412a0; MAKHIJANI VB, 1990, BIOPHYS J, V58, P1025, DOI 10.1016/S0006-3495(90)82446-2; MICKOLS W, 1985, REV SCI INSTRUM, V56, P2228, DOI 10.1063/1.1138354; MICKOLS W, 1985, P NATL ACAD SCI USA, V82, P6527, DOI 10.1073/pnas.82.19.6527; MICKOLS WE, 1988, J BIOL CHEM, V263, P4338; MICKOLS WE, 1987, POLARIZED SPECTROSCO, P297; MITZUKAMI H, 1986, AM J HEMATOL, V21, P233; MOHANDAS N, 1986, BLOOD, V68, P506; MOZZARELLI A, 1987, SCIENCE, V237, P500, DOI 10.1126/science.3603036; NOGUCHI CT, 1983, J CLIN INVEST, V72, P846, DOI 10.1172/JCI111055; PERUTZ MF, 1950, NATURE, V166, P677, DOI 10.1038/166677a0; POYART C, 1984, DYNAMIC ANAL DEOXYGE, P137; PUMPHREY JG, 1976, BIOCHEM BIOPH RES CO, V69, P99, DOI 10.1016/S0006-291X(76)80278-1; RUSSU IM, 1980, P NATL ACAD SCI-BIOL, V77, P6577, DOI 10.1073/pnas.77.11.6577; SHIBATA K, 1977, J BIOL CHEM, V252, P7468; SINGER K, 1953, BLOOD, V8, P1008, DOI 10.1182/blood.V8.11.1008.1008; SORETTE MP, 1987, BLOOD, V69, P316; SUNSHINE HR, 1979, J MOL BIOL, V133, P435, DOI 10.1016/0022-2836(79)90402-9; SUNSHINE HR, 1982, J MOL BIOL, V158, P251, DOI 10.1016/0022-2836(82)90432-6; WATERMAN MR, 1976, BIOCHEM BIOPH RES CO, V73, P639, DOI 10.1016/0006-291X(76)90858-5; WATERMAN MR, 1979, J MOL BIOL, V129, P337, DOI 10.1016/0022-2836(79)90287-0; WHITE JG, 1968, BLOOD, V31, P561, DOI 10.1182/blood.V31.5.561.561; WINSLOW RM, 1978, HEMOGLOBIN INTERACTI, P369	47	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2708	2715		10.1074/jbc.270.6.2708	http://dx.doi.org/10.1074/jbc.270.6.2708			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852341	hybrid			2022-12-25	WOS:A1995QF53500049
J	LAWLER, J; MCHENRY, K; DUQUETTE, M; DERICK, L				LAWLER, J; MCHENRY, K; DUQUETTE, M; DERICK, L			CHARACTERIZATION OF HUMAN THROMBOSPONDIN-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELET THROMBOSPONDIN; OLIGOMERIC MATRIX PROTEIN; ELECTRON-MICROSCOPY; GENE FAMILY; CARTILAGE; EXPRESSION; CLEAVAGE; CALCIUM; SITES; ACID	The thrombospondins are a family of extracellular calcium binding proteins that are involved in cell proliferation, adhesion, and migration. We have sequenced full-length human thrombospondin-4 and characterized the recombinant protein. In contrast to Xenopus laevis thrombospondin-4, the human protein contains an RGD cell binding sequence in the third type 3 repeat. Transfection of mouse NIH3T3 fibroblasts or C2C12 myoblasts with a full-length human thrombospondin-4 cDNA results in the expression of a polypeptide with a reduced molecular weight of 140,000. In the absence of reducing agent, the expressed protein has an apparent molecular weight of 550,000. Recombinant thrombospondin-4 has been purified from the culture supernatant by heparin-Sepharose and anti-thrombospondin-4 antibody-Affi-gel affinity chromatography. Electron microscopy indicates that thrombospondin-4 is composed of five subunits with globular domains at each end. The observation of a calcium-dependent change in the electron microscopic appearance of thrombospondin-4 is consistent with limited tryptic digestion data that indicate that thrombospondin-4 is resistant to digestion in the presence of calcium. These data indicate that thrombospondin-4 is a pentameric protein that binds to heparin and calcium.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; TUFTS UNIV,ST ELIZABETHS HOSP,DEPT BIOMED RES,BOSTON,MA 02135	Harvard University; Harvard Medical School; Tufts University	LAWLER, J (corresponding author), BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV VASC RES,BOSTON,MA 02115, USA.		Lawler, Jack/AAJ-1379-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028749, R01HL049081] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28749, HL49081] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; ADAMS JC, 1993, J CELL SCI, V104, P1061; BORNSTEIN P, 1993, GENOMICS, V15, P607, DOI 10.1006/geno.1993.1114; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; EFIMOV VP, 1994, FEBS LETT, V34, P54; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1993, J MOL EVOL, V36, P509, DOI 10.1007/BF00556355; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; NEWTON G, 1994, IN PRESS GENOMICS; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; OROURKE KM, 1992, J BIOL CHEM, V767, P24921; QABAR AN, 1994, J BIOL CHEM, V269, P1262; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STENFLO J, 1988, J BIOL CHEM, V263, P21; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	24	72	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2809	2814		10.1074/jbc.270.6.2809	http://dx.doi.org/10.1074/jbc.270.6.2809			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852353	hybrid, Green Submitted			2022-12-25	WOS:A1995QF53500063
J	MORRIS, JC; LEI, PS; SHEN, TY; MENSAWILMOT, K				MORRIS, JC; LEI, PS; SHEN, TY; MENSAWILMOT, K			GLYCAN REQUIREMENTS OF GLYCOSYLPHOSPHATIDYLINOSITOL PHOSPHOLIPASE-C FROM TRYPANOSOMA-BRUCEI - GLUCOSAMINYLINOSITOL DERIVATIVES INHIBIT PHOSPHATIDYLINOSITOL PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; BACILLUS-CEREUS; MEMBRANE ANCHOR; MIXED MICELLES; BIOSYNTHESIS; THURINGIENSIS; PURIFICATION; DETERGENT; MUTANTS; THY-1	Glycosylphosphatidylinositol phospholipase C (GPI-PLC) from Trypanosoma brucei and phosphatidylinositol phospholipase C (PI-PLC) from Bacillus sp. both cleave glycosylphosphatidylinositols (GPIs), However, phosphatidylinositol, which is efficiently cleaved by PI-PLC, is a very poor substrate for GPI-PLC, We examined GPI-PLC substrate requirements using glycoinositol analogs of GPI components as potential inhibitors. Glucosaminyl(alpha 1-->6)-D-myo-inositol (GlcN(alpha 1-->6)Ins), GlcN(alpha 1-->6)Ins 1,2-cyclic phosphate, GlcN(alpha 1-->6)-2-deoxy-Ins, and GlcN(alpha 1-->6)Ins 1-dodecyl phosphonate inhibited GPI-PLC. GlcN(alpha 1-->6)Ins was as effective as Man(alpha 1-->4)GlcN((alpha 1-->6)Ins; we surmise that GlcN(alpha 1-->6)Ins is the crucial glycan motif for GPI-PLC recognition. Inhibition by GlcN(alpha 1-->6)Ins 1,2-cyclic phosphate suggests product inhibition since GPIs cleaved by GPI-PLC possess a GlcN(alpha 1-->6)Ins 1,2-cyclic phosphate at the terminus of the residual glycan. The effectiveness of GlcN(alpha 1-->6)-2-deoxy-Ins indicates that the D-myo-inositol (Ins) 2-hydroxyl is not required for substrate recognition, although it is probably essential for catalysis. GlcN(alpha 1-->6)-2-deoxy-L-myo-inositol, unlike GlcN(alpha 1-->6)2-deoxy-Ins, had no effect on GPI-PLC; hence, GPI-PLC can distinguish between the two enantiomers of Ins, Surprisingly, GlcN(alpha 1-->6)Ins 1,2-cyclic phosphate was not a potent inhibitor of Bacillus cereus PI-PLC, and GlcN(alpha 1-->6)Ins had no effect on the enzyme. However, both GlcN(alpha 1-->6)Ins 1-phosphate and GlcN(alpha 1-->6)Ins 1-dodecyl phosphonate were competitive inhibitors of PI-PLC. These observations suggest an important role for a phosphoryl group at the Ins 1-position in PI-PLC recognition of GPIs. Other studies indicate that abstraction of a proton from the Ins 2-hydroxyl is not an early event in PI-PLC cleavage of GPIs. Furthermore, both GlcN(alpha 1-->6)-2-deoxy-Ins 1-phosphate and GlcN(alpha 1-->6)-2-deoxy-L-myo-inositol inhibited PI-PLC without affecting GPI-PLC. Last, the aminoglycoside G418 stimulated PI-PLC, but had no effect on GPI-PLC. Thus, these enzymes represent mechanistic subclasses of GPI phospholipases C, distinguishable by their sensitivity to GlcN(alpha 1-->6)Ins derivatives and aminoglycosides, Possible allosteric regulation of PI-PLC by GlcN(alpha 1-->6)Ins analogs is discussed.	UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA	University of Virginia	MORRIS, JC (corresponding author), UNIV GEORGIA, DEPT CELLULAR BIOL, 724 BIOL SCI BLDG, ATHENS, GA 30602 USA.			Morris, James/0000-0003-2515-5714	NIAID NIH HHS [1-T32-AIO-7322, AI 33383] Funding Source: Medline; NIGMS NIH HHS [GM 47109] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007322, R29AI033383, R01AI033383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047109] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; BERLIN WK, 1991, TETRAHEDRON, V47, P1, DOI 10.1016/0040-4020(91)80003-K; BRUZIK KS, 1992, BIOCHEMISTRY-US, V31, P5183, DOI 10.1021/bi00137a014; BULOW R, 1986, J BIOL CHEM, V261, P1918; CARRINGTON M, 1991, CELL BIOL INT REP, V15, P1101, DOI 10.1016/0309-1651(91)90058-Q; DOERING TL, 1989, J BIOL CHEM, V264, P11168; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FOX JA, 1986, J BIOL CHEM, V261, P5767; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; GUPTA D, 1988, SCIENCE, V242, P1446, DOI 10.1126/science.2904699; HENNER DJ, 1988, NUCLEIC ACIDS RES, V16, P10383, DOI 10.1093/nar/16.21.10383; HERELD D, 1986, J BIOL CHEM, V261, P3813; JAIN MK, 1993, BIOCHEMISTRY-US, V32, P8360, DOI 10.1021/bi00083a040; JAIN MK, 1989, BIOCHEMISTRY-US, V28, P4135, DOI 10.1021/bi00436a002; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; Low M.G., 1992, LIPID MODIFICATION P, P117; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Mensa-Wilmot K., 1991, P43; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MENSAWILMOT K, 1992, MOL BIOCHEM PARASIT, V56, P311, DOI 10.1016/0166-6851(92)90180-R; MENSAWILMOT K, 1995, IN PRESS METHODS ENZ; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; PLOURDE R, 1992, J ORG CHEM, V57, P2606, DOI 10.1021/jo00035a015; ROBSON RJ, 1978, BIOCHIM BIOPHYS ACTA, V508, P513, DOI 10.1016/0005-2736(78)90096-2; SHASHIDHAR MS, 1990, BIOCHIM BIOPHYS ACTA, V1042, P410, DOI 10.1016/0005-2760(90)90172-T; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; VACCA JP, 1989, TETRAHEDRON, V45, P5679, DOI 10.1016/S0040-4020(01)89510-7; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; VOLWERK JJ, 1994, BIOCHEMISTRY-US, V33, P3464, DOI 10.1021/bi00178a002; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010	36	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2517	2524		10.1074/jbc.270.6.2517	http://dx.doi.org/10.1074/jbc.270.6.2517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852313	hybrid			2022-12-25	WOS:A1995QF53500021
J	WANG, JX; KULISZEWSKI, M; YEE, W; SEDLACKOVA, L; XU, J; TSEU, I; POST, M				WANG, JX; KULISZEWSKI, M; YEE, W; SEDLACKOVA, L; XU, J; TSEU, I; POST, M			CLONING AND EXPRESSION OF GLUCOCORTICOID-INDUCED GENES IN PETAL RAT LUNG FIBROBLASTS - TRANSFORMING GROWTH FACTOR-BETA(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; TGF-BETA; PRETRANSLATIONAL LEVEL; PNEUMONOCYTE FACTOR; EPITHELIAL-CELLS; RNA EXPRESSION; MESSENGER-RNA; FETAL LUNG; TGF-BETA-1; DIFFERENTIATION	Glucocorticoids have been shown to accelerate fetal lung type II cell maturation, and this effect appears, in part, to be mediated via fibroblasts. To identify glucocorticoid induced genes in fetal lung fibroblasts, we screened a cDNA Library from cortisol-treated fetal lung fibroblasts with a subtracted cDNA probe which was enriched for sequences specific for cortisol-treated fetal lung fibroblasts. Fifty-seven clones were isolated from the cDNA library. One cDNA represented approximate to 30% of the 57 clones. Analysis of DNA sequence homology suggested that this cDNA encodes the rat transforming growth factor-beta(3) (TGF beta(3)). We found that TGF beta(3) mRNA was expressed in fetal lung fibroblasts but not epithelial cells. Expression of message in fetal lung fibroblasts was developmentally regulated. TGF beta(3) mRNA levels were low during the pseudoglandular stage (day 18), peaked during the early canalicular stage of lung development (day 19), then fell again at days 20 and 21 (term = 22 days). Exposure of fetal lung fibroblasts to cortisol increased TGF beta(3) mRNA expression in a time- and dose-dependent manner. Maternal administration of dexamethasone also enhanced mRNA expression of TGF beta(3) in fetal lung fibroblasts. These data suggest that glucocorticoids may mediate their stimulatory effect on lung maturation by inducing TGF beta(3) expression in fetal lung fibroblasts.	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DIV NEONATOL,MED RES COUNCIL,LUNG DEV GRP,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT PAEDIAT,DIV NEONATAL RES,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BASCOM CC, 1989, MOL CELL BIOL, V9, P5508, DOI 10.1128/MCB.9.12.5508; CANIGGIA I, 1991, AM J PHYSIOL, V261, pL424, DOI 10.1152/ajplung.1991.261.6.L424; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; FLOROS J, 1987, J BIOL CHEM, V262, P13592; FLOROS J, 1985, J BIOL CHEM, V260, P2265; FLOROS J, 1986, PROGR DEV BIOL, P333; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; JETTEN AM, 1986, EXP CELL RES, V167, P539, DOI 10.1016/0014-4827(86)90193-X; KELLEY J, 1993, AM J RESP CELL MOL, V8, P417, DOI 10.1165/ajrcmb/8.4.417; KELLEY J, 1991, AM J PHYSIOL, V260, pL123, DOI 10.1152/ajplung.1991.260.2.L123; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MILLER DA, 1989, MOL ENDOCRINOL, V3, P1926, DOI 10.1210/mend-3-12-1926; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; NIELSEN HC, 1992, BIOCHIM BIOPHYS ACTA, V1175, P95, DOI 10.1016/0167-4889(92)90014-3; PELTON RW, 1990, DEVELOPMENT, V110, P609; PIRCHER R, 1984, CANCER RES, V44, P5538; Post M, 1992, PULMONARY SURFACTANT, P379; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, V1, P419; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID P, 1991, DEVELOPMENT, V111, P117; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SMITH BT, 1993, CYTOKINES LUNG LUNG, P403; SMITH BT, 1989, AM J PHYSIOL, V1, pL174; SMITH BT, 1991, LUNG, V1, P671; THEODORESCU D, 1993, IN VITRO CELL DEV-AN, V29, P105; TORDAY JS, 1990, DEV BIOL, V139, P35, DOI 10.1016/0012-1606(90)90276-O; WHITSETT JA, 1987, J BIOL CHEM, V262, P7908	29	62	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2722	2728		10.1074/jbc.270.6.2722	http://dx.doi.org/10.1074/jbc.270.6.2722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852342	hybrid			2022-12-25	WOS:A1995QF53500051
J	JAYADEV, S; LIU, B; BIELAWSKA, AE; LEE, JY; NAZAIRE, F; PUSHKAREVA, MY; OBEID, LM; HANNUN, YA				JAYADEV, S; LIU, B; BIELAWSKA, AE; LEE, JY; NAZAIRE, F; PUSHKAREVA, MY; OBEID, LM; HANNUN, YA			ROLE FOR CERAMIDE IN CELL-CYCLE ARREST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NECROSIS-FACTOR-ALPHA; SPHINGOMYELIN TURNOVER; MEDIATED BIOLOGY; FREE SYSTEM; DIFFERENTIATION; ACTIVATION; SPHINGOSINE; EXPRESSION; APOPTOSIS	The dependence of some cell types on serum factors for growth may represent a powerful, but poorly studied, model for antimitogenic pathways, In this study, we examine ceramide as a candidate intracellular mediator of serum factor dependence. In Molt-4 leukemia cells, serum withdrawal caused a significant arrest in cell cycle progression (80% of cells in G(0)/G(1)), accompanied by a modest apoptotic cell death (12%), Serum deprivation of these cells resulted in significant sphingomyelin hydrolysis (72%; corresponding to hydrolysis of 47 pmol/nmol phosphate), which was accompanied by a profound and progressive elevation (up to 10-15-fold) in endogenous levels of ceramide, Withdrawal of serum caused the activation of a distinct, particulate, and magnesium-dependent sphingomyelinase. The addition of exogenous C-6-ceramide induced a dramatic arrest in the G(0)/G(1) phase of the cell cycle comparable to the effects observed with serum withdrawal, albeit occurring much sooner, Unlike serum withdrawal, however, the addition of C-6-ceramide resulted in more pronounced apoptosis, Because of the previously noted ability of exogenously added phorbol esters to inhibit ceramide-mediated apoptosis, we investigated the hypothesis that endogenous activation of the diacylglycerol/protein kinase C pathway may modulate the response to serum withdrawal. Indeed, serum withdrawal resulted in 3-4-fold elevation in endogenous diacylglycerol levels, The addition of exogenous diacylglycerols resulted in selective attenuation of ceramide's effects on apoptosis but not on cell cycle arrest, Thus, the combination of ceramide and diacylglycerol recapitulated the complex effects of serum withdrawal on cell cycle arrest and apoptosis, These studies identify a novel role for ceramide in cell cycle regulation, and they may provide the first evidence for an intracellular signal transduction pathway in mammalian cells mediating cell cycle arrest, These studies also underscore the importance of lipid second messengers and the significance of the, interplay between glycerolipid-derived and sphingolipid-derived lipid mediators.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University				obeid, lina/0000-0002-0734-0847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DEAN M, 1986, J BIOL CHEM, V261, P9161; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HEROLD P, 1988, HELV CHIM ACTA, V71, P354, DOI 10.1002/hlca.19880710208; HOWARD MK, 1993, J NEUROCHEM, V60, P1783, DOI 10.1111/j.1471-4159.1993.tb13404.x; ISHIZUKA T, 1989, FEBS LETT, V249, P234, DOI 10.1016/0014-5793(89)80630-1; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KIM MY, 1991, J BIOL CHEM, V266, P484; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PREISS J, 1986, J BIOL CHEM, V261, P8597; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173	31	450	461	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2047	2052		10.1074/jbc.270.5.2047	http://dx.doi.org/10.1074/jbc.270.5.2047			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836432	hybrid			2022-12-25	WOS:A1995QE49300013
J	NAIDU, A; QUON, D; CORDELL, B				NAIDU, A; QUON, D; CORDELL, B			BETA-AMYLOID PEPTIDE PRODUCED IN-VITRO IS DEGRADED BY PROTEINASES RELEASED BY CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-INHIBITOR DOMAIN; PRECURSOR MESSENGER-RNA; ALZHEIMERS-DISEASE; HUMAN-BRAIN; INVITRO; NEUROTOXICITY; EXPRESSION	The primary histopathological feature of Alzheimer's disease is the accumulation of beta-amyloid in the brains of afflicted individuals. This peptide has been shown to be produced and liberated both in vitro and in vivo by normal physiological processes. The mechanism by which beta-amyloid is formed, as well as that by which it may be cleared, are events likely to impact on the development and progression of this disease. Thus, the fate of beta-amyloid peptides secreted by cultured mammalian cells was investigated It was found that levels of the soluble peptide are reduced over time due to the activity of multiple types of proteinases including those from the metallo, aspartyl, and thiol classes, Inhibitors to each class of proteinase can only partially block beta-amyloid degradation, but, if used in combination, they can fully prevent its catabolism. The Kunitz serine proteinase inhibitor domain, present on two beta-amyloid precursor protein isoforms, was found to be an effective inhibitor of beta-amyloid peptide degradation. These data indicate that modulations in expression of secreted proteinases and/or beta-amyloid precursor isoforms may influence levels of beta-amyloid.	SCIOS NOVA INC,MT VIEW,CA 94043	Scios								BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; COTMAN CW, 1992, NEUROBIOL AGING, V13, P587, DOI 10.1016/0197-4580(92)90060-B; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; JOHNSON SA, 1988, EXP NEUROL, V102, P264, DOI 10.1016/0014-4886(88)90104-5; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDO H, 1990, BIOCHEM BIOPH RES CO, V167, P716, DOI 10.1016/0006-291X(90)92084-D; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; LANDSBURY PT, 1992, BIOCHEMISTRY-US, V31, P6865; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SCHILLING J, 1991, GENE, V98, P225, DOI 10.1016/0378-1119(91)90177-D; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1993, SCIENCE, V258, P126; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	29	41	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1369	1374		10.1074/jbc.270.3.1369	http://dx.doi.org/10.1074/jbc.270.3.1369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836404	hybrid			2022-12-25	WOS:A1995QB15600059
J	PFEIFFER, DR; GUDZ, TI; NOVGORODOV, SA; ERDAHL, WL				PFEIFFER, DR; GUDZ, TI; NOVGORODOV, SA; ERDAHL, WL			THE PEPTIDE MASTOPARAN IS A POTENT FACILITATOR OF THE MITOCHONDRIAL PERMEABILITY TRANSITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; RAT-LIVER MITOCHONDRIA; FREEZE-THAW EXTRUSION; WASP VENOM PEPTIDE; CYCLOSPORINE-A; MEMBRANE-PERMEABILITY; HEART-MITOCHONDRIA; INNER MEMBRANE; CA-2+ RELEASE; OXIDATIVE STRESS	Mastoparan facilitates opening of the mitochondrial permeability transition pore through an apparent bimodal mechanism of action, In the submicromolar concentration range, the action of mastoparan is dependent upon the medium Ca2+ and phosphate concentration and is subject to inhibition by cyclosporin A, At concentrations above 1 mu M, pore induction by mastoparan occurs without an apparent Ca2+ requirement and in a cyclosporin A insensitive manner, Studies utilizing phospholipid vesicles show that mastoparan perturbs bilayer membranes across both concentration ranges, through a mechanism which is strongly dependent upon transmembrane potential, However, solute size exclusion studies suggest that the pores formed in mitochondria in response to both low and high concentrations of mastoparan are the permeability transition pore, It is proposed that low concentrations of mastoparan influence the pore per se, with higher concentrations having the additional effect of depolarizing the mitochondrial inner membrane through an action exerted upon the lipid phase. It may be the combination of these effects which allow pore opening in the absence of Ca2+ and in the presence of cyclosporin A, although other interpretations remain viable, A comparison of the activities of mastoparan and its analog, MP14, on mitochondria and phospholipid vesicles provides an initial indication that a G-protein may participate in regulation of the permeability transition pore, These studies draw attention to peptides, in a broad sense, as potential pore regulators in cells, under both physiological and pathological conditions.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912	University of Minnesota System	PFEIFFER, DR (corresponding author), OHIO STATE UNIV,COLL MED,DEPT BIOCHEM MED,310A HAMILTON HALL,1645 NEIL AVE,COLUMBUS,OH 43210, USA.				NHLBI NIH HHS [HL 36124, HL 49181, HL 49182] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049182, R01HL049181, R01HL036124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; Barlett G.R., 1959, J BIOL CHEM, V234, P466; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BROEKEMEIER KM, 1992, FEBS LETT, V304, P192, DOI 10.1016/0014-5793(92)80616-O; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1991, J BIOL CHEM, V266, P20700; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; BROEKEMEIER KM, 1988, J BIOL CHEM, V264, P7826; CHAPMAN CJ, 1991, CHEM PHYS LIPIDS, V60, P201, DOI 10.1016/0009-3084(91)90042-A; CHAPMAN CJ, 1990, CHEM PHYS LIPIDS, V55, P73, DOI 10.1016/0009-3084(90)90068-3; COLOMBINI M, 1980, J MEMBRANE BIOL, V53, P79, DOI 10.1007/BF01870576; CROMPTON M, 1988, BIOCHEM J, V255, P357; DANILENKO M, 1993, BIOCHEM BIOPH RES CO, V196, P1296, DOI 10.1006/bbrc.1993.2393; DANILENKO M, 1991, BIOCHEM BIOPH RES CO, V196, P1296; EISENBERG M, 1973, J MEMBRANE BIOL, V14, P143, DOI 10.1007/BF01868075; ERDAHL WL, 1994, BIOPHYS J, V66, P1678, DOI 10.1016/S0006-3495(94)80959-2; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0; GLAVINOVIC MI, 1992, NEUROSCIENCE, V50, P675, DOI 10.1016/0306-4522(92)90456-C; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIRAI Y, 1981, BIOMED RES-TOKYO, V2, P447, DOI 10.2220/biomedres.2.447; HIRAI Y, 1980, BIOMED RES-TOKYO, V1, P185, DOI 10.2220/biomedres.1.185; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1945; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1942; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; IGBAVBOA U, 1991, BIOCHIM BIOPHYS ACTA, V1059, P339, DOI 10.1016/S0005-2728(05)80219-1; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; JOYCEBRADY M, 1991, J BIOL CHEM, V266, P6859; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; KATSU T, 1990, BIOCHIM BIOPHYS ACTA, V1027, P185, DOI 10.1016/0005-2736(90)90083-Z; KINNALLY KW, 1992, J BIOENERG BIOMEMBR, V24, P99, DOI 10.1007/BF00769536; KOMATSU M, 1993, J BIOL CHEM, V268, P23297; LATORRE R, 1981, PHYSIOL REV, V61, P77, DOI 10.1152/physrev.1981.61.1.77; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; LEQUOC K, 1985, J BIOL CHEM, V260, P7422; LITHGOW T, 1991, BIOCHEM BIOPH RES CO, V180, P1453, DOI 10.1016/S0006-291X(05)81359-2; NAZARETH W, 1991, J MOL CELL CARDIOL, V23, P1351, DOI 10.1016/0022-2828(91)90181-K; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; NOVGORODOV SA, 1993, BIOPHYS J, V64, pA107; OZAKI Y, 1990, BIOCHEM BIOPH RES CO, V170, P779, DOI 10.1016/0006-291X(90)92159-W; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PERIANIN A, 1989, J IMMUNOL, V143, P1669; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; RAYNOR RL, 1992, FEBS LETT, V307, P275, DOI 10.1016/0014-5793(92)80694-C; RILEY WW, 1985, J BIOL CHEM, V260, P2416; SCHILLER LR, 1988, GASTROENTEROLOGY, V94, P933, DOI 10.1016/0016-5085(88)90550-1; STOCCHI V, 1985, ANAL BIOCHEM, V146, P118, DOI 10.1016/0003-2697(85)90405-1; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; TAKEDA S, 1993, J BIOCHEM-TOKYO, V114, P684, DOI 10.1093/oxfordjournals.jbchem.a124237; TANIMURA A, 1991, BIOCHEM BIOPH RES CO, V177, P802, DOI 10.1016/0006-291X(91)91860-F; VERCESI AE, 1984, ARCH BIOCHEM BIOPHYS, V232, P86, DOI 10.1016/0003-9861(84)90523-X; VODYANOY I, 1993, BIOPHYS J, V65, P2097, DOI 10.1016/S0006-3495(93)81245-1; WALLACE MA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P311, DOI 10.1016/0005-2760(89)90018-0; WHEELERJONES CPD, 1992, BIOCHEM J, V281, P465, DOI 10.1042/bj2810465; WINGROVE DE, 1986, J BIOL CHEM, V261, P5166; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; YOKOKAWA N, 1989, BIOCHEM BIOPH RES CO, V158, P712, DOI 10.1016/0006-291X(89)92779-4; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	68	184	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4923	4932		10.1074/jbc.270.9.4923	http://dx.doi.org/10.1074/jbc.270.9.4923			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876267	hybrid			2022-12-25	WOS:A1995QK08400105
J	POWELL, BS; COURT, DL; INADA, T; NAKAMURA, Y; MICHOTEY, V; CUI, XW; REIZER, A; SAIER, MH; REIZER, J				POWELL, BS; COURT, DL; INADA, T; NAKAMURA, Y; MICHOTEY, V; CUI, XW; REIZER, A; SAIER, MH; REIZER, J			NOVEL PROTEINS OF THE PHOSPHOTRANSFERASE SYSTEM ENCODED WITHIN THE RPON OPERON OF ESCHERICHIA-COLI - ENZYME IIA(NTR) AFFECTS GROWTH ON ORGANIC NITROGEN AND THE CONDITIONAL LETHALITY OF AN ERA(TS) MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GRAM-POSITIVE BACTERIA; SITE-SPECIFIC MUTAGENESIS; RHIZOBIUM-MELILOTI NTRA; AMINO-ACID SEQUENCE; SIGMA-FACTOR GENE; NUCLEOTIDE-SEQUENCE; SALMONELLA-TYPHIMURIUM; PHOSPHOCARRIER PROTEIN; BACILLUS-SUBTILIS; STAPHYLOCOCCUS-CARNOSUS	Two rpoN-linked Delta Tn10-kan insertions suppress the conditionally lethal era(ts) allele. One truncates rpoN while the second disrupts another gene (ptsN) in the rpoN operon and does not affect classical nitrogen regulation. Neither alter expression of era indicating that suppression is post-translational. Plasmid clones of ptsN prevent suppression by either disruption mutation indicating that this gene is important for lethality caused by era(ts). rpoN and six neighboring genes were sequenced and compared with sequences in the database. Two of these genes encode proteins homologous to Enzyme IIA(Fru) and HPr of the phosphoenolpyruvate:sugar phosphotransferase system. We designate these proteins IIA(Ntr) (ptsN) and NPr (npr). Purified IIA(Ntr) and NPr exchange phosphate appropriately with Enzyme I, HPr, and Enzyme IIA proteins of the phosphoenolpyruvate: sugar phosphotransferase system. Several sugars and tricarboxylic acid cycle intermediates inhibited growth of the ptsN disruption mutant on medium containing an amino acid or nucleoside base as a combined source of nitrogen, carbon, and energy. This growth inhibition was relieved by supplying the ptsN gene or ammonium salts but was not aleviated by altering levels of exogenously supplied cAMP. These results support our previous proposal of a novel mechanism linking carbon and nitrogen assimilation and relates IIA(Ntr) to the unknown process regulated by the essential GTPase Era.	NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, CHROMOSOME BIOL LAB, FREDERICK, MD 21702 USA; UNIV TOKYO, INST MED SCI, DEPT TUMOR BIOL, TAKANAWA 108, JAPAN; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Tokyo; University of California System; University of California San Diego			Michotey, Valerie/AAA-4397-2021	Michotey, Valerie/0000-0001-6639-2877	NCI NIH HHS [N01-CO74101] Funding Source: Medline; NIAID NIH HHS [5RO1AI 21702, 2RO1AI 14176] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702, R01AI014176] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT LM, 1989, J BACTERIOL, V171, P1932, DOI 10.1128/jb.171.4.1932-1941.1989; ALIAS A, 1989, NUCLEIC ACIDS RES, V17, P5377, DOI 10.1093/nar/17.13.5377; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BALBAS P, 1993, GENE, V136, P211, DOI 10.1016/0378-1119(93)90466-G; BERGER DK, 1990, J BACTERIOL, V172, P4399, DOI 10.1128/jb.172.8.4399-4406.1990; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; BOYD DA, 1994, INFECT IMMUN, V62, P1156, DOI 10.1128/IAI.62.4.1156-1165.1994; BRUN YV, 1992, GENE DEV, V6, P2395, DOI 10.1101/gad.6.12a.2395; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASTANO I, 1984, MOL GEN GENET, V195, P228, DOI 10.1007/BF00332751; CHEN SM, 1990, J BIOL CHEM, V265, P2888; CONTESSE G, 1969, LACTOSE OPERON, P401; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P9092, DOI 10.1073/pnas.88.20.9092; DEREUSE H, 1985, GENE, V35, P199; DEUTSCHER J, 1994, J BACTERIOL, V176, P3336, DOI 10.1128/jb.176.11.3336-3344.1994; DEUTSCHER J, 1986, BIOCHEMISTRY-US, V25, P6543, DOI 10.1021/bi00369a031; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXON RA, 1984, J GEN MICROBIOL, V130, P2745; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; EHRT S, 1994, J BACTERIOL, V176, P3493, DOI 10.1128/JB.176.12.3493-3499.1994; EISERMANN R, 1991, EUR J BIOCHEM, V197, P9, DOI 10.1111/j.1432-1033.1991.tb15875.x; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FISCHER R, 1991, J BACTERIOL, V173, P3709, DOI 10.1128/JB.173.12.3709-3715.1991; FISCHER R, 1989, GENE, V82, P249, DOI 10.1016/0378-1119(89)90050-4; GAGNON G, 1992, Journal of Dental Research, V72, P733; GAVINI N, 1990, J BIOL CHEM, V265, P21532; GEERSE RH, 1989, MOL GEN GENET, V216, P517, DOI 10.1007/BF00334399; GONZYTREBOUL G, 1989, MOL MICROBIOL, V3, P103, DOI 10.1111/j.1365-2958.1989.tb00109.x; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HONEYMAN AL, 1992, INFECT IMMUN, V60, P3369, DOI 10.1128/IAI.60.8.3369-3375.1992; HUDSON GS, 1984, J MOL BIOL, V180, P1023, DOI 10.1016/0022-2836(84)90269-9; IMAISHI H, 1993, J BACTERIOL, V175, P1550, DOI 10.1128/JB.175.5.1550-1551.1993; INADA T, 1989, J BACTERIOL, V171, P5017, DOI 10.1128/jb.171.9.5017-5024.1989; INADA T, 1992, FUNCTIONAL STUDY RNC; INOUYE S, 1989, GENE, V85, P145; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JIN SG, 1994, J BACTERIOL, V176, P1316, DOI 10.1128/jb.176.5.1316-1322.1994; JONES DHA, 1994, MICROBIOL-SGM, V140, P1035, DOI 10.1099/13500872-140-5-1035; JONES R, 1989, MOL GEN GENET, V215, P507, DOI 10.1007/BF00427050; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOHLER T, 1989, NUCLEIC ACIDS RES, V17, P10125, DOI 10.1093/nar/17.23.10125; KOHLER T, 1994, FEMS MICROBIOL LETT, V115, P177, DOI 10.1016/0378-1097(94)90010-8; KULLIK I, 1991, J BACTERIOL, V173, P1125, DOI 10.1128/jb.173.3.1125-1138.1991; KUNDIG W, 1971, J BIOL CHEM, V246, P1393; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1986, REGULATION GENE EXPR, P139; LEE CA, 1983, J BIOL CHEM, V258, P761; LERNER CG, 1991, MOL MICROBIOL, V5, P951, DOI 10.1111/j.1365-2958.1991.tb00770.x; LONDON J, 1983, J BACTERIOL, V156, P611, DOI 10.1128/JB.156.2.611-619.1983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGASANIK B, 1982, ANNU REV GENET, V16, P135, DOI 10.1146/annurev.ge.16.120182.001031; MAGASANIK B, 1993, J CELL BIOCHEM, V51, P34, DOI 10.1002/jcb.240510108; MAGASANIK B, 1987, ESCHERICHIA COLI SAL, P302; MAGASANIK B, 1987, ESCHERICHIA COLI SAL, P1318; MARCH PE, 1988, ONCOGENE, V2, P539; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MATTOO RL, 1983, ANAL BIOCHEM, V128, P245, DOI 10.1016/0003-2697(83)90372-X; MCCLEARY WR, 1993, J BACTERIOL, V175, P2793, DOI 10.1128/JB.175.10.2793-2798.1993; MEIJER WG, 1992, J BACTERIOL, V174, P3855, DOI 10.1128/jb.174.12.3855-3866.1992; MERRICK M, 1987, MOL GEN GENET, V210, P323, DOI 10.1007/BF00325701; Merrick M. J., 1988, The Nitrogen and Sulphur Cycles. Proceedings of the 42nd Symposium of the Society for General Microbiology. Southampton, UK, January 1988., P331; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MERRICK MJ, 1985, NUCLEIC ACIDS RES, V13, P7607, DOI 10.1093/nar/13.21.7607; MERRICK MJ, 1989, MOL MICROBIOL, V3, P1765, DOI 10.1111/j.1365-2958.1989.tb00162.x; Miller J.H., 1992, SHORT COURSE BACTERI, P150; ORCHARD LMD, 1990, P ROY SOC B-BIOL SCI, V242, P87, DOI 10.1098/rspb.1990.0108; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POPHAM D, 1991, J BIOL CHEM, V266, P19510; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; POWERS DA, 1984, J BIOL CHEM, V259, P5212; PRIES A, 1991, J BACTERIOL, V173, P5843, DOI 10.1128/jb.173.18.5843-5853.1991; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; REICHE B, 1988, BIOCHEMISTRY-US, V27, P6512, DOI 10.1021/bi00417a047; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1993, J CELL BIOCHEM, V51, P19, DOI 10.1002/jcb.240510105; REIZER J, 1992, PROTEIN SCI, V1, P722, DOI 10.1002/pro.5560010604; REIZER J, 1994, FEMS MICROBIOL LETT, V118, P159, DOI 10.1111/j.1574-6968.1994.tb06819.x; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; REIZER J, 1994, PROTEIN SCI, V3, P440; REIZER J, 1988, CRC CR REV MICROBIOL, V15, P297, DOI 10.3109/10408418809104461; REIZER J, 1993, PROTEIN SCI, V2, P506; REIZER J, 1994, METHODS MOL BIOL COM, P319; RONSON CW, 1987, J BACTERIOL, V169, P2424, DOI 10.1128/jb.169.6.2424-2431.1987; RUDD KE, 1992, SHORT COURSE BACTERI; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAIER MH, 1994, MOL MICROBIOL, V13, P755; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SCHNEIDER BL, 1991, J BACTERIOL, V173, P6355, DOI 10.1128/jb.173.20.6355-6363.1991; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SHATTERS RG, 1989, J BACTERIOL, V171, P5087, DOI 10.1128/jb.171.9.5087-5094.1989; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SINGER M, 1989, MICROBIOL REV, V53, P1; SMITH DW, 1988, COMPUT APPL BIOSCI, V4, P212; SMITH GR, 1971, J BIOL CHEM, V246, P3320; SOOD P, 1994, MOL MICROBIOL, V12, P201, DOI 10.1111/j.1365-2958.1994.tb01009.x; SPRENGER GA, 1993, BIOCHIM BIOPHYS ACTA, V1158, P103, DOI 10.1016/0304-4165(93)90103-F; STIGTER J, 1993, MOL PLANT MICROBE IN, V6, P238, DOI 10.1094/MPMI-6-238; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; SUTRINA SL, 1988, J BIOL CHEM, V263, P5061; SUTRINA SL, 1990, J BIOL CHEM, V265, P18581; TAKIFF HE, 1989, J BACTERIOL, V171, P2581, DOI 10.1128/jb.171.5.2581-2590.1989; TIGEMEYER F, 1990, NUCLEIC ACIDS RES, V18, P1898, DOI 10.1093/nar/18.7.1898; ULLMANN A, 1969, P FOGARTY INT CTR, V4, P215; VANSLOOTEN JC, 1990, J BACTERIOL, V172, P5563, DOI 10.1128/jb.172.10.5563-5574.1990; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARRELMANN J, 1992, ARCH MICROBIOL, V158, P107, DOI 10.1007/BF00245213; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; WENG QP, 1992, J BIOL CHEM, V267, P19529; WU LF, 1990, J MOL BIOL, V213, P687, DOI 10.1016/S0022-2836(05)80256-6; YE JJ, 1994, P NATL ACAD SCI USA, V91, P3102, DOI 10.1073/pnas.91.8.3102; YE JJ, 1994, J BIOL CHEM, V269, P11837; ZHU PP, 1993, J BIOL CHEM, V268, P26531; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4514, DOI 10.1073/pnas.84.13.4514	123	187	198	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4822	4839		10.1074/jbc.270.9.4822	http://dx.doi.org/10.1074/jbc.270.9.4822			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876255	hybrid			2022-12-25	WOS:A1995QK08400092
J	ROUQUIER, S; LOWE, JB; KELLY, RJ; FERTITTA, AL; LENNON, GG; GIORGI, D				ROUQUIER, S; LOWE, JB; KELLY, RJ; FERTITTA, AL; LENNON, GG; GIORGI, D			MOLECULAR-CLONING OF A HUMAN GENOMIC REGION CONTAINING THE H-BLOOD-GROUP ALPHA(1,2)FUCOSYLTRANSFERASE GENE AND 2 H-LOCUS-RELATED DNA RESTRICTION FRAGMENTS - ISOLATION OF A CANDIDATE FOR THE HUMAN SECRETOR BLOOD-GROUP LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; INTERPHASE CELL-NUCLEI; HUMAN CHROMOSOME-19; ALU-PCR; DETERMINES EXPRESSION; STRUCTURAL GENE; LEWIS-X; SEQUENCES; ASSIGNMENT	We have used the human H blood group alpha(1,2)fucosyltransferase (FUT1) cDNA to screen chromosome 19 cosmid libraries in a search for the human Secretor (Se) blood group gene (FUT2), One cosmid has been isolated that contains two distinct segments that cross-hybridize with FUT1. We have assembled a 100-kilobase (kb) cosmid contig, localized to 19q13,3, encompassing FUT1 and the two FUT1-related sequences, termed Sec1 and Sec2, for Secretor candidate 1 and 2, Sec1 and Sec2 are separated by 12 kb and are 65.5 kb and 35 kb apart, respectively, from the FUT1 gene, We used a cosmid-dependent direct cDNA selection method to clone a cDNA corresponding to a transcript that emanates from Sec2. This cDNA detects a 3.35-kb transcript in human tissues known to express the Se locus, Together with sequence and expression data reported in the accompanying article (Kelly, R, J., Rouquier, S., Giorgi, D., Lennon, G. G., and Lowe, J. B. (1995) J. Biol. Chem. 270, 4640-4649), these data demonstrate that Sec2 corresponds to the human Se blood group locus (FUT2), Our results further more define the physical relationship between the LT and Se loci and confirm a hypothesis that these two loci represent distinct but closely linked alpha(1,2)fucosyltransferase genes	LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,BIOL & BIOTECHNOL RES PROGRAM,LIVERMORE,CA 94550; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48105; UNIV MICHIGAN,MED CTR,DEPT PATHOL,ANN ARBOR,MI 48105	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Lennon, Greg/T-4717-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048859] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HL48859] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASLANIDIS C, 1991, P NATL ACAD SCI USA, V88, P6765, DOI 10.1073/pnas.88.15.6765; BALL S, 1984, CYTOGENET CELL GENET, V37, P411; BALL SP, 1991, ANN HUM GENET, V55, P225, DOI 10.1111/j.1469-1809.1991.tb00417.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLASZCZYKTHURIN M, 1988, BIOCHEM BIOPH RES CO, V151, P100, DOI 10.1016/0006-291X(88)90564-5; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; COLE CG, 1991, GENOMICS, V10, P816, DOI 10.1016/0888-7543(91)90468-T; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; EIBERG H, 1983, CLIN GENET, V24, P159; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEMMILL RM, 1987, GENE ANAL TECH, V4, P119, DOI 10.1016/0735-0651(87)90010-0; GIBSON TJ, 1987, GENE, V53, P275, DOI 10.1016/0378-1119(87)90016-3; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; KUIJPERS TW, 1993, BLOOD, V81, P873; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LENGAUER C, 1992, GENOMICS, V13, P826, DOI 10.1016/0888-7543(92)90160-T; LEPENDU J, 1985, AM J HUM GENET, V37, P749; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MOHR J, 1951, ACTA PATHOL MIC SC, V28, P339; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; OLSEN AS, 1993, BIOTECHNIQUES, V14, P116; ORIOL R, 1981, AM J HUM GENET, V33, P421; ORIOL R, 1990, J IMMUNOGENET, V17, P235; ORIOL R, 1984, CYTOGENET CELL GENET, V37, P564; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PONTAROTTI P, 1988, NUCLEIC ACIDS RES, V16, P6767, DOI 10.1093/nar/16.14.6767; ROUQUIER S, 1994, CYTOGENET CELL GENET, V66, P70, DOI 10.1159/000133668; ROUQUIER S, 1993, GENOMICS, V17, P330, DOI 10.1006/geno.1993.1329; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEIZER D, 1976, CHROMOSOMA, V58, P307, DOI 10.1007/BF00292840; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SHUTLER G, 1992, GENOMICS, V13, P518, DOI 10.1016/0888-7543(92)90119-D; SICILIANO MJ, 1986, MUTAT RES, V174, P303, DOI 10.1016/0165-7992(86)90051-5; SMITH DF, 1990, J BIOL CHEM, V265, P6225; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; TRASK B, 1993, GENOMICS, V15, P133, DOI 10.1006/geno.1993.1021; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; TRASK B, 1992, GENOMICS, V14, P162, DOI 10.1016/S0888-7543(05)80299-X; TRASK BJ, 1991, AM J HUM GENET, V48, P1; TUCKER JD, 1988, CYTOGENET CELL GENET, V48, P103, DOI 10.1159/000132600; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; Watkins W M, 1980, Adv Hum Genet, V10, P1; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WHITEHEAD AS, 1982, P NATL ACAD SCI-BIOL, V79, P5021, DOI 10.1073/pnas.79.16.5021	55	152	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4632	4639		10.1074/jbc.270.9.4632	http://dx.doi.org/10.1074/jbc.270.9.4632			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876234	hybrid			2022-12-25	WOS:A1995QK08400068
J	BUBB, MR; SPECTOR, I; BERSHADSKY, AD; KORN, ED				BUBB, MR; SPECTOR, I; BERSHADSKY, AD; KORN, ED			SWINHOLIDE-A IS A MICROFILAMENT DISRUPTING MARINE TOXIN THAT STABILIZES ACTIN DIMERS AND SEVERS ACTIN-FILAMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SPONGE THEONELLA-SWINHOEI; F-ACTIN; CYTOCHALASIN-D; POLYMERIZATION; GELSOLIN; BINDING; MACROLIDE; DEPOLYMERIZATION; PENTOXIFYLLINE; ORGANIZATION	Swinholide A, isolated from the marine sponge Theonella swinhoei, is a 44-carbon ring dimeric dilactone macrolide with a 2-fold axis of symmetry. Recent studies have elucidated its unusual structure and shown that it has potent cytotoxic activity, We now report that swinholide A disrupts the actin cytoskeleton of cells grown in culture, sequesters actin dimers in vitro in both polymerizing and non-polymerizing buffers with a binding stoichiometry of one swinholide A molecule per actin dimer, and rapidly severs F-actin in vitro with high cooperativity, These unique properties are sufficient to explain the cytotoxicity of swinholide A. They also suggest that swinholide A might be a model for studies of the mechanism of action of F-actin severing proteins and be therapeutically useful in conditions where filamentous actin contributes to pathologically high viscosities.	NHLBI,CELL BIOL LAB,BETHESDA,MD 20892; SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Weizmann Institute of Science			Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295; Bershadsky, Alexander/0000-0002-9571-7375				BEARER EL, 1991, J CELL BIOL, V115, P1629, DOI 10.1083/jcb.115.6.1629; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CARMELY S, 1985, TETRAHEDRON LETT, V26, P511, DOI 10.1016/S0040-4039(00)61925-1; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; DOI M, 1991, J ORG CHEM, V56, P3629, DOI 10.1021/jo00011a033; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; GERSHMAN LC, 1984, BIOCHEMISTRY-US, V23, P2199, DOI 10.1021/bi00305a015; GODDETTE DW, 1985, BIOCHEM BIOPH RES CO, V128, P1087, DOI 10.1016/0006-291X(85)91051-4; HESTERKAMP T, 1993, EUR J BIOCHEM, V218, P507, DOI 10.1111/j.1432-1033.1993.tb18403.x; KIRKWOOD JG, 1954, J POLYM SCI, V12, P1, DOI 10.1002/pol.1954.120120102; KOBAYASHI M, 1990, CHEM PHARM BULL, V38, P2409; KOBAYASHI M, 1994, CHEM PHARM BULL, V42, P19; KORTHUIS RJ, 1991, J APPL PHYSIOL, V71, P1261, DOI 10.1152/jappl.1991.71.4.1261; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; MARUYAMA K, 1980, BIOCHIM BIOPHYS ACTA, V626, P494; MIHASHI K, 1964, ARCH BIOCHEM BIOPHYS, V107, P441, DOI 10.1016/0003-9861(64)90300-5; MILLONIG R, 1988, J CELL BIOL, V106, P785, DOI 10.1083/jcb.106.3.785; MORRIS A, 1980, NATURE, V287, P638; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; PATERSON I, 1994, J AM CHEM SOC, V116, P9391, DOI 10.1021/ja00099a091; PATTERSON GML, 1993, CELL MOTIL CYTOSKEL, V24, P39, DOI 10.1002/cm.970240105; PORTUGAL J, 1988, BIOCHIM BIOPHYS ACTA, V949, P158, DOI 10.1016/0167-4781(88)90079-6; RAO KMK, 1988, J CELL PHYSIOL, V137, P577, DOI 10.1002/jcp.1041370326; Senderowicz A. M. J., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P409; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SPUDICH JA, 1971, J BIOL CHEM, V246, P4865; SUN HQ, 1994, J BIOL CHEM, V269, P9473; TODD JS, 1992, TETRAHEDRON LETT, V33, P441, DOI 10.1016/S0040-4039(00)93962-5; VANLEENEN D, 1993, J IMMUNOL, V151, P2318; VASCONCELLOS CA, 1994, SCIENCE, V263, P969, DOI 10.1126/science.8310295; WALLING EA, 1988, ARCH BIOCHEM BIOPHYS, V264, P321, DOI 10.1016/0003-9861(88)90600-5; WODNICKA M, 1992, FOLIA HISTOCHEM CYTO, V30, P107; YIN HL, 1981, J BIOL CHEM, V256, P9693	37	153	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3463	3466		10.1074/jbc.270.8.3463	http://dx.doi.org/10.1074/jbc.270.8.3463			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876075	hybrid			2022-12-25	WOS:A1995QH68800001
J	DESTROOPER, B; CRAESSAERTS, K; DEWACHTER, I; MOECHARS, D; GREENBERG, B; VANLEUVEN, F; VANDENBERGHE, H				DESTROOPER, B; CRAESSAERTS, K; DEWACHTER, I; MOECHARS, D; GREENBERG, B; VANLEUVEN, F; VANDENBERGHE, H			BASOLATERAL SECRETION OF AMYLOID PRECURSOR PROTEIN IN MADIN-DARBY CANINE KIDNEY-CELLS IS DISTURBED BY ALTERATIONS OF INTRACELLULAR PH AND BY INTRODUCING A MUTATION ASSOCIATED WITH FAMILIAL ALZHEIMERS-DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY CEREBRAL-HEMORRHAGE; BETA-PROTEIN; HIPPOCAMPAL-NEURONS; CULTURED-CELLS; MDCK CELLS; H+-ATPASE; NEXIN-II; GENE; CLEAVAGE; PEPTIDE	The analysis of potential sorting signals in amyloid precursor protein (APP) by site-directed mutagenesis and the disturbance of metabolic pathways by drugs is used here to define the parameters that determine polarized secretion of APP in Madin-Darby canine kidney cells. Endogenously produced APP751/770 and APP695 produced from transfected constructs are secreted almost exclusively into the basolateral compartment. The sorting mechanism is highly dependent on intracellular pH as demonstrated by its sensitivity to primary amines and inhibitors of the acidifying vacuolar proton ATPase. The role of potential basolateral sorting signals in the cytoplasmic, transmembrane, and beta A4 amyloid region of APP was investigated. Neither deletion of the endocytosis and putative basolateral sorting signal GY.NPTY nor complete deletion of the cytoplasmic domain causes apical secretion of soluble APP. Further deletion of the transmembrane domain and of the beta A4 amyloid region confirmed that the major basolateral sorting determinant resides in the extracellular domain of APP. Increased beta-secretase cleavage of APP after introduction of the ''swedish'' double mutation causes apical missorting of about 20% of beta-secretase-cleaved APP. The data underline the complexity of processing and sorting APP in polarized cells and suggest a possible problem of protein sorting in Alzheimer's Disease.	KATHOLIEKE UNIV LEUVEN,CTR HUMAN GENET,DEPT HUMAN GENET,EXPTL GENET GRP,B-3000 LOUVAIN,BELGIUM; CEPHALON INC,W CHESTER,PA 19380	KU Leuven; Teva Pharmaceutical Industries; Cephalon Inc.			de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012	De Strooper, Bart/0000-0001-5455-5819; , Ilse Dewachter/0000-0001-7202-515X				BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLARK RF, 1993, ARCH NEUROL-CHICAGO, V50, P1164, DOI 10.1001/archneur.1993.00540110044004; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DESTROOPER B, 1991, EUR J BIOCHEM, V199, P25; DESTROOPER B, 1992, FEBS LETT, V308, P50, DOI 10.1016/0014-5793(92)81048-Q; DESTROOPER B, 1991, BIOCHIM BIOPHYS ACTA, V1129, P141, DOI 10.1016/0167-4781(91)90231-A; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HAASS C, 1995, IN PRESS J CELL BIOL; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HUBER LA, 1993, J CELL BIOL, V123, P47, DOI 10.1083/jcb.123.1.47; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MARTIN GM, 1990, NATURE, V347, P124, DOI 10.1038/347124a0; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; PIKE CJ, 1993, J NEUROSCI, V13, P1676; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SEILER N, 1993, NEUROCHEM RES, V18, P235, DOI 10.1007/BF00969079; SHOJI M, 1992, SCIENCE, V253, P126; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; VANLEUVEN F, 1980, CELL, V20, P37, DOI 10.1016/0092-8674(80)90232-9; VANLEUVEN F, 1982, TRENDS BIOCHEM SCI, V7, P185, DOI 10.1016/0968-0004(82)90135-9; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YANKNER BA, 1990, P NATL ACAD SCI USA, V87, P9020, DOI 10.1073/pnas.87.22.9020; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; ZEUZEM S, 1992, J MEMBRANE BIOL, V125, P231; ZHONG ZY, 1994, J BIOL CHEM, V269, P627	52	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4058	4065		10.1074/jbc.270.8.4058	http://dx.doi.org/10.1074/jbc.270.8.4058			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876155	hybrid			2022-12-25	WOS:A1995QH68800088
J	JIANG, SW; SHEPARD, AR; EBERHARDT, NL				JIANG, SW; SHEPARD, AR; EBERHARDT, NL			AN INITIATOR ELEMENT IS REQUIRED FOR MAXIMAL HUMAN CHORIONIC SOMATOMAMMOTROPIN GENE PROMOTER AND ENHANCER FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLACENTAL-LACTOGEN; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; TATA BOX; INVITRO FUNCTION; BINDING; SEQUENCES; PREGNANCY; COMPLEX; SP1	Previous studies have indicated that cell-specific expression of the human chorionic somatomammotropin (hCS) gene may be mediated by a placental-specific enhancer (CSEn). In the current studies, we have analyzed the promoter elements that are required for enhancer and promoter function in choriocarcinoma cells (BeWo). Mutation of both hCS GHF1 sites had no effect on promoter or enhancer activity. In contrast, mutation of the Spl site diminished basal and CSEn-stimulated transcription by approximate to 75% and approximate to 56%, respectively, indicating that Spl was necessary but not sufficient for maximal basal and enhancer-mediated transcription. Deletion and site-specific mutation of the proximal promoter region indicated that the TATA box and an initiator site (InrE) located between nucleotides -15/+1 of the hCS promoter were required for maximal promoter and enhancer function. Mutations of the InrE were associated with reduced basal and enhancer-stimulated activities and altered transcription initiation sites. A protein of 70-kDa mass, that was preferentially expressed in human choriocarcinoma cells (BeWo and JEG-3), bound specifically to the InrE. The data suggest that an initiator present in high concentrations in placental cells contributes to the control of cell-specific hCS gene expression at the promoter level and is required for maximal enhancer function.	MAYO CLIN & MAYO FDN,SMH,DEPT MED,ENDOCRINE RES UNIT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM MOLEC BIOL,ENDOCRINE RES UNIT,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BORODY IB, 1981, BRIT J OBSTET GYNAEC, V88, P447, DOI 10.1111/j.1471-0528.1981.tb01011.x; BRELJE TC, 1993, ENDOCRINOLOGY, V132, P879, DOI 10.1210/en.132.2.879; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; FITZPATRICK SL, 1990, MOL ENDOCRINOL, V4, P1815, DOI 10.1210/mend-4-12-1815; FREEMARK M, 1989, J CLIN INVEST, V83, P883, DOI 10.1172/JCI113972; FREEMARK M, 1993, ENDOCRINOLOGY, V133, P1830, DOI 10.1210/en.133.4.1830; HANDWERGER S, 1991, ENDOCR REV, V12, P329, DOI 10.1210/edrv-12-4-329; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HIRT H, 1987, DNA-J MOLEC CELL BIO, V6, P59, DOI 10.1089/dna.1987.6.59; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JIANG SW, 1994, J BIOL CHEM, V269, P10384; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MANTOVANI R, 1993, NUCLEIC ACIDS RES, V21, P4873, DOI 10.1093/nar/21.21.4873; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; NACHTIGAL MW, 1989, NUCLEIC ACIDS RES, V17, P4327, DOI 10.1093/nar/17.11.4327; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; NIELSEN PV, 1979, AM J OBSTET GYNECOL, V135, P322, DOI 10.1016/0002-9378(79)90698-7; POGULIS RJ, 1993, J BIOL CHEM, V268, P2493; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PURNELL BA, 1993, MOL CELL BIOL, V13, P2593, DOI 10.1128/MCB.13.4.2593; ROGERS BL, 1986, NUCLEIC ACIDS RES, V14, P7647, DOI 10.1093/nar/14.19.7647; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SEGAL R, 1991, J BIOL CHEM, V266, P20406; SELBY MJ, 1984, J BIOL CHEM, V259, P3131; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHEPARD AR, 1994, J BIOL CHEM, V269, P1804; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Snedecor G. W., 1980, STATISTICAL METHODS, P116; SUN JM, 1992, NUCLEIC ACIDS RES, V20, P6385, DOI 10.1093/nar/20.23.6385; TALKINGTON CA, 1982, NATURE, V298, P192, DOI 10.1038/298192a0; TOKUNAGA K, 1984, NUCLEIC ACIDS RES, V12, P1543, DOI 10.1093/nar/12.3.1543; VACCARO M, 1990, P NATL ACAD SCI USA, V87, P3047, DOI 10.1073/pnas.87.8.3047; WALKER WH, 1990, J BIOL CHEM, V265, P12940; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XIE W, 1991, BIOTECHNIQUES, V11, P325; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	50	29	29	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3683	3692		10.1074/jbc.270.8.3683	http://dx.doi.org/10.1074/jbc.270.8.3683			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876107	hybrid			2022-12-25	WOS:A1995QH68800036
J	ROUSSEAU, A; MICHAUD, A; CHAUVET, MT; LENFANT, M; CORVOL, P				ROUSSEAU, A; MICHAUD, A; CHAUVET, MT; LENFANT, M; CORVOL, P			THE HEMOREGULATORY PEPTIDE N-ACETYL-SER-ASP-LYS-PRO IS A NATURAL AND SPECIFIC SUBSTRATE OF THE N-TERMINAL ACTIVE-SITE OF HUMAN ANGIOTENSIN-CONVERTING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL PROLIFERATION; 2 HOMOLOGOUS DOMAINS; NEGATIVE REGULATOR; MOLECULAR-CLONING; BONE-MARROW; PLASMA; ACSDKP; BRADYKININ; EXPRESSION; HYDROLYSIS	Angiotensin I-converting enzyme (ACE) is a zinc-dipeptidyl carboxypeptidase, which contains two similar domains, each possessing a functional active site, Respective involvement of each active site in the degradation of the circulating peptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), a negative regulator of hematopoietic stem cell proliferation, was studied by using wild-type recombinant ACE and two full-length mutants containing a single functional site, Both the N- and C-active sites of ACE exhibit dipeptidyl activity toward AcSDKP, with K-m values of 31 and 39 mu M, respectively, However, the N-active site hydrolyzes the peptide 50 times faster compared with the C-active site, with k(cat)/K-m values of 0.5 and 0.01 mu M(-1).s(-1), respectively, The predominant role of the N-active site in AcSDKP hydrolysis was confirmed by the inhibition of hydrolysis using a monoclonal antibody specifically directed against the N-active site, The N-domain specificity for AcSDKP will aid the identification of specific inhibitors for this domain. This is the first report of a highly specific substrate for the N-active site of ACE, with kinetic constants in the range of physiological substrates, suggesting that ACE might be involved via its N-terminal active site in the in vivo regulation of the local concentration of this hemoregulatory peptide.	COLL FRANCE,INSERM,U36,F-75005 PARIS,FRANCE; CNRS,INST CHIM SUBST NAT,F-91198 GIF SUR YVETTE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ALHENCGELAS F, 1991, J LAB CLIN MED, V117, P33; ALHENCGELAS F, 1988, J LAB CLIN MED, V101, P83; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BOGDEN AE, 1991, ANN NY ACAD SCI, V628, P126, DOI 10.1111/j.1749-6632.1991.tb17230.x; BONNET D, 1993, BLOOD, V82, P3307; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; DANILOV S, 1994, J BIOL CHEM, V269, P26806; DANILOV SM, 1987, BIOTECHNOL APPL BIOC, V9, P319; DORER FE, 1976, BIOCHIM BIOPHYS ACTA, V429, P220, DOI 10.1016/0005-2744(76)90045-0; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; EHLERS MRW, 1988, BIOCHEMISTRY-US, V27, P5538, DOI 10.1021/bi00415a023; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; FRINDEL E, 1977, EXP HEMATOL, V5, P74; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; HUBERT C, 1991, J BIOL CHEM, V268, P15377; JASPARD E, 1993, J BIOL CHEM, V268, P9496; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LANZILLO JJ, 1985, J BIOL CHEM, V260, P4938; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; LENFANT M, 1989, P NATL ACAD SCI USA, V86, P779, DOI 10.1073/pnas.86.3.779; LIOZON E, 1993, LEUKEMIA, V7, P808; LORD BI, 1977, BIOMED EXPRESS, V27, P223; OFFORD RE, 1966, NATURE, V211, P591, DOI 10.1038/211591a0; PERSSON A, 1977, ANAL BIOCHEM, V83, P296, DOI 10.1016/0003-2697(77)90538-3; PRADELLES P, 1990, BIOCHEM BIOPH RES CO, V170, P986, DOI 10.1016/0006-291X(90)90489-A; RIEGER KJ, 1993, BIOCHEM J, V296, P373, DOI 10.1042/bj2960373; ROBINSON S, 1992, CELL PROLIFERAT, V25, P623, DOI 10.1111/j.1365-2184.1992.tb01464.x; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P3850, DOI 10.1021/bi00285a021; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SKIDGEL RA, 1985, P NATL ACAD SCI USA, V82, P1025, DOI 10.1073/pnas.82.4.1025; SOTTY D, 1991, PEPTIDES 1990, P309; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; WDZIECZAKBAKALA J, 1983, BIOMED PHARMACOTHER, V9, P467; WEI L, 1992, J BIOL CHEM, V267, P13398; WEI L, 1991, J BIOL CHEM, V266, P9002; WEI L, 1991, J BIOL CHEM, V266, P5540; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6	40	272	286	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3656	3661		10.1074/jbc.270.8.3656	http://dx.doi.org/10.1074/jbc.270.8.3656			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876104	hybrid			2022-12-25	WOS:A1995QH68800032
J	CHABRY, J; BOTTO, JM; NOUEL, D; BEAUDET, A; VINCENT, JP; MAZELLA, J				CHABRY, J; BOTTO, JM; NOUEL, D; BEAUDET, A; VINCENT, JP; MAZELLA, J			THR-422 AND TYR-424 RESIDUES IN THE CARBOXYL-TERMINUS ARE CRITICAL FOR THE INTERNALIZATION OF THE RAT NEUROTENSIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEURONS; BINDING; DOMAINS	In order to identify the amino acid sequences responsible for the internalization of the cloned rat brain neurotensin receptor, we carried out site-directed mutagenesis of the cDNA encoding the receptor followed by expression of the receptor into mammalian COS 7 cells, In cells transfected with the full-length neurotensin receptor, 56% of iodinated neurotensin specifically bound to the cells after 60 min of incubation at 37 degrees C was internalized. Deletions made in the third intracellular loop did not affect receptor internalization. By contrast, internalization was reduced to 5% of total in cells in which almost all the carboxyl-terminal tail of the receptor had been deleted (R392stop), In order to determine which part of the tail was responsible for this effect, several Ser and Thr residues were deleted in the carboxyl cytoplasmic sequence of the receptor, Almost all of these receptors were internalized as efficiently as the wild type, Only the form of the neurotensin receptor truncated at Glu-421 (deletion of the last three residues, TLY) produced a significant decrease in the amount of ligand internalized, Finally, point mutations of Thr-422 and Tyr-424 residues to Gly led to an almost complete loss of ligand internalization demonstrating the involvement of these 2 residues in the internalization process, Replacement of the last three amino acids by the cytoplasmic endocytosis signal of the vesicular stomatitis virus did not restore the efficiency of neurotensin receptor internalization. These biochemical results were confirmed by confocal microscopic analysis, Cells transfected with the wild type receptor showed a temperature-dependent intracellular accumulation of a fluorescent analog of neurotensin, whereas cells transfected with a receptor truncated at the carboxyl terminus showed a clustering of the fluorescent peptide at the cell surface.	CNRS,INST PHARMACOL MOLEC & CELLULAIRE,UPR 411,F-06560 VALBONNE,FRANCE; MCGILL UNIV,MONTREAL NEUROL INST,NEUROBIOL GRP,MONTREAL,PQ H3A 2B4,CANADA	Centre National de la Recherche Scientifique (CNRS); McGill University			Mazella, Jean/A-6767-2012; Chabry, Joelle/O-2101-2016					BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1993, J BIOL CHEM, V268, P20285; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHABRY J, 1993, J BIOL CHEM, V268, P17138; CHABRY J, 1994, J NEUROCHEM, V63, P19; FAURE MP, 1994, J HISTOCHEM CYTOCHEM, V42, P755, DOI 10.1177/42.6.8189037; GAUDRIAULT G, 1992, PEPTIDES, V13, P1187, DOI 10.1016/0196-9781(92)90027-Z; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LUTZ W, 1990, P NATL ACAD SCI USA, V87, P6507, DOI 10.1073/pnas.87.17.6507; MAZELLA J, 1991, BRAIN RES, V564, P249, DOI 10.1016/0006-8993(91)91460-I; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; PERLMAN JH, 1992, J BIOL CHEM, V267, P24413; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; Sambrook J, 1989, MOL CLONING LABORATO; SLICE LW, 1994, J BIOL CHEM, V269, P21755; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; VANISBERG MA, 1991, BIOCHEM PHARMACOL, V42, P2265, DOI 10.1016/0006-2952(91)90229-X	18	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2439	2442		10.1074/jbc.270.6.2439	http://dx.doi.org/10.1074/jbc.270.6.2439			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852303	hybrid			2022-12-25	WOS:A1995QF53500008
J	CHEN, PCH; DUBOIS, GC; CHEN, MJ				CHEN, PCH; DUBOIS, GC; CHEN, MJ			MAPPING THE DOMAIN(S) CRITICAL FOR THE BINDING OF HUMAN TUMOR-NECROSIS-FACTOR-ALPHA TO ITS 2 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; MOLECULAR-CLONING; FACTOR-BETA; EXPRESSION; 55-KDA; IDENTIFICATION; RESOLUTION; RESPONSES; MUTANTS; SITE	The extracellular domains of the two human tumor necrosis factor (TNF) receptors critical for binding TNF-alpha were examined by deletion mapping, The Ligand binding capability of full-length and truncated recombinant soluble TNF receptors (TNFRs) was assessed by ligand blot analysis and their binding affinity determined by Scatchard analysis, The results showed that deletion of the fourth cysteine-rich domain of the p55 receptor (TNFR-1) did not alter Ligand binding affinity significantly, Deletion of domains 3 and 4 of TNFR-1 resulted in no ligand binding, suggesting that domain 3, but not 4, of TNFR-1 binds directly to Ligand, Deletion of domain 4 of TNFR-2 resulted in drastically reduced protein yield and 3-fold reduction in Ligand binding affinity, while deletion of both domains 4 and 3 yielded no protein, Thus, the domain 4 of TNFR-2, but not that of TNFR-1, appears to be involved directly in binding TNF, although it is also possible that the domain 4 of TNFR-2 is involved in the correct folding of other domains. These results suggest that the modes of interaction between TNF-alpha and its dual receptors are different, providing opportunity to modulate each receptor specifically for research and therapeutic purposes.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PHARMACOL,PHILADELPHIA,PA 19107; JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University					NATIONAL CANCER INSTITUTE [R01CA059832] Funding Source: NIH RePORTER; NCI NIH HHS [CA-59832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALON R, 1994, J IMMUNOL, V152, P1304; ARAKAWA T, 1987, J BIOL CHEM, V262, P7484; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BERAN M, 1987, BLOOD, V69, P721; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CHEN MJ, 1988, MONOKINES OTHER NONL, P243; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FIERS W, 1993, TUMOR NECROSIS FACTO; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HWANG C, 1991, P ROY SOC B-BIOL SCI, V245, P115, DOI 10.1098/rspb.1991.0096; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; Kircheis R, 1992, Eur Cytokine Netw, V3, P381; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KUNITANI MG, 1988, J CHROMATOGR, V443, P205, DOI 10.1016/S0021-9673(00)94794-0; LIE BL, 1992, BIOCHEM BIOPH RES CO, V188, P503, DOI 10.1016/0006-291X(92)91084-4; LOCKSLEY RM, 1987, J IMMUNOL, V139, P1891; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LUCAS R, 1994, SCIENCE, V263, P814, DOI 10.1126/science.8303299; OSTER W, 1987, BLOOD, V70, P1700; RATHJEN DA, 1991, MOL IMMUNOL, V28, P79, DOI 10.1016/0161-5890(91)90089-3; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH RA, 1987, J BIOL CHEM, V262, P6951; Tao Deling, 1994, European Cytokine Network, V5, P90; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; VANOSTADE X, 1994, PROTEIN ENG, V7, P5, DOI 10.1093/protein/7.1.5; VANOSTADE X, 1993, NATURE, V361, P266; VILCEK J, 1991, J BIOL CHEM, V266, P7313; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	40	21	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2874	2878		10.1074/jbc.270.6.2874	http://dx.doi.org/10.1074/jbc.270.6.2874			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852363	hybrid			2022-12-25	WOS:A1995QF53500073
J	GOODSON, ML; SARGE, KD				GOODSON, ML; SARGE, KD			HEAT-INDUCIBLE DNA FINDING OF PURIFIED HEAT-SHOCK TRANSCRIPTION FACTOR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-ANALOGS; BINDING ACTIVITY; GENE-EXPRESSION; ACTIVATION; PROTEINS; STRESS; HSP70; OLIGOMERIZATION; POLYPEPTIDES; CHAPERONES	The heat-induced expression of heat shock proteins, called the cellular stress response, is mediated by heat shock transcription factor 1 (HSF1). HSF1 exists in unstressed cells in an inactive form, which is converted to the DNA binding form upon exposure of cells to elevated temperature. We have developed a protocol for isolation of the non-DNA binding form of recombinant mouse HSF1, involving expression and affinity purification of HSF1 as a fusion with the glutathione S-transferase protein in Escherichia coli, followed by specific protease cleavage to release pure HSF1 protein, We report here that the purified inactive HSF1 can be converted to the DNA binding form by heat treatment in vitro, Chemical cross-linking analysis demonstrates that this conversion is accompanied by oligomerization of HSF1 from a monomeric to a trimeric native structure, similar to that observed for HSF1 in heat-shocked cells, These results indicate that elements residing in the HSF1 polypeptide are sufficient both for maintenance of this factor in the non-DNA binding form and for its heat-induced conversion to the DNA binding form and support a role for HSF1 as the ''molecular thermostat'' in eukaryotic cells, which senses adverse environmental conditions and activates the cellular stress response.	UNIV KENTUCKY, ALBERT B CHANDLER MED CTR, DEPT BIOCHEM, LEXINGTON, KY 40536 USA	University of Kentucky			Goodson, Michael L/G-4175-2010	Goodson, Michael/0000-0002-3464-490X				ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; CLOS J, 1993, NATURE, V364, P252, DOI 10.1038/364252a0; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; EDINGTON BV, 1989, J CELL PHYSIOL, V139, P219, DOI 10.1002/jcp.1041390202; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GEKKO K, 1983, J BIOCHEM-TOKYO, V94, P199, DOI 10.1093/oxfordjournals.jbchem.a134330; GOMEZPUYOU MTD, 1978, ARCH BIOCHEM BIOPHYS, V187, P72, DOI 10.1016/0003-9861(78)90007-3; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KINGSTON RE, 1991, HORMONAL CONTROL GEN, P377; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; LIS J, 1992, TRANSCRIPTIONAL REGU, P907; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Morimoto RI, 1990, STRESS PROTEINS BIOL; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS D, 1989, GENE DEV, V2, P1851; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	37	53	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2447	2450		10.1074/jbc.270.6.2447	http://dx.doi.org/10.1074/jbc.270.6.2447			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852305	hybrid			2022-12-25	WOS:A1995QF53500010
J	KIELISZEWSKI, MJ; ONEILL, M; LEYKAM, J; ORLANDO, R				KIELISZEWSKI, MJ; ONEILL, M; LEYKAM, J; ORLANDO, R			TANDEM MASS-SPECTROMETRY AND STRUCTURAL ELUCIDATION OF GLYCOPEPTIDES FROM A HYDROXYPROLINE-RICH PLANT-CELL WALL GLYCOPROTEIN INDICATE THAT CONTIGUOUS HYDROXYPROLINE RESIDUES ARE THE MAJOR SITES OF HYDROXYPROLINE O-ARABINOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZEA-MAYS; GLYCOSYLATION SITES; CONTAINING PROTEINS; EXTENSIN; SEQUENCE; PEPTIDES; CHROMATOGRAPHY; ARABINOSIDES; ACCUMULATION; CONFORMATION	Hydroxyproline-rich glycoproteins (HRGPs) occur in the extracellular matrix of land plants and green algae. HRGPs contain from 2 to 95% of their dry weight as carbohydrate, predominantly as oligoarabinosides and/or as heteropolysaccharides which are O-linked to the hydroxyproline residues. A glycosylation code that determines the presence or absence and extent of arabinosylation at each hydroxyproline residue is likely, as each HRCP has a unique arabinosylation profile. Previously we noted a positive correlation between the contiguity of hydroxyproline residues and the extent of HRGP O-arabinosylation (Kieliszewski, M., deZacks, R., Leykam, J. F., and Lamport, D. T. A. (1992) Plant Physiol. 98, 919-926); most arabinosylated hydroxyproline residues and the longer arabinofuranoside chains occur in HRGPs where Hyp residues occur as blocks of tetrahydroxyproline, while those with little or no contiguous Hyp exhibit very little Hyp arabinosylation. In order to test this Hyp contiguity hypothesis, we have for the first time determined the arabinosylation site specifics of an HRGP, namely the proline and hydroxyproline-rich glycoprotein (PHRGP) isolated from Douglas fir (Pseudotsuga menziesii). Pronase digests of PHRGP yielded a major peptide and three glycopeptides whose structures were determined directly from the unfractionated, underivatized Pronase digest by tandem mass spectrometry using collisionally induced dissociation. We corroborated the peptide and glycopeptide structures by Edman degradation, neutral sugar analyses, hydroxyproline arabinoside profiles, and further mass spectrometric analyses after purification of the major peptide and glycopeptides by a combination of hydrophilic interaction and reverse phase column chromatography. Consistent with the Hyp contiguity hypothesis, the structural analyses indicate that while the sequence ne-Pro-Pro-Hyp is never arabinosylated and Lys-Pro-Ile-Val-Hyp is only occasionally monoarabinosylated at Hyp-5, the peptide containing contiguous Hyp, Lys-Pro-Hyp-Hyp-Val, is always arabinosylated at Hyp-3, mainly by a triarabinoside. We also obtained precise molecular masses for both intact and anhydrous hydrogen fluoride-deglycosylated PHRGPs (73.113 and 53.834 kDa) via matrix-assisted laser desorption/ionization time of flight mass spectrometry, representing the first HRGP to be analyzed by this method.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	University System of Georgia; University of Georgia; Michigan State University	KIELISZEWSKI, MJ (corresponding author), UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,220 RIVERBEND RD,ATHENS,GA 30602, USA.				NCRR NIH HHS [P41-RR05351] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKIYAMA Y, 1980, AGR BIOL CHEM TOKYO, V44, P2487, DOI 10.1080/00021369.1980.10864347; ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; ASHFORD D, 1982, BIOCHEM J, V201, P199, DOI 10.1042/bj2010199; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BIEMANN K, 1989, ANN REV BIOCH, V61, P977; BROWNLEADER MD, 1993, PLANTA, V191, P457, DOI 10.1007/BF00195747; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHEN J, 1985, EMBO J, V4, P2145, DOI 10.1002/j.1460-2075.1985.tb03908.x; CONBOY JJ, 1992, J AM SOC MASS SPECTR, V3, P804, DOI 10.1016/1044-0305(92)80003-4; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; DATTA K, 1989, PLANT CELL, V1, P945, DOI 10.1105/tpc.1.9.945; EPSTEIN L, 1984, PHYTOCHEMISTRY, V23, P1241, DOI 10.1016/S0031-9422(00)80433-1; ERTL H, 1992, EMBO J, V11, P2055, DOI 10.1002/j.1460-2075.1992.tb05263.x; ESQUERRETUGAYE MT, 1979, PLANT PHYSIOL, V64, P314, DOI 10.1104/pp.64.2.314; FINCHER GB, 1983, ANNU REV PLANT PHYS, V34, P47, DOI 10.1146/annurev.pp.34.060183.000403; HECKMAN JW, 1988, PLANT PHYSIOL, V86, P848, DOI 10.1104/pp.86.3.848; HILL JA, 1992, INT J MASS SPECTROM, V111, P1; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KELLER B, 1989, GENE DEV, V3, P1639, DOI 10.1101/gad.3.10.1639; KIELISZEWSKI M, 1987, PLANT PHYSIOL, V85, P823, DOI 10.1104/pp.85.3.823; KIELISZEWSKI M, 1992, PLANT PHYSIOL, V98, P919, DOI 10.1104/pp.98.3.919; KIELISZEWSKI M, 1994, PLANT J, V5, P1; KIELISZEWSKI M, 1994, PLANT J, V5; KIELISZEWSKI MJ, 1990, PLANT PHYSIOL, V92, P316, DOI 10.1104/pp.92.2.316; KIELISZEWSKI MJ, 1992, PLANT PHYSIOL, V99, P538, DOI 10.1104/pp.99.2.538; Lamport D. T. A., 1977, RECENT ADV PHYTOCHEM, V11, P79; LAMPORT DTA, 1967, NATURE, V216, P1322, DOI 10.1038/2161322a0; LAMPORT DTA, 1973, BIOCHEM J, V133, P125, DOI 10.1042/bj1330125; LAMPORT DTA, 1971, PLANT PHYSIOL, V48, P454, DOI 10.1104/pp.48.4.454; LAMPORT DTA, 1970, ANN REV PLANT PHYSIO, V21, P235, DOI 10.1146/annurev.pp.21.060170.001315; LOO JA, 1993, ANAL CHEM, V65, P425, DOI 10.1021/ac00052a020; MAZAU D, 1986, PHYSIOL MOL PLANT P, V29, P147, DOI 10.1016/S0048-4059(86)80017-0; MCNEIL M, 1984, ANNU REV BIOCHEM, V53, P625, DOI 10.1146/annurev.bi.53.070184.003205; MEDZIHRADSZKY KF, 1990, BIOMED ENVIRON MASS, V19, P777, DOI 10.1002/bms.1200191205; MILLER DH, 1972, SCIENCE, V176, P918, DOI 10.1126/science.176.4037.918; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; NAYLOR S, 1986, J AM CHEM SOC, V108, P6359, DOI 10.1021/ja00280a037; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; POPE DG, 1977, PLANT PHYSIOL, V59, P894, DOI 10.1104/pp.59.5.894; QI W, 1991, PLANT PHYSIOL, V96, P848, DOI 10.1104/pp.96.3.848; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SANGER MP, 1983, ANAL BIOCHEM, V128, P66, DOI 10.1016/0003-2697(83)90345-7; SETTINERI CA, 1990, BIOMED ENVIRON MASS, V19, P665, DOI 10.1002/bms.1200191106; SHOWALTER AM, 1985, P NATL ACAD SCI USA, V82, P6551, DOI 10.1073/pnas.82.19.6551; SMITH JJ, 1984, PHYTOCHEMISTRY, V23, P1233, DOI 10.1016/S0031-9422(00)80432-X; STAFSTROM JP, 1986, PLANT PHYSIOL, V81, P234, DOI 10.1104/pp.81.1.234; STIEFEL V, 1988, PLANT MOL BIOL, V11, P483, DOI 10.1007/BF00039029; TANAKA K, 1965, J BIOL CHEM, V240, P1487; TOMITA M, 1975, P NATL ACAD SCI USA, V72, P2964, DOI 10.1073/pnas.72.8.2964; TUOMANEN E, 1989, J BIOL CHEM, V264, P11093; VANDEVELDE MC, 1985, CARBOHYD POLYM, V5, P251, DOI 10.1016/0144-8617(85)90034-7; VANHOLST GJ, 1984, PLANT PHYSIOL, V74, P247, DOI 10.1104/pp.74.2.247; VANHOLST GJ, 1986, BIOCHEM J, V233, P731, DOI 10.1042/bj2330731	55	85	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2541	2549		10.1074/jbc.270.6.2541	http://dx.doi.org/10.1074/jbc.270.6.2541			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852316	hybrid			2022-12-25	WOS:A1995QF53500024
J	KURODA, S; SHIMIZU, K; YAMAMORI, B; MATSUDA, S; IMAZUMI, K; KAIBUCHI, K; TAKAI, Y				KURODA, S; SHIMIZU, K; YAMAMORI, B; MATSUDA, S; IMAZUMI, K; KAIBUCHI, K; TAKAI, Y			PURIFICATION AND CHARACTERIZATION OF REKS FROM XENOPUS EGGS - IDENTIFICATION OF REKS AS A RAS-DEPENDENT MITOGEN-ACTIVATED PROTEIN-KINASE KINASE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP EXCHANGE PROTEIN; MAP KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; ADENYLATE-CYCLASE; OOCYTES; RAF-1; CELLS; RAS-P21	We have previously identified a protein factor, named REKS (Ras-dependent Extracellular signal-regulated kinase/Mitogen-activated protein kinase kinase (MEK) Stimulator), which is necessary for Ras-dependent MEK activation. In this study, we attempted to highly purify and characterize REKS. We have highly purified REKS by successive column chromatographies using a cell-free assay system in which REKS activates recombinant extracellular signal-regulated kinase 2 through recombinant MER in a guanosine 5'-O-(thiotriphosphate) (GTP gamma S)-Ki-Ras-dependent manner. REKS formed a stable complex with GTP gamma S-Ras; REKS was coimmunoprecipitated with GTP gamma S-Ki-Ras or GTP gamma S-Ha-Ras, but not with GDP-Ki-Ras or GDP-Ha-Ras by an anti-Ras antibody. REKS was adsorbed to a GTP gamma S-glutathione S-transferase (GST)-Ha-Ras-coupled glutathione-agarose column but not to a GDP-GST-Ha-Ras-coupled glutathione-agarose column and was coeluted with GTP gamma S-GST-Ha-Ras by reduced glutathione. The minimum molecular mass of REKS was estimated to be about 98 kDa on SDS-polyacrylamide gel electrophoresis. REKS phosphorylated this 98-kDa protein as well as recombinant MEK. REKS was not recognized by any of the anti-c-Raf-1, anti-Mos, and anti-mSte11 antibodies. These results indicate that REKS is a Ras-dependent MEK kinase.	OSAKA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; Kobe University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			KURODA, SHINYA/G-4961-2014					AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; ITOH T, 1993, J BIOL CHEM, V268, P3025; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAMBROOK J, 1989, MOL CLONING LABORATO, P1574; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	52	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2460	2465		10.1074/jbc.270.6.2460	http://dx.doi.org/10.1074/jbc.270.6.2460			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852306	hybrid			2022-12-25	WOS:A1995QF53500012
J	WAHLE, E				WAHLE, E			POLY(A) TAIL LENGTH CONTROL IS CAUSED BY TERMINATION OF PROCESSIVE SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA PRECURSORS; SACCHAROMYCES-CEREVISIAE; TRANSLATION INITIATION; SPECIFICITY FACTOR; END FORMATION; POLYMERASE; POLYADENYLATION; CLEAVAGE; DEADENYLATION; PROTEIN	Poly(A) polymerase synthesizes poly(A) tails rapidly and processively only when the substrate RNA is bound simultaneously by two stimulatory proteins, the cleavage and polyadenylation specificity factor (CPSF) and poly(A)-binding protein II (PAB II). A burst of synthesis terminates after the addition of about 250 nucleotides, a length corresponding to that of newly synthesized poly(A) tails in vivo. Further elongation is slow. Length control can be reproduced with premade poly(A) tails of different lengths and is insensitive to large changes in the elongation rate. Thus, the control mechanism truly measures the length of the poly(A) tail. The stimulatory action of PAB II is similar on long and short tails. Coating of poly(A) with one PAB IT molecule for approximately 30 nucleotides is required, such that the number of PAB II molecules in the polyadenylation complex is a direct measure of poly(A) tail length. CPSF also stimulates poly(A) polymerase on long and short tails. Long tails differ from short ones only in that they do not permit the simultaneous stimulation of poly(A) polymerase by CPSF and PAB II. Consequently, elongation of long tails is distributive. Thus, length control is brought about by an interruption of the interactions responsible for rapid and processive elongation of short tails. The 3'-end of the poly(A) tail is not sequestered in the protein-RNA complex when the correct length has been reached. Neither ATP hydrolysis nor turnover of the polymerized AMP is involved in length control.			WAHLE, E (corresponding author), UNIV BASEL, BIOZENTRUM, DEPT CELL BIOL, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND.			Wahle, Elmar/0000-0003-2504-0677				ABRAHAM AK, 1978, P NATL ACAD SCI USA, V75, P2085, DOI 10.1073/pnas.75.5.2085; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAWERMAN G, 1981, CRC CR REV BIOCH MOL, V10, P1, DOI 10.3109/10409238109114634; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; GALILI G, 1988, J BIOL CHEM, V263, P5764; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; KORNBERG A, 1992, DNA REPLICATION, P130; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; ROBINSON BG, 1988, SCIENCE, V241, P342, DOI 10.1126/science.3388044; SACHS A, 1993, J BIOL CHEM, V268, P22955; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J, 1989, MOL CLONING LABORATO; SAWICKI SG, 1977, J MOL BIOL, V113, P219, DOI 10.1016/0022-2836(77)90051-1; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SCOPES RK, 1987, PROTEIN PURIFICATION, P305; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TARUI Y, 1989, EUR J BIOCHEM, V186, P591, DOI 10.1111/j.1432-1033.1989.tb15249.x; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1993, J BIOL CHEM, V268, P2937; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	52	159	179	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2800	2808		10.1074/jbc.270.6.2800	http://dx.doi.org/10.1074/jbc.270.6.2800			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852352				2022-12-25	WOS:A1995QF53500062
J	EGGLESTON, AK; ONEILL, TE; BRADBURY, EM; KOWALCZYKOWSKI, SC				EGGLESTON, AK; ONEILL, TE; BRADBURY, EM; KOWALCZYKOWSKI, SC			UNWINDING OF NUCLEOSOMAL DNA BY A DNA HELICASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECBCD ENZYME; HOMOLOGOUS PAIRING INVITRO; T7 RNA-POLYMERASE; ESCHERICHIA-COLI; DUPLEX DNA; RECOMBINATION HOTSPOT; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; RECB(2109)CD ENZYME; NUCLEASE ACTIVITY	We have asked whether a DNA helicase can unwind DNA contained within both isolated native chromatin and reconstituted chromatin containing regularly spaced arrays of nucleosome cores on a linear tandem repeat sequence, We find that Escherichia coli recBCD enzyme is capable of unwinding these DNA substrates and displacing the nucleosomes, although both the rate and the processivity of enzymatic unwinding are inhibited (a maximum of 3- and >25-fold, respectively) as the nucleosome density on the template is increased. The observed rate of unwinding is not affected if the histone octamer is chemically cross-linked; thus, dissociation, or splitting, of the histone octamer is not required for unwinding to occur, The unwinding of native chromatin isolated from HeLa cell nuclei occurs both in the absence and in the presence of linker histone H1, These results suggest that as helicases unwind DNA, they facilitate nuclear processes by acting to clear DNA of histones or DNA-binding proteins in general.	UNIV CALIF DAVIS,MICROBIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,DEPT BIOL CHEM,DAVIS,CA 95616; LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; United States Department of Energy (DOE); Los Alamos National Laboratory				Eggleston, Angela/0000-0001-8682-397X	NIGMS NIH HHS [GM-26901, GM-41347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026901, R01GM041347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MJ, 1993, BIOCHEMISTRY-US, V32, P8390, DOI 10.1021/bi00084a002; ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; BUTTIN G, 1968, COLD SPRING HARB SYM, V33, P259, DOI 10.1101/SQB.1968.033.01.030; CHENG KC, 1989, GENETICS, V123, P5; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; EGGLESTON AK, 1993, J MOL BIOL, V231, P621, DOI 10.1006/jmbi.1993.1314; EGGLESTON AK, 1993, J MOL BIOL, V231, P605, DOI 10.1006/jmbi.1993.1313; EICHLER DC, 1977, J BIOL CHEM, V252, P499; ENNIS DG, 1987, GENETICS, V115, P11; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GANESAN S, 1993, J MOL BIOL, V229, P67, DOI 10.1006/jmbi.1993.1008; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; HABER JE, 1992, TRENDS GENET, V8, P446, DOI 10.1016/0168-9525(92)90329-3; HANSEN JC, 1993, J BIOL CHEM, V268, P5840; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P2129; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; KARU AE, 1973, J BIOL CHEM, V248, P4874; KIROV N, 1992, EMBO J, V11, P1941, DOI 10.1002/j.1460-2075.1992.tb05247.x; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEBOWITZ JH, 1985, THESIS J HOPKINS U; LORENTZ A, 1992, MOL GEN GENET, V233, P436, DOI 10.1007/BF00265441; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; ONEILL TE, 1993, P NATL ACAD SCI USA, V90, P6203, DOI 10.1073/pnas.90.13.6203; PONTICELLI AS, 1992, P NATL ACAD SCI USA, V89, P227, DOI 10.1073/pnas.89.1.227; RAMDAS J, 1989, J BIOL CHEM, V264, P17395; RAMDAS J, 1991, P NATL ACAD SCI USA, V88, P1344, DOI 10.1073/pnas.88.4.1344; RANDALL SK, 1992, J BIOL CHEM, V267, P14259; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2868; RUYECHAN WT, 1976, BIOCHEMISTRY-US, V15, P5047; Sambrook J, 1989, MOL CLONING LABORATO; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SMITH GR, 1990, NUCLEIC ACIDS MOL BI, V4, P78; TAKADA S, 1989, BIOCHEM BIOPH RES CO, V160, P711, DOI 10.1016/0006-291X(89)92491-1; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TELANDERMUSKAVI.KM, 1982, J BIOL CHEM, V257, P2641; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WHITE MA, 1993, P NATL ACAD SCI USA, V90, P6621, DOI 10.1073/pnas.90.14.6621; WOLFFE A, 1992, CHROMATIN STRUCTURE; WRIGHT M, 1971, J BIOL CHEM, V246, P6543	53	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2024	2031		10.1074/jbc.270.5.2024	http://dx.doi.org/10.1074/jbc.270.5.2024			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836428				2022-12-25	WOS:A1995QE49300009
J	GUY, HI; EVANS, DR				GUY, HI; EVANS, DR			SUBSTRUCTURE OF THE AMIDOTRANSFERASE DOMAIN OF MAMMALIAN CARBAMYL-PHOSPHATE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; INITIATES PYRIMIDINE BIOSYNTHESIS; GLUTAMINE BINDING-SITE; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; NUCLEOTIDE-SEQUENCE; DIHYDROOROTASE DOMAIN; HAMSTER CELLS; YEAST GENE; SUBUNIT	The amidotransferase or glutaminase (GLNase) domain of mammalian carbamyl phosphate synthetase (CPSase), part of the 243-kDa CAD polypeptide, consists of a carboxyl half that is homologous to all trpG-type amidotransferases and an amino half unique to the carbamyl phosphate synthetases, The two halves of the mammalian GLNase domain have been cloned separately, expressed in Escherichia coli, and purified, The 21-kDa carboxyl half, the catalytic subdomain, As extraordinarily active, The k(cat) is 347-fold higher and the K-m(Gln) is 40-fold lower than the complete GLNase domain, Unlike the GLNase domain, the catalytic subdomain does not form a stable hybrid complex with the E. coli CPSase synthetase subunit, Nevertheless, titration of the synthetase subunit with the catalytic subdomain partially restores glutamine-dependent CPSase activity, The 19-kDa amino half, the interaction subdomain, binds tightly to the E. coli CPSase large subunit, Thus, the GLNase domain consists of two subdomains which can autonomously fold and function, The catalytic subdomain weakly interacts with the synthetase domain and has all of the residues necessary for catalysis, The interaction subdomain is required for complex formation and also attenuates the intrinsically high activity of the catalytic subdomain and, thus, may be a key element of the interdomain functional linkage.			GUY, HI (corresponding author), WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47399] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1973, BIOCHEM BIOPH RES CO, V55, P246, DOI 10.1016/S0006-291X(73)80086-5; ANDERSON PM, 1975, BIOCHEMISTRY-US, V14, P3688, DOI 10.1021/bi00687a027; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; BEIN K, 1991, J BIOL CHEM, V266, P3791; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUY HI, 1994, J BIOL CHEM, V269, P23808; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; KELLY RE, 1986, J BIOL CHEM, V261, P6073; KELLY RE, 1986, THESIS WAYNE STATE U; KHEDOURI E, 1966, BIOCHEMISTRY-US, V5, P3552, DOI 10.1021/bi00875a024; KILSTRUP M, 1988, EUR J BIOCHEM, V176, P421, DOI 10.1111/j.1432-1033.1988.tb14299.x; KIM HS, 1992, J BIOL CHEM, V267, P7177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MEI B, 1989, J BIOL CHEM, V264, P16613; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MIRAN SG, 1991, BIOCHEMISTRY-US, V30, P7901, DOI 10.1021/bi00246a005; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PINKUS LM, 1972, J BIOL CHEM, V247, P6119; RAUSHEL FM, 1978, BIOCHEMISTRY-US, V17, P5587, DOI 10.1021/bi00619a001; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; SIMMER JP, 1989, P NATL ACAD SCI USA, V86, P4382, DOI 10.1073/pnas.86.12.4382; SOUCIET JL, 1987, MOL GEN GENET, V79, P59; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; WELLNER VP, 1975, J BIOL CHEM, V250, P3261; WENG M, 1987, J BACTERIOL, V169, P3023, DOI 10.1128/jb.169.7.3023-3028.1987; WERNER M, 1985, EUR J BIOCHEM, V146, P371, DOI 10.1111/j.1432-1033.1985.tb08663.x; ZALKIN H, 1980, MULTIFUNCTIONAL PROT, P123	48	14	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2190	2197		10.1074/jbc.270.5.2190	http://dx.doi.org/10.1074/jbc.270.5.2190			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836449	hybrid			2022-12-25	WOS:A1995QE49300034
J	DAS, GC; SHIVAKUMAR, CV; TODD, SD				DAS, GC; SHIVAKUMAR, CV; TODD, SD			CELL-SPECIFIC MODULATION OF THE PAPOVAVIRUS PROMOTERS BY TUMOR-SUPPRESSOR PROTEIN P53 IN THE ABSENCE OF LARGE T-ANTIGEN	ONCOGENE			English	Article						P53; TUMOR-SUPPRESSOR PROTEIN; PAPOVAVIRUS PROMOTERS; TRANSACTIVATION; GENE REGULATION BY P53	WILD-TYPE P53; EMBRYONAL CARCINOMA-CELLS; POLYOMAVIRUS BK INVITRO; TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; SV40-TRANSFORMED CELLS; IDENTIFICATION; SEQUENCES; INDUCTION; ENHANCER	The oncoproteins from several DNA tumor viruses form a complex with p53 and inactivate its function. Wild-type p53 is a transcription factor and can regulate eukaryotic promoters both positively and negatively. To elucidate the basis of the opposing functions and to understand whether and how oncoprotein synthesis in papovaviruses is regulated by p53, we studied modulation of the early promoters of SV40, polyomavirus and BK virus in the absence of the interfering effect of viral large T antigens. We here show that murine p53 can regulate the viral promoters either positively or negatively depending on the cell type. A temperature-sensitive mutant p53, 135 Val, at 37 degrees C also showed a cell-specific effect. These results suggest that promoter activation by p53 is not solely determined by p53 binding site, but host factors modulate p53's transactivation function. A TATA-less polyomavirus Late promoter was also repressed in HeLa cells and the level of repression was much less in the presence of active early promoter. As p53 and 135 Val were overexpressed to similar extent in different transfected cell Lines, variation in transactivation function is not due to the difference in the level of expressed protein. Our observations thus suggest that p53 interactions with cellular factors in addition to the TATA binding protein (TBP) are important for activator and repressor functions of p53. Well-defined viral promoters could thus provide us with an important tool for the identification and characterization of cellular factors that modulate p53-binding dependent gene regulation in animal cells.			DAS, GC (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MOLEC BIOL,POB 2003,TYLER,TX 75710, USA.				NCI NIH HHS [CA 47611] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047611] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAKRABORTY T, 1989, MOL CELL BIOL, V9, P3821, DOI 10.1128/MCB.9.9.3821; CHAKRABORTY T, 1991, J GEN VIROL, V72, P1935, DOI 10.1099/0022-1317-72-8-1935; CHEN JY, 1993, ONCOGENE, V8, P2159; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DASGUPTA S, 1993, J GEN VIROL, V74, P597, DOI 10.1099/0022-1317-74-4-597; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEYERLE KL, 1987, J VIROL, V62, P3378; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1049; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1991, SCIENCE, V256, P827; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MEITZ JA, 1992, EMBO J, V11, P5013; MICHALOVITZ D, 1990, CURR OPIN CELL BIOL, V3, P282; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OROURKE RW, 1990, ONCOGENE, V5, P1829; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAGIMOV N, 1992, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAMBROOK J, 1993, MOL CLONING LABORATO; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P10277; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEGHAL PB, 1993, ONCOGENE, V8, P3417; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIVAKUMAR CV, 1994, J GEN VIROL, V75, P1281, DOI 10.1099/0022-1317-75-6-1281; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TSENG RW, 1988, J VIROL, V62, P2896, DOI 10.1128/JVI.62.8.2896-2902.1988; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZAMBETTI ZP, 1992, GENE DEV, V6, P1131	58	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					449	455						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845669				2022-12-25	WOS:A1995QF64800005
J	PILLAY, TS; SASAOKA, T; OLEFSKY, JM				PILLAY, TS; SASAOKA, T; OLEFSKY, JM			INSULIN STIMULATES THE TYROSINE DEPHOSPHORYLATION OF PP125 FOCAL ADHESION KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SWISS 3T3 CELLS; COOH-TERMINAL TRUNCATION; PHOSPHORYLATION; RECEPTOR; BOMBESIN; AUTOPHOSPHORYLATION; IDENTIFICATION; VASOPRESSIN; ACTIVATION	The phosphorylation state of pp125 focal adhesion kinase in response to insulin was examined in parental and transfected Rat-1 fibroblasts expressing both wildtype (HIRc cells) and mutant human insulin receptor cDNAs lacking the C-terminal twin tyrosine phosphorylation sites (YFB cells) or a deletion mutant lacking the distal 43 amino acids of the beta-subunit (Delta CT cells). In HIRc cells insulin stimulated the tyrosine dephosphorylation of pp125(fak), whereas IGF-I did not, In contrast, the tyrosine phosphorylation state of pp125(fak) was unchanged in the parental Rat-1 fibroblasts and the YF2 or Delta CT mutant cell lines in response to insulin. Analysis of the supernatants revealed that pp125(fak) was only one component of the major M(r) 120-130-kDa phosphotyrosine band seen in HIRc cells. We conclude that: 1) in contrast to other growth factors, insulin stimulates the dephosphorylation of pp125(fak); 2) the presence of the insulin receptor C-terminal tyrosines 1328 and 1334 is required for the insulin-stimulated tyrosine dephosphorylation of pp125(fak), suggesting a possible SH2 domain-dependent interaction; 3) insulin may modulate integrin-mediated signaling through pp125(fak) by altering the phosphorylation state of pp125(fak).	UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM MED CTR,RES SERV,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)				pillay, tahir/0000-0002-9982-9710	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COGHLAN MP, 1994, BIOCHEM J, V303, P893, DOI 10.1042/bj3030893; DEVOR BB, 1993, BIOCHEM BIOPH RES CO, V190, P1084, DOI 10.1006/bbrc.1993.1160; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LEWIS RE, 1994, J BIOL CHEM, V269, P26259; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; PILLAY TS, 1992, FEBS LETT, V308, P38, DOI 10.1016/0014-5793(92)81045-N; POLANOWSKAGRABO.R, 1993, BIOCHEM J, V296, P543; RANKIN S, 1994, J BIOL CHEM, V269, P704; SABVILLE MK, 1994, BIOCHEM J, V301, P407; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; XIAO S, 1994, J BIOL CHEM, V269, P21244; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	40	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					991	994		10.1074/jbc.270.3.991	http://dx.doi.org/10.1074/jbc.270.3.991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836419	hybrid			2022-12-25	WOS:A1995QB15600002
J	YOUNG, TN; PIZZO, SV; STACK, MS				YOUNG, TN; PIZZO, SV; STACK, MS			A PLASMA MEMBRANE-ASSOCIATED COMPONENT OF OVARIAN ADENOCARCINOMA CELLS ENHANCES THE CATALYTIC EFFICIENCY OF MATRIX METALLOPROTEINASE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN CANCER-CELLS; IV COLLAGENASE; PLASMINOGEN ACTIVATORS; PRO-UROKINASE; BINDING-SITE; IDENTIFICATION; GELATINASE; COMPLEX	Several recent investigations have demonstrated that matrix metalloproteinase-2 (MMP-2) binds to the cell surface and undergoes zymogen activation via a plasma membrane associated activity, The purpose of this study was to determine if association of MMP-2 with the plasma membrane also modulates the catalytic efficiency of the active enzyme. Using density gradient centrifugation, we isolated the plasma membrane fractions of two ovarian adenocarcinoma cell lines, DOV 13 and OVCA 432, previously described either to express MMP-2 or to express no gelatinolytic: metalloproteinases, respectively, While DOV 13 cells contained plasma membrane-associated MMP-2 and OVCA 432 did not, both cell types were able to bind exogenous MMP-2. Furthermore, plasma membrane fractions from these cells significantly enhanced the rate of cleavage of [C-14]gelatin I substrate by both MMP-2 tissue inhibitor of metalloproteinases-2 (TIMP-2) complex (2.5-8-fold) and TIMP-2-free MMP-2 (5.9-fold), This stimulatory activity was dose-dependent, soluble in Triton X-100, and abolished by trypsin treatment of the membranes, but was stable to heat treatment, Plasma membrane stimulation of MMP-2 resulted in a 3.8-4.6-fold increase in the catalytic efficiency of gelatinolysis. These data suggest that, in addition to promoting zymogen activation, cell surface binding of MMP-2 may regulate enzyme activity by increasing the rate of substrate cleavage. Via this mechanism, tumor cell types that do not express MMPs (such as OVCA 432) nevertheless may be able to utilize exogenous MMP-2 to mediate proteolysis associated with invasion and metastasis.	NORTHWESTERN UNIV,SCH MED,DEPT OBSTET & GYNECOL,CHICAGO,IL 60611; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Northwestern University; Duke University					NATIONAL CANCER INSTITUTE [R55CA058900, R01CA058900] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043339, R01HL031932] Funding Source: NIH RePORTER; NCI NIH HHS [CA-58900] Funding Source: Medline; NHLBI NIH HHS [HL-43339, HL-31932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; EMONARD HP, 1992, CANCER RES, V52, P5845; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MILES LA, 1987, THROMB HAEMOSTASIS, V58, P936; MOLL UM, 1990, CANCER RES, V50, P6995; MOSER TL, 1994, INT J CANCER, V56, P552, DOI 10.1002/ijc.2910560415; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STETLERSTEVENSO.WG, 1989, J BIOL CHEM, V264, P1353; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; YOUNG TN, 1994, AM J OBSTET GYNECOL, V170, P1285; ZUCKER S, 1990, INT J CANCER, V45, P1137, DOI 10.1002/ijc.2910450625; ZUCKER S, 1987, CANCER RES, V47, P1608	25	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					999	1002		10.1074/jbc.270.3.999	http://dx.doi.org/10.1074/jbc.270.3.999			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836420	hybrid			2022-12-25	WOS:A1995QB15600004
J	BLAYDES, JP; SCHLUMBERGER, M; WYNFORDTHOMAS, D; WYLLIE, FS				BLAYDES, JP; SCHLUMBERGER, M; WYNFORDTHOMAS, D; WYLLIE, FS			INTERACTION BETWEEN P53 AND TGF-BETA-1 IN CONTROL OF EPITHELIAL-CELL PROLIFERATION	ONCOGENE			English	Article						P53; TGF-BETA; RAS; THYROID; IMMORTALIZATION	TRANSFORMING GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; FACTOR-BETA; MURINE KERATINOCYTES; MUTANT P53; TGF-BETA; LARGE-T; RAS ONCOGENE; EXPRESSION; CARCINOMA	Although loss of sensitivity to transforming growth factor beta (TGF beta) may be a key step in the escape of epithelial tumours from normal growth control, the intracellular signals determining responsiveness remain controversial, particularly the role of p53. We have investigated this question using thyroid epithelial lines as a model. We analysed (i) human thyroid cancer cell lines having either wild-type (wt) or mutant p53; (ii) rat thyroid lines derived by spontaneous immortalisation following introduction of mutant H-ras, which exhibit high levels of wt p53 but loss of p53-mediated cell-cycle control. Loss of response to TGF beta 1 was found in all human lines bearing mutant p53, and in the majority of the functionally equivalent rat lines, consistent with a role of wt p53 in mediating response, However, introduction of a dominant negative p53 mutant into TGF beta 1 responsive human lines containing wt p53 did not reduce responsiveness, demonstrating that p53 function is not necessary for TGF beta 1 response. On the other hand, expression of a temperature-sensitive (ts) p53 gene in a partially-responsive rat line demonstrated a highly significant modulation of TGF beta response, which fell from 65% inhibition of H-3-thymidine labelling index at 32.5 degrees C (wt p53 conformation) to only 14% at 37.5 degrees C (mutant conformation), The results suggest that p53 and TGF beta generate separate but interacting inhibitory signals, i.e. that p53 modulates but does not mediate TGF beta response. This conclusion explains previous conflicting data and is consistent with current models of cell cycle control by multiple inhibitors of cyclin-dependent kinases.	UNIV WALES COLL MED,DEPT PATHOL,THYROID TUMOUR BIOL RES GRP,CANC RES CAMPAIGN,CARDIFF CF4 4XN,S GLAM,WALES; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE	Cardiff University; UNICANCER; Gustave Roussy			Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				ANTONINI P, 1993, CANCER GENET CYTOGEN, V67, P117, DOI 10.1016/0165-4608(93)90163-G; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BRASH DE, 1987, MOL CELL BIOL, V7, P2031, DOI 10.1128/MCB.7.5.2031; BURNS JS, 1989, BRIT J CANCER, V59, P755, DOI 10.1038/bjc.1989.158; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; COMPERE SJ, 1989, MOL CELL BIOL, V9, P6, DOI 10.1128/MCB.9.1.6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GORETZKI PE, 1989, ANN ENDOCRINOL, V50, P145; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE EB, 1982, J CELL BIOL, V92, P665, DOI 10.1083/jcb.92.3.665; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MACDONALD RJ, 1987, GUIDE MOL CLONING TE, P219; MANNING AM, 1991, ONCOGENE, V6, P1471; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P1385, DOI 10.1210/endo-123-3-1385; ONG G, 1991, ONCOGENE, V6, P761; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REISS M, 1990, CANCER RES, V50, P6641; REISS M, 1993, CANCER RES, V53, P899; REISS M, 1989, J INVEST DERMATOL, V93, P136, DOI 10.1111/1523-1747.ep12277384; SHIPLEY GD, 1986, CANCER RES, V43, P5915; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WILLIAMS AC, 1994, ONCOGENE, V9, P1479; WILLIAMS DW, 1989, THYROID TUMOURS MOL, P57; WILLIAMS NW, 1989, EXP CELL RES, V184, P316, DOI 10.1016/0014-4827(89)90331-5; WRIGHT PA, 1991, ONCOGENE, V6, P1693; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q; WYLLIE FS, IN PRESS ONCOGENE; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	52	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					307	317						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838530				2022-12-25	WOS:A1995QC62400010
J	FINNEGAN, JM; WIGHTMAN, RM				FINNEGAN, JM; WIGHTMAN, RM			CORRELATION OF REAL-TIME CATECHOLAMINE RELEASE AND CYTOSOLIC CA2+ AT SINGLE BOVINE CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMITTER RELEASE; ADRENAL-MEDULLA; CALCIUM INFLUX; SECRETION; CA-2+; MOBILIZATION; EXOCYTOSIS; STORES; FURA-2; MODEL	Previous investigations of the role of Ca2+ in stimulus-secretion coupling have been undertaken in populations of adrenal chromaffin cells. In the present study, the simultaneous detection of intracellular Ca2+, with the fluorescent probe fura-2, and catecholamine release, using a carbon-fiber microelectrode, are examined at single chromaffin cells in culture. Results from classic depolarizing stimuli, high potassium (30-140 mM) and 1,1-dimethyl-4-phenylpiperazinium (3-50 mu M), show a dependence of peak cytosolic Ca2+ concentration and catecholamine release on secretagogue concentration. Catecholamine release induced by transient high K+ stimulation increases logarithmically with K+ concentration. Continuous exposure to veratridine (50 mu M) induces oscillations in intracellular Ca2+ and at higher concentrations (100 mu M) concomitant fluctuation of cytosolic Ca2+ and catecholamine secretion. Mobilization of both caffeine- and inositol trisphosphate-sensitive intracellular Ca2+ stores is found to elicit secretion with or without extracellular Ca2+. Caffeine-sensitive intracellular Ca2+ stores can be depleted, refilled, and cause exocytosis in medium without Ca2+. Single cell measurement of exocytosis and the increase in cytosolic Ca2+ induced by bradykinin-activated intracellular stores reveal cell to cell variability in exocytotic responses which is masked in populations of cells. Taken together, these results show that exocytosis of catecholamines can be induced by an increase in cytosolic Ca2+ either as a result of transmembrane entry or by release of internal stores.	UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill								ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V369, P163; BLAUSTEIN MP, 1975, J PHYSIOL-LONDON, V247, P617, DOI 10.1113/jphysiol.1975.sp010950; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; CARMICHAEL SW, 1993, ADRENAL MEDULLA, P145; CHEEK TR, 1989, FEBS LETT, V247, P429, DOI 10.1016/0014-5793(89)81385-7; CHEEK TR, 1994, BIOCHEM J, V301, P879, DOI 10.1042/bj3010879; CHEEK TR, 1989, CELL CALCIUM, V10, P213, DOI 10.1016/0143-4160(89)90004-3; CHEEK TR, 1990, FEBS LETT, V266, P91, DOI 10.1016/0014-5793(90)81514-O; CHEEK TR, 1993, J EXP BIOL, V184, P183; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; CHEEK TR, 1993, J BIOL CHEM, V268, P27076; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; DOUGLAS WW, 1975, HDB PHYSL 7, V6, P366; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; HOLZ RW, 1982, J NEUROCHEM, V39, P635, DOI 10.1111/j.1471-4159.1982.tb07940.x; JANKOWSKI JA, 1992, J BIOL CHEM, V267, P18329; JANKOWSKI JA, 1994, J NEUROCHEM, V63, P1739; KAO LS, 1986, J BIOL CHEM, V261, P4881; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; KILPATRICK DL, 1982, J NEUROCHEM, V38, P427, DOI 10.1111/j.1471-4159.1982.tb08647.x; KIM KT, 1989, P NATL ACAD SCI USA, V86, P9881, DOI 10.1073/pnas.86.24.9881; KRISTENSEN EW, 1988, BRAIN RES, V461, P44, DOI 10.1016/0006-8993(88)90723-8; LESZCZYSZYN DJ, 1991, J NEUROCHEM, V56, P1855, DOI 10.1111/j.1471-4159.1991.tb03441.x; LIU PS, 1991, J NEUROCHEM, V56, P172, DOI 10.1111/j.1471-4159.1991.tb02577.x; MARTIN PT, 1991, J BIOL CHEM, V266, P7388; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; NACHSHEN DA, 1987, J PHYSIOL-LONDON, V387, P415, DOI 10.1113/jphysiol.1987.sp016581; NACHSHEN DA, 1980, J GEN PHYSIOL, V76, P709, DOI 10.1085/jgp.76.6.709; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; NOWYCKY MC, 1993, BIOPHYS J, V64, P77, DOI 10.1016/S0006-3495(93)81342-0; OHTA M, 1973, J PHARMACOL EXP THER, V154, P143; OSULLIVAN AJ, 1989, BIOSCIENCE REP, V9, P243, DOI 10.1007/BF01116001; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; OWEN PJ, 1989, J PHARMACOL EXP THER, V248, P1231; POISNER AM, 1973, P SOC EXP BIOL MED, V142, P103; SALA F, 1990, BIOPHYS J, V57, P313, DOI 10.1016/S0006-3495(90)82533-9; SCHROEDER TJ, 1992, ANAL CHEM, V64, P3077, DOI 10.1021/ac00048a003; SCHROEDER TJ, 1994, J BIOL CHEM, V269, P17215; SORIMACHI M, 1989, JPN J PHYSIOL, V39, P687, DOI 10.2170/jjphysiol.39.687; STAUDERMAN KA, 1991, BIOCHEM J, V278, P643, DOI 10.1042/bj2780643; STOEHR SJ, 1986, J NEUROCHEM, V46, P637, DOI 10.1111/j.1471-4159.1986.tb13014.x; SUI AL, 1994, NEUROCHEM RES, V19, P753, DOI 10.1007/BF00967716; TERAOKA H, 1991, J NEUROCHEM, V57, P1884, DOI 10.1111/j.1471-4159.1991.tb06399.x; TERAOKA H, 1990, BRIT J PHARMACOL, V101, P67, DOI 10.1111/j.1476-5381.1990.tb12090.x; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; TSIEN RY, 1994, CHEM ENG NEWS, V72, P34, DOI 10.1021/cen-v072n029.p034; Viveros OH, 1975, HDB PHYSIOLOGY, V6, P389; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; YAMADA WM, 1992, BIOPHYS J, V61, P671, DOI 10.1016/S0006-3495(92)81872-6	56	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5353	5359		10.1074/jbc.270.10.5353	http://dx.doi.org/10.1074/jbc.270.10.5353			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890648	hybrid, Green Published			2022-12-25	WOS:A1995QL58000062
J	EICHLER, J; SILMAN, I				EICHLER, J; SILMAN, I			THE ACTIVITY OF AN ENDOPLASMIC RETICULUM-LOCALIZED POOL OF ACETYLCHOLINESTERASE IS MODULATED BY HEAT-SHOCK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK MUSCLE CULTURES; MONOMERIC ACETYLCHOLINESTERASE; MOLECULAR-FORMS; GOLGI-APPARATUS; COATED VESICLES; PROTEIN; CHOLINESTERASE; METABOLISM; TRANSPORT; CELLS	Primary cultures prepared from embryonic chick pectoral muscle were subjected to heat shock, and the effect on acetylcholinesterase activity in the cultures was examined. A rapid recovery in enzyme activity was observed soon after an initial heat shock-induced drop and was shown to be independent of de novo synthesis of protein, since it could occur in the presence of an inhibitor of protein synthesis. Lectin binding and sucrose gradient centrifugation studies suggested that molecular monomers and dimers found in the endoplasmic reticulum are involved in the observed recovery of acetylcholinesterase activity. Enhanced activation of a preexisting pool of inactive enzyme was clearly not the main agent of the recovery in enzymic activity. Recovery relied principally on restoration of the activity of previously active, heat-denatured acetylcholinesterase molecules found in the endoplasmic reticulum. Possible agents involved in the recovery of enzymatic activity might be heat shock proteins acting as molecular chaperones.	WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			EICHLER, JERRY/F-2351-2012	EICHLER, JERRY/0000-0001-9409-8026				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BROCKMAN SK, 1986, J BIOL CHEM, V261, P1201; CHATEL JM, 1994, J NEUROCHEM, V63, P1111; CHATEL JM, 1993, P NATL ACAD SCI USA, V90, P2476, DOI 10.1073/pnas.90.6.2476; EICHLER J, 1991, FEBS LETT, V293, P16, DOI 10.1016/0014-5793(91)81142-U; Ellis R J, 1990, Semin Cell Biol, V1, P1; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hahn GM, 1990, STRESS PROTEINS BIOL, P79; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAZAR M, 1984, J BIOL CHEM, V259, P3703; LYLES JM, 1979, J NEUROCHEM, V33, P727, DOI 10.1111/j.1471-4159.1979.tb05218.x; MASSOULIE J, 1982, ANNU REV NEUROSCI, V5, P57, DOI 10.1146/annurev.ne.05.030182.000421; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; MORIMOTO R I, 1990, P1; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTUNDO RL, 1988, J BIOL CHEM, V263, P19398; ROTUNDO RL, 1980, CELL, V22, P595, DOI 10.1016/0092-8674(80)90369-4; ROTUNDO RL, 1980, CELL, V22, P583, DOI 10.1016/0092-8674(80)90368-2; ROTUNDO RL, 1984, P NATL ACAD SCI-BIOL, V81, P479, DOI 10.1073/pnas.81.2.479; ROTUNDO RL, 1989, J BIOL CHEM, V264, P3146; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STIEGER S, 1987, J NEUROCHEM, V49, P460, DOI 10.1111/j.1471-4159.1987.tb02887.x; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAVITIAN B, 1991, CHOLINESTERASES STRU, P125; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; VALLETTE FM, 1991, CHOLINESTERASES STRU, P98; WALKER CR, 1976, NEUROSCIENCE, V1, P509, DOI 10.1016/0306-4522(76)90103-2; Welch WJ, 1991, CURR OPIN CELL BIOL, V3, P1033, DOI 10.1016/0955-0674(91)90125-I; WILSON BW, 1974, P NATL ACAD SCI USA, V71, P3194, DOI 10.1073/pnas.71.8.3194	34	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4466	4472		10.1074/jbc.270.9.4466	http://dx.doi.org/10.1074/jbc.270.9.4466			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876213	hybrid			2022-12-25	WOS:A1995QK08400045
J	ERB, L; GARRAD, R; WANG, YJ; QUINN, T; TURNER, JT; WEISMAN, GA				ERB, L; GARRAD, R; WANG, YJ; QUINN, T; TURNER, JT; WEISMAN, GA			SITE-DIRECTED MUTAGENESIS OF P-2U PURINOCEPTORS - POSITIVELY CHARGED AMINO-ACIDS IN TRANSMEMBRANE HELIX-6 AND HELIX-7 AFFECT AGONIST POTENCY AND SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VASCULAR ENDOTHELIAL-CELLS; EXTRACELLULAR ATP; FUNCTIONAL EXPRESSION; PROLINE RESIDUES; CYSTIC-FIBROSIS; RECEPTOR; NUCLEOTIDES; MECHANISMS; CLONING; TRANSDUCTION	Two subtypes of G protein coupled receptors for nucleotides (P-2U and P-2Y purinoreceptors) contain several conserved positively charged amino acids in the third, sixth, and seventh putative transmembrane helices (TMHs). Since the fully ionized form of nucleotides has been shown to be an activating ligand for both P-2U and P-2Y purinoceptors (P(2U)R and P(2Y)R), we postulated that some of these positively charged amino acids are involved in binding of the negatively charged phosphate groups of nucleotides. To investigate the role of the conserved positively charged amino acids in purinoceptor function, a series of mutant P(2U)R cDNAs were constructed so that lysine 107 and arginine 110 in TMH 3, histidine 262 and arginine 265 in TMH 6, and arginine 292 in TMH 7 were changed to the neutral amino acid leucine or isoleucine, The mutated P(2U)R cDNAs were stably expressed in 1321N1 astrocytoma cells and receptor activity was monitored by quantitating changes in the concentration of intracellular Ca2+ upon stimulation with full (ATP, UTP) or partial (ADP, UDP) P(2U)R agonists, Neutralization of His(262), Arg(265), or Arg(292) caused a 100-850-fold decrease in the potency of ATP and UTP relative to the unmutated P(2U)R and rendered ADP and UDP ineffective, In contrast, neutralization of Lys(107) or Arg(110) did not alter the agonist potency or specificity of the P(2U)R. Neutralization of Lys(289) in the P(2U)R, which is expressed as a glutamine residue in the P-2Y subtype, did not alter receptor activity; however, a consersubtype, did not alter receptor activity; however, a conservative change from lysine to arginine at this position altered the rank order of agonist potency so that ADP and UDP were approximately 100-fold more potent than ATP and UTP, A three-dimensional model of the P(2U)R indicates the feasibility of His(262), Arg(265), and Arg(292) interactions with the phosphate groups of nucleotides.	UNIV MISSOURI,DEPT PHARMACOL,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia	ERB, L (corresponding author), UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212, USA.			Erb, Laurie/0000-0001-6372-3378	NIDCR NIH HHS [R01-DE07389] Funding Source: Medline; NIGMS NIH HHS [R01-GM36887] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE007389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036887] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSOTORRE SR, 1993, J BIOL CHEM, V268, P18640; BALLESTEROS JA, 1992, BIOPHYS J, V62, P107, DOI 10.1016/S0006-3495(92)81794-0; BARNARD EA, 1994, TRENDS PHARMACOL SCI, V15, P67, DOI 10.1016/0165-6147(94)90280-1; BOEYNAEMS JM, 1990, TRENDS PHARMACOL SCI, V11, P34, DOI 10.1016/0165-6147(90)90039-B; BOUTHERINFALSON O, 1990, BIOCHEM BIOPH RES CO, V172, P306, DOI 10.1016/S0006-291X(05)80210-4; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; ERB L, 1993, P NATL ACAD SCI USA, V90, P10449, DOI 10.1073/pnas.90.22.10449; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GACHET C, 1991, NOUV REV FR HEMATOL, V33, P347; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; LOUBATIERESMARI.MM, 1979, EUR J PHARMACOL, V59, P277; LUSTIG KD, 1992, BIOCHEM J, V284, P733, DOI 10.1042/bj2840733; LUSTIG KD, 1992, BIOCHIM BIOPHYS ACTA, V1134, P61, DOI 10.1016/0167-4889(92)90028-A; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MOTTE S, 1993, BRIT J PHARMACOL, V109, P967, DOI 10.1111/j.1476-5381.1993.tb13715.x; OLAH ME, 1992, J BIOL CHEM, V267, P10764; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEMMER WPC, 1992, BIOTECHNIQUES, V13, P215; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TURNER JT, 1990, J PHARMACOL EXP THER, V253, P1049; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; YU HX, 1991, J PHARMACOL EXP THER, V259, P1344	30	140	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4185	4188		10.1074/jbc.270.9.4185	http://dx.doi.org/10.1074/jbc.270.9.4185			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876172	hybrid			2022-12-25	WOS:A1995QK08400002
J	JAIN, SK; COX, MM; INMAN, RB				JAIN, SK; COX, MM; INMAN, RB			OCCURRENCE OF 3-STRANDED DNA WITHIN A RECA PROTEIN FILAMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 3-STRANDED DNA; ATP HYDROLYSIS; HOMOLOGOUS RECOGNITION; GENETIC-RECOMBINATION; NUCLEOSIDE TRIPHOSPHATE; PARANEMIC JOINTS; HELICAL DNA; EXCHANGE; COMPLEXES	A RecA protein-generated triple-stranded DNA species can be observed by electron microscopy, within narrowly defined conditions, Three stranded DNA is detected only when initiation of normal DNA strand exchange is precluded by heterologous sequences within the duplex DNA substrate, when ATP is hydrolyzed, and when the DNA is cross-linked with a psoralen derivative prior to removal of RecA filaments. When adenosine 5'-O-(thiotriphosphate) is used, only the product hybrid duplex DNA can be cross linked within the RecA filament, The third strand is either displaced or interwound in a conformation that does not permit crosslinking, When ATP is hydrolyzed by RecA, all three strands are cross-linked within the filament in a complex pattern that suggests a dynamic structure, This structure is altered when RecA protein is removed be fore cross-linking, Hsieh ct al, (1990) and Rao ct al, (1991, 1993) have proposed, on the basis of nuclease protection and chemical modification studies, that a stable triple-stranded DNA species can persist after removal of RecA protein, We have been unable to visualize these triple-stranded structures by the methods used in the present investigation, When RecA removal was followed immediately by interstrand cross-linking, only the two strands of the hybrid duplex DNA were cross linked.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM14711, GM32335] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM032335, R01GM014711, R01GM032335] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; BEDALE WA, 1993, J BIOL CHEM, V268, P15004; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; BORTNER C, 1990, J MOL BIOL, V215, P623, DOI 10.1016/S0022-2836(05)80173-1; BURNETT B, 1994, J MOL BIOL, V238, P540, DOI 10.1006/jmbi.1994.1313; CHIU SK, 1993, BIOCHEMISTRY-US, V32, P13146, DOI 10.1021/bi00211a025; CHOW SA, 1988, J BIOL CHEM, V263, P3335; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DAVIS RW, 1980, ADV BACTERIAL GENET, P116; DICAPUA E, 1987, EMBO J, V6, P2493, DOI 10.1002/j.1460-2075.1987.tb02531.x; DOMBROSKI DF, 1983, NUCLEIC ACIDS RES, V11, P7487, DOI 10.1093/nar/11.21.7487; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; ISAACS ST, 1977, BIOCHEMISTRY-US, V16, P1058, DOI 10.1021/bi00625a005; JAIN SK, 1992, J BIOL CHEM, V267, P4215; JAIN SK, 1994, J BIOL CHEM, V269, P20653; JAIN SK, 1994, THESIS U WISCONSIN M; KANNE D, 1982, J AM CHEM SOC, V104, P6754, DOI 10.1021/ja00388a046; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PUGH BF, 1987, J BIOL CHEM, V262, P1326; PUGH BF, 1987, J BIOL CHEM, V262, P1337; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; RAO BJ, 1993, J MOL BIOL, V229, P328, DOI 10.1006/jmbi.1993.1038; RAO BJ, 1993, P NATL ACAD SCI USA, V90, P6646, DOI 10.1073/pnas.90.14.6646; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; SCHNOS M, 1987, J MOL BIOL, V193, P377; SCHUTTE BC, 1988, BIOCHEMISTRY-US, V27, P7886, DOI 10.1021/bi00420a046; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; SHCHYOLKINA AK, 1994, FEBS LETT, V339, P113, DOI 10.1016/0014-5793(94)80396-X; STASIAK A, 1992, MOL MICROBIOL, V6, P3267, DOI 10.1111/j.1365-2958.1992.tb02194.x; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1994, BIOCHIMIE PARIS, V73, P219; UMLAUF S, 1990, THESIS U WISCONSIN M; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362	54	23	24	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4943	4949		10.1074/jbc.270.9.4943	http://dx.doi.org/10.1074/jbc.270.9.4943			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876269	hybrid			2022-12-25	WOS:A1995QK08400107
J	ORTIZ, DF; RUSCITTI, T; MCCUE, KF; OW, DW				ORTIZ, DF; RUSCITTI, T; MCCUE, KF; OW, DW			TRANSPORT OF METAL-BINDING PEPTIDES BY HMT1, A FISSION YEAST ABC-TYPE VACUOLAR MEMBRANE-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CADMIUM-SULFIDE CRYSTALLITES; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; MULTIDRUG RESISTANCE; P-GLYCOPROTEINS; IN-VITRO; GLUTATHIONE; VESICLES; PHYTOCHELATINS; ATP	The Schizosaccharomyces pombe hmt1 gene encodes an ABC (ATP-binding cassette)-type protein essential for Cd2+ tolerance. Immunoblot analysis of subcellular fractions indicates that the native HMT1 polypeptide is associated with the vacuolar membrane, Vacuolar membrane vesicles were purified from strains that hyperproduce, or are deficient in, the HMT1 protein, In vitro transport of radiolabeled substrates by these vesicles indicates that HMT1 is an ATP-dependent transporter of phytochelatins, the metal-chelating peptides involved in heavy metal tolerance of plants and certain fungi, Vacuolar vesicles containing HMT1 are capable of taking up both apo-phytochelatins and phytochelatin-Cd2+ complexes, HMT1 activity is sensitive to antibodies directed against this protein and to vanadate, but not to inhibitors affecting the vacuolar proton ATPase or ionophores that abolish the pH gradient across the vacuolar membrane. Vacuolar uptake of Cd2+ and of a glutathione conjugate were also observed, but are not attributable to HMT1. These studies highlight the importance of the yeast vacuole in detoxification of xenobiotics.	USDA ARS, CTR PLANT GENE EXPRESS, ALBANY, CA 94710 USA; UNIV CALIF BERKELEY, DEPT PLANT BIOL, BERKELEY, CA 94720 USA	United States Department of Agriculture (USDA); University of California System; University of California Berkeley			McCue, Kent/A-8973-2009	McCue, Kent/0000-0003-1914-4971				ABRAHAMSON SL, 1992, ANAL BIOCHEM, V200, P239, DOI 10.1016/0003-2697(92)90459-K; Ackrell B A, 1978, Methods Enzymol, V53, P466; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; AWASTHI YC, 1981, BLOOD, V58, P733; BALZI E, 1994, J BIOL CHEM, V269, P2206; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; COOPER A, 1992, J CELL BIOL, V119, P1459, DOI 10.1083/jcb.119.6.1459; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; DAMERON CT, 1989, NATURE, V338, P596, DOI 10.1038/338596a0; DAMERON CT, 1989, J BIOL CHEM, V264, P17355; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; GRILL E, 1989, P NATL ACAD SCI USA, V86, P6838, DOI 10.1073/pnas.86.18.6838; GRILL E, 1986, FEBS LETT, V197, P115, DOI 10.1016/0014-5793(86)80309-X; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORTENSTEINER S, 1993, J BIOL CHEM, V268, P18446; JUANG RH, 1993, ARCH BIOCHEM BIOPHYS, V304, P392, DOI 10.1006/abbi.1993.1367; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KNEER R, 1992, PHYTOCHEMISTRY, V31, P2663, DOI 10.1016/0031-9422(92)83607-Z; KONDO T, 1980, P NATL ACAD SCI-BIOL, V77, P6359, DOI 10.1073/pnas.77.11.6359; LELONG IH, 1992, FEBS LETT, V304, P256, DOI 10.1016/0014-5793(92)80632-Q; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; MURASUGI A, 1983, J BIOCHEM-TOKYO, V93, P661, DOI 10.1093/oxfordjournals.jbchem.a134222; NISHI K, 1992, MOL MICROBIOL, V6, P761, DOI 10.1111/j.1365-2958.1992.tb01526.x; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; Ow David W., 1994, V11, P339; PLOCKE DJ, 1992, EUR J BIOCHEM, V207, P201, DOI 10.1111/j.1432-1033.1992.tb17038.x; REESE RN, 1992, PLANT PHYSIOL, V98, P225, DOI 10.1104/pp.98.1.225; REESE RN, 1988, J BIOL CHEM, V263, P12832; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SALT DE, 1993, J BIOL CHEM, V268, P12297; SEEGER M, 1992, J CELL BIOL, V118, P531, DOI 10.1083/jcb.118.3.531; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; SPEISER DM, 1992, MOL CELL BIOL, V12, P5301, DOI 10.1128/MCB.12.12.5301; SPEISER DM, 1992, PLANT PHYSIOL, V99, P817, DOI 10.1104/pp.99.3.817; STEFFENS JC, 1986, J BIOL CHEM, V261, P13879; THUMANN J, 1991, FEBS LETT, V284, P66, DOI 10.1016/0014-5793(91)80763-S; VOGELILANGE R, 1990, PLANT PHYSIOL, V92, P1086, DOI 10.1104/pp.92.4.1086; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; ZEREZ CR, 1986, J BIOL CHEM, V261, P8877; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	51	344	371	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4721	4728		10.1074/jbc.270.9.4721	http://dx.doi.org/10.1074/jbc.270.9.4721			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876244	hybrid			2022-12-25	WOS:A1995QK08400079
J	ROTTINGEN, JA; ENDEN, T; CAMERER, E; IVERSEN, JG; PRYDZ, H				ROTTINGEN, JA; ENDEN, T; CAMERER, E; IVERSEN, JG; PRYDZ, H			BINDING OF HUMAN FACTOR VIIA TO TISSUE FACTOR INDUCES CYTOSOLIC CA2+ SIGNALS IN J82 CELLS, TRANSFECTED COS-1 CELLS, MADIN-DARBY CANINE KIDNEY-CELLS AND IN HUMAN ENDOTHELIAL-CELLS INDUCED TO SYNTHESIZE TISSUE FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM-CONCENTRATION; CYTOPLASMIC FREE CALCIUM; PROTEIN-KINASE-C; INOSITOL TRISPHOSPHATE; IFN-GAMMA; OSCILLATIONS; CDNA; COAGULATION; EXPRESSION; MONOLAYERS	Tissue factor (TF) is the most potent trigger of blood clotting known, It activates factor VII (FVII) thereby initiating a cascade of proteolytic reactions resulting in thrombin production, The cloning of TF revealed its structural characteristics to be those of a receptor related to the class 2 cytokine receptor superfamily, but until now no intracellular signal has been discovered related to binding of the ligand (FVIIa) to the putative receptor, We have studied possible intracellular signaling effects of the FVIIa-TF interaction by measuring cytosolic free Ca2+ in single fura-2-loaded cells and found that 200 nM FVIIa caused Ca2+ transients in about 30% of human umbilical vein endothelial cells treated with interleukin-1 beta to express TF, compared to below 5% in uninduced cells, A gradual increase of the basal Ca2+ level was also caused by binding of FVIIa, In the human bladder carcinoma cell line J82, which has a high constitutive TF activity, similar results were found, An antibody neutralizing TF activity decreased the response rate to control levels, COS-1 cells which do not make TF did not respond to FVIIa as opposed to COS-1 cells expressing TF after transfection with a human TF cDNA construct, The canine kidney cell line MDCK, a constitutive TF producer, responded especially well; up to 100% of the cells examined showed Ca2+ oscillations which were dose dependent with regard to frequency, latency, maximal amplitude, and recruitment of responding cells, The frequency was reduced by inhibition of Ca2+ influx with 100 mu M LaCl3, In confluent MDCK cells the Ca2+ oscillations were synchronous, constituting the first evidence of a synchronous cytosolic Ca2+ oscillator generated by global application of agonist, Thus, TF mediates a cytosolic Ca2+ signal upon interaction with its ligand FVIIa, thereby suggesting a more complex biological role for TF.	UNIV OSLO,BIOTECHNOL CTR OSLO,N-0371 OSLO,NORWAY; UNIV OSLO,INST BASIC MED SCI,DEPT PATHOL,INTRACELLULAR SIGNALLING LAB,N-0371 OSLO,NORWAY	University of Oslo; University of Oslo			Camerer, Eric/K-4161-2017	Camerer, Eric/0000-0002-6271-7125				ANDOH K, 1990, THROMB HAEMOSTASIS, V63, P298; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEVILACQUA MP, 1985, AM J PATHOL, V121, P393; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; BJORKLID E, 1973, BIOCHEM BIOPH RES CO, V55, P969, DOI 10.1016/0006-291X(73)91237-0; BODE HP, 1994, FEBS LETT, V339, P307, DOI 10.1016/0014-5793(94)80436-2; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; CARLSEN E, 1988, TRANSPLANTATION, V46, P575, DOI 10.1097/00007890-198810000-00022; CARSON SD, 1993, BLOOD COAGUL FIBRIN, V4, P281, DOI 10.1097/00001721-199304000-00010; DANDREA P, 1993, J BIOL CHEM, V268, P15213; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FISHER KL, 1987, THROMB RES, V48, P89, DOI 10.1016/0049-3848(87)90349-5; GLADHAUG A, 1970, BIOCHIM BIOPHYS ACTA, V215, P105, DOI 10.1016/0304-4165(70)90392-2; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1991, CELL CALCIUM, V12, P229, DOI 10.1016/0143-4160(91)90023-8; HJORT PF, 1957, SCAND J CLIN LAB S27, V9, P183; HVATUM M, 1966, BIOCHIM BIOPHYS ACTA, V130, P92, DOI 10.1016/0304-4165(66)90012-2; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KLEIN JB, 1990, J IMMUNOL, V144, P4305; LASKEY RE, 1992, P NATL ACAD SCI USA, V89, P1690, DOI 10.1073/pnas.89.5.1690; LE DT, 1992, J BIOL CHEM, V267, P15447; LOESSBERG PA, 1993, J BIOL CHEM, V268, P19769; MASON MJ, 1992, AM J PHYSL CELL PHYS, V264, pC654; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; NARAHARA N, 1994, ARTERIOSCLER THROMB, V14, P1815, DOI 10.1161/01.ATV.14.11.1815; NATHANSON MH, 1992, MOL BIOL CELL, V3, P113, DOI 10.1091/mbc.3.1.113; NEZU N, 1990, J IMMUNOL, V145, P3126; NGEZAHAYO A, 1993, PFLUG ARCH EUR J PHY, V422, P413, DOI 10.1007/BF00374302; OSADA S, 1994, HEPATOLOGY, V19, P514; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PICKLES RJ, 1991, P ROY SOC B-BIOL SCI, V245, P53, DOI 10.1098/rspb.1991.0087; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; REUNING U, 1993, THROMB HAEMOSTASIS, V69, P197; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROTNES JS, 1994, CELL CALCIUM, V15, P467, DOI 10.1016/0143-4160(94)90111-2; ROTNES JS, 1992, CELL CALCIUM, V13, P487, DOI 10.1016/0143-4160(92)90017-M; ROTNES JS, 1994, EUR J HAEMATOL, V53, P65; SAGE SO, 1989, J BIOL CHEM, V264, P6; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; SCHWARZ G, 1994, CELL CALCIUM, V15, P45, DOI 10.1016/0143-4160(94)90103-1; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	50	184	188	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4650	4660		10.1074/jbc.270.9.4650	http://dx.doi.org/10.1074/jbc.270.9.4650			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876236	hybrid			2022-12-25	WOS:A1995QK08400070
J	YU, X; INESI, G				YU, X; INESI, G			VARIABLE STOICHIOMETRIC EFFICIENCY OF CA2+ AND SR2+ TRANSPORT BY THE SARCOPLASMIC-RETICULUM ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; ENERGY INTERCONVERSION; PHOSPHORYL TRANSFER; TRANSIENT STATE; CALCIUM ATPASE; VESICLES; BINDING; STRONTIUM; PUMP; CONSEQUENCES	In comparative experiments with Ca2+ ATPase in native sarcoplasmic reticulum vesicles and reconstituted proteoliposomes, we find that a variable stoichiometry of Ca2+ or Sr2+ transport per ATPase cycle is observed in the absence of passive leak through independent channels. The observed ratio is commonly lower than the optimal value of 2 and depends on the composition of the reaction mixture. In all cases, a progressive rise in the lumenal concentration of Ca2+ and Sr2+ is accompanied by a parallel reduction of coupling ratios. Significant cant ATPase activity remains even after asymptotic levels of Ca2+ accumulation are reached. This residual activity subsides if the Ca2+ concentration in the outer medium is reduced below activating levels (as it would following Ca2+ transients in muscle fibers), The reduction of stoichiometric coupling is explained with a reaction scheme, including a branched pathway for hydrolytic cleavage of phosphorylated intermediate before release of Ca2+ into the lumen of the vesicles. Flux through this pathway is favored when net lumenal Ca2+ dissociation from the phosphoenzyme is impeded and results in P-i production accompanied by lumenal and medium Ca2+ exchange. Occurrence of reactions through branched pathways may have general implications for the stoichiometric efficiency of energy-transducing enzymes.			YU, X (corresponding author), UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA.				NHLBI NIH HHS [HL27867-13] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERMAN MC, 1990, BIOCHIM BIOPHYS ACTA, V1029, P235, DOI 10.1016/0005-2736(90)90159-L; de Meis L, 1974, Biochemistry, V13, P5032, DOI 10.1021/bi00721a026; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; FUJIMORI T, 1992, J BIOL CHEM, V267, P18466; GUIMARAESMOTTA H, 1984, J BIOL CHEM, V259, P8699; HASSELBACH W, 1964, PROGR BIOPHYS MOL BI, V14, P169; HILL T, 1991, STATISTICAL THERMODY; HORGAN DJ, 1972, ANAL BIOCHEM, V48, P147, DOI 10.1016/0003-2697(72)90178-9; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; INESI G, 1988, METHOD ENZYMOL, V157, P154; JOHNSON EA, 1985, P NATL ACAD SCI USA, V82, P5352, DOI 10.1073/pnas.82.16.5352; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTONOSI A, 1964, J BIOL CHEM, V239, P659; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MITCHELL P, 1979, SCIENCE, V206, P1148, DOI 10.1126/science.388618; ORLOWSKI S, 1993, FEBS LETT, V328, P296, DOI 10.1016/0014-5793(93)80947-S; PENEFSKY ZJ, 1991, ADV ENZYMOL, V64, P173; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Scarpa A, 1979, Methods Enzymol, V56, P301; SCARPA A, 1972, J GEN PHYSIOL, V60, P735, DOI 10.1085/jgp.60.6.735; SOLER F, 1990, EUR J BIOCHEM, V192, P347, DOI 10.1111/j.1432-1033.1990.tb19233.x; TAKAKUWA Y, 1981, J BIOL CHEM, V256, P2696; VERJOVSKIALMEIDA S, 1977, BIOCHEMISTRY-US, V16, P329, DOI 10.1021/bi00621a026; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; YU X, 1994, J BIOL CHEM, V269, P16656	34	82	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4361	4367		10.1074/jbc.270.9.4361	http://dx.doi.org/10.1074/jbc.270.9.4361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876199	hybrid			2022-12-25	WOS:A1995QK08400030
J	LAROSE, L; GISH, G; PAWSON, T				LAROSE, L; GISH, G; PAWSON, T			CONSTRUCTION OF AN SH2 DOMAIN-BINDING SITE WITH MIXED SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; SIGNAL TRANSDUCTION; V-SRC; PHOSPHATIDYLINOSITOL-3 KINASE; PHOSPHORYLATION SITES; PHOSPHOTYROSINE; ASSOCIATION	SH2 domains bind to specific phosphotyrosine-containing sites in a fashion dictated by the amino acids flanking the phosphotyrosine. Attention has focused on the role of the three COOH-terminal positions (+1 to +3) in generating specificity. Autophosphorylation of Tyr(1021) in the tail of the beta-receptor for platelet-derived growth factor creates a specific binding site for the COOH-terminal SH2 domain of phospholipase C (PLC)-gamma 1. We show that the residues 4 and 5 amino acids COOH-terminal to Tyr(1021) (+4 Leu and +5 Pro) are required for efficient PLC-yl binding, and that their replacement with the corresponding residues from a phosphatidylinositol 3'-kinase binding site abrogates stable association with PLC-gamma 1. In contrast, replacement of the +3 Pro with Met produces a Tyr(1021) Site with mixed specificity that binds both PLC-gamma 1 and phosphatidylinositol 3'-kinase. This motif is rendered specific for phosphatidylinositol 3'-kinase by further substitution of the +4 Leu. These results indicate that the +4 and +5 residues are important for the selective binding of specific SH2 domains. This study suggests that phosphotyrosine sites can be tailored to bind one or more SH2 domains with high affinity, depending on the combination of residues in the +1 to +5 positions.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOLEC BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013					CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GISH G, 1995, IN PRESS METHODS ENZ; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAROSE L, 1993, ONCOGENE, V8, P2493; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Payne G, 1994, Chem Biol, V1, P99, DOI 10.1016/1074-5521(94)90047-7; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3858	3862		10.1074/jbc.270.8.3858	http://dx.doi.org/10.1074/jbc.270.8.3858			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876130	hybrid			2022-12-25	WOS:A1995QH68800060
J	SCHONHORN, JE; AKOMPONG, T; WESSLINGRESNICK, M				SCHONHORN, JE; AKOMPONG, T; WESSLINGRESNICK, M			MECHANISM OF TRANSFERRIN RECEPTOR DOWN-REGULATION IN K562 CELLS IN RESPONSE TO PROTEIN-KINASE-C ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELLS; MEDIATED ENDOCYTOSIS; PHORBOL ESTERS; MEGAKARYOBLASTIC DIFFERENTIATION; GENE-EXPRESSION; GROWTH-FACTOR; IRON UPTAKE; PHOSPHORYLATION; SERINE-24; BINDING	Treatment with phorbol esters increases endocytosis of the transferrin receptor in K562 cells (Klausner, R, D,, Harford, J,, and van Renswoude, J, (1984) Proc. Natl. Acad, Sci, U, S. A. 81, 3005-3009), In this report, we demonstrate that this effect is reversible within early times of protein kinase C activation (<2 h) but that prolonged exposure to phorbol esters results in a net loss of receptors, These effects are not due to the differentiation response of K562 cells to phorbol esters since bryostatin-1 also down-regulates the endocytosis of the transferrin receptor and shut downs receptor synthesis, but does not induce differentiation (Hocevar, B, A., Morrow, D, M,, Tykocinski, M, L,, and Fields, A. P, (1992) J. Cell Sci, 101, 671-679), We have characterized the early stages of receptor down-regulation which occur due to stimulation of receptor internalization from the cell surface, The fact that fluid-phase pinocytosis is also enhanced upon protein kinase C activation indicates that this effect is not specific for the transferrin receptor itself, but is a rather general cellular response to tumor-promoting phorbol esters, The fate of down-regulated transferrin receptors was followed in morphological and subcellular fractionation studies that demonstrate localization of this pool of receptors in early endocytic and recycling compartments, Our results exclude the possibility that transferrin receptor down-regulation results in trafficking of the receptor to lysosomal compartments for degradation, This idea is consistent with the observations that the time course of transferrin receptor degradation is not enhanced in stimulated K562 cells, while transferrin receptor synthesis is shut down, Our results rigorously demonstrate that activation of protein kinase C down-regulates the K562 cell transferrin receptor in two stages: acute regulation of early steps in endocytosis that results in an immediate reduction of similar to 40% in cell surface number of receptors and a more chronic reduction in transferrin receptor synthesis upon prolonged exposure to phorbol esters (>15 h).	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health								ALITALO R, 1988, BLOOD, V71, P899; ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; BACKER JM, 1991, BIOCHEM PHARMACOL, V41, P1267, DOI 10.1016/0006-2952(91)90097-O; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; DAVIS RJ, 1986, J BIOL CHEM, V261, P9034; DICKSON RB, 1983, BIOCHEMISTRY-US, V22, P5667, DOI 10.1021/bi00293a033; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; HO PTC, 1989, CANCER RES, V49, P1989; HOCEVAR BA, 1992, J CELL SCI, V101, P671; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KRAFT AS, 1987, ONCOGENE, V1, P111; KRAFT AS, 1986, P NATL ACAD SCI USA, V84, P8438; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LUCOCQ J, 1991, J CELL SCI, V100, P753; MAY WS, 1984, P NATL ACAD SCI-BIOL, V81, P2016, DOI 10.1073/pnas.81.7.2016; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCGRAW TE, 1988, J CELL BIOL, V106, P1061, DOI 10.1083/jcb.106.4.1061; MULFORD CA, 1988, J BIOL CHEM, V263, P5455; PELICCI PG, 1984, LEUKEMIA RES, V8, P597, DOI 10.1016/0145-2126(84)90008-0; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; ROVERA G, 1982, ANN NY ACAD SCI, V397, P211, DOI 10.1111/j.1749-6632.1982.tb43428.x; SCHONHORN JE, 1994, MOL CELL BIOCHEM, V135, P159, DOI 10.1007/BF00926519; SUTHERLAND JA, 1986, J BIOL RESP MODIF, V5, P250; TESTA U, 1984, CANCER RES, V44, P4981; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P690; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x	33	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3698	3705		10.1074/jbc.270.8.3698	http://dx.doi.org/10.1074/jbc.270.8.3698			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876109	hybrid			2022-12-25	WOS:A1995QH68800038
J	SIBBESEN, O; KOCH, B; HALKIER, BA; MOLLER, BL				SIBBESEN, O; KOCH, B; HALKIER, BA; MOLLER, BL			CYTOCHROME P-450(TYR) IS A MULTIFUNCTIONAL HEME-THIOLATE ENZYME CATALYZING THE CONVERSION OF L-TYROSINE TO P-HYDROXYPHENYLACETALDEHYDE OXIME IN THE BIOSYNTHESIS OF THE CYANOGENIC GLUCOSIDE DHURRIN IN SORGHUM-BICOLOR (L) MOENCH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-PLANTS; INVITRO BIOSYNTHESIS; N-HYDROXYTYROSINE; LINN MOENCH; PURIFICATION; INTERMEDIATE; INVOLVEMENT; REDUCTASE; CULTURES	Cytochrome P-450(TYR), which catalyzes the N-hydroxylation of L-tyrosine in the biosynthesis of the cyanogenic glucoside dhurrin in Sorghum bicolor (L.) Moench has recently been isolated (Sibbesen, O., Koch, B., Halkier, B. A., and Moller, B. L. (1994) Proc. Natl. Acad. Sci. U. S. A. 92, 9740-9744). Reconstitution of the enzyme activity in lipid micelles containing cytochrome P-450, and NADPH-cytochrome P-450 oxidoreductase demonstrates that cytochrome P-450(TYR) catalyzes the conversion of L-tyrosine into p-hydroxyphenylacetaldehyde oxime. Earlier studies with microsomes have demonstrated that this conversion involves two N-hydroxylation reactions of which the first produces N-hydroxytyrosine. We propose that the product of the second N-hydroxylation reaction is N,N-dihydroxytyrosine. N,N-dihydroxytyrosine is dehydrated to 2-nitroso-3-(p-hydroxyphenyl) propionic acid which decarboxylates to p-hydroxyphenylacetaldehyde oxime. The dehydration and decarboxylation reactions may proceed non-enzymatically. The E/Z ratio of the p-hydroxyphenylacetaldehyde oxime produced by reconstituted cytochrome P-450(TYR) is 69:31. Lipid micelles made from L-alpha-dilauroyl phosphatidylcholine are more than twice as effective in reconstituting cytochrome P-450(TYR) activity as compared to other lipids. The K-m and turnover number of the enzyme is 0.14 mM and 200 min(-1), respectively, when assayed in the presence of 15 mM NaCl whereas the values are 0.21 mM and 230 min(-1) when assayed in the absence of added salt. The multifunctional nature cytochrome P-450(TYR) is confirmed by demonstrating that binding of L-tyrosine or N-hydroxytyrosine mutually excludes binding of the other substrate. These results explain why the conversion of tyrosine to p-hydroxyphenylacetaldehyde oxime as earlier reported (Moller, B. L., and Conn, E. E. (1980) J. Biol. Chem. 255, 3049-3056) shows the phenomenon of catalytic facilitation (''channeling''). Cytochrome P-450(TYR) is the first isolated multifunctional heme-thiolate enzyme from plants. N-Hydroxylases of the cytochrome P-450 type with high substrate specificity have not previously been reported.	ROYAL VET & AGR UNIV,DEPT PLANT BIOL,PLANT BIOCHEM LAB,DK-1871 FREDERIKSBERG C,DENMARK	University of Copenhagen			Møller, Birger Lindberg/H-2657-2014; Halkier, Barbara A/H-3196-2014; Møller, Birger Lindberg/GQI-1792-2022	Møller, Birger Lindberg/0000-0002-3252-3119; Halkier, Barbara A/0000-0002-3742-702X; Møller, Birger Lindberg/0000-0002-3252-3119; Koch, Birgit/0000-0002-4006-2690				AKAZAWA T, 1960, PLANT PHYSIOL, V35, P535, DOI 10.1104/pp.35.4.535; BENVENISTE I, 1986, BIOCHEM J, V235, P365, DOI 10.1042/bj2350365; EBERHART DC, 1991, ARCH BIOCHEM BIOPHYS, V291, P231, DOI 10.1016/0003-9861(91)90128-6; FARNDEN KJF, 1973, PHYTOCHEMISTRY, V12, P2673, DOI 10.1016/0031-9422(73)85078-2; FUKUDA H, 1994, BIOCHEM BIOPH RES CO, V201, P516, DOI 10.1006/bbrc.1994.1732; HALKIER BA, 1991, P NATL ACAD SCI USA, V88, P487, DOI 10.1073/pnas.88.2.487; HALKIER BA, 1990, J BIOL CHEM, V265, P21114; HALKIER BA, 1989, J BIOL CHEM, V264, P19487; HALKIER BA, 1991, PLANT PHYSIOL, V96, P10, DOI 10.1104/pp.96.1.10; HOSEL W, 1985, PLANTA, V166, P176, DOI 10.1007/BF00397345; IKUSHIRO S, 1989, BIOCHIM BIOPHYS ACTA, V984, P50, DOI 10.1016/0005-2736(89)90341-6; JEFCOATE CR, 1978, METHOD ENZYMOL, V27, P258; KOCHS G, 1989, ARCH BIOCHEM BIOPHYS, V273, P543, DOI 10.1016/0003-9861(89)90514-6; KOUKOL J, 1962, J BIOL CHEM, V237, P3223; MCFARLANE IJ, 1975, J BIOL CHEM, V250, P4708; MEIJER AH, 1993, J CHROMATOGR, V635, P237, DOI 10.1016/0021-9673(93)80366-G; MOLLER BL, 1977, ACTA CHEM SCAND B, V31, P343, DOI 10.3891/acta.chem.scand.31b-0343; MOLLER BL, 1979, J BIOL CHEM, V254, P8575; MOLLER BL, 1980, J BIOL CHEM, V255, P3049; OMURA T, 1964, J BIOL CHEM, V239, P2379; REAY PF, 1974, J BIOL CHEM, V249, P5826; SHIMADA M, 1977, ARCH BIOCHEM BIOPHYS, V180, P199, DOI 10.1016/0003-9861(77)90026-1; SIBBESEN O, 1994, SOC EXP BIOL SEMIN S, V56, P227; SIBBESEN O, 1994, P NATL ACAD SCI USA, V92, P9740; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531	26	122	127	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3506	3511		10.1074/jbc.270.8.3506	http://dx.doi.org/10.1074/jbc.270.8.3506			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876084	hybrid			2022-12-25	WOS:A1995QH68800011
J	STANLEY, SL; TIAN, KR; KOESTER, JP; LI, E				STANLEY, SL; TIAN, KR; KOESTER, JP; LI, E			THE SERINE-RICH ENTAMOEBA-HISTOLYTICA PROTEIN IS A PHOSPHORYLATED MEMBRANE-PROTEIN CONTAINING O-LINKED TERMINAL N-ACETYLGLUCOSAMINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ESCHERICHIA-COLI; ADHERENCE LECTIN; GLYCOPROTEINS; GLYCOSYLATION; EXPRESSION; THREONINE; GALACTOSE; CLONING; ANTIGEN	Previously, we described the isolation of a cDNA clone and the gene encoding a protective antigen of the protozoan parasite Entamoeba histolytica, the serine-rich Entamoeba histolytica protein (SREHP). The derived amino acid sequence of the SREHP cDNA clone was remarkable for a high serine content (52/233 amino acids), a putative signal sequence, multiple hydrophilic dodecapeptide and octapeptide tandem repeats, and a hydrophobic C-terminal putative membrane-spanning region. Here, we show that SREHP is modified by the addition of phosphate at serine residues, O-linked terminal N-acetylglucosamine residues, and by acylation. When the SREHP gene is expressed in baculovirus transformed Sf-9 cells, the product is also phosphorylated and glycosylated and is localized to the plasma membrane of the insect cells, The native SREHP molecule also serves as a potent chemoattractant for amebic trophozoites. The data presented here suggest that SREHP is a unique membrane protein with phosphorylation and glycosylation patterns usually associated with nuclear or cytoplasmic proteins.	WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	STANLEY, SL (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA.				NIAID NIH HHS [AI30084, AI01231] Funding Source: Medline; NIDDK NIH HHS [DK02072] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI001231, R01AI030084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK002072] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEIJON C, 1988, P NATL ACAD SCI USA, V85, P1010, DOI 10.1073/pnas.85.4.1010; AMES BN, 1966, METHOD ENZYMOL, V8, P155; BAILEY GB, 1985, J PROTOZOOL, V32, P341; BIZZOZERO OA, 1994, J NEUROCHEM, V62, P1163; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; DIN NU, 1992, BIOCH INT, V27, P55; FERGUSON MAJ, 1988, POST TRANSLATIONAL M, P1; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HOLDER AA, 1988, PROGR ALLERGY, V41, P148; HOLT GD, 1986, J BIOL CHEM, V261, P8049; LI E, 1988, J EXP MED, V167, P1725, DOI 10.1084/jem.167.5.1725; LI E, 1992, MOL BIOCHEM PARASIT, V50, P355, DOI 10.1016/0166-6851(92)90234-B; LI E, 1989, INFECT IMMUN, V57, P8, DOI 10.1128/IAI.57.1.8-12.1989; LI E, 1987, J BIOL CHEM, V262, P13773; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Lushbaugh W.B., 1988, P41; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MCCOY JJ, 1993, J BIOL CHEM, V268, P24223; MYUNG K, 1992, ARCHIVES OF MEDICAL RESEARCH, VOL 23, NO 2, P285; NYAME K, 1987, J BIOL CHEM, V262, P7990; PETRI WA, 1989, J BIOL CHEM, V264, P3007; QUE XC, 1994, MOL BIOCHEM PARASIT, V66, P111, DOI 10.1016/0166-6851(94)90041-8; QUE XH, 1993, MOL BIOCHEM PARASIT, V60, P161, DOI 10.1016/0166-6851(93)90128-K; STANLEY SL, 1990, P NATL ACAD SCI USA, V87, P4976, DOI 10.1073/pnas.87.13.4976; STANLEY SL, 1992, MOL BIOCHEM PARASIT, V50, P127, DOI 10.1016/0166-6851(92)90250-N; STANLEY SL, 1991, JAMA-J AM MED ASSOC, V266, P1984, DOI 10.1001/jama.266.14.1984; STANLEY SL, 1988, MOL IMMUNOL, V25, P285, DOI 10.1016/0161-5890(88)90020-X; STANLEY SL, 1993, SEMIN GASTROINTEST D, V4, P214; STOFFEL W, 1983, H-S Z PHYSIOL CHEM, V364, P1455, DOI 10.1515/bchm2.1983.364.2.1455; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; ZHANG TH, 1994, PARASITE IMMUNOL, V16, P225, DOI 10.1111/j.1365-3024.1994.tb00344.x; ZHANG TH, 1994, INFECT IMMUN, V62, P1166, DOI 10.1128/IAI.62.4.1166-1170.1994	35	57	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4121	4126		10.1074/jbc.270.8.4121	http://dx.doi.org/10.1074/jbc.270.8.4121			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876162	hybrid			2022-12-25	WOS:A1995QH68800096
J	TOWATARI, M; MAY, GE; MARAIS, R; PERKINS, GR; MARSHALL, CJ; COWLEY, S; ENVER, T				TOWATARI, M; MAY, GE; MARAIS, R; PERKINS, GR; MARSHALL, CJ; COWLEY, S; ENVER, T			REGULATION OF GATA-2 PHOSPHORYLATION BY MITOGEN-ACTIVATED PROTEIN-KINASE AND INTERLEUKIN-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTOR; MAP KINASE; ERYTHROID-DIFFERENTIATION; GROWTH-FACTORS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; STEEL FACTOR; CELL-LINE; FAMILY	GATA-2 is a member of a family of transcription factors which bind a common DNA sequence motif (WGA-TAR) through an evolutionarily conserved zinc finger domain, An essential role for GATA-2 in the development of hematopoietic stem cells has recently been shown in gene targeting experiments in mice, Here we show that GATA-2 exists in hematopoietic progenitor cells as a phosphoprotein, Stimulation of progenitors with interleukin-3 (IL-3) results in enhanced phosphorylation of GATA-2 which occurs within 5 min. IL-3 is known to signal in part through mitogen-activated protein (MAP) kinase, and evidence for MAP kinase signaling in the control of GATA-2 phosphorylation was obtained by genetically manipulating the MAP kinase pathway in COS cells using either constitutively activating or interfering mutants of MAP kinase kinase, Furthermore, using an interfering mutant of MAP kinase kinase, we directly demonstrated a critical role for the MAP kinase pathway in the IL-3-dependent phosphorylation of GATA-2 in hematopoietic progenitor cells. Finally, in vitro phosphorylation experiments using recombinant GATA-2 raise the possibility that MAP kinase itself may phosphorylate GATA-2, Our results provide evidence for phosphorylation via the MAP kinase pathway constituting a cytoplasmic link between GATA-2 and growth factor receptors and are consistent with the hypothesis that GATA-2 is involved in the growth factor responsiveness and proliferation control of hematopoietic progenitor cells,	INST CANC RES,CHESTER BEATTY LABS,LEUKAEMIA RES FUND CTR,LONDON SW3 6JB,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,CELL & MOLEC BIOL SECT,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Marais, Richard/0000-0001-7484-4183; Cowley, Sally/0000-0003-0297-6675				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CROSS MA, 1994, ONCOGENE, V9, P3013; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; DEXTER TM, 1979, NATURE, V277, P471, DOI 10.1038/277471a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LEONARD M, 1993, BLOOD, V82, P1071; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARVEL J, 1994, ONCOGENE, V9, P1117; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MIYAJIMA A, 1993, BLOOD, V82, P1960; MOUTHON MA, 1993, BLOOD, V81, P647; NAGAI T, 1994, BLOOD, V84, P1074, DOI 10.1182/blood.V84.4.1074.bloodjournal8441074; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OKUDA K, 1992, BLOOD, V79, P2880; ORKIN SH, 1992, BLOOD, V80, P575; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PERKINS GR, 1993, J EXP MED, V178, P1429, DOI 10.1084/jem.178.4.1429; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SETH A, 1991, J BIOL CHEM, V266, P23521; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER J, 1993, BLOOD, V82, P1493; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; Whetton AD, 1993, CURR OPIN CELL BIOL, V5, P1044, DOI 10.1016/0955-0674(93)90090-D; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	51	98	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4101	4107		10.1074/jbc.270.8.4101	http://dx.doi.org/10.1074/jbc.270.8.4101			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876160	hybrid, Green Submitted			2022-12-25	WOS:A1995QH68800093
J	YAMASHIRO, S; YAMAKITA, Y; YOSHIDA, KS; TAKIGUCHI, K; MATSUMURA, F				YAMASHIRO, S; YAMAKITA, Y; YOSHIDA, KS; TAKIGUCHI, K; MATSUMURA, F			CHARACTERIZATION OF THE COOH TERMINUS OF NONMUSCLE CALDESMON MUTANTS LACKING MITOSIS-SPECIFIC PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEINS; SMOOTH-MUSCLE; NONMUSCLE CALDESMON; CA-2+ REGULATION; ATPASE ACTIVITY; P34CDC2 KINASE; THIN-FILAMENTS; TROPOMYOSIN; ACTOMYOSIN; MICROFILAMENTS	Phosphorylation of rat non muscle caldesmon by cdc2 kinase causes reduction in most of caldesmon's properties, including caldesmon's binding to actin, myosin, and calmodulin, as well as its inhibition of actomyosin ATPase, We have generated and characterized the COOH terminus of caldesmon mutants lacking mitosis-specific phosphorylation sites, because the COOH-terminal half of caldesmon contains all ? putative Ser or Thr sites for cdc2 kinase. Codons for the 7 putative Ser or Thr residues have been mutated to Ala, and resultant mutants were bacterially expressed. Analyses of the phosphopeptide maps of these mutants have identified 6 sites, including Ser-249, Ser-462, Thr-468, Ser-491, Ser-497, and Ser-527 as the mitosis-specific phosphorylation sites, whereas the phosphorylation of the remaining site, Thr-377, is not detected by this assay method. Actin binding experiments have suggested that 5 sites including Ser-249, Ser-462, Thr-468, Ser-491, and Ser-497 are important for the phosphorylation-dependent reduction in actin binding. Characterization of a mutant lacking all 7 Ser or Thr sites (7-fold mutant) has revealed that 7-fold mutation eliminates all phosphorylation sites by cdc2 kinase, While the in vitro properties of the 7-fold mutant, including actin, myosin, and calmodulin binding and inhibition of actomyosin ATPase, are very similar to those of nonmutated protein, such properties are not affected by the treatment with cdc2 kinase in contrast to nonmutated protein. This mutant should thus be useful to explore the functions of the mitosis-specific phosphorylation of caldesmon.			YAMASHIRO, S (corresponding author), RUTGERS STATE UNIV,DEPT MOLEC BIOL & BIOCHEM,NELSON HALL,PISCATAWAY,NJ 08855, USA.		Yamakita, Yoshihiko/A-3003-2016	Yamashiro, Shigeko/0000-0001-7207-9406	NATIONAL CANCER INSTITUTE [R37CA042742] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA42742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CRAIG SW, 1982, TRENDS BIOCHEM SCI, V7, P88, DOI 10.1016/0968-0004(82)90153-0; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; GALAZKIEWICZ B, 1989, EUR J BIOCHEM, V181, P607, DOI 10.1111/j.1432-1033.1989.tb14767.x; GALAZKIEWICZ B, 1991, EUR J BIOCHEM, V195, P543, DOI 10.1111/j.1432-1033.1991.tb15735.x; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KORN ED, 1982, METHOD ENZYMOL, V85, P357; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1989, J CELL SCI, V92, P131; MAK AS, 1991, J BIOL CHEM, V266, P19971; MAK AS, 1991, J BIOL CHEM, V266, P6678; MARSTON SB, 1991, BIOCHEM J, V279, P1; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; NOVY RE, 1991, J BIOL CHEM, V266, P16917; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; REDWOOD CS, 1993, FEBS LETT, V327, P85, DOI 10.1016/0014-5793(93)81045-2; SANGER JW, 1976, CELL MOTILITY, P1295; SCHROEDER TE, 1976, CELL MOTILITY, P265; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; YAMAKITA Y, 1982, J BIOL CHEM, V267, P12022; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YAMASHIROMATSUM.S, 1988, J CELL BIOL, V106, P1973	34	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4023	4030		10.1074/jbc.270.8.4023	http://dx.doi.org/10.1074/jbc.270.8.4023			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876150	hybrid			2022-12-25	WOS:A1995QH68800083
J	GUBITOSIKLUG, RA; YU, SP; CHOI, DW; GROSS, RW				GUBITOSIKLUG, RA; YU, SP; CHOI, DW; GROSS, RW			CONCOMITANT ACCELERATION OF THE ACTIVATION AND INACTIVATION KINETICS OF THE HUMAN DELAYED RECTIFIER K+ CHANNEL (KV1.1) BY CA2+-INDEPENDENT PHOSPHOLIPASE A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; ARACHIDONIC-ACID METABOLITES; ION CHANNELS; POTASSIUM CHANNELS; FATTY-ACIDS; CELLS; IDENTIFICATION; PLASMALOGEN; GLYCEROPHOSPHOLIPIDS; CHROMATOGRAPHY	The electrophysiologic sequelae of arachidonic acid re lease mediated by the major phospholipase A(2)(PLA(2)) in electrically active tissues (i.e. the 40-kDa Ca2+-independent PLA(2)) were assessed in Sf9 cells expressing the human recombinant delayed rectifier K+ channel Kv1.1. Intracellular administration of Ca2+-independent PLA(2) increased the rate of activation of the macroscopic current (from tau(act) = 6.25 +/- 0.76 ms to tau(act,PLA2) = 2.78 +/- 0.78 ms at 40 mV) and resulted in channel inactivation (from no observed inactivation to tau(inact) = 103 +/- 6 ms at 40 mV), which were: 1) dependent on the enrichment of Sf9 cell phospholipids in esterified arachidonic acid; 2) ablated by pretreatment of the PLA(2) by the mechanism-based inhibitor (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one; and 3) manifest prior to development of alterations in cellular permeability. The bidirectional effects of Ca2+-independent PLA(2) were indistinguishable from the effects of exogenously applied arachidonic acid (AA), which specifically and reversibly increased the rates of channel activation (from tau(act) = 5.73 +/- 0.88 ms to tau(act,AA) = 1.91 +/- 0.39 ms at 40 mV) and inactivation (from no observed inactivation to tau(inact) = 76.6 +/- 1.4 ms at 40 mV). These electrophysiologic alterations resulted from the effects of arachidonic acid per se since Sf9 cells did not produce oxygenated eicosanoid metabolites, and neither exogenous administration nor in situ generation of other fatty acids resulted in these effects. Collectively, these results unambiguously demonstrate the role of arachidonic acid per se on Kv1.1 electrophysiologic function and suggest the importance of Ca2+-independent PLA(2) as an enzymic modulator of ion channel function in electrically active tissues.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV BIOORGAN CHEM & MOLEC PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					PHS HHS [41250] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELARDETTI F, 1989, NEURON, V3, P497, DOI 10.1016/0896-6273(89)90208-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DAMRON DS, 1993, J BIOL CHEM, V268, P27335; FRASER D, 1993, NEURON, V11, P638; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HILLE B, 1992, IONIC CHANNELS EXCIT, P1; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; HONORE E, 1994, P NATL ACAD SCI USA, V91, P1937, DOI 10.1073/pnas.91.5.1937; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KAMB A, 1992, METHOD ENZYMOL, V207, P423; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; MANCINI JA, 1993, EUR J BIOCHEM, V218, P477, DOI 10.1111/j.1432-1033.1993.tb18399.x; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; RAMASWAMI M, 1990, Molecular and Cellular Neuroscience, V1, P214, DOI 10.1016/1044-7431(90)90004-N; SALMON JA, 1982, METHOD ENZYMOL, V86, P477; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; VILLARROEL A, 1993, FEBS LETT, V335, P184, DOI 10.1016/0014-5793(93)80726-B; WANG H, 1994, J NEUROSCI, V14, P4588; WOLF RA, 1985, J BIOL CHEM, V260, P7295; YABUUCHI H, 1968, J LIPID RES, V9, P65; ZONA C, 1993, NEUROREPORT, V4, P359, DOI 10.1097/00001756-199304000-00004	28	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2885	2888		10.1074/jbc.270.7.2885	http://dx.doi.org/10.1074/jbc.270.7.2885			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852365	hybrid			2022-12-25	WOS:A1995QG47100002
J	GORVEL, JP; ESCOLA, JM; STANG, E; BAKKE, O				GORVEL, JP; ESCOLA, JM; STANG, E; BAKKE, O			INVARIANT CHAIN INDUCES A DELAYED TRANSPORT FROM EARLY TO LATE ENDOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; HLA-DR; ENDOCYTIC PATHWAY; HISTOCOMPATIBILITY ANTIGENS; INTRACELLULAR-TRANSPORT; SURFACE EXPRESSION; MEMBRANE-PROTEINS; CARRIER VESICLES; FUSION INVITRO; MOLECULES	Invariant chain associated with class II molecules is proteolytically processed in several distinct intermediates during its transport through the endocytic pathway. Using subcellular fractionation, early and late endosomal compartments were separated in human fibroblasts transfected with HLA-DR (4N5 cells) and supertransfected with invariant chain (4N5Li cells) or invariant chain lacking most of the cytoplasmic tail (4N5 Delta 20Ii cells). Early and late endosome membrane fractions were characterized by morphology and by analyzing the presence of the Rab5 and Rab7 GTPases as markers of early and late endosomes, respectively. The transfer of endocytosed horseradish peroxidase from early to late endosomes proceeded relatively rapid both in 4N5 and 4N5 Delta 20Ii cells (t(1/2) = 25 min), whereas this transfer was significantly delayed (t(1/2) = 2 h) in 4N5Ii cells. Pulse-chase experiments showed that invariant chain and its degradation products were first observed in early endosomes and thereafter in late endosomes. Our results strongly suggest that invariant chain induces a retention mechanism in the endocytic pathway.	UNIV OSLO,DEPT BIOL,DIV MOLEC CELL BIOL,N-0316 OSLO,NORWAY; CNRS,INSERM,CTR IMMUNOL,F-13288 MARSEILLE 9,FRANCE	University of Oslo; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Gorvel, Jean-Pierre/O-1332-2018	Gorvel, Jean-Pierre/0000-0002-2829-9804; Bakke, Oddmund/0000-0003-4843-7626				BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BREMNES B, 1994, J CELL SCI, V107, P2021; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAMB CA, 1992, J IMMUNOL, V148, P3478; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LOSS GE, 1993, J IMMUNOL, V150, P3187; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NGUYEN QV, 1989, J BIOL CHEM, V264, P1631; PAPINI E, 1993, J BIOL CHEM, V268, P1567; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; PIETERS J, 1993, J CELL SCI, V106, P831; QUARANTA V, 1984, J IMMUNOL, V132, P1900; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; STRUBIN M, 1984, EMBO J, V3, P869, DOI 10.1002/j.1460-2075.1984.tb01898.x; SUNG E, 1981, MOL IMMUNOL, V18, P899, DOI 10.1016/0161-5890(81)90013-4; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; ZACHGO S, 1992, J CELL SCI, V103, P811	36	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2741	2746		10.1074/jbc.270.6.2741	http://dx.doi.org/10.1074/jbc.270.6.2741			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852345	hybrid			2022-12-25	WOS:A1995QF53500054
J	LUSSIER, M; GENTZSCH, M; SDICU, AM; BUSSEY, H; TANNER, W				LUSSIER, M; GENTZSCH, M; SDICU, AM; BUSSEY, H; TANNER, W			PROTEIN O-GLYCOSYLATION IN YEAST - THE PMT2 GENE SPECIFIES A 2ND PROTEIN O-MANNOSYLTRANSFERASE THAT FUNCTIONS IN ADDITION TO THE PMT1-ENCODED ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLYCOPROTEIN-BIOSYNTHESIS; TRANSFORMATION; CELLS; ENCODES	The PMT2 gene from Saccharomyces cerevisiae was identified as FUN25, a transcribed open reading frame on the left arm of chromosome I (Ouellette, B. F. F., Clark, M. W. C., Keng, T., Storms, R. G., Zhong, W., Zeng, B., Fortin, N., Delaney, S., Barton, A., Kaback, D. B., and Bussey, H. (1993) Genome 36, 32-42). The product encoded by the PMT2 gene shows significant similarity with the dolichyl phosphate-D-mannose:protein O-D-mannosyltransferase, Pmt1p (EC 2.4.1.109), which is required for initiating the assembly of O-linked oligosaccharides in S. cerevisiae (Strahl-Bolsinger, S., Immervoll, T., Deutzmann, R., and Tanner, TY. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8164-8168). The PMT2 gene encodes a new protein O-D-mannosyltransferase. Yeast cells carrying a PMT2 disruption show a diminished in vitro and in vivo O-mannosylation activity and resemble mutants with a nonfunctional PMT1 gene. Strains bearing a pmt1 pmt2 double disruption show a severe growth defect but retain residual O-mannosylation activity indicating the presence of at least one more protein-O-mannosyltransferase.	MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; UNIV REGENSBURG, LEHRSTUHL ZELLBIOL & PFLANZENPHYSIOL, D-93040 REGENSBURG, GERMANY	McGill University; University of Regensburg			Gentzsch, Martina/AAY-1815-2021					Altschul SF, 1990, J MOL BIOL, V215, P403; BALLOU CE, 1990, METHOD ENZYMOL, V185, P441; BARTON AB, 1994, J BACTERIOL, V176, P1872, DOI 10.1128/jb.176.7.1872-1880.1994; BOONE C, 1990, J CELL BIOL, V110, P1833, DOI 10.1083/jcb.110.5.1833; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JL, 1993, MOL CELL BIOL, V13, P6346, DOI 10.1128/MCB.13.10.6346; BROWN JL, 1994, MOL GENETICS YEAST P, P217; BUSSEY H, 1991, MOL MICROBIOL, V5, P2339, DOI 10.1111/j.1365-2958.1991.tb02079.x; ELHAMMER A, 1984, J CELL BIOL, V98, P327; GENTZSCH M, 1995, IN PRESS GLYCOBIOLOG; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL K, 1992, GENETICS, V130, P273; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; LUSSIER M, 1993, YEAST, V9, P1057, DOI 10.1002/yea.320091004; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; OUELLETTE BFF, 1993, GENOME, V96, P32; RILES L, 1993, GENETICS, V134, P81; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROUSSEL P, 1988, BIOCHIMIE, V70, P1471, DOI 10.1016/0300-9084(88)90284-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHARMA CB, 1974, EUR J BIOCHEM, V46, P35, DOI 10.1111/j.1432-1033.1974.tb03594.x; STRAHLBOLSINGER S, 1993, P NATL ACAD SCI USA, V90, P8164, DOI 10.1073/pnas.90.17.8164; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723	33	78	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2770	2775		10.1074/jbc.270.6.2770	http://dx.doi.org/10.1074/jbc.270.6.2770			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852348	hybrid			2022-12-25	WOS:A1995QF53500058
J	AMRI, EZ; BONINO, F; AILHAUD, G; ABUMRAD, NA; GRIMALDI, PA				AMRI, EZ; BONINO, F; AILHAUD, G; ABUMRAD, NA; GRIMALDI, PA			CLONING OF A PROTEIN THAT MEDIATES TRANSCRIPTIONAL EFFECTS OF FATTY-ACIDS IN PREADIPOCYTES - HOMOLOGY TO PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CELL-DIFFERENTIATION; AP2 GENE-EXPRESSION; COA OXIDASE GENE; RESPONSE ELEMENT; HETERODIMER; MEMBER; IDENTIFICATION; SUPERFAMILY; MECHANISMS; INDUCTION	Exposure of preadipocytes to long chain fatty acids induces expression of several gene markers of adipocyte differentiation. This report describes the cloning, from a preadipocyte library, of a cDNA encoding a fatty acid-activated receptor, FAAR. The cDNA had the characteristics and ligand-binding domains of nuclear hormone receptors and encoded a 440 amino acid protein related to peroxisome proliferator-activated receptors, PPAR. The deduced protein sequence was 88% homologous to that of hNUC I, isolated from human osteosarcoma cells, FAAR mRNA was abundant in adipose tissue, intestine, brain, heart, and skeletal muscles and less abundant in kidney, liver, testis, and spleen, The mRNA was undetectable in growing Ob1771 and 3T3-F442A preadipocytes, was strongly induced early during differentiation, and was increased by fatty acid, Transcription assays using hybrid receptor showed strong stimulation by fatty acid and weaker induction by fibrates, Transfection of 3T3-C2 fibroblasts, with a FAAR expression vector, conferred fatty acid inducibility of the adipocyte lipid-binding protein and the fatty acid transporter, Transcriptional induction of these genes exhibited inducer specificity identical to that described in preadipocytes, In summary, the data indicate that FAAR is likely a mediator of fatty acid transcriptional effects in preadipocytes.	FAC SCI NICE,CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE,FRANCE; SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Ailhaud, Gerard/0000-0003-0596-2906; amri, Ez-Zoubir/0000-0001-8426-5396				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; AMRI EZ, 1991, J LIPID RES, V32, P1457; AMRI EZ, 1991, J LIPID RES, V32, P1449; AMRI EZ, 1986, BIOCHEM J, V238, P115, DOI 10.1042/bj2380115; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN S, 1992, BIOCHEM PHARMACOL, V43, P393, DOI 10.1016/0006-2952(92)90554-V; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LEVAYYOUNG BK, 1989, ENDOCRINOLOGY, V125, P1513; MARI E, 1994, J LIPID RES, V35, P930; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	30	339	348	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2367	2371		10.1074/jbc.270.5.2367	http://dx.doi.org/10.1074/jbc.270.5.2367			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836471	hybrid			2022-12-25	WOS:A1995QE49300059
J	COTNER, T; PIOUS, D				COTNER, T; PIOUS, D			HLA-DR-BETA CHAINS ENTER INTO AN AGGREGATED COMPLEX CONTAINING GRP-78/BIP PRIOR TO THEIR DEGRADATION BY THE PRE-GOLGI DEGRADATIVE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; VESICULAR STOMATITIS-VIRUS; NEWLY SYNTHESIZED PROTEINS; PLASMA-MEMBRANE PROTEINS; CELL-SURFACE-ANTIGENS; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; TRANSIENT ASSOCIATION	HLA class II molecules are membrane proteins which are assembled in the endoplasmic reticulum shortly after synthesis of the alpha and beta and invariant chain (Ii) monomers. DR beta chains, in the absence of DR alpha, are rapidly and completely degraded by the pre-Golgi degradative pathway, Here we have examined those factors which target DR beta chains for degradation in a DR alpha deficient cell line, 9.22.3. The DR beta monomers in 9.22.3 were initially incorporated into a proteinaceous complex containing BiP. With time, the DR beta complexes were further aggregated, In wild type cells, which can assemble DR alpha-beta dimers, the secondary phase of aggregation of DR beta was not seen, Additional evidence that aggregation of DR beta in 9.22.3 cells was progressive was that a more mature form of DR beta was found exclusively in the largest DR beta complexes, Furthermore, the most highly aggregated DR beta chains were degraded more rapidly than bulk DR beta chains, These data suggest that DR beta aggregates are intermediates in the pre-Golgi pathway of DR beta degradation, They further suggest that formation of large DR beta aggregates is a proximal event to DR beta degradation, We conclude that DR beta chains are targeted for degradation as a consequence of a change of state, coincident with their aggregation into slow forming, high molecular weight complexes.	UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	COTNER, T (corresponding author), UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI016689, R01AI016689] Funding Source: NIH RePORTER; NIAID NIH HHS [AI16689] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ANTUSCH D, 1990, J IMMUNOL, V145, P885; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CLARK EA, 1984, LEUCOCYTE TYPING, P195; COTNER T, 1981, P NATL ACAD SCI-BIOL, V78, P3858, DOI 10.1073/pnas.78.6.3858; COTNER T, 1989, J BIOL CHEM, V264, P11107; COTNER T, 1992, J IMMUNOL, V148, P2163; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GLADSTONE P, 1982, P NATL ACAD SCI-BIOL, V79, P1235, DOI 10.1073/pnas.79.4.1235; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HUBBARD AL, 1975, J CELL BIOL, V64, P461, DOI 10.1083/jcb.64.2.461; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; LE AQ, 1992, J BIOL CHEM, V267, P1072; LEAVITT R, 1977, J BIOL CHEM, V252, P9018; LIPPINCOTTSCHWA.J, 1988, CELL, V54, P209; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; NG DTW, 1989, J CELL BIOL, V109, P3273, DOI 10.1083/jcb.109.6.3273; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PIOUS D, 1985, J EXP MED, V162, P1193, DOI 10.1084/jem.162.4.1193; ROUX L, 1990, VIROLOGY, V175, P161, DOI 10.1016/0042-6822(90)90196-X; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TWETO J, 1976, J BIOL CHEM, V251, P872; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907	46	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2379	2386		10.1074/jbc.270.5.2379	http://dx.doi.org/10.1074/jbc.270.5.2379			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836473	hybrid			2022-12-25	WOS:A1995QE49300061
J	SA, G; MURUGESAN, G; JAYE, M; IVASHCHENKO, Y; FOX, PL				SA, G; MURUGESAN, G; JAYE, M; IVASHCHENKO, Y; FOX, PL			ACTIVATION OF CYTOSOLIC PHOSPHOLIPASE A(2) BY BASIC FIBROBLAST GROWTH-FACTOR VIA A P42 MITOGEN-ACTIVATED PROTEIN KINASE-DEPENDENT PHOSPHORYLATION PATHWAY IN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; ARACHIDONIC-ACID; PERTUSSIS TOXIN; 3T3 CELLS; POINT MUTATION; INHIBITION; PURIFICATION; MACROPHAGES; INVOLVEMENT; EXPRESSION	Basic fibroblast growth factor (FGF) stimulates the proliferation, differentiation, and motility of multiple cell types, Signal transduction by FGF is mediated by high affinity FGF receptors that have autophosphorylating tyrosine kinase activity and also elicit the release of low molecular weight signaling molecules, including inositol 1,4,5-trisphosphate, diacylglycerol, and arachidonate. We have shown previously that basic FGF-stimulated, phospholipase A(2) (PLA(2))-mediated arachidonate release regulates endothelial cell (EC) motility (Sa, G., and Fox, P. L. (1994) J. Biol. Chem, 269, 3219-3225). Here we identify the phospholipase responsible for basic FGF-mediated arachidonate release as cytosolic PLA(2) (cPLA(2)) by demonstrating in EC lysates a requirement for micromolar Ca2+, dithiothreitol insensitivity, and inactivation by anti-cPLA(2), antiserum, The role of cPLA(2) is also indicated by the observed mechanisms of activation which show a requirement for p42 mitogen-activated protein kinase activity, cPLA(2) phosphorylation, and cPLA(2) translocation from cytosol to membranes, Phosphorylation of cPLA(2), arachidonate release from prelabeled intact cells, and cell motility all have similar concentration dependencies on basic FGF, Since arachidonate release is required for basic FGF-stimulated motility of EC, our results show that p42 mitogen-activated protein kinase activation of cPLA, may be a regulatory event in stimulation of cellular release of this important eicosanoid precursor during cellular responses to basic FGF.	CLEVELAND CLIN FDN,RES INST,DEPT CELL BIOL,CLEVELAND,OH 44195; RHONE POULENC RORER CENT RES,DIV MOLEC BIOL,COLLEGEVILLE,PA 19426	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041178, P01HL029582, R29HL040352] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29582, HL40352, HL41178] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUTHERINFALSON O, 1990, BIOCHEM BIOPH RES CO, V172, P306, DOI 10.1016/S0006-291X(05)80210-4; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLYMAN RI, 1994, CELL ADHES COMMUN, V1, P333, DOI 10.3109/15419069409097264; COCKCROFT S, 1991, BIOCHEM SOC T, V19, P333, DOI 10.1042/bst0190333; DAVIET I, 1990, FEBS LETT, V259, P315, DOI 10.1016/0014-5793(90)80035-H; DELL RB, 1973, CIRC RES, V32, P71, DOI 10.1161/01.RES.32.1.71; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DOMIN J, 1993, J BIOL CHEM, V268, P8927; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; FOX PL, 1987, J BIOL CHEM, V262, P6046; GOLIGORSKY MS, 1989, J BIOL CHEM, V264, P16771; HAJJAR DP, 1992, FASEB J, V6, P2933, DOI 10.1096/fasebj.6.11.1644257; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAST R, 1993, J BIOL CHEM, V268, P16795; KELVIN DJ, 1989, J CELL BIOL, V108, P169, DOI 10.1083/jcb.108.1.169; KITAGAWA K, 1987, BIOCHIM BIOPHYS ACTA, V931, P110, DOI 10.1016/0167-4889(87)90056-5; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOGAN A, 1991, CELL SIGNAL, V3, P215, DOI 10.1016/0898-6568(91)90047-X; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PATTE C, 1992, CELL MOL BIOL, V38, P429; Patte C, 1992, GROWTH FACTORS, V7, P107, DOI 10.3109/08977199209046400; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRPIC V, 1984, J BIOL CHEM, V259, P1382; QIU ZH, 1993, J BIOL CHEM, V268, P24506; SA G, 1994, J BIOL CHEM, V269, P3219; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TUCKER RW, 1989, J CELL BIOCHEM, V39, P139, DOI 10.1002/jcb.240390206; VIRDEE K, 1994, BBA-MOL CELL RES, V1220, P171, DOI 10.1016/0167-4889(94)90132-5; WHATLEY RE, 1988, ARTERIOSCLEROSIS, V8, P321, DOI 10.1161/01.ATV.8.3.321; WIJKANDER J, 1992, FEBS LETT, V311, P299, DOI 10.1016/0014-5793(92)81124-5; WINITZ S, 1994, J BIOL CHEM, V269, P1889; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; XING MZ, 1994, J BIOL CHEM, V269, P3117; ZHAN X, 1993, J BIOL CHEM, V268, P24427	51	149	150	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2360	2366		10.1074/jbc.270.5.2360	http://dx.doi.org/10.1074/jbc.270.5.2360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836470	hybrid			2022-12-25	WOS:A1995QE49300058
J	KELLEY, CA; OBERMAN, F; YISRAELI, JK; ADELSTEIN, RS				KELLEY, CA; OBERMAN, F; YISRAELI, JK; ADELSTEIN, RS			A XENOPUS NONMUSCLE MYOSIN HEAVY-CHAIN ISOFORM IS PHOSPHORYLATED BY CYCLIN-P34(CDC2) KINASE DURING MEIOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; CONTROL GENE CDC2+; PROTEIN-KINASE; LIGHT CHAIN; CELL-CYCLE; M-PHASE; MESSENGER-RNAS; TYROSINE PHOSPHORYLATION; MAP KINASE; MITOSIS	There are two vertebrate nonmuscle myosin heavy chain (MHC) genes that encode two separate isoforms of the heavy chain, MHC-A and MHC-B. Recent work has identified additional, alternatively spliced isoforms of MRC-R cDNA with inserted sequences of 30 nucleotides (chicken and human) or 48 nucleotides (Xenopus) at a site corresponding to the ATP binding region in the MHC protein (Takahashi, M., Kawamoto, S. and Adelstein, R. S. (1992) J. Biol. Chem. 267, 17864-17871) and Bhatia-Dey, N., Adelstein, R. S., and Dawid, I. B. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2856-2859). The deduced amino acid sequence of these inserts contains a consensus sequence for phosphorylation by cyclin-p34(cdc2) (cdc2) kinase. In cultured Xenopus XTC cells, we have identified two inserted MHC-B isoforms and a noninserted MHC-A isoform by immunoblotting of cell extracts. When myosin was immunoprecipitated from XTC cells and phosphorylated in vitro with cdc2 kinase, the kinase catalyzed the phosphorylation of both inserted MRC-B isoforms but not MHC-A. Isoelectric focusing of tryptic peptides generated from MHC-B phosphorylated with cdc2 kinase revealed one major phosphopeptide that was purified by reverse phase high performance liquid chromatography and sequenced. The phosphorylated residue was Ser-214, the cdc2 kinase consensus site within the insert near the ATP binding region. The same site was phosphorylated in intact XTC cells during log phase of growth and in cell-free lysates of Xenopus eggs stabilized in second meiotic metaphase but not interphase. Moreover, Ser-214 phosphorylation was detected during maturation of Xenopus oocytes when the cdc2 kinase-containing maturation-promoting factor was activated, but not in G(2) interphase-arrested oocytes. These results demonstrate that MBC-B phosphorylation is tightly regulated by cdc2 kinase during meiotic cell cycles. Furthermore, MHC-A and MHC-B isoforms are differentially phosphorylated at these stages, suggesting that they may serve different functions in these cells.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT ANAT & EMBRYOL,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	KELLEY, CA (corresponding author), NHLBI,MOLEC CARDIOL LAB,BLDG 10,RM 8N-202,10 CTR DR MSC 1762,BETHESDA,MD 20892, USA.		Yisraeli, Joel/S-2031-2019	Yisraeli, Joel/0000-0001-6538-6686; Adelstein, Robert/0000-0002-8683-2144				BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BABIJ P, 1993, NUCLEIC ACIDS RES, V21, P1467, DOI 10.1093/nar/21.6.1467; BENGUR AR, 1987, J BIOL CHEM, V262, P7613; BHATIADEY N, 1993, P NATL ACAD SCI USA, V900, P2856; Capco D.G., 1991, Progress in Molecular and Subcellular Biology, V12, P59; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GRAF JD, 1991, METHOD CELL BIOL, V36, P19; HAMADA Y, 1990, BIOCHEM BIOPH RES CO, V170, P53, DOI 10.1016/0006-291X(90)91239-O; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P2713, DOI 10.1021/bi00463a014; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KAWAMOTO S, 1988, J BIOL CHEM, V263, P1099; KAWAMOTO S, 1989, J BIOL CHEM, V234, P2258; KELLEY CA, 1992, J BIOL CHEM, V267, P2127; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAUPIN P, 1994, J CELL SCI, V107, P3077; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURAKAMI N, 1990, J BIOL CHEM, V265, P1041; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NAGAI R, 1989, J BIOL CHEM, V264, P9734; NAKABAYASHI H, 1991, FEBS LETT, V294, P144, DOI 10.1016/0014-5793(91)81362-C; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NIGG EA, 1990, SEMIN CELL BIOL, V2, P261; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; PENG HB, 1991, METHOD CELL BIOL, V36, P657; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SANGER JW, 1976, CELL MOTILITY, P1295; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SCHROEDER TE, 1976, CELL MOTILITY, P265; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH JC, 1991, METHOD CELL BIOL, V36, P635; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0	58	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1395	1401		10.1074/jbc.270.3.1395	http://dx.doi.org/10.1074/jbc.270.3.1395			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836406	hybrid			2022-12-25	WOS:A1995QB15600063
J	TAKEBAYASHI, K; AKAZAWA, C; NAKANISHI, S; KAGEYAMA, R				TAKEBAYASHI, K; AKAZAWA, C; NAKANISHI, S; KAGEYAMA, R			STRUCTURE AND PROMOTER ANALYSIS OF THE GENE ENCODING THE MOUSE HELIX-LOOP-HELIX FACTOR HES-5 - IDENTIFICATION OF THE NEURAL PRECURSOR CELL-SPECIFIC PROMOTER ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; DROSOPHILA-HAIRY; NEGATIVE REGULATOR; DNA-BINDING; PROTEIN; TRANSCRIPTION; POLYMERASE; EXPRESSION; ENHANCER; CLONING	HES-5 is a mammalian basic helix-loop-helix factor that has a distant sequence homology to the product of the Drosophila pair-rule gene hairy. HES-5 mRNA is present exclusively in the developing nervous system, but its level decreases as neural differentiation proceeds. In this study, to characterize the molecular mechanism of the neural-specific expression of HES-5 we isolated the mouse HES-5 gene. This gene consists of three exons, and Southern blot analysis shows that it is a single copy gene. The transcription initiation site, determined by primer extension and reverse transcriptase-mediated polymerase chain reaction, is located 26 nucleotides downstream of a TATA box. Transient transfection analysis shows that the upstream region of the HES-5 gene can direct efficient expression in neural precursor cells and moderate expression in undifferentiated NCB20 neuroblastoma-brain hybrid cells but not in glioma or fibroblast cells. The moderate level of expression in NCB20 cells decreases when differentiation into neuron-like cells is induced. Further promoter analysis shows that this undifferentiated neural-specific expression is mediated by the multiple GC stretches present in the HES-5 promoter. Gel mobility shift analysis suggests the presence of a neural precursor cell-specific protein that binds to the GC stretches. These results raise the possibility that HES-5 expression in the developing nervous system is regulated by the GC stretch-binding protein.	KYOTO UNIV,FAC MED,INST IMMUNOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University								AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Jacobson M., 1991, DEV NEUROBIOLOGY; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KITANI H, 1991, IN VITRO CELL DEV B, V27, P615; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MACDERMOT J, 1979, P NATL ACAD SCI USA, V76, P1135, DOI 10.1073/pnas.76.3.1135; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; TOMOOKA Y, 1993, P NATL ACAD SCI USA, V90, P9683, DOI 10.1073/pnas.90.20.9683; Wilkinson D.G., 1993, ESSENTIAL DEV BIOL P, P257	26	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1342	1349		10.1074/jbc.270.3.1342	http://dx.doi.org/10.1074/jbc.270.3.1342			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836401	hybrid			2022-12-25	WOS:A1995QB15600056
J	ADNANE, J; ROBBINS, PD				ADNANE, J; ROBBINS, PD			THE RETINOBLASTOMA SUSCEPTIBILITY GENE-PRODUCT REGULATES MYC-MEDIATED TRANSCRIPTION	ONCOGENE			English	Article						RETINOBLASTOMA PROTEIN; MYC; TRANSCRIPTION	APOPTOTIC CELL-DEATH; VIRUS-40 LARGE-T; C-MYC; DNA-BINDING; MOLECULAR-CLONING; FACTOR E2F; PROTEIN; MAX; DOMAIN; ACTIVATION	The protein product of the retinoblastoma tumor suppressor gene (RE) has been demonstrated to bind c-Myc protein (Myc) in vitro. To determine whether RE regulates Myc transcriptional activity in vivo, GAL4-Myc chimeric expression plasmids were generated and cotransfected with a RE expression plasmid and a GAL4-dependent reporter plasmid. RE stimulated GAL4-Myc-mediated transcription, dependent upon a domain(s) in the amino-terminus of Myc. The stimulation of Myc-mediated transcription by RE was cell-type specific and was inhibited by SV40 T-antigen, but not by a T-antigen mutant defective in RE-binding. Moreover, RE mutants containing mutations in domain B of RE pocket were significantly reduced in their ability to stimulate GAL4-Myc mediated transcription. To determine whether RE and Myc interact in vivo either directly or indirectly, a two hybrid system was used where GAL4-Rb and Myc-VP16 expression constructs were cotransfected with a GAL4-dependent reporter plasmid. A significant increase of GAL4-dependent transcription was observed, dependent upon the presence of both GAL4-Rb and Myc-VP16 fusion proteins, Mutational analysis of the Myc-VP16 chimeric proteins suggests that the amino-terminus of Myc is essential for the interaction with RE. These results demonstrate that RE can regulate Myc-mediated transcription in vivo in a cell-type specific manner through protein-protein interactions.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA55227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEDICT WF, 1988, CANCER, V62, P1691, DOI 10.1002/1097-0142(19881015)62:1+<1691::AID-CNCR2820621306>3.0.CO;2-5; BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHENG J, 1990, BLOOD, V75, P730; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUCHER B, 1990, I MYC GENES DEV, V4, P2025; MAYOL X, 1993, ONCOGENE, V8, P2561; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SRINIVASAN A, 1989, J VIROL, P5459; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	62	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					381	387						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838535				2022-12-25	WOS:A1995QC62400017
J	CHENG, NC; VANROY, N; CHAN, A; BEITSMA, M; WESTERVELD, A; SPELEMAN, F; VERSTEEG, R				CHENG, NC; VANROY, N; CHAN, A; BEITSMA, M; WESTERVELD, A; SPELEMAN, F; VERSTEEG, R			DELETION MAPPING IN NEUROBLASTOMA CELL-LINES SUGGESTS 2 DISTINCT TUMOR-SUPPRESSOR GENES IN THE 1P35-36-REGION, ONLY ONE OF WHICH IS ASSOCIATED WITH N-MYC AMPLIFICATION	ONCOGENE			English	Article						NEUROBLASTOMA; TUMOR SUPPRESSOR GENES; N-MYC; CHROMOSOME 1	NEURO-BLASTOMA; EMBRYONIC LETHALITY; HUMAN CHROMOSOME-1; SHORT ARM; HETEROZYGOSITY; EXPRESSION; DNA; TUMORIGENICITY; MORPHOLOGY; ONCOGENE	Neuroblastoma is characterized by deletions of the short arm of chromosome 1 (1p) and amplification of the N-myc oncogene, We have made somatic cell hybrids of two human neuroblastoma cell lines, one with and one without N-myc expression and amplification, The expression of the amplified N-myc gene is completely switched off in the hybrids, This suggests that N-myc expression results from loss of a repressor function, As N-myc amplification is associated with loss of heterozygosity (LOH) of 1p36, we analysed 1p deletions in 16 neuroblastoma cell lines, The seven cell lines without N-myc amplification have no deletions or relatively small deletions, with an SRO on 1p36.23-33. This suggests that a tumor suppressor gene maps in this region, All nine cell lines with N-myc amplification have larger deletions, with an SRO from 1p35-36.1 to the telomere, This suggests that a second tumor suppressor gene which is associated with N-myc amplification maps more proximally, Fine mapping of 1p36 deletions in the two cell lines of the fusion experiment suggests that the distal locus is not a repressor of N-myc expression, but the more proximal locus could be a candidate for this function.	UNIV AMSTERDAM, ACAD MED CTR, DEPT HUMAN GENET, 1100 DE AMSTERDAM, NETHERLANDS; STATE UNIV GHENT, DEPT MED GENET, GHENT, BELGIUM	University of Amsterdam; Academic Medical Center Amsterdam; Ghent University			speleman, frank/AAR-5184-2020; Versteeg, Rogier/AAQ-1765-2020	speleman, frank/0000-0002-6628-8559; Versteeg, Rogier/0000-0001-7172-0388				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; COWELL JK, 1983, CANCER GENET CYTOGEN, V9, P273, DOI 10.1016/0165-4608(83)90011-0; DONTI E, 1988, CANCER GENET CYTOGEN, V30, P225, DOI 10.1016/0165-4608(88)90188-4; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; GILBERT F, 1984, CANCER RES, V44, P5444; GRADY EF, 1987, CANCER RES, V47, P2931; HELSON L, 1980, HUMAN CANCER ITS CHA, P86; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LAUTHIER V, 1992, HUM MOL GENET, V1, P63; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEEGER RC, 1977, CANCER RES, V37, P1364; SRIVATSAN ES, 1991, PROG CLIN BIOL RES, V366, P91; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; VERSTEEG R, 1990, MOL CELL BIOL, V10, P5416, DOI 10.1128/MCB.10.10.5416; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WHITE PS, 1994, ADV NEUROBLASTOMA RE, V4, P3; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	41	127	129	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					291	297						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838528				2022-12-25	WOS:A1995QC62400008
J	SURYA, A; FOSTER, RW; KNOX, BE				SURYA, A; FOSTER, RW; KNOX, BE			TRANSDUCIN ACTIVATION BY THE BOVINE OPSIN APOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; LIGHT-DEPENDENT PHOSPHORYLATION; CYCLIC-NUCLEOTIDE CASCADE; METARHODOPSIN-II; PHOTORECEPTOR-MEMBRANES; SCHIFF-BASE; PHOTOEXCITED RHODOPSIN; VISUAL-PIGMENT; PROTON UPTAKE; BEHAVIOR	The interaction of the bovine opsin apoprotein with transducin in rod outer segment membranes was investigated using a guanyl nucleotide exchange assay. In exhaustive binding experiments, opsin activates transducin, with half-maximal exchange activity occurring at 0.8 mol of opsin/mol of transducin. The opsin activity was light insensitive, hydroxylamine-resistant, unaffected by stoichiometric concentrations of retinaloxime, and more heat labile than rhodopsin. The t1/2 of transducin activation in the presence of excess opsin was 8.5 min, compared with 0.7 min for metarhodopsin(II). The second-order rate constants were determined to be 0.012 pmol of guanosine 5'-(gamma-thio)triphosphate (GTP gamma S) bound per min/nM opsin and 0.35 pmol of GTP gamma S bound per min/nM metarhodopsin(II). Opsin was able to activate more than one transducin, although there appeared to be a turnover-dependent inactivation of the apoprotein. Opsin showed a broad pH range (5.8-7.4) for optimal activity, with no activity in buffers of pH >9, whereas metarhodopsin(II) exhibited activity at pH >9. Regulation of opsin activity by stoichiometric amounts of retinal was observed, with inhibition by 11-cis-retinal and stimulation by all-trans-retinal. A model for opsin activity is proposed.	SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,SYRACUSE,NY 13210; SYRACUSE UNIV,DEPT PHYS,SYRACUSE,NY 13244	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Syracuse University					NATIONAL EYE INSTITUTE [R55EY009409, R01EY009409] Funding Source: NIH RePORTER; NEI NIH HHS [EY09409] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; BARLOW HB, 1964, VISION RES, V4, P47, DOI 10.1016/0042-6989(64)90031-8; BENNETT N, 1982, EUR J BIOCHEM, V127, P97, DOI 10.1111/j.1432-1033.1982.tb06842.x; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BIRGE RR, 1990, BIOCHIM BIOPHYS ACTA, V1016, P293, DOI 10.1016/0005-2728(90)90163-X; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; BRIN KP, 1977, J GEN PHYSIOL, V69, P97, DOI 10.1085/jgp.69.1.97; BRUCKERT F, 1988, EUR BIOPHYS J BIOPHY, V16, P207; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CALHOON RD, 1985, BIOCHEMISTRY-US, V24, P6446, DOI 10.1021/bi00344a021; CATT M, 1982, BIOCHEM SOC T, V10, P343, DOI 10.1042/bst0100343; CLACK JW, 1982, J GEN PHYSIOL, V80, P863, DOI 10.1085/jgp.80.6.863; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; CORNWALL MC, 1990, J GEN PHYSIOL, V96, P345, DOI 10.1085/jgp.96.2.345; CORSON DW, 1990, P NATL ACAD SCI USA, V87, P6823, DOI 10.1073/pnas.87.17.6823; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FUKADA Y, 1982, BIOCHIM BIOPHYS ACTA, V708, P12; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HOFMANN KP, 1983, BIOCHIM BIOPHYS ACTA, V725, P60, DOI 10.1016/0005-2728(83)90224-4; HUBBARD R, 1958, P NATL ACAD SCI USA, V44, P130, DOI 10.1073/pnas.44.2.130; JIN J, 1993, NEURON, V11, P513, DOI 10.1016/0896-6273(93)90155-K; JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606; KHAN SMA, 1991, EUR J BIOCHEM, V200, P53, DOI 10.1111/j.1432-1033.1991.tb21047.x; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KNOX B E, 1991, Biophysical Journal, V59, p328A; KOHRANA HG, 1992, J BIOL CHEM, V267, P1; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KOUTALOS Y, 1992, BIOPHYS J, V61, P272, DOI 10.1016/S0006-3495(92)81833-7; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; MATHEWS RG, 1963, J GEN PHYSIOL, V47, P215; MILJANICH GP, 1985, J MEMBRANE BIOL, V85, P79, DOI 10.1007/BF01872007; OKADA D, 1989, PHOTOCHEM PHOTOBIOL, V49, P197, DOI 10.1111/j.1751-1097.1989.tb04096.x; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PEPPERBERG DR, 1978, J GEN PHYSIOL, V71, P369, DOI 10.1085/jgp.71.4.369; PEPPERBERG DR, 1987, EXP EYE RES, V45, P141, DOI 10.1016/S0014-4835(87)80085-4; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RUSHTON WAH, 1961, J PHYSL, V156, P195; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SHICHI H, 1978, J BIOL CHEM, V253, P7040; VUONG TM, 1990, NATURE, V346, P71, DOI 10.1038/346071a0; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WEIGAND RD, 1982, METHOD ENZYMOL, V81, P297; WEITZ CJ, 1992, NEURON, V8, P465, DOI 10.1016/0896-6273(92)90274-H; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P12444; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WONG JK, 1973, ARCH BIOCHEM BIOPHYS, V154, P1, DOI 10.1016/0003-9861(73)90028-3; YOSHIZAWA T, 1983, BIOPHYS STRUCT MECH, V9, P245, DOI 10.1007/BF00535660	56	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5024	5031		10.1074/jbc.270.10.5024	http://dx.doi.org/10.1074/jbc.270.10.5024			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890610	hybrid			2022-12-25	WOS:A1995QL58000015
J	CHUNG, SO; KUBO, T; NATORI, S				CHUNG, SO; KUBO, T; NATORI, S			MOLECULAR-CLONING AND SEQUENCING OF ARYLPHORIN-BINDING PROTEIN IN PROTEIN GRANULES OF THE SARCOPHAGA FAT-BODY - IMPLICATION OF A POSTTRANSLATIONAL PROCESSING MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE PROTEIN; PEREGRINA; RECEPTOR; GENE; 20-HYDROXYECDYSONE; IDENTIFICATION; ACTIVATION; DROSOPHILA; CECROPIA; MEMBRANE	Previously, we identified an arylphorin-binding protein of Sarcophaga peregrina (flesh fly) with a molecular mass of 120 kDa and suggested its participation in the selective uptake of arylphorin from the hemolymph into the pupal fat body at metamorphosis (Ueno, K, and Natori, S. (1984) J, Biol, Chem, 259, 12107-12111). This paper reports the isolation and sequencing of cDNA for the 120-kDa protein. This protein consists of 1146 amino acid residues. Immunoblotting and RNA blotting experiments revealed that this protein is present as two fragments of 76 kDa (695 residues) and 53 kDa (451 residues) in the larval fat body. When larvae pupate, the 120-kDa protein gene is further activated and the complete 120-kDa protein is synthesized without fragmentation, This suggests a novel mechanism for the production of the 120-kDa protein regulated by a proteinase depending upon the stage of development of Sarcophaga. Ah of these proteins were found to be localized in protein granules in the adipocytes.	UNIV TOKYO, FAC PHARMACEUT SCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo				Kubo, Takeo/0000-0002-5914-5269				BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; HOMMA K, 1994, J BIOL CHEM, V269, P16258; KINNEAR JF, 1975, INSECT BIOCHEM, V5, P531, DOI 10.1016/0020-1790(75)90036-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE M, 1981, P NATL ACAD SCI-BIOL, V78, P2417, DOI 10.1073/pnas.78.4.2417; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASCHAT F, 1990, J MOL BIOL, V214, P359, DOI 10.1016/0022-2836(90)90186-P; MIYACHI Y, 1972, J CLIN ENDOCR METAB, V34, P23, DOI 10.1210/jcem-34-1-23; MUNN EA, 1969, J INSECT PHYSIOL, V15, P1935, DOI 10.1016/0022-1910(69)90023-7; NAKANISHI Y, 1983, P NATL ACAD SCI-BIOL, V80, P2971, DOI 10.1073/pnas.80.10.2971; NATORI S, 1986, ARCH INSECT BIOCHEM, P105, DOI 10.1002/arch.940030712; Natori S., 1989, P426; OHTAKI T, 1966, JPN J MED SCI BIOL, V19, P97, DOI 10.7883/yoken1952.19.97; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAHARA T, 1982, BIOCHEM J, V203, P571, DOI 10.1042/bj2030571; TELFER WH, 1983, INSECT BIOCHEM, V13, P601, DOI 10.1016/0020-1790(83)90034-3; TOJO S, 1978, J CELL BIOL, V78, P823, DOI 10.1083/jcb.78.3.823; UENO K, 1987, J BIOL CHEM, V262, P12780; UENO K, 1982, INSECT BIOCHEM, V12, P185, DOI 10.1016/0020-1790(82)90007-5; UENO K, 1984, J BIOL CHEM, V259, P2107; UENO K, 1983, J BIOL CHEM, V258, P2210; WEINSTOCK R, 1978, P NATL ACAD SCI USA, V75, P1299, DOI 10.1073/pnas.75.3.1299; WYATT GR, 1978, ANNU REV BIOCHEM, V47, P779, DOI 10.1146/annurev.bi.47.070178.004023	28	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4624	4631		10.1074/jbc.270.9.4624	http://dx.doi.org/10.1074/jbc.270.9.4624			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876233	hybrid			2022-12-25	WOS:A1995QK08400067
J	NIGHTINGALE, K; WOLFFE, AP				NIGHTINGALE, K; WOLFFE, AP			METHYLATION AT CPG SEQUENCES DOES NOT INFLUENCE HISTONE-H1 BINDING TO A NUCLEOSOME INCLUDING A XENOPUS-BOREALIS 5-S-RIBOSOMAL RNA GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THYMIDINE KINASE GENE; RNA POLYMERASE-II; DNA METHYLATION; CHROMATIN STRUCTURE; LINKER HISTONES; GLOBIN GENE; TRANSCRIPTION; PROTEIN; H-1; REPRESSION	We demonstrate that methylation of the 12 dinucleotide CpGs within a GC-rich DNA fragment containing a Xenopus borealis 5 S rRNA gene does not influence histone ill binding to naked or nucleosomal 5 S DNA. Thus a simple mechanism in which histone ill selectively associates with nucleosomes containing methylated CpG cannot explain the repressive effects of methylation on gene activity.	NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BALL DJ, 1983, P NATL ACAD SCI-BIOL, V80, P5490, DOI 10.1073/pnas.80.18.5490; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOULIKAS T, 1980, P NATL ACAD SCI-BIOL, V77, P127, DOI 10.1073/pnas.77.1.127; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; BUSCHHAUSEN G, 1985, NUCLEIC ACIDS RES, V13, P5503, DOI 10.1093/nar/13.15.5503; BUSSLINGER M, 1993, NUCLEIC ACIDS RES, V11, P3559; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DREW HR, 1987, J MOL BIOL, V197, P485, DOI 10.1016/0022-2836(87)90560-2; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; FELSENFELD G, 1982, COLD SPRING HARB SYM, V47, P577; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HIGURASHI M, 1991, J BIOL CHEM, V266, P8619; HOELLER M, 1988, Genes and Development, V2, P1127; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEVINE A, 1993, J BIOL CHEM, V268, P21754; Maxam A M, 1980, Methods Enzymol, V65, P499; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; SALUZ HP, 1989, ANAL BIOCHEM, V176, P201, DOI 10.1016/0003-2697(89)90296-0; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SINGER DS, 1976, NUCLEIC ACIDS RES, V3, P2531, DOI 10.1093/nar/3.10.2531; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; URA K, 1994, J BIOL CHEM, V269, P27171; WOLFFE AP, 1989, EMBO J, V8, P527, DOI 10.1002/j.1460-2075.1989.tb03407.x; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1993, METH MOL G, V2, P314; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638	41	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4197	4200		10.1074/jbc.270.9.4197	http://dx.doi.org/10.1074/jbc.270.9.4197			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876175	hybrid			2022-12-25	WOS:A1995QK08400005
J	MCLENNAN, AG; MAYERS, E; WALKERSMITH, I; CHEN, HJ				MCLENNAN, AG; MAYERS, E; WALKERSMITH, I; CHEN, HJ			LANTERNS OF THE FIREFLY PHOTINUS-PYRALIS CONTAIN ABUNDANT DIADENOSINE 5',5'''-P-1,P-4-TETRAPHOSPHATE PYROPHOSPHOHYDROLASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DINUCLEOSIDE POLYPHOSPHATES; TETRAPHOSPHATE AP4A; ESCHERICHIA-COLI; MAMMALIAN-CELLS; TUMOR-CELLS; 5',5'''-P1,P4-TETRAPHOSPHATE; APPPPA; PURIFICATION; LUCIFERASE; SYNTHETASES	The enzyme diadenosine 5',5'''-P-1,P-4-tetraphosphate (Ap(4)A) pyrophosphohydrolase has been purified to homogeneity from firefly lanterns. It is a single polypeptide of M(r) 16,000 with a K-m for Ap(4)A of 1.9 mu M and k(cat) = 3.6 s(-1). It is inhibited competitively by adenosine 5'-tetraphosphate (K-i = 7.5 nM) and non-competitively by fluoride ions (K-i = 50 mu M). The specific activity of the enzyme in crude extracts of at least 20 milliunits/mg protein is 10-100 times higher than in any other eukaryote so far examined. Interestingly, firefly luciferase is known to synthesize Ap(4)A and related adenine-containing dinucleoside tetraphosphates in vitro. The high activity of Ap,A hydrolase in lanterns may be related to this ability and could be relevant to the use of the luciferase gene as a reporter gene.			MCLENNAN, AG (corresponding author), UNIV LIVERPOOL,DEPT BIOCHEM,CELLULAR & METAB REGULAT GRP,POB 147,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							BAKER JC, 1984, ANAL BIOCHEM, V141, P451, DOI 10.1016/0003-2697(84)90070-8; BAKER JC, 1986, P NATL ACAD SCI USA, V83, P2350, DOI 10.1073/pnas.83.8.2350; BARNES LD, 1982, BIOCHEMISTRY-US, V21, P6123, DOI 10.1021/bi00267a015; BOCHNER BR, 1984, CELL, V37, P225, DOI 10.1016/0092-8674(84)90318-0; BREVET A, 1985, J BIOL CHEM, V260, P5566; CAMESELLE JC, 1982, BIOCHEM J, V201, P405, DOI 10.1042/bj2010405; DANG CV, 1989, J BIOL CHEM, V264, P5861; FARR SB, 1989, P NATL ACAD SCI USA, V86, P5010, DOI 10.1073/pnas.86.13.5010; Garrison PN, 1992, AP4A OTHER DINUCLEOS, P29; GILSON G, 1988, EXP CELL RES, V177, P143, DOI 10.1016/0014-4827(88)90032-8; GOERLICH O, 1982, EUR J BIOCHEM, V126, P135, DOI 10.1111/j.1432-1033.1982.tb06757.x; GURANOWSKI A, 1990, FEBS LETT, V271, P215, DOI 10.1016/0014-5793(90)80409-C; GURANOWSKI A, 1985, J BIOL CHEM, V260, P3542; GURANOWSKI A, 1990, FEBS LETT, V262, P205, DOI 10.1016/0014-5793(90)80190-T; GURANOWSKI A, 1992, AP4A OTHER DINUCLEOS, P81; JAKUBOWSKI H, 1983, J BIOL CHEM, V258, P9982; JOHNSTON DJ, 1990, BIOCHEM J, V268, P791, DOI 10.1042/bj2680791; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEWSKA D, 1993, PROTEIN EXPRES PURIF, V4, P45, DOI 10.1006/prep.1993.1007; MANNAERTS GP, 1987, PEROXISOMES BIOL MED, P169; MCELROY WD, 1962, ENZYMES, V6, P433; MCLENNAN AG, 1994, BIOCHEM J, V300, P183, DOI 10.1042/bj3000183; MORENO A, 1982, INT J BIOCHEM, V14, P629, DOI 10.1016/0020-711X(82)90047-7; MORIS G, 1987, BIOCHIMIE, V69, P1217, DOI 10.1016/0300-9084(87)90149-0; OGILVIE A, 1983, J BIOL CHEM, V258, P4105; ORTIZ B, 1993, EUR J BIOCHEM, V212, P263, DOI 10.1111/j.1432-1033.1993.tb17658.x; PETERSON GL, 1982, METHOD ENZYMOL, V91, P95; PLATEAU P, 1981, BIOCHEMISTRY-US, V20, P4654, DOI 10.1021/bi00519a021; PLATEAU P, 1992, AP4A OTHER DINUCLEOS, P63; PRESCOTT M, 1989, BIOCHEM J, V259, P831, DOI 10.1042/bj2590831; ROBINSON AK, 1993, BIOCHIM BIOPHYS ACTA, V1161, P139, DOI 10.1016/0167-4838(93)90207-8; SILLERO MAG, 1991, EUR J BIOCHEM, V202, P507; VALLEJO CG, 1989, INT J BIOCHEM, V21, P1223, DOI 10.1016/0020-711X(89)90007-4; YAMAGUCHI N, 1985, GASTROENTEROLOGY, V89, P732	35	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3706	3709		10.1074/jbc.270.8.3706	http://dx.doi.org/10.1074/jbc.270.8.3706			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876110	hybrid			2022-12-25	WOS:A1995QH68800039
J	MOLL, T; CZYZ, M; HOLZMULLER, H; HOFERWARBINEK, R; WAGNER, E; WINKLER, H; BACH, FH; HOFER, E				MOLL, T; CZYZ, M; HOLZMULLER, H; HOFERWARBINEK, R; WAGNER, E; WINKLER, H; BACH, FH; HOFER, E			REGULATION OF THE TISSUE FACTOR PROMOTER IN ENDOTHELIAL-CELLS - BINDING OF NF-KAPPA-B-LIKE, AP-1-LIKE, AND SP1-LIKE TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR MESSENGER-RNA; COAGULATION PROTEASE CASCADE; THP-1 MONOCYTIC CELLS; FACTOR GENE; ADHESION MOLECULE-1; PROCOAGULANT RESPONSE; CELLULAR RECEPTOR; PHORBOL ESTER; EXPRESSION	Tissue factor is up-regulated on endothelial cells and monocytes in response to cytokines and endotoxin and is the main trigger of the extrinsic pathway of the coagulation cascade. We have isolated the porcine tissue factor gene and studied the regulation of the promoter, which has not been investigated previously in endothelial cells. Comparison of the promoter sequences with the respective human and murine genes reveals short stretches of homology, which encompass potential binding sites for AP-1, NF kappa B, and Spl transcription factors. Using DNase I footprinting, we detect binding of nuclear factors to these promoter elements. Transfection experiments demonstrate that a 300-base pair fragment containing the conserved elements can mediate induced transcription and that the NF kappa B-like element is essential, In accordance, electrophoretic mobility shift assays show a strong increase in the binding of factors to the NF kappa B-like site following induction. We further provide evidence that RelA (p65), c-Rel, and possibly novel polypeptides bind to the tissue factor NF kappa B element, In addition, we show constitutive binding of members of the Fos/Jun and Spl families to the AP-1 and Spl sites, respectively, We propose a concerted action of AP-1-, NF kappa B-, and Spl-like factors in transcription from the tissue factor promoter in endothelial cells,	VIENNA INT RES COOPERAT CTR,DEPT TRANSPLANTAT IMMUNOL,A-1230 VIENNA,AUSTRIA; HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,SANDOZ CTR IMMUNOBIOL,BOSTON,MA 02215; BENDER & CO GESMBH,A-1121 VIENNA,AUSTRIA	Harvard University; Harvard Medical School; Novartis; Sandoz			Wagner, Ernst/ABB-5976-2020; Czyz, Malgorzata/AAD-1869-2020; Wagner, Ernst/A-7435-2012	Wagner, Ernst/0000-0001-8413-0934; Czyz, Malgorzata/0000-0002-8279-4742; Wagner, Ernst/0000-0001-8413-0934				AHERN SM, 1993, J BIOL CHEM, V268, P2154; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; Brenowitz M., 1989, CURRENT PROTOCOLS MO; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CLAUSS M, 1990, J BIOL CHEM, V265, P7078; COLLINS T, 1991, J BIOL CHEM, V266, P2466; CONWAY EM, 1989, THROMB RES, V53, P231, DOI 10.1016/0049-3848(89)90098-4; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; COTTEN M, 1993, METHOD ENZYMOL, V217, P618; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; CROSSMAN DC, 1990, ENDOTHELIUM INTRO CU, P119; DEMARTIN R, 1993, GENE, V124, P137, DOI 10.1016/0378-1119(93)90776-Y; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONOVANPELUSO M, 1994, J BIOL CHEM, V269, P1361; DRAKE TA, 1989, AM J PATHOL, V134, P1087; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HOFER E, 1994, TRANSPLANT P, V26, P1322; IADEMARCO MF, 1993, P NATL ACAD SCI USA, V90, P3943, DOI 10.1073/pnas.90.9.3943; ISHII H, 1992, BLOOD, V80, P2556; KADANOGA JT, 1986, P NATL ACAD SCI USA, V83, P5889; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KAUFMAN PA, 1992, J CLIN INVEST, V90, P121, DOI 10.1172/JCI115824; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LANDO PA, 1986, J IMMUNOL METHODS, V89, P131, DOI 10.1016/0022-1759(86)90041-4; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MACKMAN N, 1992, ARTERIOSCLER THROMB, V12, P474, DOI 10.1161/01.ATV.12.4.474; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NEMERSON Y, 1988, BLOOD, V71, P1; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PLATT JL, 1990, IMMUNOL TODAY, V11, P450, DOI 10.1016/0167-5699(90)90174-8; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; Sambrook J, 1989, MOL CLONING LABORATO; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WARREN JB, 1990, ENDOTHELIUM INTRO CU, P263; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839	56	140	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3849	3857		10.1074/jbc.270.8.3849	http://dx.doi.org/10.1074/jbc.270.8.3849			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876129				2022-12-25	WOS:A1995QH68800059
J	KOZAROV, E; VANDERWEL, H; FIELD, M; GRITZALI, M; BROWN, RD; WEST, CM				KOZAROV, E; VANDERWEL, H; FIELD, M; GRITZALI, M; BROWN, RD; WEST, CM			CHARACTERIZATION OF FP21, A CYTOSOLIC GLYCOPROTEIN FROM DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL-ELECTROPHORESIS; DISCOIDEUM; PROTEINS; ACID; GLYCOSYLATION; SEQUENCES; MEMBRANES; NUCLEUS; BINDING; PEPTIDE	FP21 is a glycoprotein which, when tracked by radio-activity in its fucosyl moiety, was previously detected in the cytosol, of Dictyostelium cells after cell fractionation. This compartmentalization is confirmed by SDS-polyacrylamide gel electrophoresis/Western blotting of cell fractions using three different antibodies. Although a substantial fraction of FP21 is also detected in the particulate fraction using these new antibodies, particulate FP21 is released by disrupting protein-protein interactions, but not membrane disruption. Since purified FP21 is susceptible to aggregation, and purified nuclei do not contain FP21, particulate FP21 is also part of the cytosol. Additional compositional and structural information provides strong evidence that FP21 does not at any time traverse the rough endoplasmic reticulum. First, cDNAs spanning the entire coding region of the FP21 gene predict no hydrophobic motifs expected to promote membrane insertion, but do predict an NH2-terminal coiled coil domain which could explain aggregation. Second, monosaccharide composition analysis of the predominant glycoform of FP21 yields 2 mol of galactose, 1 mol of xylose, and 1 mol of fucose/mol of polypep tide; FP21 from a fucosylation-defective mutant contains 1 additional mol of xylose in place of fucose. Thus the N-glycosylation sequon present in FP21 is not utilized by oligosaccharyl transferase, which resides in the rough endoplasmic reticulum. These findings indicate that nascent FP21 remains in the cytosol after synthesis and is therefore glycosylated by unusual cytosolic xylosyl-, galactosyl-, and fucosyltransferases.	UNIV FLORIDA,COLL MED,DEPT ANAT & CELL BIOL,GAINESVILLE,FL 32610; UNIV FLORIDA,INST FOOD & AGR SCI,DEPT FOOD SCI & HUMAN NUTR,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER; NHLBI NIH HHS [2-T35-HL07489] Funding Source: Medline; NIGMS NIH HHS [R01-GM37539] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; AUSEBEL FM, 1992, CURRENT PROTOCOLS MO; BERLOT C, 1987, METHOD CELL BIOL, V28, P333; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DERUITER GA, 1992, ANAL BIOCHEM, V207, P176, DOI 10.1016/0003-2697(92)90520-H; ELWOOD PC, 1988, ANAL BIOCHEM, V175, P202, DOI 10.1016/0003-2697(88)90379-X; FECHHEIMER M, 1984, J BIOL CHEM, V259, P4514; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GONZALEZYANES B, 1992, J BIOL CHEM, V267, P9595; GONZALEZYANES B, 1989, DEV BIOL, V133, P576, DOI 10.1016/0012-1606(89)90060-2; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Harlow E, 1988, ANTIBODIES LAB MANUA; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; JAHNEN W, 1990, BIOCHEM BIOPH RES CO, V166, P139, DOI 10.1016/0006-291X(90)91922-F; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACLEAN N, 1984, EXPERIENTIA, V40, P1207, DOI 10.1007/BF01946648; MARCHASE RB, 1993, J BIOL CHEM, V268, P8341; MCROBBIE SJ, 1983, BIOCHEM BIOPH RES CO, V115, P351, DOI 10.1016/0006-291X(83)91011-2; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEEL LF, 1991, DEV GENET, V12, P98, DOI 10.1002/dvg.1020120117; STEINBUCH M, 1969, ARCH BIOCHEM BIOPHYS, V134, P279, DOI 10.1016/0003-9861(69)90285-9; SUTTON GW, 1993, TECHNIQUES PROTEIN C, V4, P109; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WARRICK HM, 1988, NUCLEIC ACIDS RES, V16, P6617, DOI 10.1093/nar/16.14.6617; WEITZHANDLER M, 1993, J BIOL CHEM, V268, P5121	38	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3022	3030		10.1074/jbc.270.7.3022	http://dx.doi.org/10.1074/jbc.270.7.3022			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852383				2022-12-25	WOS:A1995QG47100023
J	AKAMA, H; JOHNSON, CAC; COLTEN, HR				AKAMA, H; JOHNSON, CAC; COLTEN, HR			HUMAN-COMPLEMENT PROTEIN C2 - ALTERNATIVE SPLICING GENERATES TEMPLATES FOR SECRETED AND INTRACELLULAR C2 PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-B; GENE-EXPRESSION; MESSENGER-RNA; GAMMA-INTERFERON; BLOOD MONOCYTES; COMPONENT C2; PLASMID DNA; BIOSYNTHESIS; CELLS; FIBROBLASTS	Alternative splicing of the primary transcript for human complement protein C2 generates templates for translation of a secreted (C2 long) protein and an intracellular (C2 short) form in liver, bronchoalveolar macrophages, and fibroblasts. The approximate ratio of C2 long to C2 short mRNA is 2:1. The C2 short mRNA does not contain the 396-base pair encompassed by exons 2 and 3 of the full-length C2 long and thus lacks codons for the 5 carboxyl-terminal residues of the signal peptide, Synthesis of C2 in cells transfected with full-length INA corresponding to each of the transcripts show that C2 long is secreted within a half-time of approximately 1 h and that C2 short is not secreted. Cell-free biosynthesis in the presence of microsomes demonstrate that this intracellular C2 protein (70 kDa) is apparently capable of traversing the membrane of the endoplasmic reticulum. Though the function of the intracellular C2 protein is unknown, it is abundant in all cell types that express the C2 gene.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110	Washington University (WUSTL)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017461] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024836] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37591] Funding Source: Medline; NIAID NIH HHS [AI24836] Funding Source: Medline; NICHD NIH HHS [HD17461] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARNUM SR, 1992, BIOCHEM J, V287, P595, DOI 10.1042/bj2870595; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; CARROLL MC, 1984, NATURE, V307, P237, DOI 10.1038/307237a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG JH, 1994, J IMMUNOL, V152, P1774; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE FS, 1982, IMMUNOLOGY, V46, P429; COOPER NR, 1975, BIOCHEMISTRY-US, V14, P4245, DOI 10.1021/bi00690a015; GARNIER G, 1992, J EXP MED, V175, P471, DOI 10.1084/jem.175.2.471; Garnier Gerard, 1993, Molecular Immunology, V30, P11; GILOH H, 1982, SCIENCE, V217, P1252, DOI 10.1126/science.7112126; HORIUCHI T, 1990, J BIOL CHEM, V265, P6521; ISHIKAWA N, 1990, J BIOL CHEM, V265, P19040; JOHNSON CA, 1992, J BIOL CHEM, V267, P9347; JOHNSON CA, 1992, NEW ENGL J MED, V326, P871, DOI 10.1056/NEJM199203263261306; KATZ Y, 1988, J EXP MED, V167, P1, DOI 10.1084/jem.167.1.1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPIN DF, 1992, BIOCHEM J, V281, P437, DOI 10.1042/bj2810437; MANIATIS T, 1989, MOL CLONING LABORATO, P197; MORRIS KM, 1982, J CLIN INVEST, V70, P906, DOI 10.1172/JCI110687; NONAKA M, 1989, J IMMUNOL, V142, P1377; OGLESBY TJ, 1988, J IMMUNOL, V141, P926; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; PERLMUTTER DH, 1984, J BIOL CHEM, V259, P380; PERLMUTTER DH, 1985, J CLIN INVEST, V76, P1449, DOI 10.1172/JCI112123; POLLEY MJ, 1968, J EXP MED, V128, P533, DOI 10.1084/jem.128.3.533; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STRUNK RC, 1988, J CLIN INVEST, V81, P1419, DOI 10.1172/JCI113472; STRUNK RC, 1985, J BIOL CHEM, V260, P5280; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501; WOODS DE, 1984, J CLIN INVEST, V74, P634, DOI 10.1172/JCI111461	34	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2674	2678		10.1074/jbc.270.6.2674	http://dx.doi.org/10.1074/jbc.270.6.2674			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852336	hybrid			2022-12-25	WOS:A1995QF53500044
J	GAZIT, E; SHAI, Y				GAZIT, E; SHAI, Y			THE ASSEMBLY AND ORGANIZATION OF THE ALPHA-5 AND ALPHA-7 HELICES FROM THE PORE-FORMING DOMAIN OF BACILLUS-THURINGIENSIS DELTA-ENDOTOXIN - RELEVANCE TO A FUNCTIONAL-MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; PLANAR LIPID BILAYERS; PHOSPHOLIPID-MEMBRANES; PEPTIDE ALAMETHICIN; CIRCULAR-DICHROISM; SELECTIVE CHANNELS; VAR ISRAELENSIS; SODIUM-CHANNEL; PROTEIN; SPECIFICITY	The pore-forming domain of Bacillus thuringiensis insecticidal CryIIIA delta-endotoxin contains two helices, alpha 5 and alpha 7, that are highly conserved within all different Cry S-endotoxins, To gain information on the mode of action of delta-endotoxins, we have used a spectrofluorimetric approach and characterized the structure, the organization state, and the ability to self-assemble and to co-assemble within lipid membranes of alpha 5 and alpha 7. Circular dichroism (CD) spectroscopy revealed that alpha 7 adopts a predominantly alpha-helical structure in methanol, similar to what has been found for alpha 5, and consistent with its structure in the intact molecule, The hydrophobic moment of alpha 7 is higher than that calculated for alpha 5; however, alpha 7 has a lesser ability to permeate phospholipids as compared to alpha 5. Binding experiments with 7-nitrobenz-2-oxa-1,3-diazole-4-yl (NBD)-labeled peptide demonstrated that alpha 7 binds to phospholipid vesicles with a partition coefficient in the order of 10(4) M(-1) similar to alpha 5, but with reduced kinetics and in a noncooperative manner, as opposed to the fast kinetics and cooperativity found with (alpha 5. Resonance energy transfer measurements between fluorescently labeled pairs of donor (NBD)/acceptor (rhodamine) peptides revealed that, in their membrane bound state, alpha 5 self-associates but alpha 7 does not, and that (alpha 5 coassembles with alpha 7 but not with an unrelated membrane bound alpha-helical peptide, Furthermore, resonance energy transfer experiments, using alpha 5 segments, specifically labeled in either the Nor C-terminal sides, suggest a parallel organization of alpha 5 monomers within the membranes, Taken together the results are consistent with an umbrella model suggested for the pore forming activity of delta-endotoxin (Li, J., Caroll, J., and Ellar, D. J. (1991) Nature 353, 815-821), where alpha 5 has transmembrane localization and may be part of the pore lining segment(s) while alpha 7 may serve as a binding sensor that initiates the binding of the pore domain to the membrane.	WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science			Gazit, Ehud/C-3715-2011; Gazit, Ehud/AHE-9332-2022; Gazit, Ehud/M-8026-2019	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720				AHMAD W, 1990, FEMS MICROBIOL LETT, V68, P97, DOI 10.1111/j.1574-6968.1990.tb04130.x; ANGSUTHANASOMBAT C, 1993, FEMS MICROBIOL LETT, V111, P255; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CUMMINGS CE, 1994, MOL MEMBR BIOL, V11, P87, DOI 10.3109/09687689409162225; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; ENGLISH L, 1992, INSECT BIOCHEM MOLEC, V22, P1, DOI 10.1016/0965-1748(92)90093-T; Forster T, 1959, DISCUSS FARADAY SOC, V27, P7, DOI DOI 10.1039/DF9592700007; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P3429, DOI 10.1021/bi00064a029; GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016; GE AZ, 1989, P NATL ACAD SCI USA, V86, P4037, DOI 10.1073/pnas.86.11.4037; GILL SS, 1992, ANNU REV ENTOMOL, V37, P615, DOI 10.1146/annurev.en.37.010192.003151; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HAIDER MZ, 1989, BIOCHIM BIOPHYS ACTA, V978, P216, DOI 10.1016/0005-2736(89)90118-1; Hodgman T C, 1990, DNA Seq, V1, P97, DOI 10.3109/10425179009016037; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFTE H, 1989, MICROBIOL REV, V53, P242; INOUYE M, 1974, P NATL ACAD SCI USA, V71, P2396, DOI 10.1073/pnas.71.6.2396; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KENNER RA, 1971, BIOCHEMISTRY-US, V10, P4433, DOI 10.1021/bi00800a013; KNOWLES BH, 1993, BIOESSAYS, V15, P469, DOI 10.1002/bies.950150706; KNOWLES BH, 1994, ADV INSECT PHYSIOL, V24, P275, DOI 10.1016/S0065-2806(08)60085-5; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LEE MK, 1992, J BIOL CHEM, V267, P3115; LEMON MA, 1992, CURR OPIN STRUC BIOL, V2, P511; LI J, 1992, CURR OPIN STRUC BIOL, V2, P545; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LIAO MJ, 1984, J BIOL CHEM, V259, P4200; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; MADDRELL SHP, 1989, J CELL SCI, V94, P601; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MATSUZAKI K, 1989, BIOCHIM BIOPHYS ACTA, V981, P130, DOI 10.1016/0005-2736(89)90090-4; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; PAPAHADJ.D, 1967, BIOCHIM BIOPHYS ACTA, V135, P624, DOI 10.1016/0005-2736(67)90094-6; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; RIZZO V, 1987, BIOCHEMISTRY-US, V26, P2751, DOI 10.1021/bi00384a015; SACCHI VF, 1986, FEBS LETT, V204, P213, DOI 10.1016/0014-5793(86)80814-6; SAHINTOTH M, 1993, BIOCHEMISTRY-US, V32, P10027, DOI 10.1021/bi00089a019; SCHWARTZ JL, 1993, J MEMBRANE BIOL, V132, P53, DOI 10.1007/BF00233051; SCHWARTZ JL, 1991, BIOCHIM BIOPHYS ACTA, V1065, P250, DOI 10.1016/0005-2736(91)90237-3; SCHWARZ G, 1986, BIOCHIM BIOPHYS ACTA, V861, P141, DOI 10.1016/0005-2736(86)90412-8; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1991, J BIOL CHEM, V266, P22346; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SLATIN SL, 1990, BIOCHEM BIOPH RES CO, V169, P765, DOI 10.1016/0006-291X(90)90397-6; STANKOWSKI S, 1990, BIOCHIM BIOPHYS ACTA, V1025, P164, DOI 10.1016/0005-2736(90)90094-5; THIAUDIERE E, 1991, EUR J BIOCHEM, V195, P203, DOI 10.1111/j.1432-1033.1991.tb15696.x; TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; WALTERS FS, 1993, BIOCHEM BIOPH RES CO, V196, P921, DOI 10.1006/bbrc.1993.2337; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; WU D, 1992, J BIOL CHEM, V267, P2311; YUNOVITZ H, 1988, FEBS LETT, V230, P105, DOI 10.1016/0014-5793(88)80651-3	71	78	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2571	2578		10.1074/jbc.270.6.2571	http://dx.doi.org/10.1074/jbc.270.6.2571			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852320	hybrid			2022-12-25	WOS:A1995QF53500028
J	GOODE, NT; HAJIBAGHERI, MAN; PARKER, PJ				GOODE, NT; HAJIBAGHERI, MAN; PARKER, PJ			PROTEIN-KINASE-C (PKC)-INDUCED PKC DOWN-REGULATION - ASSOCIATION WITH UP-REGULATION OF VESICLE TRAFFIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR GENETIC-ANALYSIS; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; GH4C1 CELLS; ACTIVATION; ZETA; ISOZYMES; GAMMA; ALPHA; PURIFICATION	Phorbol esters cause long term activation of protein kinase C (PKC) and frequently the down-regulation of PKC protein levels in mammalian cells. Mammalian PKC-gamma, -delta, and -eta down-regulate in response to phorbol esters when expressed in Schizosaccharomyces pombe. However, PKC-epsilon does not down-regulate in S. pombe, in contrast to the behavior of this isotype in mammalian cells. Go-expression of PKC-gamma or -delta with PKC-epsilon in S. pombe renders PKC-epsilon susceptible to down-regulation. A protein kinase defective form of PKC-delta does not downregulate efficiently in S. pombe but, like PKC-epsilon, is susceptible when co-expressed with PKC-gamma or full-length PKC-delta. Thus, down-regulation is a consequence of the catalytic function of certain PKC isotypes with other isotypes being affected in trans, PKC down-regulation parallels a striking accumulation of Vesicles in S. pombe, suggesting a direct relationship between these events.	IMPERIAL CANC RES FUND, ELECTRON MICROSCOPY UNIT, LONDON WC2A 3PX, ENGLAND; IMPERIAL CANC RES FUND, PROT PHOSPHORYLAT LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK; Cancer Research UK	GOODE, NT (corresponding author), UNIV LONDON ROYAL COLL VET SURG, DEPT VET BASIC SCI, ROYAL COLL ST, LONDON NW1 0TU, ENGLAND.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933				ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BELL RM, 1991, J BIOL CHEM, V266, P4661; CAZAUBON S, 1989, EUR J BIOCHEM, V182, P401, DOI 10.1111/j.1432-1033.1989.tb14845.x; FREISEWINKEL I, 1991, FEBS LETT, V280, P262, DOI 10.1016/0014-5793(91)80307-O; GOODE NT, 1994, MOL BIOL CELL, V5, P907, DOI 10.1091/mbc.5.8.907; GOODE NT, 1994, FEBS LETT, V340, P145, DOI 10.1016/0014-5793(94)80190-8; GRUENBERG J, 1992, Current Opinion in Cell Biology, V4, P593, DOI 10.1016/0955-0674(92)90077-P; GSCHWENDT M, 1992, FEBS LETT, V307, P151, DOI 10.1016/0014-5793(92)80756-7; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KILEY SC, 1992, MOL ENDOCRINOL, V6, P120, DOI 10.1210/me.6.1.120; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURRAY AW, 1987, TRENDS BIOCHEM SCI, V12, P53, DOI 10.1016/0968-0004(87)90026-0; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHNO S, 1990, J BIOL CHEM, V265, P6296; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; PEARS C, 1991, FEBS LETT, V284, P120, DOI 10.1016/0014-5793(91)80776-Y; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; WAYS DK, 1992, J BIOL CHEM, V267, P4799; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E; [No title captured]	37	49	49	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2669	2673		10.1074/jbc.270.6.2669	http://dx.doi.org/10.1074/jbc.270.6.2669			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852335	hybrid			2022-12-25	WOS:A1995QF53500043
J	SUN, XY; ELIASSON, R; PONTIS, E; ANDERSSON, J; BUIST, G; SJOBERG, BM; REICHARD, P				SUN, XY; ELIASSON, R; PONTIS, E; ANDERSSON, J; BUIST, G; SJOBERG, BM; REICHARD, P			GENERATION OF THE GLYCYL RADICAL OF THE ANAEROBIC ESCHERICHIA-COLI RIBONUCLEOTIDE REDUCTASE REQUIRES A SPECIFIC ACTIVATING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN; SEQUENCE; GENE; IRON	The anaerobic ribonucleotide reductase from Escherichia coli contains a glycyl radical as part of its polypeptide structure. The radical is generated by an enzyme system present in E. coli. The reductase is coded for by the nrdD gene located at 96 min. Immediately downstream, we now find an open reading frame with the potential to code for a 17.5-kDa protein with sequence homology to a protein required for the generation of the glycyl radical of pyruvate formate lyase, The protein corresponding to this open reading frame is required for the generation of the glycyl radical of the anaerobic reductase and binds tightly to the reductase, The ''activase'' contains iron, required for activity, The general requirements for generation of a glycyl radical are identical for the reductase and pyruvate formate lyase. For the reductase, the requirement of an iron-containing activase suggests the possibility that the iron-sulfur cluster of the enzyme is not involved in radical generation but may participate directly in the reduction of the ribonucleotide.	KAROLINSKA INST,MBB,MED NOBEL INST,DEPT BIOCHEM 1,S-17177 STOCKHOLM,SWEDEN; UNIV GRONINGEN,DEPT GENET,9741 NN HAREN,NETHERLANDS	Karolinska Institutet; University of Groningen				Sjoberg, Britt-Marie/0000-0001-5953-3360				ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; FREY M, 1994, J BIOL CHEM, V269, P12432; HARDER J, 1992, J BIOL CHEM, V267, P25548; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOLM RH, 1976, BIOL ASPECTS INORGAN, P71; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WONG KK, 1993, BIOCHEMISTRY-US, V32, P14102, DOI 10.1021/bi00214a005; YOUNG P, 1994, J BIOL CHEM, V269, P27815	20	77	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2443	2446		10.1074/jbc.270.6.2443	http://dx.doi.org/10.1074/jbc.270.6.2443			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852304	hybrid			2022-12-25	WOS:A1995QF53500009
J	GOROVITS, B; RAMAN, CS; HOROWITZ, PM				GOROVITS, B; RAMAN, CS; HOROWITZ, PM			HIGH HYDROSTATIC-PRESSURE INDUCES THE DISSOCIATION OF CPN60 TETRADECAMERS AND REVEALS A PLASTICITY OF THE MONOMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSIBLE DISSOCIATION; GROEL; CARBOXYLASE; NUCLEOTIDES; HYDROLYSIS; DEPENDENCE; RHODANESE; PROTEINS; MUTATION; CYCLE	Hydrostatic pressures up to 2 kbar have been used to form monomers from the 14-subunit oligomer of the chaperonin, Cpn60. The fluorescence of 1,1'-bi(4-anilino)naphthalene-5,5'-disulfonic acid (bisANS), followed at high pressure, demonstrated an increase in hydrophobic exposure on dissociation, Cpn60 dissociated with first order kinetics, The transition occurred between 1.3 and 2 kbar (P-50 = 1.75 kbar), and it was facilitated by MgATP (P-50 = 1.1 kbar), With MgATP, the fluorescence showed a rapid first order phase (t1/2 = 3.7 min) in addition to a phase that was similar to the single phase for Cpn60 alone (t1/2 = 11.4 min), The bisANS fluorescence decreased slowly after depressurization, and the relaxation was faster at 25 degrees C (t1/2 = 58 h) than at 4 degrees C (t1/2 = 86 h) and faster still if the sample at 4 degrees C contained MgATP when it was pressurized (t1/2 = 18 h). There was no significant effect if the MgATP was added after depressurization, Analytical ultracentrifugation, after depressurization, confirmed that metastable monomers were produced that slowly reassociated to form the oligomers (t1/2 = 150 h at 25 degrees C), Immediately after depressurization, the monomers (a) had all three sulfhydryl groups exposed for labeling with 6-iodoacetamidofluorescein, (5) showed a proteolytic susceptibility that was intermediate between native Cpn60 and Cpn60 in 2.5 M urea, and (c) were not able to capture a folding intermediate of the enzyme rhodanese, After incubation at atmospheric pressure, monomeric Cpn60 regained the ability to interact with rhodanese intermediates, and the sulfhydryl reactivity fell before significantly reassociating to 14-mers, The different rates of recovery of the native properties indicate that a complex series of conformational events occur following depressurization. Finally, the monomers resulting from pressure were different from those produced from Cpn60 by the action of 2.5 M urea, These results demonstrate that there is a fast, pressure-induced dissociation of the Cpn60 14-mer followed by a conformational drift of the dissociated monomers that can be influenced by the presence of MgATP.	UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio				Raman, C. S./0000-0002-1036-3193	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANEYX F, 1992, J BIOL CHEM, V267, P11637; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; ERIJMAN L, 1993, BIOCHEMISTRY-US, V32, P5187, DOI 10.1021/bi00070a030; ERIJMAN L, 1991, BIOCHEMISTRY-US, V30, P1595, DOI 10.1021/bi00220a022; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAMESON DM, 1987, BIOCHEMISTRY-US, V26, P3894, DOI 10.1021/bi00387a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1993, FEBS LETT, V324, P41, DOI 10.1016/0014-5793(93)81528-8; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; NEUMAN RC, 1973, J PHYS CHEM-US, V77, P2687, DOI 10.1021/j100640a025; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SILVA JL, 1989, J BIOL CHEM, V264, P15863; SILVA JL, 1986, BIOCHEMISTRY-US, V25, P5780, DOI 10.1021/bi00367a065; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TAGUCHI H, 1994, J BIOL CHEM, V269, P8529; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEBER G, 1983, Q REV BIOPHYS, V16, P89, DOI 10.1017/S0033583500004935; WEBER G, 1992, PROTEIN INTERACTIONS, P211	28	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2061	2066		10.1074/jbc.270.5.2061	http://dx.doi.org/10.1074/jbc.270.5.2061			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836434	hybrid			2022-12-25	WOS:A1995QE49300015
J	ISHIDA, A; FUJISAWA, H				ISHIDA, A; FUJISAWA, H			STABILIZATION OF CALMODULIN-DEPENDENT PROTEIN-KINASE-II THROUGH THE AUTOINHIBITORY DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; MOLECULAR-CLONING; CA-2+-INDEPENDENT ACTIVITY; AUTOPHOSPHORYLATION SITES; SMOOTH-MUSCLE; MUTANT MICE; BRAIN; ACTIVATION; INHIBITION; MYOSIN	The active 30-kDa chymotryptic fragment of calmodulin dependent protein kinase II (CaM kinase II), devoid of the autoinhibitory domain, and the enzyme, autothiophosphorylated at Thr(286)/Thr(287), were much more labile than was the original native enzyme. They were markedly stabilized by synthetic peptides, designed after the sequence around the autophosphorylation site in the autoinhibitory domain, such as autocamtide-2 and CaMK-(281-309), but such marked stabilizations were not observed with the ordinary exogenous substrates, such as syntide-2. These results suggest that the autoinhibitory domain of CaM kinase II plays a crucial role in stabilizing the enzyme, A nonphosphorylatable analog of autocamtide-2, AIP, strongly inhibited the activity of the 30-kDa fragment, Kinetic analysis revealed that the inhibition by AIP was competitive with respect to autocamtide-2 and CaMK-(281-289) and noncompetitive with respect to syntide-2 and ATP/Mg2+, suggesting that CaM kinase II possesses at least two distinct substrate-binding sites; one for ordinary exogenous substrates such as syntide-2 and the other for an endogenous substrate, the autophosphorylation site (Thr(286)/Thr(287)) in the autoinhibitory domain, Fluorescence analysis of the binding of 7-nitrobenz-2-oxa-1,3-diazole-4-yl labeled AIP to the 30-kDa fragment also supported this contention, Thus, the autoinhibitory domain appears to play a crucial role in keeping the enzyme stable by binding to the substrate-binding site for the autophosphorylation site.			ISHIDA, A (corresponding author), ASAHIKAWA MED COLL,DEPT BIOCHEM,ASAHIKAWA 078,HOKKAIDO,JAPAN.							ALLEGRINI PR, 1983, EUR J BIOCHEM, V132, P603, DOI 10.1111/j.1432-1033.1983.tb07406.x; BENFENATI F, 1992, NATURE, V359, P419; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; EBASHI S, 1976, J BIOCHEM-TOKYO, V79, P229, DOI 10.1093/oxfordjournals.jbchem.a131052; FAUX MC, 1993, J BIOL CHEM, V268, P12484; FUJISAWA H, 1990, BIOESSAYS, V12, P27, DOI 10.1002/bies.950120106; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HVALBY O, 1994, P NATL ACAD SCI USA, V91, P4761, DOI 10.1073/pnas.91.11.4761; IKEDA A, 1991, J BIOL CHEM, V266, P11582; ISHIDA A, 1994, J BIOCHEM-TOKYO, V115, P1075, DOI 10.1093/oxfordjournals.jbchem.a124460; KATOH T, 1991, BIOCHIM BIOPHYS ACTA, V1091, P205, DOI 10.1016/0167-4889(91)90063-4; KATOH T, 1991, J BIOL CHEM, V266, P3039; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KURET J, 1985, J BIOL CHEM, V260, P6427; KWIATKOWSKI AP, 1988, J BIOL CHEM, V263, P6484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOU LL, 1989, J NEUROSCI, V9, P2020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P8550, DOI 10.1073/pnas.86.21.8550; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; YAMAGATA Y, 1991, J BIOL CHEM, V266, P15391; YAMAUCHI T, 1980, FEBS LETT, V116, P141, DOI 10.1016/0014-5793(80)80628-4; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; YAMAUCHI T, 1981, BIOCHEM BIOPH RES CO, V100, P807, DOI 10.1016/S0006-291X(81)80246-X; YAMAUCHI T, 1985, BIOCHEM BIOPH RES CO, V129, P213, DOI 10.1016/0006-291X(85)91424-X	53	70	79	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2163	2170		10.1074/jbc.270.5.2163	http://dx.doi.org/10.1074/jbc.270.5.2163			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836445	hybrid			2022-12-25	WOS:A1995QE49300030
J	SERIZAWA, A; DANDO, PM; BARRETT, AJ				SERIZAWA, A; DANDO, PM; BARRETT, AJ			CHARACTERIZATION OF A MITOCHONDRIAL METALLOPEPTIDASE REVEALS NEUROLYSIN AS A HOMOLOG OF THIMET OLIGOPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PZ-PEPTIDASE; MICROSOMAL ENDOPEPTIDASE; INTERMEDIATE PEPTIDASE; PROCESSING PROPROTEINS; SUBSTRATE-SPECIFICITY; POTENT INHIBITORS; MOLECULAR-CLONING; BINDING PROTEIN; RAT; LIVER	We have isolated a metallopeptidase from rat liver, The peptidase is primarily located in the mitochondrial intermembrane space, where it interacts non-covalently with the inner membrane, The enzyme hydrolyzes oligopeptides, the largest substrate molecule found being dynorphin A(1-17); it has no action on proteins, and does not interact with alpha(2)-macroglobulin, and can therefore be classified as an oligopeptidase, We term the enzyme oligopeptidase M, Oligopeptidase M acts similarly to thimet oligopeptidase (EC 3.4.24.15) on bradykinin and several other peptides, but hydrolyzes neurotensin exclusively at the -Pro+Tyr- bond (the symbol + is used to indicate a scissile peptide bond) rather than the -Arg+Arg- bond. The enzyme is inhibited by chelating agents and some thiol-blocking compounds, but differs from thimet oligopeptidase in not being activated by thiol compounds, The peptidase is inhibited by Pro-Ile, unlike thimet oligopeptidase, and the two enzymes are separable in chromatography on hydroxyapatite, The N-terminal amino acid sequence of rat mitochondrial oligopeptidase M contains 19 out of 20 residues identical with a segment of rabbit microsomal endopeptidase and 17 matching the corresponding segment of pig-soluble angiotensin II-binding protein, Moreover, the rat protein is recognized by a monoclonal antibody against rabbit soluble angiotensin II-binding protein, all of which is consistent with these proteins being species variants of a single protein that is a homologue of thimet oligopeptidase, The biochemical properties of the mitochondrial oligopeptidase leave us in no doubt that it is neurolysin (EC 3.4.24.16), for which no sequence has previously been reported, and which has not been thought to be mitochondrial.	SNOW BRAND MILK PROD CO LTD, SAPPORO RES LAB, SAPPORO, HOKKAIDO 065, JAPAN; STRANGEWAYS RES LAB, DEPT BIOCHEM, CAMBRIDGE CB1 4RN, ENGLAND	Snow Brand Milk Products Co., Ltd.			Barrett, Alan J/G-8970-2013	Barrett, Alan J/0000-0002-6082-4437				Alberts B., 1994, MOL BIOL CELL; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARELLI H, 1993, EUR J BIOCHEM, V211, P79, DOI 10.1111/j.1432-1033.1993.tb19872.x; BARELLI H, 1994, BRIT J PHARMACOL, V112, P127, DOI 10.1111/j.1476-5381.1994.tb13041.x; BARELLI H, 1992, BIOCHEM J, V287, P621, DOI 10.1042/bj2870621; BARRETT AJ, 1990, BIOCHEM J, V271, P701, DOI 10.1042/bj2710701; BARRETT AJ, 1989, BIOCHEM J, V260, P259, DOI 10.1042/bj2600259; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Barrett AJ, 1977, LYSOSOMES LABORATORY, P19; BARRETT AJ, 1995, IN PRESS METHODS ENZ; BROWN JP, 1976, BIOCHEM J, V155, P419, DOI 10.1042/bj1550419; BUCHLER M, 1994, EUR J BIOCHEM, V219, P627, DOI 10.1111/j.1432-1033.1994.tb19978.x; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CONLIN CA, 1995, IN PRESS METHODS ENZ; DAHMS P, 1992, EUR J BIOCHEM, V208, P145, DOI 10.1111/j.1432-1033.1992.tb17168.x; DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451; DAUCH P, 1992, J NEUROCHEM, V59, P1862, DOI 10.1111/j.1471-4159.1992.tb11021.x; DAUCH P, 1991, EUR J BIOCHEM, V202, P269, DOI 10.1111/j.1432-1033.1991.tb16372.x; DAUCH P, 1991, BIOCHEM J, V280, P421, DOI 10.1042/bj2800421; DEVINE PL, 1990, BIOTECHNIQUES, V8, P492; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; HEIDRICH HG, 1969, H-S Z PHYSIOL CHEM, V350, P1430, DOI 10.1515/bchm2.1969.350.2.1430; HEIDRICH HG, 1973, H-S Z PHYSIOL CHEM, V354, P1399, DOI 10.1515/bchm2.1973.354.2.1399; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; ISAYA G, 1994, MOL CELL BIOL, V14, P5603, DOI 10.1128/MCB.14.8.5603; ISAYA G, 1992, P NATL ACAD SCI USA, V89, P8317, DOI 10.1073/pnas.89.17.8317; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KATO A, 1994, EUR J BIOCHEM, V221, P159, DOI 10.1111/j.1432-1033.1994.tb18725.x; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KAWABATA S, 1993, J BIOL CHEM, V268, P12498; KNIGHT CG, 1991, FEBS LETT, V294, P183, DOI 10.1016/0014-5793(91)80664-O; KNIGHT CG, 1991, BIOCHEM J, V274, P45, DOI 10.1042/bj2740045; KNIGHT CG, 1995, IN PRESS BIOCH J; LOEWENSTEIN J, 1970, Biochimica et Biophysica Acta, V223, P432, DOI 10.1016/0005-2728(70)90201-X; MCKIE N, 1993, BIOCHEM J, V295, P57, DOI 10.1042/bj2950057; MCKIE N, 1995, IN PRESS BIOCH J; MENTLEIN R, 1994, J NEUROCHEM, V62, P27; MILLICAN PE, 1991, BIOCHEM J, V276, P583, DOI 10.1042/bj2760583; MONNET V, 1995, IN PRESS METHODS ENZ; ORLOWSKI M, 1988, BIOCHEMISTRY-US, V27, P597, DOI 10.1021/bi00402a015; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; RAWLINGS ND, 1990, COMPUT APPL BIOSCI, V6, P118; RAWLINGS ND, 1995, IN PRESS METHODS ENZ; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SOFFER RL, 1991, METHODS NEUROSCI, V8, P192; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUGIURA N, 1992, J BIOL CHEM, V267, P18067; SWANSON MA, 1955, METHOD ENZYMOL, V2, P541, DOI 10.1016/S0076-6879(55)02247-7; TISLJAR U, 1990, FEBS LETT, V264, P84, DOI 10.1016/0014-5793(90)80771-A; TISLJAR U, 1990, ANAL BIOCHEM, V186, P112, DOI 10.1016/0003-2697(90)90582-T; TSURU D, 1988, J BIOCHEM, V104, P580, DOI 10.1093/oxfordjournals.jbchem.a122514; VINCENT B, 1994, EUR J BIOCHEM, V221, P297, DOI 10.1111/j.1432-1033.1994.tb18741.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WUNSCH E, 1963, H-S Z PHYSIOL CHEM, V333, P149, DOI 10.1515/bchm2.1963.333.1.149; 1994, EUR J BIOCHEM, V223, P1; 1992, ENZYME NOMENCLATURE	58	61	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2092	2098		10.1074/jbc.270.5.2092	http://dx.doi.org/10.1074/jbc.270.5.2092			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836437	hybrid			2022-12-25	WOS:A1995QE49300019
J	WEN, W; TAYLOR, SS; MEINKOTH, JL				WEN, W; TAYLOR, SS; MEINKOTH, JL			THE EXPRESSION AND INTRACELLULAR-DISTRIBUTION OF THE HEAT-STABLE PROTEIN-KINASE INHIBITOR IS CELL-CYCLE-REGULATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OOCYTE MEIOTIC MATURATION; CATALYTIC SUBUNIT; GOLGI-COMPLEX; LIVING CELLS; CHICK KIDNEY; RAT TESTIS; CAMP; AMP; LOCALIZATION; MOUSE	The heat stable protein kinase inhibitor (PKI) is a potent and specific inhibitor of the catalytic (C) subunit of the cAMP-dependent protein kinase, We report the isolation of a polyclonal antibody raised to purified recombinant PKI alpha. Using this antibody, the intracellular distribution of endogenous PKI alpha was assessed by immunostaining. The PKI alpha expression and intracellular distribution varied as a function of cell cycle progression. PKI alpha expression appeared low in serum starved cells and in cells in G(1) and increased as cells progressed through S phase, Its distribution became increasingly nuclear as cells entered G(2)/M. Nuclear levels of PKI alpha remained high through cell division and decreased again as cells reentered G(1). The cell cycle regulated expression and nuclear distribution suggests a specific role for PKI alpha in the nucleus during the G(2)/M phases of the cell cycle, Consistent with this, microinjection of PKI alpha antibody into serum-starved cells prevented their subsequent cell cycle progression, Similarly, overexpression of C subunit in cells arrested at the G(1)/S boundary prevented their subsequent division, Together these results support the idea that PKI alpha plays an important role in the inhibition of nuclear C subunit activity required for cell cycle progression, although a determination of the relative amounts of endogenous nuclear PKI and C-subunit will be required to substantiate this hypothesis.	UNIV CALIF SAN DIEGO,DEPT BIOCHEM,LA JOLLA,CA 92093; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of California System; University of California San Diego; University of Pennsylvania	WEN, W (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093, USA.		Meinkoth, Judy L/G-2900-2010					ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALABDALY FA, 1989, ENDOCRINOLOGY, V124, P2901, DOI 10.1210/endo-124-6-2901; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; COSTA M, 1977, BIOCHEM BIOPH RES CO, V78, P1311, DOI 10.1016/0006-291X(77)91435-8; DOREE M, 1981, EXP CELL RES, V135, P237, DOI 10.1016/0014-4827(81)90159-2; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; HOHMANN P, 1993, CELL PROLIFERAT, V26, P195, DOI 10.1111/j.1365-2184.1993.tb00019.x; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LANGECARTER CA, 1990, J BIOL CHEM, V265, P7814; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MEDNIEKS MI, 1987, EUR J CELL BIOL, V44, P308; MEDNIEKS MI, 1989, J HISTOCHEM CYTOCHEM, V37, P339, DOI 10.1177/37.3.2537353; MEIJER L, 1989, DEV BIOL, V133, P58, DOI 10.1016/0012-1606(89)90296-0; MEINKOTH J, 1992, J BIOL CHEM, V267, P1323; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MOLLOY S, 1992, EXP CELL RES, V201, P494, DOI 10.1016/0014-4827(92)90299-N; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P185; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; POSNER JB, 1964, BIOCHEMISTRY-US, V3, P1040, DOI 10.1021/bi00896a005; RUDACKGARCIA D, 1981, J BIOL CHEM, V256, P781; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; SCHULTZ RM, 1983, DEV BIOL, V97, P264, DOI 10.1016/0012-1606(83)90085-4; TASH JS, 1980, CELL, V21, P57, DOI 10.1016/0092-8674(80)90114-2; TASH JS, 1979, J BIOL CHEM, V254, P1241; THOMAS J, 1991, J BIOL CHEM, V266, P10906; URNER F, 1983, ENDOCRINOLOGY, V113, P1170, DOI 10.1210/endo-113-3-1170; VANPATTEN SM, 1987, J BIOL CHEM, V262, P3398; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALSH DA, 1971, J BIOL CHEM, V246, P1977	36	31	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2041	2046		10.1074/jbc.270.5.2041	http://dx.doi.org/10.1074/jbc.270.5.2041			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836431	hybrid			2022-12-25	WOS:A1995QE49300012
J	WOLF, DE; MCKINNON, CA; DAOU, MC; STEPHENS, RM; KAPLAN, DR; ROSS, AH				WOLF, DE; MCKINNON, CA; DAOU, MC; STEPHENS, RM; KAPLAN, DR; ROSS, AH			INTERACTION WITH TRKA IMMOBILIZES GP75 IN THE HIGH-AFFINITY NERVE GROWTH-FACTOR RECEPTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATERAL DIFFUSION; NGF RECEPTOR; TRANSLATIONAL DIFFUSION; NEUROTROPHIC FACTOR; LIGAND-BINDING; CHICK-EMBRYO; CELLS; MOBILITY; DIFFERENTIATION; INTERNALIZATION	It has been proposed that the high affinity nerve growth factor (NGF) receptor required for NGF response is a complex of two receptor proteins, gp75 and the tyrosine kinase TrkA, but direct biochemical or biophysical evidence has been lacking, We have previously shown using fluorescence recovery after photobleaching that gp75 is highly mobile on NGF-nonresponsive cells, but relatively immobile on NGF-responsive cells. In this report, we show that a physical interaction with TrkA causes gp75 immobilization We found that gp75 is relatively mobile on TrkA negative nnr5 cells, a PC12 variant which is nonresponsive to NGF. In contrast, on T14 nnr5 cells (which bear a TrkA expression vector) gp75 is relatively immobile, Similarly, using baculoviruses to express gp75 and TrkA on Sf9 insect cells, we found that TrkA immobilizes gp75 molecules, The related receptor, TrkB, caused a more modest immobilization of gp75. Immobilization was found to require intact TrkA kinase and gp75 cytoplasmic domains, paralleling the requirements of high affinity binding of NGF, Analysis of gp75 diffusion coefficients indicates that mutated gp75 and TrkA molecules may form a complex, even in the absence of the ability to bind NGF with high affinity.	NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	WOLF, DE (corresponding author), WORCESTER FDN EXPTL BIOL INC, 222 MAPLE AVE, SHREWSBURY, MA 01545 USA.				NINDS NIH HHS [NS21716, NS28760] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021716, R01NS028760] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; Bevington PR, 1969, DATA REDUCTION ERROR; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; EDIDIN M, 1984, J CELL BIOL, V99, P2333, DOI 10.1083/jcb.99.6.2333; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; GORDONCARDO C, 1991, CELL, V66, P173; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LIVNEH E, 1986, J CELL BIOL, V103, P327, DOI 10.1083/jcb.103.2.327; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MAO SY, 1991, J IMMUNOL, V146, P958; MARANO N, 1987, J NEUROCHEM, V48, P225, DOI 10.1111/j.1471-4159.1987.tb13151.x; PACCAUD JP, 1993, J BIOL CHEM, V268, P23191; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSS AH, 1985, ARCH BIOCHEM BIOPHYS, V242, P540, DOI 10.1016/0003-9861(85)90241-3; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SCULLION BF, 1987, J CELL BIOL, V105, P69, DOI 10.1083/jcb.105.1.69; SHEETZ MP, 1980, NATURE, V285, P510, DOI 10.1038/285510a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; SUTTER A, 1979, J BIOL CHEM, V254, P5972; VENKATAKRISHNAN G, 1991, BIOCHEMISTRY-US, V30, P2748, DOI 10.1021/bi00225a002; VENKATAKRISHNAN G, 1990, CELL REGUL, V1, P605, DOI 10.1091/mbc.1.8.605; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VOLONTE C, 1993, MOL BIOL CELL, V4, P71, DOI 10.1091/mbc.4.1.71; WADE WF, 1989, J CELL BIOL, V109, P3325, DOI 10.1083/jcb.109.6.3325; WIER M, 1988, SCIENCE, V242, P412, DOI 10.1126/science.3175663; WOLF DE, 1989, METHOD CELL BIOL, V30, P271; WOLF DE, 1980, BIOCHEMISTRY-US, V19, P3893, DOI 10.1021/bi00558a002; WOLF DE, 1981, TECHNIQUES CEL 105 P, V1, P1; ZHANG F, 1993, BIOESSAYS, V15, P579, DOI 10.1002/bies.950150903	45	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2133	2138		10.1074/jbc.270.5.2133	http://dx.doi.org/10.1074/jbc.270.5.2133			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836442				2022-12-25	WOS:A1995QE49300025
J	COMERFORD, SA; MAIKA, SD; LAIMINS, LA; MESSING, A; ELSASSER, HP; HAMMER, RE				COMERFORD, SA; MAIKA, SD; LAIMINS, LA; MESSING, A; ELSASSER, HP; HAMMER, RE			E6 AND E7 EXPRESSION FROM THE HPV-18 LCR - DEVELOPMENT OF GENITAL HYPERPLASIA AND NEOPLASIA IN TRANSGENIC MICE	ONCOGENE			English	Article						HPV-18; CERVICAL NEOPLASIA; SEMINAL VESICLE; PREPUTIAL GLAND; TRANSGENIC MICE	HUMAN PAPILLOMAVIRUS TYPE-16; CARCINOMA CELL-LINES; CERVICAL-CARCINOMA; HUMAN KERATINOCYTES; REGULATORY REGION; UTERINE CERVIX; STROMAL CELLS; GENE-PRODUCTS; T-CELL; PROTEIN	Human papillomavirus type 18 infection is highly associated with malignant tumors of the genital tract. To investigate the tissue specificity of the HPV long control region (LCR) and the transforming ability of the E6-E7 oncoproteins, an HPV-18 transgene containing the viral LCR and E6 and E7 genes was introduced into mice. Three founder males exhibited enlarged seminal vesicles and preputial glands by 50 weeks of age. A line of transgenic mice was established by in vitro fertilization, and subsequent generations of transgenic males and females were monitored for lesions. Approximately 80% of hemizygous transgenic males exhibited enlarged seminal vesicles and preputial glands as early as 12 weeks of age. Histological examination indicated that this enlargement was due to distension by fluid, along with polyploid hyperplasia of the lining secretory epithelium. E6 and E7 transcripts were limited to affected organs and kidney. Approximately 41% of transgenic females developed cervical neoplasms between 1-2 years of age. Histologically, tumors were mesenchymal rather than epithelial in origin. E6 and E7 transcripts were restricted to cervical tumor tissue and kidney. These findings suggest that the HPV-18 LCR has an element(s) which directs expression specifically to the urogenital tract in transgenic mice.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV WISCONSIN, SCH VET MED, DEPT PATHOBIOL SCI, MADISON, WI 53706 USA; UNIV MARBURG, DEPT CELL BIOL, D-35033 MARBURG, GERMANY	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Wisconsin System; University of Wisconsin Madison; Philipps University Marburg				Hammer, Robert E./0000-0001-5487-7551; Comerford, Sarah Ann/0000-0002-7452-7759				APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; BEDELL MA, 1987, J VIROL, V61, P3635, DOI 10.1128/JVI.61.11.3635-3640.1987; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BEDELL MA, 1991, J VIROL, V65, P2254, DOI 10.1128/JVI.65.5.2254-2260.1991; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; CID A, 1993, J VIROL, V67, P6742, DOI 10.1128/JVI.67.11.6742-6752.1993; CINTORINO M, 1991, INT J CANCER, V47, P843, DOI 10.1002/ijc.2910470609; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; COMERFORD SA, 1991, J VIROL, V65, P4681, DOI 10.1128/JVI.65.9.4681-4690.1991; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DIETRICH W, 1992, GENETICS, V131, P423; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOLLARD SC, 1992, GENE DEV, V6, P1131, DOI 10.1101/gad.6.7.1131; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GARCIACARRANCA A, 1988, J VIROL, V62, P4321, DOI 10.1128/JVI.62.11.4321-4330.1988; GIUS D, 1988, J VIROL, V62, P665, DOI 10.1128/JVI.62.3.665-672.1988; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JOCHMUSKUDIELKA I, 1989, J NATL CANCER I, V81, P1698, DOI 10.1093/jnci/81.22.1698; JONES MH, 1992, ONCOGENE, V7, P1631; KIRCHNER H, 1986, PROG MED VIROL, V33, P1; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; KREIDER JW, 1987, J VIROL, V61, P590, DOI 10.1128/JVI.61.2.590-593.1987; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MCCANCE DJ, 1985, BIOCHIM BIOPHYS ACTA, V823, P195, DOI 10.1016/0304-419X(86)90002-8; MCLEAN CS, 1993, J GEN VIROL, V74, P239, DOI 10.1099/0022-1317-74-2-239; MENEGUZZI G, 1991, VIROLOGY, V181, P62, DOI 10.1016/0042-6822(91)90470-V; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; MITTAL R, 1993, OBSTET GYNECOL, V81, P5; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PATER MM, 1988, NATURE, V335, P832, DOI 10.1038/335832a0; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; SANG BC, 1992, VIROLOGY, V189, P448, DOI 10.1016/0042-6822(92)90568-A; SAPPINO AP, 1988, INT J CANCER, V41, P707, DOI 10.1002/ijc.2910410512; SAPPINO AP, 1989, VIRCHOWS ARCH A, V415, P551, DOI 10.1007/BF00718649; SASAGAWA T, 1992, CANCER RES, V52, P4420; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERMAUNOURY S, 1987, J VIROL, V61, P3295, DOI 10.1128/JVI.61.10.3295-3298.1987; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SELVEY LA, 1990, J IMMUNOL, V145, P3105; SHEPHERD PS, 1992, J GEN VIROL, V73, P1269, DOI 10.1099/0022-1317-73-5-1269; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SPENCER ES, 1970, BRIT MED J, V3, P251, DOI 10.1136/bmj.3.5717.251; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; TINDLE RW, 1991, P NATL ACAD SCI USA, V88, P5887, DOI 10.1073/pnas.88.13.5887; TINSLEY JM, 1992, J GEN VIROL, V73, P1251, DOI 10.1099/0022-1317-73-5-1251; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; WANK R, 1991, NATURE, V352, P723, DOI 10.1038/352723a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986; YOKOTA J, 1989, CANCER RES, V49, P3598	68	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					587	597						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845684				2022-12-25	WOS:A1995QF64800020
J	HUEN, DS; HENDERSON, SA; CROOMCARTER, D; ROWE, M				HUEN, DS; HENDERSON, SA; CROOMCARTER, D; ROWE, M			THE EPSTEIN-BARR-VIRUS LATENT MEMBRANE PROTEIN-1 (LMP1) MEDIATES ACTIVATION OF NF-KAPPA-B AND CELL-SURFACE PHENOTYPE VIA 2 EFFECTOR REGIONS IN ITS CARBOXY-TERMINAL CYTOPLASMIC DOMAIN	ONCOGENE			English	Article						EPSTEIN-BARR VIRUS; LMP; NF-KB; CD40; CD54	NASOPHARYNGEAL CARCINOMA; BETA-GALACTOSIDASE; TRANSFORMED-CELLS; GENE-EXPRESSION; LYMPHOCYTES-B; INDUCTION; LINE; REPLICATION; DNA; HETEROGENEITY	The Epstein-Barr virus (EBV) encoded latent membrane protein, LMP1, is oncogenic in rodent fibroblasts and is an essential effector protein in EBV-induced growth-transformation of human B lymphocytes. Previous structure-function studies with LMP1 have relied largely on rodent fibroblast transformation as a functional readout, with apparently conflicting results. We have now analysed several LMP1 mutants in various human cell types, including B cells, T cells and epithelial cells, using two independent functional assays; (i) activation of NF-KB, and (ii) induction of two cell surface activation markers, CD54 and CD40. The results suggest that the cytosolic N-terminus is not essential for LMP1 function in any cell type studied. The third and fourth transmembrane helices and the intracytosolic loops are dispensable for activation of NF-KB, but they do influence the induction of CD54 and CD40. The major effector domain appears to be the cytosolic C-terminus in which were identified two 'C-terminal activating regions', CTAR-1 (residues 194-232) and CTAR-2 (residues 351-386). Whilst the exact results depended upon the host cell line, CTAR-2 was generally more important for activation of NF-KB, and both CTAR-1 and CTAR-2 were required for optimal induction of CD54 and CD40. Analysis of NF-kappa B activation by LMP1 in Rat-1 fibroblasts indicated that many mutations that were functional in human cells were poorly tolerated in the rodent cells; a result that is in broad agreement with published Rat-1 transformation data.	UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND	University of Birmingham			Rowe, Martin/B-2880-2009; Huen, David/F-3676-2014	Rowe, Martin/0000-0003-4139-7326; Huen, David/0000-0002-9900-2297; Hope, Sheila/0000-0002-3608-4379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARENZANASEISDEDOS, 1993, J VIROL, V67, P6596; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOTCHAN M, 1976, CELL, V9, P269, DOI 10.1016/0092-8674(76)90118-5; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIMALDI JC, 1991, J IMMUNOL, V149, P3921; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HU LF, 1993, ONCOGENE, V8, P1575; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KIEFF E, 1990, P1889; KIEFF E, 1994, 51ST S SOC GEN MICR, P123; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MASUCCI MG, 1989, J VIROL, V63, P3135, DOI 10.1128/JVI.63.7.3135-3141.1989; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MILLER G, 1990, P1921; MILLER WE, 1994, J GEN VIROL, V75, P2729, DOI 10.1099/0022-1317-75-10-2729; MOORTHY R, 1990, J VIROL, V64, P829, DOI 10.1128/JVI.64.2.829-837.1990; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; PENG M, 1992, ONCOGENE, V7, P1775; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PILON M, 1990, J IMMUNOL, V146, P1047; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; YOUNG DC, 1993, ANAL BIOCHEM, V215, P24, DOI 10.1006/abio.1993.1549; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	56	432	445	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					549	560						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845680				2022-12-25	WOS:A1995QF64800016
J	KNECHT, H; BACHMANN, E; BROUSSET, P; ROTHENBERGER, S; EINSELE, H; LESTOU, VS; DELSOL, G; BACHMANN, F; AMBROS, PF; ODERMATT, BF				KNECHT, H; BACHMANN, E; BROUSSET, P; ROTHENBERGER, S; EINSELE, H; LESTOU, VS; DELSOL, G; BACHMANN, F; AMBROS, PF; ODERMATT, BF			MUTATIONAL HOT-SPOTS WITHIN THE CARBOXY-TERMINAL REGION OF THE LMP1 ONCOGENE OF EPSTEIN-BARR-VIRUS ARE FREQUENT IN LYMPHOPROLIFERATIVE DISORDERS	ONCOGENE			English	Article						EPSTEIN-BARR VIRUS; ONCOGENE; LMP1; MUTATIONAL HOTSPOTS; LYMPHOMA; TRANSLOCATIONS	MEMBRANE-PROTEIN LMP-1; REED-STERNBERG CELLS; LATENT GENE-PRODUCTS; HODGKINS-DISEASE; NASOPHARYNGEAL CARCINOMA; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; B-CELLS; EXPRESSION; INFECTION; LYMPHOMAS	We have recently identified in Epstein-Barr virus (EBV) positive Hodgkin's disease (HD) a variant of the latent membrane protein 1 (LMP1) oncogene characterized by four point mutations and a 30 base pair deletion. These findings led us to test whether such mutants were also present in other lymphoproliferative disorders (LPD). We analysed 98 EBV DNA positive cases (67 LPD, 15 benign conditions, 16 lymphoblastoid cell lines) by PCR for deletions within the LMP1 gene. DNA sequencing of the region coding for the carboxy terminal protein domain was performed on 24 cases. In 13 cases the same combination of 4 point mutations at positions 168 320, 168 308, 168 295 and 168 225 was identified. Of these cases, 12 had an additional point mutation at position 168 357 and eight at position 168 355, and nine had a 30 base pair deletion including nucleotides 168 285 to 168 256. These deletion mutants were identified in HD, angioimmunoblastic lymphadenopathy, B-immunoblastic lymphoma, peripheral T-cell lymphoma, and two lymphoblastoid cell lines. Our findings reveal a high frequency of non-random point mutations at preferential sites within the 3' (carboxy terminal) region of the LMP1 oncogene. The association of these mutational hot spots with LPD suggests that they are involved in EBV related lymphomagenesis and that they define a clinically relevant EBV strain.	CHU VAUDOIS,DEPT INTERNAL MED,CH-1011 LAUSANNE,SWITZERLAND; CHU PURPAN,ANAT PATHOL LAB,TOULOUSE,FRANCE; UNIV TUBINGEN HOSP,MED CLIN,TUBINGEN,GERMANY; ST ANNA CHILDRENS HOSP,CCRI,VIENNA,AUSTRIA; UNIV ZURICH HOSP,INST PATHOL,CH-8091 ZURICH,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU de Toulouse; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Saint Anna Children's Hospital; University of Zurich; University Zurich Hospital			Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Rothenberger, Sylvia/0000-0001-8633-2994				ANAGNOSTOPOULOS I, 1992, BLOOD, V80, P1804; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Bankier A T, 1983, Mol Biol Med, V1, P425; BROUSSET P, 1992, LAB INVEST, V67, P457; BROUSSET P, 1993, BLOOD, V82, P872; CARBONE A, 1993, J CLIN ONCOL, V11, P1674, DOI 10.1200/JCO.1993.11.9.1674; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CHEN CL, 1993, J VIROL, V67, P6303, DOI 10.1128/JVI.67.10.6303-6308.1993; CHEN ML, 1992, ONCOGENE, V7, P2131; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; HERBST H, 1991, BLOOD, V78, P2666; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HU LF, 1993, ONCOGENE, V8, P1575; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; JOSKE DJL, 1992, BLOOD, V80, P2610; KAMEL OW, 1993, NEW ENGL J MED, V328, P1317, DOI 10.1056/NEJM199305063281806; KIEFF E, 1990, FUNDAMENTAL VIROLOGY, P897; KNAPP S, 1994, ONCOGENE, V9, P1501; KNECHT H, 1993, BLOOD, V82, P2937; KNECHT H, 1993, LEUKEMIA, V7, P580; KNECHT H, 1994, ACTA HAEMATOL, V90, P167; KORBJUHN P, 1993, BLOOD, V82, P217, DOI 10.1182/blood.V82.1.217.bloodjournal821217; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LESTOU VS, 1993, GENE CHROMOSOME CANC, V8, P38, DOI 10.1002/gcc.2870080108; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; MURRAY RJ, 1988, J VIROL, V62, P3747, DOI 10.1128/JVI.62.10.3747-3755.1988; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; PALLESEN G, 1993, ADV CANCER RES, V62, P179, DOI 10.1016/S0065-230X(08)60319-X; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PENG M, 1992, ONCOGENE, V7, P1775; RAABTRAUB N, 1991, J VIROL, V65, P7032, DOI 10.1128/JVI.65.12.7032-7036.1991; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; THORLEYLAWSON DA, 1987, P NATL ACAD SCI USA, V88, P5384; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; VASSALLO J, 1993, APPL IMMUNOHISTO M M, V1, P213; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WEISS LM, 1992, BLOOD, V79, P1789; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	49	87	89	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					523	528						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845677				2022-12-25	WOS:A1995QF64800013
J	ELDARFINKELMAN, H; SEGER, R; VANDENHEEDE, JR; KREBS, EG				ELDARFINKELMAN, H; SEGER, R; VANDENHEEDE, JR; KREBS, EG			INACTIVATION OF GLYCOGEN-SYNTHASE KINASE-3 BY EPIDERMAL GROWTH-FACTOR IS MEDIATED BY MITOGEN-ACTIVATED PROTEIN KINASE/P90 RIBOSOMAL-PROTEIN S6 KINASE SIGNALING PATHWAY IN NIH/3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RABBIT SKELETAL-MUSCLE; ATP-CITRATE LYASE; INSULIN ACTION; PHOSPHORYLATION; PHOSPHATASE; PURIFICATION; SEQUENCE; SUBUNIT; FAMILY; SITES	The role of the p90 ribosomal protein S6 kinase/mitogen-activated protein kinase (RSK/MAPK) signaling pathway in regulating glycogen synthase kinase-3 (GSK-3) activity was investigated. In vitro studies showed that GSK-3 was inactivated by 50% upon incubation with RSK purified from epidermal growth factor (EGF)-stimulated NIH/3T3 cells. Subsequently, the effect of EGF on GSK-3 activity was measured in NIH/3T3 cells that stably overexpressed mutated forms of MAPK kinase (MAPKK). The activation of RSK by EGF was markedly decreased in cell lines expressing the dominant negative MAPKK mutants S222A and K97A and was increased in cells expressing the S222E mutant as compared with control cell lines. EGF induced a rapid decrease in GSK-3 beta activity (50%) in control and S222E cells; however, only 25 and 10% inhibition in GSK-3 beta activity was observed in cell lines expressing the dominant negative mutants K97A and S222A, respectively, suggesting that inhibition of GSK-3 was partially blocked in these cells. Taken together, these results suggest that the action of EGF on GSK-3 inactivation is mediated by the RSK/MAPK signaling pathway in NIH/3T3 cells and provide evidence for a mechanism regulating GSK-3 activity in intact cells.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL; KATHOLIEKE UNIV LEUVEN,FAC GENEESKUNDE,AFDELING BIOCHEM,B-300 LOUVAIN,BELGIUM	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Weizmann Institute of Science; KU Leuven			Eldar-Finkelman, Hagit/AAF-8329-2019	Eldar-Finkelman, Hagit/0000-0002-8460-9686	NIDDK NIH HHS [DK 42528] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOYLE WJ, 1990, CELL, V29, P7617; CHAN CP, 1985, P NATL ACAD SCI USA, V82, P4563, DOI 10.1073/pnas.82.14.4563; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; GOODE N, 1992, J BIOL CHEM, V267, P16878; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; HUASDORFF SF, 1994, J BIOL CHEM, V269, P21391; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; RAMAKRISHNA S, 1990, BIOCHEMISTRY-US, V29, P7617, DOI 10.1021/bi00485a011; RAMAKRISHNA S, 1988, J BIOL CHEM, V263, P12677; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RYLATT DB, 1980, EUR J BIOCHEM, V107, P529; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SEGER R, 1994, J BIOL CHEM, V269, P25699; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; VANDENHEEDE JR, 1980, J BIOL CHEM, V255, P1768; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; WANG QM, 1994, J BIOL CHEM, V269, P14566; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YU JS, 1994, J BIOL CHEM, V269, P14341; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	35	190	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					987	990		10.1074/jbc.270.3.987	http://dx.doi.org/10.1074/jbc.270.3.987			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836418	hybrid			2022-12-25	WOS:A1995QB15600001
J	ALNEMRI, ES; FERNANDESALNEMRI, T; LITWACK, G				ALNEMRI, ES; FERNANDESALNEMRI, T; LITWACK, G			CLONING AND EXPRESSION OF 4 NOVEL ISOFORMS OF HUMAN INTERLEUKIN-1-BETA CONVERTING-ENZYME WITH DIFFERENT APOPTOTIC ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH GENE CED-3; CELL-DEATH; PROTEASE; ENCODES	To understand the mechanism of interleukin-1 beta converting enzyme (ICE) activation in apoptosis, we analyzed the expression of ICE mRNA in two human cell lines by reverse transcription-polymerase chain reaction technique. This resulted in the identification and cloning of four alternatively spliced ICE mRNA isoforms. Although all the alternative splicing events were within the coding sequence of ICE, the four ICE isoforms maintained open reading frames and were designated as ICE beta, gamma, delta and epsilon. In ICE gamma, most of the propeptide (amino acids 20-112) is deleted, which suggests that it may function as a catalyst for ICE autoprocessing in vivo. In ICE delta, amino acids 288-335, which contain the cleavage sites between the p20 and p10 subunits of ICE, are deleted thus resulting in its inactivation. Intriguingly, in ICE epsilon amino acids 20-335, which encompass most of the propeptide and the p20 subunit, are deleted resulting in the formation of a molecule that is homologous to the p10 subunit. Examination of the ability of these four ICE isoforms to cause apoptosis revealed that only the parental ICE alpha and isoforms beta and gamma, but not isoforms delta and epsilon, can induce apoptosis when overexpressed in Sf9 insect cells. In addition, coexpression of the p20 and p10 but not the p20 and ICE epsilon in Sf9 cells results in apoptosis. Interestingly, expression of ICE epsilon and to a lesser degree ICE delta resulted in extension of the survival of baculovirus-infected cells in a manner similar to expression of BCL2. The ability of ICE epsilon to extend the survival of Sf9 cells suggests that baculovirus-induced apoptosis in these cells is mediated by an ICE-like protease. We show that ICE epsilon can bind to the p20 subunit of ICE and potentially may compete with the p10 subunit to form an inactive ICE complex. Therefore, by acting as a dominant inhibitor of ICE activity, ICE epsilon may regulate ICE activation in vivo.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University	ALNEMRI, ES (corresponding author), THOMAS JEFFERSON UNIV,DEPT PHARMACOL,BLUEMLE LIFE SCI BLDG,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035035] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35035-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ALNEMRI ES, 1991, J BIOL CHEM, V266, P3925; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; FATH I, 1994, NATURE, V264, P971; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	22	138	163	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4312	4317		10.1074/jbc.270.9.4312	http://dx.doi.org/10.1074/jbc.270.9.4312			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876192	hybrid			2022-12-25	WOS:A1995QK08400023
J	RUAN, YM; CHEN, C; CAO, YX; GAROFALO, RS				RUAN, YM; CHEN, C; CAO, YX; GAROFALO, RS			THE DROSOPHILA INSULIN-RECEPTOR CONTAINS A NOVEL CARBOXYL-TERMINAL EXTENSION LIKELY TO PLAY AN IMPORTANT ROLE IN SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; JUXTAMEMBRANE REGION; BINDING-SPECIFICITY; LIGAND SPECIFICITY; PROMOTER REGION; GENE; SEQUENCE; PROTEIN; CELLS; CDNA	The nucleic acid and deduced amino acid sequence of the Drosophila insulin receptor homologue (dir) has been determined, The coding sequence of dir is contained within 10 exons spanning less than 8 kilobase pairs of genomic DNA. The deduced amino acid sequence of the dir encodes a protein of 2148 amino acids, larger than the human insulin receptor due to amino- and carboxyl-terminal extensions, The overall level of amino acid identity between the DIR and human insulin and insulin like growth factor-I receptors is 32.5 and 33.3%, respectively, Higher levels of identity are found in exon 2 (45 and 43%, respectively) and in the beta subunit (50 and 48%, respectively), and the positions of most cysteine residues in the ct subunit cysteine rich domain are conserved, A novel, 400-amino acid, carboxyl-terminal extension contains 9 tyrosine residues, four of which are present in YXXM or YXXL motifs, suggesting that they function as binding sites for SH2 domain-containing signaling proteins, The presence of multiple putative SH2 domain binding sites in the DIR represents a significant difference from its mammalian homologues and suggests that, unlike the human insulin and insulinlike growth factor-I receptors, the DIR forms stable complexes with signaling molecules as part of its signal transduction mechanism.	SUNY HLTH SCI CTR, DEPT ANAT & CELL BIOL, BROOKLYN, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COOKE DW, 1991, BIOCHEM BIOPH RES CO, V177, P1113, DOI 10.1016/0006-291X(91)90654-P; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FERNANDEZALMONA.R, THESIS CORNELL U MED; FERNANDEZALMONACID R, 1987, MOL CELL BIOL, V7, P2718, DOI 10.1128/MCB.7.8.2718; GAROFALO RS, 1988, MOL CELL BIOL, V8, P1638, DOI 10.1128/MCB.8.4.1638; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MAMULA PW, 1992, DNA CELL BIOL, V11, P43, DOI 10.1089/dna.1992.11.43; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; NISHIDA Y, 1986, BIOCHEM BIOPH RES CO, V141, P474, DOI 10.1016/S0006-291X(86)80197-8; PETRUZZELLI L, 1985, J BIOL CHEM, V260, P6072; PETRUZZELLI L, 1986, P NATL ACAD SCI USA, V83, P4710, DOI 10.1073/pnas.83.13.4710; PETRUZZELLI L, 1985, CANCER CELL, V3, P115; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; Sambrook J, 1989, MOL CLONING LABORATO; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHIER P, 1989, J BIOL CHEM, V264, P14605; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	81	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4236	4243		10.1074/jbc.270.9.4236	http://dx.doi.org/10.1074/jbc.270.9.4236			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876183	hybrid			2022-12-25	WOS:A1995QK08400013
J	WILCOX, MD; DINGUS, J; BALCUEVA, EA; MCINTIRE, WE; MEHTA, ND; SCHEY, KL; ROBISHAW, JD; HILDEBRANDT, JD				WILCOX, MD; DINGUS, J; BALCUEVA, EA; MCINTIRE, WE; MEHTA, ND; SCHEY, KL; ROBISHAW, JD; HILDEBRANDT, JD			BOVINE BRAIN G(O) ISOFORMS HAVE DISTINCT GAMMA-SUBUNIT COMPOSITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANINE-NUCLEOTIDE-BINDING; AMINO-ACID-SEQUENCE; G-PROTEINS; ALPHA-SUBUNIT; ADENYLATE-CYCLASE; BETA-GAMMA; 2 FORMS; SIGNAL TRANSDUCTION; MESSENGER-RNA; IDENTIFICATION	The gamma subunit composition of the major bovine brain G(O) and G(i) proteins (G(OA), G(OB), G(OC), G(i1), and G(i2)) was characterized using antibodies against specific gamma isoforms. Each of the purified Gr protein heterotrimers contained a heterogeneous population of gamma subunits, and the profiles of the gamma subunits found with G(i1), G(i2), and G, were similar. In contrast, each G(O) isoform had a distinct pattern of associated gamma subunits, These differences were surprising given that all three alpha(O) isoforms are thought to share a common amino-terminal sequence important for the binding of beta gamma dimers and that the alpha(CO) and alpha(OC) proteins may come from the same alpha(O1) mRNA. The free alpha(OA) and alpha(OC) subunits had unique elution behaviors during MonoQ chromatography, compatible with differences in their post-translational processing, These results indicate that both the alpha and gamma subunit compositions of heterotrimers define the structure of an intact G protein, Furthermore, the exact subunit composition of G protein heterotrimers may depend upon regulated expression of different subunit isoforms or upon cellular processing of alpha subunits.	MED UNIV S CAROLINA, DEPT PHARMACOL, CHARLESTON, SC 29464 USA; GEISINGER MED CLIN, WEIS CTR RES, DANVILLE, PA 17822 USA	Medical University of South Carolina; Geisinger Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039867, R01GM039867] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37219] Funding Source: Medline; NIGMS NIH HHS [GM39867] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1992, J NEUROCHEM, V58, P2176, DOI 10.1111/j.1471-4159.1992.tb10961.x; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P2039; HSU WH, 1990, J BIOL CHEM, V265, P11220; INANOBE A, 1990, FEBS LETT, V263, P369, DOI 10.1016/0014-5793(90)81416-L; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOBAYASHI I, 1989, FEBS LETT, V257, P177, DOI 10.1016/0014-5793(89)81815-0; KOHNKEN RE, 1989, J BIOL CHEM, V264, P20688; KROLL SD, 1992, J BIOL CHEM, V267, P23183; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; MORISHITA R, 1992, EUR J BIOCHEM, V210, P1061, DOI 10.1111/j.1432-1033.1992.tb17512.x; MORISHITA R, 1994, FEBS LETT, V337, P23, DOI 10.1016/0014-5793(94)80622-5; MURTAGH JJ, 1991, MOL CELL BIOL, V11, P1146, DOI 10.1128/MCB.11.2.1146; MURTAGH JJ, 1994, NUCLEIC ACIDS RES, V22, P842, DOI 10.1093/nar/22.5.842; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OVCHINNIKOV YA, 1987, FEBS LETT, V226, P91, DOI 10.1016/0014-5793(87)80557-4; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PRICE SR, 1990, BIOCHEMISTRY-US, V29, P5069, DOI 10.1021/bi00473a011; RAHMATULLAH M, 1994, J BIOL CHEM, V269, P3574; RAHMATULLAH M, 1995, J BIOL CHEM, V270, P2946, DOI 10.1074/jbc.270.7.2946; ROBISHAW JD, 1994, METHOD ENZYMOL, V237, P498; ROBISHAW JD, 1993, ANAL BIOCHEM, V208, P283, DOI 10.1006/abio.1993.1047; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIBASAKI H, 1991, FEBS LETT, V285, P268, DOI 10.1016/0014-5793(91)80814-J; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPICHER K, 1991, BIOCHEM BIOPH RES CO, V175, P473, DOI 10.1016/0006-291X(91)91588-4; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; UEDA N, 1994, J BIOL CHEM, V269, P4388; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	51	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4189	4192		10.1074/jbc.270.9.4189	http://dx.doi.org/10.1074/jbc.270.9.4189			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876173	hybrid			2022-12-25	WOS:A1995QK08400003
J	DURNER, J; BOGER, P				DURNER, J; BOGER, P			UBIQUITIN IN THE PROKARYOTE ANABAENA-VARIABILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; GEL-ELECTROPHORESIS; SYSTEM; CYANOBACTERIUM; CONJUGATION; CELLS; GENE; POLYPEPTIDE; EXPRESSION; CALMODULIN	The ubiquitin-dependent pathway for protein degradation has been found to play a major role in controlling protein turnover in the cell. Ubiquitin is one of the most conserved proteins yet identified, and up until now it has been thought to be present only in eukaryotes and archaebacteria. This is the first report on the detection and purification of ubiquitin from a eubacterium, the cyanobacterium Anabaena variabilis. The purification procedure included a heat denaturing step, fractionated ammonium sulfate precipitation, two gel filtration runs (Sephadex G-50 and Superose 12), and a final hydroxylapatite chromatography. Comparisons with bovine ubiquitin showed a high similarity with respect to antigenicity to anti-ubiquitin (bovine), molecular mass (M(r) = 6,000), isoelectric point (pi 6.5), and NH2-terminal sequence. The existence of ubiquitin in A. variabilis was confirmed by Southern hybridization. In in vitro experiments both cyanobacterial and bovine ubiquitin were covalently attached to several target proteins from A. variabilis, respectively. Data are presented which suggest ubiquitination of dinitrogenase reductase, the Fe-protein subunit of nitrogenase, Our findings imply that ubiquitination equivalent to the eukaryotic system is instrumental in this organism.	UNIV KONSTANZ,LEHRSTUHL PHYSIOL & BIOCHEM PFLANZEN,D-78434 CONSTANCE,GERMANY	University of Konstanz								ANDERSEN MW, 1981, FEBS LETT, V132, P210, DOI 10.1016/0014-5793(81)81162-3; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BOND U, 1988, J BIOL CHEM, V263, P2384; BORTHAKUR D, 1990, MOL GEN GENET, V221, P227, DOI 10.1007/BF00261725; BRASS S, 1994, APPL ENVIRON MICROB, V60, P2575, DOI 10.1128/AEM.60.7.2575-2583.1994; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1; COLLIER JL, 1994, EMBO J, V13, P1039, DOI 10.1002/j.1460-2075.1994.tb06352.x; DURNER J, 1994, EUR J BIOCHEM, V220, P125, DOI 10.1111/j.1432-1033.1994.tb18606.x; ELHAI J, 1991, 6 INT S PHOT PROK AM, pB114; FERGUSON DL, 1990, PLANT PHYSIOL, V92, P740, DOI 10.1104/pp.92.3.740; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GALLON JR, 1992, NEW PHYTOL, V122, P571; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; GOMEN H, 1994, P NATL ACAD SCI USA, V91, P7648; HASELKORN R, 1978, ANNU REV PLANT PHYS, V29, P319, DOI 10.1146/annurev.pp.29.060178.001535; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILL DR, 1994, J BIOL CHEM, V269, P7726; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; MULLIGAN ME, 1994, J MOL BIOL, V235, P1162, DOI 10.1006/jmbi.1994.1070; MURRY MA, 1983, CAN J MICROBIOL, V29, P1286, DOI 10.1139/m83-201; ONEK LA, 1994, ARCH MICROBIOL, V161, P352, DOI 10.1007/s002030050066; PARAG HA, 1987, EMBO J, V6, P55, DOI 10.1002/j.1460-2075.1987.tb04718.x; PETTERSSON A, 1989, FEMS MICROBIOL LETT, V60, P95, DOI 10.1016/0378-1097(89)90084-0; POTTS M, 1993, J BIOL CHEM, V268, P7632; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VEIERSKOV B, 1991, PLANT PHYSIOL, V96, P4, DOI 10.1104/pp.96.1.4; VIERSTRA RD, 1987, PLANT PHYSIOL, V84, P332, DOI 10.1104/pp.84.2.332; VIERSTRA RD, 1985, J BIOL CHEM, V260, P2015; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; VIJAYKUMAR S, 1987, J MOL BIOL, V195, P531; WILKINSON KD, 1980, J BIOL CHEM, V255, P7529; WOLF S, 1993, FEBS LETT, V326, P42, DOI 10.1016/0014-5793(93)81757-Q; WONG S, 1993, MOL CELL BIOL, V13, P207, DOI 10.1128/MCB.13.1.207; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747; ZHANG CC, 1993, P NATL ACAD SCI USA, V90, P11840, DOI 10.1073/pnas.90.24.11840	47	31	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3720	3725		10.1074/jbc.270.8.3720	http://dx.doi.org/10.1074/jbc.270.8.3720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876111	hybrid			2022-12-25	WOS:A1995QH68800041
J	SONG, HY; DUNBAR, JD; ZHANG, YX; GUO, DQ; DONNER, DB				SONG, HY; DUNBAR, JD; ZHANG, YX; GUO, DQ; DONNER, DB			IDENTIFICATION OF A PROTEIN WITH HOMOLOGY TO HSP90 THAT BINDS THE TYPE-1 TUMOR-NECROSIS-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF RECEPTOR; MOLECULAR-CLONING; CELL; SHOCK; ACTIVATION; CYTOTOXICITY; STIMULATION; ANTIBODIES; EXPRESSION; SIGNALS	The yeast-based two hybrid has been used to identify a novel protein that binds to the intracellular domain of the type 1 receptor for tumor necrosis factor (TNFR-1IC). The TNF receptor-associated protein, TRAP-1, shows strong homology to members of the 90-kDa family of heat shock proteins. After in vitro transcription/translation and S-35 labeling, TRAP-1 was precipitated using a fusion protein consisting of glutathione S-transferase and TNFR-1IC, showing that the two proteins directly interact. The ability of deletion mutants of TNFR-1 to interact with TRAP-1 was tested using the two hybrid system. This showed that the amino acid sequences that mediate binding are diffusely distributed outside of the domain in the C terminus of TNFR-1IC that signals cytotoxicity. The 2.4-kilobase TRAP-1 mRNA was variably expressed in skeletal muscle, Liver, heart, brain, kidney, pancreas, lung, and placenta. TRAP-1 mRNA was also detected in each of eight different transformed cell Lines. Identification of TRAP-1 may be an important step toward defining how TNFR-1, which does not contain protein tyrosine kinase activity, transmits its message to signal transduction pathways.	INDIANA UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute								AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; BAGLIONI C, 1985, J BIOL CHEM, V260, P3395; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1989, J EXP MED, V171, P415; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GEHR G, 1992, J IMMUNOL, V149, P911; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HELLER RA, 1992, CELL, V70, P47; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JACOBSEN FW, 1994, P NATL ACAD SCI USA, V91, P10695, DOI 10.1073/pnas.91.22.10695; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; KUSHER DI, 1990, J IMMUNOL, V145, P2925; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Miller J.H., 1972, EXPT MOL GENETICS; MOORE SK, 1989, J BIOL CHEM, V264, P5343; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; ROBAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301, DOI 10.1016/0006-291X(89)92135-9; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SIDHU RS, 1993, PHARMACOL THERAPEUT, V57, P79, DOI 10.1016/0163-7258(93)90037-E; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7226; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WONG GHW, 1992, J IMMUNOL, V149, P3550; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	49	187	204	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3574	3581		10.1074/jbc.270.8.3574	http://dx.doi.org/10.1074/jbc.270.8.3574			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876093	hybrid			2022-12-25	WOS:A1995QH68800020
J	TORRI, AF; ENGLUND, PT				TORRI, AF; ENGLUND, PT			A DNA-POLYMERASE-BETA IN THE MITOCHONDRION OF THE TRYPANOSOMATID CRITHIDIA-FASCICULATA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KINETOPLAST DNA; REPLICATION; MINICIRCLES; NETWORKS; TOPOISOMERASE; COMPILATION; ALIGNMENT; SITES	We previously purified a Crithidia fasciculata mitochondrial DNA polymerase that has unusual properties. Unlike a conventional mitochondrial DNA polymerase gamma, this enzyme is small, non-processive, deficient in 3'-exonuclease activity, and error prone (Torri, A. F., Kunkel, T. A., and Englund, P. T. (1994) J. Biol. Chem. 269, 8165-8171), In all of these characteristics, the enzyme resembles DNA polymerase beta, a nuclear enzyme thought to be involved in DNA repair, We have now cloned and sequenced the gene for this enzyme. The mitochondrial polymerase has significant homology, about 33% identity at the amino acid level, with human DNA polymerase beta. However, sequence analysis of the clone revealed the presence of a cleaved N-terminal presequence, presumably a mitochondrial import signal, which resembles presequences on other C. fasciculata mitochondrial proteins, The polymerase's function may be to repair the many gaps in newly replicated kinetoplast (mitochondrial) DNA minicircles in this parasite, This enzyme is the first example of a mitochondrial DNA polymerase beta.			TORRI, AF (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.				NIGMS NIH HHS [GM 27608] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027608, R01GM027608] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; EFFRON PN, 1993, MOL BIOCHEM PARASIT, V59, P191, DOI 10.1016/0166-6851(93)90217-L; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; KITCHIN PA, 1984, J BIOL CHEM, V259, P5532; Kornberg A., 1992, DNA REPLICATION; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; PASION SG, 1992, MOL BIOCHEM PARASIT, V50, P57, DOI 10.1016/0166-6851(92)90244-E; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PEREZMORGA DL, 1993, CELL, V74, P703, DOI 10.1016/0092-8674(93)90517-T; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SHLOMAI J, 1994, PARASITOL TODAY, V10, P341, DOI 10.1016/0169-4758(94)90244-5; TORRI AF, 1992, J BIOL CHEM, V267, P4786; TORRI AF, 1994, J BIOL CHEM, V269, P8165; XU CX, 1993, P NATL ACAD SCI USA, V90, P1786, DOI 10.1073/pnas.90.5.1786	19	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3495	3497		10.1074/jbc.270.8.3495	http://dx.doi.org/10.1074/jbc.270.8.3495			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876082	hybrid			2022-12-25	WOS:A1995QH68800009
J	BUKI, KG; BAUER, PI; HAKAM, A; KUN, E				BUKI, KG; BAUER, PI; HAKAM, A; KUN, E			IDENTIFICATION OF DOMAINS OF POLY(ADP-RIBOSE) POLYMERASE FOR PROTEIN-BINDING AND SELF-ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE DIPHOSPHORIBOSYL TRANSFERASE; POLYACRYLAMIDE-GEL-ELECTROPHORESIS; ADP-RIBOSYLATION; EUKARYOTE CHROMATIN; CELLULAR-REGULATION; DNA TOPOISOMERASE; CALF THYMUS; CELLS; INHIBITION; SEPARATION	Cellular proteins extracted from normal and cancer cells bind polymerizing ADP-ribose transferase (pADPRT) on nitrocellulose membrane transblots. Histones at 1 mg/ml concentration completely prevent the binding of pADPRT to cellular proteins, indicating that the binding of histones to pADPRT sites competitively blocks the association of pADPRT to proteins other than histones. The direct binding of pADPRT to histones is shown by cross-linking with glutaraldehyde. The COOH-terminal basic histone H1 tail binds to the basic polypeptide domain of pADPRT. The basic domain present in the NH2-terminal part of core histones is the probable common structural feature of all core histones that accounts for their binding to pADPRT. Two polypeptide domains of pADPRT were identified, by way of CNBr fragments, to bind histones. These two domains are located within the 64-kDa fragment of pADPRT and are contiguous with the polypeptide domains that were shown to participate in self-association of pADPRT, ending at the 606th amino acid residue. The polypeptide domains of pADPRT which participate in DNA binding are thus shown to associate also with other proteins. Intact pADPRT binds to both the zinc-free or zinc-reconstituted basic polypeptide fragments of pADPRT. Histones activate auto-poly(ADP)-ribosylation of pADPRT by increasing the number of short oligomers on pADPRT. This reaction is also dependent in a biphasic manner on the concentration of pADPRT. Histones in solution are only marginally poly(ADP)-ribosylated but are good polymer accepters when incorporated into artificial nucleosome structures.	SAN FRANCISCO STATE UNIV,ROMBERG TIBURON CTR,ENVIRONM & TOXICOL CHEM LAB,TIBURON,CA 94920; SAN FRANCISCO STATE UNIV,ROMBERG TIBURON CTR,OCTAMER RES FDN,TIBURON,CA 94920	California State University System; San Francisco State University; California State University System; San Francisco State University								ALTHAUS FR, 1992, J CELL SCI, V102, P663; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BAUER PI, 1986, FEBS LETT, V195, P331, DOI 10.1016/0014-5793(86)80188-0; BAUER PI, 1990, BIOCHEM J, V270, P17, DOI 10.1042/bj2700017; BAUER PL, 1985, ADP RIBOSYLATION PRO, P63; BOULIKAS T, 1988, EMBO J, V7, P57, DOI 10.1002/j.1460-2075.1988.tb02783.x; BRADBURY EM, 1975, EUR J BIOCHEM, V57, P521, DOI 10.1111/j.1432-1033.1975.tb02327.x; BUKI KG, 1991, BIOCHEM BIOPH RES CO, V180, P496, DOI 10.1016/S0006-291X(05)81092-7; BUKI KG, 1987, ANAL BIOCHEM, V167, P160, DOI 10.1016/0003-2697(87)90147-3; BUKI KG, 1991, FEBS LETT, V290, P181, DOI 10.1016/0014-5793(91)81255-7; BUKI KG, 1988, BIOCHEMISTRY-US, V27, P5990, DOI 10.1021/bi00416a024; COLE GA, 1991, BIOCHEM BIOPH RES CO, V180, P504, DOI 10.1016/S0006-291X(05)81093-9; DARBY MK, 1985, EMBO J, V4, P2129, DOI 10.1002/j.1460-2075.1985.tb03903.x; FERRO AM, 1984, J BIOL CHEM, V259, P547; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HAKAM A, 1987, FEBS LETT, V212, P73, DOI 10.1016/0014-5793(87)81559-4; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; HULETSKY A, 1985, EUR J BIOCHEM, V146, P277, DOI 10.1111/j.1432-1033.1985.tb08650.x; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; IKEJIMA M, 1987, J BIOL CHEM, V262, P17641; ISENBERG I, 1979, ANN REV BIOCH, V48, P151; JACKOWSKI G, 1983, J BIOL CHEM, V258, P2587; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; KASID UN, 1989, J BIOL CHEM, V264, P18687; KIRSTEN E, 1991, EXP CELL RES, V194, P1, DOI 10.1016/0014-4827(91)90122-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIG A, 1988, J BIOL CHEM, V263, P6993; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; MINAGA T, 1979, J BIOL CHEM, V254, P9663; MOLINETE M, 1992, SEP OJ INT SEM ADP R; NAEGELI H, 1991, J BIOL CHEM, V266, P10596; OHASHI Y, 1986, BIOCH BIOPHYS COMMUN, V140, P667; PANZETER PL, 1993, J BIOL CHEM, V268, P17662; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; RICE WG, 1992, P NATL ACAD SCI USA, V89, P7703, DOI 10.1073/pnas.89.16.7703; SAITO I, 1990, GENE, V90, P249, DOI 10.1016/0378-1119(90)90187-V; SASTRY SS, 1989, BIOCHEMISTRY-US, V28, P5670, DOI 10.1021/bi00439a050; SASTRY SS, 1990, BIOCHEM BIOPH RES CO, V167, P842, DOI 10.1016/0006-291X(90)92102-6; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIZUTA Y, 1985, P52; SIMBULAN CMG, 1993, J BIOL CHEM, V268, P93; SIMONIN F, 1993, J BIOL CHEM, V268, P13454; SIMONIN F, 1991, ANAL BIOCHEM, V195, P226, DOI 10.1016/0003-2697(91)90321-J; SIMONIN F, 1990, J BIOL CHEM, V256, P19249; SOOKITOTH A, 1989, EXP CELL RES, V184, P44, DOI 10.1016/0014-4827(89)90362-5; STEIN A, 1987, J BIOL CHEM, V262, P3872; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P3481, DOI 10.1073/pnas.90.8.3481; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879; YOSHIHARA K, 1975, P NATL ACAD SCI USA, V72, P289, DOI 10.1073/pnas.72.1.289; YOSHIHARA K, 1972, BIOCHEM BIOPH RES CO, V47, P119, DOI 10.1016/S0006-291X(72)80018-4; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; YOUNG LJT, 1994, 11TH INT S ADP RIB D	57	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3370	3377		10.1074/jbc.270.7.3370	http://dx.doi.org/10.1074/jbc.270.7.3370			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852424	hybrid			2022-12-25	WOS:A1995QG47100072
J	HARNICK, DJ; JAYARAMAN, T; MA, YS; MULIERI, P; GO, LO; MARKS, AR				HARNICK, DJ; JAYARAMAN, T; MA, YS; MULIERI, P; GO, LO; MARKS, AR			THE HUMAN TYPE-1 INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR FROM T-LYMPHOCYTES - STRUCTURE, LOCALIZATION, AND TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL CHANNEL COMPLEX; MUSCLE SARCOPLASMIC-RETICULUM; SWISS 3T3 CELLS; RYANODINE RECEPTOR; PLASMA-MEMBRANE; SMOOTH-MUSCLE; TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; PROTEIN-KINASE	Inositol 1,4,5-trisphosphate receptors (IP3R) are intracellular calcium release channels involved in diverse signaling pathways. An IP3R is thought to play a role in mobilizing calcium required for activation of T lymphocytes. The IP3R is a tetrameric structure comprised of four similar to 300-kDa subunits encoded by a similar to 10-kilobase mRNA. In the present study we determined the structure of the human type 1 IP3R expressed in T lymphocytes (Jurkats). The IP3R in human T cells had a predicted molecular mass of 308 kDa and was most similar to the non-neuronal form of the rodent type 1 IP3R. Two putative tyrosine phosphorylation sites were identified, one near the amino terminus and one near the putative channel pore at the carboxyl terminus. During T cell activation the IP3R was tyrosine phosphorylated. A site-specific anti-IP3R antibody was used to localize the carboxyl terminus of the IP3R to the cytoplasm in T cells.	CUNY MT SINAI SCH MED,INST CARDIOVASC,DEPT MED,PROGRAM MOLEC MED,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029814] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29814] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLA T, 1994, MOL BIOL CELL, V5, P17, DOI 10.1091/mbc.5.1.17; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1994, MOL BIOL CELL, V5, P97, DOI 10.1091/mbc.5.1.97; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; CIAPA B, 1994, NATURE, V368, P875, DOI 10.1038/368875a0; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; JUNE CH, 1990, J IMMUNOL, V144, P1591; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KIJIMA Y, 1993, J BIOL CHEM, V268, P3499; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; PETERSON RHF, 1978, J SUPRAMOL STR CELL, V9, P289, DOI 10.1002/jss.400090302; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; Sambrook J, 1989, MOL CLONING LABORATO; SOMLYO AV, 1977, J CELL BIOL, V74, P828, DOI 10.1083/jcb.74.3.828; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUDHOF T, 1991, EMBO J, V11, P3199; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	50	68	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2833	2840		10.1074/jbc.270.6.2833	http://dx.doi.org/10.1074/jbc.270.6.2833			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852357	hybrid			2022-12-25	WOS:A1995QF53500067
J	KRUSE, M; BRUNKE, M; ESCHER, A; SZALAY, AA; TROPSCHUG, M; ZIMMERMANN, R				KRUSE, M; BRUNKE, M; ESCHER, A; SZALAY, AA; TROPSCHUG, M; ZIMMERMANN, R			ENZYME ASSEMBLY AFTER DE-NOVO SYNTHESIS IN RABBIT RETICULOCYTE LYSATE INVOLVES MOLECULAR CHAPERONES AND IMMUNOPHILINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; HEAT-SHOCK PROTEINS; M13 PROCOAT PROTEIN; BACTERIAL LUCIFERASE; NEUROSPORA-CRASSA; BINDING PROTEIN; CYCLOSPORINE-A; TRIPLE-HELIX; CYCLOPHILIN; MICROSOMES	The folding kinetics of two luciferases were studied after synthesis in reticulocyte lysates to investigate whether molecular chaperones and/or folding catalysts are involved in the folding reactions. Two bacterial luciferases were used as model proteins: heterodimeric Vibrio harveyi luciferase (LuxAB), and a monomeric luciferase fusion protein (Fab2). Data indicate that folding of these enzymes to the native state occurs in the translation system, and that the extent of folding can be quantified It was found that (i) folding of LuxAB and Faba can clearly be separated in time from synthesis, (ii) folding of Faba and LuxAB is slow because it involves either transient (Faba) or permanent (LuxAB) interaction of polypeptides, (iii) preservation of the assembly competent state of LuxA and/or LuxB and folding of Faba depend on ATP-hydrolysis, (iv) folding of Fab2 and LuxAB is partially sensitive to cyclosporin A (CsA) and FK506, i.e. inhibitors of two distinct peptidylprolyl cis/trans-isomerases. Thus, bacterial luciferases provide a unique system for direct measurement of the effects of ATP-dependent molecular chaperones on protein folding and enzyme assembly in reticulocyte lysates. Furthermore, these two luciferases provide the first direct evidence documenting the involvement of peptidylprolyl cis/trans-isomerases in protein biogenesis in a eukaryotic cytosol.	UNIV GOTTINGEN,INST BIOCHEM & MOLEK ZELLBIOL,D-37073 GOTTINGEN,GERMANY; UNIV ALBERTA,DEPT PLANT SCI,PLANT MOLEC GENET LABS,EDMONTON,AB T6G 2P5,CANADA; UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY	University of Gottingen; University of Alberta; University of Freiburg								BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ESCHER A, 1993, MOL GEN GENET, V238, P65, DOI 10.1007/BF00279532; ESCHER A, 1989, P NATL ACAD SCI USA, V86, P6528, DOI 10.1073/pnas.86.17.6528; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLYNN GC, 1993, P NATL ACAD SCI USA, V90, P10826, DOI 10.1073/pnas.90.22.10826; FOXWELL BMJ, 1988, BIOCHIM BIOPHYS ACTA, V938, P447, DOI 10.1016/0005-2736(88)90142-3; FRESKGARD PO, 1992, SCIENCE, V258, P486; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; OLSSON O, 1988, MOL GEN GENET, V215, P1, DOI 10.1007/BF00331295; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; SYKES K, 1993, P NATL ACAD SCI USA, V90, P5853, DOI 10.1073/pnas.90.12.5853; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; WIECH H, 1987, EMBO J, V6, P1011, DOI 10.1002/j.1460-2075.1987.tb04853.x; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZIEGLER MM, 1993, J BIOL CHEM, V268, P10760; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	35	46	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2588	2594		10.1074/jbc.270.6.2588	http://dx.doi.org/10.1074/jbc.270.6.2588			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852322	hybrid			2022-12-25	WOS:A1995QF53500030
J	NISHIZAWA, K; SHIMODA, E; KASAHARA, M				NISHIZAWA, K; SHIMODA, E; KASAHARA, M			SUBSTRATE RECOGNITION DOMAIN OF THE GAL2 GALACTOSE TRANSPORTER IN YEAST SACCHAROMYCES-CEREVISIAE AS REVEALED BY CHIMERIC GALACTOSE-GLUCOSE TRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID; GLUT1; PERMEASE; TRYPTOPHAN-412; SUBSTITUTION; SEQUENCES; MEMBRANE; PROTEINS; NUMBER; GENE	The Gal2 galactose transporter takes up galactose in yeast. A homologous glucose transporter from the same organism, Hxt2, was selected, and various chimeras between these two transporters were constructed by making use of homologous recombination in Escherichia coli. Comparison of the galactose transport activities of three series of chimeras enabled us to positively identify a crucial substrate recognition region of 101 amino acids that lies close to the carboxyl terminus of the Gal2 transporter.	TEIKYO UNIV, SCH MED, BIOPHYS LAB, HACHIOJI, TOKYO 19203, JAPAN	Teikyo University								ASANO T, 1991, J BIOL CHEM, V266, P24632; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BISSON LF, 1993, CRIT REV BIOCHEM MOL, V28, P259, DOI 10.3109/10409239309078437; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; CARON MG, 1993, NATURE, V366, P409, DOI 10.1038/366409a0; CASPARI T, 1994, J BIOL CHEM, V269, P3498; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GIROS B, 1994, J BIOL CHEM, V269, P15985; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HEIN J, 1989, MOL BIOL EVOL, V6, P649; HEIN J, 1989, MOL BIOL EVOL, V6, P669; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; INA Y, 1994, COMPUT APPL BIOSCI, V10, P11; ISHIHARA H, 1991, BIOCHEM BIOPH RES CO, V176, P922, DOI 10.1016/S0006-291X(05)80274-8; KABACK HR, 1992, INT REV CYTOL, V137A, P97; KATAGIRI H, 1991, J BIOL CHEM, V266, P7769; KATAGIRI H, 1992, J BIOL CHEM, V267, P22550; KRUCKEBERG AL, 1990, MOL CELL BIOL, V10, P5903, DOI 10.1128/MCB.10.11.5903; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARSHALLCARLSON L, 1990, MOL CELL BIOL, V10, P1105, DOI 10.1128/MCB.10.3.1105; MORI H, 1994, J BIOL CHEM, V269, P11578; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1994, J BIOL CHEM, V269, P17765; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; NEHLIN JO, 1989, GENE, V85, P313, DOI 10.1016/0378-1119(89)90423-X; OGAWA T, 1992, J MOL BIOL, V226, P651, DOI 10.1016/0022-2836(92)90622-Q; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; RAMOS J, 1989, J BACTERIOL, V171, P3539, DOI 10.1128/jb.171.6.3539-3544.1989; SEOL W, 1992, BIOCHEMISTRY-US, V31, P3550, DOI 10.1021/bi00128a032; SHERMAN F, 1986, LABORATORY COURSE MA; SZKUTNICKA K, 1989, J BACTERIOL, V171, P4486, DOI 10.1128/JB.171.8.4486-4493.1989; TAJIMA M, 1986, MOL CELL BIOL, V6, P246, DOI 10.1128/MCB.6.1.246; TAKATA K, 1991, J HISTOCHEM CYTOCHEM, V39, P287, DOI 10.1177/39.3.1993828; TAMORI Y, 1994, J BIOL CHEM, V269, P2982; TSCHOPP JF, 1986, J BACTERIOL, V166, P313, DOI 10.1128/jb.166.1.313-318.1986; WANDEL S, 1994, FEBS LETT, V348, P114, DOI 10.1016/0014-5793(94)00558-3; [No title captured]	38	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2423	2426		10.1074/jbc.270.6.2423	http://dx.doi.org/10.1074/jbc.270.6.2423			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852299	hybrid			2022-12-25	WOS:A1995QF53500004
J	GAN, T; MUNOZ, A; SHAW, CF; PETERING, DH				GAN, T; MUNOZ, A; SHAW, CF; PETERING, DH			REACTION OF CD-111(7)-METALLOTHIONEIN WITH EDTA - A REAPPRAISAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEINS	The ligand substitution reaction of EDTA with Cd-7-metallothionein (Cd-7-MT) has been reinvestigated, NMR titration of the Cd-111-protein with EDTA showed that the ligand interacts preferentially and cooperatively with Cd2+ ions in the beta-domain cluster. NMR and ultra-filtration kinetic analysis of this reaction using 5.6 mM Cd2+ as Cd-111(7)-MT and 56 mM EDTA indicated that cadmium-EDTA formed less rapidly than Cd-111 peak intensity declined. Spectrophotometric and gel filtration studies of the reaction with 20 mu M Cd2+ as Cd-7-MT with various concentrations of EDTA revealed biphasic kinetics with much larger rate constants than observed in the NMR experiments. The fraction of total ligand substitution occurring in each kinetic step varied with EDTA concentration. The EDTA concentration depend of both kinetic steps was consistent with the initial formation of protein EDTA adducts, followed by their breakdown into products. Kinetic measurements were also made for the reactions of the isolated Cd-4-alpha- and Cd-3-beta-domains with EDTA. The Cd-4 domain reacted with EDTA with biphasic kinetics, in which one Cd2+ was removed rapidly with first-order kinetics, which were zero-order in EDTA. The other three reacted with kinetics like those for the slower step of the holoprotein, Cd-3-beta reacted with EDTA like the faster rate process associated with the Cd-7-protein, The observed rate constants for the reaction of Cd7-metallothionein with EDTA and the fraction of reaction in the faster rate process were sensitive to protein concentration. These results are consistent with the hypothesis that the monomer-dimer equilibrium of the protein controls its kinetic reactivity with EDTA.	UNIV WISCONSIN, DEPT CHEM, MILWAUKEE, WI 53201 USA	University of Wisconsin System; University of Wisconsin Milwaukee				Munoz, Amalia/0000-0002-1858-0379	NIEHS NIH HHS [ES-04026] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004026] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BUHLER RHO, 1979, METALLOTHIONEIN, P211; CARR JD, 1967, INORG CHEM, V6, P1083, DOI 10.1021/ic50052a003; DALGARNO DC, 1986, ADV INORG BIOCHEM, V6, P113; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GALE GR, 1985, RES COMMUN CHEM PATH, V49, P423; LI TY, 1980, P NATL ACAD SCI-BIOL, V77, P6334, DOI 10.1073/pnas.77.11.6334; MINKEL DT, 1980, BIOCHEM J, V191, P475, DOI 10.1042/bj1910475; NICHOLSON JK, 1987, METALLOTHIONEIN, V2, P191; OH SH, 1978, AM J PHYSIOL, V243, pE252; Otvos J. D., 1989, COMMENTS INORG CHEM, V9, P1, DOI DOI 10.1080/02603598908035801; OTVOS JD, 1993, METALLOTHIONEIN, V3, P57; PATTANAIK A, 1992, J BIOL CHEM, V267, P16121; RIVERA M, 1991, CHEM RES TOXICOL, V4, P572, DOI 10.1021/tx00023a014; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; VAZQUEZ F, 1988, BIOCHEM J, V253, P611, DOI 10.1042/bj2530611; WINGE DR, 1991, METHOD ENZYMOL, V205, P438; WINGE DR, 1978, ARCH BIOCHEM BIOPHYS, V188, P466, DOI 10.1016/S0003-9861(78)80031-9	17	56	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5339	5345		10.1074/jbc.270.10.5339	http://dx.doi.org/10.1074/jbc.270.10.5339			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890646	hybrid			2022-12-25	WOS:A1995QL58000060
J	HEMMING, NJ; ANSTEE, DJ; STARICOFF, MA; TANNER, MJA; MOHANDAS, N				HEMMING, NJ; ANSTEE, DJ; STARICOFF, MA; TANNER, MJA; MOHANDAS, N			IDENTIFICATION OF THE MEMBRANE ATTACHMENT SITES FOR PROTEIN-4.1 IN THE HUMAN ERYTHROCYTE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELL; SIALOGLYCOPROTEIN-BETA; GLYCOPHORIN-C; SKELETON; BINDING; PURIFICATION; KINASE	The nature of the membrane attachment site(s) for protein 4.1 in the human erythrocyte membrane has yet to be fully elucidated. In this paper we show that the major attachment site is glycophorin (GP) C/D, and that purified protein 4.1 can bind to two distinct sites on glycophorin C/D. One of these interactions is direct, involving residues 82-98 on glycophorin C (61-77 on glycophorin D), while the other interaction is mediated by p55. We have localized the binding site for p55 on glycophorin C to residues 112-128 (glycophorin D 91-107). We also provide evidence that band 3 is an additional, minor, protein 4.1 binding site. The binding sites for band 3, glycophorin C/D, and p55 are all located within the 30-kDa domain of protein 4.1. We estimate that the relative utilization of the three sites in normal membranes comprises 40% to p55, 40% to GPC/D, and 20% to band 3. The same region of protein 4.1 binds GPC/D and band 3, while the p55 binding site is distinct. The interactions involving protein 4.1 with p55 and p55 with GPC/D are of high affinity (nM), while those involving GPC/D and band 3 are 100 fold lower (mu M). These results suggest that the most significant interactions between protein 4.1 and the membrane are those involving p55.	UNIV BRISTOL,DEPT BIOCHEM,BRISTOL B58 1TD,AVON,ENGLAND; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	University of Bristol; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	HEMMING, NJ (corresponding author), INT BLOOD GRP REFERENCE LAB,SOUTHMEAD RD,BRISTOL BS10 5ND,AVON,ENGLAND.		Anstee, David/AAE-9231-2020					ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; ALLOISIO N, 1985, BIOCHIM BIOPHYS ACTA, V816, P57, DOI 10.1016/0005-2736(85)90392-X; ANSTEE DJ, 1984, BIOCHEM J, V218, P615, DOI 10.1042/bj2180615; COHEN AM, 1988, BIOCHEMISTRY-US, V276, P614; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DISCHER D, 1993, BLOOD, V82, pA309; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; GASCARD P, 1994, BLOOD, V83, P1102; GILLIGAN DM, 1993, SEMIN HEMATOL, V30, P74; HEMMING NJ, 1994, BIOCHEM J, V299, P191, DOI 10.1042/bj2990191; HUSAINCHISHTI A, 1989, J BIOL CHEM, V264, P8985; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; LETO TL, 1984, J BIOL CHEM, V259, P4603; LIU SC, 1992, SEMIN HEMATOL, V29, P231; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOVRIEN RE, 1980, J CELL BIOL, V85, P534, DOI 10.1083/jcb.85.3.534; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MUELLER TJ, 1981, ERYTHROCYTE MEMBRANE, V2; OKUBO Y, 1988, VOX SANG, V54, P107, DOI 10.1111/j.1423-0410.1988.tb01626.x; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PINDER JC, 1993, BLOOD, V82, P3482; REID ME, 1990, BLOOD, V75, P2229; REID ME, 1990, TRANSFUS MED S1, V1, P66; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; SATO SB, 1983, EUR J BIOCHEM, V130, P19; SCOTT ML, 1992, Patent No. 111764; SHIFFER KA, 1984, P NATL ACAD SCI-BIOL, V81, P4404, DOI 10.1073/pnas.81.14.4404; SMYTHE J, 1994, BLOOD, V83, P1668; TANNER MJA, 1988, BIOCHEM J, V250, P407, DOI 10.1042/bj2500407; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	34	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5360	5366		10.1074/jbc.270.10.5360	http://dx.doi.org/10.1074/jbc.270.10.5360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890649	hybrid			2022-12-25	WOS:A1995QL58000063
J	SEKSEK, O; BIWERSI, J; VERKMAN, AS				SEKSEK, O; BIWERSI, J; VERKMAN, AS			DIRECT MEASUREMENT OF TRANS-GOLGI PH IN LIVING CELLS AND REGULATION BY 2ND MESSENGERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE-A; CHLORIDE CONDUCTANCE; ELECTRON-MICROSCOPY; ACIDIFICATION; MEMBRANE; FIBROBLASTS; APPARATUS; ORGANELLES; VESICLES; NETWORK	In the endocytic compartment, an acidic pH plays a key role in receptor and ligand sorting, vesicular transport, and protein degradation. In the secretory compartment, indirect estimates of trans-Golgi pH based on partitioning of weak bases and following viral infection suggest a mildly acidic pH of >6.0. We developed a liposome microinjection method to introduce fluorescent indicators into the aqueous compartment of trans-Golgi in living cells. In the presence of ATP and at 37 degrees C, 70-nm diameter liposomes delivered their fluid-phase contents selectively into the trans-Golgi compartment as assessed by colocalization with the trans-Golgi stain N-{6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl}-sphingosine (C-6-NBD-ceramide). Liposome fusion was ATP- and temperature-dependent and blocked by N-ethylmaleimide but not by guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S). trans-Golgi pH in skin fibroblasts was 6.17 +/- 0.02 (S.E., n = 174) as measured by ratio imaging confocal microscopy using fluorescein and rhodamine based indicators and an in vivo calibration procedure. trans-Gels pH increased to 6.8 +/- 0.1 by cAMP agonists and to 6.5 +/- 0.1 by protein kinase C activation. These results provide the first direct measurement of trans-Golgi pH in living cells and demonstrate pH regulation by second messengers.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Seksek, Olivier/AAO-1837-2020	Seksek, Olivier/0000-0002-3053-3022	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043840] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK43840] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BRADBURY NA, 1992, BIOCHEM BIOPH RES CO, V184, P1173, DOI 10.1016/S0006-291X(05)80006-3; BRIGHT GR, 1989, METHOD CELL BIOL, V30, P157; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHAO AC, 1989, BIOPHYS J, V56, P1071, DOI 10.1016/S0006-3495(89)82755-9; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; FREEDMAN SD, 1993, BIOCHEM BIOPH RES CO, V197, P992, DOI 10.1006/bbrc.1993.2577; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HAUGLAND RP, 1992, HDB FLUORESCENT PROB, P159; KOBAYASHI T, 1988, CELL, V55, P797, DOI 10.1016/0092-8674(88)90135-3; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUWAHARA M, 1988, BIOPHYS J, V54, P595, DOI 10.1016/S0006-3495(88)82994-1; LEE GM, 1989, J CELL SCI, V94, P443; MELLMAN I, 1992, J EXP BIOL, V172, P39; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PARK J, 1990, BIOL CELL, V70, P177, DOI 10.1016/0248-4900(90)90375-D; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Salzman N H, 1993, Subcell Biochem, V19, P95; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WHITE J, 1983, Q REV BIOPHYS, V16, P151, DOI 10.1017/S0033583500005072; WILSON DW, 1993, J BIOL CHEM, V268, P7465; XU HX, 1994, J BIOL CHEM, V269, P22875; YILLA M, 1993, J BIOL CHEM, V268, P19092; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99	32	114	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					4967	4970		10.1074/jbc.270.10.4967	http://dx.doi.org/10.1074/jbc.270.10.4967			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890600	hybrid			2022-12-25	WOS:A1995QL58000004
J	DIMENT, S; EIDELMAN, M; RODRIGUEZ, GM; ORLOW, SJ				DIMENT, S; EIDELMAN, M; RODRIGUEZ, GM; ORLOW, SJ			LYSOSOMAL HYDROLASES ARE PRESENT IN MELANOSOMES AND ARE ELEVATED IN MELANIZING CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NORMAL HUMAN MELANOCYTES; BIOSYNTHESIS; PROTEIN-1; MUTATIONS; BROWN	Melanosomes, the subcellular site of melanin synthesis and deposition, may be related to the endolysosomal lineage of organelles, To determine if melanosomes contain lysosomal hydrolases, we examined the subcellular distribution of five of these enzymes in melanocytes cultured from C57BL/6J mice, Analyses of Percoll gradient density centrifugations demonstrated that beta-hexosaminidase, beta-galactosidase, beta-glucuronidase, and cathepsins B and L all co-sedimented with tyrosinase-rich densely sedimenting melanosomes. The melanosomal distribution of these enzymes was confirmed in studies of melanocytes cultured from albino mice and of melanocytes rendered amelanotic by transfection with the v-ras(Ha) oncogene (which lack dense, melanized melanosomes). In these cells, only a less dense peak of activity for each hydrolase was present, The level of each hydrolase was elevated in black cells when compared with albino cells. Metabolic labeling studies confirmed that the increase in beta-glucuronidase in black versus albino cells resulted mainly from increased synthesis of this enzyme. The data suggest that melanosomes represent specialized lysosomes present within melanocytes, that they contain a broad array of lysosomal hydrolases, and that the levels of these hydrolases are elevated in cells actively engaged in pigment production.	NYU, MED CTR, SCH MED, RONALD O PERELMAN DEPT DERMATOL, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT CELL BIOL, NEW YORK, NY 10016 USA	New York University; New York University; New York University				Orlow, Seth/0000-0003-2548-7380; Diment, Stephanie/0000-0003-0673-2862	NIAMS NIH HHS [AR41880] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041880, R55AR041880] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BHATNAGAR V, 1993, ARCH BIOCHEM BIOPHYS, V307, P183, DOI 10.1006/abbi.1993.1577; Gorlin RJ, 1990, SYNDROMES HEAD NECK, P124; HICKMAN S, 1972, BIOCHEM BIOPH RES CO, V49, P992, DOI 10.1016/0006-291X(72)90310-5; KOLODNY EH, 1976, CLIN CHIM ACTA, V70, P247, DOI 10.1016/0009-8981(76)90426-5; LEPOOLE IC, 1993, EXP CELL RES, V205, P388, DOI 10.1006/excr.1993.1102; LUO D, 1994, EXP CELL RES, V213, P231, DOI 10.1006/excr.1994.1195; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Moellmann G, 1988, PIGMENT CELL RES, V1, P79, DOI DOI 10.1111/J.1600-0749.1988.TB00798.X; NOVAK EK, 1979, GENETICS, V92, P189; ORLOW SJ, 1993, J INVEST DERMATOL, V100, P55, DOI 10.1111/1523-1747.ep12354138; ORLOW SJ, 1994, CURR PROBL DERMATOL, V6, P157; SEIJI M, 1969, J INVEST DERMATOL, V52, P212, DOI 10.1038/jid.1969.33; SMIT NPM, 1993, BIOCHIM BIOPHYS ACTA, V1181, P1, DOI 10.1016/0925-4439(93)90082-C; TSUKAMOTO K, 1992, PIGM CELL RES, P181; VARKI A, 1982, AM J HUM GENET, V34, P717; VIJAYASARADHI S, 1991, EXP CELL RES, V196, P233, DOI 10.1016/0014-4827(91)90256-T; WINDER AJ, 1993, J CELL SCI, V106, P153; WOLFF K, 1971, ARCH DERMATOL FORSCH, V241, P255, DOI 10.1007/BF00595442; ZHOU BK, 1993, J INVEST DERMATOL, V100, P110, DOI 10.1111/1523-1747.ep12462775	21	89	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4213	4215		10.1074/jbc.270.9.4213	http://dx.doi.org/10.1074/jbc.270.9.4213			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876179	hybrid			2022-12-25	WOS:A1995QK08400009
J	SELBY, CP; SANCAR, A				SELBY, CP; SANCAR, A			STRUCTURE AND FUNCTION OF TRANSCRIPTION-REPAIR COUPLING FACTOR .2. CATALYTIC PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; NUCLEOTIDE EXCISION REPAIR; TERMINATION FACTOR-RHO; STRAND-SPECIFIC REPAIR; ESCHERICHIA-COLI; ECORI ENDONUCLEASE; (A)BC EXCINUCLEASE; CLEAVAGE CENTER; DNA STRAND; INVITRO	The transcription repair coupling factor (TRCF) of Escherichia coli has the so-called helicase motifs, is a DNA-, RNA Pol-, and UvrA-binding protein, and is required for the coupling of repair to transcription, We investigated the potential helicase, transcription termination, and transcription-repair coupling activities of TRCF on various substrates, We found that TRCF does not have a helicase activity on any of the substrates tested, However, the TRCF releases both RNA Pol and the truncated transcript from a transcriptional road block caused by a lesion, a ''missing base,'' or a DNA-bound protein, It does not have any effect on rho-dependent or rho-independent transcriptional termination, However, some premature terminations were induced by TRCF at other sites, The coupling of transcription to repair occurs with supercolied and relaxed circular DNA and with linear DNA. However, the coupling with linear DNA is strongly affected by the length of the DNA and does not occur with fragments in which the lesion is closer than 90 nucleotides to the 5' terminus of the template strand, Under transcription conditions the repair of lesions in the promoter region and up to the eleventh transcribed base is inhibited even in the presence of TRCF, Stimulation of repair in the transcribed strand starts at lesions at +15 nucleotides, Stimulation of repair occurs via facilitating the delivery of the A(2)B(1) complex to the lesion site by the TCRF and can be inhibited by excess UvrA which binds to the TRCF off DNA. In vitro, strand-specific repair is not dependent on the MutL and MutS proteins which have recently been implicated in preferential repair in vivo.			SELBY, CP (corresponding author), UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; KING K, 1989, J BIOL CHEM, V264, P11807; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MULLIGAN ME, 1985, J BIOL CHEM, V260, P3529; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; RUTESHOUSER EC, 1989, J MOL BIOL, V208, P23, DOI 10.1016/0022-2836(89)90085-5; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; ZOU LL, 1991, J BIOL CHEM, V266, P10201	26	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4890	4895		10.1074/jbc.270.9.4890	http://dx.doi.org/10.1074/jbc.270.9.4890			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876262	hybrid			2022-12-25	WOS:A1995QK08400100
J	SAUNIER, B; TOURNIER, C; JACQUEMIN, C; PIERRE, M				SAUNIER, B; TOURNIER, C; JACQUEMIN, C; PIERRE, M			STIMULATION OF MITOGEN-ACTIVATED PROTEIN-KINASE BY THYROTROPIN IN PRIMARY CULTURED HUMAN THYROID-FOLLICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MAP KINASE; CYCLIC-AMP; PHOSPHOLIPASE-C; TSH RECEPTOR; CELLS; PHOSPHORYLATION; INHIBITION; PATHWAY; PROLIFERATION	In the thyroid, thyrotropin (TSH) stimulates both growth and function, and stimulates the production of cAMP which reproduces most of the effects of TSH, Here, we report evidence that TSH stimulates the mitogen-activated protein (MAP) kinase cascade through a cAMP-independent pathway, in human thyroid. TSH stimulated MAP kinase activity (4-9-fold the basal level) measured in the cytosolic fractions of primary cultured thyroid follicles. Maximal activity was reached after 20 min and remained sustained for 1-3 h, TSH being as potent as EGF; EC(50) was 1.5 nM TSH. Only a single isoform of MAP kinase (p42) was detected in the follicles. p42 was phosphorylated on tyrosine residues and showed a reduced electrophoretic mobility in follicles stimulated by TSH, All these effects on MAP kinase were decreased by preincubation of the follicles with human anti-TSH receptor antibodies. The stimulation of MAP kinase by TSH was neither blocked by pertussis toxin nor reproduced by forskolin, cholera toxin, or 8-bromo-cAMP. In conclusion, in human thyroid cells, in contrast with previous observations on dog thyroid cells, TSH stimulates strongly MAP kinase through a pertussis toxin-insensitive and cAMP-independent pathway.			SAUNIER, B (corresponding author), INSERM,U96,80 RUE GEN LECLERC,F-94276 LE KREMLIN BICETR,FRANCE.			Saunier, Bertrand/0000-0002-0700-3082				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARMELIN HA, 1973, P NATL ACAD SCI USA, V70, P2702, DOI 10.1073/pnas.70.9.2702; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COOK S, 1994, NATURE, V369, P361, DOI 10.1038/369361a0; CORDA D, 1988, HORIZONS ENDOCRINOLO, P169; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DERWAHL M, 1993, BIOCHEM BIOPH RES CO, V191, P1131, DOI 10.1006/bbrc.1993.1334; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; FAURE M, 1994, J BIOL CHEM, V269, P7851; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GRAFF I, 1987, FEBS LETT, V210, P204, DOI 10.1016/0014-5793(87)81338-8; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; HAYE B, 1973, FEBS LETT, V30, P253, DOI 10.1016/0014-5793(73)80664-7; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAURENT E, 1987, MOL CELL ENDOCRINOL, V52, P273, DOI 10.1016/0303-7207(87)90055-4; MADEC AM, 1988, ENDOCRINOLOGY, V123, P2062, DOI 10.1210/endo-123-4-2062; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P151; ORGIAZZI JJ, 1990, THYROID GLAND, P405; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; ROGER PP, 1982, FEBS LETT, V144, P209, DOI 10.1016/0014-5793(82)80639-X; ROGER PP, 1987, BIOCHEM BIOPH RES CO, V149, P707, DOI 10.1016/0006-291X(87)90425-6; SAUNIER B, 1993, EUR J BIOCHEM, V218, P1091, DOI 10.1111/j.1432-1033.1993.tb18469.x; TOURNIER C, 1995, IN PRESS EUR J BIOCH; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; VILLONE G, 1993, MOL CELL ENDOCRINOL, V95, P85, DOI 10.1016/0303-7207(93)90032-F; WESTERMARK K, 1982, EXP CELL RES, V138, P47, DOI 10.1016/0014-4827(82)90089-1; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	42	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3693	3697		10.1074/jbc.270.8.3693	http://dx.doi.org/10.1074/jbc.270.8.3693			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876108	hybrid			2022-12-25	WOS:A1995QH68800037
J	LIN, RT; GEWERT, D; HISCOTT, J				LIN, RT; GEWERT, D; HISCOTT, J			DIFFERENTIAL TRANSCRIPTIONAL ACTIVATION IN-VITRO BY NF-KAPPA-B/REL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-INTERFERON GENE; VIRUS-INDUCIBLE ENHANCER; DNA-BINDING SUBUNIT; B PROTEINS; REGULATORY ELEMENTS; NUCLEAR FACTOR; PROTO-ONCOGENE; REL ONCOGENE; C-REL; IFN	Distinct NF-kappa B subunit combinations contribute to the specificity of NF-kappa B-mediated transcriptional activation and to the induction of multiple cytokine genes including interferon-beta (IFN-beta). To evaluate the regulatory influence of different homo- and heterodimers, NF-kappa B subunits were analyzed for transcriptional activity in vitro using test templates containing two types of NF-kappa B recognition elements (the human immunodeficiency virus type 1 enhancer and the IFN-beta-positive regulatory domain II (PRDII)) as well as IFN-beta PRDIII-PRDI-PRDII linked to the -56 minimal promoter of rabbit beta-globin. Recombinant NF-kappa B subunits (p50, p65, c-Rel, p52, and I kappa B alpha) and interferon regulatory factor 1 were produced from either Escherichia coli or baculovirus expression systems, Transcriptional analysis in vitro demonstrated that 1) various dimeric complexes of NF-kappa B differentially stimulated transcription through the human immunodeficiency virus enhancer or PRDII up to 20-fold; 2) recombinant I kappa B alpha specifically inhibited NF-kappa B-dependent transcription in vitro; and 3) different NF-kappa B complexes and interferon regulatory factor 1 cooperated to stimulate transcription in vitro through the PRDIII-PRDI-PRDII virus-inducible regulatory domains of the IFN-beta promoter. These results demonstrate the role of NF-kappa B protein dimerization in differential transcriptional activation in vitro and emphasize the role of cooperativity between transcription factor families as an additional regulatory level to maintain transcriptional specificity.	MCGILL UNIV, JEWISH GEN HOSP, LADY DAVIS INST MED RES, TERRY FOX MOLEC ONCOL GRP, MONTREAL, PQ H3T 1E2, CANADA; MCGILL UNIV, DEPT MICROBIOL & IMMUNOL, MONTREAL, PQ H3T 1E2, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ H3T 1E2, CANADA; WELLCOME FDN LTD, DEPT CELL BIOL, BECKENHAM BR3 3BS, KENT, ENGLAND	Lady Davis Institute; McGill University; McGill University; McGill University; GlaxoSmithKline			Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROWNELL E, 1989, ONCOGENE, V4, P935; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHANG CC, 1994, ONCOGENE, V9, P923; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN L, 1992, VIROLOGY, V191, P589, DOI 10.1016/0042-6822(92)90234-G; COHEN L, 1992, J CELL PHYSIOL, V152, P10, DOI 10.1002/jcp.1041520103; COHEN L, 1991, CELL GROWTH DIFFER, V2, P3233; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KAUFMAN PA, 1992, J CLIN INVEST, V90, P121, DOI 10.1172/JCI115824; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LANOIX J, 1994, ONCOGENE, V9, P841; LEBAIL O, 1993, EMBO J, V12, P5042; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Leveillard Thierry, 1993, Gene Expression, V3, P135; LIN RT, 1994, J BIOL CHEM, V269, P17542; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYAMOTO M, 1994, MOL CELL BIOL, V14, P3276; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	75	100	100	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3123	3131		10.1074/jbc.270.7.3123	http://dx.doi.org/10.1074/jbc.270.7.3123			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852394	hybrid			2022-12-25	WOS:A1995QG47100037
J	FUCHS, B; OCONNOR, D; FALLIS, L; SCHEIDTMANN, KH; LU, X				FUCHS, B; OCONNOR, D; FALLIS, L; SCHEIDTMANN, KH; LU, X			P53 PHOSPHORYLATION MUTANTS RETAIN TRANSCRIPTION ACTIVITY	ONCOGENE			English	Note						P53; PHOSPHORYLATION; TRANSCRIPTION GROWTH SUPPRESSION	CASEIN KINASE-II; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; NUCLEAR-LOCALIZATION; SEQUENCE; SITE; TRANSACTIVATION; EXPRESSION; MUTATION; P34CDC2	To investigate the effect of phosphorylation on the transcription activity of p53, ten phosphorylation mutants were constructed covering all the identified phosphorylation sites of rat p53. These included mutants of two casein kinase I sites (Ser6 and Ser9), two DNA-PK sites (Ser15 and Ser39), a p34cdc2 site(Ser313), the adjacent Ser312 and a casein kinase II site (Ser390). Two double phosphorylation mutants (Ser4, 6 and Ser15, 390) and one triple phosphorylation mutant (Ser4, 6 and 15) were also constructed. The transcription activity of all the p53 phosphorylation mutants was tested by transfection into two different types of cells, Saos-2 cells and p53(-/-) fibroblasts derived from p53 knock out mice, which both lack endogenouse p53. Surprisingly, all the p53 phosphorylation mutants retain transcription activity and the seven mutants tested can also suppress cell growth.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; UNIV BONN,INST GENET,MOLEK GENET ABT,D-53117 BONN,GERMANY	Imperial College London; Ludwig Institute for Cancer Research; University of Bonn				Lu, Xin/0000-0002-6587-1152				ADDISON C, 1990, ONCOGENE, V5, P423; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHEN JY, 1993, ONCOGENE, V8, P2159; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1993, ONCOGENE, V8, P1519; FREBOURG T, 1992, CANCER RES, V52, P6976; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V289, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231	32	72	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					789	793						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862459				2022-12-25	WOS:A1995QH61200022
J	BLASCO, MA; MENDEZ, J; LAZARO, JM; BLANCO, L; SALAS, M				BLASCO, MA; MENDEZ, J; LAZARO, JM; BLANCO, L; SALAS, M			PRIMER TERMINUS STABILIZATION AT THE PHI-29 DNA-POLYMERASE ACTIVE-SITE - MUTATIONAL ANALYSIS OF CONSERVED MOTIF KXY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; EXONUCLEASE ACTIVITY; PROTEIN; PHAGE-PHI-29; INITIATION; REPLICATION; POLYMERIZATION; MUTAGENESIS; EXPRESSION; MUTANTS	phi 29 DNA polymerase shares with other DNA-dependent DNA polymerases several regions of amino acid homology along the primary structure. A conserved amino acid motif, located in the C-terminal portion of the polypeptide and characterized by the amino acid sequence KK(K/R)Y, is conserved in the group of eukaryotic-type DNA polymerases. In the subgroup of DNA polymerases that have a protein-priming mechanism, this motif is restricted to the sequence KXY, X never being a positively charged amino acid. Residues Lys(498) and Tyr(500) form this conserved motif in phi 29 DNA polymerase. Mutant K498T, in which the positive charge of the motif has been eliminated, was strongly affected both in initiation (terminal protein-dAMP formation, using terminal protein as primer) and DNA polymerization reactions. Mutants K498R and Y500S were able to carry out the initiation reaction to a higher or similar extent, respectively, than wild-type phi 29 DNA polymerase but were affected in DNA polymerization reactions. Ah of the mutations severely affected the stable binding of the polymerase to a primer-template DNA. In addition, all of the mutant polymerases analyzed in this work showed an unusually strong 3'-5' exonuclease activity both under polymerization or non-polymerization conditions. The results obtained suggest a role of the conserved residues of the KXY motif in stabilizing the primer terminus at the polymerization active site, the positive charge of residue Lys(498) being critical for the synthetic activities of phi 29 DNA polymerase.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Mendez, Juan/K-8001-2014; Blanco, Luis/I-1848-2015; Salas, Margarita/J-9873-2014; Blasco, Maria A./M-1694-2014	Mendez, Juan/0000-0002-3235-2559; Salas, Margarita/0000-0001-5939-3441; Blasco, Maria A./0000-0002-4211-233X	NIGMS NIH HHS [5R01 GM27242-15] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BLANCO L, 1985, NUCLEIC ACIDS RES, V13, P1239, DOI 10.1093/nar/13.4.1239; BLANCO L, 1985, P NATL ACAD SCI USA, V82, P6404, DOI 10.1073/pnas.82.19.6404; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1986, VIROLOGY, V153, P179, DOI 10.1016/0042-6822(86)90021-8; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BLANCO L, 1992, J BIOL CHEM, V267, P1225; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; BLASCO MA, 1993, J BIOL CHEM, V268, P24106; BLASCO MA, 1991, J BIOL CHEM, V266, P7904; BLASCO MA, 1990, NUCLEIC ACIDS RES, V18, P4763; BLASCO MA, 1992, CHROMOSOMA, V102, P32; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CULLMANN G, 1993, GENE, V134, P191, DOI 10.1016/0378-1119(93)90093-I; ESTEBAN JA, 1993, J BIOL CHEM, V268, P2719; GARMENDIA C, 1992, J BIOL CHEM, V267, P2594; GIBBS JS, 1988, P NATL ACAD SCI USA, V85, P6672, DOI 10.1073/pnas.85.18.6672; HERMOSO JM, 1985, NUCLEIC ACIDS RES, V13, P7715, DOI 10.1093/nar/13.21.7715; HWANG CBC, 1992, J VIROL, V66, P1774, DOI 10.1128/JVI.66.3.1774-1776.1992; INCIARTE MR, 1976, VIROLOGY, V74, P314, DOI 10.1016/0042-6822(76)90338-X; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; LAZARO JM, 1994, IN PRESS METHODS ENZ; MENDEZ J, 1994, J BIOL CHEM, V269, P30030; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; RODRIGUEZ JM, 1993, GENE, V136, P103, DOI 10.1016/0378-1119(93)90453-A; ROHE M, 1991, CURR GENET, V20, P527, DOI 10.1007/BF00334782; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WATABE K, 1984, BIOCHEM BIOPH RES CO, V123, P1019, DOI 10.1016/S0006-291X(84)80235-1; ZABALLOS A, 1989, GENE, V83, P187, DOI 10.1016/0378-1119(89)90104-2	37	36	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2735	2740		10.1074/jbc.270.6.2735	http://dx.doi.org/10.1074/jbc.270.6.2735			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852344	hybrid			2022-12-25	WOS:A1995QF53500053
J	FISONE, G; SNYDER, GL; FRYCKSTEDT, J; CAPLAN, MJ; APERIA, A; GREENGARD, P				FISONE, G; SNYDER, GL; FRYCKSTEDT, J; CAPLAN, MJ; APERIA, A; GREENGARD, P			NA+,K+-ATPASE IN THE CHOROID-PLEXUS - REGULATION BY SEROTONIN PROTEIN-KINASE-C PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CEREBROSPINAL-FLUID PRODUCTION; EPITHELIAL-CELLS; BRAIN-BARRIER; RAPHE ORIGIN; PHOSPHORYLATION; NA,K-ATPASE; ATPASE; RAT; LOCALIZATION; RECEPTOR	In the choroid plexus, the ion pump Na+,K+-ATPase regulates the production of cerebrospinal fluid. We now report that incubation of choroid plexus with an activator of protein kinase C, phorbol 12,13-dibutyrate, strongly stimulates the phosphorylation of Na+,K+-ATPase and inhibits its activity. Similar effects were obtained with serotonin, which in the choroid plexus stimulates phosphoinositide turnover, thereby activating protein kinase C. Serotonin (10 mu M) increased by about 10-fold the amount of phosphorylated Na+,K+-ATPase and significantly reduced its activity. Two-dimensional peptide mapping showed comigration of Na+,K+-ATPase phosphorylated by either phorbol 12,13-dibutyrate or serotonin in intact cells and by protein kinase C in vitro. These results demonstrate that first messengers can regulate the activity of Na+,K+-ATPase through a mechanism involving protein phosphorylation. Moreover, they provide a plausible mechanism for the demonstrated ability of serotonin to decrease cerebrospinal fluid production.	KAROLINSKA INST,ST GORANS CHILDRENS HOSP,DEPT PEDIAT,S-11281 STOCKHOLM,SWEDEN; YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510	Karolinska Institutet; Yale University	FISONE, G (corresponding author), ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.			Fisone, Gilberto/0000-0002-0719-8000; Caplan, Michael/0000-0001-5768-4405; Fryckstedt, Jessica/0000-0003-4944-8909	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-40899] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGHAJANIAN GK, 1975, BRAIN RES, V88, P221, DOI 10.1016/0006-8993(75)90386-8; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; CONN PJ, 1986, P NATL ACAD SCI USA, V83, P4086, DOI 10.1073/pnas.83.11.4086; CONN PJ, 1986, J NEUROCHEM, V47, P1754, DOI 10.1111/j.1471-4159.1986.tb13085.x; CONN PJ, 1987, BRAIN RES, V400, P396, DOI 10.1016/0006-8993(87)90641-X; DOUCET A, 1979, AM J PHYSIOL, V237, pF105, DOI 10.1152/ajprenal.1979.237.2.F105; ERNST SA, 1986, J HISTOCHEM CYTOCHEM, V34, P189, DOI 10.1177/34.2.3003182; FISONE G, 1994, J BIOL CHEM, V269, P9368; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDVALL M, 1979, EXP NEUROL, V64, P132, DOI 10.1016/0014-4886(79)90010-4; LINDVALL M, 1978, SCIENCE, V201, P176, DOI 10.1126/science.663649; LINDVALLAXELSSO.M, 1988, EXP NEUROL, V99, P362; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; MAEDA K, 1983, Nihon University Journal of Medicine, V25, P155; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; MOSKOWITZ MA, 1979, BRAIN RES, V169, P590, DOI 10.1016/0006-8993(79)90410-4; PAZOS A, 1985, EUR J PHARMACOL, V106, P539; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; POLLAY M, 1985, NEUROSURGERY, V17, P768, DOI 10.1227/00006123-198511000-00007; QUINTON PM, 1973, J CELL BIOL, V58, P724, DOI 10.1083/jcb.58.3.724; STEARDO L, 1987, SCIENCE, V235, P470, DOI 10.1126/science.2879355; WRIGHT EM, 1978, REV PHYSIOL BIOCH P, V83, P1; YAGALOFF KA, 1985, J NEUROSCI, V5, P3178; ZLOKOVIC BV, 1993, J BIOL CHEM, V268, P8019	26	84	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2427	2430		10.1074/jbc.270.6.2427	http://dx.doi.org/10.1074/jbc.270.6.2427			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852300	hybrid			2022-12-25	WOS:A1995QF53500005
J	KIM, EJ; ZHEN, RG; REA, PA				KIM, EJ; ZHEN, RG; REA, PA			SITE-DIRECTED MUTAGENESIS OF VACUOLAR H+-PYROPHOSPHATASE - NECESSITY OF CYS(634) FOR INHIBITION BY MALEIMIDES BUT NOT CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING INORGANIC PYROPHOSPHATASE; SUBSTRATE-BINDING SUBUNIT; PHENOTYPIC SELECTION; MOLECULAR-CLONING; MEMBRANE; PLANTS; CELLS; METABOLISM; KINETICS; ATPASES	A characteristic feature of the vacuolar H+-translocating inorganic pyrophosphatase (V-PPase) of plant cells is its high sensitivity to irreversible inhibition by N-ethylmaleimide (NEM) and other sulfhydryl reagents, Previous investigations in this laboratory have demonstrated that the primary site for substrate-protectable covalent modification of the V-PPase by C-14-labeled NEM maps to a single M(r) 14,000 V8 protease fragment (V8(14K)) (Zhen, R.-G., Kim, E. J., and Rea, P. A. (1994) J. Biol. Chem. 269, 23342-23350). Here, we describe site-directed mutagenesis of the cDNA encoding the V-PPase hom Arabidopsis thaliana, its heterologous expression in Saccharomyces cerevisiae and single substitution of all 9 conserved Cys residues to either Ser or Ala. In all cases, except one, Cys mutagenesis exerts little or no effect on either the catalytic activity or susceptibility of the enzyme to inhibition by NEM. By contrast, and in complete agreement with the results of peptide mapping experiments, substitution of Cys(634), the sole conserved cysteine residue encompassed by V8(14K), with Ser or Ala generates enzyme that is insensitive to NEM but active in both PPi hydrolysis and PPi-dependent H+ translocation. The specific requirement for Cys(634) for inhibition by NEM and the dispensability of all of the conserved Cys residues, including Cys(634), for V-PPase function indicate that the inhibitory action of maleimides reflects steric constraints imposed by the addition of a substituted alkyl group to the side chain of Cys(634) rather than direct participation of this amino acid residue in catalysis.	UNIV PENN, INST PLANT SCI, DEPT BIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania								Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BAYKOV AA, 1993, FEBS LETT, V327, P199, DOI 10.1016/0014-5793(93)80169-U; BAYKOV AA, 1993, EUR J BIOCHEM, V217, P755, DOI 10.1111/j.1432-1033.1993.tb18303.x; BLACK CC, 1987, PHYSIOL PLANTARUM, V69, P387, DOI 10.1111/j.1399-3054.1987.tb04305.x; BRITTEN CJ, 1989, FEBS LETT, V256, P200, DOI 10.1016/0014-5793(89)81748-X; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; DENNIS DT, 1987, PHYSIOL PLANTARUM, V69, P395, DOI 10.1111/j.1399-3054.1987.tb04306.x; HUBER SC, 1986, PLANT PHYSIOL, V81, P1008, DOI 10.1104/pp.81.4.1008; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KABACK HR, 1992, INT REV CYTOL, V137A, P97; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; KIM YC, 1994, PLANT PHYSIOL, V106, P375, DOI 10.1104/pp.106.1.375; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEIGH RA, 1992, PLANT PHYSIOL, V100, P1698, DOI 10.1104/pp.100.4.1698; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; QUICK P, 1989, BIOCHIM BIOPHYS ACTA, V973, P263, DOI 10.1016/S0005-2728(89)80431-1; Rea P.A., 1990, METHODS PLANT BIOCH, V3, P385, DOI DOI 10.1016/B978-0-12-461013-2.50035-6; REA PA, 1992, PLANT PHYSIOL, V100, P723, DOI 10.1104/pp.100.2.723; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; TAIZ L, 1994, BBA-BIOMEMBRANES, V1194, P329, DOI 10.1016/0005-2736(94)90315-8; TANAKA Y, 1993, BIOCHEM BIOPH RES CO, V190, P1110, DOI 10.1006/bbrc.1993.1164; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; ZHEN RG, 1994, J BIOL CHEM, V269, P23342	31	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2630	2635		10.1074/jbc.270.6.2630	http://dx.doi.org/10.1074/jbc.270.6.2630			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852329	hybrid			2022-12-25	WOS:A1995QF53500037
J	WEIL, R; CLOUTIER, JF; FOURNEL, M; VEILLETTE, A				WEIL, R; CLOUTIER, JF; FOURNEL, M; VEILLETTE, A			REGULATION OF ZAP-70 BY SRC FAMILY TYROSINE PROTEIN-KINASES IN AN ANTIGEN-SPECIFIC T-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZETA-CHAIN; RECEPTOR STIMULATION; CD4 RECEPTOR; ACTIVATION; P56LCK; PHOSPHORYLATION; RESPONSIVENESS; IDENTIFICATION; COMPONENTS; BINDS	To further understand the interactions between Zap-70, Src family kinases, and other T-cell proteins, we have examined the regulation of Zap-70 in the antigen-specific T-cell line BI-141. By analyzing derivatives containing an activated version of either p56(lck) or p59(fynT), it was observed that the two Src-related enzymes augmented T-cell receptor (TCR)-mediated tyrosine phosphorylation of Zap-70, as well as its association with components of the antigen receptor complex. Importantly, the accumulation of TCR Zap-70 complexes quantitatively and temporally correlated with the induction of tyrosine phosphorylation of the CD3 and zeta chains of TCR, Using a CD4-positive variant of BI-141, we also found that the ability of Zap-70 to undergo tyrosine phosphorylation and associate with TCR was enhanced by aggregation of TCR with the CD4 co-receptor. Further studies allowed the identification of two distinct pools of tyrosine-phosphorylated Zap-70 in activated T-cells. While one population was associated with TCR, the other was co-immunoprecipitated with a 120-kDa tyrosine-phosphorylated protein of unknown identity, In addition to supporting the notion that Src-related enzymes regulate the recruitment of Zap-70 in TCR signaling, these data added further complexity to previous models of regulation of Zap-70. Furthermore, they suggested that p120 may be an effector and/or a regulator of Zap-70 in activated T-lymphocytes.	MCGILL UNIV, MCGILL CANC CTR, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT BIOCHEM & ONCOL, MONTREAL, PQ H3G 1Y6, CANADA; MONTREAL GEN HOSP, DEPT MED, MONTREAL, PQ H3G 1A4, CANADA; MONTREAL GEN HOSP, DEPT ONCOL, MONTREAL, PQ H3G 1A4, CANADA	McGill University; McGill University; McGill University; McGill University; McGill University			Cloutier, Jean-François/K-2003-2012	Weil, Robert/0000-0001-5235-0932				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; QIAN DP, 1993, J BIOL CHEM, V268, P4488; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TIMSONGAUEN LK, 1994, MOL CELL BIOL, V14, P3729; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEIL R, 1994, J BIOL CHEM, V269, P22830; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILDE DB, 1983, J IMMUNOL, V131, P2178	37	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2791	2799		10.1074/jbc.270.6.2791	http://dx.doi.org/10.1074/jbc.270.6.2791			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852351	hybrid			2022-12-25	WOS:A1995QF53500061
J	BLOMMAART, EFC; LUIKEN, JJFP; BLOMMAART, PJE; VANWOERKOM, GM; MEIJER, AJ				BLOMMAART, EFC; LUIKEN, JJFP; BLOMMAART, PJE; VANWOERKOM, GM; MEIJER, AJ			PHOSPHORYLATION OF RIBOSOMAL-PROTEIN S6 IS INHIBITORY FOR AUTOPHAGY IN ISOLATED RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACIDS; HEPATIC PROTEOLYSIS; PLASMA-MEMBRANE; OKADAIC ACID; DEGRADATION; GLUCAGON; INSULIN; KINASE; LIVER; SITES	In rat hepatocytes, autophagy is known to be inhibited by amino acids, Insulin and cell swelling promote inhibition by amino acids, Each of the conditions leading to inhibition of autophagic proteolysis was found to be associated with phosphorylation of a 31-kDa protein that we identified as ribosomal protein S6. A combination of leucine, tyrosine, and phenylalanine, which efficiently inhibits autophagic proteolysis, was particularly effective in stimulating S6 phosphorylation, The relationship between the percentage inhibition of proteolysis and the degree of Se phosphorylation was linear, Thus, inhibition of autophagy and phosphorylation of S6 are under the control of the same signal transduction pathway, Stimulation of S6 phosphorylation by the presence of amino acids was due to activation of S6 kinase and not to inhibition of S6 phosphatase. The inhibition by amino acids of both autophagic proteolysis and autophagic sequestration of electro-injected cytosolic [C-14]sucrose was partially prevented by rapamycin, a compound known to inhibit activation of p70 S6 kinase, In addition, rapamycin partially inhibited the rate of protein synthesis. We conclude that the fluxes through the autophagic and protein synthetic pathways are regulated in an opposite manner by the degree to which S6 is phosphorylated. Possible mechanisms by which S6 phosphorylation can cause inhibition of autophagy are discussed.	UNIV AMSTERDAM, EC SLATER INST, ACAD MED CTR, DEPT BIOCHEM, 1100 DE AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, DEPT ANAT & EMBRYOL, AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam								BANDI HR, 1993, J BIOL CHEM, V268, P4530; BLOMMAART PJE, 1993, J BIOL CHEM, V268, P1610; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DAHL SV, 1991, BIOCHEM J, V278, P771, DOI 10.1042/bj2780771; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; FURUNO K, 1990, EXP CELL RES, V189, P261, DOI 10.1016/0014-4827(90)90245-6; GARRISON JC, 1978, J BIOL CHEM, V253, P7091; GROEN AK, 1982, EUR J BIOCHEM, V122, P87, DOI 10.1111/j.1432-1033.1982.tb05851.x; HENSGENS HESJ, 1979, BIOCHIM BIOPHYS ACTA, V582, P525, DOI 10.1016/0304-4165(79)90143-0; HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JONSSON LMV, 1987, EUR J BIOCHEM, V164, P171, DOI 10.1111/j.1432-1033.1987.tb11008.x; Kacser H, 1979, BIOCHEM SOC T, V7, P1149, DOI 10.1042/bst0071149; KADOWAKI M, 1992, J BIOL CHEM, V267, P22060; KOZMA SC, 1989, CELL SIGNAL, V1, P219, DOI 10.1016/0898-6568(89)90039-9; KRIEG J, 1988, J BIOL CHEM, V263, P11473; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEVERVE XM, 1987, FEBS LETT, V219, P455, DOI 10.1016/0014-5793(87)80271-5; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MEIJER AJ, 1993, EUR J BIOCHEM, V215, P449, DOI 10.1111/j.1432-1033.1993.tb18053.x; MEIJER AJ, 1985, EUR J BIOCHEM, V148, P189, DOI 10.1111/j.1432-1033.1985.tb08824.x; MIOTTO G, 1992, J BIOL CHEM, V267, P22066; MORLEY SJ, 1993, BIOCHIMIE, V75, P985, DOI 10.1016/0300-9084(93)90149-M; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; MORTIMORE GE, 1987, J BIOL CHEM, V262, P16322; MORTIMORE GE, 1994, BIOCHEM BIOPH RES CO, V203, P200, DOI 10.1006/bbrc.1994.2168; PALEN E, 1987, J BIOL CHEM, V262, P3518; POLI A, 1981, J CELL SCI, V48, P1; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SCHWORER CM, 1979, P NATL ACAD SCI USA, V76, P3169, DOI 10.1073/pnas.76.7.3169; SEGLEN PO, 1984, J CELL BIOL, V99, P435, DOI 10.1083/jcb.99.2.435; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TEWS JK, 1974, BIOCHEM PHARMACOL, V23, P1777, DOI 10.1016/0006-2952(74)90404-3; THOMAS G, 1993, BIOCHEM SOC T, V21, P901, DOI 10.1042/bst0210901; WETTENHALL REH, 1982, FEBS LETT, V148, P207, DOI 10.1016/0014-5793(82)80809-0; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443	39	542	554	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2320	2326		10.1074/jbc.270.5.2320	http://dx.doi.org/10.1074/jbc.270.5.2320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836465	hybrid			2022-12-25	WOS:A1995QE49300053
J	THEILE, M; HARTMANN, S; SCHERTHAN, H; ARNOLD, W; DEPPERT, W; FREGE, R; GLAAB, F; HAENSCH, W; SCHERNECK, S				THEILE, M; HARTMANN, S; SCHERTHAN, H; ARNOLD, W; DEPPERT, W; FREGE, R; GLAAB, F; HAENSCH, W; SCHERNECK, S			SUPPRESSION OF TUMORIGENICITY OF BREAST-CANCER CELLS BY TRANSFER OF HUMAN-CHROMOSOME-17 DOES NOT REQUIRE TRANSFERRED BRCA1 AND P53 GENES	ONCOGENE			English	Article						BREAST CANCER CELLS; HUMAN CHROMOSOME 17; CHROMOSOME TRANSFER; TUMOR SUPPRESSOR GENES	DENATURANT GEL-ELECTROPHORESIS; LINKAGE ANALYSIS; OVARIAN-CANCER; ALLELE LOSS; LINE; CARCINOMAS; DISTINCT; REGIONS; HYBRIDIZATION; POLYMORPHISMS	A number of candidate tumor suppressor genes located on the human chromosome 17 are thought to have a role to play in the development of breast cancer. In addition to the p53 gene on 17p13.1 and the BRCA1 gene mapped to 17q12-21, other chromosomal regions for tumor suppressor genes have been suggested to exist on 17p13.3 and both the central and the distal parts of 17q, although definitive functional proof of their involvement in breast cancer tumorigenesis is still lacking. In this report we show that microcell transfer of a human chromosome 17 into wild-type p53 breast cancer cells CAL51 results in loss of tumorigenicity and anchorage-independent growth, changes in cell morphology and a reduction of cell growth rates of the neo-selected microcell hybrids. In the hybrid cells, which express the p53 wild-type protein, only the p- and the distal parts of the q arm of donor chromosome 17 are transferred. Thus, our results provide functional evidence for the presence of one or more tumor suppressor gene(s) on chromosome 17, which are distinct from the p53 and the BRCA1 genes.	MAX DELBRUCK CTR MOLEK MED,FORSCH GRP MED ONKOL & TUMORIMMUNOL,D-13122 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,ROBERT ROSSLE KLIN,BEREICH PATHOL,D-13122 BERLIN,GERMANY; UNIV KAISERSLAUTERN,HUMANBIOL & HUMANGENET ABT,D-67663 KAISERSLAUTERN,GERMANY; HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,TUMORVIROL ABT,D-20251 HAMBURG,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kaiserslautern; Heinrich Pette Institute	THEILE, M (corresponding author), MAX DELBRUCK CTR MOLEK MED,ARBEITSGRP TUMORGENET,ROBERT ROSSLE STR 10,D-13122 BERLIN,GERMANY.							ALBERTSEN H, 1994, AM J HUM GENET, V54, P516; ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; ANDERSON MJ, 1993, FASEB J, V7, P826, DOI 10.1096/fasebj.7.10.8344482; BAKER JM, 1993, ONCOGENE, V8, P497; BENCHEICKH M, 1992, INT J CANCER, V51, P542, DOI 10.1002/ijc.2910510407; BORG A, 1994, J NATL CANCER I, V86, P792, DOI 10.1093/jnci/86.10.792; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CHANG F, 1993, BRIT J CANCER, V68, P653, DOI 10.1038/bjc.1993.404; CHEN LC, 1991, P NATL ACAD SCI USA, V88, P3847, DOI 10.1073/pnas.88.9.3847; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; COLLINS C, 1991, GENOMICS, V11, P997, DOI 10.1016/0888-7543(91)90025-A; CORNELIS RS, 1993, ONCOGENE, V8, P781; CORNELIS RS, 1994, CANCER RES, V54, P4200; CROPP CS, 1993, CANCER RES, V53, P5617; CROPP CS, 1994, CANCER RES, V54, P2548; EASTON DF, 1993, AM J HUM GENET, V52, P678; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FUJIMORI M, 1991, CANCER RES, V51, P89; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GOLDGAR DE, 1993, AM J HUM GENET, V52, P743; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JM, 1992, AM J HUM GENET, V50, P1235; ISOMURA M, 1994, GENE CHROMOSOME CANC, V9, P173, DOI 10.1002/gcc.2870090305; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KLEIN G, 1993, FASEB J, V7, P821, DOI 10.1096/fasebj.7.10.8344481; KLEVER M, 1991, HUM GENET, V86, P484; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KUGOH HM, 1990, ONCOGENE, V5, P1637; LALLE P, 1994, ONCOGENE, V9, P437; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1991, SCIENCE, V250, P1233; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MERLO GR, 1992, AM J PATHOL, V140, P215; NAGAI MA, 1994, BRIT J CANCER, V69, P754, DOI 10.1038/bjc.1994.142; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1994, CANCER RES, V54, P1818; NEGRINI M, 1992, ONCOGENE, V7, P2013; NORMAND T, 1993, HUM MOL GENET, V2, P479, DOI 10.1093/hmg/2.4.479; OCONNELL P, 1994, AM J HUM GENET, V54, P526; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P689, DOI 10.1093/nar/19.3.689; SATO T, 1992, CANCER RES, V52, P1643; SATO T, 1990, CANCER RES, V50, P7184; SAXENA A, 1992, CANCER RES, V52, P6716; SHIMIZU M, 1990, ONCOGENE, V5, P185; SMITH SA, 1994, GENE CHROMOSOME CANC, V10, P71, DOI 10.1002/gcc.2870100112; SMITHSORENSEN B, 1993, HUM MUTAT, V2, P274, DOI 10.1002/humu.1380020407; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Stanbridge E.J., 1987, ADV VIRAL ONCOL, V6, P83; TAKITA K, 1992, CANCER RES, V52, P3914; THEILE M, 1994, INT J ONCOL, V4, P1067; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TRIPATHY D, 1993, ONCOGENES THMOR SUPP; VALERA A, 1994, HUM GENE THER, V5, P449, DOI 10.1089/hum.1994.5.4-449; VONDERWETH A, 1993, J VIROL, V67, P886, DOI 10.1128/JVI.67.2.886-893.1993; WATATANI M, 1993, BREAST CANCER RES TR, V28, P231, DOI 10.1007/BF00666584; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; ZIMMERMANN W, 1993, AM J HUM GENET, V52, P789	63	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					439	447						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845668				2022-12-25	WOS:A1995QF64800004
J	HALL, A; HAKANSSON, K; MASON, RW; GRUBB, A; ABRAHAMSON, M				HALL, A; HAKANSSON, K; MASON, RW; GRUBB, A; ABRAHAMSON, M			STRUCTURAL BASIS FOR THE BIOLOGICAL SPECIFICITY OF CYSTATIN-C - IDENTIFICATION OF LEUCINE-9 IN THE N-TERMINAL BINDING REGION AS A SELECTIVITY-CONFERRING RESIDUE IN THE INHIBITION OF MAMMALIAN CYSTEINE PEPTIDASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE CYSTATIN; RAY CRYSTAL-STRUCTURE; HUMAN GAMMA-TRACE; PROTEINASE-INHIBITOR; CHICKEN CYSTATIN; ESCHERICHIA-COLI; CATHEPSIN-S; GEL ELECTROPHORESIS; MOLECULAR-CLONING; SEQUENCE-ANALYSIS	The structural basis for the biological specificity of human cystatin C has been investigated. Cystatin C and other inhibitors belonging to family 2 of the cystatin superfamily interact reversibly with target peptidases, seemingly by independent affinity contributions from a wedge-shaped binding region built from two loop-forming inhibitor segments and a binding region corresponding to the N-terminal segment of the inhibitor. Human cystatin C variants with Gly substitutions for residues Arg-8, Leu-9, and/or Val-10 of the N-terminal binding region, and/or the evolutionarily conserved Trp-106 in the wedge shaped binding region, were produced by site-directed mutagenesis and Escherichia coli expression. A total of 10 variants were isolated, structurally verified, and compared to wild-type cystatin C with respect to inhibition of the mammalian cysteine peptidases, cathepsins B, H, L, and S. Varying contributions from the N-terminal binding region and the wedge-shaped binding region to cystatin C affinity for the four target peptidases were observed. Interactions from the side chains of residues in the N-terminal binding region and Trp-106 are jointly responsible for the major part of cystatin C affinity for cathepsin L and are also of considerable importance for cathepsin B and H affinity. In contrast, for cathepsin S inhibition these interactions are of lesser significance, as reflected by a K-i value of 10(-8) M. for the cystatin C variant devoid of Arg-8, Leu-9, Val-10, and Trp 106 side chains. The side chain of Val-10 is responsible for most of the affinity contribution from the N terminal binding region, for all four enzymes. The contribution of the Arg-8 side chain is minor, but significant for cystatin C interaction with cathepsin B. The Leu-9 side chain confers selectivity to the inhibition of the target peptidases; it contributes to cathepsin B and L affinity by factors of 200 and 50, respectively, to cathepsin S binding by a factor of 5 only, and results in a 10-fold decreased affinity between cystatin C and cathepsin H.	ALFRED I DUPONT INST,NEMOURS RES PROGRAMS,DEPT MED CELL BIOL,WILMINGTON,DE 19803; UNIV LUND HOSP,DEPT CLIN CHEM,S-22185 LUND,SWEDEN	Nemours Alfred I. duPont Hospital for Children; Lund University; Skane University Hospital			Abrahamson, Magnus/CAG-9507-2022	Grubb, Anders/0000-0002-0125-3662				ABRAHAMSON M, 1994, P NATL ACAD SCI USA, V91, P1416, DOI 10.1073/pnas.91.4.1416; ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688; ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6; ABRAHAMSON M, 1991, BIOCHEM J, V273, P621, DOI 10.1042/bj2730621; ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; AUERSWALD EA, 1992, EUR J BIOCHEM, V209, P837, DOI 10.1111/j.1432-1033.1992.tb17355.x; BALBIN M, 1994, J BIOL CHEM, V269, P23156; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1984, BIOCHEM BIOPH RES CO, V120, P631, DOI 10.1016/0006-291X(84)91302-0; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BJORCK L, 1990, J VIROL, V64, P941; BJORK I, 1994, BIOCHEM J, V299, P219, DOI 10.1042/bj2990219; BJORK I, 1992, FEBS LETT, V299, P66, DOI 10.1016/0014-5793(92)80102-M; BLUMBERG S, 1970, EUR J BIOCHEM, V15, P97, DOI 10.1111/j.1432-1033.1970.tb00981.x; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BODE W, 1990, BIOL CHEM H-S, V371, P111; BROMME D, 1991, BIOMED BIOCHIM ACTA, V50, P631; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; COLLINS AR, 1991, ANTIMICROB AGENTS CH, V35, P2444, DOI 10.1128/AAC.35.11.2444; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; DIECKMANN T, 1993, J MOL BIOL, V234, P1048, DOI 10.1006/jmbi.1993.1658; FREIJE JP, 1993, J BIOL CHEM, V268, P15737; GRUBB A, 1982, P NATL ACAD SCI-BIOL, V79, P3024, DOI 10.1073/pnas.79.9.3024; HALL A, 1992, J ENZYM INHIB, V6, P113, DOI 10.3109/14756369209040742; HALL A, 1993, BIOCHEM J, V291, P123, DOI 10.1042/bj2910123; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; ISEMURA S, 1991, J BIOCHEM, V110, P648, DOI 10.1093/oxfordjournals.jbchem.a123634; ISEMURA S, 1986, FEBS LETT, V198, P145, DOI 10.1016/0014-5793(86)81201-7; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; KAWAHARA K, 1966, J BIOL CHEM, V241, P3228; KEPPLER D, 1994, BIOCHEM SOC T, V22, P43, DOI 10.1042/bst0220043; KORANT BD, 1985, BIOCHEM BIOPH RES CO, V127, P1072, DOI 10.1016/S0006-291X(85)80054-1; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; LINDAHL P, 1988, BIOCHEMISTRY-US, V27, P5074, DOI 10.1021/bi00414a019; LINDAHL P, 1994, BIOCHEMISTRY-US, V33, P4384, DOI 10.1021/bi00180a036; LINDAHL P, 1992, BIOCHEM J, V286, P165, DOI 10.1042/bj2860165; LUACES AL, 1988, BIOCHEM J, V250, P903, DOI 10.1042/bj2500903; MACHLEIDT W, 1989, FEBS LETT, V243, P234, DOI 10.1016/0014-5793(89)80135-8; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MASON RW, 1986, BIOCHEM J, V240, P285, DOI 10.1042/bj2400285; MASON RW, 1986, BIOMED BIOCHIM ACTA, V45, P1433; MASON RW, 1993, ADV CELL MOL BIOL M, V1, P81; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; NICKLIN MJH, 1984, BIOCHEM J, V223, P245, DOI 10.1042/bj2230245; NORTH MJ, 1990, PARASITOL TODAY, V6, P270, DOI 10.1016/0169-4758(90)90189-B; OLAFSSON I, 1990, SCAND J CLIN LAB INV, V50, P85, DOI 10.3109/00365519009091569; RAWLINGS ND, 1990, COMPUT APPL BIOSCI, V6, P118; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHI GP, 1992, J BIOL CHEM, V267, P7258; XIN XQ, 1992, ARCH BIOCHEM BIOPHYS, V299, P334, DOI 10.1016/0003-9861(92)90283-3	53	112	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5115	5121		10.1074/jbc.270.10.5115	http://dx.doi.org/10.1074/jbc.270.10.5115			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890620	hybrid			2022-12-25	WOS:A1995QL58000027
J	LI, CY; SUARDET, L; LITTLE, JB				LI, CY; SUARDET, L; LITTLE, JB			POTENTIAL ROLE OF WAF1/CIP1/P21 AS A MEDIATOR OF TGF-BETA CYTOINHIBITORY EFFECT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLORECTAL-CANCER; INHIBITION; PROTEIN; KINASES; P21; G1	Transforming growth factor-beta (TGF-beta) inhibits cell cycle progression of many types of human cells by arresting them in the G(1) phase of the cell cycle, The arrest is mediated through interactions of various cyclin-dependent protein kinases (CDKs) and their inhibitors, We demonstrate that treatment with TGF-beta induces increased levels of WAF1/Cip1/p21, a potent inhibitor of various cyclin-CDK kinase activities, in two colon cancer cell lines (LS1034 and LS513), which are sensitive to TGF-beta-induced growth arrest. The induction in at least one of these cells lines (LS1034, p53-) is p53-independent. No WAF1 induction was observed after TGF-beta treatment in a third cell line (HT-29), which is completely insensitive to the cytoinhibitory effect of TGB-beta. In both LS513 and LS1034, WAF1 induction correlated with reduced cyclin E-associated kinase activity in vitro and suppression of the retinoblastoma susceptibility gene (Rb) protein phosphorylation in vivo. In addition, WAF1 was physically associated with cyclin E in the two sensitive cell lines. These results suggest that WAF1/Cip1/p21 is a mediator of cellular sensitivity to TGF-beta.			LI, CY (corresponding author), HARVARD UNIV, SCH PUBL HLTH, RADIOBIOL LAB, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Li, Chuan-Yuan/H-4148-2013		NCI NIH HHS [CA-47542] Funding Source: Medline; NIEHS NIH HHS [ES0002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		DANEILPOUR D, 1990, J IMMUNOL METHODS, V158, P17; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1991, CANCER RES, V51, P6304; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PIENTENPOL JA, 1990, CELL, V61, P777; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SUARDET L, 1992, CANCER RES, V52, P3705; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	26	239	243	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					4971	4974		10.1074/jbc.270.10.4971	http://dx.doi.org/10.1074/jbc.270.10.4971			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890601	hybrid			2022-12-25	WOS:A1995QL58000005
J	JANNATIPOUR, M; ROKEACH, LA				JANNATIPOUR, M; ROKEACH, LA			THE SCHIZOSACCHAROMYCES-POMBE HOMOLOG OF THE CHAPERONE CALNEXIN IS ESSENTIAL FOR VIABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SCHISTOSOMA-MANSONI ANTIGEN; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEINS; UNFOLDED PROTEINS; BINDING PROTEIN; BIP GENE; CALRETICULIN; YEAST; SEQUENCE	We have cloned a Schizosaccharomyces pombe gene, here designated cnx1, encoding the homologue of the endoplasmic reticulum molecular chaperone calnexin. Disruption of the cnx1 gene was lethal, demonstrating that it has an essential cellular function. Transcription of cnx1 mRNA is initiated at multiple sites, and it can be induced by various stress treatments that lead to the accumulation of unfolded and/or misfolded proteins in the endoplasmic reticulum. The encoded Cnx1p protein more closely resembles its plant and animal calnexin homologues than that of Saccharomyces cerevisiae. Cnx1p is acidic and migrates aberrantly on SDS-polyacrylamide gel electrophoresis, similar to its mammalian counterparts. Cnx1p contains the hallmark KPEDWD motifs that are found in all members of the calnexin/calreticulin family of proteins. Using an in vitro translation-processing system, we have shown that Cnx1p has the characteristic type I topology of calnexin proteins. Unlike its higher eukaryotic homologues, Cnx1p has a site for N-glycosylation that was modified in an in vitro translation-processing assay.	UNIV MONTREAL, DEPT BIOCHIM, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ARMSTRONG J, 1993, MOL BIOL CELL, V4, P583, DOI 10.1091/mbc.4.6.583; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BROWN DJ, 1988, J VIROL, V62, P3824, DOI 10.1128/JVI.62.10.3824-3831.1988; Burns K, 1994, Trends Cell Biol, V4, P152; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CALA SE, 1993, J BIOL CHEM, V268, P2969; CHAPPELL TG, 1989, J CELL BIOL, V109, P2693, DOI 10.1083/jcb.109.6.2693; CHEN FQ, 1994, PLANT CELL, V6, P835, DOI 10.1105/tpc.6.6.835; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVIRGILIO C, 1993, YEAST, V9, P185, DOI 10.1002/yea.320090209; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; HAWN TR, 1993, J BIOL CHEM, V268, P7692; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUANG LQ, 1993, J BIOL CHEM, V268, P6560; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; KENNEDY TE, 1992, NEURON, V9, P1013, DOI 10.1016/0896-6273(92)90062-I; KHALIFE J, 1993, MOL BIOCHEM PARASIT, V57, P193, DOI 10.1016/0166-6851(93)90195-4; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; MERTINS P, 1987, NUCLEIC ACIDS RES, V15, P7369, DOI 10.1093/nar/15.18.7369; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1985, ARCH MICROBIOL, V142, P370, DOI 10.1007/BF00491906; MORI K, 1993, CELL, V74, P743; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARTALEDIS JA, 1993, P NATL ACAD SCI USA, V90, P5450, DOI 10.1073/pnas.90.12.5450; PIDOUX AL, 1992, EMBO J, V11, P1583, DOI 10.1002/j.1460-2075.1992.tb05203.x; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; ROKEACH LA, 1994, INFECT IMMUN, V62, P3696, DOI 10.1128/IAI.62.9.3696-3704.1994; ROKEACH LA, 1989, J BIOL CHEM, V264, P5024; ROKEACH LA, 1991, PROTEIN ENG, V4, P981, DOI 10.1093/protein/4.8.981; ROKEACH LA, 1991, J IMMUNOL, V147, P3031; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZ RT, 1977, J VIROL, V23, P217, DOI 10.1128/JVI.23.2.217-226.1977; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; Smith M.J., 1992, DNA Sequence, V2, P235, DOI 10.3109/10425179209020808; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; STEINER S, 1973, Cancer Research, V33, P2402; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; UNNASCH TR, 1988, J CLIN INVEST, V82, P262, DOI 10.1172/JCI113581; WADA I, 1991, J BIOL CHEM, V266, P19599; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145	63	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4845	4853		10.1074/jbc.270.9.4845	http://dx.doi.org/10.1074/jbc.270.9.4845			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876257	hybrid			2022-12-25	WOS:A1995QK08400094
J	ARAR, C; CARPENTIER, V; LECAER, JP; MONSIGNY, M; LEGRAND, A; ROCHE, AC				ARAR, C; CARPENTIER, V; LECAER, JP; MONSIGNY, M; LEGRAND, A; ROCHE, AC			ERGIC-53, A MEMBRANE-PROTEIN OF THE ENDOPLASMIC RETICULUM-GOLGI INTERMEDIATE COMPARTMENT, IS IDENTICAL TO MR60, AN INTRACELLULAR MANNOSE-SPECIFIC LECTIN OF MYELOMONOCYTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; EXPRESSION; RESOLUTION; RECEPTOR; SEQUENCE; COMPLEX; L-14-II; LACTOSE; ER	A mannose specific membrane lectin (MR60) isolated from human myelomonocytic HL60 cells by affinity chromatography is expressed in intracellular organelles of immature monocytes (Pimpaneau, V., Midoux, P., Monsigny, M., and Roche, A. C. (1991) Carbohydr. Res. 213, 95-108). It is not present at the cell surface and is immunochemically and structurally distinct from the M(r) 175,000 mannose receptor of mature macrophages. MR60 cDNA was isolated and characterized; on the basis of its sequence, MR60 is not related to any known mammalian lectins. Surprisingly, MR60 was found to be identical to ERGIC-53 (Schindler, R., Itin, C., Zerial, M., Lottspeich, F., and Hauri, H. P. (1993) Eur. J. Cell Biol. 61, 1-9), a type I integral membrane protein, defined as a marker of the intermediate compartment that recycles between the Golgi apparatus and endoplasmic reticulum; MR60/ERGIC-53 shares with VIP-36 significant homologies with leguminous plant lectins (Fiedler, K., and Simmons, R. (1994) Cell 77, 625-626). We extend these findings in evidencing a structural homology between MR60/ERGIC-53 and mammalian galectins (soluble beta galactose binding proteins). MR60/ERGIC-53 is the first lectin characterized as an endoplasmic reticulum-Golgi protein. Accordingly, this intracellular mannose binding protein could be involved in the traffic of glycoproteins between endoplasmic reticulum and the Golgi apparatus.	UNIV ORLEANS,BIOCHIM GLYCOCANJUGUES & LECTINES ENDOGENES LAB,F-45071 ORLEANS 02,FRANCE; CNRS,CTR BIOPHYS MOLEC,F-45071 ORLEANS 02,FRANCE; INST ALFRED H FESSARD,CNRS,F-91198 GIF SUR YVETTE,FRANCE	Universite de Orleans; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Monsigny, Michel/AAZ-6728-2020					AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; CARPENTIER V, 1994, GLYCOCONJUGATE J, V11, P333, DOI 10.1007/BF00731206; CARPENTIER V, 1992, THESIS U ORLEANS; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HIGGINS TJV, 1983, J BIOL CHEM, V258, P9544; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPPINCOTTSCHWA.J, 1990, CELL, V60, P821; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; PIMPANEAU V, 1991, CARBOHYD RES, V213, P95, DOI 10.1016/S0008-6215(00)90601-3; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; STAHL P, 1982, J CELL BIOL, V93, P49, DOI 10.1083/jcb.93.1.49	21	98	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3551	3553		10.1074/jbc.270.8.3551	http://dx.doi.org/10.1074/jbc.270.8.3551			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876089	hybrid			2022-12-25	WOS:A1995QH68800016
J	ARNER, ESJ; BJORNSTEDT, M; HOLMGREN, A				ARNER, ESJ; BJORNSTEDT, M; HOLMGREN, A			1-CHLORO-2,4-DINITROBENZENE IS AN IRREVERSIBLE INHIBITOR OF HUMAN THIOREDOXIN REDUCTASE - LOSS OF THIOREDOXIN DISULFIDE REDUCTASE-ACTIVITY IS ACCOMPANIED BY A LARGE INCREASE IN NADPH OXIDASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IMMUNOHISTOCHEMICAL LOCALIZATION; RAT-LIVER; KAPPA-B; PURIFICATION; INVOLVEMENT; GLUTATHIONE; SKIN; SELENODIGLUTATHIONE; MUTAGENESIS; ACTIVATION	Human thioredoxin reductase is a dimeric enzyme that catalyzes reduction of the disulfide in oxidized thioredoxin by a mechanism involving transfer of electrons from NADPH via FAD to a redox-active disulfide. 1-Chloro-2,4-dinitrobenzene (DNCB) is an alkylating agent used for depleting intracellular GSH and also showing distinct immunomodulatory properties, We have discovered that low concentrations of DNCB completely inactivated human or bovine thioredoxin reductase, with a second order rate constant in excess of 200 M(-1) S-1, which is almost 10,000-fold faster than alkylation of GSH. Total inactivation of 50 nM reduced thioredoxin reductase was obtained by 100 mu M DNCB after 5 min of incubation at 20 degrees C also in the presence of 1 mM GSH, The inhibition occurred with enzyme only in the presence of NADPH and persisted after removal of DNCB, suggesting alkylation of the active site nascent thiols as the mechanism of inactivation, Thioredoxin reductase modified by DNCB lacked reducing activity with oxidized thioredoxin, 5,5'-dithiobis-(2-nitrobenzoic acid), or sodium selenite, However, the DNCB-modified enzyme oxidized NADPH at a rate of 4.7 nmol/min/nmol of enzyme in the presence of atmospheric oxygen, This activity was not dependent on the presence of DNCB in solution and constituted a 34-fold increase of the inherent low NADPH oxidase activity of the native enzyme. DNCB is a specific inhibitor of mammalian thioredoxin reductase, which reacted 100-fold faster than glutathione reductase, The inactivation of the disulfide reducing activity of thioredoxin reductase and thioredoxin with a concomitant large increase of the NADPH oxidase activity producing reactive oxygen intermediates may mediate effects of DNCB on cells in vivo.	KAROLINSKA INST, MED NOBEL INST BIOCHEM, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet			Arnér, Elias/K-6737-2019; Arnér, Elias S.J./J-5832-2012	Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114				AHMED AR, 1983, ARCH DERMATOL, V119, P934, DOI 10.1001/archderm.119.11.934; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; CARLBERG I, 1975, J BIOL CHEM, V250, P5475; ERICSON ML, 1992, LYMPHOKINE CYTOK RES, V11, P201; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HANSSON HA, 1986, CELL TISSUE RES, V245, P189; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1988, PLASMA MEMBRANE OXID, P295; Ifversen Peter, 1993, Human Antibodies and Hybridomas, V4, P115; JAKOBSSON PJ, 1992, P NATL ACAD SCI USA, V89, P3521, DOI 10.1073/pnas.89.8.3521; KULKARNI AP, 1990, BIOCHEM BIOPH RES CO, V166, P417, DOI 10.1016/0006-291X(90)91961-Q; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; SCHALLREUTER KU, 1991, INT J CANCER, V48, P15; SCHALLREUTER KU, 1992, BIOCHIM BIOPHYS ACTA, V1160, P127, DOI 10.1016/0167-4838(92)90046-G; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHMIDT RJ, 1992, ARCH DERMATOL RES, V284, P400, DOI 10.1007/BF00372070; STRICKER RB, 1993, IMMUNOL LETT, V36, P1, DOI 10.1016/0165-2478(93)90060-F; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TONISSEN K, 1993, J BIOL CHEM, V268, P22485; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; YODOI J, 1991, ADV CANCER RES, V57, P381	33	155	157	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3479	3482		10.1074/jbc.270.8.3479	http://dx.doi.org/10.1074/jbc.270.8.3479			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876079	hybrid			2022-12-25	WOS:A1995QH68800005
J	GARTNER, F; VOOS, W; QUEROL, A; MILLER, BR; CRAIG, EA; CUMSKY, MG; PFANNER, N				GARTNER, F; VOOS, W; QUEROL, A; MILLER, BR; CRAIG, EA; CUMSKY, MG; PFANNER, N			MITOCHONDRIAL IMPORT OF SUBUNIT VA OF CYTOCHROME-C-OXIDASE CHARACTERIZED WITH YEAST MUTANTS - INDEPENDENCE FROM RECEPTORS, BUT REQUIREMENT FOR MATRIX HSP70 TRANSLOCASE FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-70; INTERMEMBRANE SPACE; INNER MEMBRANE; PRECURSOR PROTEINS; HEME LYASE; MOM19; PREPROTEINS; SEQUENCES; MECHANISM; PATHWAY	We have investigated the unusual import pathway of cytochrome c oxidase subunit Va (COXVa) into the yeast mitochondrial inner membrane by use of mutants that lack import receptors or are defective in matrix hsp70. (i) Mitochondria lacking the receptor MOM72 are not impaired in import of COXVa. Mitochondria lacking the main receptor MOM19 are moderately reduced in import of COXVa; this, however, is caused by a reduction of the inner membrane potential and not by a lack of specific receptor functions. (ii) Mitochondria defective in the unfoldase function of matrix hsp70 efficiently import COXVa, whereas mitochondria defective in the translocase function of the hsp70 are blocked in import of COXVa. A COXVa construct where the internal hydrophobic sorting signal is placed close to the presequence does not require either hsp70 function. These results demonstrate that import of COXVa does not require MOM19 or MOM72, but they unexpectedly reveal a strong dependence on the translocase function of matrix hsp70. Two important implications about the characterization of mitochondrial protein import in general are obtained. First, the interpretation of import results with mutants lacking MOM19 have to consider effects on the membrane potential. Second, the distance between a matrix targeting sequence and a hydrophobic sorting sequence within a precursor appears to determine if the inner membrane sorting machinery can substitute for the translocase function of hsp70 or not.	UNIV FREIBURG, INST BIOCHEM, D-79104 FREIBURG, GERMANY; UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA; UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA	University of Freiburg; University of California System; University of California Irvine; University of Wisconsin System; University of Wisconsin Madison			Querol, Amparo/H-3782-2012; Querol, Amparo/AAW-7469-2020; Pfanner, Nikolaus/AAV-7878-2021	Querol, Amparo/0000-0002-6478-6845; Querol, Amparo/0000-0002-6478-6845; 				BAKER A, 1987, P NATL ACAD SCI USA, V84, P3117, DOI 10.1073/pnas.84.10.3117; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; BRINKS S, 1994, J BIOL CHEM, V269, P16478; DAUM G, 1982, J BIOL CHEM, V257, P3028; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GLASER SM, 1990, MOL CELL BIOL, V10, P1873, DOI 10.1128/MCB.10.5.1873; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Horwich A, 1990, CURR OPIN CELL BIOL, V2, P625, DOI 10.1016/0955-0674(90)90103-L; JORDI W, 1992, EUR J BIOCHEM, V204, P841, DOI 10.1111/j.1432-1033.1992.tb16703.x; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; LITHGOW T, 1994, J BIOL CHEM, V269, P15325; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MILLER BR, 1993, J CELL BIOL, V121, P1021, DOI 10.1083/jcb.121.5.1021; MILLER BR, 1991, J CELL BIOL, V112, P833, DOI 10.1083/jcb.112.5.833; MOCZKO M, 1993, FEBS LETT, V326, P251, DOI 10.1016/0014-5793(93)81801-6; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119	37	67	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3788	3795						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876120				2022-12-25	WOS:A1995QH68800050
J	PILON, M; WIENK, H; SIPS, W; DESWAAF, M; TALBOOM, I; VANTHOF, R; DEKORTEKOOL, G; DEMEL, R; WEISBEEK, P; DEKRUIJFF, B				PILON, M; WIENK, H; SIPS, W; DESWAAF, M; TALBOOM, I; VANTHOF, R; DEKORTEKOOL, G; DEMEL, R; WEISBEEK, P; DEKRUIJFF, B			FUNCTIONAL DOMAINS OF THE FERREDOXIN TRANSIT SEQUENCE INVOLVED IN CHLOROPLAST IMPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEINS; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; SECONDARY STRUCTURE; ENVELOPE MEMBRANE; PEPTIDE; TRANSPORT; BINDING; MITOCHONDRIAL; TRANSLOCATION; CLEAVAGE	In order to analyze the information content of a chloroplast transit sequence, we have constructed and analyzed by in vitro assays seven substitution and 20 deletion mutants of the ferredoxin transit sequence. The N-terminal part and the C-terminal part are important for targeting, and in addition the C-terminal region is required for processing. A third region is important for translocation but not for the initial interaction with the envelope. A fourth region is less essential for in vitro import. Purified precursors were tested for their ability to compete for the in vitro import of radiolabeled wildtype precursor, which confirmed the important role in chloroplast recognition of both the N- and the C-terminal domain of the transit sequence. Monolayer experiments showed that the N terminus was mainly involved in the insertion into mono-galactolipid-containing lipid surfaces whereas the C terminus mediates the recognition of negatively charged lipids. A sequence comparison to other transit sequences suggests that the domain structure of the ferredoxin transit sequence can be extended to these sequences and thus reveals a general structural design of transit sequences.	UNIV UTRECHT,INST BIOMEMBRANES,3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,DEPT MEMBRANE BIOCHEM,3584 CH UTRECHT,NETHERLANDS; UNIV CALIF BERKELEY,DEPT MOLEC CELL BIOL,BERKELEY,CA 94720	Utrecht University; Utrecht University; University of California System; University of California Berkeley			Wienk, Hans/P-8929-2015	Wienk, Hans/0000-0001-9577-0064				ARCHER EK, 1993, PLANT MOL BIOL, V23, P1105, DOI 10.1007/BF00042345; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHUA NH, 1979, J CELL BIOL, V81, P461, DOI 10.1083/jcb.81.3.461; CHUPIN V, 1994, RECL TRAV CHIM PAY B, V113, P237; CLARK SE, 1991, J CELL BIOL, V114, P681, DOI 10.1083/jcb.114.4.681; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DEBOER D, 1991, EMBO J, V10, P2765, DOI 10.1002/j.1460-2075.1991.tb07825.x; DEKRUIJFF B, 1994, FEBS LETT, V346, P78, DOI 10.1016/0014-5793(94)00404-8; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; DOUCE R, 1990, ANNU REV CELL BIOL, V6, P173, DOI 10.1146/annurev.cb.06.110190.001133; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HORNIAK L, 1993, FEBS LETT, V334, P241, DOI 10.1016/0014-5793(93)81720-K; HUANG JT, 1990, PLANT CELL, V2, P1249, DOI 10.1105/tpc.2.12.1249; KARLINNEUMANN GA, 1986, EMBO J, V5, P9, DOI 10.1002/j.1460-2075.1986.tb04170.x; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHENY EA, 1994, PLANT CELL, V6, P427, DOI 10.2307/3869762; Margulis L, 1970, ORIGIN EUKARYOTIC CE; OBLONG JE, 1992, EMBO J, V11, P4401, DOI 10.1002/j.1460-2075.1992.tb05540.x; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; OSTREM JA, 1989, J BIOL CHEM, V264, P3662; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PILON M, 1990, J BIOL CHEM, V265, P3358; PILON M, 1992, J BIOL CHEM, V267, P2548; PILON M, 1992, J BIOL CHEM, V267, P19907; RAVEN PH, 1970, SCIENCE, V169, P641, DOI 10.1126/science.169.3946.641; REISS B, 1987, MOL GEN GENET, V209, P116, DOI 10.1007/BF00329845; REISS B, 1989, P NATL ACAD SCI USA, V86, P886, DOI 10.1073/pnas.86.3.886; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; Sambrook J., 1989, MOL CLONING; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1989, MOL GEN GENET, V216, P178, DOI 10.1007/BF00332249; SMEEKENS S, 1987, PLANT MOL BIOL, V9, P377, DOI 10.1007/BF00014912; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEG SM, 1989, J BIOL CHEM, V264, P6730; VANDEENEN LLM, 1964, ADV LIPID RES, V2, P167; VANTHOF R, 1991, FEBS LETT, V291, P350, DOI 10.1016/0014-5793(91)81318-3; VANTHOF R, 1993, J BIOL CHEM, V268, P4037; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1991, PLANT MOL BIOL REP, V9, P104	53	77	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3882	3893		10.1074/jbc.270.8.3882	http://dx.doi.org/10.1074/jbc.270.8.3882			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876133	hybrid			2022-12-25	WOS:A1995QH68800064
J	ZOLOTARJOVA, N; PERIYASAMY, SM; HUANG, WH; ASKARI, A				ZOLOTARJOVA, N; PERIYASAMY, SM; HUANG, WH; ASKARI, A			FUNCTIONAL COUPLING OF PHOSPHORYLATION AND NUCLEOTIDE-BINDING SITES IN THE PROTEOLYTIC FRAGMENTS OF NA+/K+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; K+)-DEPENDENT ADENOSINE-TRIPHOSPHATASE; ISOTHIOCYANATE REACTIVE SITE; AMINO-ACID-SEQUENCE; ALPHA-SUBUNIT; FLUORESCEIN ISOTHIOCYANATE; ACTIVE-SITE; CHYMOTRYPTIC CLEAVAGE; INORGANIC-PHOSPHATE; LIGAND-BINDING	Cleavage of the alpha-subunit of Na+/K+-ATPase by trypsin at Arg(438)-Ala(439) causes enzyme inhibition which has been suggested to be due to altered alignment of phosphorylation site on the 48-kDa N-terminal fragment with nucleotide binding site on the 64-kDa C-terminal fragment. Our aims were to test this hypothesis and to assess the effect of the cleavage on the enzyme's two ATP sites. Na+-dependent phosphorylation of the partially cleaved enzyme by ATP showed that K-0.5 values of ATP for phosphorylations of intact alpha and 48-kDa peptide were the same (0.4 mu M). Unchanged interactions among the residues across the cleavage site were also indicated by data showing that reaction of fluorescein isothiocyanate with the 64-kDa peptide blocked phosphorylation of the 48-kDa peptide by ATP. ATP is known to block the reaction of fluorescein isothiocyanate with the enzyme, Experiments on the partially cleaved enzyme showed that K-0.5 of ATP for protection of alpha was 30-60 mu M, and the value for the protection of interacting 48-kDa and 64-kDa peptides was 1-3 mM. Evidently, while the cleavage does not affect the high affinity catalytic site, it disrupts the allosteric low affinity ATP site. Experiments on reconstituted preparations showed that the cleavage abolished ATP-dependent Na+/K+ exchange, P-i + ATP-dependent Rb+/Rb+ exchange, ATP-dependent Na+/Na+ exchange, and ADP + ATP-dependent Na+/Na+ exchange activities, Selective disruption of the low affinity ATP site accounts for the inhibitions of all functions involving K+(Rb+), based on the established role of this site in the control of K+ access channels. Cleavage-induced inhibitions of other activities, however, suggest additional roles of the low affinity ATP site in the reaction cycle.			ZOLOTARJOVA, N (corresponding author), MED COLL OHIO, DEPT PHARMACOL, POB 10008, TOLEDO, OH 43699 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT AJ, 1991, BIOCHEMISTRY-US, V30, P1692, DOI 10.1021/bi00220a035; ASKARI A, 1984, J BIOL CHEM, V259, P4169; ASKARI A, 1988, J BIOL CHEM, V263, P235; ASKARI A, 1983, J BIOL CHEM, V258, P3453; Askari A, 1988, Prog Clin Biol Res, V268A, P149; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BLOSTEIN R, 1975, J BIOL CHEM, V250, P6118; CAMPOS M, 1994, J BIOL CHEM, V269, P18028; CARILLI CT, 1982, J BIOL CHEM, V257, P5601; CORNELIUS F, 1987, BIOCHIM BIOPHYS ACTA, V904, P353, DOI 10.1016/0005-2736(87)90385-3; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1071, P19, DOI 10.1016/0304-4157(91)90011-K; CORNELIUS F, 1985, BIOCHIM BIOPHYS ACTA, V818, P211, DOI 10.1016/0005-2736(85)90572-3; Dzhandzhugazyan K N, 1988, Prog Clin Biol Res, V268A, P181; ESMANN M, 1988, METHOD ENZYMOL, V156, P72; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; GARNER MH, 1987, DIABETES, V36, P716, DOI 10.2337/diabetes.36.6.716; HASENAUER J, 1993, J BIOL CHEM, V268, P3289; HENDERSON GR, 1977, ARCH BIOCHEM BIOPHYS, V182, P221, DOI 10.1016/0003-9861(77)90302-2; HUANG WH, 1990, BIOCHIM BIOPHYS ACTA, V1030, P65, DOI 10.1016/0005-2736(90)90239-K; JORGENSEN PL, 1977, BIOCHIM BIOPHYS ACTA, V466, P97, DOI 10.1016/0005-2736(77)90211-5; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1982, ANN NY ACAD SCI, V402, P207, DOI 10.1111/j.1749-6632.1982.tb25743.x; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; KAKAR SS, 1985, BIOCHEM INT, V11, P611; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KENNEDY BG, 1986, J GEN PHYSIOL, V87, P47, DOI 10.1085/jgp.87.1.47; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NORBY JG, 1983, J GEN PHYSIOL, V82, P725, DOI 10.1085/jgp.82.6.725; NORBY JG, 1988, METHOD ENZYMOL, V156, P191; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PELUFFO RD, 1992, J BIOL CHEM, V267, P6596; PELUFFO RD, 1994, J BIOL CHEM, V269, P1051; PLESNER IW, 1985, BIOCHIM BIOPHYS ACTA, V818, P235, DOI 10.1016/0005-2736(85)90564-4; PLESNER IW, 1987, BIOPHYS J, V51, P69, DOI 10.1016/S0006-3495(87)83312-X; POST RL, 1972, J BIOL CHEM, V247, P6530; ROBINSON JD, 1976, BIOCHIM BIOPHYS ACTA, V440, P711, DOI 10.1016/0005-2728(76)90053-0; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SEN PC, 1981, ARCH BIOCHEM BIOPHYS, V211, P652, DOI 10.1016/0003-9861(81)90501-4; TRAN CM, 1994, J BIOL CHEM, V269, P6558; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70; WINTER CG, 1978, BIOCHEM BIOPH RES CO, V84, P474, DOI 10.1016/0006-291X(78)90193-6; XIE ZJ, 1994, SODIUM PUMP, P49; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010; YODA A, 1984, BIOCHIM BIOPHYS ACTA, V778, P332, DOI 10.1016/0005-2736(84)90377-8	47	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3989	3995		10.1074/jbc.270.8.3989	http://dx.doi.org/10.1074/jbc.270.8.3989			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876146	hybrid			2022-12-25	WOS:A1995QH68800079
J	TILBROOK, PA; PATERSON, HF; MARSHALL, CJ				TILBROOK, PA; PATERSON, HF; MARSHALL, CJ			REVERSION OF A HUMAN TUMOR-CELL LINE CONTAINING ONCOGENIC P21(RAS) IS ASSOCIATED WITH A DEFECT IN THE POSTTRANSLATIONAL PROCESSING OF THE RAS PROTEIN	ONCOGENE			English	Note						RAS; ISOPRENYLATION; POSTTRANSLATIONAL MODIFICATIONS; REVERTANT	P21RAS ONCOPROTEIN; PLASMA-MEMBRANE; TRANSFORMATION; PRODUCT; SIGNAL; KINASE; MOTIF; ACID; CAAX	Correct post-translational modifications of the ras proteins are essential for their membrane localisation and functioning. The flat revertant cell lines 1aCB and 8b, derived from the human bladder carcinoma cell line EJ, contain the transforming gene V12Ha-ras and are resistant to retransformation by vas protein or DNA, but still do require the presence of ras for proliferation. Both revertant cell lines demonstrated reduced levels of membrane associated p21(ras) when compared to their parental EJ cell lines. This reduced level in 1aCB was reflected by an increase in nuclear associated p21(ras), as seen by immunofluorescence of endogenous and introduced ras. In addition, 1aCB had a reduced ratio of ras in the detergent to aqueous phases after triton X114 partitioning, suggesting a defect in Step I processing of the p21(ras) in the cell line. This was not however due to defects in the Step I enzymes farnesyltransferase or carboxymethyltransferase whose activities were not reduced.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOSS JL, 1988, MUTAT RES, V195, P255; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P1167; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, SCIENCE, V220, P1175, DOI 10.1126/science.6304875; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1986, J BIOL CHEM, V261, P963; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HUANG S, 1991, ONCOGENE, V6, P1211; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MORRIS JDH, 1989, ONCOGENE, V4, P27; PATERSON HF, 1989, CIBA F S, V142, P135; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHULZ TF, 1988, IMMUNOLOGY, V64, P581; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x	25	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					805	809						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862461				2022-12-25	WOS:A1995QH61200024
J	DIEHL, JA; TONG, W; SUN, G; HANNINK, M				DIEHL, JA; TONG, W; SUN, G; HANNINK, M			TUMOR NECROSIS FACTOR-ALPHA-DEPENDENT ACTIVATION OF A RELA HOMODIMER IN ASTROCYTES - INCREASED PHOSPHORYLATION OF RELA AND MAD-3 PRECEDE ACTIVATION OF RELA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; PROTEIN; KINASE; INHIBITOR; INVITRO; BETA	Rel proteins are important intracellular mediators of cytokine-induced signal transduction. To understand how cytokines affect different cell populations in the brain, we have characterized Rel activation in astrocytes. A RelA homodimer is uniquely activated in cytokine-stimulated astrocytes. Cytokine-dependent phosphorylation of the RelA inhibitor MAD-3 occurred on discrete peptides prior to its dissociation from RelA. A transient hyperphosphorylation of RelA was also induced. Antioxidant treatment inhibited both RelA activation and phosphorylation of the RelA(.)MAD-3 complex, These results demonstrate that cytokine-dependent activation of the RelA homodimer involves phosphorylation of both RelA and its associated inhibitor. The sole activation of a RelA homodimer suggests that cytokines will activate a unique set of Rel-regulated genes in astrocytes.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia					NATIONAL CANCER INSTITUTE [R29CA055027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030178] Funding Source: NIH RePORTER; NCI NIH HHS [CA55027] Funding Source: Medline; NINDS NIH HHS [NS30178] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BAUERLE PA, 1988, CELL, V53, P211; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HERTZ L, 1990, IMMUNOL TODAY, V8, P265; INTEBI AD, 1990, NEUROSCIENCE, V34, P545, DOI 10.1016/0306-4522(90)90163-X; KALTSCHMIDT C, 1994, MOL CELL BIOL, V11, P3981; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LINK E, 1992, J BIOL CHEM, V267, P239; Maniatis T., 1982, MOL CLONING; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; RADANY EH, 1992, P NATL ACAD SCI USA, V89, P6467, DOI 10.1073/pnas.89.14.6467; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943	24	46	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2703	2707		10.1074/jbc.270.6.2703	http://dx.doi.org/10.1074/jbc.270.6.2703			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852340	hybrid			2022-12-25	WOS:A1995QF53500048
J	MCMILLAN, NAJ; CARPICK, BW; HOLLIS, B; TOONE, WM; ZAMANIANDARYOUSH, M; WILLIAMS, BRG				MCMILLAN, NAJ; CARPICK, BW; HOLLIS, B; TOONE, WM; ZAMANIANDARYOUSH, M; WILLIAMS, BRG			MUTATIONAL ANALYSIS OF THE DOUBLE-STRANDED-RNA (DSRNA) BINDING DOMAIN OF THE DSRNA-ACTIVATED PROTEIN-KINASE, PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P68 KINASE; INTERFERON ACTION; ESCHERICHIA-COLI; GENE; IDENTIFICATION; EXPRESSION; PHOSPHORYLATION; MECHANISM; MUTAGENESIS; GROWTH	The interferon-induced, double-stranded RNA (dsRNA)-dependent protein kinase, PKR, is an inhibitor of translation and has antiviral, antiproliferative, and antitumor properties, Previously, the dsRNA binding domain had been located within the N-terminal region of PKR and subsequently shown to include two nearly identical domains comprising residues 55-75 and 145-166. We have undertaken both random and site-directed, alanine-scanning mutagenesis in order to investigate the contribution of individual amino acids within these domains to dsRNA binding, Here we identify 2 residues that were absolutely required for dsRNA binding, glycine 57 and lysine 60, Mutation of 2 other residues within the domain (lysine 64 and leucine 75) resulted in less than 10% binding (compared to wild type), We have also identified a number of other residues that influence dsRNA binding to varying degrees, Mutants that were unable to bind dsRNA were not active in vitro and possessed no antiproliferative activity in vivo, However, dsRNA binding mutants were partially transdominant over wild type PKR in mammalian cells, suggesting that binding of dsRNA activator is not the mechanism responsible for the phenotype of PKR mutants.	CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			McMillan, Nigel/AAQ-5416-2021; Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151; McMillan, Nigel/0000-0002-9471-1406	PHS HHS [R01 A1 34039-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BUSBY S, 1982, J MOL BIOL, V154, P197, DOI 10.1016/0022-2836(82)90060-2; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LUNDBLAD V, 1994, CURRENT PROTOCOLS MO; MAITRA RK, 1994, VIROLOGY, V204, P823, DOI 10.1006/viro.1994.1601; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MARCH PE, 1985, NUCLEIC ACIDS RES, V13, P4677, DOI 10.1093/nar/13.13.4677; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1994, J BIOL CHEM, V269, P18593; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837	38	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2601	2606		10.1074/jbc.270.6.2601	http://dx.doi.org/10.1074/jbc.270.6.2601			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852324	hybrid			2022-12-25	WOS:A1995QF53500032
J	MUKHOPADHYAY, B; PURWANTINI, E; PIHL, TD; REEVE, JN; DANIELS, L				MUKHOPADHYAY, B; PURWANTINI, E; PIHL, TD; REEVE, JN; DANIELS, L			CLONING, SEQUENCING, AND TRANSCRIPTIONAL ANALYSIS OF THE COENZYME F-420-DEPENDENT METHYLENE-5,6,7,8-TETRAHYDROMETHANOPTERIN DEHYDROGENASE GENE FROM METHANOBACTERIUM-THERMOAUTOTROPHICUM STRAIN MARBURG AND FUNCTIONAL EXPRESSION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; DELTA-H; N-10-METHYLENETETRAHYDROMETHANOPTERIN DEHYDROGENASE; METHYLENETETRAHYDROMETHANOPTERIN DEHYDROGENASE; METHANOGENIC BACTERIA; M REDUCTASE; HYDROGENASE; RNA; SUBUNITS; RELATEDNESS	Two methylenetetrahydromethanopterin dehydrogenases have been purified from Methanobacterium thermoautotrophicum strain Marburg: one (MTD) is coenzyme F-420-dependent and oxygen-stable (Mukhopadhyay, B., and Daniels, L. (1989) Can. J. Microbiol. 35, 499-507), and the other (MTH) is coenzyme F-420-independent (or hydrogenase-type) and oxygen-sensitive (Zirngibl, C., Hedderich, R., and Thauer, R. K. (1990) FEES Lett. 261, 112-116). Based on the NH2-terminal sequence of MTD, a 36-mer oligonucleotide was designed and used to identify and clone a 6.1-kilobase pair EcoRI fragment of M. thermoautotrophicum DNA. Sequencing of this fragment revealed an 825-base pair (bp) MTD encoding gene (mtd), which was expressed in Escherichia coli yielding an enzyme that, like the native enzyme, was oxygen-stable, strictly dependent on coenzyme F-420 thermostable, thermophilic, and exhibited maximum activitythermostable, thermophilic, and exhibited maximum activity at an acidic pH. The amino acid sequence predicts that MTD is a hydrophobic and acidic protein with no identifiable homology to MTH (von Bunau, R., Zirngibl, C., Thauer, R. K., and Klein, A. (1991) Eur. J. Biochem. 202, 1205-1208), but comparisons with coenzyme F-420 utilizing enzymes revealed a conserved region at the NH2 terminus of MTD that could correspond to the ability to interact with coenzyme F-420. The mtd transcript was similar to 900 nucleotides long and initiated 8 bp upstream of the translation initiation codon and 22 bp downstream from an archaeal promoter sequence. The mtd coding sequence was followed by several poly(dT) sequences and an inverted repeat that could be transcription termination signals.	UNIV IOWA, DEPT MICROBIOL, IOWA CITY, IA 52242 USA; OHIO STATE UNIV, DEPT MICROBIOL, COLUMBUS, OH 43210 USA	University of Iowa; University System of Ohio; Ohio State University				Mukhopadhyay, Biswarup/0000-0003-0736-0298				ALEX LA, 1990, BIOCHEMISTRY-US, V29, P7237, DOI 10.1021/bi00483a011; BERGHOFER B, 1988, NUCLEIC ACIDS RES, V16, P8113, DOI 10.1093/nar/16.16.8113; BOKRANZ M, 1988, J BACTERIOL, V170, P568, DOI 10.1128/jb.170.2.568-577.1988; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDIS A, 1981, ZBL BAKT MIK HYG I C, V2, P311, DOI 10.1016/S0721-9571(81)80023-3; CLEMENTS AP, 1992, J BACTERIOL, V174, P5244, DOI 10.1128/JB.174.16.5244-5250.1992; CRAM DS, 1987, P NATL ACAD SCI USA, V84, P3992, DOI 10.1073/pnas.84.12.3992; DANIELS L, 1984, BIOTECHNOL BIOENG, V14, P199; DASSARMA S, 1984, P NATL ACAD SCI-BIOL, V81, P125, DOI 10.1073/pnas.81.1.125; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; DIMARCO AA, 1990, J BIOL CHEM, V265, P472; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P663; EKER APM, 1990, J BIOL CHEM, V265, P8009; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; ENSSLE M, 1991, ARCH MICROBIOL, V155, P483, DOI 10.1007/BF00244966; HARTZELL PL, 1985, THESIS U ILLINOIS UR; HENNIGAN AN, 1994, MOL MICROBIOL, V11, P655, DOI 10.1111/j.1365-2958.1994.tb00344.x; JENAL U, 1991, J BIOL CHEM, V266, P10570; KALMOKOFF ML, 1991, J BACTERIOL, V173, P7113, DOI 10.1128/jb.173.22.7113-7125.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEAKIN SA, 1991, J MICROBIOL METH, V14, P119, DOI 10.1016/0167-7012(91)90041-N; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; MUKHOPADHYAY B, 1989, CAN J MICROBIOL, V35, P499, DOI 10.1139/m89-077; MUKHOPADHYAY B, 1993, THESIS U IOWA IOWA C; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; OSTERGAARD L, 1987, SYST APPL MICROBIOL, V9, P199; PIHL TD, 1994, J BACTERIOL, V176, P6384, DOI 10.1128/jb.176.20.6384-6391.1994; PURWANTINI E, 1992, ANAL BIOCHEM, V205, P342, DOI 10.1016/0003-2697(92)90446-E; REEVE JN, 1989, P NATL ACAD SCI USA, V86, P3031, DOI 10.1073/pnas.86.9.3031; REEVE JN, 1992, ANNU REV MICROBIOL, V46, P165; Sambrook J, 1989, MOL CLONING LABORATO; SCHWORER B, 1991, ARCH MICROBIOL, V155, P459, DOI 10.1007/BF00244962; SHUBER AP, 1986, J BIOL CHEM, V261, P2942; TAKAO M, 1991, J BIOL CHEM, V266, P14151; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONBUNAU R, 1991, EUR J BIOCHEM, V202, P1205; YASUI A, 1988, NUCLEIC ACIDS RES, V16, P447; ZIRNGIBL C, 1990, FEBS LETT, V261, P112, DOI 10.1016/0014-5793(90)80649-4; ZIRNGIBL C, 1992, EUR J BIOCHEM, V208, P511, DOI 10.1111/j.1432-1033.1992.tb17215.x	39	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2827	2832		10.1074/jbc.270.6.2827	http://dx.doi.org/10.1074/jbc.270.6.2827			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852356	hybrid			2022-12-25	WOS:A1995QF53500066
J	VOGEL, LB; FUJITA, DJ				VOGEL, LB; FUJITA, DJ			P70 PHOSPHORYLATION AND BINDING TO P56(LCK) IS AN EARLY EVENT IN INTERLEUKIN-2-INDUCED ONSET OF CELL-CYCLE PROGRESSION IN T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAINS; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; SRC-FAMILY; RECEPTOR; PROTEIN; ACTIVATION; CD4; EXPRESSION; KINASES	The cytoplasmic protein tyrosine kinase p56(lck) has been implicated as an effector of interleukin-2-induced cell division in T-lymphocytes, but Little is known about physiological substrates for p56(lck) during these events. We have used p56(lck) fusion proteins to identify potential cytoplasmic signal transduction proteins that bind to p56(lck) in mitotically activated human peripheral blood lymphocytes and in constitutively dividing leukemic T-cell lines. In peripheral blood lymphocytes, we have observed an interleukin-2-dependent tyrosine phosphorylation of a 70-kDa protein and binding of tyrosine phosphorylated p70 to the SH2 domain of p56(lck). A 70-kDa phosphoprotein was also observed to constitutively bind p56(lck) in leukemic T-cells. Affinity purification of p56(lck)-associated p70 and sequencing of proteolytic fragments revealed identity to a 62-kDa protein that has been identified as a ras-GTPase activating protein. These results demonstrate a stimulation-dependent tyrosine phosphorylation of p70 and its interaction with p56(lck) and may provide a link between p56(lck) and GTPase-mediated signal transduction pathways in activated T-lymphocytes.	UNIV CALGARY, MED CTR, CALGARY, AB T2N 4N1, CANADA	University of Calgary	VOGEL, LB (corresponding author), CNRS, BIOL STN, F-29680 ROSCOFF, FRANCE.							BIERER BE, 1989, IMMUNOL REV, V111, P267, DOI 10.1111/j.1600-065X.1989.tb00549.x; BOLEN JB, 1991, ADV CANCER RES, V57, P103; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUTIERREZ C, 1979, J IMMUNOL METHODS, V29, P57, DOI 10.1016/0022-1759(79)90125-X; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; JANEWAY CA, 1989, IMMUNOL TODAY, V10, P234, DOI 10.1016/0167-5699(89)90260-0; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MILLS GB, 1990, J BIOL CHEM, V265, P3561; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH KA, 1989, CANCER CELL, V3, P205; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	32	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2506	2511		10.1074/jbc.270.6.2506	http://dx.doi.org/10.1074/jbc.270.6.2506			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852312	hybrid			2022-12-25	WOS:A1995QF53500019
J	ENG, C; SMITH, DP; MULLIGAN, LM; HEALEY, CS; ZVELEBIL, MJ; STONEHOUSE, TJ; PONDER, MA; JACKSON, CE; WATERFIELD, MD; PONDER, BAJ				ENG, C; SMITH, DP; MULLIGAN, LM; HEALEY, CS; ZVELEBIL, MJ; STONEHOUSE, TJ; PONDER, MA; JACKSON, CE; WATERFIELD, MD; PONDER, BAJ			A NOVEL POINT MUTATION IN THE TYROSINE KINASE DOMAIN OF THE RET PROTOONCOGENE IN SPORADIC MEDULLARY-THYROID CARCINOMA AND IN A FAMILY WITH FMTC	ONCOGENE			English	Article						MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; RECEPTOR TYROSINE KINASE GENE	MULTIPLE ENDOCRINE NEOPLASIA; PROTOONCOGENE; FEATURES	Germline mutations within one of six codons of the RET proto-oncogene account for the majority of cases of multiple endocrine neoplasia (MEN) type 2A and type 2B and familial medullary thyroid carcinoma (FMTC). MEN 2A and FMTC mutations characterised thus far occur exclusively in the cysteine-rich domain of the extracellular region of RET. We now report a missense mutation in the intracellular tyrosine kinase domain of RET in the germline of a family with FMTC that does not have a cysteine codon mutation. In this family, the mutation, which alters GAG (GIu) to GAC (Asp) at codon 768, segregates with the FMTC phenotype. The same mutation was also detected in sporadic MTC but not in corresponding constitutional DNA, confirming that it is likely to be of pathological significance rather than a rare polymorphism.	UNIV CAMBRIDGE, DEPT PATHOL, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1QP, ENGLAND; HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DEPT MED, DIV MED ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DEPT MED, DIV CANC EPIDEMIOL & CONTROL, BOSTON, MA 02115 USA; QUEENS UNIV, DEPT PEDIAT, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; HENRY FORD HOSP, DEPT MED, DETROIT, MI 48202 USA; UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON, ENGLAND	University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Queens University - Canada; Queens University - Canada; Ludwig Institute for Cancer Research; Henry Ford Health System; Henry Ford Hospital; University of London; University College London				Zvelebil, Marketa/0000-0001-8018-5591; Eng, Charis/0000-0002-3693-5145				CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, IN PRESS GENES CHROM; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JACKSON C E, 1986, Materia Medica Polona, V18, P59; JACKSON CE, 1973, ANN INTERN MED, V78, P845, DOI 10.7326/0003-4819-78-6-845; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SUGAYA R, 1994, MECH DEVELOP, V45, P139, DOI 10.1016/0925-4773(94)90027-2; WOLFE HJ, 1973, NEW ENGL J MED, V289, P437, DOI 10.1056/NEJM197308302890901	22	253	257	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					509	513						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845675				2022-12-25	WOS:A1995QF64800011
J	PETERSON, SR; JESCH, SA; CHAMBERLIN, TN; DVIR, A; RABINDRAN, SK; WU, C; DYNAN, WS				PETERSON, SR; JESCH, SA; CHAMBERLIN, TN; DVIR, A; RABINDRAN, SK; WU, C; DYNAN, WS			STIMULATION OF THE DNA-DEPENDENT PROTEIN-KINASE BY RNA-POLYMERASE-II TRANSCRIPTIONAL ACTIVATOR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL TRANSACTIVATION DOMAIN; HEAT-SHOCK PROTEIN; GAL4 DERIVATIVES; GENE-TRANSCRIPTION; BINDING ACTIVITY; KU-AUTOANTIGEN; CELL EXTRACTS; PHOSPHORYLATION; TEMPLATE; INVITRO	The DNA dependent protein kinase (DNA-PK) phosphorylates RNA polymerase II and a number of transcription factors. We now show that the activity of DNA-PK is directly stimulated by certain transcriptional activator proteins, including the human heat shock transcription factor 1 (HSF1) and a transcriptionally active N-terminal 147 amino acid GAL4 derivative. Stimulation of DNA-PK activity required specific sequences in the activator proteins outside the minimal DNA binding domains. The stimulation of DNA-PK activity also required DNA and was greater with DNA containing relevant activator binding sites. Comparison of different HSF binding fragments showed that optimal stimulation occurred when two HSF binding sites were present. Stimulation with HSF and GALE was synergistic with Ku protein, another regulator of DNA-PK activity. DNA-PK is tightly associated with the transcriptional template, and an increase in its activity could potentially influence transcription through the phosphorylation of proteins associated with the transcription complex.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; NCI,BIOCHEM LAB,BETHESDA,MD 20892	University of Colorado System; University of Colorado Boulder; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Dynan, William/0000-0002-4045-5662	NIGMS NIH HHS [GM 35866] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035866] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; DYNAN WS, 1987, GENETIC ENG PRINCIPL, V9, P75; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IIJIMA S, 1992, EUR J BIOCHEM, V206, P595, DOI 10.1111/j.1432-1033.1992.tb16964.x; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEGAGNEUX V, 1990, EUR J BIOCHEM, V193, P121, DOI 10.1111/j.1432-1033.1990.tb19312.x; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LIU SH, 1993, J BIOL CHEM, V268, P21147; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PETERSON SR, 1993, THESIS U COLORADO; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	43	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1449	1454		10.1074/jbc.270.3.1449	http://dx.doi.org/10.1074/jbc.270.3.1449			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836414	hybrid			2022-12-25	WOS:A1995QB15600071
J	URADE, Y; TANAKA, T; EGUCHI, N; KIKUCHI, M; KIMURA, H; TOH, H; HAYAISHI, O				URADE, Y; TANAKA, T; EGUCHI, N; KIKUCHI, M; KIMURA, H; TOH, H; HAYAISHI, O			STRUCTURAL-SIGNIFICANCE AND FUNCTIONAL-SIGNIFICANCE OF CYSTEINE RESIDUES OF GLUTATHIONE-INDEPENDENT PROSTAGLANDIN-D SYNTHASE - IDENTIFICATION OF CYS(65) AS AN ESSENTIAL THIOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING-PROTEIN; VESICULAR GLAND MICROSOMES; BOVINE BETA-LACTOGLOBULIN; RAT-BRAIN; D SYNTHETASE; CEREBROSPINAL-FLUID; CHOROID-PLEXUS; PURIFICATION; SLEEP; CDNA	Glutathione-independent prostaglandin D synthase in rat brain is composed of 189 amino acid residues and catalyzes the isomerization of prostaglandin H-2,to prostaglandin D-2, an endogenous sleep-promoting substance. This enzyme is the only enzyme among members of the lipocalin superfamily composed of various secretory lipophilic ligand-carrier proteins and is recently identified to be a beta-trace protein, a major constituent of human cerebrospinal fluid. We expressed the active enzyme in Escherichia coli and then systematically substituted all cysteine residues of the Delta 1-29 enzyme at positions of 65, 89, and 186 with alanine or serine. The parent and mutant enzymes were purified to apparent homogeneity with a recovery of similar to 30% by chromatography with Sephadex G-50 and S-Sepharose, by which all the enzymes showed identical elution profiles. The purified enzymes, irrespective of the mutation, showed almost the same circular dichroism spectral characteristics as displayed by a highly ordered beta-structure. The recombinant enzymes containing Cys(65) showed the activity comparable with that of the enzyme purified hom rat brain (similar to 3 mu mol/min/mg of protein) in the presence, but not in the absence, of sulfhydryl compounds. However, all of the single, double, and triple mutants without Cys(65) lost the enzyme activity. The purified Delta 1-29 Ala(89,186) enzyme was inactivated reversibly by conjugation with glutathione at Cys(65) and irreversibly by the stoichiometric chemical modification with N-ethylmaleimide. These results indicate that Cys(65) is an essential thiol of the enzyme and that both the intrinsic and extrinsic sulfhydryl groups are necessary for nonoxidative rearrangement of 9,11-endoperoxide of prostaglandin H-2 to produce prostaglandin D-2 catalyzed by the enzyme.	OSAKA BIOSCI INST,DEPT MOLEC BEHAV BIOL,SUITA,OSAKA 565,JAPAN; PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; KYUSHU INST TECHNOL,IIZUKA,FUKUOKA 820,JAPAN	Kyushu Institute of Technology								ACHEN MG, 1992, J BIOL CHEM, V267, P23170; ALEXANDER LJ, 1989, NUCLEIC ACIDS RES, V17, P6739, DOI 10.1093/nar/17.16.6739; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERGER MP, 1991, COMPUT APPL BIOSCI, V7, P479; COLANTUONI V, 1983, NUCLEIC ACIDS RES, V11, P7769, DOI 10.1093/nar/11.22.7769; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FENG DF, 1987, J MOL BIOL, V195, P351; HAYAISHI O, 1991, FASEB J, V5, P2575, DOI 10.1096/fasebj.5.11.1907936; HAYAISHI O, 1993, J LIPID MEDIATOR, V6, P429; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOFFMANN A, 1993, J NEUROCHEM, V61, P451; IGARASHI M, 1992, P NATL ACAD SCI USA, V89, P5376, DOI 10.1073/pnas.89.12.5376; ISLAM F, 1991, ARCH BIOCHEM BIOPHYS, V289, P161, DOI 10.1016/0003-9861(91)90456-S; ITO S, 1989, PROSTAG LEUKOTR ESS, V37, P219, DOI 10.1016/0952-3278(89)90033-1; JOHNSON CW, 1990, PROTEIN-STRUCT FUNCT, V7, P205; LANDS W, 1971, ANN NY ACAD SCI, V180, P107, DOI 10.1111/j.1749-6632.1971.tb53190.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUMURA H, 1991, P NATL ACAD SCI USA, V88, P9046, DOI 10.1073/pnas.88.20.9046; MATSUMURA H, 1994, IN PRESS P NATL ACAD, V91; MCLACHLAN AD, 1971, J MOL BIOL, V61, P409, DOI 10.1016/0022-2836(71)90390-1; MONACO HL, 1987, J MOL BIOL, V197, P695, DOI 10.1016/0022-2836(87)90476-1; MOONEN P, 1982, METHOD ENZYMOL, V86, P84; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; OGINO N, 1977, J BIOL CHEM, V252, P890; PEITSCH MC, 1991, TRENDS BIOCHEM SCI, V16, P363, DOI 10.1016/0968-0004(91)90149-P; PENTREATH VW, 1990, T ROY SOC TROP MED H, V84, P795, DOI 10.1016/0035-9203(90)90085-S; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANAKA Y, 1987, J BIOL CHEM, V262, P1374; Toh H, 1992, Mediators Inflamm, V1, P223, DOI 10.1155/S0962935192000346; TOWNEND R, 1967, J BIOL CHEM, V242, P4538; ULLRICH V, 1994, ANGEW CHEM INT EDIT, V33, P1911, DOI 10.1002/anie.199419111; URADE Y, 1989, J BIOL CHEM, V264, P1041; URADE Y, 1987, J BIOL CHEM, V262, P15132; URADE Y, 1993, P NATL ACAD SCI USA, V90, P9070, DOI 10.1073/pnas.90.19.9070; URADE Y, 1985, J BIOL CHEM, V260, P2410; URADE Y, 1994, IN PRESS J LIPID MED; WATANABE K, 1994, BIOCHEM BIOPH RES CO, V203, P1110, DOI 10.1006/bbrc.1994.2297; WHITE DM, 1992, J BIOL CHEM, V267, P23202	41	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1422	1428		10.1074/jbc.270.3.1422	http://dx.doi.org/10.1074/jbc.270.3.1422			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836410	hybrid			2022-12-25	WOS:A1995QB15600067
J	VANLINT, J; SINNETTSMITH, J; ROZENGURT, E				VANLINT, J; SINNETTSMITH, J; ROZENGURT, E			EXPRESSION AND CHARACTERIZATION OF PKD, A PHORBOL ESTER AND DIACYLGLYCEROL-STIMULATED SERINE PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C FAMILY; MITOGENIC RESPONSE; MOLECULAR-CLONING; REGULATORY DOMAIN; RAT-BRAIN; BINDING; IDENTIFICATION; ZETA; PURIFICATION; SPECIFICITY	A novel protein kinase (named PKD) with an NH2-terminal region containing two cysteine-rich motifs has been expressed in COS-7 cells and identified as a receptor for phorbol esters. COS-7 cells transfected with a PKD cDNA construct (pcDNA3-PKD) exhibit a marked (4.8-fold) increase in [H-3]phorbol 12,13-dibutyrate binding. An antiserum raised against the COOH-terminal 15 amino acids of PKD specifically recognized a single 110-kDa band in PKD-transfected cells, PKD prepared by elution from immunoprecipitates with the immunizing peptide efficiently phosphorylated the synthetic peptide syntide-2. The enzyme only poorly phosphorylated a variant syntide-2 where arginine 4 has been replaced by an alanine. The addition of [H-3]phorbol 12,13-dibutyrate, 1-oleoyl-2-acetylglycerol, or 1,2-dioctanoyl-sn-glycerol in the presence of dioleoylphosphatidylserine stimulated the syntide-2 kinase activity of PKD in a synergistic fashion (4-6-fold), Furthermore, the autophosphorylation of PKD was strikingly stimulated by the same lipid activators (14-24-fold). Similar properties were found with PKD isolated from mouse lung. The substrate specificity of PKD is different from that of previously identified members of the protein kinase C family since it does not efficiently phosphorylate histone III-S, protamine sulfate, or a synthetic peptide based upon the conserved pseudosubstrate region of the protein kinase C family. Taken together, these data unambiguously establish PKD as a phorbol ester receptor and as a novel phospholipid/diacylglycerol-stimulated protein kinase.	IMPERIAL CANC RES FUND, GROWTH REGULAT LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Van Lint, Johan/P-9073-2019	Van Lint, Johan/0000-0002-0275-571X				ARECES LB, 1994, J BIOL CHEM, V269, P19553; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; COLLINS MKL, 1982, J CELL PHYSIOL, V112, P42, DOI 10.1002/jcp.1041120108; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; EXTON JH, 1990, J BIOL CHEM, V265, P1; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GUAN C, 1988, GENE, V67, P21; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUBBARD SR, 1991, SCIENCE, V254, P1776; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WEINSTEIN IB, 1988, CANCER RES, V48, P4135	36	151	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1455	1461		10.1074/jbc.270.3.1455	http://dx.doi.org/10.1074/jbc.270.3.1455			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836415	hybrid			2022-12-25	WOS:A1995QB15600072
J	THOMAS, M; MASSIMI, P; JENKINS, J; BANKS, L				THOMAS, M; MASSIMI, P; JENKINS, J; BANKS, L			HPV-18 E6 MEDIATED INHIBITION OF P53 DNA-BINDING ACTIVITY IS INDEPENDENT OF E6 INDUCED DEGRADATION	ONCOGENE			English	Article						P53; HPV18 E6; OLIGOMERIZATION; DNA BINDING	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSCRIPTIONAL ACTIVATION; MUTANT P53; GENE-EXPRESSION; CELLULAR P53; PROTEIN; TRANSACTIVATION; CELLS; WILD-TYPE-P53	A key activity of the p53 protein during suppression of cell growth is its ability to stimulate transcription from promoters of cellular genes which contain a p53 responsive element. The E6 proteins from the oncogenic associated Human Papillomaviruses (HPVs) have been shown to inhibit specifically the p53 transcriptional activation and this has been proposed as a mechanism whereby the virus prevents the suppression of cell cycle progression and the induction of apoptosis. However, the mechanism by which E6 exercises this function is unknown, as is the ability of E6 to associate with different oligomeric forms of p53. In this study we demonstrate that E6 induces changes within the p53 protein which result both in inhibition of DNA binding and in dissociation of p53 protein previously bound to the DNA. These activities correlate exactly with the ability of E6 to inhibit p53 transcriptional activation and are independent of the ability of E6 to direct the degradation of the p53 protein. Further, we show that E6 labels wild type tetrameric and dimeric forms of p53 proteins for ubiquitin mediated degradation more readily than monomeric forms of the protein. However, in vivo analyses indicate that E6 is capable of inhibiting the transcriptional activation induced by the tetrameric, dimeric and monomeric forms of p53.	MARIE CURIE RES INST,OXTED RH8 0TL,SURREY,ENGLAND		THOMAS, M (corresponding author), INT CTR GENET ENGN & BIOTECHNOL,PADRICIANO 99,I-34012 TRIESTE,ITALY.							BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HAINAUT P, 1993, CANCER RES, V53, P4469; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1988, ONCOGENE HDB, P403; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V362, P857; PIM D, 1994, ONCOGENE, V9, P1869; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROVINSKI B, 1988, ONCOGENE, V2, P445; SANG BC, 1994, ONCOGENE, V9, P853; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STOREY A, 1993, ONCOGENE, V8, P919; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	52	74	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					261	268						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838526				2022-12-25	WOS:A1995QC62400005
J	VIEIRA, L; SLOTKI, I; CABANTCHIK, ZI				VIEIRA, L; SLOTKI, I; CABANTCHIK, ZI			CHLORIDE CONDUCTIVE PATHWAYS WHICH SUPPORT ELECTROGENIC H+ PUMPING BY LEISHMANIA-MAJOR PROMASTIGOTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED MACROPHAGES; TRYPANOSOMA-BRUCEI; MEMBRANE; PH; TRANSPORT; DONOVANI; GRADIENT; EXCHANGE; GLUCOSE; ATPASE	The proton extrusion mechanisms of Leishmania promastigotes were studied in terms of electrogenic movements of protons and anions (Cl- and HCO3-). Changes in membrane potential (V-m) and intracellular pH (pH(i)) were monitored fluorimetrically with the potential sensitive dye bis oxonol and the pH-sensitive dye tetraacethoxymethyl 2',7'-bis-(carboxyethyl)-5,6 carboxyfluorescein, respectively. In nominal bicarbonate-free medium (pH(e) 7.4, 28 degrees C), V-m and pH(i) of Leishmania promastigotes were maintained at -113 +/- 4 mV and 6.75 +/- 0.02, respectively. In Cl- free (gluconate based) medium, cells underwent a time dependent acidification (0.3 pH units) and a long term membrane hyperpolarization (7-10 mV), both of which were greatly enhanced in the presence of. the anion blocker, 4,4'-diisothiocyanodihydrostilbene-2,2'-disulfonic acid (H2DIDS). Cells in Cl--free medium underwent a marked depolarization upon treatment with the H+-ATPase inhibitor dicyclohexylcarbodiimide (DCCD), but hyperpolarized after repletion with Cl-. In Cl--depleted cells, replenishment of Cl- led to a H2DIDS-sensitive cytoplasmic alkalinization and a small initial hyperpolarization. Cells exposed either to DCCD or to the H+ uncoupler carbonylcyanide chloraphenylhydrazone caused a marked cytoplasmic acidification and membrane depolarization. In the presence of 25 mM HCO3-, promastigotes maintained an almost neutral cytosol, irrespective of H+ pump action or ionic composition of the medium, The present observations provide evidence for the operation of a DCCD-sensitive electrogenic H+ ATPase which contributes to the maintenance of a highly hyperpolarized plasma membrane in Leishmania promastigotes. H+ pump activity required a parallel pathway of Cl- ions in order to dissipate the pump generated electrical potential, In nominally CO2-free media, the two electrogenic systems are implicated in the maintenance of cell pH and indirectly in electrochemically driven nutrient uptake, In physiological CO2/HCO3-, containing media, the H+ pump and Cl- channel play a role only secondary to that of HCO3-, in pH(i) homeostasis.	HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,RENAL UNIT,IL-91931 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Shaare Zedek Medical Center					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020342, R22AI020342] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20342] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTOINE JC, 1990, INFECT IMMUN, V58, P779, DOI 10.1128/IAI.58.3.779-787.1990; BLUM JJ, 1993, PARASITOL TODAY, V9, P118, DOI 10.1016/0169-4758(93)90168-F; BOYARSKY G, 1990, P NATL ACAD SCI USA, V87, P5921, DOI 10.1073/pnas.87.15.5921; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CASSEL D, 1985, J CELL PHYSIOL, V122, P178, DOI 10.1002/jcp.1041220203; GLASER TA, 1992, MOL BIOCHEM PARASIT, V51, P9, DOI 10.1016/0166-6851(92)90195-P; GLASER TA, 1988, P NATL ACAD SCI USA, V85, P7602, DOI 10.1073/pnas.85.20.7602; HEYTLER P, 1978, METHOD ENZYMOL, V55, P435; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; JIANG SP, 1994, J CELL PHYSIOL, V159, P60, DOI 10.1002/jcp.1041590109; KABACK HR, 1983, J MEMBRANE BIOL, V76, P95; KANAANI J, 1989, J BIOL CHEM, V264, P3194; KRASNE S, 1978, MEMBRANE PHYSL, P217; MIKKELSEN RB, 1986, MOL BIOCHEM PARASIT, V21, P83, DOI 10.1016/0166-6851(86)90082-4; POOLE RJ, 1978, ANNU REV PLANT PHYS, V29, P437, DOI 10.1146/annurev.pp.29.060178.002253; RINK TJ, 1980, BIOCHIM BIOPHYS ACTA, V595, P15, DOI 10.1016/0005-2736(80)90243-6; RINK TJ, 1992, J CELL BIOL, V95, P189; RUSSELL DG, 1992, J CELL SCI, V103, P1193; SCHLEIN Y, 1993, PARASITOL TODAY, V9, P255, DOI 10.1016/0169-4758(93)90070-V; SCHMID A, 1989, J MEMBRANE BIOL, V11, P265; SPANSWICK RM, 1981, ANNU REV PLANT PHYS, V32, P267, DOI 10.1146/annurev.pp.32.060181.001411; STEVENS TH, 1992, J EXP BIOL, V172, P47; TERKUILE BH, 1993, PARASITOL TODAY, V9, P206, DOI 10.1016/0169-4758(93)90009-5; TERKUILE BH, 1993, MOL BIOCHEM PARASIT, V60, P313, DOI 10.1016/0166-6851(93)90142-K; TERKUILE BH, 1992, MOL BIOCHEM PARASIT, V55, P21, DOI 10.1016/0166-6851(92)90123-2; THISSEN JA, 1991, EXP PARASITOL, V72, P243, DOI 10.1016/0014-4894(91)90143-K; VIEIRA L, 1994, J BIOL CHEM, V269, P16254; WAGGONER AS, 1979, ANNU REV BIOPHYS BIO, V8, P47, DOI 10.1146/annurev.bb.08.060179.000403; XIE XS, 1989, J BIOL CHEM, V264, P18870; ZILBERSTEIN D, 1988, BIOCHEM J, V256, P13, DOI 10.1042/bj2560013; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313	32	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5299	5304		10.1074/jbc.270.10.5299	http://dx.doi.org/10.1074/jbc.270.10.5299			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890641	hybrid			2022-12-25	WOS:A1995QL58000054
J	CATERINA, MJ; HERELD, D; DEVREOTES, PN				CATERINA, MJ; HERELD, D; DEVREOTES, PN			OCCUPANCY OF THE DICTYOSTELIUM CAMP RECEPTOR, CAR1, INDUCES A REDUCTION IN AFFINITY WHICH DEPENDS UPON COOH-TERMINAL SERINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; ADENOSINE 3'-5'-MONOPHOSPHATE RECEPTOR; CYCLIC-AMP RECEPTOR; INDUCED DESENSITIZATION; ADENYLATE-CYCLASE; DOWN-REGULATION; LIGAND-BINDING; DISCOIDEUM; INTERNALIZATION; CELLS	Many G-protein coupled receptors display a rapid decrease in ligand binding following pretreatment with agonist, cAR1, a cAMP receptor expressed early in the developmental program of Dictyostelium, mediates chemotaxis, activation of adenylyl cyclase, and gene expression changes that bring about the aggregation of 10(5) amoebae to form a multicellular structure. Occupancy of cAR1 by cAMP initiates multiple desensitization processes, one of which is an apparent reduction in binding sites. In transformed cells expressing cAR1 constitutively, Scatchard analyses revealed that this apparent loss of ligand binding is largely due to a significant reduction in the affinity of cAR1 for cAMP, A parallel increase in the dose dependence of cAR1-mediated cAMP uptake was observed, Consistent with these findings, proteolysis of intact cells and immunofluorescence suggested that cAR1 remains on the cell-surface following cAMP treatment, Finally, agonist-induced loss of ligand binding is impaired in cAR1 mutants lacking a cluster of cytoplasmic serine residues, which are targets of cAMP-induced phosphorylation.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University					NIGMS NIH HHS [GM 34933] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034933] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BRENNER M, 1984, DEV BIOL, V101, P136, DOI 10.1016/0012-1606(84)90124-6; CATERINA MJ, 1994, J BIOL CHEM, V269, P1523; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; CHEUNG AH, 1988, MOL PHARMACOL, V34, P132; CHUANG DM, 1979, P NATL ACAD SCI USA, V76, P3024, DOI 10.1073/pnas.76.6.3024; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DEVREOTES PN, 1985, J BIOL CHEM, V260, P6378; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HENDERSON EJ, 1975, J BIOL CHEM, V250, P4730; HERELD D, 1994, J BIOL CHEM, V269, P7036; HERTEL C, 1983, BIOCHEM J, V216, P669, DOI 10.1042/bj2160669; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; JOHNSON RL, 1992, J BIOL CHEM, V267, P4600; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; JULIANI MH, 1981, J BIOL CHEM, V256, P613; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KLEIN C, 1977, CELL, V10, P329, DOI 10.1016/0092-8674(77)90227-6; KLEIN C, 1979, J BIOL CHEM, V254, P2573; KLEIN P, 1987, J BIOL CHEM, V262, P358; KLEIN P, 1985, J BIOL CHEM, V260, P1757; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LOUIS JM, 1994, GENE DEV, V8, P2086, DOI 10.1101/gad.8.17.2086; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P6566, DOI 10.1073/pnas.82.19.6566; MORO O, 1993, J BIOL CHEM, V268, P22273; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ROOS W, 1977, NATURE, V266, P259, DOI 10.1038/266259a0; SAXE CL, 1993, GENE DEV, V7, P262, DOI 10.1101/gad.7.2.262; SNAARJAGALSKA BE, 1988, J BIOL CHEM, V263, P897; TAO YP, 1990, J BIOL CHEM, V265, P15584; TOEWS ML, 1984, J BIOL CHEM, V259, P1844; VANHAASTERT PJM, 1987, J BIOL CHEM, V262, P7700; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V845, P254, DOI 10.1016/0167-4889(85)90184-3; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VANHAASTERT PJM, 1992, MOL BIOL CELL, V3, P603, DOI 10.1091/mbc.3.6.603; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WANG HY, 1989, BIOCHEM J, V263, P533, DOI 10.1042/bj2630533; WANG M, 1988, DEV BIOL, V128, P72, DOI 10.1016/0012-1606(88)90268-0; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; YU SS, 1993, J BIOL CHEM, V268, P337	49	27	28	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4418	4423		10.1074/jbc.270.9.4418	http://dx.doi.org/10.1074/jbc.270.9.4418			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876207	hybrid			2022-12-25	WOS:A1995QK08400039
J	CONROY, WG; BERG, DK				CONROY, WG; BERG, DK			NEURONS CAN MAINTAIN MULTIPLE CLASSES OF NICOTINIC ACETYLCHOLINE-RECEPTORS DISTINGUISHED BY DIFFERENT SUBUNIT COMPOSITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY GANGLION NEURONS; MONOCLONAL-ANTIBODIES; BINDING-SITES; MESSENGER-RNA; BRAIN; SUBTYPES; LOCALIZATION; EXPRESSION; COMPONENT; GENES	Although 10 genes have been cloned encoding putative subunits of neuronal nicotinic acetylcholine receptors, little is known about the variety or subunit composition of such receptors expressed by individual neurons, Chick ciliary ganglion neurons express five of the known genes and assemble a class of synaptic-type receptors collectively containing gene products from three of them: alpha 3, beta 4, and alpha 5. Using subunit-specific monoclonal antibodies, we show here that all of the synaptic-type acetylcholine receptors having alpha 3 also have beta 4 subunits and vice versa. In addition, most, if not all, of the alpha 5 gene product present in fully assembled receptors is associated with both alpha 3 and beta 4 subunits, Although the receptors may be homogeneous in these respects, only about 20% of them also contain the fourth gene product, beta 2, newly identified in the ganglion; essentially all of the neurons express the beta 2 gene, No beta 2 subunits are found coassembled with the fifth acetylcholine receptor gene product expressed by the neurons, alpha 7, which has been shown previously to comprise a class of abundant, nonsynaptic receptors on the cells, The identification of three acetylcholine receptor subtypes distinguished by subunit composition on the same neurons provokes questions about their individual physiological roles.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NINDS NIH HHS [R01 NS12601, P01 NS25916] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012601, P01NS025916] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANAND R, 1991, J BIOL CHEM, V266, P11192; BOYD RT, 1991, J NEUROBIOL, V22, P1, DOI 10.1002/neu.480220102; BOYD RT, 1988, NEURON, V1, P495; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; CORRIVEAU RA, 1993, J NEUROSCI, V13, P2662, DOI 10.1523/JNEUROSCI.13-06-02662.1993; HALVORSEN SW, 1987, J NEUROSCI, V7, P2547; HALVORSEN SW, 1990, J NEUROSCI, V10, P1711; HALVORSEN SW, 1991, J NEUROSCI, V11, P2177; JACOB MH, 1984, P NATL ACAD SCI-BIOL, V81, P3223, DOI 10.1073/pnas.81.10.3223; JACOB MH, 1983, J NEUROSCI, V3, P260; LINDSTROM J, 1981, METHOD ENZYMOL, V74, P452; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; LORING RH, 1987, J NEUROSCI, V7, P2153; MANDELZYS A, 1994, J NEUROSCI, V14, P2357; MARGIOTTA JF, 1989, DEV BIOL, V135, P326, DOI 10.1016/0012-1606(89)90183-8; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; RAVDIN PM, 1979, P NATL ACAD SCI USA, V76, P2072, DOI 10.1073/pnas.76.4.2072; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SCHOEPFER R, 1988, NEURON, V1, P241, DOI 10.1016/0896-6273(88)90145-6; SMITH MA, 1985, J NEUROSCI, V5, P2726; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; WHITING P, 1987, FEBS LETT, V219, P459, DOI 10.1016/0014-5793(87)80272-7; WHITING P, 1991, MOL PHARMACOL, V40, P463; WHITING PJ, 1991, MOL BRAIN RES, V10, P61, DOI 10.1016/0169-328X(91)90057-5; WHITING PJ, 1986, BIOCHEMISTRY-US, V25, P2082, DOI 10.1021/bi00356a037; WHITING PJ, 1987, J NEUROSCI, V7, P4005; ZHANG ZW, 1994, NEURON, V12, P167, DOI 10.1016/0896-6273(94)90161-9	31	253	254	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4424	4431		10.1074/jbc.270.9.4424	http://dx.doi.org/10.1074/jbc.270.9.4424			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876208	hybrid			2022-12-25	WOS:A1995QK08400040
J	DENU, JM; ZHOU, GC; WU, L; ZHAO, R; YUVANIYAMA, JD; SAPER, MA; DIXON, JE				DENU, JM; ZHOU, GC; WU, L; ZHAO, R; YUVANIYAMA, JD; SAPER, MA; DIXON, JE			THE PURIFICATION AND CHARACTERIZATION OF A HUMAN DUAL-SPECIFIC PROTEIN-TYROSINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC25 PROTEIN; VACCINIA VIRUS; DEPHOSPHORYLATION; ACTIVATION; KINASE; PEPTIDES; P34CDC2; SYSTEM; YEAST	An expression and purification method was developed to obtain the recombinant human dual specific protein tyrosine phosphatase (PTPase) VHR in quantities suitable for both kinetic studies and crystallization. Physical characterization of the homogeneous recombinant protein verified the mass to be 20,500 +/- 100 by matrix-assisted laser desorption mass spectrometry, confirmed the anticipated NH2-terminal amino acid sequence and demonstrated that the protein exists as a monomer. Conditions were developed to obtain crystals which were suitable for x-ray structure determination. Using synthetic diphosphorylated peptides corresponding to MAP(177-189) (mitogen-activated protein) kinase (DHTGFLpTEpYVATR), an assay was devised which permitted the determination of the rate constants for dephosphorylation of the diphosphorylated peptide on threonine and tyrosine residues. The diphosphorylated peptides are preferred over the singly phosphorylated on tyrosine by 3-8-fold. The apparent second-order rate constant k(cat)/K-m for dephosphorlyation of phosphotyrosine on DHTGFLpTEpYVATR was 32,000 M(-1) s(-1) while dephosphorylation of phosphothreonine was 14 M(-1) s(-1) (pH 6). The reaction of DHTGFLpTEpYVATR with VHR is ordered, with rapid dephosphorylation on tyrosine occurring first followed by slow dephosphorylation on threonine. Similar results were obtained with F(NLe) (NLe)pTPpYVVTR, a peptide corresponding to a MAP kinase-like protein (JNK1(180-189)) which is involved in the stress response signaling pathway.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Yuvaniyama, Jirundon/0000-0002-6800-8944	NIAMS NIH HHS [P560 AR20557] Funding Source: Medline; NIDDK NIH HHS [NIDDKD 18849, NIDDKD 18024] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018024, R01DK018849, R37DK018024] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS DM, 1991, INT J PEPT PROT RES, V38, P469; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KITAS EA, 1991, 12TH AM PEPT S BOST; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; MILLAR JBA, 1991, EMBO J, V10, P4302; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	27	98	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3796	3803		10.1074/jbc.270.8.3796	http://dx.doi.org/10.1074/jbc.270.8.3796			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876121	hybrid			2022-12-25	WOS:A1995QH68800051
J	LAI, A; SISODIA, SS; TROWBRIDGE, IS				LAI, A; SISODIA, SS; TROWBRIDGE, IS			CHARACTERIZATION OF SORTING SIGNALS IN THE BETA-AMYLOID PRECURSOR PROTEIN CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ACID-PHOSPHATASE; HUMAN TRANSFERRIN RECEPTOR; ALZHEIMERS-DISEASE; INTERNALIZATION SIGNALS; INSULIN-RECEPTOR; CELL-SURFACE; ENDOCYTOSIS; SEQUENCE; CLEAVAGE; MEMBRANE	The beta-amyloid precursor protein (APP) is proteolytically processed to generate beta-amyloid protein, the principal protein component of neuropathological lesions characteristic of Alzheimer's disease. To investigate potential sorting signals in the cytoplasmic tail of APP, we transplanted APP cytoplasmic tail sequences into the cytoplasmic tail of the human transferrin receptor (TR) and showed that two sequence moths from the APP cytoplasmic tail promote TR internalization. One sequence, GYENPTY, is related to the low density lipoprotein receptor internalization signal, FDNPVY, but also involves a critical glycine residue; the other, YTSI, conforms to the 4-residue tyrosine based internalization signal consensus sequence. Furthermore, a chimeric molecule (APP-TR) consisting of the cytoplasmic domain of APP and the transmembrane and external domains of TR was rapidly internalized enabling the transport of iron into the cell at similar to 50% the rate of wild-type TR. Alanine scanning mutations indicated that the two sequences identified in transplantation experiments were required for internalization of the chimera. Metabolic pulse-chase experiments showed that the APP-TR chimeras were degraded in a post-Golgi membrane compartment within 2-4 h following normal glycosylation. Degradation was partially dependent upon the two internalization signals and was inhibited by ammonium chloride. A fraction of APP-TR chimeras traffic to a degradative endocytic compartment after appearing on the cell surface. Comparison of soluble APP released from cells expressing either full-length human APP or mutant APP with the sequence YENPTY deleted indicated that this sequence is required for sorting of full-length APP along similar trafficking pathways as the APP-TR chimera.	SALK INST, DEPT CANC BIOL, SAN DIEGO, CA 92186 USA; UNIV CALIF SAN DIEGO, BIOMED SCI GRAD PROGRAM, LA JOLLA, CA 92037 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, NEUROPATHOL LAB, BALTIMORE, MD 21205 USA	Salk Institute; University of California System; University of California San Diego; Johns Hopkins University					NIGMS NIH HHS [GM07198] Funding Source: Medline; NINDS NIH HHS [NSAG05146, NS20471] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS020471, P01NS020471] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GARIPPA RJ, 1994, J CELL BIOL, V124, P705, DOI 10.1083/jcb.124.5.705; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HUGHES SH, 1990, J REPROD FERTIL, P39; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; JADOT M, 1992, J BIOL CHEM, V267, P11069; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JING SQ, 1990, J BIOL CHEM, V265, P11555; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; NORSTEDT C, 1993, J BIOL CHEM, V268, P608; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; OMARY MB, 1981, J BIOL CHEM, V256, P2888; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SUBRAMANI S, 1981, MOL CELL BIOL, V7, P2745; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANNER LI, 1987, J BIOL CHEM, V262, P8975; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2551, DOI 10.1073/pnas.89.7.2551; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	44	169	173	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3565	3573		10.1074/jbc.270.8.3565	http://dx.doi.org/10.1074/jbc.270.8.3565			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876092				2022-12-25	WOS:A1995QH68800019
J	YANO, M; ELHAYEK, R; IKEMOTO, N				YANO, M; ELHAYEK, R; IKEMOTO, N			CONFORMATIONAL-CHANGES IN THE JUNCTIONAL FOOT PROTEIN CA2+ RELEASE CHANNEL MEDIATE DEPOLARIZATION-INDUCED CA2+ RELEASE FROM SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKINNED MUSCLE-FIBERS; SKELETAL-MUSCLE; CALCIUM-RELEASE; RYANODINE RECEPTOR; TRANSVERSE TUBULE; DIHYDROPYRIDINE RECEPTORS; CHARGE MOVEMENT; PURIFICATION; VESICLES; TOAD	In an attempt to monitor the kinetic events occurring in the junctional foot protein (JFP) during excitation-contraction coupling, the JFP moiety of isolated triads was covalently labeled in a site-directed manner with methylcoumarin acetate (MCA) using a recently developed technique (Kang, J. J., Tarcsafalvi, A., Carlos, A. D., Fujimoto, E., Shahrokh, Z., Thevenin, B. J. M., Shohet, S. B., and Ikemoto, N. (1992) Biochemistry 31, 3288-3293). Chemical depolarization of the transverse tubular system (T-tubule) moiety of labeled triads after appropriate priming induced first a rapid increase of the fluorescence intensity of the JFP-bound MCA probe, and then sarcoplasmic reticulum (SR) Ca2+ release. Upon increasing the magnitude of T-tubule depolarization by increasing the degree of ionic replacement, both the amplitude of the MCA fluorescence change and the amount of released Ca2+ increased in parallel. Blockers of T-tubuleto-SR communication, such as nimodipine and low concentration of neomycin, inhibited both the MCA fluorescence change and the SR Ca2+ release. In contrast, the release blocking concentration of Mg2+ (2 mM) inhibited only SR Ca2+ release without affecting the fluorescence change. These results suggest that upon T-tubule depolarization the original state of the JFP (R) isomerizes to an activated state with higher MCA fluorescence (*R), which in turn changes into a subsequent state in which the release channel is open (*R(0)):R-->R-->R(0).	BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School					NIAMS NIH HHS [AR 16922] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIANCHI CP, 1968, FED PROC, V27, P126; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CALVIELLO G, 1989, BIOCHEMISTRY-US, V28, P1301, DOI 10.1021/bi00429a053; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CHANDLER WK, 1976, J PHYSIOL-LONDON, V254, P285, DOI 10.1113/jphysiol.1976.sp011233; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; IKEMOTO N, 1994, BIOCHEMISTRY-US, V33, P10961, DOI 10.1021/bi00202a015; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; KANG JJ, 1992, BIOCHEMISTRY-US, V31, P3288, DOI 10.1021/bi00127a034; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAMB GD, 1990, J PHYSIOL-LONDON, V423, P519, DOI 10.1113/jphysiol.1990.sp018037; LAMB GD, 1990, J PHYSIOL-LONDON, V423, P495, DOI 10.1113/jphysiol.1990.sp018036; LU XY, 1994, J BIOL CHEM, V269, P6511; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; PALADE P, 1987, J BIOL CHEM, V262, P6149; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; YANOS M, 1994, FEBS LETT, V351, P346	27	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3017	3021		10.1074/jbc.270.7.3017	http://dx.doi.org/10.1074/jbc.270.7.3017			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852382	hybrid			2022-12-25	WOS:A1995QG47100022
J	BARTKOVA, J; LUKAS, J; STRAUSS, M; BARTEK, J				BARTKOVA, J; LUKAS, J; STRAUSS, M; BARTEK, J			CYCLIN D1 ONCOPROTEIN ABERRANTLY ACCUMULATES IN MALIGNANCIES OF DIVERSE HISTOGENESIS	ONCOGENE			English	Note						CELL CYCLE; OVER-EXPRESSION OF CYCLIN D1; HUMAN TUMORS; ONCOGENE	ASSISTED IMAGE-ANALYSIS; BREAST-CANCER; RETINOBLASTOMA PROTEIN; SQUAMOUS-CELL; AMPLIFICATION; GENES; CARCINOMAS; EXPRESSION; ONCOGENE; BCL-1	Cyclin D1 is a cell cycle regulator essential for G1 phase progression and a candidate proto-oncogene whose deregulated expression has been implicated in pathogenesis of several types of cancer. We have examined expression of cyclin D1 in 212 primary tumours of five histogenetically distinct types by immunohistochemistry and found strong aberrant accumulation of the protein in 21%, and a moderate overabundance in further 25% of cases. While the abnormalities were more frequent in carcinomas of the breast, i.e. the cancer type known for cyclin D1 gene amplification, aberrant expression was also seen in significant subsets of colorectal cancers, soft tissue sarcomas, uterine carcinomas and malignant melanomas. Comparison of distinct stages of tumour progression showed concordant cyclin D1 patterns in the in situ vs invasive breast carcinoma components (n=37) and between primary and metastatic lesions (n=51) of several tumour types. The specificity of the immunohistochemical data was supported by immunoblotting analysis of tissue and tumour lysates, and the tumour-specific over-expression was confirmed by computer-assisted image analysis. These observations suggest that alterations of cyclin D1 expression represent a common feature of malignancies of diverse histogenesis and indicate that both the spectrum of tumour types and the frequency of cyclin D1 aberrations significantly exceed previous estimations based on genetic analyses.	DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN,DENMARK; MAX PLANCK GESELL,MAX DELBRUCK HANS,D-13122 BERLIN,GERMANY	Danish Cancer Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				BACUS S, 1988, AM J CLIN PATHOL, V90, P233, DOI 10.1093/ajcp/90.3.233; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; BERENSON JR, 1989, ONCOGENE, V4, P1111; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CZERNIAK B, 1990, J HISTOCHEM CYTOCHEM, V38, P463, DOI 10.1177/38.4.1969431; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GILLETT C, 1994, CANCER RES, V54, P1812; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEACH FS, 1993, CANCER RES, V53, P1986; LOVEC H, 1994, ONCOGENE, V9, P323; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TAM SW, 1994, ONCOGENE, V9, P2663; THEILLET C, 1990, ONCOGENE, V5, P147; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	39	201	203	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					775	778						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862456				2022-12-25	WOS:A1995QH61200019
J	FERNANDEZ, A; FOSDICK, LJ; MARIN, MC; DIAZ, C; MCDONNELL, TJ; ANANTHASWAMY, HN; MCCONKEY, DJ				FERNANDEZ, A; FOSDICK, LJ; MARIN, MC; DIAZ, C; MCDONNELL, TJ; ANANTHASWAMY, HN; MCCONKEY, DJ			DIFFERENTIAL REGULATION OF ENDOGENOUS ENDONUCLEASE ACTIVATION IN ISOLATED MURINE FIBROBLAST NUCLEI BY RAS AND BCL-2	ONCOGENE			English	Note						APOPTOSIS; RAS; BCL-2; NUCLEI	TUMOR NECROSIS FACTOR; FACTOR-MEDIATED CYTOTOXICITY; DNA FRAGMENTATION; MEMBRANE PROTEIN; CELL LINES; APOPTOSIS; EXPRESSION; THYMOCYTES; DEATH	Transfection of a murine fibroblast cell line with an activated form of the Harvey ras oncogene conferred sensitivity to apoptosis induced by various agents. This intrinsic sensitivity to apoptosis correlated with the expression of endogenous endonuclease activity in isolated nuclei that was undetectable in the untransfected parental cell line. Subsequent transfection with the human bcl-2 oncogene prevented the morphological and biochemical features of apoptosis in whole cells, although it failed to confer complete protection against cell death. Furthermore, transfection of the bcl-2 oncogene also inhibited the enhanced endonuclease activity in isolated nuclei. Our results indicate that some of the effects of Ha-ras and bcl-2 and potentially other oncogenes, are exerted on the biochemical machinery of apoptosis at the level of the nucleus.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Marin, Maria C/G-1040-2010; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X	NATIONAL CANCER INSTITUTE [R01CA046523, R01CA062597] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09255-02, R01-CA-46523, R01-CA-62597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BAFFY G, 1993, J BIOL CHEM, V268, P6511; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; DEJONG D, 1994, CANCER RES, V54, P256; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENNET T, 1993, CANCER RES, V53, P1456; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITOH N, 1993, J IMMUNOL, V151, P621; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LASTER SM, 1988, J IMMUNOL, V141, P2629; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	25	44	44	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					769	774						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862455				2022-12-25	WOS:A1995QH61200018
J	PULS, A; PROIKASCEZANNE, T; MARQUARDT, B; PROPST, F; STABEL, S				PULS, A; PROIKASCEZANNE, T; MARQUARDT, B; PROPST, F; STABEL, S			KINASE-ACTIVITIES OF C-MOS AND V-MOS PROTEINS - A SINGLE AMINO-ACID EXCHANGE IS RESPONSIBLE FOR CONSTITUTIVE ACTIVATION OF THE 124-V-MOS KINASE	ONCOGENE			English	Article						PROTEIN KINASE ACTIVITY; C-MOS; V-MOS; MAP KINASE ACTIVATION; PHOSPHORYLATION; ONCOGENE; ATP BINDING MUTATION	MURINE SARCOMA-VIRUS; MAMMALIAN SOMATIC-CELLS; PROTO-ONCOGENE PRODUCT; XENOPUS OOCYTES; CYTOSTATIC FACTOR; MAP KINASE; NUCLEOTIDE-SEQUENCE; MEIOTIC MATURATION; CRYSTAL-STRUCTURE; FROG OOCYTES	The Mos protein kinase is a serine-/threonine-specific protein kinase with a crucial role in meiotic cell divisions in vertebrates. Several oncogenic derivatives of the c-Mos protein have been discovered in murine retroviruses. These proteins have acquired mutations and exhibit different degrees of protein kinase activity in vitro. In an attempt to understand the factors governing Mos protein kinase activity we have compared the kinase activities of the wild-type c-Mos protein and of two v-Mos proteins (strain HT1 and MSV124) after expression in insect cells. Only the 124 v-Mos protein showed kinase activity in vitro as measured by autophosphorylation, vimentin phosphorylation or by phosphorylation and activation of MAP kinase kinase. By domain swapping and site-directed mutagenesis we identified a single point mutation in the 124 v-Mos protein (Arg(145)-->Gly) which is responsible for its constitutive activity. This residue is located in the alpha-helix C of the kinase domain close to the ATP binding fold and is conserved in all known c-Mos proteins. Introduction of the corresponding mutation into HT1 v-Mos and into murine c-Mos activated bath proteins for autophosphorylation, vimentin phosphorylation and for signalling via MAP kinase kinase in vitro. We hypothesize that the Arg(145)-->Gly mutation found in 124 v-Mos mimicks a conformational change which might be an obligatory step in the activation of c-Mos in vivo.	MAX PLANCK GESELL, MAX DELBRUCK LAB, D-50829 COLOGNE, GERMANY; UNIV VIENNA, BIOZENTRUM, INST BIOCHEM & MOLEK ZELLBIOL, A-1030 VIENNA, AUSTRIA	Max Planck Society; University of Vienna				Proikas-Cezanne, Prof. Dr. Tassula/0000-0001-6934-132X				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLAIR DG, 1984, CANCER CELLS ONCOGEN, P281; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HASHIMOTO N, 1994, NATURE, V370, P58; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARQUARDT B, 1992, GENE, V120, P297, DOI 10.1016/0378-1119(92)90109-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAULES RS, 1992, ONCOGENE, V7, P2489; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PROPST F, 1992, J NEUROPATH EXP NEUR, V51, P499, DOI 10.1097/00005072-199209000-00004; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1989, VIROLOGY, V173, P144, DOI 10.1016/0042-6822(89)90230-4; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMERS MD, 1987, TEXAS EXP STATION B, V1555; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	45	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					623	630						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862439				2022-12-25	WOS:A1995QH61200001
J	LARK, MW; GORDY, JT; WEIDNER, JR; AYALA, J; KIMURA, JH; WILLIAMS, HR; MUMFORD, RA; FLANNERY, CR; CARLSON, SS; IWATA, M; SANDY, JD				LARK, MW; GORDY, JT; WEIDNER, JR; AYALA, J; KIMURA, JH; WILLIAMS, HR; MUMFORD, RA; FLANNERY, CR; CARLSON, SS; IWATA, M; SANDY, JD			CELL-MEDIATED CATABOLISM OF AGGRECAN EVIDENCE THAT CLEAVAGE AT THE AGGRECANASE SITE (GLU(373)-ALA(37) PROTEOLYSIS OF THE INTERGLOBULAR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-FLUID; PROTEOGLYCAN FRAGMENTS; CARTILAGE CULTURES; LINK PROTEIN; CATHEPSIN-B; OSTEOARTHRITIS; CHONDROCYTES; DEGRADATION; SEQUENCE; RELEASE	A rat chondrosarcoma cell line and primary bovine chondrocytes have been used to study cell-mediated aggrecan catabolism. Addition of 1 mu M retinoic acid to chondrosarcoma cultures resulted in aggrecan proteolysis with the release of greater than 90% of the cell layer aggrecan into the medium within 4 days. NH2-terminal sequencing of chondroitin sulfate-substituted catabolic products gave a single major NH2-terminal sequence of ARGNVILTXK, initiating at Ala(374). This showed that the proteinase, commonly referred to as ''aggrecanase,'' which cleaves the Glu(373)-Ala(374) bond of the interglobular domain of aggrecan (Sandy, J. D., Neame, P. J., Boynton, R. E., and Flannery, C. R. (1990) J. Biol. Chem. 266, 8683-8685), is active in this cell system. Aggrecan G1 domain, generated by cleavage of the interglobular domain, was also liberated during catabolism and this was characterized with three antipeptide antisera. Anti-CDAGWL was used as a general probe for G1 domain. Anti-FVDIPEN was used to specifically detect G1 domain with COOH terminus of Asn(341), the form which is readily generated by cleavage of aggrecan by a wide range of matrix metalloproteinases. Anti-NITEGE antiserum was used to specifically detect G1 domain with COOH terminus of Glu(373), the form which is the expected product of ''aggrecanase''-mediated cleavage of aggrecan. Western blot analysis indicated that a single form of G1 domain of about 60 kDa was formed. G1 domain of this size reacted with both anti-CDAGWL and anti-NITEGE but not with anti-FVDIPEN. Similar experiments with primary bovine chondrocyte cultures, treated with either retinoic acid or interleukin 1, showed that two forms of catabolic G1 domain, of about 62 and 66 kDa, were formed. Both of these forms reacted on Western blots with anti-CDAGWL and also with anti-NITEGE. It is suggested that cell-mediated catabolism of the aggrecan interglobular domain in these culture systems, whether promoted by retinoic acid or interleukin 1, primarily involves cleavage of the Glu(373)-Ala(374) bond by aggrecanase. The accumulation of G1 domain with a COOH-terminal of Glu(373) shows that such aggrecanase-mediated cleavage can occur independent of the cleavage of the Asn(341)-phe(342) bond by matrix metalloproteinases.	SHRINERS HOSP CRIPPLED CHILDREN,TAMPA,FL 33612; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT IMMUNOL & INFLAMMAT RES,RAHWAY,NJ 07065; UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195; HENRY FORD HOSP,CTR BONE & JOINT,DETROIT,MI 48202; UNIV S FLORIDA,COLL MED,TAMPA,FL 33612	Merck & Company; University of Washington; University of Washington Seattle; Henry Ford Health System; Henry Ford Hospital; State University System of Florida; University of South Florida				Gordy, John/0000-0003-2097-872X				BUTTLE DJ, 1993, ARTHRITIS RHEUM, V36, P1709, DOI 10.1002/art.1780361210; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, ORTHOP T, V17, P677; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; HUA Q, 1993, J CELL SCI, V106, P365; ILIE MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115; IWATA M, 1993, J NEUROSCI, V13, P195; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; KUCHARSKA AM, 1990, J ORTHOPAED RES, V8, P781, DOI 10.1002/jor.1100080602; LARK MW, 1994, IN PRESS BIOCH J; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; MORALES TI, 1988, J BIOL CHEM, V263, P3632; PLAAS AHK, 1992, MATRIX, V13, P135; RATCLIFFE A, 1986, BIOCHEM J, V238, P571, DOI 10.1042/bj2380571; RHODES C, 1988, J BIOL CHEM, V263, P6063; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1991, ARTICULAR CARTILAGE, P21	24	170	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2550	2556		10.1074/jbc.270.6.2550	http://dx.doi.org/10.1074/jbc.270.6.2550			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852317				2022-12-25	WOS:A1995QF53500025
J	RYU, S; RAMSEIER, TM; MICHOTEY, V; SAIER, MH; GARGES, S				RYU, S; RAMSEIER, TM; MICHOTEY, V; SAIER, MH; GARGES, S			EFFECT OF THE FRUR REGULATOR ON TRANSCRIPTION OF THE PTS OPERON IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; CAMP RECEPTOR PROTEIN; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-SEQUENCE; POSITIVE REGULATION; MOLECULAR-CLONING; 2 PROMOTERS; CRR GENES; FRUCTOSE; PHOSPHOENOLPYRUVATE	The promoters of the pts operon of Escherichia coli are controlled by the cyclic AMP receptor protein (CRP) complexed with cAMP (CRP.cAMP). In addition, glucose stimulates pts operon expression in vivo. The pts promoter region has a fructose repressor (FruR)-binding site (the FruR box) that partially overlaps with one of the CRP.cAMP-binding sites. The effects of the pleiotropic transcriptional regulator FruR on pfs operon expression were studied to determine whether the in vivo glucose effect on pts operon expression is mediated by FruR. In vitro, FruR can repress P1b transcription, which is activated by CRP.cAMP, and restore P1a transcription, which is repressed by CRP.cAMP. FruR can displace CRP cAMP from its binding site in the presence of RNA polymerase even though FruR and CRP.cAMP can bind simultaneously to their partially overlapping binding sites in the absence of RNA polymerase. FruR had very little effect on the transcription of the P0 promoter, which is most important for regulation by glucose. Consistent with the in vitro results, pts P0 transcription did not increase as much In cells grown in the presence of fructose or in fruR(-) mutant cells as in cells grown in the presence of glucose. These results suggest that FruR alone does not mediate the in vivo glucose effect on pts operon expression.	NCI, MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego			Michotey, Valerie/AAA-4397-2021	Michotey, Valerie/0000-0001-6639-2877				Adhya S, 1987, ESCHERICHIA COLI SAL, P1503; BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; BURGESS RR, 1991, METHOD ENZYMOL, V208, P3; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; CHIN AM, 1989, J BACTERIOL, V171, P2424, DOI 10.1128/jb.171.5.2424-2434.1989; CHIN AM, 1987, J BACTERIOL, V169, P897, DOI 10.1128/jb.169.2.897-899.1987; CORDARO JC, 1972, J BACTERIOL, V112, P17, DOI 10.1128/JB.112.1.17-29.1972; CRASNIER M, 1994, MOL GEN GENET, V243, P409, DOI 10.1007/BF00280471; DEREUSE H, 1988, J BACTERIOL, V170, P3827, DOI 10.1128/jb.170.9.3827-3837.1988; DEREUSE H, 1992, J MOL BIOL, V226, P623, DOI 10.1016/0022-2836(92)90620-Y; DEREUSE H, 1991, J BACTERIOL, V173, P727, DOI 10.1128/jb.173.2.727-733.1991; DEREUSE H, 1985, GENE, V35, P199; DEUSCHLE U, 1986, P NATL ACAD SCI USA, V83, P4134, DOI 10.1073/pnas.83.12.4134; FOX DK, 1992, P NATL ACAD SCI USA, V89, P7056, DOI 10.1073/pnas.89.15.7056; FRAENKEL DG, 1968, J BIOL CHEM, V243, P6451; GEERSE RH, 1986, MOL GEN GENET, V203, P435, DOI 10.1007/BF00422068; HANAMURA A, 1992, MOL MICROBIOL, V6, P2489; IRANI M, 1989, J BACTERIOL, V171, P1623, DOI 10.1128/jb.171.3.1623-1630.1989; JAHREIS K, 1991, MOL GEN GENET, V226, P332, DOI 10.1007/BF00273623; KORNBERG HL, 1987, J GEN MICROBIOL, V133, P341; LECLERC G, 1990, J BACTERIOL, V172, P4696, DOI 10.1128/jb.172.8.4696-4700.1990; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Miller J.H., 1992, SHORT COURSE BACTERI, P150; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RAMSEIER TM, 1993, J MOL BIOL, V234, P28, DOI 10.1006/jmbi.1993.1561; REINER AM, 1977, J BACTERIOL, V132, P166, DOI 10.1128/JB.132.1.166-173.1977; REPHAELI AW, 1980, J BACTERIOL, V141, P658, DOI 10.1128/JB.141.2.658-663.1980; RYU S, 1994, P NATL ACAD SCI USA, V91, P8582, DOI 10.1073/pnas.91.18.8582; RYU S, 1994, J BIOL CHEM, V269, P4767; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SAIER MH, 1993, J CELL BIOCHEM, V51, P62, DOI 10.1002/jcb.240510112; Sambrook J, 1989, MOL CLONING LABORATO; SOGAARDANDERSEN L, 1990, J BACTERIOL, V172, P5706, DOI 10.1128/jb.172.10.5706-5713.1990; VARTAK NB, 1991, RES MICROBIOL, V142, P951, DOI 10.1016/0923-2508(91)90005-U; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869	37	36	38	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2489	2496		10.1074/jbc.270.6.2489	http://dx.doi.org/10.1074/jbc.270.6.2489			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852310	hybrid			2022-12-25	WOS:A1995QF53500017
J	YAMAMOTOHONDA, R; TOBE, K; KABURAGI, Y; UEKI, K; ASAI, S; YACHI, M; SHIROUZU, M; YODOI, J; AKANUMA, Y; YOKOYAMA, S; YAZAKI, Y; KADOWAKI, T				YAMAMOTOHONDA, R; TOBE, K; KABURAGI, Y; UEKI, K; ASAI, S; YACHI, M; SHIROUZU, M; YODOI, J; AKANUMA, Y; YOKOYAMA, S; YAZAKI, Y; KADOWAKI, T			UPSTREAM MECHANISMS OF GLYCOGEN-SYNTHASE ACTIVATION BY INSULIN AND INSULIN-LIKE GROWTH-FACTOR-I - GLYCOGEN-SYNTHASE ACTIVATION IS ANTAGONIZED BY WORTMANNIN OR LY294002 BUT NOT BY RAPAMYCIN OR BY INHIBITING P21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; S6 PROTEIN-KINASE; PHEOCHROMOCYTOMA CELLS; SIGNAL TRANSDUCTION; MAP KINASES; PHOSPHORYLATION; RECEPTOR; RAS; IDENTIFICATION; PURIFICATION	This study was undertaken to define intracellular signaling pathways upstream to glycogen synthase activation, First, we examined the role of the two pathways of insulin signaling, Ras-dependent and wortmannin/LY294002-sensitive, in glycogen synthase activation, Although negative dominant Ras (Ras17N) induction in PC12 cells markedly decreased activities of mitogen-activated protein kinase (MAP) and pp90 S6 kinase in response to insulin or insulin-like growth factor I (IGF-I), activation of glycogen synthase by these agents was unaffected by negative dominant Ras induction. In contrast, wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002), inhibitors of phosphatidylinositol 3-kinase, antagonized glycogen synthase activation in response to insulin or IGF-I. Next, we examined the contribution of pp70 S6 kinase, one of the wortmannin/LY294002-sensitive signaling molecules on glycogen synthase activation, Immunosuppressant rapamycin completely blocked activation of pp70 S6 kinase by insulin or IGF-I, but rapamycin alone or in combination with induction of negative dominant Ras failed to antagonize glycogen synthase activation by these hormones, These data suggest that 1) activation of Ras-MAP kinase is not necessary for stimulation of glycogen synthase and 2) activation of wortmannin/LY294002-sensitive pathway, independent of pp70 S6 kinase, plays a key role in glycogen synthase regulation in PC12 cells.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN; KYOTO UNIV, DEPT BIOL RESPONSES, INFECT LAB, KYOTO 606, JAPAN; KYOTO UNIV, PREVENT INST VIRUS RES, KYOTO 606, JAPAN; ASAHI LIFE FDN, INST DIABET CARE & RES, CHIYODA KU, TOKYO 100, JAPAN	University of Tokyo; University of Tokyo; Kyoto University; Kyoto University; Asahi Life Foundation			Shirouzu, Mikako/A-6521-2016; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BLENIS J, 1986, EMBO J, V5, P3411; BOGARDUS C, 1984, J CLIN INVEST, V73, P1185, DOI 10.1172/JCI111304; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BURGERING BM, 1990, EMBO J, V10, P1103; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN CP, 1987, J BIOL CHEM, V262, P276; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DAHMER MK, 1989, J NEUROCHEM, V53, P1036, DOI 10.1111/j.1471-4159.1989.tb07392.x; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KIDA Y, 1990, J CLIN INVEST, V85, P476, DOI 10.1172/JCI114462; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OKADA T, 1994, J BIOL CHEM, V269, P3568; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RYLATT DB, 1980, EUR J BIOCHEM, V107, P529; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHIROUZU M, 1992, ONCOGENE, V7, P475; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STURGILL TW, 1988, NATURE, V344, P7150; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P518; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1992, J BIOL CHEM, V267, P21089; TOBE K, 1991, J BIOL CHEM, V266, P4220; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777	50	83	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2729	2734		10.1074/jbc.270.6.2729	http://dx.doi.org/10.1074/jbc.270.6.2729			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852343	hybrid			2022-12-25	WOS:A1995QF53500052
J	SUN, ZJ; YERGEAU, DA; TUYPENS, T; TAVERNIER, J; PAUL, CC; BAUMANN, MA; TENEN, DG; ACKERMAN, SJ				SUN, ZJ; YERGEAU, DA; TUYPENS, T; TAVERNIER, J; PAUL, CC; BAUMANN, MA; TENEN, DG; ACKERMAN, SJ			IDENTIFICATION AND CHARACTERIZATION OF A FUNCTIONAL PROMOTER REGION IN THE HUMAN EOSINOPHIL IL-5 RECEPTOR-ALPHA SUBUNIT GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN INTERLEUKIN-5 RECEPTOR; LUCIFERASE REPORTER GENE; RNA POLYMERASE-II; B-CELL GROWTH; DIFFERENTIATION FACTOR; TRANSCRIPTION INITIATION; HEMATOPOIETIC-CELLS; MOLECULAR-BASIS; CD11B PROMOTER	The molecular basis for the commitment of multipotential myeloid progenitors to the eosinophil lineage, and the transcriptional mechanisms by which eosinophil-specific genes are subsequently expressed and regulated during eosinophil development are currently unknown. Interleukin-5 (IL-5) is a T cell and mast cell-derived cytokine with actions restricted to the eosinophil and closely related basophil lineages in humans. The high affinity receptor for IL-5 (IL-5R) is composed of an alpha subunit (IL-5R alpha) expressed by the eosinophil lineage, that associates with a beta(c) subunit shared with the receptors for IL-3 and granulocyte macrophage colony stimulating factor (GM-CSF). As a prerequisite to studies of the transcriptional regulation of the IL-5R alpha subunit gene, we used three different methods, including primer extension, RNase protection, and 5'-RACE to precisely map the transcriptional start site to a position 15 base pairs (bp) upstream of the 5' end of the published sequence of IL-5R alpha exon 1. To initially identify the IL-5R alpha promoter, 3.5 kilobases (kb) and 561 bp of the 5' sequence flanking the transcriptional start site were subcloned into the promoterless pXP2-luciferase vector, Transient transfection of these constructs into an eosinophil-committed HL-60 subline, clone HL-60-C15, induced the expression of similar to 240-fold greater luciferase activity than the promoterless vector, identifying a strong functionally active promoter region within the 561 bp of sequence proximal to the transcriptional start site and with activity equivalent to pXP2 constructs containing the entire 3.5 kb of upstream sequence. To more precisely localize the cis-acting regulatory elements in this region important for promoter activity, a series of 5' deletion mutants of the 561-bp region were generated in the pXP2-luciferase vector. Deletion of the region between bp -432 and -398 reduced promoter activity by more than 80% in the HL-60-C15 cell line. Further analyses of the activity of the IL-5R alpha promoter constructs in various other eosinophil, myeloid, and non-myeloid cell lines indicated that the promoter was relatively myeloid and eosinophil lineage-specific in its expression. Consensus sequences for known transcription factor binding sites were not present in the 34-bp region of the promoter required for maximal activity, suggesting unique myeloid- and possibly eosinophil-specific regulatory elements, Using electrophoretic mobility shift assays, we have identified a nuclear factor(s) that binds to the 34-bp functional region of the the promoter and that is expressed in the myeloid and eosinophilic cell Lines in which the promoter is active, but not in non-myeloid or non-hematopoietic lines. This functional promoter segment likely serves as the binding site for a myeloid- and possibly eosinophil-specific transcription factor(s). Further study of the IL-5R alpha promoter should elucidate unique transcriptional features of this gene whose expression is essential to the commitment and differentiation of multipotential myeloid progenitors to the eosinophil lineage and to the functional activation of the mature cell.	BETH ISRAEL HOSP,DEPT MED,DIV INFECT DIS,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; HOFFMAN LA ROCHE,ROCHE RES GENT,GHENT,BELGIUM; DAYTON VET ADM MED CTR,RES SERV,DAYTON,OH 45435; WRIGHT STATE UNIV,SCH MED,DIV HEMATOL ONCOL,DAYTON,OH 45435	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University System of Ohio; Wright State University Dayton				Tenen, Daniel/0000-0002-6423-3888	NCI NIH HHS [CA41456] Funding Source: Medline; NIAID NIH HHS [AI33043] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033043] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; BAUMANN MA, 1993, BLOOD, V82, pA241; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURN TC, 1992, BLOOD, V80, P3051; CLUTTERBUCK E, 1987, EUR J IMMUNOL, V17, P1743, DOI 10.1002/eji.1830171210; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; DEVOS R, 1993, J BIOL CHEM, V268, P6581; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING DXH, 1994, P NATL ACAD SCI USA, V91, P2537, DOI 10.1073/pnas.91.7.2537; FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145-2126(88)90103-8; GALLI SJ, 1994, EOSINOPHILS ALLERGY, V2, P255; GHOSH D, 1992, NUCLEIC ACIDS RES, V11, P2091; GOMOLIN HI, 1993, BLOOD, V82, P1868; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; HOHAUS S, 1994, BLOOD, V84, pA510; IMAMURA F, 1994, DNA CELL BIOL, V13, P283, DOI 10.1089/dna.1994.13.283; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; Lopez A F, 1992, Immunol Ser, V57, P549; LOPEZ AF, 1991, J BIOL CHEM, V266, P24741; MITA S, 1993, J IMMUNOL, V151, P6924; MITA S, 1989, P NATL ACAD SCI USA, V86, P2311, DOI 10.1073/pnas.86.7.2311; MIYAJIMA A, 1993, BLOOD, V82, P1960; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; NAKAGAWA Y, 1994, J BIOL CHEM, V269, P10905; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORKIN SH, 1992, BLOOD, V80, P575; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; PAHL HL, 1992, BLOOD, V79, P865; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PAUL CC, 1994, J LEUKOCYTE BIOL, V56, P74, DOI 10.1002/jlb.56.1.74; PAUL CC, 1993, BLOOD, V81, P1193; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROBERTS WM, 1992, BLOOD, V79, P586; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; Sanderson C J, 1990, Immunol Ser, V49, P231; SANDERSON CJ, 1991, INT ARCH ALLER A IMM, V94, P122, DOI 10.1159/000235342; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SETO Y, 1992, J IMMUNOL, V148, P259; SHOWE MK, 1992, NUCLEIC ACIDS RES, V20, P3153, DOI 10.1093/nar/20.12.3153; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMITH LA, 1993, BLOOD, V82, pA184; SMITH LT, 1994, BLOOD, V84, pA372; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAKATSU K, 1988, IMMUNOL REV, V102, P107, DOI 10.1111/j.1600-065X.1988.tb00743.x; TAKATSU K, 1989, COLD SPRING HARB SYM, V2, P745; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; Tuypens T, 1992, Eur Cytokine Netw, V3, P451; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; YAMAGUCHI Y, 1994, J BIOL CHEM, V269, P19410; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZON LI, 1993, BLOOD, V81, P3234	67	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1462	1471		10.1074/jbc.270.3.1462	http://dx.doi.org/10.1074/jbc.270.3.1462			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836416	hybrid			2022-12-25	WOS:A1995QB15600073
J	EASON, MG; MOREIRA, SP; LIGGETT, SB				EASON, MG; MOREIRA, SP; LIGGETT, SB			4 CONSECUTIVE SERINES IN THE 3RD INTRACELLULAR LOOP ARE THE SITES FOR BETA-ADRENERGIC-RECEPTOR KINASE-MEDIATED PHOSPHORYLATION AND DESENSITIZATION OF THE ALPHA(2A)-ADRENERGIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-PROMOTED DESENSITIZATION; ALPHA-2-ADRENERGIC RECEPTORS; BETA-2-ADRENERGIC RECEPTOR; DOWN-REGULATION; EXPRESSION; CELLS; ALPHA-2C10; MECHANISM; CLONING; DRUGS	During short term agonist exposure, the alpha(2A)-adrenergic receptor (alpha(2A)AR) undergoes rapid functional desensitization caused by phosphorylation of the receptor by the beta-adrenergic receptor kinase (beta ARK), This signal quenching is similar in nature to that found with a number of G-protein coupled receptors in which agonist-promoted desensitization is due to beta ARK phosphorylation; like these other receptors, the precise molecular determinants of the receptor required for beta ARK phosphorylation are not known. To delineate such a motif in the human alpha(2A)AR(alpha C10), we constructed six mutated receptors consisting of deletions or substitutions of Ser-296-299 in the EESSSS sequence of the third intracellular loop of the receptor, These were expressed in Chinese hamster ovary and COS-7 cells, and agonist-promoted desensitization and receptor phosphorylation were assessed, Deletion of the EESSSS sequence and substitution of alanine for all four serines resulted in a total loss of phosphorylation and desensitization. Mutant receptors that retained two of the original serines (AASS and SSAA) underwent agonist-promoted phosphorylation of 55 +/- 7% and 57 +/- 8% of the phosphorylation found for wild type alpha(2)C10, Additional substitution mutants (SSSA and SAAA) underwent 77 +/- 1% and 27 +/- 4% of wild type phosphorylation, respectively. Thus, substitution of alanine for each additional serine decreased overall phosphorylation as compared with wild type alpha(2)C10 by similar to 25%, which is consistent with all 4 serines being phosphorylated, Mutated receptors that only partially phosphorylated (as compared with wild type) failed to undergo agonist-promoted desensitization. Thus, beta ARK-mediated phosphorylation of alpha(2)C10 occurs at Ser-296-299 in the third intracellular loop, and this represents the critical step in rapid agonist-promoted desensitization. A number of other G-protein coupled receptors that undergo desensitization have a sequence motif similar to that which we have found for beta ARK-mediated phosphorylation of alpha(2)C10, suggesting that these receptors may also be substrates far beta ARK.	UNIV CINCINNATI, COLL MED, DEPT PULM MED, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati			liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669				BARTON AC, 1990, MOL PHARMACOL, V38, P531; BARTON AC, 1991, MOL PHARMACOL, V39, P650; BATES MD, 1991, MOL PHARMACOL, V39, P55; BATES MD, 1992, AM J PHYSIOL, V260, pF937; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BLAXALL HS, 1994, MOL PHARMACOL, V45, P176; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1981, MOL PHARMACOL, V21, P5; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1994, MOL PHARMACOL, V45, P696; EASON MG, 1992, J BIOL CHEM, V267, P25473; EASON MG, 1993, BIOCHEM BIOPH RES CO, V193, P318, DOI 10.1006/bbrc.1993.1626; FREEDMAN NJ, 1994, CIRCULATION, V90, P1; GARCIASEVILLA JA, 1986, BRIT J PHARMACOL, V89, P673, DOI 10.1111/j.1476-5381.1986.tb11171.x; GORDON YKN, 1994, EUR J PHARMACOL, V267, P7; HAMILTON CA, 1990, BRIT J CLIN PHARMACO, V30, pS131, DOI 10.1111/j.1365-2125.1990.tb05484.x; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1984, J PHARMACOL EXP THER, V231, P685; ISHII K, 1994, J BIOL CHEM, V269, P1125; JONES SB, 1990, J PHARMACOL EXP THER, V254, P294; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUROSE H, 1994, J BIOL CHEM, V269, P10093; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1993, BAILLIERE CLIN ENDOC, V7, P279, DOI 10.1016/S0950-351X(05)80178-8; LIGGETT SB, 1994, REGULATION CELLULAR, V3, P71; LIMBIRD LE, 1985, RECEPTORS, V2, P281; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; RAMKUMAR V, 1993, BIOCHIM BIOPHYS ACTA, V1179, P89, DOI 10.1016/0167-4889(93)90075-Z; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; THOMAS JM, 1986, ENDOCRINOLOGY, V119, P1305, DOI 10.1210/endo-119-3-1305	41	112	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4681	4688		10.1074/jbc.270.9.4681	http://dx.doi.org/10.1074/jbc.270.9.4681			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876239	hybrid			2022-12-25	WOS:A1995QK08400074
J	EDWARDS, SL; DAVIDSON, VL; HYUN, YL; WINGFIELD, PT				EDWARDS, SL; DAVIDSON, VL; HYUN, YL; WINGFIELD, PT			SPECTROSCOPIC EVIDENCE FOR A COMMON ELECTRON-TRANSFER PATHWAY FOR 2 TRYPTOPHAN TRYPTOPHYLQUINONE ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOPROTEIN METHYLAMINE DEHYDROGENASE; C-TYPE CYTOCHROMES; PARACOCCUS-DENITRIFICANS; ALCALIGENES-FAECALIS; CRYSTAL-STRUCTURE; METHYLOTROPHIC BACTERIA; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; QUINONE COFACTOR	Aromatic amine dehydrogenase (AADH) and methylamine dehydrogenase (MADH) are the only two enzymes known to use the cofactor tryptophan tryptophylquinone (TTQ). Each catalyzes oxidative deamination of a distinct class of primary amines. A detailed comparison of their circular dichroic spectra indicates that both proteins share a similar fold with their TTQ cofactors residing in similar environments and that this may be a useful diagnostic probe for TTQ enzymes. Alcaligenes faecalis cells induced to express AADH also express a large amount of the blue copper protein, azurin. Oxidized azurin is rapidly reduced by a catalytic amount of AADH in the presence of the substrate, tyramine. Three A. faecalis cytochromes-c and three other cytochromes-c were tested for electron transfer activity with AADH. Azurin markedly facilitated electron transfer from AADH to each cytochrome. This suggests that AADH and azurin may form an electron transfer complex with a c-type cytochrome, analogous to the crystallographically determined MADH-amicyanin-cytochrome c-551i complex (Chen, L., Durley, R. C. E., Matthews, F. S., and Davidson, V. L. (1994) Science 264, 86-90). The similarities of MADH and AADH plus the demonstration of azurin and multiple cytochromes as functional electron-transfer partners suggest that both TTQ-bearing enzymes share common mechanisms for oxidative deamination and subsequent electron transfer.	NIAMSD,STRUCT BIOL RES LAB,BETHESDA,MD 20892; UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216; NIH,OFF DIRECTOR,PROT EXPRESS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Mississippi; University of Mississippi Medical Center; National Institutes of Health (NIH) - USA				Wingfield, Paul/0000-0002-9515-4752; Davidson, Victor/0000-0002-1966-7302	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041574, R01GM041574] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41574] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; AMBLER RP, 1971, RECENT DEV CHEM STUD, P289; ANDERSON GL, 1992, J BIOL CHEM, V267, P23674; BACKES G, 1991, BIOCHEMISTRY-US, V30, P9201, DOI 10.1021/bi00102a011; BAIOCCHI M, 1993, BIOCHEM MOL BIOL INT, V31, P389; BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BOSSARTWHITAKER P, 1993, J MOL BIOL, V232, P1069, DOI 10.1006/jmbi.1993.1461; BROOKS HB, 1993, BIOCHEMISTRY-US, V32, P2725, DOI 10.1021/bi00061a034; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN LY, 1993, PROTEIN SCI, V2, P147; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; CHEN LY, 1991, FEBS LETT, V287, P163, DOI 10.1016/0014-5793(91)80041-Z; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; CHEN LY, 1992, PROTEINS, V14, P288, DOI 10.1002/prot.340140214; CHISTOSERDOV AY, 1990, BIOCHEM BIOPH RES CO, V172, P211, DOI 10.1016/S0006-291X(05)80195-0; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DAVIDSON VL, 1990, METHOD ENZYMOL, V188, P241; DAVIDSON VL, 1993, PRINCIPLES APPL QUIN, P73; DURLEY R, 1993, PROTEIN SCI, V2, P739, DOI 10.1002/pro.5560020506; FRANCIS RT, 1984, ANAL BIOCHEM, V136, P509, DOI 10.1016/0003-2697(84)90253-7; GOVINDARAJ S, 1994, J BACTERIOL, V176, P2922, DOI 10.1128/JB.176.10.2922-2929.1994; HUIZINGA EG, 1992, BIOCHEMISTRY-US, V31, P9789, DOI 10.1021/bi00155a036; HUSAIN M, 1986, J BIOL CHEM, V261, P8577; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; HUSAIN M, 1987, J BACTERIOL, V169, P1712, DOI 10.1128/jb.169.4.1712-1717.1987; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; IWAKI M, 1983, ARCH BIOCHEM BIOPHYS, V220, P253, DOI 10.1016/0003-9861(83)90408-3; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; ROSEN P, 1981, EUR J BIOCHEM, V120, P339, DOI 10.1111/j.1432-1033.1981.tb05709.x; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VELLIEUX FMD, 1986, EUR J BIOCHEM, V154, P383, DOI 10.1111/j.1432-1033.1986.tb09409.x; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; WHERLAND S, 1978, BIOCHEMISTRY-US, V17, P2585, DOI 10.1021/bi00606a020; XIA ZX, 1992, J BIOL CHEM, V267, P22289	39	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4293	4298		10.1074/jbc.270.9.4293	http://dx.doi.org/10.1074/jbc.270.9.4293			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876189	hybrid			2022-12-25	WOS:A1995QK08400020
J	BYRNES, WM; HU, WJ; YOUNATHAN, ES; CHANG, SH				BYRNES, WM; HU, WJ; YOUNATHAN, ES; CHANG, SH			A CHIMERIC BACTERIAL PHOSPHOFRUCTOKINASE EXHIBITS COOPERATIVITY IN THE ABSENCE OF HETEROTROPIC REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; SITE-DIRECTED MUTAGENESIS; ALLOSTERIC PHOSPHOFRUCTOKINASE; BACILLUS-STEAROTHERMOPHILUS; SUBSTRATE-BINDING; NUCLEOTIDE-SEQUENCE; ACTIVE-SITE; DISSOCIATION; FLUORESCENCE; MECHANISM	The phosphofructokinases (PFKs) hom the bacteria Escherichia coli and Bacillus stearothermophilus differ markedly in their regulation by ATP. Whereas E. coli PFK (EcPFK) is profoundly inhibited by ATP, B. stearothermophilus PFH (BsPFH) is only slightly inhibited. The structural basis for this difference could be closure of the active site via a conformational transition that occurs in the ATP-binding domain of EcPFK but is absent in BsPFK To investigate the role of this transition in ATP inhibition of EcPFK we have constructed a chimeric enzyme that contains the ''rigid'' ATP-binding domain of BsPFK grafted onto the remainder of the EcPFK subunit. The chimeric PFH has the following characteristics: (i) tetrameric structure and kinetic parameters similar to those of the native enzymes, (ii) insensitivity to regulation by the effector phosphoenolpyruvate despite its ability to bind to the enzyme, and (iii) a sigmoidal (n(H) around 2) fructose B-phosphate saturation curve. From the results, it is concluded that the active site regions of the two native enzymes are remarkably similar, but their effector sites and their mechanisms of heterotropic regulation are different. The chimeric subunit is locked in a structure resembling that of activated E. coli PFK yet the enzyme can exist in two different conformational states. Mechanisms for its sigmoidal kinetics are discussed.	LOUISIANA STATE UNIV,DEPT BIOCHEM,BATON ROUGE,LA 70803	Louisiana State University System; Louisiana State University					NIDDK NIH HHS [DK 31676] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031676] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSLIE GR, 1972, J BIOL CHEM, V247, P7088; AUZAT I, 1994, P NATL ACAD SCI USA, V91, P5242, DOI 10.1073/pnas.91.12.5242; BERGER SA, 1992, BIOCHEMISTRY-US, V31, P9237, DOI 10.1021/bi00153a017; BERGER SA, 1990, NATURE, V343, P575, DOI 10.1038/343575a0; BERGER SA, 1991, BIOCHEMISTRY-US, V30, P8477, DOI 10.1021/bi00098a027; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; BYRNES M, 1994, BIOCHEMISTRY-US, V33, P3424, DOI 10.1021/bi00177a036; Cleland W W, 1979, Methods Enzymol, V63, P103; DEVILLEBONNE D, 1991, FEBS LETT, V290, P173, DOI 10.1016/0014-5793(91)81253-5; DEVILLEBONNE D, 1991, BIOCHEMISTRY-US, V30, P5750, DOI 10.1021/bi00237a017; DEVILLEBONNE D, 1992, BIOCHEMISTRY-US, V31, P1695, DOI 10.1021/bi00121a017; DEVILLEBONNE D, 1989, BIOCHEMISTRY-US, V28, P1917, DOI 10.1021/bi00430a073; EVANS PR, 1981, PHILOS T ROY SOC B, V293, P53, DOI 10.1098/rstb.1981.0059; EVANS PR, 1992, P RA WELCH F C CHEM, V36, P39; FERDINAND W, 1966, BIOCHEM J, V98, P278, DOI 10.1042/bj0980278; FRENCH BA, 1987, GENE, V54, P65, DOI 10.1016/0378-1119(87)90348-9; HELLINGA HW, 1985, EUR J BIOCHEM, V149, P363, DOI 10.1111/j.1432-1033.1985.tb08934.x; JOHNSON JL, 1992, BIOCHEMISTRY-US, V31, P11510, DOI 10.1021/bi00161a032; KIM SJ, 1993, BIOPHYS J, V65, P215, DOI 10.1016/S0006-3495(93)81070-1; KOTLARZ D, 1982, METHOD ENZYMOL, V90, P60; KUNDROT CE, 1991, BIOCHEMISTRY-US, V30, P1478, DOI 10.1021/bi00220a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU FTK, 1989, BIOCHEMISTRY-US, V28, P6841, DOI 10.1021/bi00443a010; LEBRAS G, 1982, BIOCHEMISTRY-US, V21, P6656, DOI 10.1021/bi00269a007; LEBRAS G, 1989, BIOCHEMISTRY-US, V28, P6836, DOI 10.1021/bi00443a009; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MONOD J, 1965, J MOL BIOL, V3, P318; Neet K E, 1980, Methods Enzymol, V64, P192; Segel IH, 1975, ENZYME KINETICS, P460; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SHIRMER T, 1990, NATURE, V343, P140; TESCHNER W, 1990, FEBS LETT, V267, P96, DOI 10.1016/0014-5793(90)80297-V; VALDEZ BC, 1989, J BIOL CHEM, V264, P131; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009; ZHENG RL, 1994, J BIOL CHEM, V269, P18475; ZHENG RL, 1992, J BIOL CHEM, V267, P23640	36	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3828	3835		10.1074/jbc.270.8.3828	http://dx.doi.org/10.1074/jbc.270.8.3828			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876126	hybrid			2022-12-25	WOS:A1995QH68800056
J	ISHIKAWA, Y; MUKAIDA, N; KUNO, K; RICE, N; OKAMOTO, S; MATSUSHIMA, K				ISHIKAWA, Y; MUKAIDA, N; KUNO, K; RICE, N; OKAMOTO, S; MATSUSHIMA, K			ESTABLISHMENT OF LIPOPOLYSACCHARIDE-DEPENDENT NUCLEAR FACTOR KAPPA-B ACTIVATION IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-TYROSINE PHOSPHORYLATION; MESSENGER-RNA EXPRESSION; FACTOR-ALPHA; BACTERIAL LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTOR; INTERLEUKIN-8 GENE; BINDING PROTEIN; INFLAMMATORY CYTOKINES; MURINE MACROPHAGES	Nuclear factor kappa B (NF-kappa B), consisting of p50 and p65, is bound to a cytoplasmic retention protein, I kappa B, in a resting state, and the stimulation of cells with a variety of inflammatory stimuli induces the dissociation of NF-kappa B from I kappa B and the nuclear translocation of NF-kappa B, thereby activating several genes involved in inflammatory responses, such as interleukin (IL)-6, IL-8, and tumor necrosis factor alpha. In order to elucidate the precise mechanism of NE-kappa B activation, we have established Lipopolysaccharide (LPS)-dependent NF-kappa B activation in a cell-free system using plasma membrane-enriched, cytosol, and nuclear fractions extracted from a human monocytic cell Line, THP-1, by disruption with sonication followed by a differential centrifugation. The combination of plasma membrane enriched fraction and cytosol was sufficient to activate NF-kappa B in a LPS/CD14-dependent manner only in the presence of ATP as judged by the binding of NF-kappa B to the IL-8 gene kappa B site on an electrophoretic mobility shift assay. LPS-dependent NP-kappa B activation was inhibited by protein kinase inhibitors, such as staurosporine, herbimycin A, tyrphostin, and genistein, but not mitogen-activated protein kinase substrate, cGMP-dependent protein kinase, cAMP-dependent protein kinase, protein kinase C, and calmodulin-dependent protein kinase II inhibitory peptides, suggesting that staurosporine-sensitive kinase(s) as well as tyrosine kinase(s) are involved in LPS-mediated NF-kappa B activation. In addition, LPS induced the phosphorylation of I kappa B-alpha, starting at 5 min after the stimulation in a cell-free system. Moreover, the phosphorylation was inhibited by herbimycin A and tyrphostin, but not staurosporine, suggesting that these protein kinase inhibitors act at distinct steps of signal transmission. Establishment of ligand-dependent activation of NF-kappa B in a cell-free system will facilitate identification of protein kinase(s) and its substrate(s) involved in LPS-mediated NF-kappa B activation.	KANAZAWA UNIV,CANC RES INST,DEPT PHARMACOL,KANAZAWA,ISHIKAWA 920,JAPAN; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Kanazawa University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Mukaida, Naofumi/D-7623-2011; KUNO, Kouji/D-8439-2015	Mukaida, Naofumi/0000-0002-4193-1851; 				BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAGASRA O, 1992, P NATL ACAD SCI USA, V89, P6285, DOI 10.1073/pnas.89.14.6285; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROWNELL E, 1989, ONCOGENE, V4, P935; CAVAILLON J-M, 1990, Cytokine, V2, P313, DOI 10.1016/1043-4666(90)90061-W; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; COUTURIER C, 1992, EUR J IMMUNOL, V22, P1461, DOI 10.1002/eji.1830220619; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING A, 1993, J IMMUNOL, V151, P5596; DONG ZY, 1993, J EXP MED, V177, P1071, DOI 10.1084/jem.177.4.1071; ENDO H, 1991, LYMPHOKINE CYTOK RES, V10, P245; GENG Y, 1993, J IMMUNOL, V151, P6692; HAN JH, 1993, J BIOL CHEM, V268, P25009; HARADA A, 1993, INT IMMUNOL, V5, P681, DOI 10.1093/intimm/5.6.681; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HEUMANN D, 1992, J IMMUNOL, V148, P3505; KOVACS EJ, 1989, J IMMUNOL, V143, P3532; KOVACS EJ, 1988, J IMMUNOL, V141, P3101; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; OLIVEIRA IC, 1994, MOL CELL BIOL, V147, P5300; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PRABHAKAR U, 1993, EUR CYTOKINE NETW, V4, P31; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	42	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4158	4164		10.1074/jbc.270.8.4158	http://dx.doi.org/10.1074/jbc.270.8.4158			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876168	hybrid			2022-12-25	WOS:A1995QH68800102
J	MATSUDA, T; SAIJO, M; KURAOKA, I; KOBAYASHI, T; NAKATSU, Y; NAGAI, A; ENJOJI, T; MASUTANI, C; SUGASAWA, K; HANAOKA, F; YASUI, A; TANAKA, K				MATSUDA, T; SAIJO, M; KURAOKA, I; KOBAYASHI, T; NAKATSU, Y; NAGAI, A; ENJOJI, T; MASUTANI, C; SUGASAWA, K; HANAOKA, F; YASUI, A; TANAKA, K			DNA-REPAIR PROTEIN XPA BINDS REPLICATION PROTEIN-A (RPA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; NUCLEOTIDE EXCISION REPAIR; PIGMENTOSUM GROUP-F; XERODERMA-PIGMENTOSUM; POLYMERASE-ALPHA; DAMAGED DNA; FACTOR-A; GENE; INVITRO; COMPLEMENTATION	XPA is a zinc finger DNA-binding protein, which is missing or altered in group A xeroderma pigmentosum cells and known to be involved in the damage-recognition step of the nucleotide excision repair (NER) processes. Using the yeast two-hybrid system to search for proteins that interact with XPA, we obtained the 34-kDa subunit of replication protein A (RPA, also known as HSSB and RFA). RPA is a stable complex of three polypeptides of 70, 34, 11 kDa and has been shown to be essential in the early steps of NER as well as in replication and recombination. We also demonstrate here that the RPA complex associates with XPA. These results suggest that RPA may cooperate with XPA in the early steps of the NER processes.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,AOBA KU,SENDAI,MIYAGI 980,JAPAN	Osaka University; RIKEN; Tohoku University			Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227; Kuraoka, Isao/0000-0001-6391-3411; Nakatsu, Yoshimichi/0000-0001-7408-7071				ASAHINA H, 1994, MUTAT RES-DNA REPAIR, V315, P229, DOI 10.1016/0921-8777(94)90034-5; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DEWEERDKASTELEI, 1972, NATURE NEW BIOL, V238, P80; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MIURA N, 1991, J BIOL CHEM, V266, P19786; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SHIMAMOTO T, 1991, BIOCHEM BIOPH RES CO, V181, P1231, DOI 10.1016/0006-291X(91)92070-Z; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	45	162	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4152	4157		10.1074/jbc.270.8.4152	http://dx.doi.org/10.1074/jbc.270.8.4152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876167	hybrid			2022-12-25	WOS:A1995QH68800101
J	XU, WH; SATO, Y; IKEDA, M; YAMASHITA, O				XU, WH; SATO, Y; IKEDA, M; YAMASHITA, O			STAGE-DEPENDENT AND TEMPERATURE-CONTROLLED EXPRESSION OF THE GENE ENCODING THE PRECURSOR PROTEIN OF DIAPAUSE HORMONE AND PHEROMONE BIOSYNTHESIS ACTIVATING NEUROPEPTIDE IN THE SILKWORM, BOMBYX-MORI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGMENTS; SEQUENCE; MOTH	Embryonic diapause and sex pheromone biosynthesis in the silkworm, Bombyx mori, are, respectively, induced by diapause hormone (DH) and pheromone biosynthesis activating neuropeptide (PBAN), which are produced in the subesophageal ganglion from a common polyprotein precursor (DH-PBAN precursor) encoded by a single gene (DH-PBAN gene). Using DH-PBAN cDNA as a probe, we quantitatively measured DH-PBAN mRNA content throughout embryonic and postembryonic development and observed the effects of incubation temperature, which is a key factor for determination of diapause, on DH-PBAN gene expression, The silkworm, which is programmed to lay diapause eggs by being incubated at 25 degrees C, showed peaks of DH-PBAN mRNA content at five different stages throughout the Life cycle: at the late embryonic stage, at the middle of the fourth and the fifth larval instars, and at early and late stages of pupal-adult development. In the non-diapause type silkworms programmed by a 15 degrees C incubation, only the last peak of DH-PBAN mRNA in pupal-adult development was found, and the other peaks were absent. Furthermore, interruption of the incubation period at 25 degrees C by incubation at 15 degrees C decreased both DH-PEAN mRNA content in mature embryos and in subesophageal ganglia of day 3 pupae and the incidence of diapause eggs, Thus, there were two types of regulatory mechanisms for DH-PBAN gene expression, One is a temperature-controlled expression that is responsible for diapause induction, and the other is a temperature-independent, stage dependent expression related to pheromone production.	NAGOYA UNIV,SCH AGR SCI,SERICULTURAL SCI & ENTOMORESOURCES LAB,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; NAGOYA UNIV,RADIOISOTOPE RES CTR,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN	Nagoya University; Nagoya University								ANDO T, 1988, AGR BIOL CHEM TOKYO, V52, P473; ARIMA R, 1991, APPL ENTOMOL ZOOL, V26, P137, DOI 10.1303/aez.26.137; CHENG JF, 1986, J BIOL CHEM, V261, P839; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULONBUBLEX M, 1991, ROUX ARCH DEV BIOL, V199, P469, DOI 10.1007/BF01705783; DALLMAN MJ, 1991, PCR PRACTICAL APPROA, P215; Denlinger D.L., 1985, P353; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HASEGAWA K, 1964, J EXP BIOL, V41, P855; IKEDA M, 1993, J INSECT PHYSIOL, V39, P889, DOI 10.1016/0022-1910(93)90122-8; IMAI K, 1991, P JPN ACAD B-PHYS, V67, P98, DOI 10.2183/pjab.67.98; KOGURE MAKITA, 1933, JOUR DEPT AGRIC KYUSHU IMP UNIV, V4, P1; KOSEGAWA E, 1992, Journal of Sericultural Science of Japan, V61, P180; KOSEGAWA E, 1991, Journal of Sericultural Science of Japan, V60, P511; MOUNIER N, 1986, BIOCHIMIE, V68, P1053, DOI 10.1016/S0300-9084(86)80179-1; PEARSE V, 1987, LIVING INVERTEBRATES, P573; Sambrook J, 1989, MOL CLONING LABORATO; SATO Y, 1992, P JPN ACAD B-PHYS, V68, P75, DOI 10.2183/pjab.68.75; SATO Y, 1993, P NATL ACAD SCI USA, V90, P3251, DOI 10.1073/pnas.90.8.3251; SATO Y, 1994, GEN COMP ENDOCR, V96, P27, DOI 10.1006/gcen.1994.1156; SAUNDERS DS, 1982, INSECT CLOCKS, P156; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SU ZH, 1994, BBA-GENE STRUCT EXPR, V1218, P366, DOI 10.1016/0167-4781(94)90190-2; Watanabe K., 1924, Bulletin of the Imperial Sericultural Experiment Station, V6, P411; XU WH, IN PRESS BIOCH BIOPH; Yamashita O., 1991, P424; Yamashita O., 1985, P407; YAMASHITA O, 1991, MORPHOGENIC HORMONES, P82	28	60	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3804	3808		10.1074/jbc.270.8.3804	http://dx.doi.org/10.1074/jbc.270.8.3804			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876122	hybrid			2022-12-25	WOS:A1995QH68800052
J	FERRARI, G; ANDERSON, BL; STEPHENS, RM; KAPLAN, DR; GREENE, LA				FERRARI, G; ANDERSON, BL; STEPHENS, RM; KAPLAN, DR; GREENE, LA			PREVENTION OF APOPTOTIC NEURONAL DEATH BY G(M1) GANGLIOSIDE - INVOLVEMENT OF TRK NEUROTROPHIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; DEPENDENT PROTEIN-KINASE; CYTOPLASMIC FREE CA2+; AMINO-ACID RECEPTORS; FACTOR DEPRIVATION; GM1 GANGLIOSIDE; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; SYMPATHETIC NEURONS; NEURITE OUTGROWTH	We have used serum-deprived cultures of wild type and genetically modified PC12 cells to investigate the molecular mechanisms by which monosialoganglioside (G(M1)) rescues neuronal cells from apoptotic death elicited by withdrawal of trophic support, Our findings indicate that G(M1)-promoted survival can be mediated in part by the Trk NGF receptor as well as by TrkB, and potentially by tyrosine kinase receptors for additional neurotrophic growth factors. Experiments employing K-252a, an inhibitor of Trk kinases, and PC12 cells overexpressing a dominant inhibitory form of Trk both indicate that a portion of the survival-promoting activity of G(M1) is evoked by receptor dimerization and autophosphorylation, In consonance with this we find that G(M1) stimulates Trk tyrosine autophosphorylation and Trk-associated protein kinase activity, These observations may provide a mechanism to account for the reported in vitro and in vivo trophic actions of G(M1).	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N0I-CO-7410I] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPEL SH, 1981, ANN NEUROL, V10, P499, DOI 10.1002/ana.410100602; ARGENTINO C, 1989, STROKE, V20, P1143, DOI 10.1161/01.STR.20.9.1143; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BERG MM, 1992, J BIOL CHEM, V267, P13; BREMER EG, 1984, J BIOL CHEM, V259, P6818; CHANG JY, 1990, J NEUROCHEM, V55, P436, DOI 10.1111/j.1471-4159.1990.tb04155.x; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CUELLO AC, 1989, P NATL ACAD SCI USA, V86, P2056, DOI 10.1073/pnas.86.6.2056; DEERAUSQUIN GA, 1990, P NATL ACAD SCI USA, V87, P8017, DOI 10.1073/pnas.87.20.8017; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; FACCI L, 1984, J NEUROCHEM, V42, P299, DOI 10.1111/j.1471-4159.1984.tb02678.x; FACCI L, 1990, NEUROSCIENCE, V37, P709, DOI 10.1016/0306-4522(90)90101-9; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; FERRARI G, 1983, DEV BRAIN RES, V8, P215, DOI 10.1016/0165-3806(83)90006-8; FERRARI G, 1993, J NEUROSCI, V13, P1879; FERRARI G, 1992, DEV BRAIN RES, V65, P35, DOI 10.1016/0165-3806(92)90005-H; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; GHIDONI R, 1986, BIOCHEM J, V237, P147, DOI 10.1042/bj2370147; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1991, CULTURING NERVE CELL, P207; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; IP NY, 1993, NEURON, V10, P1; JING S, 1992, NEURON, V9, P1076; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KARPIAK SE, 1990, CRIT REV NEUROBIOL, V5, P221; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; LEDEEN R, 1985, TRENDS NEUROSCI, V8, P169, DOI 10.1016/0166-2236(85)90064-5; LEON A, 1988, J NEUROSCI, V8, P746; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LOEB DM, 1993, J NEUROSCI, V13, P2919; MANEV H, 1990, FASEB J, V4, P2789, DOI 10.1096/fasebj.4.10.2165013; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MILANI D, 1991, J NEUROSCI RES, V28, P434, DOI 10.1002/jnr.490280317; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; NAKAMURA K, 1992, J NEUROSCI RES, V31, P245, DOI 10.1002/jnr.490310205; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Purves D, 1985, PRINCIPLES NEURAL DE, P131; RICH KM, 1990, SCIENCE, V248, P1419, DOI 10.1126/science.2356470; RUKENSTEIN A, 1961, J NEUROSCI, V11, P2552; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER JS, 1992, SCIENCE, V256, P843, DOI 10.1126/science.1350379; SEREN MS, 1990, STROKE, V21, P1607, DOI 10.1161/01.STR.21.11.1607; SKAPER SD, 1989, MOL NEUROBIOL, V3, P173, DOI 10.1007/BF02935630; SKAPER SD, 1989, EXP NEUROL, V106, P297, DOI 10.1016/0014-4886(89)90163-5; SKAPER SD, 1993, J NEUROSCI RES, V33, P330; SKAPER SD, 1985, DEV BRAIN RES, V398, P19; SOTO AM, 1985, J STEROID BIOCHEM, V23, P87, DOI 10.1016/0022-4731(85)90265-1; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; TOMASI M, 1980, EUR J BIOCHEM, V111, P315, DOI 10.1111/j.1432-1033.1980.tb04944.x; TSUJI S, 1985, J BIOCHEM-TOKYO, V97, P969, DOI 10.1093/oxfordjournals.jbchem.a135140; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1992, NEURON, V9, P1067; VACCARINO F, 1987, P NATL ACAD SCI USA, V84, P8707, DOI 10.1073/pnas.84.23.8707; VANBUSKIRK R, 1985, MOL CELL BIOL, V5, P1984, DOI 10.1128/MCB.5.8.1984; VANTINI G, 1988, BRAIN RES, V448, P252, DOI 10.1016/0006-8993(88)91262-0; YATES AJ, 1989, J NEUROCHEM, V53, P162, DOI 10.1111/j.1471-4159.1989.tb07308.x	73	191	205	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3074	3080		10.1074/jbc.270.7.3074	http://dx.doi.org/10.1074/jbc.270.7.3074			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852388	hybrid			2022-12-25	WOS:A1995QG47100030
J	UCHIDA, Y; IHARA, Y				UCHIDA, Y; IHARA, Y			THE N-TERMINAL PORTION OF GROWTH-INHIBITORY FACTOR IS SUFFICIENT FOR BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; CEREBRAL CORTICAL-NEURONS; MOLECULAR-CLONING; BASAL NUCLEUS; METAL-BINDING; FACTOR CDNA; METALLOTHIONEIN; DEMENTIA; PROTEINS; DEGENERATION	To determine its active site, growth inhibitory factor (GIF), a central nervous system-specific metallothionein-like protein, was digested with trypsin followed by Staphylococcus aureus protease V8 digestion. Of 5 peptide fragments separated from trypsin-digested GIF by reverse-phase high pressure liquid chromatography and gel filtration, only GIF1-26 or longer peptides showed growth inhibitory activity on cortical neurons in culture. A shorter peptide, GIF5-23, which was obtained by further digestion of GIF1-26 with V8 protease, also showed growth inhibitory activity. However, a synthetic peptide corresponding to GIF5-23 did not show growth inhibitory activity. Metal-free GIF1-26 prepared by acid treatment showed a similar level of growth inhibitory activity to that of metal-containing GIF1-26, indicating that metal in the peptide does not affect the activity. Treatment of metal-free GIF1-26 with beta-mercaptoethanol resulted in the loss of activity. The CD spectrum of beta-mercaptoethanol-treated metal-free GIF1-26 was different from that of nontreated metal-free GIF1-26. These results indicate that the N-terminal portion of GIF is required for growth inhibitory activity and that folding of the peptide via S-metal bonding is critical for biological activity.	UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROPATHOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	UCHIDA, Y (corresponding author), TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT NEUROPATHOL,ITABASHI KU,35-2 SAKAECHO,TOKYO 173,JAPAN.							APPEL SH, 1981, ANN NEUROL, V10, P499, DOI 10.1002/ana.410100602; ARENDT T, 1986, NEUROSCIENCE, V19, P1265, DOI 10.1016/0306-4522(86)90141-7; ARENDT T, 1992, NEUROSCI LETT, V148, P63, DOI 10.1016/0304-3940(92)90805-H; BRIGGS RW, 1982, J BIOL CHEM, V257, P1259; FERRER I, 1983, ACTA NEUROPATHOL, V59, P167, DOI 10.1007/BF00703200; FERRER I, 1990, NEUROSCI LETT, V114, P11, DOI 10.1016/0304-3940(90)90420-E; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; KILLE P, 1992, J BIOL CHEM, V267, P8042; KOBAYASHI H, 1993, MOL BRAIN RES, V19, P188, DOI 10.1016/0169-328X(93)90025-K; MCKEE AC, 1989, ANN NEUROL, V26, P652, DOI 10.1002/ana.410260511; NIELSON KB, 1983, J BIOL CHEM, V258, P3063; NUKINA N, 1983, P JPN ACAD B-PHYS, V59, P288, DOI 10.2183/pjab.59.288; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; PAULABARBOSA MM, 1980, J NEUROL SCI, V45, P129, DOI 10.1016/S0022-510X(80)80014-1; POUNTNEY DL, 1994, FEBS LETT, V345, P193, DOI 10.1016/0014-5793(94)00452-8; PROBST A, 1983, BRAIN RES, V268, P249, DOI 10.1016/0006-8993(83)90490-0; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V533, P209, DOI 10.1016/0005-2795(78)90565-2; SCHEIBEL AB, 1978, EXP NEUROL, V60, P1, DOI 10.1016/0014-4886(78)90164-4; SUZUKI KT, 1981, BIOCHEM J, V199, P289, DOI 10.1042/bj1990289; TSUJI S, 1992, EMBO J, V11, P4843, DOI 10.1002/j.1460-2075.1992.tb05590.x; UCHIDA Y, 1989, BRAIN RES, V481, P190, DOI 10.1016/0006-8993(89)90503-9; UCHIDA Y, 1988, BIOCHEM BIOPH RES CO, V150, P1263, DOI 10.1016/0006-291X(88)90765-6; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249	26	59	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3365	3369		10.1074/jbc.270.7.3365	http://dx.doi.org/10.1074/jbc.270.7.3365			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852423	hybrid			2022-12-25	WOS:A1995QG47100071
J	ELDERING, E; VERPY, E; ROEM, D; MEO, T; TOSI, M				ELDERING, E; VERPY, E; ROEM, D; MEO, T; TOSI, M			COOH-TERMINAL SUBSTITUTIONS IN THE SERPIN C1 INHIBITOR THAT CAUSE LOOP OVERINSERTION AND SUBSEQUENT MULTIMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY ANGIONEUROTIC-EDEMA; REACTIVE-BOND LOOP; ALPHA-1-PROTEINASE INHIBITOR; ALPHA-1-ANTITRYPSIN DEFICIENCY; CONFORMATIONAL STABILITY; PROTEINASE-INHIBITORS; MONOCLONAL-ANTIBODY; PLASMA KALLIKREIN; C1-BAR INHIBITOR; STRUCTURAL BASIS	The region COOH-terminal to the reactive center loop is highly conserved in the serine protease inhibitor (serpin) family, We have studied the structural consequences of three substitutions (Val(451) --> Met, Phe(455) --> Ser, and Pro(476) --> Ser) found in this region of C1 inhibitor in patients suffering from hereditary angioedema, Equivalent substitutions have been described in alpha 1-antitrypsin and antithrombin m. The mutant C1 inhibitor proteins were only partially secreted upon transient transfection into COS-7 cells and were found to be dysfunctional, Immunoprecipitation of conditioned media demonstrated that in the intact, uncleaved form they all bind to a monoclonal antibody which recognizes specifically the protease-complexed or reactive center-cleaved normal C1 inhibitor, A second indication for an intrinsic conformational change was the increased thermostability compared to the normal protein. Furthermore, gel filtration studies showed that the Val(451) --> Met and Pro(476) --> Ser mutant proteins, and to a lesser extent Phe(455) --> Ser, were prone to spontaneous multimerization. Finally, a reduced susceptibility to reactive center cleavage by trypsin was observed for all three mutants, and the cleaved Val(451) --> Met and Pro(476) --> Ser mutants failed to adopt the conformation recognized by a cleavage-specific monoclonal antibody, Investigation of plasmas of patients with the Val(451) --> Met or Pro(476) --> Ser substitutions showed that these dysfunctional proteins circulate at low levels and are recognized by the complex-specific antibody. These results strongly indicate a conformational change as a result of these carboxyl-terminal substitutions, such that anchoring of the reactive center loop at the COOH-terminal side is not achieved properly. We propose that this results in over-insertion of the loop into beta-sheet A, which subsequently leads to multimerization.	INST PASTEUR,INSERM,U276,UNITE IMMUNOGENET,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	ELDERING, E (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT AUTOIMMUNE DIS,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.							AULAK KS, 1993, J BIOL CHEM, V268, P18088; AULAK KS, 1990, BIOCHEM J, V271, P565, DOI 10.1042/bj2710565; AUSTIN RC, 1991, BLOOD, V77, P2185; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BOCK SC, 1988, BIOCHEMISTRY-US, V27, P6171, DOI 10.1021/bi00416a052; BRODBECK RM, 1992, J BIOL CHEM, V267, P294; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CASO R, 1991, BRIT J HAEMATOL, V77, P87, DOI 10.1111/j.1365-2141.1991.tb07953.x; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CUGNO M, 1990, J CLIN INVEST, V85, P1215, DOI 10.1172/JCI114555; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DAVIS AE, 1993, NAT GENET, V1, P354; DAWES J, 1994, BIOCHEMISTRY-US, V33, P4375, DOI 10.1021/bi00180a035; DEAGOSTINI A, 1985, P NATL ACAD SCI USA, V82, P5190; DESMET BJGL, 1993, BLOOD, V81, P56, DOI 10.1182/blood.V81.1.56.bloodjournal81156; ELDERING E, 1992, J BIOL CHEM, V267, P7013; ELDERING E, 1988, J BIOL CHEM, V263, P11776; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HARPEL PC, 1975, J CLIN INVEST, V55, P593, DOI 10.1172/JCI107967; HOFKER MH, 1989, HUM GENET, V81, P264, DOI 10.1007/BF00279001; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LANE DA, 1992, J CLIN INVEST, V90, P2422, DOI 10.1172/JCI116133; LEWIN MF, 1983, J BIOL CHEM, V258, P6415; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V5, P1295; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NUIJENS JH, 1989, J CLIN INVEST, V84, P443, DOI 10.1172/JCI114185; NUIJENS JH, 1988, BLOOD, V72, P1841; NUIJENS JH, 1987, IMMUNOLOGY, V61, P387; ODERMATT E, 1981, FEBS LETT, V131, P283, DOI 10.1016/0014-5793(81)80385-7; OLDS RJ, 1992, BLOOD, V79, P1206, DOI 10.1182/blood.V79.5.1206.bloodjournal7951206; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PEMBERTON PA, 1989, BIOCHEM J, V258, P193, DOI 10.1042/bj2580193; PERKINS SJ, 1990, J MOL BIOL, V214, P751, DOI 10.1016/0022-2836(90)90290-3; PERRY DJ, 1991, FEBS LETT, V285, P248, DOI 10.1016/0014-5793(91)80809-H; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VERPY E, 1995, IN PRESS J CLIN INVE	56	91	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2579	2587		10.1074/jbc.270.6.2579	http://dx.doi.org/10.1074/jbc.270.6.2579			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852321	hybrid			2022-12-25	WOS:A1995QF53500029
J	KULIAWAT, R; LISANTI, MP; ARVAN, P				KULIAWAT, R; LISANTI, MP; ARVAN, P			POLARIZED DISTRIBUTION AND DELIVERY OF PLASMA-MEMBRANE PROTEINS IN THYROID FOLLICULAR EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOPEPTIDASE-N; SURFACE DISTRIBUTION; MDCK CELLS; ANCHORED PROTEINS; IODIDE TRANSPORT; PEROXIDASE; THYROGLOBULIN; LOCALIZATION; LINE; IODINATION	Thyroid follicular cells coordinate several oppositely located surface enzyme activities. Recent studies have raised questions about the basic mechanisms used to achieve thyroid surface polarity. We investigated these mechanisms in primary thyroid epithelial monolayers cultured on porous filters. In the steady state, most Na+/K+-ATPase and aminopeptidase N were available for surface biotinylation, and these proteins exhibited physiological distributions (basolateral and apical, respectively). Glycosylphosphatidylinositol-anchored proteins were also apically distributed. By pulse-chase, newly synthesized transmembrane proteins exhibited polarized surface delivery that was oriented similarly to that observed at steady state. Little time elapsed between acquisition of Golgi-specific processing and cell surface arrival. Interestingly when either newly synthesized or steady state-labeled thyroid peroxidase was similarly analyzed, only similar to 30% of the enzyme was ever detected at the cell surface. Of this, the majority was localized apically. The data suggest that most thyroid peroxidase remains intracellular in these monolayers, consistent with the possibility of intracellular iodination activity in addition to apical extracellular iodination. Nevertheless, in filter-polarized thyrocytes, most newly synthesized plasma membrane proteins appear to be sorted in the Golgi complex for direct delivery to apical and basolateral domains.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV ENDOCRINOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, PROGRAM BIOL & BIOMED SCI, BOSTON, MA 02215 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute			Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018	Lisanti, Michael/0000-0003-2034-1382; Kuliawat, Regina/0000-0001-8386-2279	NIDDK NIH HHS [DK07516, DK 40344] Funding Source: Medline; NIGMS NIH HHS [GM 50443] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007516, R01DK107516, R29DK040344, R01DK040344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALQUIER C, 1989, AUTOIMMUNITY, V3, P113, DOI 10.3109/08916938909019960; ARVAN P, 1991, J CELL BIOL, V112, P365, DOI 10.1083/jcb.112.3.365; BALCAROVASTANDER J, 1984, EMBO J, V3, P2687, DOI 10.1002/j.1460-2075.1984.tb02194.x; BARRIERE H, 1986, CELL TISSUE RES, V245, P159; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BJORKMAN U, 1988, ENDOCRINOLOGY, V122, P488; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHAMBARD M, 1983, J CELL BIOL, V96, P1172, DOI 10.1083/jcb.96.4.1172; CHOW SY, 1986, AM J PHYSIOL, V250, pE464, DOI 10.1152/ajpendo.1986.250.4.E464; CONTRERAS RG, 1989, AM J PHYSIOL, V257, pC896, DOI 10.1152/ajpcell.1989.257.5.C896; CZARNOCKA B, 1986, J ENDOCRINOL INVEST, V9, P135, DOI 10.1007/BF03348084; FERACCI H, 1981, CELL TISSUE RES, V221, P137, DOI 10.1007/BF00216576; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; GERARD C, 1985, EUR J CELL BIOL, V38, P134; GOLSTEIN P, 1992, AM J PHYSIOL, V263, pC590, DOI 10.1152/ajpcell.1992.263.3.C590; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GRUFFAT D, 1991, J ENDOCRINOL, V128, P51, DOI 10.1677/joe.0.1280051; HALLER C, 1993, AM J PHYSIOL, V265, pC1069, DOI 10.1152/ajpcell.1993.265.4.C1069; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; HANSEN GH, 1987, EUR J CELL BIOL, V43, P253; HERZLINGER DA, 1984, J CELL BIOL, V98, P1777, DOI 10.1083/jcb.98.5.1777; HERZOG V, 1992, J CELL BIOL, V118, P1071, DOI 10.1083/jcb.118.5.1071; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KOTANI T, 1986, J CLIN ENDOCR METAB, V62, P928, DOI 10.1210/jcem-62-5-928; KULIAWAT R, 1994, J BIOL CHEM, V269, P4922; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LONG Y, 1991, EUR J BIOCHEM, V202, P501, DOI 10.1111/j.1432-1033.1991.tb16401.x; MAGNUSSON RP, 1987, J BIOL CHEM, V262, P13885; MATSUKAWA S, 1979, J BIOCHEM-TOKYO, V86, P199; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MAUCHAMP J, 1987, ACTA ENDOCRINOL-COP, V115, P220; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NAKAMURA Y, 1990, J ENDOCRINOL, V126, P275, DOI 10.1677/joe.0.1260275; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NILSSON M, 1987, CELL TISSUE RES, V250, P295, DOI 10.1007/BF00219074; NILSSON M, 1992, ACTA ENDOCRINOL-COP, V126, P67, DOI 10.1530/acta.0.1260067; NITSCH L, 1985, EUR J CELL BIOL, V38, P57; OFVERHOLM T, 1984, ENDOCRINOLOGY, V114, P827; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PRABAKARAN D, 1993, J BIOL CHEM, V268, P9041; RAWITCH AB, 1992, ARCH BIOCHEM BIOPHYS, V297, P321, DOI 10.1016/0003-9861(92)90679-Q; RINDLER MJ, 1985, J CELL BIOL, V100, P136, DOI 10.1083/jcb.100.1.136; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROLLAND M, 1976, BIOCHIM BIOPHYS ACTA, V427, P696, DOI 10.1016/0005-2795(76)90213-0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; VILIJN F, 1989, J BIOL CHEM, V264, P11901; WATANABE K, 1991, ENDOCRINOL JAPON, V38, P89; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923; WOLLMAN SH, 1989, EUR J CELL BIOL, V50, P247; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; ZURZOLO C, 1993, SCIENCE, V260, P550, DOI 10.1126/science.8386394; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031; ZURZOLO C, 1992, J CELL BIOL, V117, P551, DOI 10.1083/jcb.117.3.551; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x; ZURZOLO C, 1992, EMBO J, V11, P2337, DOI 10.1002/j.1460-2075.1992.tb05293.x	57	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2478	2482		10.1074/jbc.270.6.2478	http://dx.doi.org/10.1074/jbc.270.6.2478			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852309	hybrid			2022-12-25	WOS:A1995QF53500015
J	LEE, HC; AARHUS, R				LEE, HC; AARHUS, R			A DERIVATIVE OF NADP MOBILIZES CALCIUM STORES INSENSITIVE TO INOSITOL TRISPHOSPHATE AND CYCLIC ADP-RIBOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; CA2+ RELEASE; METABOLITE; ENZYME; FERTILIZATION	We have previously shown that alkaline treatment of NADP generates a derivative which can mobilize Ca2+ from sea urchin egg homogenates (Clapper, D. L., Walseth, T. F., Dargie, P. J., and Lee, H. C. (1987) J. Biol. Chem. 262, 9561-9568), In this study, the active derivative was purified and shown by high pressure liquid chromatography to be distinct from NADP and NADPH. However, its proton NMR spectrum was virtually identical to that of NADP. The mass of its molecular ion was measured by high resolution mass spectrometry to be 743.0510, one mass unit larger than the corresponding ion of NADP, These results are consistent with the active derivative being nicotinic acid adenine dinucleotide phosphate (NAADP). Ca2+ release induced by NAADP was saturable with a half-maximal concentration of about 30 nM. The release was specific since NADP and nicotinic acid adenine dinucleotide were ineffective even at 10-40-fold higher concentrations, The NAADP-dependent Ca2+ release showed desensitization and was insensitive to heparin and a specific antagonist of cyclic ADP-ribose (cADPR), 8-amino-cADPR. The release mechanism did not require calmodulin, This is similar to the inositol trisphosphate-sensitive release but distinct from that of cADPR. That the NAADP-sensitive Ca2+ stores were different from those sensitive to inositol trisphosphate- or cADPR was further indicated by their differences in distribution on Percoll density gradients. Microinjection of NAADP into live sea urchin eggs induced transient elevation of intracellular Ca2+ and triggered the cortical reaction, indicating the NAADP dependent mechanism is operative in intact cells.			LEE, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,LYON LAB 6-182,MINNEAPOLIS,MN 55455, USA.		Lee, Hon Cheung/C-4329-2009		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484, R01HD032040] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484, HD32040] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; EPEL D, 1981, CELL, V23, P543, DOI 10.1016/0092-8674(81)90150-1; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; LEE HC, 1994, NEWS PHYSIOL SCI, V9, P134; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; Lee Hon Cheung, 1994, V48, P199; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; YAN C, 1987, J BIOL CHEM, V262, P9082	19	392	399	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2152	2157		10.1074/jbc.270.5.2152	http://dx.doi.org/10.1074/jbc.270.5.2152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836444	hybrid			2022-12-25	WOS:A1995QE49300028
J	SHENNAN, KIJ; TAYLOR, NA; JERMANY, JL; MATTHEWS, G; DOCHERTY, K				SHENNAN, KIJ; TAYLOR, NA; JERMANY, JL; MATTHEWS, G; DOCHERTY, K			DIFFERENCES IN PH OPTIMA AND CALCIUM REQUIREMENTS FOR MATURATION OF THE PROHORMONE CONVERTASES PC2 AND PC3 INDICATES DIFFERENT INTRACELLULAR LOCATIONS FOR THESE EVENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROINJECTED XENOPUS OOCYTES; SITE-DIRECTED MUTAGENESIS; KEX2; CDNA; IDENTIFICATION; PROINSULIN; CLEAVAGE; CELLS; ENDOPEPTIDASE; GLYCOSYLATION	PC2 and PC3, which is also known as PC1, are subtilisin-like proteases that are involved in the intracellular processing of prohormones and proneuropeptides. Both enzymes are synthesized as propolypeptides that undergo proteolytic maturation within the secretory pathway. An in vitro translation/translocation system from Xenopus egg extracts was used to investigate mechanisms in the maturation of pro-PC3 and pro-PC2. Pro-PC3 underwent rapid (t(1/2) < 10 min) processing of the 88-kDa propolypeptide at the sequence RSKR(83) to generate the 80-kDa active form of the enzyme. This processing was blocked when the active site aspartate was changed to asparagine, suggesting that an autocatalytic mechanism was involved. In this system, processing of pro-PCS was optimal between pH 7.0 and 8.0 and was not dependent on additional calcium. These results are consistent with pro-PCS maturation occurring at an early stage in the secretory pathway, possibly within the endoplasmic reticulum, where the pH would be close to neutral and the calcium concentration less than that observed in later compartments. Processing of pro-PC2 in the Xenopus egg extract was much slower than that of pro-PC3 (t(1/2) = 8 h). It exhibited a pH optimum of 5.5-6.0 and was dependent on calcium (K-0.5 = 2-4 mM), The enzymatic properties of pro-PCB processing were similar to that of the mature enzyme. Further studies using mutant pro PCB constructs suggested that cleavage of pro-PC2 was catalyzed by the mature 68-kDa PC2 molecule. The results were consistent with pro-PC2 maturation occurring within a late compartment of the secretory pathway that contains a high calcium concentration and low pH.	UNIV BIRMINGHAM, QUEEN ELIZABETH HOSP, DEPT MED, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; UNIV BIRMINGHAM, SCH BIOCHEM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND	University of Birmingham; University of Birmingham				Docherty, Kevin/0000-0001-6765-2060				ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; BAILYES EM, 1992, BIOCHEM J, V285, P391, DOI 10.1042/bj2850391; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRENNER C, 1993, CURR BIOL, V3, P498, DOI 10.1016/0960-9822(93)90040-U; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GUEST PC, 1992, J BIOL CHEM, V267, P22401; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; LAU JTY, 1983, J BIOL CHEM, V258, P5255; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P263, DOI 10.1006/mcne.1994.1030; MACH L, 1994, J BIOL CHEM, V269, P13030; MATTHEWS G, 1991, NUCLEIC ACIDS RES, V19, P6405, DOI 10.1093/nar/19.23.6405; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; RHODES CJ, 1993, J BIOL CHEM, V268, P4267; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; VINDROLA O, 1993, NEUROPEPTIDES, V25, P151, DOI 10.1016/0143-4179(93)90096-S; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU Y, 1994, J BIOL CHEM, V269, P18408	31	87	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1402	1407		10.1074/jbc.270.3.1402	http://dx.doi.org/10.1074/jbc.270.3.1402			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836407	hybrid			2022-12-25	WOS:A1995QB15600064
J	PERTILE, P; LISCOVITCH, M; CHALIFA, V; CANTLEY, LC				PERTILE, P; LISCOVITCH, M; CHALIFA, V; CANTLEY, LC			PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE SYNTHESIS IS REQUIRED FOR ACTIVATION OF PHOSPHOLIPASE-D IN U937 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; PHOSPHATIDYLCHOLINE BREAKDOWN; SIGNAL TRANSDUCTION; PHOSPHATIDIC-ACID; HUMAN PLATELETS; 3T3 CELLS; PROTEIN; HYDROLYSIS; INHIBITION; KINASE	Phospholipase D (PLD) has been implicated in signal transduction and membrane traffic. We have previously shown that phosphatidylinositol 4,5-bisphosphate (PtdIns-4,5-P-2) stimulates in vitro partially purified brain membrane PLD activity, defining a novel function of PtdIns-4,5-P-2 as a PLD cofactor. In the present study we extend these observations to permeabilized U937 cells. In these cells, the activation of PLD by guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) is greatly potentiated by MgATP. We have utilized this experimental system to test the hypothesis that MgATP potentiates PLD activation by G proteins because it is required for PtdIns-4,5-P-2 synthesis by phosphoinositide kinases. As expected, MgATP was absolutely required for maintaining elevated phosphatidylinositol 4-phosphate (PtdIns-4-P) and PtdIns-4,5-P-2 levels in the permeabilized cells. In the presence of MgATP, GTP gamma S further elevated the levels of the phosphoinositides. The importance of PtdIns-4,5-P-2 for PLD activation was examined by utilizing a specific inhibitory antibody directed against phosphatidylinositol 4 kinase (PtdIns 4-kinase), the enzyme responsible for the first step in the synthesis of PtdIns-4,5-P-2. Anti-PtdIns 4-kinase completely inhibited PtdIns 4-kinase activity in vitro and reduced by 75-80% PtdIns-4-P and PtdIns-4,5-P-2 levels in the permeabilized cells. In parallel, the anti-PtdIns 4-kinase fully inhibited the activation of PLD by GTP gamma S and caused a 60% inhibition of PLD activation by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate, indicating that elevated PtdIns-4,5-P-2 levels are required for PLD activation. This conclusion is supported by the fact that neomycin, a high affinity ligand of PtdIns-4,5-P-2, also blocked PLD activation. Furthermore, the activity of PLD in U937 cell lysate was stimulated by PtdIns-4,5-P-2 in a dose-dependent manner. The current results indicate that PtdIns-4,5-P-2 synthesis is required for PLD activation in permeabilized U937 cells and strongly support the proposed function of PtdIns-4,5-P-2 as a cofactor for PLD. In addition, the results further establish PtdIns-4,5-P-2 as a key component in the generation of second messengers via multiple pathways including phosphoinositide-phospholipase C, phosphoinositide 3-kinase and PLD.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; WEIZMANN INST SCI, DEPT HORMONE RES, IL-76100 REHOVOT, ISRAEL	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Weizmann Institute of Science			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Chalifa-Caspi, Vered/0000-0001-6030-5816	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36624] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1991, CANCER CELLS, V8, P268; BALBOA MA, 1992, J EXP MED, V176, P9, DOI 10.1084/jem.176.1.9; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURGOYNE RD, 1994, TRENDS BIOCHEM SCI, V19, P55, DOI 10.1016/0968-0004(94)90032-9; CANO E, 1992, EUR J IMMUNOL, V22, P1883, DOI 10.1002/eji.1830220731; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHAHWALA SB, 1987, BIOCHEMISTRY-US, V26, P612, DOI 10.1021/bi00376a037; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; COORSSEN JR, 1993, FEBS LETT, V316, P170, DOI 10.1016/0014-5793(93)81209-I; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; HEISS SG, 1991, BIOCHEMISTRY-US, V30, P8753, DOI 10.1021/bi00100a006; HUANG CF, 1992, J BIOL CHEM, V267, P16859; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KANOH H, 1993, NEUROSCI LETT, V151, P146, DOI 10.1016/0304-3940(93)90007-8; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KISS Z, 1990, J BIOL CHEM, V265, P7345; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LISCOVITCH M, 1991, BIOCHEM J, V279, P319, DOI 10.1042/bj2790319; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LISCOVITCH M, 1991, CELL REGUL, V2, P1011, DOI 10.1091/mbc.2.12.1011; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; MULLMANN TJ, 1990, BIOCHEM BIOPH RES CO, V170, P1197, DOI 10.1016/0006-291X(90)90520-W; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OZAKI Y, 1993, BIOCHEM PHARMACOL, V46, P395; PERRY DK, 1992, J IMMUNOL, V149, P2749; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RHEE SG, 1994, SIGNAL ACTIVATED PHO, P1; SCHACHT J, 1978, J LIPID RES, V19, P1063; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; STEWART SJ, 1991, CELL REGUL, V2, P841, DOI 10.1091/mbc.2.10.841; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TOKER A, 1994, J BIOL CHEM, V269, P32358; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; WANG BM, 1984, BIOCHEM PHARMACOL, V33, P3257, DOI 10.1016/0006-2952(84)90087-X; WANG P, 1991, J BIOL CHEM, V266, P14877; WONG K, 1994, J BIOL CHEM, V269, P28878; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382	63	110	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5130	5135		10.1074/jbc.270.10.5130	http://dx.doi.org/10.1074/jbc.270.10.5130			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890622	hybrid			2022-12-25	WOS:A1995QL58000029
J	CHO, HS; CRONAN, JE				CHO, HS; CRONAN, JE			DEFECTIVE EXPORT OF A PERIPLASMIC ENZYME DISRUPTS REGULATION OF FATTY-ACID SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; GENE	Escherichia coli thioesterase I (TesA) encoded by the tesA gene is located in the cellular periplasm. The tesA gene was modified by deletion of the leader sequence such that the mature enzyme was instead localized to the cellular cytosol. Production of thioesterase I in the cytosol results in striking changes in the pattern of E. coli lipid synthesis. In contrast to normal E. coli cells, cells producing cytosolic TesA synthesize large amounts of free fatty acid at all stages of growth. Moreover, cultures of the cytosolic TesA-producing strain continue lipid synthesis (as free fatty acid) in stationary phase whereas lipid synthesis is normally strongly inhibited in such cultures. Surprisingly, production of cytosolic thioesterase I gave only modest inhibition of membrane phospholipid synthesis. These results demonstrate that internalization of a normally secreted enzyme can disrupt normal cellular regulatory mechanisms.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMSON L, 1970, LACTOSE OPERON, P317; ALPERS DH, 1965, P NATL ACAD SCI USA, V68, P3720; BOWDEN GA, 1993, J BACTERIOL, V174, P3407; CHO H, 1994, J BACTERIOL, V176, P1793, DOI 10.1128/jb.176.6.1793-1795.1994; CHO HS, 1993, J BIOL CHEM, V268, P9238; Christie W.W., 2003, LIPID ANAL; CRONAN JE, 1968, J BACTERIOL, V95, P2054, DOI 10.1128/JB.95.6.2054-2061.1968; DEMAIN AI, 1993, SCIENCE, V262, P1744; DEMAIN AI, 1993, EMBO J, V12, P879; GUZMAN LM, 1992, J BACTERIOL, V174, P7716, DOI 10.1128/JB.174.23.7717-7728.1992; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; HIREL P, 1989, P NATL ACAD SCI USA, V91, P8247; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; KEPES A, 1967, BIOCHIM BIOPHYS ACTA, V138, P107, DOI 10.1016/0005-2787(67)90591-6; KNOLL LJ, 1993, J BIOL CHEM, V268, P4281; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PEYPOUX F, 1970, Biochimica et Biophysica Acta, V218, P453, DOI 10.1016/0005-2760(70)90008-1; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; Reid T.W., 1971, ENZYMES, V4, P373; Sambrook J, 1989, MOL CLONING LABORATO; SCHULMAN RG, 1979, SCIENCE, V205, P160; STUDIER FW, 1990, METHOD ENZYMOL, V185, P61	24	125	159	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4216	4219		10.1074/jbc.270.9.4216	http://dx.doi.org/10.1074/jbc.270.9.4216			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876180	hybrid			2022-12-25	WOS:A1995QK08400010
J	KLODOS, I; FEDOSOVA, NU; PLESNER, L				KLODOS, I; FEDOSOVA, NU; PLESNER, L			INFLUENCE OF INTRAMEMBRANE ELECTRIC CHARGE ON NA,K-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; SODIUM-POTASSIUM PUMP; ATP-ADP EXCHANGE; CONFORMATIONAL TRANSITIONS; ADENOSINE-TRIPHOSPHATASE; PHOSPHOLIPID-VESICLES; NA+/K+-ATPASE; NA,K PUMP; OX BRAIN; K+	Effects of lipophilic ions, tetraphenylphosphonium (TPP+) and tetraphenylboron (TPB-), on interactions of Na+ and K+ with Na,K-ATPase were studied with membrane-bound enzyme from bovine brain, pig kidney, and shark rectal gland. Na+ and K+ interactions with the inward-facing binding sites, monitored by eosin fluorescence and phosphorylation, were not influenced by lipophilic ions. Phosphoenzyme interactions with extracellular cations were evaluated through K+-, ADP-, and Na+-dependent dephosphorylation. TPP+ decreased: 1) the rate of transition of ADP-insensitive to ADP-sensitive phosphoenzyme, 2) the K+ affinity and the rate coefficient for dephosphorylation of the K-sensitive phosphoenzyme, 3) the Na+ affinity and the rate coefficient for Na+-dependent dephosphorylation, Pre steady state phosphorylation experiments indicate that the subsequent occlusion of extracellular cations was prevented by TPP+, TPB- had opposite effects. Effects of lipophilic ions on the transition between phosphoenzymes were significantly diminished when Na+ was replaced by N methyl-D-glucamine or Tris(+), but were unaffected by the replacement of Cl- by other anions. Lipophilic ions affected Na-ATPase, Na,K-ATPase, and p-nitrophenylphosphatase activities in accordance with their effects on the partial reactions. Effects of lipophilic ions appear to be due to their charge indicating that Na+ and K+ access to their extracellular binding sites is modified by the intramembrane electric field.			KLODOS, I (corresponding author), AARHUS UNIV, INST BIOPHYS, OLE WORMS ALLE 185, DK-8000 AARHUS C, DENMARK.			Fedosova, Natalya U./0000-0002-1706-6108				ANDERSEN OS, 1978, BIOPHYS J, V21, P35, DOI 10.1016/S0006-3495(78)85507-6; APELL HJ, 1989, J MEMBRANE BIOL, V110, P103, DOI 10.1007/BF01869466; BEAUGE L, 1983, BIOCHIM BIOPHYS ACTA, V727, P336, DOI 10.1016/0005-2736(83)90419-4; BERBERIAN G, 1985, BIOCHIM BIOPHYS ACTA, V821, P17, DOI 10.1016/0005-2736(85)90148-8; BUHLER R, 1991, J MEMBRANE BIOL, V121, P141, DOI 10.1007/BF01870529; DRAPEAU P, 1980, J BIOL CHEM, V255, P7827; ESMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1110, P20, DOI 10.1016/0005-2736(92)90289-X; FEDOSOVA NU, 1994, SODIUM PUMP, P565; FLASCHKA H, 1960, ADV ANALYT CHEM INST, V1, P1; FLEWELLING RF, 1986, BIOPHYS J, V49, P541, DOI 10.1016/S0006-3495(86)83664-5; FLEWELLING RF, 1986, BIOPHYS J, V49, P531, DOI 10.1016/S0006-3495(86)83663-3; GADSBY DC, 1992, ACTA PHYSIOL SCAND, V146, P111; GADSBY DC, 1991, SOC GEN PHY, V46, P355; Glynn I M, 1988, Prog Clin Biol Res, V268A, P435; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1976, J PHYSIOL-LONDON, V256, P465, DOI 10.1113/jphysiol.1976.sp011333; GLYNN IM, 1987, J PHYSIOL-LONDON, V383, P477; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; GLYNN IM, 1982, MEMBRANES TRANSPORT, V1, P529; GOLDSHLEGER DM, 1994, SODIUM PUMP STRUCTUR, P309; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; HARA Y, 1981, J BIOCHEM, V90, P923, DOI 10.1093/oxfordjournals.jbchem.a133580; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; JENSEN J, 1983, CURR TOP MEMBR TRANS, V19, P223; JENSEN J, 1984, J PHYSIOL-LONDON, V346, P219, DOI 10.1113/jphysiol.1984.sp015018; JENSEN J, 1983, BIOCHIM BIOPHYS ACTA, V731, P282, DOI 10.1016/0005-2736(83)90020-2; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1991, SOC GEN PHY, V46, P189; JORGENSEN PL, 1994, SODIUM PUMP, P297; KAPLAN JH, 1982, J GEN PHYSIOL, V80, P915, DOI 10.1085/jgp.80.6.915; KAPLAN JH, 1980, NATURE, V288, P587, DOI 10.1038/288587a0; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V525, P252, DOI 10.1016/0005-2744(78)90219-X; KLODOS I, 1981, BIOCHIM BIOPHYS ACTA, V643, P463, DOI 10.1016/0005-2736(81)90089-4; KLODOS I, 1975, ANAL BIOCHEM, V67, P397, DOI 10.1016/0003-2697(75)90311-5; KLODOS I, 1987, BIOCHIM BIOPHYS ACTA, V897, P302, DOI 10.1016/0005-2736(87)90426-3; KLODOS I, 1994, J BIOL CHEM, V269, P1734; KLODOS I, 1992, ACTA PHYSIOL SCAND, V146, P235; KLODOS I, 1985, SODIUM PUMP, P383; KLODOS I, 1979, NA K ATPASE STRUCTUR, P331; LANGER P, 1991, SODIUM PUMP STRUCTUR, P303; LAUGER P, 1991, ELECTROGENIC ION PUM, P177; LINDBERG O, 1956, METHODS BIOCHEMICAL, V3, P1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARDH S, 1975, BIOCHIM BIOPHYS ACTA, V391, P464; Norby J G, 1988, Prog Clin Biol Res, V268A, P249; NORBY JG, 1971, BIOCHIM BIOPHYS ACTA, V233, P104, DOI 10.1016/0005-2736(71)90362-2; NORBY JG, 1983, J GEN PHYSIOL, V82, P725, DOI 10.1085/jgp.82.6.725; OTTOLENGHI P, 1975, BIOCHEM J, V151, P61, DOI 10.1042/bj1510061; POST RL, 1975, J SUPRAMOL STR CELL, V3, P479, DOI 10.1002/jss.400030508; POST RL, 1991, SOC GEN PHY, V46, P201; POST RL, 1972, J BIOL CHEM, V247, P6530; RAKOWSKI RF, 1991, J MEMBRANE BIOL, V121, P177, DOI 10.1007/BF01870531; RAKOWSKI RF, 1991, SOC GEN PHY, V46, P339; REPHAELI A, 1986, J BIOL CHEM, V261, P2437; REPHAELI A, 1986, J BIOL CHEM, V261, P6248; ROBINSON JD, 1993, BIOCHIM BIOPHYS ACTA, V1154, P83, DOI 10.1016/0304-4157(93)90018-J; SAGAR A, 1994, J GEN PHYSIOL, V103, P869, DOI 10.1085/jgp.103.5.869; SCHWARZ W, 1991, SOC GEN PHY, V46, P327; SKOU JC, 1979, BIOCHIM BIOPHYS ACTA, V567, P436, DOI 10.1016/0005-2744(79)90129-3; SKOU JC, 1980, BIOCHIM BIOPHYS ACTA, V601, P386, DOI 10.1016/0005-2736(80)90543-X; SKOU JC, 1983, BIOCHIM BIOPHYS ACTA, V746, P101, DOI 10.1016/0167-4838(83)90016-X; STEINBERG M, 1989, J BIOL CHEM, V264, P2726; STIMERS JR, 1993, J MEMBRANE BIOL, V135, P39; STURMER W, 1991, J MEMBRANE BIOL, V121, P163, DOI 10.1007/BF01870530; VASILETS LA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P201, DOI 10.1016/0304-4157(93)90012-D; VASILETS LA, 1991, J BIOL CHEM, V266, P16285; YODA A, 1987, J BIOL CHEM, V262, P110	68	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4244	4254		10.1074/jbc.270.9.4244	http://dx.doi.org/10.1074/jbc.270.9.4244			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876184	hybrid			2022-12-25	WOS:A1995QK08400014
J	KUMAR, AP; MAR, PK; ZHAO, BW; MONTGOMERY, RL; KANG, DC; BUTLER, AP				KUMAR, AP; MAR, PK; ZHAO, BW; MONTGOMERY, RL; KANG, DC; BUTLER, AP			REGULATION OF RAT ORNITHINE DECARBOXYLASE PROMOTER ACTIVITY BY BINDING OF TRANSCRIPTION FACTOR SP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TRANS-ACTING FACTOR; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; HEPATOMA-CELLS; STIMULATION; CLONING; GROWTH; FIBROBLASTS	Ornithine decarboxylase (ODC) is the rate-limiting enzyme of polyamine biosynthesis, We investigated the transcriptional regulation of the rat ODC gene using transient expression assays, The 5'-flanking region (-1156 to +13) of the ODC gene was sufficient to mediate strong basal expression of a luciferase reporter. Sequences between -345 and -93 contributed to basal promoter activity. This region, containing five potential Sp1 binding sites, was analyzed by electrophoretic mobility shift assays. Three specific DNA-protein complexes were identified using H35 nuclear extracts and the -345/-93 ODC probe, Binding to all three was eliminated by competition with an oligonucleotide containing an Sp1 binding site, but not by a mutant Sp1 oligonucleotide. Preincubation with an antibody against Sp1 supershifted complexes associated with one or more of Sp1 binding sites 1-4 as well as with site 5, DNase I footprinting revealed two protected regions: PR-I (-92 to -130) and PR-II (-304 to -332), PR-I contains a putative binding site for Sp1 that was protected by recombinant Sp1 protein, Transfection studies in Schneider SL2 cells demonstrated that the ODC promoter is trans-activated up to 350-fold by Sp1 and that this trans-activation is dependent on the presence of Sp1 binding sites 1-4. Thus, although the ODC promoter binds multiple nuclear proteins, Sp1 or a related protein appears to be a critical determinant of ODC transcription, possibly through cooperative interactions between Sp1 and additional transcription factors.	UNIV TEXAS, MD ANDERSON CANC CTR, DIV SCI PK RES, SMITHVILLE, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA046629] Funding Source: NIH RePORTER; NCI NIH HHS [CA-46629] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ABRAHAMSEN MS, 1992, J BIOL CHEM, V267, P18866; ABRAHAMSEN MS, 1991, PERSPECTIVES CELL RE, P107; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERGER FG, 1984, J BIOL CHEM, V259, P7941; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BRABANT M, 1988, P NATL ACAD SCI USA, V85, P2200, DOI 10.1073/pnas.85.7.2200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BUTLER AP, 1987, BIOCHEM BIOPH RES CO, V147, P809, DOI 10.1016/0006-291X(87)91002-3; BUTLER AP, 1991, EXP CELL RES, V194, P56, DOI 10.1016/0014-4827(91)90129-I; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FEINSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P5761, DOI 10.1073/pnas.82.17.5761; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GEISER AG, 1993, GENE, V129, P223, DOI 10.1016/0378-1119(93)90272-5; GILMOUR SK, 1989, CARCINOGENESIS, V10, P157, DOI 10.1093/carcin/10.1.157; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HOVIS JG, 1986, J BIOL CHEM, V261, P380; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; IYER RR, 1991, GENE, V105, P97, DOI 10.1016/0378-1119(91)90518-G; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM YJ, 1994, MOL CARCINOGEN, V10, P169, DOI 10.1002/mc.2940100308; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MOSHIER JA, 1993, CANCER RES, V53, P2618; MOSHIER JA, 1990, J BIOL CHEM, V265, P4884; MOSHIER JA, 1992, NUCLEIC ACIDS RES, V20, P2581, DOI 10.1093/nar/20.10.2581; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; OBRIEN TG, 1975, CANCER RES, V35, P1662; PALVIMO JJ, 1991, NUCLEIC ACIDS RES, V19, P3921, DOI 10.1093/nar/19.14.3921; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PENA A, 1993, J BIOL CHEM, V268, P27277; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; Sambrook J, 1989, MOL CLONING LABORATO; SCALABRINO G, 1981, ADV CANCER RES, V35, P151, DOI 10.1016/S0065-230X(08)60911-2; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; STEGLICH C, 1985, SOMAT CELL MOLEC GEN, V11, P11, DOI 10.1007/BF01534730; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TSENG CP, 1994, CARCINOGENESIS, V15, P707, DOI 10.1093/carcin/15.4.707; VANSTEEG H, 1989, NUCLEIC ACIDS RES, V17, P8855, DOI 10.1093/nar/17.21.8855; VANSTEEG H, 1990, GENE, V93, P249, DOI 10.1016/0378-1119(90)90232-G; VANSTEEG H, 1988, NUCLEIC ACIDS RES, V16, P8173, DOI 10.1093/nar/16.16.8173; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657	63	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4341	4348		10.1074/jbc.270.9.4341	http://dx.doi.org/10.1074/jbc.270.9.4341			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876196	hybrid			2022-12-25	WOS:A1995QK08400027
J	TAMAKI, T; OHNISHI, K; HARTL, C; LEROY, EC; TROJANOWSKA, M				TAMAKI, T; OHNISHI, K; HARTL, C; LEROY, EC; TROJANOWSKA, M			CHARACTERIZATION OF A GC-RICH REGION CONTAINING SP1 BINDING SITE(S) AS A CONSTITUTIVE RESPONSIVE ELEMENT OF THE ALPHA-2(I) COLLAGEN GENE IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; NUCLEAR FACTOR-I; TRANSCRIPTIONAL ACTIVATION; PROMOTER; EXPRESSION; ALPHA-1(I); INTERACT; CELLS	To analyze regulatory elements in the human alpha 2(I) collagen gene (COL1A2) promoter, a series of deletion mutants from -323 to -186 base pairs was tested in transient transfection assays in human fibroblasts. A strong positive responsive element was mapped to a GC-rich region located between base pairs -303 and -271. This region contains three binding sites (GC-boxes) resembling recognition sites for the transcription factor Sp1. Substitution mutations in the GC-boxes abolished binding to the GC-rich region in gel shift analyses and resulted in 90% reduction of promoter activity in transient transfection assays. We demonstrated that transcription factor Sp1 is essential for binding based on the following observations, 1) Sp1 consensus binding site alone competes by binding to the GC-rich region in the DNase I protection assay; 2) both Sp1 consensus binding site and Sp1 antibodies prevent the formation of a DNA-protein complex in the mobility shift assay; 3) anti-Sp1 antibodies recognize a component of the complex competed for by Sp1 consensus binding site.	MED UNIV S CAROLINA,DEPT MED,DIV RHEUMATOL & IMMUNOL,CHARLESTON,SC 29425	Medical University of South Carolina				Trojanowska, Maria/0000-0001-9550-7178				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BOAST S, 1990, J BIOL CHEM, V265, P13351; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; KIKUCHI K, 1992, BIOCHEM BIOPH RES CO, V187, P45, DOI 10.1016/S0006-291X(05)81456-1; KING SL, 1994, J BIOL CHEM, V269, P13156; LEROY EC, 1992, CECIL TXB MED, P1530; Liska Deann J., 1992, Gene Expression, V2, P379; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Tamaki T., 1993, Molecular Biology of the Cell, V4, p65A; VOGELI G, 1981, P NATL ACAD SCI-BIOL, V78, P5334, DOI 10.1073/pnas.78.9.5334; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201	23	107	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4299	4304		10.1074/jbc.270.9.4299	http://dx.doi.org/10.1074/jbc.270.9.4299			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876190	hybrid			2022-12-25	WOS:A1995QK08400021
J	KALAFATIS, M; BERTINA, RM; RAND, MD; MANN, KG				KALAFATIS, M; BERTINA, RM; RAND, MD; MANN, KG			CHARACTERIZATION OF THE MOLECULAR DEFECT IN FACTOR V-R506Q	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; POOR ANTICOAGULANT RESPONSE; COAGULATION FACTOR-V; INACTIVATION; THROMBOPHILIA; MECHANISM; COFACTOR; MEMBRANE; ANTIBODY; THROMBIN	A poor anticoagulant response of plasma to activated protein C is correlated with a single mutation in the factor V molecule (Arg(506) --> Gln), Factor V was purified to homogeneity from plasma of two unrelated patients (patient I, factor V-I, and patient II, factor V-II), who are homozygous for this mutation, The factor V molecule from both patients has normal procoagulant activity when compared with factor V isolated from normal plasma in both a clotting time-based assay and in an assay measuring alpha-thrombin formation, The cleavage and subsequent inactivation by activated protein C (APC) of the alpha-thrombin-activated membrane-bound cofactor (factor Va) from both patients were analyzed and compared with the cleavage and inactivation of normal human factor Va, In normal factor Va, cleavage at Arg(506) generates a M(r) = 75,000 fragment and a M(r) = 28,000/26,000 doublet and is necessary for the optimum exposure of the sites for subsequent cleavage at Arg(306) and Arg(679), Proteolysis at these sites leads to the appearance of M(r) = 45,000 and 30,000 fragments and a M(r) = 22,000/20,000 doublet. Cleavage at Arg(306) is membrane-dependent and is required for complete inactivation, Following 5 min of incubation with APC (5.4 nM) membrane-bound normal factor Va (280 nM) has virtually no cofactor activity whereas under similar experimental conditions factor Va(I) and factor Va(II) retain approximately 50% of their initial activity, After 1 h of incubation with APC, factor Va(I) retains 20% of its initial cofactor activity whereas factor Va(II) has 10% remaining cofactor activity, The initial loss in cofactor activity (similar to 70%) of membrane-bound factor Va(I) and factor Va(II) during the first 10 min of the inactivation reaction is correlated with cleavage at Arg(306) and appearance of a M(r) = 45,000 fragment and a M(r) = 62,000/60,000 doublet, Subsequently, the M(r) = 62,000/60,000 doublet is cleaved at Arg(679) to generate a M(r) = 56,000/54,000 doublet resulting in complete loss of cofactor activity. Both procofactors, factor V-I and factor V-II were inactivated following cleavage at Arg(306) and Arg(679), With APC inactivation rates equivalent to those observed for normal factor V. Our data demonstrate that; 1) cleavage of Arg(506) is required for optimum exposure of the cleavage sites at Arg(306) and Arg(679) and rapid inactivation of membrane-bound factor Va; and 2) cleavage at Arg(306) by APC On membrane-bound factor V occurs at the same rate in both normal and APC-resistant individuals, Thus cleavage at Arg(306) and Arg(679) and subsequent inactivation of the membrane-bound procofactor, factor V, does not require prior cleavage at Arg(506) for optimum exposure.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405; UNIV LEIDEN HOSP,HEMOSTASIS & THROMBOSIS RES CTR,2300 RC LEIDEN,NETHERLANDS	University of Vermont; Leiden University; Leiden University Medical Center (LUMC)			Bertina, Rogier/AGQ-5246-2022		NHLBI NIH HHS [R37 HL34575] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034575] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALHENCGELAS M, 1994, LANCET, V343, P555; BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOKAREWA M, 1994, THROMB RES, V75, P395, DOI 10.1016/0049-3848(94)90254-2; CHURCH WR, 1988, J BIOL CHEM, V263, P6259; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; GIROLAMI A, 1994, LANCET, V343, P1288, DOI 10.1016/S0140-6736(94)92177-6; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; GRIFFIN JH, 1993, BLOOD, V82, P1989; HALBMAYER WM, 1994, BLOOD COAGUL FIBRIN, V5, P51, DOI 10.1097/00001721-199402000-00008; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LEGNANI C, 1994, LANCET, V343, P1289; LEGNANI C, 1994, LANCET, V343, P541, DOI 10.1016/S0140-6736(94)91494-X; LU DS, 1994, BLOOD, V84, P687; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; ROSENDAAL FR, 1994, LANCET, V343, P1289; ROSENDAAL FR, 1995, IN PRESS BLOOD; SHEN L, 1994, J BIOL CHEM, V269, P18735; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SUN X, 1994, BLOOD, V83, P3120; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4	36	244	251	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4053	4057		10.1074/jbc.270.8.4053	http://dx.doi.org/10.1074/jbc.270.8.4053			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876154	hybrid			2022-12-25	WOS:A1995QH68800087
J	SLEPAK, VZ; KATZ, A; SIMON, MI				SLEPAK, VZ; KATZ, A; SIMON, MI			FUNCTIONAL-ANALYSIS OF A DOMINANT-NEGATIVE MUTANT OF G-ALPHA(I2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; GTP-BINDING PROTEINS; ADENYLYL-CYCLASE; ALPHA-SUBUNIT; NUCLEOTIDE-BINDING; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; RECEPTOR; STIMULATION; INHIBITION	The key event in receptor-catalyzed activation of heterotrimeric G proteins is binding of GTP, which leads to subunit dissociation generating GTP-bound alpha subunits and free beta gamma complexes, We have previously identified a mutation that abolished GTP binding in G alpha(o) (S47C) and demonstrated that the mutant retained the ability to bind beta gamma and could act in a dominant negative fashion when expressed in Xenopus oocytes (Slepak, V, Z,, Quick, M, W,, Aragay, A. M,, Davidson, N,, Lester, H. A., and Simon, M. I, (1993) J, Biol, Chem, 268, 21889-21894), In the current work, we investigated the effects of the homologous mutant of G alpha(i2) (S48C) upon signaling pathways reconstituted in transiently transfected COS-7 cells, We found that expression of the G alpha(i2), S48C mutant prevented stimulation of phospholipase C (PLC) beta 2 by free beta gamma subunit complexes, This effect of G alpha(i) S48C was not readily reversible in contrast to the inhibitory effect of wild-type G alpha(i2), which could be reversed upon activation of the cotransfected muscarinic M2 receptor, presumably by release of beta gamma from the G protein heterotrimer, Coexpression of G alpha(i) S48C or the wild-type G alpha(i) also dramatically decreased G(16)-mediated stimulation of PLC by C5a in the cells transfected with cDNAs encoding C5a receptor and G alpha(16). Activation of PLC via endogenous G(q) or G(11) in the presence of alpha 1C adrenergic receptors was similarly attenuated by coexpression of G alpha(i) or G alpha(i) S48C, Pertussis toxin treatment of the transfected cells enhanced the inhibition of the receptor-stimulated PLC by wild-type G alpha(i) subunits but did not influence the effects of the dominant negative mutant, The enhancement of the wild-type G alpha(i) inhibitory effect by pertussis toxin can be explained by stabilization of G alpha(i) binding to beta gamma as a result of ADP-ribosylation, while G alpha(i) S48C mutant binds beta gamma irreversibly even without pertussis toxin treatment, Therefore, a feasible mechanism to rationalize the attenuation of the G alpha(16) and G(q/11)-mediated activation of PLC by cotransfected G alpha(i) is the competition between G alpha(i) and G alpha(16) or G(q/11) for the beta gamma complexes, which are necessary for the G protein coupling with receptors, These experiments provide new evidence for the role of beta gamma in the integration of signals controlling phosphoinositide release through different G alpha families.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Katz, Arieh/F-5836-2012					AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CARREL F, 1994, MOL BIOL CELL, V5, P7, DOI 10.1091/mbc.5.1.7; COWEN DS, 1990, J BIOL CHEM, V265, P16181; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HIGUCHI R, 1989, NUCLEIC ACIDS RES, V16, P7351; HUFF RM, 1986, J BIOL CHEM, V261, P1105; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KATADA T, 1987, J BIOL CHEM, V262, P11897; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OSAWA S, 1991, J BIOL CHEM, V266, P4673; PITHCER JA, 1992, SCIENCE, V257, P1264; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SMRCKA AV, 1992, J BIOL CHEM, V268, P9667; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WINITZ S, 1994, J BIOL CHEM, V269, P1889; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	39	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4037	4041		10.1074/jbc.270.8.4037	http://dx.doi.org/10.1074/jbc.270.8.4037			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876152	hybrid, Green Accepted			2022-12-25	WOS:A1995QH68800085
J	VANDIJL, JM; DEJONG, A; VENEMA, G; BRON, S				VANDIJL, JM; DEJONG, A; VENEMA, G; BRON, S			IDENTIFICATION OF THE POTENTIAL ACTIVE-SITE OF THE SIGNAL PEPTIDASE SIPS OF BACILLUS-SUBTILIS - STRUCTURAL AND FUNCTIONAL SIMILARITIES WITH LEXA-LIKE PROTEASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; YEAST SEC11 PROTEIN; ESCHERICHIA-COLI; CATALYTIC MECHANISM; POLYACRYLAMIDE GELS; SECRETORY PROTEINS; PLASMA-MEMBRANE; RECA PROTEIN; CLEAVAGE; SEQUENCE	Signal peptidases remove signal peptides from secretory proteins. By comparing the type I signal peptidase, SipS, of Bacillus subtilis with signal peptidases from prokaryotes, mitochondria, and the endoplasmic reticular membrane, patterns of conserved amino acids were discovered. The conserved residues of SipS were altered by site-directed mutagenesis. Replacement of methionine 44 by alanine yielded an enzyme with increased activity. Two residues (aspartic acid 146 and arginine 84) appeared to be conformational determinants; three other residues (serine 43, lysine 83, and aspartic acid 153) were critical for activity. Comparison of SipS with other proteases requiring serine, lysine, or aspartic acid residues in catalysis revealed sequence similarity between the region of SipS around serine 43 and lysine 83 and the active-site region of LexA-like proteases. Furthermore, self-cleavage sites of LexA-like proteases closely resembled signal peptidase cleavage sites. Together with the finding that serine and lysine residues are critical for activity of the signal peptidase of Escherichia coli (Tschantz, W. R., Sung, M., Delgado-Partin, V. M., and Dalbey, R. E. (1993) J. Biol. Chem. 268, 27349-27354), our data indicate that type I signal peptidases and LexA-like proteases are structurally and functionally related serine proteases. A model envisaging a catalytic serine-lysine dyad in prokaryotic type I signal peptidases is proposed to accommodate our observations.	GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST, DEPT GENET, 9751 NN HAREN, NETHERLANDS	University of Groningen			van Dijl, Jan Maarten/G-1205-2013					BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DEV IK, 1990, J BIOENERG BIOMEMBR, V22, P271, DOI 10.1007/BF00763168; DEV IK, 1990, J BIOL CHEM, V265, P20069; DIERSTEIN R, 1986, EMBO J, V5, P427, DOI 10.1002/j.1460-2075.1986.tb04228.x; DOBBERSTEIN B, 1994, NATURE, V367, P599, DOI 10.1038/367599a0; DRIJFHOUT JW, 1990, ANAL BIOCHEM, V187, P349, DOI 10.1016/0003-2697(90)90468-O; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; Dunn BM, 1989, PROTEOLYTIC ENZYMES; GIMBLE FS, 1986, J MOL BIOL, V192, P39, DOI 10.1016/0022-2836(86)90462-6; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; HORII T, 1981, CELL, V27, P515, DOI 10.1016/0092-8674(81)90393-7; KOK J, 1984, APPL ENVIRON MICROB, V48, P726, DOI 10.1128/AEM.48.4.726-731.1984; KUO DW, 1993, ARCH BIOCHEM BIOPHYS, V303, P274, DOI 10.1006/abbi.1993.1283; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LITTLE JW, 1993, J BACTERIOL, V175, P4943, DOI 10.1128/JB.175.16.4943-4950.1993; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Pero Janice, 1993, P939; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROLAND KL, 1990, J BIOL CHEM, V265, P12828; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER RT, 1982, J BIOL CHEM, V257, P4458; SCHNEIDER A, 1994, J BIOL CHEM, V269, P8635; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; SUNG M, 1992, J BIOL CHEM, V267, P13154; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; VANDIJL JM, 1990, MOL GEN GENET, V223, P233, DOI 10.1007/BF00265059; VANDIJL JM, 1993, DNA TRANSFER GENE EX, P251; VEHMAANPERA J, 1993, FEMS MICROBIOL LETT, V114, P207, DOI 10.1111/j.1574-6968.1993.tb06575.x; von Heijne G, 1990, CURR OPIN CELL BIOL, V2, P604, DOI 10.1016/0955-0674(90)90100-S; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WOODGATE R, 1989, P NATL ACAD SCI USA, V86, P7301, DOI 10.1073/pnas.86.19.7301	50	89	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3611	3618		10.1074/jbc.270.8.3611	http://dx.doi.org/10.1074/jbc.270.8.3611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876097				2022-12-25	WOS:A1995QH68800025
J	ALONSO, JC; WEISE, F; ROJO, F				ALONSO, JC; WEISE, F; ROJO, F			THE BACILLUS-SUBTILIS HISTONE-LIKE PROTEIN HBSU IS REQUIRED FOR DNA RESOLUTION AND DNA INVERSION MEDIATED BY THE BETA-RECOMBINASE OF PLASMID PSM19035	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; BINDING PROTEIN; TN3 RESOLVASE; CURVED DNA; HU; GENE; REPLICATION; EXPRESSION; DEFICIENT; INDUCTION	The beta recombinase, encoded by the Gram-positive bacterial plasmid pSM19035, is unable to mediate DNA recombination in vitro unless a host factor is provided. The factor has now been identified as the Bacillus subtilis Hbsu protein. Hbsu is a nonspecific DNA-binding and DNA-bending protein. The beta recombinase, in the presence of highly purified Hbsu protein, is able to catalyze in vitro intramolecular recombination between two specific recombination sites on a supercolied DNA molecule. DNA resolution was obtained when the two crossing over sites (six sites) were directly oriented, whereas DNA inversion was the product when the six sites were in inverse orientation. The ability of the Escherichia coli chromatin associated proteins HU, IHF, Fis, and H-NS to substitute for Hbsu was investigated. HU efficiently stimulated beta-mediated recombination, while the effect of IHF was partial and that of Fis and H-NS was undetectable. In addition, the beta protein was able to mediate DNA recombination in both wildtype and IHF-deficient E. coli cells, but failed to do so in an HU-deficient strain. The data presented provide direct evidence that a chromatin-associated protein is strictly required for beta-mediated recombination.	MAX PLANCK INST MOLEC GENET, D-14195 BERLIN, GERMANY	Max Planck Society	ALONSO, JC (corresponding author), UNIV AUTONOMA MADRID, CSIC, CTR NACL BIOTECNOL, CANTO BLANCO, E-28049 MADRID, SPAIN.		Alonso, Juan Carlos/D-2595-2009; Rojo, Fernando/A-7038-2008	Alonso, Juan Carlos/0000-0002-5178-7179; Rojo, Fernando/0000-0003-1848-7745				BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BEDNARZ AL, 1990, GENE DEV, V4, P2366, DOI 10.1101/gad.4.12b.2366; BEHNKE D, 1980, PLASMID, V4, P139, DOI 10.1016/0147-619X(80)90003-7; BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; BOITSOV AS, 1979, FEMS MICROBIOL LETT, V6, P11; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; CEGLOWSKI P, 1994, GENE, V145, P33, DOI 10.1016/0378-1119(94)90319-0; CEGLOWSKI P, 1993, FEMS MICROBIOL LETT, V109, P145, DOI 10.1016/0378-1097(93)90011-P; CEGLOWSKI P, 1993, GENE, V136, P1, DOI 10.1016/0378-1119(93)90441-5; Cox M. M., 1989, MOBILE DNA, P661; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; FLASHNER Y, 1988, CELL, V54, P713, DOI 10.1016/S0092-8674(88)80016-3; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GASSEL M, 1989, MOL MICROBIOL, V3, P1269, DOI 10.1111/j.1365-2958.1989.tb00277.x; GLASGOW AC, 1989, MOBILE DNA, P637; GROCH N, 1992, EUR J BIOCHEM, V207, P677, DOI 10.1111/j.1432-1033.1992.tb17095.x; HAIMA P, 1987, MOL GEN GENET, V209, P335, DOI 10.1007/BF00329663; HAYKINSON MJ, 1993, EMBO J, V12, P2503, DOI 10.1002/j.1460-2075.1993.tb05905.x; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; HWANG DS, 1992, J BIOL CHEM, V267, P23083; IMBER R, 1987, EUR J BIOCHEM, V165, P547, DOI 10.1111/j.1432-1033.1987.tb11474.x; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KAWAMURA F, 1984, J BACTERIOL, V160, P442, DOI 10.1128/JB.160.1.442-444.1984; LAMMI M, 1984, ADV EXP MED BIOL, V179, P467; LAUNDON CH, 1987, BIOCHEMISTRY-US, V26, P3759, DOI 10.1021/bi00387a003; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; MICKA B, 1992, BIOCHIMIE, V74, P641, DOI 10.1016/0300-9084(92)90136-3; MICKA B, 1991, J BACTERIOL, V173, P3191, DOI 10.1128/JB.173.10.3191-3198.1991; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; ROJO F, 1993, FEBS LETT, V328, P169, DOI 10.1016/0014-5793(93)80987-6; ROJO F, 1994, J MOL BIOL, V238, P159, DOI 10.1006/jmbi.1994.1278; SAMBROOK J, 1986, MOL CLONING LABORATO; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SHERRATT D, 1989, MOBILE DNA, P163; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; THOMPSON JF, 1989, MOBILE DNA, P1; VANPUTTE P, 1992, TRENDS GENET, V8, P457; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WELFLE H, 1992, EUR J BIOCHEM, V204, P1049, DOI 10.1111/j.1432-1033.1992.tb16727.x; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; WILSON KS, 1990, PROTEIN ENG, V4, P11, DOI 10.1093/protein/4.1.11; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	54	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2938	2945		10.1074/jbc.270.7.2938	http://dx.doi.org/10.1074/jbc.270.7.2938			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852372	hybrid			2022-12-25	WOS:A1995QG47100011
J	BLANDINO, G; SCARDIGLI, R; RIZZO, MG; CRESCENZI, M; SODDU, S; SACCHI, A				BLANDINO, G; SCARDIGLI, R; RIZZO, MG; CRESCENZI, M; SODDU, S; SACCHI, A			WILD-TYPE P53 MODULATES APOPTOSIS OF NORMAL, IL-3 DEPRIVED, HEMATOPOIETIC-CELLS	ONCOGENE			English	Article						P53; APOPTOSIS; IL-3-DEPENDENCE	DIFFERENTIATION; GROWTH; LINE; CYCLE; GENE; SUPPRESSION; EXPRESSION; INDUCTION; MUTANT; TRANSFORMATION	Apoptotic cell death is an active process which regulates the maintenance of the hematopoietic homeostasis. It has been reported that wild-type p53 (wt-p53) protein induces apoptosis in leukemia cells. To assess whether p53 is involved in the apoptotic process of normal hematopoietic cells, we introduced the temperature-sensitive p53Val(135) mutant into the murine myeloid precursor cell line 32Dcl3. These are diploid, non-tumorigenic cells whose survival and proliferation are dependent upon growth factor supply (IL-3 and serum). Overexpression of wt-p53 protein does not affect morphology and proliferation of 32D cells as long as they are maintained in the presence of IL-3. However, after IL-3 withdrawal, wt-p53 overexpression significantly accelerates apoptosis. This phenomenon is IL-3 specific since no differences in death rates induced by serum starvation are found between parental cells and p53-transfectants. When the latter experiments are carried out at 37 degrees C with p53 protein in mutant conformation, an extended survival of 32D cells is observed after IL-3 deprivation, but not after serum withdrawal. Taken together, these results show that wt-p53 actively mediates the apoptosis due to the absence of specific growth factors, such as IL-3, suggesting that p53 might be involved in the response of myeloid precursors to environmental cytokines for the maintenance of the hematopoietic homeostasis.	CRS,REGINA ELENA CANC INST,MOLEC ONCOGENESIS LAB,I-00158 ROME,ITALY				Crescenzi, Marco/J-3603-2018; Soddu, Silvia/ABH-6774-2020; Blandino, Giovanni/B-1137-2013; Rizzo, Maria Giulia/B-2107-2018; Soddu, Silvia/K-2467-2018	Crescenzi, Marco/0000-0003-0156-1494; Soddu, Silvia/0000-0001-8526-0044; Blandino, Giovanni/0000-0002-6970-2241; Rizzo, Maria Giulia/0000-0002-5009-2412; Soddu, Silvia/0000-0001-8526-0044; Scardigli, Raffaella/0000-0003-1369-0496				ANDERSON SM, 1990, ONCOGENE, V5, P317; ASKEW DS, 1991, ONCOGENE, V6, P1915; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUKE RC, 1983, J IMMUNOL, V137, P1442; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; GREENBERGER JS, 1983, FED PROC, V42, P2762; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LEE JC, 1982, J IMMUNOL, V128, P2393; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; MAVILIO F, 1989, ONCOGENE, V4, P301; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; RIZZO MG, 1993, CLIN EXP METASTAS, V11, P368, DOI 10.1007/BF00132980; ROVERA G, 1987, ONCOGENE, V1, P29; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	34	64	65	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					731	737						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862450				2022-12-25	WOS:A1995QH61200013
J	YOUNG, NM; WATSON, DC; YAGUCHI, M; ADAR, R; ARANGO, R; RODRIGUEZARANGO, E; SHARON, N; BLAY, PKS; THIBAULT, P				YOUNG, NM; WATSON, DC; YAGUCHI, M; ADAR, R; ARANGO, R; RODRIGUEZARANGO, E; SHARON, N; BLAY, PKS; THIBAULT, P			C-TERMINAL POSTTRANSLATIONAL PROTEOLYSIS OF PLANT-LECTINS AND THEIR RECOMBINANT FORMS EXPRESSED IN ESCHERICHIA-COLI - CHARACTERIZATION OF RAGGED ENDS BY MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHRINA-CORALLODENDRON LECTIN; AMINO-ACID-SEQUENCE; CONCANAVALIN-A; SEED LECTIN; PEANUT AGGLUTININ; PHYTOHEMAGGLUTININ; PROTEINS; PRECURSOR; SUBUNITS; VACUOLES	Electrospray mass spectrometry was used to accurately measure the molecular masses of single chain lectins from legume seeds and also of three recombinant lectins, expressed in Escherichia coli, The five single chain lectins, Erythrina corallodendron lectin, soybean and peanut agglutinins, Dolichos biflorus lectin, and Phaseolus vulgaris hemagglutinin E, all showed evidence of C-terminal proteolytic processing, in some cases to ''ragged'' ends, when their masses were compared to those expected from their cDNA sequences and their known carbohydrate chains. Recombinant forms of the lectins from E, corallodendron, soybean, and peanut also showed C-terminal trimming, but not to the same points as the natural forms, Discrepancies between the protein and cDNA sequences of the E. corallodendron lectin were resolved by combined liquid chromatography-mass spectrometry peptide mapping and protein sequencing experiments, and the presence of a second glycosylation site was demonstrated, Our data show that all of these lectins undergo C-terminal proteolytic processing of a readily attacked peptide segment, This trimming is frequently imprecise, and the resulting heterogeneity may be a major contributor to the appearance of isolectin forms of these proteins.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL; NATL RES COUNCIL CANADA,INST MARINE BIOSCI,HALIFAX,NS B3H 3Z1,CANADA	Weizmann Institute of Science; International Business Machines (IBM); National Research Council Canada	YOUNG, NM (corresponding author), NATL RES COUNCIL CANADA,INST BIOL SCI,100 SUSSEX DR,OTTAWA,ON K1A 0R6,CANADA.			Arango, Rafael/0000-0002-7276-6035; Thibault, Pierre/0000-0001-5993-0331				ABE Y, 1993, J BIOL CHEM, V268, P3525; ADAR R, 1989, FEBS LETT, V257, P81, DOI 10.1016/0014-5793(89)81791-0; ARANGO R, 1990, FEBS LETT, V264, P109, DOI 10.1016/0014-5793(90)80777-G; ARANGO R, 1992, EUR J BIOCHEM, V205, P575, DOI 10.1111/j.1432-1033.1992.tb16815.x; ASHFORD DA, 1991, CARBOHYD RES, V213, P215, DOI 10.1016/S0008-6215(00)90610-4; BORREBAECK CAK, 1981, J BIOL CHEM, V256, P4723; BOWLES DJ, 1986, J CELL BIOL, V102, P1284, DOI 10.1083/jcb.102.4.1284; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; CHRISPEELS MJ, 1992, CELL, V68, P613, DOI 10.1016/0092-8674(92)90134-X; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DORLAND L, 1981, J BIOL CHEM, V256, P7708; ETZLER ME, 1981, J BIOL CHEM, V256, P2367; FAYE L, 1986, EUR J BIOCHEM, V158, P655, DOI 10.1111/j.1432-1033.1986.tb09803.x; HARADA JJ, 1990, J BIOL CHEM, V265, P4997; HIGGINS TJV, 1983, J BIOL CHEM, V258, P9544; HIGGINS TJV, 1984, ANNU REV PLANT PHYS, V35, P191, DOI 10.1146/annurev.pp.35.060184.001203; HOEDEMAEKER FJ, 1994, PLANT MOL BIOL, V24, P75, DOI 10.1007/BF00040575; HOFFMAN LM, 1987, BIO-TECHNOL, V5, P157, DOI 10.1038/nbt0287-157; HOFFMAN LM, 1985, EMBO J, V4, P883, DOI 10.1002/j.1460-2075.1985.tb03714.x; LIS H, 1985, PHYTOCHEMISTRY, V24, P2803, DOI 10.1016/0031-9422(85)80004-2; MANDAL DK, 1994, EUR J BIOCHEM, V221, P547, DOI 10.1111/j.1432-1033.1994.tb18767.x; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MIN W, 1992, EMBO J, V11, P1303, DOI 10.1002/j.1460-2075.1992.tb05174.x; MURAMATSU M, 1993, EUR J BIOCHEM, V215, P123, DOI 10.1111/j.1432-1033.1993.tb18014.x; PUEPPKE SG, 1991, ARCH BIOCHEM BIOPHYS, V212, P254; ROBERTS DM, 1982, ARCH BIOCHEM BIOPHYS, V218, P213, DOI 10.1016/0003-9861(82)90338-1; RODRIGUEZARANGO E, 1992, FEBS LETT, V307, P185, DOI 10.1016/0014-5793(92)80764-8; SCHROEDER MR, 1993, J EXP BOT, V44, P315; SHELDON PS, 1992, EMBO J, V11, P1297, DOI 10.1002/j.1460-2075.1992.tb05173.x; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; STUBBS ME, 1986, J BIOL CHEM, V261, P6141; STURM A, 1992, EUR J BIOCHEM, V204, P313, DOI 10.1111/j.1432-1033.1992.tb16639.x; THIBAULT P, 1993, TECHNIQUES PROTEIN C, V4, P91; VODKIN LO, 1983, CELL, V34, P1023, DOI 10.1016/0092-8674(83)90560-3; VONSCHAEWEN A, 1993, J EXP BOT, V44, P339; YOUNG NM, 1991, EUR J BIOCHEM, V196, P631, DOI 10.1111/j.1432-1033.1991.tb15859.x; YOUNG NM, 1985, CAN J BIOCHEM CELL B, V63, P268, DOI 10.1139/o85-039	37	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2563	2570		10.1074/jbc.270.6.2563	http://dx.doi.org/10.1074/jbc.270.6.2563			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852319	hybrid			2022-12-25	WOS:A1995QF53500027
J	MASUDA, T; KARIYA, K; SHINKAI, M; OKADA, T; KATAOKA, T				MASUDA, T; KARIYA, K; SHINKAI, M; OKADA, T; KATAOKA, T			PROTEIN-KINASE BYR2 IS A TARGET OF RAS1 IN THE FISSION YEAST SCHIZOSACCHAROMYCES-POMBE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SACCHAROMYCES-CEREVISIAE; ADENYLYL CYCLASE; GENE; ENCODES; DOMAIN; RAF-1; MEK	Conservation of the structure and function of Ras proteins has been observed in a variety of eukaryotic organisms, However, the nature of their downstream effecters appears to be quite divergent; adenylyl cyclase and a protein kinase Raf-l, which do not share any structural homology with each other, are effecters of has in the budding yeast and in higher organisms, respectively, We show here that a protein kinase Byr2, which has been known to act downstream of Ras1 in a mating pheromone signal transduction system of Schizosaccharomyces pombe, binds directly to Ras proteins in a GTP-dependent manner, The region of Byr2 responsible for the Has binding was mapped by a gene deletion analysis to its N-terminal segment of 206 amino acid residues, which does not possess any significant homology with the other effecters of Ras, The affinity of the Byr2 N terminus for Saccharomyces cerevisiae Ras2 was determined by measuring its activity to competitively inhibit has-dependent adenylyl cyclase activity and found to be comparable with those of yeast adenylyl cyclase and human Raf-l, with a dissociation constant (K-d) of about 1 nM. Furthermore, Byr2 inhibited a has GTPase-activating activity of IraS, a S, cerevisiae homologue of neurofibromin. These results indicate that Byr2 is an immediate downstream target of Ras1 in S. pombe.	KOBE UNIV, SCH MED, DEPT PHYSIOL 2, CHUO KU, KOBE 650, JAPAN	Kobe University								BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GOTOH Y, 1993, MOL CELL BIOL, V13, P6427, DOI 10.1128/MCB.13.10.6427; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; MINATO T, 1994, J BIOL CHEM, V269, P20845; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; RODRIGUEZVICIAN.P, 1994, SCIENCE, V370, P527; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG J, 1992, MOL CELL BIOL, V12, P4937, DOI 10.1128/MCB.12.11.4937; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	23	62	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					1979	1982		10.1074/jbc.270.5.1979	http://dx.doi.org/10.1074/jbc.270.5.1979			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836423	hybrid			2022-12-25	WOS:A1995QE49300003
J	MCMAHON, HT; SUDHOF, TC				MCMAHON, HT; SUDHOF, TC			SYNAPTIC CORE COMPLEX OF SYNAPTOBREVIN, SYNTAXIN, AND SNAP25 FORMS HIGH-AFFINITY ALPHA-SNAP FINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER RELEASE; FUSION PROTEIN; MEMBRANE-FUSION; CLEAVAGE; TETANUS; TRANSPORT; YEAST	SNAPs (soluble NSF attachment proteins) are cytoplasmic proteins that bind to specific membrane receptors and mediate the membrane binding of NSF (N-ethylmaleimide-sensitive factor), a protein that is required for membrane fusion reactions. Three synaptic proteins in brain (SNAP25 (synaptosomal-associated protein of 25 kDa; no relation to the SNAPs for NSF), synaptobrevin/VAMP, and syntaxin) were identified as SNAP receptors by affinity chromatography on immobilized alpha-SNAP complexed to NSF (Sollner, T., Whiteheart, S. W., Brunner, M., Erdjument-Bromage, H., Geromanos, S., Tempst, P. and Rothman, J. E. (1993) Nature 362, 318-324). However, the nature of the alpha-SNAP binding site is unclear. We now show that alpha-SNAP binds tightly to the complex of syntaxin with synaptobrevin. SNAP25 is not required for tight binding of alpha-SNAP to this complex but stabilizes the syntaxin synaptobrevin complex by forming a trimeric core complex with it. alpha-SNAP does not bind to synaptobrevin individually and binds only weakly to syntaxin and SNAP25 in the absence of synaptobrevin. These data suggest that the complex of the vesicular protein synaptobrevin with the plasma membrane protein syntaxin is required for physiological alpha-SNAP binding. Thus, alpha-SNAP probably functions in a late step of the membrane fusion reaction after the formation of the synaptobrevin-syntaxin-SNAP25 core complex.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1989, NATURE, V339, P389; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GEPPERT M, 1994, CELL, V79, P1; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; Sambrook J, 1989, MOL CLONING LABORATO; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1993, CELL, V75, P1; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	25	161	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2213	2217		10.1074/jbc.270.5.2213	http://dx.doi.org/10.1074/jbc.270.5.2213			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836452	hybrid			2022-12-25	WOS:A1995QE49300037
J	TANG, XR; LI, HO; SAKATSUME, O; OHTA, T; TSUTSUI, H; SMIT, AFA; HORIKOSHI, M; KOURILSKY, P; ISRAEL, A; GACHELIN, G; YOKOYAMA, K				TANG, XR; LI, HO; SAKATSUME, O; OHTA, T; TSUTSUI, H; SMIT, AFA; HORIKOSHI, M; KOURILSKY, P; ISRAEL, A; GACHELIN, G; YOKOYAMA, K			COOPERATIVITY BETWEEN AN UPSTREAM TATA-LIKE SEQUENCE AND A CAA REPEATED ELEMENT MEDIATES E1A-DEPENDENT NEGATIVE REPRESSION OF THE H-2K(B) CLASS-I GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; NF-KAPPA-B; TRANSFORMED RAT-CELLS; DNA-BINDING PROTEIN; HEAT-SHOCK GENE; RETINOIC ACID; TRANSCRIPTIONAL ACTIVATION; ADENOVIRUS-TYPE-12 E1A; EXPRESSION; MHC	In primary rodent cells transformed by the E1A region of the highly oncogenic adenovirus type 12, repression of transcription mediated by the far upstream TATA-like element was observed only in conjunction with either possible juxtaposition of a CAA repeated element in the presence of E1A and was dependent upon the relative arrangement of both the TATA-like and CAA repeated motifs in both homologous and heterologous promoter constructs, A gel shift competition study demonstrated that the TATA-binding protein (TBP) or a TBP-like protein can bind to both the upstream TATA-like sequence and the regular TATA box on the H-2K(b) basal promoter, Moreover, employing immunoselection and cyclic amplification and selection of targets (CASTing) methods with nuclear extracts derived from Ad12-E1A transformants, we have identified a high affinity binding site in the H-2K(b) class I promoter for E1A-associated DNA-binding proteins. The sequences of the binding sites were identified and were found to contain both the upstream TATA like motif and the CAA repeated motifs. Our results suggest that the TATA like sequence in the far upstream region of the H-2K(b) gene is one of the elements that is required for Ad12-E1A-mediated negative repression.	INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, TSUKUBA, IBARAKI 305, JAPAN; CITY HOPE NATL MED CTR, BECKMAN RES INT, DEPT BIOL, DUARTE, CA 91010 USA; UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; INST PASTEUR, DEPT MOLEC BIOL, UNITE BIOL MOLEC EXPRESS GEN, F-75724 PARIS 15, FRANCE; INST PASTEUR, DEPT IMMUNOL, UNITE BIOL MOLEC GENE, F-75724 PARIS 15, FRANCE	RIKEN; City of Hope; Beckman Research Institute of City of Hope; University of Tokyo; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Sakatsume, Osamu/0000-0003-1340-3661				ACKRILL AM, 1988, ONCOGENE, V3, P483; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BURKE PA, 1989, J EXP MED, V169, P1309, DOI 10.1084/jem.169.4.1309; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FLINT SJ, 1980, MOL BIOL TUMOR VIRUS, V2, P383; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KATOH S, 1990, EMBO J, V9, P127, DOI 10.1002/j.1460-2075.1990.tb08088.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU XH, 1994, ONCOGENE, V9, P2183; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEIJER I, 1991, ONCOGENE, V6, P911; MEIJER I, 1989, J VIROL, V63, P4039, DOI 10.1128/JVI.63.9.4039-4042.1989; NAGATA T, 1992, P NATL ACAD SCI USA, V89, P937, DOI 10.1073/pnas.89.3.937; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; OZAWA K, 1990, NUCLEIC ACIDS RES, V18, P4185, DOI 10.1093/nar/18.14.4185; OZAWA K, 1993, J BIOL CHEM, V268, P27258; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; SAMBROOK DL, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHIROKI K, 1983, J VIROL, V45, P1074, DOI 10.1128/JVI.45.3.1074-1082.1983; SHIROKI K, 1992, J VIROL, V66, P1449, DOI 10.1128/JVI.66.3.1449-1457.1992; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; TANAKA K, 1988, ANNU REV IMMUNOL, V6, P359; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; VAESSEN RTMJ, 1986, EMBO J, V5, P335, DOI 10.1002/j.1460-2075.1986.tb04217.x; VANTVEER LJ, 1992, P NATL ACAD SCI USA, V89, P8971, DOI 10.1073/pnas.89.19.8971; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	59	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2327	2336		10.1074/jbc.270.5.2327	http://dx.doi.org/10.1074/jbc.270.5.2327			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836466	hybrid			2022-12-25	WOS:A1995QE49300054
J	CHAKRAVARTHY, BR; ISAACS, RJ; MORLEY, P; DURKIN, JP; WHITFIELD, JF				CHAKRAVARTHY, BR; ISAACS, RJ; MORLEY, P; DURKIN, JP; WHITFIELD, JF			STIMULATION OF PROTEIN-KINASE-C DURING CA2+-INDUCED KERATINOCYTE DIFFERENTIATION - SELECTIVE BLOCKADE OF MARCKS PHOSPHORYLATION BY CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; BINDING; ACTIVATION; SUBSTRATE; INVITRO; FAMILY; GROWTH; DOMAIN; BRAIN; CELLS	Raising the external Ca2+ concentration from 0.05 to 1.8 mM stimulated membrane-associated protein kinase Cs (PKCs) activity as strongly as the specific PKCs activator, 12-O-tetradecanoyl phorbol-13-acetate (TPA) in BALB/MK mouse keratinocytes. This was indicated by the increased phosphorylation of a PKC-selective peptide substrate, Ac-FKKSFKL-NH2, by membranes isolated from the Ca2+- or TPA-stimulated keratinocytes. Raising the external Ca2+ concentration to 1.8 mM also triggered a 4-fold rise in the intracellular free Ca2+ concentration. As reported elsewhere (Moscat, J. Fleming, T. P., Molloy, C. J. Lopez-Barahona, M., and Aaronson, S. A. (1989) J. Biol. Chem. 264, 11228-11235), TPA stimulated the phosphorylation of the PKCs substrate, the 85-kDa myristoylated alanine-rich kinase C substrate (MARCKS) protein, in intact keratinocytes, but Ca2+ did not. Furthermore, Ca2+-pretreatment reduced the TPA-induced phosphorylation of the 85-kDa protein in intact cells. There was no significant increase in MARCKS phosphorylation when keratinocytes were treated with a Ca2+.CaM-dependent phosphatase inhibitor, cyclosporin A, before stimulation with 1.8 mM Ca2+.Ca2+.calmodulin suppressed the ability of isolated membranes to phosphorylate the 85-kDa MARCKS holoprotein in vitro in the presence of phosphatase inhibitors such as fluoride, pyrophosphate, and vanadate, and this inhibition was overcome by a calmodulin antagonist, the calmodulin-binding domain peptide. Thus, the ability of 1.8 mM Ca2+ to strongly stimulate the membrane PKCs activity without stimulating the phosphorylation of the MARCKS protein in keratinocytes is consistent with the possibility of Ca2+.calmodulin complexes, formed by the internal Ca2+ surge, binding to, and blocking the phosphorylation of, this PKC protein substrate.			CHAKRAVARTHY, BR (corresponding author), NATL RES COUNCIL CANADA, INST BIOL SCI, 100 SUSSEX DR, OTTAWA, ON K1A 0R6, CANADA.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BUSSE R, 1988, N-S ARCH PHARMACOL, V337, P79; CHAKRAVARTHY BR, 1989, BIOCHEM BIOPH RES CO, V160, P340, DOI 10.1016/0006-291X(89)91661-6; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CHAKRAVARTHY BR, 1994, IN PRESS BIOCH J; CHAN SY, 1986, J NEUROSCI, V6, P3618; CHIDA K, 1986, J BIOL CHEM, V261, P3013; CLARKE PR, 1993, FEBS LETT, V336, P37, DOI 10.1016/0014-5793(93)81604-X; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; FALCO JP, 1988, ONCOGENE, V2, P573; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEEMSKERK FMJ, 1993, BIOCHEM BIOPH RES CO, V190, P236, DOI 10.1006/bbrc.1993.1036; HEGEMANN L, 1991, PHARM SKIN, P357; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORLEY P, 1993, J CELL PHYSIOL, V156, P219, DOI 10.1002/jcp.1041560202; MOSCAT J, 1989, J BIOL CHEM, V264, P11228; NAIRN AC, 1992, CIBA F SYMP, V164, P145; ORR JW, 1992, J BIOL CHEM, V267, P15263; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; ROBINSON PJ, 1993, ANAL BIOCHEM, V210, P172, DOI 10.1006/abio.1993.1169; Sharma R K, 1979, Adv Cyclic Nucleotide Res, V10, P187; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WHITFIELD JF, 1992, J CELL PHYSIOL, V150, P299, DOI 10.1002/jcp.1041500212; WILLIAMS RE, 1992, PEPTIDES CHEM BIOL, P923; YUSPA SH, 1988, ANN NY ACAD SCI, V548, P191, DOI 10.1111/j.1749-6632.1988.tb18806.x; YUSPA SH, 1991, ENVIRON HEALTH PERSP, V93, P3, DOI 10.2307/3431160; Yuspa Stuart H., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P560	39	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1362	1368		10.1074/jbc.270.3.1362	http://dx.doi.org/10.1074/jbc.270.3.1362			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836403	hybrid			2022-12-25	WOS:A1995QB15600058
J	GLIBETIC, M; TAYLOR, L; LARSON, D; HANNAN, R; SELLS, B; ROTHBLUM, L				GLIBETIC, M; TAYLOR, L; LARSON, D; HANNAN, R; SELLS, B; ROTHBLUM, L			THE RNA POLYMERASE-I TRANSCRIPTION FACTOR UBF IS THE PRODUCT OF A PRIMARY RESPONSE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR-TIF-IA; RDNA; TRANSACTIVATION; CULTURE; CELLS	Transcription of the ribosomal RNA genes by RNA polymerase I is tightly coordinated with the rate of cell growth. The RNA polymerase I transcription factor, UBF, activates transcription by binding to elements within the promoter and enhancer elements within the intergenic spacer but is not required for basal transcription. To assess the role of UBF in modulating ribosomal DNA transcription, we studied its expression in NIH3T6 fibroblasts when transcription was repressed in response to serum starvation and stimulated following refeeding. Our results demonstrate a correlation be tween the amounts of UBF protein and the rates of ribosomal DNA transcription in quiescent and serum-stimulated cells. Nuclear run-on assays and Northern blot analyses demonstrated that the UBF gene was a primary response gene, exhibiting characteristics similar to those of c-myc and SRF. These results suggest that the regulation of transcription of the UBF gene by polymerase II represents a pathway by which cells modulate transcription by RNA polymerase I.	GEISINGER MED CLIN,SIGFRIED & JANET WEIS CTR RES,DANVILLE,PA 17822; UNIV GUELPH,DEPT MOLEC BIOL & GENET,GUELPH,ON N1G 2W1,CANADA	Geisinger Medical Center; University of Guelph				Hannan, Ross/0000-0002-2166-4493	NHLBI NIH HHS [HL47638] Funding Source: Medline; NIGMS NIH HHS [GM46991] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046991] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUN RP, 1994, MOL CELL BIOL, V14, P5010, DOI 10.1128/MCB.14.7.5010; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CAVANAUGH AH, 1983, J BIOL CHEM, V258, P9768; DEAN M, 1986, J BIOL CHEM, V261, P9161; FINANCSEK I, 1982, P NATL ACAD SCI-BIOL, V79, P3092, DOI 10.1073/pnas.79.10.3092; GLIBETIC M, 1993, MOL CELL ENDOCRINOL, V94, P243, DOI 10.1016/0303-7207(93)90173-H; GRUMMT I, 1987, CELL NUCLEUS, V5, P373; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; LARSON DE, 1991, BIOCHEM CELL BIOL, V69, P5, DOI 10.1139/o91-002; MAHAJAN P, 1990, J BIOL CHEM, V265, P16234; MOSS T, 1995, IN PRESS PROG NUCLEI; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; PAULE MR, 1984, NUCLEIC ACIDS RES, V12, P8161, DOI 10.1093/nar/12.21.8161; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; XIE WQ, 1993, TRENDS CARDIOVAS MED, V3, P7, DOI 10.1016/1050-1738(93)90021-W; XIE WQ, 1991, BIOTECHNIQUES, V11, P324	24	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4209	4212		10.1074/jbc.270.9.4209	http://dx.doi.org/10.1074/jbc.270.9.4209			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876178	hybrid			2022-12-25	WOS:A1995QK08400008
J	MENG, QH; SPARKS, DL; MARCEL, YL				MENG, QH; SPARKS, DL; MARCEL, YL			EFFECT OF LPA-I COMPOSITION AND STRUCTURE ON CHOLESTEROL TRANSFER BETWEEN LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; GRADIENT GEL-ELECTROPHORESIS; CELL-DERIVED CHOLESTEROL; HUMAN-PLASMA LECITHIN; MICELLAR COMPLEXES; PARTICLE-SIZE; ACYLTRANSFERASE; EXCHANGE; MECHANISM	The effect of high density lipoprotein composition on the rates of unesterified cholesterol exchange between low density lipoproteins (LDL) and well-defined homogeneous discoidal lipoproteins (LpA-I) reconstituted with phosphatidylcholine, cholesterol, and apolipoprotein A-I (apoA-I) has been investigated, LpA-I containing cholesterol and 2, 3, and 4 apoA-I molecules per particle differed in their ability to accept or donate cholesterol, A significant cholesterol exchange occurs between LDL and Lp2A-I (7.8 and 9.6 nm), while there is little or no cholesterol exchange detectable between LDL and Lp3A-I (10.8 and 13.4 nm) and Lp4A-I (17.0 nm) complexes, The cholesterol transfer from LDL to the cholesterol-free Lp2A-I (9.6 nm), Lp3A-I (13.4 nm), and Lp4A-I (17.0 nm) particles also shows significant cholesterol transfer to Lp2A-I, while there is no detectable transfer to Lp3- and 4A-I particles, The rates of cholesterol transfer to cholesterol-free and cholesterol-containing Lp2A-I appear to differ significantly, Cholesterol transfer from LDL to cholesterol-free Lp2A-I is zero order with respect to acceptor concentrations when the Lp2A-I/LDL ratio is above 10, Transfer rates from LDL to cholesterol-free Lp2A-I are faster for the smaller Lp2A-I (8.5 nn) than to the larger Lp2A-I (9.7 nm) and exhibit half-times (t(1/2)) at 25 degrees C of 4.0 and 5.3 h, respectively, In contrast, cholesterol transfer from LDL to cholesterol-containing Lp2A-I remains dependent upon acceptor concentrations to an acceptor/donor particle ratio of 80, In addition, transfer from LDL to cholesterol-containing Lp2A-I is faster to the 9.6 nm than to 7.8 nn particles, with t(1/2) of 1.4 and 2.3 h, respectively, The rates of cholesterol transfer from Lp2A-I to LDL are higher than in the opposite direction, in particular for the small Lp2A-I (7.8 nm), which has a t(1/2) of approximately 50 min, The results show that changes in the composition and structure of apoA-I-containing particles have a significant effect on inter-lipoprotein exchange of cholesterol. This suggests that the kinetics of cholesterol transfer to and from reconstituted discoidal LpA-I particles cannot be fully explained by passive aqueous diffusion.	UNIV OTTAWA, DEPT PATHOL & LAB MED, OTTAWA, ON K1Y 4E9, CANADA; UNIV OTTAWA, DEPT BIOCHEM, OTTAWA, ON K1Y 4E9, CANADA	University of Ottawa; University of Ottawa	MENG, QH (corresponding author), UNIV OTTAWA, INST HEART, LIPOPROT & ATHEROSCLEROSIS GRP, OTTAWA, ON K1Y 4E9, CANADA.							AGNANI G, 1993, BIOCHEMISTRY-US, V32, P2643, DOI 10.1021/bi00061a024; BACKER JM, 1981, BIOCHEMISTRY-US, V20, P3805, DOI 10.1021/bi00516a021; BAR LK, 1986, BIOCHEMISTRY-US, V25, P6701, DOI 10.1021/bi00369a056; BITTMAN R, 1984, BIOCHIM BIOPHYS ACTA, V772, P117, DOI 10.1016/0005-2736(84)90034-8; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEUNG MC, 1989, J LIPID RES, V30, P499; FIELDING CJ, 1981, J BIOL CHEM, V256, P2102; FIELDING PE, 1991, BIOCHEMISTRY-US, V30, P8551, DOI 10.1021/bi00099a009; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GURD FRN, 1960, LIPID CHEM, P208; HUANG YD, 1993, ARTERIOSCLER THROMB, V13, P445, DOI 10.1161/01.ATV.13.3.445; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1994, J LIPID RES, V35, P860; LETIZIA JY, 1991, BIOCHEMISTRY-US, V30, P866, DOI 10.1021/bi00217a041; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1984, BIOCHEMISTRY-US, V23, P1130, DOI 10.1021/bi00301a015; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; LUNDKATZ S, 1982, BIOCHEMISTRY-US, V21, P2964, DOI 10.1021/bi00541a025; MASSEY JB, 1985, BIOCHEMISTRY-US, V24, P7110, DOI 10.1021/bi00346a014; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MAYFIELD C, 1979, CLIN CHEM, V25, P1309; McKay HAC, 1938, NATURE, V142, P997, DOI 10.1038/142997b0; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MENG QH, 1993, J BIOL CHEM, V268, P16966; MIIDA T, 1990, BIOCHEMISTRY-US, V29, P10469, DOI 10.1021/bi00498a007; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; PARK MSC, 1987, ARCH BIOCHEM BIOPHYS, V258, P545, DOI 10.1016/0003-9861(87)90376-6; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; TAJIMA S, 1983, J BIOL CHEM, V258, P73; TALL AR, 1978, BIOCHIM BIOPHYS ACTA, V513, P185, DOI 10.1016/0005-2736(78)90172-4; WILLIAMS PT, 1990, J LIPID RES, V31, P1131	41	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4280	4287		10.1074/jbc.270.9.4280	http://dx.doi.org/10.1074/jbc.270.9.4280			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876187	hybrid			2022-12-25	WOS:A1995QK08400018
J	REHN, M; PIHLAJANIEMI, T				REHN, M; PIHLAJANIEMI, T			IDENTIFICATION OF 3 N-TERMINAL ENDS OF TYPE-XVIII COLLAGEN CHAINS AND TISSUE-SPECIFIC DIFFERENCES IN THE EXPRESSION OF THE CORRESPONDING TRANSCRIPTS - THE LONGEST FORM CONTAINS A NOVEL MOTIF HOMOLOGOUS TO RAT AND DROSOPHILA FRIZZLED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELICAL REGION; MESSENGER-RNA; EXTENSIVE INTERRUPTIONS; GENE; VARIANTS; DOMAINS; EXON; SPECTRUM; SITES; LOCUS	Transcripts for the alpha 1 chain of mouse type XVIII collagen were found to be heterogeneous at their 5'-ends and to encode three variant N-terminal sequences of the ensuing 1315-, 1527-, or 1774-residue collagen chains. The variant mRNAs appeared to originate from the use of two alternate promoters of the alpha 1(XVIII) chain gene, resulting in the synthesis of either short or long N-terminal non-collagenous NC1 domains, the latter being further subject to modification due to alternative splicing of the transcripts. As a result, the 1527- and 1774-residue polypeptides share the same signal peptide, and the lengths of their NC1 domains are 517 or 764 amino acid residues, respectively, while the 1315-residue polypeptide has a different signal peptide and a 301-residue NC1 domain, The longest NC1 domain was strikingly characterized by a 110-residue sequence with 10 cysteines, which was found to be homologous with the previously identified frizzled proteins belonging to the family of G-protein-coupled membrane receptors. Thus, it is proposed that the cysteine-rich motif, termed fi, represents a new sequence motif that can be found in otherwise unrelated proteins, Tissues containing mainly one or two NC1 domain mRNA variants or all three NC1 domains were identified, indicating that there is tissue-specific utilization of two alternate promoters and alternative splicing of alpha 1(XVIII) transcripts.	UNIV OULU, DEPT MED BIOCHEM, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND	University of Oulu; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045				ABE N, 1993, BIOCHEM BIOPH RES CO, V196, P576, DOI 10.1006/bbrc.1993.2288; ADLER PN, 1987, DEV GENET, V8, P99, DOI 10.1002/dvg.1020080206; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; Dayhoff M. O., 1979, ATLAS PROTEIN SEQUEN, P345; DELEAGE G, 1989, COMPUT APPL BIOSCI, V5, P159; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLIANA R, 1990, J CELL BIOL, V111, P2197, DOI 10.1083/jcb.111.5.2197; FENG LL, 1994, J BIOL CHEM, V269, P2342; GERECKE DR, 1993, J BIOL CHEM, V268, P12177; HUEBNER K, 1992, GENOMICS, V14, P220, DOI 10.1016/S0888-7543(05)80209-5; JUVONEN M, 1992, J BIOL CHEM, V267, P24693; JUVONEN M, 1992, J BIOL CHEM, V267, P24700; JUVONEN M, 1993, LAB INVEST, V69, P541; KERE J, 1992, GENOMICS, V14, P241, DOI 10.1016/S0888-7543(05)80212-5; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KIVIRIKKO S, 1994, J BIOL CHEM, V269, P4773; KRASNOW RE, 1994, DEVELOPMENT, V120, P1883; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Mayne R, 1993, CURR OPIN CELL BIOL, V5, P883, DOI 10.1016/0955-0674(93)90039-S; MURAGAKI Y, 1994, J BIOL CHEM, V269, P4042; MYERS JC, 1992, P NATL ACAD SCI USA, V89, P10144, DOI 10.1073/pnas.89.21.10144; NAH HD, 1994, J BIOL CHEM, V269, P16443; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OH SP, 1994, GENOMICS, V19, P494, DOI 10.1006/geno.1994.1098; REHN M, 1994, J BIOL CHEM, V269, P13929; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; SAITTA B, 1992, J BIOL CHEM, V267, P6188; SAITTA B, 1990, J BIOL CHEM, V265, P6473; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOKES DG, 1991, J BIOL CHEM, V266, P8626; TRUEB J, 1992, BIOCHIM BIOPHYS ACTA, V1171, P97, DOI 10.1016/0167-4781(92)90145-P; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; ZANUSSI S, 1992, J BIOL CHEM, V267, P24082	41	107	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4705	4711		10.1074/jbc.270.9.4705	http://dx.doi.org/10.1074/jbc.270.9.4705			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876242	hybrid			2022-12-25	WOS:A1995QK08400077
J	SUZUKI, JY; BAUER, CE				SUZUKI, JY; BAUER, CE			ALTERED MONOVINYL AND DIVINYL PROTOCHLOROPHYLLIDE POOLS IN BCHJ MUTANTS OF RHODOBACTER-CAPSULATUS - POSSIBLE MONOVINYL SUBSTRATE DISCRIMINATION OF LIGHT-INDEPENDENT PROTOCHLOROPHYLLIDE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST BIOGENESIS; RHODOPSEUDOMONAS-CAPSULATA; HIGHER-PLANTS; QUANTITATIVE-DETERMINATION; BIOSYNTHESIS; GENES; PHOTOSYNTHESIS; CHLOROPHYLL; SPECTROFLUOROMETRY; MOBILIZATION	In land plants in particular, it has been well established that chlorophyll intermediates, Mg-protoporphyrin, Mg-protoporphyrin monomethylester, protochlorophyllide, and chlorophyllide occur as monovinyl and divinyl forms, The pool of monovinyl and divinyl intermediates differ according to species, age of tissue, and light regime, In this study, we investigated the monovinyl and divinyl characteristics of protochlorophyllide and chlorophyllide in the purple non-sulfur photosynthetic eubacterium Rhodobacter capsulatus. Our results indicate that mutations in genes known to completely block the reduction of protochlorophyllide to chlorophyllide (such as bchN, bchB, and bchL mutants), accumulate a pool of monovinyl and divinyl forms of protochlorophyllide just as observed in plants, However, we also observed that directed insertion and deletion mutations in bchJ, a gene located in the photosynthesis gene cluster, affected the ratio of monovinyl and divinyl protochlorophyllide, Specifically, bchJ-disrupted strains accumulate reduced levels of bacteriochlorophyll concomitant with the accumulation of divinyl protochlorophyllide, Mutants of bchJ in combination with a second mutation in bchL still produce a mixed pool of monovinyl and divinyl protochlorophyllide; however, the ratio of monovinyl to divinyl protochlorophyllide is skewed in favor of divinyl protochlorophyllide. These results thus identify bchJ as the first sequenced gene that affects the divinyl to monovinyl ratio of photopigment intermediates in any photosynthetic organism, In addition, the results of our study also suggest that light-independent protochlorophyllide reductase is discriminatory for a monovinyl substrate.	INDIANA UNIV,DEPT BIOL,MOLEC CELLULAR & DEV BIOL PROGRAM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NIGMS NIH HHS [R01 GM053940] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053940] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAUER CE, 1993, J BACTERIOL, V175, P3919, DOI 10.1128/JB.175.13.3919-3925.1993; BAZZAZ MB, 1982, FEBS LETT, V138, P104, DOI 10.1016/0014-5793(82)80405-5; BELANGER FC, 1982, J BIOL CHEM, V257, P1360; BOLLIVAR DW, 1994, BIOCHEMISTRY-US, V33, P12763, DOI 10.1021/bi00209a006; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; CAREY EE, 1985, PLANT PHYSIOL, V79, P1, DOI 10.1104/pp.79.1.1; CHISHOLM SW, 1992, ARCH MICROBIOL, V157, P297, DOI 10.1007/BF00245165; CHISHOLM SW, 1990, NATURE, V334, P340; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; IOANNIDES IM, 1992, PLANT PHYSL LIFE SCI, V11, P79; MARRS B, 1981, J BACTERIOL, V146, P1003, DOI 10.1128/JB.146.3.1003-1012.1981; PARHAM R, 1992, BIOCHEMISTRY-US, V31, P8460, DOI 10.1021/bi00151a011; PARTENSKY F, 1993, PLANT PHYSIOL, V101, P285, DOI 10.1104/pp.101.1.285; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; REBEIZ CA, 1988, CRIT REV PLANT SCI, V6, P384; REBEIZ CA, 1994, BIOSYNTHESIS TETRAPY, P177; SCOLNIK PA, 1984, NATURE, V307, P289, DOI 10.1038/307289a0; SCOLNIK PA, 1980, J BIOL CHEM, V255, P2427; SHIOI Y, 1992, PLANT PHYSIOL, V100, P1291, DOI 10.1104/pp.100.3.1291; SHIOI Y, 1988, ARCH BIOCHEM BIOPHYS, V267, P69, DOI 10.1016/0003-9861(88)90009-4; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SMITH WL, 1991, TEACH SOCIOL, V19, P237, DOI 10.2307/1317856; SOJKA GA, 1970, ARCH BIOCHEM BIOPHYS, V136, P578, DOI 10.1016/0003-9861(70)90231-6; TAYLOR DP, 1983, J BACTERIOL, V154, P580, DOI 10.1128/JB.154.2.580-590.1983; TRIPATHY BC, 1985, ANAL BIOCHEM, V149, P43, DOI 10.1016/0003-2697(85)90475-0; TRIPATHY BC, 1988, PLANT PHYSIOL, V87, P89, DOI 10.1104/pp.87.1.89; TRIPATHY BC, 1986, J BIOL CHEM, V261, P3556; WHYTE BJ, 1993, BIOCHEM J, V291, P939, DOI 10.1042/bj2910939; WU SM, 1989, ANAL BIOCHEM, V178, P294, DOI 10.1016/0003-2697(89)90641-6; YANG ZM, 1990, J BACTERIOL, V172, P5001, DOI 10.1128/jb.172.9.5001-5010.1990; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YEN HC, 1976, J BACTERIOL, V126, P619, DOI 10.1128/JB.126.2.619-629.1976; YILDIZ FH, 1992, MOL MICROBIOL, V6, P2683, DOI 10.1111/j.1365-2958.1992.tb01445.x; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558; ZESBO KM, 1984, CELL, V37, P937	36	51	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3732	3740		10.1074/jbc.270.8.3732	http://dx.doi.org/10.1074/jbc.270.8.3732			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876113	hybrid			2022-12-25	WOS:A1995QH68800043
J	ZHOU, Z; MISLER, S				ZHOU, Z; MISLER, S			ACTION POTENTIAL-INDUCED QUANTAL SECRETION OF CATECHOLAMINES FROM RAT ADRENAL CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET B-CELLS; TRANSMITTER RELEASE; CALCIUM CHANNELS; ELECTRICAL-ACTIVITY; NERVE-TERMINALS; ACETYLCHOLINE; FACILITATION; MEDULLA; STIMULATION; MUSCARINE	Using single rat adrenal chromaffin cells, we examined the coupling of action potential activity to quantal release of catecholamines by combining perforated patch current-clamp recording with electrochemical microcarbon fiber amperometry. Chromaffin cells display steeper dependence of quantal release on action potential frequency than many nerve terminals, as well as more desynchronized release following an action potential. Also in contrast to neurons, in chromaffin cells, a major chemical secretagogue (acetylcholine) triggers potent quantal release even in the absence of electrical activity. These findings are consistent with an hypothesis that a major component of exocytosis from chromaffin cells involves diffusion of Ca2+ to secretion sites which are less well co-localized with Ca2+ channels than those in nerve terminals.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MED, DIV RENAL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL PHYSIOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)			zhou, zhuan/A-8285-2011		NIDDK NIH HHS [DK37380] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037380] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGUSTINE GJ, 1991, ANN NY ACAD SCI, V635, P365, DOI 10.1111/j.1749-6632.1991.tb36505.x; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BOOKMAN RJ, 1991, ANN NY ACAD SCI, V635, P352, DOI 10.1111/j.1749-6632.1991.tb36504.x; BRANDT BL, 1976, J PHYSIOL-LONDON, V263, P417, DOI 10.1113/jphysiol.1976.sp011638; BROCK JA, 1988, J PHYSIOL-LONDON, V399, P607; CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CHOW RH, 1995, IN PRESS P NATL ACAD; COUTEAUX R, 1974, CR ACAD SCI D NAT, V278, P291; DUNN LA, 1983, J BIOL CHEM, V258, P4989; FALKE LC, 1989, FEBS LETT, V251, P167, DOI 10.1016/0014-5793(89)81448-6; Feldberg W, 1934, J PHYSIOL-LONDON, V81, P286, DOI 10.1113/jphysiol.1934.sp003136; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; GERSDORFF HV, 1994, NATURE, V367, P735; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; HERRINGTON J, 1993, PULSE CONTROL DOCUME; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; JACKSON MB, 1991, P NATL ACAD SCI USA, V88, P380, DOI 10.1073/pnas.88.2.380; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P483, DOI 10.1098/rspb.1965.0016; Katz B., 1969, RELEASE NEURAL TRANS; KIDOKORO Y, 1980, J PHYSIOL-LONDON, V307, P199, DOI 10.1113/jphysiol.1980.sp013431; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MAGLEBY KL, 1973, J PHYSIOL-LONDON, V234, P327, DOI 10.1113/jphysiol.1973.sp010348; MALHOTRA RK, 1988, NEUROSCIENCE, V26, P313, DOI 10.1016/0306-4522(88)90147-9; MISLER S, 1977, THESIS NEW YORK U; MONCK JR, 1994, BIOPHYS J, V67, P505, DOI 10.1016/S0006-3495(94)80554-5; NEELY A, 1992, J PHYSIOL-LONDON, V453, P97, DOI 10.1113/jphysiol.1992.sp019220; NEELY A, 1992, J PHYSIOL-LONDON, V453, P133, DOI 10.1113/jphysiol.1992.sp019221; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; NOHMI M, 1992, J PHYSIOL-LONDON, V458, P171, DOI 10.1113/jphysiol.1992.sp019412; PRESSEL DM, 1991, J MEMBRANE BIOL, V124, P239, DOI 10.1007/BF01994357; PUMPLIN DW, 1981, P NATL ACAD SCI-BIOL, V78, P7210, DOI 10.1073/pnas.78.11.7210; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; RUDEN L, 1993, SCIENCE, V262, P1061; SACHI O, 1971, PFLUGERS ARCH, V329, P209; SCHROEDER TJ, 1994, J BIOL CHEM, V269, P17215; TOLEDO GA, 1993, NATURE, V363, P554; WAKADE AR, 1983, NEUROSCIENCE, V10, P973, DOI 10.1016/0306-4522(83)90235-X; WARASHINA A, 1989, BIOMED RES-TOKYO, V10, P157, DOI 10.2220/biomedres.10.157; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; ZHOU Z, 1994, J GEN PHYSIOL, V104, pA28; ZHOU Z, 1994, BIOPHYS J, V66, pA54; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813; ZUCKER RS, 1973, J PHYSIOL-LONDON, V229, P787, DOI 10.1113/jphysiol.1973.sp010167	48	123	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3498	3505		10.1074/jbc.270.8.3498	http://dx.doi.org/10.1074/jbc.270.8.3498			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876083	hybrid			2022-12-25	WOS:A1995QH68800010
J	BLACK, BL; MARTIN, JF; OLSON, EN				BLACK, BL; MARTIN, JF; OLSON, EN			THE MOUSE MRF4 PROMOTER IS TRANS-ACTIVATED DIRECTLY AND INDIRECTLY BY MUSCLE-SPECIFIC TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENHANCER-BINDING-FACTOR; REGULATORY ELEMENTS; MYOGENIC LINEAGE; GENE-PRODUCTS; EXPRESSION; PROTEINS; MEMBER; FAMILY; DIFFERENTIATION; IDENTIFICATION	MRF4 is a member of the basic helix-loop-helix (bHLH) family of muscle-specific transcription factors, which also includes MyoD, myogenin, and myf5. The myocyte enhancer binding factor 2 (MEF2) proteins also serve as important muscle-specific transcription factors. In addition to activating the expression of many muscle specific structural genes, various members of these two classes of proteins activate their own expression and the expression of each other in a complex transcriptional network that results in the establishment and maintenance of the muscle phenotype. To begin to determine how the expression of MRF4 is regulated by other muscle-specific transcription factors, we have isolated a region of the MRF4 gene that confers muscle-specific expression and have analyzed this promoter region for cis-acting elements involved in trans-activation by the myogenic bHLH and MEF2 transcription factors. Here, we show that in 10T1/2 fibroblasts the MRF4 promoter is trans-activated by myogenin, MyoD, myf5, and by the MEF2 factors, but that MRF4 does not activate expression of its own promoter. Myogenin activated the MRF4 promoter directly by an E box-dependent mechanism, while MEF2 factors activated the prometer through an indirect pathway. The E box-dependent regulation of the MRF4 promoter is in contrast to the regulation of the myogenin and MyoD promoters and may represent a mechanism for the differential expression of these factors during myogenesis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center				Black, Brian/0000-0002-6664-8913				BLACK BL, 1992, J VIROL, V66, P4058, DOI 10.1128/JVI.66.7.4058-4064.1992; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DECHESNE CA, 1994, MOL CELL BIOL, V14, P5474, DOI 10.1128/MCB.14.8.5474; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HINTERBERGER TJ, 1992, GENE, V117, P201, DOI 10.1016/0378-1119(92)90730-D; Horton R.M., 1993, PCR PROTOCOLS CURREN, V15, P251; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PATAPOUTIAN A, 1993, DEVELOPMENT, V118, P61; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Sambrook J, 1989, MOL CLONING LABORATO; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	42	85	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2889	2892		10.1074/jbc.270.7.2889	http://dx.doi.org/10.1074/jbc.270.7.2889			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852366	hybrid			2022-12-25	WOS:A1995QG47100003
J	SJOBERG, ER; CHAMMAS, R; OZAWA, H; KAWASHIMA, I; KHOO, KH; MORRIS, HR; DELL, A; TAI, T; VARKI, A				SJOBERG, ER; CHAMMAS, R; OZAWA, H; KAWASHIMA, I; KHOO, KH; MORRIS, HR; DELL, A; TAI, T; VARKI, A			EXPRESSION OF DE-N-ACETYL-GANGLIOSIDES IN HUMAN-MELANOMA CELLS IS INDUCED BY GENISTEIN OR NOCODAZOLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; RECEPTOR TYROSINE KINASE; PROTEIN-KINASE; SERIES GANGLIOSIDES; MONOCLONAL-ANTIBODIES; MASS-SPECTROMETRY; O-ACETYLATION; SIALIC ACIDS; GROWTH; DIFFERENTIATION	Neuraminic acid is the core structure of most known sialic acids. In natural systems, the amino group at the 5 position of neuraminic acid residues is usually assumed to be acylated. Previously, synthetic de-N-acetyl-gangliosides (with free amino groups at the 5 position of neuraminic acids) have been shown to modulate cellular proliferation and tyrosine phosphokinase reactions. While indirect evidence has suggested that traces of these molecules exist naturally in certain tumor cells, further exploration has been hampered by the lack of a system showing consistent expression at an easily detectable level. Using synthetic compounds as antigens, we have developed highly specific monoclonal antibodies against de-N-acetyl-G(M3) and de-N-acetyl-G(D3) that require both the free amino group and the exocyclic side chain of sialic acids for recognition. Cultured human melanoma cells showed low but variably detectable levels of reactivity with these antibodies. The ability of various biologically active molecules to stimulate this reactivity was explored. Of many compounds tested, only the tyrosine kinase inhibitor genistein induced reactivity in a dose dependent manner. Antibody reactivity with ganglioside extracts from genistein-treated cells was abolished by chemical re-N-acetylation and/or truncation of sialic acid side chains by mild periodate oxidation. High performance thin layer chromatography immune-overlay analysis confirmed the presence of the novel compound de-N-acetyl-G(D3) in these extracts. Several other tyrosine kinase inhibitors tested did not give the same increase in de-N-acetyl-ganglioside expression. However, the microtubule inhibitor nocodazole caused a similar accumulation of these molecules, particularly in non-adherent cells expected to be arrested at metaphase. Thus, genistein may induce de-N-acetyl-ganglioside expression by virtue of its known ability to arrest cells in the G(2)M phase, rather than as a general consequence of tyrosine kinase inhibition. These studies also provide a system in which to analyze the enzymatic basis of de-N-acetyl-ganglioside expression and their potential roles as growth regulating molecules.	UNIV CALIF SAN DIEGO, SCH MED, CTR CANC, GYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; TOKYO METROPOLITAN INST MED SCI, DEPT TUMOR IMMUNOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV LONDON IMPERIAL COLL SCI & TECHNOL, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND	University of California System; University of California San Diego; University of California System; University of California San Diego; Tokyo Metropolitan Institute of Medical Science; Imperial College London			Chammas, Roger/A-8004-2011; Khoo, Kay-Hooi/E-1989-2019	Chammas, Roger/0000-0003-0342-8726; Khoo, Kay-Hooi/0000-0003-2906-406X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM32373] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ABLER A, 1992, J BIOL CHEM, V267, P3946; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BREMER EG, 1984, J BIOL CHEM, V259, P6818; CHAOHSING KAO, 1991, ARCH DERMATOL RES, V283, P119, DOI 10.1007/BF00371620; CHERESH DA, 1986, J CELL BIOL, V102, P1887, DOI 10.1083/jcb.102.5.1887; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; DAWSON G, 1990, CANCER CELL-MON REV, V2, P327; DEKAN G, 1990, AM J PATHOL, V137, P913; DELL A, 1990, METHOD ENZYMOL, V193, P647, DOI 10.1016/0076-6879(90)93443-O; DYATLOVITSKAYA EV, 1991, EUR J BIOCHEM, V199, P643, DOI 10.1111/j.1432-1033.1991.tb16165.x; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HANAI N, 1988, J BIOL CHEM, V263, P6296; HAVERKAMP J, 1975, H-S Z PHYSIOL CHEM, V356, P1575, DOI 10.1515/bchm2.1975.356.2.1575; HSU CYJ, 1991, J BIOL CHEM, V266, P21105; HUANG JM, 1992, J BIOL CHEM, V267, P15511; ITOH K, 1991, NEUROSCI RES, V9, P279, DOI 10.1016/0168-0102(91)90029-X; KARKAS JD, 1964, J BIOL CHEM, V239, P949; KAWASHIMA I, 1992, MOL IMMUNOL, V29, P625; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; KOTANI M, 1992, BIOCHIM BIOPHYS ACTA, V1117, P97, DOI 10.1016/0304-4165(92)90168-T; KUSUNOKI S, 1993, BRAIN RES, V623, P83, DOI 10.1016/0006-8993(93)90013-D; LADISCH S, 1987, J CLIN INVEST, V79, P1879, DOI 10.1172/JCI113031; LEVINE JM, 1984, J NEUROSCI, V4, P820; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; MANZI AE, 1990, J BIOL CHEM, V265, P8094; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NEUFELD EJ, 1978, ARCH BIOCHEM BIOPHYS, V188, P323, DOI 10.1016/S0003-9861(78)80016-2; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; NORES GA, 1988, CARBOHYD RES, V179, P393, DOI 10.1016/0008-6215(88)84135-1; OZAWA H, 1992, BIOCHIM BIOPHYS ACTA, V1123, P184, DOI 10.1016/0005-2760(92)90110-H; OZAWA H, 1992, BIOCH BIOPHYS ACTA L, V294, P42; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RANDO RR, 1988, FASEB J, V2, P2348, DOI 10.1096/fasebj.2.8.3282960; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SCHAUER R, 1982, CELL BIOL MONOGRAPHS, V18; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P348; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; SJOBERG ER, 1992, J BIOL CHEM, V267, P16200; SONG WX, 1991, J BIOL CHEM, V266, P10174; SONNINO S, 1985, J LIPID RES, V26, P248; SORIO C, 1993, BIOCHEM BIOPH RES CO, V191, P1105, DOI 10.1006/bbrc.1993.1330; STRULOVICI B, 1984, SCIENCE, V225, P837, DOI 10.1126/science.6089331; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; TSUJI S, 1992, NEUROCHEM INT, V21, P549, DOI 10.1016/0197-0186(92)90087-8; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VONSCHAEWEN A, 1993, PLANT PHYSIOL, V102, P1109, DOI 10.1104/pp.102.4.1109; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217; ZHOU QG, 1994, J BIOL CHEM, V269, P1959; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	70	50	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					2921	2930		10.1074/jbc.270.7.2921	http://dx.doi.org/10.1074/jbc.270.7.2921			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852370	hybrid			2022-12-25	WOS:A1995QG47100009
J	TSUMAKI, N; KIMURA, T				TSUMAKI, N; KIMURA, T			DIFFERENTIAL EXPRESSION OF AN ACIDIC DOMAIN IN THE AMINO-TERMINAL PROPEPTIDE OF MOUSE PRO-ALPHA-2(XI) COLLAGEN BY COMPLEX ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-RICH PROTEIN; XI COLLAGEN; MESSENGER-RNA; II COLLAGEN; NH2-TERMINAL DOMAIN; V COLLAGEN; MOLECULAR-CLONING; CARTILAGE; CHAIN; GENE	We isolated and sequenced genomic and cDNA clones encoding the complete amino-terminal portion and the 5'-untranslated region of mouse pro-alpha 2(XI) collagen mRNA. Fourteen exons encoded the amino-terminal propeptide, which was divided into three consecutive domains (a long globular domain, an amino-terminal triple helical domain, and a telopeptide domain), The long globular domain was further divided into an upstream basic subdomain and a downstream highly acidic subdomain, as is the case for the amino-terminal propeptides of pro-alpha 1(V) and pro-alpha 1(XI) collagens, We also demonstrated that the primary transcript undergoes complex alternative splicing, Three consecutive exons (exons 6, 7, and 8) encoding most of the acidic subdomain showed alternative splicing which dramatically affected the structure of the amino-terminal propeptide of pro-alpha 2(XI) collagen, Using the reverse transcription-polymerase chain reaction, we analyzed the expression of these exons in various tissues and in developing limb buds of mice, The pro-alpha 2(XI) transcripts were abundant in cartilage, but most of them lacked the 3-exon sequences encoding the acidic domain, Most of other tissues also contained mRNAs that corresponded to longer splice variants, including exons 6-8. The differential expression of specific domains of pro-alpha 2(XI) collagen may be important in modulating interactions between various components of the extracellular matrix and/or may influence heterotypic collagen assembly.			TSUMAKI, N (corresponding author), OSAKA UNIV,SCH MED,DEPT ORTHOPAED SURG,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.			Tsumaki, Noriyuki/0000-0002-0520-3654				BALVAY L, 1993, BIOESSAYS, V15, P165, DOI 10.1002/bies.950150304; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BROWN KE, 1991, J BIOL CHEM, V266, P23268; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; DOLIANA R, 1990, J CELL BIOL, V111, P2197, DOI 10.1083/jcb.111.5.2197; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FENG LL, 1994, J BIOL CHEM, V269, P2342; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FURUTO DK, 1983, ARCH BIOCHEM BIOPHYS, V226, P604, DOI 10.1016/0003-9861(83)90329-6; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; KIMURA T, 1989, J BIOL CHEM, V264, P13910; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; METSARANTA M, 1991, J BIOL CHEM, V266, P16862; MORIKAWA T, 1980, BIOCHEMISTRY-US, V19, P2646, DOI 10.1021/bi00553a017; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MORRIS NP, 1994, 40TH ANN M ORTH RES, V19, P423; NAH HD, 1992, J BIOL CHEM, V267, P22581; NAH HD, 1991, J BIOL CHEM, V266, P23446; NAKATA K, 1992, FEBS LETT, V299, P278, DOI 10.1016/0014-5793(92)80131-Y; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PETIT B, 1993, HISTOCHEMISTRY, V100, P231, DOI 10.1007/BF00269096; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAITTA B, 1990, J BIOL CHEM, V265, P6473; SANDBERG MM, 1993, BIOCHEM J, V294, P595, DOI 10.1042/bj2940595; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SMBROOK J, 1989, MOL CLONING LABORATO; STUBBS L, 1993, MAMM GENOME, V4, P95, DOI 10.1007/BF00290433; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; THOM JR, 1991, J BIOL CHEM, V266, P7262; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; YAMADA Y, 1980, CELL, V22, P887, DOI 10.1016/0092-8674(80)90565-6; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M	47	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2372	2378		10.1074/jbc.270.5.2372	http://dx.doi.org/10.1074/jbc.270.5.2372			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836472	hybrid			2022-12-25	WOS:A1995QE49300060
J	TZENG, MC; YEN, CH; HSEU, MJ; DUPUREUR, CM; TSAI, MD				TZENG, MC; YEN, CH; HSEU, MJ; DUPUREUR, CM; TSAI, MD			CONVERSION OF BOVINE PANCREATIC PHOSPHOLIPASE A(2) AT A SINGLE-SITE INTO A COMPETITOR OF NEUROTOXIC PHOSPHOLIPASES A(2) BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GUINEA-PIG BRAIN; BINDING-PROTEIN; BETA-BUNGAROTOXIN; GEL-ELECTROPHORESIS; SYNAPTIC-MEMBRANES; ENZYMATIC-ACTIVITY; CHICK BRAIN; SNAKE-VENOM; CROTOXIN	A 45-kDa polypeptide preferentially present in neuronal membranes was previously identified as a subunit of a binding (or receptor) protein for several phospholipase A(2) variants with neurotoxicity, including crotoxin, by chemical cross-linking experiments (Yen, C.-H., and Tzeng, M. C. (1991) Biochemistry 30, 11473-11477), The binding of crotoxin to this receptor protein was completely suppressed by sufficient F22Y, a mutated bovine pancreatic phospholipase A(2) generated by site-directed mutagenesis of Phe(22) of the wild-type enzyme to Tyr, The IC50 of this inhibition was estimated to be 1 mu M. In sharp contrast, the wild-type enzyme gave no effect even at 50 mu M. This mutation resulted in only minor and localized structural perturbations with little effect on enzymatic activity. Other phospholipase A(2) molecules capable of competing with crotoxin for this binding invariably have Tyr at this position, It was concluded that this Tyr residue is an important determinant for the binding of a number of phospholipase A(2) variants to the 45-kDa receptor.	NATL TAIWAN UNIV, INST BIOCHEM SCI, TAIPEI 107, TAIWAN; OHIO STATE UNIV, DEPT CHEM, COLUMBUS, OH 43210 USA	National Taiwan University; University System of Ohio; Ohio State University	TZENG, MC (corresponding author), ACAD SINICA, INST BIOL CHEM, POB 23-106, TAIPEI 107, TAIWAN.		Tsai, Ming-Daw/G-4689-2019	Tsai, Ming-Daw/0000-0003-1374-0414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041788] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41788] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAVIDSON FF, 1991, HDB NATURAL TOXINS, V5, P107; de ROBERTIS E., 1963, JOUR NEUROCHEM, V10, P225; DEGN LL, 1991, TOXICON, V29, P973, DOI 10.1016/0041-0101(91)90080-B; DENG TL, 1990, GENE, V93, P229, DOI 10.1016/0378-1119(90)90229-K; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DUPUREUR CM, 1992, BIOCHEMISTRY-US, V31, P10576, DOI 10.1021/bi00158a021; HARRIS JB, 1991, SNAKE TOXINS, P61; Harvey A L, 1990, Int Rev Neurobiol, V32, P201; Hawgood B., 1991, HDB NATURAL TOXINS R, V5, P3; HEINRIKSON RL, 1991, METHOD ENZYMOL, V197, P201; HENDON RA, 1979, BIOCHIM BIOPHYS ACTA, V578, P243, DOI 10.1016/0005-2795(79)90132-6; HENDON RA, 1971, P NATL ACAD SCI USA, V68, P1560, DOI 10.1073/pnas.68.7.1560; HSEU MJ, 1990, J BIOENERG BIOMEMBR, V22, P39, DOI 10.1007/BF00762844; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KINI RM, 1986, TOXICON, V24, P527, DOI 10.1016/0041-0101(86)90173-X; KRIZAJ I, 1989, BIOCHIM BIOPHYS ACTA, V999, P198, DOI 10.1016/0167-4838(89)90218-5; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1989, J BIOL CHEM, V264, P11503; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; Mebs D., 1991, SNAKE TOXINS, P425; MOLLIER P, 1989, EUR J BIOCHEM, V185, P263, DOI 10.1111/j.1432-1033.1989.tb15111.x; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NOEL JP, 1991, BIOCHEMISTRY-US, V30, P11801, DOI 10.1021/bi00115a010; NOEL JP, 1989, J CELL BIOCHEM, V40, P309, DOI 10.1002/jcb.240400307; ONO T, 1984, J BIOCHEM-TOKYO, V96, P785, DOI 10.1093/oxfordjournals.jbchem.a134896; OTHMAN IB, 1982, EUR J BIOCHEM, V128, P267; REHM H, 1983, EMBO J, V2, P1119, DOI 10.1002/j.1460-2075.1983.tb01555.x; REHM H, 1982, J BIOL CHEM, V257, P15; REHM H, 1988, BIOCHEM BIOPH RES CO, V153, P231, DOI 10.1016/S0006-291X(88)81213-0; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; RITONJA A, 1986, BIOL CHEM H-S, V367, P919, DOI 10.1515/bchm3.1986.367.2.919; Rosenberg P., 1990, HDB TOXINOLOGY, P67; RUBSAMEN K, 1971, N-S ARCH PHARMAKOL, V270, P274; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; SCHANBERG SM, 1967, J PHARMACOL EXP THER, V157, P311; SCHWEITZ H, 1984, TOXICON, V22, P308, DOI 10.1016/0041-0101(84)90032-1; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; TAKASAKI C, 1990, TOXICON, V28, P107, DOI 10.1016/0041-0101(90)90012-V; TSAI IH, 1987, BIOCHIM BIOPHYS ACTA, V916, P94, DOI 10.1016/0167-4838(87)90215-9; TSAI IH, 1991, PEPTIDES CHEM BIOL, P460; TZENG MC, 1986, J PROTEIN CHEM, V5, P221, DOI 10.1007/BF01025490; TZENG MC, 1993, J TOXICOL-TOXIN REV, V12, P1; TZENG MC, 1983, ANAL BIOCHEM, V128, P412, DOI 10.1016/0003-2697(83)90394-9; TZENG MC, 1989, BIOCHEM BIOPH RES CO, V165, P689, DOI 10.1016/S0006-291X(89)80021-X; WHITTAKER VP, 1959, BIOCHEM J, V72, P694, DOI 10.1042/bj0720694; YANG CC, 1986, J PROTEIN CHEM, V5, P15, DOI 10.1007/BF01025581; YANG CC, 1991, BIOCHEM J, V280, P739, DOI 10.1042/bj2800739; YANG CC, 1994, J TOXICOL-TOXIN REV, V13, P125, DOI 10.3109/15569549409089958; YEN CH, 1991, BIOCHEMISTRY-US, V30, P11473, DOI 10.1021/bi00112a015	50	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2120	2123		10.1074/jbc.270.5.2120	http://dx.doi.org/10.1074/jbc.270.5.2120			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836440	Green Submitted, hybrid			2022-12-25	WOS:A1995QE49300023
J	GESSNER, JE; GRUSSENMEYER, T; KOLANUS, W; SCHMIDT, RE				GESSNER, JE; GRUSSENMEYER, T; KOLANUS, W; SCHMIDT, RE			THE HUMAN LOW-AFFINITY IMMUNOGLOBULIN-G FC RECEPTOR III-A AND III-B GENES - MOLECULAR CHARACTERIZATION OF THE PROMOTER REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; GAMMA-RIII CD16; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; RESPONSE ELEMENTS; ALPHA-CHAIN; EXPRESSION; ACTIVATION; NEUTROPHILS; INTERFERON	The human Fc receptor with low affinity for IgG (Fc gamma RIII, CD16) is encoded by two nearly identical genes, Fc gamma RIII-A and Fc gamma RIII-B, resulting in tissue-specific expression of alternative membrane-anchored isoforms, The transmembrane CD16 receptor forms a heteromeric structure with the Fc epsilon RI (gamma) and/or CD3 (zeta) subunits on the surface of activated monocytes/macrophages, NK cells, and a subset of T cells, The expression of the glycosylphosphatidylinositol-anchored CD16 isoform encoded by the Fc gamma RIII-B gene is restricted to polymorphonuclear leukocytes and can be induced by Me(2)SO differentiation of HL60 cells, We have isolated and sequenced genomic clones of the human Fc gamma RIII-A and Fc gamma RIII-B genes, located their transcription initiation sites, identified a different organization of their 5' regions, and demonstrated four distinct classes of Fc gamma RIII-A transcripts (a1-a4) com pared with a single class of Fc gamma RIII-Bb1 transcripts, Both CD16 promoters (positions -198 to -10) lack the classical ''TATA'' positioning consensus sequence but confer transcriptional activity when coupled to the human lysozyme enhancer, Both promoters also display different tissue-specific transcriptional activities reflecting the expected gene expression of Fc gamma RIII-A and Fc gamma RIII-B in NH cells versus polymorphonuclear leukocytes. Within the -198/-10 fragments, the sequences of the two CD16 genes have been identified to differ in 10 positions. It is suggested that these nucleotide differences might contribute to cell type-specific transcription of Fc gamma RIII genes.	HANNOVER MED SCH, DEPT IMMUNOL, D-30625 HANNOVER, GERMANY; LUDWIG MAXIMILIANS UNIV MUNCHEN, GENZENTRUM, MOLEC BIOL LAB, D-82152 MARTINSRIED, GERMANY	Hannover Medical School; University of Munich			Grussenmeyer, Thomas/B-9859-2009	Grussenmeyer, Thomas/0000-0002-6236-9976				ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BENECH PD, 1992, J EXP MED, V176, P1115, DOI 10.1084/jem.176.4.1115; BONNEROT C, 1990, J IMMUNOL, V144, P323; BONNEROT C, 1988, J IMMUNOL, V141, P1026; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1987, BLOOD, V70, P1233; ERNST LK, 1992, J BIOL CHEM, V267, P15692; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HARTNELL A, 1992, J IMMUNOL, V148, P1471; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2365; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; HUNDT M, 1992, EUR J IMMUNOL, V22, P811, DOI 10.1002/eji.1830220327; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; MCKENZIE SE, 1992, MOL IMMUNOL, V29, P1165, DOI 10.1016/0161-5890(92)90052-Y; OSMAN N, 1992, J IMMUNOL, V148, P1570; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PELTZ GA, 1989, P NATL ACAD SCI USA, V86, P1013, DOI 10.1073/pnas.86.3.1013; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PERUSSIA B, 1991, EUR J IMMUNOL, V21, P425, DOI 10.1002/eji.1830210226; PETERS CWB, 1989, EUR J BIOCHEM, V182, P507, DOI 10.1111/j.1432-1033.1989.tb14857.x; PHILLIPS JH, 1991, EUR J IMMUNOL, V21, P895, DOI 10.1002/eji.1830210406; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RADEKE HH, 1994, J IMMUNOL, V153, P1281; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TEPLER I, 1989, J BIOL CHEM, V264, P5912; UCIECHOWSKI P, 1992, EUR J IMMUNOL, V22, P1635, DOI 10.1002/eji.1830220643; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WERFEL T, 1989, J IMMUNOL, V142, P1102; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381; WISKOCIL R, 1985, J IMMUNOL, V134, P1599; YE ZS, 1992, J IMMUNOL, V149, P897; YODOI J, 1985, J IMMUNOL, V134, P1623	49	38	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1350	1361		10.1074/jbc.270.3.1350	http://dx.doi.org/10.1074/jbc.270.3.1350			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836402	hybrid			2022-12-25	WOS:A1995QB15600057
J	ALLEN, S; NAIM, HY; BULLEID, NJ				ALLEN, S; NAIM, HY; BULLEID, NJ			INTRACELLULAR FOLDING OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR - EFFECTS OF DISULFIDE BOND FORMATION ON N-LINKED GLYCOSYLATION AND SECRETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; STRUCTURAL REQUIREMENTS; INTERFERON-GAMMA; AMINO-ACID; G-PROTEIN; SITES; TRANSPORT; GLYCOPROTEINS; MEMBRANE	The addition of N-linked core oligosaccharides to membrane and secretory glycoproteins occurs co-translationally at asparagine residues in the tripeptide sequon Asn-Xaa-Ser/Thr soon after translocation of the nascent polypeptide into the lumen of the endoplasmic reticulum. However, the presence of the sequon does not automatically ensure core glycosylation, as many proteins contain sequons that remain either unglycosylated or glycosylated to a variable extent. To investigate whether intracellular protein folding can influence sequon utilization, we have expressed tissue-type plasminogen activator (t-PA) in cell culture in the presence of mild concentrations of the reducing agent dithiothreitol to prevent cc-translational disulfide bond formation in the endoplasmic reticulum. We show that conditions that prevent disulfide bond formation lead to complete glycosylation of a sequon that otherwise undergoes variable glycosylation in untreated cells. This demonstrated that folding and disulfide bond formation of t-PA determines its extent of core N-linked glycosylation. When dithiothreitol was removed from the cells, the reduced and overglycosylated t-PA formed disulfide bonds, folded and was secreted We also show t-PA present within cells is more susceptible to reduction with low concentrations of dithiothreitol than secreted t-PA.	UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND; UNIV DUSSELDORF,INST MIKROBIOL,W-4000 DUSSELDORF,GERMANY	University of Manchester; Heinrich Heine University Dusseldorf				Bulleid, Neil/0000-0002-9839-5279	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERG DT, 1993, BLOOD, V81, P1312; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BULLEID NJ, 1992, BIOCHEM J, V286, P275, DOI 10.1042/bj2860275; BULLEID NJ, 1990, BIOCHEM J, V268, P777, DOI 10.1042/bj2680777; CARSON DD, 1981, J BIOL CHEM, V256, P1552; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CURLING EMA, 1990, BIOCHEM J, V272, P333, DOI 10.1042/bj2720333; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; GALLAGHER PJ, 1992, J VIROL, V66, P7136, DOI 10.1128/JVI.66.12.7136-7145.1992; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HANSEN L, 1988, J BIOL CHEM, V263, P15713; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HOTCHKISS A, 1988, THROMB HAEMOSTASIS, V60, P225; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KONRAD M, 1994, J BIOL CHEM, V269, P8659; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LUI T, 1979, J BIOL CHEM, V254, P4554; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; Marshall R D, 1974, Biochem Soc Symp, P17; MONONEN I, 1984, BIOCHIM BIOPHYS ACTA, V788, P364, DOI 10.1016/0167-4838(84)90050-5; NAKAI K, 1988, J BIOCHEM-TOKYO, V104, P693, DOI 10.1093/oxfordjournals.jbchem.a122535; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OPSTELTEN DJ, 1994, J VIROL, V67, P7394; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; PLUMMER TH, 1964, J BIOL CHEM, V239, P2530; POHL G, 1984, BIOCHEMISTRY-US, V23, P3701, DOI 10.1021/bi00311a020; POHL G, 1987, BLOOD, V81, P1312; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; SAMBROOK J, 1985, EMBO J, V4, P91, DOI 10.1002/j.1460-2075.1985.tb02322.x; SAMBROOK J, 1986, MOL BIOL MED, V3, P459; Shakin-Eshleman W. H., 1993, TRENDS GLYCOSCI GLYC, V5, P355; SMEDSROD B, 1990, THROMB HAEMOSTASIS, V63, P60; SPELLMAN MW, 1989, J BIOL CHEM, V264, P14100; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; STRUCK DK, 1978, J BIOL CHEM, V253, P5786; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; TAYLOR AK, 1988, MOL CELL BIOL, V8, P4197, DOI 10.1128/MCB.8.10.4197; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780; WITTWER AJ, 1989, BIOCHEMISTRY-US, V28, P7662, DOI 10.1021/bi00445a022	54	107	108	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4797	4804		10.1074/jbc.270.9.4797	http://dx.doi.org/10.1074/jbc.270.9.4797			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876253	hybrid			2022-12-25	WOS:A1995QK08400089
J	CHOI, YH; MATSUZAKI, R; FUKUI, T; SHIMIZU, E; YORIFUJI, T; SATO, H; OZAKI, Y; TANIZAWA, K				CHOI, YH; MATSUZAKI, R; FUKUI, T; SHIMIZU, E; YORIFUJI, T; SATO, H; OZAKI, Y; TANIZAWA, K			COPPER TOPA QUINONE-CONTAINING HISTAMINE OXIDASE FROM ARTHROBACTER-GLOBIFORMIS - MOLECULAR-CLONING AND SEQUENCING, OVERPRODUCTION OF PRECURSOR ENZYME, AND GENERATION OF TOPA QUINONE COFACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM AMINE OXIDASE; ACTIVE-SITE; ESCHERICHIA-COLI; STRUCTURAL GENE; EXPRESSION; 6-HYDROXYDOPA; MECHANISM; DNA	The gene coding for histamine oxidase has been cloned and sequenced from a Coryneform bacterium Arthrobacter globiformis, The deduced amino acid sequence consists of 684 residues with a calculated molecular mass of 75,109 daltons and shows a high overall identity (58%) with that of phenethylamine oxidase derived from the same bacterial strain, Although the sequence similarities are rather low when compared with copper amine oxidases from other organisms, the consensus Asn-Tyr-Asp/Glu sequence, in which the middle Tyr is the precursor to the quinone cofactor (the quinone of 2,4,5-trihydroxyphenylalanine, topa) covalently bound to this class of enzymes, is also conserved in the histamine oxidase sequence. To identify the quinone cofactor, an overexpression plasmid has been constructed for the recombinant histamine oxidase. The inactive enzyme purified from the transformed Escherichia coli cells grown in a copper-depleted medium gained maximal activity upon stoichiometric binding of cupric ions, Concomitantly with the enzyme activation by copper, a brownish pink compound was generated in the enzyme, which was identified as the quinone of topa by absorption and resonance Raman spectroscopies of the p-nitrophenylhydrazine-derivatized enzyme and found at the position corresponding to the precursor Tyr (Tyr-402). Therefore, the copper-dependent autoxidation of a specific tyrosyl residue operates on the formation of the topa quinone cofactor in this enzyme, as recently demonstrated with the precursor form of phenethylamine oxidase (Matsuzaki, R., Fukui, T., Sato, H., Ozaki, Y., and Tanizawa, K, (1994)FEBS Lett. 351, 360-364).	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN; SHINSHU UNIV,DEPT BIOSCI & BIOTECHNOL,NAGANO 39945,JAPAN; KWANSEI GAKUIN UNIV,SCH SCI,DEPT CHEM,NISHINOMIYA,HYOGO 662,JAPAN	Osaka University; Shinshu University; Kwansei Gakuin University			Ozaki, Yukihiro/B-4760-2011					ALLAIN CC, 1974, CLIN CHEM, V20, P470; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; AZAKAMI H, 1994, J FERMENT BIOENG, V77, P315, DOI 10.1016/0922-338X(94)90241-0; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BARKER GJ, 1985, BIOCHEM J, V237, P609; BROWN DE, 1991, J BIOL CHEM, V266, P4049; BRUINENBERG PG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P157, DOI 10.1016/0167-4781(80)90003-2; CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; COLLISON D, 1989, BIOCHEM J, V264, P663, DOI 10.1042/bj2640663; COOPER RA, 1992, BIOCHEM J, V288, P337, DOI 10.1042/bj2880337; HARTMANN C, 1991, BIOCHEMISTRY-US, V30, P4605, DOI 10.1021/bi00232a035; HARTMANN C, 1993, BIOCHEMISTRY-US, V32, P2234, DOI 10.1021/bi00060a015; JANES SM, 1991, BIOCHEMISTRY-US, V30, P4599, DOI 10.1021/bi00232a034; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KUMAGAI H, 1985, STRUCTURE FUNCTION A, P37; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MCCRACKEN J, 1987, J AM CHEM SOC, V109, P4064, DOI 10.1021/ja00247a037; McIntire W. S., 1993, COPPER CONTAINING AM, P97; MORPURGO L, 1992, BIOCHEMISTRY-US, V31, P2615, DOI 10.1021/bi00124a023; MU D, 1994, J BIOL CHEM, V269, P9926; MU D, 1992, J BIOL CHEM, V267, P7979; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; NOVOTNY WF, 1994, J BIOL CHEM, V269, P9921; ROSSI A, 1992, FEBS LETT, V301, P253, DOI 10.1016/0014-5793(92)80251-B; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT RA, 1985, J AM CHEM SOC, V107, P4348, DOI 10.1021/ja00300a055; SHIMIZU E, 1994, BIOSCI BIOTECH BIOCH, V58, P2118, DOI 10.1271/bbb.58.2118; SHIMIZU E, 1990, AGR BIOL CHEM TOKYO, V54, P851, DOI 10.1080/00021369.1990.10870020; SUGINO H, 1992, J BACTERIOL, V174, P2485, DOI 10.1128/jb.174.8.2485-2492.1992; SUZUKI S, 1983, BIOCHEMISTRY-US, V22, P1630, DOI 10.1021/bi00276a016; TANIZAWA K, 1994, BIOCHEM BIOPH RES CO, V199, P1096, DOI 10.1006/bbrc.1994.1343; WARNCKE K, 1994, J AM CHEM SOC, V116, P4028, DOI 10.1021/ja00088a042; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; ZHANG XP, 1993, J BACTERIOL, V175, P5617, DOI 10.1128/JB.175.17.5617-5627.1993	38	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4712	4720		10.1074/jbc.270.9.4712	http://dx.doi.org/10.1074/jbc.270.9.4712			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876243	hybrid			2022-12-25	WOS:A1995QK08400078
J	OBOYLE, DR; WAGERSMITH, K; STEVENS, JT; WEINHEIMER, SP				OBOYLE, DR; WAGERSMITH, K; STEVENS, JT; WEINHEIMER, SP			THE EFFECT OF INTERNAL AUTOCLEAVAGE OIL KINETIC-PROPERTIES OF THE HUMAN CYTOMEGALOVIRUS PROTEASE CATALYTIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; COMPLETE DNA-SEQUENCE; ASSEMBLY PROTEIN; READING FRAME; IDENTIFICATION; CLEAVAGE; GENE; UL26; EXPRESSION; PRODUCTS	The 28-kilodalton (kDa) catalytic domain of the human cytomegalovirus (HCMV) protease undergoes autoproteolytic cleavage at an internal site (I site), yielding amino terminal 15-kDa (N15) and carboxyl terminal 13-kDa (C13) fragments. I site autocleavage has been postulated to inactivate the protease and provide a mechanism for the negative regulation of enzyme activity during viral infection, We purified recombinant enzymes to demonstrate I site autocleavage in vitro and used site directed mutagenesis of the I site to stabilize the protease. No difference in the kinetic properties of wild type and stabilized mutant proteases were ob served in an in vitro peptide cleavage assay. The consequences of I site cleavage on enzyme activity were investigated two ways. First, autodigestion of the wild type enzyme converted the intact protease to N15 and C13 autocleavage products without a corresponding loss in enzyme activity. Second, genetic constructs encoding the N15 and C13 autocleavage products were generated and expressed separately in Escherichia coli, and each fragment was purified. An active enzyme was reconstituted by refolding a mixture of the purified fragments in vitro to form a noncovalent complex. The kinetic properties of this complex were very similar to the wild type and stabilized enzymes under optimal reaction conditions. We concluded from these studies that I site cleavage does not inactivate the HCMV protease, in the absence of other virally induced factors, and that limited potential exists for the regulation of catalytic activity by I site cleavage.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT VIROL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; CHEE MS, 1990, CURR TOP MICROBIOL I, V154, P126; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DAVISON MD, 1992, J GEN VIROL, V73, P2709, DOI 10.1099/0022-1317-73-10-2709; DECKMAN IC, 1992, J VIROL, V66, P7362, DOI 10.1128/JVI.66.12.7362-7367.1992; DILANNI CL, 1993, J BIOL CHEM, V268, P2048; DUDA CT, 1982, J BIOL CHEM, V257, P9866; GAO M, 1994, J VIROL, V68, P3702, DOI 10.1128/JVI.68.6.3702-3712.1994; JONES TR, 1994, J VIROL, V68, P3742, DOI 10.1128/JVI.68.6.3742-3752.1994; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LIU FY, 1991, J VIROL, V65, P206, DOI 10.1128/JVI.65.1.206-212.1991; LIU FY, 1993, J VIROL, V67, P1300, DOI 10.1128/JVI.67.3.1300-1309.1993; LIU FY, 1992, P NATL ACAD SCI USA, V89, P2076, DOI 10.1073/pnas.89.6.2076; MCCANN PJ, 1994, J VIROL, V68, P526, DOI 10.1128/JVI.68.1.526-529.1994; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; NEURATH H, 1989, PROTEOLYTIC ENZYMES, P1; PERSON S, 1993, J GEN VIROL, V74, P2269, DOI 10.1099/0022-1317-74-10-2269; PRESTON VG, 1992, VIROLOGY, V186, P87, DOI 10.1016/0042-6822(92)90063-U; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; RIXON FJ, 1988, J GEN VIROL, V69, P2879, DOI 10.1099/0022-1317-69-11-2879; Sambrook J, 1989, MOL CLONING LABORATO; SARDANA VV, 1994, J BIOL CHEM, V269, P14337; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHENK P, 1991, J VIROL, V65, P1525, DOI 10.1128/JVI.65.3.1525-1529.1991; STEVENS JT, 1994, EUR J BIOCHEM, V226, P361, DOI 10.1111/j.1432-1033.1994.tb20060.x; WEINHEIMER SP, 1993, J VIROL, V67, P5813, DOI 10.1128/JVI.67.10.5813-5822.1993; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993	31	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4753	4758		10.1074/jbc.270.9.4753	http://dx.doi.org/10.1074/jbc.270.9.4753			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876248	hybrid			2022-12-25	WOS:A1995QK08400084
J	WARE, FE; VASSILAKOS, A; PETERSON, PA; JACKSON, MR; LEHRMAN, MA; WILLIAMS, DB				WARE, FE; VASSILAKOS, A; PETERSON, PA; JACKSON, MR; LEHRMAN, MA; WILLIAMS, DB			THE MOLECULAR CHAPERONE CALNEXIN BINDS GLC(1)MAN(9)GLCNAC(2) OLIGOSACCHARIDE AS AN INITIAL STEP IN RECOGNIZING UNFOLDED GLYCOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN; IDENTIFICATION; PURIFICATION; MEMBRANE; PEPTIDE; LECTINS; CELLS; GENE; IP90	Calnexin is a molecular chaperone that resides in the membrane of the endoplasmic reticulum, Most proteins that calnexin binds are N-glycosylated, and treatment of cells with tunicamycin or inhibitors of initial glucose trimming steps interferes with calnexin binding. To test if calnexin is a lectin that binds early oligosaccharide processing intermediates, a recombinant soluble calnexin was created, Incubation of soluble calnexin with a mixture of Glc(0-3)Man(9)GlcNAc(2) oligosaccharides resulted in specific binding of the Glc(1)Man(9)GlcNAc(2) species, Furthermore, Glc(1)Man(5-7)GlcNAc(2) oligosaccharides bound relatively poorly, suggesting that, in addition to a requirement for the single terminal glucose residue, at least one of the terminal mannose residues was important for binding, To assess the involvement of oligosaccharide-protein interactions in complexes of calnexin and newly synthesized glycoproteins, alpha(1)-antitrypsin or the heavy chain of the class I histocompatibility molecule were purified as complexes with calnexin and digested with endoglycosidase H. All oligosaccharides on either glycoprotein were accessible to this probe and could be removed without disrupting the association with calnexin, Furthermore, the addition of 1 M alpha-methyl glucoside or alpha-methyl mannoside had no effect on complex stability, These findings suggest that once complexes between calnexin and glycoproteins are formed, oligosaccharide binding does not contribute significantly to the overall interaction, However, it is likely that the binding of Glc(1)Man(9)GlcNAc(2) oligosaccharides is a crucial event during the initial recognition of newly synthesized glycoproteins by calnexin.	UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5S 1A8, CANADA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; BW JOHNSON PHARMACEUT RES INST, LA JOLLA, CA 92121 USA	University of Toronto; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM38545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038545, R56GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CALA SE, 1993, J BIOL CHEM, V268, P2969; CAMP LA, 1993, J BIOL CHEM, V268, P6721; Capps G. G., 1993, Molecular Biology of the Cell, V4, p206A; CAPPS GG, 1994, J BIOL CHEM, V269, P11634; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GANAN S, 1991, BIOCHEMISTRY-US, V30, P3098, DOI 10.1021/bi00226a017; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LE AQ, 1994, J BIOL CHEM, V269, P7514; LENTER M, 1994, J BIOL CHEM, V269, P12263; LOO TW, 1994, J BIOL CHEM, V269, P28683; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; OU WJ, 1992, J BIOL CHEM, V267, P23789; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; OU WJ, 1994, MOL BIOL CELL, V5, P202; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; SCHREIBER KL, 1994, INT IMMUNOL, V6, P101, DOI 10.1093/intimm/6.1.101; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUGITA M, 1994, J EXP MED, V180, P2163, DOI 10.1084/jem.180.6.2163; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T; ZHU XY, 1992, J BIOL CHEM, V267, P8895	42	384	387	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4697	4704		10.1074/jbc.270.9.4697	http://dx.doi.org/10.1074/jbc.270.9.4697			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876241	hybrid			2022-12-25	WOS:A1995QK08400076
J	KAPLAN, RS; MAYOR, JA; GREMSE, DA; WOOD, DO				KAPLAN, RS; MAYOR, JA; GREMSE, DA; WOOD, DO			HIGH-LEVEL EXPRESSION AND CHARACTERIZATION OF THE MITOCHONDRIAL CITRATE TRANSPORT PROTEIN FROM THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ASPARTATE GLUTAMATE CARRIER; BOVINE HEART-MITOCHONDRIA; BROWN FAT MITOCHONDRIA; ADP ATP TRANSLOCASE; TRICARBOXYLATE CARRIER; KINETIC CHARACTERIZATION; STRUCTURAL RELATIONSHIP; UNCOUPLING PROTEIN; ACID SYNTHESIS	The gene encoding the mitochondrial citrate transport protein (CTP) in the yeast Saccharomyces cerevisiae has been identified, and its protein product has been overexpressed in Escherichia coli, The expressed CTP accumulates in inclusion bodies and can be solubilized with sarkosyl, Approximately 25 mg of solubilized CTP at a purity of 75% is obtained per liter of E, coli culture, The function of the solubilized CTP has been reconstituted in a Liposomal system where both its kinetic parameters (i.e, K-m = 0.36 mM and V-max = 2.5 mu mol/ min/mg protein) and its substrate specificity have been determined, Notably, the yeast CTP displays a stricter specificity for tricarboxylates than do CTPs from higher eukaryotic organisms. Dot matrix analysis of the yeast CTP sequence indicates the presence of three homologous sequence domains (each approximately 100 residues in length), which are also related to domains in other CTPs, Thus, the yeast CTP displays the tripartite structure characteristic of other mitochondrial transporters, Alignment of the yeast CTP sequence with CTPs from other sources defines a consensus sequence that displays 89 positions of amino acid identity, as well as the more generalized mitochondrial transporter-associated sequence motif, Based on hydropathy analysis, the yeast CTP contains six putative membrane-spanning cy-helices, Finally, Southern blot analysis indicates that the yeast genome contains a single gene encoding the mitochondrial CTP, Our data indicate that, based on both its structural and functional properties, the expressed yeast CTP can be assigned membership in the mitochondrial carrier family, The identification of the yeast CTP gene, and the expression and purification of large quantities of its protein product, pave the way for investigations into the roles of specific amino acids in the CTP translocation mechanism, as well as for the initiation of crystallization trials.	UNIV SO ALABAMA,COLL MED,DEPT PEDIAT,MOBILE,AL 36688; UNIV SO ALABAMA,COLL MED,DEPT MICROBIOL & IMMUNOL,MOBILE,AL 36688	University of South Alabama; University of South Alabama	KAPLAN, RS (corresponding author), UNIV SO ALABAMA,COLL MED,DEPT PHARMACOL,MOBILE,AL 36688, USA.		Mayor, June/AAP-1544-2021					ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; BISACCIA F, 1992, BIOCHIM BIOPHYS ACTA, V1106, P291, DOI 10.1016/0005-2736(92)90008-A; BISACCIA F, 1990, BIOCHIM BIOPHYS ACTA, V1019, P250, DOI 10.1016/0005-2728(90)90201-E; BISACCIA F, 1989, BIOCHIM BIOPHYS ACTA, V977, P171, DOI 10.1016/S0005-2728(89)80068-4; BRUNENGR.H, 1973, FEBS LETT, V36, P130, DOI 10.1016/0014-5793(73)80353-9; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; CLAEYS D, 1989, J BIOL CHEM, V264, P14627; CONOVER TE, 1987, TRENDS BIOCHEM SCI, V12, P88, DOI 10.1016/0968-0004(87)90042-9; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; EVANS CT, 1983, EUR J BIOCHEM, V130, P195; FERNANDEZ M, 1994, MOL GEN GENET, V242, P727; FERREIRA GC, 1989, J BIOL CHEM, V264, P15628; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; GLERUM DM, 1990, EUR J BIOCHEM, V194, P681, DOI 10.1111/j.1432-1033.1990.tb15668.x; HOLMSTROM K, 1994, YEAST, V10, pS47, DOI 10.1002/yea.320100007; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1993, J BIOENERG BIOMEMBR, V25, P503, DOI 10.1007/BF01108407; KAPLAN RS, 1985, J BIOL CHEM, V260, P293; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; KOLAROV J, 1972, BIOCHIM BIOPHYS ACTA, V267, P457, DOI 10.1016/0005-2728(72)90173-9; KRAMER R, 1986, ARCH BIOCHEM BIOPHYS, V251, P166, DOI 10.1016/0003-9861(86)90063-9; Krumer R., 1992, MOL MECHANISMS BIOEN, P359, DOI DOI 10.1016/50167-7306(08)60184-2; KUAN J, 1993, RES MICROBIOL, V144, P671, DOI 10.1016/0923-2508(93)90073-B; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; PERKINS M, 1973, BIOCHEM J, V134, P923, DOI 10.1042/bj1340923; PERSSON LO, 1992, BIOCHEM BIOPH RES CO, V183, P70, DOI 10.1016/0006-291X(92)91610-3; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; ROISE D, 1988, J BIOL CHEM, V263, P4509; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; VINAS O, 1990, BIOCHEM J, V265, P321, DOI 10.1042/bj2650321; WATSON JA, 1970, J BIOL CHEM, V245, P5993; WOHLRAB H, 1994, BIOCHEMISTRY-US, V33, P9371, DOI 10.1021/bi00198a001	43	129	134	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4108	4114		10.1074/jbc.270.8.4108	http://dx.doi.org/10.1074/jbc.270.8.4108			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876161				2022-12-25	WOS:A1995QH68800094
J	MOURAO, PAS; ASSREUY, AMS				MOURAO, PAS; ASSREUY, AMS			TREHALOSE AS A POSSIBLE PRECURSOR OF THE SULFATED L-GALACTAN IN THE ASCIDIAN TUNIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRANCHED CHONDROITIN SULFATE; PLICATA CHORDATA-TUNICATA; URONOSYL C-5 EPIMERASE; SEA-CUCUMBER; BODY WALL; GLYCANS; POLYSACCHARIDES; BIOSYNTHESIS; FRACTIONATION; HETEROGENEITY	Among sulfated polysaccharides, those in the tunic of ascidians are unique: their major constituent sugar is galactose, which occurs exclusively in the L-enantiomeric form. Incorporation of D-[C-14]glucose into tunic slices in. vitro revealed that the cells epimerize D-glucose into L-galactose during biosynthesis of the sulfated polysaccharides. The interconversion of these two sugars involves exchange of hydrogen atoms at the epimerization sites with protons of the medium. Tunic cells also synthesize trehalose, although this disaccharide is not a prominent constituent of the tissue. Pulse-chase experiments using D-[C-14]glucose reveal that incorporation of label into trehalose precedes the synthesis of the sulfated L-galactan. In addition, the loss of label from trehalose coincides with the appearance of label in the sulfated L-galactan. Based on these results, we speculate that trehalose in the ascidian tunic may be a precursor of the sulfated L-galactan.			MOURAO, PAS (corresponding author), UNIV FED RIO DE JANEIRO,INST CIENCIAS BIOMED,DEPT BIOQUIM,CAIXA POSTAL 68041,BR-21941590 RIO JANEIRO,BRAZIL.		Mourao, Paulo/AAA-5386-2020					ADAMS E, 1976, ADV ENZYMOL RAMB, V44, P69; ALBANO RM, 1983, BIOCHIM BIOPHYS ACTA, V760, P192, DOI 10.1016/0304-4165(83)90143-5; ALBANO RM, 1990, CARBOHYD RES, V208, P163, DOI 10.1016/0008-6215(90)80096-L; ALBANO RM, 1986, J BIOL CHEM, V261, P758; ANDERSON E, 1947, J BIOL CHEM, V168, P284; AVIGAD G, 1962, J BIOL CHEM, V237, P2736; BARBER GA, 1980, J BIOL CHEM, V254, P7600; BARNES RD, 1980, INVERTEBRATE ZOOLOGY, P1030; Bell DJ, 1941, J CHEM SOC, P125, DOI 10.1039/jr9410000125; CORREA JOAO BATISTA CHAVES, 1967, CARBOHYD RES, V3, P445, DOI 10.1016/S0008-6215(00)81676-6; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FEINGOLD DS, 1982, ENCY PLANT PHYS A, V13, P37; GABRIEL O, 1978, TRENDS BIOCHEM SCI, V3, P193, DOI 10.1016/S0968-0004(78)91666-3; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; LELOIR LF, 1960, COMP BIOCH, V2, P117; MALMSTROM A, 1980, J BIOL CHEM, V255, P3878; MAYER RM, 1987, METHOD ENZYMOL, V138, P648; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P431, DOI 10.1111/j.1432-1033.1987.tb13534.x; MOURAO PAS, 1991, BIOCHEMISTRY-US, V30, P3458, DOI 10.1021/bi00228a016; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P639, DOI 10.1111/j.1432-1033.1987.tb13561.x; MULLOY B, 1994, J BIOL CHEM, V269, P22113; Painter T.J., 1983, POLYSACCHARIDES, P196, DOI DOI 10.1016/B978-0-12-065602-8.50009-1; PANEK AD, 1991, YEASTS, V4, P655; PAVAO MSG, 1989, J BIOL CHEM, V264, P9972; PAVAO MSG, 1994, BBA-GEN SUBJECTS, V1199, P229, DOI 10.1016/0304-4165(94)90001-9; PAVAO MSG, 1989, CARBOHYD RES, V189, P374, DOI 10.1016/0008-6215(89)84115-1; PAVAO MSG, 1990, CARBOHYD RES, V208, P153, DOI 10.1016/0008-6215(90)80095-K; PRIHAR HS, 1980, BIOCHEMISTRY-US, V19, P495, DOI 10.1021/bi00544a016; RIBEIRO AC, 1994, CARBOHYD RES, V255, P225, DOI 10.1016/S0008-6215(00)90981-9; SANTOS JA, 1992, EUR J BIOCHEM, V204, P669, DOI 10.1111/j.1432-1033.1992.tb16680.x; SLEIN MW, 1955, METHOD ENZYMOL, V1, P299, DOI 10.1016/0076-6879(55)01041-0; STAMBUK BU, 1993, ANAL BIOCHEM, V212, P150, DOI 10.1006/abio.1993.1305; VIEIRA RP, 1993, BIOCHEMISTRY-US, V32, P2254, DOI 10.1021/bi00060a018; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530	36	13	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3132	3140		10.1074/jbc.270.7.3132	http://dx.doi.org/10.1074/jbc.270.7.3132			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852395	hybrid			2022-12-25	WOS:A1995QG47100038
J	ALEXANDER, WS; DUNN, AR				ALEXANDER, WS; DUNN, AR			STRUCTURE AND TRANSCRIPTION OF THE GENOMIC LOCUS ENCODING MURINE C-MPL, A RECEPTOR FOR THROMBOPOIETIN	ONCOGENE			English	Note						C-MPL; THROMBOPOIETIN; HEMATOPOIETIN RECEPTOR; ALTERNATIVE SPLICING; GENE STRUCTURE	GROWTH-HORMONE RECEPTOR; MOLECULAR-CLONING; SUPERFAMILY; EXPRESSION; MEMBER; BINDING; FAMILY; PROTOONCOGENE; INITIATOR; ONCOGENE	We have cloned and characterised the murine gene encoding c-Mpl, a receptor for thrombopoietin and member of the hematopoietin receptor superfamily. The gene encompasses 15 kb of the mouse genome and the organisation of its 12 exons conforms closely to the pattern observed for the genes of other hematopoietin receptor family members. A site for initiation of c-mpl transcription was identified 13 nucleotides upstream of the proposed translation initiation codon. The murine mpl promoter sequence lacks conventional TATA and CAAT motifs although the transcription initiation site shares homology with the initiator sequence that specifies transcription initiation in the terminal deoxynucleotidyl transferase gene. The promoter contains consensus binding sequences for several transcriptional regulators including Ets and GATA factors, which have been implicated in control of transcription in megakaryocytes, a cell type that expresses mpl. The generation of multiple transcripts is a feature of the mpl locus. Two distinct mpl transcripts differing by an in-frame insertion of 24 nucleotides were detected in mouse spleen cells. Genomic sequence analysis identified differential splicing of alternative exon 4 sequences as the likely basis for these transcripts, which are predicted to encode receptors which differ within the first Mpl hematopoietin receptor domain.			ALEXANDER, WS (corresponding author), ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, MELBOURNE, VIC 3050, AUSTRALIA.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GORDON MS, 1992, BLOOD, V80, P302; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; METHIA N, 1993, BLOOD, V82, P1395; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; NAKAGAWA Y, 1994, J BIOL CHEM, V269, P10905; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; ORKIN SH, 1992, BLOOD, V80, P575; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WANG HM, 1992, J BIOL CHEM, V267, P979; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; WENDLING F, 1989, LEUKEMIA, V3, P475; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; Wrighton N, 1992, GROWTH FACTORS, V6, P103, DOI 10.3109/08977199209011014	32	36	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					795	803						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862460				2022-12-25	WOS:A1995QH61200023
J	BUDHRAMMAHADEO, V; MORRIS, PJ; LAKIN, ND; THEIL, T; CHING, GY; LILLYCROP, KA; MOROY, T; LIEM, RKH; LATCHMAN, DS				BUDHRAMMAHADEO, V; MORRIS, PJ; LAKIN, ND; THEIL, T; CHING, GY; LILLYCROP, KA; MOROY, T; LIEM, RKH; LATCHMAN, DS			ACTIVATION OF THE ALPHA-INTERNEXIN PROMOTER BY THE BRN-3A TRANSCRIPTION FACTOR IS DEPENDENT ON THE N-TERMINAL REGION OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEIN; POU-DOMAIN PROTEIN; FUNCTIONAL-ANALYSIS; REPORTER GENE; I-POU; HOMEODOMAIN; NEURONS; OCT-2; CELLS; PHOSPHORYLATION	The Brn-3a, Brn-3b, and Brn-3c proteins are closely related POU (Pit-Oct-Unc) family transcription factors which are expressed predominantly in neuronal cells, We have identified the alpha-internexin gene as the first reported, neuronally expressed, target gene whose promoter activity is modulated by these factors, Both the Brn-3a and Brn-3c factors can activate the alpha-internexin promoter while Brn-3b represses it and can prevent activation by Brn-3a. Using chimeric constructs containing different regions of Brn-3a or Brn-3b, we show that activation of the alpha-internexin promoter requires the N-terminal region of Brn-3a. In contrast the activation by Brn-3a but not Brn-3b, of an artificial promoter containing a synthetic Brn-3 binding site can be shown using the same constructs to be dependent on the POU domain of Brn-3a. Moreover, the isolated POU domain of Brn-3a can activate this artificial promoter but not the alpha-internexin promoter. Hence Brn-3a contains two distinct transactivation domains, at the N terminus and within the POU domain, whose effect is dependent upon the target promoter, The relationship of gene transactivation by Brn-3a to its ability to transform primary cells which is also dependent on the N-terminal region of the protein is discussed.	UCL, SCH MED, DEPT MOLEC PATHOL, MED MOLEC BIOL UNIT, LONDON W1P 6DB, ENGLAND; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY; COLUMBIA UNIV, COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA	University of London; University College London; UCL Medical School; Philipps University Marburg; Columbia University			Moroy, Tarik/D-9923-2011	Theil, Thomas/0000-0001-6590-8309				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROAD PM, 1989, NUCLEIC ACIDS RES, V17, P6999, DOI 10.1093/nar/17.17.6999; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; CHING GY, 1991, J BIOL CHEM, V266, P19459; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; LALLI E, 1994, J BIOL CHEM, V269, P17359; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; RING CJA, 1993, NUCLEIC ACIDS RES, V21, P2946, DOI 10.1093/nar/21.12.2946; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; VICKERS JC, 1992, BRAIN RES, V585, P205, DOI 10.1016/0006-8993(92)91208-V; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; ZIANG M, 1993, NEURON, V11, P689	39	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2853	2858		10.1074/jbc.270.6.2853	http://dx.doi.org/10.1074/jbc.270.6.2853			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852360	hybrid			2022-12-25	WOS:A1995QF53500070
J	IZUTA, S; ROBERTS, JD; KUNKEL, TA				IZUTA, S; ROBERTS, JD; KUNKEL, TA			REPLICATION ERROR RATES FOR G-CENTER-DOT-DGTP, T-CENTER-DOT-DGTP, AND A-CENTER-DOT-DGTP MISPAIRS AND EVIDENCE FOR DIFFERENTIAL PROOFREADING BY LEADING AND LAGGING-STRAND DNA-REPLICATION COMPLEXES IN HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UV-IRRADIATED DNA; FRAMESHIFT FIDELITY; POLYMERASE; INVITRO; ALPHA; EXONUCLEASE; EXTRACTS; DELTA	We have determined the fidelity of DNA replication by human cell extracts in reactions containing excess dGTP, Replication errors were scored using two M13 DNA substrates having the replication origin on opposite sides of the lacZ alpha-complementation gene, The data suggest that the average rates for replication errors resulting from G(template), T(.)dGTP, and A(.)dGTP mispairs are 25 x 10(-6), 12 x 10(-6), and 3 x 10(-6), respectively. The data also suggest that error rates for both the (+) and (-) strands differ by less than 2-fold when they are replicated either as the leading or lagging strand. This is in contrast to the 33- and 8-fold differences observed earlier for G(.)dTTP and C(.)dTTP mispairs on the (+) strand when replicated by the leading or lagging strand complex (Roberts, J. D., Izuta, S., Thomas, D. C., and Kunkel, T. A. (1994) J. Biol. Chem. 269, 1711-1717), Thus, the relative fidelity of the leading and lagging strand replication proteins varies with the mispair and sequence considered, Misincorporation of dGTP preferentially occurs at template positions where dGTP is the next correct nucleotide to be incorporated, This ''next nucleo tide'' effect is characteristic of reduced exonucleolytic proofreading and suggests that these replication errors are normally proofread efficiently, Fidelity measure ments performed in the absence or presence of dGMP, an inhibitor of proofreading exonuclease activity, suggest that the leading strand replication complex proofreads some mispairs more efficiently than does the lagging strand replication complex.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BIALEK G, 1993, J BIOL CHEM, V268, P6024; CARTY MP, 1992, MUTAT RES, V274, P29, DOI 10.1016/0921-8777(92)90041-Z; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; HAUSER J, 1988, MOL CELL BIOL, V8, P3267, DOI 10.1128/MCB.8.8.3267; HAY RT, 1982, CELL, V28, P769; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1993, NUCLEIC ACIDS RES, V21, P1935, DOI 10.1093/nar/21.8.1935; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; MELENDY T, 1989, J BIOL CHEM, V266, P1942; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; ROBERTS JD, 1994, J BIOL CHEM, V269, P1711; ROBERTS JD, 1993, BIOCHEMISTRY-US, V32, P4083, DOI 10.1021/bi00066a033; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; THOMAS DC, 1994, P NATL ACAD SCI USA, V91, P7752, DOI 10.1073/pnas.91.16.7752; THOMAS DC, 1993, P NATL ACAD SCI USA, V90, P7744, DOI 10.1073/pnas.90.16.7744; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; THOMAS DC, 1993, BIOCHEMISTRY-US, V32, P11476, DOI 10.1021/bi00094a002; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WOLD MS, 1988, CANCER CELL, V6, P133	29	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2595	2600		10.1074/jbc.270.6.2595	http://dx.doi.org/10.1074/jbc.270.6.2595			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852323	hybrid			2022-12-25	WOS:A1995QF53500031
J	TARUMI, K; YONESAKI, T				TARUMI, K; YONESAKI, T			FUNCTIONAL INTERACTIONS OF GENE-32, GENE-41, AND GENE-59 PROTEINS OF BACTERIOPHAGE-T4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; PURIFICATION; UVSX	Genes 41 and 59 of bacteriophage T4 are involved in DNA recombination as well as in DNA replication. The 41 protein has a DNA helicase activity. The 59 protein has been recently purified and found to have a specific affinity for both 32 protein (single-stranded DNA-binding protein) and 41 protein (Yonesaki 1994, J. Biol. Chem. 269, 1284-1289). We examined the effects of 59 protein on ssDNA-dependent ATPase activity and DNA helicase activity of 41 protein in the presence or absence of 32 protein. The ATPase activity of 41 protein was strongly inhibited by 32 protein over a wide range of amounts from subsaturation to oversaturation of ssDNA. The 32 protein was also inhibitory toward DNA helicase activity. Addition of 59 protein effectively eliminated these inhibitory effects of 32 protein. Moreover, 59 protein facilitated 41 protein to overcome the barrier to initiate the unwinding reaction with a duplex nanking a single-stranded DNA gap. Intriguingly, 32 protein at an amount optimal for saturation of ssDNA stimulated the overcoming of the barrier when 59 protein was present. For the best circumvention of this initiation barrier, only eight monomers of 59 protein/one DNA substrate molecule containing 2900 nucleotides of ssDNA were required. These results strongly suggest that 59 protein modulates 41 protein activities by forming a complex with 41 protein and that 41 protein can produce recombinogenic ssDNA with the aid of 32 and 59 proteins.	OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN	Osaka University								BARRY J, 1994, IN PRESS J BIOL CHEM; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; HINTON DM, 1985, J BIOL CHEM, V260, P2851; LIU CC, 1981, J BIOL CHEM, V256, P2813; MORRIS CF, 1979, J BIOL CHEM, V254, P6797; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; NOSSAL NG, 1979, J BIOL CHEM, V254, P6026; NOSSAL NG, 1983, BACTERIOPHAGE T, V4, P71; PRASHAD N, 1972, J MOL BIOL, V70, P617, DOI 10.1016/0022-2836(72)90562-1; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; SHIGESADA K, 1984, GENE, V29, P199; VONHIPPEL PH, 1983, BACTERIOPHAGE T, V4, P202; WAKEM LP, 1981, VIROLOGY, V112, P472; WU R, 1974, VIROLOGY, V59, P108, DOI 10.1016/0042-6822(74)90209-8; YONESAKI T, 1994, GENETICS, V138, P247; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	19	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2614	2619		10.1074/jbc.270.6.2614	http://dx.doi.org/10.1074/jbc.270.6.2614			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852326	hybrid			2022-12-25	WOS:A1995QF53500034
J	WANG, ZQ; LIN, HN; LI, SS; HUANG, CH				WANG, ZQ; LIN, HN; LI, SS; HUANG, CH			PHASE-TRANSITION BEHAVIOR AND MOLECULAR-STRUCTURES OF MONOUNSATURATED PHOSPHATIDYLCHOLINES - CALORIMETRIC STUDIES AND MOLECULAR MECHANICS SIMULATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-CHAIN PHOSPHATIDYLCHOLINES; MODEL MEMBRANES; PACKING; PHOSPHOLIPIDS; DISPERSIONS; MOIETIES; SERIES	High resolution differential scanning calorimetric studies were performed to investigate the thermotropic phase behavior of 26 molecular species of sn-l saturated/sn-2 monounsaturated phosphatidylcholines. In parallel with calorimetric studies, the energy-minimized structures and steric energies of the diglyceride moieties of these monoenoic lipids were determined using a molecular mechanics approach, The combined calorimetric and computational studies led to the following results and conclusions, (i) When a single cis-carbon-carbon double bond (Delta) is incorporated into a saturated diacylphosphatidylcholine molecule at any position within the central segment of the long sn-2 acyl chain, the resulting monoenoic lipid molecules will, in excess water, exhibit reduced phase transition temperature (T-m) and transition enthalpy (Delta H) as they undergo the gel to liquid-crystalline phase transition, The T-m and Delta H-lowering effects of the Delta bond can be attributed to a decrease in the chain length of the sn-2 acyl chain, a change in the chain length difference between the sn-l and sn-2 acyl chains, and a local perturbation of the chain chain van der Waals interaction in the vicinity of the Delta bond, (ii) For a series of positional isomers of 1-stearoyl-2-cis-octadecenoylphosphatidylcholine, C(18):C(18:1 Delta(n))PC, with a Delta bond at different positions along the sn-2 acyl chain, the T-m value depends critically on the position of the Delta bond, Specifically, the T-m value is minimal as the Delta bond is located at the geometric center of the linear segment of the sn-2 acyl chain, and the T-m value is progressively increased as the Delta bond migrates toward either end of the sn-2 acyl chain, (iii) The various monoenoic phosphatidylcholines under study can be divided into two groups, The T-m values of most lipids in each group can be correlated in an identical manner with their structural parameters, yielding a common T-m-structure relationship.	UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908	University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017452] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-17452] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLINGER NL, 1977, J AM CHEM SOC, V99, P8127, DOI 10.1021/ja00467a001; BARTON PG, 1975, J BIOL CHEM, V250, P4470; BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; CHAPMAN D., 1967, CHEM PHYS LIPIDS, V1, P445, DOI 10.1016/0009-3084(67)90023-0; Chapman D., 1993, BIOMEMBRANES PHYSICA, P29; COOLBEAR KP, 1983, BIOCHEMISTRY-US, V22, P1466, DOI 10.1021/bi00275a022; CURATOLO W, 1985, BIOCHIM BIOPHYS ACTA, V817, P261, DOI 10.1016/0005-2736(85)90027-6; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GAO Q, 1986, J LIPID RES, V27, P1214; GOERKE J, 1974, BIOCHIM BIOPHYS ACTA, V344, P241, DOI 10.1016/0304-4157(74)90009-4; HUANG C, 1994, BBA-BIOMEMBRANES, V1189, P7, DOI 10.1016/0005-2736(94)90273-9; KEOUGH KMW, 1987, BIOCHIM BIOPHYS ACTA, V902, P1, DOI 10.1016/0005-2736(87)90129-5; KUNAU WH, 1976, ANGEW CHEM INT EDIT, V15, P61, DOI 10.1002/anie.197600611; LANDS WEM, 1966, J AM OIL CHEM SOC, V43, P290, DOI 10.1007/BF02609676; LEWIS RNAH, 1987, BIOCHEMISTRY-US, V26, P6118, DOI 10.1021/bi00393a026; LI SS, 1993, BIOPHYS J, V65, P1415, DOI 10.1016/S0006-3495(93)81205-0; LI SS, 1994, BIOPHYS J, V66, P2005, DOI 10.1016/S0006-3495(94)80993-2; LIN HN, 1990, BIOCHEMISTRY-US, V29, P7063, DOI 10.1021/bi00482a017; LITMAN BJ, 1991, BIOCHEMISTRY-US, V30, P313, DOI 10.1021/bi00216a001; LIU S, 1994, BIOCHEM J, V299, P831, DOI 10.1042/bj2990831; MENA PL, 1985, CHEM PHYS LIPIDS, V37, P257, DOI 10.1016/0009-3084(85)90014-3; MYHER JJ, 1982, CAN J BIOCHEM CELL B, V60, P638, DOI 10.1139/o82-079; OBRIEN JF, 1974, J LIPID RES, V15, P44; TATTRIE NH, 1968, CAN J BIOCHEM CELL B, V46, P819, DOI 10.1139/o68-124; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; WANG ZQ, 1994, J BIOL CHEM, V269, P23491	26	36	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2014	2023		10.1074/jbc.270.5.2014	http://dx.doi.org/10.1074/jbc.270.5.2014			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836427	hybrid			2022-12-25	WOS:A1995QE49300008
J	JOOSS, KU; MULLER, R				JOOSS, KU; MULLER, R			DEREGULATION OF GENES ENCODING MICROFILAMENT-ASSOCIATED PROTEINS DURING FOS-INDUCED MORPHOLOGICAL TRANSFORMATION	ONCOGENE			English	Note						FOS; MORPHOLOGICAL TRANSFORMATION; CYTOSKELETON; TROPOMYOSINS; EZRIN; GENE EXPRESSION	GROWTH-FACTORS; JUN; CELLS; SUPPRESSION; EXPRESSION; INDUCTION; ONCOGENE; VIRUS; AP-1; CDNA	The mechanism of Fos-induced transformation is still poorly understood. In the present study, we have asked whether genes whose products play a role in determining cell morphology might become deregulated in the course of Fos-induced transformation. A clear up-regulation in Fos-transformed rat fibroblasts was seen with ezrin, as well as tropomyosin (TM) -3 and -5B, while TM-1 was down-regulated. Significantly, the same genes were deregulated in a very similar, but hormone-inducible may in cells expressing a Fos-estrogen receptor fusion protein. In agreement with these results, Fos-expressing cells showed decreased levels of two TM isoforms of 36 and 38 kDa, and showed an impaired TM network. The significance of these observations is strengthened by the fact that the deregulation of TM expression has been shown to contribute to morphological transformation in other experimental systems. Deregulation of the TM and ezrin genes precedes the induction of morphological transformation suggesting that this deregulation is not merely a consequence of transformation. On the other hand, deregulation follows the induction of direct Fos target genes. We therefore propose that a cascade of regulatory events is triggered by Fos oncoproteins which eventually leads to the deregulation of genes encoding cytoskeleton-associated proteins.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ALGRAIN M, 1993, CURR BIOL, V3, P451, DOI 10.1016/0960-9822(93)90354-Q; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BRASELMANN S, 1992, J CELL SCI, P97; BURGER C, 1994, J CELL SCI, V107, P241; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; JOOSS KU, 1994, EMBO J, V13, P1467, DOI 10.1002/j.1460-2075.1994.tb06401.x; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NEUBERG M, 1991, ONCOGENE, V6, P1325; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SEWING A, 1993, J CELL SCI, V104, P545; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x	29	46	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					603	608						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845686				2022-12-25	WOS:A1995QF64800022
J	KIM, S; LAKHANI, V; COSTA, DJ; SHARARA, AI; FITZ, JG; HUANG, LW; PETERS, KG; KINDMAN, LA				KIM, S; LAKHANI, V; COSTA, DJ; SHARARA, AI; FITZ, JG; HUANG, LW; PETERS, KG; KINDMAN, LA			SPHINGOLIPID-GATED CA2+ RELEASE FROM INTRACELLULAR STORES OF ENDOTHELIAL-CELLS IS MEDIATED BY A NOVEL CA2+-PERMEABLE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; CALCIUM RELEASE; SPHINGOSINE-1-PHOSPHATE; RECEPTOR; PROLIFERATION; DERIVATIVES; SPHINGOSINE; CDNA	Sphingolipid gated Ca2+ signaling is mediated through Ca2+-permeable channels. In this report, we characterize the properties of the channel in a human endothelial cell line (EA.hy926). Ca2+ release from intracellular stores is not antagonized by nifedipine, omega conotoxin G-VIa, or heparin. To further characterize the molecular properties of the channel, we developed a novel assay to directly measure efflux of Ca2+ from intracellular stores of permeabilized Xenopus oocytes. Following size fractionation by sucrose gradient, poly(A)(+) RNA from EA,hy926 cells is microinjected into oocytes of Xenopus laevis. We find that the mRNA encoding Ca2+ release activity is similar to 1.5-2.0 kilobases in length. The sphingolipid gated Ca2+-permeable channel is thus likely to be a novel Ca2+-permeable channel distinct from other characterized intracellular Ca2+ channels such as the ryanodyne receptor and the inositol 1,4,5-trisphosphate receptor. The method described here provides a new approach to further characterizing this channel and other intracellular Ca2+ channels.	DUKE UNIV,MED CTR,DIV CARDIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV GASTROENTEROL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,PROGRAM MOLEC MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002361] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02361] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DETTBARN CA, 1994, J MOL CELL CARDIOL, V26, P229, DOI 10.1006/jmcc.1994.1026; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; EPPIG JJ, 1976, IN VITRO CELL DEV B, V12, P418; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; KINDMAN LA, 1994, J BIOL CHEM, V269, P13088; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MCDONOUGH PM, 1994, CIRC RES, V75, P981, DOI 10.1161/01.RES.75.6.981; MUSLIN AJ, 1994, MOL CELL BIOL, V14, P3006, DOI 10.1128/MCB.14.5.3006; NAKAZAWA K, 1993, J GEN PHYSIOL, V101, P377, DOI 10.1085/jgp.101.3.377; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Rusakov S A, 1993, Biokhimiia, V58, P724; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; Sambrook J, 1989, MOL CLONING LABORATO; SCHMALZING G, 1990, BIOCHEM J, V269, P757, DOI 10.1042/bj2690757; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SUMIKAWA K, 1982, NUCLEIC ACIDS RES, V10, P5809, DOI 10.1093/nar/10.19.5809; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WADA E, 1991, NEURON, V6; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	30	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5266	5269		10.1074/jbc.270.10.5266	http://dx.doi.org/10.1074/jbc.270.10.5266			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890637	hybrid			2022-12-25	WOS:A1995QL58000049
J	MAO, QC; SCHUNK, T; FLUKIGER, K; ERNI, E				MAO, QC; SCHUNK, T; FLUKIGER, K; ERNI, E			FUNCTIONAL RECONSTITUTION OF THE PURIFIED MANNOSE PHOSPHOTRANSFERASE SYSTEM OF ESCHERICHIA-COLI INTO PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE-LAMBDA-DNA; SUGAR-TRANSPORT; STREPTOCOCCUS-LACTIS; GLUCOSE-TRANSPORT; PHOSPHOENOLPYRUVATE; PHOSPHORYLATION; MEMBRANE; PERMEASE; PROTEINS; PHOSPHOCYSTEINE	The mannose transporter complex acts by a mechanism which couples translocation with phosphorylation of the substrate. It consists of a hydrophilic subunit (IIAB(Man)) and two transmembrane subunits (IICMan, IIDMan). The purified complex was reconstituted into phospholipid vesicles by octyl glucoside dilution. Glucose export was measured with proteoliposomes which were loaded with radiolabeled glucose and to which purified ILAB(Man), cytoplasmic phosphorylcarrier proteins, and P-enolpyruvate were added from the outside. Vectorial transport was accompanied by stoichiometric phosphorylation of the transported sugar. Glucose added to the outside of the proteoliposomes was also phosphorylated rapidly but did not compete with vectorial export and phosphorylation of internal glucose. Glucose uptake was measured with proteoliposomes which were loaded with the cytoplasmic phosphoryl carrier proteins and P-enolpyruvate and to which glucose was added from the outside. Vectorial import and phosphorylation occurred with a higher specificity (K-m 30 +/- 6 mu M, k(cat) 401 +/- 32 pmol of Glc/mu g of IICDMan/min) than nonvectorial phosphorylation (K-m 201 +/- 43 mu M, k(cat) 975 +/- 88 pmol of Glc/mu g of IICDMan/min). A new plasmid pTSHIC9 for the controlled overexpression of the cytoplasmic phosphoryl carrier proteins, enzyme I, HPr, and IIA(Glc), and a simplified procedure for the purification of these proteins are also described.	UNIV BERN, INST BIOCHEM, CH-3012 BERN, SWITZERLAND; UNIV MARBURG, DEPT BIOL, W-3550 MARBURG, GERMANY	University of Bern; Philipps University Marburg								APELL HJ, 1985, J MEMBRANE BIOL, V85, P49, DOI 10.1007/BF01872005; BENESKI DA, 1982, J BIOL CHEM, V257, P4565; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CHONN A, 1991, BIOCHIM BIOPHYS ACTA, V1070, P215, DOI 10.1016/0005-2736(91)90167-7; CONSLER TG, 1993, P NATL ACAD SCI USA, V90, P6934, DOI 10.1073/pnas.90.15.6934; DEREUSE H, 1988, J BACTERIOL, V170, P3827, DOI 10.1128/jb.170.9.3827-3837.1988; DEREUSE H, 1992, J MOL BIOL, V226, P623, DOI 10.1016/0022-2836(92)90620-Y; ELFERINK MGL, 1990, J BACTERIOL, V172, P7119, DOI 10.1128/jb.172.12.7119-7125.1990; ELLIOTT J, 1978, MOL GEN GENET, V161, P1, DOI 10.1007/BF00266608; ERNI B, 1992, INT REV CYTOL, V137A, P127; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; ERNI B, 1982, J BIOL CHEM, V257, P13726; ERNI B, 1989, J BIOL CHEM, V264, P18733; ERNI B, 1987, J BIOL CHEM, V262, P5238; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; KUKURUZINSKA MA, 1982, METHOD ENZYMOL, V90, P431; KUNDIG W, 1971, J BIOL CHEM, V246, P1407; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P6716, DOI 10.1021/bi00241a012; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEADOW ND, 1986, J BIOL CHEM, V261, P3504; MEADOW ND, 1982, METHOD ENZYMOL, V90, P439; NAKAZAWA A, 1982, METHOD ENZYMOL, V90, P436; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PAS HH, 1991, J BIOL CHEM, V266, P6690; PEERCE BE, 1990, J BIOL CHEM, V265, P1731; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; REIDER E, 1979, P NATL ACAD SCI USA, V76, P5529, DOI 10.1073/pnas.76.11.5529; RHIEL E, 1994, BIOL CHEM H-S, V375, P551, DOI 10.1515/bchm3.1994.375.8.551; ROBILLARD GT, 1981, BIOCHEMISTRY-US, V20, P5025, DOI 10.1021/bi00520a032; ROBILLARD GT, 1982, EUR J BIOCHEM, V127, P597; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SCARBOROUGH GA, 1985, MICROBIOL REV, V49, P214, DOI 10.1128/MMBR.49.3.214-231.1985; SCHUNK T, 1992, THESIS U MARBURG GER; SINGH SP, 1985, J BACTERIOL, V164, P367, DOI 10.1128/JB.164.1.367-378.1985; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SRIVASTAVA DK, 1986, SCIENCE, V234, P1081, DOI 10.1126/science.3775377; STOLZ B, 1993, J BIOL CHEM, V268, P27094; THOMPSON J, 1985, J BACTERIOL, V162, P224, DOI 10.1128/JB.162.1.224-234.1985; THOMPSON J, 1985, J BACTERIOL, V162, P217, DOI 10.1128/JB.162.1.217-223.1985; WELCH GR, 1994, TRENDS BIOCHEM SCI, V19, P193; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	45	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5258	5265		10.1074/jbc.270.10.5258	http://dx.doi.org/10.1074/jbc.270.10.5258			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890636	hybrid			2022-12-25	WOS:A1995QL58000048
J	BANNO, Y; NAKASHIMA, S; HACHIYA, T; NOZAWA, Y				BANNO, Y; NAKASHIMA, S; HACHIYA, T; NOZAWA, Y			ENDOGENOUS CLEAVAGE OF PHOSPHOLIPASE C-BETA-3 BY AGONIST-INDUCED ACTIVATION OF CALPAIN IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEIN; C ISOZYMES; ALPHA-SUBUNITS; THROMBOXANE-A2 RECEPTOR; BINDING PROTEIN; PURIFICATION; STIMULATION; CELLS; FORMS	Two membrane-associated phosphoinositide-specific phospholipase Cs (mPI-PLC-1 and mPI-PLC-2) and a cytosolic enzyme (cPI-PLC) that were activated by brain G-protein beta gamma subunits have been isolated from human platelets. The truncation of mPI-PLC-1 that was mediated by mu-calpain induced much higher activation by beta gamma subunits (Banno, Y., Asano, T., and Nozawa, Y. (1994) FEES Lett. 340, 185-188). On the basis of size and immunological cross-reactivity, mPI-PLC-1 (155 kDa) was PLC-beta 3, and mPI-PLC-2 (100 kDa) was its truncated form. The cPI-PLC (140 kDa) was recognized by the antibody selective for internal sequences of PLC-beta 3 but not by the antibody raised against its carboxyl terminus, indicating that it may be related to PLC-beta 3. Treatment of human platelets with A23187 and dibucaine, activators of calpain, caused cleavage of actin-binding protein and talin in a time-dependent manner. At the same time, decrease of PLC-beta 3 (155 and 140 kDa) and concomitant increase of the 100-kDa product of cleavage were observed on immunoblots with the antibody to internal sequences of PLC-beta 3. Furthermore, stimulation of platelets by natural agonists, thrombin and collagen, caused the cleavage of PLC-beta 3 (155 and 140 kDa) and an increase of 100 kDa PLC-beta 3 in a time- and dose dependent manner. The cleavage of these PLC-beta 3 enzymes was completely blocked by calpain inhibitor, calpeptin, indicating that the PLC-beta 3 modification may be a consequence of platelet activation leading to activation of calpain. This is the first demonstration that PLC-beta 3 is indeed cleaved by calpain upon platelet activation by physiological agonists. The cleavage of PLC-beta 3 evoked by thrombin and collagen but not ADP was correlated with irreversible aggregation, suggesting that the PLC-beta 3 modification may play a role in secondary irreversible aggregation in agonist-stimulated human platelets.	GIFU UNIV, SCH MED, DEPT BIOCHEM, GIFU 500, JAPAN; MED & BIOL LABS CO LTD, NAKA KU, NAGOYA, AICHI 460, JAPAN	Gifu University								ANAGLI J, 1991, BIOCHEM J, V274, P497, DOI 10.1042/bj2740497; ANDO Y, 1987, BIOCHEM BIOPH RES CO, V144, P484, DOI 10.1016/S0006-291X(87)80535-1; ARIYOSHI H, 1991, BIOCHEM INT, V23, P1019; ASANO T, 1993, J BIOL CHEM, V268, P20512; BAHK YY, 1994, J BIOL CHEM, V269, P8240; BALDASSARE JJ, 1993, BIOCHEM J, V291, P235, DOI 10.1042/bj2910235; BANNO Y, 1994, FEBS LETT, V340, P185, DOI 10.1016/0014-5793(94)80134-7; BANNO Y, 1992, J BIOL CHEM, V267, P6488; BANNO Y, 1987, BIOCHEM BIOPH RES CO, V146, P861, DOI 10.1016/0006-291X(87)90610-3; BANNO Y, 1992, PLATELETS, V2, P69; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLANK JL, 1993, J BIOL CHEM, V268, P25184; BRASS LP, 1993, ADV EXP MED BIOL, V344, P17; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; ISHII H, 1990, THROMB RES, V57, P847, DOI 10.1016/0049-3848(90)90152-3; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE SB, 1993, J BIOL CHEM, V268, P25952; LOW MG, 1986, BIOCHEM J, V237, P139, DOI 10.1042/bj2370139; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MARTIN TFJ, 1991, BIOCHEM J, V280, P753, DOI 10.1042/bj2800753; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOZAWA Y, 1993, ADV EXP MED BIOL, V344, P37; ODA A, 1993, J BIOL CHEM, V268, P12603; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DG, 1993, J BIOL CHEM, V268, P3710; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201; TOSHIDA N, 1983, J BIOL CHEM, V258, P7168; TSUJINAKA T, 1982, THROMB RES, V28, P149, DOI 10.1016/0049-3848(82)90257-2; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WU DQ, 1992, J BIOL CHEM, V267, P1811	52	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4318	4324		10.1074/jbc.270.9.4318	http://dx.doi.org/10.1074/jbc.270.9.4318			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876193	hybrid			2022-12-25	WOS:A1995QK08400024
J	KELLY, RJ; ROUQUIER, S; GIORGI, D; LENNON, GG; LOWE, JB				KELLY, RJ; ROUQUIER, S; GIORGI, D; LENNON, GG; LOWE, JB			SEQUENCE AND EXPRESSION OF A CANDIDATE FOR THE HUMAN SECRETOR BLOOD-GROUP ALPHA(1,2)FUCOSYLTRANSFERASE GENE (FUT2) - HOMOZYGOSITY FOR AN ENZYME-INACTIVATING NONSENSE MUTATION COMMONLY CORRELATES WITH THE NON-SECRETOR PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICOBACTER-PYLORI INFECTION; GDP-L-FUCOSE; GASTRIC-CARCINOMA; HUMAN-SERUM; H-GENE; MOLECULAR-CLONING; ABO; SYSTEMS; LEWIS; PURIFICATION	Synthesis of soluble A, B, H, and Lewis b blood group antigens in humans is determined by the Secretor (Se) (FUT2) blood group locus. Genetic, biochemical, and molecular analyses indicate that this locus corresponds to an alpha(1,2)fucosyltransferase gene distinct from the genetically-linked H blood group alpha(1,2)fucosyltransferase lo cus. The accompanying paper (Rouquier, S., Lowe, J, B., Kelly, R. J., Fertitta, A L., Lennon, G. G., and Giorgi, D. (1995) J. Biol. Chem. 270, 4632-4639) describes the molecular cloning and mapping of two human DNA segments that are physically linked to, and cross-hybridize with, the H locus. We present here an analysis of these two new DNA segments. One of these, termed Sec1, is a pseudogene, because translational frameshifts and termination codons interrupt potential open reading frames that would otherwise share primary sequence similarity with the H alpha(1,2)fucosyltransferase. The other DNA segment, termed Seca, predicts a 332-amino acid-long polypeptide, and a longer isoform, that share 68% sequence identity with the COOH-terminal 292 residues of the human H blood group alpha(1,2)fucosyltransferase. Sec2 encodes an alpha(1,2)fucosyltransferase with catalytic properties that mirror those ascribed to the Secretor locus-encoded alpha(1,2)fucosyltransferase. Approximately 20% of randomly-selected individuals were found to be apparently homozygous for an enzyme-inactivating nonsense allele (Trp(143) --> ter) at this locus, in correspondence to the frequency of the non-secretor phenotype in most human populations. Furthermore, each of six unrelated non-secretor individuals are also apparentry homozygous for this null allele. These results indicate that Seca corresponds to the human Secretor blood group locus (FUT2) and indicate that homozygosity for a common nonsense allele is responsible for the nonsecretor phenotype in many non-secretor individuals.	UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PATHOL, ANN ARBOR, MI 48109 USA; LAWRENCE LIVERMORE NATL LAB, CTR HUMAN GENOME, BIOL & BIOTECHNOL RES PROGRAM, LIVERMORE, CA 94550 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; United States Department of Energy (DOE); Lawrence Livermore National Laboratory			Lennon, Greg/T-4717-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048859] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00042] Funding Source: Medline; NHLBI NIH HHS [1R01HL48859] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER BK, 1994, CURR OPIN GENET DEV, V4, P316, DOI 10.1016/S0959-437X(05)80060-7; AUSUBEL BW, 1987, MOL BIOL LABORATORY, V2; AUSUBEL J, 1987, MOL BIOL LABORATORY, V1; BLASZCZYKTHURIN M, 1988, BIOCHEM BIOPH RES CO, V151, P100, DOI 10.1016/0006-291X(88)90564-5; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; CHA JHJ, 1994, MOL BRAIN RES, V22, P323, DOI 10.1016/0169-328X(94)90061-2; CHAN WY, 1991, HISTOPATHOLOGY, V19, P47, DOI 10.1111/j.1365-2559.1991.tb00893.x; CHESTER MA, 1976, EUR J BIOCHEM, V69, P583, DOI 10.1111/j.1432-1033.1976.tb10944.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKEY W, 1993, GUT, V34, P351, DOI 10.1136/gut.34.3.351; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; GAENSSLEN RE, 1987, J FORENSIC SCI, V32, P1016; HENRY SM, 1993, VOX SANG, V65, P62, DOI 10.1111/j.1423-0410.1993.tb04527.x; HENRY SM, 1990, VOX SANG, V58, P61, DOI 10.1111/j.1423-0410.1990.tb02057.x; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HIGUCHI R, 1988, NATURE, V332, P543, DOI 10.1038/332543a0; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUMAZAKI T, 1984, P NATL ACAD SCI-BIOL, V81, P4193, DOI 10.1073/pnas.81.13.4193; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEPENDU J, 1985, AM J HUM GENET, V37, P749; Lowe J B, 1991, Semin Cell Biol, V2, P289; MENTIS A, 1991, EPIDEMIOL INFECT, V106, P221, DOI 10.1017/S0950268800048366; MILNE RW, 1973, VOX SANG, V25, P298, DOI 10.1111/j.1423-0410.1973.tb04377.x; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; Mourant AE., 1976, DISTRIBUTION HUMAN B; MOURANT AE, 1978, BLOOD GROUPS DISEASE; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; ORIOL R, 1981, AM J HUM GENET, V33, P421; ORIOL R, 1990, J IMMUNOGENET, V17, P235; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PUCHALSKI RB, 1994, NEURON, V13, P131, DOI 10.1016/0896-6273(94)90464-2; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; RAJPUT B, 1994, J BIOL CHEM, V269, P9590; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; ROTH MS, 1990, TRANSPLANTATION, V49, P714, DOI 10.1097/00007890-199004000-00012; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; WALKER RH, 1990, AM ASS BLOOD BANSK T; Watkins W M, 1980, Adv Hum Genet, V10, P1; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1993, VOX SANG, V64, P171, DOI 10.1111/j.1423-0410.1993.tb05157.x; YAMAMOTO FI, 1993, VOX SANG, V64, P120, DOI 10.1111/j.1423-0410.1993.tb02529.x; YAMAMOTO FI, 1993, VOX SANG, V64, P116, DOI 10.1111/j.1423-0410.1993.tb02528.x	53	415	448	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4640	4649		10.1074/jbc.270.9.4640	http://dx.doi.org/10.1074/jbc.270.9.4640			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876235	hybrid			2022-12-25	WOS:A1995QK08400069
J	LUJAN, HD; MAROTTA, A; MOWATT, MR; SCIAKY, N; LIPPINCOTTSCHWARTZ, J; NASH, TE				LUJAN, HD; MAROTTA, A; MOWATT, MR; SCIAKY, N; LIPPINCOTTSCHWARTZ, J; NASH, TE			DEVELOPMENTAL INDUCTION OF GOLGI STRUCTURE AND FUNCTION IN THE PRIMITIVE EUKARYOTE GIARDIA-LAMBLIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; BREFELDIN-A; GUANINE-NUCLEOTIDE; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE; ELECTRON-MICROSCOPY; ORGANELLE STRUCTURE; BINDING PROTEINS; CHOLERA-TOXIN	A fundamental characteristic of eukaryotic cells is the presence of membrane bound compartments and membrane transport pathways in which the Golgi complex plays a central role in the selective processing, sorting, and secretion of proteins. The parasitic protozoan Giardia lamblia belongs to the earliest identified Lineage among eukaryotes and therefore offers unique insight into the progression from primitive to more complex eukaryotic cells. Here, we report that Giardia trophozoites undergo a developmental induction of Golgi enzyme activities, which correlates with the appearance of a morphologically identifiable Golgi complex, as they differentiate to cysts. Prior to this induction, no morphologically or biochemically identifiable Golgi complex exists within nonencysting cells. Remarkably, protein secretion in both nonencysting and encysting trophozoites is inhibited by brefeldin A, and brefeldin A-sensitive membrane association of ADP-ribosylation factor and beta-COP is observed. These results suggest that the secretory machinery of Giardia resembles that of higher eukaryotes despite the absence of a Golgi complex in nonencysting trophozoites. These findings have implications both for defining the minimal machinery for protein secretion in eukaryotes and for examining the biogenesis of Golgi structure and function.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	LUJAN, HD (corresponding author), NIAID, PARASIT DIS LAB, 9000 ROCKVILLE PIKE, BLDG 4, RM 126, BETHESDA, MD 20892 USA.							ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BENNETT MK, 1988, EMBO J, V7, P4075, DOI 10.1002/j.1460-2075.1988.tb03301.x; BOUCHER SEM, 1990, INFECT IMMUN, V58, P3516, DOI 10.1128/IAI.58.11.3516-3522.1990; BRACKER CE, 1967, ANNU REV PHYTOPATHOL, V5, P343, DOI 10.1146/annurev.py.05.090167.002015; BRESTSCHER MS, 1993, SCIENCE, V261, P1280; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; Feely D.E., 1984, P3; FRIEND DS, 1966, J CELL BIOL, V29, P317, DOI 10.1083/jcb.29.2.317; GRIFFITHS G, 1986, SCIENCE, V234, P434; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; JARROLL EL, 1989, MOL BIOCHEM PARASIT, V32, P121, DOI 10.1016/0166-6851(89)90063-7; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KREIS TE, 1994, CURR OPIN CELL BIOL, V6, P533, DOI 10.1016/0955-0674(94)90073-6; KULDA J, 1978, PARASITIC PROTOZOA, P2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FJS, 1992, J BIOL CHEM, V267, P24441; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LINDMARK DG, 1980, MOL BIOCHEM PARASIT, V1, P1, DOI 10.1016/0166-6851(80)90037-7; LINDMARK DG, 1988, EXP PARASITOL, V65, P141, DOI 10.1016/0014-4894(88)90116-6; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUJAN HD, 1994, J BIOL CHEM, V269, P13069; LUJAN HD, 1994, J EUKARYOT MICROBIOL, V41, P169, DOI 10.1111/j.1550-7408.1994.tb01491.x; MACECHKO PT, 1992, MOL BIOCHEM PARASIT, V56, P301, DOI 10.1016/0166-6851(92)90179-N; MANNING P, 1992, J PROTOZOOL, V39, P290, DOI 10.1111/j.1550-7408.1992.tb01317.x; MELLMAN L, 1992, CELL, V68, P829; MOSS J, 1993, CELL SIGNAL, V5, P367, DOI 10.1016/0898-6568(93)90076-X; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; NASH TE, 1988, J IMMUNOL, V141, P636; NASH TE, 1983, J IMMUNOL, V131, P2004; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NOTHWEHR SF, 1994, J BIOL CHEM, V269, P10185; ORCI L, 1991, CELL, V64, P1183; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PIMENTA PFP, 1991, INFECT IMMUN, V59, P3989, DOI 10.1128/IAI.59.11.3989-3996.1991; RAMBOURG A, 1993, ANAT REC, V237, P441, DOI 10.1002/ar.1092370402; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; REINER DS, 1990, EUR J CELL BIOL, V53, P142; ROSENWALD AG, 1993, ADV LIPID RES, V26, P101; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SLUSAREWUCZ O, 1994, J CELL BIOL, V124, P405; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STIBBS HH, 1989, J CLIN MICROBIOL, V27, P2582, DOI 10.1128/JCM.27.11.2582-2588.1989; THOMPSON RCA, 1993, ADV PARASIT, V32, P71, DOI 10.1016/S0065-308X(08)60207-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI SC, 1993, J BIOL CHEM, V268, P10820; WATERS MG, 1991, NATURE, V339, P355	67	133	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4612	4618		10.1074/jbc.270.9.4612	http://dx.doi.org/10.1074/jbc.270.9.4612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876232	hybrid			2022-12-25	WOS:A1995QK08400065
J	MACDONALD, PN; SHERMAN, DR; DOWD, DR; JEFCOAT, SC; DELISLE, RK				MACDONALD, PN; SHERMAN, DR; DOWD, DR; JEFCOAT, SC; DELISLE, RK			THE VITAMIN-D-RECEPTOR INTERACTS WITH GENERAL TRANSCRIPTION FACTOR-IIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-TFIIB; THYROID-HORMONE; RETINOIC ACID; EXPRESSION; ACTIVATION; PROTEIN; BINDING; CLONING; INVIVO; BETA	The vitamin D receptor (VDR) heterodimerizes with retinoid X receptors (RXR) on many vitamin D-responsive promoter elements, suggesting that this complex is the active factor in vitamin D-mediated transcription. However, the mechanism of transcriptional regulation following VDR . RXR binding to DNA is not well characterized, Using a yeast two-hybrid protein interaction assay, we demonstrate that VDR forms specific protein: protein contacts with the basal transcription factor TFIIB, Deletion analysis indicated that the carboxyl terminal ligand binding domain of VDR interacted with a 43-residue amino-terminal domain in TFIIB. The interaction with TFIIB showed selectivity for the ligand binding domain of VDR as similar regions of RXR alpha or of retinoic acid receptor cu did not couple with TFIIB. Binding assays with purified proteins showed a direct inter action between VDR and TFIIB in vitro. These data suggest a mechanism for VDR-dependent transcription in which protein contacts between VDR and TFIIB may impart regulatory information to the transcription preinitiation complex.	ST LOUIS UNIV,HLTH SCI CTR,EA DOISY DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104; PATHOGENESIS CORP,SEATTLE,WA 98119	Saint Louis University	MACDONALD, PN (corresponding author), ST LOUIS UNIV,HLTH SCI CTR,SCH MED,DEPT PHARMACOL & PHYSIOL SCI,1402 S GRAND BLVD,ST LOUIS,MO 63104, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047293] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29DK47293] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; GIETZ D, 1991, NUCLEIC ACIDS RES, V20, P1425; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; ING NH, 1992, J BIOL CHEM, V267, P17617; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MACDONALD PN, 1994, SEMIN NEPHROL, V14, P101; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SONE T, 1991, J BIOL CHEM, V266, P23296; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	29	141	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4748	4752		10.1074/jbc.270.9.4748	http://dx.doi.org/10.1074/jbc.270.9.4748			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876247	hybrid			2022-12-25	WOS:A1995QK08400083
J	MEINKE, A; DAMUDE, HG; TOMME, P; KWAN, E; KILBURN, DG; MILLER, RC; WARREN, RAJ; GILKES, NR				MEINKE, A; DAMUDE, HG; TOMME, P; KWAN, E; KILBURN, DG; MILLER, RC; WARREN, RAJ; GILKES, NR			ENHANCEMENT OF THE ENDO-BETA-1,4-GLUCANASE ACTIVITY OF AN EXOCELLOBIOHYDROLASE BY DELETION OF A SURFACE LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOMONAS-FIMI; BETA-GLUCOSIDASE; FAMILIES; BINDING; BETA-1,4-GLYCANASES; AGROBACTERIUM; CELLULASES; DOMAINS	In the commonly accepted mechanism for enzymatic hydrolysis of cellulose, endo-beta-1,4-glucanases randomly cleave glucosidic bonds within glucan polymers, providing sites for attack by exo-cellobiohydrolases (EC 3.2.1.91), It has been proposed that hydrolysis by Trichoderma reesei cellobiohydrolase II is restricted to the ends of cellulose polymers because two surface loops cover its active site to form a tunnel, In a closely related endoglucanase, E2 from Thermomonospora fusca, access to the substrate appears to be relatively unhindered because the carboxyl-proximal loop is shortened, and the amino-proximal loop is displaced, The hypothesis was examined by deletion of a region in Cellulomonas fimi cellobiohydrolase A corresponding to part of the carboxyl-proximal loop of T. reesei cellobiohydrolase II, The mutation enhanced the endoglucanase activity of the enzyme on soluble O-(carboxymethyl)cellulose and altered its activities on 2',4'-dinitrophenyl-beta-D-cellobioside, insoluble cellulose, and cellotetraose,	UNIV BRITISH COLUMBIA,DEPT MICROBIOL & IMMUNOL,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,PROT ENGN NETWORK CTR EXCELLENCE,VANCOUVER,BC V6T 1Z3,CANADA	University of British Columbia; University of British Columbia								Chaplin M.F., 1986, MASS SPECTROM, P1; COUTINHO JB, 1992, MOL MICROBIOL, V6, P1243, DOI 10.1111/j.1365-2958.1992.tb01563.x; DAY AG, 1986, BIOCHEM CELL BIOL, V64, P914, DOI 10.1139/o86-122; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GILKES NR, 1984, J BIOL CHEM, V259, P455; GILKES NR, 1991, EUR J BIOCHEM, V202, P367, DOI 10.1111/j.1432-1033.1991.tb16384.x; GILKES NR, 1988, J BIOL CHEM, V263, P10401; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; MCGINNIS K, 1993, BIOCHEMISTRY-US, V32, P8151, DOI 10.1021/bi00083a014; MEINKE A, 1993, J BACTERIOL, V175, P1910, DOI 10.1128/JB.175.7.1910-1918.1993; MEINKE A, 1994, MOL MICROBIOL, V12, P413, DOI 10.1111/j.1365-2958.1994.tb01030.x; MEINKE A, 1993, GENETICS BIOCH ECOLO, P286; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SPEZIO M, 1993, BIOCHEMISTRY-US, V32, P9906, DOI 10.1021/bi00089a006; WAKARCHUK WW, 1986, MOL GEN GENET, V205, P146, DOI 10.1007/BF02428044	17	77	84	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4383	4386		10.1074/jbc.270.9.4383	http://dx.doi.org/10.1074/jbc.270.9.4383			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876202	hybrid			2022-12-25	WOS:A1995QK08400033
J	BOULARAND, S; DARMON, MC; RAVASSARD, P; MALLET, J				BOULARAND, S; DARMON, MC; RAVASSARD, P; MALLET, J			CHARACTERIZATION OF THE HUMAN TRYPTOPHAN-HYDROXYLASE GENE PROMOTER - TRANSCRIPTIONAL REGULATION BY CAMP REQUIRES A NEW MOTIF DISTINCT FROM THE CAMP-RESPONSIVE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCTAMER BINDING-PROTEINS; RAT PINEAL-GLAND; BETA-GLOBIN GENE; CYCLIC-AMP; DNA ELEMENTS; CCAAT BOX; EXPRESSION; CELLS; BRAIN; IDENTIFICATION	We isolated and sequenced 2,117 nucleotides of the promoter region of the human tryptophan hydroxylase (TPH) gene. Transient transfection in pinealocyte cultures and PC12 cells was used to investigate the human TPH (hTPH) gene promoter activity and its regulation by the cAMP signaling pathway. A region of 2,117 base pairs upstream of the transcription initiation site of the hTPH gene efficiently directed the transcription of a luciferase reporter gene but not in a cell-specific manner. The hTPH promoter activity was significantly enhanced by a cyclic AMP analog in the two cell types. Deletion analysis showed that the promoter region from -73 to +2 is sufficient to direct cAMP-dependent transcription, although it does not contain a motif exhibiting a significant identity to the cAMP-responsive element (CRE) or AP-2 binding site, Following site-directed mutagenesis of the region between -73 and -51, an inverted CCAAT box motif was identified as essential for cAMP inducibility of the hTPH promoter. This sequence between -73 and -51 alone allowed cAMP enhancement of transcription when fused to a heterologous promoter. Additionally, electrophoretic mobility shift assays showed that a specific protein-DNA complex is formed between an oligonucleotide corresponding to the inverted CCAAT box motif and nuclear proteins from pinealocytes treated or not treated with cAMP. Thus cAMP responsiveness of hTPH gene expression is mediated by a cis-acting element, which shares strong identitiy with an inverted CCAAT box and which binds to a constitutively produced nuclear factor.			BOULARAND, S (corresponding author), CNRS,GENET MOLEC NEUROTRANSMISS & PROC NEURODEGENERATI,F-91198 GIF SUR YVETTE,FRANCE.		Darmon, Michele/F-8708-2011	Darmon, Michele/0000-0001-9730-6273; ravassard, philippe/0000-0002-0393-9262				BEGEOT M, 1993, J BIOL CHEM, V268, P17317; BLUNDELL JE, 1984, NEUROPHARMACOLOGY, V23, P1537, DOI 10.1016/0028-3908(84)90098-4; BOULARAND S, 1995, J BIOL CHEM, V270, P3748, DOI 10.1074/jbc.270.8.3748; BUDA M, 1978, ENDOCRINOLOGY, V103, P1483, DOI 10.1210/endo-103-4-1483; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DYNAM WS, 1985, NATURE, V319, P246; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; EHRET M, 1991, J NEUROCHEM, V57, P1516, DOI 10.1111/j.1471-4159.1991.tb06346.x; EHRET M, 1989, J NEUROCHEM, V52, P1886, DOI 10.1111/j.1471-4159.1989.tb07272.x; FOGUET M, 1993, EMBO J, V12, P903, DOI 10.1002/j.1460-2075.1993.tb05731.x; FRAMPTON J, 1990, MOL CELL BIOL, V164, P149; GARBER SL, 1987, MOL BRAIN RES, V3, P1, DOI 10.1016/0169-328X(87)90038-6; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HART R P, 1991, Molecular and Cellular Neuroscience, V2, P71, DOI 10.1016/1044-7431(91)90041-L; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; Higuchi R., 1989, PCR TECHNOLOGY, P61; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KINANE TB, 1993, J BIOL CHEM, V268, P24669; LERNER AB, 1959, J AM CHEM SOC, V80, P6084; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LI XB, 1994, J NEUROCHEM, V63, P28; LOEFFLER JP, 1990, J NEUROCHEM, V54, P1815; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; LUND J, 1990, J BIOL CHEM, V265, P3304; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MIKUNI M, 1981, J NEUROCHEM, V36, P1295, DOI 10.1111/j.1471-4159.1981.tb01733.x; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MURO AF, 1992, J BIOL CHEM, V267, P12767; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; PARK K, 1993, J BIOL CHEM, V268, P17811; QUAY WB, 1963, GEN COMP ENDOCR, V3, P473, DOI 10.1016/0016-6480(63)90079-0; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1966, ENDOCRINOLOGY, V79, P1168, DOI 10.1210/endo-79-6-1168; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SHEIN HM, 1971, LIFE SCI, V10, P935, DOI 10.1016/0024-3205(71)90358-4; SHIBUYA H, 1978, BRAIN RES, V138, P364; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STOLL J, 1991, J NEUROSCI RES, V28, P457, DOI 10.1002/jnr.490280402; SZE PY, 1976, J NEUROCHEM, V26, P169; VRANA KE, 1994, LIFE SCI, V55, P1045, DOI 10.1016/0024-3205(94)00639-3	50	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3757	3764		10.1074/jbc.270.8.3757	http://dx.doi.org/10.1074/jbc.270.8.3757			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876116	hybrid			2022-12-25	WOS:A1995QH68800046
J	DEMCHYSHYN, LL; SUGAMORI, KS; LEE, FJS; HAMADANIZADEH, SA; NIZNIK, HB				DEMCHYSHYN, LL; SUGAMORI, KS; LEE, FJS; HAMADANIZADEH, SA; NIZNIK, HB			THE DOPAMINE D1D RECEPTOR - CLONING AND CHARACTERIZATION OF 3 PHARMACOLOGICALLY DISTINCT D1-LIKE RECEPTORS FROM GALLUS-DOMESTICUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; MOLECULAR-CLONING; CORTICAL MEMBRANES; PHOSPHOLIPASE-C; D(1) RECEPTORS; RAT-BRAIN; EXPRESSION; STIMULATION; AGONISTS; GENE	Three genomic clones encoding dopamine D1-like receptors were isolated from the avian species Gallus domesticus. Two of these genes encode proteins of 451 and 488 amino acids, which, based on deduced amino acid sequence identity and homology of exhibited pharmacological profiles, appear to be species homologs of mammalian and vertebrate D1/D1A and D5/D1B receptors, respectively, The third genomic clone, termed D1D, encodes a protein of 445 amino acids displaying a deduced amino acid sequence identity within putative transmembrane domains of 75% to mammalian D1/D1A and 77% to D5/D1B receptors with overall sequence homologies of only 49% and 46%, respectively, Membranes from COS-7 cells transfected with D1D DNA bound [H-3]SCH-23390 in a saturable manner with high affinity (similar to 300 pM) and with a pharmacological profile clearly indicative of a dopamine D1-like receptor, The DID receptor exhibited affinities for 6,7-dihydroxy-2-aminotetralin and dopamine 10-fold higher than D1/D1A receptors, characteristic of the D5/D1B receptor subfamily, In contrast, the D1D receptor bound dopaminergic agents, such as SKF-38393, apomorphine, pergolide, and lisuride, with affinities 10-fold higher than other cloned mammalian or vertebrate D1A/D1B receptor subtypes, while both clozapine and haloperidol displayed considerably lower affinity for the D1D receptor. Based on the low overall amino acid sequence identity (54%) and unique pharmacological profile, the avian dopamine D1D receptor does not appear to be a species homolog of the recently cloned vertebrate D1C receptor (Sugamori, K. S,, Demchyshyn, L, L,, Chung, M,, and Niznik, H, B, (1994) Proc. Natl. Acad. Sci, U. S. A. 91, 10536-10540), As with all cloned mammalian and vertebrate D1-like receptors, the D1D receptor stimulates adenylate cyclase activity in the presence of dopamine or SKF-82526. Northern blot analysis reveals the selective expression of both avian D1D and D1A receptor mRNAs only in brain with the D1B receptor more widely distributed and localized in tissues such as brain, kidney, and spleen, The isolation of four distinct vertebrate dopamine D1 receptor subtypes suggests the existence of additional mammalian D1 like receptor genes that may account for the observed pharmacological and biochemical multiplicity of dopamine D1-like receptor mediated events.	CLARKE INST PSYCHIAT,MOLEC NEUROBIOL LAB,TORONTO,ON M5T 1R8,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT PSYCHIAT,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto			Lee, Frank J.S./D-5899-2017	Lee, Frank J.S./0000-0002-5768-3776				ANDERSEN PH, 1990, TRENDS PHARMACOL SCI, V11, P231, DOI 10.1016/0165-6147(90)90249-8; ARIASMONTANO JA, 1993, MOL BRAIN RES, V19, P233, DOI 10.1016/0169-328X(93)90033-L; ARNT J, 1992, EUR J PHARMACOL, V213, P259, DOI 10.1016/0014-2999(92)90690-6; BARONTI F, 1992, ANN NEUROL, V32, P776, DOI 10.1002/ana.410320611; BARRETO C, 1993, SCIENCE, V262, P2020, DOI 10.1126/science.262.5142.2020; BOUVIER C, 1993, J RECEPTOR RES, V13, P559, DOI 10.3109/10799899309073679; CASTO JM, 1994, J NEUROBIOL, V25, P767, DOI 10.1002/neu.480250703; CIVELLI O, 1993, ANN REV PHARM TOXICO, V32, P281; DALY SA, 1993, PSYCHOPHARMACOLOGY, V113, P45, DOI 10.1007/BF02244332; DIETL MM, 1988, BRAIN RES, V439, P354, DOI 10.1016/0006-8993(88)91494-1; DOWNES RP, 1993, EUR J PHARMACOL, V234, P135, DOI 10.1016/0014-2999(93)90718-W; FELDER CC, 1989, J BIOL CHEM, V264, P8739; FELDER CC, 1993, AM J PHYSIOL, V264, pF1032, DOI 10.1152/ajprenal.1993.264.6.F1032; FRAIL DE, 1993, MOL PHARMACOL, V44, P1113; FRYXELL KJ, 1994, DOPAMINE RECEPTORS T, P237; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; HALL H, 1994, DOPAMINE RECEPTORS T, P3; HEDGES SB, 1994, P NATL ACAD SCI USA, V91, P2621, DOI 10.1073/pnas.91.7.2621; JARVIE KR, 1993, ADV NEUROL, V60, P325; JARVIE KR, 1993, J RECEPTOR RES, V13, P573, DOI 10.3109/10799899309073680; KATZ JL, 1993, PSYCHOPHARMACOLOGY, V118, P19; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOPIN IJ, 1993, ANN REV PHARM TOXICO, V32, P467; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAITINEN JT, 1993, J NEUROCHEM, V61, P1461, DOI 10.1111/j.1471-4159.1993.tb13641.x; LIU YF, 1992, MOL ENDOCRINOL, V6, P1815, DOI 10.1210/me.6.11.1815; MACHIDA CA, 1992, MOL PHARMACOL, V41, P652; MacKenzie R. G., 1994, DOPAMINE RECEPTORS T, P283; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MAILMAN RB, 1986, PSYCHOPHARMACOL BULL, V22, P593; MEYER ME, 1993, PHARMACOL BIOCHEM BE, V46, P269, DOI 10.1016/0091-3057(93)90352-T; MOONS L, 1994, J COMP NEUROL, V346, P97, DOI 10.1002/cne.903460107; NASH SR, 1993, MOL PHARMACOL, V44, P918; NIZNIK HB, 1987, MOL CELL ENDOCRINOL, V54, P1, DOI 10.1016/0303-7207(87)90134-1; NIZNIK HB, 1992, J PSYCHIATR NEUROSCI, V17, P158; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLANOW CW, 1994, MOVEMENT DISORD, V9, P40, DOI 10.1002/mds.870090107; PEDERSEN UB, 1994, EUR J PHARM-MOLEC PH, V267, P85, DOI 10.1016/0922-4106(94)90228-3; POLLOCK NJ, 1992, J BIOL CHEM, V267, P17780; ROSENGARTEN H, 1993, PHARMACOL BIOCHEM BE, V45, P921, DOI 10.1016/0091-3057(93)90140-O; ROSENZWEIGLIPSON S, 1993, J PHARMACOL EXP THER, V267, P765; SCHAMBRA UB, 1994, NEUROSCIENCE, V62, P66; SEEMAN P, 1988, ISI ATLAS-PHARMACOL, V2, P161; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SMEETS WJAJ, 1990, NEUROSCI LETT, V114, P248, DOI 10.1016/0304-3940(90)90571-P; SUGAMORI KS, 1994, P NATL ACAD SCI USA, V91, P10536, DOI 10.1073/pnas.91.22.10536; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; UNDIE AS, 1990, J PHARMACOL EXP THER, V253, P987; UNDIE AS, 1994, J NEUROCHEM, V62, P2045; VENTURA ALM, 1990, BRAIN RES, V530, P301; VENTURA ALM, 1992, DEV BRAIN RES, V69, P199; VERNIER P, 1993, COMP MOL NEUROBIOLOG, P297; WALDMANN C, 1993, BRAIN RES, V600, P225, DOI 10.1016/0006-8993(93)91377-5; WALLACE MA, 1993, NEUROCHEM RES, V18, P139, DOI 10.1007/BF01474676; WEINSHANK RL, 1991, J BIOL CHEM, V266, P22427; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	57	96	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4005	4012		10.1074/jbc.270.8.4005	http://dx.doi.org/10.1074/jbc.270.8.4005			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876148	hybrid			2022-12-25	WOS:A1995QH68800081
J	YAMADA, K; CARPENTIER, JL; CHEATHAM, B; GONCALVES, E; SHOELSON, SE; KAHN, CR				YAMADA, K; CARPENTIER, JL; CHEATHAM, B; GONCALVES, E; SHOELSON, SE; KAHN, CR			ROLE OF THE TRANSMEMBRANE DOMAIN AND FLANKING AMINO-ACIDS IN INTERNALIZATION AND DOWN-REGULATION OF THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; JUXTAMEMBRANE REGION; MEDIATED INTERNALIZATION; POLYPEPTIDE HORMONES; DIABETIC RATS; ENDOCYTOSIS; BINDING; DEGRADATION; SEQUENCE; PROTEIN	We have characterized the internalization and downregulation of the insulin receptor and nine receptors with mutations in the transmembrane (TM) domain and/or flanking charged amino acids to define the role of this domain in receptor cycling, When expressed in Chinese hamster ovary cells, all had normal tetrameric structure and normal insulin-stimulated autophosphorylation/kinase activity, Replacement of the TM domain with that of the platelet derived growth factor receptor, insertion of 3 amino acids, and substitution of Asp for Val(938) or of Ala for either Gly(933) Or Pro(934) had no effect on internalization Replacement of the TER domain with that of c-neu or conversion of the charged amino acids on the cytoplasmic Bank to uncharged amino acids, on the other hand, resulted in a 40-60% decrease in insulin-dependent internalization rate constants, By contrast, substitution of Ala for both Gly(933) and Pro(934) increases lateral diffusion mobility and accelerates internalization rate, These changes in internalization were due to decreased or increased rates of redistribution of receptors from microvilli to the nonvillous cell surface, In all cases, receptor down-regulation and receptor-mediated insulin degradation paralleled the changes in internalization Thus, the structure of the transmembrane domain of the insulin receptor and flanking amino acids are major determinants of receptor internalization, insulin degradation, and receptor down-regulation.	JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; UNIV GENEVA, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; University of Geneva; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021; Goncalves, Edison/AAR-3280-2020	Kahn, Ronald/0000-0002-7583-9228; Goncalves, Edison/0000-0002-7887-1231	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK031036, R37DK031036] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 31036, DK 36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDROLEWICZ MJ, 1989, BIOCHEMISTRY-US, V28, P9750, DOI 10.1021/bi00451a031; BACKER JM, 1989, J BIOL CHEM, V264, P1694; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BERHANU P, 1990, J BIOL CHEM, V265, P9505; CARPENTIER JL, 1978, J CLIN INVEST, V61, P1057, DOI 10.1172/JCI109005; CARPENTIER JL, 1993, HISTOCHEMISTRY, V100, P169, DOI 10.1007/BF00269090; CARPENTIER JL, 1989, DIABETOLOGIA, V32, P627; CARPENTIER JL, 1986, J CLIN ENDOCR METAB, V63, P151, DOI 10.1210/jcem-63-1-151; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1984, J BIOL CHEM, V259, P4190; CARPENTIER JL, 1979, J CLIN INVEST, V63, P1249, DOI 10.1172/JCI109420; CARPENTIER JL, 1993, J CELL BIOL, V118, P831; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; GEIGER D, 1989, EXP CELL RES, V185, P33, DOI 10.1016/0014-4827(89)90034-7; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; GORDEN P, 1980, DIABETOLOGIA, V18, P263; GORDEN P, 1982, YALE J BIOL MED, V55, P101; GORDEN P, 1987, SCIENCE, V200, P782; HARI J, 1987, J BIOL CHEM, V262, P15341; JOCHEN AL, 1986, J CLIN ENDOCR METAB, V62, P268, DOI 10.1210/jcem-62-2-268; JUHANBAGUE I, 1986, DIABETOLOGIA, V29, P471; KANTAR A, 1991, BIOCHEM MED METAB B, V46, P422, DOI 10.1016/0885-4505(91)90090-8; KASUGA M, 1982, J BIOL CHEM, V257, P392; KRISCHER J, 1993, DIABETES, V42, P1303, DOI 10.2337/diabetes.42.9.1303; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LUND KA, 1990, J BIOL CHEM, V265, P15713; MASSAGUE J, 1980, P NATL ACAD SCI-BIOL, V77, P7137, DOI 10.1073/pnas.77.12.7137; MASUDA M, 1990, DIABETES, V39, P466, DOI 10.2337/diabetes.39.4.466; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PACCAUD JP, 1993, J BIOL CHEM, V268, P23191; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SHOELSON SE, 1992, BIOCHEMISTRY-US, V31, P1757, DOI 10.1021/bi00121a025; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THIES RS, 1990, J BIOL CHEM, V265, P10132; TRISCHITTA V, 1986, J CLIN ENDOCR METAB, V62, P522, DOI 10.1210/jcem-62-3-522; TRISCHITTA V, 1989, DIABETES, V38, P1579, DOI 10.2337/diabetes.38.12.1579; TRISCHITTA V, 1989, J BIOL CHEM, V264, P5041; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHIE MF, 1994, J BIOL CHEM, V269, P1; YAMADA K, 1992, J BIOL CHEM, V267, P12452	51	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3115	3122		10.1074/jbc.270.7.3115	http://dx.doi.org/10.1074/jbc.270.7.3115			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852393	hybrid			2022-12-25	WOS:A1995QG47100036
J	ANDO, K; GRIFFIN, JD				ANDO, K; GRIFFIN, JD			CDK4 INTEGRATES GROWTH-STIMULATORY AND INHIBITORY SIGNALS DURING G1 PHASE OF HEMATOPOIETIC-CELLS	ONCOGENE			English	Article						HEMATOPOIESIS; CYCLINS; CELL CYCLE, INTERLEUKIN-3; CDK4; TGF-BETA-1; RETINOBLASTOMA	RETINOBLASTOMA-SUSCEPTIBILITY GENE; D-TYPE CYCLINS; TGF-BETA; PROTEIN-KINASES; PRODUCT; EXPRESSION; PROGRESSION; SUBUNIT; ENTRY	Proliferation of hematopoietic cells is controlled by both growth stimulatory and inhibitory cytokines acting primarily in G1, but the mechanism which integrate these disparate signals are unknown. In a myeloid cell line dependent on interleukin-3 (IL-3) for proliferation, expression of the cyclin dependent kinase Cdk4 and D-type cyclin partners, D2 and D3, in mid G1 was found to be directly related to the concentration of IL-3. TGF beta 1, which induces cell cycle arrest in mid-G1, blocked IL-3-induced expression of Cdk4, but had no effect on expression of cyclins D2 or D3. Sublines made to constitutively express Cdk4, but not lines constitutively expressing cyclins D2 or D3, were hyper responsive to IL-3 and resistant to TGF beta 1. Using an in vitro kinase assay with recombinant retinoblastoma protein (Rb) as a substrate, cyclin D2-associated kinase activity was shown to be induced in G1 by IL-3 and inhibited by TGF beta 1. Constitutive expression of Cdk4, but not cyclin D2 or D3, increased cyclin D2-associated Rb kinase activity and this activity could no longer be inhibited by TGF beta 1. Also, in vivo phosphorylation of Rb was inhibited by TGF beta 1 in wild type but not in Cdk4 lines. Cdk2 kinase activity was also decreased by TGF beta 1, and restored by overexpression of Cdk4. These results implicate Cdk4 activity as a mid G1 checkpoint sensitive to both growth stimulatory and inhibitory cytokines.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATUSHIME H, 1991, CELL, V65, P701; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	31	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					751	755						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862452				2022-12-25	WOS:A1995QH61200015
J	HERMOLIN, J; FILLINGAME, RH				HERMOLIN, J; FILLINGAME, RH			ASSEMBLY OF F-0 SECTOR OF ESCHERICHIA-COLI H+ ATP SYNTHASE - INTERDEPENDENCE OF SUBUNIT INSERTION INTO THE MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; OXIDATIVE-PHOSPHORYLATION; F0 SUBUNITS; GENES; F1F0; OVERPRODUCTION; F1F0-ATPASE; MUTATIONS; PROTEINS; COMPLEX	The F-0 sector of the Escherichia coli H+ transporting ATP synthase is composed of a complex of three subunits, each of which traverses the inner membrane. We have studied the interdependence of subunit insertion into the membrane in a series of chromosomal mutants in which the primary mutation prevented insertion of one of the F-0 subunits. Subunit insertion was assessed using Western blots of mutant membrane preparations. Subunit b and subunit c were found to insert into the membrane independently of the other two F-0 subunits. On the other hand, subunit a was not inserted into membranes that lacked either subunit b or subunit c. The conclusion that subunit a insertion is dependent upon the co-insertion of subunits b and c differs from the conclusion of several studies, where subunits were expressed from multicopy plasmids.	UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM23105] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DECKERSHEBESTRE.G, 1986, EUR J BIOCHEM, V161, P225; DOWNIE JA, 1981, J BACTERIOL, V145, P200, DOI 10.1128/JB.145.1.200-210.1981; EYA S, 1989, J BACTERIOL, V171, P6853, DOI 10.1128/jb.171.12.6853-6858.1989; EYA S, 1991, ARCH BIOCHEM BIOPHYS, V284, P71, DOI 10.1016/0003-9861(91)90265-K; FELTON J, 1980, J BACTERIOL, V142, P221, DOI 10.1128/JB.142.1.221-228.1980; FILLINGAME RH, 1986, J BACTERIOL, V165, P244, DOI 10.1128/jb.165.1.244-251.1986; FILLINGAME RH, 1983, J BIOL CHEM, V258, P604; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FRAGA D, 1994, J BIOL CHEM, V269, P7532; FRAGA D, 1994, J BIOL CHEM, V269, P2562; FRIEDL P, 1981, P NATL ACAD SCI-BIOL, V78, P6643, DOI 10.1073/pnas.78.11.6643; FRIEDL P, 1983, EMBO J, V2, P99, DOI 10.1002/j.1460-2075.1983.tb01388.x; GIBSON F, 1977, BIOCHEM J, V162, P665, DOI 10.1042/bj1620665; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; GOODFRIEND TL, 1964, SCIENCE, V144, P1344, DOI 10.1126/science.144.3624.1344; GUNSALUS RP, 1982, P NATL ACAD SCI-BIOL, V79, P320, DOI 10.1073/pnas.79.2.320; Harlow E, 1988, ANTIBODIES LABORATOR, P471; JANS DA, 1985, J BACTERIOL, V160, P764; KLIONSKY DJ, 1983, J BIOL CHEM, V258, P136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller J. H., 1972, EXPT MOL GENETICS, P431; MONTICELLO RA, 1992, J BACTERIOL, V174, P3370, DOI 10.1128/jb.174.10.3370-3376.1992; MOSHER ME, 1983, J BACTERIOL, V156, P1078, DOI 10.1128/JB.156.3.1078-1092.1983; PAULE CR, 1989, ARCH BIOCHEM BIOPHYS, V274, P270, DOI 10.1016/0003-9861(89)90439-6; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; SCHNEIDER E, 1984, P NATL ACAD SCI-BIOL, V81, P7279, DOI 10.1073/pnas.81.23.7279; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIK SB, 1987, J BIOL CHEM, V262, P8340; VONMEYENBURG K, 1985, EMBO J, V4, P2357, DOI 10.1002/j.1460-2075.1985.tb03939.x	33	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2815	2817		10.1074/jbc.270.6.2815	http://dx.doi.org/10.1074/jbc.270.6.2815			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852354	hybrid			2022-12-25	WOS:A1995QF53500064
J	HAIN, J; ONOUE, H; MAYRLEITNER, M; FLEISCHER, S; SCHINDLER, H				HAIN, J; ONOUE, H; MAYRLEITNER, M; FLEISCHER, S; SCHINDLER, H			PHOSPHORYLATION MODULATES THE FUNCTION OF THE CALCIUM-RELEASE CHANNEL OF SARCOPLASMIC-RETICULUM FROM CARDIAC-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RYANODINE RECEPTOR; SKELETAL-MUSCLE; FEET STRUCTURES; CALMODULIN; CA-2+; HEART; RECONSTITUTION; BIOCHEMISTRY; PURIFICATION	The cardiac calcium release channel (CRC) of sarcoplasmic reticulum vesicles was incorporated into planar lipid membranes to evaluate modulation of channel activity by phosphorylation and dephosphorylation. For this purpose a microsyringe application directly to the membrane was used to achieve sequential and multiple treatments of channels with highly purified kinases and phosphatases. Cyclic application of protein kinase A (PKA) or Ca2+/calmodulin-dependent protein kinase II (CalPK) and potato acid phosphatase or protein phosphatase 1 revealed a channel block by Mg2+ (similar to mM), that is referable to dephosphorylated states of the channel, and that the Mg2+ block could be removed by phosphorylation of the CRC by either PKA or CalPK, By contrast, activation of endogenous CalPK (end CalPK) led to channel closure which could be reversed by dephosphorylation using potato acid phosphatase or protein phosphatase 1, Calmodulin by itself (which activates end CalPK in the presence of MgATP) blocks the channel in the dephosphorylated state, which can be overcome by treatment with CalPK but not PKA. Our findings reveal important insights regarding channel regulation of the ryanodine receptor: 1) the calcium release channel must be phosphorylated to be in the active state at conditions approximating physiological Mg2+ concentrations (similar to mM); and 2) there are multiple sites of phosphorylation on the calcium release channel with different functional consequences, which may be relevant to the regulation of E-C coupling, Phosphorylation of the CRC may be involved in recruitment of active channels, and/or it may be directly involved in each Ca2+ contraction cycle of the heart, For example, Ca2+ release may require phosphorylation of the CRC by protein kinases at sites which overcome the block by Mg2+, Inactivation may involve CRC block by calmodulin and/or phosphorylation by endogenous CalPK at the junctional face membrane.	UNIV LINZ, INST BIOPHYS, A-4040 LINZ, AUSTRIA; VANDERBILT UNIV, DEPT MOLEC BIOL, NASHVILLE, TN 37235 USA	Johannes Kepler University Linz; Vanderbilt University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711, P01HL046681] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46681, HL32711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; BORGATTA L, 1991, P NATL ACAD SCI USA, V88, P2486, DOI 10.1073/pnas.88.6.2486; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; COX JA, 1984, FED PROC, V43, P3000; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GLOSSMANN H, 1988, VITAM HORM, V44, P155; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HAIN J, 1994, BIOPHYS J, V66, pA225; HERRMANNFRANK A, 1993, FEBS LETT, V332, P237, DOI 10.1016/0014-5793(93)80640-G; HYMEL L, 1988, BIOCHEM BIOPH RES CO, V152, P308, DOI 10.1016/S0006-291X(88)80715-0; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; INUI M, 1988, J BIOL CHEM, V263, P10843; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; NAGASAKI K, 1989, CELL CALCIUM, V10, P63, DOI 10.1016/0143-4160(89)90045-6; NAGASAKI K, 1983, J BIOCHEM-TOKYO, V94, P1101, DOI 10.1093/oxfordjournals.jbchem.a134453; OTSU K, 1990, J BIOL CHEM, V265, P13472; RENTER H, 1983, NATURE, V325, P717; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; WANG JX, 1992, NATURE, V359, P739, DOI 10.1038/359739a0; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; WOLFE L, 1987, J BIOL CHEM, V262, P16906; YOSHIDA A, 1992, J BIOCHEM-TOKYO, V111, P186, DOI 10.1093/oxfordjournals.jbchem.a123735; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484	39	247	258	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2074	2081		10.1074/jbc.270.5.2074	http://dx.doi.org/10.1074/jbc.270.5.2074			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836435	hybrid			2022-12-25	WOS:A1995QE49300017
J	KOZLOSKY, CJ; MARASKOVSKY, E; MCGREW, JT; VANDENBOS, T; TEEPE, M; LYMAN, SD; SRINIVASAN, S; FLETCHER, FA; GAYLE, RB; CERRETTI, DP; BECKMANN, MP				KOZLOSKY, CJ; MARASKOVSKY, E; MCGREW, JT; VANDENBOS, T; TEEPE, M; LYMAN, SD; SRINIVASAN, S; FLETCHER, FA; GAYLE, RB; CERRETTI, DP; BECKMANN, MP			LIGANDS FOR THE RECEPTOR TYROSINE KINASES HEK AND ELK - ISOLATION OF CDNAS ENCODING A FAMILY OF PROTEINS	ONCOGENE			English	Article						LIGANDS; ELK; HEK; RECEPTOR TYROSINE KINASES	TUMOR-NECROSIS-FACTOR; PROTO-ONCOGENE; IL-1 RECEPTOR; GENE; EXPRESSION; SEQUENCE; CLONING; CELLS; IDENTIFICATION; STIMULATION	Hek is a member of the eph subfamily of receptor tyrosine kinases whose members include elk, hek2, sek, eph and eck among others. Using a soluble form of hek consisting of the extracellular region of the receptor fused to the Fc domain of human IgG1 and an expression cloning strategy, we have isolated two different but related cDNAs from the human T-lymphoma line HSB-2 that encode ligands for hek. The cDNAs encode proteins of 238 and 201 amino acids (44% amino acid identity) that are anchored to the membrane by glycosyl-phosphatidylinositol (GPI)-linkage. The proteins encoded by these cDNAs are bound by hek with affinity constants of 2 x 10(8) m(-1). These proteins also bind the elk tyrosine kinase receptor. These cDNAs are related to other cDNAs that we have recently isolated from a human placental library that encode ligands for both hek and elk and define an emerging family of ligands for eph-related kinases (LERKs).	IMMUNEX RES & DEV CORP,DEPT GENE EXPRESS,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT CELLULAR IMMUNOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT BIOCHEM,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT MOLEC GENET,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT PROT CHEM,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT MOLEC IMMUNOL,SEATTLE,WA 98101									ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BOHME B, 1993, ONCOGENE, V8, P2857; BOYD AW, 1992, J BIOL CHEM, V267, P3262; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; GRUBER LN, 1983, AM J CLIN HYPN, V25, P263; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCGREW JT, 1991, CELL IMMUNOL, V137, P118, DOI 10.1016/0008-8749(91)90062-G; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; SAJJADI FG, 1991, NEW BIOL, V3, P769; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILLIAMS D E, 1991, Progress in Growth Factor Research, V3, P235, DOI 10.1016/0955-2235(91)90002-L; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	39	82	91	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					299	306						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838529				2022-12-25	WOS:A1995QC62400009
J	SHAO, ZH; ROBBINS, PD				SHAO, ZH; ROBBINS, PD			DIFFERENTIAL REGULATION OF E2F AND SP1-MEDIATED TRANSCRIPTION BY G1 CYCLINS	ONCOGENE			English	Article						RETINOBLASTOMA PROTEIN; CYCLINS; SP1; E2F	RETINOBLASTOMA GENE-PRODUCT; PROTEIN-KINASE-C; HUMAN CELL-CYCLE; RB PROTEIN; BINDING-ACTIVITY; RNA-POLYMERASE; CDC2 KINASE; PHOSPHORYLATION; EXPRESSION; PHASE	Cyclins have been demonstrated to mediate phosphorylation of the retinoblastoma tumor suppressor gene product (Rb) and/or to bind directly to Rb. Since Rb is a regulator of E2F and Sp1-mediated transcription, we have examined the effect of overexpression of cyclins on transcription mediated by E2F-dependent adenovirus E2 promoter and by Sp1 in a cotransfection assay in 3T3 cells. All the G1 cyclins tested, C, D1, D2, D3 and E, as well as cyclin A were able to stimulate E2 promoter activity to various levels with D3 showing the strongest stimulation. For stimulation of the E2 promoter by cyclins A, E and D-type cyclins was dependent upon the presence of functional E2F and ATF binding sites. Cyclin C, however, was able to stimulate both E2F and ATF-dependent transcription to the same level as the wild type E2 promoter. In addition, cyclin C was able to stimulate transcription mediated by Sp1, GAL4-Sp1 and GAL4-VP16, suggesting that cyclin C affects a general pathway of transcriptional activation. In contrast, cyclin D1 was able to repress specifically Sp1-mediated transcription through an Rb-independent pathway, These results suggest that cyclins can regulate transcription mediated by specific transcription factors in both positive and negative manners. Furthermore, the results demonstrate clear functional differences between the G1 cyclins, in particular, functional differences between the related D-type cyclins.	UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA55227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, ONCOGENE, V6, P2179; ADNANE S, 1995, IN PRESS ONCOGENE; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KATO J, 1993, GENE DEV, V7, P331; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	58	50	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					221	228						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838522				2022-12-25	WOS:A1995QC62400001
J	SHORE, JD; DAY, DE; FRANCISCHMURA, AM; VERHAMME, I; KVASSMAN, J; LAWRENCE, DA; GINSBURG, D				SHORE, JD; DAY, DE; FRANCISCHMURA, AM; VERHAMME, I; KVASSMAN, J; LAWRENCE, DA; GINSBURG, D			A FLUORESCENT-PROBE STUDY OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 - EVIDENCE FOR REACTIVE CENTER LOOP INSERTION AND ITS ROLE IN THE INHIBITORY MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; ANTITHROMBIN; SERPINS; HEPARIN; SITE	A mutant recombinant plasminogen activator inhibitor 1 (PAI-1) was created (Ser-338 --> Cys) in which cysteine was placed at the P-9 position of the reactive center loop. Labeling this mutant with N,N'-dimethyl-N-(acetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) ethylene diamine (NBD) provided a molecule with a fluorescent probe at that position. The NBD-labeled mutant was almost as reactive as wild type but was considerably more stable. Complex formation with tissue or urokinase type plasminogen activator (tPA or uPA), and cleavage between P-3 and P-4 with a catalytic concentration of elastase, all resulted in identical 13-nm blue shifts of the peak fluorescence emission wavelength and 6.2-fold fluorescence enhancements. Formation of latent PAI showed the same 13-nm spectral shift with a 6.7-fold fluorescence emission increase, indicating that the NBD probe is in a slightly more hydophobic milieu. These changes can be attributed to insertion of the reactive center loop into the beta sheet A of the inhibitor in a manner that exposes the NBD probe to a more hydrophobic milieu. The rate of loop insertion due to tPA complexation was followed using stopped flow fluorimetry. This rate showed a hyperbolic dependence on tPA concentration, with a half-saturation concentration of 0.96 mu M and a maximum rate constant of 3.4 s(-1), These results demonstrate experimentally that complexation with proteases is presumably associated with loop insertion. The identical fluorescence changes obtained with tPA . PAI-1 and uPA . PAI-1 complexes and elastase-cleaved PAI-1 strongly suggest that in the stable protease-PAI-1 complex the reactive center loop is cleaved and inserted into beta sheet A and that this process is central to the inhibition mechanism.	UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; HENRY FORD HOSP,HOWARD HUGHES MED INST,DETROIT,MI 48202	University of Michigan System; University of Michigan; Henry Ford Health System; Henry Ford Hospital; Howard Hughes Medical Institute	SHORE, JD (corresponding author), HENRY FORD HOSP,DIV BIOCHEM RES,E&R RM 3126 ,2799 W GRAND BLVD,DETROIT,MI 48202, USA.			Lawrence, Daniel/0000-0003-3126-1935	NHLBI NIH HHS [HL49184, HL45930] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045930, R01HL049184] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KEIJER J, 1991, BLOOD, V78, P1254; LAWRENCE D, 1987, EUR J BIOCHEM, V186, P523; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LOBERMANN H, 1984, J MOL BIOL, V177, P531; LOBERMANN H, 1982, Z PHYSL CHEM, P1377; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHORE JD, 1992, FIBRINOLYSIS S2, V6; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; STRANDBERG L, 1992, FIBRINOLYSIS S2, V6; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251	18	134	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5395	5398		10.1074/jbc.270.10.5395	http://dx.doi.org/10.1074/jbc.270.10.5395			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890653	hybrid			2022-12-25	WOS:A1995QL58000068
J	LIANG, QW; HE, JS; FULCO, AJ				LIANG, QW; HE, JS; FULCO, AJ			THE ROLE OF BARBIE BOX SEQUENCES AS CIS-ACTING ELEMENTS INVOLVED IN THE BARBITURATE-MEDIATED INDUCTION OF CYTOCHROMES P45(BM-1) AND P450(BM-3) IN BACILLUS-MEGATERIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID MONOOXYGENASE; PHENOBARBITAL INDUCTION; ESCHERICHIA-COLI; CYP2B2 GENE; EXPRESSION; PROTEIN; SYSTEM; CYTOCHROME-P-450BM-3; IDENTIFICATION; HYDROXYLATION	In a previous publication (He, J,-S,, and Fulco, A. J, (1991) J, Biol, Chem, 266, 7864-7869), we reported that a 15-17-base pair DNA sequence (designated a Barbie box element) in the 5'-regulatory regions of cytochrome P450(BM-1) and P450(BM-3) genes from Bacillus megaterium was recognized by a barbiturate-regulated protein. It is now recognized that essentially all eukaryotic and prokaryotic genes whose 5'-flanking regions are known and that encode barbiturate-inducible proteins contain the Barbie box element, A 4-base pair sequence (AAAG) is found in the same relative position in all Barbie box elements, In B. megaterium, mutation of the Barbie box located in the P450(BM-1) gene leads to the constitutive synthesis of cytochrome P450(BM-1) and a 10-fold increase of expression of Bm1P1, a small gene located upstream of the P450(BM-1) gene, that encodes a putative regulatory protein, Mutation of the P450(BM-3) Barbie box significantly increased the expression of both P450(BM-3) and Bm3P1 (another small gene located upstream of the P450(BM-3) gene that encodes a second putative regulatory protein) in response to pentobarbital induction but left the basal levels unaffected, In gel mobility shift assays, Bm3R1, a repressor of the P450(BM-3), gene, was found to specifically interact with the Barbie box sequences of the B, megaterium P450 genes, Mutated Barbie boxes showed a decreased binding affinity for Bm3R1 compared to their wild type (unmutated) counterparts, Barbie box sequences were also shown to specifically interact with putative positive regulatory factors of B. megaterium cells, These putative positive factors were induced by pentobarbital and were also present at high levels during late stationary phase of B, megaterium cell cultures grown in the absence of barbiturates, The mutated Barbie box sequences had greater binding affinity for these positive factors than did unmutated Barbie box sequences, DNase I footprinting analysis of the 5'-flanking region of the P450(BM-1) gene revealed that these positive factors protected a segment of DNA covering a portion of the Barbie box sequence and a small flanking region, Similar footprinting experiments with the 5'-flanking region of the P450(BM-3) gene failed, however, to unambiguously reveal protected sequences in the Barbie box region, The evidence suggests that the positive factors and Bm3R1 compete with each other for binding to the Barbie box region, especially in the 5'-flanking region of the P450(BM-1) gene, and for putative roles in the regulation of transcription from the B, megaterium P450 genes, This inference was further supported by evidence derived from a nested-deletion analysis in and around the Barbie box of the P450(BM-1) regulatory region that showed that a repressor binding site and a positive factor binding site overlap at the Barbie box sequence, In tote, these experimental results indicate that, in B. megaterium at least, the Barbie box sequences are important cis acting elements for coordinately regulating the barbiturate-mediated expression of the P450(BM-1) and P450(BM-3) genes and the genes encoding their positive regulatory factors.	UNIV CALIF LOS ANGELES,SCH MED,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIGMS NIH HHS [GM23913] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023913] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, V2, P1; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; FULCO AJ, 1987, LIFE SCI, V40, P1769, DOI 10.1016/0024-3205(87)90087-7; Gallaghar S.R., 1989, CURRENT PROTOCOLS MO, P1; HAHN CN, 1991, J BIOL CHEM, V266, P17031; HE JS, 1991, J BIOL CHEM, V266, P7864; HE JS, 1989, BIOCHIM BIOPHYS ACTA, V1009, P301, DOI 10.1016/0167-4781(89)90120-6; JAISWAL AK, 1990, NUCLEIC ACIDS RES, V18, P4237, DOI 10.1093/nar/18.14.4237; KIM BH, 1983, BIOCHEM BIOPH RES CO, V116, P843, DOI 10.1016/S0006-291X(83)80219-8; LIANG QW, 1992, BIOTECHNIQUES, V13, P730; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; MIURA Y, 1974, J BIOL CHEM, V249, P1880; NARHI LO, 1982, J BIOL CHEM, V257, P2147; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NARHI LO, 1988, MOL CELL BIOCHEM, V79, P63, DOI 10.1007/BF00229399; NARHI LO, 1987, J BIOL CHEM, V262, P6683; PATEL NV, 1992, GENE, V112, P67, DOI 10.1016/0378-1119(92)90304-8; RAMSDEN R, 1993, J BIOL CHEM, V268, P21722; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; RUETTINGER RT, 1981, J BIOL CHEM, V256, P5728; SCHWALB H, 1985, BIOCHIM BIOPHYS ACTA, V838, P302, DOI 10.1016/0304-4165(85)90227-2; SHAW GC, 1992, J BIOL CHEM, V267, P5515; SHAW GC, 1993, J BIOL CHEM, V268, P2997; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; UPADHYA P, 1992, NUCLEIC ACIDS RES, V20, P557, DOI 10.1093/nar/20.3.557; WEN LP, 1989, J BIOL CHEM, V264, P10996; WEN LP, 1987, J BIOL CHEM, V262, P6676	28	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4438	4450		10.1074/jbc.270.9.4438	http://dx.doi.org/10.1074/jbc.270.9.4438			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876210	hybrid			2022-12-25	WOS:A1995QK08400042
J	SHERIDAN, PL; SCHORPP, M; VOZ, ML; JONES, KA				SHERIDAN, PL; SCHORPP, M; VOZ, ML; JONES, KA			CLONING OF AN SNF2/SWI2-RELATED PROTEIN THAT BINDS SPECIFICALLY TO THE SPH MOTIFS OF THE SV40 ENHANCER AND TO THE HIV-1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; NEGATIVE REGULATOR; GLOBAL ACTIVATOR; GENE-EXPRESSION; SNF6 PROTEINS; T-ANTIGEN; SEQUENCE; CONTAINS; FAMILY	We have isolated a human cDNA clone encoding HIP116, a protein that binds to the SPH repeats of the SV40 enhancer and to the TATA/initiator region of the human immunodeficiency virus (HIV)-1 promoter. The predicted HIP116 protein is related to the yeast SNF2/SW12 transcription factor and to other members of this extended family and contains seven domains similar to those found in the vaccinia NTP1 ATPase. Interestingly, HIP116 also contains a C3HC4 zinc-binding motif (RING: finger) interspersed between the ATPase motifs in an arrangement similar to that found in the yeast RADS and RAD16 proteins. The HIP116 amino terminus is unique among the members of this family, and houses a specific DNA-binding domain, Antiserum raised against HIP116 recognizes a 116-kDa nuclear protein in Western blots and specifically supershifts SV40 and HIV-1 protein-DNA complexes in gel shift experiments. The binding site for HIP116 on the SV40 enhancer directly overlaps the site for TEF-1, and like TEF-1, binding of HIP116 to the SV40 enhancer is destroyed by mutations that inhibit SPH enhancer activity in vivo. Purified fractions of HIP116 display strong ATPase activity that is preferentially stimulated by SPH DNA and can be inhibited specifically by antibodies to HIP116. These findings suggest that HIP116 might affect transcription, directly or indirectly, by acting as a DNA binding site-specific ATPase.	SALK INST BIOL STUDIES, DEPT REGULAT BIOL, LA JOLLA, CA 92037 USA	Salk Institute					NIGMS NIH HHS [GM38166] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038166] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1989, New Biologist, V1, P35; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; EVERETT RD, 1988, J MOL BIOL, V202, P87, DOI 10.1016/0022-2836(88)90521-9; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GRUDA MC, 1991, J VIROL, V65, P3553, DOI 10.1128/JVI.65.7.3553-3558.1991; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; Jones KA, 1993, CURR OPIN CELL BIOL, V5, P461, DOI 10.1016/0955-0674(93)90012-F; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LIN Y, 1994, IN PRESS GENOMICS; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MANNHAUPT G, 1992, YEAST, V8, P397, DOI 10.1002/yea.320080507; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MURCHARDT C, 1993, EMBO J, V12, P4279; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SARAGOSTI S, 1980, CELL, V20, P65, DOI 10.1016/0092-8674(80)90235-4; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	57	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4575	4587		10.1074/jbc.270.9.4575	http://dx.doi.org/10.1074/jbc.270.9.4575			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876228	hybrid			2022-12-25	WOS:A1995QK08400061
J	TAIPALE, J; LOHI, J; SAARINEN, J; KOVANEN, PT; KESKIOJA, J				TAIPALE, J; LOHI, J; SAARINEN, J; KOVANEN, PT; KESKIOJA, J			HUMAN MAST-CELL CHYMASE AND LEUKOCYTE ELASTASE RELEASE LATENT TRANSFORMING GROWTH FACTOR-B1 FROM THE EXTRACELLULAR-MATRIX OF CULTURED HUMAN EPITHELIAL AND ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE PANCREATIC ELASTASE; SMOOTH-MUSCLE CELLS; FACTOR-BETA; BINDING-PROTEIN; CATHEPSIN-G; TGF-BETA; PLASMINOGEN ACTIVATION; PERICELLULAR MATRIX; NEUTROPHIL ELASTASE; MOLECULAR-CLONING	Monolayer cultures of human epithelial and endothelial cells were used to study the association of latent transforming growth factor-beta 1 (TGF-beta 1) to extracellular matrices and its release and activation during matrix degradation, Human umbilical vein endothelial cells and embryonic lung fibroblasts produced relatively high revels of TGF-beta 1, its propeptide (beta 1-latency-associated protein), and latent TGF-beta-binding protein and incorporated latent TGF-beta 1 into their matrices as shown by immunoblotting, Amnion epithelial cells produced lower levels of these proteins, Confluent cultures of epithelial cells were exposed to matrix-degrading proteases and glycosidases, Mast cell chymase, leukocyte elastase, and plasmin efficiently released matrix-bound latent TGF-beta 1 complexes, while chondroitinase ABC and heparitinases were ineffective, The ability of the proteases to activate recombinant latent TGF-beta 1 was tested using growth inhibition assays and a novel sodium deoxycholate-polyacrylamide gel electrophoresis followed by immunoblotting. Sodium deoxycholate solubilized M(r) 25,000 TGF-beta 1 but did not dissociate high M(r) latent TGF-beta 1 complexes, allowing separation of these forms by polyacrylamide gel electrophoresis, Mast cell chymase and leukocyte elastase did not activate latent TGF-beta 1, suggesting that its release from matrix and activation are controlled by different mechanisms. The release of TGF-beta from the matrix by leukocyte and mast cell enzymes may contribute to the accumulation of connective tissue in inflammation.	UNIV HELSINKI, DEPT VIROL, SF-00014 HELSINKI, FINLAND; UNIV HELSINKI, DEPT DERMATOL & VENEREOL, SF-00014 HELSINKI, FINLAND; WIHURI RES INST, SF-00140 HELSINKI, FINLAND	University of Helsinki; University of Helsinki; Wihuri Research Institute								ALITALO K, 1980, CELL, V19, P1053, DOI 10.1016/0092-8674(80)90096-3; BENEZRA M, 1993, BLOOD, V81, P3324; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; BROMLEY M, 1984, ANN RHEUM DIS, V43, P76, DOI 10.1136/ard.43.1.76; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; COLOSETTI P, 1993, FEBS LETT, V320, P140, DOI 10.1016/0014-5793(93)80079-A; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; DABBOUS MK, 1986, BRIT J CANCER, V54, P459, DOI 10.1038/bjc.1986.198; DAYTON ET, 1989, J IMMUNOL, V142, P4307; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; FLAUMENHAFT R, 1992, MOL BIOL CELL, V3, P1057, DOI 10.1091/mbc.3.10.1057; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GRUHER BL, 1989, J CLIN INVEST, V84, P1657; HARPER JW, 1984, BIOCHEMISTRY-US, V23, P2995, DOI 10.1021/bi00308a023; HARVIMA IT, 1988, BIOCHIM BIOPHYS ACTA, V957, P71, DOI 10.1016/0167-4838(88)90158-6; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HEDMAN K, 1979, J CELL BIOL, V81, P83, DOI 10.1083/jcb.81.1.83; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; HEINE UI, 1990, DEVELOPMENT, V109, P29; HUBER D, 1992, J IMMUNOL, V148, P277; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; JAFFE EA, 1976, J EXP MED, V144, P209, DOI 10.1084/jem.144.1.209; JULLIEN P, 1989, INT J CANCER, V43, P886, DOI 10.1002/ijc.2910430525; KAARTINEN M, 1994, CIRCULATION, V90, P1669, DOI 10.1161/01.CIR.90.4.1669; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOVACS EJ, 1994, FASEB J, V8, P854, DOI 10.1096/fasebj.8.11.7520879; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOHI J, 1992, J CELL BIOCHEM, V50, P337, DOI 10.1002/jcb.240500402; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MALONE DG, 1987, ARTHRITIS RHEUM, V30, P130, DOI 10.1002/art.1780300202; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCRAE B, 1980, BIOCHEMISTRY-US, V19, P3973, DOI 10.1021/bi00558a013; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MIYAZONO K, 1993, ADV IMMUNOL, V55, P1994; MIZOI T, 1993, CANCER RES, V53, P183; MOSES HL, 1985, CANCER CELL, V3, P65; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; OKADA F, 1989, FEBS LETT, V242, P240, DOI 10.1016/0014-5793(89)80477-6; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; PAREKH T, 1994, J IMMUNOL, V152, P2456; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; PENNINGTON DW, 1992, J CLIN INVEST, V90, P35, DOI 10.1172/JCI115853; PORTEU F, 1991, J BIOL CHEM, V266, P18846; POSTLETHWAITE AE, 1987, J EXP MED, V165, P251, DOI 10.1084/jem.165.1.251; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; Robbins K. C., 1970, METHOD ENZYMOL, V19, P184; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SATO Y, 1993, J CELL BIOL, V123, P1249, DOI 10.1083/jcb.123.5.1249; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; SCHECHTER NM, 1990, J IMMUNOL, V145, P2652; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; TAIPALE J, 1994, MOL BIOL CELL, V5, P1808; TANAKA T, 1985, BIOCHEMISTRY-US, V24, P2040, DOI 10.1021/bi00329a036; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; VALLE M, 1962, ANN MED EXP BIOL FEN, V40, P342; VARTIO T, 1981, J BIOL CHEM, V256, P471; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WALTENBERGER J, 1993, J IMMUNOL, V151, P1147; WALTENBERGER J, 1993, AM J PATHOL, V142, P71; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	93	328	340	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4689	4696		10.1074/jbc.270.9.4689	http://dx.doi.org/10.1074/jbc.270.9.4689			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876240	hybrid			2022-12-25	WOS:A1995QK08400075
J	VIEILLEGROSJEAN, I; HUBER, P				VIEILLEGROSJEAN, I; HUBER, P			TRANSCRIPTION FACTOR GATA-1 REGULATES HUMAN HOXB2 GENE-EXPRESSION IN ERYTHROID-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; DNA-BINDING PROTEIN; MAMMALIAN-CELLS; HOMEOBOX GENES; IMMUNOGLOBULIN GENES; HEMATOPOIETIC-CELLS; ENDOTHELIAL-CELLS; NUCLEAR FACTOR; RETINOIC ACID; PROMOTER	The human HOXB2 gene is a member of the vertebrate Hox gene family that contains genes coding for specific developmental stage DNA-binding proteins. Remarkably, within the hematopoietic compartment, genes of the HOXB complex are expressed specifically in erythro-megakaryocytic cell lines and, for some of them, in hematopoietic progenitors, Here, we report the study of HOXB2 gene transcriptional regulation in hematopoietic cells, an initial step in understanding the lineage-specific expression of the whole HOXB complex in these cells. We have isolated the HOXB2 5'-flanking sequence and have characterized a promoter fragment extending 323 base pairs upstream from the transcriptional start site, which, in transfection experiments, was sufficient to direct the tissue specific expression of HOXB2 in the erythroid cell Line K562. In this fragment, we have identified a potential GATA-binding site that is essential to the promoter activity as demonstrated by point mutation experiments. Gel shift analysis revealed the formation of a specific complex in both erythroleukemic lines K562 and HEL that could be prevented by the addition of a specific antiserum raised against GATA-1 protein. These findings suggest a regulatory hierarchy in which GATA-1 is upstream of the HOXB2 gene in erythroid cells.	CEN GRENOBLE,DEPT BIOL MOLEC & STRUCT,INSERM,U217,HEMATOL LAB,F-38054 GRENOBLE 09,FRANCE	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)			Huber, Philippe/C-7971-2019	Huber, Philippe/0000-0002-4153-7694				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; ARCIONI L, 1992, EMBO J, V11, P265, DOI 10.1002/j.1460-2075.1992.tb05049.x; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; GALANG CK, 1993, MOL CELL BIOL, V13, P4609, DOI 10.1128/MCB.13.8.4609; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALLIGAN BD, 1987, P NATL ACAD SCI USA, V84, P7019, DOI 10.1073/pnas.84.20.7019; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KONDO T, 1992, NUCLEIC ACIDS RES, V20, P5729, DOI 10.1093/nar/20.21.5729; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LEONARD M, 1993, BLOOD, V82, P1071; LUEKOW B, 1987, NUCLEIC ACIDS RES, V15, P1311; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARTIN F, 1993, J BIOL CHEM, V268, P21606; MATHEWS CHE, 1991, BLOOD, V78, P2248; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1992, BLOOD, V80, P575; PAN JL, 1993, J BIOL CHEM, V268, P22600; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SENGUPTA PK, 1994, BLOOD, V83, P1420; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SHEN WF, 1992, EMBO J, V11, P983, DOI 10.1002/j.1460-2075.1992.tb05137.x; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VERRIJZER P, 1988, NUCLEIC ACIDS RES, V16, P2729, DOI 10.1093/nar/16.6.2729; VIEILLEGROSJEAN I, 1992, BIOCHEM BIOPH RES CO, V183, P1124, DOI 10.1016/S0006-291X(05)80307-9; VIEILLEGROSJEAN I, 1992, BIOCHEM BIOPH RES CO, V185, P785, DOI 10.1016/0006-291X(92)91694-L; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638; ZON LI, 1993, BLOOD, V81, P3234	63	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4544	4550		10.1074/jbc.270.9.4544	http://dx.doi.org/10.1074/jbc.270.9.4544			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876223	hybrid			2022-12-25	WOS:A1995QK08400056
J	BALLATORI, N; TRUONG, AT				BALLATORI, N; TRUONG, AT			MULTIPLE CANALICULAR TRANSPORT MECHANISMS FOR GLUTATHIONE S-CONJUGATES - TRANSPORT ON BOTH ATP-DEPENDENT AND VOLTAGE-DEPENDENT CARRIERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; RAT-LIVER; HUMAN-ERYTHROCYTES; BILIARY TRANSPORT; ORGANIC-ANIONS; DINITROPHENYL GLUTATHIONE; OXIDIZED GLUTATHIONE; INHIBITION; SYSTEM; METABOLISM	A large number of structurally distinct electrophiles are conjugated to glutathione within hepatocytes, and the resulting glutathione S-conjugates are selectively transported across the canalicular membrane into bile. To test the hypothesis that a single multi-specific, ATP-dependent carrier mediates biliary secretion of glutathione S-conjugates, the present study compared the driving forces and substrate specificity for canalicular transport of S-ethylglutathione (ethyl-SG), a low molecular weight and relatively hydrophilic thioether, and S-(2,4-dinitrophenyl)-glutathione (DNP-SG), a larger and more hydrophobic anion, using isolated rat liver canalicular membrane vesicles. In agreement with previous findings, DNP-SG transport was stimulated by ATP, although there was considerable transport in the absence of ATP. ATP-independent DNP-SG transport was unaffected by a Na+ gradient, was enhanced by a valinomycin-induced K+ diffusion potential, and was saturable, with both high affinity (K-m = 8 +/- 2 mu M) and low affinity (K-m = 0.5 +/- 0.1 mM) components. High affinity ATP-independent DNP-SG uptake was cis-inhibited by GSH, GSH monoethyl ester, glutathione S-conjugates, other gamma-glutamyl compounds, sulfobromophthalein, and 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS). In contrast, ATP-dependent DNP-SG uptake was unaffected by GSH, GSH ester, S-methyl glutathione, or S-carbamidomethyl glutathione, but was strongly inhibited by sulfobromophthalein, DIDS, and by high molecular weight and relatively hydrophobic glutathione S-conjugates. Transport of the low molecular weight ethyl SG conjugate was only minimally stimulated by ATP (10-20%). ATP-independent ethyl-SG uptake was electrogenic, saturable (K-m = 10 +/- 1 mu M) and was inhibited by GSH and all glutathione S-conjugates tested. These findings indicate the presence of multiple canalicular transport mechanisms for glutathione S-conjugates and demonstrate that the physicochemical properties of the S moiety are major determinants of transport. Relatively high molecular weight hydrophobic conjugates are substrates for both ATP-dependent and -independent mechanisms, whereas low molecular weight glutathione S-conjugates are transported largely by electrogenic carriers.			BALLATORI, N (corresponding author), UNIV ROCHESTER,SCH MED,DEPT ENVIRONM MED,ROCHESTER,NY 14642, USA.				NIEHS NIH HHS [ES-01247, ES-06484] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006484, P30ES001247] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKERBOOM T, 1984, EUR J BIOCHEM, V141, P211, DOI 10.1111/j.1432-1033.1984.tb08177.x; AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; ANDERSON ME, 1985, ARCH BIOCHEM BIOPHYS, V239, P538, DOI 10.1016/0003-9861(85)90723-4; ANDERSON ME, 1983, ANNU REV BIOCHEM, V52, P711; ARIAS IM, 1993, HEPATOLOGY, V17, P318, DOI 10.1002/hep.1840170225; BALLATORI N, 1992, AM J PHYSIOL, V263, pG617, DOI 10.1152/ajpgi.1992.263.5.G617; BALLATORI N, 1994, J BIOL CHEM, V269, P19731; BALLATORI N, 1986, J BIOL CHEM, V261, P6216; BARTOSZ G, 1993, BIOCHEM J, V292, P171, DOI 10.1042/bj2920171; BOARD P, 1992, HEPATOLOGY, V15, P722, DOI 10.1002/hep.1840150428; BOYLAND E, 1969, ADV ENZYMOL RELAT AR, V32, P172; BUTLER J, 1976, ANAL BIOCHEM, V75, P674, DOI 10.1016/0003-2697(76)90129-9; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; DUTCZAK WJ, 1994, J BIOL CHEM, V269, P9746; ELFERINK RPJO, 1991, BIOCHEM J, V274, P281, DOI 10.1042/bj2740281; ELFERINK RPJO, 1990, AM J PHYSIOL, V258, pG699, DOI 10.1152/ajpgi.1990.258.5.G699; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; Gibaldi M., 1975, PHARMACOKINETICS DRU; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HINCHMAN CA, 1994, J TOXICOL ENV HEALTH, V41, P387, DOI 10.1080/15287399409531852; HINCHMAN CA, 1991, J BIOL CHEM, V266, P22179; INOUE M, 1984, J BIOL CHEM, V259, P4998; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; ISHIKAWA T, 1989, FEBS LETT, V259, P95, DOI 10.1016/0014-5793(89)81503-0; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; KOBAYASHI K, 1991, BIOCHEM BIOPH RES CO, V176, P622, DOI 10.1016/S0006-291X(05)80229-3; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; KONDO T, 1982, EUR J BIOCHEM, V125, P551, DOI 10.1111/j.1432-1033.1982.tb06717.x; LABELLE EF, 1986, BIOCHEM BIOPH RES CO, V139, P538, DOI 10.1016/S0006-291X(86)80024-9; LABELLE EF, 1986, BIOCHEM J, V238, P443, DOI 10.1042/bj2380443; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meier P J, 1993, Prog Liver Dis, V11, P27; MEIER PJ, 1984, J BIOL CHEM, V259, P614; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MOORE S, 1948, J BIOL CHEM, V176, P367; MULLER M, 1991, J BIOL CHEM, V266, P18920; NISHIDA T, 1992, J CLIN INVEST, V90, P2130, DOI 10.1172/JCI116098; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P676; PLOEMEN JHTM, 1990, BIOCHEM PHARMACOL, V40, P1631, DOI 10.1016/0006-2952(90)90465-W; Saunders BC, 1934, BIOCHEM J, V28, P1977, DOI 10.1042/bj0281977; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SCHAUB T, 1991, FEBS LETT, V279, P83, DOI 10.1016/0014-5793(91)80256-3; SIMMONS TW, 1990, BIOCHIM BIOPHYS ACTA, V1023, P462, DOI 10.1016/0005-2736(90)90140-J; SIMMONS TW, 1992, J PHARMACOL EXP THER, V262, P1182; VINCE R, 1971, J MED CHEM, V14, P402, DOI 10.1021/jm00287a006; VORE M, 1993, TOXICOL APPL PHARM, V118, P2, DOI 10.1006/taap.1993.1002; WHELAN G, 1970, J LAB CLIN MED, V75, P542; ZIMNIAK P, 1993, HEPATOLOGY, V17, P330, DOI 10.1002/hep.1840170226	53	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3594	3601		10.1074/jbc.270.8.3594	http://dx.doi.org/10.1074/jbc.270.8.3594			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876095	hybrid			2022-12-25	WOS:A1995QH68800023
J	COTE, J; BEAUDOIN, J; TACKE, R; CHABOT, B				COTE, J; BEAUDOIN, J; TACKE, R; CHABOT, B			THE U1 SMALL NUCLEAR RIBONUCLEOPROTEIN 5' SPLICE-SITE INTERACTION AFFECTS U2AF(65) BINDING TO THE DOWNSTREAM 3' SPLICE-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLYPYRIMIDINE TRACT; BIOCHEMICAL-CHARACTERIZATION; MAMMALIAN SPLICEOSOME; AUXILIARY FACTOR; U2; PROTEIN; IDENTIFICATION; PURIFICATION; SELECTION	In the gene of the neural cell adhesion molecule, the 5' splice site of the alternate exon 18 plays an important role in establishing regulated splicing profiles, To understand how the 5' splice site of exon 18 contributes to splicing regulation, we have investigated the interaction of the U2AF(65) splicing factor to pre-mRNAs that contained portions of the constitutive exon 17 or the alternate exon 18 fused to exon 19 and separated by a shortened intron, Despite sharing an identical 3' splice site, only the pre-mRNA that contained a portion of exon 17 and its associated 5' splice site displayed efficient U2AF(65) cross-linking, Strikingly, a G --> U mutation at position +6 of the intron, converting the 5' splice site of exon 18 into that of exon 17, stimulated U2AF(65) crosslinking, The improved cross-linking efficiency of U2AF(65) to a pre-mRNA carrying the 5' splice site of exon 17 required the integrity of the 5' end of U1 but not of U2 small nuclear RNA, Our results indicate that neural cell adhesion molecule 5' splice site sequences influence U2AF(65) binding through a U1 small nuclear ribonucleoprotein/U2AF interaction that occurs at the commitment stage of spliceosome assembly, before stable binding of the U2 small nuclear ribonucleoprotein, Thus, the 5' splice sites of exons 17 and 18 differentially affect U2AF(65) binding to the 3' splice site of exon 19. Factors that modulate U1 small nuclear ribonucleoprotein binding to these 5' splice sites may play a critical role in regulating exon 18 skipping,	UNIV SHERBROOKE, FAC MED, DEPT MICROBIOL, SHERBROOKE, PQ J1H 5N4, CANADA; CNRS MARSEILLE LUMINY, CTR IMMUNOL, F-13288 MARSEILLE 9, FRANCE	University of Sherbrooke; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Cote, Jocelyn/O-2351-2018; Chabot, Benoit/A-8943-2008	Cote, Jocelyn/0000-0001-9551-2284; Chabot, Benoit/0000-0003-0994-0042				ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; CHABOT B, 1992, NUCLEIC ACIDS RES, V20, P5197, DOI 10.1093/nar/20.19.5197; Chabot B., 1994, RNA PROCESSING PRACT, VI, P1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GRABOWSKI PJ, 1991, MOL CELL BIOL, V11, P5919, DOI 10.1128/MCB.11.12.5919; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; LABRANCHE H, 1991, NUCLEIC ACIDS RES, V19, P4509, DOI 10.1093/nar/19.16.4509; MCALLISTER G, 1989, EMBO J, V8, P1177, DOI 10.1002/j.1460-2075.1989.tb03489.x; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore MJ, 1993, RNA WORLD, P1; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; STAKNIS D, 1994, MOL CELL BIOL, V14, P2994, DOI 10.1128/MCB.14.5.2994; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; TACKE R, 1991, GENE DEV, V5, P1416, DOI 10.1101/gad.5.8.1416; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363	37	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4031	4036		10.1074/jbc.270.8.4031	http://dx.doi.org/10.1074/jbc.270.8.4031			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876151	hybrid			2022-12-25	WOS:A1995QH68800084
J	JAIN, JN; BURGEON, E; BADALIAN, TM; HOGAN, PG; RAO, A				JAIN, JN; BURGEON, E; BADALIAN, TM; HOGAN, PG; RAO, A			A SIMILAR DNA-BINDING MOTIF IN NFAT FAMILY PROTEINS AND THE REL HOMOLOGY REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; KAPPA-B; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; CYCLOSPORINE-A; C-REL; CALCINEURIN; FOS; JUN; PROMOTER	The cyclosporin-sensitive factor NFATp cooperates with Fos and Jun family proteins to regulate transcription of the interleukin 2 gene in activated T cells. We have defined a 187-amino acid fragment of NFATp, located centrally within the protein sequence, as the minimal region required for DNA binding and for complex formation with Fos and Jun. The sequence of this region of NFATp shows a low degree of similarity to the Rel homology region. One specific short sequence in NFATp (RAHYETEG), located near the NH, terminus of the DNA-binding domain, resembles a highly conserved sequence (RFRYxCEG) that is located near the NH, terminus of the Rel homology region and that has been implicated in DNA binding by Rel family proteins. Mutational analysis demonstrates that the residues in this sequence that are identical in NFATp, and Rel family proteins contribute to DNA binding by NFATp. Further, mutation of the threonine residue in this sequence to cysteine, as in Rel proteins, confers on NFATp a sensitivity to sulfhydryl modification similar to that of Rel family proteins. The results suggest that NFATp and Rel family proteins bind to DNA using similar structural motifs.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA042471, R37CA042471] Funding Source: NIH RePORTER; NCI NIH HHS [CA42471] Funding Source: Medline; NIGMS NIH HHS [GM46227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BUISE LH, 1993, MOL CELL BIOL, V13, P1911; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COLEMAN TA, 1993, MOL CELL BIOL, V13, P3850, DOI 10.1128/MCB.13.7.3850; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; NOLAN GP, 1994, CELL, V77, P1; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; YASEEN NR, 1994, MOL CELL BIOL, V14, P6886, DOI 10.1128/MCB.14.10.6886	41	128	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4138	4145		10.1074/jbc.270.8.4138	http://dx.doi.org/10.1074/jbc.270.8.4138			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876165	hybrid			2022-12-25	WOS:A1995QH68800099
J	KOBAYASHI, M; SHOUN, H				KOBAYASHI, M; SHOUN, H			THE COPPER-CONTAINING DISSIMILATORY NITRITE REDUCTASE INVOLVED IN THE DENITRIFYING SYSTEM OF THE FUNGUS FUSARIUM-OXYSPORUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACHROMOBACTER-CYCLOCLASTES; INDUCIBLE CYTOCHROME-P-450; ALCALIGENES-FAECALIS; DENITRIFICATION; PURIFICATION; XYLOSOXIDANS; BACTERIUM; PROTEINS; TYPE-1	A copper-containing nitrite reductase (Cu-NiR) was purified to homogeneity from the denitrifying fungus Fusarium oxysporum. The enzyme seemed to consist of two subunits with almost the same M(r),value of 41,800 and contains two atoms of copper per subunit. The electron paramagnetic resonance spectrum showed that both type 1 and type 2 copper centers are present in the protein, whereas the visible absorption spectrum exhibited a sole and strong absorption maximum at 595 nm, causing a blue but not green color. The reaction product due to the Cu-NiR was mainly nitric oxide (NO), whereas a stoichiometric amount of nitrous oxide (N2O) was formed when cytochrome P-450nor was further added 60 the assay system. Therefore, the denitrifying (N2O forming) nitrite reductase activity that we had detected in the cell-free extract of the denitrifying cells (Shoun, Il., and Tanimoto, T. (1991) J. Biol. Chem. 266, 11078-11082) could be reconstituted upon combination of the purified Cu-NiR and P-450nor. The K-m, for nitrite and specific activity at pH 7.0 were estimated as 49 mu M and 447 mu mol NO.min(-1).mg protein(-1), respectively. Its activity was strongly inhibited by cyanide, carbon monoxide, and diethyldithiocarbamate, whereas enormously restored by the addition of cupric ions. An azurin-like blue copper protein (M(r) = 15,000) and a cytochrome c were also isolated from the same fungus, both of which together with cytochrome c of the yeast Saccharomyces cerevisiae were effective in donating electrons to the fungal Cu-NiR. The result suggested that the physiological electron donor of the Cu-NiR is the respiratory electron transport system. The intracellular localization of Cu-NiR was investigated, and it was suggested that the Cu-NiR localizes in an organelle such as mitochondrion. These findings showed the identity in many aspects between the fungal nitrite reductase and bacterial dissimilatory Cu-NiRs. This is the first isolation of dissimilatory NiR from a eukaryote.	UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba								ABRAHAM ZHL, 1993, BIOCHEM J, V295, P587, DOI 10.1042/bj2950587; ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; [Anonymous], 2002, HIST PHIL LIFE SCI; COYNE MS, 1990, J BACTERIOL, V172, P2558, DOI 10.1128/jb.172.5.2558-2562.1990; DENARIAZ G, 1991, BIOCHIM BIOPHYS ACTA, V1056, P225, DOI 10.1016/S0005-2728(05)80053-2; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; GORETSKI J, 1988, J BIOL CHEM, V263, P2316; GROSSMANN JG, 1993, BIOCHEMISTRY-US, V32, P7360, DOI 10.1021/bi00080a005; HOWES BD, 1994, BIOCHEMISTRY-US, V33, P3171, DOI 10.1021/bi00177a005; IWASAKI H, 1971, J BIOCHEM, V69, P847, DOI 10.1093/oxfordjournals.jbchem.a129536; IWASAKI H, 1972, J BIOCHEM, V71, P645; IWASAKI H, 1975, J BIOCHEM-TOKYO, V78, P355, DOI 10.1093/oxfordjournals.jbchem.a130915; JACKSON MA, 1991, FEBS LETT, V291, P41, DOI 10.1016/0014-5793(91)81099-T; JOHN P, 1975, NATURE, V254, P495, DOI 10.1038/254495a0; KAKUTANI T, 1981, J BIOCHEM, V89, P453, DOI 10.1093/oxfordjournals.jbchem.a133220; KIZAWA H, 1991, J BIOL CHEM, V266, P10632; KNOWLES R, 1982, MICROBIOL REV, V46, P43, DOI 10.1128/MMBR.46.1.43-70.1982; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; LIU MY, 1986, J BACTERIOL, V166, P604, DOI 10.1128/jb.166.2.604-608.1986; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASUKO M, 1984, J BIOCHEM, V96, P447, DOI 10.1093/oxfordjournals.jbchem.a134856; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; Payne W. J., 1981, DENITRIFICATION; SAWADA E, 1978, PLANT CELL PHYSIOL, V19, P1339; SHOUN H, 1983, J BIOCHEM, V94, P1219, DOI 10.1093/oxfordjournals.jbchem.a134467; SHOUN H, 1992, FEMS MICROBIOL LETT, V94, P277, DOI 10.1111/j.1574-6968.1992.tb05331.x; SHOUN H, 1989, FEBS LETT, V244, P11, DOI 10.1016/0014-5793(89)81151-2; SHOUN H, 1991, J BIOL CHEM, V266, P11078; SUZUKI S, 1993, INORG CHIM ACTA, V208, P107, DOI 10.1016/S0020-1693(00)82892-3; TOMURA D, 1994, J BIOCHEM-TOKYO, V116, P88, DOI 10.1093/oxfordjournals.jbchem.a124508; WEBER K, 1969, J BIOL CHEM, V244, P4406; YAMANAKA T, 1964, NATURE, V204, P253, DOI 10.1038/204253a0; ZUMFT WG, 1987, EUR J BIOCHEM, V168, P301, DOI 10.1111/j.1432-1033.1987.tb13421.x; Zumft WG, 1992, PROKARYOTES, P554	34	81	85	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4146	4151		10.1074/jbc.270.8.4146	http://dx.doi.org/10.1074/jbc.270.8.4146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876166	hybrid			2022-12-25	WOS:A1995QH68800100
J	SHAO, HN; LOU, LD; PANDEY, A; VERDERAME, MF; SIEVER, DA; DIXIT, VM				SHAO, HN; LOU, LD; PANDEY, A; VERDERAME, MF; SIEVER, DA; DIXIT, VM			CDNA CLONING AND CHARACTERIZATION OF A CEK7 RECEPTOR PROTEIN-TYROSINE KINASE LIGAND THAT IS IDENTICAL TO THE LIGAND (ELF-1) FOR THE MEK-4 AND SEK RECEPTOR PROTEIN-TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACID-REQUIREMENTS ADJACENT; MEMBRANE-PROTEINS; GENE; CLEAVAGE; ATTACHMENT; ENCODES; MOUSE; CELLS; SITE	We have isolated a murine cDNA encoding a ligand for the Cek7 receptor protein-tyrosine kinase (RPTK), a member of the Eph/Eck RPTK subfamily. Sequence analysis predicts an open reading frame of 209 amino acids with a predicted molecular mass of 24 kDa. The Cek7 ligand shows a 48% sequence identity at the protein level to B61, a ligand for the related Eck RPTK, 30% to the Cek5 ligand, 59% to the recently cloned Ehk1-L, and identity to ELF-1, a recently described ligand for the Mek4 and Sek RPTKs. The expressed Cek7 ligand is functionally active as it induces autophosphorylation of the Cek7 RPTK.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; PENN STATE UNIV,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health			Pandey, Akhilesh/B-4127-2009; dixit, vishva m/A-4496-2012	Pandey, Akhilesh/0000-0001-9943-6127; dixit, vishva m/0000-0001-6983-0326; Verderame, Michael F./0000-0001-7046-0879	NCI NIH HHS [CA60395, CA52791] Funding Source: Medline; NIDDK NIH HHS [DK39255] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA060395, R01CA052791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6314; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; SAJJADI FG, 1991, NEW BIOL, V3, P769; SEED B, 1987, P NATL ACAD SCI USA, V87, P3365; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SIEVER DA, 1994, GENE, V148, P219, DOI 10.1016/0378-1119(94)90692-0; SMITH PL, 1994, J BIOL CHEM, V269, P15162; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	25	38	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3467	3470		10.1074/jbc.270.8.3467	http://dx.doi.org/10.1074/jbc.270.8.3467			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876076	hybrid			2022-12-25	WOS:A1995QH68800002
J	FRANZUSOFF, A; VOLPE, AM; JOSSE, D; PICHUANTES, S; WOLF, JR				FRANZUSOFF, A; VOLPE, AM; JOSSE, D; PICHUANTES, S; WOLF, JR			BIOCHEMICAL AND GENETIC DEFINITION OF THE CELLULAR PROTEASE REQUIRED FOR HIV-1 GP160 PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; YEAST SACCHAROMYCES-CEREVISIAE; PSEUDOMONAS EXOTOXIN-A; ENVELOPE GLYCOPROTEIN; KEX2 PROTEASE; GOLGI-APPARATUS; ALPHA-FACTOR; PROHORMONE; EXPRESSION; PRECURSOR	The surface glycoproteins of enveloped viruses bind to target cell receptors and trigger membrane fusion for infection. The human immunodeficiency virus 1 (HIV-1) envelope glycoproteins gp120 (CD4 binding protein) and gp41 (transmembrane fusion protein) are initially synthesized as a gp160 precursor. The intracellular cleavage of gp160 by a host cell protease during transit through the secretory pathway is essential for viral activities such as infectivity, membrane fusion, and T-cell syncytium formation. We report that gp160 biogenesis, protein processing, and cell-surface expression have been successfully reproduced in the yeast Saccharomy cerevisiae. Genetic and biochemical approaches are used for defining that the unique cellular protease, Kex2p, is directly responsible for HIV-gp160 processing in yeast, in vivo and in vitro. The yeast system described in this report represents a powerful strategy for identifying, characterizing and inhibiting the host T-cell protease essential for HIV infectivity and AIDS.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	FRANZUSOFF, A (corresponding author), UNIV COLORADO,HLTH SCI CTR,SCH MED,DEPT CELLULAR & STRUCT BIOL,BOX B-111,4200 E 9TH AVE,DENVER,CO 80262, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034747, R21AI034747] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-34747] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BARR PJ, 1987, VACCINE, V5, P90, DOI 10.1016/0264-410X(87)90053-3; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; DECROLY E, 1994, J BIOL CHEM, V269, P12240; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991; FRANZUSOFF A, 1992, NATURE, V355, P173, DOI 10.1038/355173a0; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HASELTINE W, 1991, FASEB J, V5, P2849; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INOCENCIO NM, 1993, J VIROL, V67, P593, DOI 10.1128/JVI.67.1.593-595.1993; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KIDO H, 1993, J BIOL CHEM, V268, P13406; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; PICHUANTES S, 1995, IN PRESS PRINCIPLES; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; RENNEISEN K, 1990, J BIOL CHEM, V265, P16337; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER BD, 1987, P NATL ACAD SCI USA, V84, P8120, DOI 10.1073/pnas.84.22.8120; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580	42	27	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3154	3159		10.1074/jbc.270.7.3154	http://dx.doi.org/10.1074/jbc.270.7.3154			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852398	hybrid			2022-12-25	WOS:A1995QG47100041
J	BELOGRUDOV, GI; TOMICH, JM; HATEFI, Y				BELOGRUDOV, GI; TOMICH, JM; HATEFI, Y			ATP SYNTHASE COMPLEX - PROXIMITIES OF SUBUNITS IN BOVINE SUBMITOCHONDRIAL PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVITY-CONFERRING PROTEIN; DICYCLOHEXYLCARBODIIMIDE-BINDING PROTEIN; OXIDATIVE-PHOSPHORYLATION SYSTEM; COUPLING FACTOR-B; ESCHERICHIA-COLI; HEART-MITOCHONDRIA; DELTA-SUBUNIT; BEEF-HEART; ALPHA-SUBUNIT; F1-ATPASE	The catalytic sector, F-1, and the membrane sector, F-0, of the mitochondrial ATP synthase complex are joined together by a 45-Angstrom-long stalk. Knowledge of the composition and structure of the stalk is crucial to investigating the mechanism of conformational energy transfer between F-0 and F-1. This paper reports on the near neighbor relationships of the stalk subunits with one another and with the subunits of F-1 and F-0, as revealed by cross-linking experiments. The preparations subjected to cross-linking were bovine heart submitochondrial particles (SMP) and F-1-deficient SMP. The cross-linkers were three reagents of different chemical specificities and different lengths of cross-linking from zero to 10 Angstrom. Cross-linked products were identified after gel electrophoresis of the particles and immunoblotting with subunit-specific antibodies to the individual subunits alpha, beta gamma, delta, OSCP, F-6, A6L, a (subunit 6), b, c, and d. The results suggested that the two b subunits form the principal stem of the stalk to which OSCP, d, and F-6 are bound independent of one another. Subunits b, OSCP, d, and F-6 cross-linked to alpha and/or beta, but not to gamma or delta. The COOH-terminal half of A6L, which is extramembranous, crosslinked to d but not to any other stalk or F-1 subunit. No cross-links of subunits a and c with any stalk or F-1 subunits were detected. In F-1-deficient SMP, cross-linked b + b and d + F-6 dimers appeared, and the extent of cross-linking between b and OSCP diminished greatly. The addition of F-1 to F-1-deficient particles appeared to reverse these changes. Treatment of F-1-deficient particles with trypsin rapidly hydrolyzed away OSCP and F-6, fragmented b to membrane bound 18-, 12-, and 8-9-kDa antigenic fragments, which cross-linked to d and/or with one another. Trypsin also removed the COOH-terminal part of A6L, but the remainder still cross-linked to subunit d. Models showing the near neighbor relationships of the stalk subunits with one another and with the alpha and beta subunits at a level near the proximal end (bottom) of F-1 and at the membrane-matrix interface are presented.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA; KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, MANHATTAN, KS 66506 USA	Scripps Research Institute; Kansas State University					NIDDK NIH HHS [DK08126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK008126, R37DK008126] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; ARCHINARD P, 1986, BIOCHEMISTRY-US, V25, P3397, DOI 10.1021/bi00359a045; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; BELOGRUDOV GI, 1988, BIOL MEMBRANY, V5, P677; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1992, J BIOENERG BIOMEMBR, V24, P435, DOI 10.1007/BF00762359; COLLINSON IR, 1994, BIOCHEM J, V303, P639, DOI 10.1042/bj3030639; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; DUBACHEV GE, 1993, FEBS LETT, V336, P181, DOI 10.1016/0014-5793(93)81636-E; DUNN SD, 1980, J BIOL CHEM, V255, P6891; DUNN SD, 1981, ARCH BIOCHEM BIOPHYS, V210, P421, DOI 10.1016/0003-9861(81)90206-X; DUPUIS A, 1983, BIOCHEMISTRY-US, V22, P5951, DOI 10.1021/bi00294a039; DUPUIS A, 1985, BIOCHEMISTRY-US, V24, P728, DOI 10.1021/bi00324a029; EYTAN GD, 1990, J BIOL CHEM, V265, P12949; FESSENDENRADEN JM, 1972, J BIOL CHEM, V247, P2351; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GALANTE YM, 1981, ARCH BIOCHEM BIOPHYS, V211, P643, DOI 10.1016/0003-9861(81)90500-2; GALANTE YM, 1979, J BIOL CHEM, V254, P2372; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; GRAF T, 1978, FEBS LETT, V94, P218, DOI 10.1016/0014-5793(78)80941-7; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; HUNDAL T, 1983, FEBS LETT, V162, P5, DOI 10.1016/0014-5793(83)81038-2; JOSHI S, 1990, J BIOL CHEM, V265, P14518; KIEHL R, 1980, BIOCHEMISTRY-US, V19, P541, DOI 10.1021/bi00544a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTTER R, 1993, BIOCHEM J, V295, P799, DOI 10.1042/bj2950799; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; MATSUNOYAGI A, 1990, J BIOL CHEM, V265, P82; MATSUNOYAGI A, 1984, BIOCHEMISTRY-US, V23, P3508, DOI 10.1021/bi00310a019; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OVCHINNIKOV YA, 1984, FEBS LETT, V166, P19, DOI 10.1016/0014-5793(84)80036-8; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; RACKER E, 1967, J BIOL CHEM, V242, P2547; SANADI DR, 1982, BIOCHIM BIOPHYS ACTA, V683, P39; SEBALD W, 1979, EUR J BIOCHEM, V93, P587, DOI 10.1111/j.1432-1033.1979.tb12859.x; Senior A E, 1979, Methods Enzymol, V55, P391; SOPER JW, 1979, J BIOL CHEM, V254, P1170; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; STEFFENS K, 1987, J BIOL CHEM, V262, P5866; STEINMEIER RC, 1979, BIOCHEMISTRY-US, V18, P11, DOI 10.1021/bi00568a002; STIGGALL DL, 1979, ARCH BIOCHEM BIOPHYS, V196, P638, DOI 10.1016/0003-9861(79)90318-7; STIGGALL DL, 1978, J BIOL CHEM, V253, P956; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WALKER JE, 1982, FEBS LETT, V146, P393, DOI 10.1016/0014-5793(82)80960-5; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; YAGI T, 1984, BIOCHEMISTRY-US, V23, P2449, DOI 10.1021/bi00306a020; YOU KS, 1976, BIOCHIM BIOPHYS ACTA, V423, P398, DOI 10.1016/0005-2728(76)90196-1; ZANOTTI F, 1988, FEBS LETT, V237, P9, DOI 10.1016/0014-5793(88)80161-3	57	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2053	2060		10.1074/jbc.270.5.2053	http://dx.doi.org/10.1074/jbc.270.5.2053			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836433	hybrid			2022-12-25	WOS:A1995QE49300014
J	IZBAN, MG; SAMKURASHVILI, I; LUSE, DS				IZBAN, MG; SAMKURASHVILI, I; LUSE, DS			RNA-POLYMERASE-II TERNARY COMPLEXES MAY BECOME ARRESTED AFTER TRANSCRIBING TO WITHIN 10 BASES OF THE END OF LINEAR TEMPLATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-SII; TRANSCRIPTION ELONGATION; DEPENDENT TRANSCRIPTION; ATTENUATION SITE; INVITRO; DNA; TERMINATION; CLEAVAGE; IDENTIFICATION; INITIATION	In the presence of elongation factor SII, arrested RNA polymerase II ternary complexes cleave 7-17 nucleotides from the 3'-ends of their nascent RNAs. It has been shown that transcription of linear templates generates apparent run-off RNAs, which are nevertheless truncated upon incubation with SII. By using high resolution gels, we demonstrate that transcription of blunt or 3'-overhung templates with RNA polymerase II generates two populations of ternary complexes, The first class pauses 5-10 bases prior to the end of the template strand, These complexes respond to SII by cleaving approximately 9-17 nucleotide RNAs from their 3'-ends and therefore may be termed arrested, A second class of complexes, which fail to respond to SII, transcribe to within 3 bases of the end of the template strand, These complexes appear to have run off the template since they have released their nascent RNAs. Run-off transcription occurs on all types of templates, but it is the predominant reaction on DNAs with 5'-overhung ends. Thus, RNA polymerase II ternary complexes that retain 5-10 bases of contact with the template strand downstream of the catalytic site become arrested, Further reduction of downstream template contacts can lead to termination, We also show that the addition of Sarkosyl to the elongation reactions significantly changes the pattern of transcriptional arrest near the end of linear templates.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; CAHMBERLIN MJ, 1994, HARVEY LECT, P1; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JACOB GA, 1994, J BIOL CHEM, V269, P3655; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KESSLER M, 1989, J BIOL CHEM, V264, P9785; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RESNEKOV O, 1989, J BIOL CHEM, V264, P9953; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	33	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2290	2297		10.1074/jbc.270.5.2290	http://dx.doi.org/10.1074/jbc.270.5.2290			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836462	hybrid			2022-12-25	WOS:A1995QE49300049
J	LI, LX; MACPHERSON, JJ; ADELSTEIN, S; BUNN, CL; ATKINSON, K; PHADKE, K; KRILIS, SA				LI, LX; MACPHERSON, JJ; ADELSTEIN, S; BUNN, CL; ATKINSON, K; PHADKE, K; KRILIS, SA			CONDITIONED MEDIA FROM A CELL STRAIN DERIVED FROM A PATIENT WITH MASTOCYTOSIS INDUCES PREFERENTIAL DEVELOPMENT OF CELLS THAT POSSESS HIGH-AFFINITY IGE RECEPTORS AND THE GRANULE PROTEASE PHENOTYPE OF MATURE CUTANEOUS MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; C-KIT LIGAND; MURINE BONE-MARROW; FETAL LIVER-CELLS; GROWTH-FACTOR; RECOMBINANT HUMAN; CARBOXYPEPTIDASE-A; COMPLEMENTARY-DNA; HUMAN TRYPTASE; MOUSE	We have demonstrated for the first time that a conditioned medium from a human cell strain can induce morphologically mature mast cells that express Fc epsilon RI and three mast cell-specific proteases from normal bone marrow progenitor cells. In contrast, recombinant human Kit ligand induced the differentiation of mast cells that were tryptase-positive but negative for chymase, carboxypeptidase, and Fc epsilon RI. This data indicates that factors other than Kit ligand are critical for inducing the differentiation and maturation of mast cells in the human. The HBM-M cell was originally derived from a patient with mastocytosis, As mastocytosis is thought to represent a reactive hyperplasia rather than a mast cell malignancy, the factor secreted by the HBM-M cell strain could well be responsible for the mast cell hyperplasia seen in some patients with mastocytosis.	ST GEORGE HOSP,DEPT IMMUNOL ALLERGY & INFECT DIS,KOGARAH,NSW 2217,AUSTRALIA; ST GEORGE HOSP,DEPT ONCOL,KOGARAH,NSW 2217,AUSTRALIA; UNIV NEW S WALES,SCH MED,KENSINGTON,NSW 2033,AUSTRALIA; ST VINCENTS HOSP,DEPT HAEMATOL,SYDNEY,NSW 2010,AUSTRALIA	St George Hospital; St George Hospital; University of New South Wales Sydney; St Vincents Hospital Sydney			Adelstein, Stephen/I-7936-2016; Macpherson, Janet/D-8702-2012	Adelstein, Stephen/0000-0001-7221-6298; Macpherson, Janet/0000-0003-0702-9546				BRESSLER RB, 1989, J IMMUNOL, V143, P135; CAUGHEY GH, 1991, J BIOL CHEM, V266, P12956; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DEVRIES P, 1991, J EXP MED, V173, P1205, DOI 10.1084/jem.173.5.1205; DVORAK AM, 1989, LAB INVEST, V61, P116; EKLUND KK, 1993, J IMMUNOL, V151, P4266; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FURITSU T, 1989, P NATL ACAD SCI USA, V86, P10039, DOI 10.1073/pnas.86.24.10039; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1992, J BIOL CHEM, V267, P8473; GOLDSTEIN SM, 1987, J IMMUNOL, V139, P2724; GOLDSTEIN SM, 1989, J CLIN INVEST, V83, P1630, DOI 10.1172/JCI114061; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HAMAGUCHI Y, 1987, J EXP MED, V165, P268, DOI 10.1084/jem.165.1.268; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; IHLE JN, 1983, J IMMUNOL, V131, P282; IRANI AA, 1992, IMMUNOLOGY, V77, P136; IRANI AMA, 1992, BLOOD, V80, P3009; IRANI AMA, 1991, J IMMUNOL, V147, P247; ISHIZAKA T, 1991, INT ARCH ALLER A IMM, V94, P116, DOI 10.1159/000235341; ISHIZAKA T, 1989, MAST CELL BASOPHIL D, P39; KILGUS O, 1993, ADV EXP MED BIOL, V329, P237; KIRAHENBAUM AS, 1992, J IMMUNOL, V148, P772; KRILIS SA, 1991, BLOOD, V78, P290; KRILIS SA, 1992, BLOOD, V79, P144, DOI 10.1182/blood.V79.1.144.bloodjournal791144; KURIU A, 1991, BLOOD, V78, P2834; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P3431; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P494; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; MACPHERSON JL, 1992, INT ARCH ALLERGY IMM, V99, P346, DOI 10.1159/000236281; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; NILSSON G, 1993, IMMUNOLOGY, V79, P325; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; REYNOLDS DS, 1992, J CLIN INVEST, V89, P273, DOI 10.1172/JCI115571; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SCHECHTER NM, 1986, J IMMUNOL, V137, P962; SCHNEIDER E, 1987, J IMMUNOL, V139, P3710; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TOKSOZ D, 1992, P NATL ACAD SCI USA, V89, P7350, DOI 10.1073/pnas.89.16.7350; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; TSUJI K, 1991, J CELL PHYSIOL, V148, P362, DOI 10.1002/jcp.1041480306; URATA H, 1991, J BIOL CHEM, V266, P17173; VALENT P, 1992, BLOOD, V80, P2237; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	54	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2258	2263		10.1074/jbc.270.5.2258	http://dx.doi.org/10.1074/jbc.270.5.2258			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836459	hybrid			2022-12-25	WOS:A1995QE49300044
J	NORDSTROM, T; ROTSTEIN, OD; ROMANEK, R; ASOTRA, S; HEERSCHE, JNM; MANOLSON, MF; BRISSEAU, GF; GRINSTEIN, S				NORDSTROM, T; ROTSTEIN, OD; ROMANEK, R; ASOTRA, S; HEERSCHE, JNM; MANOLSON, MF; BRISSEAU, GF; GRINSTEIN, S			REGULATION OF CYTOPLASMIC PH IN OSTEOCLASTS - CONTRIBUTION OF PROTON PUMPS AND A PROTON-SELECTIVE CONDUCTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-ION CURRENTS; VACUOLAR H+-ATPASE; BONE-RESORPTION; INTRACELLULAR PH; CARBONIC-ANHYDRASE; CHLORIDE-BICARBONATE; PARATHYROID HORMONE; RABBIT OSTEOCLASTS; AVIAN OSTEOCLASTS; PLASMA-MEMBRANE	Osteoclasts resorb bone by secreting protons into an extracellular resorption zone through vacuolar-type proton pumps located in the ruffled border, The present study was undertaken to evaluate whether proton pumps also contribute to intracellular pH (pH(i)) regulation. Fluorescence imaging and photometry, and electrophysiological methods were used to characterize the mechanisms of pH regulation in isolated rabbit osteoclasts. The fluorescence of single osteoclasts cultured on glass coverslips and loaded with a pH-sensitive indicator was measured in nominally HCO3--free solutions. When suspended in Na+-rich medium, the cells recovered from an acute acid load primarily by means of an amiloride sensitive Na+/H+ antiporter. However, rapid recovery was also observed in Na+-free medium when K+ was used as the substitute. Bafilomycin-sensitive, vacuolar-type pumps were found to contribute marginally to pH regulation and no evidence was found for K+/H+ exchange. In contrast, pH(i) recovery in high K+ medium was largely attributed to a Zn2+-sensitive proton conductive pathway. The properties of this conductance were analyzed by patch-clamping osteoclasts in the whole-cell configuration. Depolarizing pulses induced a slowly developing outward current and a concomitant cytosolic alkalinization. Determination of the reversal potential during ion substitution experiments indicated that the current was due to H+ (equivalent) translocation across the membrane. The H+ current was greatly stimulated by reducing pH(i), consistent with a homeostatic role of the conductive pathway during intracellular acidosis. These results suggest that vacuolar-type proton pumps contribute minimally to the recovery of cytoplasmic pH from intracellular acid loads. Instead, the data indicate the presence of a pH- and membrane potential-sensitive H+ conductance in the plasma membrane of osteoclasts. This conductance may contribute to translocation of charges and acid equivalents during bone resorption and/or generation of reactive oxygen intermediates by osteoclasts.	HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; TORONTO GEN HOSP,DEPT SURG,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,TORONTO,ON M5G 2C4,CANADA; UNIV TORONTO,FAC DENT,TORONTO,ON M5G 1G6,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto			Nordström, Tommy/H-9111-2016	Nordström, Tommy/0000-0002-2153-5819; Manolson, Morris/0000-0001-8755-5460				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ARKETT SA, 1994, J MEMBRANE BIOL, V140, P163; ARKETT SA, 1992, J PHYSIOL-LONDON, V458, P633, DOI 10.1113/jphysiol.1992.sp019438; ASOTRA S, 1994, J BONE MINER RES, V9, P1115; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; DECOURSEY TE, 1994, J MEMBRANE BIOL, V141, P203; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; FERRIER J, 1986, J CELL PHYSIOL, V128, P23, DOI 10.1002/jcp.1041280105; FUSHIMI H, 1993, DIABETES RES CLIN PR, V20, P191, DOI 10.1016/0168-8227(93)90077-I; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; GOLDHABER P, 1987, AM J PHYSIOL, V253, pE90, DOI 10.1152/ajpendo.1987.253.1.E90; GRINSTEIN S, 1994, AM J PHYSIOL-CELL PH, V267, pC1152, DOI 10.1152/ajpcell.1994.267.4.C1152; HALL GE, 1987, CALCIFIED TISSUE INT, V40, P212, DOI 10.1007/BF02556624; HALL TJ, 1990, J CELL PHYSIOL, V142, P420, DOI 10.1002/jcp.1041420227; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUNTER SJ, 1991, J BONE MINER RES, V6, P61; KALLIO DM, 1971, J ULTRA MOL STRUCT R, V37, P169, DOI 10.1016/S0022-5320(71)80048-5; KANEHISA J, 1988, BONE, V9, P73, DOI 10.1016/8756-3282(88)90106-8; KAPUS A, 1993, J GEN PHYSIOL, V102, P729, DOI 10.1085/jgp.102.4.729; KEY LL, 1990, BONE, V11, P115, DOI 10.1016/8756-3282(90)90058-7; LAITALA T, 1993, J BONE MINER RES, V8, P119; LUKACS GL, 1993, AM J PHYSIOL, V265, pC3, DOI 10.1152/ajpcell.1993.265.1.C3; MAHAUTSMITH MP, 1989, J EXP BIOL, V145, P455; MEARS DC, 1971, ENDOCRINOLOGY, V88, P1021, DOI 10.1210/endo-88-4-1021; MOONGA BS, 1994, J BONE MINER RES  S1, V9, pB236; NEUMAN WF, 1958, CHEM DYNAMICS BONE M, pCH2; RAVESLOOT JH, 1989, P NATL ACAD SCI USA, V86, P6821, DOI 10.1073/pnas.86.17.6821; REDHEAD CR, 1988, CALCIFIED TISSUE INT, V42, P237, DOI 10.1007/BF02553749; ROMANEK R, 1994, IN PRESS CELL BIOL L; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SHIBATA Y, 1993, J BONE MINER RES, V8, pS379; SHIBUTANI T, 1993, J BONE MINER RES, V8, P331; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SIMMS SM, 1989, AM J PHYSIOL, V256, pC1277; SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006-291X(90)91709-2; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; TETI A, 1989, J CLIN INVEST, V83, P227, DOI 10.1172/JCI113863; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSIEN RY, 1989, FLUORESCENCE MICROSC, P127; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; WALSH CA, 1990, J BONE MINER RES, V5, P1243; XIE XS, 1993, J BIOL CHEM, V268, P25063; YAMAGUCHI M, 1987, BIOCHEM PHARMACOL, V36, P4007, DOI 10.1016/0006-2952(87)90471-0; ZHANG K, 1992, J BIOL CHEM, V267, P14539	47	82	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2203	2212		10.1074/jbc.270.5.2203	http://dx.doi.org/10.1074/jbc.270.5.2203			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836451	hybrid			2022-12-25	WOS:A1995QE49300036
J	CARPENTIER, JL; MCCLAIN, D				CARPENTIER, JL; MCCLAIN, D			INSULIN-RECEPTOR KINASE ACTIVATION RELEASES A CONSTRAINT MAINTAINING THE RECEPTOR ON MICROVILLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LIGAND-INDUCED INTERNALIZATION; CULTURED HUMAN-LYMPHOCYTES; LOW-DENSITY-LIPOPROTEIN; COATED PITS; MEDIATED ENDOCYTOSIS; JUXTAMEMBRANE REGION; RAT HEPATOCYTES; SURFACE REDISTRIBUTION; CLATHRIN	To examine whether the surface redistribution of the insulin receptor from microvilli, where it sits in its unoccupied form, to the nonvillous domain, where it is internalized through clathrin-coated pits, is an active movement or a passive redistribution linked to the release of a restraint maintaining it on microvilli, we have generated a mutated insulin receptor with a truncation of exons 17-22 and tracked it biochemically and morphologically. Biochemical analysis indicates that this mutated receptor is constitutively internalized and recycled even in the absence of ligand. Quantitative electron microscope autoradiography analysis reveals that it does not preferentially associate with microvilli in its unoccupied form but is normally segregated in clathrin-coated pits through the preserved signal sequence(s) of exon 16. We conclude that (a) insulin receptor internalization is initiated through receptor kinase activation and autophosphorylation, which free the receptor from constraints maintaining it on microvilli; (b) the signal sequences contained in exon 16 are entirely sufficient to promote clathrin coated pit-mediated internalization of insulin receptors; (c) these sequences are not uncovered by kinase activation; and (d) the ''code'' maintaining the unoccupied receptors on microvilli is contained within exons 17-21 of the receptor.	UNIV MISSISSIPPI, MED CTR, DEPT MED, JACKSON, MS 39218 USA; VET ADM MED CTR, DIV ENDOCRINOL, JACKSON, MS USA	University of Mississippi; University of Mississippi Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	CARPENTIER, JL (corresponding author), UNIV GENEVA, UNIV MED CTR, SCH MED, DEPT MORPHOL, 1 RUE MICHEL SERVET, CH-1211 GENEVA 4, SWITZERLAND.							AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CARPENTIER JL, 1978, J CLIN INVEST, V61, P1057, DOI 10.1172/JCI109005; CARPENTIER JL, 1993, HISTOCHEMISTRY, V100, P169, DOI 10.1007/BF00269090; CARPENTIER JL, 1989, DIABETOLOGIA, V32, P627; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1982, J CELL BIOL, V95, P73, DOI 10.1083/jcb.95.1.73; CARPENTIER JL, 1981, J CELL BIOL, V91, P17, DOI 10.1083/jcb.91.1.17; CARPENTIER JL, 1985, DIABETES, V34, P1002, DOI 10.2337/diabetes.34.10.1002; CARPENTIER JL, 1979, J CLIN INVEST, V63, P1249, DOI 10.1172/JCI109420; CARPENTIER JL, 1993, J CELL BIOL, V118, P831; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; FAN JY, 1982, P NATL ACAD SCI-BIOL, V79, P7788, DOI 10.1073/pnas.79.24.7788; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRUNBERGER G, 1985, J LAB CLIN MED, V106, P211; HEIDENREICH KA, 1984, J BIOL CHEM, V259, P6511; JADOT M, 1992, J BIOL CHEM, V267, P11069; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LECONTE I, 1994, J BIOL CHEM, V269, P18062; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEVY JR, 1986, ENDOCRINOLOGY, V119, P572, DOI 10.1210/endo-119-2-572; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; PACCAUD JP, 1993, J BIOL CHEM, V268, P23191; PACCAUD JP, 1992, J BIOL CHEM, V267, P13101; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SMITH RM, 1991, J BIOL CHEM, V266, P17522; SMITH RM, 1993, ENDOCRINOLOGY, V132, P1453, DOI 10.1210/en.132.4.1453; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; THIES RS, 1990, J BIOL CHEM, V265, P10132; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WELSH JB, 1994, MOL BIOL CELL, V5, P539, DOI 10.1091/mbc.5.5.539; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4	53	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5001	5006		10.1074/jbc.270.10.5001	http://dx.doi.org/10.1074/jbc.270.10.5001			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890606	hybrid			2022-12-25	WOS:A1995QL58000011
J	FUJITAYOSHIGAKI, J; SHIROUZU, M; ITO, Y; HATTORI, S; FURUYAMA, S; NISHIMURA, S; YOKOYAMA, S				FUJITAYOSHIGAKI, J; SHIROUZU, M; ITO, Y; HATTORI, S; FURUYAMA, S; NISHIMURA, S; YOKOYAMA, S			CONSTITUTIVE EFFECTOR REGION ON THE C-TERMINAL SIDE OF SWITCH-I OF THE RAS PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; GTPASE-ACTIVATING PROTEIN; AMINO-ACID-RESIDUES; MAP KINASE; HA-RAS; PC12 CELLS; SIGNAL TRANSDUCTION; GENE-PRODUCT; MOLECULAR-CLONING; NEURITE OUTGROWTH	The ''switch I'' region (Asp(30)-Asp(38)) of the Ras protein takes remarkably different conformations between the GDP- and GTP-bound forms and coincides with the so-called ''effector region.'' As for a region on the C-terminal side of switch I, the V45E and G48C mutants of Pas failed to promote neurite outgrowth of PC12 cells (Fujita-Yoshigaki, J., Shirouzu, Pd, Koide, H., Nishimura, S., and Yokoyama, S. (1991) FEBS Lett 294, 187-190). In the present study, we performed alanine-scanning mutagenesis within the region Lys(42)-Ile(55) Of Pas and found that the K42A, I46A, G48A, E49A, and L53A mutations significantly reduced the neurite-inducing activity. This is an effector region by definition, but its conformation is known to be unaffected by GDP --> GTP exchange. So, this region is referred to as a ''constitutive'' effector (E(c)) region, distinguished from switch I, a ''switch'' effector (E(s)) region. The E(c) region mutants exhibiting no neurite-inducing activity were found to be correlatably unable to activate mitogen-activated protein (MAP) kinase in PC12 cells. Therefore, the E(c) region is essential for the MAP kinase activation in PC12 cells, whereas mutations in this region only negligibly affect the binding of Ras to Raf-1 (Shirouzu, M., Koide, H., Fujita-Yoshigaki, J., Oshio, Il., Toyama, Y., Yamasaki, H., Fuhrman, S. A., Villafranca, E., Kaziro, Y., and Yokoyama, S. (1994) Oncogene 9, 2153-2157).	UNIV TOKYO, SCH SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN; NIHON UNIV, SCH DENT, DEPT PHYSIOL, MATSUDO, CHIBA 271, JAPAN; INST PHYS & CHEM RES, BIODESIGN RES GRP, WAKO, SAITAMA 35101, JAPAN; NATL CTR NEUROL & PSYCHIAT, NATL INST NEUROSCI, DIV BIOCHEM & CELLULAR BIOL, KODAIRA, TOKYO 187, JAPAN; BANYU PHARMACEUT CO LTD, MERCK SHARP & DOHME RES LABS, BANYU TSUKUBA RES INST, TSUKUBA, IBARAKI 30033, JAPAN	University of Tokyo; Nihon University; RIKEN; National Center for Neurology & Psychiatry - Japan; Merck & Company			Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016; Yoshigaki, Junko/AAE-6702-2020; Ito, Yutaka/P-2604-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Ito, Yutaka/0000-0002-1030-4660; Fujita-Yoshigaki, Junko/0000-0002-3271-6498				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FUJITAYOSHIGAKI J, 1992, ONCOGENE, V7, P2019; FUJITAYOSHIGAKI J, 1991, FEBS LETT, V294, P187, DOI 10.1016/0014-5793(91)80665-P; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ITO T, 1993, P NATL ACAD SCI USA, V90, P975; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER AF, 1993, BIOCHEMISTRY-US, V32, P7367, DOI 10.1021/bi00080a006; MIURA K, 1986, JPN J CANCER RES, V77, P45; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PIZON V, 1988, ONCOGENE, V3, P201; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SEGER R, 1992, J BIOL CHEM, V267, P25628; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SHIROUZU M, 1992, ONCOGENE, V7, P475; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STEIN RB, 1986, J VIROL, V60, P782, DOI 10.1128/JVI.60.2.782-786.1986; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLUMSEN BM, 1989, NATO ADV SCI I A-LIF, V165, P165; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YAMASAKI K, 1989, BIOCHEM BIOPH RES CO, V162, P1054, DOI 10.1016/0006-291X(89)90780-8; YAMASAKI K, 1994, BIOCHEMISTRY-US, V33, P65, DOI 10.1021/bi00167a009; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	71	26	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4661	4667		10.1074/jbc.270.9.4661	http://dx.doi.org/10.1074/jbc.270.9.4661			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876237	hybrid			2022-12-25	WOS:A1995QK08400071
J	HU, MJ; BIGGER, CB; GARDNER, PD				HU, MJ; BIGGER, CB; GARDNER, PD			A NOVEL REGULATORY ELEMENT OF A NICOTINIC ACETYLCHOLINE-RECEPTOR GENE INTERACTS WITH A DNA-BINDING ACTIVITY ENRICHED IN RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; FUNCTIONAL EXPRESSION; ALPHA-SUBUNIT; GROWTH-FACTOR; FAMILY; DIVERSITY; PROMOTERS; SUBTYPES; ONCOGENE; MEMBERS	Nicotinic acetylcholine receptors are ligand-gated ion channels that play a critical role in signal transmission in the nervous system. The genes encoding the Various subunits that comprise functional acetylcholine receptors are expressed in distinct temporal and spatial patterns. Studies to understand the molecular mechanisms underlying the differential expression of the receptor subunit genes have led to the identification, in this report, of a 19-base pair cis-acting element that is required for transcriptional activation of the rat beta 4 subunit gene. Screening of computer data bases with the 19-base pair element revealed the sequence to be unique among known transcriptional regulatory elements. Loss of this element resulted in drastically reduced beta 4 promoter activity in transfected cholinergic SN17 cells. Furthermore, this element specifically interacts with nuclear proteins prepared from both SN17 cells and adult rat brain. UV cross-linking experiments indicated the presence, in SN17 nuclear extracts, of a prominent protein species (approximately 50 kDa) that interacts specifically with the Is-base pair element. These results lead us to hypothesize that interactions between the 50-kDa protein and the novel 19-base pair element are necessary for transcriptional activation of the beta 4 subunit gene.	UNIV TEXAS, HLTH SCI CTR, CTR MOLEC MED, INST BIOTECHNOL, SAN ANTONIO, TX 78245 USA; DARTMOUTH COLL SCH MED, BIOCHEM PROGRAM, HANOVER, NH 03755 USA	University of Texas System; University of Texas Health San Antonio; Dartmouth College					NINDS NIH HHS [NS30243, R01 NS030243] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030243] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; BOULTER J, 1990, J BIOL CHEM, V265, P4472; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREHM P, 1988, DEV BIOL, V129, P1, DOI 10.1016/0012-1606(88)90156-X; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DAUBAS P, 1993, P NATL ACAD SCI USA, V90, P2237, DOI 10.1073/pnas.90.6.2237; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; DINELEYMILLER K, 1992, MOL BRAIN RES, V16, P339, DOI 10.1016/0169-328X(92)90244-6; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; EVANS BA, 1985, EMBO J, V4, P133, DOI 10.1002/j.1460-2075.1985.tb02327.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HAMMOND DN, 1990, BRAIN RES, V512, P190, DOI 10.1016/0006-8993(90)90626-M; HEINEMANN S, 1990, PROG BRAIN RES, V86, P195; HU MJ, 1994, J NEUROCHEM, V62, P392; LAMAR E, 1990, SOC NEUR ABSTR, V16, P581; LUETJE CW, 1991, J NEUROSCI, V11, P837; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MIHOVILOVIC M, 1993, SOC NEUR ABSTR, V123, P13; MORRIS BJ, 1990, MOL BRAIN RES, V7, P305, DOI 10.1016/0169-328X(90)90081-N; MULLE C, 1991, J NEUROSCI, V11, P2588; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; PATRICK J, 1993, PROG BRAIN RES, V98, P113; PEREIRA EFR, 1994, SOC NEUR ABSTR, V468, P12; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SCHOEPFER R, 1988, NEURON, V1, P241, DOI 10.1016/0896-6273(88)90145-6; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; SEGUELA P, 1993, J NEUROSCI, V13, P596; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; van der Eb A J, 1980, Methods Enzymol, V65, P826; WADA E, 1990, BRAIN RES, V526, P45, DOI 10.1016/0006-8993(90)90248-A; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; YANG XD, 1994, J BIOL CHEM, V269, P10252	48	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4497	4502		10.1074/jbc.270.9.4497	http://dx.doi.org/10.1074/jbc.270.9.4497			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876217	hybrid			2022-12-25	WOS:A1995QK08400050
J	MAROTO, M; ARREDONDO, JJ; SANROMAN, M; MARCO, R; CERVERA, M				MAROTO, M; ARREDONDO, JJ; SANROMAN, M; MARCO, R; CERVERA, M			ANALYSIS OF THE PARAMYOSIN MINIPARAMYOSIN GENE - MINIPARAMYOSIN IS AN INDEPENDENTLY TRANSCRIBED, DISTINCT PARAMYOSIN ISOFORM, WIDELY DISTRIBUTED IN INVERTEBRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; DROSOPHILA-MELANOGASTER PARAMYOSIN; THICK FILAMENT STRUCTURE; INSECT FLIGHT MUSCLE; BOX-BINDING PROTEINS; CAENORHABDITIS-ELEGANS; MULTIPLE PROTEINS; MYOD FAMILY; EXPRESSION; IDENTIFICATION	Miniparamyosin, a distinct Drosophila melanogaster paramyosin isoform of 60 kDa, is shown here to be encoded by the same gene as paramyosin. The gene, located at 66D14, spans over 12.8 kilobases (kb) and is organized into 10 exons, 9 of which code for the paramyosin transcripts, An exon, located between exons 7 and 8, codes for the 5'-end of the miniparamyosin, and the two proteins share the two last exons of the gene, Mapping of the 5'-ends of these transcripts indicates that the paramyosin and miniparamyosin mRNAs arise from two overlapping transcriptional units; the miniparamyosin transcription initiation site is located inside a paramyosin intron, 8 kb downstream of the one used for paramyosin transcription, The existence of two differ ent promoters and the conserved and nonconserved features of their sequences suggest a very complex regulation of these two muscle proteins, In fact, while paramyosin is expressed at two distinct stages of development as most other Drosophila muscle proteins, miniparamyosin appears late in development, being present only in the adult musculature, The absence of exon 1B, the specific exon of miniparamyosin, in the nematode Caenorhabditis elegans, as web as additional lines of evidence support the lack of miniparamyosin in this particular organism, However, it is present in most invertebrate species examined, including different arthropod, annelid, mollusc, and echinoderm species.	UNIV AUTONOMA MADRID, FAC MED, CSIC, DEPT BIOQUIM, E-28029 MADRID, SPAIN; UNIV AUTONOMA MADRID, FAC MED, CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Arredondo, Juan/L-2404-2013	Arredondo, Juan/0000-0002-6784-0990				BANDMAN E, 1992, DEV BIOL, V154, P273, DOI 10.1016/0012-1606(92)90067-Q; BECKER KD, 1992, J CELL BIOL, V116, P669, DOI 10.1083/jcb.116.3.669; BEINBRECH G, 1985, CELL TISSUE RES, V241, P607; BERNSTEIN SI, 1986, MOL CELL BIOL, V6, P2511, DOI 10.1128/MCB.6.7.2511; BERNSTEIN SI, 1993, INT REV CYTOL, V143, P63; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BULLARD B, 1973, J MOL BIOL, V75, P359, DOI 10.1016/0022-2836(73)90026-0; BULLARD B, 1973, BIOCHEM J, V135, P277, DOI 10.1042/bj1350277; CASTELLANI L, 1992, J MUSCLE RES CELL M, V13, P174, DOI 10.1007/BF01874154; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; COHEN CAROLYN, 1963, JOUR MOLECULAR BIOL, V6, P423; COLLIER VL, 1990, GENE DEV, V4, P885, DOI 10.1101/gad.4.6.885; DEITIKER PR, 1993, J CELL BIOL, V123, P303, DOI 10.1083/jcb.123.2.303; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EPSTEIN HF, 1985, J CELL BIOL, V100, P904, DOI 10.1083/jcb.100.3.904; EPSTEIN HF, 1986, J CELL BIOL, V103, P985, DOI 10.1083/jcb.103.3.985; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; EPSTEIN HF, 1988, J CELL BIOL, V106, P1985, DOI 10.1083/jcb.106.6.1985; EPSTEIN HF, 1992, DEV BIOL, V154, P231, DOI 10.1016/0012-1606(92)90064-N; FALKENTHAL S, 1987, DEV BIOL, V121, P263, DOI 10.1016/0012-1606(87)90158-8; FIRE A, 1989, EMBO J, V8, P3419, DOI 10.1002/j.1460-2075.1989.tb08506.x; FYRBERG E, 1990, TRENDS GENET, V6, P126, DOI 10.1016/0168-9525(90)90127-R; GENYOANDO K, 1991, J MOL BIOL, V219, P429; GIL I, 1987, NUCLEIC ACIDS RES, V15, P6007, DOI 10.1093/nar/15.15.6007; HANKE PD, 1988, MOL CELL BIOL, V8, P3591, DOI 10.1128/MCB.8.9.3591; HARLOW E, 1988, ANTIBODIES LABORATOR; HONDA S, 1990, P NATL ACAD SCI USA, V87, P876, DOI 10.1073/pnas.87.3.876; KAGAWA H, 1989, J MOL BIOL, V207, P311, DOI 10.1016/0022-2836(89)90257-X; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; MACKENZIE JM, 1980, CELL, V22, P747, DOI 10.1016/0092-8674(80)90551-6; MAROTO M, 1992, J MOL BIOL, V224, P287, DOI 10.1016/0022-2836(92)90994-U; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NGUYEN HT, 1994, IN PRESS P NATL ACAD; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PARKER VP, 1985, MOL CELL BIOL, V5, P3058, DOI 10.1128/MCB.5.11.3058; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ F, 1983, J MOL BIOL, V163, P533, DOI 10.1016/0022-2836(83)90111-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Smith D.S., 1984, P111; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TRIEZENBERG SJ, 1993, CURRENT PROTOCOLS MO; VIGOREAUX JO, 1993, J CELL BIOL, V121, P587, DOI 10.1083/jcb.121.3.587; VINOS J, 1992, MOL GEN GENET, V231, P385, DOI 10.1007/BF00292707; VINOS J, 1991, J MOL BIOL, V220, P687, DOI 10.1016/0022-2836(91)90110-R; WATERSTON RH, 1977, J MOL BIOL, V117, P679, DOI 10.1016/0022-2836(77)90064-X	54	36	37	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4375	4382		10.1074/jbc.270.9.4375	http://dx.doi.org/10.1074/jbc.270.9.4375			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876201	hybrid			2022-12-25	WOS:A1995QK08400032
J	ROLL, JT; SHAH, VK; DEAN, DR; ROBERTS, GP				ROLL, JT; SHAH, VK; DEAN, DR; ROBERTS, GP			CHARACTERISTICS OF NIFNE IN AZOTOBACTER-VINELANDII STRAINS - IMPLICATIONS FOR THE SYNTHESIS OF THE IRON-MOLYBDENUM COFACTOR OF DINITROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE; NUCLEOTIDE-SEQUENCE; NITROGEN-FIXATION; GENETIC-ANALYSIS; STRUCTURAL GENE; PROTEIN; BIOSYNTHESIS; HOMOCITRATE; PRODUCTS; CLUSTER	The products of the nifN and nifE genes of Azotobacter vinelandii function as a 200-kDa alpha 2 beta 2 tetramer (NIFNE) in the synthesis of the iron-molybdenum cofactor (FeMo-co) of nitrogenase, the enzyme system required for biological nitrogen fixation. NIFNE was purified using a modification of the published protocol. Immunoblot analysis of anoxic native gels indicated that distinct forms of NIFNE accumulate in strains deficient in either NIFB (Delta nifB::kan Delta nifDK) or NIFH (Delta nifHDK). During the purification of NIFNE from the Delta nifHDK mutant, its mobility in these gels changed, becoming similar to that of NIFNE from the Delta nifB::kan Delta nifDK mutant. While NIFB activity initially co-purified with the NIFNE activity from the Delta nifHDK mutant, further purification of NIFNE activity resulted in the loss of the co-purifying NIFB activity; this loss correlated with the change in NIFNE mobility on native gels. These results suggest that the form of NIFNE accumulated in the Delta nifHDK mutant is associated with NIFB activity in crude extract but loses this association during NIFNE purification. Addition of the purified metabolic product of NIFB, termed NifB-co, to either NIFNE purified from the Delta nifHDK strain or to the NIFNE in crude extract of the Delta nif::kan Delta DK strain caused a change in the mobility of NIFNE on anoxic native gels to that of the form accumulated in a Delta nifHDK mutant. These results support a model where both NifB-co and dinitrogenase reductase participate in FeMo-co synthesis through NIFNE, which serves as a scaffold for this process.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,COLL AGR & LIFE SCI,CTR STUDIES NITROGEN FIXAT,MADISON,WI 53706; VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM & ANAEROB MICROBIOL,BLACKSBURG,VA 24061	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Virginia Polytechnic Institute & State University	ROLL, JT (corresponding author), UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; BISHOP PE, 1986, SCIENCE, V232, P92, DOI 10.1126/science.232.4746.92; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; DEAN DR, 1985, P NATL ACAD SCI USA, V82, P5720, DOI 10.1073/pnas.82.17.5720; DOWNS DM, 1990, J BACTERIOL, V172, P6084, DOI 10.1128/jb.172.10.6084-6089.1990; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HARLOW E, 1988, ANTIBODIES LABORATOR, P574; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; IMPERIAL J, 1984, J BACTERIOL, V158, P187, DOI 10.1128/JB.158.1.187-194.1984; IMPERIAL J, 1988, NITROGEN FIXATION 10, P128; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM S, 1993, J BIOL CHEM, V269, P4215; LJONES T, 1978, BIOCHEM BIOPH RES CO, V80, P22, DOI 10.1016/0006-291X(78)91098-7; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; MASEPOHL B, 1993, MOL GEN GENET, V238, P369, DOI 10.1007/BF00291996; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; OKA A, 1981, J MOL BIOL, V147, P217, DOI 10.1016/0022-2836(81)90438-1; PAUSTIAN TD, 1989, P NATL ACAD SCI USA, V86, P6082, DOI 10.1073/pnas.86.16.6082; RAWLINGS J, 1978, J BIOL CHEM, V253, P1001; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; Shah V. K., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P115; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1978, BIOCHEM BIOPH RES CO, V81, P232, DOI 10.1016/0006-291X(78)91654-6; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P25, DOI 10.1139/m68-005; UGALDE RA, 1985, J BACTERIOL, V164, P1081, DOI 10.1128/JB.164.3.1081-1087.1985; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WHITE TC, 1992, J BIOL CHEM, V267, P24007	41	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4432	4437		10.1074/jbc.270.9.4432	http://dx.doi.org/10.1074/jbc.270.9.4432			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876209	hybrid			2022-12-25	WOS:A1995QK08400041
J	TRAUB, LM; KORNFELD, S; UNGEWICKELL, E				TRAUB, LM; KORNFELD, S; UNGEWICKELL, E			DIFFERENT DOMAINS OF THE AP-1 ADAPTER COMPLEX ARE REQUIRED FOR GOLGI MEMBRANE-BINDING AND CLATHRIN RECRUITMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; ASSEMBLY PROTEIN AP-2; COATED VESICLE ADAPTERS; FACTOR-II RECEPTOR; PLASMA-MEMBRANE; SUBUNIT; PITS; IDENTIFICATION; POLYPEPTIDES; PURIFICATION	The assembly of clathrin-coated buds on the Golgi requires the recruitment of the heterotetrameric AP-1 adaptor complex, which is dependent on both guanine nucleotides and the small GTP-binding protein ADP-ribosylation factor (ARF). Here, we have investigated the structural domains of the AP-1 complex necessary for ARF-mediated translocation of the adaptor complex onto Golgi membranes and the subsequent recruitment of clathrin onto the membrane. Controlled proteolysis of purified AP-1, derived from bovine adrenal coated vesicles, was used to generate AP-1 core fragments composed of the amino-terminal trunk regions of the beta 1 and gamma subunits and associated mu 1 and sigma 1 subunits, and lacking either the beta 1 subunit carboxyl-terminal appendage or both beta 1 and gamma subunit appendages. On addition of these truncated fragments to AP-1-depleted adrenal cytosol, both types of core fragments were efficiently recruited onto Golgi membranes in the presence of GTP gamma S. Recruitment of both core fragments was inhibited by the fungal metabolite brefeldin A, indicative of an ARF-dependent process, Limited tryptic digestion of recruited, intact cytosolic AP-1 resulted in the quantitative release of the globular carboxyl-terminal appendage domains of the beta 1 and gamma subunits. The adaptor core complex remained associated with the Golgi membranes. Recruitment of cytosolic clathrin onto the Golgi membranes was strictly dependent on the presence of intact AP-1. Tryptic removal of the beta 1 subunit appendage prevented subsequent clathrin recruitment. We conclude that the structural determinants required for the ARF-mediated binding of cytosolic AP-1 onto Golgi membranes are contained within the adaptor core, and that the carboxyl-terminal appendage domains of the beta 1 and gamma subunits do not play any role in this process. Subsequent recruitment of cytosolic clathrin, however, requires an intact beta 1 subunit.	WASHINGTON UNIV, SCH MED, DEPT MED, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CTR IMMUNOL, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)				Traub, Linton/0000-0002-1303-0298	NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BELTZER JP, 1991, EMBO J, V10, P3739; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; HINDSHAW JE, 1994, MOL BIOL CELL, V5, P75; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEEN JH, 1991, J BIOL CHEM, V266, P7950; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; ROBINSON MS, 1993, J CELL BIOL, V123, P67, DOI 10.1083/jcb.123.1.67; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TRAUB LM, 1991, J BIOL CHEM, V266, P24642; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; UNGEWICKELL E, 1994, EUR J BIOCHEM, V222, P33, DOI 10.1111/j.1432-1033.1994.tb18838.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	50	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4933	4942		10.1074/jbc.270.9.4933	http://dx.doi.org/10.1074/jbc.270.9.4933			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876268	hybrid			2022-12-25	WOS:A1995QK08400106
J	KATAYAMA, E; SCOTTWOO, G; IKEBE, M				KATAYAMA, E; SCOTTWOO, G; IKEBE, M			EFFECT OF CALDESMON ON THE ASSEMBLY OF SMOOTH-MUSCLE MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD MYOSIN; VERTEBRATE NON-MUSCLE; LIGHT CHAIN KINASE; CALMODULIN-BINDING; NONMUSCLE CALDESMON; HEAVY-MEROMYOSIN; ACTIN-FILAMENTS; ATPASE ACTIVITY; CROSS-LINKING; SIDE-POLAR	Smooth muscle myosin filaments are much less stable than the skeletal muscle counterpart. Smooth myosin requires higher concentration of Mg2+ than skeletal myosin to form thick filaments and addition of ATP disassembles the dephosphorylated smooth muscle myosin filaments into monomers but not phosphorylated ones. We found that the addition of caldesmon to dephosphorylated myosin induced the formation of the filaments under the conditions where myosin by itself is soluble or disassembled. Although the induced filaments mere short at 1 mM Mg2+, they became medium sized and seemed like side polar filaments with prominent 14 nm periodicity at higher Mg2+ conditions (8 mM). In the presence of F-actin, myosin filaments induced by caldesmon were associated along actin filaments to form large structures. The association of actin and myosin filaments was observed only in the presence of caldesmon, suggesting that caldesmon cross-linked actin and myosin filaments. This cross-linking was disrupted by the addition of calmodulin. Caldesmon-induced filament formation of dephosphorylated myosin in the presence of Mg2+-ATP may explain the existence of myosin filaments in relaxed smooth muscle fibers. A similar effect of telokin on myosin filament assembly was also examined and is discussed.	UNIV TOKYO,INST MED SCI,DEPT FINE MORPHOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo	KATAYAMA, E (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44118, USA.				NHLBI NIH HHS [HL37117] Funding Source: Medline; NIAMS NIH HHS [AR41653, AR38888] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, R01AR038888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; COOKE PH, 1989, J MUSCLE RES CELL M, V10, P206, DOI 10.1007/BF01739811; CRAIG R, 1977, J CELL BIOL, V75, P990, DOI 10.1083/jcb.75.3.990; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; DINGUS J, 1986, J CELL BIOL, V102, P1748, DOI 10.1083/jcb.102.5.1748; FUJII T, 1987, J BIOL CHEM, V262, P2757; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P2929; HUBER PAJ, 1993, J MUSCLE RES CELL M, V14, P385, DOI 10.1007/BF00121289; IKEBE M, 1977, J BIOCHEM-TOKYO, V82, P299, DOI 10.1093/oxfordjournals.jbchem.a131684; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1988, J BIOL CHEM, V263, P3055; ITO M, 1989, J BIOL CHEM, V264, P13971; ITO T, 1989, NATURE, V338, P164; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KATAYAMA E, 1989, J BIOCHEM-TOKYO, V106, P751, DOI 10.1093/oxfordjournals.jbchem.a122928; KATAYAMA E, 1989, BIOCHEM BIOPH RES CO, V160, P1316, DOI 10.1016/S0006-291X(89)80147-0; KATAYAMA E, 1989, J BIOCHEM-TOKYO, V106, P988, DOI 10.1093/oxfordjournals.jbchem.a122987; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; KENDRICKJONES J, 1987, J MOL BIOL, V198, P241, DOI 10.1016/0022-2836(87)90310-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1989, BIOCHEM J, V259, P303, DOI 10.1042/bj2590303; MORNET D, 1988, BIOCHEM BIOPH RES CO, V154, P564, DOI 10.1016/0006-291X(88)90177-5; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOMLYO AV, 1981, NATURE, V294, P567, DOI 10.1038/294567a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SUZUKI H, 1978, J BIOCHEM, V84, P1529, DOI 10.1093/oxfordjournals.jbchem.a132278; Trybus KM, 1991, CURR OPIN CELL BIOL, V3, P105, DOI 10.1016/0955-0674(91)90172-U; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; TRYBUS KM, 1987, J CELL BIOL, V105, P3021, DOI 10.1083/jcb.105.6.3021; TSUKITA S, 1982, EUR J CELL BIOL, V28, P195; WANG CLA, 1991, J BIOL CHEM, V266, P9166; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0	50	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3919	3925		10.1074/jbc.270.8.3919	http://dx.doi.org/10.1074/jbc.270.8.3919			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876138	hybrid			2022-12-25	WOS:A1995QH68800069
J	MOSCOSO, M; DELSOLAR, G; ESPINOSA, M				MOSCOSO, M; DELSOLAR, G; ESPINOSA, M			SPECIFIC NICKING-CLOSING ACTIVITY OF THE INITIATOR OF REPLICATION PROTEIN REPB OF PLASMID PMV158 ON SUPERCOILED OR SINGLE-STRANDED-DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROLLING-CIRCLE REPLICATION; PT181 PLASMID; ORIGIN RECOGNITION; FUNCTIONAL ORIGIN; SEQUENCE MOTIFS; PLS1; ELEMENT; FAMILY; MOBILIZATION; NUCLEOTIDE	Asymmetric rolling circle replication of the promiscuous replicon pMV158 is initiated by the plasmid-encoded RepB protein. In vitro, purified RepB protein introduces a nick within the leading strand origin of replication by a nucleophylic attack on the phosphodiester bond at the dinucleotide GpA. Some changes within and around this dinucleotide were recognized by the protein. RepB nicked and closed supercoiled pMV158 DNA, having an optimum activity at 60 degrees C. We have imitated, in vitro, a process of rolling circle replication, since RepB was able to nick (initiation) and to covalently close (termination) single-stranded oligonucleotides containing the protein cleavage sequence. Covalent DNA-protein complexes were not found, indicating that RepB has unique features among plasmid-encoded proteins involved in rolling circle replication or conjugative mobilization.	CSIC, CTR INVEST BIOL, E-28006 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Espinosa, Manuel/M-5282-2019; del Solar, Gloria/K-2485-2014; del Solar, Gloria/ABD-2668-2020	del Solar, Gloria/0000-0002-7356-9164; del Solar, Gloria/0000-0002-7356-9164; Moscoso, Miriam/0000-0001-8977-3269				AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; BAAS PD, 1988, CURR TOP MICROBIOL, V136, P31; BOWATER R, 1991, BIOCHEMISTRY-US, V30, P11495, DOI 10.1021/bi00113a003; DELACAMPA AG, 1990, J MOL BIOL, V213, P247, DOI 10.1016/S0022-2836(05)80188-3; DELSOLAR G, 1987, MOL GEN GENET, V206, P428, DOI 10.1007/BF00428882; DELSOLAR G, 1992, MOL MICROBIOL, V6, P83; DELSOLAR G, 1993, MOL MICROBIOL, V8, P789; DELSOLAR G, 1993, MOL GEN GENET, V237, P65, DOI 10.1007/BF00282785; DELSOLAR GH, 1990, J BIOL CHEM, V265, P12569; DEMPSEY LA, 1992, J BIOL CHEM, V267, P24538; GRUSS A, 1989, MICROBIOL REV, V53, P231, DOI 10.1128/MMBR.53.2.231-241.1989; HIGASHITANI A, 1994, J MOL BIOL, V237, P388, DOI 10.1006/jmbi.1994.1242; HORIUCHI K, 1986, J MOL BIOL, V188, P215, DOI 10.1016/0022-2836(86)90306-2; ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279; KHAN SA, 1982, P NATL ACAD SCI-BIOL, V79, P4580, DOI 10.1073/pnas.79.15.4580; KOEPSEL RR, 1987, NUCLEIC ACIDS RES, V15, P4085, DOI 10.1093/nar/15.10.4085; KORNBERG A, 1992, DNA REPLICATION, P311; LANGEVELD SA, 1978, NATURE, V271, P417, DOI 10.1038/271417a0; LEHMAN IR, 1974, SCIENCE, V186, P790; MEYER TF, 1979, J BIOL CHEM, V254, P2642; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; NOVICK RP, 1989, ANNU REV MICROBIOL, V43, P537, DOI 10.1146/annurev.micro.43.1.537; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P2925, DOI 10.1073/pnas.90.7.2925; PANSEGRAU W, 1991, NUCLEIC ACIDS RES, V19, P3455, DOI 10.1093/nar/19.12.3455; PRIEBE SD, 1989, J BACTERIOL, V171, P4778, DOI 10.1128/jb.171.9.4778-4784.1989; PUYET A, 1988, NUCLEIC ACIDS RES, V16, P115, DOI 10.1093/nar/16.1.115; RASOOLY A, 1993, SCIENCE, V262, P1048, DOI 10.1126/science.8235621; RASOOLY A, 1994, J BACTERIOL, V176, P2450, DOI 10.1128/JB.176.8.2450-2453.1994; RIELE HT, 1986, EMBO J, V5, P631, DOI 10.1002/j.1460-2075.1986.tb04257.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHERZINGER E, 1992, NUCLEIC ACIDS RES, V20, P41, DOI 10.1093/nar/20.1.41; THOMAS CD, 1990, J BIOL CHEM, V265, P5519; VANMANSFELD ADM, 1980, NATURE, V288, P561, DOI 10.1038/288561a0; WANG PZ, 1992, J MOL BIOL, V223, P145, DOI 10.1016/0022-2836(92)90722-V; WANG PZ, 1993, EMBO J, V12, P45, DOI 10.1002/j.1460-2075.1993.tb05630.x; WATERS VL, 1993, MOL MICROBIOL, V9, P1123, DOI 10.1111/j.1365-2958.1993.tb01242.x	37	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3772	3779		10.1074/jbc.270.8.3772	http://dx.doi.org/10.1074/jbc.270.8.3772			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876118	hybrid, Green Submitted			2022-12-25	WOS:A1995QH68800048
J	ISOM, LL; SCHEUER, T; BROWNSTEIN, AB; RAGSDALE, DS; MURPHY, BJ; CATTERALL, WA				ISOM, LL; SCHEUER, T; BROWNSTEIN, AB; RAGSDALE, DS; MURPHY, BJ; CATTERALL, WA			FUNCTIONAL COEXPRESSION OF THE BETA-1 AND TYPE IIA ALPHA-SUBUNITS OF SODIUM-CHANNELS IN A MAMMALIAN-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RAT-BRAIN; XENOPUS-OOCYTES; MESSENGER-RNA; NA CHANNELS; CLONED CDNA; INACTIVATION	Brain sodium channels are a complex of alpha (260 kDa), beta 1 (36 kDa), and beta 2 (33 kDa) subunits, a subunits are functional as voltage-gated sodium channels by themselves. When expressed in Xenopus oocytes, beta 1 subunits accelerate the time course of sodium channel activation and inactivation by shifting them to a fast gating mode, but alpha subunits expressed alone in mammalian cells activate and inactivate rapidly without co-expression of beta 1 subunits. In these experiments, we show that the Chinese hamster cell lines CHO and 1610 do not express endogenous beta 1 subunits as determined by Northern blotting, immunoblotting, and assay for beta 1 subunit function by expression of cellular mRNA in Xenopus oocytes. alpha subunits expressed alone in stable lines of these cells activate and inactivate rapidly. Co-expression of beta 1 subunits increases the level of sodium channels 2- to 4-fold as determined hom saxitoxin binding, but does not affect the K-d for saxitoxin. Co-expression of beta 1 subunits also shifts the voltage dependence of sodium channel inactivation to more negative membrane potentials by 10 to 12 mV and shifts the voltage dependence of channel activation to more negative membrane potentials by 2 to 11 mV. These effects of beta 1 subunits on sodium channel function in mammalian cells may be physiologically important determinants of sodium channel function in vivo.			ISOM, LL (corresponding author), UNIV WASHINGTON, DEPT PHARMACOL, SJ-30, SEATTLE, WA 98195 USA.			Isom, Lori/0000-0002-9479-6729				AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; Hille B., 1992, IONIC CHANNELS EXCIT; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; MAKITA N, 1994, J BIOL CHEM, V269, P7571; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MCPHERSON GA, 1987, LIGAND EBDA; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NUMA S, 1989, HARVEY LECT, V83, P121; PATTON DE, 1994, J BIOL CHEM, V269, P17649; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; QU YS, 1994, P NATL ACAD SCI USA, V91, P3289, DOI 10.1073/pnas.91.8.3289; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMMER JS, 1989, ANNU REV PHYSIOL, V51, P401, DOI 10.1146/annurev.physiol.51.1.401; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; UKOMADU C, 1992, NEURON, V8, P663, DOI 10.1016/0896-6273(92)90088-U; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; YANG JS, 1993, NEURON, V11, P915, DOI 10.1016/0896-6273(93)90121-7; ZHOU JY, 1991, NEURON, V7, P775, DOI 10.1016/0896-6273(91)90280-D	33	189	192	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3306	3312		10.1074/jbc.270.7.3306	http://dx.doi.org/10.1074/jbc.270.7.3306			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852416	hybrid			2022-12-25	WOS:A1995QG47100063
J	CREEMERS, JWM; VEY, M; SCHAFER, W; AYOUBI, TAY; ROEBROEK, AJM; KLENK, HD; GARTEN, W; VANDEVEN, WJM				CREEMERS, JWM; VEY, M; SCHAFER, W; AYOUBI, TAY; ROEBROEK, AJM; KLENK, HD; GARTEN, W; VANDEVEN, WJM			ENDOPROTEOLYTIC CLEAVAGE OF ITS PROPEPTIDE IS A PREREQUISITE FOR EFFICIENT TRANSPORT OF FURIN OUT OF THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN PROCESSING ENZYME; CONSTITUTIVE SECRETORY PATHWAY; SITE-DIRECTED MUTAGENESIS; SUBTILISIN-LIKE PROTEASE; HAMSTER OVARY CELLS; GLYCOSYLATION SITES; VIRUS HEMAGGLUTININ; PRECURSOR CLEAVAGE; GENE-EXPRESSION; ACTIVATION	The trans-Golgi network (TGN) proprotein convertase furin is synthesized in a zymogenic form and is activated by intramolecular, autoproteolytic cleavage of the propeptide from its precursor. To obtain insight in possible functions of the furin propeptide, we have studied biosynthesis, propeptide cleavage, biological activity, and intracellular localization of human and bovine furin. Analysis of autocatalytic cleavage site mutants of furin revealed that efficient propeptide cleavage requires the presence of the complete furin cleavage consensus sequence Arg-X-Lys Arg. In studies of a mutant in which the P1+P4+P5 residues of the autoproteolytic cleavage site were substituted, no substrate processing activity could be demonstrated, indicating a complete block of maturation. In immunofluorescence analysis, this mutant was found in the endoplasmic reticulum (ER), suggesting ER retention of profurin. This ER retention, however, appeared saturable. Furin proteins encoded by oxyanion hole mutant N188A and negative side chain mutant D248L, which possess autoprocessing activity but lack substrate processing activity, were found in the Golgi and the ER, respectively. Finally, analysis of a furin mutant, in which all three potential sites for N-linked glycosylation were altered, revealed autocatalytic cleavage, substrate processing, and transport to the Golgi. Our results indicate that cleavage of the propeptide occurs in the endoplasmic reticulum and is necessary but not sufficient for transport of furin out of this compartment.	CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,MOLEC ONCOL LAB,B-3000 LOUVAIN,BELGIUM; UNIV MARBURG,INST VIROL,D-35037 MARBURG,GERMANY	KU Leuven; Philipps University Marburg								Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GETHING MJ, 1992, NATURE, V335, P33; HALBAN PA, 1994, BIOCHEM J, V299, P1; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KLENK HD, 1993, VIRUS STRATEGIES MOL, P195; LEDUC R, 1992, J BIOL CHEM, V267, P14304; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; OU WJ, 1993, NATURE, V264, P771; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; ROBERTS PC, 1993, J VIROL, V67, P3048, DOI 10.1128/JVI.67.6.3048-3060.1993; Roebroek A. J. M., 1992, MOL BIOL LIFE SCI AD, V11, P127; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; VANDENOUWELAND AMW, 1989, NUCLEIC ACIDS RES, V17, P7101, DOI 10.1093/nar/17.17.7101; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1992, CRIT REV ONCOGENESIS, V4, P115; VANDUIJNHOVEN HLP, 1992, HYBRIDOMA, V11, P71, DOI 10.1089/hyb.1992.11.71; VEY M, 1995, IN PRESS J CELL BIOL; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WEITZ G, 1992, J BIOL CHEM, V267, P10039; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230	36	98	101	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2695	2702		10.1074/jbc.270.6.2695	http://dx.doi.org/10.1074/jbc.270.6.2695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852339	hybrid			2022-12-25	WOS:A1995QF53500047
J	GEREN, LM; BEASLEY, JR; FINE, BR; SAUNDERS, AJ; HIBDON, S; PIELAK, GJ; DURHAM, B; MILLETT, F				GEREN, LM; BEASLEY, JR; FINE, BR; SAUNDERS, AJ; HIBDON, S; PIELAK, GJ; DURHAM, B; MILLETT, F			DESIGN OF A RUTHENIUM CYTOCHROME-C DERIVATIVE TO MEASURE ELECTRON-TRANSFER TO THE INITIAL ACCEPTOR IN CYTOCHROME-C-OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; YEAST ISO-1-CYTOCHROME-C; PROTON TRANSLOCATION; TUNNELING PATHWAYS; HIGH-AFFINITY; COPPER-A; SITE; HORSE; IDENTIFICATION; BINDING	A ruthenium-labeled cytochrome c derivative was prepared to meet two design criteria: the ruthenium group must transfer an electron rapidly to the heme group, but not alter the interaction with cytochrome c oxidase. Site-directed mutagenesis was used to replace His(39) on the backside of yeast C102T iso-1-cytochrome c with a cysteine residue, and the single sulfhydryl group was labeled with (4-bromomethyl-4'methylbipyridine) (bis-bipyridine)ruthenium(II) to form Ru-39-cytochrome c (cyt c), There is an efficient pathway for electron transfer from the ruthenium group to the heme group of Ru-39-cyt c comprising 13 covalent bonds and one hydrogen bond. Electron transfer from the excited state Ru(II*) to ferric heme c occurred with a rate constant of (6.0 +/- 2.0) x 10(5) s(-1), followed by electron transfer from ferrous heme c to Ru(III) with a rate constant of (1.0 +/- 0.2) x 10(6) s(-1), Laser excitation of a complex between Ru-39-cyt c and beef cytochrome c oxidase in low ionic strength buffer (5 mM phosphate, pH 7) resulted in electron transfer from photoreduced heme c to Cu-A with a rate constant of (6 +/- 2) x 10(4) s(-1), followed by electron transfer from Cu-A to heme a with a rate constant of (1.8 +/- 0.3) x 10(4) s(-1), Increasing the ionic strength to 100 mM leads to bimolecular kinetics as the complex is dissociated. The second-order rate constant is (2.5 +/- 0.4) x 10(7) M(-1) s(-1) at 230 mM ionic strength, nearly the same as that of wild-type iso-1-cytochrome c.	UNIV ARKANSAS,DEPT CHEM & BIOCHEM,FAYETTEVILLE,AR 72701; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of Arkansas System; University of Arkansas Fayetteville; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Saunders, Aleister/0000-0002-7298-7823	NIGMS NIH HHS [GM42501, GM08332, GM20488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042501, R29GM042501, T32GM008332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD I, 1982, BIOCHEMISTRY-US, V21, P3122, DOI 10.1021/bi00256a014; ANTALIS TM, 1982, J BIOL CHEM, V257, P6194; ANTHOLINE WE, 1992, EUR J BIOCHEM, V209, P875, DOI 10.1111/j.1432-1033.1992.tb17360.x; AULD DS, 1993, PROTEIN SCI, V2, P2187, DOI 10.1002/pro.5560021218; BERATAN DN, 1990, J AM CHEM SOC, V112, P7915, DOI 10.1021/ja00178a011; BERGHUIS AM, 1992, J MOL BIOL, V223, P959, DOI 10.1016/0022-2836(92)90255-I; BETZ SF, 1992, BIOCHEMISTRY-US, V31, P12337, DOI 10.1021/bi00164a007; BLAIR DF, 1982, BIOCHEMISTRY-US, V21, P6928, DOI 10.1021/bi00269a048; BLAIR DF, 1983, CHEM SCRIPTA, V21, P43; CAPALDI RA, 1972, FEBS LETT, V26, P261, DOI 10.1016/0014-5793(72)80587-8; COOPER CE, 1990, BIOCHIM BIOPHYS ACTA, V1017, P187, DOI 10.1016/0005-2728(90)90184-6; CUTLER RL, 1987, PROTEIN ENG, V1, P95, DOI 10.1093/protein/1.2.95; DETHMERS JK, 1979, J BIOL CHEM, V254, P1973; DURHAM B, 1990, ADV CHEM SER, V226, P181; DURHAM B, 1989, BIOCHEMISTRY-US, V28, P8659, DOI 10.1021/bi00447a057; ELTIS LD, 1991, BIOCHEMISTRY-US, V30, P3663, DOI 10.1021/bi00229a011; ERECINSKA M, 1971, FEBS LETT, V16, P284, DOI 10.1016/0014-5793(71)80371-X; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; GAO Y, 1990, BIOCHEMISTRY-US, V29, P6994, DOI 10.1021/bi00482a007; GARBER EAE, 1990, BIOCHIM BIOPHYS ACTA, V1015, P279, DOI 10.1016/0005-2728(90)90032-Y; GEREN L, 1991, BIOCHEMISTRY-US, V30, P9450, DOI 10.1021/bi00103a009; GUPTE SS, 1988, J BIOL CHEM, V263, P5241; GURBIEL RJ, 1993, J AM CHEM SOC, V115, P10888, DOI 10.1021/ja00076a053; HAHM S, 1994, BIOCHEMISTRY-US, V33, P1473, DOI 10.1021/bi00172a025; HAHM S, 1992, BIOCHEMISTRY-US, V31, P3472, DOI 10.1021/bi00128a022; HALL J, 1988, J BIOL CHEM, V263, P8142; HAWKINS BK, 1994, J AM CHEM SOC, V116, P3111, DOI 10.1021/ja00086a046; HAZZARD JT, 1991, BIOCHEMISTRY-US, V30, P213, DOI 10.1021/bi00215a031; HILGEN SE, 1991, PROT ENG, V5, P575; HILL BC, 1991, J BIOL CHEM, V266, P2219; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; KOBAYASHI K, 1989, J BIOL CHEM, V264, P7976; KRONECK PMH, 1990, FEBS LETT, V268, P274, DOI 10.1016/0014-5793(90)81026-K; LARSEN RW, 1992, J PHYS CHEM-US, V96, P8023, DOI 10.1021/j100199a036; LEMASTERS JJ, 1978, FEBS LETT, V88, P10, DOI 10.1016/0014-5793(78)80595-X; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; MARTIN CT, 1988, J BIOL CHEM, V263, P8420; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; MINNAERT K, 1961, BIOCHIM BIOPHYS ACTA, V50, P23, DOI 10.1016/0006-3002(61)91055-1; Moore G. R., 1990, CYTOCHROMES C EVOLUT; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P6975, DOI 10.1021/bi00443a030; NILSSON T, 1992, P NATL ACAD SCI USA, V89, P6497, DOI 10.1073/pnas.89.14.6497; NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/science.2838904; PAN LP, 1990, BIOCHEMISTRY-US, V29, P3231, DOI 10.1021/bi00465a013; PAN LP, 1988, BIOCHEMISTRY-US, V27, P7180, DOI 10.1021/bi00419a003; PAN LP, 1992, BIOCHEMISTRY-US, V32, P8492; RIEDER R, 1980, J BIOL CHEM, V255, P4732; ROUSSEAU DL, 1993, J BIOENERG BIOMEMBR, V25, P165, DOI 10.1007/BF00762858; SCHROEDL NA, 1977, BIOCHEMISTRY-US, V16, P4961, DOI 10.1021/bi00642a003; SCOTT JR, 1993, J AM CHEM SOC, V115, P6820, DOI 10.1021/ja00068a045; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; SINJORGO KMC, 1984, BIOCHIM BIOPHYS ACTA, V767, P48, DOI 10.1016/0005-2728(84)90078-1; SMITH HT, 1977, BIOCHEMISTRY-US, V16, P4971, DOI 10.1021/bi00642a005; SMITH HT, 1981, J BIOL CHEM, V256, P4984; STEVENS TH, 1982, J BIOL CHEM, V257, P2106; THERIEN MJ, 1990, J AM CHEM SOC, V112, P2420, DOI 10.1021/ja00162a054; WACHENFELDT CV, 1994, FEBS LETT, V340, P109; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WILLIE A, 1992, BIOCHEMISTRY-US, V31, P7237, DOI 10.1021/bi00147a005; WILLIE A, 1993, BIOCHEMISTRY-US, V32, P7519, DOI 10.1021/bi00080a025; WILMS J, 1981, BIOCHIM BIOPHYS ACTA, V635, P13, DOI 10.1016/0005-2728(81)90003-7; WILSON DF, 1976, ARCH BIOCHEM BIOPHYS, V175, P160, DOI 10.1016/0003-9861(76)90495-1; WILSON DF, 1972, BIOCHIM BIOPHYS ACTA, V256, P277, DOI 10.1016/0005-2728(72)90058-8; WILSON MT, 1975, BIOCHEM J, V147, P145, DOI 10.1042/bj1470145; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007; YONETANI T, 1965, J BIOL CHEM, V240, P3392	67	80	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2466	2472		10.1074/jbc.270.6.2466	http://dx.doi.org/10.1074/jbc.270.6.2466			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852307	hybrid, Green Published			2022-12-25	WOS:A1995QF53500013
J	POLLER, W; WILLNOW, TE; HILPERT, J; HERZ, J				POLLER, W; WILLNOW, TE; HILPERT, J; HERZ, J			DIFFERENTIAL RECOGNITION OF ALPHA(1)-ANTITRYPSIN-ELASTASE AND ALPHA(1)-ANTICHYMOTRYPSIN-CATHEPSIN-G COMPLEXES BY THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEYMANN NEPHRITIS ANTIGEN; ALPHA-2-MACROGLOBULIN RECEPTOR; ALPHA-1-PROTEINASE INHIBITOR; PLASMINOGEN-ACTIVATOR; HIGH-AFFINITY; LUNG-DISEASE; BINDING; ALPHA-1-ANTITRYPSIN; CELLS; ALPHA-1-ANTICHYMOTRYPSIN	Two multifunctional receptors, low density lipoprotein receptor-related protein (LRP) and gp330, have been implicated in the cellular uptake and degradation of a wide spectrum of functionally diverse ligands including plasma lipoproteins, proteases, and proteinase-inhibitor complexes, The two receptors show distinct tissue-specific expression patterns, suggesting different physiological functions, We have examined the cellular degradation of two serine proteinase inhibitor (serpin)-protease complexes, alpha(1)-antitrypsin-neutrophil elastase (alpha(1)AT-NEL) and alpha(1)-antichymotsypsin-cathepsin G (alpha(1)ACT-CathG) by normal murine fibroblasts (MEF) expressing LRP, and by a mutant fibroblast cell line (PEA13) which is genetically deficient for LRP, alpha(1)AT-NEL complexes bound to LRP on ligand blots and were degraded efficiently by the MEF cells, but not by PEA13 cells, Degradation of the complexes was also significantly reduced by antibodies directed against LRP, further suggesting that fibroblasts require LRP for the cellular uptake and degradation of alpha(1)AT-NEL complexes, In contrast to alpha(1)AT-NEL, MEF cells did not degrade alpha(1)ACT-CathG complexes, However, these complexes were rapidly degraded by the rat embryonal carcinoma cell line L2p58 which abundantly expresses gp330, raising the possibility that the alpha(1)ACT-CathG complex might be recognized by gp330, Both complexes were efficiently metabolized by the hepatoma cell line HepG2, presumably involving the serpin-enzyme complex receptor, The differential recognition of serpin-protease complexes by fibroblasts and hepatoma cells, however, indicates that LRP, gp330, and the serpin-enzyme complex receptor are distinct proteins.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Poller, Wolfgang/AAB-2185-2021	Poller, Wolfgang/0000-0002-2805-6634; Willnow, Thomas/0000-0001-9515-7921	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILLINGSLEY GD, 1993, AM J HUM GENET, V52, P343; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BURNETT D, 1984, AM REV RESPIR DIS, V129, P473; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; Cox DW, 1989, METABOLIC BASIS INHE, P2409; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; FABER JP, 1993, J HEPATOL, V18, P313, DOI 10.1016/S0168-8278(05)80275-2; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KOTAS RV, 1991, PEDIATR PULM, V10, P260, DOI 10.1002/ppul.1950100407; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KURDOWSKA A, 1990, J BIOL CHEM, V265, P21023; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MORNEX JF, 1986, J CLIN INVEST, V77, P1952, DOI 10.1172/JCI112524; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORLANDO RA, 1993, P NATL ACAD SCI USA, V90, P4082, DOI 10.1073/pnas.90.9.4082; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; POLLER W, 1993, GENOMICS, V17, P740, DOI 10.1006/geno.1993.1396; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; STOUFFER GA, 1993, J BIOL CHEM, V268, P18340; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TRAVIS J, 1988, AM J MED, V84, P37; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WOLF BB, 1992, AM J PATHOL, V141, P37	48	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2841	2845		10.1074/jbc.270.6.2841	http://dx.doi.org/10.1074/jbc.270.6.2841			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852358	hybrid			2022-12-25	WOS:A1995QF53500068
J	SCHONHERR, E; WITSCHPREHM, P; HARRACH, B; ROBENEK, H; RAUTERBERG, J; KRESSE, H				SCHONHERR, E; WITSCHPREHM, P; HARRACH, B; ROBENEK, H; RAUTERBERG, J; KRESSE, H			INTERACTION OF BIGLYCAN WITH TYPE-I COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; BOVINE ARTICULAR-CARTILAGE; GROWTH-FACTOR-BETA; CORE PROTEIN; EXTRACELLULAR-MATRIX; KERATAN SULFATE; VI COLLAGEN; FIBRILLAR COLLAGEN; HUMAN-SKIN; DECORIN	The small proteoglycan decorin is known to interact with type I collagen fibrils, thereby influencing the kinetics of fibril formation and the distance between adjacent collagen fibrils. The structurally related proteoglycan biglycan has been proposed not to bind to fibrillar collagens. However, when osteosarcoma cells were cultured on reconstituted type I collagen fibrils, both decorin and biglycan were retained by the matrix. Immunogold labeling at the electron microscopic level showed that both proteoglycans were distributed along collagen fibrils not only in osteosarcoma cell-populated collagen lattices but also in human skin. Reconstituted type I collagen fibrils were able to bind in vitro native and N-glycan-free biglycan as well as recombinant biglycan core protein. From Scatchard plots dissociation, constants were obtained that were higher for glycanated biglycan (8.7 x 10(-8) mol/liter) than for glycanated decorin (7 x 10(-10) mol/liter and 3 x 10(-9) mol/liter, respectively). A similar number of binding sites for either proteoglycan was calculated. Recombinant biglycan and decorin were characterized by lower dissociation constants compared with the glycanated forms. Glycanated as well as recombinant decorin competed with glycanated biglycan for collagen binding, suggesting that identical or adjacent binding sites on the fibril are used by both proteoglycans. These data suggest that, because of its trivalency, biglycan could have a special organizing function on the assembly of the extracellular matrix.	UNIV MUNSTER, INST ARTERIOSCLEROSIS RES, W-4400 MUNSTER, GERMANY	University of Munster	SCHONHERR, E (corresponding author), UNIV MUNSTER, INST PHYSIOL CHEM & PATHOBIOCHEM, WALDEYERSTR 15, D-48149 MUNSTER, GERMANY.							BEAVAN LA, 1993, J BIOL CHEM, V268, P9856; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BREUER B, 1990, BIOCHEM J, V269, P551, DOI 10.1042/bj2690551; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CHOI HU, 1989, J BIOL CHEM, V264, P2876; FEDARKO NS, 1992, J CELL PHYSIOL, V151, P215, DOI 10.1002/jcp.1041510202; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; FUJII T, 1975, H-S Z PHYSIOL CHEM, V356, P1793, DOI 10.1515/bchm2.1975.356.2.1793; GREVE H, 1990, BIOCHEM J, V269, P149, DOI 10.1042/bj2690149; HAUSSER H, 1989, BIOCHEM J, V263, P137, DOI 10.1042/bj2630137; HAUSSER H, 1992, J BIOL CHEM, V267, P11559; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HENKEL W, 1982, EUR J BIOCHEM, V122, P205, DOI 10.1111/j.1432-1033.1982.tb05868.x; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LINSENMAYER TF, 1986, DEV BIOL, V118, P425, DOI 10.1016/0012-1606(86)90013-8; MIOSGE N, 1995, IN PRESS HISTOCHEM J; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; POGANY G, 1992, BIOCHEM BIOPH RES CO, V189, P165, DOI 10.1016/0006-291X(92)91539-3; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; RIESSEN R, 1994, AM J PATHOL, V144, P962; ROSENBERG L, 1993, DERMATAN SULPHATE PR, P225; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAITO H, 1968, J BIOL CHEM, V243, P1536; Sambrook J, 1989, MOL CLONING LABORATO; SCHONHERR E, 1993, BIOCHEM J, V290, P893, DOI 10.1042/bj2900893; SCHWARZ K, 1990, J BIOL CHEM, V265, P22023; SCOTT JE, 1985, BIOSCIENCE REP, V5, P71, DOI 10.1007/BF01117443; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1988, BIOCHEM J, V253, P607, DOI 10.1042/bj2530607; SCOTT JE, 1993, DERMATAN SULPHATE PR, P165; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; SVOBODA M, 1985, ANAL BIOCHEM, V151, P16, DOI 10.1016/0003-2697(85)90046-6; TAKAHASHI T, 1993, J HISTOCHEM CYTOCHEM, V41, P1447, DOI 10.1177/41.10.8245404; THIE M, 1991, EUR J CELL BIOL, V55, P295; VOGEL KG, 1987, BIOCHEM BIOPH RES CO, V148, P658, DOI 10.1016/0006-291X(87)90927-2; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOLKER W, 1985, J MICROSC-OXFORD, V138, P91; WRANA JL, 1988, J CELL BIOL, V106, P915, DOI 10.1083/jcb.106.3.915	48	310	315	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2776	2783		10.1074/jbc.270.6.2776	http://dx.doi.org/10.1074/jbc.270.6.2776			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852349	hybrid			2022-12-25	WOS:A1995QF53500059
J	REUSCH, JEB; BHURIPANYO, P; CAREL, K; LEITNER, JW; HSIEH, P; DEPAOLO, D; DRAZNIN, B				REUSCH, JEB; BHURIPANYO, P; CAREL, K; LEITNER, JW; HSIEH, P; DEPAOLO, D; DRAZNIN, B			DIFFERENTIAL REQUIREMENT FOR P21(RAS) ACTIVATION IN THE METABOLIC SIGNALING BY INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CARBOXYL METHYLATION; GUANINE-NUCLEOTIDES; GLUCOSE-TRANSPORT; KINASE-KINASE; RAS; P21RAS; TRANSDUCTION; STIMULATION	To evaluate the role of the ''Ras pathway'' in mediating metabolic signaling by insulin, we employed lovastatin to inhibit isoprenilation of Ras proteins in Rat-1 fibroblasts transfected with human insulin receptors (HIRc cells) and in differentiated 3T3-L1 adipocytes, Lovastatin blocked an ability of insulin to activate p21(ras) and mitogen-activated protein kinase, Lovastatin also significantly (p < 0.01) reduced insulin effects on thymidine incorporation and glucose incorporation into glycogen, Nevertheless, an effect of insulin on glucose uptake remained unaffected, It appears that in contrast to its mitogenic action and to its effect on glycogenesis, an effect of insulin on glucose uptake does not require p21(ras) activation.	VET AFFAIRS MED CTR,MED RES SERV,ENDOCRINOL SECT 111H,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Reusch, Jane/0000-0001-8620-1003				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; CASEY PJ, 1994, RECENT PROG HORM RES, V49, P215; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CLORE JN, 1994, DIABETES, V43, P256, DOI 10.2337/diabetes.43.2.256; COX AD, 1993, J BIOL CHEM, V268, P11548; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; DRAZNIN B, 1982, J BIOL CHEM, V257, P1988; FINGAR DC, 1994, J BIOL CHEM, V269, P10127; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; HEASLEY LE, 1994, IN PRESS AM J PHYSL; HEIDENREICH KA, 1989, J NEUROSCI RES, V22, P397, DOI 10.1002/jnr.490220405; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OKADA T, 1994, J BIOL CHEM, V269, P3568; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; THIES RS, 1989, J BIOL CHEM, V264, P12820; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; VOLKER C, 1991, J BIOL CHEM, V266, P21515; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597	27	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2036	2040		10.1074/jbc.270.5.2036	http://dx.doi.org/10.1074/jbc.270.5.2036			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836430	hybrid			2022-12-25	WOS:A1995QE49300011
J	DEGROOT, RP; SCHOUTEN, GJ; DEWIT, L; BALLOU, LM; VANDEREB, AJ; ZANTEMA, A				DEGROOT, RP; SCHOUTEN, GJ; DEWIT, L; BALLOU, LM; VANDEREB, AJ; ZANTEMA, A			INDUCTION OF THE MITOGEN-ACTIVATED P70 S6 KINASE BY ADENOVIRUS E1A	ONCOGENE			English	Article						E1A; ONCOGENE; TRANSCRIPTION; P70 S6 KINASE; PHOSPHORYLATION; TRANSFORMATION	RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; HUMAN CYCLIN-A; CELL-CYCLE; PROTEIN-KINASE; MAP KINASES; C-JUN; PHOSPHORYLATION; GROWTH; TRANSFORMATION	Adenovirus E1A proteins can transform primary cells in culture in conjunction with other oncogenes, such as E1B or activated ras. The modulation of various cell cycle regulators by E1A is thought to be involved in this transformation process. In this paper we show that E1A enhances the expression of the mitogen-inducible p70 S6 kinase (70(s6k)), a kinase which is essential for G1 progression. p70(s6k) mRNA and protein levels are enhanced 3-4-fold in various E1A-expressing cell lines. Similarly, the activity of p70(s6k) is enhanced in E1A-expressing cells in a manner partially independent of enhanced expression of p70(s6k) The induction of p70(s6k) correlates with the presence of conserved region 1 (CR1) of E1A and with morphological transformation by E1A. These results suggest that induction of p70(s6k) by E1A might be involved in transformation by E1A.	LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,LEIDEN,NETHERLANDS; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Leiden University; Leiden University - Excl LUMC; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)								BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BANNERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCHOU T, 1993, ONCOGENE, V8, P1765; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1991, ONCOGENE, V6, P2357; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FLINT SJ, 1990, MOL BIOL TUMOR VIRUS, V2, P547; FRANCO R, 1990, J BIOL CHEM, V265, P4321; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KIMELMAN D, 1986, MOL CELL BIOL, V6, P1487, DOI 10.1128/MCB.6.5.1487; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MORAN E, 1986, MOL CELL BIOL, V7, P3470; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; MUMMERY CL, 1985, DEV BIOL, V109, P402, DOI 10.1016/0012-1606(85)90466-X; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	59	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					543	548						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845679				2022-12-25	WOS:A1995QF64800015
J	LIU, QY; YAN, YX; MCCLURE, M; NAKAGAWA, H; FUJIMURA, F; RUSTGI, AK				LIU, QY; YAN, YX; MCCLURE, M; NAKAGAWA, H; FUJIMURA, F; RUSTGI, AK			MTS-1 (CDKN2) TUMOR-SUPPRESSOR GENE DELETIONS ARE A FREQUENT EVENT IN ESOPHAGUS SQUAMOUS CANCER AND PANCREATIC ADENOCARCINOMA CELL-LINES	ONCOGENE			English	Note						TUMOR SUPPRESSOR GENE; ESOPHAGUS CANCER; PANCREAS CANCER	BLADDER-CANCER; CHROMOSOME-9; EXPRESSION; RETINOBLASTOMA; MUTATION; RECEPTOR; REGION	MTS-1 is a candidate tumor suppressor gene on chromosome 9p21-22, a region frequently observed to have loss of heterozygosity in esophagus squamous cell carcinomas and pancreatic ductal adenocarcinomas. In order to determine whether MTS-1 sequences are deleted or mutated in cell lines derived from these cancers, we performed PCR amplification of MTS-1 exons 1 and 2. In this fashion, we found that 67% of esophagus squamous cancer cell lines have deletions of both exons 1 and 2, and 50% of pancreatic cancer cell lines have similar deletions. Furthermore, an additional 30% of pancreatic cancer cell lines harbored point mutations or microdeletions based on DNA sequencing. MTS-1 encodes p16, an inhibitor of cyclin-dependent kinase 4 (cdk4) which complexes with cyclin D1. Our data suggest that MTS-1 deletions and mutations may play an important role in the molecular pathogenesis of esophagus squamous cell and pancreatic cancers.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, GASTROINTESTINAL UNIT, BOSTON, MA 02114 USA; MYRIAD GENET INC, SALT LAKE CITY, UT 84108 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Myriad Genetics, Inc								ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; CAIRNS P, 1993, CANCER RES, V53, P1230; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HOHNE MW, 1992, CANCER RES, V52, P2616; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HORII A, 1992, CANCER RES, V52, P6696; HUANG Y, 1992, CANCER RES, V52, P6525; JAMES CD, 1993, CANCER RES, V53, P3674; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1992, CANCER RES, V52, P2980; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; LU SH, 1988, INT J CANCER, V42, P502, DOI 10.1002/ijc.2910420406; MERLO A, 1994, CANCER RES, V54, P640; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; REDSTON MS, 1994, CANCER RES, V54, P3025; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; RUPPERT JM, 1993, CANCER RES, V53, P5093; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEYMOUR AB, 1994, CANCER RES, V54, P2761; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; VANDERRIET P, 1994, CANCER RES, V54, P1156	26	84	88	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					619	622						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845688				2022-12-25	WOS:A1995QF64800024
J	VANDEL, L; PFARR, CM; HUGUIER, S; LOISEAU, L; SERGEANT, A; CASTELLAZZI, M				VANDEL, L; PFARR, CM; HUGUIER, S; LOISEAU, L; SERGEANT, A; CASTELLAZZI, M			INCREASED TRANSFORMING ACTIVITY OF JUNB AND JUND BY INTRODUCTION OF AN HETEROLOGOUS HOMODIMERIZATION DOMAIN	ONCOGENE			English	Article						CELLULAR TRANSFORMATION; JUN; DIMERIZATION; BZIP TRANSCRIPTION FACTOR; AP1	CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING PROTEIN; C-JUN; LEUCINE ZIPPER; ONCOGENE JUN; TRANSCRIPTIONAL ACTIVATION; CELLULAR-TRANSFORMATION; SARCOMA VIRUS; FOS PROTEINS; GENE FAMILY	The closely-related proteins c-Jun, JunB and JunD form a family of transcription factors which require dimerization for DNA-binding and transcriptional activity. Dimerization is mediated by a conserved amphipathic a-helix located adjacent to a highly charged DNA-binding domain. The Jun proteins can form both homo and heterodimers within the Jun family and can-also cross-dimerize with the Fos proteins. When expressed at high levels in primary chicken cells, each mouse Jun displays distinct transforming capacities: c-Jun transforms efficiently, JunB transforms poorly, and JunD does not transform at all, The composition of the transforming dimers; however, is unknown. To study the activity of Jun-Jun homodimers we constructed artificial derivatives, denoted Jun(eb1), the naturally occurring dimerization been replaced by an heterologous homodimerization domain from the Epstein-Barr virus transcription factor EB1. These derivatives were introduced into chicken cells and assayed for their ability to affect growth. Unexpectedly, all three Jun(eb1) proteins conferred a transformed phenotype to primary cultures, promoting sustained growth in low-serum medium and colony formation from single cells in agar. These data demonstrate that when forced to accumulate as homodimers, both JunB and JunD can transform cells. They also suggest that the poor transforming activity of JunB and the absence of transforming activity of JunD may be due to their inability to accumulate to high levels as homodimers.	ECOLE NORMALE SUPER LYON,INSERM,U412,UNITE VIROL HUMAINE,F-69364 LYON 07,FRANCE; ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,F-69364 LYON 07,FRANCE; INST PASTEUR,DEPT BIOTECHNOL,CNRS,URA 1644,UNITE VIRUS ONCOGENES,F-75724 PARIS,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Pfarr, Curt/HHD-1410-2022	Vandel, Laurence/0000-0002-3692-2942				ANDERSON DD, 1981, J VIROL, V37, P445, DOI 10.1128/JVI.37.1.445-458.1981; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BERGER I, 1991, ONCOGENE, V6, P561; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3241; CHIU R, 1989, CELL, V54, P541; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARRISON SC, 1991, NATURE, V363, P715; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1991, ONCOGENE, V6, P1623; HARTL M, 1992, CELL GROWTH DIFFER, V3, P909; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAVISTA N, 1994, ONCOL REP, V1, P185; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; METIVIER C, 1993, ONCOGENE, V8, P2311; MORGAN IM, 1992, ONCOGENE, V7, P1119; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TEMIN HM, 1960, VIROLOGY, V10, P182, DOI 10.1016/0042-6822(60)90038-6; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	64	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					495	507						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845674				2022-12-25	WOS:A1995QF64800010
J	ALLEN, DH; TRACY, PB				ALLEN, DH; TRACY, PB			HUMAN COAGULATION-FACTOR-V IS ACTIVATED TO THE FUNCTIONAL COFACTOR BY ELASTASE AND CATHEPSIN-G EXPRESSED AT THE MONOCYTE SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PLATELET ACTIVATION; FACTOR PATHWAY INHIBITOR; NEUTROPHIL ELASTASE; FACTOR-X; LEUKOCYTE ELASTASE; ALVEOLAR MACROPHAGES; DEGRADATION INVITRO; NEUTRAL PROTEASES; HUMAN-PROTHROMBIN; HEPARIN COFACTOR	The ability of intact peripheral blood monocytes to modulate factor V procoagulant activity was studied using electrophoretic and autoradiographic techniques coupled to functional assessment of cofactor activity. Incubation of plasma concentrations of factor V with monocytes (5 x 10(6)/ml) resulted in the time-dependent cleavage of the 330-kDa protein. Activation occurred via several high molecular mass intermediates (greater than or equal to 200 kDa) to yield peptides of 150, 140, 120, 94, 98, 82, and 80 kDa, which paralleled the expression of cofactor activity. The cleavage pattern observed differed from that obtained with either thrombin or factor Xa as an activator. The incubation time required to achieve full cofactor activity was dependent on the monocyte donor and ranged from 10 min to 1 h and was consistently slightly lower than that obtained with thrombin-activated factor Va. Cofactor activity was not diminished by additional incubation. The cofactor activity generated bound to the monocyte such that a competent prothrombinase complex was formed at the monocyte membrane surface. Furthermore, within 5 min of factor V addition to monocytes, near maximal cofactor activity (similar to 70%) was bound and expressed on the monocyte membrane. The proteolytic activity toward factor V was associated primarily with the monocyte membrane, as little proteolytic activity was released into the cell-free supernatant. Proteolytic activity was inhibited by diisopropyl fluorophosphate and phenylmethanesulfonyl fluoride. However, the inhibitor profile obtained with alpha(1)-antiproteinase inhibitor, alpha(1)-antichymotrypsin, and alpha(2)-macroglobulin suggested membrane-bound forms of elastase and cathepsin G were mediating, in large part, the proteolysis observed. These data were confirmed using purified preparations of both proteases and a specific anti-human leukocyte elastase antibody. Thus, expression of these proteases at the monocyte surface may contribute to thrombin generation at extravascular tissue sites by catalyzing the activation of the essential cofactor, factor Va, which binds to the monocyte surface and supports the factor Xa catalyzed activation of prothrombin.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405	University of Vermont					NHLBI NIH HHS [HL-34863, HL-46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL034863, R01HL034863, P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1989, J BIOL CHEM, V264, P2969; ANDERSSEN T, 1993, THROMB HAEMOSTASIS, P414; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAKER JB, 1979, NATURE, V278, P743, DOI 10.1038/278743a0; BARSHAVIT R, 1983, J CELL BIOL, V96, P282, DOI 10.1083/jcb.96.1.282; BINI A, 1989, ARTERIOSCLEROSIS, V9, P109, DOI 10.1161/01.ATV.9.1.109; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROWER MS, 1982, J BIOL CHEM, V257, P9849; CAMPBELL EJ, 1989, J IMMUNOL, V143, P2961; CAMPBELL EJ, 1987, CHEST, V92, P161, DOI 10.1378/chest.92.1.161; COLVIN RB, 1975, J IMMUNOL, V114, P377; ECKLE I, 1993, SCAND J CLIN LAB INV, V53, P281, DOI 10.3109/00365519309088420; ECKLE I, 1991, BIOL CHEM H-S, V372, P1007, DOI 10.1515/bchm3.1991.372.2.1007; EDWARDS RL, 1984, PROGR HEMOSTASIS THR, P183; FENTON JW, 1977, CHEM BIOL THROMBIN, P43; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; FUKS A, 1983, BIOCHIM BIOPHYS ACTA, V755, P195, DOI 10.1016/0304-4165(83)90203-9; HATTLER BG, 1973, CELL IMMUNOL, V9, P289, DOI 10.1016/0008-8749(73)90080-4; HIGUCHI DA, 1992, BLOOD, V79, P1712; Jesty J, 1976, Methods Enzymol, V45, P95; JOCHUM M, 1981, H-S Z PHYSIOL CHEM, V362, P103, DOI 10.1515/bchm2.1981.362.1.103; JORDAN RE, 1987, SCIENCE, V237, P777, DOI 10.1126/science.3649921; KANE WH, 1982, J CLIN INVEST, V70, P1092, DOI 10.1172/JCI110697; KARGI HA, 1990, J HISTOCHEM CYTOCHEM, V38, P1179, DOI 10.1177/38.8.2164060; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KOPEC M, 1980, THROMB HAEMOSTASIS, V43, P211; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; MACHOVICH R, 1989, BIOCHEMISTRY-US, V28, P4517, DOI 10.1021/bi00436a059; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MCGEE MP, 1991, J BIOL CHEM, V266, P8079; MCGOWAN SE, 1983, AM REV RESPIR DIS, V128, P688; MENKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAISEN EM, 1993, FEBS LETT, V317, P245, DOI 10.1016/0014-5793(93)81285-8; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OATES AM, 1987, BLOOD, V70, P846; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; OWEN WG, 1975, BIOCHIM BIOPHYS ACTA, V405, P380, DOI 10.1016/0005-2795(75)90103-8; PELLEGRINO MA, 1976, J IMMUNOL METHODS, V11, P273, DOI 10.1016/0022-1759(76)90120-4; PEMBERTON PA, 1989, BIOCHEM J, V258, P193, DOI 10.1042/bj2580193; PETERSEN LC, 1992, THROMB HAEMOSTASIS, V67, P537; RENESTO P, 1993, BLOOD, V82, P139, DOI 10.1182/blood.V82.1.139.bloodjournal821139; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; SCHMIDT W, 1975, THROMB RES, V6, P315, DOI 10.1016/0049-3848(75)90081-X; SELAK MA, 1992, THROMB HAEMOSTASIS, V68, P570; SIE P, 1987, THROMB RES, V47, P657, DOI 10.1016/0049-3848(87)90104-6; SMITH EB, 1990, ARTERIOSCLEROSIS, V10, P263, DOI 10.1161/01.ATV.10.2.263; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; TAKAKI A, 1983, J CLIN INVEST, V72, P1706, DOI 10.1172/JCI111130; TRACY PB, 1982, BLOOD, V60, P59; TRACY PB, 1985, J BIOL CHEM, V260, P2119; TRACY PB, 1983, J BIOL CHEM, V258, P7264; TRACY PB, 1983, FED PROC, V42, pA117; TURKINGTON PT, 1986, THROMB RES, V44, P339, DOI 10.1016/0049-3848(86)90008-3; TURKINGTON PT, 1991, HAEMOSTASIS, V21, P111; WEITZ JI, 1987, J EXP MED, V166, P1836, DOI 10.1084/jem.166.6.1836; WORFOLK LA, 1992, BLOOD, V80, P1989; WORFOLK LA, 1991, BLOOD S1, V78, pA58	60	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1408	1415		10.1074/jbc.270.3.1408	http://dx.doi.org/10.1074/jbc.270.3.1408			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836408	hybrid			2022-12-25	WOS:A1995QB15600065
J	PLAZA, S; TURQUE, N; DOZIER, C; BAILLY, M; SAULE, S				PLAZA, S; TURQUE, N; DOZIER, C; BAILLY, M; SAULE, S			C-MYB ACTS AS TRANSCRIPTIONAL ACTIVATOR OF THE QUAIL PAX6 (PAX-QNR) PROMOTER THROUGH 2 DIFFERENT MECHANISMS	ONCOGENE			English	Article						C-MYB; PAX-6-REGULATION; NEURORETINA	HOMEOBOX-CONTAINING GENE; DNA-BINDING DOMAIN; AVIAN-MYELOBLASTOSIS VIRUS; V-MYB; MIM-1 GENE; B-MYB; SYNERGISTIC ACTIVATION; FUNCTIONAL DOMAINS; PROTEIN TRUNCATION; ESTROGEN-RECEPTOR	To understand the regulation of the Pax-6 gene, which plays an important role in eye development, we have characterized the promoter region of the quail Pax-6(Pax-QNR) gene. In addition to TATA and CAAT boxes, sequence analysis revealed several putative cis-regulatory elements among which three myb-responsive elements (MRE). C-myb encodes a nuclear, DNA-binding phosphoprotein that functions as transcriptional regulator. Co-transfection in quail embryo cells of the Pax-QNRlpax-6 promoter with a vector expressing the 75 kDa c-myb protein resulted in an increase in Pax-QNR promoter activity. By footprinting experiments we identified multiple binding sites for the myb protein within the promoter region. Protein containing the myb DNA-binding domain fused to the VP16-transactivation domain was fully efficient in Pax-QNR promoter transactivation, demonstrating that myb can transactivate through a direct binding on DNA. However, a myb truncated protein devoid of DNA-binding domain was also able to transactivate the Pax-QNR promoter. These results show that this promoter can be transactivated by the myb protein directly as well as indirectly. Finally we show by in situ hybridization that c-myb is strongly expressed in the developing neuroretina, simultaneously with Pax-QNR. These observations suggest that the c-myb protein may be a regulator of Pax-QNR/pax-6.	INST PASTEUR,DIFFERENCIAT CELLULAIRE & MOLEC LAB,CNRS,EP56,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			DOZIER, Christine/P-1539-2014; plaza, serge/F-5290-2015					AKAM M, 1987, DEVELOPMENT, V101, P1; ANANTHAN J, 1993, MOL CELL BIOL, V13, P1599, DOI 10.1128/MCB.13.3.1599; ANSIEAU S, 1993, GENOMICS, V18, P537, DOI 10.1016/S0888-7543(11)80010-8; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; Crepieux Pascale, 1993, Gene Expression, V3, P215; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DOZIER C, 1993, CELL GROWTH DIFFER, V4, P281; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRASSER FA, 1992, ONCOGENE, V7, P1005; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LAM EWF, 1992, ONCOGENE, V7, P1185; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MARTIN P, 1992, ONCOGENE, V7, P1721; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MOELLING K, 1984, CELL, V40, P983; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKANO T, 1992, ONCOGENE, V7, P527; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NOMURA T, 1993, J BIOL CHEM, V268, P21914; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; QUEVA C, 1992, DEVELOPMENT, V114, P125; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	60	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					329	340						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838532				2022-12-25	WOS:A1995QC62400012
J	JONES, MJ; MURRAY, AW				JONES, MJ; MURRAY, AW			EVIDENCE THAT CERAMIDE SELECTIVELY INHIBITS PROTEIN-KINASE C-ALPHA TRANSLOCATION AND MODULATES BRADYKININ ACTIVATION OF PHOSPHOLIPASE-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN FIBROBLASTS; PROGRAMMED CELL-DEATH; LEUKEMIA HL-60 CELLS; SPHINGOID BASES; GROWTH-FACTOR; PHOSPHATIDYLCHOLINE; SPHINGOMYELINASE; DIACYLGLYCEROL; PHOSPHATIDYLINOSITOL; PROLIFERATION	Sphingomyelinase (SMase) treatment (0.1 unit/ml for up to 30 min) of mouse epidermal (HEL 37) or human skin fibroblast (SF 3155) cells preincubated with [H-3]serine to label the sphingomyelin pool caused the accumulation of labeled ceramide but not sphingosine or ceramide 1-phosphate. Incubation of HEL-37 cells with dioctanoylglycerol (diC(8)) or SF 3155 cells with bradykinin caused translocation of calcium/phosphatidylserine-dependent protein kinase C (PKC) activity to particulate material. In both cell lines the translocation was blocked by SMase treatment of the cells or by incubation with the cell-permeable ceramide analogue N-acetylsphingosine (C-2-Cer). Western blot analysis indicated that treatment of HEL-37 cells with diC(8) or SF 3155 cells with bradykinin resulted in the translocation of both PKC-alpha and PKC-epsilon to particulate material. Treatment with SMase or C-2-Cer specifically blocked the translocation of PKC-alpha but not that of PKC-epsilon. Pretreatment of cells with SMase or C-2-Cer also inhibited the activation of phospholipase D activity induced by either diC(8) (HEL-37 cells) or bradykinin (SF 3155 cells). The data provide strong evidence that ceramide can negatively regulate the translocation of PKC-alpha but not PKC-epsilon and further suggest that PKC-alpha may be involved in regulating phospholipase D activity.			JONES, MJ (corresponding author), FLINDERS UNIV S AUSTRALIA,FAC SCI & ENGN,SCH BIOL SCI,GPO BOX 2100,ADELAIDE,SA 5001,AUSTRALIA.							BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BALLOU LR, 1992, IMMUNOL TODAY, V13, P339, DOI 10.1016/0167-5699(92)90167-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAWSON RMC, 1967, BIOCHEM J, V102, P205, DOI 10.1042/bj1020205; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FU T, 1989, BIOCHEM BIOPH RES CO, V162, P1279, DOI 10.1016/0006-291X(89)90812-7; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GODSON C, 1990, J BIOL CHEM, V265, P8369; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HA KS, 1993, J BIOL CHEM, V268, P10534; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; IWATA M, 1994, INT IMMUNOL, V6, P431, DOI 10.1093/intimm/6.3.431; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MERRILL AH, 1992, NUTR REV, V50, P78; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MURRAY AW, 1979, BIOCHEM BIOPH RES CO, V91, P395, DOI 10.1016/0006-291X(79)91535-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; TAPLEY PM, 1984, BIOCHEM BIOPH RES CO, V118, P835, DOI 10.1016/0006-291X(84)91470-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANNAM RR, 1979, BIOCHIM BIOPHYS ACTA, V573, P73; YANG SF, 1967, J BIOL CHEM, V242, P477; YOUNES A, 1992, J BIOL CHEM, V267, P842	45	146	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5007	5013		10.1074/jbc.270.10.5007	http://dx.doi.org/10.1074/jbc.270.10.5007			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890607	hybrid			2022-12-25	WOS:A1995QL58000012
J	KATZ, RW; SUBAUSTE, JS; KOENIG, RJ				KATZ, RW; SUBAUSTE, JS; KOENIG, RJ			THE INTERPLAY OF HALF-SITE SEQUENCE AND SPACING ON THE ACTIVITY OF DIRECT REPEAT THYROID-HORMONE RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; VITAMIN-D RECEPTOR; DNA-BINDING; NUCLEAR RECEPTORS; AUXILIARY PROTEIN; HIGH-AFFINITY; X-RECEPTORS; PROMOTER; GENE; IDENTIFICATION	Direct repeats of the hexamer AGGTCA can serve as response elements for vitamin D, thyroid hormone, or retinoic acid. The specificity of the response appears to reside in the spacing between the hexamers, with response elements for vitamin D restricted to direct repeats separated by a 3-base pair (bp) spacer, thyroid hormone a 4-bp spacer, and retinoic acid a 5-bp spacer (3-4-5 rule). Recently we have shown that the optimum thyroid hormone receptor binding site consists of an 8-bp sequence (TAAGGTCA), not a hexamer. Therefore we tested whether the 3-4-5 rule is valid for octamer sequence direct repeats. In transfection experiments octamer direct repeats with 3-, 4-, or 5-bp spacers conferred equivalently strong thyroid hormone responses, although a repeat with a 9-bp spacer was substantially weaker. For the 4 and 5-bp spacer constructs, the 5' half-site octamer had as strong an influence on thyroid hormone induction as did the 3' half-site octamer, although for the 3-bp spacer construct the 5' octamer was marginally less potent than the 3' octamer. Transfection and gel shift experiments did not suggest a simple correlation between the binding of thyroid hormone receptor-retinoid X receptor heterodimers and thyroid hormone induction from these response elements. We conclude that half site sequence can override the effect of spacing in determining the hormone responsiveness of a direct repeat response element. In addition, the thyroid hormone response may not be due simply to the binding of thyroid hormone receptor-retinoid X receptor heterodimers to the DNA.			KATZ, RW (corresponding author), UNIV MICHIGAN,MED CTR,5560 MSRB II,1150 W MED CTR DR,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE00301] Funding Source: Medline; NIDDK NIH HHS [DK44155] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FREEDMAN LP, 1994, MOL ENDOCRINOL, V8, P265, DOI 10.1210/me.8.3.265; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KATZ RW, 1994, J BIOL CHEM, V269, P9500; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MADER S, 1993, J BIOL CHEM, V268, P591; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MOORE DD, 1986, GENE AMST, V45, P107; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NISHIKAWA J, 1993, J BIOL CHEM, V268, P19739; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PROST E, 1988, NUCLEIC ACIDS RES, V16, P6248, DOI 10.1093/nar/16.13.6248; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J BIOL CHEM, V268, P6444; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SUBAUSTE JS, 1994, J BIOL CHEM, V269, P30232; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	40	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 10	1995	270	10					5238	5242		10.1074/jbc.270.10.5238	http://dx.doi.org/10.1074/jbc.270.10.5238			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QL580	7890633	hybrid			2022-12-25	WOS:A1995QL58000045
J	DANAIE, P; WITTMER, B; ALTMANN, M; TRACHSEL, H				DANAIE, P; WITTMER, B; ALTMANN, M; TRACHSEL, H			ISOLATION OF A PROTEIN COMPLEX CONTAINING TRANSLATION INITIATION-FACTOR PRT1 FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; YEAST; TEMPERATURE; REGULATORS; GENES; GCN4	Translation initiation factor Prt1 was purified from a ribosomal salt wash fraction of Saccharomyces cerevisiae cells by ammonium sulfate precipitation, DEAE chromatography, phosphocellulose chromatography, sucrose density gradient centrifugation, and non-denaturing polyacrylamide gel electrophoresis. Prt1 protein cofractionates with four other polypeptides during all steps of purification suggesting that it is part of a protein complex containing polypeptide subunits with apparent molecular masses of 130, 80, 75 (Prt1), 40, and 32 kDa. Deletion of the first AUG codon in the published sequence of the PRT1 gene results in the synthesis of functional Prt1 protein indicating that the actual molecular mass of the Prt1 subunit is 82.7 kDa. This is in agreement with results from primer extension experiments reported earlier by Keierleber ct al, (Keierleber, C., Wittekind, M., Qin, S., and McLaughlin, C. S. (1986) Mol. Cell. Biol. 6, 4419-4424). The Prt1-containing protein complex is an active translation factor as shown by its ability to restore translation in a cell-free system derived from a temperature sensitive prt1 mutant strain in which endogenous Prt1 activity is inactivated by heating the extract to 37 degrees C. The question of whether the Prt1-containing protein complex represents the yeast homologue of mammalian translation initiation factor eIF-3 is discussed.	UNIV BERN,INST BIOCHEM & MOLEC BIOL,CH-3012 BERN,SWITZERLAND	University of Bern								ACHSTETTER T, 1984, J BIOL CHEM, V259, P3334; ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; CIGAN AM, 1993, P NATL ACAD SCI USA, V90, P5350, DOI 10.1073/pnas.90.11.5350; FEINBERG B, 1982, J BIOL CHEM, V257, P846; FENG L, 1993, TRANSLATIONAL REGULA, V2, P69; GASIOR E, 1979, J BIOL CHEM, V254, P3965; HANICJOYCE PJ, 1987, J BIOL CHEM, V262, P2845; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1993, TRANSLATIONAL REGULA, V2, P87; KEIERLEBER C, 1986, MOL CELL BIOL, V6, P4419, DOI 10.1128/MCB.6.12.4419; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LINDER P, 1992, ANTON LEEUW INT J G, V62, P47, DOI 10.1007/BF00584462; MANDEL T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P80, DOI 10.1016/0167-4781(89)90133-4; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MOLDAVE K, 1988, NATO ASI SER, V14, P271; MULLER PP, 1990, EUR J BIOCHEM, V191, P257, DOI 10.1111/j.1432-1033.1990.tb19118.x; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; Tuite M F, 1986, Yeast, V2, P35, DOI 10.1002/yea.320020103; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	27	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4288	4292		10.1074/jbc.270.9.4288	http://dx.doi.org/10.1074/jbc.270.9.4288			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876188	hybrid			2022-12-25	WOS:A1995QK08400019
J	LU, G; KOCHOUMIAN, L; KING, TP				LU, G; KOCHOUMIAN, L; KING, TP			SEQUENCE IDENTITY AND ANTIGENIC CROSS-REACTIVITY OF WHITE FACE HORNET VENOM ALLERGEN, ALSO A HYALURONIDASE, WITH OTHER PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM SURFACE PROTEIN; YELLOW JACKET VENOM; MOLECULAR-STRUCTURE; HYMENOPTERA VENOM; CDNA CLONING; BEE VENOM; T-CELL; SIMILARITY; MELITTIN; GENE	White face hornet (Dolichovespula maculata) venom has three known protein allergens which induce IgE response in susceptible people, They are antigen 5, phospholipase A(1), and hyaluronidase, also known as Dol m 5, 1, and 2, respectively, We have cloned Dol m 2, a protein of 331 residues, When expressed in bacteria, a mixture of recombinant Dol m 2 and its fragments was obtained, The fragments were apparently generated by proteolysis of a Met-Met bond at residue 122, as they were not observed for a Dol m 2 mutant with a Leu-Met bond. Dol m 2 has 56% sequence identity with the honey bee venom allergen hyaluronidase and 27% identity with PH-20, a human sperm protein with hyaluronidase activity, A common feature of hornet venom allergens is their sequence identity with other proteins in our environment, We showed previously the sequence identity of Dol m 5 with a plant protein and a mammalian testis protein and of Dol m 1 with mammalian lipases. In BALB/c mice, Dol m 2 and bee hyaluronidase showed cross-reactivity at both antibody and T cell levels, These findings are relevant to some patients' multiple sensitivity to hornet and bee stings.			LU, G (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017021] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17021] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CLARK MA, 1987, J BIOL CHEM, V262, P4402; DEVRIES JE, 1994, ALLERGY CLIN IMMUNOL, V6, P49; DORFMAN A, 1955, METHOD ENZYMOL, V1, P166, DOI 10.1016/0076-6879(55)01023-9; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1990, AMPLIFICATIONS, V5, P11; GEFTER ML, 1992, CURRENT THERAPY ALLE, P376; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; GMACHL M, 1993, FEBS LETT, V336, P545, DOI 10.1016/0014-5793(93)80873-S; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN DR, 1984, ANN ALLERGY, V52, P276; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P187; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; KAETZEL MA, 1987, J BIOL CHEM, V262, P3726; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; KING TP, 1995, J IMMUNOL, V154, P577; KING TP, 1994, WHO B, V72, P797; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE RO, 1989, J IMMUNOL, V143, P553; LATHROP WF, 1990, J CELL BIOL, V111, P2939, DOI 10.1083/jcb.111.6.2939; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LIN Y, 1993, P NATL ACAD SCI USA, V90, P10071, DOI 10.1073/pnas.90.21.10071; LU G, 1993, J IMMUNOL, V150, P2823; MIZUKI N, 1992, MAMM GENOME, V3, P274, DOI 10.1007/BF00292155; NORMAN PS, 1993, CURR OPIN IMMUNOL, V5, P968, DOI 10.1016/0952-7915(93)90114-8; REISMAN RE, 1994, NEW ENGL J MED, V331, P523, DOI 10.1056/NEJM199408253310808; SOLDATOVA L, 1993, J ALLERGY CLIN IMMUN, V91, P283; SOLDATOVA L, 1993, FEBS LETT, V320, P145, DOI 10.1016/0014-5793(93)80080-E; VERHEIJ HM, 1983, BIOCHIM BIOPHYS ACTA, V747, P93, DOI 10.1016/0167-4838(83)90126-7; WYPCH J, 1989, INT ARCH ALLER A IMM, V89, P60	40	69	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4457	4465		10.1074/jbc.270.9.4457	http://dx.doi.org/10.1074/jbc.270.9.4457			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876212	hybrid			2022-12-25	WOS:A1995QK08400044
J	ODERMATT, A; SOLIOZ, M				ODERMATT, A; SOLIOZ, M			2 TRANS-ACTING METALLOREGULATORY PROTEINS CONTROLLING EXPRESSION OF THE COPPER-ATPASES OF ENTEROCOCCUS-HIRAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON DISEASE GENE; CANDIDATE GENE; MENKES DISEASE; BACILLUS-LICHENIFORMIS; TRANSCRIPTION FACTOR; TRANSPORTING ATPASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; BINDING-PROTEIN; RESISTANCE	Enterococcus hirae possesses two P-type ATPases, CopA and CopB, that are involved in copper homeostasis. These enzymes are induced by extracellular copper concentrations that are either tao low or too high for optimal growth, To identify the regulatory proteins involved in induction, the DNA upstream of copA was cloned and sequenced. Following a putative promoter region, it contains two genes, copY and copZ, that encode proteins of 145 and 69 amino acids, respectively. Both proteins contain metal binding motifs and exhibit significant sequence similarity to known regulatory proteins, Gene disruption of CopY by reverse genetics caused constitutive overexpression of CopA and CopB, generating a copper-dependent phenotype, In contrast, disruption of copZ suppressed the expression of the two copper-ATPases, rendering the cells copper-sensitive. Both null mutations could be complemented in trans with plasmids bearing copY or copZ. Thus, copY and copZ encode trans acting metalloregulatory proteins that are required for induction of the cop operon by copper. In this mechanism, CopY apparently acts as a metal-fist type repressor and CopZ as an activator.	UNIV BERN,DEPT CLIN PHARMACOL,CH-3010 BERN,SWITZERLAND	University of Bern			Solioz, Marc/I-3162-2013	Solioz, Marc/0000-0002-7989-6721; Odermatt, Alex/0000-0002-6820-2712				ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DODD IB, 1987, J MOL BIOL, V194, P557, DOI 10.1016/0022-2836(87)90681-4; FURST P, 1989, P NATL ACAD SCI USA, V86, P5267, DOI 10.1073/pnas.86.14.5267; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; HIMENO T, 1986, J BACTERIOL, V168, P1128, DOI 10.1128/jb.168.3.1128-1132.1986; INOUE C, 1989, GENE, V84, P47, DOI 10.1016/0378-1119(89)90138-8; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KAHN D, 1989, J BACTERIOL, V171, P929, DOI 10.1128/jb.171.2.929-939.1989; KANAMARU K, 1994, MOL MICROBIOL, V13, P369, DOI 10.1111/j.1365-2958.1994.tb00430.x; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; MACRINA FL, 1982, GENE, V19, P345, DOI 10.1016/0378-1119(82)90025-7; Maniatis T., 1982, MOL CLONING; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; MILLS SD, 1994, MOL GEN GENET, V244, P341, DOI 10.1007/BF00286685; MILLS SD, 1993, J BACTERIOL, V175, P1656, DOI 10.1128/JB.175.6.1656-1664.1993; MISRA TK, 1984, P NATL ACAD SCI USA, V81, P5974; NUCIFORA G, 1989, J BACTERIOL, V171, P4241, DOI 10.1128/JB.171.8.4241-4247.1989; ODERMATT A, 1994, BIOCHEM BIOPH RES CO, V202, P44, DOI 10.1006/bbrc.1994.1891; ODERMATT A, 1992, ANN NY ACAD SCI, V671, P484, DOI 10.1111/j.1749-6632.1992.tb43836.x; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER S, 1993, CHEM COPPER ZINC TRI; SOLIOZ M, 1994, FEBS LETT, V346, P44, DOI 10.1016/0014-5793(94)00316-5; SOLIOZ M, 1990, BIOCHIMIE, V72, P279, DOI 10.1016/0300-9084(90)90084-T; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WITTMAN V, 1988, J BACTERIOL, V170, P3206, DOI 10.1128/jb.170.7.3206-3212.1988; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112	36	134	140	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4349	4354		10.1074/jbc.270.9.4349	http://dx.doi.org/10.1074/jbc.270.9.4349			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876197	hybrid			2022-12-25	WOS:A1995QK08400028
J	OKAMOTO, T; TAKEDA, S; MURAYAMA, Y; OGATA, E; NISHIMOTO, I				OKAMOTO, T; TAKEDA, S; MURAYAMA, Y; OGATA, E; NISHIMOTO, I			LIGAND-DEPENDENT G-PROTEIN COUPLING FUNCTION OF AMYLOID TRANSMEMBRANE PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FAMILIAL ALZHEIMERS-DISEASE; NUCLEOTIDE-BINDING PROTEINS; ISLET-ACTIVATING PROTEIN; GROWTH-FACTOR; REGULATORY COMPONENT; SIGNAL-TRANSDUCTION; MISSENSE MUTATION; ADENYLYL CYCLASE; HORMONE RECEPTOR; PERTUSSIS TOXIN	Amyloid precursor protein (APP), a transmembrane precursor of beta-amyloid, possesses a function whereby it associates with G(o) through its cytoplasmic His(657)- Lys(676). Here we demonstrate that APP has a receptor function. In phospholipid vesicles consisting of baculovirally made APP(695) and brain trimeric G(o), 22C11, a monoclonal antibody against the extracellular domain of APP, increased GTP gamma S binding and the turnover number of GTPase of G(o) without affecting its intrinsic GTPase activity. This effect of 22C11 was specific among various antibodies and was observed neither in G(o) vesicles nor in APP(695)/G(i2) vesicles. In APP(695)/G(o) vesicles, synthetic APP(66-81), the epitope of 22C11, competitively antagonized the action of 22C11. Monoclonal antibody against APP(657-676), the G(o) binding domain of APP(695), specifically blocked 22C11-dependent activation of G(o). Therefore, APP has a potential receptor function whereby it specifically activates G(o) in a ligand-dependent and ligand-specific manner.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02129; UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,BUNKYO KU,TOKYO 112,JAPAN; CANC RES INST,TOSHIMA KU,TOKYO 170,JAPAN	Harvard University; Harvard Medical School; University of Tokyo	OKAMOTO, T (corresponding author), MASSACHUSETTS GEN HOSP E,CARDIOVASC RES CTR,149 13TH ST,BOSTON,MA 02129, USA.							BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BODMER S, 1990, BIOCHEM BIOPH RES CO, V171, P890, DOI 10.1016/0006-291X(90)91229-L; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHEN M, 1991, NEUROSCI LETT, V125, P223, DOI 10.1016/0304-3940(91)90034-Q; COWBURN RF, 1992, J NEUROCHEM, V58, P1409, DOI 10.1111/j.1471-4159.1992.tb11357.x; COWBURN RF, 1993, NEUROSCI LETT, V155, P163, DOI 10.1016/0304-3940(93)90698-K; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FLYNN DD, 1991, ANN NEUROL, V29, P256, DOI 10.1002/ana.410290305; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GIBSON GE, 1992, MECH AGEING DEV, V63, P1, DOI 10.1016/0047-6374(92)90012-3; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HILBICH C, 1993, J BIOL CHEM, V268, P26571; HUANG HM, 1993, J BIOL CHEM, V268, P14616; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; IYENGAR R, 1982, P NATL ACAD SCI-BIOL, V79, P5179, DOI 10.1073/pnas.79.17.5179; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; KATADA T, 1986, J BIOL CHEM, V261, P8182; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KNOPS J, 1991, J BIOL CHEM, V266, P7285; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; MONNING U, 1992, J BIOL CHEM, V267, P23950; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SMITH CJ, 1989, BIOCHEM SOC T, V17, P202, DOI 10.1042/bst0170202; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; UEDA K, 1989, ANN NEUROL, V25, P246, DOI 10.1002/ana.410250307; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z	49	149	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4205	4208		10.1074/jbc.270.9.4205	http://dx.doi.org/10.1074/jbc.270.9.4205			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876177	hybrid			2022-12-25	WOS:A1995QK08400007
J	ROS, R; ROMIEU, C; GIBRAT, R; GRIGNON, C				ROS, R; ROMIEU, C; GIBRAT, R; GRIGNON, C			THE PLANT INORGANIC PYROPHOSPHATASE DOES NOT TRANSPORT K+ IN VACUOLE MEMBRANE-VESICLES MULTILABELED WITH FLUORESCENT-PROBES FOR H+,K+, AND MEMBRANE-POTENTIAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TONOPLAST VESICLES; PROTON TRANSPORT; ANION TRANSPORT; OAT ROOTS; PUMPING PYROPHOSPHATASE; H+; POTASSIUM; ACTIVATION; CELLS	It has been claimed that the inorganic pyrophosphatase (PPase) of the plant vacuolar membrane transports K+ in addition to H+ in intact vacuoles (Davies, J. M., Poole, R. J., Rea, P. A., and Sanders, D. (1992) Proc. Natl. Acad. Sci. U. S. A, 89, 11701-11705). Since this was not confirmed using the purified and reconstituted PPase consisting of a 75-kDa polypeptide (Sate, M, H,, Kasahara, M., Ishii, N., Homareda, H., Matsui, H., and Yoshida, M. (1994) J. Biol. Chem. 269, 6725-6728), these authors proposed that K+ transport by the PPase is dependent on its association with other membrane components lost during purification. We have examined the hypothesis of K+ translocation by the PPase using native vacuolar membrane vesicles from Vitis vinifera suspension cells, multilabeled with fluorescent probes for K+, H+, and membrane potential. This material con contained a high proportion of right-side-out, tightly sealed vesicles, exhibiting high PPase activity which was strongly stimulated by uncouplers and K+. Proton pumping occurred in response to pyrophosphate addition in the absence of K+. No K+ incorporation into the vesicles could be observed after PPase energization in the presence of K+, although H+ transport was highly stimulated. The hydrolytic activity was stimulated by a protonophore and by a H+/B+ exchanger but not by the K+ ionophore valinomycin. No evidence could be obtained supporting the operation of an endogenous K+/H+ exchanger capable to dissipate the putative active K+ flux generated by the PPase, We conclude that PPase in native vacuolar membrane vesicles does not transport K+.	INRA,ENSA M,INST PROD VIGNE,CNRS,URA 573,F-34060 MONTPELLIER 1,FRANCE; UNIV VALENCIA,FAC CIENCIES BIOL,DEPT BIOL VEGETAL,E-46100 BURJASSOT,SPAIN	Centre National de la Recherche Scientifique (CNRS); INRAE; Universite de Montpellier; University of Valencia			Ros, Roc/F-3033-2015; romieu, charles/C-2115-2015	Ros, Roc/0000-0003-4254-8368; romieu, charles/0000-0003-2607-8335				AMBID C, 1983, PHYSIOL VEG, V21, P87; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BRAUER D, 1988, PLANT PHYSIOL, V87, P598, DOI 10.1104/pp.87.3.598; BRITTEN CJ, 1992, J BIOL CHEM, V267, P21850; COOPER S, 1991, PLANT PHYSIOL, V97, P1212, DOI 10.1104/pp.97.3.1212; DAVIES JM, 1992, P NATL ACAD SCI USA, V89, P11701, DOI 10.1073/pnas.89.24.11701; DAVIES JM, 1991, FEBS LETT, V278, P66, DOI 10.1016/0014-5793(91)80085-H; GIANNINI JL, 1987, PLANT PHYSIOL, V84, P613, DOI 10.1104/pp.84.3.613; GIBRAT R, 1990, PLANT PHYSIOL, V93, P1183, DOI 10.1104/pp.93.3.1183; HEDRICH R, 1989, ANNU REV PLANT PHYS, V40, P539, DOI 10.1146/annurev.pp.40.060189.002543; KAESTNER KH, 1987, PLANT PHYSIOL, V83, P483, DOI 10.1104/pp.83.3.483; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; LUTTGE U, 1979, TRANSPORT PLANTS, P124; MACROBBIE E A C, 1970, Quarterly Reviews of Biophysics, V3, P251; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; MARQUARDTJARCZYK G, 1990, J PLANT PHYSIOL, V136, P129, DOI 10.1016/S0176-1617(11)81654-8; POPE AJ, 1987, PLANTA, V172, P91, DOI 10.1007/BF00403033; REA PA, 1992, PLANT PHYSIOL, V100, P723, DOI 10.1104/pp.100.2.723; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; SARAFIAN V, 1992, P NATL ACAD SCI USA, V89, P1775, DOI 10.1073/pnas.89.5.1775; SATO MH, 1994, J BIOL CHEM, V269, P6725; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SZE H, 1985, ANNU REV PLANT PHYS, V36, P175, DOI 10.1146/annurev.pp.36.060185.001135; TAKESHIGE K, 1988, PLANT CELL PHYSIOL, V29, P649; VENEMA K, 1993, BIOCHIM BIOPHYS ACTA, V1146, P87, DOI 10.1016/0005-2736(93)90342-W; WANG YZ, 1986, PLANT PHYSIOL, V81, P497, DOI 10.1104/pp.81.2.497; WHITE PJ, 1990, PLANT PHYSIOL, V93, P1063, DOI 10.1104/pp.93.3.1063	28	28	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4368	4374		10.1074/jbc.270.9.4368	http://dx.doi.org/10.1074/jbc.270.9.4368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876200	hybrid, Green Submitted			2022-12-25	WOS:A1995QK08400031
J	YOSHIKAWA, S; MOCHIZUKI, M; ZHAO, XJ; CAUGHEY, WS				YOSHIKAWA, S; MOCHIZUKI, M; ZHAO, XJ; CAUGHEY, WS			EFFECTS OF OVERALL OXIDATION-STATE ON INFRARED-SPECTRA OF HEME A(3) CYANIDE IN BOVINE HEART CYTOCHROME-C-OXIDASE - EVIDENCE OF NOVEL MECHANISTIC ROLES FOR CU-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTROSCOPY; PRIMARY OXYGEN INTERMEDIATE; OUTER CATION INTERACTIONS; ELECTRON-TRANSFER; DIOXYGEN REDUCTION; BRIDGED COPPER(II); MAGNETIC EXCHANGE; BINDING; LIGAND; TEMPERATURE	Effects of changes in oxidation state at the other metal centers on oxidized heme alpha(3) cyanide of bovine heart cytochrome c oxidase have been investigated. Only one CN- binds, giving Fea33+CN, in fully-oxidized cytochrome c oxidase and its 1-, 2-, and 3-electron reduction products. Soret/visible spectra for the heme alpha(3) cyanide are independent of overall redox level, whereas distinct shifts in C-N infrared stretch band frequency occur upon reduction, reflecting changes in the polarity of the ligand (CN-) environment. Catalysis of O-2 reduction can be critically dependent upon such changes in polarity at the reduction site. These findings indicate that Cu-B, when reduced, exists in two forms whose relative stabilities are independent of Fe-a and Cu-A oxidation states and, when oxidized, is in only one stable form. These results are consistent with the oxidation of Cu-B(+) triggering proton pumping and with the involvement of a Cu-B Ligand in respiratory control. Electron equivalents introduced into the enzyme are distributed equally among Fe-a, Cu-A, and Cu-B, which raises the possibility that ah four electrons used in O-2 reduction are donated via Cu-B(+), which is favorably positioned with respect to Fe-a3 (the O-2 binding site) in order to carry out this role in electron transfers.	HIMEJI INST TECHNOL, DEPT LIFE SCI, AKOH, HYOGO 67812, JAPAN	University of Hyogo	YOSHIKAWA, S (corresponding author), COLORADO STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, FT COLLINS, CO 80523 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM030306, R01GM030306] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30306] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBEN JO, 1981, P NATL ACAD SCI-BIOL, V78, P234, DOI 10.1073/pnas.78.1.234; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BERRY KJ, 1980, NOUV J CHIM, V4, P581; BERTRAN JF, 1990, SPECTROCHIM ACTA A, V46, P685, DOI 10.1016/0584-8539(90)80023-R; BERTRAN JF, 1990, SPECTROCHIM ACTA A, V46, P1679, DOI 10.1016/0584-8539(90)80237-S; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; Caughey W. S., 1980, METHODS DETERMINING, P95; CAUGHEY WS, 1993, J BIOENERG BIOMEMBR, V25, P81, DOI 10.1007/BF00762850; CAUGHEY WS, 1976, ENZYMES, V13, P299; COPELAND RA, 1991, P NATL ACAD SCI USA, V88, P7281, DOI 10.1073/pnas.88.16.7281; DOORN SK, 1993, J AM CHEM SOC, V115, P6398, DOI 10.1021/ja00067a065; DUGGAN DM, 1974, J AM CHEM SOC, V96, P3443, DOI 10.1021/ja00818a017; DUGGAN DM, 1974, INORG CHEM, V13, P1911, DOI 10.1021/ic50138a024; EINARSDOTTIR O, 1988, J BIOL CHEM, V263, P13641; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; GUNTER MJ, 1984, J AM CHEM SOC, V106, P4227, DOI 10.1021/ja00327a027; HAN S, 1990, P NATL ACAD SCI USA, V87, P8408, DOI 10.1073/pnas.87.21.8408; HILL BC, 1984, BIOCHEM J, V218, P913, DOI 10.1042/bj2180913; HILL BC, 1994, J BIOL CHEM, V269, P2419; HILL BC, 1983, BIOCHEM J, V215, P57, DOI 10.1042/bj2150057; HILL BC, 1986, BIOCHIM BIOPHYS ACTA, V256, P258; JOHNSON MK, 1981, BIOCHEM J, V193, P699, DOI 10.1042/bj1930699; Keilin D, 1939, PROC R SOC SER B-BIO, V127, P167, DOI 10.1098/rspb.1939.0016; LANDEE CP, 1979, INORG CHEM, V18, P2317, DOI 10.1021/ic50198a055; LI WB, 1993, BIOCHEMISTRY-US, V32, P1833, DOI 10.1021/bi00058a018; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; Nakamoto K., 1978, INFRARED RAMAN SPECT; OGURA T, 1991, B CHEM SOC JPN, V64, P2901, DOI 10.1246/bcsj.64.2901; OGURA T, 1993, J AM CHEM SOC, V115, P8527, DOI 10.1021/ja00072a002; OLIVEBERG M, 1992, BIOCHEMISTRY-US, V31, P3560, DOI 10.1021/bi00129a002; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; SCOTT RA, 1989, ANNU REV BIOPHYS BIO, V18, P137, DOI 10.1146/annurev.bb.18.060189.001033; SHERMAN D, 1991, P NATL ACAD SCI USA, V88, P4265, DOI 10.1073/pnas.88.10.4265; THOMSON AJ, 1982, BIOCHEM J, V207, P167, DOI 10.1042/bj2070167; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P9262, DOI 10.1021/bi00086a038; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P164, DOI 10.1021/bi00052a022; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; Warburg O, 1929, BIOCHEM Z, V214, P64; WEINTRAUB ST, 1981, J BIOL CHEM, V256, P1669; WIKSTROM M, 1992, J BIOL CHEM, V267, P10266; WOODRUFF WH, 1991, P NATL ACAD SCI USA, V88, P2588, DOI 10.1073/pnas.88.6.2588; YOSHIKAWA S, 1985, J BIOL CHEM, V260, P3518; YOSHIKAWA S, 1982, J BIOL CHEM, V257, P412; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354; YOSHIKAWA S, 1990, J BIOL CHEM, V265, P7945; YOSHIKAWA S, 1973, J BIOCHEM, V73, P637, DOI 10.1093/oxfordjournals.jbchem.a130122; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P9757	50	40	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4270	4279		10.1074/jbc.270.9.4270	http://dx.doi.org/10.1074/jbc.270.9.4270			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876186	hybrid			2022-12-25	WOS:A1995QK08400017
J	HABUCHI, H; HABUCHI, O; KIMATA, K				HABUCHI, H; HABUCHI, O; KIMATA, K			PURIFICATION AND CHARACTERIZATION OF HEPARAN-SULFATE 6-SULFOTRANSFERASE FROM THE CULTURE-MEDIUM OF CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; D-GLUCOSAMINYLTRANSFERASE REACTIONS; CHICK-EMBRYO CHONDROCYTES; RAT-LIVER; CHONDROITIN 6-SULFOTRANSFERASE; POLYMER-MODIFICATION; MOLECULAR-CLONING; O-SULFATION; BIOSYNTHESIS; SULFOTRANSFERASE	Heparan sulfate 6-sulfotransferase, which catalyzes the transfer of sulfate from S'-phosphoadenylyl sulfate to position 6 of N-sulfoglucosamine in heparan sulfate, was purified 10,700-fold to apparent homogeneity with a 40% yield from the serum-free culture medium of Chinese hamster ovary cells. The isolation procedure included affinity chromatography of the first heparin-Sepharose CL-GB column (stepwise elution), 3',5'-ADP-agarose, and the second heparin-Sepharose CL-6B column (gradient elution). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the purified enzyme showed two protein bands with molecular masses of 52 and 45 kDa. Both proteins appeared to be glycoproteins, because their molecular masses decreased after N-glycanase digestion. When completely desulfated and N-resulfated heparin was used as acceptor, the purified enzyme transferred sulfate to position 6 of N-sulfoglucosamine residue but did not transfer sulfate to the amino group of glucosamine residue or to position 2 of the iduronic acid residue. Heparan sulfate was also sulfated by the purified enzyme at position 6 of N-sulfoglucosamine residue. Chondroitin and chondroitin sulfate did not serve as accepters. The optimal pH for enzyme activity was around 6.3. The enzyme activity was inhibited by dithiothreitol and was stimulated strongly by protamine. The K-m, value for adenosine S'-phosphate 5'-phosphosulfate was 0.44 mu M.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN; AICHI UNIV EDUC,DEPT LIFE SCI,KARIYA,AICHI 448,JAPAN	Aichi Medical University; Aichi University Education								AVIEZER D, 1994, J BIOL CHEM, V269, P114; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; GOHLER D, 1984, EUR J BIOCHEM, V138, P301, DOI 10.1111/j.1432-1033.1984.tb07915.x; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HABUCHI O, 1991, BIOCHIM BIOPHYS ACTA, V1133, P9; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; INOUE H, 1986, J BIOL CHEM, V261, P4460; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; ISHIHARA M, 1992, GLYCOBIOLOGY, V3, P400; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS G, 1989, BIOCHEM J, V261, P389, DOI 10.1042/bj2610389; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIND T, 1993, J BIOL CHEM, V268, P20705; Lindahl U., 1989, HEPARIN, P159; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MANDON E, 1994, J BIOL CHEM, V269, P11729; NAKANISHI H, 1992, BIOCHEM J, V288, P215, DOI 10.1042/bj2880215; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; STROMINGER JL, 1959, J BIOL CHEM, V234, P3263; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WEINSTEIN J, 1987, J BIOL CHEM, V263, P17735; WLAD H, 1994, J BIOL CHEM, V269, P24538; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69	44	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					4172	4179		10.1074/jbc.270.8.4172	http://dx.doi.org/10.1074/jbc.270.8.4172			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876170	hybrid			2022-12-25	WOS:A1995QH68800104
J	AMIRHAERI, S; WOHLRAB, F; WELLS, RD				AMIRHAERI, S; WOHLRAB, F; WELLS, RD			DIFFERENTIAL-EFFECTS OF SIMPLE REPEATING DNA-SEQUENCES ON GENE-EXPRESSION FROM THE SV40 EARLY PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENT INVERSION SITE; B-DNA; TRINUCLEOTIDE REPEAT; SECONDARY STRUCTURE; MUSCULAR-ATROPHY; POLY(DG) REGION; ENDONUCLEASE-G; TELOMERIC DNA; FRAGILE-X; MUTATIONS	The influence of simple repeat sequences, cloned into different positions relative to the SV40 early promoter/enhancer, on the transient expression of the chloramphenicol acetyltransferase (CAT) gene was investigated. Insertion of (G)(29).(C)(29) in either orientation into the 5'-untranslated region of the CAT gene reduced expression in CV-1 cells 50-100 fold when compared with controls with random sequence inserts. Analysis of CAT-specific mRNA levels demonstrated that the effect was due to a reduction of CAT mRNA production rather than to posttranscriptional events. In contrast, insertion of the same insert in either orientation upstream of the promoter enhancer or downstream of the gene stimulated gene expression 2-3-fold. These effects could be reversed by cotransfection of a competitor plasmid carrying (G)(25).(C)(25) sequences. The results suggest that a G.C-binding transcription factor modulates gene expression in this system and that promoter strength can be regulated by providing protein binding sites in trans. Although constructs containing longer tracts of alternating (C-G), (T-G), or (A-T) sequences inhibited CAT expression when inserted in the 5'-untranslated region of the CAT gene, the amount of CAT mRNA was unaffected. Hence, these inhibitions must be due to posttranscriptional events, presumably at the level of translation. These effects of microsatellite sequences on gene expression are discussed with respect to recent data on related simple repeat sequences which cause several human genetic diseases.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294; TEXAS A&M UNIV,TEXAS MED CTR,INST BIOSCI & TECHNOL,HOUSTON,TX 77030	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Baylor College of Medicine; Texas A&M University System					NIGMS NIH HHS [GM 30822] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030822] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BERGER SL, 1987, METHOD ENZYMOL, V152, P182; Biancalana V., 1992, Human Molecular Genetics, V1, P255, DOI 10.1093/hmg/1.4.255; BLAHO JA, 1988, J BIOL CHEM, V263, P14446; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; CASASNOVAS JM, 1987, EUR J BIOCHEM, V167, P489, DOI 10.1111/j.1432-1033.1987.tb13363.x; CASKEY CT, 1991, SCIENCE, V256, P784; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SP, 1990, NUCLEIC ACIDS RES, V18, P5119, DOI 10.1093/nar/18.17.5119; COTE J, 1989, J BIOL CHEM, V264, P3301; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTLIEB J, 1988, MOL CELL BIOL, V6, P2513; HAPGOOD J, 1994, MOL CELL BIOL, V14, P1402, DOI 10.1128/MCB.14.2.1402; HIGGINS GJ, 1992, NAT GENET, V2, P186; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOWARD H, 1984, MOL CELL BIOL, V4, P2622; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; KOHWI Y, 1989, NUCLEIC ACIDS RES, V17, P4493, DOI 10.1093/nar/17.12.4493; KOHWISHIGEMATSU T, 1986, CELL, V43, P199; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEWIS CD, 1988, GENE DEV, V2, P863, DOI 10.1101/gad.2.7.863; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; LU GH, 1993, INT J BIOCHEM, V25, P1529, DOI 10.1016/0020-711X(93)90508-C; LUKOMSKI S, 1994, P NATL ACAD SCI USA, V91, P9980, DOI 10.1073/pnas.91.21.9980; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCARTHY JG, 1987, NUCLEIC ACIDS RES, V15, P8069, DOI 10.1093/nar/15.19.8069; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MIVA S, 1994, NAT GENET, V6, P3; MURCHIE AIH, 1992, BIOCHIM BIOPHYS ACTA, V1131, P1, DOI 10.1016/0167-4781(92)90091-D; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; RUIZCARRILLO A, 1987, EMBO J, V6, P401, DOI 10.1002/j.1460-2075.1987.tb04769.x; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; USSERY DW, 1993, BIOCHEMISTRY-US, V32, P6206, DOI 10.1021/bi00075a013; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WELLS R D, 1990, P25; WELLS RD, 1982, J BIOL CHEM, V257, P166; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WOHLRAB F, 1989, J BIOL CHEM, V264, P8207; WOHLRAB F, 1991, P NATL ACAD SCI USA, V88, P6432, DOI 10.1073/pnas.88.15.6432; WOHLRAB F, 1987, J BIOL CHEM, V262, P6407; YEE CJ, 1994, CANCER RES, V54, P1641; ZACHARIAS W, 1988, P NATL ACAD SCI USA, V85, P7069, DOI 10.1073/pnas.85.19.7069; ZHENG GX, 1991, J MOL BIOL, V221, P107, DOI 10.1016/0022-2836(91)80208-C; ZHU QS, 1990, NUCLEIC ACIDS RES, V18, P7119, DOI 10.1093/nar/18.23.7119; 1993, CELL, V72, P971	61	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3313	3319		10.1074/jbc.270.7.3313	http://dx.doi.org/10.1074/jbc.270.7.3313			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852417				2022-12-25	WOS:A1995QG47100064
J	INAGAKI, Y; TRUTER, S; TANAKA, S; DILIBERTO, M; RAMIREZ, F				INAGAKI, Y; TRUTER, S; TANAKA, S; DILIBERTO, M; RAMIREZ, F			OVERLAPPING PATHWAYS MEDIATE THE OPPOSING ACTIONS OF TUMOR-NECROSIS-FACTOR-ALPHA AND TRANSFORMING GROWTH-FACTOR-BETA ON ALPHA-2(I) COLLAGEN GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; FUNCTIONAL-ANALYSIS; DNA-SEQUENCES; KAPPA-B; EXPRESSION; FIBROBLASTS; ACTIVATION; ELEMENTS; PROMOTER; STIMULATION	Transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha) are multifunctional peptides intimately involved in the process of exhacellular matrix remodeling. We recently showed that TGF-beta stimulates the human alpha 2(I) collagen gene by increasing the affinity of an Sp1-containing transcriptional complex bound to an upstream sequence termed the TbRE (Inagaki, Y., Truter, S, and Ramirez, F. (1994) J. Biol, Chem. 269, 14828-14834). Here, we report that the TbRE-bound complex also mediates the inhibitory signal of TNF-alpha. Nuclear proteins from cells treated with TNF-alpha bind to the TbRE sequence substantially more strongly than those from untreated cells. Additionally, TNF-alpha increases binding of a second protein complex that recognizes the negatively cis-acting element located immediately next to the TbRE. Thus, we postulate that TNF-alpha counteracts the TGF-beta-elicited stimulation of collagen gene expression through overlapping nuclear signaling pathways. One modifies the TGF-beta-targeted transcrip tional complex, probably by reducing its stimulatory effect on collagen transcription. The other acts on the binding of the adjacent factor, presumably by increasing its effectiveness in repressing the activity of the collagen promoter. The convergence of the TGF-beta and TNF-alpha pathways on the same sequence of the alpha 2(I) collagen promoter is yet another example of combinatorial gene regulation achieved through composite response elements.	CUNY MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA; KANAZAWA UNIV, SCH MED, DEPT INTERNAL MED 1, KANAZAWA, ISHIKAWA 920, JAPAN	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Kanazawa University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038648, R37AR038648] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-38648] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOAST S, 1990, J BIOL CHEM, V265, P13351; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; BUTLER DM, 1988, J RHEUMATOL, V15, P1463; DIEGELMANN RF, 1988, COLLAGEN BIOCH BIOME, V2, P113; EDWARDS DR, 1987, EMBO J, V7, P2977; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HILL DJ, 1986, J CELL PHYSIOL, V128, P322, DOI 10.1002/jcp.1041280226; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KIKUCHI K, 1992, BIOCHEM BIOPH RES CO, V187, P45, DOI 10.1016/S0006-291X(05)81456-1; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; SAXNE T, 1988, ARTHRITIS RHEUM, V31, P1041, DOI 10.1002/art.1780310816; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; YAMAMOTO KR, 1992, TRANSCRIPTIONAL REGU, P1169	34	98	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3353	3358		10.1074/jbc.270.7.3353	http://dx.doi.org/10.1074/jbc.270.7.3353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852421	hybrid			2022-12-25	WOS:A1995QG47100069
J	HARTMANN, A; BLASZYK, H; MCGOVERN, RM; SCHROEDER, JJ; CUNNINGHAM, J; DEVRIES, EMG; KOVACH, JS; SOMMER, SS				HARTMANN, A; BLASZYK, H; MCGOVERN, RM; SCHROEDER, JJ; CUNNINGHAM, J; DEVRIES, EMG; KOVACH, JS; SOMMER, SS			P53 GENE-MUTATIONS INSIDE AND OUTSIDE OF EXONS-5-8 - THE PATTERNS DIFFER IN BREAST AND OTHER CANCERS	ONCOGENE			English	Article						P53 GENE; MUTATIONAL PATTERN; GENETIC EPIDEMIOLOGY	TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; MOLECULAR EPIDEMIOLOGY; BINDING-SITE; MUTANT P53; CELL-LINES; T-ANTIGEN; PROTEIN; INVITRO; DNA	Most studies of mutations in the p53 tumor suppressor gene in tumors have examined only exons 5-8. Our laboratory previously round 64 mutations in exons 5-8 of the p53 gene in 194 primary breast cancers. Herein, we report 18 additional mutations found outside of exons 5-8. Mutations are present in exons 4, 9 and 10, and flanking splice junctions, but not in the promotor region or in exons 1, 2, 3 and 11. No missense mutations are found outside of exons 5-8, is predominance of frameshift mutations lesser numbers of nonsense and splice site mutations. In contrast, the majority of mutations in exons 5-8 in this sample are missense changes and all of these are at amino acids that are identical in the 11 known p53 sequences that represent about 1.6 billion years of evolutionary divergence. The difference in mutational pattern between these two regions of the p53 gene is due to a lack of missense mutations and inframe microdeletions outside of exons 5-8, A review of our database of p53 mutations (De Vries et al., in preparation) shows that the patterns of mutation inside and outside of exons 5-8 differ in other types of cancers as well. The paucity of missense mutations in exons 2-4 and 9-11 in breast and other cancers (even at amino acids identical throughout p53 gene evolution) suggest that at least some missense mutations result in a phenotype other than malignant transformation. These data also illustrate the importance of examining identical exons when comparing the pattern of p53 gene mutations in different populations.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NCI NIH HHS [R01 CA56881-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056881] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1990, ONCOGENE, V5, P423; AHUJA HG, 1990, ONCOGENE, V5, P1409; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BLASZYK H, 1994, LANCET, V343, P1195, DOI 10.1016/S0140-6736(94)92403-1; BLASZYK H, 1994, HUM MUTAT, V4, P158, DOI 10.1002/humu.1380040212; BLASZYK H, 1994, IN PRESS BIOTECHNIQU; BOTTEMA CDK, 1991, AM J HUM GENET, V49, P820; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; COLES C, 1992, CANCER RES, V52, P5291; DAMICO D, 1992, ONCOGENE, V7, P339; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V56, P215; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FELLEYBOSCO E, 1993, AM J HUM GENET, V53, P752; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JONES PA, 1991, CANCER RES, V51, P3617; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NISHIDA N, 1993, CANCER RES, V53, P368; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PURDIE CA, 1994, ONCOGENE, V9, P603; SAITOH S, 1994, ONCOGENE, V9, P2869; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SOMMER SS, 1990, NATURE, V346, P22, DOI 10.1038/346022b0; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; Sommer Steve S., 1994, P214; SOUSSI T, 1990, ONCOGENE, V5, P945; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TSUDA H, 1993, JPN J CANCER RES, V84, P393; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; 1991, STATXACT VER 2 0	64	121	127	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					681	688						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862445				2022-12-25	WOS:A1995QH61200007
J	DESHPANDE, RV; GOUST, JM; CHAKRABARTI, AK; BARBOSA, E; HOGAN, EL; BANIK, NL				DESHPANDE, RV; GOUST, JM; CHAKRABARTI, AK; BARBOSA, E; HOGAN, EL; BANIK, NL			CALPAIN EXPRESSION IN LYMPHOID-CELLS - INCREASED MESSENGER-RNA AND PROTEIN-LEVELS AFTER CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-ACTIVATED NEUTRAL PROTEASE; CALCIUM-DEPENDENT PROTEASE; LEUCINE METHYL-ESTER; LARGE SUBUNIT; MULTIPLE-SCLEROSIS; SPINAL-CORD; CDNA; INTERLEUKIN-1-ALPHA; LYMPHOCYTES; PRECURSOR	Although calpain is ubiquitously present in human tissues and is thought to play a role in demyelination, its activity is very low in resting normal lymphocytes. To determine the nature of calpain expression at the mRNA and protein levels in human lymphoid cells, we studied human T lymphocytic, B lymphocytic, and monocytic Lines as well as peripheral blood mononuclear cells. Stimulation of cells with the phorbol ester phorbol myristate acetate and the calcium ionophore A23187 resulted in increased calpain mRNA and protein expression. Calpain mRNA expression is also increased in human T cells stimulated with anti-CD3. A dissociation between the increases of RNA and protein suggested that calpain could be released from the cells; the subsequent experiments showed its presence in the extracellular environment, 5,6-Dichloro-1b-D-ribofuranosylbenzimidazoIe, a reversible inhibitor of mRNA synthesis, reduced calpain mRNA levels by 50-67% and protein levels by 72-91%, Its removal resulted in resumption of both calpain mRNA and protein synthesis. Cycloheximide, a translational inhibitor, reduced calpain protein levels by 77-81% and calpain mRNA levels by 96% in activated THP-1 cells. Interferon-gamma induced calpain mRNA and protein in U-937 and THP-1 cells. Dexamethasone increased mRNA expression in THP-1 cells, Our results indicate that activation of lymphoid cells results in de novo synthesis and secretion of calpain.	MED UNIV S CAROLINA,DEPT NEUROL,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT MICROBIOL & IMMUNOL,CHARLESTON,SC 29425	Medical University of South Carolina; Medical University of South Carolina					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031622, P01NS011066, F32NS011066] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-11066, NS-31622] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; Banik Naren L., 1992, P571; BANIK NL, 1992, CRIT REV NEUROBIOL, V16, P257; CABANAS C, 1990, EUR J BIOCHEM, V191, P599, DOI 10.1111/j.1432-1033.1990.tb19163.x; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; DESHPANDE RV, 1993, NEUROCHEM RES, V18, P767, DOI 10.1007/BF00966771; DESHPANDE RV, 1992, T AM SOC NEUROCHEM, V23, P158; EFRAT S, 1984, P NATL ACAD SCI-BIOL, V81, P2601, DOI 10.1073/pnas.81.9.2601; EMORI Y, 1986, J BIOL CHEM, V261, P9465; GRAY PW, 1986, J IMMUNOL, V137, P3644; HATA A, 1989, J BIOL CHEM, V264, P6404; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HOGAN EL, 1987, CELLULAR HUMORAL COM, V129, P479; IMAJOH S, 1988, BIOCHEMISTRY-US, V27, P8122, DOI 10.1021/bi00421a022; MANGER B, 1988, T CELL RECEPTORS, P133; MERRILL JE, 1988, P NATL ACAD SCI USA, V89, P574; MURACHI T, 1989, BIOCHEM INT, V18, P263; NAMAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133; NOELLE RJ, 1991, FASEB J, V5, P2770, DOI 10.1096/fasebj.5.13.1833257; NOLFO R, 1989, PROSTAGLANDINS, V39, P157; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; PING L, 1992, J IMMUNOL, V148, P3354; RAINE CS, 1991, NEUROPATH APPL NEURO, V17, P265, DOI 10.1111/j.1365-2990.1991.tb00724.x; SCHMAIER AH, 1990, BLOOD, V75, P1273; SHAU H, 1985, J IMMUNOL, V134, P1136; SIMMONS RD, 1990, J NEUROL SCI, V100, P37, DOI 10.1016/0022-510X(90)90010-K; TAMM I, 1978, ADV VIRUS RES, V22, P188; THIELE DL, 1986, J IMMUNOL, V136, P1038; TSUBATA T, 1989, J BIOCHEM-TOKYO, V105, P23, DOI 10.1093/oxfordjournals.jbchem.a122611; WANG IY, 1988, HYBRIDOMA, V7, P529, DOI 10.1089/hyb.1988.7.529; WERNERFELMAYER G, 1990, CANCER RES, V50, P2863; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	34	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2497	2505		10.1074/jbc.270.6.2497	http://dx.doi.org/10.1074/jbc.270.6.2497			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852311	hybrid			2022-12-25	WOS:A1995QF53500018
J	LAI, K; BOLOGNESE, CP; SWIFT, S; MCGRAW, P				LAI, K; BOLOGNESE, CP; SWIFT, S; MCGRAW, P			REGULATION OF INOSITOL TRANSPORT IN SACCHAROMYCES-CEREVISIAE INVOLVES INOSITOL-INDUCED CHANGES IN PERMEASE STABILITY AND ENDOCYTIC DEGRADATION IN THE VACUOLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; PHOSPHATIDYLINOSITOL SYNTHASE; TRANSCRIPTIONAL REGULATOR; GENE ENCODES; YEAST; INVIVO; PURIFICATION; BIOSYNTHESIS; PROTEOLYSIS; REPRESSOR	Uptake of inositol by Saccharomyces cerevisiae is mediated by a specific inositol permease encoded by the ITR1 gene, Removal of inositol from the growth medium results in an increase in ITR1 mRNA abundance, The increase in ITR1 mRNA is accompanied by an increase in de novo synthesis of the Itr1 permease leading to an increased capacity for uptake, When inositol is added to the growth medium inactivation of uptake activity occurs, and both transcription of ITR1 and uptake activity are repressed to a basal level of function, The transcriptional regulation of ITR1 depends on the INO2, INO4, and OPI1 genes, In addition, repression is also achieved by regulation of ITR1 expression at the post-translational level, In this study, we show that there is a change in the stability of the Itr1 permease after the addition of inositol to the growth medium, Immunoblot analysis using a monoclonal antibody against an epitope attached to the Itr1 permease showed that the addition of inositol causes a dramatic increase in the rate of degradation of the permease, After the repressed (basal) level is achieved, turnover continues to be rapid, The increased rate of degradation was also observed in strains with mutations that block conjugation to ubiquitin, Degradation was not observed in strains defective in the END3/END4 endocytic pathway or in the production of vacuolar proteases (PEP4). Thus, inactivation of the Itr1 permease is accompanied by endocytic internalization followed by degradation in the vacuole, Inactivation may be a separate process that precedes and signals endocytic degradation, Since the end3/end4 mutations did not affect uptake activity under derepressed conditions, endocytosis is not required for normal inositol uptake.	UNIV MARYLAND,DEPT BIOL SCI,BALTIMORE,MD 21228	University System of Maryland; University of Maryland Baltimore				Swift, Steven/0000-0002-3840-4401				CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GREENBERG ML, 1982, GENETICS, V100, P19; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JONES EW, 1991, J BIOL CHEM, V266, P7963; KARIN M, 1981, J BIOL CHEM, V256, P3245; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Knop M, 1993, CURR OPIN CELL BIOL, V5, P990, DOI 10.1016/0955-0674(93)90082-2; LAI K, 1994, J BIOL CHEM, V269, P2245; LUCERO P, 1993, FEBS LETT, V333, P165, DOI 10.1016/0014-5793(93)80397-D; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; NIKAWA J, 1991, J BIOL CHEM, V266, P11184; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; POSTERNAK T, 1965, CYCLITOLS; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; REIZMAN H, 1993, TRENDS CELL BIOL, V3, P273; SCHORK SM, 1994, NATURE, V369, P283, DOI 10.1038/369283a0; SIMEON A, 1992, FEBS LETT, V301, P231, DOI 10.1016/0014-5793(92)81254-J; SPIEGEL S, 1993, AV LIPID RES, VA, P105; SPRAGUE GF, 1991, TRENDS GENET, V7, P393, DOI 10.1016/0168-9525(91)90262-O; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500	30	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2525	2534		10.1074/jbc.270.6.2525	http://dx.doi.org/10.1074/jbc.270.6.2525			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852314	hybrid			2022-12-25	WOS:A1995QF53500022
J	RAY, MK; MAGDALENO, SW; FINEGOLD, MJ; DEMAYO, FJ				RAY, MK; MAGDALENO, SW; FINEGOLD, MJ; DEMAYO, FJ			CIS-ACTING ELEMENTS INVOLVED IN THE REGULATION OF MOUSE CLARA CELL-SPECIFIC 10-KDA PROTEIN GENE - IN-VITRO AND IN-VIVO ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; PULMONARY SURFACTANT PROTEINS; RABBIT UTEROGLOBIN GENE; TRANSGENIC MICE; BRONCHIOLAR EPITHELIUM; KDA PROTEIN; RAT; LUNG; TRANSCRIPTION; FRAGMENTS	Transient transfection and murine germ line gene transfer analysis was used to determine the regions of DNA necessary to confer the appropriate level and cell specificity of the expression of the gene coding for the murine Clara cell 10-kDa protein, mCC10. To identify the cis-acting elements involved in the regulation of mCC10 gene, different lengths of the B'-flanking sequence were ligated to the bacterial chloramphenicol acetyltransferase gene for transient transfection to H441 cells (human lung adenocarcinoma cell line). The corresponding sequences were also fused to the human growth hormone gene and transferred to the murine genome for an in vivo analysis of mCC10 promoter activity, The results of the transient transfection analysis identified the region from -166 to -124 of the 5'-flanking region of the mCC10 gene as necessary for the expression of this gene in H441 cells, The transgenic mouse analysis confirmed that the 166 base pairs of 5'-flanking DNA was sufficient to confer cell specific expression, However, the transgenic mouse analysis also showed that, to achieve the full quantitative level of transgene (human growth hormone) expression, regions between -803 and -166 base pairs of the B'-flanking sequences are required for maximum expression of mCC10 gene promoter activity.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine			DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336	NHLBI NIH HHS [HL47620] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047620] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUMULLER G, 1985, HISTOCHEMISTRY, V83, P413, DOI 10.1007/BF00509202; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; CATO ACB, 1984, EMBO J, V3, P2771, DOI 10.1002/j.1460-2075.1984.tb02208.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DEMAYO FJ, 1991, MOL ENDOCRINOL, V5, P311, DOI 10.1210/mend-5-3-311; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAIL DB, 1983, AM REV RESPIR DIS, V127, P366; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; HACKETT BP, 1992, AM J PHYSIOL, V262, pL399, DOI 10.1152/ajplung.1992.262.4.L399; HACKETT BP, 1992, P NATL ACAD SCI USA, V89, P9079, DOI 10.1073/pnas.89.19.9079; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; HOGAN B, 1986, COLD SPRING HARB SYM, V98, P503; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; LACAZEMASMONTEIL T, 1992, EUR J BIOCHEM, V206, P613, DOI 10.1111/j.1432-1033.1992.tb16966.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUND J, 1988, BIOCHEMISTRY-US, V27, P7895, DOI 10.1021/bi00420a047; LYNCH DC, 1994, MOL CELL BIOL, V14, P999; MANIATIS T, 1983, MOL CLONING; MARGRAF LR, 1993, AM J RESP CELL MOL, V9, P231, DOI 10.1165/ajrcmb/9.3.231; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; RAY MK, 1993, BIOCHEM BIOPH RES CO, V197, P163, DOI 10.1006/bbrc.1993.2455; REID L, 1979, FED PROC, V38, P191; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRIPP BR, 1994, GENOMICS, V20, P27, DOI 10.1006/geno.1994.1123; STRIPP BR, 1990, AM J PHYSIOL, V259, pL185, DOI 10.1152/ajplung.1990.259.4.L185; STRIPP BR, 1992, J BIOL CHEM, V261, P14703; Suske Guntram, 1992, Gene Expression, V2, P339; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; UMLAND TC, 1992, J MOL BIOL, V224, P441, DOI 10.1016/0022-2836(92)91006-B; WIKENHEISER KA, 1992, AM J PHYSIOL, V262, pL32, DOI 10.1152/ajplung.1992.262.1.L32; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807	37	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2689	2694		10.1074/jbc.270.6.2689	http://dx.doi.org/10.1074/jbc.270.6.2689			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852338	hybrid			2022-12-25	WOS:A1995QF53500046
J	GRUNE, T; REINHECKEL, T; JOSHI, M; DAVIES, KJA				GRUNE, T; REINHECKEL, T; JOSHI, M; DAVIES, KJA			PROTEOLYSIS IN CULTURED LIVER EPITHELIAL-CELLS DURING OXIDATIVE STRESS - ROLE OF THE MULTICATALYTIC PROTEINASE COMPLEX, PROTEASOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-FUNCTION OXIDATION; RAT SKELETAL-MUSCLE; RED BLOOD-CELLS; GLUTAMINE-SYNTHETASE; OXYGEN RADICALS; DENATURED PROTEINS; MAMMALIAN-CELLS; HUMAN-ERYTHROCYTES; ALKALINE PROTEASE; MOLECULAR-CLONING	Exposure to various forms of mild oxidative stress significantly increased the intracellular degradation of both ''short-lived'' and ''long-lived,'' metabolically radiolabeled, cell proteins in cultures of Clone 9 liver cells (normal liver epithelia), The oxidative stresses employed were bolus H2O2 addition; continuous H2O2 flux; the redox cycling quinones, menadione and paraquat; and the aldehydic products of lipid peroxidation, 4-hydroxynonenal, malonyldialdehyde, and hexenal. In general, exposure to more severe oxidative stress produced a concentration-dependent decline in intracellular proteolysis, in some cases to below baseline levels, Oxidatively modified ''foreign'' proteins (superoxide dismutase and hemoglobin) were also selectively degraded, in comparison with untreated foreign proteins, when added to lysates of Clone 9 liver cells. As with intracellular proteolysis, the degradation of foreign proteins added to cell lysates was greatly increased by mild oxidative modification, but depressed by more severe oxidative modification, The proteinase activity was recovered in >300-kDa cell fractions, and inhibitor profiles and immunoprecipitation studies indicated that the multicatalytic proteinase complex, proteasome, was responsible for most of the selective degradation observed with mild oxidative stress; up to approximately 95% for intracellular proteolysis and 65-80% for degradation of foreign modified proteins, Seven days of daily treatment with an antisense oligodeoxynucleotide, directed against the initiation codon region of the proteasome C2 subunit gene, severely depressed the intracellular levels of several proteasome subunit polypeptides (by Western blot analysis), and also depressed the H2O2 induced increase in intracellular proteolysis by approximately 95%, without significantly affecting baseline proteolytic rates. Extensive studies revealed only small or no increases in the overall capacity of oxidatively stressed cells to degrade oxidatively modified protein substrates; a finding supported by both Western blot and Northern blot analyses which revealed no significant increase in the levels of proteasome subunit polypeptides or mRNA transcripts. We conclude that mild oxidative stress increases intracellular proteolysis by modifying cellular proteins, thus increasing their proteolytic susceptibility, In contrast, severe oxidative stress diminishes intracellular proteolysis, probably by generating severely damaged cell proteins that cannot be easily degraded (e.g, cross-linked/aggregated proteins), and by damaging proteolytic enzymes, We further conclude that the multicatalytic proteinase complex proteasome is responsible for most of the recognition and selective degradation of oxidatively modified proteins in Clone 9 Liver cells.	ALBANY MED COLL, DEPT BIOCHEM & MOLEC BIOL, ALBANY, NY 12208 USA	Albany Medical College			Reinheckel, Thomas/AAL-9761-2021	Reinheckel, Thomas/0000-0001-9866-9105; Grune, Tilman/0000-0003-4775-9973; Davies, Kelvin/0000-0001-7790-3003	NIEHS NIH HHS [ES-03598] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R23ES003598, R56ES003598, R01ES003598] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHN JY, 1991, J BIOL CHEM, V266, P15746; ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; DAHLMANN B, 1983, FEBS LETT, V160, P243, DOI 10.1016/0014-5793(83)80975-2; DAHLMANN B, 1988, BIOCHEM J, V255, P750; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1993, BIOCHEM SOC T, V21, P346, DOI 10.1042/bst0210346; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P215, DOI 10.1016/0891-5849(88)90015-9; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P225, DOI 10.1016/0891-5849(88)90016-0; DAVIES KJA, 1987, J BIOL CHEM, V262, P8220; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DEAN RT, 1986, BIOCHEM J, V240, P489, DOI 10.1042/bj2400489; DEAN RT, 1993, TRENDS BIOCHEM SCI, V18, P437, DOI 10.1016/0968-0004(93)90145-D; DEMARTINO GN, 1979, J BIOL CHEM, V254, P3712; FALKENBURG PE, 1988, NATURE, V331, P190, DOI 10.1038/331190a0; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; FUJIWARA T, 1989, BIOCHEMISTRY-US, V28, P7332, DOI 10.1021/bi00444a028; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GIULIVI C, 1993, J BIOL CHEM, V268, P8752; HOUGH R, 1987, J BIOL CHEM, V262, P8303; ISHIURA S, 1985, FEBS LETT, V189, P119, DOI 10.1016/0014-5793(85)80854-1; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; MARCILLAT O, 1988, BIOCHEM J, V254, P677, DOI 10.1042/bj2540677; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; MICHIELS C, 1991, TOXICOLOGY, V66, P225, DOI 10.1016/0300-483X(91)90221-L; MURAKAMI K, 1990, FREE RADICAL BIO MED, V8, P217, DOI 10.1016/0891-5849(90)90066-R; NAKAMURA K, 1984, P NATL ACAD SCI-BIOL, V81, P2011, DOI 10.1073/pnas.81.7.2011; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; RAY K, 1985, P NATL ACAD SCI USA, V82, P7545, DOI 10.1073/pnas.82.22.7545; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SALO DC, 1990, J BIOL CHEM, V265, P11919; SALO DC, 1988, FREE RADICAL BIO MED, V5, P335, DOI 10.1016/0891-5849(88)90105-0; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8; WOLFF SP, 1986, BIOCHEM J, V234, P399, DOI 10.1042/bj2340399	59	380	385	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2344	2351		10.1074/jbc.270.5.2344	http://dx.doi.org/10.1074/jbc.270.5.2344			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836468				2022-12-25	WOS:A1995QE49300056
J	JERKINS, AA; LIU, WR; LEE, S; SUL, HS				JERKINS, AA; LIU, WR; LEE, S; SUL, HS			CHARACTERIZATION OF THE MURINE MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; FATTY-ACID SYNTHASE; CARBOHYDRATE RESPONSE ELEMENT; HORMONAL-REGULATION; MESSENGER-RNAS; 3T3-L1 CELLS; EXPRESSION; LIVER; IDENTIFICATION; FRAGMENTS	Glycerol-3-phosphate acyltransferase (GPAT) catalyzes the acylation of sn-glycerol 3-phosphate to form 1-acyl-sn-glycerol 3-phosphate, a committed step in triacylglycerol and phospholipid biosynthesis, We have previously reported the cDNA cloning and transcriptional regulation of the murine mitochondrial GPAT (mGPAT), We now report the cloning of the 5'-flanking region of the murine mitochondrial GPAT, The transcription start site was identified by primer extension and RNase protection assays, A TATA box-like motif (TTATTAT) was located between -34 and -29 and a reverse CCAAT box (ATTGG) was located between -78 and -74 relative to the transcription start site. To begin studying mechanisms underlying transcriptional regulation of the mGPAT gene, chimeric luciferase (LUG) plasmids containing serial deletions, from -1447 to -38, of the 5'-flanking region of the murine mGPAT gene were prepared and transfected into 3T3-L1 cells, The fusion construct -1447 GPAT.LUC showed high promoter activity and deletions to -1353, -747, -322, and -86 did not markedly change the promoter activity, With all constructs, luciferase activity was 2-fold higher when plasmids were transfected into 3T3-L1 adipocytes, However, deletion of sequences between -86 and -55 resulted in a 9-fold decrease in LUC activity in both preadipocytes and adipocytes. Deletion of sequences between -55 and -38 did not alter promoter activity, DNase I footprint analysis revealed a protected region between -95 and -65 which included the putative CTF/NF1 binding site, Electrophoretic mobility shift assays demonstrated a single protein-DNA complex formation. Oligonucleotides synthesized according to the CTF/NF1 consensus sequence or the adenovirus NF-1 site showed a different and more complex pattern of protein-DNA interaction and were not able to compete away the mGPAT promoter-protein complex, indicating that a distinct protein was bound to -86/-55, a region important for the basal promoter activity in 3T3-L1 cells, Luciferase activity was increased 2.8- and 8-fold when adipocytes stably transfected with -322 GPAT.LUC were treated with 5 and 25 mM glucose, respectively, in the presence of 10 nM insulin. These results indicate that carbohydrate-responsive sequences are located within -322 base pairs of the mGPAT promoter.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	University of California System; University of California Berkeley; Harvard University; Harvard T.H. Chan School of Public Health			Han, Zaiqi/AAI-2233-2019		NIDDK NIH HHS [DK 36264] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036264] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1990, BIOCHEM J, V271, P675, DOI 10.1042/bj2710675; BELL RM, 1983, ENZYMES, P87; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brindley D. N, 1991, BIOCH LIPIDS LIPOPRO, P171; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEKAKIS N, 1994, BIOCHEMISTRY-US, V33, P1771, DOI 10.1021/bi00173a021; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; LIU ZR, 1993, J BIOL CHEM, V268, P12787; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; MONROY G, 1972, J BIOL CHEM, V247, P6884; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; RONGNOPARUT P, 1991, J BIOL CHEM, V266, P8086; ROSENTHAL N, 1987, GUIDE MOL CLONING TE, P718; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOSSMAN DM, 1976, J BIOL CHEM, V251, P5738; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SHIN DH, 1991, J BIOL CHEM, V266, P23834; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPOEREL NA, 1987, METHOD ENZYMOL, V152, P598; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029	31	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1416	1421		10.1074/jbc.270.3.1416	http://dx.doi.org/10.1074/jbc.270.3.1416			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836409	hybrid			2022-12-25	WOS:A1995QB15600066
J	SUGITA, M; BRENNER, MB				SUGITA, M; BRENNER, MB			ASSOCIATION OF THE INVARIANT CHAIN WITH MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I MOLECULES DIRECTS TRAFFICKING TO ENDOCYTIC COMPARTMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; ANTIGEN PRESENTATION; T-CELL; INTRACELLULAR-TRANSPORT; EXOGENOUS ANTIGEN; PEPTIDE; EFFICIENT; PATHWAYS; ANTIBODY; PROTEIN	Major histocompatibility complex (MHC) class I and class II molecules have been shown to present peptides of different origin to alpha beta T cells. Most peptides presented by class I molecules are derived from endogenously synthesized proteins, whereas most peptides presented by class II molecules are from exogenous sources. This functional dichotomy can largely be achieved by the preferential intracellular association of the invariant chain (Ii) with MHC class II molecules, which may inhibit binding of endogenous peptides to class II molecules and direct them to endocytic compartments where extracellularly derived peptides can be sampled. Here, we show that Ii also can associate with a subset of MHC class I molecules and direct them to endocytic compartments. Ii was coprecipitated with class I molecules after lysis of human lymphocytes in mild detergent such as 3-[ (3-cholamidopropyl)dimethylammonio]-1-propane-sulfonic acid or digitonin, and the association was more clearly visualized by the use of dithiobis[succinimidylpropionate], a homobifunctional chemical cross-linker. The class I.Ii complex was reconstituted in Ii negative cells by transfection of corresponding cDNA clones and was found to be transported through the Golgi to acidic endocytic compartments. These observations may explain how same exogenous antigens can be presented by MHC class I molecules and how MHC class II molecules can bind self peptides derived from MHC class I molecules in endocytic compartments.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School								AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BRODSKY FM, 1982, J IMMUNOL, V128, P129; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CERUNDOLO V, 1992, EUR J IMMUNOL, V22, P2243, DOI 10.1002/eji.1830220910; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; HAMMERLING GJ, 1990, IMMUNOL TODAY, V11, P337; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMB CA, 1992, J IMMUNOL, V148, P3478; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MALNATI MS, 1992, NATURE, V357, P702, DOI 10.1038/357702a0; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; SCHREIBER KL, 1994, INT IMMUNOL, V6, P101, DOI 10.1093/intimm/6.1.101; STAM NJ, 1986, J IMMUNOL, V137, P2299; STRUBIN M, 1984, EMBO J, V3, P869, DOI 10.1002/j.1460-2075.1984.tb01898.x; STRUBIN M, 1986, EMBO J, V5, P3483, DOI 10.1002/j.1460-2075.1986.tb04673.x; SUGITA M, 1994, J EXP MED, V180, P2163, DOI 10.1084/jem.180.6.2163; SWANSON J, 1989, METHOD CELL BIOL, V29, P137; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VANBLEEK GM, 1990, NATURE, V348, P213; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; YILLA M, 1993, J BIOL CHEM, V268, P19092	55	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1443	1448		10.1074/jbc.270.3.1443	http://dx.doi.org/10.1074/jbc.270.3.1443			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836413	hybrid			2022-12-25	WOS:A1995QB15600070
J	HARRINGTON, JJ; LIEBER, MR				HARRINGTON, JJ; LIEBER, MR			DNA STRUCTURAL ELEMENTS REQUIRED FOR FEN-1 BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINATION	In eukaryotic cells, a 5'-flap DNA endonuclease and a double-stranded DNA 5'-exonuclease activity reside within a 42-kDa enzyme called FEN-1 (flap endonuclease-1 and 5(five)'-exonuclease), This endo/exonuclease has been shown to be highly homologous to human XP-G, Saccharomyces cerevisiae RAD2, and S. cerevisiae YKL510. Like FEN-1, these related structure-specific nucleases recognize and cleave a branched DNA structure called a DNA flap and its derivative, called a pseudo Y-structure, To dissect the important structural components of the DNA flap structure, we have developed a mobility shift assay, We find that the F-adj strand (located adjacent to the displaced flap strand) is necessary for efficient binding and cleavage of flap structures by FEN-1. When this strand is absent or when it is present, but recessed from the elbow of the flap strand, binding efficiency drops, Further investigation of the role of the F-adj strand using double flap structures reveals that the F-adj strand is necessary to provide a double-stranded template upon which FEN-1 can bind near the elbow of the flap strand, These results provide a basis for understanding how this structure-specific nuclease recognizes a variety of DNA substrates.	STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,PROGRAM CANC BIOL,STANFORD,CA 94305; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Stanford University; Stanford University; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HABER J E, 1992, Current Opinion in Cell Biology, V4, P401, DOI 10.1016/0955-0674(92)90005-W; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; KORNBERG A, 1992, DNA REPLICATION, P931; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; PONTKINGDON G, 1993, EMBO J, V12, P23, DOI 10.1002/j.1460-2075.1993.tb05628.x; ROBINS P, 1994, J BIOL CHEM, V269, P28535; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0	13	81	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4503	4508		10.1074/jbc.270.9.4503	http://dx.doi.org/10.1074/jbc.270.9.4503			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876218	hybrid			2022-12-25	WOS:A1995QK08400051
J	LEDUC, I; MELOCHE, S				LEDUC, I; MELOCHE, S			ANGIOTENSIN-II STIMULATES TYROSINE PHOSPHORYLATION OF THE FOCAL ADHESION-ASSOCIATED PROTEIN PAXILLIN IN AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; KINASE-C; RECEPTOR ANTAGONISTS; BOMBESIN; VASOPRESSIN; ENDOTHELIN; EXPRESSION; INHIBITION; CLONING; GROWTH	Treatment of vascular smooth muscle cells (SMC) with angiotensin II (AII) leads to an increase in the tyrosine phosphorylation of multiple cellular substrates. Here, we have demonstrated that All stimulates tyrosine phosphorylation of the focal adhesion-associated protein paxillin in rat aortic SMC. AII-induced phosphorylation of paxillin was detectable within 1 min and was sustained up to 60 min. Preincubation with the AT(1)-selective antagonist losartan abolished this response. The stimulatory effect of AII on paxillin tyrosine phosphorylation was observed only in aortic SMC and not in other target cells such as adrenal zona glomerulosa cells, chromaffin cells, or hepatocytes. The effect of AII was dependent on the activation of phospholipase C. Chelation of intracellular calcium completely inhibited the ability of AII to stimulate paxillin tyrosine phosphorylation, while selective inhibition of protein kinase C partially attenuated the response. in contrast, treatment of the cells with pertussis toxin had no effect on AII-induced paxillin tyrosine phosphorylation. These findings identify paxillin as a new substrate for AII-stimulated tyrosine phosphorylation and suggest a role for cytoskeleton-associated proteins in the growth response of aortic SMC.	HOTEL DIEU MONTREAL, CTR RECH, MONTREAL, PQ H2W 1T8, CANADA; UNIV MONTREAL, DEPT PHARMACOL, MONTREAL, PQ H2W 1T8, CANADA	Universite de Montreal; Universite de Montreal								BABINSKI K, 1992, FEBS LETT, V313, P300, DOI 10.1016/0014-5793(92)81214-7; BALLA T, 1991, MOL PHARMACOL, V40, P401; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; CRAWFORD KW, 1992, MOL PHARMACOL, V41, P154; DELEAN A, 1984, ENDOCRINOLOGY, V115, P485, DOI 10.1210/endo-115-2-485; FORCE T, 1991, J BIOL CHEM, V266, P6650; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HADRAVA V, 1989, HYPERTENSION, V13, P589, DOI 10.1161/01.HYP.13.6.589; HAIMOVICI J, 1994, AM J PHYSIOL, V267, pG364, DOI 10.1152/ajpgi.1994.267.3.G364; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHELLING P, 1991, J HYPERTENS, V9, P3; SECKL M, 1993, J BIOL CHEM, V268, P9548; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WONG PC, 1992, TRENDS ENDOCRIN MET, V3, P211, DOI 10.1016/1043-2760(92)90030-5; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	33	81	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4401	4404		10.1074/jbc.270.9.4401	http://dx.doi.org/10.1074/jbc.270.9.4401			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876204	hybrid			2022-12-25	WOS:A1995QK08400036
J	LINNEKIN, D; MOU, SM; GREER, P; LONGO, DL; FERRIS, DK				LINNEKIN, D; MOU, SM; GREER, P; LONGO, DL; FERRIS, DK			PHOSPHORYLATION OF A FES-RELATED PROTEIN IN RESPONSE TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HL-60 LEUKEMIA-CELLS; TYROSINE KINASE; ERYTHROPOIETIN RECEPTOR; SIGNAL-TRANSDUCTION; INTERLEUKIN-3; EXPRESSION; DIFFERENTIATION; GENE; IDENTIFICATION; ASSOCIATION	Previous work has suggested that a 97-kDa protein (p97) is involved in the signal transduction pathway of granulocyte-macrophage colony stimulating factor (GMCSF) as well as interleukin 3, erythropoietin, and interleukin 2, We have examined the relationship of p97 to the protein tyrosine kinase Fes in the GM-CSF signal transduction pathway in erythroid and myeloid cell lines. GM-CSF stimulation of three different cell lines induced tyrosine phosphorylation of p97 as well as a number of other phosphotyrosylproteins. Although each cell Line expressed the proto-oncogene product Fes, antisera specific for Pes did not recognize p97 in immunoblotting experiments. Furthermore, immunodepletion of Fes did not reduce the amount of p97 in GM-CSF treated cells. Two dimensional gel electrophoresis demonstrated that p97 and Fes have similar charge to mass ratios, and limited proteolytic mapping of p97 and Fes suggested that these proteins may be related but are not identical. Our studies demonstrate that p97 is not Fes but is probably a Fes related protein.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; QUEENS UNIV,DEPT PATHOL,CANC RES LABS,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT BIOCHEM,CANC RES LABS,KINGSTON,ON K7L 3N6,CANADA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Queens University - Canada; Queens University - Canada	LINNEKIN, D (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RECOURSES INC DYNCORP,DIV CANC TREATMENT,FREDERICK,MD 21702, USA.		Longo, Dan L./F-6022-2011					ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; CARE A, 1994, ONCOGENE, V9, P739; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FERRIS DK, 1989, LYMPHOKINE RES, V8, P215; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING D, 1988, EMBO J, V8, P3667; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; KANAKURA Y, 1990, BLOOD, V76, P706; LESHET E, 1990, MOL CELL BIOL, V10, P5021; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; LINNEKIN D, 1994, BLOOD, V84, P94, DOI 10.1182/blood.V84.1.94.bloodjournal84194; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; QUELLE FW, 1992, J BIOL CHEM, V267, P17055; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; TORIGOE T, 1992, BLOOD, V80, P617; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YU G, 1989, J BIOL CHEM, V264, P10276; YU G, 1987, J BIOL CHEM, V262, P17543	31	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4950	4954		10.1074/jbc.270.9.4950	http://dx.doi.org/10.1074/jbc.270.9.4950			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876270	hybrid			2022-12-25	WOS:A1995QK08400108
J	OPRESKO, LK; CHANG, CP; WILL, BH; BURKE, PM; GILL, GN; WILEY, HS				OPRESKO, LK; CHANG, CP; WILL, BH; BURKE, PM; GILL, GN; WILEY, HS			ENDOCYTOSIS AND LYSOSOMAL TARGETING OF EPIDERMAL GROWTH-FACTOR RECEPTORS ARE MEDIATED BY DISTINCT SEQUENCES INDEPENDENT OF THE TYROSINE KINASE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; EGF RECEPTOR; MULTIVESICULAR BODY; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEINS; PLASMA-MEMBRANE; DOWN-REGULATION; BETA-RECEPTOR; BINDING; CELLS	Ligand-induced internalization of the epidermal growth factor receptor (EGFR) leads to accelerated receptor degradation, Two models have been proposed to explain this. In the first model, induced internalization expands the intracellular pool of receptors, leading to enhanced lysosomal targeting. The second model proposes that activation of intrinsic receptor kinase activity induces inward vesiculation of endosomes, thus interrupting receptor recycling. To test these models, we created EGFR mutants that lack the conserved tyrosine kinase domain, but retain different parts of the distal carboxyl terminus regulatory region. Mutants lacking all distal regulatory sequences underwent slow internalization (0.02 min(-1)) and turnover (t(1/2) similar to 24 h), similar to unoccupied, holo-EGFR. Mutant receptors that lacked the kinase domain, but retained the entire distal regulatory domain, were constitutively internalized and targeted to lysosomes, even in the absence of EGF. The turnover of these receptors (t(1/2) similar to 11 h) was similar to that of occupied, kinase-active holo-EGFR (t(1/2) similar to 9.5 h). These results show that receptor tyrosine kinase activity is not required for the targeting of EGFR to lysosomes, Receptor mutants which expressed previously identified endocytic sequences underwent rapid internalization. Unexpectedly, enhanced turnover of EGFR mutants required additional sequences located between residues 945 and 991 in the holo-EGFR. Thus, internalization and lysosomal targeting of EGFR are separate processes mediated by distinct sequences. Our results indicate that induced internalization is necessary, but not sufficient, for enhanced EGFR degradation. Instead, down-regulation requires exposure of previously cryptic internalization and lysosomal targeting sequences. Occupied EGFR thus appear to be handled by the endocytic machinery in the same fashion as other constitutively internalized or lysosomally targeted receptors.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	OPRESKO, LK (corresponding author), UNIV UTAH, SCH MED, DEPT PATHOL, SALT LAKE CITY, UT 84132 USA.			Wiley, Steven/0000-0003-0232-6867	NCI NIH HHS [P01CA 58689] Funding Source: Medline; NICHD NIH HHS [P01HD28528] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD028528] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERLIN CM, 1965, MOL PHARMACOL, V1, P149; BRAMHALL S, 1969, ANAL BIOCHEM, V31, P146, DOI 10.1016/0003-2697(69)90251-6; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CADENA DL, 1994, J BIOL CHEM, V269, P260; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN S, 1982, J BIOL CHEM, V257, P1523; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GAMOU S, 1987, J BIOL CHEM, V262, P6708; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GILL GN, 1988, COLD SPRING HARB SYM, V53, P467, DOI 10.1101/SQB.1988.053.01.054; GILL GN, 1984, J BIOL CHEM, V259, P7755; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRAKO KA, 1992, ENDOCRINOLOGY, V130, P3441, DOI 10.1210/en.130.6.3441; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KAMPS MP, 1988, ONCOGENE, V2, P305; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KORC M, 1985, P NATL ACAD SCI USA, V82, P6172, DOI 10.1073/pnas.82.18.6172; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; LUND KA, 1990, J BIOL CHEM, V265, P15713; LUND KA, 1990, J BIOL CHEM, V265, P20517; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORI S, 1993, J BIOL CHEM, V268, P577; MOSTOV K, 1993, J CELL SCI, P21; OGATA S, 1994, J BIOL CHEM, V269, P5210; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; SWANSON JA, 1992, J CELL SCI, V103, P201; WEBER W, 1984, J BIOL CHEM, V259, P4631; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WELSH JB, 1994, MOL BIOL CELL, V5, P539, DOI 10.1091/mbc.5.5.539; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1985, CURR TOP MEMBR TRANS, V24, P369; WILEY HS, 1985, J BIOL CHEM, V260, P5290; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	64	135	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4325	4333		10.1074/jbc.270.9.4325	http://dx.doi.org/10.1074/jbc.270.9.4325			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876194	hybrid			2022-12-25	WOS:A1995QK08400025
J	PARK, CH; MU, D; REARDON, JT; SANCAR, A				PARK, CH; MU, D; REARDON, JT; SANCAR, A			THE GENERAL TRANSCRIPTION-REPAIR FACTOR TFIIH IS RECRUITED TO THE EXCISION-REPAIR COMPLEX BY THE XPA PROTEIN INDEPENDENT OF THE TFIIE TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; STRANDED-DNA ENDONUCLEASE; XERODERMA-PIGMENTOSUM; COCKAYNE SYNDROME; DAMAGED DNA; MINIMAL SET; IDENTIFICATION; INITIATION; AFFINITY; EXTRACTS	Recent studies have revealed that the general transcription factor TFIIH is also a general excision repair factor which, along with several other proteins, is required for transcription-independent excision reaction, As a general transcription factor, TFIIH is recruited to RNA polymerase II-promoter complex by another general transcription factor called TFIIE, We were interested in knowing whether TFIIE is also involved in recruiting TFIIH to the excision repair complex, We found that cell-free extract depleted of TFIIE carried out excision repair at a normal rate, leading us to conclude that TFIIE is not involved in recruiting TFIIH to the damage site and has no role in general excision repair, In contrast, the human damage recognition protein XPA specifically binds to TFIIH and apparently recruits it to the damage site. The carboxyl-terminal half of XPA is responsible for specific interaction with TFIIH. The C261S/C264S mutant of XPA bound the ERCC1 . XPF complex normally, but failed to bind TFIIH and failed to complement an XP-A mutant cell-free extract indicating that the XPA-TFIIH interaction is essential to effecting the excision reaction. Interestingly, XPA also binds to the p34 subunit of TFIIE specifically and in competition with the p56 subunit of TFIIE, This latter interaction has no apparent role in general excision repair but may be relevant in the transcription-coupled repair reaction.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; CLEAVER JE, 1989, METABOLIC BASIS INHE, P2959; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FLORES O, 1989, J BIOL CHEM, V264, P8913; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HABRAKEN Y, 1994, NATURE, V371, P531, DOI 10.1038/371531a0; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12095; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARK CH, 1993, NUCLEIC ACIDS RES, V21, P5110, DOI 10.1093/nar/21.22.5110; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZAWEL L, 1995, IN PRESS ANN REV BIO, V64	48	179	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4896	4902		10.1074/jbc.270.9.4896	http://dx.doi.org/10.1074/jbc.270.9.4896			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876263	hybrid, Green Published			2022-12-25	WOS:A1995QK08400101
J	SHIMEKAKE, Y; NAGATA, K; OHTA, S; KAMBAYASHI, Y; TERAOKA, H; KITAMURA, K; ETO, T; KANGAWA, K; MATSUO, H				SHIMEKAKE, Y; NAGATA, K; OHTA, S; KAMBAYASHI, Y; TERAOKA, H; KITAMURA, K; ETO, T; KANGAWA, K; MATSUO, H			ADRENOMEDULLIN STIMULATES 2 SIGNAL-TRANSDUCTION PATHWAYS, CAMP ACCUMULATION AND CA2+ MOBILIZATION, IN BOVINE AORTIC ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED RAT SOMATOTROPHS; SMOOTH-MUSCLE CELLS; GH-RELEASING FACTOR; PROTEIN-KINASE; NITRIC-OXIDE; HYPOTENSIVE PEPTIDE; NATRIURETIC PEPTIDE; MOLECULAR-CLONING; GROWTH-FACTOR; RECEPTOR	The biological action of adrenomedullin, a novel hypotensive peptide, on bovine aortic endothelial cells, was examined. The specific binding of adrenomedullin to these cells was observed, and adrenomedullin was found to induce intracellular cAMP accumulation in a dose-dependent manner. EC(50) for the cAMP accumulation was about 100 times lower than the apparent IC50 for the binding assay. Adrenomedullin also induced increase of intracellular free Ca2+ in endothelial cells in a dose-dependent manner. The Ca2+ response to adrenomedullin was biphasic with an initial transient increase due to the release from thapsigargin-sensitive intracellular Ca2+ storage and a prolonged increase by influx through the ion channel on the plasma membrane. This intracellular free Ca2+ increase resulted from phospholipase C activation and inositol 1,4,5-trisphosphate formation, and seemed to cause nitric oxide synthase activation by monitoring intracellular cGMP accumulation. Both cAMP accumulation and Ca2+ increased responses to adrenomedullin were mediated by cholera toxin-sensitive G protein, but the two signal transduction pathways were independent. Thus, the results suggest that adrenomedullin elicits the hypotensive effect through at least two mechanisms, a direct action on vascular smooth muscle cells to increase intracellular cAMP and an action on endothelial cells to stimulate nitric oxide release, with both leading to vascular relaxation.	SHIONOGI & CO LTD,SHIONOGI RES LABS,FUKUSHIMA KU,OSAKA 553,JAPAN; MIYAZAKI MED COLL,DEPT INTERNAL MED 1,MIYAZAKI 88916,JAPAN; NATL CARDIOVASC CTR,RES INST,SUITA,OSAKA 564,JAPAN	Shionogi & Company Limited; University of Miyazaki; National Cerebral & Cardiovascular Center - Japan			Ohta, shigeki/L-1677-2013; Ohta, Shigeki/Y-4455-2019	Ohta, Shigeki/0000-0003-2994-4278				ADAMS DJ, 1994, TRENDS CARDIOVAS MED, V4, P18, DOI 10.1016/1050-1738(94)90021-3; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; EGUCHI S, 1994, FEBS LETT, V340, P226, DOI 10.1016/0014-5793(94)80143-6; EMORI T, 1991, BIOCHEM BIOPH RES CO, V174, P228, DOI 10.1016/0006-291X(91)90510-E; EMORI T, 1991, HYPERTENSION, V18, P165, DOI 10.1161/01.HYP.18.2.165; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; GEILEN CC, 1992, FEBS LETT, V309, P381, DOI 10.1016/0014-5793(92)80811-T; GILLONGO J, 1993, EUR J PHARM-MOLEC PH, V247, P119, DOI 10.1016/0922-4106(93)90068-K; HIRANO K, 1993, EUR J PHARM-MOLEC PH, V244, P133, DOI 10.1016/0922-4106(93)90018-5; ICHIKI Y, 1994, FEBS LETT, V338, P6, DOI 10.1016/0014-5793(94)80106-1; IGNARRO LJ, 1993, THROMB HAEMOSTASIS, V70, P148; ISHIZAKA Y, 1994, BIOCHEM BIOPH RES CO, V200, P642, DOI 10.1006/bbrc.1994.1496; ITAZAKI K, 1993, EUR J PHARM-MOLEC PH, V245, P147, DOI 10.1016/0922-4106(93)90122-P; KAMBAYASHI Y, 1989, FEBS LETT, V248, P28, DOI 10.1016/0014-5793(89)80425-9; KITAMURA K, 1994, FEBS LETT, V338, P306, DOI 10.1016/0014-5793(94)80289-0; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KUBALAK SW, 1993, AM J PHYSIOL, V264, pH86, DOI 10.1152/ajpheart.1993.264.1.H86; LAMPUGNANI MG, 1989, THROMB RES, V54, P75, DOI 10.1016/0049-3848(89)90338-1; LIANO JK, 1993, CIRC RES, V70, P1018; LIU YF, 1992, MOL ENDOCRINOL, V6, P1815, DOI 10.1210/me.6.11.1815; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P570, DOI 10.1210/endo-128-1-570; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P592, DOI 10.1210/endo-128-1-592; MACHRTHUR H, 1993, BRIT J PHARMACOL, V108, P100; MYERS DE, 1989, CELL SIGNAL, V1, P335, DOI 10.1016/0898-6568(89)90052-1; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NUKI C, 1993, BIOCHEM BIOPH RES CO, V196, P245, DOI 10.1006/bbrc.1993.2241; ODA K, 1992, FEBS LETT, V299, P187, DOI 10.1016/0014-5793(92)80244-B; SAKATA J, 1993, BIOCHEM BIOPH RES CO, V195, P921, DOI 10.1006/bbrc.1993.2132; SHIMEKAKE Y, 1994, EUR J BIOCHEM, V222, P645, DOI 10.1111/j.1432-1033.1994.tb18908.x; SHIMEKAKE Y, 1992, FEBS LETT, V309, P185, DOI 10.1016/0014-5793(92)81091-Y; SUGO S, 1994, BIOCHEM BIOPH RES CO, V201, P1160, DOI 10.1006/bbrc.1994.1827; YU YM, 1992, J CELL PHYSIOL, V150, P559, DOI 10.1002/jcp.1041500317; ZIEGELSTEIN RC, 1994, CIRC RES, V74, P151, DOI 10.1161/01.RES.74.1.151	35	334	343	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4412	4417		10.1074/jbc.270.9.4412	http://dx.doi.org/10.1074/jbc.270.9.4412			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876206	hybrid			2022-12-25	WOS:A1995QK08400038
J	THOMPSON, MA; GINTY, DD; BONNI, A; GREENBERG, ME				THOMPSON, MA; GINTY, DD; BONNI, A; GREENBERG, ME			L-TYPE VOLTAGE-SENSITIVE CA2+ CHANNEL ACTIVATION REGULATES C-FOS TRANSCRIPTION AT MULTIPLE LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; IMMEDIATE EARLY GENES; AMP-RESPONSIVE ELEMENT; CYCLIC-AMP; SUPRACHIASMATIC NUCLEUS; MEMBRANE DEPOLARIZATION; PHOSPHORYLATED CREB; SOMATOSTATIN GENE; SERUM STIMULATION; NERVOUS-SYSTEM	A mechanism by which voltage-sensitive Ca2+ channel (VSCC) activation triggers c-fos transcription has been characterized, Ca2+ influx through VSCCs stimulates phosphorylation of the transcription factor cAMP response element-binding protein (CREB) on serine 133 leading to an increase in the formation of transcription complexes that can elongate through a transcription pause site within the c-fos gene, Ca2+-stimulated CREB serine 133 phosphorylation is mediated by a Ca2+-activated kinase and is not dependent on the cAMP-dependent protein kinase (PKA), While necessary for c-fos transcriptional induction following VSCC opening, CREB serine 133 phosphorylation is not sufficient for transcriptional activation. A second, PKA-dependent event is required. Following induction, c-fos transcription is rapidly down-regulated, Dephosphorylation of CREB serine 133 parallels and likely mediates the transcriptional shut-off event, These results suggest that the phosphorylation and dephosphorylation of CREB controls its ability to regulate transcription in membrane-depolarized cells and that multiple pathways contribute to Ca2+-activated gene expression.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NINDS NIH HHS [NS28829] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829, R37NS028829] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MELLSTROM B, 1993, NEURON, V10, P655, DOI 10.1016/0896-6273(93)90167-P; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NGUYEN TV, 1992, P NATL ACAD SCI USA, V89, P4270, DOI 10.1073/pnas.89.10.4270; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SPENCER CA, 1990, ONCOGENE, V5, P777; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WERLEN G, 1993, J BIOL CHEM, V268, P16596; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	63	138	138	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4224	4235		10.1074/jbc.270.9.4224	http://dx.doi.org/10.1074/jbc.270.9.4224			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876182	hybrid			2022-12-25	WOS:A1995QK08400012
J	WANG, JZ; GONG, CX; ZAIDI, T; GRUNDKEIQBAL, I; IQBAL, K				WANG, JZ; GONG, CX; ZAIDI, T; GRUNDKEIQBAL, I; IQBAL, K			DEPHOSPHORYLATION OF ALZHEIMER PAIRED HELICAL FILAMENTS BY PROTEIN PHOSPHATASE-2A AND PHOSPHATASE-2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABNORMAL PHOSPHORYLATION; NEUROFIBRILLARY TANGLES; SKELETAL-MUSCLE; DISEASE BRAIN; NORMAL-TAU; IDENTIFICATION; LOCALIZATION; POLYPEPTIDES; PURIFICATION; RABBIT	Microtubule associated protein tau is abnormally hyperphosphorylated in the brain of patients with Alzheimer disease and in this form is the major protein subunit of the paired helical filaments (PHF), the most prominent lesion of the disease. In this study the dephosphorylation of sparingly soluble PHF, PHF II-tau by brain protein phosphatase (PP)-2A(1) and PP-2B, and the resulting biochemical, biological, and structural alterations were investigated. Both of the phosphatases dephosphorylated PHF II-tau at the sites of Ser-199/Ser-202 and partially dephosphorylated it at Ser-396/Ser-404; in addition, PHF II-tau was dephosphorylated at Ser-46 by PP-2A(1) and Ser-235 by PP-2B. The relative electrophoretic mobility of PHF II-tau increased after dephosphorylation by either enzyme. Bivalent cations, manganese, and magnesium increased the activities of PP-2A(1) and PP-SB toward PHF II-tau. Dephosphorylation both by PP-2B and PP-2A(1) decreased the resistance of PHF II-tau to proteolysis by the brain calcium-activated neutral proteases (CANP). The ability of PHF II-tau to promote the in vitro microtubule assembly was restored after dephosphorylation by PP-2A(1) and PP-2B. Microtubules assembled by the dephosphorylated PHF II-tau were structurally identical to those assembled by bovine tau used as a control, The dephosphorylation both by PP-2A(1) and PP-2B caused dissociation of the tangles and the PHF; some of the PHF dissociated into straight protofilaments/subfilaments. Approximately 25% of the total tau was released from PHF on dephosphorylation by PP-2A(1). These observations demonstrate that PHF II-tau is accessible to dephospho rylation by PP-2A(1) and PP-2B, and dephosphorylation makes PHF dissociate, accessible to proteolysis by CANP, and biologically active in promoting the assembly of tubulin into microtubules.	NEW YORK STATE INST BASIC RES DEV DISABIL,STATEN ISL,NY 10314	Institute for Basic Research in Developmental Disabilities					NIA NIH HHS [AG 05892, AG 08076] Funding Source: Medline; NINDS NIH HHS [NS 18105] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005892, R01AG008076] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIERNAT J, 1992, EMBO J, V11, P1593, DOI 10.1002/j.1460-2075.1992.tb05204.x; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BRION JP, 1991, BIOCHEM J, V273, P127, DOI 10.1042/bj2730127; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN P, 1989, ANN REV BIOCH, V58, P543; DREWES G, 1993, FEBS LETT, V336, P425, DOI 10.1016/0014-5793(93)80850-T; FRIBERG L, 1986, HDB TOXICOLOGY METHO, V2, P364; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GONG CX, 1994, NEUROSCIENCE, V61, P765, DOI 10.1016/0306-4522(94)90400-6; GONG CX, 1994, FEBS LETT, V341, P94, DOI 10.1016/0014-5793(94)80247-5; GONG CX, 1994, J NEUROCHEM, V62, P803; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1984, ACTA NEUROPATHOL, V62, P259, DOI 10.1007/BF00687607; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; GRUNDKEIQBAL I, 1988, MOL BRAIN RES, V4, P43, DOI 10.1016/0169-328X(88)90017-4; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; IQBAL K, 1986, LANCET, V2, P421; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; IQBAL K, 1984, ACTA NEUROPATHOL, V62, P167, DOI 10.1007/BF00691849; IQBAL K, 1994, FEBS LETT, V349, P104, DOI 10.1016/0014-5793(94)00650-4; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; KANEMARU K, 1992, J NEUROCHEM, V58, P1667, DOI 10.1111/j.1471-4159.1992.tb10039.x; KAWASHIMA S, 1984, J BIOCHEM-TOKYO, V95, P95, DOI 10.1093/oxfordjournals.jbchem.a134608; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; KIDD M, 1964, BRAIN, V87, P307, DOI 10.1093/brain/87.2.307; KOPKE E, 1993, J BIOL CHEM, V268, P24374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LICHTENBERGKRAA.B, 1992, P NATL ACAD SCI USA, V82, P5384; MALIK MN, 1983, J BIOL CHEM, V258, P8955; MORISHIMAKAWASH.M, 1993, NEURON, V10, P1151; MORISHIMAKAWASHIMA, 1995, J BIOL CHEM, V270, P823; PEI JJ, 1994, BRAIN RES, V655, P70, DOI 10.1016/0006-8993(94)91598-9; SHARMA RK, 1983, METHOD ENZYMOL, V102, P210; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SLOBODA RD, 1979, BIOCHEMISTRY-US, V18, P48, DOI 10.1021/bi00568a008; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WISNIEWSKI HM, 1984, J NEUROPATH EXP NEUR, V43, P643, DOI 10.1097/00005072-198411000-00008	44	251	283	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 3	1995	270	9					4854	4860		10.1074/jbc.270.9.4854	http://dx.doi.org/10.1074/jbc.270.9.4854			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QK084	7876258	hybrid			2022-12-25	WOS:A1995QK08400095
J	HAUCK, W; STANNERS, CP				HAUCK, W; STANNERS, CP			TRANSCRIPTIONAL REGULATION OF THE CARCINOEMBRYONIC ANTIGEN GENE - IDENTIFICATION OF REGULATORY ELEMENTS AND MULTIPLE NUCLEAR FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE; CARCINOMA CELL-LINE; COLON-CARCINOMA; DNA-BINDING; FACTOR USF; BILIARY GLYCOPROTEIN; FACTOR SP1; EXPRESSION; FAMILY; PROMOTER	Human carcinoembryonic antigen (CEA) belongs to a family of membrane glycoproteins that are overexpressed in many carcinomas; CEA functions in vitro as a homotypic intercellular adhesion molecule and can inhibit differentiation when expressed ectopically in myoblasts. The regulation of expression of CEA is therefore of considerable interest. The CEA gene promoter region between -403 and -124 base pairs upstream of the translation initiation site directed high levels of expression in CEA-expressing SW403 cells and was 3 times more active in differentiated than in undifferentiated Caco-2 cells, correlating exactly with the 3-fold increase in CEA mRNA seen in differentiated Caco-2 cells. Inclusion of additional upstream sequences between -1098 and -403 base pairs repressed all activity. By in vitro footprinting and deletion analyses, four cis-acting elements were mapped within the positive regulatory region, and one element within the silencing region. Several nuclear factors binding to these domains were identified: USF, Spl, and an Spl-like factor. By co-transfection, USF directly activated the CEA gene promoter in vivo in both SW403 and Caco-2 cells. In addition, the levels of factors binding to each positively acting element increased dramatically with differentiation in Caco-2 cells. Thus the transcriptional control of the CEA gene depends on the interaction of several regulatory elements that bind multiple specific factors.	MCGILL UNIV, MCGILL CANC CTR, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA	McGill University; McGill University								ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984; AHNEN DJ, 1982, CANCER, V49, P2077, DOI 10.1002/1097-0142(19820515)49:10<2077::AID-CNCR2820491020>3.0.CO;2-X; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BASERGA R, 1980, INTRO MACROMOLECULES, V1; BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUCHER D, 1989, CANCER RES, V49, P847; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROPHY BK, 1992, BIOCHIM BIOPHYS ACTA, V1131, P119, DOI 10.1016/0167-4781(92)90110-L; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; FINLEY GG, 1989, ONCOGENE, V4, P963; FISHER DE, 1992, P NATL ACAD SCI USA, V89, P11779, DOI 10.1073/pnas.89.24.11779; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAUCK W, 1991, CANCER RES, V51, P3526; HAUCK W, 1994, EUR J BIOCHEM, V223, P529, DOI 10.1111/j.1432-1033.1994.tb19022.x; HOPPESEYLER F, 1992, NUCLEIC ACIDS RES, V20, P6701, DOI 10.1093/nar/20.24.6701; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; JESSUP JM, 1989, CANCER METAST REV, V8, P263; JOTHY S, 1993, AM J PATHOL, V143, P250; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; MELHEM MF, 1992, CANCER RES, V52, P5853; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V146, P464, DOI 10.1016/0006-291X(87)90552-3; PINTO M, 1983, BIOL CELL, V47, P323; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SCHREWE H, 1990, MOL CELL BIOL, V10, P2738, DOI 10.1128/MCB.10.6.2738; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STANNERS CP, 1971, NATURE-NEW BIOL, V230, P52, DOI 10.1038/newbio230052a0; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; THOMPSON J, 1990, BIOCHEM BIOPH RES CO, V167, P848, DOI 10.1016/0006-291X(90)92103-7; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; TRAN R, 1988, CANCER RES, V48, P5674; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WILLCOCKS TC, 1990, GENOMICS, V8, P492, DOI 10.1016/0888-7543(90)90036-T; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	56	60	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	1995	270	8					3602	3610		10.1074/jbc.270.8.3602	http://dx.doi.org/10.1074/jbc.270.8.3602			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QH688	7876096				2022-12-25	WOS:A1995QH68800024
J	FARRELL, CM; LUKENS, LN				FARRELL, CM; LUKENS, LN			NATURALLY-OCCURRING ANTISENSE TRANSCRIPTS ARE PRESENT IN CHICK-EMBRYO CHONDROCYTES SIMULTANEOUSLY WITH THE DOWN-REGULATION OF THE ALPHA-1(I) COLLAGEN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; II COLLAGEN; C-ELEGANS; RNA; EXPRESSION; PROMOTER; DNA; SWITCH; 5-BROMO-2'-DEOXYURIDINE; CHONDROGENESIS	It has previously been shown that very low steady state levels of alpha 1(I) collagen mRNA are present in chick embryo sternal chondrocytes (Askew, G. R., Wang, S., and Lukens, L. N. (1991) J. Biol. Chem. 266, 16834-16841), yet nuclear run-on experiments with double-stranded cDNA probes indicated a high transcription rate at this locus. These findings were investigated in this study using single-stranded probes, where nuclear run on experiments showed that antisense transcription of the alpha 1(I) collagen gene was occurring in chondrocytes, while sense strand transcription was down-regulated. Treatment of these chondrocytes with 5-bromo-2'-deoxyuridine (BrdU), which causes the cells to resemble their mesenchymal precursors, resulted in an antiparallel situation, where antisense transcription was lost, and instead, sense strand transcription was acquired, suggesting that the reverse switch from sense to antisense transcription occurs during chondrogenesis. Very large (> 10 kilobases) and heterogeneous antisense transcripts of moderate stability were shown to span both ends of the gene in chondrocytes, while their absence was shown in BrdU-treated chondrocytes, chick embryo fibroblasts, and a variety of other tissues. The function of these antisense transcripts is so far unknown, but their unusual chondrocyte-specific appearance, concurrent with little or no sense strand transcription, suggests a possible functional role in the down-regulation of the alpha 1(I) collagen gene.			FARRELL, CM (corresponding author), WESLEYAN UNIV, DEPT MOLEC BIOL & BIOCHEM, MIDDLETOWN, CT 06459 USA.							ABBOTT J, 1968, P NATL ACAD SCI USA, V59, P1144, DOI 10.1073/pnas.59.4.1144; ADAMS SL, 1982, CELL, V30, P373, DOI 10.1016/0092-8674(82)90235-5; ALLEBACH ES, 1985, MOL CELL BIOL, V5, P1002, DOI 10.1128/MCB.5.5.1002; ASKEW GR, 1991, J BIOL CHEM, V266, P16834; BECK KM, 1991, NUCLEIC ACIDS RES, V19, P4975, DOI 10.1093/nar/19.18.4975; BENNETT VD, 1989, J BIOL CHEM, V264, P8402; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; FINER MH, 1984, P NATL ACAD SCI-BIOL, V81, P1659, DOI 10.1073/pnas.81.6.1659; FINER MH, 1985, MOL CELL BIOL, V5, P1415, DOI 10.1128/MCB.5.6.1415; FINER MH, 1987, J BIOL CHEM, V262, P13323; FOCHT RJ, 1984, MOL CELL BIOL, V4, P1843, DOI 10.1128/MCB.4.9.1843; FREMEAU RT, 1990, EMBO J, V9, P3533, DOI 10.1002/j.1460-2075.1990.tb07562.x; GERSTENFELD LC, 1984, MOL CELL BIOL, V4, P1483, DOI 10.1128/MCB.4.8.1483; GERSTENFELD LC, 1989, J BIOL CHEM, V264, P5112; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; Kimelman D., 1992, Gene regulation: biology of antisense RNA and DNA., P1; Krystal G. W., 1992, Gene regulation: biology of antisense RNA and DNA., P11; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MAYNE R, 1975, P NATL ACAD SCI USA, V72, P4511, DOI 10.1073/pnas.72.11.4511; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; NOWAK R, 1994, SCIENCE, V263, P608, DOI 10.1126/science.7508142; PACIFICI M, 1977, AM J ANAT, V150, P207, DOI 10.1002/aja.1001500116; PACIFICI M, 1977, CELL, V11, P891, DOI 10.1016/0092-8674(77)90300-2; PAWLOWSKI PJ, 1982, BIOCHEMISTRY-US, V21, P34, DOI 10.1021/bi00530a006; Sambrook J, 1989, MOL CLONING LABORATO; SAXE SA, 1985, J BIOL CHEM, V260, P3812; Schiltz J., 1973, DIFFERENTIATION, V1, P97; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; VALES LD, 1989, GENE DEV, V3, P49, DOI 10.1101/gad.3.1.49; von der Mark K, 1980, Curr Top Dev Biol, V14, P199; WANG S, 1994, MATRIX BIOL, V14, P313, DOI 10.1016/0945-053X(94)90197-X; WICKENS M, 1994, NATURE, V367, P17, DOI 10.1038/367017a0; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; YOSHIDA H, 1994, NUCLEIC ACIDS RES, V22, P41, DOI 10.1093/nar/22.1.41; 1991, PROTOCOLS APPLICATIO, P125	44	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3400	3408		10.1074/jbc.270.7.3400	http://dx.doi.org/10.1074/jbc.270.7.3400			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852426	hybrid			2022-12-25	WOS:A1995QG47100076
J	MOREL, C; CORDIERBUSSAT, M; PHILIPPE, J				MOREL, C; CORDIERBUSSAT, M; PHILIPPE, J			THE UPSTREAM PROMOTER ELEMENT OF THE GLUCAGON GENE, G1, CONFERS PANCREATIC ALPHA CELL-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; INSULIN GENE; IDENTIFICATION; TRANSCRIPTION; SEQUENCES; NEURONS	The glucagon gene is expressed in the endocrine pancreas, the intestine, and the brain. In the endocrine pancreas, expression of the glucagon gene is restricted to the alpha cells of the islets of Langerhans. We previously showed that 168 base pairs of the promoter was critical for this restricted expression. To further characterize the mechanisms involved in alpha cell specificity, we analyzed the responsible DNA sequences by transient transfection studies into glucagon- and insulin-producing cell Lines. We localized alpha cell-specific sequences between nt 100 and 52, a region that corresponds to the upstream promoter element G1. Four protein complexes, B1, B2, B3, and B6 interact with G1; B6 requires most of G1 to be formed. B1, B2, and B3, by contrast, bind on closely overlapping sequences, display similar methylation interference patterns, and appear to be related complexes. Point mutations of G1 indicate, however, that their binding specificities are different. All four complexes are islet-specific, and impairment of their binding results in decreased transcription. We conclude that G1 interacts with islet cell-specific proteins to restrict glucagon gene expression to the alpha cells.	CTR MED UNIV GENEVA,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND; CTR MED UNIV GENEVA,DEPT MED,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Geneva			Cordier-Bussat, Martine/G-4019-2014					ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ARONHEIM A, 1993, NUCLEIC ACIDS RES, V7, P1601; BALL DW, 1992, NUCLEIC ACIDS RES, V20, P117, DOI 10.1093/nar/20.1.117; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; HUTCHISON CA, 1978, J BIOL CHEM, V253, P6551; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KOBR M, 1990, MOL CELL BIOL, V10, P965, DOI 10.1128/MCB.10.3.965; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1994, MOL CELL BIOL, V14, P3514, DOI 10.1128/MCB.14.5.3514; PHILIPPE J, 1990, DNA CELL BIOL, V10, P119; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TAKAKI R, 1985, IN VITRO CELL DEV, V22, P120; WANG TC, 1990, J BIOL CHEM, V265, P8908; WHEELER MB, 1992, MOL CELL BIOL, V12, P3531, DOI 10.1128/MCB.12.8.3531; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1	32	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3046	3055		10.1074/jbc.270.7.3046	http://dx.doi.org/10.1074/jbc.270.7.3046			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852385	hybrid			2022-12-25	WOS:A1995QG47100026
J	WILLIAMS, PF; MYNARCIK, DC; YU, GQ; WHITTAKER, J				WILLIAMS, PF; MYNARCIK, DC; YU, GQ; WHITTAKER, J			MAPPING OF AN NH2-TERMINAL LIGAND-BINDING SITE OF THE INSULIN-RECEPTOR BY ALANINE SCANNING MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; ALPHA-SUBUNIT; GROWTH-FACTOR; HORMONE; DOMAIN; IDENTIFICATION; DETERMINANTS; SPECIFICITY; ECTODOMAIN; AFFINITY	Affinity labeling studies and mutational analyses have implicated the involvement of a predicted domain of the insulin receptor (L1, amino acids 1-119) in ligand binding. In order to obtain a higher resolution localization of this ligand binding site, we have performed alanine scanning mutagenesis of this domain. Alanine mutant cDNAs encoding a secreted recombinant insulin receptor extracellular domain were expressed transiently in adenovirus transformed human embryonic kidney cells and the affinity of the expressed receptor for insulin was determined. Mutation of 14 amino acids located in four discontinuous peptide segments to alanine was disruptive of insulin binding: Segment 1 amino acids 12-15; Segment 2, amino acids 34-44; Segment 3, amino acids 64-67; and Segment 4, amino acids 89-91. The quantitative contribution of the four segments to the free energy of insulin binding was 1 > 3 > 2 > 4. Of the 14 amino acids whose mutation compromised insulin binding, 3 are charged, 3 hydrophobic, 5 aromatic, and 3 are amides.	SUNY STONY BROOK, HLTH SCI CTR, DEPT MED, DIV ENDOCRINOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIDDK NIH HHS [DK 42171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FABRY M, 1992, J BIOL CHEM, V267, P8950; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Sambrook J, 1989, MOL CLONING LABORATO; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SHIER P, 1989, J BIOL CHEM, V264, P14605; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237	29	86	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3012	3016		10.1074/jbc.270.7.3012	http://dx.doi.org/10.1074/jbc.270.7.3012			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852381	hybrid			2022-12-25	WOS:A1995QG47100021
J	WONG, K; LI, XB; HUNCHUK, N				WONG, K; LI, XB; HUNCHUK, N			N-ACETYLSPHINGOSINE (C-2-CERAMIDE) INHIBITED NEUTROPHIL SUPEROXIDE FORMATION AND CALCIUM INFLUX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTRACELLULAR CALCIUM; HUMAN-PLATELETS; CA2+ INFLUX; STORES; SPHINGOSINE; MESSENGER; CERAMIDE; LYSOSPHINGOLIPIDS; INVOLVEMENT	Ceramide, a product arising from sphingomyelinase activity, has been shown to act as an intracellular second messenger in effecting growth inhibition, cellular differentiation, and apoptosis, In the present study, the relative effects of cell-permeable ceramides, N-acetylsphingosine (C-2-ceramide) and N-hexanoylsphingosine (C-2-ceramide), on neutrophil responses were measured, When cells were activated with fMet-Leu-Phe, C-2-ceramide both potentiated (<1 mu M) and inhibited (>1 mu M) superoxide generation, C-2- and C-6-ceramide inhibited phorbol ester induced superoxide release from neutrophils at IC50 values of 5 and 120 mu M, respectively. C-2-ceramide had no effect on semipurified protein kinase C activity, Neither ceramide affected significantly the general level of phosphorylated proteins in phorbol ester-treated cells, C-2-ceramide (1-20 mu M) alone did not change cytosolic free Ca2+ levels but inhibited Ca2+ and Mn2+ influx in fMet-Leu-Phe-activated neutrophils. In contrast, sphingosine enhanced Ca2+ entry; thus, ceramide conversion to sphingosine was not significant, Unlike C-2-ceramide, C-2-dihydroceramide failed to block superoxide generation or Ca2+ influx, Preincubation of cells with 10 nM okadaic acid reversed slightly the effects of C-2-ceramide, Calyculin A, tautomycin, and much higher concentrations of okadaic acid inhibited agonist-induced Ca2+ influx. We postulate that C-2-ceramide may inhibit neutrophil superoxide release by activation of type 2A protein phosphatases. Results suggest that protein phosphatase type 1 up-regulates Ca2+ entry, whereas type 2A (or a ceramide-activated subtype) forestalls Ca2+ entry by inactivating a calcium influx factor.	UNIV CALGARY,DEPT PHARMACOL & THERAPEUT,CALGARY,AB T2N 4N1,CANADA	University of Calgary	WONG, K (corresponding author), CANADIAN RED CROSS SOC,CTR BLOOD TRANSFUS,737 13 AVE SW,CALGARY,AB T2R 1J1,CANADA.							BERLIN RD, 1993, CELL CALCIUM, V14, P379, DOI 10.1016/0143-4160(93)90042-5; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; DELLABIANCA V, 1986, BIOCHEM BIOPH RES CO, V135, P556; DING JB, 1992, J BIOL CHEM, V267, P6442; DIVIRGILIO F, 1990, CURR TOP MEMBR TRANS, V35, P180; DOBROWSKY RT, 1993, ADV LIPID RES, V25, P91; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, CLIN CHIM ACTA, V185, P333, DOI 10.1016/0009-8981(89)90224-6; HANNUN YA, 1993, ADV LIPID RES, V25, P43; LAGAST H, 1984, J CLIN INVEST, V73, P878, DOI 10.1172/JCI111284; LU DJ, 1992, AM J PHYSIOL, V262, pC39, DOI 10.1152/ajpcell.1992.262.1.C39; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MONTERO M, 1993, BIOCHIM BIOPHYS ACTA, V1177, P127, DOI 10.1016/0167-4889(93)90031-J; MONTERO M, 1994, J BIOL CHEM, V269, P3963; MURATA K, 1993, J CELL BIOCHEM, V51, P442, DOI 10.1002/jcb.2400510409; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARENTE JE, 1989, MOL PHARMACOL, V35, P26; Pittet D, 1992, Adv Second Messenger Phosphoprotein Res, V26, P369; Putney J W Jr, 1991, Adv Pharmacol, V22, P251, DOI 10.1016/S1054-3589(08)60037-X; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SNYDERMAN R, 1991, AGENT ACTION SUPPL, V35, P3; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; TYAGT SR, 1985, J BIOL CHEM, V263, P12191; Walker Blair A. M., 1992, Biological Signals, V1, P237; WONG K, 1993, CELL CALCIUM, V14, P493, DOI 10.1016/0143-4160(93)90008-T; WONG K, 1990, J BIOL CHEM, V265, P21454; WONG K, 1992, BIOCHEM J, V283, P499, DOI 10.1042/bj2830499; YANAGA F, 1994, BIOCHEM J, V298, P733, DOI 10.1042/bj2980733	38	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3056	3062		10.1074/jbc.270.7.3056	http://dx.doi.org/10.1074/jbc.270.7.3056			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852386	hybrid			2022-12-25	WOS:A1995QG47100027
J	KOLOSHA, VO; MARTIN, SL				KOLOSHA, VO; MARTIN, SL			POLYMORPHIC SEQUENCES ENCODING THE FIRST OPEN READING FRAME PROTEIN FROM LINE-1 RIBONUCLEOPROTEIN-PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; TRANSPOSABLE ELEMENT; 5' END; RNA; DNA	The mouse LINE-1 (L1) retrotransposon contains two open reading frames (ORFs), Three classes of the protein encoded by the first open reading frame (ORF1) are expressed in the mouse embryonal carcinoma cell Line, F9; the apparent molecular sizes of these proteins are 41.3, 43, and 43.5 kDa. Two of these three proteins (41.3 and 43 kDa) are translated in vitro from full-length, sense strand L1 RNA isolated from ribonucleoprotein particles. A reverse transcription-polymerase chain reaction approach was used to clone the ORF1 region from RNA isolated from ribonucleoprotein particles, then the coding capacity of these clones was examined using in vitro transcription and translation. Multiple sequences that encode ORF1 were recovered by this approach, indicating that multiple loci of L1 in the mouse genome are expressed in F9 cells. In addition, L1 sequences with intact ORF1 regions appear to be selectively enriched in the ribonucleoprotein particles.	UNIV COLORADO, SCH MED, DEPT CELLULAR & STRUCT BIOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [GM40367] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040367, R29GM040367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; DEMERS GW, 1989, J MOL EVOL, V29, P3, DOI 10.1007/BF02106177; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; HARDIES SC, 1990, UCLA SYM BI, V122, P127; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HOLMES SE, 1992, J BIOL CHEM, V267, P19765; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIEBOLD DM, 1990, P NATL ACAD SCI USA, V87, P6990; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; Martin SL, 1991, CURR OPIN GENET DEV, V1, P505, DOI 10.1016/S0959-437X(05)80199-6; MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; PERLER F, 1980, CELL, V20, P555, DOI 10.1016/0092-8674(80)90641-8; SCHICHMAN SA, 1992, J MOL BIOL, V224, P559, DOI 10.1016/0022-2836(92)90544-T; SHEHEE WR, 1987, J MOL BIOL, V196, P757, DOI 10.1016/0022-2836(87)90402-5; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; [No title captured]	22	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 10	1995	270	6					2868	2873		10.1074/jbc.270.6.2868	http://dx.doi.org/10.1074/jbc.270.6.2868			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QF535	7852362	hybrid			2022-12-25	WOS:A1995QF53500072
J	CREMO, CR; SELLERS, JR; FACEMYER, KC				CREMO, CR; SELLERS, JR; FACEMYER, KC			2 HEADS ARE REQUIRED FOR PHOSPHORYLATION-DEPENDENT REGULATION OF SMOOTH-MUSCLE MYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN; HEAVY-MEROMYOSIN; ACTIN-FILAMENTS; GIZZARD MYOSIN; MOVEMENT; SUBFRAGMENT-1; CONFORMATION; PROTEOLYSIS; CONTRACTION; FRAGMENTS	Recent structural evidence (Rayment, I., Holden, H. M., Whittaker, M., Yohn, C. B., Lorenz, M., Holmes, K. C., and Milligan, R. A. (1993) Science 261, 58-65) suggests that the two heads of skeletal muscle myosin interact when the protein is bound to filamentous actin, Direct chemical cross-linking experiments show that the two heads of smooth muscle myosin interact in the presence of filamentous actin and the absence of ATP (Onishi, H., Maita, T., Matsuda, G., and Fujiwara, K. (1992) Biochemistry 31, 1201-1210). Head-head interactions may be important in the mechanism of phosphorylation-dependent regulation of smooth muscle myosin. To explore the structural elements essential for phosphorylation-dependent regulation, we purified a proteolytic fragment of chicken gizzard myosin containing only one head attached to an intact tail. This molecule contained a partially digested regulatory light chain, which was replaced with exogenously added intact light chain in either the thiophosphorylated or the unphosphorylated state, Control experiments showed that this replacement was nearly quantitative and did not alter the actin-activated ATPase of this myosin. Electron micrographs confirmed that the single-headed preparation contained an intact form of single-headed myosin. The unphosphorylated single-headed myosin hydrolyzed ATP rapidly and moved actin filaments in an in vitro motility assay, Phosphorylation had minimal effects upon these properties, Therefore, we conclude that phosphorylation-dependent regulation in this myosin requires two heads. These findings may have important implications in studies of other regulated motor proteins that contain two motor domains.	NHLBI,MOLEC CARDIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	CREMO, CR (corresponding author), WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164, USA.							COOKE R, 1978, J MOL BIOL, V120, P861; FACEMYER KC, 1992, BIOCONJUGATE CHEM, V3, P408, DOI 10.1021/bc00017a009; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; HASEGAWA Y, 1990, J BIOCHEM-TOKYO, V108, P909, DOI 10.1093/oxfordjournals.jbchem.a123313; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; IKEBE M, 1982, J BIOCHEM-TOKYO, V91, P1809, DOI 10.1093/oxfordjournals.jbchem.a133874; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1991, J BIOL CHEM, V266, P21339; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; JACKSON AP, 1988, BIOCHEM J, V251, P515, DOI 10.1042/bj2510515; JAKES R, 1976, FEBS LETT, V70, P229, DOI 10.1016/0014-5793(76)80763-6; KENDRICKJONES J, 1977, EXCITATION CONTRACTI, P348; Lowey S, 1974, J Mechanochem Cell Motil, V2, P241; MARGOSSIAN SS, 1973, J MOL BIOL, V74, P301, DOI 10.1016/0022-2836(73)90375-6; MARGOSSIAN SS, 1984, J BIOL CHEM, V259, P3534; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; NATH N, 1982, BIOPHYS J, V37, P47; ONISHI H, 1992, BIOCHEMISTRY-US, V31, P1201, DOI 10.1021/bi00119a033; PERSECHINI A, 1981, SCIENCE, V213, P1383, DOI 10.1126/science.6455737; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P1; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1983, J BIOL CHEM, V258, P4181; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SELLERS JR, 1987, ENZYMES, P381; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAFFORD WF, 1979, BIOCHEMISTRY-US, V18, P5273, DOI 10.1021/bi00591a002; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1989, J CELL BIOL, V109, P2887, DOI 10.1083/jcb.109.6.2887; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; XIE X, 1994, SCIENCE, V368, P306	40	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2171	2175		10.1074/jbc.270.5.2171	http://dx.doi.org/10.1074/jbc.270.5.2171			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836446				2022-12-25	WOS:A1995QE49300031
J	PLEY, UM; HILL, BL; ALIBERT, C; BRODSKY, FM; PARHAM, P				PLEY, UM; HILL, BL; ALIBERT, C; BRODSKY, FM; PARHAM, P			THE INTERACTION OF CALMODULIN WITH CLATHRIN-COATED VESICLES, TRISKELIONS, AND LIGHT-CHAINS - LOCALIZATION OF A BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOATING ATPASE; AXONAL-TRANSPORT; CELL-GROWTH; PROTEINS; KINASE; RECOGNITION; DOMAINS; PHOSPHORYLATION; PURIFICATION; SEQUENCES	The binding of clathrin-coated vesicles, clathrin triskelions, and free clathrin light chains to calmodulin-Sepharose was compared, When isolated from bovine brain, all three components bound to calmodulin-Sepharose in the presence of calcium and could be eluted by its removal, In contrast, coated vesicles and triskelions isolated from bovine adrenal gland did not bind to calmodulin-Sepharose, although the free light chains from adrenal gland bound as effectively as those from brain, As distinct isoforms of the clathrin light chains are expressed by brain and adrenal gland, these results implicate the clathrin light chains as the calmodulin-binding component of coated vesicles and triskelions. Furthermore, the insertion sequences found in the neuron-specific isoforms, although not necessary for the binding of free clathrin light chains to calmodulin, must facilitate the interaction of heavy chain-associated light chains with calmodulin, Recombinant mutants of LCa, with deletions spanning the entire sequence, were tested for binding to calmodulin-Sepharose. Those mutants retaining structural integrity, as assessed by the binding of a panel of monoclonal antibodies, exhibited varying amounts of calmodulin binding activity, However, deletion of the carboxyl-terminal 20 residues abolished calmodulin interaction, Thus, the carboxyl terminus of LCa appears to constitute a calmodulin-binding site, Peptides corresponding to the carboxyl terminus of LCa or LCb inhibited the interaction of the light chains with calmodulin, suggesting that this region forms the calmodulin-binding site of both LCa and LCb, The carboxyl-terminal peptides of LCa and LCb inhibited the interaction of light chains with calmodulin similar to 10-fold less effectively than a calmodulin-binding peptide derived from smooth muscle myosin light chain kinase, but much more effectively than a calmodulin-binding peptide derived from adenylate cyclase, This comparison places the clathrin light chain-calmodulin interaction within the physiological range seen for other calmodulin-binding proteins.	STANFORD UNIV,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARM & PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	Stanford University; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Brodsky, Frances/0000-0002-1334-9258	NIGMS NIH HHS [GM38093] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038093] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARZVI D, 1986, J BIOL CHEM, V261, P9614; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BRODSKY FM, 1991, TRENDS BIOCHEM SCI, V16, P208, DOI 10.1016/0968-0004(91)90087-C; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; BRODSKY FM, 1983, J CELL BIOL, V96, P911, DOI 10.1083/jcb.96.3.911; BRODSKY FM, 1987, NATURE, V326, P203, DOI 10.1038/326203a0; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DEWAEGH S, 1989, J NEUROSCI RES, V23, P433, DOI 10.1002/jnr.490230409; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON AP, 1988, J BIOL CHEM, V263, P16688; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; LADANT D, 1989, J BIOL CHEM, V264, P4015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDEN CD, 1981, P NATL ACAD SCI USA, V78, P3008; LISANTI MP, 1982, EUR J BIOCHEM, V125, P463, DOI 10.1111/j.1432-1033.1982.tb06706.x; LISANTI MP, 1982, EUR J BIOCHEM, V121, P617, DOI 10.1111/j.1432-1033.1982.tb05830.x; LITTLE AM, 1993, HISTOCOMPATIBILITY T, P159; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MERISKO EM, 1988, J BIOL CHEM, V263, P15705; MERISKO EM, 1985, EUR J CELL BIOL, V39, P167; MOOIBROEK MJ, 1987, J BIOL CHEM, V262, P25; MORGAN K, 1985, J BIOL CHEM, V260, P3595; MOSKOWITZ N, 1982, J NEUROCHEM, V38, P1742, DOI 10.1111/j.1471-4159.1982.tb06657.x; NATHKE I, 1990, J BIOL CHEM, V265, P18621; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PARHAM P, 1989, BIOCHEM J, V257, P775, DOI 10.1042/bj2570775; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; SCHMID SL, 1984, NATURE, V311, P228, DOI 10.1038/311228a0; SILVEIRA LA, 1990, J CELL BIOL, V111, P1437, DOI 10.1083/jcb.111.4.1437; TYTELL M, 1981, SCIENCE, V214, P179, DOI 10.1126/science.6169148; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; WYLIE DC, 1988, CALMODULIN, P1	43	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 3	1995	270	5					2395	2402		10.1074/jbc.270.5.2395	http://dx.doi.org/10.1074/jbc.270.5.2395			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QE493	7836475	hybrid			2022-12-25	WOS:A1995QE49300063
J	BARKER, KT; MARTINDALE, JE; MITCHELL, PJ; KAMALATI, T; PAGE, MJ; PHIPPARD, DJ; DALE, TC; GUSTERSON, BA; CROMPTON, MR				BARKER, KT; MARTINDALE, JE; MITCHELL, PJ; KAMALATI, T; PAGE, MJ; PHIPPARD, DJ; DALE, TC; GUSTERSON, BA; CROMPTON, MR			EXPRESSION PATTERNS OF THE NOVEL RECEPTOR-LIKE TYROSINE KINASE, DDR, IN HUMAN BREAST-TUMORS	ONCOGENE			English	Article						DDR (DISCOIDIN DOMAIN RECEPTOR); PROTEIN TYROSINE KINASE; BREAST TUMOR; IN SITU HYBRIDIZATION	GROWTH-FACTOR RECEPTORS; HUMAN INSULIN-RECEPTOR; PROTEIN OVEREXPRESSION; SIGNAL TRANSDUCTION; DISCOIDIN-I; CANCER; ONCOGENE; FAMILY; AMPLIFICATION; DISEASE	Using a reverse transcriptase-polymerase chain reaction based differential screening procedure, Rie have identified the discoidin domain receptor as a protein tyrosine kinase that is expressed in lymph nodes containing breast tumour metastases. By Northern blotting and in situ hybridisation we have demonstrated the expression of the discoidin domain receptor in human primary breast tumour samples, metastasis-containing lymph nodes and a numb;er of normal tissues. Direct comparison of malignant breast and adjacent normal epithelial tissue revealed over expression in the tumour cells.	INST CANC RES,CELL BIOL & EXPTL PATHOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; WELLCOME RES LABS,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND	University of London; Institute of Cancer Research - UK; GlaxoSmithKline; Wellcome Research Laboratories			Mitchell, Philip J/F-6393-2013; Dale, Trevor C/D-3749-2009; gusterson, barry a/D-3752-2009	Dale, Trevor C/0000-0002-4880-9963; 				ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BOLEN JB, 1993, ONCOGENE, V8, P2025; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GASPARINI G, 1994, BREAST CANCER RES TR, V29, P59, DOI 10.1007/BF00666182; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENNIPMAN A, 1989, CANCER RES, V49, P516; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KARN T, 1993, ONCOGENE, V8, P3433; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; LAI C, 1994, ONCOGENE, V9, P877; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LATHE R, 1989, IN SITU HYBRIDISATIO, P71; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MARSHALL E, 1993, SCIENCE, V259, P618, DOI 10.1126/science.8430308; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PATERSON MC, 1991, CANCER RES, V51, P556; PEREZ R, 1984, BREAST CANCER RES TR, V4, P189, DOI 10.1007/BF01806484; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SAINSBURY JRC, 1985, LANCET, V1, P364; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; TOI M, 1994, BREAST CANCER RES TR, V29, P51, DOI 10.1007/BF00666181; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YIE Y, 1993, NUCLEIC ACIDS RES, V21, P361, DOI 10.1093/nar/21.2.361; ZERLIN M, 1993, ONCOGENE, V8, P2731	48	84	92	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					569	575						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845682				2022-12-25	WOS:A1995QF64800018
J	GROBLEWSKI, GE; WANG, YL; ERNST, SA; KENT, C; WILLIAMS, JA				GROBLEWSKI, GE; WANG, YL; ERNST, SA; KENT, C; WILLIAMS, JA			CHOLECYSTOKININ STIMULATES THE DOWN-REGULATION OF CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE IN PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; HELA-CELLS; CALYCULIN-A; PHOSPHATIDYLCHOLINE; PHOSPHORYLATION; LOCALIZATION; HYDROLYSIS; BREAKDOWN; ACID	Stimulation of rat pancreatic acinar cells with cholecystokinin (CCK) is known to result in a significant inhibition of CTP:phosphocholine cytidylyltransferase (CT), a rate-limiting enzyme in phosphatidylcholine biosynthesis. Immunoprecipitation of CT from P-32-labeled acinar cells revealed that CCK treatment also caused a marked reduction in CT phosphate levels. The effects of CCK were maximal over 60 min and dependent on concentration, exhibiting an EC(50) of 800 pM. Other calcium mobilizing secretagogues such as carbamylcholine (100 mu M) and bombesin (10 nM) also reduced CT phosphate levels to 20 and 39% of control, respectively, Treatment of cells with thapsigargin and/or 12-O-tetradecanoylphorbol-13-acetate established that a combination of increased intracellular Ca2+ and protein kinase C activation was necessary to decrease phosphorylated CT content. Conversely, secretin (10 nM) or 8-(4-chlorophenylthio) -cAMP (100 mu M) added alone had no effects. Use of the compound JMV-180 indicated CCK was acting through the low affinity state of the CCKA receptor to reduce CT phosphate levels. Further, the decrease in phosphorylated CT caused by CCB was blocked by the phosphatase inhibitors okadaic acid (3 mu M) and calyculin A (100 nM). Finally, immunoblotting from whole cell lysates revealed CT was partially degraded in response to CCK, providing a novel mechanism by which the inhibition of CT enzyme activity occurs in response to the hormone. Moreover, this degradation was also blocked by a phosphatase inhibitor. These data suggest that the dephosphorylation of either CT itself or some other regulatory molecule(s) which mediates the CCH-induced protease activation may play a central role in reducing CT enzyme levels in acinar cells.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	GROBLEWSKI, GE (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,7737 MED SCI II,ANN ARBOR,MI 48109, USA.			Williams, John/0000-0002-6063-7615	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK041122, R01DK041122, F32DK008819] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-41122, DK-08819] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; ERNST SA, 1995, AM J PHYSIOL, V267, pC990; EXTON JH, 1990, J BIOL CHEM, V265, P1; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MATOZAKI T, 1991, J BIOL CHEM, V266, P22246; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MEYERALBER A, 1994, BIOCHEM BIOPH RES CO, V201, P1470, DOI 10.1006/bbrc.1994.1869; RIVARD N, 1994, AM J PHYSIOL, V266, pG62, DOI 10.1152/ajpgi.1994.266.1.G62; RUBIN RP, 1992, BIOCHIM BIOPHYS ACTA, V1133, P127, DOI 10.1016/0167-4889(92)90059-K; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; UTAL AK, 1991, J BIOL CHEM, V266, P24084; WAGNER ACC, 1992, BIOCHEM BIOPH RES CO, V189, P1606, DOI 10.1016/0006-291X(92)90260-R; WAGNER ACC, 1992, AM J PHYSIOL, V262, pC1172; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1994, BBA-LIPID LIPID MET, V1210, P335, DOI 10.1016/0005-2760(94)90238-0; WILLIAMS JA, 1993, PHYSIOL REV, V73, P701, DOI 10.1152/physrev.1993.73.4.701; YULE DI, 1994, PHYSL GASTROINTESTIN, P1477	29	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 20	1995	270	3					1437	1442		10.1074/jbc.270.3.1437	http://dx.doi.org/10.1074/jbc.270.3.1437			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QB156	7836412	hybrid			2022-12-25	WOS:A1995QB15600069
